PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lau, PP; Zhu, HJ; Nakamuta, M; Chan, L				Lau, PP; Zhu, HJ; Nakamuta, M; Chan, L			Cloning of an apobec-1-binding protein that also interacts with apolipoprotein B mRNA and evidence for its involvement in RNA editing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOLECULAR-CLONING; CATALYTIC SUBUNIT; BINDING PROTEINS; EXPRESSION; EXTRACT; ENZYME; GENE; SITE; P27	Apolipoprotein (apo)B mRNA editing is mediated by a multiprotein editosome complex. Apobec-1 is the catalytic component of this complex, but other proteins involved in editing have not been identified. We used the yeast two-hybrid system to identify an apobec-1-interacting protein, ABBP-1. ABBP-1 contains 331 amino acid residues and is identical to a previously reported human type A/B hnRNP except for a 47-residue insertion at its C-terminal region. It contains typical RNP motifs at its N-terminal half and glycine-rich motifs in the C-terminal region. Northern blot analysis indicates that ABBP-1 mRNA is distributed in multiple human tissues. By deletion analysis, we mapped the apobec-1-binding region to the glycine-rich domain. ABBP-1 also binds to apoB mRNA transcripts around the editing site and can be UV-cross-linked to them in vitro. Immnodepletion of ABBP-1 from an active apoB mRNA editing tissue extract inhibits its editing activity. Down-regulation of ABBP-1 in an apobec-1-expressing HepGa cell line by transfection with an antisense ABBP-1 cDNA construct leads to inhibition of endogenous apoB mRNA editing. We conclude that ABBP-1 is an apobec-1-interacting protein that may play an important role in apoB mRNA editing.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine	Lau, PP (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056668] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56668] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHAN L, 1995, SCI MED, V2, P68; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HARPER JW, 1993, CELL, V75, P805; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; KHAN FA, 1991, FEBS LETT, V290, P159, DOI 10.1016/0014-5793(91)81249-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; LAU PP, 1991, J BIOL CHEM, V266, P20550; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; NAVARATNAM N, 1993, J BIOL CHEM, V268, P20709; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	26	83	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1452	1455		10.1074/jbc.272.3.1452	http://dx.doi.org/10.1074/jbc.272.3.1452			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999813	hybrid			2022-12-25	WOS:A1997WD05800011
J	Dembinsky, A; Rubin, H; Ravid, S				Dembinsky, A; Rubin, H; Ravid, S			Autophosphorylation of Dictyostelium myosin II heavy chain-specific protein kinase C is required for its activation and membrane dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOATTRACTANT-ELICITED INCREASES; PHOSPHORYLATION; DOMAIN; ALPHA; SITE; LOCALIZATION; DISCOIDEUM; CELLS	Myosin II heavy chain (MHC) specific protein kinase C (MHC-PKC) isolated from the ameba, Dictyostelium discoideum, regulates myosin II assembly and localization in response to the chemoattractant cAMP. cAMP stimulation of Dictyostelium cells leads to translocation of MHC-PKC from the cytosol to the membrane fraction, as well as causing an increase in both MHC-PKC phosphorylation and its kinase activity. MHC-PKC undergoes autophosphorylation with each mole of kinase incorporating about 20 mol of phosphate. The MHC-PKC autophosphorylation sites are thought to be located within a domain at the COOH-terminal region of MHC-PKC that contains a cluster of 21 serine and threonine residues. Here we report that deletion of this domain abolished the ability of the enzyme to undergo autophosphorylation in vitro. Furthermore, after this deletion, cAMP dependent autophosphorylation of MHC-PKC as well as cAMP-dependent increases in kinase activity and subcellular localization were also abolished. These results provide evidence for the role of autophosphorylation in the regulation of MHC-PKC and indicate that this MHC-PKC autophosphorylation is required for the kinase activation in response to cAMP and for subcellular localization.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT BIOCHEM, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BERLOT CH, 1987, J BIOL CHEM, V262, P3918; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; Dembinsky A, 1996, J CELL BIOL, V134, P911, DOI 10.1083/jcb.134.4.911; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; HOUSE C, 1989, FEBS LETT, V249, P243, DOI 10.1016/0014-5793(89)80632-5; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUANG KP, 1986, J BIOL CHEM, V261, P2134; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOMIS WF, 1971, EXP CELL RES, V64, P484, DOI 10.1016/0014-4827(71)90107-8; MALCHOW D, 1981, EUR J BIOCHEM, V17, P213; MANSTEIN DJ, 1995, GENE, V162, P129, DOI 10.1016/0378-1119(95)00351-6; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOLINA CA, 1991, CANCER RES, V51, P4624; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; NEWTON AC, 1987, J BIOL CHEM, V262, P10185; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNO S, 1990, J BIOL CHEM, V265, P6296; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAHMSDORF HJ, 1978, FEBS LETT, V88, P322, DOI 10.1016/0014-5793(78)80203-8; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SU LH, 1993, RECEPTOR CHANNEL, V1, P1; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TSUTAKAWA SE, 1995, J BIOL CHEM, V270, P26807, DOI 10.1074/jbc.270.45.26807; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	37	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					828	834		10.1074/jbc.272.2.828	http://dx.doi.org/10.1074/jbc.272.2.828			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995370	hybrid			2022-12-25	WOS:A1997WC04800021
J	Krump, E; Sanghera, JS; Pelech, SL; Furuya, W; Grinstein, S				Krump, E; Sanghera, JS; Pelech, SL; Furuya, W; Grinstein, S			Chemotactic peptide N-formyl-Met-Leu-Phe activation of p38 mitogen-activated protein kinase (MAPK) and MAPK-activated protein kinase-2 in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-27; TYROSINE PHOSPHORYLATION; PHOSPHATIDYLINOSITOL TRISPHOSPHATE; SELECTIVE INHIBITOR; MAMMALIAN-CELLS; C ISOTYPES; MODULATION; CASCADE; STRESS; INTERLEUKIN-1	Activation of polymorphonuclear leukocytes (PMN) by chemotactic peptides initiates a series of functional responses that serve to eliminate pathogens. The intermediate steps that link engagement of the chemoattractant receptor to the microbicidal responses involve protein kinases that have yet to be identified. In this study we detected in human PMN the presence of p38 mitogen activated protein kinase (MAPK), which became rapidly tyrosine phosphorylated and activated in response to the chemotactic peptide N-formyl-methionyl-leucylphenylalanine (fMLP). Pretreatment of PMN with wortmannin, a phosphatidylinositol 3-kinase inhibitor, or bis-indolylmaleimide, a protein kinase C antagonist, resulted in partial inhibition of p38 phosphorylation upon fMLP stimulation. Similarly, phosphorylation of p38 was only partially inhibited when the fMLP-induced cytosolic calcium transient was prevented. Stimulation of PMN by the chemoattractant also resulted in the rapid phosphorylation and activation of MAPK-activated protein kinase-2 (MAPKAPK-2), which was completely inhibited by the specific p38 inhibitor, SB203580. The physical interaction of p38 with MAPKAPK-2 was studied by coimmunoprecipitation. These two kinases were found to be associated in unstimulated PMN but dissociated upon activation of the cells by fMLP. Together these findings demonstrate the activation of p38 by chemotactic peptides in human PMN by a process involving phosphatidylinositol 3-kinase, protein kinase C, and calcium. p38, in turn, is an upstream activator of MAPKAPK-2.	HOSP SICK CHILDREN,DIV CELL BIOL,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 1A1,CANADA; KINETEK PHARMACEUT INC,VANCOUVER,BC V5Z 1A1,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of British Columbia								ANDREWS PC, 1983, BLOOD, V61, P333; Baggiolini Marco, 1992, News in Physiological Sciences, V7, P215; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERKOW RL, 1990, BLOOD, V75, P2445; BERKOW RL, 1993, LIFE SCI, V52, P1727, DOI 10.1016/0024-3205(93)90481-H; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DING JB, 1992, J BIOL CHEM, V267, P6442; EBERLE M, 1990, J BIOL CHEM, V265, P16725; ELION EA, 1995, TRENDS CELL BIOL, V5, P322, DOI 10.1016/S0962-8924(00)89055-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; GRINSTEIN S, 1993, J BIOL CHEM, V268, P20223; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HSIAO KM, 1994, P NATL ACAD SCI USA, V91, P5480, DOI 10.1073/pnas.91.12.5480; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAJUMDAR S, 1991, J BIOL CHEM, V266, P9285; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; MERRITT JE, 1993, BIOCHEM J, V289, P919, DOI 10.1042/bj2890919; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NACCACHE PH, 1990, BLOOD, V76, P2098; NIESSEN HWM, 1994, BBA-MOL CELL RES, V1223, P267, DOI 10.1016/0167-4889(94)90236-4; PONTREMOLI S, 1990, J BIOL CHEM, V265, P706; POWIS G, 1994, CANCER RES, V54, P2419; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; SMALLWOOD JI, 1992, J LEUKOCYTE BIOL, V51, P84, DOI 10.1002/jlb.51.1.84; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VLAHOS CJ, 1995, J IMMUNOL, V154, P2413; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WALKER BAM, 1991, LAB INVEST, V64, P105; WENZELSEIFERT K, 1994, BIOCHEM BIOPH RES CO, V200, P1536, DOI 10.1006/bbrc.1994.1625; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	55	163	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					937	944		10.1074/jbc.272.2.937	http://dx.doi.org/10.1074/jbc.272.2.937			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995385	hybrid			2022-12-25	WOS:A1997WC04800036
J	Parkinson, SJ; Alekseev, AE; Gomez, LA; Wagner, F; Terzic, A; Waldman, SA				Parkinson, SJ; Alekseev, AE; Gomez, LA; Wagner, F; Terzic, A; Waldman, SA			Interruption of Escherichia coli heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; DEPENDENT PROTEIN-KINASE; AFFINITY RECEPTORS; CYCLIC-GMP; ACTIVATION; TRANSPORT; IDENTIFICATION; MEMBRANES; DIARRHEA; CHANNEL	Diarrhea induced by Escherichia coli heat-stable enterotoxin (STa) is mediated by a receptor guanylyl cyclase cascade. The present study establishes that an intracellular nucleotide-dependent pathway disrupts toxin-induced cyclic GMP (cGMP) production and the associated chloride (Cl-) flux that underlie intestinal secretion. Incubation of Caco 2 human intestinal epithelial cells with the nucleoside analog 2-chloroadenosine (2ClAdo) resulted in a concentration- and time-dependent inhibition of toxin-induced cGMP production. Inhibition of cGMP production correlated with the metabolic conversion of 2ClAdo to 2-chloroadenosine triphosphate. The effect of 2ClAdo did not reflect activation of adenosine receptors, inhibition of adenosine deaminase, or modification of the binding or distribution of STa receptors. Guanylyl cyclase activity in membranes prepared from 2ClAdo-treated cells was inhibited, in contrast to membranes from cells not exposed to 2ClAdo, demonstrating that inhibition of guanylyl cyclase C (GCC) was mediated by a noncompetitive mechanism, Treatment of Caco 2 cells with 2ClAdo also prevented STa induced Cl- current. Application of 8-bromo-cGMP, the cell-permeant analog of cGMP, to 2ClAdo-treated cells reconstituted the Cl- current, demonstrating that inhibition of Cl- flux reflected selective disruption of ligand stimulation of GCC rather than the chloride channel itself. Thus, the components required for adenine nucleotide inhibition of GCC signaling are present in intact mammalian cells, establishing the utility of this pathway to elucidate the mechanisms regulating ST-dependent guanylyl cyclase signaling and intestinal fluid homeostasis. In addition, these data suggest that the adenine nucleotide inhibitory pathway may be a novel target to develop antisecretory therapy for enterotoxigenic diarrhea.	THOMAS JEFFERSON UNIV, DEPT MED, DIV CLIN PHARMACOL, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV, DEPT PHARMACOL, DIV CLIN PHARMACOL, PHILADELPHIA, PA 19107 USA; MAYO CLIN & MAYO FDN, DEPT MED, DIV CARDIOVASC DIS, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT PHARMACOL, DIV CARDIOVASC DIS, ROCHESTER, MN 55905 USA	Jefferson University; Jefferson University; Mayo Clinic; Mayo Clinic			Grosso, Luis Alberto Gomez/Q-3185-2019; Alekseev, Alexey/I-5346-2013	Grosso, Luis Alberto Gomez/0000-0001-6998-9556; 				Alekseev AE, 1996, BIOPHYS J, V70, P786, DOI 10.1016/S0006-3495(96)79618-2; Alekseev AE, 1996, J MOL CELL CARDIOL, V28, P1193, DOI 10.1006/jmcc.1996.0110; BELT JA, 1993, ADV ENZYME REGUL, V33, P235; BLAIS A, 1987, J MEMBRANE BIOL, V99, P113, DOI 10.1007/BF01871231; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; CRANE JK, 1992, INFECT IMMUN, V60, P5004, DOI 10.1128/IAI.60.12.5004-5012.1992; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; DALY JW, 1982, J MED CHEM, V25, P197, DOI 10.1021/jm00345a001; DESHMANE SP, 1995, BIOCHEMISTRY-US, V34, P9095, DOI 10.1021/bi00028a019; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; FIELD M, 1978, P NATL ACAD SCI USA, V75, P2800, DOI 10.1073/pnas.75.6.2800; FORTE LR, 1992, AM J PHYSIOL, V263, pC607, DOI 10.1152/ajpcell.1992.263.3.C607; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; GOLD R, 1988, DRUGS, V36, P1, DOI 10.2165/00003495-198800364-00003; HAKKI S, 1993, BIOCHIM BIOPHYS ACTA, V1152, P1, DOI 10.1016/0005-2736(93)90224-N; HUGHES JM, 1978, NATURE, V271, P755, DOI 10.1038/271755a0; HUGUES M, 1991, BIOCHEMISTRY-US, V30, P10738, DOI 10.1021/bi00108a019; HUOTT PA, 1988, J CLIN INVEST, V82, P514, DOI 10.1172/JCI113626; PARKINSON SJ, 1994, J BIOL CHEM, V269, P22683; Parkinson SJ, 1996, BIOCHEMISTRY-US, V35, P3213, DOI 10.1021/bi9524326; PATRINELLIS AC, 1994, BIOCHIM BIOPHYS ACTA, V1243, P143; ROHDE JE, 1984, REV INFECT DIS, V6, P840; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; SHEPPARD DN, 1992, J GEN PHYSIOL, V100, P573, DOI 10.1085/jgp.100.4.573; SIMON LN, 1970, BIOCHEMISTRY-US, V9, P573, DOI 10.1021/bi00805a018; TIEN XY, 1994, J BIOL CHEM, V269, P51; URBANSKI R, 1995, BBA-GEN SUBJECTS, V1245, P29, DOI 10.1016/0304-4165(95)00068-M; VAANDRAGER AB, 1994, J BIOL CHEM, V269, P16409	28	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					754	758		10.1074/jbc.272.2.754	http://dx.doi.org/10.1074/jbc.272.2.754			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995360	hybrid			2022-12-25	WOS:A1997WC04800011
J	Dick, LR; Cruikshank, AA; Destree, AT; Grenier, L; McCormack, TA; Melandri, FD; Nunes, SL; Palombella, VJ; Parent, LA; Plamondon, L; Stein, RL				Dick, LR; Cruikshank, AA; Destree, AT; Grenier, L; McCormack, TA; Melandri, FD; Nunes, SL; Palombella, VJ; Parent, LA; Plamondon, L; Stein, RL			Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEXES; NF-KAPPA-B; GLUTATHIONE; ACTIVATION; PATHWAY; TRANSCRIPTION; DEGRADATION; INHIBITION; EXPORT	The natural product lactacystin exerts its cellular antiproliferative effects through a mechanism involving acylation and inhibition of the proteasome, a cytosolic proteinase complex that is an essential component of the ubiquitin-proteasome pathway for intracellular protein degradation, In vitro, lactacystin does not react with the proteasome; rather, it undergoes a spontaneous conversion (lactonization) to the active proteasome inhibitor, clasto-lactacystin beta-lactone. We show here that when the beta-lactone is added to mammalian cells in culture, it rapidly enters the cells, where it can react with the sulfhydryl of glutathione to form a thioester adduct that is both structurally and functionally analogous to lactacystin, We call this adduct lactathione, and like lactacystin, it does not react with the proteasome, but can undergo lactonization to yield back the active beta-lactonee, We have studied the kinetics of this reaction under appropriate in vitro conditions as well as the kinetics of lactathione accumulation and proteasome inhibition in cells treated with lactacystin or beta-lactone, The results indicate that only the beta-lactone (not lactacystin) can enter cells and suggest that the formation of lactathione serves to concentrate the inhibitor inside cells, providing a reservoir for prolonged release of the active beta-lactone.			Dick, LR (corresponding author), PROSCRIPT INC,38 SIDNEY ST,CAMBRIDGE,MA 02139, USA.		Dick, Lawrence/ABA-8831-2021	Dick, Larry/0000-0002-6880-0405				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COREY EJ, 1992, J AM CHEM SOC, V114, P10677, DOI 10.1021/ja00052a096; COREY EJ, 1993, TETRAHEDRON LETT, V34, P6977, DOI 10.1016/S0040-4039(00)61575-7; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; Hollo Z, 1996, FEBS LETT, V383, P99, DOI 10.1016/0014-5793(96)00237-2; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; JENSSON H, 1985, METHOD ENZYMOL, V113, P504; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; OMURA S, 1991, J ANTIBIOT, V44, P113, DOI 10.7164/antibiotics.44.113; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN D, 1995, CURR BIOL, V3, P854; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Shen HX, 1996, BIOCHEMISTRY-US, V35, P5719, DOI 10.1021/bi960098n; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TANAKA K, 1995, MOL BIOL REP, V21, P21, DOI 10.1007/BF00990966; WILK S, 1993, ENZYME PROTEIN, V47, P187, DOI 10.1159/000468677	26	217	225	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					182	188						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995245				2022-12-25	WOS:A1997WA56400032
J	MeyTal, SV; Schechter, C; Ehrlich, R				MeyTal, SV; Schechter, C; Ehrlich, R			Synthesis and turnover of beta(2)-microglobulin in Ad12-transformed cells defective in assembly and transport of class I major histocompatibility complex molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-2 MICROGLOBULIN; SURFACE EXPRESSION; T-CELLS; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; PEPTIDE TRANSPORTER; HUMAN ADENOVIRUSES; HEAVY-CHAIN; FC RECEPTOR; B-CELLS	In primary embryonal fibroblasts from transgenic mice expressing H-2 genes and a miniature swine class I transgene (PD1), transformation with the highly oncogenic Ad12 results in a reduction in peptide transporter and proteasome-associated (LMP2 and LMP7) gene expression, and suppression in transport and cell surface expression of all class I antigens, The selective suppression in transport of H-2 (but not of PD1) molecules in cells reconstituted for the expression of peptide transporter and LMP genes implied that an additional factor(s) is involved in the assembly of class I complexes. Here we show that the beta(2)m, H-2D(b), and H-2K(b) genes are transcribed and translated in Ad12-transformed cells. However, unlike normal and E1Ad5-transformed cells, in which beta(2)m is either secreted unbound or bound to class I heavy chains, in Ad12-transformed cells significant amounts of beta(2)m are retained in the cell bound to the membrane, but free of class I heavy chains. This abnormal turnover of beta(2)m in the Ad12-transformed cells suggests the existence of a novel beta(2)m-binding molecule(s) that sequesters beta(2)m, and this process may provide a mechanism by which transformation with Ad12 may subvert class I complex formation.	TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT CELL RES & IMMUNOL,IL-64978 RAMAT AVIV,ISRAEL	Tel Aviv University								ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BECKMAN EM, 1995, IMMUNOL TODAY, V16, P349, DOI 10.1016/0167-5699(95)80154-5; BEORCHIA S, 1981, CLIN CHIM ACTA, V109, P245, DOI 10.1016/0009-8981(81)90310-7; BOYD LF, 1992, P NATL ACAD SCI USA, V89, P2242, DOI 10.1073/pnas.89.6.2242; BRINCKERHOFF CE, 1989, SCIENCE, V243, P655, DOI 10.1126/science.2536953; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CARRENO BM, 1995, J IMMUNOL, V155, P4726; CENTRELLA M, 1989, J BIOL CHEM, V264, P18268; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHILD JA, 1980, CANCER-AM CANCER SOC, V45, P318, DOI 10.1002/1097-0142(19800115)45:2<318::AID-CNCR2820450220>3.0.CO;2-C; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; Coligan JE., 1994, CURRENT PROTOCOLS IM; DARGEMONT C, 1989, SCIENCE, V246, P803, DOI 10.1126/science.2683083; DARGEMONT C, 1991, J CELL SCI, V98, P559; DAVIS WC, 1987, VET IMMUNOL IMMUNOP, V15, P337, DOI 10.1016/0165-2427(87)90005-5; EHRLICH RE, 1995, IMMUNOL RES, V14, P77, DOI 10.1007/BF02918170; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDMAN MH, 1982, TRANSPLANT P, V14, P437; GOLDS EE, 1989, BIOCHEM J, V259, P585, DOI 10.1042/bj2590585; GOODENOW RS, 1985, SCIENCE, V230, P777, DOI 10.1126/science.2997918; HAMMERLING GJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P245, DOI 10.1016/0304-419X(87)90008-4; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HOFFMANN B, 1992, CLIN EXP IMMUNOL, V88, P548; HOMMA T, 1992, EUR SURG RES, V24, P204, DOI 10.1159/000129208; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; JACOBY WB, 1979, METHOD ENZYMOL, V58, P110; JONES RA, 1990, BRIT J CANCER, V61, P675, DOI 10.1038/bjc.1990.153; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KOZLOWSKI S, 1991, NATURE, V349, P74, DOI 10.1038/349074a0; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; MANICOURT D, 1978, ANN RHEUM DIS, V37, P328, DOI 10.1136/ard.37.4.328; MAURY CPJ, 1982, RHEUMATOL INT, V2, P145, DOI 10.1007/BF00286135; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; MISNER V, 1991, INT IMMUNOL, V3, P1129; MOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160; MOTAL UMA, 1993, SCAND J IMMUNOL, V38, P395, DOI 10.1111/j.1365-3083.1993.tb01743.x; OTTEN GR, 1992, J IMMUNOL, V148, P3723; OZATO K, 1981, J IMMUNOL, V126, P317; RAMADORI G, 1988, EUR J CLIN INVEST, V18, P343, DOI 10.1111/j.1365-2362.1988.tb01022.x; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; ROCK KL, 1990, P NATL ACAD SCI USA, V87, P7517, DOI 10.1073/pnas.87.19.7517; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P301, DOI 10.1073/pnas.88.1.301; ROCK KL, 1993, J IMMUNOL, V150, P1244; ROMAGNOLI P, 1995, J EXP MED, V182, P2027, DOI 10.1084/jem.182.6.2027; ROTEMYEHUDAR R, 1994, J EXP MED, V180, P477, DOI 10.1084/jem.180.2.477; RotemYehudar R, 1996, J EXP MED, V183, P499, DOI 10.1084/jem.183.2.499; SHEMESH J, 1993, J BIOL CHEM, V268, P15704; SHEMESH J, 1991, J VIROL, V65, P5544, DOI 10.1128/JVI.65.10.5544-5548.1991; SOLHEIM JC, 1995, EUR J IMMUNOL, V25, P3011, DOI 10.1002/eji.1830251104; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; TAKEMORI T, 1990, EMBO J, V9, P2493, DOI 10.1002/j.1460-2075.1990.tb07428.x; VALLET JL, 1991, J ENDOCRINOL, V130, pR1, DOI 10.1677/joe.0.130R001; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZINKERNAGEL R, 1979, ADV IMMUNOL, V22, P51	65	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					353	361						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995269	hybrid			2022-12-25	WOS:A1997WA56400056
J	Olah, ME				Olah, ME			Identification of A(2a) adenosine receptor domains involved in selective coupling to G(s) - Analysis of chimeric A(1)/A(2a) adenosine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; NUCLEOTIDE-BINDING PROTEINS; 3RD INTRACELLULAR LOOP; PHOSPHATIDYLINOSITOL HYDROLYSIS; CYTOPLASMIC DOMAINS; MOLECULAR-CLONING; ADENYLATE-CYCLASE; TYROSINE RESIDUE; AMINO-ACID	Responses to adenosine are governed by selective activation of distinct G proteins by adenosine receptor (AR) subtypes. The A(2a)AR couples via G(s) to adenylyl cyclase stimulation while the A(1)AR couples to G(i) to inhibit adenylyl cyclase. To determine regions of the A(2a)AR that selectively couple to G(s), chimeric A(1)/A(2A)Rs were expressed in Chinese hamster ovary cells and ligand binding and adenylyl cyclase activity analyzed. Replacement of the third intracellular loop of the A(2a)AR with that of the A(1)AR reduced maximal adenylyl cyclase stimulation and decreased agonist potency. Restricted chimeras indicated that the NH2-terminal portion of intracellular loop 3 was predominantly responsible for this impairment. Reciprocal chimeras composed primarily of A(1)AR sequence with limited A(2a)AR sequence substitution stimulated adenylyl cyclase and thus supported these findings. A lysine and glutamic acid residue were identified as necessary for efficient A(2a)AR-G(s) coupling. Analysis of chimeric receptors in which sequence of intracellular loop 2 was substituted indicated that the nature of amino acids in this domain may indirectly modulate A(2a)AR-G(s) coupling. Replacement of the cytoplasmic tail of the A(2a)AR with the A(1)AR tail did not affect adenylyl cyclase stimulation. Thus, selective activation of G(s) is predominantly dictated by the NH2-terminal segment of the third intracellular loop of the A(2a)AR.			Olah, ME (corresponding author), DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710, USA.				NHLBI NIH HHS [P50HL54314] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054314] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRINGTON WW, 1989, P NATL ACAD SCI USA, V86, P6572, DOI 10.1073/pnas.86.17.6572; BLUML K, 1994, J BIOL CHEM, V269, P402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULLOUGH DA, 1995, J IMMUNOL, V155, P2579; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; CUSHING DJ, 1991, AM J PHYSIOL, V261, pH343, DOI 10.1152/ajpheart.1991.261.2.H343; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DOWNEY JM, 1994, ANN NY ACAD SCI, V723, P82, DOI 10.1111/j.1749-6632.1994.tb36719.x; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; HOGGER P, 1995, J BIOL CHEM, V270, P7405; HUNYADY L, 1995, J BIOL CHEM, V270, P9702, DOI 10.1074/jbc.270.17.9702; JOCKERS R, 1994, J BIOL CHEM, V269, P32077; Kleppisch T, 1995, P NATL ACAD SCI USA, V92, P12441, DOI 10.1073/pnas.92.26.12441; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; Liu J, 1996, J BIOL CHEM, V271, P8772, DOI 10.1074/jbc.271.15.8772; MACEWAN DJ, 1995, MOL PHARMACOL, V48, P316; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MALEK D, 1993, FEBS LETT, V325, P215; Maniatis T, 1989, DECONTAMINATION DILU; MCCLUE SJ, 1994, EUR J PHARM-MOLEC PH, V267, P185, DOI 10.1016/0922-4106(94)90170-8; MORO O, 1993, J BIOL CHEM, V268, P22273; MULLANE K, 1995, J MOL CELL CARDIOL, V27, P1041, DOI 10.1016/0022-2828(95)90073-X; MUNSHI R, 1991, J BIOL CHEM, V266, P22285; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NANOFF C, 1991, MOL PHARMACOL, V39, P130; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; NUSSENZVEIG DR, 1994, J BIOL CHEM, V269, P28123; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; OLAH ME, 1994, J BIOL CHEM, V269, P24692; OLAH ME, 1992, ANNU REV PHYSIOL, V54, P211, DOI 10.1146/annurev.physiol.54.1.211; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; PALMER TM, 1995, J BIOL CHEM, V270, P16895, DOI 10.1074/jbc.270.28.16895; Palmer TM, 1995, MOL PHARMACOL, V48, P970; Palmer TM, 1996, J BIOL CHEM, V271, P15272, DOI 10.1074/jbc.271.25.15272; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STRADER CD, 1987, J BIOL CHEM, V262, P16439; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Taylor JM, 1996, J BIOL CHEM, V271, P3336; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; TUCKER AL, 1993, CARDIOVASC RES, V27, P62, DOI 10.1093/cvr/27.1.62; VOGEL WK, 1995, J BIOL CHEM, V270, P15485, DOI 10.1074/jbc.270.26.15485; WESS J, 1990, MOL PHARMACOL, V38, P517; WHALEY BS, 1994, MOL PHARMACOL, V45, P481; WONG SKF, 1994, J BIOL CHEM, V269, P18968; WONG SKF, 1990, J BIOL CHEM, V265, P6219; ZHANG Y, 1990, J PHARMACOL EXP THER, V254, P270; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	58	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					337	344						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995267				2022-12-25	WOS:A1997WA56400054
J	Pfuetzner, RA; Bochkarev, A; Frappier, L; Edwards, AM				Pfuetzner, RA; Bochkarev, A; Frappier, L; Edwards, AM			Replication protein A - Characterization and crystallization of the DNA binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; STRUCTURAL-ANALYSIS; FUNCTIONAL DOMAINS; EXCISION-REPAIR; A BINDS; PURIFICATION; POLYMERASE; SUBUNIT; ANTIGEN; EBNA-1	Replication protein A (RPA) is a heterotrimeric single-stranded DNA-binding protein in eukaryotic cells. The DNA binding activity of human RPA has been previously localized to the N-terminal 441 amino acids of the 70-kDa subunit, RPA70. We have used a combination of limited proteolysis and mutational analysis to define the smallest soluble fragment of human RPA70 that retains complete DNA binding activity. This fragment comprises residues 181-422. RPA(181-422) bound DNA with the same affinity as the 1-441 fragment and had a DNA binding site of 8 nucleotides or less. RPA70 fragments were subjected to crystal trials in the presence of single-stranded DNA, and diffraction quality crystals were obtained for RPA(181-422) bound to oetadeoxycytidine. The RPA(181-422) co-crystals belonged to the P2(1)2(1)2(1) space group, with unit cell dimensions of a = 34.3 Angstrom, b = 78.0 Angstrom and c = 95.4 Angstrom and diffracted to a resolution of 2.1 Angstrom.	MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, CANC RES GRP, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, DEPT PATHOL, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, DEPT BIOCHEM, HAMILTON, ON L8N 3Z5, CANADA	McMaster University; McMaster University; McMaster University				Edwards, Aled/0000-0002-4782-6016				ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BOCHKAREV A, IN PRESS NATURE; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FINNIN MS, 1993, J MOL BIOL, V232, P301, DOI 10.1006/jmbi.1993.1384; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOSTOMSKA Z, 1991, J BIOL CHEM, V266, P14697; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KYCIA JH, 1995, BIOCHEMISTRY-US, V34, P6183, DOI 10.1021/bi00018a022; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SHAH WA, 1992, J VIROL, V66, P3355, DOI 10.1128/JVI.66.6.3355-3362.1992; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TONG X, 1995, J VIROL, V69, P585, DOI 10.1128/JVI.69.1.585-588.1995; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	29	67	69	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					430	434						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995279				2022-12-25	WOS:A1997WA56400066
J	Raussens, V; Ruysschaert, JM; Goormaghtigh, E				Raussens, V; Ruysschaert, JM; Goormaghtigh, E			Fourier transform infrared spectroscopy study of the secondary structure of the gastric H+,K+-ATPase and of its membrane-associated proteolytic peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROGEN-DEUTERIUM EXCHANGE; NEGATIVELY STAINED CRYSTALS; ALPHA-HELICAL STRUCTURE; H+-ATPASE; SARCOPLASMIC-RETICULUM; PROTEIN BACTERIORHODOPSIN; CONFORMATIONAL-CHANGES; BETA-SUBUNIT; RESOLUTION; TOPOLOGY	Membrane topology of the H+,K+-ATPase has been studied after proteolytic degradation of the protein by proteinase K. Proteinase K had access to either the cytoplasmic part of the protein or to both sides of the membrane. Fourier transform infrared attenuated total reflection spectroscopy indicated that membrane-associated domain of the protein represented about 55% of the native protein, meanwhile the cytoplasmic part represented only 27% of the protein. The secondary structure of the ATPase and of its membrane-associated domains was investigated by infrared spectroscopy, The secondary structure of the membrane-associated structures and of the entire protein was quite similar (alpha-helices, 35%; beta-sheets, 35%; turns, 20%; random, 15%), These data were in agreement with 10 alpha-helical transmembrane segments but suggested a participation of beta-sheet structures in the membrane-associated part of the protein, Polarized infrared spectroscopy indicated that the alpha-helices were oriented nearly perpendicular to the membrane plane, No preferential orientation could be attributed to the beta-sheets, Monitoring the amide hydrogen/deuterium exchange kinetics demonstrated that the membrane associated part of the ATPase molecule is characterized by a relatively high accessibility to the solvent, quite different from that observed for bacteriorhodopsin membrane segments.	FREE UNIV BRUSSELS,LAB CHIM PHYS MACROMOL INTERFACES,B-1050 BRUSSELS,BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel				Goormaghtigh, Erik/0000-0002-2071-2262				ALVAREZ J, 1987, J BIOL CHEM, V262, P3502; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRUNE DC, 1992, ANAL BIOCHEM, V207, P285, DOI 10.1016/0003-2697(92)90013-W; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CALLAGHAN JM, 1992, BIOCHEM J, V283, P63, DOI 10.1042/bj2830063; CHALLOU N, 1994, BIOCHEMISTRY-US, V33, P6902, DOI 10.1021/bi00188a020; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORBALANGARCIA S, 1994, BIOCHEMISTRY-US, V33, P8247, DOI 10.1021/bi00193a011; COWAN SW, 1994, SCIENCE, V264, P914, DOI 10.1126/science.8178151; DOWNER NW, 1986, J BIOL CHEM, V261, P3640; DRAHEIM JE, 1991, BIOPHYS J, V60, P89, DOI 10.1016/S0006-3495(91)82033-1; DUMONT ME, 1985, J MEMBRANE BIOL, V88, P233, DOI 10.1007/BF01871088; EARNEST TN, 1990, BIOPHYS J, V58, P1539, DOI 10.1016/S0006-3495(90)82498-X; FIMMEL S, 1989, BIOCHIM BIOPHYS ACTA, V978, P231, DOI 10.1016/0005-2736(89)90120-X; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; FRINGELI UP, 1981, MEMBRANE SPECTROSCOP, P270; GOLDSHLEGER R, 1995, BIOCHEMISTRY-US, V34, P8668, DOI 10.1021/bi00027a016; GOORMAGHTIGH E, 1993, BIOCHEMISTRY-US, V32, P6104, DOI 10.1021/bi00074a023; Goormaghtigh E, 1994, Subcell Biochem, V23, P363; Goormaghtigh E, 1994, Subcell Biochem, V23, P405; GOORMAGHTIGH E, 1994, J BIOL CHEM, V269, P27409; GOORMAGHTIGH E, 1990, EUR J BIOCHEM, V193, P409, DOI 10.1111/j.1432-1033.1990.tb19354.x; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOORMAGHTIGH E, 1990, MOL DESCRIPTION BIOL, P285; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; GRESALFI TJ, 1984, J BIOL CHEM, V259, P2622; Harrick N.J., 1967, INTERNAL REFLECTION; HENNESSEY JP, 1990, J BIOL CHEM, V265, P532; HENNESSEY JP, 1988, J BIOL CHEM, V263, P3123; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P8829, DOI 10.1021/bi00152a020; KAHN TW, 1992, BIOCHEMISTRY-US, V31, P6144, DOI 10.1021/bi00141a027; KAUPPINEN JK, 1981, APPL OPTICS, V20, P1866, DOI 10.1364/AO.20.001866; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGSTROM M, 1984, BIOCHIM BIOPHYS ACTA, V769, P209, DOI 10.1016/0005-2736(84)90025-7; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHEL H, 1982, J MOL BIOL, V158, P567, DOI 10.1016/0022-2836(82)90216-9; NABEDRYK E, 1988, BIOPHYS J, V53, P671, DOI 10.1016/S0006-3495(88)83148-5; PAUL C, 1985, EMBO J, V4, P1593, DOI 10.1002/j.1460-2075.1985.tb03822.x; POPOT JL, 1987, J MOL BIOL, V198, P655, DOI 10.1016/0022-2836(87)90208-7; RAO US, 1988, ANAL BIOCHEM, V173, P251, DOI 10.1016/0003-2697(88)90187-X; RATH P, 1991, BIOPHYS J, V59, P516, DOI 10.1016/S0006-3495(91)82268-8; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; SACHS G, 1993, ANN NY ACAD SCI, V671, P204; SAMI M, 1988, FEBS LETT, V240, P211, DOI 10.1016/0014-5793(88)80370-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIRMER T, 1993, PROTEIN SCI, V2, P1361, DOI 10.1002/pro.5560020820; SCOTT DR, 1992, BIOCHIM BIOPHYS ACTA, V1112, P246, DOI 10.1016/0005-2736(92)90398-6; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SONVEAUX N, 1994, J BIOL CHEM, V269, P25637; SOUMARMON A, 1980, J BIOL CHEM, V255, P1682; STANTON MG, 1968, ANAL BIOCHEM, V22, P27, DOI 10.1016/0003-2697(68)90255-8; STOKES DL, 1990, BIOCHEM SOC T, V18, P841, DOI 10.1042/bst0180841; SWARTS HGP, 1991, BIOCHIM BIOPHYS ACTA, V1070, P283, DOI 10.1016/0005-2736(91)90068-J; SWEADNER KJ, 1992, ANN NY ACAD SCI, V671, P217, DOI 10.1111/j.1749-6632.1992.tb43798.x; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VIGNERON L, 1995, J BIOL CHEM, V270, P17685, DOI 10.1074/jbc.270.30.17685; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2	66	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					262	270						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995257				2022-12-25	WOS:A1997WA56400044
J	vanWeering, DHJ; Bos, JL				vanWeering, DHJ; Bos, JL			Glial cell line-derived neurotrophic factor induces Ret-mediated lamellipodia formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL GROWTH CONE; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; NERVOUS-SYSTEM; RECEPTOR RET; PROTOONCOGENE; ACTIVATION; MUTATIONS; GDNF; KINASE	Ret is a receptor tyrosine kinase required during embryogenesis for the survival of enteric and sympathetic neuroblasts. Recently, glial cell line-derived neurotrophic factor (GDNF) has been identified as a ligand for Ret. We investigated early events in GDNF-induced signal transduction. We show that GDNF activates the Ras-ERK2 signaling pathway in SK-N-MC cells stably transfected with a full-length Ret construct. In addition, activation of Ret tyrosine kinase activity, either via GDNF stimulation of full-length Ret or via epidermal growth factor stimulation of an epidermal growth factor receptor-Ret chimeric receptor, results in phosphatidylinositol 3-kinase activation and phosphatidylinositol 3-kinase-dependent formation of large lamellipodia. Our results indicate that GDNF can serve as a genuine ligand for Ret. In addition, we show that GDNF can induce Ret-mediated formation of lamellipodia, cell surface protrusions that are implicated in neuritogenesis.	UNIV UTRECHT,GRAD SCH DEV BIOL,PHYSIOL CHEM LAB,NL-3508 TA UTRECHT,NETHERLANDS	Utrecht University								ASAI N, 1995, MOL CELL BIOL, V15, P1613; BELLO AB, 1995, NEURON, V15, P821; BENTLEY D, 1986, NATURE, V323, P712, DOI 10.1038/323712a0; Borrello MG, 1995, ONCOGENE, V11, P2419; BRAY D, 1985, J NEUROSCI, V5, P3204; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Durbec PL, 1996, DEVELOPMENT, V122, P349; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GOLDBERG DJ, 1986, J CELL BIOL, V103, P1921, DOI 10.1083/jcb.103.5.1921; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Hou JGG, 1996, J NEUROCHEM, V66, P74; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAZIAUSKAS A, 1989, CELL, V58, P1121; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LO LC, 1995, NEURON, V15, P527, DOI 10.1016/0896-6273(95)90142-6; MOUNT HTJ, 1995, P NATL ACAD SCI USA, V92, P9092, DOI 10.1073/pnas.92.20.9092; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NOBES CD, 1995, J CELL SCI, V108, P225; OPPENHEIM RW, 1995, NATURE, V373, P344, DOI 10.1038/373344a0; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TOMAC A, 1995, P NATL ACAD SCI USA, V92, P8274, DOI 10.1073/pnas.92.18.8274; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUPP M, 1995, J CELL BIOL, V130, P137, DOI 10.1083/jcb.130.1.137; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WENNSTROM S, 1994, ONCOGENE, V9, P651; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0	41	88	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					249	254						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995255				2022-12-25	WOS:A1997WA56400042
J	Jiang, H; Xie, YQ; Houston, P; Stemkehale, K; Mortensen, UH; Rothstein, R; Kodadek, T				Jiang, H; Xie, YQ; Houston, P; Stemkehale, K; Mortensen, UH; Rothstein, R; Kodadek, T			Direct association between the yeast Rad51 and Rad54 recombination proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; ESCHERICHIA-COLI RUVA; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; DNA HELICASE; BRANCH MIGRATION; HOLLIDAY JUNCTIONS; HOMOLOGOUS RECOMBINATION; COMPLEX; EXCHANGE	The RAD54 and RAD51 genes are involved in genetic recombination and double-strand break repair in the yeast Saccharomyces cerevisiae. The Rad51 protein is thought to be a yeast analogue of the Escherichia coli recA gene product and catalyzes strand exchange between homologous single- and double-stranded DNAs in vitro, RAD54 exhibits homologies to several known ATPases and is a member of the SWI2/MOT1 family. We show here that the Rad54 protein interacts with the Rad51 protein in vivo and in vitro and that the NH2-terminal 115 residues of the Rad54 protein are necessary for this interaction. Combined with previously reported results, these data imply that the Rad54 protein is part of a multiprotein yeast recombination complex.	UNIV TEXAS, DEPT CHEM & BIOCHEM, AUSTIN, TX 78712 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT GENET & DEV, NEW YORK, NY 10032 USA	University of Texas System; University of Texas Austin; Columbia University			Stemke-Hale, Katherine/K-9113-2013; Mortensen, Uffe/AAQ-1150-2021	Stemke-Hale, Katherine/0000-0002-1231-4192; Rothstein, Rodney/0000-0002-4107-9654				ALANI E, 1989, GENETICS, V122, P47; AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EMERY HS, 1991, GENE, V104, P103, DOI 10.1016/0378-1119(91)90473-O; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FISHMANLOBELL J, 1992, MOL CELL BIOL, V12, P1292, DOI 10.1128/MCB.12.3.1292; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KODADEK T, 1991, J BIOL CHEM, V266, P9712; KODADEK T, 1987, NATURE, V326, P312, DOI 10.1038/326312a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LAURENT B, 1992, MOL CELL BIOL, V12, P1839; LAURENT BC, 1992, GENE DEV, V6, P1707, DOI 10.1101/gad.6.9.1707; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; MOORE PD, 1993, CURR GENET, V23, P1, DOI 10.1007/BF00336741; MOREL P, 1993, NUCLEIC ACIDS RES, V21, P3205, DOI 10.1093/nar/21.14.3205; MULLER B, 1993, J BIOL CHEM, V268, P17185; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PETERSON CL, 1992, CELL, V68, P573, DOI 10.1016/0092-8674(92)90192-F; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; POON D, 1994, J BIOL CHEM, V269, P23135; RATTRAY AJ, 1995, GENETICS, V139, P45; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SALINAS F, 1994, BIOCHEM BIOPH RES CO, V205, P1004, DOI 10.1006/bbrc.1994.2766; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P387, DOI 10.1016/S0968-0004(00)89085-4; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMITH J, 1995, MOL CELL BIOL, V15, P1632; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315	45	136	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33181	33186		10.1074/jbc.271.52.33181	http://dx.doi.org/10.1074/jbc.271.52.33181			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969173	hybrid			2022-12-25	WOS:A1996WA71300007
J	Mortl, S; Fischer, M; Richter, G; Tack, J; Weinkauf, S; Bacher, A				Mortl, S; Fischer, M; Richter, G; Tack, J; Weinkauf, S; Bacher, A			Biosynthesis of riboflavin - Lumazine synthase of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT CAPSIDS; CRYSTAL-STRUCTURE ANALYSIS; BACILLUS-SUBTILIS; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; 4-CARBON PRECURSOR; COMPLEX; PURIFICATION; PROTEIN; GENE; RESOLUTION	A gene located at 443 kilobases on the Escherichia coli chromosome (subsequently designated ribE) was expressed in a recombinant E. coli strain and was shown to code for the enzyme 6,7-dimethyl-8-ribityllumazine synthase. The recombinant enzyme was purified to homogeneity. The protein is an icosahedral capsid of 60 subunits with a mass of about 1 MDa as shown by hydrodynamic studies and by electron microscopy. In contrast to the icosahedral lumazine synthase-riboflavin synthase complex of Bacillus subtilis, the lumazine synthase of E. coli is not physically associated with another enzyme of the riboflavin pathway, and the core of the icosahedral capsid is empty. The RIB4 gene of Saccharomyces cerevisiae was also expressed to a high level (about 40% of cellular protein) in E. coli. The recombinant protein is a pentamer of 90 kDa. An insertion of 4 amino acids into helix alpha(4) is likely to hinder the formation of an icosahedral capsid by the yeast protein, The kinetic properties of lumazine synthase of E. coli, B. subtilis, and S. cerevisiae are similar.	TECH UNIV MUNICH,DEPT CHEM,D-85747 GARCHING,GERMANY	Technical University of Munich			Fischer, Markus/H-2870-2012; Moertl, Simone/M-7353-2014	Moertl, Simone/0000-0003-0644-0878				BACHER A, 1986, METHOD ENZYMOL, V122, P192; BACHER A, 1980, J BIOL CHEM, V255, P632; BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; BACHER A, 1991, CHEM BIOCH FLAVOPROT, V1, P293; BACHMANN L, 1989, J MOL BIOL, V207, P575, DOI 10.1016/0022-2836(89)90466-X; BRAUN N, 1996, IN PRESS THIN SOLID; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; EDSALL JT, 1943, PROTEINS AMINO ACIDS, P57; FISCHER M, 1996, BIOCH SOC T S, V24, P35; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GARCIARAMIREZ JJ, 1995, J BIOL CHEM, V270, P23801, DOI 10.1074/jbc.270.40.23801; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; LADENSTEIN R, 1994, EUR J BIOCHEM, V223, P1007, DOI 10.1111/j.1432-1033.1994.tb19079.x; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LANE TM, 1992, ANAL ULTRACENTRIFUGA, P90; LEE CY, 1992, BIOCHEM BIOPH RES CO, V186, P690, DOI 10.1016/0006-291X(92)90802-R; LOGVINENKO E M, 1985, Biokhimiya, V50, P744; MIRONOV VN, 1989, DOKL AKAD NAUK SSSR+, V305, P482; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; OLTMANNS O, 1969, MOL GEN GENET, V105, P306, DOI 10.1007/BF00277585; Perkins John B., 1993, P319; PLAUT GWE, 1974, ANNU REV BIOCHEM, V43, P899, DOI 10.1146/annurev.bi.43.070174.004343; RICHTER G, 1992, J BACTERIOL, V174, P4050, DOI 10.1128/jb.174.12.4050-4056.1992; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; RITZ H, 1993, J BACTERIOL, V175, P4045; SCHOTT K, 1990, J BIOL CHEM, V265, P12686; SEDLMAIER H, 1987, Z NATURFORSCH C, V42, P425; Sloma A, 1991, European patent, Patent No. [EP0405370, 0405370, 405370]; STOOPS JK, 1992, J BIOL CHEM, V267, P24769; TAURA T, 1992, MOL GEN GENET, V234, P429, DOI 10.1007/BF00538702; VOLK R, 1990, J BIOL CHEM, V265, P19479; VOLK R, 1988, J AM CHEM SOC, V110, P3651, DOI 10.1021/ja00219a047; WACKER H, 1964, J BIOL CHEM, V239, P3493; WEINKAUF S, 1991, J MOL BIOL, V221, P637, DOI 10.1016/0022-2836(91)80078-9	34	65	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33201	33207		10.1074/jbc.271.52.33201	http://dx.doi.org/10.1074/jbc.271.52.33201			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969176	hybrid			2022-12-25	WOS:A1996WA71300010
J	Smyth, EM; Nestor, PV; FitzGerald, GA				Smyth, EM; Nestor, PV; FitzGerald, GA			Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ADENYLATE-CYCLASE; CELL-LINE; SELECTIVE INHIBITOR; THROMBIN RECEPTOR; THROMBOXANE A(2); BINDING PROTEIN; HUMAN PLATELETS; DESENSITIZATION; PROSTAGLANDIN	An epitope-tagged human prostacyclin receptor (HA-hIP) was constructed and stably transfected into human embryonic kidney 293 cells. The receptor exhibited high (K-d = 0.4 +/- 0.08 nM, B-max = 0.7 +/- 0.2 pmol/mg protein; n = 4) and low (K-d = 75 +/- 27.4 nM, B-max = 7.1 +/- 3.6 pmol/mg protein; n = 4) affinity for iloprost and coupled to both cAMP (EC(50) = 0.1 +/- 0.03 nM) and inositol phosphate (EC(50) = 43.1 +/- 10 nM) production. The receptor resolved on SDS-polyacrylamide gel electrophoresis as a broad complex with a molecular mass of 44-62 kDa and is glycosylated and phosphorylated. Stimulation of transfected cells with iloprost induced a rapid time- and concentration-dependent phosphorylation of HAhIP. Pretreatment of cells with a protein kinase C (PKC) inhibitor (GF109203X; 5 mu M) abolished basal phosphorylation and dramatically reduced iloprost-induced HAhIP phosphorylation. A protein kinase A (PKA) inhibitor (H89) was largely ineffective under the same conditions. HAhIP phosphorylation was stimulated by receptor dependent (thrombin, 2 units/ml) or receptor-independent (phorbol 12-myristate 13-acetate, 5 mu M) PKC activation; both were abolished by pretreatment of cells with GF109203X. In contrast, receptor independent (forskolin (5 mu M) or dibutyryl cAMP (1 mu M)) activation of PKA did not induce HAhIP phosphorylation. These results indicate that the human prostacyclin receptor may be regulated by agonist-dependent phosphorylation. This appears to be mediated, in part, by activation of PKC but not by PKA.	UNIV PENN,CTR EXPT THERAPEUT,PHILADELPHIA,PA 19104	University of Pennsylvania			FitzGerald, Garret A/A-4222-2010					ADIE EJ, 1992, BIOCHEM J, V285, P529, DOI 10.1042/bj2850529; ALI H, 1994, J BIOL CHEM, V269, P24557; Allan CJ, 1996, J PHARMACOL EXP THER, V277, P1132; BOIE Y, 1994, J BIOL CHEM, V269, P12173; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; COLEMAN RA, 1994, PHARMACOL REV, V46, P206; DARIUS H, 1995, J AM COLL CARDIOL, V26, P800, DOI 10.1016/0735-1097(95)00264-5; DEWITT DL, 1983, J BIOL CHEM, V258, P3285; DONG YJ, 1986, BRIT J PHARMACOL, V87, P97, DOI 10.1111/j.1476-5381.1986.tb10161.x; FITZGERALD DJ, 1986, NEW ENGL J MED, V315, P983, DOI 10.1056/NEJM198610163151602; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GALLINO A, 1985, CIRCULATION, V72, P27, DOI 10.1161/01.CIR.72.1.27; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; HASHIMOTO H, 1990, PROSTAGLANDINS, V40, P491, DOI 10.1016/0090-6980(90)90111-8; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; ISHII K, 1994, J BIOL CHEM, V269, P1125; JOSEPH A, 1992, AM J PHYSIOL, V269, pE1083; KELLY E, 1990, BRIT J PHARMACOL, V99, P309, DOI 10.1111/j.1476-5381.1990.tb14700.x; KINSELLA BT, 1994, J BIOL CHEM, V269, P29914; KRONMAN C, 1992, GENE, V121, P295, DOI 10.1016/0378-1119(92)90134-B; LEIGH PJ, 1985, BRIT J PHARMACOL, V85, P237, DOI 10.1111/j.1476-5381.1985.tb08852.x; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; MURRAY R, 1990, J BIOL CHEM, V265, P21670; NAMBA T, 1994, J BIOL CHEM, V269, P9986; OKA M, 1993, CELL SIGNAL, V5, P643, DOI 10.1016/0898-6568(93)90059-U; OKWU AK, 1992, J PHARMACOL EXP THER, V262, P238; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; SAWAI T, 1993, J BIOL CHEM, V268, P1995; SCHWANER I, 1992, BIOCHEM J, V281, P301, DOI 10.1042/bj2810301; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; SWEWEN K, 1988, EMBO J, V7, P161; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; VANE JR, 1995, AM J CARDIOL, V75, pA3, DOI 10.1016/S0002-9149(99)80377-4; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; WONG SKF, 1994, J BIOL CHEM, V269, P18968	42	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33698	33704		10.1074/jbc.271.52.33698	http://dx.doi.org/10.1074/jbc.271.52.33698			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969241	hybrid			2022-12-25	WOS:A1996WA71300075
J	DeTure, MA; Zhang, EY; Bubb, MR; Purich, DL				DeTure, MA; Zhang, EY; Bubb, MR; Purich, DL			In vitro polymerization of embryonic MAP-2c and fragments of the MAP-2 microtubule binding region into structures resembling paired helical filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER NEUROFIBRILLARY TANGLES; PROTEIN-TAU; QUICK-FREEZE; DISEASE; NEUROFILAMENTS; EXPRESSION; MECHANISM; PEPTIDES; SEQUENCE; EPITOPES	The microtubule-associated protein Tau is widely regarded as the principal component of paired helical filaments comprising Alzheimer neurofibrillary tangles. Tau fragments containing the non identical repeat region formed structures resembling paired helical filaments (Schweers, O., Mandelkow, M., Biernat, J., and Mandelkom, E. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8463-8467). MAP-5, the other structurally related neuronal microtubule-associated protein, has not been implicated in paired helical filament formation. We now describe the assembly of paired helical filament-like structures from MAP-S polypeptides containing only 100 residues. A dimeric species, stabilized by an interchain disulfide, appears to be involved in the assembly reaction. We also investigated the polymerization of embryonic MAP-2c, which, except for its microtubule binding region, is structurally distinct from Tau. Full-length MAP-2c formed paired helical filament-like polymers. Polymerized MAP-2c and the microtubule binding region fragment readily bound thioflavin-S, a dye that stains paired helical filaments in the histochemical diagnosis of Alzheimer's disease. Our unprecedented finding that a small MAP-2 microtubule binding region fragment and MAP-2c can form structures resembling straight filaments or Pronase-treated paired helical filaments raises fundamental questions concerning the role of MAP-2 in the pathobiology of Alzheimer disease.	UNIV FLORIDA,COLL MED,HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,HLTH SCI CTR,DEPT MED,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida								AINSZTEIN AM, 1994, J BIOL CHEM, V269, P28465; ANDERTON BH, 1993, HIPPOCAMPUS, V3, P227; BUBB MR, 1991, J BIOL CHEM, V266, P3820; COFFEY RL, 1994, BIOCHEMISTRY-US, V33, P13199, DOI 10.1021/bi00249a006; CROWTHER RA, 1994, FEBS LETT, V337, P135, DOI 10.1016/0014-5793(94)80260-2; DAMMERMAN M, 1989, J NEUROSCI RES, V24, P487, DOI 10.1002/jnr.490240405; DINGUS J, 1991, J BIOL CHEM, V266, P18854; ENNULAT DJ, 1989, J BIOL CHEM, V264, P5327; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; JOLY JC, 1990, BIOCHEMISTRY-US, V29, P8916, DOI 10.1021/bi00490a006; JOLY JC, 1989, J CELL BIOL, V109, P2289, DOI 10.1083/jcb.109.5.2289; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; KOSIK KS, 1984, P NATL ACAD SCI-BIOL, V81, P7941, DOI 10.1073/pnas.81.24.7941; LETERRIER JF, 1982, J CELL BIOL, V95, P982, DOI 10.1083/jcb.95.3.982; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; NUKINA N, 1983, P JPN ACAD B-PHYS, V59, P284, DOI 10.2183/pjab.59.284; Purich D L, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P121; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; TERRY RD, 1963, J NEUROPATH EXP NEUR, V22, P629, DOI 10.1097/00005072-196310000-00005; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; VALLEE RB, 1977, J BIOL CHEM, V252, P377; WILLE H, 1992, J BIOL CHEM, V267, P10737; WILSON DM, 1995, J BIOL CHEM, V270, P24306, DOI 10.1074/jbc.270.41.24306; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WISNIEWSKI HM, 1976, J NEUROL SCI, V27, P173, DOI 10.1016/0022-510X(76)90059-9; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32702	32706		10.1074/jbc.271.51.32702	http://dx.doi.org/10.1074/jbc.271.51.32702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955102	hybrid			2022-12-25	WOS:A1996VZ37300037
J	Hu, X; Srivastava, SK; Xia, H; Awasthi, YC; Singh, SV				Hu, X; Srivastava, SK; Xia, H; Awasthi, YC; Singh, SV			An alpha class mouse glutathione S-transferase with exceptional catalytic efficiency in the conjugation of glutathione with 7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIASTEREOMERIC BENZO<A>PYRENE 7,8-DIOL-9,10-EPOXIDES; OPTICAL ENANTIOMERS; RAT-LIVER; EPOXIDE HYDRASE; ACTIVATION; BENZO(A)PYRENE; METABOLISM; BINDING	The kinetics of the conjugation of glutathione (GSH) with anti-7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-oxy-7,8,9,10- tetrahydrobenzo(a)pyrene (anti-BPDE) catalyzed by GSH S-transferase (GST) isoenzymes purified from the liver and forestomach of female A/J mouse has been investigated. The GST isoenzymes studied included an alpha class isoenzyme of forestomach (GST 9.5), alpha class hepatic isoenzymes mGSTA3-3 and mGSTA4-4, pi class hepatic isoenzyme mGSTP1-1, and mu class hepatic isoenzyme mGSTM1-1. When the concentration of (+)-anti-BPDE was varied (5-120 mu m) at a fixed GSH concentration (2 mM), linear Lineweaver-Burk plots were observed for each isoenzyme. The k(cat) values for GST 9.5, mGSTA3-3, mGSTP1-1, and mGSTA4-4 were 2.0, 0.02, 0.40, 0.05, and 0.01 s(-1), respectively, with corresponding K-m values of 16, 12, 29, 27, and 49 mu m. The catalytic efficiency (k(cat)/K-m) of GST 9.5 in the conjugation of GSH with (+)-anti-BPDE, which is believed to be the ultimate carcinogenic metabolite of benzo(a)pyrene, was about 9-625-fold higher as compared with other mouse GST isoenzymes. These results indicate that GST 9.5 of forestomach is different among mammalian alpha class GSTs because (+)-anti-BPDE has been shown to be a poor substrate for alpha class rate or human GST isoenzymes. The catalytic efficiency of GST 9.5 was approximately 4.5-fold higher than that of pi class human isoenzyme (hGSTP1-1), which among human GSTs is reported to be most efficient in the detoxification of (+)-anti-BPDE. Unlike rat GST isoenzymes, linear Lineweaver-Burk plots were observed for mouse GSTs when GSH was used as a variable substrate. The catalytic efficiencies of the mouse GSTs toward (+)-anti-BPDE were about 2-20-fold higher as compared with the (-)-enantiomer of anti-BPDE. The results of the present study suggest that GST 9.5 may play an important role in the detoxification of (+)-anti-BPDE.	MERCY HOSP,MERCY CANC INST,CANC RES LAB,PITTSBURGH,PA 15219; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Medical Branch Galveston					NCI NIH HHS [R01 CA 27967, R01 CA 55589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055589, R01CA027967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENSON AM, 1978, CANCER RES, V38, P4486; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUENING MK, 1978, P NATL ACAD SCI USA, V75, P5358, DOI 10.1073/pnas.75.11.5358; COOK JW, 1933, J CHEM SOC, V1, P395; COOPER CS, 1983, PROG DRUG METAB, V7, P295; DANIELSON UH, 1985, BIOCHEM J, V231, P263, DOI 10.1042/bj2310263; DOCK L, 1986, CHEM-BIOL INTERACT, V58, P301, DOI 10.1016/S0009-2797(86)80105-3; Dragsted L O, 1993, Pharmacol Toxicol, V72 Suppl 1, P116, DOI 10.1111/j.1600-0773.1993.tb01679.x; DUBOIS GC, 1978, J BIOL CHEM, V253, P2932; GELBOIN HV, 1980, PHYSIOL REV, V60, P1107, DOI 10.1152/physrev.1980.60.4.1107; GOZUKARA EM, 1980, MOL PHARMACOL, V19, P153; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARVEY RG, 1989, CONFORMATIONAL ANAL, P269; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HESSE S, 1980, BIOCHEM BIOPH RES CO, V94, P612, DOI 10.1016/0006-291X(80)91276-0; *INT AG CANC RES, 1973, IARC MON EV CARC RIS, V3; JERNSTROM B, 1985, CARCINOGENESIS, V6, P85, DOI 10.1093/carcin/6.1.85; Jernstrom B, 1996, CARCINOGENESIS, V17, P1491, DOI 10.1093/carcin/17.7.1491; LISTOWSKY I, 1988, DRUG METAB REV, V19, P305, DOI 10.3109/03602538808994138; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; ROBERTSON IGC, 1986, CARCINOGENESIS, V7, P295; ROBERTSON IGC, 1986, CANCER RES, V46, P2220; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; Sims P, 1974, Adv Cancer Res, V20, P165, DOI 10.1016/S0065-230X(08)60111-6; SLAGA TJ, 1979, CANCER RES, V39, P67; THAKKER DR, 1977, J BIOL CHEM, V252, P6328; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; WEINSTEIN IB, 1978, POLYCYCLIC HYDROCARB, P4; WOOD AW, 1978, CANCER RES, V38, P1967; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V77, P1389, DOI 10.1016/S0006-291X(77)80133-2; WOOD AW, 1977, BIOCHEM BIOPH RES CO, V78, P847, DOI 10.1016/0006-291X(77)90500-9; YANG SK, 1976, CANCER RES, V36, P4185; ZIMNIAK P, 1994, J BIOL CHEM, V269, P992; [No title captured]	36	56	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32684	32688		10.1074/jbc.271.51.32684	http://dx.doi.org/10.1074/jbc.271.51.32684			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955099	hybrid			2022-12-25	WOS:A1996VZ37300034
J	Krause, E; Pfeiffer, F; Schmid, A; Schulz, I				Krause, E; Pfeiffer, F; Schmid, A; Schulz, I			Depletion of intracellular calcium stores activates a calcium conducting nonselective cation current in mouse pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE INHIBITORS; CAPACITATIVE CA2+ INFLUX; MAST-CELLS; PLASMA-MEMBRANE; CHANNELS; ENTRY; THAPSIGARGIN; SECRETION; MECHANISM; MESSENGER	Receptor-mediated Ca2+ release from inositol (1,4,5)trisphosphate (IP3) sensitive Ca2+ stores causes ''capacitative calcium entry'' in many cell types (Putney, J, W,, Jr, (1986) Cell Calcium 7, 1-12; Putney, J. W,, Jr, (1990) Cell Calcium 11, 611-624), We used patch clamp and fluorescence techniques in isolated mouse pancreatic acinar cells to identify ion currents and cytosolic calcium concentrations under conditions in which intracellular Ca2+ stores were emptied, We found that depletion of Ca2+ stores activated a calcium-release-activated nonselective cation current (I-CRANC) which did not discriminate between monovalent cations. I-CRANC possessed a significant conductance for Ca2+ and Ba2+, It was not inhibited by La3+, Gd3+, Co2+, or Cd2+ but was completely abolished by flufenamic acid or genistein, In whole cell and cell-attached recordings, a 40-45 pS nonselective cation channel was identified which was activated by Ca2+ store depletion, Calcium entry as detected by single cell fluorescence measurements with fluo-3 or fura-2, showed the same pharmacological properties as I-CRANC. We conclude that in mouse pancreatic acinar cells 40-45 pS nonselective cation channels serve as a pathway for capacitative Ca2+ entry. This entry pathway differs from the previously described I-CRAC (Hoth, M,, and Penner, R. (1992) Nature 355, 353-356) in its ion-selectivity, pharmacological profile, and single-channel conductance.	UNIV SAARLAND,INST PHYSIOL 2,D-66421 HOMBURG,GERMANY	Saarland University				Krause, Elmar/0000-0003-0891-2373				BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; DUAN RG, 1994, AM J PHYSIOL, V266, pG303, DOI 10.1152/ajpgi.1994.266.2.G303; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; GOGELEIN H, 1990, FEBS LETT, V268, P79, DOI 10.1016/0014-5793(90)80977-Q; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LEE KM, 1993, J BIOL CHEM, V268, P9945; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MARUYAMA Y, 1982, NATURE, V299, P159, DOI 10.1038/299159a0; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; METZ DC, 1992, J BIOL CHEM, V267, P20620; NILIUS B, 1993, PFLUG ARCH EUR J PHY, V424, P285, DOI 10.1007/BF00384354; OCHS DL, 1983, BIOCHEM BIOPH RES CO, V117, P122, DOI 10.1016/0006-291X(83)91549-8; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; PETERSEN OH, 1983, SINGLE CHANNEL RECOR, P425; PFEIFFER F, 1995, PFLUG ARCH EUR J PHY, V430, P916, DOI 10.1007/BF01837405; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SCHMID A, 1995, J PHYSIOL-LONDON, V484, P661, DOI 10.1113/jphysiol.1995.sp020694; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TOESCUEC, 1995, J BIOL CHEM, V270, P6528; TSUNODA Y, 1990, AM J PHYSIOL, V259, pG792, DOI 10.1152/ajpgi.1990.259.5.G792; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; YULE DI, 1994, BIOCHEM BIOPH RES CO, V202, P1697, DOI 10.1006/bbrc.1994.2130; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	39	86	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32523	32528		10.1074/jbc.271.51.32523	http://dx.doi.org/10.1074/jbc.271.51.32523			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955076	hybrid			2022-12-25	WOS:A1996VZ37300011
J	Suh, BC; Song, SK; Kim, YK; Kim, KT				Suh, BC; Song, SK; Kim, YK; Kim, KT			Induction of cytosolic Ca2+ elevation mediated by Mas-7 occurs through membrane pore formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; GTP-BINDING PROTEINS; NEUROBLASTOMA SK-N-BE(2)C CELLS; FURA-2-LOADED HUMAN-PLATELETS; WASP VENOM MASTOPARAN; INOSITOL 1,4,5-TRISPHOSPHATE; CONDUCTANCE CHANNEL; GUANYLATE-CYCLASE; HL-60 MEMBRANES; PLASMA-MEMBRANE	Mas-7, a mastoparan derivative, induces elevation of intracellular free Ca2+ concentration ([Ca2+](i)) along two independent pathways. The minor contribution occurs via phospholipase C activation and is negatively regulated by treatment with phorbol 12-myristate 13-acetate, a protein kinase C activator. The major contribution involves plasma membrane pores allowing not only Ca2+, Mn2+, and Na+ to enter but also the uptake of ethidium bromide (314 Pa) and lucifer yellow (457 Da), but not fura-2 (831 Pa), Evans blue (961 Pa), and fluorescein-conjugate phalloidin (1,175 Da). Mas-7-induced current, as measured in planar lipid bilayers, reveals that Mas-7-induced pores have two slope conductances, 290 and 94 pS, and that the pores are nonselective for cations. The results also indicate that Mas-7 can produce pores by direct interaction with the plasma membrane without the involvement of membrane proteins and cytosolic factors. Besides in human neuroblastoma cells, similar Mas-7 effects were also observed in other cell lines such as HL-60, 1321N1 human astrocytoma, and bovine chromaffin cells. The data suggest that the Mas 7-induced [Ca2+](i) elevation is the combined result of Ca2+ release from stores via phosphoinositide turnover and prolonged Ca2+ influx through membrane pores.	POHANG UNIV SCI & TECHNOL, DEPT LIFE SCI, POHANG 790784, SOUTH KOREA; POHANG UNIV SCI & TECHNOL, BASIC SCI RES INST, POHANG 790784, SOUTH KOREA; CHUNGBUK NATL UNIV, DEPT AGR CHEM, CHEONGJU 361763, SOUTH KOREA	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Chungbuk National University				KIM, KYONG-TAI/0000-0001-7292-2627				ARGIOLAS A, 1983, J BIOL CHEM, V258, P3697; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUEB JL, 1990, MOL PHARMACOL, V38, P816; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Chuang CC, 1996, BBA-PROTEIN STRUCT M, V1292, P1, DOI 10.1016/0167-4838(95)00168-9; CHUEH SH, 1994, MOL PHARMACOL, V45, P532; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; DANILENKO M, 1993, BIOCHEM BIOPH RES CO, V196, P1296, DOI 10.1006/bbrc.1993.2393; DENKER BM, 1991, BIOCHEM J, V278, P341, DOI 10.1042/bj2780341; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DOWNES CP, 1986, BIOCHEM J, V238, P501, DOI 10.1042/bj2380501; EDDLESTONE GT, 1995, MOL PHARMACOL, V47, P787; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; GORDON LGM, 1972, BIOCHIM BIOPHYS ACTA, V255, P1014, DOI 10.1016/0005-2736(72)90415-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIGASHIJIMA T, 1983, FEBS LETT, V152, P227, DOI 10.1016/0014-5793(83)80385-8; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KARIMI K, 1995, J IMMUNOL, V155, P5786; KATSU T, 1990, BIOCHIM BIOPHYS ACTA, V1027, P185, DOI 10.1016/0005-2736(90)90083-Z; KHURANA ML, 1995, ARCH BIOCHEM BIOPHYS, V316, P392, DOI 10.1006/abbi.1995.1052; KIKKAWA S, 1992, FEBS LETT, V305, P237, DOI 10.1016/0014-5793(92)80676-8; KILPATRICK DL, 1980, J NEUROCHEM, V35, P679, DOI 10.1111/j.1471-4159.1980.tb03707.x; KIM YK, 1992, BIOPHYS J, V63, P1379, DOI 10.1016/S0006-3495(92)81702-2; KLINKER JF, 1994, BIOCHEM J, V304, P377, DOI 10.1042/bj3040377; KLINKER JF, 1995, BIOCHEM BIOPH RES CO, V209, P575, DOI 10.1006/bbrc.1995.1539; KOCH G, 1991, FEBS LETT, V291, P336, DOI 10.1016/0014-5793(91)81315-Y; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEGENDRE L, 1993, J BIOL CHEM, V268, P24559; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; MATSUZAKI K, 1989, BIOCHIM BIOPHYS ACTA, V981, P130, DOI 10.1016/0005-2736(89)90090-4; MEISSNER G, 1986, J BIOL CHEM, V261, P6300; MINTA A, 1989, J BIOL CHEM, V264, P19449; MOUSLI M, 1989, J PHARMACOL EXP THER, V250, P329; MULLER RU, 1972, J GEN PHYSIOL, V60, P263, DOI 10.1085/jgp.60.3.263; Murga C, 1996, J BIOL CHEM, V271, P985, DOI 10.1074/jbc.271.2.985; NORGAUER J, 1992, BIOCHEM J, V282, P393, DOI 10.1042/bj2820393; OKANO Y, 1985, FEBS LETT, V188, P363, DOI 10.1016/0014-5793(85)80403-8; OZAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P779, DOI 10.1016/0006-291X(90)92159-W; PERIANIN A, 1989, J IMMUNOL, V143, P1669; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; RAYNOR RL, 1992, FEBS LETT, V307, P275, DOI 10.1016/0014-5793(92)80694-C; RAYNOR RL, 1991, J BIOL CHEM, V266, P2753; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SONG DL, 1993, EUR J PHARM-MOLEC PH, V247, P283; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SUH BC, 1995, J NEUROCHEM, V65, P2124; SUH BC, 1995, J NEUROCHEM, V64, P2500; TANIMURA A, 1991, BIOCHEM BIOPH RES CO, V177, P802, DOI 10.1016/0006-291X(91)91860-F; TOHKIN M, 1990, FEBS LETT, V260, P179, DOI 10.1016/0014-5793(90)80098-4; TOMITA U, 1991, J BIOCHEM-TOKYO, V109, P184, DOI 10.1093/oxfordjournals.jbchem.a123342; TOSTESON MT, 1989, P NATL ACAD SCI USA, V86, P707, DOI 10.1073/pnas.86.2.707; VITALE N, 1993, J BIOL CHEM, V268, P14715; WAKAMATSU K, 1983, FEBS LETT, V162, P123, DOI 10.1016/0014-5793(83)81062-X; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WOJCIKIEWICZ RJH, 1989, FEBS LETT, V247, P341, DOI 10.1016/0014-5793(89)81366-3; YOKOKAWA N, 1989, BIOCHEM BIOPH RES CO, V158, P712, DOI 10.1016/0006-291X(89)92779-4	60	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32753	32759		10.1074/jbc.271.51.32753	http://dx.doi.org/10.1074/jbc.271.51.32753			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955110	hybrid			2022-12-25	WOS:A1996VZ37300045
J	Zollner, O; Vestweber, D				Zollner, O; Vestweber, D			The E-selectin ligand-1 is selectively activated in Chinese hamster ovary cells by the alpha(1,3)-fucosyltransferases IV and VII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; P-SELECTIN; GLYCOPROTEIN LIGAND; MOLECULAR-CLONING; MYELOID CELLS; T-CELLS; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; DIFFERENTIAL EXPRESSION; DETERMINES EXPRESSION	The E-selectin ligand-1 (ESL-1) has recently been identified as the major ligand on mouse neutrophils using a recombinant antibody-like form of E-selectin as affinity probe, The remarkable selectivity with which ESL-1 can be affinity-isolated is unexplained, Since ESL-1 is endogenously expressed in Chinese hamster ovary (CHO) cells in a non-E-selectin binding form, which can become activated upon transfection of a fucosyltransferase (FucT), we analyzed various CHO cell clones, each overexpressing one of seven different fucosyltransferases, by affinity isolation experiments with E-selectin-IgG, Two of the cell lines mere the regulatory CHO mutants LEC11 and LEC12, each overexpressing a different hamster FucT, while the five other clones were stably transfected with human FucTIII to -VII. A large panel of glycoproteins was affinity-isolated with E-selectin-IgG from LEC11 cells and FucTIII transfectants, demonstrating that many different glycoproteins can acquire ligand activity upon alpha(1,3)-fucosylation. In contrast, ESL-1 was almost exclusively isolated as the dominant glycoprotein ligand from LEC12 cells as well as from FucTIV and FucTVII transfectants and less selectively from FucTV and FucTVI transfectants. The selective generation of ligand activity correlated with the selective generation of the HECA452-reactive carbohydrate epitope, which is known to bind to E-selectin, These data suggest that, dependent on the type of fucosyltransferase, ESL-1 is a strongly preferred target molecule for the generation of E-selectin-binding carbohydrate modifications.	UNIV MUNSTER,INST CELL BIOL,ZMBE,D-48149 MUNSTER,GERMANY	University of Munster				Vestweber, Dietmar/0000-0002-3517-732X				ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; BERG EL, 1991, J BIOL CHEM, V266, P14869; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; CAMPBELL C, 1983, CELL, V35, P303, DOI 10.1016/0092-8674(83)90233-7; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; FUCUSHIMA K, 1984, CANCER RES, V44, P5279; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; HOWARD DR, 1987, J BIOL CHEM, V262, P16830; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MCEVER RP, 1994, CURR OPIN IMMUNOL, V6, P75, DOI 10.1016/0952-7915(94)90037-X; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STANLEY P, 1988, J BIOL CHEM, V263, P11374; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALCHECK B, 1993, J EXP MED, V178, P853, DOI 10.1084/jem.178.3.853; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; YAGO K, 1993, CANCER RES, V53, P5559	41	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33002	33008		10.1074/jbc.271.51.33002	http://dx.doi.org/10.1074/jbc.271.51.33002			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955145	hybrid			2022-12-25	WOS:A1996VZ37300080
J	Aprelikova, O; Kuthiala, A; Bessho, M; Ethier, S; Liu, ET				Aprelikova, O; Kuthiala, A; Bessho, M; Ethier, S; Liu, ET			BRCA1 protein level is not affected by peptide growth factors in MCF1OA cell line	ONCOGENE			English	Article						breast cancer; BRCA1 protein; cell cycle; EGF; NDF	OVARIAN-CANCER; BREAST-CANCER; MUTATIONS; FAMILIES; GENE; LOCALIZATION; EXPRESSION	The breast cancer susceptibility gene (BRCA1) has been identified as a putative tumor suppressor on chromosome 17. We raised antibody against Ring-finger domain of BRCA1, The antibody recognizes a specific BRCA1 protein doublet of about 220 kD, The majority of BRCA1 protein is localized to the nuclear fraction of untreated MCF10A cells. Though BRCA1 is thought to be a growth suppressor gene, no change in BRCA1 protein level was found when MCF10A cells were arrested by growth factor deprivation or stimulation of cell proliferation by re-addition of growth factors, Furthermore the subcellular localization of the BRCA1 protein does not change throughout the cell cycle, These results suggest that BRCA1 may not be directly involved in the regulation of the cell cycle of breast cancer cell line.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT MED,CURRICULUM GENET & MOL BIOL,CHAPEL HILL,NC 27599; UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,DIV RADIAT & CANC BIOL,ANN ARBOR,MI 48109	University of North Carolina; University of North Carolina Chapel Hill; University of Michigan System; University of Michigan			Liu, Edison/C-4141-2008					CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; ETHIER SP, 1991, CELL GROWTH DIFFER, V2, P593; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GUDAS JM, 1995, CANCER RES, V55, P4561; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P444; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	17	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2487	2491						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957093				2022-12-25	WOS:A1996VX10800024
J	Florenes, VA; Bhattacharya, N; Bani, MR; BenDavid, Y; Kerbel, RS; Slingerland, JM				Florenes, VA; Bhattacharya, N; Bani, MR; BenDavid, Y; Kerbel, RS; Slingerland, JM			TGF-beta mediated G(1) arrest in a human melanoma cell line lacking p15(INK4B): Evidence for cooperation between p21(Cip1/WAF1) and p27	ONCOGENE			English	Article						G(1) arrest; TGF-beta; p15(INK4B)-negative; p27(Kip1); p21(Cip1/WAF1); melanoma	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA GENE-PRODUCT; CYCLE ARREST; CDK INHIBITOR; DNA-REPLICATION; MAMMALIAN-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; EPITHELIAL-CELLS; PROTEIN	We have studied TGF-beta mediated G(1) arrest in WM35, an early stage human melanoma cell line. These cells have lost p15(INK4B) expression through loss of one chromosome 9 and rearrangement of the other. In asynchronously growing WM35, TGF-beta caused reductions in cyclin D1, cyclin A and cdk4 proteins and their associated kinase activities and an increase in both p21(Cip1/WAF1) and p27(Kip1). These findings were confirmed in cells released from quiescence in the presence of TGF-beta, in which TGF-beta inhibited or delayed the reduction in the cdk inhibitors that normally occurs in late G(1). In contrast to observations in other cell types, there was an increased association of both p21(Cip1/WAF1) and p27(Kip1) with cyclin D1/cdk4 and with cyclin E/cdk2 during TGF-beta mediated arrest of asynchronously growing cells. Upregulation of p21(Cip1/WAF1) preceded that of p27(Kip1). Furthermore, p21(Cip1/WAF1) and p27(Kip1) were not present in the same cdk complexes but bound distinct populations of target cdk molecules. Both p21(Cip1/WAF1) and p27(Kip1) immunoprecipitates from asynchronously growing cells contained active kinase complexes. These KIP-associated kinase activities were reduced in TGF-beta arrested cells. It has been proposed that in TGF-beta arrested epithelial cells, up-regulation of p15(INK4B) and of p15(INK4B) binding to cdk4 serves to destabilize the association of p27(Kip1) with cyclin D1/cdk4, promoting p27(Kip1) binding and inhibition of cyclin E/cdk2. Our findings demonstrate that this is not a universal mechanism of G(1) arrest by TGF-beta, In TGF-beta arrested WM35, which lack p15(INK4B), the increased p21(Cip1/WAF1) may serve a similar function to that of p15(INK4B): initiating kinase inhibition and providing an additional mechanism to supplement the effect of p27(Kip1) on G(1) cyclin/cdks.	UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED BIOPHYS, DIV CANC BIOL, TORONTO, ON M4N 3M5, CANADA; UNIV TORONTO, SUNNYBROOK HLTH SCI CTR, DEPT MED, TORONTO, ON M4N 3M5, CANADA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center					NCI NIH HHS [CA41233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041233] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; Bani MR, 1996, CANCER RES, V56, P3075; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CORNIL I, 1991, P NATL ACAD SCI USA, V88, P6028, DOI 10.1073/pnas.88.14.6028; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; Enders GH, 1996, ONCOGENE, V12, P1239; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jiang HP, 1996, MOL CELL DIFFER, V4, P67; JIANG HP, 1995, ONCOGENE, V10, P1855; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAMER IM, 1994, J CELL SCI, V107, P3469; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIU L, 1995, ONCOGENE, V11, P405; LIU L, 1995, UNPUB ONCOGENE; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MacDougall John R., 1993, Molecular and Cellular Differentiation, V1, P21; MAELANDSMO GM, IN PRESS AM J PATHOL; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEI WQ, 1996, CANCER RES, V56, P264; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOSES HL, 1992, MOL REPROD DEV, V32, P179, DOI 10.1002/mrd.1080320215; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; Petrocelli T, 1996, ONCOGENE, V12, P1387; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REED SI, 1994, J CELL SCI, P69; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; RODECK U, 1994, CANCER RES, V54, P575; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SLINGERLAND J, 1996, UNPUB; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Welch DR, 1996, MOL CELL DIFFER, V4, P91; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	80	84	88	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2447	2457						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957087				2022-12-25	WOS:A1996VX10800018
J	Hardiman, G; Rock, FL; Balasubramanian, S; Kastelein, RA; Bazan, JF				Hardiman, G; Rock, FL; Balasubramanian, S; Kastelein, RA; Bazan, JF			Molecular characterization and modular analysis of human MyD88	ONCOGENE			English	Article						MyD88; death domain; dendritic cells; interleukin-1 receptor; Toll; cloning	PROTEIN SECONDARY STRUCTURE; MESSENGER-RNA DEGRADATION; IMMEDIATE EARLY RESPONSE; DROSOPHILA TOLL PROTEIN; FACTOR TNF RECEPTOR; RESISTANCE GENE-N; DEATH DOMAIN; SIGNAL-TRANSDUCTION; CELL-DEATH; TERMINAL DIFFERENTIATION	MyD88 was first characterized as a myeloid differentiation primary response gene in mice, activated in M1 myeloleukemic cells following interleukin-6 (IL-6) induced growth arrest and terminal differentiation. Analysis of expressed sequence tags (ESTs) from activated dendritic cell libraries led to the indentification of cDNAs encoding the human homolog (hMyD88). The original description of MyD88 as a 243 aa protein may reflect a truncated mouse cDNA since the 2682 nt hMyD88 cDNA predicts a 296 aa cytoplasmic protein. Consistent with this proposal is the detection of a 33 kDa protein in human heart, kidney and liver tissue. The expression pattern of MyD88 is also more widespread than originally believed: a 2.6 kb hMyD88 mRNA species was found to be constitutively expressed in many adult human tissues; in addition MyD88 expression was observed in monocyte, T, B, NK and dendritic cells. The MyD88 protein has a modular structure composed of an N-terminal 'death domain' (DD) similar to the intracellular segments of TNF receptor 1 (TNFR1) and FAS and a C-terminal region related to the signaling domains of vertebrate interleukin-1 receptors (IL-1R) and the Drosophila morphogen Toll. This intriguing structural framework may endow MyD88 with unique signaling capabilities	DNAX RES INST MOL & CELLULAR BIOL INC,DEPT MOL BIOL,PALO ALTO,CA 94304	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Bazan, J. Fernando/B-4562-2010	Hardiman, Gary/0000-0003-4558-0400				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BARKER PA, 1994, J BIOL CHEM, V269, P30645; Bazan JF, 1996, PROTEINS, V24, P1; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; BROOKS JW, 1994, EUR CYTOKINE NETW, V5, P547; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CAOPONE MC, 1996, J IMMUNOL, V157, P969; CAUX C, 1995, J IMMUNOL, V155, P5427; CAUX C, 1995, IMMUNOL TODAY, V16, P2, DOI 10.1016/0167-5699(95)80061-1; CHIANG C, 1994, MECH DEVELOP, V47, P225; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; ELDON E, 1994, DEVELOPMENT, V120, P885; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HEGUY A, 1992, J BIOL CHEM, V267, P2605; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; HULTMARK D, 1994, BIOCHEM BIOPH RES CO, V199, P144, DOI 10.1006/bbrc.1994.1206; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ITOH N, 1993, J BIOL CHEM, V268, P10932; KEITH FJ, 1990, EMBO J, V9, P4299, DOI 10.1002/j.1460-2075.1990.tb07878.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LOVENBERG TL, 1996, IN PRESS J NEUROIMMU; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; Parnet P, 1996, J BIOL CHEM, V271, P3967; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAMBROOK J, 1909, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; STINGL G, 1995, IMMUNOL TODAY, V16, P330, DOI 10.1016/0167-5699(95)80148-0; STJOHNSTON D, 1992, CELL, V68, P201; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torcia M, 1996, CELL, V85, P345, DOI 10.1016/S0092-8674(00)81113-7; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; YAMAGATA M, 1994, GENE, V139, P223, DOI 10.1016/0378-1119(94)90760-9	63	98	109	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2467	2475						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957090				2022-12-25	WOS:A1996VX10800021
J	Shu, JY; Hitomi, M; Stacey, D				Shu, JY; Hitomi, M; Stacey, D			Activation of JNK/SAPK pathway is not directly inhibitory for cell cycle progression in NIH3T3 cells	ONCOGENE			English	Article						JNK; SAPK; kinase; cell cycle; growth inhibition; c-jun	NERVE GROWTH-FACTOR; PROTEIN-KINASE ACTIVATION; SIGNAL-TRANSDUCTION PATHWAYS; DNA-DAMAGING AGENTS; C-JUN; TYROSINE KINASE; PC12 CELLS; TRANSCRIPTION FACTOR; RAS ACTIVITY; MITOGEN	In this study the induction of stress activated protein kinase (SAPK) activity by protein synthesis inhibitors was shown not to inhibit cellular proliferation. Anisomycin induced strong SAPK activity at non-inhibitory concentrations for either protein or DNA synthesis, while the other two inhibitors, emetine and cycloheximide, blocked cell cycle progression without strong SAPK induction. With all three inhibitors, the induction of SAPK activity was always accompanied by protein synthesis inhibition to some extent. Stimulation of mRNA expression of the genes c-jun, c-fos and c-myc correlated well with SAPK induction, but not with cell cycle inhibition. With concentrations of each inhibitor able to block DNA synthesis, no induction of message for the cyclin dependent kinase inhibitor waf-1 was observed;,while induction of gadd45 message indicated that the cells might be responding to growth-arrest or DNA damage. The inability of microinjected E2F/DP1 transcription factor proteins to overcome the inhibition of DNA synthesis induced by protein synthesis inhibitors indicate that blockage of an early event in cell cycle progression had occurred. These results indicate that the SAPK induction by protein synthesis inhibitors has no proliferative consequences.	CLEVELAND CLIN FDN,RES INST,DEPT MOL BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation					NCI NIH HHS [CA53496] Funding Source: Medline; NIGMS NIH HHS [GM52271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; BIRD TA, 1994, J BIOL CHEM, V269, P31836; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; Cano E, 1996, ONCOGENE, V12, P805; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CONRAD KE, 1994, MOL CELL BIOL, V14, P1553, DOI 10.1128/MCB.14.3.1553; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREUZET C, 1995, J NEUROCHEM, V64, P1541; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Franklin CC, 1995, ONCOGENE, V11, P2365; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Graves LM, 1996, J BIOL CHEM, V271, P505, DOI 10.1074/jbc.271.1.505; HARPER JW, 1993, CELL, V75, P805; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; Hitomi M, 1996, J BIOL CHEM, V271, P9376, DOI 10.1074/jbc.271.16.9376; HOWE PH, 1993, J BIOL CHEM, V268, P21448; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KRACHT M, 1994, J EXP MED, V180, P2017, DOI 10.1084/jem.180.6.2017; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; KYRIAKIS JM, 1991, J BIOL CHEM, V266, P10043; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LUBINUS M, 1994, J BIOL CHEM, V269, P9822; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHU JY, 1994, CELL IMMUNOL, V159, P170, DOI 10.1006/cimm.1994.1305; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; YAN MH, 1994, NATURE, V372, P798; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHENG CF, 1993, J BIOL CHEM, V268, P23933; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	74	25	25	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2421	2430						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957084				2022-12-25	WOS:A1996VX10800015
J	Li, RX; Ladisch, S				Li, RX; Ladisch, S			Inhibition of endogenous ganglioside synthesis does not block neurite formation by retinoic acid-treated neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; GLYCOLIPID SYNTHESIS; INDUCED DIFFERENTIATION; DEVELOPMENTAL-CHANGES; SERIES GANGLIOSIDES; CERAMIDE ANALOG; LEUKEMIA-CELLS; BLASTOMA CELLS; NEURO-2A CELLS	Gangliosides are believed to play a critical role in cellular differentiation. To test this concept, we determined the effect of inhibition of endogenous ganglioside synthesis upon neurite formation induced by retinoic acid in LAN-B human neuroblastoma cells. Ganglioside synthesis and content of LAN-B cells exposed for 6 days to 10 mu M D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP) (an inhibitor of glucosylceramide synthase) were reduced by >90%. However, these ganglioside depleted cells were not blocked from forming neurites when exposed to 10 mu M retinoic acid. Even more extensive treatment of LAN-5 cells with 20 mu M D-PDMP (6 day pretreatment followed by 6 days together with 10 mu M retinoic acid) still did not block the retinoic acid induced neurite formation. An element of neuroblastoma tumor cell differentiation, neurite formation, is therefore dependent neither on an intact cellular ganglioside complement nor on new ganglioside synthesis.	CHILDRENS RES INST,CTR CANC TRANSPLANTAT BIOL,GLYCOBIOL PROGRAM,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT PEDIAT & BIOCHEM,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,SCH MED,DEPT MOL BIOL,WASHINGTON,DC 20010	George Washington University; George Washington University					NATIONAL CANCER INSTITUTE [R01CA042361, R01CA061010] Funding Source: NIH RePORTER; NCI NIH HHS [CA61010, CA42361] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIGA T, 1995, BIOCHEMISTRY-US, V34, P11500, DOI 10.1021/bi00036a024; CAMPBELL XZ, 1995, J NEUROSCI RES, V42, P207, DOI 10.1002/jnr.490420208; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; DAHMS NM, 1983, J NEUROSCI, V3, P806; DREYFUS H, 1980, NEUROSCIENCE, V5, P1647, DOI 10.1016/0306-4522(80)90028-7; DREYFUS H, 1975, J NEUROCHEM, V25, P245, DOI 10.1111/j.1471-4159.1975.tb06960.x; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FACCI L, 1984, J NEUROCHEM, V42, P299, DOI 10.1111/j.1471-4159.1984.tb02678.x; FENDERSON BA, 1992, EXP CELL RES, V198, P362, DOI 10.1016/0014-4827(92)90392-L; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HAN GY, 1995, DIFFERENTIATION, V59, P61, DOI 10.1046/j.1432-0436.1995.5910061.x; INOKUCHI J, 1995, J BIOCHEM-TOKYO, V117, P766, DOI 10.1093/oxfordjournals.jbchem.a124774; INOKUCHI JI, 1987, J LIPID RES, V28, P565; IRWIN LN, 1979, DEV NEUROSCI-BASEL, V2, P129, DOI 10.1159/000112447; KAN CC, 1992, J BIOL CHEM, V267, P9663; KANNAGI R, 1983, P NATL ACAD SCI-BIOL, V80, P2844, DOI 10.1073/pnas.80.10.2844; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; LADISCH S, 1985, ANAL BIOCHEM, V146, P220, DOI 10.1016/0003-2697(85)90419-1; LEDEEN RW, 1982, METHOD ENZYMOL, V83, P139; LEDEEN RW, 1984, J NEUROSCI RES, V12, P147, DOI 10.1002/jnr.490120204; LEON A, 1982, DEV NEUROSCI-BASEL, V5, P108, DOI 10.1159/000112666; LI RX, 1992, J NEUROCHEM, V59, P2297; LI RX, 1991, BIOCHIM BIOPHYS ACTA, V1083, P57, DOI 10.1016/0005-2760(91)90124-Z; MOSKAL JR, 1987, CANCER RES, V47, P787; MOSKAL JR, 1980, CELL SURFACE GLYCOLI, P241; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NAGAI Y, 1995, BEHAV BRAIN RES, V66, P99, DOI 10.1016/0166-4328(94)00130-8; NOJIRI H, 1986, P NATL ACAD SCI USA, V83, P782, DOI 10.1073/pnas.83.3.782; NOJIRI H, 1988, J BIOL CHEM, V263, P7443; OGISO M, 1991, NEUROSCIENCE, V41, P167, DOI 10.1016/0306-4522(91)90207-5; RABIN SJ, 1995, J NEUROCHEM, V65, P347; RADIN NS, 1993, ADV LIPID RES, V26, P183; ROBSON JA, 1985, NEUROSCIENCE, V14, P1149, DOI 10.1016/0306-4522(85)90284-2; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SIDELL N, 1983, MODULATION MEDIATION, P228; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; TETTAMANTI G, 1994, PROG BRAIN RES, V101, P77; TSUJI S, 1985, J BIOCHEM-TOKYO, V97, P969, DOI 10.1093/oxfordjournals.jbchem.a135140; WALTON KM, 1989, J NEUROCHEM, V52, P1537, DOI 10.1111/j.1471-4159.1989.tb09205.x; WU GS, 1994, MOL CHEM NEUROPATHOL, V21, P259, DOI 10.1007/BF02815354; WU GS, 1990, J NEUROCHEM, V55, P484, DOI 10.1111/j.1471-4159.1990.tb04161.x; WU GS, 1995, J NEUROSCI, V15, P3739; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670	47	30	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1349	1354		10.1074/jbc.272.2.1349	http://dx.doi.org/10.1074/jbc.272.2.1349			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995443	hybrid			2022-12-25	WOS:A1997WC04800094
J	Sweet, MT; Carlson, G; Cook, RG; Nelson, D; Allis, CD				Sweet, MT; Carlson, G; Cook, RG; Nelson, D; Allis, CD			Phosphorylation of linker histones by a protein kinase A-like activity in mitotic nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOME CONDENSATION; CYCLIC-AMP; TETRAHYMENA-THERMOPHILA; CHROMATIN CONDENSATION; SUBSTRATE-SPECIFICITY; P34CDC2 KINASE; CELLS; H1; PURIFICATION; MICRONUCLEI	Micronuclear linker histones of the ciliated protozoan, Tetrahymena thermophila, are extensively phosphorylated in vivo. Each of these polypeptides, alpha, beta, gamma, and delta, contains sites for phosphorylation by cyclic-AMP dependent protein kinase (PKA) but not Cdc2 kinase, and some data have been presented implicating PKA kinase in their phosphorylation in vitro and in vivo (Sweet, M. T., and Allis, C. D. (1993) Chromosoma 102, 637-647; Sweet, M. T., Jones, K., and Allis, C. D. (1996) J. Cell Biol., in press). In this report we have extended these analyses by showing that Cdc2 and PKA kinase are not evenly distributed between micro- and macronuclei. Macronuclei, but not micronuclei, contain a 36-kDa polypeptide that is immunoreactive with p34(Cdc2) antibodies. In contrast, a 40-kDa polypeptide is detected with PKA antibodies in micronuclei, that is not detected in macronuclei. In support, extracts from micronuclei, but not macronuclei, contain a kinase activity that resembles some, but not all, characteristics of PKA from other sources. Immunodepletion experiments using anti-PKA antibodies show that a 40-kDa polypeptide can be specifically removed from these extracts with a concomitant loss in kinase activity. Microsequence analyses of delta demonstrate that this linker histone is phosphorylated in vivo on two PKA consensus sequences located in its carboxyl-terminal domain, an optimum PKA consensus sequence, Arg-Lys-Asn-Ser, and a less optimal PKA sequence, Lys-Ser-Ser-Val. Collectively, these results suggest that PKA or a PKA-like kinase is responsible for the phosphorylation of linker histone in mitotically dividing micronuclei. In contrast, macronuclei, which divide amitotically, phosphorylate linker histone H1 using a distinct, Cdc2-like kinase.	UNIV ROCHESTER, DEPT BIOL, ROCHESTER, NY 14627 USA; SYRACUSE UNIV, DEPT BIOL, SYRACUSE, NY 13244 USA; UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA; BAYLOR COLL MED, DEPT MICROBIOL & IMMUNOL, HOUSTON, TX 77030 USA	University of Rochester; Syracuse University; University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine					NIGMS NIH HHS [GM 40922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040922] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALIMI E, 1993, BIOTECHNIQUES, V15, P912; ALLIS CD, 1979, P NATL ACAD SCI USA, V76, P4857, DOI 10.1073/pnas.76.10.4857; ALLIS CD, 1982, DEV BIOL, V93, P519, DOI 10.1016/0012-1606(82)90139-7; ALLIS CD, 1981, BIOCHEMISTRY-US, V20, P3828, DOI 10.1021/bi00516a025; BEEBE SJ, 1994, SEMIN CANCER BIOL, V5, P285; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BRUNS PJ, 1974, J EXP ZOOL, V188, P337, DOI 10.1002/jez.1401880309; CARLSON G, 1994, THESIS U WISCONSIN M; DADD CA, 1993, BIOTECHNIQUES, V14, P266; DASSO M, 1994, P NATL ACAD SCI USA, V91, P12477, DOI 10.1073/pnas.91.26.12477; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; GIBBS CS, 1991, BIOCHEMISTRY-US, V30, P5329, DOI 10.1021/bi00236a001; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; Gorovsky M A, 1975, Methods Cell Biol, V9, P311, DOI 10.1016/S0091-679X(08)60080-1; GUO XW, 1995, EMBO J, V14, P976, DOI 10.1002/j.1460-2075.1995.tb07078.x; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HOCHSTRASSER M, 1989, J BIOL CHEM, V264, P14510; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JEKEL PA, 1983, ANAL BIOCHEM, V134, P347, DOI 10.1016/0003-2697(83)90308-1; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LAMB NJC, 1991, EMBO J, V10, P1523, DOI 10.1002/j.1460-2075.1991.tb07672.x; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; LU MJ, 1994, CHROMOSOMA, V103, P111; MASON PA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P116, DOI 10.1016/0167-4889(89)90191-2; MEINKOTH JL, 1990, P NATL ACAD SCI USA, V87, P9595, DOI 10.1073/pnas.87.24.9595; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg E A, 1990, Adv Cancer Res, V55, P271, DOI 10.1016/S0065-230X(08)60471-6; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHSUMI K, 1993, SCIENCE, V262, P2033, DOI 10.1126/science.8266099; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RODRIGUEZALFAGEME C, 1980, CHROMOSOMA, V78, P1; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; ROTH SY, 1991, EMBO J, V10, P2069, DOI 10.1002/j.1460-2075.1991.tb07738.x; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STARGELL LA, 1993, GENE DEV, V7, P2641, DOI 10.1101/gad.7.12b.2641; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; Sweet MT, 1996, J CELL BIOL, V135, P1219, DOI 10.1083/jcb.135.5.1219; SWEET MT, 1993, CHROMOSOMA, V102, P637, DOI 10.1007/BF00352312; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; VERON M, 1988, DEV GENET, V9, P247, DOI 10.1002/dvg.1020090407; WALSH DA, 1971, J BIOL CHEM, V246, P1977; WEST MHP, 1984, ELECTROPHORESIS, V5, P133, DOI 10.1002/elps.1150050302; WOFFENDIN C, 1986, DEV BIOL, V115, P1, DOI 10.1016/0012-1606(86)90221-6; WU M, 1994, MOL CELL BIOL, V14, P10, DOI 10.1128/MCB.14.1.10; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0	57	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					916	923		10.1074/jbc.272.2.916	http://dx.doi.org/10.1074/jbc.272.2.916			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995382	hybrid			2022-12-25	WOS:A1997WC04800033
J	Askwith, C; Kaplan, J				Askwith, C; Kaplan, J			An oxidase-permease-based iron transport system in Schizosaccharomyces pombe and its expression in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC REDUCTASE; MOLECULAR CHARACTERIZATION; TRANSCRIPTIONAL CONTROL; FET3 GENE; PROTEIN; YEAST; ENCODES; COPPER; CERULOPLASMIN	Genetic studies have demonstrated that high affinity ferrous transport in Saccharomyces cerevisiae requires an oxidase (Fet3p) and a permease (Ftr1p). Using an iron-independent galactose-based expression system, we show that expression of these two genes can mediate high affinity ferrous iron transport, indicating that these two genes are not only necessary, but sufficient for high affinity iron transport. Schizosaccharomyces pombe also employ an oxidase-permease system for high affinity iron transport, The S. pombe genes, fio1(+) (ferrous iron oxidase) and fip1(+) (ferriferous permease), share significant similarity to FET3 and FTR1 hom S. cerevisiae. Both fio1(+) and fip1(+) are transcriptionally regulated by iron need, and disruption of fio1(+) results in a loss of high affinity iron transport. Expression of fio1(+) alone in an S. cerevisiae fet3 disruption strain does not result in high affinity iron transport, This result indicates that the S. pombe ferroxidase, while functionally homologous to the S. cerevisiae ferroxidase, does not have enough similarity to interact with the S. cerevisiae permease, Simultaneous expression of both S. pombe genes, fio1(+) and fip1(+), in S, cerevisiae can reconstitute high affinity iron transport. These results demonstrate that the oxidase and permease are all that is required to reconstitute high affinity iron transport and suggest that such transport systems are found in other eukaryotes.	UNIV UTAH, SCH MED, DEPT PATHOL, DIV CELL BIOL & IMMUNOL, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah					NCI NIH HHS [CA 42014] Funding Source: Medline; NIDDK NIH HHS [DK30534] Funding Source: Medline; NIGMS NIH HHS [T32 GM07464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	15	119	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					401	405						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995275				2022-12-25	WOS:A1997WA56400062
J	Waksman, M; Tang, XQ; Eli, Y; Gerst, JE; Liscovitch, M				Waksman, M; Tang, XQ; Eli, Y; Gerst, JE; Liscovitch, M			Identification of a novel Ca2+-dependent, phosphatidylethanolamine-hydrolyzing phospholipase D in yeast bearing a disruption in PLD1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PARTIAL-PURIFICATION; BRAIN; PHOSPHATIDYLCHOLINE; ACTIVATION; PROTEIN; ENZYMES; CELLS; ARF	We have previously reported the identification and partial characterization of a gene encoding a phospholipase D activity (PLD1) in the yeast, Saccharomyces cerevisiae. Here we report the existence of a second phospholipase D activity, designated PLD2, in yeast cells bearing disruption at the PLD1 locus. PLD2 is a Ca2+-dependent enzyme which preferentially utilizes phosphatidylethanolamine over phosphatidylcholine as a substrate, In contrast to PLD1, the activity of PLD2 is insensitive to phosphatidylinositol 4,5-bisphosphate, and the enzyme is incapable of catalyzing the transphosphatidylation reaction with short chain alcohols as accepters, Subcellular fractionation shows that PLD2 localizes mainly to the cytosol, but could also be detected in the particulate fraction. Thus, the biochemical properties of PLD2 appear to be substantially different from those of PLD1. PLD2 activity is significantly and transiently elevated upon exit of wild type yeast cells from stationary phase, suggesting that it may play a role in the initiation of mitotic cell division in yeast, In view of the significantly different properties of PLD1 and PLD2, and because the yeast genome contains PLD1 as the sole member of the recently defined PLD gene family, it may be concluded that PLD2 is structurally unrelated to PLD1. Thus, the novel PLD2 activity described herein is likely to represent the first identified member of a new PLD gene family.	WEIZMANN INST SCI,DEPT REGULAT BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Cockcroft S, 1996, CHEM PHYS LIPIDS, V80, P59, DOI 10.1016/0009-3084(96)02546-7; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DANIN M, 1993, LIPID METABOLISM SIG, P14; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; GHOSH SS, 1992, BIOCHEM CELL BIOL, V70, P43, DOI 10.1139/o92-006; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Heller M, 1978, Adv Lipid Res, V16, P267; HONIGBERG S, 1994, P NATL ACAD SCI USA, V91, P6550; HUANG CF, 1992, J BIOL CHEM, V267, P16859; JUNEJA LR, 1988, BIOCHIM BIOPHYS ACTA, V960, P334, DOI 10.1016/0005-2760(88)90041-0; Kaszkin M, 1996, BIOCHEM J, V314, P129, DOI 10.1042/bj3140129; Kiss Z, 1996, CHEM PHYS LIPIDS, V80, P81, DOI 10.1016/0009-3084(96)02547-9; KISS Z, 1992, BIOCHEM J, V285, P229, DOI 10.1042/bj2850229; Liscovitch M, 1996, CHEM PHYS LIPIDS, V80, P37, DOI 10.1016/0009-3084(96)02544-3; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MEZNA M, 1994, ANAL BIOCHEM, V218, P370, DOI 10.1006/abio.1994.1194; Ponting CP, 1996, PROTEIN SCI, V5, P914; Ribbes G, 1996, BIOCHEM BIOPH RES CO, V224, P206, DOI 10.1006/bbrc.1996.1008; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Rose MD., 1990, METHODS YEAST GENETI; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; TAKI T, 1979, J BIOL CHEM, V254, P9761; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; WANG P, 1991, J BIOL CHEM, V266, P14877; WANG XM, 1994, J BIOL CHEM, V269, P20312	37	73	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					36	39						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995222				2022-12-25	WOS:A1997WA56400009
J	Quill, TA; Garbers, DL				Quill, TA; Garbers, DL			Sperad is a novel sperm-specific plasma membrane protein homologous to a family of cell adhesion proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIARY GLYCOPROTEIN-I; GUINEA-PIG; CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN SUPERFAMILY; INTERCELLULAR-ADHESION; MOLECULAR-CLONING; ACROSOME REACTION; AUTO-ANTIGENS; SURFACE; DOMAIN	A hallmark of fertilization is a high degree of species specificity, implying gamete-specific recognition signals. To identify sperm-specific plasma membrane proteins, an antiserum to sperm plasma membranes was produced in female guinea pigs. The screening of a testis cDNA expression library with this antiserum resulted in the isolation of two clones encoding a predicted protein containing two extracellular immunoglobulin-like domains, a transmembrane segment, and an intracellular proline-rich domain, The predicted protein (named sperad) is closely related to a large family (biliary glycoproteins) of putative cell adhesion molecules. Sperad is first expressed by the haploid spermatid and is localized to the plasma membrane overlying the acrosome, supportive of a role in cell. adhesion/signaling. However, sperad expression in Sf9 cells does not result in Sf9 cell aggregation or in sperm adhesion to the infected insect cells, suggesting that sperad is involved in heterotypic interactions. The open reading frame of the two cDNA clones predicts proteins of either 32.2 or 33.3 kDa. Antibody produced to sperad recognizes three sperm plasma membrane proteins on immunoblots (M(r) 55,000, 36,000, and 28,000), but the lower molecular weight proteins are degradation products; deglycosylation confirmed that the M(r) 55,000 sperm plasma membrane represents the full-length protein encoded by the clone, induction of the acrosome reaction does not appear to alter the molecular weight of sperad but does result in its loss from the sperm cells, Thus, sperad is likely involved in heterotypic interactions prior to interaction of spermatozoa with the egg plasma membrane.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ANAKWE OO, 1991, MOL REPROD DEV, V29, P172, DOI 10.1002/mrd.1080290213; ARBOLEDA CE, 1988, DEV BIOL, V125, P217, DOI 10.1016/0012-1606(88)90075-9; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BDAVIS LG, 1986, BASIC METHODS MOL BI, P139; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; CHEUNG PH, 1993, BIOCHEM J, V295, P427, DOI 10.1042/bj2950427; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWAN AE, 1993, DEV BIOL, V155, P124, DOI 10.1006/dbio.1993.1012; Eddy E. M., 1994, P29; HARDY DM, 1988, BIOL REPROD, V38, P423, DOI 10.1095/biolreprod38.2.423; HINODA Y, 1988, P NATL ACAD SCI USA, V85, P6959, DOI 10.1073/pnas.85.18.6959; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHROP WF, 1990, J CELL BIOL, V111, P2939, DOI 10.1083/jcb.111.6.2939; LIN SH, 1989, J BIOL CHEM, V264, P14408; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; ORAND MG, 1981, BIOL REPROD, V25, P621, DOI 10.1095/biolreprod25.3.621; PHELPS BM, 1987, DEV BIOL, V123, P63, DOI 10.1016/0012-1606(87)90428-3; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; PRIMAKOFF P, 1983, DEV BIOL, V98, P417, DOI 10.1016/0012-1606(83)90371-8; RICHARDSON RT, 1994, DEV BIOL, V165, P688, DOI 10.1006/dbio.1994.1285; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TEIXEIRA AM, 1994, BLOOD, V84, P211; THOMPSON JA, 1995, TUMOR BIOL, V16, P10, DOI 10.1159/000217923; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TUNG KSK, 1980, BIOL REPROD, V23, P877, DOI 10.1095/biolreprod23.4.877; TURBIDE C, 1991, J BIOL CHEM, V266, P309; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WESTBROOKCASE VA, 1994, MOL REPROD DEV, V39, P309, DOI 10.1002/mrd.1080390308; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Yanagimachi R., 1994, P189; YANAGIMACHI R, 1981, BIOL REPROD, V24, P512, DOI 10.1095/biolreprod24.3.512; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	40	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33509	33514		10.1074/jbc.271.52.33509	http://dx.doi.org/10.1074/jbc.271.52.33509			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969215	hybrid			2022-12-25	WOS:A1996WA71300049
J	Takeuchi, K; Guggino, SE				Takeuchi, K; Guggino, SE			24R,25-(OH)(2) vitamin D-3 inhibits 1 alpha,25-(OH)(2) vitamin D-3 and testosterone potentiation of calcium channels in osteosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOMIC BIOLOGICAL RESPONSES; CONFLUENT MOUSE OSTEOBLASTS; OSTEO-SARCOMA CELLS; INOSITOL 1,4,5-TRISPHOSPHATE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; PERFUSED DUODENA; PHOSPHOLIPASE-C; CA2+ CHANNELS; NORMAL CHICKS; G-PROTEIN	Calcium influx via L-type calcium channels in osteoblast cells causes a rapid (in seconds) elevation in intracellular calcium initiated by plasma membrane receptors for 1 alpha,25-dihydroxyvitamin D-3 (1 alpha,25-D-3). 24R,25-Dihydroxyvitamin D-3 (24,25-D-3) alone, in concentrations up to 200 nM, does not cause potentiation of calcium currents in osteoblasts, but it does inhibit the current potentiation by 1 alpha,25-D-3. To determine how various steroids interact in their potentiation of calcium channels, the action of vitamin D-3 analogues and testosterone with calcium channels in the rat osteoblast-like cell line ROS 17/2.8 was investigated. Bath additions of both 1 alpha,25-D-3 and testosterone at doses below K-1/2 (the dose causing 50% left shift in the current-voltage relationship) are additive in their ability to potentiate calcium channels. When 1 alpha,25-D-3 and testosterone are added together at concentrations that would cause a maximal shift in the current-voltage relationship by each agent alone (V-max), the effect of these steroids is not additive. Taken together these data suggest one population of calcium channels is activated by 1 alpha,25-D-3 or testosterone. The shift in the current-voltage relationship caused by 1 alpha,25-D-3 is reduced by 1 beta,25-dihydroxvitamin D-3 (1 beta,25-D-3), an agent which is thought to act specifically on the plasma membrane receptor for 1 alpha,25-D-3, but the potentiation caused by testosterone is not blocked by 1 beta,25-D-3. However, 24,25-D-3 inhibits the left shift in the peak current-voltage relationship mediated by either 1 alpha,25-D-3 and testosterone. This result implies that 1) 1 beta,25-D-3 directly displaces 1 alpha,25-D-3 but not testosterone from its plasma membrane receptor, and 2) the rapid (in seconds) stimulatory effects of 1 alpha,25-D-3 and testosterone on calcium channels are mediated by separate plasma membrane receptors for testosterone and 1 alpha,25-D-3, which are blocked by another receptor for 24,25-D-3. The interaction of these three receptors with L-type calcium channels is pertussis toxin-sensitive.	JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43423] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAN BP, 1989, ANNU REV PHYSIOL, V51, P367, DOI 10.1146/annurev.physiol.51.1.367; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CHESNOYMARCHAIS D, 1988, J PHYSIOL-LONDON, V398, P291, DOI 10.1113/jphysiol.1988.sp017043; ERIKSEN EF, 1988, SCIENCE, V241, P84, DOI 10.1126/science.3388021; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; FERRARA J, 1994, J BIOL CHEM, V269, P2971; GROSSE B, 1993, J BONE MINER RES, V8, P1059; GUGGINO SE, 1989, P NATL ACAD SCI USA, V86, P2957, DOI 10.1073/pnas.86.8.2957; IMOTO Y, 1988, AM J PHYSIOL, V255, pH722, DOI 10.1152/ajpheart.1988.255.4.H722; KOMM BS, 1988, SCIENCE, V241, P81, DOI 10.1126/science.3164526; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LANGSTON GG, 1990, CALCIFIED TISSUE INT, V47, P230, DOI 10.1007/BF02555924; Li B, 1996, CELL CALCIUM, V19, P193, DOI 10.1016/S0143-4160(96)90020-2; LIEBERHERR M, 1994, J BIOL CHEM, V269, P7217; LIEBERHERR M, 1993, J BONE MINER RES, V8, P1365; LIEBERHERR M, 1987, J BIOL CHEM, V262, P13168; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MILLER RJ, 1992, J BIOL CHEM, V267, P1403; NEMERE I, 1984, ENDOCRINOLOGY, V115, P1476, DOI 10.1210/endo-115-4-1476; NEMERE I, 1994, J BIOL CHEM, V269, P23750; NORMAN AW, 1993, J BIOL CHEM, V268, P20022; NORMAN AW, 1993, J BIOL CHEM, V268, P13811; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; POSNER GH, 1993, BIOORG MED CHEM LETT, V3, P1829, DOI 10.1016/S0960-894X(00)80114-6; POSNER GH, 1994, BIOORG MED CHEM LETT, V4, P2919, DOI 10.1016/S0960-894X(01)80840-4; PROCSAL DA, 1975, J BIOL CHEM, V250, P8382; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SCULPTOREANU A, 1993, NATURE, V364, P240, DOI 10.1038/364240a0; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STEB H, 1983, NATURE, V306, P67; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; TRAUTWEIN W, 1990, ANNU REV PHYSIOL, V52, P257, DOI 10.1146/annurev.ph.52.030190.001353; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999; YOSHIMOTO Y, 1986, ENDOCRINOLOGY, V118, P2300, DOI 10.1210/endo-118-6-2300; YOSHIMOTO Y, 1986, J STEROID BIOCHEM, V25, P905, DOI 10.1016/0022-4731(86)90322-5; YUKIHIRO S, 1994, J BIOL CHEM, V269, P23889; ZHOU LX, 1992, J BONE MINER RES, V7, P457	41	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33335	33343		10.1074/jbc.271.52.33335	http://dx.doi.org/10.1074/jbc.271.52.33335			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969193	hybrid			2022-12-25	WOS:A1996WA71300027
J	Wiland, AM; Denu, JM; Mourey, RJ; Dixon, JE				Wiland, AM; Denu, JM; Mourey, RJ; Dixon, JE			Purification and kinetic characterization of the mitogen-activated protein kinase phosphatase rVH6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; HEAT-SHOCK; SPECIFICITY; GENE; EXPRESSION; MODELS; 1B	The dual specificity protein-tyrosine phosphatase rVH6 belongs to a subfamily of enzymes that have in vivo and in vitro catalytic activity against mitogen-activated protein kinases, A method was developed for the expression and efficient purification of recombinant rVH6 in quantities sufficient for physical and kinetic character ization of the enzyme. Matrix-assisted laser desorption mass spectrometry verified the mass of purified rVH6 to be 43,500 +/- 150, and NH2-terminal sequence analysis confirmed the predicted amino acid sequence. Kinetic characterization of full length rVH6 identified the critical ionizations involved in the K-cat/K-m parameter (apparent pK(a) values 5.1 and 6.6) and revealed a pH-independent k(cat) value of 0.014 s(-1). In an attempt to define the essential catalytic core of this enzyme, amino acids 134-381 of rVH6 were expressed, purified, and characterized enzymatically. Kinetic analysis revealed that the truncated enzyme exhibited a turnover value similar to that of the full-length enzyme (k(cat) = 0.017 s(-1)), with p-nitrophenyl phosphate as substrate, Secondary structure prediction and molecular modeling of rVH6 based on the x-ray structure of the dual specificity protein tyrosine phosphatase, VHR, further supported the assignment of residues 134-381 to the core catalytic domain of rVH6, These results demonstrate that the NH2 terminus of rVH6 (residues 1-133) is not required for full enzyme activity and comprises a separate domain that may play a distinct physiological function.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIDDK NIH HHS [NIDDKD 18024, DK07245-17] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, T32DK007245, R01DK018024] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CM, 1979, SCIENCE, V204, P375, DOI 10.1126/science.220706; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BRUNGER TA, 1993, XPLOR MANUAL SYSTEM; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; GERONDAKIS S, 1994, GENOMICS, V24, P182, DOI 10.1006/geno.1994.1598; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; RIFE JE, 1980, BIOCHEMISTRY-US, V19, P2328, DOI 10.1021/bi00552a008; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Rost B, 1996, METHOD ENZYMOL, V266, P525; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8482, DOI 10.1021/bi00151a014; SCHUBERT HL, 1995, PROTEIN SCI, V4, P1904, DOI 10.1002/pro.5560040924; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1994, J BIOL CHEM, V269, P8140; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	38	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33486	33492		10.1074/jbc.271.52.33486	http://dx.doi.org/10.1074/jbc.271.52.33486			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969212	hybrid			2022-12-25	WOS:A1996WA71300046
J	Busch, AE; Quester, S; Ulzheimer, JC; Waldegger, S; Gorboulev, V; Arndt, P; Lang, F; Koepsell, H				Busch, AE; Quester, S; Ulzheimer, JC; Waldegger, S; Gorboulev, V; Arndt, P; Lang, F; Koepsell, H			Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL BRUSH-BORDER; MEMBRANE-VESICLES; ORGANIC CATIONS; PROXIMAL TUBULE; KIDNEY; PH; N1-METHYLNICOTINAMIDE; TETRAETHYLAMMONIUM; KINETICS	The previously cloned rat cation transporter rOCT1 detected in renal proximal tubules and hepatocytes (Grundemann, D,, Gorboulev, V,, Gambaryan, S,, Veyhl, M,, and Koepsell, H, (1994) Nature 372, 549-552) was expressed in Xenopus oocytes, and transport properties were analyzed using tracer uptake studies and electro-physiological measurements, rOCT1 induced highly active transport of a variety of cations, including the classical substrates for cation transport, such as N-1-methylnicotinamide, 1-methyl-4-phenylpyridinium (MPP), and tetraethylammonium (TEA), but also the physiologically important choline, In oocytes rOCT1 also mediated efflux of MPP, which could be trans-stimulated by MPP and TEA, Cation transport via rOCT1 was electrogenic. In voltage-clamped oocytes, transport of TEA and choline via rOCT1 produced inwardly directed currents, which were independent of extracellular ion composition or pH. The choline- and TEA-induced currents were voltage-dependent at nonsaturating concentrations, and the apparent affinity of these cations was decreased at depolarized voltages, Other substrates transported by rOCT1 were the polyamines spermine and spermidine, Interestingly, the previously described potent inhibitors of rOCT1, cyanine 863, quinine, and D-tubocurarine were substrates themselves, The data indicate that rOCT1 is an effective transport system that is responsible for electrogenic uptake of a wide variety of organic cations into epithelial cells of renal proximal tubules and hepatocytes.	UNIV TUBINGEN,INST PHYSIOL,D-72076 TUBINGEN,GERMANY; UNIV WURZBURG,INST ANAT,D-97070 WURZBURG,GERMANY	Eberhard Karls University of Tubingen; University of Wurzburg								Busch AE, 1996, J PHYSIOL-LONDON, V491, P735, DOI 10.1113/jphysiol.1996.sp021253; DAVID C, 1995, PFLUG ARCH EUR J PHY, V430, P477, DOI 10.1007/BF00373884; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Groothuis GMM, 1996, J HEPATOL, V24, P3; GRUNDEMANN D, 1994, NATURE, V372, P549, DOI 10.1038/372549a0; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HOLOHAN PD, 1981, J PHARMACOL EXP THER, V216, P294; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; MOSELEY RH, 1990, AM J PHYSIOL, V259, pG973, DOI 10.1152/ajpgi.1990.259.6.G973; OTT RJ, 1991, AM J PHYSIOL, V261, pF443, DOI 10.1152/ajprenal.1991.261.3.F443; PETERS L, 1955, J PHARMACOL EXP THER, V113, P148; Roch-Ramel F., 1992, HDB PHYSL 8, P2189; STEEN H, 1991, PROG PHARM CLIN PHAR, V8, P239; ULLRICH KJ, 1991, PFLUG ARCH EUR J PHY, V419, P84, DOI 10.1007/BF00373751; ULLRICH KJ, 1994, BBA-REV BIOMEMBRANES, V1197, P45, DOI 10.1016/0304-4157(94)90018-3; ULLRICH KJ, 1996, PFLUG ARCH EUR J PHY, V424, P1; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6; WRIGHT SH, 1987, AM J PHYSIOL, V253, pF1040, DOI 10.1152/ajprenal.1987.253.5.F1040; WRIGHT SH, 1992, J MEMBRANE BIOL, V126, P51; WRIGHT SH, 1995, PFLUG ARCH EUR J PHY, V429, P313, DOI 10.1007/BF00374145; WRIGHT SH, 1985, AM J PHYSIOL, V249, pF903, DOI 10.1152/ajprenal.1985.249.6.F903	23	165	170	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32599	32604		10.1074/jbc.271.51.32599	http://dx.doi.org/10.1074/jbc.271.51.32599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955087	hybrid			2022-12-25	WOS:A1996VZ37300022
J	Huang, SY; Luca, M; Gutman, M; McConkey, DJ; Langley, KE; Lyman, SD; BarEli, M				Huang, SY; Luca, M; Gutman, M; McConkey, DJ; Langley, KE; Lyman, SD; BarEli, M			Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential	ONCOGENE			English	Article						c-KIT; tumor metastasis; melanoma; apoptosis	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR; TUMOR NECROSIS FACTOR; W-MUTANT MICE; NUDE-MICE; MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; DNA FRAGMENTATION; HUMAN PIEBALDISM; RNA EXPRESSION	Expression of the tyrosine-kinase receptor encoded by the c-KIT proto-oncogene progressively decreases during local tumor growth and invasion of human melanomas, To provide direct evidence that c-KIT plays a role in metastasis of human melanoma, we transfected the c-KIT gene into the c-KIT negative highly metastatic human melanoma cell line A375SM and subsequently analysed its tumorigenic and metastatic potential, A375SM parental cells, A375SM-NOT (neo, control), and A375SM-KIT-positive cells were injected s.c. and i.v. into nude mice, A375SM-KIT cells produced significantly slower growing s.c. tumors and fewer lung metastases than control cells. Exposure of c-KIT-positive melanoma cells in vitro and in vivo to stem cell factor (SCF), the ligand for c-KIT, triggered apoptosis of these cells but not of c-KIT-negative melanoma cells or normal melanocytes. Since SCF is produced by keratinocytes and other dermal cells in the skin, these results suggest that the loss of c-KIT receptor expression may allow malignant melanoma cells to escape SCF/c-KIT-mediated apoptosis, hence contributing to tumor growth and eventually metastasis, The antitumor and antimetastatic properties of SCF may be useful in treating human melanomas in early stages.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; AMGEN INC,THOUSAND OAKS,CA 91320; IMMUNEX RES & DEV CORP,SEATTLE,WA 98103	University of Texas System; UTMD Anderson Cancer Center; Amgen					NCI NIH HHS [CA64137, CA 41524] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041524, R21CA064137] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P3775; ALBELDA SM, 1990, CANCER RES, V50, P6757; ALBINO AP, 1991, CANCER RES, V51, P4815; ANDRE C, 1989, ONCOGENE, V4, P1047; ARMSTRONG CA, 1994, J INVEST DERMATOL, V102, P278, DOI 10.1111/1523-1747.ep12371782; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CACERESCORTES J, 1994, J BIOL CHEM, V269, P12084; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FIDLER IJ, 1990, CANCER RES, V50, P6130; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLEISCHMAN RA, 1992, J CLIN INVEST, V89, P1713, DOI 10.1172/JCI115772; FLEISCHMAN RA, 1991, P NATL ACAD SCI USA, V88, P10885, DOI 10.1073/pnas.88.23.10885; FLEMING WH, 1993, P NATL ACAD SCI USA, V90, P3760, DOI 10.1073/pnas.90.8.3760; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GIEBEL LB, 1991, P NATL ACAD SCI USA, V88, P8696, DOI 10.1073/pnas.88.19.8696; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; GUTMAN M, 1994, ANTICANCER RES, V14, P1759; HUANG SY, 1994, CANCER IMMUNOL IMMUN, V39, P231, DOI 10.1007/BF01525986; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; LASSAM N, 1992, ONCOGENE, V7, P51; LASTER SM, 1988, J IMMUNOL, V141, P2629; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LI LM, 1989, JNCI-J NATL CANCER I, V81, P1406, DOI 10.1093/jnci/81.18.1406; LONGLEY BJ, 1993, NEW ENGL J MED, V328, P1302, DOI 10.1056/NEJM199305063281803; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; Lu Chao, 1994, Current Opinion in Oncology, V6, P212, DOI 10.1097/00001622-199403000-00015; LUCA M, 1993, MELANOMA RES, V3, P35, DOI 10.1097/00008390-199304000-00006; LUCA M, 1993, INT J ONCOL, V3, P19; LUCA M, 1995, ONCOGENE, V11, P1399; MCGREGOR BC, 1989, AM J CLIN PATHOL, V92, P495, DOI 10.1093/ajcp/92.4.495; MEKORI YA, 1993, J IMMUNOL, V151, P3775; MILLER AD, 1986, SOMAT CELL MOLEC GEN, V12, P175, DOI 10.1007/BF01560664; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORITA E, 1994, ARCH DERMATOL RES, V286, P273, DOI 10.1007/BF00387600; NATALI P, 1990, CANCER RES, V50, P1271; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; Radinsky R, 1991, Semin Cancer Biol, V2, P169; RADINSKY R, 1994, ONCOGENE, V9, P1977; RADIZADEH S, 1993, SCIENCE, V261, P345; REAL FX, 1986, CANCER RES, V46, P4726; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; SCHMID DS, 1987, LYMPHOKINE RES, V6, P195; SINGH RK, 1995, CANCER RES, V55, P3669; SINGH RK, 1994, CANCER RES, V54, P3242; SPRITZ RA, 1992, AM J HUM GENET, V50, P261; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VERSCHRAEGEN CF, 1991, ANTICANCER RES, V11, P529; VILE RG, 1994, CANCER RES, V54, P6228; WILKS AF, 1993, ADV CANCER RES, V60, P43; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, EMBO J, V6, P3342; ZAKUT R, 1993, ONCOGENE, V8, P2221; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	63	130	132	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2339	2347						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957075				2022-12-25	WOS:A1996VX10800006
J	Gaben, AM; Saucier, C; Bedin, M; Barbu, V; Courilleau, D; BonHoa, DH; Mester, J				Gaben, AM; Saucier, C; Bedin, M; Barbu, V; Courilleau, D; BonHoa, DH; Mester, J			Activation of p21ras is not sufficient to ensure a complete G(1) phase of the cell division cycle in mouse fibroblasts	ONCOGENE			English	Article						p21ras; cell cycle; growth factor requirement; SRE-dependent transcription; insulin signalling	EPIDERMAL GROWTH-FACTOR; MITOGENIC SIGNAL TRANSDUCTION; NUCLEOTIDE EXCHANGE FACTOR; SERUM-RESPONSE ELEMENT; NIH 3T3 CELLS; FACTOR-I; C-FOS; TYPE-1 NEUROFIBROMATOSIS; GUANINE-NUCLEOTIDES; GENE-EXPRESSION	In the mouse BP-A31 fibroblasts, mRNAs coding the three isoforms (Ha, Ki, N) of ras are expressed, and there are no activating mutations in the codons 12, 13 or 61. We have produced a subline (Ras2) expressing an oestrogen-inducible v-Ha-ras gene. The contribution of v-Ha-ras to the overall p21ras-GTP content was evaluated by metabolic labelling with P-32. Surprisingly, p21ras-GTP complexes were predominant in the serum-deprived BP-A31 cells as well as in the Ras2 cells. The excess of p21ras-GTP was not due to the lack of the GTPase activating protein. In transient transfection experiments, the serum response element (SRE)-directed CAT was expressed in serum-deprived BP-A31 cells, and insulin caused a further two- to threefold increase in CAT activity. A dominant negative ras mutant (Ha-Ras Asn-17) cancelled both the basal and insulin-induced CAT expression in the BP-A31 but not in the Ras2 cells. Expression of v-Ha-ras in Ras2 cells did not relax their growth factor-dependence and oestradiol had only a minor mitogenic effect. We conclude that p21ras activation does not ensure a complete cell division cycle in these cells, and does not entirely account for the transduction of the mitogenic signal initiated by insulin.	UNIV PARIS 06,FAC MED,F-75012 PARIS,FRANCE	UDICE-French Research Universities; Sorbonne Universite	Gaben, AM (corresponding author), HOP ST ANTOINE,INSERM U55,184 RUE FAUBOURG ST ANTOINE,F-75012 PARIS,FRANCE.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BRUNET A, 1994, ONCOGENE, V9, P3379; BUCHOU T, 1989, EXP CELL RES, V182, P129, DOI 10.1016/0014-4827(89)90285-1; BUCHOU T, 1990, J CELL PHYSIOL, V142, P559, DOI 10.1002/jcp.1041420315; BuquetFagot C, 1996, J CELL PHYSIOL, V166, P631, DOI 10.1002/(SICI)1097-4652(199603)166:3<631::AID-JCP18>3.0.CO;2-9; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHAROLLAIS RH, 1990, J CELL PHYSIOL, V145, P46, DOI 10.1002/jcp.1041450108; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAGOT D, 1991, ENDOCRINOLOGY, V129, P1033, DOI 10.1210/endo-129-2-1033; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GAUTHIERROUVIERE C, 1990, EMBO J, V9, P171, DOI 10.1002/j.1460-2075.1990.tb08093.x; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MOLLAT P, 1992, BIO-TECHNOL, V10, P1151, DOI 10.1038/nbt1092-1151; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSTROWSKI MC, 1983, MOL CELL BIOL, V3, P2045, DOI 10.1128/MCB.3.11.2045; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; SAMBROOK J, 1989, MOL CLONING LAB HDB; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Winston JT, 1996, ONCOGENE, V12, P127; Yenush L, 1996, MOL CELL BIOL, V16, P2509	52	3	3	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2113	2120						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950978				2022-12-25	WOS:A1996VV14500008
J	Leeuwenburgh, C; Hardy, MM; Hazen, SL; Wagner, P; Ohishi, S; Steinbrecher, UP; Heinecke, JW				Leeuwenburgh, C; Hardy, MM; Hazen, SL; Wagner, P; Ohishi, S; Steinbrecher, UP; Heinecke, JW			Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYL RADICAL PRODUCTION; NITRIC-OXIDE; PEROXYNITRITE; MYELOPEROXIDASE; SUPEROXIDE; CATALYST; NO	Oxidized low density lipoprotein (LDL) may be of central importance in triggering atherosclerosis. One potential pathway involves the production of nitric oxide (NO) by vascular wall endothelial cells and macrophages. NO reacts with superoxide to form peroxynitrite (ONOO-), a potent agent of LDL oxidation in vitro. ONOO- nitrates the aromatic ring of free tyrosine to produce 3-nitrotyrosine, a stable product. To explore the role of reactive nitrogen species such as ONOO- in the pathogenesis of vascular disease, we developed a highly sensitive and specific method involving gas chromatography and mass spectrometry to quantify 3-nitrotyrosine levels in proteins. In vitro studies demonstrated that 3 nitrotyrosine was a highly specific marker for LDL oxidized by ONOO-. LDL isolated from the plasma of healthy subjects had very low levels of 3-nitrotyrosine (9 +/- 7 mu mol/mol of tyrosine). In striking contrast, LDL isolated from aortic atherosclerotic intima had 90-fold higher levels (840 +/- 140 mu mol/mol of tyrosine). These observations strongly support the hypothesis that reactive nitrogen species such as ONOO- form in the human artery wall and provide direct evidence for a specific reaction pathway that promotes LDL oxidation in vivo. The detection of 3-nitrotyrosine in LDL isolated from vascular lesions raises the possibility that NO, by virtue of its ability to form reactive nitrogen intermediates, may promote atherogenesis, counteracting the well established anti-atherogenic effects of NO.	WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; MONSANTO CO,SEARLE RES,ST LOUIS,MO 63167; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER,BC V5Z 4E3,CANADA	Washington University (WUSTL); Washington University (WUSTL); Monsanto; University of British Columbia			Hazen, Stanley L/ABD-5845-2021	Leeuwenburgh, Christiaan/0000-0003-0826-4257	NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [R01 AG12293] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN SJ, 1994, BIOL CHEM HOPPESEYLE, V375, P81; Berliner JA, 1996, FREE RADICAL BIO MED, V20, P707, DOI 10.1016/0891-5849(95)02173-6; BUCHMULLERROUILLER Y, 1992, BIOCHEM BIOPH RES CO, V183, P150, DOI 10.1016/0006-291X(92)91621-V; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; KRUL ES, 1992, BIOCHEM BIOPH RES CO, V189, P1069, DOI 10.1016/0006-291X(92)92313-M; LEIS JR, 1993, J CHEM SOC CHEM COMM, V16, P1298; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; RANKIN SM, 1991, J LIPID RES, V32, P449; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; SOLKOLOVSKY M, 1966, BIOCHEMISTRY-US, V5, P3582; VANDERVLIET A, 1994, FEBS LETT, V339, P89, DOI 10.1016/0014-5793(94)80391-9; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	22	408	423	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1433	1436		10.1074/jbc.272.3.1433	http://dx.doi.org/10.1074/jbc.272.3.1433			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999808	hybrid			2022-12-25	WOS:A1997WD05800006
J	Vescovi, EG; Ayala, YM; DiCera, E; Groisman, EA				Vescovi, EG; Ayala, YM; DiCera, E; Groisman, EA			Characterization of the bacterial sensor protein PhoQ - Evidence for distinct binding sites for Mg2+ and Ca2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; SIGNAL-TRANSDUCTION; VIRULENCE; EXPRESSION; HISTIDINE; REGULON	The PhoP/PhoQ two component regulatory system governs several virulence properties in the Gram-negative bacterium Salmonella typhimurium. The PhoQ protein is a Mg2+ and Ca2+ sensor that modulates transcription of PhoP-regulated genes in response to the extracellular concentrations of these divalent cations. We have purified a 146-amino acid polypeptide corresponding to the periplasmic (i.e. sensing) domain of the PhoQ protein. Mg2+ altered the tryptophan intrinsic fluorescence of this polypeptide whereas Ba2+, which is unable to modulate transcription of PhoP-regulated genes, did not. Mg2+ was more effective than Ca2+ at repressing transcription of PhoP-activated genes in vivo. However, maximal repression was achieved when both cations were present. An avirulent mutant harboring a single amino acid substitution in the sensing domain of PhoQ exhibited lower affinity for Ca2+ but similar affinity for Mg2+. Cumulatively, these experiments demonstrate that Mg2+ can bind to the sensing domain of PhoQ and establish the presence of distinct binding sites for Mg2+ and Ca2+ in the PhoQ protein.	WASHINGTON UNIV,SCH MED,DEPT MOL MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)				Garcia Vescovi, Eleonora/0000-0002-4431-8606				ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Di Cera E., 1995, THERMODYNAMIC THEORY; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; GROISMAN EA, 1989, P NATL ACAD SCI USA, V86, P7077, DOI 10.1073/pnas.86.18.7077; GROISMAN EA, 1995, 2 COMPONENT SIGNAL T, P319, DOI DOI 10.1128/9781555818319; GUNN JS, 1995, J BACTERIOL, V177, P5040, DOI 10.1128/jb.177.17.5040-5047.1995; LEE SC, 1992, J BIOL CHEM, V267, P2849; Miller J.H., 1972, EXPT MOL GENETICS; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; REINHART RA, 1988, ARCH INTERN MED, V148, P2415, DOI 10.1001/archinte.148.11.2415; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SNAVELY MD, 1991, J BIOL CHEM, V266, P824; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; SONCINI FC, 1995, J BACTERIOL, V177, P4364, DOI 10.1128/jb.177.15.4364-4371.1995; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; SWANSON RV, 1994, TRENDS BIOCHEM SCI, V19, P485, DOI 10.1016/0968-0004(94)90135-X; VESCOVI EG, 1994, RES MICROBIOL, V145, P473, DOI 10.1016/0923-2508(94)90096-5; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630	24	103	111	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1440	1443		10.1074/jbc.272.3.1440	http://dx.doi.org/10.1074/jbc.272.3.1440			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999810	hybrid			2022-12-25	WOS:A1997WD05800008
J	Blake, AD; Bot, G; Freeman, JC; Reisine, T				Blake, AD; Bot, G; Freeman, JC; Reisine, T			Differential opioid agonist regulation of the mouse mu opioid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIATE RECEPTORS; ADENYLYL-CYCLASE; CLONED HUMAN; MORPHINE; CELLS; MECHANISMS; ETORPHINE; TOLERANCE; MODEL	mu opioid receptors mediate the analgesia induced by morphine. Prolonged use of morphine causes tolerance development and dependence. To investigate the molecular basis of tolerance and dependence, the cloned mouse mu opioid receptor with an amino-terminal epitope tag was stably expressed in human embryonic kidney (HEK) 293 cells, and the effects of prolonged opioid agonist treatment on receptor regulation were examined, In HEK 293 cells the expressed mu receptor showed high affinity, specific, saturable binding of radioligands and a pertussis toxin-sensitive inhibition of adenylyl cyclase. Pretreatment (1 h, 3 h, or overnight) of cells with 1 mu M morphine or [D-Ala(2)MePhe(4),Gly(ol)(5)] enkephalin (DAMGO) resulted in no apparent receptor desensitization, as assessed by opioid inhibition of forskolin-stimulated cAMP levels. In contrast, the morphine and DAMGO pretreatments (3 h) resulted in a 3-4-fold compensatory increase in forskolin-stimulated cAMP accumulation. The opioid agonists methadone and buprenorphine are used in the treatment of addiction because of a markedly lower abuse potential. Pretreatment of mu receptor-expressing HEK 293 cells with methadone or buprenorphine abolished the ability of opioids to inhibit adenylyl cyclase. No compensatory increase in forskolin-stimulated cAMP accumulation was found with methadone or buprenorphine; these opioids blocked the compensatory effects observed with morphine and DAMGO. Taken together, these results indicate that methadone and buprenorphine interact differently with the mouse mu receptor than either morphine or DAMGO. The ability of methadone and buprenorphine to desensitize the mu receptor and block the compensatory rise in forskolin stimulated cAMP accumulation may be an underlying mechanism by which these agents are effective in the treatment of morphine addiction.	UNIV PENN,SCH MED,DEPT PHARMACOL,PHILADELPHIA,PA 19104	University of Pennsylvania					NIDA NIH HHS [DA05636, DA08951] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008951, F32DA005636] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ARDEN JR, 1995, J NEUROCHEM, V65, P1636; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; Blake A., 1995, Society for Neuroscience Abstracts, V21, P1350; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; CHAKRABARTI S, 1995, MOL BRAIN RES, V30, P269, DOI 10.1016/0169-328X(95)00014-J; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cowan Alan, 1995, BUPRENORPHINE COMBAT; FUKUDA K, 1995, J BIOL CHEM, V270, P6702, DOI 10.1074/jbc.270.12.6702; Harlow E., 1988, ANTIBODIES LAB MANUA; HEERDING J, 1994, REGUL PEPTIDES, V54, P119, DOI 10.1016/0167-0115(94)90418-9; HERZ A, 1993, HDB EXPT THERAPEUTIC, V104; JASINSKI DR, 1975, CLIN PHARMACOL THER, V17, P267; KAUFMAN DL, 1995, J BIOL CHEM, V270, P15877, DOI 10.1074/jbc.270.26.15877; KOSTERLITZ HW, 1972, AGONIST ANTAGONIST A, P121; Law S. F., 1995, Society for Neuroscience Abstracts, V21, P1350; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; PUTTFARCKEN PS, 1989, LIFE SCI, V45, P1937, DOI 10.1016/0024-3205(89)90548-1; PUTTFARCKEN PS, 1988, MOL PHARMACOL, V33, P520; RAYNOR K, 1995, J PHARMACOL EXP THER, V272, P423; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REISINE T, 1993, TRENDS NEUROSCI, V16, P506, DOI 10.1016/0166-2236(93)90194-Q; REISINE T, 1995, NEUROPHARMACOLOGY, V34, P463, DOI 10.1016/0028-3908(95)00025-2; REISINE T, 1996, PHARMACOL BASIS THER, P521; ROTHMAN RB, 1995, SYNAPSE, V21, P60, DOI 10.1002/syn.890210109; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Thomas JM, 1996, MOL PHARMACOL, V49, P907; TOLKOVSKY AM, 1982, MOL PHARMACOL, V22, P648; TSU RC, 1995, J NEUROCHEM, V64, P2700; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; WHEELERACETO H, 1991, EUR J PHARMACOL, V195, P411, DOI 10.1016/0014-2999(91)90485-9	33	117	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					782	790		10.1074/jbc.272.2.782	http://dx.doi.org/10.1074/jbc.272.2.782			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995364	hybrid			2022-12-25	WOS:A1997WC04800015
J	Bohle, DS; Dinnebier, RE; Madsen, SK; Stephens, PW				Bohle, DS; Dinnebier, RE; Madsen, SK; Stephens, PW			Characterization of the products of the heme detoxification pathway in malarial late trophozoites by X-ray diffraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM; BETA-HEMATIN; FERRIPROTOPORPHYRIN-IX; POWDER DIFFRACTION; PIGMENT; CHLOROQUINE; POLYMERIZATION; HAEMOZOIN	In a process inhibited by the quinoline antimalarial drugs, Plasmodia detoxify heme released during the degradation of hemoglobin by aggregating it into malarial pigment, an insoluble crystalline heme coordination polymer. Synchrotron x-ray powder diffraction patterns for intact desiccated malarial trophozoites and synthetic beta-hematin have been measured; both materials correspond to a single crystalline triclinic lattice with unit cell parameters a = 12.2176(4), b = 14.7184(5), c = 8.0456(3) Angstrom; alpha = 90.200(2), beta = 96.806(3), gamma = 97.818(3) degrees and Z = 2. These results unambiguously demonstrate that hemozoin crystallites are identical to synthetic beta-hematin.	SUNY STONY BROOK,DEPT PHYS,STONY BROOK,NY 11794; BROOKHAVEN NATL LAB,NATL SYNCHROTRON LIGHT SOURCE,UPTON,NY 11973	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; United States Department of Energy (DOE); Brookhaven National Laboratory	Bohle, DS (corresponding author), UNIV WYOMING,DEPT CHEM,LARAMIE,WY 82071, USA.		Dinnebier, Robert/B-5642-2015	Dinnebier, Robert/0000-0003-2778-2113				BENDRAT K, 1995, NATURE, V378, P138, DOI 10.1038/378138a0; Bohle D. S., 1994, ACS SYM SER, V572, P495; BOHLE DS, 1993, BIOCHEM BIOPH RES CO, V193, P504, DOI 10.1006/bbrc.1993.1652; Cannon J B, 1995, PDA J Pharm Sci Technol, V49, P77; CHOU AC, 1980, BIOCHEMISTRY-US, V19, P1543, DOI 10.1021/bi00549a600; DORN A, 1995, NATURE, V374, P269, DOI 10.1038/374269a0; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; Giacovazzo C, 1996, ACTA CRYSTALLOGR A, V52, P331, DOI 10.1107/S0108767395013651; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; Langford JI, 1996, REP PROG PHYS, V59, P131, DOI 10.1088/0034-4885/59/2/002; LE BAIL A, 1988, MATER RES BULL, V23, P447, DOI 10.1016/0025-5408(88)90019-0; LEMBERG R, 1949, HEMATIN COMPOUNDS BI, P171; MOORE GA, 1974, ANN TROP MED PARASIT, V68, P489, DOI 10.1080/00034983.1974.11686977; PADMANABAN G, 1989, TRENDS BIOCHEM SCI, V14, P492, DOI 10.1016/0968-0004(89)90182-5; RIDLEY RG, 1995, NATURE, V378, P138, DOI 10.1038/378138b0; RODRIGUEZCARVAJAL J, 1993, PHYSICA B, V192, P55, DOI 10.1016/0921-4526(93)90108-I; Ruetz S, 1996, P NATL ACAD SCI USA, V93, P9942, DOI 10.1073/pnas.93.18.9942; SCHWARZER E, 1992, J EXP MED, V176, P1033, DOI 10.1084/jem.176.4.1033; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; STEPHENS PW, 1992, PHYS REV B, V45, P543, DOI 10.1103/PhysRevB.45.543; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; VANDERJAGT DI, 1986, MOL BIOCHEM PARASIT, V18, P389, DOI 10.1016/0166-6851(86)90095-2; WARHURST DC, 1995, PARASITOL TODAY, V11, P204, DOI 10.1016/0169-4758(95)80076-X; WERNER P, 1964, Z KRISTALLOGR, V120, P375, DOI 10.1524/zkri.1964.120.4-5.375; WILES DB, 1981, J APPL CRYSTALLOGR, V14, P149, DOI 10.1107/S0021889881008996; YAMADA KA, 1979, EXP PARASITOL, V48, P61, DOI 10.1016/0014-4894(79)90055-9	29	135	136	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					713	716		10.1074/jbc.272.2.713	http://dx.doi.org/10.1074/jbc.272.2.713			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995354	hybrid			2022-12-25	WOS:A1997WC04800005
J	Chuprun, JK; Raymond, JR; Blackshear, PJ				Chuprun, JK; Raymond, JR; Blackshear, PJ			The heterotrimeric G protein G(alpha i2) mediates lysophosphatidic acid-stimulated induction of the c-fos gene in mouse fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CATALYZED ADP-RIBOSYLATION; BETA-GAMMA-SUBUNITS; PERTUSSIS TOXIN; GROWTH-FACTOR; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; DNA-SYNTHESIS; MAP-KINASE; SIGNAL-TRANSDUCTION	Lysophosphatidic acid (LPA) utilizes a heterotrimeric guanine nucleotide regulatory (G) protein-coupled receptor to activate the mitogen-activated protein kinase pathway and induce mitogenesis in fibroblasts and other cells. A single cell assay system was used to examine the functional interaction of the LPA receptor with G proteins in intact mouse fibroblasts, by measuring LPA-stimulated induction of the immediate early gene, c-fos, as read out by a stably expressed fos-lacZ reporter gene. Pretreatment of these cells with pertussis toxin at 100 ng/ml almost completely abolished LPA-stimulated c-fos induction. Western blotting revealed that two pertussis toxin (PTX)-sensitive G proteins, G(alpha i2) and G(alpha i3), were present in membranes prepared from these cells, and Northern blotting confirmed the absence of message for other PTX-sensitive subunits. Microinjection of an alpha(i1)/alpha(i2)-specific antibody into living cells decreased LPA stimulated induction of c-fos by 60%, whereas introduction of antibodies to either alpha(i3) or alpha(16), a subtype not present in these cells but used as a control, decreased LPA-stimulated c-fos induction by only 19%. In contrast, the alpha(i1)/alpha(i2)-specific antibody had no effect on insulin-induced c-fos expression, which is thought to utilize a G protein independent mechanism of signaling. In addition, cellular expression of an epitope-tagged PTX-resistant mutant of G(alpha i2), but not PTX-resistant G(alpha i3), restored LPA-stimulated c-fos induction in cells in which endogenous G protein alpha subunits were uncoupled from the receptor by pretreatment with PTX. Together, these results provide conclusive in vivo evidence that G(alpha i2) is the PTX sensitive G protein alpha subunit which mediates LPA-stimulated c-fos induction and perhaps mitogenesis in these cells.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; HOWARD HUGHES MED INST,DURHAM,NC; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; VET AFFAIRS MED CTR,DURHAM,NC 27705	Duke University; Howard Hughes Medical Institute; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529				BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CARR C, 1994, BIOCHEM J, V298, P493, DOI 10.1042/bj2980493; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROUCH MF, 1991, FASEB J, V5, P200, DOI 10.1096/fasebj.5.2.1900794; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FARGIN A, 1991, CELL SIGNAL, V3, P547, DOI 10.1016/0898-6568(91)90031-O; FAURE M, 1994, J BIOL CHEM, V269, P7851; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; GERHARDT MA, 1991, MOL PHARMACOL, V40, P707; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUNT TW, 1994, J BIOL CHEM, V269, P29565; JONES DT, 1987, J BIOL CHEM, V262, P14241; KOBAYASHI I, 1990, EUR J BIOCHEM, V191, P499, DOI 10.1111/j.1432-1033.1990.tb19149.x; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUMAGAI N, 1993, FEBS LETT, V329, P273, DOI 10.1016/0014-5793(93)80236-N; KUROSE H, 1991, BIOCHEMISTRY-US, V30, P3335, DOI 10.1021/bi00227a024; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMORTE VJ, 1993, J CELL BIOL, V121, P91, DOI 10.1083/jcb.121.1.91; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LETTERIO JJ, 1986, SCIENCE, V234, P1117, DOI 10.1126/science.3465038; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MCCLUE SJ, 1992, BIOCHEM J, V284, P565, DOI 10.1042/bj2840565; OBERDICK J, 1990, SCIENCE, V248, P223, DOI 10.1126/science.2109351; PACE AM, 1991, P NATL ACAD SCI USA, V88, P7031, DOI 10.1073/pnas.88.16.7031; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; POBINER BF, 1991, MOL PHARMACOL, V40, P156; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; RIBEIRONETO FAP, 1989, P NATL ACAD SCI USA, V86, P2577, DOI 10.1073/pnas.86.8.2577; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook T, 1989, MOL CLONING LAB MANU; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; STUMPO DJ, 1991, J BIOL CHEM, V266, P455; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAKEI Y, 1992, J BIOL CHEM, V267, P5085; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; VANDERBEND RL, 1992, EMBO J, V11, P2495, DOI 10.1002/j.1460-2075.1992.tb05314.x; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; VOGT W, 1963, BIOCHEM PHARMACOL, V12, P415, DOI 10.1016/0006-2952(63)90074-1; WEST RE, 1985, J BIOL CHEM, V260, P4428; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; XIE W, 1991, BIOTECHNIQUES, V11, P325; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	59	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					773	781		10.1074/jbc.272.2.773	http://dx.doi.org/10.1074/jbc.272.2.773			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995363	hybrid			2022-12-25	WOS:A1997WC04800014
J	Grant, SK; Green, BG; Wang, R; Pacholok, SG; Kozarich, JW				Grant, SK; Green, BG; Wang, R; Pacholok, SG; Kozarich, JW			Characterization of inducible nitric-oxide synthase by cytochrome P-450 substrates and inhibitors - Inhibition by chlorzoxazone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL CEREBRAL-ISCHEMIA; HYDROXY-L-ARGININE; LIVER-MICROSOMES; HEME COORDINATION; IMIDAZOLE AGENTS; N-HYDROXYLATION; INDAZOLE AGENTS; RAT; CITRULLINE; P450	Nitric oxide synthases (NOS, EC 1.14.13.39) are heme-containing enzymes that catalyze the formation of nitric oxide from L-Arg, General cytochrome P-450 inhibitors and cytochrome P-450 isoform-selective substrates and inhibitors were used to characterize the activity of recombinant human inducible NOS (iNOS). Classical cytochrome P-450 ligands such as the mechanism-based inactivator 1-aminobenzotriazole did not inhibit iNOS. Of a panel of 30 human cytochrome P-450 isoform selective substrates and inhibitors, only chlorzoxazone, a cytochrome P-450 2E1 (CYP2E1) substrate, showed any significant inhibition of iNOS activity. Chlorzoxazone was not a substrate for iNOS but was a potent competitive inhibitor with respect to L-Arg with K-i = 3.3 +/- 0.7 mu M. The binding of chlorzoxazone to iNOS and human and rat liver microsomal cytochrome P-450 induced a high spin, type I spectra, which was reversed by imidazole, Although the binding of chlorzoxazone to iNOS and its inhibition of iNOS activity suggest some similarity between iNOS and CYP2E1 activity, other CYP2E1 substrates and inhibitors including zoxazolamine were not inhibitors of iNOS. Overall, iNOS activity is distinctly different from the major cytochrome P-450 enzymes in human liver microsomes.	MERCK RES LABS, DEPT DRUG METAB, RAHWAY, NJ 07065 USA	Merck & Company	Grant, SK (corresponding author), MERCK RES LABS, DEPT ENZYMOL IMMUNOL & INFLAMMAT, POB 2000, RAHWAY, NJ 07065 USA.							ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; BABBEDGE RC, 1993, BRIT J PHARMACOL, V110, P225, DOI 10.1111/j.1476-5381.1993.tb13796.x; BLANDWARD PA, 1995, LIFE SCI, V57, pPL131, DOI 10.1016/0024-3205(95)02046-L; BOUCHER JL, 1992, BIOCHEM BIOPH RES CO, V187, P880, DOI 10.1016/0006-291X(92)91279-Y; Calaycay J, 1996, PORTL PR P, V10, P56; CAMPOS KL, 1995, J BIOL CHEM, V270, P1721, DOI 10.1074/jbc.270.4.1721; CARRIERE V, 1993, CHEM RES TOXICOL, V6, P852, DOI 10.1021/tx00036a015; CATTELL V, 1995, HISTOCHEM J, V27, P777; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CLEMENT B, 1994, XENOBIOTICA, V24, P671, DOI 10.3109/00498259409043269; CLEMENT B, 1993, BIOCHEM PHARMACOL, V46, P2249, DOI 10.1016/0006-2952(93)90616-5; DEGTYARENKO KN, 1995, PROTEIN ENG, V8, P737, DOI 10.1093/protein/8.8.737; DEMONTELLANO PRO, 1981, ARCH BIOCHEM BIOPHYS, V210, P717, DOI 10.1016/0003-9861(81)90239-3; DEMONTELLANO PRO, 1981, BIOCHEM J, V195, P761, DOI 10.1042/bj1950761; DEMONTELLANO PRO, 1983, J BIOL CHEM, V258, P8623; DEVRIES JD, 1994, BIOPHARM DRUG DISPOS, V15, P587, DOI 10.1002/bdd.2510150706; DUDEK RR, 1995, P SOC EXP BIOL MED, V209, P60; EVANS TG, 1993, J IMMUNOL, V151, P907; GELBOIN HV, 1993, PHARMACOL REV, V45, P413; GILLAM EMJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P59, DOI 10.1006/abbi.1994.1280; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Green BG, 1996, BIOCHEM BIOPH RES CO, V225, P621, DOI 10.1006/bbrc.1996.1220; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HALPERT JR, 1994, TOXICOL APPL PHARM, V125, P163, DOI 10.1006/taap.1994.1061; HALPERT JR, 1995, ANNU REV PHARMACOL, V35, P29, DOI 10.1146/annurev.pharmtox.35.1.29; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; JAYYOSI Z, 1995, J PHARMACOL EXP THER, V273, P1156; KATO R, 1969, J BIOCHEM-TOKYO, V66, P739; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; KHARASCH ED, 1993, CLIN PHARMACOL THER, V53, P643, DOI 10.1038/clpt.1993.85; KIM RB, 1995, CLIN PHARMACOL THER, V57, P645, DOI 10.1016/0009-9236(95)90227-9; KNICKLE LC, 1992, CAN J PHYSIOL PHARM, V70, P1610, DOI 10.1139/y92-231; KWON NS, 1990, J BIOL CHEM, V265, P13442; LEONE AM, 1991, J BIOL CHEM, V266, P23790; LI HY, 1995, ACTA CRYSTALLOGR D, V51, P21, DOI 10.1107/S0907444994009194; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1994, FEBS LETT, V350, P199, DOI 10.1016/0014-5793(94)00766-7; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Miller MJS, 1995, MEDIAT INFLAMM, V4, P387, DOI 10.1155/S0962935195000639; MOLINA JA, 1995, EUR J NEUROL, V2, P225, DOI 10.1111/j.1468-1331.1995.tb00123.x; MUGFORD CA, 1992, FUND APPL TOXICOL, V19, P43, DOI 10.1016/0272-0590(92)90026-E; NAGAFUJI T, 1995, NEUROREPORT, V6, P1541, DOI 10.1097/00001756-199507310-00019; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NEDELCHEVA V, 1994, XENOBIOTICA, V24, P1151, DOI 10.3109/00498259409038673; NEWTON DJ, 1995, DRUG METAB DISPOS, V23, P154; OLKEN NM, 1994, BIOCHEMISTRY-US, V33, P14784, DOI 10.1021/bi00253a017; OSHEA D, 1994, CLIN PHARMACOL THER, V56, P359, DOI 10.1038/clpt.1994.150; OYEKAN AO, 1994, J PHARMACOL EXP THER, V268, P262; PETER R, 1990, CHEM RES TOXICOL, V3, P566, DOI 10.1021/tx00018a012; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; REYNOLDS CH, 1995, ACS SYM SER, V589, P171; ROBERTSON CA, 1993, BIOCHEM BIOPH RES CO, V197, P523, DOI 10.1006/bbrc.1993.2510; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Sari MA, 1996, BIOCHEMISTRY-US, V35, P7204, DOI 10.1021/bi960087u; SCHENKMAN JB, 1970, BIOCHEMISTRY-US, V9, P2081, DOI 10.1021/bi00812a009; SCHENKMAN JB, 1982, HEPATIC CYTOCHROME P, P587; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STEVENSTRUSS R, 1995, BIOCHEMISTRY-US, V34, P15638, DOI 10.1021/bi00048a006; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WALSH C, 1979, ENZYMATIC REACTION M, P464; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG RW, 1988, BIOCHEM PHARMACOL, V37, P3049, DOI 10.1016/0006-2952(88)90298-5; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; Wolfe GC, 1996, PORTL PR P, V10, P60; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P300, DOI 10.1006/abbi.1994.1241; WOLFF DJ, 1993, J BIOL CHEM, V268, P9430; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V314, P360, DOI 10.1006/abbi.1994.1454; WOLFF DJ, 1994, ARCH BIOCHEM BIOPHYS, V311, P293, DOI 10.1006/abbi.1994.1240; WOODCROFT KJ, 1990, CAN J PHYSIOL PHARM, V68, P1278, DOI 10.1139/y90-192; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YAMAZAKI H, 1995, DRUG METAB DISPOS, V23, P438	81	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					977	983		10.1074/jbc.272.2.977	http://dx.doi.org/10.1074/jbc.272.2.977			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995391	hybrid			2022-12-25	WOS:A1997WC04800042
J	Powlowski, J; Sealy, J; Shingler, V; Cadieux, E				Powlowski, J; Sealy, J; Shingler, V; Cadieux, E			On the role of DmpK, an auxiliary protein associated with multicomponent phenol hydroxylase from Pseudomonas sp. strain CF600	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GENES; PURIFICATION; ORGANIZATION; DEGRADATION; EXPRESSION; BIOCHEMISTRY; ACTIVATION; CLEAVAGE; CLONING	DmpK from Pseudomonas sp. strain CF600 represents a group of proteins required by phenol-degrading bacteria that utilize a multicomponent iron-containing phenol hydroxylase, DmpK has been overexpressed in Escherichia coli and purified to homogeneity; it lacks redox cofactors and was found to strongly inhibit phenol hydroxylase in vitro, Chemical cross-linking experiments established that DmpK binds to the two largest subunits of the oxygenase component of the hydroxylase; this may interfere with binding of the hydroxylase activator protein, DmpM, causing inhibition, Since expression of DmpK normally appears to be much lower than that of the components of the oxygenase, inhibition may not occur in vivo. Hence, the interaction between DmpK and the oxygenase manifested in the inhibition and crosslinking results prompted construction of E. coli strains in which the oxygenase component was expressed in the presence and absence of a low molar ratio of DmpK, Active oxygenase was detected only when expressed in the presence of DmpK, Furthermore, inactive oxygenase could be activated in vitro by adding ferrous iron, in a process that was dependent on the presence of DmpK, These results indicate that DmpK plays a role in assembly of the active form of the oxygenase component of phenol hydroxylase.	UMEA UNIV,DEPT CELL & MOL BIOL,S-90187 UMEA,SWEDEN	Umea University	Powlowski, J (corresponding author), CONCORDIA UNIV,DEPT CHEM & BIOCHEM,1455 DE MAISONNEUVE BLVD W,MONTREAL,PQ H3G 1M8,CANADA.			Shingler, Victoria/0000-0002-7349-1678				ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; BAGDASARIAN MM, 1983, GENE, V26, P273, DOI 10.1016/0378-1119(83)90197-X; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; EHRT S, 1995, MOL MICROBIOL, V18, P13, DOI 10.1111/j.1365-2958.1995.mmi_18010013.x; FOX BG, 1994, BIOCHEMISTRY-US, V33, P12776, DOI 10.1021/bi00209a008; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; FURSTE JP, 1986, GENE AMST, V48, P199; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HERRMANN H, 1995, MOL GEN GENET, V247, P240, DOI 10.1007/BF00705655; JOHNSON GR, 1995, APPL ENVIRON MICROB, V61, P3336, DOI 10.1128/AEM.61.9.3336-3346.1995; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; LIPSCOMB JD, 1994, ANNU REV MICROBIOL, V48, P371, DOI 10.1146/annurev.mi.48.100194.002103; MASSEY V, 1957, J BIOL CHEM, V229, P763; MATSUDAIRA P, 1993, PRACTICAL GUIDE PROT, P71; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; NEWMAN LM, 1995, BIOCHEMISTRY-US, V34, P14066, DOI 10.1021/bi00043a012; NG LC, 1994, GENE, V151, P29, DOI 10.1016/0378-1119(94)90629-7; NORDLUND I, 1990, J BACTERIOL, V172, P6826, DOI 10.1128/jb.172.12.6826-6833.1990; NORDLUND I, 1993, J GEN MICROBIOL, V139, P2695, DOI 10.1099/00221287-139-11-2695; PARK IS, 1994, P NATL ACAD SCI USA, V91, P3233, DOI 10.1073/pnas.91.8.3233; POWLOWSKI J, 1990, J BACTERIOL, V172, P6834, DOI 10.1128/jb.172.12.6834-6840.1990; Powlowski Justin, 1994, Biodegradation, V5, P219, DOI 10.1007/BF00696461; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHINGLER V, 1989, J GEN MICROBIOL, V135, P1083; WHITE TC, 1992, J BIOL CHEM, V267, P24007; YEN KM, 1991, J BACTERIOL, V173, P5315, DOI 10.1128/jb.173.17.5315-5327.1991	32	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					945	951		10.1074/jbc.272.2.945	http://dx.doi.org/10.1074/jbc.272.2.945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995386	hybrid			2022-12-25	WOS:A1997WC04800037
J	Sleat, DE; Lobel, P				Sleat, DE; Lobel, P			Ligand binding specificities of the two mannose 6-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; PHOSPHORYLATED OLIGOSACCHARIDES; TARGETED DISRUPTION; CYTOPLASMIC DOMAIN; BOVINE TESTES; ENDOCYTOSIS; MUTATIONS; PROTEINS	Two mannose 6-phosphate (Man-6-P) receptors (MPRs) direct the vesicular transport of newly synthesized lysosomal enzymes that contain Man-6-P from the Gels to a prelysosomal compartment. In order to understand the respective roles of the M(r) = 46,000 cation-dependent (CD-) MPR and the M(r) = 300,000 cation-independent (CI-) MPR in lysosomal targeting, an assay has been developed that simultaneously measures the relative affinity of each MPR for multiple ligands. Glycoproteins containing Man-6-P were affinity purified from the metabolically labeled secretions of mutant mouse fibroblasts lacking both MPRs. They were incubated with purified MPRs, and the resulting receptor ligand complexes were immunoprecipitated by anti-MPR monoclonal antibodies coupled to agarose beads. Ligands were eluted with Man-6-P and then quantified following SDS-polyacrylamide gel electrophoresis. Saturating concentrations of CI-MPR resulted in the complete recovery of each Man-6-P glycoprotein in receptor-ligand complexes. Apparent affinity constants ranged between 1 and 5 nM for the individual species. Ligands precipitated by the CD-MPR appeared identical to those bound by the CI-MPR, with apparent affinity constants ranging between 7 and 28 nM. The binding affinities of the two receptors for different ligands were not correlated, indicating that the two MPRs preferentially recognize different subsets of lysosomal enzymes. In addition, saturating levels of CD-MPR resulted in the precipitation of only 50% of the total input ligands, suggesting that the CD-MPR binds a subpopulation of the Man-6-P glycoproteins bound by the CI-MPR. These results provide a biochemical mechanism, which, in part, may explain the interaction of the two MPRs with overlapping yet distinct subsets of ligands in vivo.	RUTGERS STATE UNIV, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08854 USA; UNIV MED & DENT NEW JERSEY, DEPT PHARMACOL, PISCATAWAY, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45992] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DISTLER JJ, 1987, METHOD ENZYMOL, V138, P504; DISTLER JJ, 1991, J BIOL CHEM, V266, P21687; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FILSON AJ, 1993, DEVELOPMENT, V118, P731; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1993, ADV CELL MOL BIOL M, V1, P51; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JOURDIAN GW, 1987, PROTIDES BIOL FLUIDS, V35, P395; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MA ZM, 1991, J BIOL CHEM, V266, P10589; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; NISSLEY P, 1991, ADV EXP MED BIOL, V293, P311; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; SAHAGIAN GG, 1982, METHOD ENZYMOL, V83, P392; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VALENZANO KJ, 1993, ANAL BIOCHEM, V209, P156, DOI 10.1006/abio.1993.1096; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036	28	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					731	738		10.1074/jbc.272.2.731	http://dx.doi.org/10.1074/jbc.272.2.731			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995357	hybrid			2022-12-25	WOS:A1997WC04800008
J	Yin, TG; Shen, R; Feng, GS; Yang, YC				Yin, TG; Shen, R; Feng, GS; Yang, YC			Molecular characterization of specific interactions between SHP-2 phosphatase and JAK tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-2 DOMAINS; ERYTHROPOIETIN RECEPTOR; SIGNAL-TRANSDUCTION; SYP PHOSPHATASE; PROTEIN-KINASE; ACTIVATION; INSULIN; BETA	Interactions between SHP-2 phosphotyrosine phosphatase and JAK tyrosine kinases have recently been implicated in cytokine signal transduction. However, the molecular basis of these interactions is not well understood. In this study, we demonstrate that SHP-2 is tyrosine-phosphorylated by and associated with JAK1 and JAK2 but not JAK3 in COS-1 cell cotransfection experiments. SHP-2 phosphatase activity appears not to be required for JAK and SHP-2 interactions because SHP-2 with a mutation at amino acid 463 from Cys to Ser, which renders SHP-2 inactive, can still bind JAKs. We further demonstrate that SHP-2 SH2 domains (amino acids 1-209) are not essential for the association of JAKs with SHP-2, and the region between amino acids 232 and 272 in SHP-2 is important for the interactions. Furthermore, tyrosine residues 304 and 327 in SHP-2 are phosphorylated by JAKs, and phosphorylated SHP-2 can associate with the downstream adapter protein Grb2. Finally, deletion of the N terminus but not the kinase like domain of JAK2 abolishes the association of JAK2 with SHP-2. Taken together, these studies identified novel sequences for SHP-2 and JAK interactions that suggest unique signaling mechanisms mediated by these two molecules.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL018819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL18819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NIGMS NIH HHS [R29GM53660] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARTGETSINGER LS, 1993, CELL, V74, P237; CASE RD, 1994, J BIOL CHEM, V269, P10467; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KUHNE MR, 1994, J BIOL CHEM, V269, P15833; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YIN TG, 1993, J IMMUNOL, V151, P2555; YIN TG, 1995, J BIOL CHEM, V270, P20497, DOI 10.1074/jbc.270.35.20497; YIN TG, 1994, J BIOL CHEM, V269, P26614; YIN TG, 1994, EXP HEMATOL, V22, P467	31	108	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1032	1037		10.1074/jbc.272.2.1032	http://dx.doi.org/10.1074/jbc.272.2.1032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995399	hybrid			2022-12-25	WOS:A1997WC04800050
J	Beecher, DJ; Wong, ACL				Beecher, DJ; Wong, ACL			Tripartite hemolysin BL from Bacillus cereus - Hemolytic analysis of component interactions and a model for its characteristic paradoxical zone phenomenon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT; ATTACK	Hemolysin BL (HBL) is a unique membrane-lytic toxin from Bacillus cereus composed of three distinct proteins, designated B, L(1), and L(2). HBL produces a paradoxical zone phenomenon in gel diffusion assays in sheep blood agar, Lysis does not begin immediately adjacent to the source of diffusion; rather, it begins several millimeters away. Cells near the source and at intersections of lysis zones remain intact longer. Here, we developed a spectrophotometric hemolysis assay system that measures the activities of the individual HBL components and used it to analyze the mechanisms of hemolysis and the paradoxical zone phenomenon. The B component was rate-limiting, and erythrocytes were slowly primed by B at an optimal concentration of about 1.3 nM to rapid lytic action by the combination of the L components (L(1+2)). All of the individual components bound to cells independently, and membrane-associated HBL components were neutralized by specific antibodies, suggesting that lysis was caused by formation of a membrane attack complex on the cell surface, Osmotic protection experiments indicate a colloid osmotic lysis mechanism. Concentrations of the B component above 1.3 nM caused inhibition of L(1)-mediated lysis, and L(1) inhibited the priming reaction of B over a similar concentration range. From analyses of spectrophotometric and diffusion assays we constructed a basic model for the interactions between HBL components and for the paradoxical zone phenomenon in blood agar. In the latter, areas of slow lysis near diffusion sources are caused primarily by the accumulation of inhibitory levels of L(1) reached before cells are primed by B.			Beecher, DJ (corresponding author), UNIV WISCONSIN,INST FOOD RES,DEPT FOOD MICROBIOL & TOXICOL,1925 WILLOW DR,MADISON,WI 53706, USA.							ALOUF JE, 1994, ZBL BAKT S, V24, P3; BAUMANN P, 1991, MICROBIOL REV, V55, P425, DOI 10.1128/MMBR.55.3.425-436.1991; BEECHER DJ, 1995, INFECT IMMUN, V63, P632, DOI 10.1128/IAI.63.2.632-639.1995; BEECHER DJ, 1995, INFECT IMMUN, V63, P4423, DOI 10.1128/IAI.63.11.4423-4428.1995; BEECHER DJ, 1990, INFECT IMMUN, V58, P2220, DOI 10.1128/IAI.58.7.2220-2227.1990; BEECHER DJ, 1994, INFECT IMMUN, V62, P980, DOI 10.1128/IAI.62.3.980-986.1994; BEECHER DJ, 1994, APPL ENVIRON MICROB, V60, P1646, DOI 10.1128/AEM.60.5.1646-1651.1994; BEECHER DJ, 1991, INFECT IMMUN, V59, P1778, DOI 10.1128/IAI.59.5.1778-1784.1991; BHAKDI S, 1991, IMMUNOL TODAY, V12, P318, DOI 10.1016/0167-5699(91)90007-G; BHAKDI S, 1996, ARCH MICROBIOL, V165, P71; ESSER AF, 1991, IMMUNOL TODAY, V12, P316, DOI 10.1016/0167-5699(91)90006-F; ESSER AF, 1994, TOXICOLOGY, V87, P229, DOI 10.1016/0300-483X(94)90253-4; Fehrenbach F.J., 1991, SOURCEBOOK BACTERIAL, P187; HEINRICHS JH, 1993, J BACTERIOL, V175, P6760, DOI 10.1128/jb.175.21.6760-6766.1993; Leppla S.H., 1991, SOURCEBOOK BACTERIAL, P277; LINDER R, 1991, SOURCEBOOK BACTERIAL, P101; MOAYERI M, 1994, INFECT IMMUN, V62, P4124, DOI 10.1128/IAI.62.10.4124-4134.1994; PONDER E, 1948, HEMOLYSIS RELATED PH, P168; PREVOST G, 1995, INFECT IMMUN, V63, P4121; PREVOST G, 1994, ZBL BAKT S, V24, P284; RYAN PA, 1996, 96 GEN M AM SOC MICR, P384; [No title captured]	22	94	99	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					233	239						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995253				2022-12-25	WOS:A1997WA56400040
J	Gilleron, M; Himoudi, N; Adam, O; Constant, P; Venisse, A; Riviere, M; Puzo, G				Gilleron, M; Himoudi, N; Adam, O; Constant, P; Venisse, A; Riviere, M; Puzo, G			Mycobacterium smegmatis phosphoinositols-glyceroarabinomannans - Structure and localization of alkali-labile and alkali-stable phosphoinositides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BOVIS BCG; MYOINOSITOL PHOSPHATES; NONREDUCING TERMINI; MASS-SPECTROMETRY; NMR-SPECTROSCOPY; FACTOR-ALPHA; LIPOARABINOMANNAN; TUBERCULOSIS; STRAINS	Lipoarabinomannans from fast growing Mycobacterium sp., namely AraLAMs, stimulate the early events of macrophage activation. The immunological activities of all of these AraLAMs drastically decrease with the loss of the mild alkali groups, which were believed to be restricted to the fatty acid residues from the phosphatidyl-myo-inositol anchor. This report reveals the presence and the structure of mild alkali-labile phosphoinositide units linked via the phosphate to the C-5 of the beta-D-Araf in the AraLAMs of Mycobacterium smegmatis, a fast growing mycobacterial species. Their structure was unambiguously established with a strategy based on both one-dimensional P-31 and two-dimensional H-1-P-31 heteronuclear multiple quantum correlation spectroscopy (HMQC) and HMQC-homonuclear Hartmann-Hahn spectroscopy NMR experiments applied to native AraLAMs and to AraLAMs treated in mild alkali conditions. Next to these alkali-labile phosphoinositides estimated at three per molecule, two other mild alkali-stable phosphoinositide units were identified: the expected (myo-inositol-1)-phosphate-(3-glycerol) unit typifying the well known glycosylphosphatidylinositol anchor of the mannan core and, more surprisingly, one (myo-inositol-1)-phosphate-(5-beta-D-Araf) unit having the same structure as the alkali-labile ones. Moreover, these four phosphoinositide units were found capping the arabinan side chains. Thus, their different behavior toward mild alkaline hydrolysis was explained according to their accessibility to the alkali reagent. This novel class of LAMs, namely phosphoinositols-glyceroarabinomannans (PI-GAMs), are characterized by their phosphoinositide units but also by the absence of fatty acid residues. These PI-GAMs were found to elicit the secretion of tumor necrosis factor-alpha, suggesting that phosphoinositides are the major PI-GAM epitope involved in this process.	CNRS, INST PHARMACOL & BIOL STRUCT, F-31062 TOULOUSE, FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)				GILLERON, Martine/0000-0002-2581-3302				ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; ANGYAL SJ, 1972, AUST J CHEM, V25, P1695, DOI 10.1071/CH9721695; ANGYAL SJ, 1979, CARBOHYD RES, V77, P37, DOI 10.1016/S0008-6215(00)83791-X; BARNES PF, 1992, J IMMUNOL, V149, P541; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BRENNAN PJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P55; CERDAN S, 1986, J BIOL CHEM, V261, P4676; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1991, J BIOL CHEM, V266, P9652; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DANIEL TM, 1984, MYCOBACTERIA SOURCE, P417; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; GLUSHKA J, 1992, BIOCHEMISTRY-US, V31, P10741, DOI 10.1021/bi00159a014; HENDERSON TO, 1974, BIOCHEMISTRY-US, V13, P623, DOI 10.1021/bi00700a034; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; JOHANSSON C, 1990, CARBOHYD RES, V207, P177, DOI 10.1016/0008-6215(90)84047-X; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; LERNER L, 1986, J MAGN RESON, V69, P375, DOI 10.1016/0022-2364(86)90091-0; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; ROACH TIA, 1994, INFECT IMMUN, V62, P1176, DOI 10.1128/IAI.62.4.1176-1184.1994; ROACH TIA, 1993, J IMMUNOL, V150, P1886; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; VENISSE A, 1993, J BIOL CHEM, V268, P12401; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; VENISSE A, 1995, J BIOL CHEM, V270, P15012, DOI 10.1074/jbc.270.25.15012; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3; YAN H, 1989, J BIOL CHEM, V264, P18667; ZHANG YH, 1993, J CLIN INVEST, V91, P2076, DOI 10.1172/JCI116430	37	94	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					117	124						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995236				2022-12-25	WOS:A1997WA56400023
J	Welch, H; MaridonneauParini, I				Welch, H; MaridonneauParini, I			Hck is activated by opsonized zymosan and A23187 in distinct subcellular fractions of human granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; FC-GAMMA-RI; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; NADPH-OXIDASE; FUNCTIONAL ASSOCIATION; CELL ACTIVATION; GENE HCK; TRANSLOCATION; SRC	Regulation of neutrophil responses is known to involve tyrosine phosphorylation. Hck, a major neutrophil protein-tyrosine kinase, becomes expressed during differentiation of human promyelocytic NB4 cells into neutrophil-like cells. Hck is mainly localized in a secretory granule-enriched cell fraction, but it is also present in a granule-free membrane fraction and the cytosol. Hck is rapidly and transiently activated upon stimulation of differentiated NB4 cells or human neutrophils with serum-opsonized zymosan or the calcium ionophore A23187, but not by phorbol 12-myristate 13 acetate. In NB4 cells, Hck is also weakly activated by fMet-Leu-Phe. Cell fractionation showed that opsonized zymosan and A23187 induce Hck activation in distinct subcellular fractions. Both stimuli activate Hck in the secretory granule-enriched fraction, but only A23187 activates the kinase in the granule-free membrane fraction. Our results suggest that Hck might regulate early signal transduction events induced by opsonized zymosan and A23187, and that the different subcellular fractions of Hck might serve discrete functions, one of which could be regulation of the degranulation response.	INST PHARMACOL & BIOL STRUCT,CNRS,UPR 9062,F-31077 TOULOUSE,FRANCE	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS)			Maridonneau-Parini, Isabelle/F-1985-2011	Welch, Heidi/0000-0001-7865-7000; Maridonneau-Parini, Isabelle/0000-0003-0189-0976				BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BLACKWELL GJ, 1985, BIOCHEM BIOPH RES CO, V127, P950, DOI 10.1016/S0006-291X(85)80036-X; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DURDEN DL, 1995, J IMMUNOL, V154, P4039; ENGLISH BK, 1993, J EXP MED, V178, P1017, DOI 10.1084/jem.178.3.1017; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GHAZIZADEH S, 1994, J BIOL CHEM, V269, P8878; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HENSON PM, 1992, INFLAMMATION BASIC P, P411; KRYPTA RM, 1988, EMBO J, V7, P3837; LANOTTE M, 1991, BLOOD, V77, P1080; LECABEC V, 1994, BIOCHEM J, V303, P481, DOI 10.1042/bj3030481; LECABEC V, 1995, J BIOL CHEM, V270, P2067; LINSTEDT AD, 1992, J CELL BIOL, V117, P1077, DOI 10.1083/jcb.117.5.1077; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; Lowell CA, 1996, BLOOD, V87, P1780; MARIDONNEAUPARINI I, 1986, J IMMUNOL, V137, P2925; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MarieCardine A, 1996, J BIOL CHEM, V271, P20734, DOI 10.1074/jbc.271.34.20734; MOHN H, 1995, BIOCHEM J, V309, P657; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RENDU F, 1989, BLOOD, V73, P1545; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TESTA U, 1994, CANCER RES, V54, P4508; WALKER F, 1993, J BIOL CHEM, V268, P19552; WANG AVT, 1994, J EXP MED, V180, P1165, DOI 10.1084/jem.180.3.1165; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZIEGLER SF, 1987, MOL CELL BIOL, V7, P2276, DOI 10.1128/MCB.7.6.2276	40	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					102	109						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995234				2022-12-25	WOS:A1997WA56400021
J	Williams, CE; Grotewold, E				Williams, CE; Grotewold, E			Differences between plant and animal myb domains are fundamental for DNA binding activity, and chimeric Myb domains have novel DNA binding specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-RELATED MOTIF; ONCOGENE C-MYB; GENE V-MYB; ZEA-MAYS; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE PRODUCT; NUCLEOTIDE-SEQUENCE; HORDEUM-VULGARE; PETUNIA-HYBRIDA; CDNA CLONES	Several Myb domain proteins have been identified in plants, in which they play important regulatory roles in specific cellular processes. Plant and animal Myb domains have significant differences, but how these differences are important for function is not yet understood. The P gene encodes a Myb domain protein that activates a subset of flavonoid biosynthetic genes in maize floral organs. P and v-Myb bind different DNA sequences in vitro. Here we show that the Myb domain is solely responsible for the sequence-specific DNA binding activity of P, which binds DNA only in the reduced state. Differences in the DNA binding domains of v-Myb and P, which are conserved among animal and plant Myb domains, are fundamental for the high affinity DNA binding activity of these proteins to the corresponding binding sites but are not sufficient for the distinct DNA binding specificities of P and v-Myb. We conclude that significant structural differences distinguish plant from animal Myb domains. A chimeric Myb domain with a novel DNA binding specificity was created by combining Myb repeats of P and v-Myb. This approach could be used to artificially create novel Myb domains and to target transcription factors to genes containing specific promoters or to modify Myb-mediated interactions with other cellular factors.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724; DOWLING COLL,OAKDALE,NY 11769	Cold Spring Harbor Laboratory				Grotewold, Erich/0000-0002-4720-7290				AMARAVADI L, 1994, ONCOGENE, V9, P971; AVILA J, 1993, PLANT J, V3, P553, DOI 10.1046/j.1365-313X.1993.03040553.x; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; Carr MD, 1996, EUR J BIOCHEM, V235, P721, DOI 10.1111/j.1432-1033.1996.00721.x; Chopra S, 1996, PLANT CELL, V8, P1149, DOI 10.1105/tpc.8.7.1149; DOONER HK, 1991, ANNU REV GENET, V25, P173, DOI 10.1146/annurev.ge.25.120191.001133; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARCIA A, 1991, ONCOGENE, V6, P265; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRASSER FA, 1992, ONCOGENE, V7, P1005; GROTEWOLD E, 1991, P NATL ACAD SCI USA, V88, P4587, DOI 10.1073/pnas.88.11.4587; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; GUBLER F, 1995, PLANT CELL, V7, P1879, DOI 10.1105/tpc.7.11.1879; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KOES RE, 1994, BIOESSAYS, V16, P123, DOI 10.1002/bies.950160209; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Li SF, 1995, PLANT J, V8, P963, DOI 10.1046/j.1365-313X.1995.8060963.x; LIFSON S, 1961, J CHEM PHYS, V34, P1963, DOI 10.1063/1.1731802; MAROCCO A, 1989, MOL GEN GENET, V216, P183, DOI 10.1007/BF00334354; Mink S, 1996, MOL CELL BIOL, V16, P1316; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NODA K, 1994, NATURE, V369, P661, DOI 10.1038/369661a0; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; SABLOWSKI RWM, 1994, EMBO J, V13, P128, DOI 10.1002/j.1460-2075.1994.tb06242.x; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Sambrook J., 2002, MOL CLONING LAB MANU; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SOLANO R, 1995, EMBO J, V14, P1773, DOI 10.1002/j.1460-2075.1995.tb07166.x; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; STURM RA, 1988, NATURE, V336, P601, DOI 10.1038/336601a0; STYLES ED, 1989, MAYDICA, V34, P227; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WISSENBACH M, 1993, PLANT J, V4, P411, DOI 10.1046/j.1365-313X.1993.04030411.x	53	78	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					563	571						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995298				2022-12-25	WOS:A1997WA56400085
J	Gladysheva, T; Liu, JY; Rosen, BP				Gladysheva, T; Liu, JY; Rosen, BP			His-8 lowers the pK(a) of the essential Cys-12 residue of the ArsC arsenate reductase of plasmid R773	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESISTANCE OPERON; ACTIVE-SITE; PROTEIN; GLUTATHIONE; DSBA	The 141-residue ArsC arsenate reductase of plasmid R773 has an essential cysteine residue, Cys-12. The pK(a) of Cys-12 was determined to be 6.4, compared with a pK(a) of 8.3 for free cysteine. The possibility of the formation of an ion pair between Cys-12 and a basic residue was investigated. Enzymatic activity was rapidly inactivated by the histidine-modifying reagent diethylpyrocarbonate. The codons for the two histidine residues in ArsC, His-8 and His-88, were changed by site directed mutagenesis. Cells expressing arsC(H88R), arsC(H88S), arsC(H88W), or arsC(H88V) genes retained arsenate resistance, and the purified proteins had wild type level of reductase activity, Cells expressing arSC(H8P), arsC(H8S), arsC(H8G), or arsC(H8R), genes were each sensitive to arsenate, and the purified H8P, H8G, and H8R proteins each lacked enzymatic activity, Using the single histidine proteins it was shown that both histidines react with dethylpyrocarbonate but that only reaction with His-8 resulted in inactivation. The pK(a) value of Cys-12 was determined to be 6.3 in the H8R enzyme and 8.3 in the H8G enzyme. These results indicate that His-8 is essential for catalytic activity and that a positively charged residue is required at position 8 to lower the pK(a) of the cysteine thiolate at position 12.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM52216] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDDERMAN PJ, 1974, ANAL BIOCHEM, V61, P298, DOI 10.1016/0003-2697(74)90360-1; CARDEMIL E, 1987, CHEM MODIFICATION EN, P25; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DEY S, 1996, HDB BIOL PHYS, V2, P1; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GLADYSHEVA TB, 1994, BIOCHEMISTRY-US, V33, P7287; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; JI GY, 1992, P NATL ACAD SCI USA, V89, P9474, DOI 10.1073/pnas.89.20.9474; LIU J, 1995, BIOCHEMISTRY-US, V34, P13572; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MELCHIOR WB, 1970, BIOCHEMISTRY-US, V9, P251, DOI 10.1021/bi00804a010; Miles E W, 1977, Methods Enzymol, V47, P431; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; ODEN KL, 1994, MOL MICROBIOL, V12, P301, DOI 10.1111/j.1365-2958.1994.tb01018.x; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; POLGAR L, 1989, MECH PROTEASE ACTION, P1; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WERNEBURG BG, 1993, ARCH BIOCHEM BIOPHYS, V303, P214, DOI 10.1006/abbi.1993.1275	23	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33256	33260		10.1074/jbc.271.52.33256	http://dx.doi.org/10.1074/jbc.271.52.33256			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969183	hybrid			2022-12-25	WOS:A1996WA71300017
J	Huang, ZM; Chen, Y; Pratt, S; Chen, TH; Bambino, T; Nissenson, RA; Shoback, DM				Huang, ZM; Chen, Y; Pratt, S; Chen, TH; Bambino, T; Nissenson, RA; Shoback, DM			The N-terminal region of the third intracellular loop of the parathyroid hormone (PTH)/PTH-related peptide receptor is critical for coupling to cAMP and inositol phosphate/Ca2+ signal transduction pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS-OOCYTES; ADENYLATE-CYCLASE; PROTEIN; EXPRESSION; ACTIVATION; CELLS; PTH; MUTAGENESIS; CALCITONIN; CALCIUM	Structural determinants within the parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor that mediate G-protein activation of adenylate cyclase and phospholipase C are unknown. We investigated the role of the N-terminal region of the third intracellular loop of the opossum PTH/PTHrP receptor in coupling to two signal transduction pathways, We mutated residues in this region by tandem-alanine scanning and expressed these mutant receptors in COS-7 cells and/or Xenopus oocytes. AU mutant receptors retained high affinity PTH binding in COS-7 cells, indistinguishable from wild-type receptors, Receptors with tandem-alanine substitutions in two N-terminal segments ((377)RVL(379) and (381)TKLR(384)) demonstrated impaired adenylate cyclase and phospholipase C activation. Receptor mutants with single alanine substitutions scanning these two segments showed three different signaling defects in COS-7 cells, 1) Two mutant receptors (V378A and L379A) had reduced inositol phosphate (IP), but normal cAMP responses to PTH, 2) Mutant receptor T381A showed reduced cAMP, but wild-type IP responses to PTH. 3) Mutant receptor K382A demonstrated both markedly reduced cAMP and IP production due to PTH, In oocytes, mutants T381A and K382A showed decreased PTH-stimulated cAMP accumulation and intracellular Ca2+ mobilization. Thus, the N-terminal region of the third intracellular loop of this receptor plays a critical role in coupling to both G(s)- and G(q)-mediated second-messenger generation.	VET AFFAIRS MED CTR,ENDOCRINE UNIT,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94121	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009187] Funding Source: NIH RePORTER; NIDDK NIH HHS [1-F32-DK09187, DK43400] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANTONELLI M, 1994, FEBS LETT, V340, P249, DOI 10.1016/0014-5793(94)80148-7; CHEN TH, 1994, J BONE MINER RES, V9, P293; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; GREENFIELD LJ, 1990, AM J PHYSIOL, V259, pG775; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG ZM, 1995, MOL ENDOCRINOL, V9, P1240, DOI 10.1210/me.9.9.1240; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; Juppner H, 1994, Curr Opin Nephrol Hypertens, V3, P371; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MOORE EE, 1995, MOL ENDOCRINOL, V9, P959, DOI 10.1210/me.9.8.959; NABHAN C, 1995, BIOCHEM BIOPH RES CO, V212, P1015, DOI 10.1006/bbrc.1995.2071; NISSENSON RA, 1993, RECEPTOR, V3, P193; NISSENSON RA, 1988, J BIOL CHEM, V263, P12866; NISSENSON RA, 1985, CANCER RES, V45, P5358; Offermanns S, 1996, MOL ENDOCRINOL, V10, P566, DOI 10.1210/me.10.5.566; ORON Y, 1992, METHOD ENZYMOL, V207, P381; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Philbrick WM, 1996, PHYSIOL REV, V76, P127, DOI 10.1152/physrev.1996.76.1.127; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; STEHNOBITTEL L, 1995, J BIOL CHEM, V270, P30068; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; STRAUB RE, 1990, P NATL ACAD SCI USA, V87, P9514, DOI 10.1073/pnas.87.24.9514; Takhar S, 1996, ENDOCRINOLOGY, V137, P2175, DOI 10.1210/en.137.5.2175; Turner PR, 1996, MOL ENDOCRINOL, V10, P132, DOI 10.1210/me.10.2.132; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WHITE MM, 1990, P NATL ACAD SCI USA, V87, P133, DOI 10.1073/pnas.87.1.133; WONG SKF, 1990, J BIOL CHEM, V265, P6219; ZHU X, 1994, MOL PHARMACOL, V46, P460	34	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33382	33389		10.1074/jbc.271.52.33382	http://dx.doi.org/10.1074/jbc.271.52.33382			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969199	hybrid			2022-12-25	WOS:A1996WA71300033
J	Itabe, H; Yamamoto, H; Suzuki, M; Kawai, Y; Nakagawa, Y; Suzuki, A; Imanaka, T; Takano, T				Itabe, H; Yamamoto, H; Suzuki, M; Kawai, Y; Nakagawa, Y; Suzuki, A; Imanaka, T; Takano, T			Oxidized phosphatidylcholines that modify proteins - Analysis by monoclonal antibody against oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING FACTOR-ACETYLHYDROLASE; SMOOTH-MUSCLE CELLS; ATHEROSCLEROTIC LESIONS; FOAM CELLS; PLASMA-LIPOPROTEINS; ENDOTHELIAL-CELLS; MACROPHAGES; LDL; EXPRESSION; OXIDATION	Oxidatively modified low density lipoprotein (OxLDL) is known to be involved in atherogenesis, We hare previously developed a murine monoclonal antibody, FOH1a/DLH3, which recognized oxidatively modified lipoproteins as well as foam cells in human atherosclerotic lesions (Itabe, H., Takeshima, E., Iwasaki, H., Kimura, J., Yoshida, Y., Imanaka, T., and Takano, T. (1994) J. Biol. Chem. 269, 15274-15279). The antigen of this monoclonal antibody was formed by peroxidation of phosphatidylcholine (PC), and the antigenic oxidized PC (OxPC) derivatives are thought to form complexes with polypeptides including apolipoproteins, OxLDL was measured by a sensitive sandwich enzyme-linked immunosorbent assay using the monoclonal antibody and anti-human apolipoprotein B antibody, in which antigenic OxPC competed with OxLDL. When antigenic activities of PC analogs were tested by the competition assay, 1-palmitoyl-2-(9-oxononanoyl) PC (9-CHO PC) and the hydroperoxide of egg PC potently inhibited the detection of OxLDL. 1-Palmitoyl-2-linoleoyl PC was oxidized with ferrous ion and ascorbic acid, and the antigenic products were purified from the OxPC extracts on high pressure liquid chromatography columns and subsequently analyzed by laser desorption mass spectrometry. Molecular weight determination and retention times of high pressure liquid chromatography suggest that one of these products was 9-CHO PC. Other products are thought to be 8-carbon aldehyde, dihydroxy, and ketohydroxy derivatives of PC. When a C-terminal 16-mer synthetic peptide of the 70-kDa peroxisomal membrane protein was simply incubated with 9-CHO PC, it was found to be reactive in a sandwich enzyme-linked immunosorbent assay using FOH1a/DLH3 and an anti-peptide antiserum. These results suggest that the anti-OxLDL monoclonal antibody FOH1a/DLH3 reacts with several oxidized products of PC including aldehyde derivatives of PC, which covalently modify polypeptides.	KITASATO UNIV,SCH PHARMACEUT SCI,MINATO KU,TOKYO 108,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT BIOMEMBRANES,BUNKYO KU,TOKYO 113,JAPAN	Kitasato University; Tokyo Metropolitan Institute of Medical Science	Itabe, H (corresponding author), TEIKYO UNIV,FAC PHARMACEUT SCI,DEPT MICROBIOL & MOL PATHOL,SAGAMIKO,KANAGAWA 19901,JAPAN.		板部板部, 洋之/ABC-7746-2020	Imanaka, Tsuneo/0000-0003-4677-1356				BANERJI B, 1989, J LIPID RES, V30, P1907; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; DRAKE TA, 1991, AM J PATHOL, V138, P601; FRANKEL EN, 1981, LIPIDS, V16, P279, DOI 10.1007/BF02534950; GALIS ZS, 1992, LAB INVEST, V66, P624; GUPTA CM, 1977, P NATL ACAD SCI USA, V74, P4315, DOI 10.1073/pnas.74.10.4315; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HAMBERG M, 1983, BIOCHIM BIOPHYS ACTA, V752, P353, DOI 10.1016/0005-2760(83)90134-0; HAMBERG M, 1983, BIOCHIM BIOPHYS ACTA, V752, P191, DOI 10.1016/0005-2760(83)90112-1; HARDUIN P, 1995, J LIPID RES, V36, P919; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HOFF HF, 1993, J LIPID RES, V34, P1919; Itabe H, 1996, J LIPID RES, V37, P45; ITABE H, 1994, J BIOL CHEM, V269, P15274; ITABE H, 1988, BIOCHIM BIOPHYS ACTA, V962, P8; Kaiserling E, 1996, GASTROENTEROLOGY, V110, P369, DOI 10.1053/gast.1996.v110.pm8566582; KAMIDO H, 1995, J LIPID RES, V36, P1876; LIAO JK, 1995, J CLIN INVEST, V95, P1457, DOI 10.1172/JCI117816; LOUGHEED M, 1991, J BIOL CHEM, V266, P14519; MARTINNIZARD F, 1991, FEBS LETT, V293, P127, DOI 10.1016/0014-5793(91)81167-7; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; OU ZL, 1995, ANAL BIOCHEM, V227, P289, DOI 10.1006/abio.1995.1283; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PATAKI M, 1992, ARTERIOSCLER THROMB, V12, P936, DOI 10.1161/01.ATV.12.8.936; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RICEEVANS CA, 1991, TECHNIQUES FREE RADI, P207; ROMA P, 1992, J LIPID RES, V33, P819; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; SHACKELFORD RE, 1995, J BIOL CHEM, V270, P3475, DOI 10.1074/jbc.270.8.3475; SHERMA J, 1972, HDB CHROMATOGRAPHY, V2, P155; SKIDMORE WD, 1962, J LIPID RES, V3, P471; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; TOKUMURA A, 1988, BIOCHEM BIOPH RES CO, V155, P863, DOI 10.1016/S0006-291X(88)80575-8; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Watson AD, 1995, J CLIN INVEST, V96, P2882, DOI 10.1172/JCI118359; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZHANG HF, 1993, J BIOL CHEM, V268, P5535; ZHOU X, 1992, J LIPID RES, V33, P1233; ZWIJSEN RML, 1992, BIOCHEM BIOPH RES CO, V186, P1410, DOI 10.1016/S0006-291X(05)81563-3	45	114	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33208	33217		10.1074/jbc.271.52.33208	http://dx.doi.org/10.1074/jbc.271.52.33208			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969177	hybrid			2022-12-25	WOS:A1996WA71300011
J	Fleming, IN; Elliott, CM; Exton, JH				Fleming, IN; Elliott, CM; Exton, JH			Differential translocation of Rho family GTPases by lysophosphatidic acid, endothelin-1, and platelet-derived growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GDP DISSOCIATION INHIBITOR; ACTIN STRESS FIBERS; RAS TRANSFORMATION; REGULATORY PROTEIN; PHOSPHOLIPASE-D; ACTIVATION; CDC42HS; 3-KINASE; KINASE	The small GTPases of the Rho family play a key role in a number of signaling pathways activated by lysophosphatidic acid (LPA). However, little is known concerning the mechanism of regulation of these proteins. In this study we demonstrate that in Swiss 3T3 fibroblasts, LPA induces a sustained, time-dependent relocalization of RhoA to the Triton X-100-soluble low speed membrane fraction, which can be reversed by removal of LPA from the medium, Translocation was only observed with micromolar concentrations of LPA and was inhibited by pretreating the cells with pertussis toxin but not with tyrosine kinase inhibitors. LPA also induced translocation of CDC42Hs to the membranes but had no effect on the distribution of Rad, RhoB, or Rho-GDI. Translocation of RhoA was also induced by endothelin-1. Conversely, platelet-derived growth factor did not cause the translocation of RhoA to any membrane fraction but stimulated relocalization of Rad to the high speed membrane fraction, Significantly, incubation of cell lysates with guanosine 5'-O-(thiotriphosphate) was sufficient to translocate RhoA, Rad, and CDC42Hs from the cytosol to the membranes, whereas incubation with GDP had the opposite effect. These data suggest that the translocation of the Rho family proteins to the membrane fraction is controlled by their activation state and that agonists show selectivity in inducing the activation/translocation of these proteins.	HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MOL PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University				Fleming, Ian/0000-0001-9505-6418				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; FROST AJ, 1996, MOL CELL BIOL, V18, P3707; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWE LR, 1993, J BIOL CHEM, V268, P20717; ISOMURA M, 1991, ONCOGENE, V6, P119; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Malcolm KC, 1996, J BIOL CHEM, V271, P13135, DOI 10.1074/jbc.271.22.13135; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; PARKER PJ, 1995, CURR BIOL, V5, P577, DOI 10.1016/S0960-9822(95)00113-8; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SASAKI T, 1993, J BIOL CHEM, V268, P23959; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; UEDA T, 1990, J BIOL CHEM, V265, P9373; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	37	138	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33067	33073		10.1074/jbc.271.51.33067	http://dx.doi.org/10.1074/jbc.271.51.33067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955154	hybrid			2022-12-25	WOS:A1996VZ37300089
J	Hoffman, L; Rechsteiner, M				Hoffman, L; Rechsteiner, M			Nucleotidase activities of the 26 S proteasome and its regulatory complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; MULTICATALYTIC PROTEINASE COMPLEX; RABBIT RETICULOCYTE LYSATE; UBIQUITIN-LIGATED PROTEINS; HIGH-MOLECULAR-WEIGHT; ESCHERICHIA-COLI; PROTEOLYTIC COMPLEX; 11-S REGULATOR; HYDROLYZES ATP; DYNEIN ATPASE	The 26 S proteasome can be assembled from the multicatalytic protease (or 20 S proteasome) and a large multisubunit regulatory complex in an ATP-dependent reaction. The 26 S proteasome and its regulatory complex were purified from rabbit reticulocytes for characterization of their nucleotidase properties. Both particles hydrolyze ATP, CTP, GTP, and UTP to the corresponding nucleoside diphosphate and inorganic phosphate. The K-m values for hydrolysis of specific nucleotides by the 26 S proteasome are 15 mu M for ATP and CTP, 50 mu M for GTP, and 100 mu M for UTP; K-m values for nucleotide hydrolysis by the regulatory complex are 2-4-fold higher for each nucleotide. Several ATPase inhibitors (erythro-9-[3-(2-hydroxynonyl)] adenine, oligo-mycin, ouabain, and thapsigargin) had no effect on ATP hydrolysis by either complex whereas known inhibitors of proteolysis by the 26 S enzyme (hemin, N-ethylmale imide (NEM), and vanadate) significantly reduced ATP hydrolysis by both particles. Hydrolysis of all nucleotides was inhibited by 5 mM NEM but only GTP and UTP hydrolysis was significantly reduced at 50 mu M NEM, The 15 mu M K-m for ATP hydrolysis by the 26 S proteasome is virtually identical to the observed K-m of 12 mu M ATP for Ub-conjugate degradation, Although nucleotide hydrolysis is required for protein degradation by the 26 S proteasome, nucleotide hydrolysis and peptide bond cleavage are not strictly coupled, Substrate specificity constants (k(cat)/K-m) are similar for hydrolysis of each nucleotide, yet GTP and UTP barely supported Ub-conjugate degradation, Further evidence that nucleotide hydrolysis is not coupled to peptide bond cleavage was obtained using N-acetyl-leucyl-leucyl-norleucinal (LLnL). This compound inhibited peptide hydrolysis by the multicatalytic protease and Ub-conjugate degradation by the 26 S proteasome, but it had little effect on ATP or UTP hydrolysis by the 26 S enzyme.	UNIV UTAH,SCH MED,DEPT BIOCHEM,SALT LAKE CITY,UT 84132	Utah System of Higher Education; University of Utah					NIGMS NIH HHS [GM37009] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037009] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMON T, 1990, J BIOL CHEM, V265, P20723; BINASTEIN M, 1976, MOL PHARMACOL, V12, P191; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BOUCHARD P, 1981, P NATL ACAD SCI-BIOL, V78, P1033, DOI 10.1073/pnas.78.2.1033; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; Cleland W W, 1979, Methods Enzymol, V63, P103; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P23726, DOI 10.1074/jbc.270.40.23726; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1995, FEBS LETT, V363, P97, DOI 10.1016/0014-5793(95)00288-K; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; FISCHER H, 1993, J BIOL CHEM, V268, P22502; FISCHER H, 1994, FEBS LETT, V356, P101, DOI 10.1016/0014-5793(94)01244-X; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; GANOTH D, 1988, J BIOL CHEM, V263, P12412; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/S0968-0004(96)10012-8; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; KOMINAMI K, 1995, EMBO J, V14, P3105, DOI 10.1002/j.1460-2075.1995.tb07313.x; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LARIMORE FS, 1982, J BIOL CHEM, V257, P4187; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LINGRELL JB, 1972, METHOD MOL BIOL, V2, P234; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUCERO HA, 1995, J BIOL CHEM, V270, P9178, DOI 10.1074/jbc.270.16.9178; MA CP, 1994, J BIOL CHEM, V269, P3539; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P722; NADEAU K, 1993, J BIOL CHEM, V268, P1479; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; PENNINGROTH SM, 1982, BIOCHEM BIOPH RES CO, V104, P234, DOI 10.1016/0006-291X(82)91964-7; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1994, J BIOL CHEM, V269, P7709; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; PLAGEMANN PG, 1972, J CELL BIOL, V52, P131, DOI 10.1083/jcb.52.1.131; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; UGAI S, 1993, J BIOCHEM, V113, P754, DOI 10.1093/oxfordjournals.jbchem.a124116; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; WAXMAN L, 1982, P NATL ACAD SCI-BIOL, V79, P4883, DOI 10.1073/pnas.79.16.4883; WEBER MJ, 1971, J BIOL CHEM, V246, P1828; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Yokota K, 1996, MOL BIOL CELL, V7, P853, DOI 10.1091/mbc.7.6.853	66	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32538	32545		10.1074/jbc.271.51.32538	http://dx.doi.org/10.1074/jbc.271.51.32538			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955078	hybrid			2022-12-25	WOS:A1996VZ37300013
J	Penninga, D; vanderVeen, BA; Knegtel, RMA; vanHijum, SAFT; Rozeboom, HJ; Kalk, KH; Dijkstra, BW; Dijkhuizen, L				Penninga, D; vanderVeen, BA; Knegtel, RMA; vanHijum, SAFT; Rozeboom, HJ; Kalk, KH; Dijkstra, BW; Dijkhuizen, L			The raw starch binding domain of cyclodextrin glycosyltransferase from Bacillus circulans strain 251	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIGER; BETA-CYCLODEXTRIN; CYCLOMALTODEXTRIN GLUCANOTRANSFERASE; MACROMOLECULAR STRUCTURES; ESCHERICHIA-COLI; GLUCOAMYLASE; SPECIFICITY; SEQUENCE; PROTEIN; CRYSTALLIZATION	The E-domain of cyclodextrin glycosyltransferase (CGTase) (EC 2.4.1.19) from Bacillus circulans strain 251 is a putative raw starch binding domain. Analysis of the maltose-dependent CGTase crystal structure revealed that each enzyme molecule contained three maltose molecules, situated at contact points between protein molecules. Two of these maltoses were bound to specific sites in the E-domain, the third maltose was bound at the C-domain. To delineate the roles in raw starch binding and cyclization reaction kinetics of the two maltose binding sites in the E-domain, we replaced Trp-616 and Trp-662 of maltose binding site 1 and Tyr-633 of maltose binding site 2 by alanines using site-directed mutagenesis. Purified mutant CGTases were characterized with respect to raw starch binding and cyclization reaction kinetics on both soluble and raw starch. The results show that maltose binding site 1 is most important for raw starch binding, whereas maltose binding site 2 is involved in guiding linear starch chains into the active site. beta-Cyclodextrin causes product inhibition by interfering with catalysis in the active site and the function of maltose binding site 2 in the E-domain. CGTase mutants in the E-domain maltose binding site 1 could no longer be crystallized as maltose-dependent monomers. Instead, the W616A mutant CGTase protein was successfully crystallized as a carbohydrate-independent dimer; its structure has been refined to 2.2 Angstrom resolution. The three-dimensional structure shows that, within the error limits, neither the absence of carbohydrates nor the W616A mutation caused significant further conformational changes. The modified starch binding and cyclization kinetic properties observed with the mutant CGTase proteins thus can be directly related to the amino acid replacements.	UNIV GRONINGEN,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,DEPT MICROBIOL,NL-9751 NN HAREN,NETHERLANDS; UNIV GRONINGEN,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,BIOPHYS CHEM LAB,NL-9747 AG GRONINGEN,NETHERLANDS; UNIV GRONINGEN,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,BIOSON RES INST,NL-9747 AG GRONINGEN,NETHERLANDS	University of Groningen; University of Groningen; University of Groningen			Dijkhuizen, Lubbert/K-3539-2019; Dijkhuizen, Lubbert/E-9454-2014; Dijkstra, Bauke W./H-4308-2019; van Hijum, Sacha/F-6445-2014	Dijkhuizen, Lubbert/0000-0003-2312-7162; Dijkstra, Bauke W./0000-0001-9731-6586; Rozeboom, Henriette/0000-0002-1656-6477				BELSHAW NJ, 1993, EUR J BIOCHEM, V211, P717, DOI 10.1111/j.1432-1033.1993.tb17601.x; BERGSMA J, 1988, P 4 INT S CYCL, P41; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRON S, 1990, MODERN MICROBIOLOGIC, P146; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CHEN LJ, 1991, GENE, V99, P121; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P329; Crowther R. A., 1972, MOL REPLACEMENT METH, P173; CROWTHER RA, 1967, ACTA CRYSTALLOGR, V23, P544, DOI 10.1107/S0365110X67003172; DALMIA BK, 1991, ENZYME MICROB TECH, V13, P982, DOI 10.1016/0141-0229(91)90121-P; DALMIA BK, 1995, BIOTECHNOL BIOENG, V47, P575, DOI 10.1002/bit.260470510; FAGERSTROM R, 1994, MICROBIOL-UK, V140, P2399, DOI 10.1099/13500872-140-9-2399; FRENCH D, 1957, ADV CARBOHYD CHEM, V12, P189; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HOFMANN BE, 1989, J MOL BIOL, V209, P793, DOI 10.1016/0022-2836(89)90607-4; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JESPERSEN HM, 1991, BIOCHEM J, V280, P51, DOI 10.1042/bj2800051; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KIEL JAKW, 1987, MOL GEN GENET, V207, P294, DOI 10.1007/BF00331592; KLEIN C, 1991, J MOL BIOL, V217, P737, DOI 10.1016/0022-2836(91)90530-J; KNEGTEL RMK, 1995, J BIOL CHEM, V270, P29256, DOI 10.1074/jbc.270.49.29256; Kubota M., 1991, DENPUN KAGAKU, V38, P141; KUSNADI AR, 1994, ANN NY ACAD SCI, V721, P168, DOI 10.1111/j.1749-6632.1994.tb47390.x; LAWSON CL, 1994, J MOL BIOL, V236, P590, DOI 10.1006/jmbi.1994.1168; LAWSON CL, 1990, J MOL BIOL, V214, P807, DOI 10.1016/0022-2836(90)90335-J; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; PENNINGA D, 1995, BIOCHEMISTRY-US, V34, P3368, DOI 10.1021/bi00010a028; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SAENGER W, 1980, ANGEW CHEM INT EDIT, V19, P344, DOI 10.1002/anie.198003441; Sambrook J, 1989, MOL CLONING LAB MANU; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHMID G, 1989, TRENDS BIOTECHNOL, V7, P244, DOI 10.1016/0167-7799(89)90015-2; SIGURSKJOLD BW, 1994, EUR J BIOCHEM, V225, P133, DOI 10.1111/j.1432-1033.1994.00133.x; SMITH H, 1988, GENE, V70, P351, DOI 10.1016/0378-1119(88)90207-7; SUNDBERG L, 1974, J CHROMATOGR, V90, P87, DOI 10.1016/S0021-9673(01)94777-6; SVENSSON B, 1986, EUR J BIOCHEM, V154, P497, DOI 10.1111/j.1432-1033.1986.tb09425.x; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; SVENSSON B, 1992, CARBOHYD RES, V227, P29, DOI 10.1016/0008-6215(92)85059-9; SVENSSON B, 1986, CARLSBERG RES COMMUN, V51, P61, DOI 10.1007/BF02907996; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDERVOSSEN JMBM, 1992, APPL ENVIRON MICROB, V58, P3142, DOI 10.1128/AEM.58.9.3142-3149.1992; Vikmon M., 1982, 1ST P INT S CYCL BUD, P69; VILLETTE JR, 1992, BIOTECHNOL APPL BIOC, V16, P57	45	169	188	2	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32777	32784		10.1074/jbc.271.51.32777	http://dx.doi.org/10.1074/jbc.271.51.32777			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955113	Green Published, hybrid			2022-12-25	WOS:A1996VZ37300048
J	Vielhaber, G; Hurwitz, R; Sandhoff, K				Vielhaber, G; Hurwitz, R; Sandhoff, K			Biosynthesis, processing, and targeting of sphingolipid activator protein (SAP) precursor in cultured human fibroblasts - Mannose 6-phosphate receptor-independent endocytosis of SAP precursor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOPROTEIN-1 SGP-1; ACID ALPHA-GLUCOSIDASE; LYSOSOMAL-ENZYMES; INTRACELLULAR-TRANSPORT; LATE ENDOSOMES; BREFELDIN-A; CATHEPSIN-D; CELLS; RAT; DISEASE	Sphingolipid activator proteins (SAPs) are essential cofactors for the lysosomal degradation of glycosphingolipids with short oligosaccharide chains by acidic exohydrolases. SAP-A, -B, -C, and -D derive from proteolysis of a 73-kDa glycoprotein, the SAP precursor. In the present publication, we studied the intracellular transport and the endocytosis of SAP precursor in human skin fibroblasts. Our data indicate that SAP precursor bears phosphate residues on noncomplex carbohydrate chains linked to the SAP-C and the SAP-D domain and sulfate residues on complex carbohydrate chains located within the SAP-A, -C, and possibly the SAP-D domain. Treatment of fibroblasts with either bafilomycin A(1) or 3-methyladenine indicates that proteolytic cleavage of SAP precursor begins as early as in the late endosomes. To determine whether targeting of SAP precursor depends on mannose g-phosphate residues, we analyzed the processing of SAP precursor in I-cell disease fibroblasts. In these cells nearly normal amounts of newly synthesized SAP-C were found, although secretion of SAP precursor was enhanced 2-3-fold. Moreover, SAP-C could be localized to lysosomal structures by indirect immunofluorescence in normal and in I-cell disease fibroblasts. Mannose g-phosphate was not found to interfere significantly with endocytosis of SAP precursor. Normal fibroblasts internalized SAP precursor secreted from I-cells nearly as efficiently as the protein secreted from normal cells. To our surprise, deglycosylated SAP precursor was taken up by mannose 6-phosphate receptor double knock out mouse fibroblasts more efficiently than the glycosylated protein. We propose that intracellular targeting of SAP precursor to lysosomes is only partially dependent on mannose 6-phosphate residues, whereas its endocytosis occurs in a carbohydrate-independent manner.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; UNIV BONN,INST PHYSIOL CHEM,D-53115 BONN,GERMANY	University of Bonn; University of Bonn								BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRAULKE T, 1987, BIOCHEM BIOPH RES CO, V143, P178, DOI 10.1016/0006-291X(87)90647-4; CARSON GS, 1995, J NEUROCHEM, V64; CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; CLAGUE MJ, 1994, J BIOL CHEM, V269, P21; COLLARD MW, 1988, BIOCHEMISTRY-US, V27, P4557, DOI 10.1021/bi00412a050; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; FUJIBAYASHI S, 1985, CLIN CHIM ACTA, V146, P147, DOI 10.1016/0009-8981(85)90053-1; FUJIBAYASHI S, 1986, BIOCHIM BIOPHYS ACTA, V875, P554; FUJIBAYASHI S, 1986, J BIOL CHEM, V261, P5339; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GLICKMAN JN, 1993, J CELL BIOL, V123, P99, DOI 10.1083/jcb.123.1.99; GONZALEZNORIEGA A, 1980, J CELL BIOL, V85, P839, DOI 10.1083/jcb.85.3.839; HASILIK A, 1980, J BIOL CHEM, V255, P4937; Henseler M, 1996, AM J HUM GENET, V58, P65; Henseler M, 1996, J BIOL CHEM, V271, P8416, DOI 10.1074/jbc.271.14.8416; HERMO L, 1992, ANAT REC, V232, P401, DOI 10.1002/ar.1092320310; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HOLTSCHMIDT H, 1991, J BIOL CHEM, V266, P7556; IGDOURA SA, 1993, ANAT RECORD, V235, P411, DOI 10.1002/ar.1092350310; Igdoura SA, 1996, CELL TISSUE RES, V283, P385, DOI 10.1007/s004410050549; INUI K, 1984, ARCH BIOCHEM BIOPHYS, V233, P556, DOI 10.1016/0003-9861(84)90479-X; KAPLAN J, 1981, CELL, V24, P925, DOI 10.1016/0092-8674(81)90118-5; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KLEIN A, 1994, BIOCHEM BIOPH RES CO, V200, P1440, DOI 10.1006/bbrc.1994.1612; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMONTAGNE S, 1994, J BIOL CHEM, V269, P20528; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORIMOTO S, 1990, P NATL ACAD SCI USA, V87, P3493, DOI 10.1073/pnas.87.9.3493; NAKANO T, 1989, J BIOCHEM-TOKYO, V105, P152, DOI 10.1093/oxfordjournals.jbchem.a122629; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; PUNNONEN EL, 1994, EUR J CELL BIOL, V65, P14; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SANO A, 1989, BIOCHEM BIOPH RES CO, V165, P1191, DOI 10.1016/0006-291X(89)92728-9; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SCHWARZMANN GOH, 1978, J BIOL CHEM, V253, P6983; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; SYLVESTER SR, 1989, BIOL REPROD, V41, P941, DOI 10.1095/biolreprod41.5.941; TSUJI A, 1987, BIOCHEM INT, V15, P945; Vaccaro AM, 1995, J BIOL CHEM, V270, P30576, DOI 10.1074/jbc.270.51.30576; VANDONGEN JM, 1985, EUR J CELL BIOL, V39, P179; VANLEUVEN F, 1980, CELL, V20, P37, DOI 10.1016/0092-8674(80)90232-9; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; VOGEL A, 1987, ARCH BIOCHEM BIOPHYS, V259, P627, DOI 10.1016/0003-9861(87)90529-7; WAHEED A, 1982, BIOCHEM BIOPH RES CO, V105, P1052, DOI 10.1016/0006-291X(82)91076-2; WISSELAAR HA, 1993, J BIOL CHEM, V268, P2223; ZHU Y, 1994, J BIOL CHEM, V269, P3846	56	55	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32438	32446		10.1074/jbc.271.50.32438	http://dx.doi.org/10.1074/jbc.271.50.32438			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943309	hybrid			2022-12-25	WOS:A1996VY34000100
J	Buttice, G; DuterqueCoquillaud, M; Basuyaux, JP; Carrere, S; Kurkinen, M; Stehelin, D				Buttice, G; DuterqueCoquillaud, M; Basuyaux, JP; Carrere, S; Kurkinen, M; Stehelin, D			Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex	ONCOGENE			English	Article						extracellular matrix; metalloproteinases; oncogenes; gene regulation	SERUM RESPONSE ELEMENT; DNA-BINDING MOTIF; TRANSCRIPTION FACTORS; C-FOS; EXTRACELLULAR-MATRIX; DOMAIN PROTEINS; AP-1 SITE; ACTIVATION; ENHANCER; PROMOTER	Collagenase1 (MMP1) and stromelysin1 (MMP3) are extracellular proteolytic enzymes that degrade connective tissue macromolecules and basement membranes. Both genes are regulated by the Ets and Fos/Jun families of transcription factors/oncoproteins. Here, we show that two members of the Ets-family, Ets2 and Erg and their combinations differentially regulate collagenase1 and stromelysin1 promoter activity. In transiently transfected cells, Ets2 activates both promoters whereas Erg induces collagenase1 but not stromelysin1 promoter activity. Moreover, Erg completely inhibits stromelysin1 promoter activation by Ets2. In gel shift assays however, the Erg protein bound little or not to the collagenase1 promoter, whereas it bound to the stromelysin1 promoter. By site-specific mutagenesis, we identified one major site at -88 that abolished collagenase1 promoter activation by Erg. Surprisingly, mutation of the collagenase1 AP1 site at -73 also abolished the activation by Erg suggesting that Erg cooperates with Fos/Jun in collagenase1 promoter regulation. Indeed, gel shift and in vitro protein interaction studies showed that Erg binds to the Fos/Jun complex. Thus, Erg represents the first example of a transcription factor that can distinguish between the collagenase1 and stromelysin1 promoters in that when Erg is recruited by Fos/Jun at the promoter, it transcriptionally activates collagenase1 gene but not stromelysin1 expression.	WAYNE STATE UNIV, SCH MED, DEPT PATHOL, DETROIT, MI 48202 USA; WAYNE STATE UNIV, SCH MED, CTR MOL MED GENET, DETROIT, MI 48202 USA	Wayne State University; Wayne State University	Buttice, G (corresponding author), INST PASTEUR, CNRS URA 1160, MOL ONCOL LAB, 1 RUE CALMETTE, BP 245, F-59019 LILLE, FRANCE.			Duterque-Coquillaud, Martine/0000-0003-3943-5629; Buttice', Giovanna/0000-0001-6550-5585				ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BUTTICE G, 1990, NUCLEIC ACIDS RES, V18, P3079, DOI 10.1093/nar/18.10.3079; BUTTICE G, 1994, CONTRIB NEPHROL, V107, P101; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; GACK S, 1995, CELL GROWTH DIFFER, V6, P759; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GRANT PA, 1995, EMBO J, V14, P4501, DOI 10.1002/j.1460-2075.1995.tb00129.x; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; ICHIKAWA H, 1994, CANCER RES, V54, P2865; IMAI K, 1995, J BIOL CHEM, V270, P6691, DOI 10.1074/jbc.270.12.6691; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JOHN S, 1995, MOL CELL BIOL, V15, P1786; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NERLOV C, 1991, ONCOGENE, V6, P1583; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SHAPIRO SD, 1995, J BIOL CHEM, V270, P6351, DOI 10.1074/jbc.270.11.6351; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WERB Z, 1994, PROTEINASES MATRIX D; WERNERT N, 1992, AM J PATHOL, V140, P119; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129	57	140	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2297	2306						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957070				2022-12-25	WOS:A1996VX10800001
J	Smith, ML; Kontny, HU; Zhan, QM; Sreenath, A; OConnor, PM; Fornace, AJ				Smith, ML; Kontny, HU; Zhan, QM; Sreenath, A; OConnor, PM; Fornace, AJ			Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to uv-irradiation or cisplatin	ONCOGENE			English	Article						p53; GADD45; repair	NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL DOMAIN; NUCLEAR ANTIGEN; GROWTH ARREST; G1 CHECKPOINT; P53; DAMAGE; PROTEIN; INHIBITION; REPLICATION	Loss of p53 function in cancer cells commonly results in a condition of genomic instability. This is believed to emanate from a loss of the G(1) checkpoint response to DNA damage. While the role of p53 in the induction of a G(1) arrest is well-accepted, additional p53 functions are being discovered. Cell cycle checkpoints presumably function to allow additional time for DNA repair after damage is incurred, however, genetic studies in yeast suggest that components of the checkpoint pathway may also be involved in DNA lesion processing (Lydall and Weinert, 1995). Recent evidence suggests that this may also be the case for p53, as suggested by numerous reports linking p53 function to DNA repair. Thus, loss of p53 function might contribute to genomic instability independent of G(1)-arrest. In the present study, we explored the effect of p53 disruption and consequences of antisense GADD45 expression on the DNA repair capacity of human colon carcinoma RKO cells. DNA repair was assayed using host-cell reactivation of u.v.-damaged reporter plasmids and unscheduled DNA synthesis experiments in transiently-transfected cells. We show that a number of transfected genes that suppress p53 function reduce the ability of cells to repair u.v.-induced DNA damage. Moreover, cells in which expression of the p53-regulated gene GADD45 was blocked by antisense vectors, also showed altered levels of DNA repair. Blocking Gadd45 expression by constitutive antisense expression sensitized cells to killing by u.v.-radiation or by cis-platinum (II) diamine-dichloride (CDDP, or cisplatin), a cancer chemotherapy drug which produces DNA cross-links. These findings suggest the involvement of downstream effecters of the p53 pathway in the coordination of cell cycle arrest and DNA repair.			Smith, ML (corresponding author), NCI,DIV CANC TREATMENT,MOL PHARMACOL LAB,DEV THERAPEUT PROGRAM,NIH,BLDG 37,ROOM 5C09,BETHESDA,MD 20892, USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Bae I, 1996, CANCER RES, V56, P840; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; BURK PG, 1971, J LAB CLIN MED, V77, P759; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN IT, 1995, ONCOGENE, V11, P1931; COFFER PJ, 1995, ONCOGENE, V11, P561; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FAN SJ, 1995, CANCER RES, V55, P1649; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FRIEDBERG EC, 1995, DNA REPAIR; HALL PA, 1995, ONCOGENE, V10, P2427; HAVRE PA, 1995, CANCER RES, V55, P4420; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLANDER MC, 1993, J BIOL CHEM, V268, P24385; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KLOCKER H, 1985, European Journal of Cell Biology, V39, P346; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Li G, 1996, AM J PATHOL, V148, P1113; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; McDonald E, 1996, CANCER RES, V56, P2250; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PROTIC M, 1988, SOMAT CELL MOLEC GEN, V14, P351, DOI 10.1007/BF01534643; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1990, MOL CELL BIOL, V10, P6003, DOI 10.1128/MCB.10.11.6003; Smith ML, 1996, AM J PATHOL, V148, P1019; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vairapandi M, 1996, ONCOGENE, V12, P2579; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; ZENG XR, 1994, J BIOL CHEM, V269, P13748; Zhan QM, 1996, DNA CELL BIOL, V15, P805, DOI 10.1089/dna.1996.15.805; ZHAN QM, 1995, INT J ONCOL, V6, P937	44	144	153	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2255	2263						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950993				2022-12-25	WOS:A1996VV14500023
J	Eisenreich, W; Kupfer, E; Weber, W; Bacher, A				Eisenreich, W; Kupfer, E; Weber, W; Bacher, A			Tracer studies with crude U-C-13-lipid mixtures - Biosynthesis of the lipase inhibitor lipstatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; PANCREATIC LIPASE; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; STREPTOMYCES-TOXYTRICINI; BETA-OXIDATION; TETRAHYDROLIPSTATIN; SPECTROSCOPY; MAGNETIZATION; SPECTRA; RAT	The biosynthesis of the pancreatic lipase inhibitor lipstatin was investigated by fermentation experiments using cultures of Streptomyces toxytricini, which were supplied with soybean oil and a crude mixture of U-C-13-lipids obtained from algal biomass cultured with (CO2)-C-13. Lipstatin was analyzed by one- and two-dimensional NMR spectroscopy. C-13 total correlation spectroscopy and INADEQUATE experiments show that two fatty acid fragments containing 14 and 8 carbon atoms, respectively, are incorporated en bloc into lipstatin. The 14 carbon fragment is preferentially derived from the unsaturated fatty acid fraction, as shown by an experiment with hydrogenated U-C-13-lipid mixture, which is conducive to labeling of the 8-carbon moiety but not of the 14-carbon moiety. The data indicate that the lipstatin molecule can be assembled by Claisen condensation of octanoyl-CoA with 3-hydroxy-Delta(5,8)-tetradecanoyl-CoA obtained by beta oxidation of linoleic acid. The formation of lipstatin from acetate units by a polyketide-type pathway is ruled out conclusively by these data. The data show that surprisingly clear labeling patterns can be obtained in studies with crude, universally C-13-labeled precursor mixtures that are proffered together with a large excess of unlabeled material. One- and two dimensional C-13 total correlation spectroscopy analyses are suggested as elegant methods for the delineation of contiguously C-13-labeled biosynthetic blocks.	TECH UNIV MUNICH,DEPT ORGAN CHEM & BIOCHEM,D-85747 GARCHING,GERMANY; F HOFFMANN LA ROCHE & CO LTD,PHARMA PRECLIN RES & DEV,DEPT BIOTECHNOL,CH-4070 BASEL,SWITZERLAND	Technical University of Munich; Roche Holding			Eisenreich, Wolfgang/A-1258-2013	Eisenreich, Wolfgang/0000-0002-9832-8279				BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1986, J AM CHEM SOC, V108, P2093, DOI 10.1021/ja00268a061; BAX A, 1986, J MAGN RESON, V67, P565, DOI 10.1016/0022-2364(86)90395-1; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BORGSTROM B, 1988, BIOCHIM BIOPHYS ACTA, V962, P308, DOI 10.1016/0005-2760(88)90260-3; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; FERNANDEZ E, 1989, BIOCHIM BIOPHYS ACTA, V1001, P249, DOI 10.1016/0005-2760(89)90107-0; HADVARY P, 1988, BIOCHEM J, V256, P357, DOI 10.1042/bj2560357; HANESSIAN S, 1993, J ORG CHEM, V58, P7768, DOI 10.1021/jo00079a022; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HOCHULI E, 1987, J ANTIBIOT, V40, P1086, DOI 10.7164/antibiotics.40.1086; KONDO S, 1978, J ANTIBIOT, V31, P797, DOI 10.7164/antibiotics.31.797; LUO MJ, 1994, J BIOL CHEM, V269, P2384; LUTHIPENG QQ, 1992, FEBS LETT, V299, P111, DOI 10.1016/0014-5793(92)80112-T; WEIBEL EK, 1987, J ANTIBIOT, V40, P1081, DOI 10.7164/antibiotics.40.1081	15	27	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					867	874		10.1074/jbc.272.2.867	http://dx.doi.org/10.1074/jbc.272.2.867			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995375	hybrid			2022-12-25	WOS:A1997WC04800026
J	Guo, K; Walsh, K				Guo, K; Walsh, K			Inhibition of myogenesis by multiple cyclin-Cdk complexes - Coordinate regulation of myogenesis and cell cycle activity at the level of E2F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F-1; DEPENDENT KINASE-ACTIVITY; RETINOBLASTOMA PROTEIN; TERMINAL DIFFERENTIATION; GENE-TRANSCRIPTION; CREATINE-KINASE; MUSCLE; EXPRESSION; P107; ACTIVATION	During skeletal myogenesis, cell cycle withdrawal accompanies the expression of the contractile phenotype. Here we show that ectopic expression of each D-type cyclin is sufficient to inhibit the transcriptional activation of the muscle-specific creatine kinase (MCK) gene. In contrast, ectopic expression of cyclin A or cyclin E inhibits MCK expression only when they are co-expressed with their catalytic partner cyclin-dependent kinase 2 (Cdk2). For each of these conditions, myogenic transcriptional inhibition is reversed by the ectopic co-expression of the general Cdk inhibitor p21. Inhibition of MCK expression by cyclins or cyclin-Cdk combinations correlates with E2F activation, suggesting that the inhibition is mediated by the overall Rb-kinase activities of the Cdk complexes. In support of this hypothesis, a hyperactive mutant of Rb was found to partially re verse the inhibition of MCK expression by cyclin D1 and by the combination of cyclin A and Cdk2. These data demonstrate that the inhibition of myogenic transcriptional activity is a general feature of overall Cdk activity which is mediated, at least in part, by an pocket protein/E2F-dependent pathway, MCK promoter activity is also inhibited by ectopic E2F1 expression, but this inhibition is not reversed by the co-expression of p21. Analyses of a series of E2F1 mutants revealed that the transcriptional activation, leucine zipper, basic, and cyclin A/Cdk2-binding domains are dispensable, but the helix-loop-helix region is essential for myogenic inhibition. These data demonstrate that myocyte proliferation and differentiation are coordinated at the level of E2F and that these opposing activities are regulated by different E2F domains.	TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,MED CTR,DIV CARDIOVASC RES,BOSTON,MA 02135; CASE WESTERN RESERVE UNIV,DEPT CHEM,SCH MED,CLEVELAND,OH 44106	Tufts University; Case Western Reserve University					NHLBI NIH HHS [HL50692] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRES V, 1995, MOL CELL BIOL, V15, P4272; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENTHORN P, 1988, P NATL ACAD SCI USA, V87, P6922; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KRATZKE RA, 1992, J BIOL CHEM, V267, P25998; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; QIN XQ, 1995, MOL CELL BIOL, V15, P742; RAO SS, 1994, MOL CELL BIOL, V14, P5259, DOI 10.1128/MCB.14.8.5259; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1996, CELL GROWTH DIFFER, V7, P1471; WANG J, 1995, CELL GROWTH DIFFER, V6, P1299; YI TM, 1991, NUCLEIC ACIDS RES, V19, P3027, DOI 10.1093/nar/19.11.3027; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	29	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					791	797		10.1074/jbc.272.2.791	http://dx.doi.org/10.1074/jbc.272.2.791			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995365	hybrid			2022-12-25	WOS:A1997WC04800016
J	Lookene, A; Groot, NB; Kastelein, JJP; Olivecrona, G; Bruin, T				Lookene, A; Groot, NB; Kastelein, JJP; Olivecrona, G; Bruin, T			Mutation of tryptophan residues in lipoprotein lipase - Effects on stability, immunoreactivity, and catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; PANCREATIC LIPASE; HEPATIC LIPASE; BINDS; IDENTIFICATION; DOMAIN; CELLS; MILK; SITE	Previous studies had pointed to an important function of a putative exposed loop in the C-terminal domain of lipoprotein lipase for activity against emulsified lipid substrates. This loop contains 3 tryptophan residues (Trp(390), Trp(393), and Trp(394)). We have expressed and characterized lipase mutants with tryptophan to alanine substitutions at positions 55, 114, 382, 390, 393, and 394 and a double mutant at residues 393 and 394, The substitutions in the N-terminal domain (W55A and W114A) led to poor expression of completely inactive lipase variants. Heparin-Sepharose chromatography showed that mutant W114A eluted at the same salt concentration as inactive wild-type monomers, indicating that this substitution prevented subunit interaction or led to an unstable dimer. In contrast, all mutants in the C-terminal domain were expressed as mixtures of monomers and dimers similarly to the wild-type. The dimers displayed at least some catalytic activity and had the same apparent heparin affinity as the active wild-type dimers. The mutants W390A, W393A, W394A, and W393A/W394A had decreased reactivity with the monoclonal antibody 5D2, indicating that the 5D2 epitope is longer than was reported earlier, or that conformational changes affecting the epitope had occurred. The mutants W390A, W393A, W394A, and W393A/W394A had decreased catalytic activity against a synthetic lipid emulsion of long-chain triacylglycerols (Intralipid(R)) and in particular against rat lymph chylomicrons. The most pronounced decrease of activity was found for the double mutant W393A/W394A which retained only 6% of the activity of the wild-type lipase, while 70% of the activity against water-soluble tributyrylglycerol was retained, In the case of chylomicrons also the affinity for the substrate particles was lowered, as indicated by severalfold higher apparent K-m values. This effect was less prominent with the synthetic lipid emulsion. We conclude that the tryptophan cluster Trp(390) Trp(393)-Trp(394) contributes to binding of lipoprotein lipase to lipid/water interfaces. Utilizing different lipid substrates in different physical states, we have demonstrated that the tryptophan residues in the C-terminal domain may have a role also in the productive orientation of the enzyme at the lipid/water interface.	UNIV AMSTERDAM, ACAD MED CTR, CTR THROMBOSIS HEMOSTASIS ATHEROSCLEROSIS & INFLAM, NL-1105 AZ AMSTERDAM, NETHERLANDS; UMEA UNIV, DEPT MED BIOCHEM & BIOPHYS, S-90187 UMEA, SWEDEN	University of Amsterdam; Academic Medical Center Amsterdam; Umea University			Kastelein, John/AAF-7950-2020					BELFRAGE P, 1969, J LIPID RES, V10, P341; BENGTSSON G, 1980, EUR J BIOCHEM, V106, P549, DOI 10.1111/j.1432-1033.1980.tb04602.x; Bengtsson-Olivecrona G., 1992, LIPOPROTEIN ANAL PRA, P169; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BRUIN T, 1993, J LIPID RES, V34, P2109; Brunzell J.D., 1995, METABOLIC MOL BASES, P1913; CARRIERE F, 1995, INTERFACE CHEM BIOCH, P3; DAVIS RC, 1992, J BIOL CHEM, V267, P21499; DICHEK HL, 1993, J LIPID RES, V34, P1393; DUGI KA, 1995, J BIOL CHEM, V270, P25396, DOI 10.1074/jbc.270.43.25396; DUGI KA, 1992, J BIOL CHEM, V267, P25086; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; KIRCHGESSNER TG, 1987, J BIOL CHEM, V262, P8463; KRAPP A, 1995, J LIPID RES, V36, P2362; LIU MS, 1992, BIOCHIM BIOPHYS ACTA, V1128, P113, DOI 10.1016/0005-2760(92)90264-V; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1983, BIOCHIM BIOPHYS ACTA, V752, P38, DOI 10.1016/0005-2760(83)90230-8; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PERSSON B, 1991, FEBS LETT, V288, P33, DOI 10.1016/0014-5793(91)80997-H; Santamarina-Fojo Silvia, 1994, Current Opinion in Lipidology, V5, P117; SKOTTOVA N, 1995, J LIPID RES, V36, P1334; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VERGER R, 1976, ANNU REV BIOPHYS BIO, V5, P77, DOI 10.1146/annurev.bb.05.060176.000453; VILELLA E, 1993, J LIPID RES, V34, P1555; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653	30	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					766	772		10.1074/jbc.272.2.766	http://dx.doi.org/10.1074/jbc.272.2.766			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995362	Green Published, hybrid			2022-12-25	WOS:A1997WC04800013
J	Marshall, LA; Bolognese, B; Winkler, JD; Roshak, A				Marshall, LA; Bolognese, B; Winkler, JD; Roshak, A			Depletion of human monocyte 85-kDa phospholipase A(2) does not alter leukotriene formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MOUSE PERITONEAL-MACROPHAGES; GROUP-II PHOSPHOLIPASE-A(2); PLATELET-ACTIVATING-FACTOR; RAT MESANGIAL CELLS; CYTOSOLIC PHOSPHOLIPASE-A2; PROSTAGLANDIN SYNTHESIS; HUMAN NEUTROPHILS; SYNOVIAL-FLUID; MAST-CELL	Human monocytes possess several acylhydrolase activities and are capable of producing both prostanoids (PG) and leukotriene (LT) products upon acute stimulation with calcium ionophore, A23187 or phagocytosis of zymosan particles. The cytosolic 85-kDa phospholipase (PLA) A(2) co exists with the 14-kDa PLA(2) in the human monocyte, but their respective roles in LT production are not well understood, Reduction in 85-kDa PLA(2) cellular protein levels by initiation site-directed antisense (SK 7111) or exposure to the 85-kDa PLA(2) inhibitor, arachidonyl trifluoromethyl ketone (AACOCF(3)), prevented A23187 or zymosan-stimulated monocyte prostanoid formation. In contrast, neither treatment altered stimulated LTC(4) production. This confirmed the important role of the 85-kDa PLA(2) in prostanoid formation but suggests that it has less of a role in LT biosynthesis, Alternatively, treatment of monocytes with the selective, active site directed 14-kDa PLA(2) inhibitor, SB 203347, prior to stimulation had no effect on prostanoid formation at concentrations that totally inhibited LT formation. Addition of 20 mu M exogenous arachidonic acid to monocytes exposed to SK 7111 or SB 203347 did not alter A23187-induced PGE(2) or LTC(4) generation, respectively, indicating that these agents had no effect on downstream arachidonic acid-metabolizing enzymes in this setting, Taken together, these results provide evidence that the 85-kDa PLA(2) may play a more significant role in the formation of PG than LT. Further, utilization of SB 203347 provides intriguing data to form the hypothesis that a non-85-kDa PLA(2) sn-2 acyl hydrolase, possibly the 14-kDa PLA(2), may provide substrate for LT formation.			Marshall, LA (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT IMMUNOPHARMACOL,UW2532,709 SWEDELAND RD,KING OF PRUSSIA,PA 19406, USA.							Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; BARNETTE MS, 1994, BIOCHEM PHARMACOL, V47, P1661, DOI 10.1016/0006-2952(94)90545-2; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; BOLOGNESE B, 1995, BBA-LIPID LIPID MET, V1256, P201, DOI 10.1016/0005-2760(95)00023-6; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1990, ADV PROSTAGLANDIN TH, P217; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; DIEZ E, 1992, J BIOL CHEM, V267, P18342; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; GLASER KB, 1994, INFLAMMATION RES ASS; Griswold DE, 1996, MED RES REV, V16, P181, DOI 10.1002/(SICI)1098-1128(199603)16:2<181::AID-MED3>3.0.CO;2-X; GRONICH J, 1994, J CLIN INVEST, V93, P1224, DOI 10.1172/JCI117076; HSUEH W, 1981, NATURE, V290, P710, DOI 10.1038/290710a0; HUMES JL, 1982, J BIOL CHEM, V257, P1591; KANDA A, 1989, BIOCHEM BIOPH RES CO, V163, P42, DOI 10.1016/0006-291X(89)92096-2; KERR JS, 1990, 5 INT C INFL RES ASS; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRUMP E, 1995, BIOCHEM J, V310, P681, DOI 10.1042/bj3100681; LAI CY, 1988, BIOCHEM BIOPH RES CO, V157, P488, DOI 10.1016/S0006-291X(88)80275-4; LIN LL, 1992, J BIOL CHEM, V267, P23451; MARSHALL LA, 1992, BIOCHEM PHARMACOL, V44, P1849, DOI 10.1016/0006-2952(92)90081-S; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; MARSHALL LA, 1993, BIOCHEM CELL BIOL, V71, P331, DOI 10.1139/o93-050; MARSHALL LA, 1994, J PHARMACOL EXP THER, V268, P1; MARSHALL LA, 1993, PHARM COMMUN, V5, P27; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MCCORD M, 1995, BRIT J PHARMACOL, V116, P2575, DOI 10.1111/j.1476-5381.1995.tb17210.x; MCCORD M, 1994, J INVEST DERMATOL, V102, P980, DOI 10.1111/1523-1747.ep12384234; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1995, PHOSPHOLIPASE A2 CLI, P93; MURAKAMI M, 1993, EUR J BIOCHEM, V218, P807; NAKAGAWA Y, 1989, PROG LIPID RES, V28, P205, DOI 10.1016/0163-7827(89)90013-1; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PFEILSCHIFTER J, 1995, PHOSPHOLIPASE A2 CLI, P25; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; RAMESHA CS, 1993, BIOCHIM BIOPHYS ACTA, V1168, P37, DOI 10.1016/0005-2760(93)90263-9; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; TRAMPOSCH KM, 1994, J PHARMACOL EXP THER, V271, P852; TRIGGIANI M, 1992, BIOCHEM J, V286, P497, DOI 10.1042/bj2860497; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; WIGHTMAN PD, 1981, BIOCHEM J, V195, P427, DOI 10.1042/bj1950427; WIJKANDER J, 1994, J LIPID MEDIAT CELL, V10, P23; WINKLER JD, 1995, J PHARMACOL EXP THER, V274, P1338	55	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					759	765		10.1074/jbc.272.2.759	http://dx.doi.org/10.1074/jbc.272.2.759			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995361	hybrid			2022-12-25	WOS:A1997WC04800012
J	Cai, ZZ; Korner, M; Tarantino, N; Chouaib, S				Cai, ZZ; Korner, M; Tarantino, N; Chouaib, S			I kappa B alpha overexpression in human breast carcinoma MCF7 cells inhibits nuclear factor-kappa B activation but not tumor necrosis factor-alpha-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; SIGNAL-TRANSDUCTION; TNF-ALPHA; PHOSPHORYLATION; GENE; PROTEOLYSIS; RECEPTOR; FAMILY; AUTOREGULATION; ORGANIZATION	Nuclear factor-kappa B (NF-kappa B) is one of major component induced by turner necrosis factor-alpha (TNF), and its role in the signaling of TNF-induced cell death remains controversial, In order to delineate whether the involvement of NF-kappa B activation is required for triggering of the apoptotic signal of TNF, we inhibited the nuclear translocation of this transcription factor in TNF-sensitive MCF7 cells by introducing a human MAD-3 mutant cDNA coding for a mutated I kappa B alpha that is resistant to both phosphorylation and proteolytic degradation and that behaves as a potent dominant negative I kappa B alpha protein. Our results demonstrated that the mutated I kappa B alpha was stably expressed in the transfected MCF7 cells and blocked the TNF-induced NF-kappa B nuclear translocation. Indeed, TNF treatment of these cells induced the proteolysis of only the endogenous I kappa B alpha but not the mutated I kappa B alpha. The nuclear NF-kappa B released from the endogenous I kappa B alpha within 30 min of TNF treatment was rapidly inhibited by the mutated I kappa B alpha. There was no significant difference either in cell viability or in the kinetics of cell death between control cells and the mutated I kappa B alpha transfected cells. Furthermore, electron microscopic analysis showed that the cell death induced by TNF in both control and mutated I kappa B alpha transfected cells was apoptotic. The inhibition of NF-kappa B translocation in mutated I kappa B alpha-transfected cells persisted throughout the same time course that apoptosis was occurring. Our data provide direct evidence that the inhibition of NF-kappa B did not alter TNF-induced apoptosis in MCF7 cells and support the view that TNF-mediated apoptosis is NF-kappa B independent.	INST GUSTAVE ROUSSY,INSERM,CJF 9411,F-94805 VILLEJUIF,FRANCE; HOP LA PITIE SALPETRIERE,IMMUNOL CELLULAIRE & TISSULAIRE LAB,CNRS,URA 625,F-75013 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite			Chouaib, Salem/F-7939-2016					Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BEG AA, 1993, GENE DEV, V7, P1564; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CHOUAIB S, 1992, B CANCER, V79, P935; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FEUILLARD J, 1991, CYTOKINE, V3, P1; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WAN XS, 1994, DNA CELL BIOL, V13, P1127, DOI 10.1089/dna.1994.13.1127; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT SC, 1992, J CELL BIOCHEM, V48, P344, DOI 10.1002/jcb.240480403; YANG ZH, 1993, J BIOL CHEM, V268, P20520; ZYAD A, 1994, CANCER RES, V54, P825	40	94	94	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					96	101						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995233				2022-12-25	WOS:A1997WA56400020
J	Gorovits, BM; Horowitz, PM				Gorovits, BM; Horowitz, PM			Conditions of forming protein complexes with GroEL can influence the mechanism of chaperonin-assisted refolding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROFOLATE-REDUCTASE; BINDING; POLYPEPTIDE; RELEASE	The interaction of GroEL with urea-unfolded dihydrofolate reductase (DHFR) has been studied in the presence of DHFR substrates by investigating the ability of GroES to release enzyme under conditions where a stable GroES-GroEL-DHFR ternary complex can be formed. In these circumstances, GroES could only partially discharge the DHFR if ADP was present in the solution and approximately half of the DHFR remained bound on the chaperonin. This bound DHFR could be rescued by addition of ATP and KCI into the refolding mixture. The stable ternary complex did not show any significant protection of bound DHFR against proteolysis by Proteinase K. These results are in contrast to those observed with the GroEL-DHFR complex formed by thermal inactivation of DHFR at 45 degrees C in which GroES addition leads to partial protection of bound DHFR. Thus, the method of presentation influences the properties of the bound intermediates. It is suggested that the ability of GroES to bind on the same side of the GroEL double toroid as the target protein and displace it into the central cavity depends on the way the protein-substrate is presented to the GroEL molecule. Therefore, the compact folding intermediate formed by thermal unfolding can be protected against proteolysis after GroES binds to form a ternary complex. In addition, structural changes within GroEL induced by the experimental conditions may contribute to differences in the properties of the complexes. The more open urea-unfolded DHFR binds on the surface of chaperonin and can be displaced into solution by the tighter binding GroES molecule. It is suggested that the state of the unfolded protein when it is presented to GroEL determines the detailed mechanism of its assisted refolding, It follows that individual proteins, having characteristic folding intermediates, can have different detailed mechanisms of chaperonin-assisted folding.	UNIV TEXAS,HLTH SCI CTR,DEPT BIOCHEM,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio					NIEHS NIH HHS [ES05729] Funding Source: Medline; NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005729] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNE KC, 1967, J BIOL CHEM, V242, P4486; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRANDSCH R, 1992, J BIOL CHEM, V267, P20844; Clarke AR, 1996, CURR OPIN STRUC BIOL, V6, P43, DOI 10.1016/S0959-440X(96)80093-5; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; ELLIS RJ, 1994, CURR BIOL, V4, P633; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; KAUFMAN BT, 1976, ARCH BIOCHEM BIOPHYS, V172, P289, DOI 10.1016/0003-9861(76)90078-3; Mayhew M, 1996, NATURE, V379, P420, DOI 10.1038/379420a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MIZOBATA T, 1992, J BIOL CHEM, V267, P1773; SASSO S, 1995, J BIOMOL STRUCT DYN, V12, P1023, DOI 10.1080/07391102.1995.10508794; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	22	8	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					32	35						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995221				2022-12-25	WOS:A1997WA56400008
J	Keech, AM; LeBrun, NE; Wilson, MT; Andrews, SC; Moore, GR; Thomson, AJ				Keech, AM; LeBrun, NE; Wilson, MT; Andrews, SC; Moore, GR; Thomson, AJ			Spectroscopic studies of cobalt(II) binding to Escherichia coli bacterioferritin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME; SITE; FERRITIN; ACID	The iron storage protein bacterioferritin (BFR) consists of 24 identical subunits, each containing a dinuclear metal binding site called the ferroxidase center, which is essential for fast iron core formation, Cobalt(II) binding to wild-type and site-directed variants of Escherichia coli BFR was studied by optical and magnetic techniques, Data from absorption spectroscopy demonstrate the binding of two cobalt(II) ions per subunit of wild type and heme-free BFR, each with a pseudotetrahedral or pentacoordinate geometry, and EPR studies show that the two cobalt(II) ions are weakly magnetically coupled. Studies of variants of BFR in which a single glutamic acid residue at the ferroxidase center is replaced by alanine confirm that this is the site of cobalt(II) binding, since the altered centers bind only one cobalt(II) ion, This work shows that the electroneutrality of the ferroxidase center is preserved on binding a pair of divalent metal ions. Optical and EPR data show that cobalt(II) binding to BFR exhibits positive cooperativity, with an average K-d of similar to 1 x 10(-5) M. The favored filling of the ferroxidase center with pairs of metal ions may have mechanistic implications for the iron(II) binding process, Discrimination against oxidation of single iron(II) ions avoids odd electron reduction products of oxygen.	UNIV E ANGLIA,SCH CHEM SCI,CTR MET PROT SPECT & BIOL,NORWICH NR4 7TJ,NORFOLK,ENGLAND; UNIV ESSEX,DEPT CHEM & BIOL CHEM,COLCHESTER CO4 3SQ,ESSEX,ENGLAND; UNIV SHEFFIELD,KREBS INST,DEPT MOL BIOL & BIOTECHNOL,SHEFFIELD S10 2UH,S YORKSHIRE,ENGLAND	University of East Anglia; University of Essex; University of Sheffield				Le Brun, Nick/0000-0001-9780-4061; Andrews, Simon/0000-0003-4295-2686	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS SC, 1995, J BIOL CHEM, V270, P23268, DOI 10.1074/jbc.270.40.23268; ANDREWS SC, 1989, BIOCHEM BIOPH RES CO, V158, P489, DOI 10.1016/S0006-291X(89)80075-0; BANCI L, 1982, STRUCT BOND, V52, P37, DOI 10.1007/BFb0111296; BAUMINGER ER, 1991, BIOCHIM BIOPHYS ACTA, V1118, P48, DOI 10.1016/0167-4838(91)90440-B; Carvalho E, 1996, J INORG BIOCHEM, V62, P147, DOI 10.1016/0162-0134(95)00143-3; CHEESMAN MR, 1990, NATURE, V346, P771, DOI 10.1038/346771a0; CHEESMAN MR, 1993, BIOCHEM J, V292, P47, DOI 10.1042/bj2920047; ELGREN TE, 1994, INORG CHEM, V33, P891, DOI 10.1021/ic00083a011; Falk J.E, 1964, PORPHYRINS METALLOPO, P181, DOI [10.1002/jobm.19640040512, DOI 10.1002/JOBM.19640040512]; FERSHT A, 1985, ENZYME STRUCTURE MEC, P190; FROLOW F, 1994, NAT STRUCT BIOL, V1, P453, DOI 10.1038/nsb0794-453; HEMPSTEAD PD, 1994, FEBS LETT, V350, P258, DOI 10.1016/0014-5793(94)00781-0; LAWSON DM, 1991, NATURE, V349, P541, DOI 10.1038/349541a0; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEBRUN N, 1995, FEBS LETT, V333, P197; LEBRUN NE, 1995, BIOCHEM J, V312, P385, DOI 10.1042/bj3120385; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; WERTH MT, 1995, INORG CHEM, V34, P218, DOI 10.1021/ic00105a037; YARIV J, 1981, BIOCHEM J, V197, P171, DOI 10.1042/bj1970171; ZHANG JH, 1992, INORG CHEM, V31, P1359, DOI 10.1021/ic00034a013	20	23	24	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					422	429						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995278				2022-12-25	WOS:A1997WA56400065
J	Kuroda, M; Dey, S; Sanders, OI; Rosen, BP				Kuroda, M; Dey, S; Sanders, OI; Rosen, BP			Alternate energy coupling of ArsB, the membrane subunit of the Ars anion-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENICAL RESISTANCE OPERON; ESCHERICHIA-COLI; ARSENATE RESISTANCE; PLASMID; PROTEIN; EFFLUX; EXPRESSION; VESICLES; SEQUENCE; PUMP	The arsenical resistance (ars) operon of the conjugative R-factor R773 confers resistance to arsenical and antimonial compounds in Escherichia coli, where resistance results from active extrusion of arsenite catalyzed by the products of the arsA and arsB genes. Previous in vivo studies on the energetics of arsenite extrusion showed that expression of both genes produced an ATP-coupled arsenite extrusion system that was independent of the electrochemical proton gradient. In contrast, in cells expressing only the arsB gene, arsenite extrusion was coupled to electrochemical energy and independent of ATP, suggesting that the Ars transport system exhibits a dual mode of energy coupling depending on the subunit composition. In vitro the ArsA-ArsB complex has been shown to catalyze ATP-coupled uptake of (AsO2-1)-As-73 in everted membrane vesicles, However, transport catalyzed by ArsB alone has not previously been observed in vitro. In this study we demonstrate everted membrane vesicles prepared from cells expressing only arsB exhibit uptake of (AsO2-1)-As-73 coupled to electrochemical energy.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19793] Funding Source: Medline; NIGMS NIH HHS [GM08167] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBUDKAR SV, 1984, J BIOL CHEM, V259, P6142; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; BROER S, 1993, J BACTERIOL, V175, P3480, DOI 10.1128/jb.175.11.3480-3485.1993; Bruhn DF, 1996, FEMS MICROBIOL LETT, V139, P149, DOI 10.1016/0378-1097(96)00134-6; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHEN CM, 1986, J BIOL CHEM, V261, P5030; Chen YX, 1996, J BACTERIOL, V178, P911, DOI 10.1128/jb.178.3.911-913.1996; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEY S, 1995, J BACTERIOL, V177, P385, DOI 10.1128/jb.177.2.385-389.1995; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DEY S, 1994, J BIOL CHEM, V269, P25442; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; DOU DX, 1994, ANTON LEEUW INT J G, V65, P359, DOI 10.1007/BF00872219; DOU DX, 1992, J BIOL CHEM, V267, P25768; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOBLEY HLT, 1982, P NATL ACAD SCI-BIOL, V79, P6119, DOI 10.1073/pnas.79.20.6119; OWOLABI JB, 1990, J BACTERIOL, V172, P2367, DOI 10.1128/jb.172.5.2367-2371.1990; PERLIN DS, 1984, J BIOL CHEM, V259, P7884; REAY PF, 1977, ANAL BIOCHEM, V78, P557, DOI 10.1016/0003-2697(77)90117-8; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; Rosen BP, 1996, J BIOL INORG CHEM, V1, P273, DOI 10.1007/s007750050053; ROSEN BP, 1984, BIOCHEM BIOPH RES CO, V124, P760, DOI 10.1016/0006-291X(84)91023-4; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVER S, 1982, P NATL ACAD SCI-BIOL, V79, P6114, DOI 10.1073/pnas.79.20.6114; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; WU JH, 1992, J BIOL CHEM, V267, P12570	30	65	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					326	331						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995265				2022-12-25	WOS:A1997WA56400052
J	Soubeyrand, S; Khadir, A; Brindle, Y; Manjunath, P				Soubeyrand, S; Khadir, A; Brindle, Y; Manjunath, P			Purification of a novel phospholipase A(2) from bovine seminal plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; HUMAN SYNOVIAL-FLUID; ACROSOME REACTION; LYSOPHOSPHOLIPASE ACTIVITY; SPERMATOZOA; EXPRESSION; ACTIVATION; PROTEINS; CLONING; ENZYMES	Phospholipases A(2) are enzymes believed to play important roles in numerous physiological systems including sperm cell maturation. Relatively little work has, however, been devoted to study these enzymes in seminal plasma, We therefore undertook the purification and characterization of this enzyme from bovine seminal plasma, After a 330-fold purification, an activity corresponding to a protein of 100 kDa was identified by gel filtration, SDS-polyacrylamide gel electrophoresis analysis of the purified fraction revealed the presence of a 60-kDa band that comigrated with the activity during ion-exchange and gel filtration chromatography as well as polyacrylamide gel electrophoresis. The enzyme possessed a pH optimum around pH 6.5 and was calcium-dependent. Using isoelectric focusing, its isoelectric point was determined to be 5.6 +/- 0.07. The enzymatic activity was resistant to p-bromophenacyl bromide, but was sensitive to gossypol and dithiothreitol, The enzyme was 2 orders of magnitude more active toward micelles formed with deoxycholate than with Triton X-100, Slight differences in the specificity toward head groups and/or sn-2-side chains were found in both assay systems. The enzyme was acid-labile and did not display affinity for heparin. It would therefore appear that the phospho lipase A(2) form isolated from bovine seminal plasma is of a novel type.	HOP MAISON NEUVE ROSEMONT,GUY BERNIER RES CTR,MONTREAL,PQ H1T 2M4,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT BIOCHEM,MONTREAL,PQ H3C 3J7,CANADA; CTR INSEMINAT ARTIFICIEL QUEBEC,ST HYACINTHE,PQ,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal				soubeyrand, sebastien/0000-0002-9317-301X				ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; ANTAKI P, 1988, GAMETE RES, V19, P305, DOI 10.1002/mrd.1120190309; ANTAKI P, 1989, BIOL REPROD, V41, P241, DOI 10.1095/biolreprod41.2.241; BARTOLF M, 1990, BIOCHIM BIOPHYS ACTA, V1042, P247, DOI 10.1016/0005-2760(90)90016-Q; BENNETT CF, 1990, BIOCHIM BIOPHYS ACTA, V1047, P271, DOI 10.1016/0005-2760(90)90526-4; BORGSTROM B, 1993, LIPIDS, V28, P371, DOI 10.1007/BF02535932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; BUHL WJ, 1995, BIOCHEM J, V311, P147, DOI 10.1042/bj3110147; CHEN HY, 1993, ANAL BIOCHEM, V212, P295, DOI 10.1006/abio.1993.1330; CHEN J, 1994, J BIOL CHEM, V269, P2365; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DECARVALHO MGS, 1995, J BIOL CHEM, V270, P20439, DOI 10.1074/jbc.270.35.20439; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; FRY MR, 1992, BIOL REPROD, V47, P751, DOI 10.1095/biolreprod47.5.751; GARCIA R, 1991, ARCH ANDROLOGY, V26, P93, DOI 10.3109/01485019108987632; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HARA S, 1988, J BIOCHEM-TOKYO, V104, P326, DOI 10.1093/oxfordjournals.jbchem.a122467; HARA S, 1989, J BIOCHEM-TOKYO, V105, P395, DOI 10.1093/oxfordjournals.jbchem.a122675; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; KINKAID AR, 1995, BIOCHEM J, V308, P507, DOI 10.1042/bj3080507; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUNZE H, 1974, BIOCHIM BIOPHYS ACTA, V348, P35, DOI 10.1016/0005-2760(74)90090-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LUI CW, 1979, J EXP ZOOL, V207, P173, DOI 10.1002/jez.1402070202; MANJUNATH P, 1994, BIOCHEM J, V303, P121, DOI 10.1042/bj3030121; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MINAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1170, P125; MUKHERJEE AB, 1994, BIOCHEM PHARMACOL, V48, P1, DOI 10.1016/0006-2952(94)90216-X; NAKAGUCHI K, 1986, ENZYME, V35, P2, DOI 10.1159/000469312; NAKAMURA H, 1995, J CLIN INVEST, V95, P1062, DOI 10.1172/JCI117752; REHFELDT W, 1993, BIOCHEM J, V293, P255, DOI 10.1042/bj2930255; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; RIFFO M, 1992, HISTOCHEMISTRY, V97, P25, DOI 10.1007/BF00271278; ROLDAN ERS, 1993, J BIOL CHEM, V268, P13962; RONKKO S, 1992, INT J BIOCHEM, V24, P987, DOI 10.1016/0020-711X(92)90108-D; RONKKO S, 1991, INT J BIOCHEM, V23, P595, DOI 10.1016/0020-711X(87)90054-1; RONKKO S, 1993, PROSTATE, V22, P265, DOI 10.1002/pros.2990220309; ROSS BM, 1995, J NEUROCHEM, V64, P2213; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1994, BIOPHYS J, V67, P493, DOI 10.1016/S0006-3495(94)80546-6; SHARP JD, 1991, J BIOL CHEM, V266, P14850; TAKAYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P1505, DOI 10.1016/0006-291X(91)91064-J; THAKKAR JK, 1984, BIOL REPROD, V30, P679, DOI 10.1095/biolreprod30.3.679; THOMSON FJ, 1995, BIOCHEM J, V306, P305, DOI 10.1042/bj3060305; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WANG R, 1994, BIOCHEM J, V304, P131, DOI 10.1042/bj3040131; WINKLER JD, 1994, J LIPID MEDIAT CELL, V10, P315; WURL M, 1985, BIOCHIM BIOPHYS ACTA, V834, P411, DOI 10.1016/0005-2760(85)90015-3; Yanagimachi R., 1988, P135; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	53	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					222	227						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995251	hybrid			2022-12-25	WOS:A1997WA56400038
J	Wang, WJ; Acs, P; Goodnight, JA; Giese, T; Blumberg, PM; Mischak, H; Mushinski, JF				Wang, WJ; Acs, P; Goodnight, JA; Giese, T; Blumberg, PM; Mischak, H; Mushinski, JF			The catalytic domain of protein kinase C-delta in reciprocal delta and epsilon chimeras mediates phorbol ester-induced macrophage differentiation of mouse promyelocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 FIBROBLASTS; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; REGULATORY DOMAIN; PKC-DELTA; ISOZYMES; LOCALIZATION; ACTIVATION; ISOFORM; ALPHA	The overexpression of protein kinase C-delta (PKC-delta), but not PKC-epsilon, enables the mouse myeloid cell line 32D to differentiate into macrophages when treated with phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA). To determine the domain of PKC-delta that is responsible for this isotype-specific function, cDNAs that encode reciprocal chimeras of PKC-delta and -epsilon (PKC-delta epsilon and PKC-epsilon delta) were constructed by exchanging regulatory and kinase domains using polymerase chain reaction technology. Both chimeras were stably expressed in 32D cells using the pLTR expression vector and displayed protein kinase activity upon TPA treatment. TPA treatment of L epsilon delta, cells that overexpressed the PKC-epsilon delta chimera, induced a dramatically increased cell volume, surface adherence, surface expression of Mac-1 and Mac-3, lysozyme production, and phagocytosis. These are the characteristics of the macrophage phenotype found in TPA-treated 32D cells that overexpressed PKC-delta. In contrast, little effect was seen in L delta epsilon, 32D cells that overexpressed PKC-delta epsilon, with or without TPA treatment. A PKC inhibitor directed toward the catalytic domain of PKC, GF109203X, and a selective inhibitor of PKC-delta, Rottlerin, blocked the TPA-induced differentiation of PKC-epsilon delta-overexpressing 32D cells. These results demonstrate that the catalytic domain of PKC-delta contains the primary determinants for its activity in phorbol ester-induced macrophage differentiation.	NIH,GENET LAB,BETHESDA,MD 20892; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Mischak, Harald/E-8685-2011; Wang, Qiming Jane/B-6064-2012	Wang, Qiming Jane/0000-0002-9502-4851; Mischak, Harald/0000-0003-0323-0306				BABIOR BM, 1981, LEUKOCYTE FUNCTION, P1; CACACE AM, 1993, ONCOGENE, V8, P2095; COUSSENS L, 1987, DNA-J MOLEC CELL BIO, V6, P389, DOI 10.1089/dna.1987.6.389; DISTANIK MH, 1994, EXP CELL RES, V210, P287; FINKENZELLER G, 1992, CELL SIGNAL, V4, P163, DOI 10.1016/0898-6568(92)90080-R; GOODE NT, 1994, FEBS LETT, V340, P145, DOI 10.1016/0014-5793(94)80190-8; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GORDON S, 1974, J EXP MED, V139, P1228, DOI 10.1084/jem.139.5.1228; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; GSCHWENDT M, 1991, FEBS LETT, V290, P115, DOI 10.1016/0014-5793(91)81239-5; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; LEHEL C, 1995, J BIOL CHEM, V270, P19651, DOI 10.1074/jbc.270.33.19651; LEIBERSPERGER H, 1990, J BIOL CHEM, V265, P16108; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, J IMMUNOL, V147, P3981; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PEARS C, 1991, BIOCHEM J, V276, P257, DOI 10.1042/bj2760257; SHARKEY NA, 1985, CANCER RES, V45, P19; Singer WD, 1996, J BIOL CHEM, V271, P4504; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159	31	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					76	82						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995230				2022-12-25	WOS:A1997WA56400017
J	Chen, G; Lee, EYHP				Chen, G; Lee, EYHP			The product of the ATM gene is a 370-kDa nuclear phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; CYCLE CHECKPOINT PATHWAY; ACTIVATED PROTEIN-KINASE; DNA-DAMAGE; IONIZING-RADIATION; BINDING; CANCER; P53; FAMILIES; BREAST	Neuronal degeneration, gonadal abnormalities, and immune deficiency are some of the major manifestations of the hereditary disease ataxia telangiectasia, which is caused by mutations in a single gene, designated ATM. Here we show that the product of the ATM gene is a 370-kDa nuclear phosphoprotein. Because ATM knock-out mice recapitulate the clinical symptoms of the human disease, we have examined ATM gene expression in mice. In mouse embryos at gestation day 13.5, ATM mRNA is expressed ubiquitously, with high levels detected in the nervous system and lung. Elevated ATM mRNA levels were also found in the thymus of mouse embryos at gestation day 18.5, a time when V(D)J recombination is occurring. In adult mice, ATM protein was detected in all tissues examined and was present at elevated levels in the testis, spleen, and thymus. The ATM expression pattern and the nuclear localization of the ATM protein are consistent with the proposed function of ATM in the activation of cell cycle checkpoints, DNA repair, and genetic recombination.	UNIV TEXAS,HLTH SCI CTR,DEPT MOL MED,INST BIOTECHNOL,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA49649] Funding Source: Medline; NICHD NIH HHS [HD30625] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R43HD030625] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA049649, R29CA049649, R37CA049649] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGAMANOLIS DP, 1979, J NEUROPATHOL EXP NE, V39, P475; AMROMIN GD, 1979, J NEUROPATH EXP NEUR, V38, P621, DOI 10.1097/00005072-197911000-00007; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; ARTUSO M, 1995, ONCOGENE, V11, P1427; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BIRRELL GW, 1995, BRIT J CANCER, V72, P1096, DOI 10.1038/bjc.1995.471; BODER E, 1958, PEDIATRICS, V21, P526; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; CANMAN CE, 1994, CANCER RES, V54, P5054; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P662; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Huang LC, 1996, CANCER RES, V56, P2940; Jorgensen TJ, 1996, INT J RADIAT BIOL, V69, P527, DOI 10.1080/095530096145535; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MEYN MS, 1995, CANCER RES, V55, P5991; Pecker I, 1996, GENOMICS, V35, P39, DOI 10.1006/geno.1996.0320; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; THACKER J, 1994, INT J RADIAT BIOL, V66, P87; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	36	113	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33693	33697		10.1074/jbc.271.52.33693	http://dx.doi.org/10.1074/jbc.271.52.33693			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969240	hybrid			2022-12-25	WOS:A1996WA71300074
J	Enguita, FJ; Liras, P; Leitao, AL; Martin, JF				Enguita, FJ; Liras, P; Leitao, AL; Martin, JF			Interaction of the two proteins of the methoxylation system involved in cephamycin C biosynthesis - Immunoaffinity, protein cross-linking, and fluorescence spectroscopy studies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-CLAVULIGERUS; NOCARDIA-LACTAMDURANS; CEPHALOSPORIN 7-ALPHA-HYDROXYLASE; ESCHERICHIA-COLI; BINDING PROTEIN; ENZYME-SYSTEM; GENES; ORGANIZATION; EXPRESSION; PURIFICATION	Cephamycin C-producing microorganisms contain a two-protein enzyme system that converts cephalosporins to 7-methoxycephalosporins. interaction between the two component proteins P-7 (M(r) 27,000) and P-8 (M(r) 32,000) has been studied by immunoaffinity chromatography using anti-P-7 and anti-P-8 antibodies, cross-linking with glutaraldehyde, and fluorescence spectroscopy analysis. Co-renaturation of the P-7 and P-8 polypeptides resulted in the formation of a protein complex with a molecular mass of 59 kDa, which corresponds to a heterodimer of P-7 and P-8. Glutaraldehyde cross-linking of the polypeptides after assembly of the protein complex showed the presence of a single heterodimer form that reacted with antibodies against P-7 and P-8. Each separate protein did not associate with itself into multimers. The P-7 . P-8 complex co-purified by immunoaffinity chromatography from extracts of Nocardia lactamdurans and Streptomyces clavuligerus, suggesting that both proteins are present as an aggregate in vivo. Fluorescence spectroscopy studies of 5-methylaminonaphthalene-1-sulfonyl-P-7 in response to increasing concentrations of P-8 showed a blue shift in the fluorophore emission, indicating a conformational change of P-7 in response to the interaction of P-8 with an apparent dissociation constant of 47 mu M. NADH showed affinity for the P-7 component. The P-7 . P-8 complex interacted strongly with the substrates S-adenosylmethionine and cephalosporin C, differently from that occurring with the separate P-7 or P-8 components, resulting in a strong blue shift in the fluorescence emission spectra of the complex.	UNIV LEON, FAC BIOL, DEPT ECOL GENET & MICROBIOL, E-24071 LEON, SPAIN; INST BIOTECHNOL, INBIOTEC, LEON 24006, SPAIN	Universidad de Leon			Leitão, Ana Lúcia/AAF-7114-2020; Enguita, Francisco J./A-2347-2009	Enguita, Francisco J./0000-0002-8072-8557; Leitao, Ana Lucia/0000-0001-8548-8655				AHARONOWITZ Y, 1992, ANNU REV MICROBIOL, V46, P461, DOI 10.1146/annurev.mi.46.100192.002333; ARUNACHALAM U, 1992, J BIOL CHEM, V267, P25848; BUNZ PV, 1993, J BACTERIOL, V175, P6467; CASCANTE M, 1994, BIOCHEM J, V298, P313, DOI 10.1042/bj2980313; COQUE JJR, 1993, EMBO J, V12, P631, DOI 10.1002/j.1460-2075.1993.tb05696.x; COQUE JJR, 1991, MOL MICROBIOL, V5, P1125, DOI 10.1111/j.1365-2958.1991.tb01885.x; COQUE JJR, 1995, J BACTERIOL, V177, P2230, DOI 10.1128/jb.177.8.2230-2235.1995; COQUE JJR, 1995, GENE, V162, P21, DOI 10.1016/0378-1119(95)00308-S; Demain AL, 1983, ANTIBIOTICS CONTAINI, P189; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; EISENSTEIN E, 1990, PROTEIN FUNCTION PRA, P135; Enguita FJ, 1996, FEMS MICROBIOL LETT, V137, P135; GUAN C, 1988, GENE, V67, P21; Harlow E., 1988, ANTIBODIES LAB MANUA; HOOD JD, 1983, J CHEM SOC CHEM COMM, P1187, DOI 10.1039/c39830001187; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; Kleinkauf H, 1996, EUR J BIOCHEM, V236, P335, DOI 10.1111/j.1432-1033.1996.00335.x; Kyte J., 1995, MECH PROTEIN CHEM, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHER HH, 1991, BIOCHEM J, V274, P833, DOI 10.1042/bj2740833; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; Martin J F, 1989, Adv Biochem Eng Biotechnol, V39, P153; MARTIN JF, 1989, ANNU REV MICROBIOL, V43, P173, DOI 10.1146/annurev.micro.43.1.173; MARTIN JF, 1981, BIOTECHNOLOGY, V1, P211; MARTIN JF, 1981, ACTINOMYCETES, P417; MARTIN JF, 1996, ENCY MOL BIOL; OSULLIVAN J, 1979, BIOCHEM J, V179, P47, DOI 10.1042/bj1790047; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; POL E, 1995, BIOCHEM J, V311, P275, DOI 10.1042/bj3110275; XIAO XF, 1993, ANTIMICROB AGENTS CH, V37, P84, DOI 10.1128/AAC.37.1.84; XIAO XF, 1991, BIOCHEM J, V280, P471, DOI 10.1042/bj2800471	32	21	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33225	33230		10.1074/jbc.271.52.33225	http://dx.doi.org/10.1074/jbc.271.52.33225			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969179	hybrid			2022-12-25	WOS:A1996WA71300013
J	Lonnerberg, P; Schoenherr, CJ; Anderson, DJ; Ibanez, CF				Lonnerberg, P; Schoenherr, CJ; Anderson, DJ; Ibanez, CF			Cell type-specific regulation of choline acetyltransferase gene expression - Role of the neuron-restrictive silencer element and cholinergic-specific enhancer sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; PROMOTER REGION; TRANSGENIC MICE; MAMMALIAN-CELLS; MESSENGER-RNA; SPINAL-CORD; DIFFERENTIATION; IDENTIFICATION; LOCALIZATION; EXTRACTION	This study demonstrates the presence of positive and negative regulatory elements within a 2336-base pair-long region of the rat choline acetyltransferase (ChAT) gene promoter that cooperate to direct cell type-specific expression in cholinergic cells, A 21-base pair-long neuron-restrictive silencer element (NRSE) was identified in the proximal part of this region, This element was recognized by the neuron-restrictive silencer factor (NRSF), previously shown to regulate expression of other neuron-specific genes, The ChAT NRSE was inactive in both cholinergic and non-cholinergic neuronal cells, but repressed expression from a heterologous promoter in non-neuronal cells, Specific deletion of this element allowed ChAT gene promoter activity in non-neuronal cells, and overexpression of NRSF repressed ChAT gene promoter activity in cholinergic cells, The distal part of the ChAT gene promoter showed cholinergic-specific enhancing activity, which stimulated promoter activity in cholinergic cells, but was inactive in non-cholinergic neuronal and non-neuronal cells, This enhancer region suppressed the activity of the ChAT NRSE in cholinergic cells, even after NRSF overexpression, Thus, at least two kinds of regulatory elements cooperate to direct ChAT gene expression to cholinergic neurons, namely a neuron-restrictive silencer element and a cholinergic-specific enhancer.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Lonnerberg, P (corresponding author), KAROLINSKA INST,DEPT NEUROSCI,MOL NEUROBIOL LAB,S-17177 STOCKHOLM,SWEDEN.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEJANIN S, 1992, J NEUROCHEM, V58, P1580, DOI 10.1111/j.1471-4159.1992.tb11383.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P102; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABECKER BA, 1994, SCIENCE, V264, P1602, DOI 10.1126/science.8202714; HAMMOND DN, 1986, SCIENCE, V234, P1237, DOI 10.1126/science.3775382; HERSH LB, 1993, J NEUROCHEM, V61, P306, DOI 10.1111/j.1471-4159.1993.tb03569.x; IBANEZ CF, 1991, EUR J NEUROSCI, V3, P1309, DOI 10.1111/j.1460-9568.1991.tb00063.x; IBANEZ CF, 1991, J NEUROSCI RES, V29, P163, DOI 10.1002/jnr.490290205; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; JONAKAIT GM, 1994, NEURON, V12, P1149; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; KITAMOTO T, 1993, ROUX ARCH DEV BIOL, V202, P159, DOI 10.1007/BF00365306; KITAMOTO T, 1995, J NEUROBIOL, V28, P70, DOI 10.1002/neu.480280107; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LONNERBERG P, 1995, P NATL ACAD SCI USA, V92, P4046, DOI 10.1073/pnas.92.9.4046; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MISAWA H, 1992, J BIOL CHEM, V267, P20392; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PU HF, 1993, MOL CELL NEUROSCI, V4, P131, DOI 10.1006/mcne.1993.1017; RAO MS, 1992, DEVELOPMENT, V116, P731; SALAZARGRUESO EF, 1991, NEUROREPORT, V2, P505, DOI 10.1097/00001756-199109000-00002; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; WEISER M, 1994, SYNAPSE, V16, P81, DOI 10.1002/syn.890160202; WU DH, 1994, J NEUROCHEM, V62, P1653	34	89	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33358	33365		10.1074/jbc.271.52.33358	http://dx.doi.org/10.1074/jbc.271.52.33358			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969196	hybrid			2022-12-25	WOS:A1996WA71300030
J	Rucker, P; Torti, FM; Torti, SV				Rucker, P; Torti, FM; Torti, SV			Role of H and L subunits in mouse ferritin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; L-CHAIN; MOLECULAR-CLONING; MESSENGER-RNA; HEAVY-CHAIN; IRON-UPTAKE; HUMAN-LIVER; GENE; SITE; HETEROPOLYMERS	Ferritin is an iron-binding protein composed of two subunits, H and L. Tuenty-four of these subunits assemble to form apoferritins whose subunit composition varies in a characteristic way in different tissues, Using recombinant proteins, we have assessed the role of H and L subunits in mouse ferritin function and compared these to human ferritin subunits, We report that mouse ferritin subunits exhibit considerable functional similarity to their human counterparts, including a prominent role of the H subunit in the facilitation of rapid iron uptake, and a key role of amino acid residues Glu-62 and His-65 in this process, In addition, amino acid residues important to assembly of the protein are conserved between mouse and human, permitting the formation of fully functional hybrid proteins containing both mouse and human subunits, However, murine and human ferritin H subunits also evidenced substantial functional differences; murine ferritin H showed a consistent reduction in iron uptake activity relative to human ferritin H, Creation of chimeric human/mouse ferritin H subunits by ''helix swapping'' mapped the domain of the protein critical to this activity difference to the DE helix, These findings suggest a novel functional role for carboxyl-terminal domains of the ferritin H subunit.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT CANC BIOL,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT MED,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,CTR COMPREHENS CANC,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NIDDK NIH HHS [DK 42412] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK042412, R01DK042412] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUMONT C, 1989, J BIOL CHEM, V264, P7498; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; CHOU CC, 1986, MOL CELL BIOL, V6, P566, DOI 10.1128/MCB.6.2.566; COX F, 1988, J BIOL CHEM, V263, P7060; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; GIULIAN GG, 1983, ANAL BIOCHEM, V129, P277, DOI 10.1016/0003-2697(83)90551-1; HUDSON AJ, 1993, EUR J BIOCHEM, V218, P985, DOI 10.1111/j.1432-1033.1993.tb18457.x; JAPPELLI R, 1992, J MOL BIOL, V227, P532, DOI 10.1016/0022-2836(92)90905-Y; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON DM, 1989, FEBS LETT, V254, P207, DOI 10.1016/0014-5793(89)81040-3; LEVI S, 1989, BIOCHEMISTRY-US, V28, P5179, DOI 10.1021/bi00438a040; LEVI S, 1987, GENE, V51, P269, DOI 10.1016/0378-1119(87)90315-5; LEVI S, 1994, J MOL BIOL, V238, P649, DOI 10.1006/jmbi.1994.1325; LEVI S, 1988, J BIOL CHEM, V263, P18086; LEVI S, 1992, BIOCHEM J, V288, P591, DOI 10.1042/bj2880591; Liu P, 1996, CAN J CARDIOL, V12, P155; Mulvey MR, 1996, J BIOL CHEM, V271, P9851, DOI 10.1074/jbc.271.16.9851; OTSUKA S, 1980, J BIOL CHEM, V255, P6234; Picard V, 1996, BLOOD, V87, P2057; SANTAMBROGIO P, 1992, J BIOL CHEM, V267, P14077; SANTAMBROGIO P, 1993, J BIOL CHEM, V268, P12744; SUN SJ, 1993, BIOCHEMISTRY-US, V32, P9362, DOI 10.1021/bi00087a015; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TORTI SV, 1988, J BIOL CHEM, V263, P12638; TREFFRY A, 1989, FEBS LETT, V247, P268, DOI 10.1016/0014-5793(89)81350-X; TSUJI Y, 1995, MOL CELL BIOL, V15, P5152; WADE VJ, 1991, J MOL BIOL, V221, P1443, DOI 10.1016/0022-2836(91)80137-J; WAGSTAFF M, 1978, BIOCHEM J, V173, P969, DOI 10.1042/bj1730969; WAGSTAFF M, 1982, CLIN SCI, V62, P529, DOI 10.1042/cs0620529; WALDO GS, 1993, SCIENCE, V259, P796, DOI 10.1126/science.8430332; WEI Y, 1990, BIOCHEM BIOPH RES CO, V169, P289, DOI 10.1016/0006-291X(90)91466-6	32	67	69	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33352	33357		10.1074/jbc.271.52.33352	http://dx.doi.org/10.1074/jbc.271.52.33352			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969195	hybrid			2022-12-25	WOS:A1996WA71300029
J	Biere, AL; Ostaszewski, B; Stimson, ER; Hyman, BT; Maggio, JE; Selkoe, DJ				Biere, AL; Ostaszewski, B; Stimson, ER; Hyman, BT; Maggio, JE; Selkoe, DJ			Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-BRAIN-BARRIER; HUMAN APOLIPOPROTEIN-E; ISOFORM-SPECIFIC BINDING; ONSET ALZHEIMER-DISEASE; CEREBROSPINAL-FLUID; ENDOGENOUS ALBUMIN; PROTEIN-PRECURSOR; SENILE PLAQUES; SOLUBLE FORM; E GENOTYPE	The amyloid beta-peptide (A beta) is the major constituent of neuritic plaques in Alzheimer's disease and occurs as a soluble 40-42-residue peptide in cerebrospinal fluid and blood of both normal and AD subjects. It is unclear whether A beta, once it is secreted by cells, remains free in biological fluids or is associated with other proteins and thus transported and metabolized with them. Such knowledge of the normal fate of A beta is a prerequisite for understanding the changes that may lead to the pathological aggregation of soluble A beta in vivo, the possible influence of certain extracellular proteins, particularly apolipoprotein E, on plaque formation, and the pharmacology of putative A beta-lowering drugs. To address the question of A beta distribution in human biological fluids, we incubated fresh human plasma from 38 subjects with physiological concentrations (0.5-0.7 nM) of radioiodinated A beta(1-40) and seven plasma samples with A beta(1-42). Lipoproteins and lipid-free proteins were separated and analyzed for bound iodinated A beta(1-40). We found that up to 5% of A beta added to plasma is bound to selected lipoproteins: very low density, low density, and high density, but not lipoprotein(a). The large majority (approximate to 89%), however, is bound to albumin, and very little A beta is free. A beta distribution in plasma was not significantly influenced by apolipoprotein E genotype. We conclude that A beta is normally bound to and transported by albumin and specific lipoproteins in human plasma under physiological conditions.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOL PHARMACOL,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,DEPT NEUROL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital					NHLBI NIH HHS [HL49552] Funding Source: Medline; NIA NIH HHS [AG12749] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049552] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012749] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Benson J.R., 1981, PEPTIDES, P217; BERR C, 1994, NEUROSCI LETT, V178, P221, DOI 10.1016/0304-3940(94)90763-3; Biere AL, 1995, NEUROBIOL DIS, V2, P177, DOI 10.1006/nbdi.1995.0019; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; Braunwald E., 1987, HARRISONS PRINCIPLES; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Chan W, 1996, BIOCHEMISTRY-US, V35, P7123, DOI 10.1021/bi952852v; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Claudio L, 1996, ACTA NEUROPATHOL, V91, P6; DONG LM, 1994, J BIOL CHEM, V269, P22358; DOVEY HF, 1993, NEUROREPORT, V4, P1039, DOI 10.1097/00001756-199308000-00011; Esler WP, 1996, J NEUROCHEM, V66, P723; Esler WP, 1996, BIOCHEMISTRY-US, V35, P749, DOI 10.1021/bi951685w; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; FUNKE H, 1995, NAT GENET, V10, P6, DOI 10.1038/ng0595-6; GHILARDI JR, 1996, IN PRESS NEUROREPORT; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; HIXSON JE, 1990, J LIPID RES, V31, P545; HYMAN BT, 1995, P NATL ACAD SCI USA, V92, P3586, DOI 10.1073/pnas.92.8.3586; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; KOUDINOV A, 1994, BIOCHEM BIOPH RES CO, V205, P1164, DOI 10.1006/bbrc.1994.2788; LADU MJ, 1994, J BIOL CHEM, V269, P23403; LADU MJ, 1995, J BIOL CHEM, V270, P9039, DOI 10.1074/jbc.270.16.9039; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MANESS LM, 1994, LIFE SCI, V55, P1643, DOI 10.1016/0024-3205(94)00331-9; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mills G.L., 1984, GUIDEBOOK LIPOPROTEI, V14; MOTTER R, 1995, ANN NEUROL, V38, P643, DOI 10.1002/ana.410380413; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; NOBLE RP, 1968, J LIPID RES, V9, P693; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PITAS RE, 1987, J BIOL CHEM, V262, P14352; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1283; Putnam F.W, 1975, PLASMA PROTEINS, V2nd, DOI DOI 10.1016/B978-0-12-568401-9.50009-8; REBECK GW, 1994, NEUROLOGY, V44, P1513, DOI 10.1212/WNL.44.8.1513; REBECK GW, 1993, NEURON, V11, P575; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROHEIM PS, 1979, P NATL ACAD SCI USA, V76, P4646, DOI 10.1073/pnas.76.9.4646; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; SALAHUDDIN TS, 1988, ACTA NEUROPATHOL, V77, P5, DOI 10.1007/BF00688236; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SOKRAB TEO, 1988, ACTA NEUROPATHOL, V75, P557, DOI 10.1007/BF00686200; STEINMETZ A, 1989, ARTERIOSCLEROSIS, V9, P405, DOI 10.1161/01.ATV.9.3.405; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; VANGOOL WA, 1995, ANN NEUROL, V37, P277, DOI 10.1002/ana.410370221; VORBRODT AW, 1995, ACTA NEUROPATHOL, V89, P491; VORBRODT AW, 1994, J NEUROCYTOL, V23, P792, DOI 10.1007/BF01268091; WESTERGREN I, 1990, EXP NEUROL, V107, P192, DOI 10.1016/0014-4886(90)90158-O; WISNIEWSKI HM, 1994, ACTA NEUROPATHOL, V87, P233; WISNIEWSKI T, 1993, BIOCHEM BIOPH RES CO, V192, P359, DOI 10.1006/bbrc.1993.1423; ZLOKOVIC BV, 1993, BIOCHEM BIOPH RES CO, V197, P1043	69	277	281	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32916	32922		10.1074/jbc.271.51.32916	http://dx.doi.org/10.1074/jbc.271.51.32916			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955133	hybrid			2022-12-25	WOS:A1996VZ37300068
J	Carmel, G; Mager, EM; Binder, LI; Kuret, J				Carmel, G; Mager, EM; Binder, LI; Kuret, J			The structural basis of monoclonal antibody Alz50's selectivity for Alzheimer's disease pathology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; PROTEIN-TAU TAU; LINKED-IMMUNOSORBENT-ASSAY; CENTRAL NERVOUS-SYSTEM; NORMAL HUMAN-BRAIN; NEUROFIBRILLARY TANGLES; CASEIN KINASE-1; ELECTRON-MICROSCOPY; ALZ-50 EPITOPE; LOCALIZATION	The epitope on tau protein recognized by the monoclonal antibody Alz50 was defined through internal deletion mutagenesis and quantified by affinity measurements. The epitope is discontinuous and requires both a previously identified N-terminal segment and the microtubule binding region for efficient binding of Alz50. The interaction between these regions is consistent with an intramolecular reaction mechanism, suggesting that Alz50 binding depends on the conformation of individual tau monomers. The results suggest that tau adopts a distinct conformation when polymerized into filaments and that this conformation is recognized selectively by Alz50.	NORTHWESTERN UNIV,SCH MED,DEPT CELL & MOL BIOL,CHICAGO,IL 60611; NORTHWESTERN UNIV,INST NEUROSCI,CHICAGO,IL 60611	Northwestern University; Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044806] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009466, R01AG009031] Funding Source: NIH RePORTER; NIA NIH HHS [AG09466, AG09031] Funding Source: Medline; NIGMS NIH HHS [GM44806] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; BENZING WC, 1993, J COMP NEUROL, V334, P176, DOI 10.1002/cne.903340203; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOWSER R, 1995, DEV NEUROSCI-BASEL, V17, P20, DOI 10.1159/000111270; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CARMEL G, 1992, ANAL BIOCHEM, V203, P274, DOI 10.1016/0003-2697(92)90313-V; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DAVIS PK, 1995, J NEUROSCI RES, V39, P589; DEKEYSER F, 1996, PEPTIDES IMMUNOLOGY, P239; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; GHANBARI HA, 1990, JAMA-J AM MED ASSOC, V263, P2907, DOI 10.1001/jama.263.21.2907; GOEDERT M, 1991, NEUROSCI LETT, V126, P149, DOI 10.1016/0304-3940(91)90541-Z; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Harlow E., 1988, ANTIBODIES LAB MANUA; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; Hulme E. C., 1992, RECEPTOR LIGAND INTE, P63; Hwang SC, 1996, J BIOL CHEM, V271, P18342, DOI 10.1074/jbc.271.31.18342; HYMAN BT, 1988, ANN NEUROL, V23, P371, DOI 10.1002/ana.410230410; IKONOMOVIC MD, 1995, AM J PATHOL, V147, P516; KIDD M, 1963, NATURE, V197, P192, DOI 10.1038/197192b0; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOSIK KS, 1986, P NATL ACAD SCI USA, V83, P4044, DOI 10.1073/pnas.83.11.4044; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; KSIEZAKREDING H, 1995, BRAIN RES, V697, P63, DOI 10.1016/0006-8993(95)00785-O; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P412, DOI 10.1002/jnr.490250319; KSIEZAKREDING H, 1988, J BIOL CHEM, V263, P7943; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LIU WK, 1993, J NEUROSCI RES, V34, P371, DOI 10.1002/jnr.490340315; LOPRESTI P, 1995, P NATL ACAD SCI USA, V92, P10369, DOI 10.1073/pnas.92.22.10369; MESELSON M, 1968, NATURE, V217, P1110, DOI 10.1038/2171110a0; PAPASOZOMENOS SC, 1987, CELL MOTIL CYTOSKEL, V8, P210, DOI 10.1002/cm.970080303; PAPASOZOMENOS SC, 1989, LAB INVEST, V60, P375; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; RUBEN GC, 1993, BRAIN RES, V602, P1, DOI 10.1016/0006-8993(93)90234-E; RUBEN GC, 1995, BRAIN RES, V675, P1, DOI 10.1016/0006-8993(94)01437-M; RYE DB, 1993, NEUROSCIENCE, V56, P109, DOI 10.1016/0306-4522(93)90567-Y; SCHWEERS O, 1994, J BIOL CHEM, V269, P24290; Skoog I, 1995, NEURODEGENERATION, V4, P433, DOI 10.1006/neur.1995.0052; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; UEDA K, 1990, J NEUROSCI, V10, P3295; VANCURA A, 1994, J BIOL CHEM, V269, P19271; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; WANG PC, 1994, J BIOL CHEM, V269, P12014; WATANABE N, 1992, J NEUROCHEM, V58, P960, DOI 10.1111/j.1471-4159.1992.tb09349.x; WISCHIK CM, 1985, J CELL BIOL, V100, P1905, DOI 10.1083/jcb.100.6.1905; WOLOZIN B, 1987, ANN NEUROL, V22, P521, DOI 10.1002/ana.410220412; WOLOZIN B, 1988, P NATL ACAD SCI USA, V85, P6202, DOI 10.1073/pnas.85.16.6202; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; WOOD JG, 1986, P NATL ACAD SCI USA, V83, P4040, DOI 10.1073/pnas.83.11.4040	62	356	371	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32789	32795		10.1074/jbc.271.51.32789	http://dx.doi.org/10.1074/jbc.271.51.32789			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955115	hybrid			2022-12-25	WOS:A1996VZ37300050
J	Kudo, M; Kitajima, K; Inoue, S; Shiokawa, K; Morris, HR; Dell, A; Inoue, Y				Kudo, M; Kitajima, K; Inoue, S; Shiokawa, K; Morris, HR; Dell, A; Inoue, Y			Characterization of the major core structures of the alpha 2->8-linked polysialic acid-containing glycan chains present in neural cell adhesion molecule in embryonic chick brains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROUT EGG POLYSIALOGLYCOPROTEINS; ENDO-N-ACETYLNEURAMINIDASE; CARBOHYDRATE UNITS; FREE SIALOOLIGOSACCHARIDES; DEVELOPMENTAL EXPRESSION; UNFERTILIZED EGGS; ESCHERICHIA-COLI; MEDAKA FISH; OLIGOSACCHARIDES; GLYCOPROTEINS	To gain more insight into the possible functional significance of the core glycan chain(s) on which polysialylation takes place in polysialic acid (poly-Sia) containing glycoproteins, the structure of the core glycans in the embryonic form of chick brain neural cell adhesion molecule (N-CAM) were examined using chemical and instrumental techniques. The following new structural features, which had not been reported by the early pioneering study by Finne (Finne, J. (1982) J. Biol. Chem. 257, 11966-11970), were revealed (Structure I). (i) Two distinct types of multiantennary N-linked glycans, i.e. tri- and tetra-antennary structures, are present; (ii) an alpha 1-->6-linked fucosyl residue is attached to the proximal GlcNAc residue of the di-N-acetylchitobiosyl unit; (iii) that the action of GlcNAc-transferase V, which catalyzes the attachment of the beta-(1-->6)-alpha-linked GlcNAc residue on the (1-->6)-alpha-linked mannose (Man) arm, appears to be essential for polysialylation to occur on the core glycan chain is suggested by the fact that the Man residue alpha 1-->6-linked to the beta-linked Man residue is invariably 2,6-di-O-substituted by the GlcNAc residue; (iv) both type 1 (Gal beta 1-->3GlcNAc) and type 2 (Gal beta 1-->4GlcNAc) sequences are present in the peripheral portion of the core glycan structure. An extended form of the type 2 chain, i,e. Gal beta 1-->4GlcNAc beta 1-->3Gal beta 1--4GlcNAc, is also expressed on the (1-->3)- and (1-->6)-alpha-linked Man arms; (v) on average about 1.4 mol of sulfate is attached to the type 2 N-acetyllactosamine chain(s), where in the extended form the sulfate group is probably substituted at the O-3 position of the outmost GlcNAc residue, i.e. Gal beta 1-->4(HSO3-->3)GlcNAc beta 1-->3Gal beta 1-->4GlcNAc beta 1-->Man. It is possible that the unusual structural features identified in this study might play a role in the initiation of polysialylation and our data should facilitate future research regarding the signals that control polysialylation.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT ZOOL,TOKYO 113,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,TOKYO 142,JAPAN; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AZ,ENGLAND	University of Tokyo; University of Tokyo; Showa University; Imperial College London			Kudo, Masatoshi/AAA-9744-2019	Kudo, Masatoshi/0000-0002-4102-3474	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; ANGATA T, 1994, GLYCOCONJUGATE J, V11, P493, DOI 10.1007/BF00731286; ANUMULA KR, 1992, ANAL BIOCHEM, V203, P101, DOI 10.1016/0003-2697(92)90048-C; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DELL A, 1994, METHOD ENZYMOL, V230, P108; DEWAARD P, 1991, J BIOL CHEM, V266, P4237; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FINNE J, 1982, J BIOL CHEM, V257, P1966; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HIGA HH, 1988, J BIOL CHEM, V263, P8872; HOOPER LV, 1995, J BIOL CHEM, V270, P16327, DOI 10.1074/jbc.270.27.16327; Ijuin T, 1996, GLYCOCONJUGATE J, V13, P401, DOI 10.1007/BF00731473; INOUE S, 1989, J BIOL CHEM, V264, P18520; ISHII K, 1989, J BIOL CHEM, V264, P1623; IWASAKI M, 1990, J BIOL CHEM, V265, P2596; KATO Y, 1989, J BIOL CHEM, V264, P3364; KITAJIMA K, 1992, ANAL BIOCHEM, V205, P244, DOI 10.1016/0003-2697(92)90430-F; KITAJIMA K, 1988, J BIOL CHEM, V263, P18269; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KITAZUME S, 1994, J BIOL CHEM, V269, P22712; KITAZUME S, 1992, ANAL BIOCHEM, V202, P25, DOI 10.1016/0003-2697(92)90200-Q; Kitazume S, 1996, J BIOL CHEM, V271, P6694, DOI 10.1074/jbc.271.12.6694; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KOJIMA N, 1995, FEBS LETT, V373, P116; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; LIVINGSTON BD, 1988, J BIOL CHEM, V263, P9443; LOGUIDICE JM, 1994, J BIOL CHEM, V269, P18794; MARGOLIS RK, 1983, BIOCHEM BIOPH RES CO, V116, P889, DOI 10.1016/S0006-291X(83)80225-3; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; Nakayama J, 1996, J BIOL CHEM, V271, P1829, DOI 10.1074/jbc.271.4.1829; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; NIMTZ M, 1993, EUR J BIOCHEM, V213, P39, DOI 10.1111/j.1432-1033.1993.tb17732.x; NOMOTO H, 1982, ARCH BIOCHEM BIOPHYS, V218, P335, DOI 10.1016/0003-9861(82)90352-6; OKA S, 1995, J BIOL CHEM, V270, P19357, DOI 10.1074/jbc.270.33.19357; ROTH J, 1987, P NATL ACAD SCI USA, V84, P1969, DOI 10.1073/pnas.84.7.1969; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SARFF LD, 1975, LANCET, V1, P1099; SATO C, 1993, J BIOL CHEM, V268, P23675; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKO A, 1991, J BIOL CHEM, V266, P22110; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SORKIN BC, 1984, SCIENCE, V225, P1476, DOI 10.1126/science.6474186; SPILLMANN D, 1995, J BIOL CHEM, V270, P5089, DOI 10.1074/jbc.270.10.5089; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; SVENNERHOLM L, 1957, BIOCHIM BIOPHYS ACTA, V24, P604, DOI 10.1016/0006-3002(57)90254-8; TAGUCHI T, 1993, J BIOL CHEM, V268, P2353; TANPHAICHITR N, 1993, DEV BIOL, V156, P164, DOI 10.1006/dbio.1993.1067; UCHIDA Y, 1977, J BIOCHEM-TOKYO, V82, P1425, DOI 10.1093/oxfordjournals.jbchem.a131830; VANHALBEEK H, 1994, METHOD ENZYMOL, V230, P132; VARKI AP, 1981, P NATL ACAD SCI-BIOL, V78, P7773, DOI 10.1073/pnas.78.12.7773	58	58	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32667	32677		10.1074/jbc.271.51.32667	http://dx.doi.org/10.1074/jbc.271.51.32667			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955097	hybrid			2022-12-25	WOS:A1996VZ37300032
J	Saxena, AK; Saxena, P; Monnier, VM				Saxena, AK; Saxena, P; Monnier, VM			Purification and characterization of a membrane-bound deglycating enzyme (1-deoxyfructosyl alkyl amino acid oxidase, EC 1.5.3) from a Pseudomonas sp soil strain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; COMPLICATIONS; PROTEINS; BINDING; INVIVO; PLASMA	Searching for novel approaches for uncoupling glycation from hyperglycemia as a cause of diabetic complications, a Pseudomonas sp. soil strain containing a membrane-bound enzyme that deglycates amino acids under release of free fructosamine was isolated (Gerhardinger, C., Marion, S. M., Rovner, A., Glomb, M., and Monnier, V. M. (1995) J. Biol. Chem. 270, 218-224). This enzymatic activity was found to be very sensitive to inactivation by most detergents. From the plasma membrane (similar to 3 mg/ml protein concentration), the enzyme could be solubilized in active form using 10 mM 3-[(3-chlolamidopropyl)dimethylammonio] -2-hydroxy-1-propanesulfonate aided by 2 M NaCl and 10% glycerol (27% optimal solubilization yield). The supernatant from a 55% saturation (NH4)(2)SO4 cut was fractionated onto a phenyl-Superose HR 5/5 column and enzymatic activity was eluted with a inverse gradient of (NH4)(2)SO4. Following removal of (NH4)(2)SO4 with PD-10 columns and fractionation with a Mono & HR 5/5 column, a sharp peak of enzyme activity was eluted, Analysis on sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed a major band at 106 kDa and, on isoelectrofocusing gel, a pI of 5.1. The activity was completely inhibited by CN- and N-3(-) suggestive of copper as a likely cofactor. Identification of the protein was confirmed by affinity labeling with (CN-)-C-14 and isoelectrofocusing. The ''amadoriase'' activity was also inhibited by Hg2+, Ag2+, Cu2+, and Zn2+ and had K-m and V-max values of 0.14 mM and 0.48 unit/ml (16 units/mg of protein), respectively, for epsilon-(1-deoxyfructosyl) aminocaproate. Significant activity was noted toward many glycated amino acids (highest with epsilon-fructosyl lysine) but not with glycated proteins. The sequence of the first 16 NH2-terminal amino acids and a search in various data bases revealed that this amadoriase enzyme is a novel protein. Based on its properties, this deglycating enzyme, which degrades Amadori products oxidatively into free fructosamine, is classified as fructosyl aminocaproate:oxygen oxidoreductase (EC 1.5.3).	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA	Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NEI NIH HHS [EY 07099] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARKER R, 1979, BIOCHEM J, V177, P289, DOI 10.1042/bj1770289; Baynes JW., 1989, PROG CLIN BIOL RES, V304, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; COHEN MP, 1994, KIDNEY INT, V45, P1673, DOI 10.1038/ki.1994.219; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; DOOLEY DM, 1987, LIFE CHEM REPORTS, V5, P91; FINOT PA, 1969, HELV CHIM ACTA, V52, P1488, DOI 10.1002/hlca.19690520609; GACHERU SN, 1990, J BIOL CHEM, V265, P19022; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GERHARDINGER C, 1994, J BIOL CHEM, V269, P27297; GREENE DA, 1988, DIABETES METAB REV, V4, P202; HE ZW, 1995, ARCH BIOCHEM BIOPHYS, V319, P185, DOI 10.1006/abbi.1995.1281; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; HOUEN G, 1993, ACTA CHEM SCAND, V47, P902, DOI 10.3891/acta.chem.scand.47-0902; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHLER HR, 1966, BIOL CHEM, P643; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MIYATA S, 1992, J CLIN INVEST, V89, P1102, DOI 10.1172/JCI115690; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; PAGE MI, 1984, CHEM ENZYME ACTION, P267; ROBINSON J, 1970, ANAL BIOCHEM, V33, P390, DOI 10.1016/0003-2697(70)90310-6; SABBATINI M, 1992, KIDNEY INT, V42, P875, DOI 10.1038/ki.1992.363; SAKAI Y, 1995, BIOSCI BIOTECH BIOCH, V59, P487, DOI 10.1271/bbb.59.487; SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; VLASSARA H, 1994, J LAB CLIN MED, V124, P19; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; YAN SD, 1994, J BIOL CHEM, V269, P9889	32	33	42	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32803	32809		10.1074/jbc.271.51.32803	http://dx.doi.org/10.1074/jbc.271.51.32803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955117	hybrid			2022-12-25	WOS:A1996VZ37300052
J	Enyedi, A; Verma, AK; Filoteo, AG; Penniston, JT				Enyedi, A; Verma, AK; Filoteo, AG; Penniston, JT			Protein kinase C activates the plasma membrane Ca2+ pump isoform 4b by phosphorylation of an inhibitory region downstream of the calmodulin-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2+ PUMP; HUMAN-ERYTHROCYTES; SMOOTH-MUSCLE; DEPENDENT PHOSPHORYLATION; SARCOLEMMAL CA-2+-ATPASE; CALCIUM-PUMP; SITE; IDENTIFICATION; SUBSTRATE; RESIDUES	The carboxyl-terminal region of the plasma membrane Ca2+ pump isoform 4b contains two autoinhibitory regions which keep the pump inactive in the absence of activators such as calmodulin, One of these regions is approximately coterminous with the calmedulin-binding domain, while the second region is downstream (Verma, A. K., Enyedi, A., Filoteo, A. G., and Penniston, J. T. (1994) J. Biol. Chem. 269, 1687-1691). The carboxyl-terminal region has also been identified as the site for phosphorylation of this isoform by protein kinase C (Wang, K. H. W., Wright, L. C., Machan, C. L., Alien, B. G., Conigrave, A. D., and Roufogalis, B. D. (1991) J. Biol. Chem. 266, 9078-9085). Using constructs lacking various numbers of residues at the carboxyl terminus, we studied the degree of phosphorylation by protein kinase C and the resultant activation of Ca2+ transport. The results showed that the most specific and easy phosphorylation occurred in a region of about 20 residues which is downstream of the calmodulin-binding domain, and that the downstream inhibitory domain had also about the same size and location. Phosphorylation partially activated the pump by removing only the inhibition due to this region, Binding of calmodulin to the calmodulin-binding domain activated the pump more fully by removing the inhibition due to both regions, regardless of the state of phosphorylation at the downstream inhibitory region.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905	Mayo Clinic			Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APEL ED, 1990, BIOCHEMISTRY-US, V29, P2330, DOI 10.1021/bi00461a017; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; FARRAR YJK, 1994, FASEB J, V8, pA1390; FUKUDA T, 1990, J BIOCHEM-TOKYO, V108, P629, DOI 10.1093/oxfordjournals.jbchem.a123254; FURUKAWA KI, 1989, J BIOL CHEM, V264, P4844; GRAFF JM, 1989, J BIOL CHEM, V264, P11912; HASHIMOTO Y, 1989, J BIOL CHEM, V264, P16524; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HOUSE C, 1987, J BIOL CHEM, V262, P772; JAMES P, 1988, J BIOL CHEM, V263, P2905; KUO TH, 1991, J BIOL CHEM, V266, P2520; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MONTEITH GR, 1995, CELL CALCIUM, V19, P459; OGURUSU T, 1990, J BIOCHEM-TOKYO, V108, P222, DOI 10.1093/oxfordjournals.jbchem.a123184; PEARSON RB, 1986, J BIOL CHEM, V261, P25; QU Y, 1992, CAN J PHYSIOL PHARM, V70, P1230, DOI 10.1139/y92-171; ROUFOGALIS BD, 1993, TODAYS LIFE SCI, V5, P24; SMALLWOOD JI, 1988, J BIOL CHEM, V263, P2195; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VERMA AK, 1988, J BIOL CHEM, V263, P14152; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1991, ARCH BIOCHEM BIOPHYS, V289, P103, DOI 10.1016/0003-9861(91)90448-R; WRIGHT LC, 1993, ARCH BIOCHEM BIOPHYS, V306, P277, DOI 10.1006/abbi.1993.1512	29	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32461	32467		10.1074/jbc.271.50.32461	http://dx.doi.org/10.1074/jbc.271.50.32461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943312	hybrid			2022-12-25	WOS:A1996VY34000103
J	Buettner, VL; Hill, KA; Nishino, H; Schaid, DJ; Frisk, CS; Sommer, SS				Buettner, VL; Hill, KA; Nishino, H; Schaid, DJ; Frisk, CS; Sommer, SS			Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53 Big Blue double transgenic mice	ONCOGENE			English	Article						point mutations; Big Blue; mutator phenotype; transitions; deletions with insertions; inversions	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR DEFICIENCY; COLON-CANCER; MICROSATELLITE INSTABILITY; SUPPRESSOR GENE; GASTRIC-CANCER; LACI GENE; HOMOLOG; CARCINOGENESIS; CARCINOMA	p53 (-/-), lacI (+/-) double transgenic (p53/Big Blue(R)) mice provide an opportunity to examine the relationship in vivo between somatic mutation and tumorigenesis, Previously, the frequency and spectra of Cad mutations were found to be similar in normal tissues of 6 week old p53 (-/-) lacI (+/-) and p53 (+/+) lacI (+/-) mice, Herein, p53 (-/-), lacI (+/-) mice were used to examine the frequency and spectrum of spontaneous mutation in thymic lymphomas, Four mice with thymic lymphomas were sacrificed at 2.5, 3, 4 and 4.5 months of age, Normal thymus harvested from two p53 (+/+) lacI (+/-) mice and two p53 (-/-) lacI (+/-) mice served as controls, The mutation frequency in tumor 108 (6.8 x 10(-5)) was elevated 2.3-fold relative to the p53 (-/-) control (P<0.0001; chi(2) test), The mutation spectra were also different (P=0.0009; Fisher exact test); in particular, A:T-->G:C transitions were prominently overrepresented in tumor 108, In addition, there were two examples of unusual deletions with inversions, In tumors 44 and 115, but not 110, there were trends toward increased mutation frequencies and altered spectra, but, within the constraints of present sample sizes, the results are not statistically significant, In conclusion, these findings suggest that altered frequencies and spectra exist in a subset of thymic lymphomas, perhaps due to somatic mutation in one or more DNA repair genes.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT VET MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A., 1994, Cancer Bulletin (Houston), V46, P161; DOUGLAS GR, 1994, MUTAGENESIS, V9, P451, DOI 10.1093/mutage/9.5.451; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gartenhaus R, 1996, BLOOD, V87, P38; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1994, MUTAT RES-FUND MOL M, V310, P125, DOI 10.1016/0027-5107(94)90016-7; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINE AJ, 1992, CANCER SURV, V12, P59; LI FP, 1988, CANCER RES, V48, P5358; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIRONOV NM, 1994, CANCER RES, V54, P41; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHINO H, 1995, ONCOGENE, V11, P263; NISHINO H, 1995, BIOTECHNIQUES, V19, P587; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	40	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2407	2413						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957082				2022-12-25	WOS:A1996VX10800013
J	deVet, ECJM; Zomer, AWM; Lahaut, GJHTJ; vandenBosch, H				deVet, ECJM; Zomer, AWM; Lahaut, GJHTJ; vandenBosch, H			Polymerase chain reaction-based cloning of alkyl-dihydroxyacetonephosphate synthase complementary DNA from guinea pig liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; 3-KETOACYL-COA THIOLASE; MESSENGER-RNAS; ANIMAL-CELLS; PURIFICATION; PEROXISOMES; PROTEIN; ACYLTRANSFERASE; PLASMALOGENS; BIOSYNTHESIS	Peroxisomes are indispensable organelles for ether lipid biosynthesis in mammalian tissues, and the deficiency of these organelles in a number of peroxisomal disorders leads to deficiencies in ether phospholipids. We have previously purified the committed enzyme for ether lipid biosynthesis, i.e. alkyl-dihydroxyac etonephosphate synthase, to homogeneity. We have now determined the N-terminal amino acid sequence, as well as additional internal sequences obtained after cyanogen bromide cleavage of the enzyme. With primers directed against the N-terminal sequence and against a cyanogen bromide fragment sequence, a 1100-bp cDNA fragment was obtained by conventional polymerase chain reaction using first-strand cDNA from guinea pig liver as a template, The 5' and 3' ends of the cDNA were obtained by rapid amplification of cDNA ends, The open reading frame encodes a protein of 658 amino acids, containing the N terminal amino acid sequence as well as the cyanogen bromide cleavage fragment sequences, The derived amino acid sequence includes a mature protein 600 amino acids long and a presequence 58 amino acids long. The latter contains a stretch of amino acids known as peroxisomal targeting signal 2, The size of the mRNA was estimated to be around 4200 nucleotides. Recombinant His-tagged alkyl-dihydroxyacetonephosphate synthase expressed in Escherichia coli was enzymatically active.	UNIV UTRECHT, CTR BIOMEMBRANES & LIPID ENZYMOL, BIOMEMBRANE INST, DEPT BIOCHEM LIPIDS, NL-3584 CH UTRECHT, NETHERLANDS	Utrecht University								AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BOUT A, 1988, NUCLEIC ACIDS RES, V16, P10369, DOI 10.1093/nar/16.21.10369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN AJ, 1983, J BIOL CHEM, V258, P4184; BROWN AJ, 1982, J BIOL CHEM, V257, P8835; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gros E., 1967, METHOD ENZYMOL, V11, P238; Hajra AK, 1995, PROG LIPID RES, V34, P343, DOI 10.1016/0163-7827(95)00013-5; HAJRA AK, 1982, ANN NY ACAD SCI, V386, P170, DOI 10.1111/j.1749-6632.1982.tb21415.x; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HIJIKATA M, 1990, J BIOL CHEM, V265, P4600; HOEFLER G, 1988, J PEDIATR-US, V112, P726, DOI 10.1016/S0022-3476(88)80689-9; HORIE S, 1992, METHOD ENZYMOL, V209, P385; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODI T, 1993, MOL GEN GENET, V238, P315, DOI 10.1007/BF00291989; McNew JA, 1996, TRENDS BIOCHEM SCI, V21, P54, DOI 10.1016/S0968-0004(96)80181-2; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MORAND OH, 1988, J BIOL CHEM, V263, P11597; OFMAN R, 1994, BBA-PROTEIN STRUCT M, V1206, P27, DOI 10.1016/0167-4838(94)90068-X; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; Rehling P, 1996, EMBO J, V15, P2901, DOI 10.1002/j.1460-2075.1996.tb00653.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHRAKAMP G, 1988, J LIPID RES, V29, P325; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; SWINKELS BW, 1991, EMBO J, V10, P3255, DOI 10.1002/j.1460-2075.1991.tb04889.x; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; WEBBER KO, 1993, ARCH BIOCHEM BIOPHYS, V300, P88, DOI 10.1006/abbi.1993.1013; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590; ZOMER AWM, 1993, BIOCHIM BIOPHYS ACTA, V1170, P189, DOI 10.1016/0005-2760(93)90070-P	33	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					798	803		10.1074/jbc.272.2.798	http://dx.doi.org/10.1074/jbc.272.2.798			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995366	hybrid			2022-12-25	WOS:A1997WC04800017
J	Fernandes, MJG; Yew, S; Leclerc, D; Henrissat, B; Vorgias, CE; Gravel, RA; Hechtman, P; Kaplan, F				Fernandes, MJG; Yew, S; Leclerc, D; Henrissat, B; Vorgias, CE; Gravel, RA; Hechtman, P; Kaplan, F			Identification of candidate active site residues in lysosomal beta-hexosaminidase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; ACID-SEQUENCE SIMILARITIES; ALPHA-SUBUNIT; GM2 GANGLIOSIDOSIS; DIRECTED MUTAGENESIS; EXTENSIVE HOMOLOGY; ESCHERICHIA-COLI; ADULT FORM; NUCLEOPHILE; MUTATION	The beta-hexosaminidases (Hex) catalyze the cleavage of terminal amino sugars on a broad spectrum of glycoconjugates. The major Hex isozymes in humans, Hex A, a heterodimer of alpha and beta subunits (alpha beta), and Hex B, a homodimer of beta subunits (beta beta), have different substrate specificities. The beta subunit (HEXB gene product), hydrolyzes neutral substrates. The alpha subunit (HEXA gene product), hydrolyzes both neutral and charged substrates. Only Hex A is able to hydrolyze the most important natural substrate, the acidic glycolipid GM(2) ganglioside. Mutations in the HEXA gene cause Tay-Sachs disease (TSD), a GM(2) ganglioside storage disorder. We investigated the role of putative active site residues Asp-alpha 258, Glu-alpha 307, Glu-alpha 323, and Glu-alpha 462 in the alpha subunit of Hex A. A mutation at codon 258 which we described was associated with the TSD B1 phenotype, characterized by the presence of normal amounts of mature but catalytically inactive enzyme. TSD-B1 mutations are believed to involve substitutions of residues at the enzyme active site. Glu-alpha 307, Glu-alpha 323, and Glu-alpha 462 were predicted to be active site residues by homology studies and hydrophobic cluster analysis. We used site-directed mutagenesis and expression in a novel transformed human fetal TSD neuroglial (TSD-NG) cell line (with very low levels of endogenous Hex A activity), to study the effects of mutation at candidate active site residues. Mutant HEXA cDNAs carrying conservative or isofunctional substitutions at these positions were expressed in TSD-NG cells. alpha E323D, alpha E462D, and alpha D258N cDNAs produced normally processed peptide chains with drastically reduced activity toward the alpha subunit-specific substrate 4MUGS. The alpha E307D cDNA produced a precursor peptide with significant catalytic activity. Kinetic analysis of enzymes carrying mutations at Glu-alpha 323 and Asp-alpha 258 (reported earlier by Bayleran, J., Hechtman, P., Kolodny, E., and Kaback, M. (1987) Am. J. Hum. Genet. 41, 532-548) indicated no significant change in substrate binding properties. Our data, viewed in the context of homology studies and modeling, and studies with suicide substrate, suggest that Glu-alpha 323 and Asp-alpha 258 are active site residues and that Glu-alpha 323 is involved in catalysis.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT HUMAN GENET,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT BIOL,MONTREAL,PQ H3H 1P3,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT PEDIAT,MONTREAL,PQ H3H 1P3,CANADA; CNRS,CTR RECH MACROMOL VEGETALES,F-38041 GRENOBLE 9,FRANCE; DESY,EUROPEAN MOL BIOL LAB,D-22603 HAMBURG,GERMANY	McGill University; McGill University; McGill University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)			Leclerc, Daniel/B-6375-2012; Leclerc, Daniel/AAB-4524-2021; Henrissat, Bernard/J-2475-2012	Leclerc, Daniel/0000-0002-9766-8941; Henrissat, Bernard/0000-0002-3434-8588				BAYLERAN J, 1987, AM J HUM GENET, V41, P532; BAYLERAN J, 1984, CLIN CHIM ACTA, V143, P73, DOI 10.1016/0009-8981(84)90215-8; BROWN CA, 1991, J BIOL CHEM, V266, P15855; BROWN CA, 1989, J BIOL CHEM, V264, P21705; BROWN CA, 1993, AM J HUM GENET, V53, P497; BURG J, 1985, ANN HUM GENET, V49, P41, DOI 10.1111/j.1469-1809.1985.tb01674.x; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; DAVIES G, 1995, STRUCTURE, V3, P781; Fernandes Maria, 1992, Human Molecular Genetics, V1, P759, DOI 10.1093/hmg/1.9.759; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; HEARING J, 1989, J CELL BIOL, V108, P339, DOI 10.1083/jcb.108.2.339; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HERMANS MMP, 1991, J BIOL CHEM, V266, P13507; HOLM L, 1994, FEBS LETT, V340, P129, DOI 10.1016/0014-5793(94)80187-8; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRESSE H, 1981, J BIOL CHEM, V256, P2926; KYTZIA HJ, 1985, J BIOL CHEM, V260, P7568; LAKE BD, 1974, HISTOCHEM J, V6, P211, DOI 10.1007/BF01011808; LEGLER G, 1992, CARBOHYD RES, V233, P113, DOI 10.1016/S0008-6215(00)90924-8; LEGLER G, 1991, BIOCHIM BIOPHYS ACTA, V1080, P89, DOI 10.1016/0167-4838(91)90133-K; LIESSEM B, 1995, J BIOL CHEM, V270, P23693, DOI 10.1074/jbc.270.40.23693; MIAO SC, 1994, J BIOL CHEM, V269, P10975; MILEWSKI S, 1992, J GEN MICROBIOL, V138, P2545, DOI 10.1099/00221287-138-12-2545; MITSUISHI Y, 1990, FEBS LETT, V275, P135, DOI 10.1016/0014-5793(90)81457-Y; NAVAS J, 1992, BIOCHEM BIOPH RES CO, V189, P807, DOI 10.1016/0006-291X(92)92274-2; NAVON R, 1989, SCIENCE, V243, P1471, DOI 10.1126/science.2522679; ODOWD BF, 1986, J BIOL CHEM, V261, P2680; OHNO K, 1988, J NEUROCHEM, V50, P316, DOI 10.1111/j.1471-4159.1988.tb13266.x; Pennybacker M, 1996, J BIOL CHEM, V271, P17377, DOI 10.1074/jbc.271.29.17377; PROIA RL, 1988, P NATL ACAD SCI USA, V85, P1883, DOI 10.1073/pnas.85.6.1883; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; Tanaka A, 1990, Am J Hum Genet, V47, P568; Tews I, 1996, GENE, V170, P63, DOI 10.1016/0378-1119(95)00848-9; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; TOMME P, 1995, FEBS LETT, P239; Trop Isabelle, 1992, Human Mutation, V1, P35, DOI 10.1002/humu.1380010106; Tse R, 1996, BIOCHEMISTRY-US, V35, P7599, DOI 10.1021/bi960246+; Tse R, 1996, BIOCHEMISTRY-US, V35, P10894, DOI 10.1021/bi960503a; WACKER H, 1992, J BIOL CHEM, V267, P18744; WANG QP, 1993, J BIOL CHEM, V268, P14096; WITHERS SG, 1992, BIOCHEMISTRY-US, V31, P9979, DOI 10.1021/bi00156a017; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043	45	37	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					814	820		10.1074/jbc.272.2.814	http://dx.doi.org/10.1074/jbc.272.2.814			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995368	hybrid			2022-12-25	WOS:A1997WC04800019
J	Gerik, KJ; Gary, SL; Burgers, PMJ				Gerik, KJ; Gary, SL; Burgers, PMJ			Overproduction and affinity purification of Saccharomyces cerevisiae replication factor C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; DNA POLYMERASE-DELTA; ACCESSORY PROTEINS; PRIMER-TEMPLATE; SUBUNIT; COMPLEX; ACTIVATOR-1; INVITRO; BINDING; GENES	Yeast replication factor C (RF-C) is a heteropentamer encoded by the RFC1-5 genes. RF-C activity in yeast extracts was overproduced about 80-fold after induction of a strain containing all five genes on a single plasmid, with expression of each gene placed under control of the galactose-inducible GAL1-10 promoter. This strongly indicates that overexpression of the five known RFC genes is sufficient for overproduction of RF-C. Overexpression of all five genes was also necessary to achieve overproduction of RF-C as omission of any single gene from the plasmid gave uninduced, i.e. normal cellular levels of RF-C. The interaction between RF-C and proliferating cell nuclear antigen (PCNA) was studied with PCNA-agarose beads. Binding of RF C to PCNA-agarose beads is negligible in buffers containing 0.3 M NaCl. However, addition of Mg-ATP to the binding buffer caused strong binding of RF-C to the beads even at 0.8 M NaCl. Binding of ATP, but not its hydrolysis, was required for the strong binding mode as nonhydrolyzable analogs were also effective. The existence of two distinct binding modes between PCNA and RF C was used as the key step in a greatly improved procedure for the purification of RF-C. RF-C from the overproduction strain purified by this procedure was essentially homogeneous and had a severalfold higher specific activity than RF-C preparations that had previously been purified through multicolumn procedures.	WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOL BIOPHYS,ST LOUIS,MO 63110	Washington University (WUSTL)			Burgers, Peter M/AAW-6621-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032431] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32431, R01 GM032431] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; Gary SL, 1995, NUCLEIC ACIDS RES, V23, P4986, DOI 10.1093/nar/23.24.4986; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LEE SH, 1990, P NATL ACAD SCI USA, V87, P5672, DOI 10.1073/pnas.87.15.5672; LEE SH, 1991, J BIOL CHEM, V266, P594; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; LI XY, 1992, J BIOL CHEM, V267, P25321; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; OKUMURA K, 1995, GENOMICS, V25, P274, DOI 10.1016/0888-7543(95)80135-9; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; YODER BL, 1991, J BIOL CHEM, V266, P22689	24	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1256	1262		10.1074/jbc.272.2.1256	http://dx.doi.org/10.1074/jbc.272.2.1256			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995429	hybrid			2022-12-25	WOS:A1997WC04800080
J	Hori, R; Carey, M				Hori, R; Carey, M			Protease footprinting analysis of ternary complex formation by human TFIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION FACTOR-IIA; BOX-BINDING-PROTEIN; ACTIVATED TRANSCRIPTION; CRYSTAL-STRUCTURE; TATA-ELEMENT; PROMOTER; SUBUNITS; TBP; DOMAINS	Transcription factor (TF) IIA performs two important regulatory functions during RNA polymerase II transcription: it is required for efficient binding of TFIID to a core promoter and it mediates the effects of upstream activators, both through direct interaction with the TATA box binding protein (TBP). To begin studying how TFIIA mediates these effects, we used a highly sensitive protease footprinting methodology to identify surfaces of human TFIIA participating in TFIIA . TBP . TATA ternary complex formation. Chymotrypsin and proteinase K cleavage patterns of TFIIA bearing a P-32-end-labeled gamma subunit revealed that amino acids 59-73 were protected from cleavage both in the context of an immobilized ternary complex and in a binary complex with TBP alone. In contrast, amino acids 341-367 in the beta portion of a P-32-labeled alpha-beta subunit were protected in the ternary but not in the binary complex, implying that those residues interact with promoter DNA. The regions of human TFIIA identified by protease footprinting are homologous to and encompass the yeast TFIIA residues that contact TBP and DNA in the recently solved crystal structure of the yeast ternary complex. The conservation of the regions and residues mediating complex formation implies that yeast and human TFIIA employ the same mechanism to stabilize the binding of TFIID to a core promoter.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Carey, Michael/0000-0003-3899-6280	NIGMS NIH HHS [GM46424] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046424] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Greiner DP, 1996, P NATL ACAD SCI USA, V93, P71, DOI 10.1073/pnas.93.1.71; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; Juo ZS, 1996, J MOL BIOL, V261, P239, DOI 10.1006/jmbi.1996.0456; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEGRANGE T, 1996, P NATL ACAD SCI USA, V93, P10620; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Ozer J, 1996, J BIOL CHEM, V271, P11182, DOI 10.1074/jbc.271.19.11182; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	49	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1180	1187		10.1074/jbc.272.2.1180	http://dx.doi.org/10.1074/jbc.272.2.1180			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995419	hybrid			2022-12-25	WOS:A1997WC04800070
J	Li, XD; Xu, J; Li, M				Li, XD; Xu, J; Li, M			The human Delta 1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-ARRHYTHMIA; PATCH-CLAMP; DROSOPHILA; EAG; RECEPTOR; FAMILY; CELLS	HERG (human eag-related gene) encodes an inward-rectifier potassium channel formed by the assembly of four subunits. Since the truncated HERG protein in patients with long QT syndrome induces a dominant phenotype, that is, cardiac sudden death, the assembly of nonfunctional complexes between wild-type and mutated subunits was implicated in causing the disease. To understand HERG-mediated cardiac sudden death at the molecular level, it is important to determine which regions in the HERG protein participate in subunit interaction, We therefore report the identification of a subunit interaction domain, NAB(HERB), that is localized at the hydrophilic cytoplasmic N terminus and can form a tetramer in the absence of the rest of the HERG protein, Truncated HERG proteins containing NAB(HERG), including one that resulted from the Delta 1261 human mutation, inhibit the functional expression of the HERG channel in transfected cells. Together, these results sup port the notion that the expression of HERG in the human heart may be decreased in the presence of the truncated subunit, Such a decrease of potassium channel expression can contribute to the longer QT intervals observed in the patients with the HERG mutation.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University								Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DRYSDALE R, 1991, GENETICS, V127, P497; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Sambrook J., 1989, MOL CLONING; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TU LW, 1995, BIOPHYS J, V68, P147, DOI 10.1016/S0006-3495(95)80169-4; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; XU J, 1995, J BIOL CHEM, V270, P24761, DOI 10.1074/jbc.270.42.24761; Yang J, 1995, NEURON, V15, P1441, DOI 10.1016/0896-6273(95)90021-7; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0	25	82	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					705	708		10.1074/jbc.272.2.705	http://dx.doi.org/10.1074/jbc.272.2.705			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995352	hybrid			2022-12-25	WOS:A1997WC04800003
J	Ma, YZ; Taylor, EW				Ma, YZ; Taylor, EW			Interacting head mechanism of microtubule-kinesin ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR DOMAIN; HYDROLYSIS; MYOSIN	Kinetic and equilibrium properties are compared for a monomeric kinesin construct (K332) and a dimeric construct (K379), MtK379 has a low affinity (5 x 10(4) M(-1)) and a high affinity (5 x 10(6) M(-1)) binding site for mant ADP while MtK332 has a single low affinity site (5 x 10(4) M-1). Rate constants of dissociation of mant ADP are <1 s(-1) for the high affinity site and 75-100 s(-1) for the low affinity site for MtK379. For MtK332, the effective rate constant is 200-300 s(-1). It is proposed that the two heads of the dimer are different through the interaction with the microtubule, a strongly bound head with low affinity for 2'-(3')-O-(N-methylanthraniloyl) adenosine 5'-diphosphate (mant ADP), similar to the single strongly bound head of the monomer and a weakly bound or detached head with high affinity for mant ADP. Rate of binding of mant ADP gave an ''S''-shaped dependence on concentration for MtK379 and a hyperbolic dependence for MtK332. Binding of K379 mant ADP dimer to microtubules releases only one mant ADP at a rate of 50 s(-1). The second strongly bound mant ADP is released by binding of nucleotides to the other head. Rates are 100 s(-1) for ATP, 30 s(-1) for AMPPNP or ATP gamma S, and 2 s(-1) for ADP, The rate of binding of mant ATP to MtK379 showed an ''S''-shaped concentration dependence and limiting rate at zero concentration is <1 s-1 while MtK332 gave a hyperbolic dependence and limiting rate of 100 s(-1). The limiting rate is determined by the rate of dissociation of mant ADP in the hydrolysis cycle. The evidence is consistent with an interacting site model in which binding of ATP to one head is required for release of ADP from the other head in the hydrolysis cycle. This model, in which the cycles are maintained partly out of phase, is an extension of the alternating site model of Hackney (Hackney, D. D. (1994) Proc. Nat. Acad. Sci. U. S. A. 91, 6865-6869). It provides a basis for a processive mechanism.	UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM 51858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLOCK SM, 1990, NATURE, V348, P349; Coppin C. M., 1996, Biophysical Journal, V70, pA6; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Ma Y. Z., 1995, Biophysical Journal, V68, pA28; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Ma YZ, 1997, J BIOL CHEM, V272, P717, DOI 10.1074/jbc.272.2.717; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	17	164	167	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					724	730		10.1074/jbc.272.2.724	http://dx.doi.org/10.1074/jbc.272.2.724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995356	hybrid			2022-12-25	WOS:A1997WC04800007
J	Ahmad, F; Goldstein, BJ				Ahmad, F; Goldstein, BJ			Functional association between the insulin receptor and the transmembrane protein-tyrosine phosphatase LAR in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; GROWTH-FACTOR; XENOPUS OOCYTES; RAT ADIPOCYTES; KINASE; PHOSPHORYLATION; ACTIVATION; DEPHOSPHORYLATION; INTERNALIZATION; EXPRESSION	The receptor-type protein-tyrosine phosphatase LAR (for leukocyte common antigen-related) has been implicated as a physiological regulator of the insulin receptor. To demonstrate a functional interaction between LAR and the insulin receptor, we incubated CHO cells overexpressing the human insulin receptor with an antibody to the extracellular domain of LAR and found a 47% decrease in insulin receptor autophosphorylation and kinase activity. A physical association between LAR and the insulin receptor was then shown by immunoprecipitation of LAR from cell lysates and immunoblotting with antibody to the insulin receptor, or vice versa. Up to 11.8% of the LAR protein in the lysates of CHO cells overexpressing both the insulin receptor and LAR coimmunoprecipitated with the insulin receptor. The LAR/insulin receptor association was related to the level of LAR or insulin receptor overexpression and was increased 6.5-fold by chemical cross-linking and 3.9 fold by treatment with insulin, suggesting that receptor activation influences the affinity of LAR for the insulin receptor. In insulin-stimulated rat liver, LAR was temporally enriched in endosomes with the insulin receptor, and incubation of endosomes with neutralizing LAR antibodies decreased insulin receptor dephosphorylation in situ by 28% (p = 0.01 versus control). These data provide more direct evidence of a role for LAR in the physiological regulation of insulin action at the receptor level.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, DEPT MED, DIV ENDOCRINOL DIABET & METAB DIS, PHILADELPHIA, PA 19107 USA	Jefferson University			Khan, Faiyaz Ahmad/AAW-7944-2021		NIDDK NIH HHS [R01-DK43396] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043396] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHMAD F, 1995, J BIOL CHEM, V270, P20503, DOI 10.1074/jbc.270.35.20503; ALTIN JG, 1995, ANAL BIOCHEM, V224, P382, DOI 10.1006/abio.1995.1054; BAASS PC, 1995, TRENDS CELL BIOL, V5, P465, DOI 10.1016/S0962-8924(00)89116-3; BACKER JM, 1989, J BIOL CHEM, V264, P1694; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BEVAN AP, 1995, J BIOL CHEM, V270, P10784, DOI 10.1074/jbc.270.18.10784; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS JW, 1992, J BIOL CHEM, V267, P10077; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CICIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514, DOI 10.1073/pnas.87.14.5514; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; FAURE R, 1992, J BIOL CHEM, V267, P11215; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Goldstein Barry J., 1996, P174; Goldstein BJ, 1995, PROTEIN PROFILE, V2, P1425; GOLDSTEIN BJ, 1991, ADV PROTEIN PHOSPHAT, V6, P1; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARING HU, 1984, BIOCHEMISTRY-US, V23, P3298, DOI 10.1021/bi00309a028; HARLOW E, 1988, ANTIBODIES LABORATOR, P313; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HUBBARD AL, 1983, J CELL BIOL, V96, P217, DOI 10.1083/jcb.96.1.217; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; KHAN MN, 1989, J BIOL CHEM, V264, P12931; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; KOONTZ JW, 1981, SCIENCE, V211, P947, DOI 10.1126/science.7008195; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Kulas DT, 1996, J BIOL CHEM, V271, P748, DOI 10.1074/jbc.271.2.748; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; LI PM, 1997, IN PRESS CELL SIGNAL; LONGO FM, 1993, J BIOL CHEM, V268, P26503; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MOONEY RA, 1992, J BIOL CHEM, V267, P14054; RIEDEL H, 1986, NATURE, V324, P68, DOI 10.1038/324068a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; STAROS JV, 1989, METHOD ENZYMOL, V172, P609; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; WHITE MF, 1994, J BIOL CHEM, V269, P1; YU Q, 1992, ONCOGENE, V7, P1051; ZHANG WR, 1994, BIOCHEM J, V302, P39, DOI 10.1042/bj3020039; Zhang WR, 1996, MOL ENDOCRINOL, V10, P575, DOI 10.1210/me.10.5.575; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	52	92	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					448	457						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995282				2022-12-25	WOS:A1997WA56400069
J	Gentile, F; Ferranti, P; Mamone, G; Malorni, A; Salvatore, G				Gentile, F; Ferranti, P; Mamone, G; Malorni, A; Salvatore, G			Identification of hormonogenic tyrosines in fragment 1218-1591 of bovine thyroglobulin by mass spectrometry - Hormonogenic acceptor TYR-1291 and donor TYR-1375	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; THYROID-HORMONE SYNTHESIS; RAT THYROGLOBULIN; CONGENITAL GOITER; AFRIKANDER CATTLE; DEHYDROALANINE RESIDUES; PORCINE THYROGLOBULIN; INVITRO IODINATION; COMPLEMENTARY-DNA; TYROSYL RESIDUES	A fragment of bovine thyroglobulin encompassing residues 1218-1591 was prepared by limited proteolysis with thermolysin and continuous-elution polyacrylamide gel electrophoresis in SDS. The reduced and carboxymethylated peptide was digested with endoproteinase Asp-N and fractionated by reverse-phase high performance liquid chromatography. The fractions were analyzed by electrospray and fast atom bombardment mass spectrometry in combination with Edman degradation. The post-translational modifications of all seven tyrosyl residues of the fragment were characterized at an unprecedented level of definition. The analysis revealed the formation of: 1) monoiodotyrosine from tyrosine 1234; 2) monoiodotyrosine, diiodotyrosine, triiodothyronine (T-3), and tetraiodothyronine (thyroxine, T-4) from tyrosine 1291; and 3) monoiodotyrosine, diiodotyrosine, and dehydroalanine from tyrosine 1375. Iodothyronine formation from tyrosine 1291 accounted for 10% of total T-4 of thyroglobulin (0.30 mol of T-4/mol of 660-kDa thyroglobulin), and 8% of total T-3 (0.08 mol of T-3/mol of thyroglobulin). This is the first documentation of the hormonogenic nature of tyrosine 1291 of bovine thyroglobulin, as thyroxine formation at a corresponding site was so far reported only in rabbit, guinea pig, and turtle thyroglobulin. This is also the first direct identification of tyrosine 1375 of bovine thyroglobulin as a donor residue. It is suggested that tyrosyl residues 1291 and 1375 may support together the function of an independent hormonogenic domain in the mid-portion of the polypeptide chain of thyroglobulin.	CNR, SERV SPETTROMETRIA MASSA, I-80131 NAPLES, ITALY	Consiglio Nazionale delle Ricerche (CNR)	Gentile, F (corresponding author), UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL, CONSIGLIO NAZL RIC, I-80131 NAPLES, ITALY.		Gentile, Fabrizio/K-2475-2012; Ferranti, Pasquale/ABF-8111-2021; Mamone, Gianfranco/AAX-8690-2020	Gentile, Fabrizio/0000-0002-6704-3115; Mamone, Gianfranco/0000-0002-0394-7617; FERRANTI, Pasquale/0000-0002-6250-6512				ASUNCION M, 1992, FEBS LETT, V297, P266, DOI 10.1016/0014-5793(92)80553-S; BURLINGAME AL, 1994, ANAL CHEM, V66, pR634; CAHNMANN HJ, 1977, P NATL ACAD SCI USA, V74, P5333, DOI 10.1073/pnas.74.12.5333; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; DUNN JT, 1987, J BIOL CHEM, V262, P16948; EDELHOCH H, 1962, J BIOL CHEM, V237, P2788; EDELHOCH H, 1962, J BIOL CHEM, V237, P2778; FASSLER CA, 1988, J BIOL CHEM, V263, P17366; GAVARET JM, 1981, J BIOL CHEM, V256, P9167; GAVARET JM, 1977, J BIOL CHEM, V252, P3281; GAVARET JM, 1980, J BIOL CHEM, V255, P5281; GENTILE F, 1993, EUR J BIOCHEM, V218, P603, DOI 10.1111/j.1432-1033.1993.tb18414.x; Gentile F., 1995, ENDOCRINOLOGY, P517; IZUMI M, 1977, J CLIN INVEST, V59, P1105, DOI 10.1172/JCI108734; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAS L, 1974, J BIOL CHEM, V249, P2732; LAMAS L, 1989, J BIOL CHEM, V264, P13541; LEJEUNE PJ, 1983, BIOCHEM BIOPH RES CO, V114, P73, DOI 10.1016/0006-291X(83)91595-4; MALTHIERY Y, 1987, EUR J BIOCHEM, V165, P491, DOI 10.1111/j.1432-1033.1987.tb11466.x; MARRIQ C, 1984, FEBS LETT, V175, P140, DOI 10.1016/0014-5793(84)80587-6; MARRIQ C, 1991, MOL CELL ENDOCRINOL, V81, P155, DOI 10.1016/0303-7207(91)90214-D; MARRIQ C, 1982, EMBO J, V1, P397, DOI 10.1002/j.1460-2075.1982.tb01181.x; MARRIQ C, 1986, FEBS LETT, V207, P302, DOI 10.1016/0014-5793(86)81509-5; MARRIQ C, 1983, BIOCHEM BIOPH RES CO, V112, P206, DOI 10.1016/0006-291X(83)91817-X; MARRIQ C, 1981, ANAL BIOCHEM, V116, P89, DOI 10.1016/0003-2697(81)90326-2; MERCKEN L, 1985, NATURE, V316, P647, DOI 10.1038/316647a0; MUSTI AM, 1986, P NATL ACAD SCI USA, V83, P323, DOI 10.1073/pnas.83.2.323; OGAWARA H, 1972, BIOCHIM BIOPHYS ACTA, V257, P339, DOI 10.1016/0005-2795(72)90286-3; OHMIYA Y, 1990, J BIOL CHEM, V265, P9066; PALUMBO G, 1990, J BIOL CHEM, V265, P8887; PALUMBO G, 1982, ANAL BIOCHEM, V123, P183, DOI 10.1016/0003-2697(82)90641-8; PALUMBO G, 1987, J BIOL CHEM, V262, P17182; PUCCI P, 1988, BIOMED ENVIRON MASS, V17, P287, DOI 10.1002/bms.1200170410; PUCCI P, 1985, BIOCHEM BIOPH RES CO, V130, P84, DOI 10.1016/0006-291X(85)90385-7; RAWITCH AB, 1984, BIOCHEM BIOPH RES CO, V118, P423, DOI 10.1016/0006-291X(84)91320-2; RAWITCH AB, 1983, J BIOL CHEM, V258, P2079; RICKETTS MH, 1987, P NATL ACAD SCI USA, V84, P3181, DOI 10.1073/pnas.84.10.3181; RICKETTS MH, 1985, EMBO J, V4, P731, DOI 10.1002/j.1460-2075.1985.tb03690.x; ROE MT, 1989, ENDOCRINOLOGY, V124, P1327, DOI 10.1210/endo-124-3-1327; SORIMACH.K, 1974, J BIOCHEM-TOKYO, V76, P39, DOI 10.1093/oxfordjournals.jbchem.a130557; STERK A, 1989, ENDOCRINOLOGY, V124, P477, DOI 10.1210/endo-124-1-477; TASSI VPN, 1984, J BIOL CHEM, V259, P507; VANVOORTHUIZEN WF, 1978, ENDOCRINOLOGY, V103, P2105, DOI 10.1210/endo-103-6-2105; VEENBOER GJM, 1993, ENDOCRINOLOGY, V132, P377, DOI 10.1210/en.132.1.377; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	45	19	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					639	646						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995307				2022-12-25	WOS:A1997WA56400094
J	Shuck, ME; Piser, TM; Bock, JH; Slightom, JL; Lee, KS; Bienkowski, MJ				Shuck, ME; Piser, TM; Bock, JH; Slightom, JL; Lee, KS; Bienkowski, MJ			Cloning and characterization of two K+ inward rectifier (K-ir) 1.1 potassium channel homologs from human kidney (K(ir)1.2 and K(ir)1.3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEART; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; VENTRICULAR CELLS; ATP CHANNEL; PROTEIN; BRAIN; LOCALIZATION; CONDUCTANCE; RECTIFICATION	The DNA sequence encoding the rat brain inward rectifier-10 K+ channel was amplified from rat brain RNA using reverse transcription-polymerase chain reaction and used to clone the human homolog. Low stringency screening of a human kidney cDNA library and subsequent DNA sequence analysis identified two related K+ inward rectifier cDNAs, referred to as K(ir)1.2 and K(ir)1.3, which were derived from transcription of distinct human genes, K(ir)1.2 represents the human homolog of the rat BIRK-10 sequence, whereas K(ir)1.3 was unique compared with all available sequence data bases, The genes that encode K(ir)1.2 and K(ir)1.3 were mapped to human chromosomes 1 and 21, respectively. Both genes showed tissue-specific expression when analyzed by Northern blots, K(ir)1.2 was only detected in brain much greater than kidney and was detected at high levels in all brain regions examined, K(ir)1.3 was most readily detected in kidney and was also expressed in pancreas > lung, Comparative analysis of the predicted amino acid sequences for K(ir)1.2 and K(ir)1.3 revealed they were 62% identical, The most remarkable difference between the two polypeptides is that the Walker Type A consensus binding motif present in both K(ir)1.1 and K(ir)1.2 was not conserved in the K(ir)1.3 sequence. Expression of the K(ir)1.2 polypeptide in Xenopus oocytes resulted in the synthesis of a K+-selective channel that exhibited an inwardly rectifying current voltage relationship and was inhibited by external Ba2+ and Cs+. K(ir)1.2 current amplitude was reduced by >85% when the pH was decreased from pH 7.4 to 5.9 using the membrane-permeant buffer acetate but was relatively unaffected when pH was similarly lowered using membrane impermeant biphthalate, The inhibition by intracellular protons was voltage-independent with an IC50 of pH 6.2 and a Hill coefficient of 1.9, suggesting the cooperative binding of 2 protons to the intracellular face of the channel. In contrast, K(ir)1.3 expression in Xenopus oocytes was not detectable despite the fact that the cRNA efficiently directed the synthesis of a polypeptide of the expected M(r) in an in vitro translation system. Go-expression of K(ir)1.3 with either K(ir)1.1 or K(ir)1.2 reduced currents resulting from expression of these inward-rectifier subunits alone, consistent with a dominant negative influence on K(ir)1.1 and K(ir)1.2 expression.	PHARMACIA & UPJOHN INC,DEPT CELL BIOL & INFLAMMAT RES,KALAMAZOO,MI 49007; PHARMACIA & UPJOHN INC,DEPT CARDIOVASC PHARMACOL & MOL BIOL,KALAMAZOO,MI 49007	Pfizer; Pfizer								ASHEN MD, 1994, AM J PHYSIOL, V268, pH506; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BOND CT, 1995, FEBS LETT, V367, P61, DOI 10.1016/0014-5793(95)00497-W; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; BREDT DS, 1995, P NATL ACAD SCI USA, V92, P6753, DOI 10.1073/pnas.92.15.6753; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FALK T, 1995, FEBS LETT, V367, P127, DOI 10.1016/0014-5793(95)00527-G; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1995, BIOCHEMISTRY-US, V34, P13133, DOI 10.1021/bi00040a026; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MAKHINA EN, 1994, J BIOL CHEM, V269, P20468; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MORISHIGE K, 1993, FEBS LETT, V336, P375, DOI 10.1016/0014-5793(93)80840-Q; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; PERIER F, 1994, P NATL ACAD SCI USA, V91, P6240, DOI 10.1073/pnas.91.13.6240; RAABGRAHAM KF, 1994, NEUROREPORT, V5, P2501, DOI 10.1097/00001756-199412000-00024; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P659, DOI 10.1113/jphysiol.1984.sp015089; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SAKURA H, 1995, FEBS LETT, V367, P193, DOI 10.1016/0014-5793(95)00498-X; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; TANG WM, 1994, FEBS LETT, V348, P239, DOI 10.1016/0014-5793(94)00612-1; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; TSAUR ML, 1995, DIABETES, V44, P592, DOI 10.2337/diabetes.44.5.592; Tucker SJ, 1996, J BIOL CHEM, V271, P5866, DOI 10.1074/jbc.271.10.5866; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WANG WH, 1990, AM J PHYSIOL, V259, pF494, DOI 10.1152/ajprenal.1990.259.3.F494; WIBLE BA, 1995, CIRC RES, V76, P343, DOI 10.1161/01.RES.76.3.343; WIBLE BA, 1994, NATURE, V371, P243; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	45	88	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					586	593						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995301				2022-12-25	WOS:A1997WA56400088
J	Maschera, B; Darby, G; Palu, G; Wright, LL; Tisdale, M; Myers, R; Blair, ED; Furfine, ES				Maschera, B; Darby, G; Palu, G; Wright, LL; Tisdale, M; Myers, R; Blair, ED; Furfine, ES			Human immunodeficiency virus - Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SELECTION; HIV-1 PROTEASE; CROSS-RESISTANCE; TYPE-1 VARIANTS; RO 31-8959; DECREASED SENSITIVITY; PROTEINASE-INHIBITOR; DRUG-RESISTANCE; SPECIFICITY; INFECTION	Mutations in the human immunodeficiency virus (HIV) protease (L90M, G48V, and L90M/G48V) arise when HIV is passaged in the presence of the HIV protease inhibitor saquinavir. These mutations yield a virus with less sensitivity to the drug (L90M > G48V >> L90M/ G48V). L90M, G48V, and L90M/G48V proteases have 1/20, 1/160, and 1/1000 the affinity for saquinavir compared to WT protease, respectively. Therefore, the affinity of mutant protease for saquinavir decreased as the sensitivity of the virus to saquinavir decreased. Association rate constants for WT and mutant proteases with saquinavir were similar, ranging from 2 to 4 x 10(7) m(-1) s(-1). In contrast, the dissociation rate constants for WT, L90M, G48V, and L90M/G48V proteases complexed with saquinavir were 0.0014, 0.019, 0.128, and 0.54 s(-1), respectively. This indicated that the reduced affinity for mutant proteases and saquinavir is primarily the result of larger dissociation rate constants. The increased dissociation rate constants may be the result of a decrease in the internal equilibrium between the bound inhibitor with the protease flaps up and the bound inhibitor with the flaps down, Interestingly, the affinity of these mutant proteases for VX-478, ABT-538, AG-1343, or L-735,524 was not reduced as much as that for saquinavir. Finally, the catalytic constants of WT and mutant proteases were determined for eight small peptide substrates that mimic the viral cleavage sites in vivo. WT and L90M proteases had similar catalytic constants for these substrates. In contrast, G48V and L90M/G48V proteases had catalytic efficiency (k(cat)/K-m) values with TLNF-PISP, RKIL-FLDG, and AETF-YVDG that were 1/10 to 1/20 the value of WT protease, The decreased catalytic efficiencies were primarily the result of increased K-m values. Thus, mutations in the protease decrease the affinity of the enzyme for saquinavir and the catalytic efficiency with peptide substrates.	GLAXO WELLCOME INC, DEPT MOL BIOCHEM, RES TRIANGLE PK, NC 27709 USA; GLAXO WELLCOME RES & DEV LTD, DEPT VIROL, STEVENAGE SG1 2NY, HERTS, ENGLAND; UNIV PADUA, IST MICROBIOL, I-35100 PADUA, ITALY	GlaxoSmithKline; GlaxoSmithKline; University of Padua								BALDWIN ET, 1995, NAT STRUCT BIOL, V2, P244, DOI 10.1038/nsb0395-244; Bevington P. R., 1969, DATA REDUCTION ERROR; CHEN ZG, 1995, J BIOL CHEM, V270, P21433, DOI 10.1074/jbc.270.37.21942; COLLINS JR, 1995, NAT STRUCT BIOL, V2, P334, DOI 10.1038/nsb0495-334; CONDRA JH, 1995, NATURE, V374, P569, DOI 10.1038/374569a0; CRAIG JC, 1991, ANTIVIR RES, V16, P295, DOI 10.1016/0166-3542(91)90045-S; CRAIG JC, 1993, ANTIVIR CHEM CHEMOTH, V4, P335, DOI 10.1177/095632029300400605; Darke P L, 1994, Adv Pharmacol, V25, P399, DOI 10.1016/S1054-3589(08)60438-X; DIANZANI F, 1993, ANTIVIR CHEM CHEMOTH, V4, P329, DOI 10.1177/095632029300400604; FURFINE ES, 1992, BIOCHEMISTRY-US, V31, P7886, DOI 10.1021/bi00149a020; GULNIK SV, 1995, BIOCHEMISTRY-US, V34, P9282, DOI 10.1021/bi00029a002; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1994, J VIROL, V68, P2016, DOI 10.1128/JVI.68.3.2016-2020.1994; HUFF JR, 1991, J MED CHEM, V34, P2305, DOI 10.1021/jm00112a001; HUI JO, 1993, J PROTEIN CHEM, V12, P323, DOI 10.1007/BF01028194; JACOBSEN H, 1995, VIROLOGY, V206, P527, DOI 10.1016/S0042-6822(95)80069-7; JACOBSEN H, 1994, 3 INT WORKSH HIV RES, V3, P16; KAPLAN AH, 1994, P NATL ACAD SCI USA, V91, P5597, DOI 10.1073/pnas.91.12.5597; LAMARRE D, 1995, HIV DRUG RES 4 INT W; LIN YZ, 1995, BIOCHEMISTRY-US, V34, P1143, DOI 10.1021/bi00004a007; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; MASCHERA B, 1995, J VIROL, V69, P5431, DOI 10.1128/JVI.69.9.5431-5436.1995; MOODY MD, 1995, VIROLOGY, V207, P475, DOI 10.1006/viro.1995.1107; MOORE ML, 1989, BIOCHEM BIOPH RES CO, V159, P420, DOI 10.1016/0006-291X(89)90008-9; NORBECK DW, 1991, ANNU REP MED CHEM, V26, P141; PARTALEDIS JA, 1995, J VIROL, V69, P5228, DOI 10.1128/JVI.69.9.5228-5235.1995; Patick AK, 1996, ANTIMICROB AGENTS CH, V40, P292, DOI 10.1128/AAC.40.2.292; RICHMAN DD, 1995, NATURE, V374, P494, DOI 10.1038/374494a0; RIDKY T, 1995, J BIOL CHEM, V270, P29621, DOI 10.1074/jbc.270.50.29621; Rose RE, 1996, P NATL ACAD SCI USA, V93, P1648, DOI 10.1073/pnas.93.4.1648; TISDALE M, 1995, ANTIMICROB AGENTS CH, V39, P1704, DOI 10.1128/AAC.39.8.1704; Tisdale M., 1996, International Antiviral News, V4, P41; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOTH MV, 1990, INT J PEPT PROT RES, V36, P544; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	36	127	130	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33231	33235		10.1074/jbc.271.52.33231	http://dx.doi.org/10.1074/jbc.271.52.33231			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969180	hybrid			2022-12-25	WOS:A1996WA71300014
J	Dunstan, CAN; Salafranca, MN; Adhikari, S; Xia, YY; Feng, LL; Harrison, JK				Dunstan, CAN; Salafranca, MN; Adhikari, S; Xia, YY; Feng, LL; Harrison, JK			Identification of two rat genes orthologous to the human interleukin-8 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CC-CHEMOKINE RECEPTOR; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; GENOMIC ORGANIZATION; IL-8 RECEPTOR; CELL-LINE; CHEMOATTRACTANT; NEUTROPHIL; PROTEIN; HOMOLOG	The genes encoding two functional human interleukin-8 (IL-8) receptors have been identified by molecular cloning techniques and they are members of the rhodopsin G-protein coupled receptor (GCR) superfamily. We report the molecular cloning of two rat GCR genes (rat CXCR1-like and rat CXCR2) whose conceptualized amino acid sequences are approximately 70% identical to the human IL-8 A and B receptor subtypes. The murine GRO-like peptide, macrophage inflammatory peptide-2 (MIP-2), elevates intracellular calcium levels in HEK293 cells expressing the rat CXCR2 receptor. Southern blot analysis of restriction-digested rodent and human genomic DNAs indicate that rat CXCR1-like and CXCR2 are: 1) each single copy genes in the rat genome; 2) most closely related to the human IL-8 receptor genes; and 3) orthologous to two previously identified murine genes. CXCR2 mRNA is detected in adult rat lung, spleen, and neutrophils. CXCR1-like mRNA can be detected in adult rat lung, native rat macrophages, and a rat alveolar macrophage cell line (NR8383). These data identify the rat orthologs of the human IL-8 receptors, and describe cellular and tissue targets of rat C-X-C chemokine peptides.	UNIV FLORIDA, COLL MED, DEPT PHARMACOL & THERAPEUT, GAINESVILLE, FL 32610 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	State University System of Florida; University of Florida; Scripps Research Institute								AHUJA SK, 1994, J BIOL CHEM, V269, P26381; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Boring L, 1996, J BIOL CHEM, V271, P7551, DOI 10.1074/jbc.271.13.7551; BOZIC CR, 1994, J BIOL CHEM, V269, P29355; BUHL R, 1993, J IMMUNOL, V150, P1019; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CERRETTI DP, 1993, GENOMICS, V18, P410, DOI 10.1006/geno.1993.1486; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG L, 1994, AM J PHYSIOL, V266, pF713, DOI 10.1152/ajprenal.1994.266.5.F713; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; HARADA A, 1994, GENE, V142, P297, DOI 10.1016/0378-1119(94)90278-X; HARRISON JK, 1994, NEUROSCI LETT, V169, P85, DOI 10.1016/0304-3940(94)90362-X; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; JAFFE HA, 1991, J CLIN INVEST, V88, P297, DOI 10.1172/JCI115291; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kurihara T, 1996, J BIOL CHEM, V271, P11603, DOI 10.1074/jbc.271.20.11603; LEE J, 1995, J IMMUNOL, V155, P2158; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NAKAGAWA H, 1994, BIOCHEM J, V301, P545, DOI 10.1042/bj3010545; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POST TW, 1995, J IMMUNOL, V155, P5299; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Sambrook J., 2002, MOL CLONING LAB MANU; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; SPRENGER H, 1994, J BIOL CHEM, V269, P11065; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; WATANABE K, 1989, J BIOL CHEM, V264, P19559; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53	38	67	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32770	32776		10.1074/jbc.271.51.32770	http://dx.doi.org/10.1074/jbc.271.51.32770			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955112	hybrid			2022-12-25	WOS:A1996VZ37300047
J	Grasser, KD; Grimm, R; Ritt, C				Grasser, KD; Grimm, R; Ritt, C			Maize chromosomal HMGc - Two closely related structure-specific DNA-binding proteins specify a second type of plant high mobility group box protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOPROTEIN COMPLEXES; DROSOPHILA-MELANOGASTER; ARCHITECTURAL ELEMENTS; ETHIDIUM-BROMIDE; DOMAIN; TRANSCRIPTION; CHROMATIN; GENE; SEQUENCE; MOTIF	The chromosomal high mobility group (HMG) proteins are small and abundant non-histone proteins common to eukaryotes. We have purified the maize HMGc protein from immature kernels and characterized it by mass spectrometry and amino acid sequence analysis. HMGc could be resolved into two similar proteins by reversed phase chromatography. Cloning and characterization of the corresponding cDNAs revealed that they encode two closely related maize HMGc proteins, now termed HMGc1 and HMGc2. Their theoretical masses of 15,316 and 15,007 Da are >300 Da lower than the masses determined for the proteins purified from maize, indicating post-translational modifications of the proteins. Despite sequence similarity to maize HMGa (and previously described homologous proteins of other species) amino acid sequence alignments reveal that HMGc is in several conserved regions distinct from these proteins, Consequently, we have identified a novel type of plant protein containing an HMG box DNA binding domain and belonging to the HMG1 protein family. HMGc1 and HMGc2 were expressed in Escherichia coli, purified to homogeneity, and analyzed for their DNA binding properties. They proved to bind to DNA structure-specifically since they formed complexes with DNA minicircles at concentrations similar to 100-fold lower than the concentrations required to form complexes with linear fragments of identical sequence. Furthermore, HMGc1 and HMGc2 can constrain negative superhelical turns in plasmid DNA.	HEWLETT PACKARD GMBH,D-76337 WALDBRONN,GERMANY	Hewlett-Packard	Grasser, KD (corresponding author), UNIV FREIBURG,INST BIOL 3,SCHANZLESTR 1,D-79104 FREIBURG,GERMANY.							ARWOOD LJ, 1991, PHYSIOL PLANTARUM, V82, P419; ARWOOD LJ, 1990, J BIOL CHEM, V265, P9771; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BIANCHI ME, 1995, DNA PROTEIN STRUCTUR, P177; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CARBALLO M, 1984, EMBO J, V3, P1255, DOI 10.1002/j.1460-2075.1984.tb01960.x; CHURCHILL MEA, 1995, EMBO J, V14, P1264, DOI 10.1002/j.1460-2075.1995.tb07110.x; CROTHERS DM, 1993, CURR BIOL, V3, P675, DOI 10.1016/0960-9822(93)90065-V; EINCK L, 1985, EXP CELL RES, V156, P296; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GRASSER KD, 1994, PLANT J, V6, P351, DOI 10.1046/j.1365-313X.1994.06030351.x; GRASSER KD, 1995, PLANT J, V7, P185, DOI 10.1046/j.1365-313X.1995.7020185.x; GRASSER KD, 1993, PLANT MOL BIOL, V23, P619, DOI 10.1007/BF00019309; GRASSER KD, 1991, NUCLEIC ACIDS RES, V19, P2573, DOI 10.1093/nar/19.10.2573; GRASSER KD, 1991, PLANTA, V185, P350, DOI 10.1007/BF00201055; GRASSER KD, 1990, J BIOL CHEM, V265, P4185; GROSSCHEDL R, 1995, CURR OPIN CELL BIOL, V7, P362, DOI 10.1016/0955-0674(95)80091-3; Grove A, 1996, J MOL BIOL, V260, P120, DOI 10.1006/jmbi.1996.0386; HAMADA H, 1985, BIOCHEMISTRY-US, V24, P1428, DOI 10.1021/bi00327a022; Hardman CH, 1995, BIOCHEMISTRY-US, V34, P16596, DOI 10.1021/bi00051a007; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; Johns EW, 1982, HMG CHROMOSOMAL PROT; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LAUX T, 1991, NUCLEIC ACIDS RES, V19, P4769, DOI 10.1093/nar/19.17.4769; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; MEGRAW TL, 1993, J BIOL CHEM, V268, P12758; NER SS, 1993, NUCLEIC ACIDS RES, V21, P4369, DOI 10.1093/nar/21.18.4369; PANI B, 1989, EXP CELL RES, V180, P557, DOI 10.1016/0014-4827(89)90083-9; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; PEDERSEN TJ, 1991, PLANT MOL BIOL, V16, P95, DOI 10.1007/BF00017920; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Read C., 1995, NUCL ACIDS MOL BIOL, P222; READ CM, 1994, EMBO J, V13, P5639, DOI 10.1002/j.1460-2075.1994.tb06902.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; SCHROTER H, 1985, EMBO J, V4, P3867, DOI 10.1002/j.1460-2075.1985.tb04159.x; SCHULMAN IG, 1991, MOL CELL BIOL, V11, P166, DOI 10.1128/MCB.11.1.166; SEGALL AM, 1994, EMBO J, V13, P4536, DOI 10.1002/j.1460-2075.1994.tb06775.x; SHEFLIN LG, 1989, BIOCHEMISTRY-US, V28, P5658, DOI 10.1021/bi00439a048; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SPIKER S, 1988, PHYSIOL PLANTARUM, V74, P200, DOI 10.1111/j.1399-3054.1988.tb04964.x; SPIKER S, 1984, J BIOL CHEM, V259, P2007; STROS M, 1994, NUCLEIC ACIDS RES, V22, P1044, DOI 10.1093/nar/22.6.1044; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; WAGNER CR, 1992, MOL CELL BIOL, V12, P1915, DOI 10.1128/MCB.12.5.1915; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P10713; WISNIEWSKI JR, 1994, J BIOL CHEM, V269, P29261; WRIGHT JM, 1988, BIOCHEMISTRY-US, V27, P576, DOI 10.1021/bi00402a012	58	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32900	32906		10.1074/jbc.271.51.32900	http://dx.doi.org/10.1074/jbc.271.51.32900			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955131	hybrid			2022-12-25	WOS:A1996VZ37300066
J	Kaczmarek, E; Koziak, K; Sevigny, J; Siegel, JB; Anrather, J; Beaudoin, AR; Bach, FH; Robson, SC				Kaczmarek, E; Koziak, K; Sevigny, J; Siegel, JB; Anrather, J; Beaudoin, AR; Bach, FH; Robson, SC			Identification and characterization of CD39 vascular ATP diphosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR ADENINE-NUCLEOTIDES; ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; ECTO-ATPASE; PURIFICATION; EXPRESSION; MEMBRANE	Vascular ATP diphosphohydrolase (ATPDase) is a plasma membrane-bound enzyme that hydrolyses extracellular ATP and ADP to AMP, Analysis of amino acid sequences available from various mammalian and avian ATPDases revealed their close homology with CD39, a putative B-cell activation marker, We, therefore, isolated CD39 cDNA from human endothelial cells and expressed this in COS-7 cells, CD39 was found to have both immunological identity to, and functional characteristics of, the vascular ATPDase, We also demonstrated that ATPDase could inhibit platelet aggregation in response to ADP, collagen, and thrombin, and that this activity in transfected COS-7 cells was lost following exposure to oxidative stress. ATPDase mRNA was present in human placenta, lung, skeletal muscle, kidney, and heart and was not detected in brain. Multiple RNA bands were detected with the CD39 cDNA probe that most probably represent different splicing products, Finally, we identified an unique conserved motif, DLG-GASTQ, that could be crucial for nucleotide binding, activity, and/or structure of ATPDase, Because ATPDase activity is lost with endothelial cell activation, overexpression of the functional enzyme, or a truncated mutant thereof, may prevent platelet activation associated with vascular inflammation.	HARVARD UNIV,SANDOZ CTR IMMUNOBIOL,NEW ENGLAND DEACONESS HOSP,SCH MED,BOSTON,MA 02215; UNIV SHERBROOKE,DEPT BIOL,SHERBROOKE,PQ J1K 2R1,CANADA	Harvard University; Harvard Medical School; Novartis; Sandoz; University of Sherbrooke			Sévigny, Jean/AGH-9323-2022; Koziak, Katarzyna/V-2323-2019; Robson, Simon C./AAA-8537-2021; Sevigny, Jean/E-8039-2012	Sévigny, Jean/0000-0003-2922-1600; Sevigny, Jean/0000-0003-2922-1600				ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; Bach FH, 1996, IMMUNOL TODAY, V17, P379, DOI 10.1016/0167-5699(96)10024-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANDINAS D, 1996, IN PRESS THROMB HAEM; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTOFORIDIS S, 1995, EUR J BIOCHEM, V234, P66, DOI 10.1111/j.1432-1033.1995.066_c.x; CUMMINS J, 1962, BIOCHIM BIOPHYS ACTA, V60, P271, DOI 10.1016/0006-3002(62)90403-1; ELMOATASSIM C, 1992, BIOCHIM BIOPHYS ACTA, V1134, P31, DOI 10.1016/0167-4889(92)90025-7; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GORDON EL, 1986, J BIOL CHEM, V261, P5496; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; KANSAS GS, 1991, J IMMUNOL, V146, P2235; KARASAKI S, 1977, CANCER RES, V37, P3516; KOYAMADA N, 1996, IN PRESS TRANSPLANTA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1989, J BIOL CHEM, V264, P14403; LUTHJE J, 1989, KLIN WOCHENSCHR, V67, P317, DOI 10.1007/BF01741386; MALISZEWSKI CR, 1994, J IMMUNOL, V153, P3574; NAGY AK, 1986, J NEUROCHEM, V47, P976; NIEWIAROWSKI S, 1969, NATURE, V222, P1269, DOI 10.1038/2221269a0; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; PLESNER L, 1995, INT REV CYTOL, V158, P141; PREISSNER KT, 1988, HAEMOSTASIS, V18, P271; Robson SC, 1996, TRANSPLANT P, V28, P536; SEVIGNY J, 1995, BIOCHEM J, V312, P351, DOI 10.1042/bj3120351; SEVIGNY J, 1996, IN PRESS BIOCH BIOPH; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; TRAMS EG, 1978, COMP BIOCHEM PHYS B, V59, P191, DOI 10.1016/0305-0491(78)90243-2; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WELFORD LA, 1987, EUR J PHARMACOL, V141, P123, DOI 10.1016/0014-2999(87)90418-3; WRIGHTON CJ, 1995, TRANSPLANT P, V27, P288; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	33	443	463	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33116	33122		10.1074/jbc.271.51.33116	http://dx.doi.org/10.1074/jbc.271.51.33116			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955160	hybrid			2022-12-25	WOS:A1996VZ37300095
J	Persinger, J; Bartholomew, B				Persinger, J; Bartholomew, B			Mapping the contacts of yeast TFIIIB and RNA polymerase III at various distances from the major groove of DNA by DNA photoaffinity labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; TRANSCRIPTION FACTOR-TFIIIB; CROSS-LINKING; PROMOTER; GENE; TBP; COMPONENTS; COMPLEXES; HOMOLOGY; ENCODES	The structure of the Saccharomyces cerevisiae RNA polymerase III transcription complex on the SUP4 tRNA(Tyr) gene was probed at distances of similar to 10 to similar to 23 Angstrom from the C-5 methyl of thymidine in the major groove of DNA using photoreactive aryl azides attached to deoxyuridine by variable chain lengths. The nucleotide analogs contained an azidobenzoyl group attached with chain lengths that were incrementally increased by similar to 4.3 Angstrom by inserting 1-3 glycine residues into the chain. Another photoreactive deoxyuridine analog was made that contained a butyl chain (ABU-dUMP) to assess the effect of the chain's hydrophobicity on its ability to photoaffinity label the transcription complex. These nucleotide analogs were incorporated at base pairs (bp) -26/-21, -17, or -3/-2 on the nontranscribed strand of the SUP4 tRNA(Tyr) gene along with an [alpha-P-32]dNMP by primer extension using an immobilized single-stranded DNA template annealed to specific oligonucleotides. The 27-kDa subunit of TFIIIB or the TATA box binding protein was photoaffinity labeled at bp -26/-21 with nucleotide analogs containing a similar to 19- or similar to 23-Angstrom chain and not with shorter chains of similar to 10 to similar to 15 Angstrom in length. The B '' subunit of TFIIIB (M(r) 90 kDa) was photoaffinity labeled at bps -26/-21 with DNA containing a similar to 14-Angstrom chain and not with shorter or longer chains. Cross-linking of the B '' subunit was inhibited by binding of RNA polymerase III (Pol III) to the TFIIIB-DNA complex and suggested that Pol III binding causes a conformational change in the TFIIIB-DNA complex resulting in the displacement of the 90-kDa subunit at bps -26/-21. Next, the chain length dependence of photoaffinity labeling the 34-kDa subunit of Pol III at bps -17 and -3/-2 indicated that the 34-kDa subunit of Pol III is slightly removed from the major groove at bp -17 in the initiation complex and makes closer contact at bps -3/-2 in a stalled elongation complex.			Persinger, J (corresponding author), SO ILLINOIS UNIV, SCH MED, DEPT BIOCHEM MED, CARBONDALE, IL 62901 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048413, R01GM048413] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48413-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1991, MOL CELL BIOL, V11, P5181, DOI 10.1128/MCB.11.10.5181; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BRAUN BR, 1992, J MOL BIOL, V228, P1063, DOI 10.1016/0022-2836(92)90315-B; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; CHONG PCS, 1981, J BIOL CHEM, V256, P5064; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; ESCHENLAUER JB, 1993, MOL CELL BIOL, V13, P3015, DOI 10.1128/MCB.13.5.3015; GALARDY RE, 1974, J BIOL CHEM, V249, P3510; GEIDUSCHEK EP, 1992, TRANSCRIPTIONAL REGU, V11, P247; GONG XL, 1995, MOL CELL BIOL, V15, P4956; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HUET J, 1992, NUCLEIC ACIDS RES, V20, P6451, DOI 10.1093/nar/20.24.6451; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI TH, 1983, METHOD ENZYMOL, V91, P580; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1994, TRANSCRIPTION MECHAN, P107; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; Sentenac A., 1992, TRANSCRIPTIONAL REGU, V1, P27; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	36	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33039	33046		10.1074/jbc.271.51.33039	http://dx.doi.org/10.1074/jbc.271.51.33039			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955150	hybrid			2022-12-25	WOS:A1996VZ37300085
J	Tsai, AL; Berka, V; Chen, PF; Palmer, G				Tsai, AL; Berka, V; Chen, PF; Palmer, G			Characterization of endothelial nitric-oxide synthase and its reaction with ligand by electron paramagnetic resonance spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRIC CYTOCHROME P-450-CAM; LOW-SPIN FORMS; HEME COORDINATION; L-ARGININE; RE-EXAMINATION; AXIAL LIGAND; COMPLEXES; EPR; CHLOROPEROXIDASE; IDENTIFICATION	Electron paramagnetic resonance was used to characterize the heme structure of resting endothelial nitric-oxide synthase (eNOS), eNOS devoid of its myristoylation site (G2A mutant), and their heme complexes formed with 16 different ligands. Resting eNOS and the G2A mutant have a mixture of low spin and high spin P450-heme with widely different relaxation behavior and a stable flavin semiquinone radical identified by EPR as a neutral radical. This flavin radical showed efficient electron spin relaxation as a consequence of dipolar interaction with the heme center; P 1/2 is independent of Ca2+-calmodulin and tetrahydrobiopterin. Seven of the 16 ligands led to the formation of low spin heme complexes. In order of increasing rhombicity they are pyrimidine, pyridine, thiazole, L-lysine, cyanide, imidazole, and 4-methylimidazole. These seven low spin eNOS complexes fell in a region between the P and O zones on the ''truth diagram'' originally derived by Blumberg and Peisach (Blumberg, W. E., and Peisach, J. (1971) in Probes and Structure and Function of Macromolecules and Membranes (Chance, B., Yonetani, T., and Mildvan, A. S., eds) Vol. 2, pp. 215-229, Academic Press, New York) and had significant overlap with complexes of chloroperoxidase. A re definition of the P and O zones is proposed. As eNOS and chloroperoxidase lie closer than do eNOS and P450(cam) on the truth diagram, it implies that the distal heme environment in eNOS resembles chloroperoxidase more than P450(cam). In contrast, 4-ethylpyridine, 4-methylpyrimidine, acetylguanidine, ethylguanidine, 2-aminothiazole, 2-amino-4,5-dimethylthiazole, L-histidine, and 7-nitroindazole resulted in high spin heme complexes of eNOS, similar to that observed with L-arginine. This contrasting EPR behavior caused by families of ligands such as imidazole/L-histidine or thiazole/2-aminothiazole confirms the conclusion derived from parallel optical and kinetic studies. The ligands resulting in the low spin complexes bind directly to the heme iron, while their cognate ligands induce the formation of high spin complexes by indirectly perturbing the heme structure and excluding the original axial heme ligand in the resting eNOS (V. Berka, P.-E. Chen, and A.-L. Tsai (1997) J. Biol. Chem. 272, in press). The difference in EPR spectra of these high spin eNOS complexes, although subtle, are different for different homologs.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	Tsai, AL (corresponding author), UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,POB 20708,HOUSTON,TX 77225, USA.				NIGMS NIH HHS [GM44911, GM21337] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021337, R01GM021337] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; APPLEBY CA, 1976, J BIOL CHEM, V251, P6090; BERKA V, IN PRESS J BIOL CHEM, V272; Blumberg WE, 1971, PROBES STRUCTURE FUN, V2, P215; BOHAN TL, 1977, J MAGN RESON, V26, P109, DOI 10.1016/0022-2364(77)90240-2; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHEVION M, 1977, J BIOL CHEM, V252, P3637; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; Galli C, 1996, BIOCHEMISTRY-US, V35, P2804, DOI 10.1021/bi9520444; Goldfarb D, 1996, J AM CHEM SOC, V118, P2686, DOI 10.1021/ja951307e; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; HERRICK RC, 1976, J CHEM PHYS, V65, P4778, DOI 10.1063/1.432948; HERRICK RC, 1976, J CHEM PHYS, V65, P4786, DOI 10.1063/1.432949; HOLLENBERG PF, 1980, J BIOL CHEM, V255, P4801; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; MARLETTA MA, 1993, ADV EXP MED BIOL, V338, P281; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Palmer G., 1971, FLAVINS FLAVOPROTEIN, P123; Palmer G., 1979, PORPHYRINS, P313; PEISACH J, 1970, P NATL ACAD SCI USA, V67, P172, DOI 10.1073/pnas.67.1.172; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; SATO M, 1977, BIOCHIM BIOPHYS ACTA, V498, P403, DOI 10.1016/0304-4165(77)90279-3; SONO M, 1986, BIOCHEMISTRY-US, V25, P347, DOI 10.1021/bi00350a011; SONO M, 1982, J BIOL CHEM, V257, P5496; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; SONO M, 1991, BIOCHIM BIOPHYS ACTA, V1078, P351, DOI 10.1016/0167-4838(91)90156-T; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TAYLOR CPS, 1977, BIOCHIM BIOPHYS ACTA, V491, P137, DOI 10.1016/0005-2795(77)90049-6; TEIXEIRA M, 1993, FEBS LETT, V317, P233, DOI 10.1016/0014-5793(93)81282-5; TSAI AL, 1993, J BIOL CHEM, V268, P8554; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; WALKER FA, 1986, J AM CHEM SOC, V108, P5288, DOI 10.1021/ja00277a038; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020	43	53	53	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32563	32571		10.1074/jbc.271.51.32563	http://dx.doi.org/10.1074/jbc.271.51.32563			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955082	hybrid			2022-12-25	WOS:A1996VZ37300017
J	Lei, JY; Zou, TT; Shi, YQ; Zhou, XL; Smolinski, KN; Yin, J; Souza, RF; Appel, R; Wang, S; Cymes, K; Chan, O; Abraham, JM; Harpaz, N; Meltzer, SJ				Lei, JY; Zou, TT; Shi, YQ; Zhou, XL; Smolinski, KN; Yin, J; Souza, RF; Appel, R; Wang, S; Cymes, K; Chan, O; Abraham, JM; Harpaz, N; Meltzer, SJ			Infrequent DPC4 gene mutation in esophageal cancer, gastric cancer and ulcerative colitis-associated neoplasms	ONCOGENE			English	Article						DPC4; mutation; tumor suppressor gene; esophageal cancer; gastric cancer; DNA sequencing	TUMOR-SUPPRESSOR GENE; ADENOMATOUS POLYPOSIS; DROSOPHILA; DYSPLASIAS; ALLELOTYPE; DELETIONS; CARCINOMA; BETA; P53	Homozygously Deleted in Pancreatic Cancer 4 (DPC4), a recently identified candidate tumor suppressor gene, was previously shown to be altered in human pancreatic cancers, We examined DPC4 mutation in 30 examples of three other types of gastrointestinal malignancy: 10 esophageal cancers, 10 gastric cancers and 10 colorectal cancers occurring in the preneoplastic condition, ulcerative colitis, The entire coding region of DPC4 (including all 11 exons) was analysed by either direct sequencing of PCR product or the in vitro synthesized protein assay. No coding region mutations of DPC4 were found in any of the samples examined, Our results suggest that inactivation of DPC4 may not be important in the majority of these types of gastrointestinal cancer.	UNIV MARYLAND,SCH MED,DEPT MED,DIV GASTROENTEROL,BALTIMORE,MD 21201; VET AFFAIRS HOSP,BALTIMORE,MD 21201; MT SINAI UNIV,SCH MED,DEPT PATHOL,NEW YORK,NY	University System of Maryland; University of Maryland Baltimore; Icahn School of Medicine at Mount Sinai			Harpaz, Noam/L-3411-2017	Harpaz, Noam/0000-0003-4923-2200				ALEXANDROW MG, 1995, CANCER RES, V55, P1452; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HURSH DA, 1993, DEVELOPMENT, V117, P1211; Kim SK, 1996, CANCER RES, V56, P2519; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MELTZER SJ, 1990, CANCER RES, V50, P3627; Nagatake M, 1996, CANCER RES, V56, P2718; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; SEKELSKY JJ, 1995, GENETICS, V139, P1347; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SHUTTE M, 1996, CANCER RES, V56, P2527; TARMIN L, 1995, CANCER RES, V55, P2035; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; TOYOOKA M, 1995, CANCER RES, V55, P3165; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; XIAO S, 1995, CANCER RES, V55, P2968	20	70	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2459	2462						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957088				2022-12-25	WOS:A1996VX10800019
J	BaierBitterlich, G; Baier, G; Fuchs, D; Bock, G; Hausen, A; Utermann, G; Pavelka, M; Wachter, H				BaierBitterlich, G; Baier, G; Fuchs, D; Bock, G; Hausen, A; Utermann, G; Pavelka, M; Wachter, H			Role of 7,8-dihydroneopterin in T-cell apoptosis and HTLV-1 transcription in vitro	ONCOGENE			English	Article						HTLV infection; apoptosis; neopterin; 7,8-dihydroneopterin; HTLV LTR; reactive oxygen intermediates	VIRUS TYPE-I; NF-KAPPA-B; LUMINOL-DEPENDENT CHEMILUMINESCENCE; INTERFERON-GAMMA; OXIDATIVE STRESS; REACTIVE OXYGEN; TRANSACTIVATOR TAX; HIV-INFECTION; NEOPTERIN; LEUKEMIA	Adult T-cell leukemia is associated with high levels of neopterin, released in large amounts from human macrophages upon stimulation with interferon-gamma. Recent data suggested a potential role of neopterin-derivatives in oxygen radical-mediated processes, and evidence accumulates that oxidative stress is involved in the pathogenesis of viral diseases. We now report that increased concentrations of 7,8-dihydroneopterin may lead to enhanced apoptosis and disturbance of the redox-balance of human leukemic Jurkat T cells. Additionally, we demonstrate that 7,8-dihydroneopterin and hydrogen peroxide activate the type 1 human T-cell leukemia virus (HTLV-1) long terminal repeat (LTR). Furthermore, we found that the activity of the HTLV-1 transactivator protein Tax is amplified by an elevated concentration of 7,8-dihydroneopterin. Tax did not significantly augment 7,8-dihydroneopterin mediated apoptosis. Based on our data we propose that 7,8-dihydroneopterin may be involved in the progression to higher stages of HTLV-1 associated disease.	UNIV INNSBRUCK, LUDWIG BOLTZMANN INST AIDS RES, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST MED BIOL & HUMAN GENET, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST EXPT PATHOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST HISTOL & EMBRYOL, A-6020 INNSBRUCK, AUSTRIA	Ludwig Boltzmann Institute; University of Innsbruck; University of Innsbruck; University of Innsbruck; University of Innsbruck	BaierBitterlich, G (corresponding author), UNIV INNSBRUCK, INST MED CHEM & BIOCHEM, FRITZ PREGL STR 3, A-6020 INNSBRUCK, AUSTRIA.		Fuchs, Dietmar/AAL-8011-2021; Baier, Gottfried/E-8755-2012	Fuchs, Dietmar/0000-0003-1627-9563; Baier, Gottfried/0000-0002-2085-8325				BAIERBITTERELIC.G, IN PRESS AIDS RES HU; BAIERBITTERLICH G, 1995, FEBS LETT, V364, P234, DOI 10.1016/0014-5793(95)00403-V; BAIERBITTERLICH G, 1994, ONCOGENE, V9, P319; BAIERBITTERLICH G, IN PRESS AIDS RES HU; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BILLIAU A, 1990, BIOCHEM PHARMACOL, V40, P1433, DOI 10.1016/0006-2952(90)90437-P; BITTERLICH G, 1988, IMMUNOBIOLOGY, V176, P228, DOI 10.1016/S0171-2985(88)80055-X; CHLICHLIA K, 1995, ONCOGENE, V10, P269; CRAWFORD D, 1988, ONCOGENE, V3, P27; DAEFLER S, 1991, MOL F ONCOLOGY, P229; DATTA R, 1992, BIOCHEMISTRY-US, V31, P8300, DOI 10.1021/bi00150a025; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FUCHS D, 1988, IMMUNOL TODAY, V9, P150, DOI 10.1016/0167-5699(88)91203-0; FUCHS D, 1989, CLIN CHEM, V35, P2305; FUCHS D, 1994, IMMUNOL TODAY, V15, P496, DOI 10.1016/0167-5699(94)90197-X; FUJII N, 1992, MICROBIOL IMMUNOL, V36, P425, DOI 10.1111/j.1348-0421.1992.tb02041.x; FUJISAWA J, 1989, J VIROL, V63, P3234, DOI 10.1128/JVI.63.8.3234-3239.1989; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENSPAN HC, 1994, IMMUNOL TODAY, V15, P209, DOI 10.1016/0167-5699(94)90245-3; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; KLEBANOFF SJ, 1992, INFLAMMATION BASIC P; MERL S, 1984, BLOOD, V64, P967; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MURR C, 1994, FEBS LETT, V338, P223, DOI 10.1016/0014-5793(94)80369-2; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; REIBNEGGER G, 1995, FREE RADICAL BIO MED, V18, P515, DOI 10.1016/0891-5849(94)00164-F; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; TAN TH, 1989, J VIROL, V63, P3761, DOI 10.1128/JVI.63.9.3761-3768.1989; UBERALL F, 1994, FEBS LETT, V352, P11, DOI 10.1016/0014-5793(94)00899-X; WACHTER H, 1989, ADV CLIN CHEM, V27, P81, DOI 10.1016/S0065-2423(08)60182-1; WACHTER H, 1979, H-S Z PHYSIOL CHEM, V360, P1957; Wachter H, 1992, NEOPTERIN BIOCH METH, V10, P289; WEISS G, 1993, FEBS LETT, V321, P89, DOI 10.1016/0014-5793(93)80627-7; WERNER ER, 1989, BIOCHEM J, V262, P861, DOI 10.1042/bj2620861; WERNER ER, 1990, J BIOL CHEM, V265, P3189; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WONGSTAAL F, 1985, NATURE, V317, P395, DOI 10.1038/317395a0; YODOI J, 1992, IMMUNOL TODAY, V13, P405, DOI 10.1016/0167-5699(92)90091-K; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOUNG HA, 1990, PHARMACOL THERAPEUT, V45, P137, DOI 10.1016/0163-7258(90)90012-Q	50	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2281	2285						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950996				2022-12-25	WOS:A1996VV14500026
J	Hall, CL; Lange, LA; Prober, DA; Zhang, S; Turley, EA				Hall, CL; Lange, LA; Prober, DA; Zhang, S; Turley, EA			pp60(c-src) is required for cell locomotion regulated by the hyaluronan receptor RHAMM	ONCOGENE			English	Article						migration; focal adhesions; cytoskeleton; tyrosine phosphorylation	ROUS-SARCOMA VIRUS; PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; EPIDERMAL GROWTH-FACTOR; C-SRC; V-SRC; SIGNAL-TRANSDUCTION; TRANSFORMED-CELLS; MEMBRANE INTERACTIONS; PP60C-SRC EXPRESSION	The tyrosine kinase pp60(c-src) has been implicated as a regulator of focal adhesion formation and cell spreading. Here we show that c-src also regulates cell motility and is a key component in the signaling pathway triggered by the motogenic hyaluronan receptor RHAMM, which has been shown to regulate focal adhesion turnover and to regulate ras. Fibroblasts derived from mice lacking src, (src (-/-), have a random locomotion rate that is significantly slower than the corresponding wild-type fibroblasts. Cell locomotion in these mutant cells is restored by the expression of c-src containing a functional kinase domain, but not by the expression of a kinase-deficient src or by a truncated src containing only functional SH2 and SH3 domains. RHAMM is also required for the restoration of src (-/-) cell locomotion. Thus, the motility of cells expressing c-src is reduced to src (-/-) levels by anti-RHAMM blocking antibodies while the cell locomotion of src (-/-) fibroblasts remains unaffected by anti-RHAMM antibodies. We predict that src acts downstream of RHAMM in the regulation of motility, since the expression of a dominant negative src significantly inhibits RHAMM-dependent ras and serum regulated cell locomotion, the expression of v-src enhances cell motility in a RHAMM independent fashion, and there is a physical and functional association between src and RHAMM in ras-transformed cells. However, we suggest that RHAMM regulates focal adhesion turnover via additional src-independent mechanisms. Thus, v-src is unable to turnover focal adhesions in the absence of RHAMM. These results directly demonstrate for the first time a role for src in the regulation of cell locomotion and confirm a key and complex role for src in the regulation of the actin cycle.	HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV MANITOBA, MANITOBA INST CELL BIOL, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PEDIAT, WINNIPEG, MB R3E 0V9, CANADA; UNIV MANITOBA, DEPT PHYSIOL, WINNIPEG, MB R3E 0V9, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Manitoba; University of Manitoba; University of Manitoba								Anderson R G, 1994, Semin Immunol, V6, P89, DOI 10.1006/smim.1994.1013; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BELL L, 1992, J CLIN INVEST, V89, P315, DOI 10.1172/JCI115578; BOCKHOLT SM, 1993, MOL BIOL CELL S, V4; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ENTWISTLE J, 1995, GENE, V163, P233, DOI 10.1016/0378-1119(95)00398-P; ENTWISTLE J, 1996, IN PRESS J CELL BIOC; FLY CM, 1994, J NEUROCHEM, V62, P923; FUKUI Y, 1991, MOL CELL BIOL, V11, P1207, DOI 10.1128/MCB.11.3.1207; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Hall CL, 1995, J NEURO-ONCOL, V26, P221, DOI 10.1007/BF01052625; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HOLME TC, 1986, BRIT J CANCER, V53, P465, DOI 10.1038/bjc.1986.74; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KELLIE S, 1986, EXP CELL RES, V165, P216, DOI 10.1016/0014-4827(86)90546-X; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KUNDRA V, 1994, ONCOGENE, V9, P1429; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; MACAULEY A, 1989, MOL CELL BIOL, V9, P2648, DOI 10.1128/MCB.9.6.2648; Maness P.F., 1992, Seminars in Cell Biology, V3, P117; MARCHISIO PC, 1987, EXP CELL RES, V169, P202, DOI 10.1016/0014-4827(87)90238-2; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McCarthy J., 1993, Critical Reviews in Oral Biology and Medicine, V4, P619; NAKAMURA N, 1993, J CELL SCI, V106, P1057; NEET K, 1995, MOL CELL BIOL, V15, P4908; NERMUT MV, 1991, EXP CELL RES, V193, P382, DOI 10.1016/0014-4827(91)90111-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OCHIENG J, 1991, INVAS METAST, V11, P38; OCONNOR TJ, 1992, CELL GROWTH DIFFER, V3, P435; ODDIE KM, 1989, J NEUROSCI RES, V24, P38, DOI 10.1002/jnr.490240107; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARTIN AW, 1988, CANCER RES, V48, P6050; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1990, ONCOGENE, V5, P1437; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SANKAR S, 1995, AM J PATHOL, V147, P601; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Savani RC, 1995, INT J TISSUE REACT, V17, P141; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STOKER M, 1991, BIOCHIM BIOPHYS ACTA, V1072, P81, DOI 10.1016/0304-419X(91)90008-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TARONE G, 1985, EXP CELL RES, V159, P141, DOI 10.1016/S0014-4827(85)80044-6; THOMAS JE, 1993, ONCOGENE, V8, P2521; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TOOLE BP, 1989, BIOL HYAL CIB FDN S, V143, P150; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TURLEY E, 1989, EXP CELL RES, V182, P340, DOI 10.1016/0014-4827(89)90239-5; TURLEY EA, 1990, EXP CELL RES, V187, P243, DOI 10.1016/0014-4827(90)90087-Q; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; TURLEY EA, 1989, CIBA F SYMP, V143, P121; VALLES AM, 1990, CELL REGUL, V1, P975, DOI 10.1091/mbc.1.13.975; WARREN SL, 1987, MOL CELL BIOL, V7, P1326, DOI 10.1128/MCB.7.4.1326; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YANG B, 1993, UNPUB	87	127	134	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2213	2224						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950989				2022-12-25	WOS:A1996VV14500019
J	Leonardsen, L; DeClue, JE; Lybaek, H; Lowy, DR; Willumsen, BM				Leonardsen, L; DeClue, JE; Lybaek, H; Lowy, DR; Willumsen, BM			Rasp21 sequences opposite the nucleotide binding pocket are required for GRF-mediated nucleotide release	ONCOGENE			English	Article						Rasp21-mutants; GRF; GNEF; Ras-loop 7; nucleotide-exchange	MURINE SARCOMA-VIRUS; GTPASE-ACTIVATING PROTEIN; SWITCH-II REGION; GUANINE-NUCLEOTIDE; SACCHAROMYCES-CEREVISIAE; EXCHANGE FACTOR; CATALYTIC DOMAIN; SIGNAL TRANSDUCTION; TERMINAL DOMAIN; TYROSINE KINASE	The substrate requirements for the catalytic activity of the mouse Cdc25 homolog Guanine nucleotide Release Factor, GRF, were determined using the catalytic domain of GRF expressed in insect cells and E. coli expressed H-Ras mutants. We found a requirement for the loop 7 residues in Ras (amino acids 102 to 105) for stimulation of guanine nucleotide release. The dependence on the switch I and II regions of Rasp21 (encompassing the residues that shift position in the GTP- versus GDP-bound protein), which had been seen with Sdc25-mediated exchange, was also found for GRF. In addition, the sensitivity of H-Ras to GRF was abolished when residues 130-139 were replaced by proline-aspartic acid-glutamine, whereas substitution of the entire loop 8 (residues 123-130 replaced by leucine-isoleucine-arginine) had no effect on the stimulation of guanine nucleotide release by GRF. Substrate activity of Ras proteins were independent of their post-translational processing, GDP release was stimulated threefold more effectively by GRF than was GTP release, and no major differences were found between the mammalian N-, H- and K-Ras proteins. Examining the responsiveness of the Ras protein from S. pombe and the human Ras like proteins RhoA, Rap1A, Rad and G25K revealed a strict Ras specificity; of these only S. pombe Ras was GRF sensitive.	UNIV COPENHAGEN, DEPT MOL CELL BIOL, DK-1353 COPENHAGEN, DENMARK; NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA	University of Copenhagen; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEVALLIERMULTON MC, 1993, J BIOL CHEM, V268, P11113; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DECLUE JE, 1991, MOL CELL BIOL, V11, P3132, DOI 10.1128/MCB.11.6.3132; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; DHAR R, 1982, SCIENCE, V217, P934, DOI 10.1126/science.6287572; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HANEY SA, 1994, J BIOL CHEM, V269, P16541; HOWE LR, 1993, ONCOGENE, V8, P2583; HWANG YW, 1993, J BIOL CHEM, V268, P24692; JACQUET E, 1992, J BIOL CHEM, V267, P24181; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; JACQUET E, 1994, BIOCHEM BIOPH RES CO, V199, P497, DOI 10.1006/bbrc.1994.1256; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LACAL JC, 1986, MOL CELL BIOL, V6, P4214, DOI 10.1128/MCB.6.12.4214; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIRISOLA MG, 1994, J BIOL CHEM, V269, P15740; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOODIE SA, 1995, ONCOGENE, V11, P447; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAPAGEORGE AG, 1989, J VIROL, V44, P509; POULLET P, 1995, EUR J BIOCHEM, V227, P537, DOI 10.1111/j.1432-1033.1995.tb20421.x; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; REDDY EP, 1985, J VIROL, V53, P984, DOI 10.1128/JVI.53.3.984-987.1985; RUTA M, 1986, MOL CELL BIOL, V6, P1706, DOI 10.1128/MCB.6.5.1706; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; STONE JC, 1988, MOL CELL BIOL, V8, P3565, DOI 10.1128/MCB.8.8.3565; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WANG XZ, 1991, GENE, V100, P131, DOI 10.1016/0378-1119(91)90358-I; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WILLUMSEN BM, 1989, NATO ADV SCI I A-LIF, V165, P165; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1995, METHOD ENZYMOL, V250, P269	54	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2177	2187						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950985				2022-12-25	WOS:A1996VV14500015
J	Clair, T; Lee, HY; Liotta, LA; Stracke, ML				Clair, T; Lee, HY; Liotta, LA; Stracke, ML			Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I NUCLEOTIDE PYROPHOSPHATASE; MOTILITY-STIMULATING PROTEIN; MEMBRANE GLYCOPROTEIN PC-1; FIBROBLAST GROWTH-FACTOR; AMINO-ACID-SEQUENCE; ECTO-ATPASE; CDNA CLONING; NEUTROPHIL CHEMOTAXIS; MOLECULAR-CLONING; PLASMA-MEMBRANE	Autotaxin (ATX) is an extracellular enzyme and an autocrine motility factor that stimulates pertussis toxin-sensitive chemotaxis in human melanoma cells at picomolar to nanomolar concentrations. This 125-kDa glycoprotein contains a peptide sequence identified as the catalytic site in type I alkaline phosphodiesterases (PDEs), and it possesses 5'-nucleotide PDE (EC 3.1.4.1) activity (Stracke, M. L., Krutzsch, H. C., Unsworth, E. J., Arestad, A., Cioce, V., Schiffmann, E., and Liotta, L. (1992) J. Biol. Chem. 267, 2524-2529 Murata, J., Lee, H. Y., Clair, T., Krutsch, H. C., Arestad, A. A., Sobel, M. E., Liotta, L. A., and Stracke, M. L. (1994) J. Biol. Chem. 269, 30479-30484). ATX binds ATP and is phosphorylated only on threonine. Thr(210) at the PDE active site of ATX is required for phosphorylation, 5'-nucleotide PDE, and motility-stimulating activities (Lee, H. Y., Clair, T., Mulvaney, P. T., Woodhouse, E. C., Aznavoorian, S., Liotta, L. A., and Stracke, M. L. (1996) J. Biol. Chem. 271, 24408-24412). In this article we report that the phosphorylation of ATX is a transient event, being stable at 0 degrees C but unstable at 37 degrees C, and that ATX has adenosine-5'-triphosphatase (ATPase; EC 3.6.1.3) and ATP pyrophosphatase (EC 3.6.1.8) activities. Thus ATX catalyzes the hydrolysis of the phosphodiester bond on either side of the beta-phosphate of ATP. ATX also catalyzes the hydrolysis of GTP to GDP and GMP, of either AMP or PPi to P-i, and the hydrolysis of NAD to AMP, and each of these substrates can serve as a phosphate donor in the phosphorylation of ATX. ATX possesses no detectable protein kinase activity toward histone, myelin basic protein, or casein. These results lead to the proposal that ATX is capable of at least two alternative reaction mechanisms, threonine (T-type) ATPase and 5'-nucleotide PDE/ATP pyrophosphatase, with a common site (Thr(210)) for the formation of covalently bound reaction intermediates threonine phosphate and threonine adenylate, respectively.			Clair, T (corresponding author), NCI, PATHOL LAB,DIV CLIN SCI,NIH,BLDG 10, RM 2A33, BETHESDA, MD 20892 USA.							AURIVILLIUS M, 1990, FEBS LETT, V264, P267, DOI 10.1016/0014-5793(90)80264-J; BELLI SI, 1995, EUR J BIOCHEM, V228, P669, DOI 10.1111/j.1432-1033.1995.tb20308.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; CHE MX, 1992, J BIOL CHEM, V267, P9684; CHEN ZP, 1995, J NEUROENDOCRINOL, V7, P83, DOI 10.1111/j.1365-2826.1995.tb00671.x; CULP JS, 1985, J BIOL CHEM, V260, P8320; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; DECKER K, 1971, FEBS LETT, V21, P95; DEISSLER H, 1995, J BIOL CHEM, V270, P9849, DOI 10.1074/jbc.270.17.9849; DRAWBRIDGE J, 1991, Journal of Cell Biology, V115, p145A; DUSSEAU JW, 1988, RESP PHYSIOL, V71, P33, DOI 10.1016/0034-5687(88)90113-2; EHRLICH YH, 1990, ANN NY ACAD SCI, V603, P401; EVANS WH, 1973, BIOCHEM J, V135, P819, DOI 10.1042/bj1350819; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GARCIACASTRO I, 1983, J BIOL CHEM, V258, P4345; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; HALEY BE, 1974, P NATL ACAD SCI USA, V71, P3367, DOI 10.1073/pnas.71.9.3367; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LIN SH, 1989, J BIOL CHEM, V264, P14403; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MEININGER CJ, 1988, AM J PHYSIOL, V255, pH554, DOI 10.1152/ajpheart.1988.255.3.H554; Morley DJ, 1987, J HISTOCHEM CYTOCHEM, V35, P75, DOI 10.1177/35.1.3025290; MURATA J, 1994, J BIOL CHEM, V269, P30479; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; ODA Y, 1993, J BIOL CHEM, V268, P27318; PEARSON JD, 1980, BIOCHEM J, V190, P421, DOI 10.1042/bj1900421; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; PLESNER L, 1995, INT REV CYTOL, V158, P141; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; REBBE NF, 1991, P NATL ACAD SCI USA, V88, P5192, DOI 10.1073/pnas.88.12.5192; REEVES RE, 1976, TRENDS BIOCHEM SCI, V1, P53, DOI 10.1016/S0968-0004(76)80189-2; ROSE FR, 1988, J EXP MED, V167, P1186, DOI 10.1084/jem.167.3.1186; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SHAPIRO R, 1986, BIOCHEMISTRY-US, V25, P3527, DOI 10.1021/bi00360a008; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; STILES GL, 1992, J BIOL CHEM, V267, P6451; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Strobel RS, 1996, J BIOL CHEM, V271, P16323, DOI 10.1074/jbc.271.27.16323; SUPRENANT A, 1996, SCIENCE, V272, P735; TRAMS EG, 1980, J THEOR BIOL, V87, P609, DOI 10.1016/0022-5193(80)90239-8; URIARTE M, 1995, BIOCHEM J, V306, P271, DOI 10.1042/bj3060271; VANDRIEL IR, 1985, P NATL ACAD SCI USA, V82, P8619, DOI 10.1073/pnas.82.24.8619; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898	48	134	137	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					996	1001		10.1074/jbc.272.2.996	http://dx.doi.org/10.1074/jbc.272.2.996			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995394	hybrid			2022-12-25	WOS:A1997WC04800045
J	Gallie, DR; Le, H; Caldwell, C; Tanguay, RL; Hoang, NX; Browning, KS				Gallie, DR; Le, H; Caldwell, C; Tanguay, RL; Hoang, NX; Browning, KS			The phosphorylation state of translation initiation factors is regulated developmentally and following heat shock in wheat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS INITIATION; CAP-BINDING-PROTEIN; MESSENGER-RNA CAP; POLY(A) TAIL FUNCTION; ISOZYME FORM; ELONGATION-FACTORS; HELA-CELLS; GERM; IDENTIFICATION; INHIBITION	Several translation initiation factors in mammals and yeast are regulated by phosphorylation. The phosphorylation state of these factors is subject to alteration during development, environmental stress (heat shock, starvation, or heme deprivation), or viral infection. The phosphorylation state and the effect of changes in phosphorylation of the translation initiation factors of higher plants have not been previously investigated, We have determined the isoelectric states for the wheat translation initiation factors eIF-4A, eIF-4B, eIF-4F, eIF-iso4F, and eIF-2 and the poly(A)-binding protein in the seed, during germination, and following heat shock of wheat seedlings using two-dimensional gel electrophoresis and Western analysis. We found that the developmentally induced changes in isoelectric state observed during germination or the stress-induced changes were consistent with changes in phosphorylation. Treatment of the phosphorylated forms of the factors with phosphatases confirmed that the nature of the modification was due to phosphorylation. The isoelectric states of eIF-4B, eIF-4F (eIF-4E, p26), eIF-iso4F (eIF-iso4E, p28), and eIF-2 alpha (p42) were altered during germination, suggesting that phosphorylation of these factors is developmentally regulated and correlates with the resumption of protein synthesis that occurs during germination. The phosphorylation of eIF-2 beta (p38) or poly(A)-binding protein did not change either during germination or following a thermal stress. Only the phosphorylation state of two factors, eIF-4A and eIF-4B, changed following a heat shock, suggesting that plants may differ significantly from animals in the way in which their translational machinery is modified in response to a thermal stress.	UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712	University of Texas System; University of Texas Austin	Gallie, DR (corresponding author), UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521, USA.							ALLEN ML, 1992, J BIOL CHEM, V267, P23232; BENNE R, 1980, EUR J BIOCHEM, V104, P109, DOI 10.1111/j.1432-1033.1980.tb04406.x; BIENZ M, 1984, P NATL ACAD SCI-BIOL, V81, P3138, DOI 10.1073/pnas.81.10.3138; BIENZ M, 1982, CELL, V29, P811, DOI 10.1016/0092-8674(82)90443-3; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1989, J BIOL CHEM, V264, P8491; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; BROWNING KS, 1987, J BIOL CHEM, V262, P538; CALLIS J, 1988, PLANT PHYSIOL, V88, P965, DOI 10.1104/pp.88.4.965; CLARKE RD, 1987, MOL CELL BIOCHEM, V74, P129; DRAWBRIDGE J, 1990, MOL CELL BIOL, V10, P3994, DOI 10.1128/MCB.10.8.3994; DUNCAN R, 1985, J BIOL CHEM, V260, P5493; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FABBRI BJ, 1994, TRANSLATIONAL CONTRO, P66; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; GALLIE DR, 1995, PLANT PHYSIOL, V108, P1703, DOI 10.1104/pp.108.4.1703; GALLIE DR, 1994, J BIOL CHEM, V269, P7174; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; HERSHEY JWB, 1990, ENZYME, V44, P17, DOI 10.1159/000468744; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; HWANG CH, 1989, PLANT PHYSIOL, V91, P552, DOI 10.1104/pp.91.2.552; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KASPAR RL, 1990, J BIOL CHEM, V265, P3619; KEY JL, 1981, P NATL ACAD SCI-BIOL, V78, P3526, DOI 10.1073/pnas.78.6.3526; KRISHNAN M, 1989, PLANT PHYSIOL, V90, P140, DOI 10.1104/pp.90.1.140; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; Lasko P., 1995, Molecular Biology of the Cell, V6, p80A; LAX SR, 1986, METHOD ENZYMOL, V118, P109; LAX SR, 1986, J BIOL CHEM, V261, P5632; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MERRICK WC, 1994, BIOCHIMIE, V76, P822, DOI 10.1016/0300-9084(94)90183-X; METZ AM, 1993, GENE, V131, P299, DOI 10.1016/0378-1119(93)90310-Y; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURTHARIEL P, 1993, J BIOL CHEM, V268, P12946; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; PANNIERS R, 1994, BIOCHIMIE, V76, P737, DOI 10.1016/0300-9084(94)90078-7; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHONFELDER M, 1985, P NATL ACAD SCI USA, V82, P6884, DOI 10.1073/pnas.82.20.6884; SEAL SN, 1983, J BIOL CHEM, V258, P573; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; VANBOXBERG Y, 1994, ANAL BIOCHEM, V219, P32; VANHEERDEN A, 1994, J BIOL CHEM, V269, P17454; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; YANG JJ, 1992, PLANT PHYSIOL, V98, P1115, DOI 10.1104/pp.98.3.1115; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007	63	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1046	1053		10.1074/jbc.272.2.1046	http://dx.doi.org/10.1074/jbc.272.2.1046			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995401	hybrid			2022-12-25	WOS:A1997WC04800052
J	Korzus, E; Nagase, H; Rydell, R; Travis, J				Korzus, E; Nagase, H; Rydell, R; Travis, J			The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; TRANSCRIPTION FACTORS; ALZHEIMERS-DISEASE; COLLAGENASE GENE; TISSUE INHIBITOR; PHORBOL ESTER; BINDING-SITES; GROWTH-FACTOR; C-JUN; CELLS	Both astrocytes in the central nervous system and fibroblasts in somatic tissues are not only the major sources of extracellular matrix components but also of matrix metalloproteinases (MMPs), a family of enzymes directly involved in extracellular matrix breakdown. We have analyzed the regulation of the expression of MMPs and TIMPs (tissue inhibitors of metalloproteinases) in human primary astrocytes stimulated with oncostatin M (OSM) and other extracellular mediators in comparison with normal human dermal fibroblasts. It was found that OSM induced/enhanced transcription of MMP-1 (interstitial collagenase) and MMP-3 (stromelysin 1) in astrocytes, and MMP-1, MMP-9 (gelatinase B), and TIMP-1 in fibroblasts. Analysis of the signal transduction leading to activation of the MMP-1 gene revealed the presence of an OSM-responsive element (OMRE) encompassing the AP-1 binding site and the signal transducer and activator of transcription (STAT) binding element, which mediate activation by OSM. OMRE is also present in the TIMP-1 gene promoter and, although there are some differences in these two motifs, both appear to be targets for the simultaneous action of OSM-induced nuclear effecters. The induced enhancement of transcription by synergistically acting AP-1 and STAT binding elements in response to OSM is Raf-dependent. Cross-talk between the mitogen-activated protein kinase and JAX-STAT pathways is required to achieve maximal induction of the OMRE-driven transcription by OSM.	UNIV GEORGIA,DEPT BIOCHEM & MOL BIOL,ATHENS,GA 30602; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOL BIOL,KANSAS CITY,KS 66160; ATHENA NEUROSCI INC,S SAN FRANCISCO,CA 94080	University System of Georgia; University of Georgia; University of Kansas; University of Kansas Medical Center					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL137090, R01HL037090, R37HL037090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 37090] Funding Source: Medline; NIAMS NIH HHS [AR39189] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; APODACA G, 1990, CANCER RES, V50, P2322; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BACKSTROM JR, 1992, J NEUROCHEM, V58, P983, DOI 10.1111/j.1471-4159.1992.tb09352.x; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BENBROOK DM, 1990, ONCOGENE, V5, P295; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BIRKEDALHANSEN H, 1993, J PERIODONTAL RES, V28, P500, DOI 10.1111/j.1600-0765.1993.tb02113.x; BROWN TJ, 1991, J IMMUNOL, V147, P2175; BROWN TJ, 1987, J IMMUNOL, V139, P2977; Bruce A. Gregory, 1992, Progress in Growth Factor Research, V4, P157, DOI 10.1016/0955-2235(92)90029-H; BRUCE AG, 1992, J IMMUNOL, V149, P1271; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Bugno M, 1995, NUCLEIC ACIDS RES, V23, P5041, DOI 10.1093/nar/23.24.5041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, NEW BIOL, V4, P61; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIM K, 1989, BIOTECHNIQUES, V7, P576; LIU JW, 1992, CELL GROWTH DIFFER, V3, P307; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MALIK N, 1995, MOL CELL BIOL, V15, P2349; MASHALL C, 1994, CURR OPIN CELL BIOL, V4, P82; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; MIYAZAKI K, 1993, NATURE, V362, P839, DOI 10.1038/362839a0; Moore DD, 1995, GLOB MOB SURV; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NELSON RB, 1993, J NEUROCHEM, V61, P567; Pope A., 1978, DYNAMIC PROPERTIES G, P13; PRICE DL, 1995, CURR OPIN NEUROL, V8, P268, DOI 10.1097/00019052-199508000-00004; RICHARDS CD, 1993, J IMMUNOL, V150, P5596; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIFKIN DB, 1989, AM REV RESPIR DIS, V140, P1112, DOI 10.1164/ajrccm/140.4.1112; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHNITKA TK, 1993, ADV NEURAL SCI, V1, P161; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; THOMA B, 1994, J BIOL CHEM, V269, P6215; UCHIJIMA M, 1994, J BIOL CHEM, V269, P14946; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Werb Z, 1992, Matrix Suppl, V1, P337; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	75	147	147	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1188	1196		10.1074/jbc.272.2.1188	http://dx.doi.org/10.1074/jbc.272.2.1188			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995420	hybrid			2022-12-25	WOS:A1997WC04800071
J	Nakamura, RL; Anderson, JA; Gaber, RF				Nakamura, RL; Anderson, JA; Gaber, RF			Determination of key structural requirements of a K+ channel pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; SACCHAROMYCES-CEREVISIAE; GUARD-CELLS; FUNCTIONAL EXPRESSION; ARABIDOPSIS-THALIANA; VOLTAGE-DEPENDENCE; PLASMA-MEMBRANE; DROSOPHILA; TRANSPORT; YEAST	Among the highly conserved sites in K+ channel pores, the tyrosine-glycine sequence is believed to play an important role in selectivity. Here we describe a novel approach in which comprehensive mutagenesis of the YG sites of the voltage-gated K+ channel, Kat1, is combined with phenotypic screening in Saccharomyces cerevisiae and electrophysiological analysis in Xenopus oocytes to determine the roles of these sites in K+ selectivity, We show that structural constraints necessitate a tyrosine or phenylalanine at the first position to confer full K+ selectivity, Substitution to arginine creates a channel titratable by external pH, suggesting that the side group at this position may line the channel pore. Permeation is abolished by any increase in bulk at the adjacent glycine position unless accompanied by a compensatory mutation at the tyrosine site, These results suggest a model in which the selectivity filter of the K+ channel requires an aromatic residue paired with glycine within the pore loop in order to maintain maximal K+ selectivity.	NORTHWESTERN UNIV, DEPT BIOCHEM MOL BIOL & CELL BIOL, EVANSTON, IL 60208 USA	Northwestern University								AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ANDERSON JA, 1994, S SOC EXP BIOL, V48, P35; ATKINSON NS, 1991, SCIENCE, V253, P551, DOI 10.1126/science.1857984; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Benzanilla F, 1977, J GEN PHYSIOL, V70, P549; BERTL A, 1995, P NATL ACAD SCI USA, V92, P2701, DOI 10.1073/pnas.92.7.2701; BUTLER A, 1989, SCIENCE, V243, P943, DOI 10.1126/science.2493160; CAO YW, 1995, J BIOL CHEM, V270, P17697, DOI 10.1074/jbc.270.30.17697; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Hille B., 1991, IONIC CHANNELS EXCIT; HOSHI T, 1995, J GEN PHYSIOL, V105, P309, DOI 10.1085/jgp.105.3.309; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KO CH, 1991, MOL CELL BIOL, V11, P4266, DOI 10.1128/MCB.11.8.4266; KO CH, 1990, GENETICS, V125, P305; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; LIPKIND GM, 1995, P NATL ACAD SCI USA, V92, P9215, DOI 10.1073/pnas.92.20.9215; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Navarro B, 1996, SCIENCE, V272, P1950, DOI 10.1126/science.272.5270.1950; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SCHROEDER JI, 1988, J GEN PHYSIOL, V92, P667, DOI 10.1085/jgp.92.5.667; SCHROEDER JI, 1991, P NATL ACAD SCI USA, V88, P11583, DOI 10.1073/pnas.88.24.11583; Schroeder Julian I., 1994, Methods (Orlando), V6, P70, DOI 10.1006/meth.1994.1009; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Slesinger PA, 1996, NEURON, V16, P321, DOI 10.1016/S0896-6273(00)80050-1; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511	44	88	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1011	1018		10.1074/jbc.272.2.1011	http://dx.doi.org/10.1074/jbc.272.2.1011			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995396	hybrid			2022-12-25	WOS:A1997WC04800047
J	Snijders, AJ; Ho, SC; Haase, VH; Pillai, S; Bernards, A				Snijders, AJ; Ho, SC; Haase, VH; Pillai, S; Bernards, A			A lymphocyte-specific Ltk tyrosine kinase isoform is retained in the endoplasmic reticulum in association with calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEINS; EXTRACELLULAR DOMAIN; GENE; RECEPTOR; NEURONS; CELLS	A lymphocyte specific murine Ltk tyrosine kinase isoform was previously found to reside in the endoplasmic reticulum and to be potently activated upon treatment of cells with alkylating or thiol oxidizing agents, Based on these observations, a unique role for Ltk was proposed as an endoplasmic reticulum-resident transmembrane kinase regulated by redox changes (Bauskin, A. R., Alkalay, I., and Ben-Neriah, Y. (1991) Cell 66, 685-696), To analyze why this Ltk isoform is retained in the endoplasmic reticulum, we investigated its behavior in over-expressing cells, Our results indicate that lymphoid Ltk exhibits a dual N-exo/C-cyt and N-cyt/C-exo transmembrane topology in transfected cells, This unusual behavior may be responsible for retention in the endoplasmic reticulum since mutants with an increased number of positive amino acids downstream of the transmembrane segment exhibit a conventional N-exo/C-cyt orientation and proceed to the cell surface, Endoplasmic reticulum retained Ltk forms a prominent complex with the chaperone calnexin, suggesting that Ltk may be retained by the mechanism that prevents surface expression of inappropriately folded proteins or incompletely assembled protein complexes.	HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Harvard University	Snijders, AJ (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOL GENET LAB,CHARLESTOWN,MA 02129, USA.		Haase, Volker Hans/A-6758-2013; Haase, Volker Hans/AAJ-5061-2021	Haase, Volker Hans/0000-0002-7051-8994; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028735] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33507] Funding Source: Medline; NINDS NIH HHS [NS28735] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; BEN-NERIAH Y, 1988, NATURE, V333, P672, DOI 10.1038/333672a0; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HAASE VH, 1991, ONCOGENE, V6, P2319; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KROLEWSKI JJ, 1991, EMBO J, V10, P2911, DOI 10.1002/j.1460-2075.1991.tb07841.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; SNIJDERS AJ, 1993, ONCOGENE, V8, P27; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8	20	4	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1297	1301		10.1074/jbc.272.2.1297	http://dx.doi.org/10.1074/jbc.272.2.1297			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995435	hybrid			2022-12-25	WOS:A1997WC04800086
J	An, XL; Takakuwa, Y; Nunomura, W; Manno, S; Mohandas, N				An, XL; Takakuwa, Y; Nunomura, W; Manno, S; Mohandas, N			Modulation of band 3-ankyrin interaction by protein 4.1 - Functional implications in regulation of erythrocyte membrane mechanical properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-BLOOD-CELL; ANION-EXCHANGER; BINDING-SITES; CYTOPLASMIC DOMAIN; ATTACHMENT SITES; 2 DISTINCT; SPECTRIN; STABILITY; IDENTIFICATION; SKELETAL	Protein 4.1 is an important structural component of the erythrocyte membrane. In contrast to our detailed understanding of the role of protein 4.1 in regulating membrane mechanical properties through modulation of spectrin-actin interaction, very little is known regarding the functional implications of protein 4.1 interaction with band 3. In the present study, me explored the potential role of protein 4.1-band 3 interaction in modulating membrane mechanical properties. Based on recent studies which identified the sequence motif IRRRY in band 3 as the protein 4.1 interacting domain, we studied the functional consequences of specific dissociation of band 3-protein 4.1 interaction by the synthetic peptide IRRRY. We show that protein 4.1 bound to the inside-out vesicles could be dissociated from band 3 but not from glycophorin C by IRRRY. Furthermore, incorporation of IRRRY into resealed ghosts resulted in decreased membrane deformability and increased membrane mechanical stability. The observed alterations in membrane properties appears to result from increased band 3-ankyrin interaction following dissociation of protein 4.1 from band 3. These studies have enabled us to identify an important functional role for band 3-protein 4.1 interaction in modulating erythrocyte membrane properties.	UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BERKELEY,CA 94720; TOKYO WOMENS MED COLL,DEPT BIOCHEM,SHINJUKU KU,TOKYO 162,JAPAN	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tokyo Women's Medical University					NIDDK NIH HHS [DK32094, DK26263] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK032094, R37DK026263, R01DK026263] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLOISIO N, 1985, BIOCHIM BIOPHYS ACTA, V816, P57, DOI 10.1016/0005-2736(85)90392-X; Atherton E., 1981, J CHEM SOC P1, V1, P538; BECKER PS, 1990, EUR J BIOCHEM, V193, P827, DOI 10.1111/j.1432-1033.1990.tb19406.x; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; CHASIS JA, 1986, J CELL BIOL, V103, P343, DOI 10.1083/jcb.103.2.343; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DANILOV YN, 1990, J BIOL CHEM, V265, P2556; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; EDER PS, 1986, BIOCHEMISTRY-US, V25, P1764, DOI 10.1021/bi00355a047; GASCARD P, 1994, BLOOD, V83, P1102; GILLIGAN DM, 1993, SEMIN HEMATOL, V30, P74; HEMMING NJ, 1995, J BIOL CHEM, V270, P5360, DOI 10.1074/jbc.270.10.5360; Inaba M, 1996, J CLIN INVEST, V97, P1804, DOI 10.1172/JCI118610; JONS T, 1992, EMBO J, V11, P2863, DOI 10.1002/j.1460-2075.1992.tb05354.x; KNOWLES DW, 1994, BIOPHYS J, V66, P1726, DOI 10.1016/S0006-3495(94)80965-8; LETO TL, 1984, J BIOL CHEM, V259, P4603; LIU SC, 1990, NEW ENGL J MED, V323, P1530, DOI 10.1056/NEJM199011293232205; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LOVRIEN RE, 1980, J CELL BIOL, V85, P534, DOI 10.1083/jcb.85.3.534; LOW PS, 1991, BLOOD, V77, P1581; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MOHANDAS N, 1982, BLOOD, V59, P768; PASTERNACK GR, 1985, J BIOL CHEM, V260, P3676; Peters L. L., 1995, Blood, V86, p124A; PINDER JC, 1993, BLOOD, V82, P3482; PODGORSKI A, 1985, BIOCHEMISTRY-US, V24, P7871, DOI 10.1021/bi00348a004; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; TYLER JM, 1979, P NATL ACAD SCI USA, V76, P5192, DOI 10.1073/pnas.76.10.5192; VANDORT HM, 1994, BLOOD, V84, pA3	34	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33187	33191		10.1074/jbc.271.52.33187	http://dx.doi.org/10.1074/jbc.271.52.33187			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969174	hybrid			2022-12-25	WOS:A1996WA71300008
J	Bouma, CL; Roseman, S				Bouma, CL; Roseman, S			Sugar transport by the marine chitinolytic bacterium Vibrio furnissii - Molecular cloning and analysis of the glucose and N-acetylglucosamine permeases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSE PHOSPHOTRANSFERASE SYSTEM; ESCHERICHIA-COLI K-12; SALMONELLA-TYPHIMURIUM; NAG REGULON; KLEBSIELLA-PNEUMONIAE; ENZYME-I; PHOSPHOENOLPYRUVATE; PROTEIN; DNA; PHOSPHORYLATION	Chitin catabolism by the marine bacterium Vibrio furnissii involves chemotaxis to and transport of N-acetyl-D-glucosamine (GlcNAc) and D-glucose. We report the properties of the respective permeases that complemented E. coli Glc(-) Man(-) mutants. Although the V. furnissii Glc-specific permease (55,941 Da) shares 38% identity with E. coli IIGlc (ptsG), it is 67% identical to MalX of the E. coli maltose operon (Reidl, J., and Boos, W. (1991) J. Bacteriol. 173, 4862-4876), An adjacent open reading frame encodes a protein with 52% identity to E. coli MalY, Glc phospholylation requires only V. Furnissii MalX and the accessory phosphoenolpyruvate:glycose phosphotransferase system proteins. The V. furnissii equivalent of IIGlc was not found in the 25,000 transformants screened. The GlcNAc/Glc-specific permease (52,894 Da) shares 47% identity with the N-terminal, hydrophobic domain of E. coli IINag, but is unique among IINag proteins in that it lacks the C-terminal domain and thus requires IIIGlc for sugar fermentation in vivo and phosphorylation in vitro. While there are similarities between the phosphoenolpyruvate:glycose phosphotransferase system of V. furnissii and enteric bacteria, the differences may be important for survival of V. furnissii in the marine environment.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University					NIGMS NIH HHS [GM51215, GM38759, T32 GM07321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R01GM051215, R37GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDERSON S, 1981, NUCLEIC ACIDS RES, V9, P3015, DOI 10.1093/nar/9.13.3015; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; BERG OG, 1988, J MOL BIOL, V200, P709, DOI 10.1016/0022-2836(88)90482-2; BOUMA CL, 1987, P NATL ACAD SCI USA, V84, P930, DOI 10.1073/pnas.84.4.930; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; BOUVET OMM, 1987, ANN INST PASTEUR MIC, V138, P3, DOI 10.1016/0769-2609(87)90048-2; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; BRENDEL V, 1984, NUCLEIC ACIDS RES, V12, P4411, DOI 10.1093/nar/12.10.4411; BUHR A, 1992, J BIOL CHEM, V267, P3847; Colwell R. R., 1984, VIBRIOS ENV, P367; CORDARO JC, 1972, J BACTERIOL, V112, P17, DOI 10.1128/JB.112.1.17-29.1972; Cronan Jr. J.E., 1987, ESCHERICHIA COLI SAL, P474; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; HENDERSON PJF, 1977, BIOCHEM J, V162, P309, DOI 10.1042/bj1620309; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; KUBOTA Y, 1979, MICROBIOL IMMUNOL, V23, P131, DOI 10.1111/j.1348-0421.1979.tb00450.x; KUBOTA Y, 1982, FEMS MICROBIOL LETT, V13, P5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MANIATIS T, 1982, COL CLONING LAB MANU; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1987, J BACTERIOL, V169, P4893, DOI 10.1128/jb.169.11.4893-4900.1987; MEINS M, 1993, J BIOL CHEM, V268, P11604; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PAS HH, 1988, BIOCHEMISTRY-US, V27, P5835, DOI 10.1021/bi00416a002; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERI KG, 1990, BIOCHEM CELL BIOL, V68, P123, DOI 10.1139/o90-017; PLUMBRIDGE J, 1991, J MOL BIOL, V217, P661, DOI 10.1016/0022-2836(91)90524-A; PLUMBRIDGE JA, 1989, MOL MICROBIOL, V3, P505, DOI 10.1111/j.1365-2958.1989.tb00197.x; PLUMBRIDGE JA, 1991, MOL MICROBIOL, V5, P2053, DOI 10.1111/j.1365-2958.1991.tb00828.x; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PULLEYBLANK D, 1983, MOL BIOL REP, V9, P191, DOI 10.1007/BF00775367; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; ROBILLARD GT, 1979, BIOCHEMISTRY-US, V18, P2984, DOI 10.1021/bi00581a012; ROMANO AH, 1970, J BACTERIOL, V104, P808, DOI 10.1128/JB.104.2.808-813.1970; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOLLE RR, 1987, J BACTERIOL, V169, P2685, DOI 10.1128/jb.169.6.2685-2690.1987; Schwartz M, 1987, ESCHERICHIA COLI SAL, P1482; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; Silhavy TJ, 1984, EXPT GENE FUSIONS, P137; SPRENGER GA, 1984, J BACTERIOL, V157, P39, DOI 10.1128/JB.157.1.39-45.1984; STOCK JB, 1982, J BIOL CHEM, V257, P4543; VOGLER AP, 1989, MOL GEN GENET, V219, P97, DOI 10.1007/BF00261163; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WAYGOOD EB, 1982, METHOD ENZYMOL, V90, P423; WILLIAMS N, 1986, P NATL ACAD SCI USA, V83, P8934, DOI 10.1073/pnas.83.23.8934; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260; ZDYCH E, 1995, J BACTERIOL, V177, P5035, DOI 10.1128/jb.177.17.5035-5039.1995	58	40	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33457	33467		10.1074/jbc.271.52.33457	http://dx.doi.org/10.1074/jbc.271.52.33457			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969209	hybrid			2022-12-25	WOS:A1996WA71300043
J	Furuyama, T; Inagaki, S; Kosugi, A; Noda, S; Saitoh, S; Ogata, M; Iwahashi, Y; Miyazaki, N; Hamaoka, T; Tohyama, M				Furuyama, T; Inagaki, S; Kosugi, A; Noda, S; Saitoh, S; Ogata, M; Iwahashi, Y; Miyazaki, N; Hamaoka, T; Tohyama, M			Identification of a novel transmembrane semaphorin expressed on lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH CONE GUIDANCE; FAMILY; MEMBER; COLLAPSIN; NETRINS; PROTEIN; AXONS	Semaphorin (also known as collapsin) members are thought to be involved in axon guidance during neural network formation, Here, we report the isolation of a novel member, mouse semaphorin G (M-sema G), which encodes a semaphorin domain followed by a single putative immunoglobulin-like domain, a transmembrane domain, and a cytoplasmic domain, M-sema G; is most closely related to M-sema F, which we previously reported, and semB and semC, These four members appear to constitute a transmembrane type subfamily in mouse semaphorins, In contrast to the predominant expression of M-sema G mRNAs in the nervous tissues, M-sema G mRNAs are strongly expressed in lymphoid tissues, especially in the thymus, as well as in the nervous tissues, The mRNAs are also detected in various cell lines from hematopoietic cells, By generating specific antibodies, we confirmed the strong expression of M-Sema G proteins on the surface of lymphocytes, These results provide the first evidence that semaphorin is expressed on lymphocytes and suggest that semaphorins may play an important role in the immune system, as well as in the nervous system.	OSAKA UNIV,SCH MED,BIOMED RES CTR,OSAKA 565,JAPAN; OSAKA UNIV,SCH ALLIED HLTH SCI,OSAKA 565,JAPAN	Osaka University; Osaka University	Furuyama, T (corresponding author), OSAKA UNIV,SCH MED,DEPT ANAT & NEUROSCI,2-2 YAMADAOKA,SUITA,OSAKA 565,JAPAN.			Furuyama, Tatsuo/0000-0001-7349-103X				BUTCHER EC, 1989, FUNDAMENTAL IMMUNOLO, P117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; INAGAKI S, 1995, FEBS LETT, V370, P269, DOI 10.1016/0014-5793(95)00850-9; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KOLODKIN AL, 1992, NEURON, V9, P831, DOI 10.1016/0896-6273(92)90237-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LUO YL, 1995, NEURON, V14, P1131, DOI 10.1016/0896-6273(95)90261-9; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; OGATA M, 1994, J IMMUNOL, V153, P4478; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L	17	90	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33376	33381		10.1074/jbc.271.52.33376	http://dx.doi.org/10.1074/jbc.271.52.33376			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969198	hybrid			2022-12-25	WOS:A1996WA71300032
J	Graveley, BR; Fleming, ES; Gilmartin, GM				Graveley, BR; Fleming, ES; Gilmartin, GM			Restoration of both structure and function to a defective poly(A) site by in vitro selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNAS; POLYADENYLATION SPECIFICITY FACTOR; CLEAVAGE; AAUAAA; RECOGNITION; UPSTREAM; INVITRO; ELEMENT; SIGNAL; SEQUENCE	Efficient cleavage and polyadenylation at the human immunodeficiency virus type-1 (HTV-1) poly(A) site re quires an upstream 3'-processing enhancer to overcome the suboptimal sequence context of the AAUAAA hexamer. The HTV-1 3'-processing enhancer functions to stabilize the association of the pre-mRNA with cleavage and polyadenylation specificity factor (CPSF), the factor tor responsible for recognition of the AAUAAA hexamer. Intriguingly, in the absence of the 3'-processing enhancer, CPSF binding and polyadenylation efficiency could be restored to near wild-type levels upon replacement of the 14-nucleotide region immediately 5' of the HIV-1 AAUAAA hexamer (the B segment) by the analogous sequences from the efficient adenovirus L3 poly(A) site. To further investigate the contributions of RNA sequence and structure to poly(A) site recognition, we have used an in vitro selection system to identify B segment sequences that enhance the polyadenylation efficiency of a pre-cleaved RNA lacking a 3'-processing enhancer. The final RNA selection pool was composed of two predominant classes of RNAs. Nuclease probing revealed that the selected sequences restored an RNA conformation that facilitates recognition of the AAUAAA hexamer by CPSF. These results indicate that both the sequence and structural context of the AAUAAA hexamer contribute to poly(A) site recognition by CPSF.	UNIV VERMONT,MARKEY CTR MOL GENET,DEPT MOL GENET & MICROBIOL,BURLINGTON,VT 05405	University of Vermont			Graveley, Brenton R/C-3108-2013	Graveley, Brenton/0000-0001-5777-5892	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046624] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46624] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED YF, 1991, CELL, V64, P727, DOI 10.1016/0092-8674(91)90502-P; BARDWELL VJ, 1991, CELL, V65, P125, DOI 10.1016/0092-8674(91)90414-T; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; BIENROTH S, 1991, J BIOL CHEM, V266, P19768; CHRISTOFORI G, 1989, MOL CELL BIOL, V9, P193, DOI 10.1128/MCB.9.1.193; DAY INM, 1992, GENE, V110, P245, DOI 10.1016/0378-1119(92)90656-A; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GILMARTIN GM, 1995, GENE DEV, V9, P72, DOI 10.1101/gad.9.1.72; GILMARTIN GM, 1992, EMBO J, V11, P4419, DOI 10.1002/j.1460-2075.1992.tb05542.x; GIMMI ER, 1989, NUCLEIC ACIDS RES, V17, P6983, DOI 10.1093/nar/17.17.6983; Graveley BR, 1996, MOL CELL BIOL, V16, P4942; Graveley BR, 1996, J VIROL, V70, P1612, DOI 10.1128/JVI.70.3.1612-1617.1996; JENNY A, 1994, MOL CELL BIOL, V14, P8183, DOI 10.1128/MCB.14.12.8183; KELLER W, 1995, CELL, V81, P829, DOI 10.1016/0092-8674(95)90001-2; KELLER W, 1991, EMBO J, V10, P4241, DOI 10.1002/j.1460-2075.1991.tb05002.x; MACDONALD CC, 1994, MOL CELL BIOL, V14, P6647, DOI 10.1128/MCB.14.10.6647; MURTHY KGK, 1992, J BIOL CHEM, V267, P14804; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; VALSAMAKIS A, 1991, P NATL ACAD SCI USA, V88, P2108, DOI 10.1073/pnas.88.6.2108; VALSAMAKIS A, 1992, MOL CELL BIOL, V12, P3699, DOI 10.1128/MCB.12.9.3699; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; WAHLE E, 1995, BBA-GENE STRUCT EXPR, V1261, P183, DOI 10.1016/0167-4781(94)00248-2	24	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33654	33663		10.1074/jbc.271.52.33654	http://dx.doi.org/10.1074/jbc.271.52.33654			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969235	hybrid			2022-12-25	WOS:A1996WA71300069
J	MundinaWeilenmann, C; Vittone, L; Ortale, M; deCingolani, GC; Mattiazzi, A				MundinaWeilenmann, C; Vittone, L; Ortale, M; deCingolani, GC; Mattiazzi, A			Immunodetection of phosphorylation sites gives new insights into the mechanisms underlying phospholamban phosphorylation in the intact heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; CARDIAC SARCOPLASMIC-RETICULUM; BETA-ADRENERGIC STIMULATION; OKADAIC ACID; PROTEIN PHOSPHATASE-1; IDENTIFICATION; VENTRICLES; TRANSPORT; MYOCYTES; GLYCOGEN	Phosphorylation site-specific antibodies, quantification of P-32 incorporation into phospholamban, and simultaneous measurements of mechanical activity were used in Langendorff-perfused rat hearts to provide further insights into the underlying mechanisms of phospholamban phosphorylation. Immunological detection of phospholamban phosphorylation sites showed that the isoproterenol concentration-dependent increase in phospholamban phosphorylation was due to increases in phosphorylation of both Ser(16) and Thr(17) residues. When isoproterenol concentration was increased at extremely low Ca2+ supply to the myocardium, phosphorylation of Thr(17) was virtually absent. Under these conditions, P-32 incorporation into phospholamban, due to Ser(16), decreased by 50%, Changes in Ca2+ supply to the myocardium either at constant beta-adrenergic stimulation or in the presence of okadaic acid, a phosphatase inhibitor, exclusively modified Thr(17) phosphorylation. Changes in phospholamban phosphorylation due to either Ser(16) and/or Thr(17) were paralleled by changes in myocardial relaxation. The results indicate that cAMP-(Ser(16)) and Ca2+-calmodulin (Thr(17))-dependent pathways of phospholamban phosphorylation can occur independently of each other. However, in the absence of beta-adrenergic stimulation, phosphorylation of Thr(17) could only be detected after simultaneous activation of Ca2+-calmodulin-dependent protein kinase and inactivation of phosphatase. It is suggested that under physiological conditions, this requisite is only filled by cAMP-dependent mechanisms.	NATL UNIV LA PLATA,FAC CIENCIAS MED,CTR INVEST CARDIOVASC,RA-1900 LA PLATA,ARGENTINA	National University of La Plata			Mattiazzi, Alicia/L-1512-2019					AHMAD Z, 1989, J BIOL CHEM, V264, P3859; BARRON JT, 1979, J BIOL CHEM, V254, P4954; BASSANI RA, 1995, AM J PHYSIOL-HEART C, V268, pH703, DOI 10.1152/ajpheart.1995.268.2.H703; BILEZIKJIAN LM, 1981, CIRC RES, V49, P1356, DOI 10.1161/01.RES.49.6.1356; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; Gupta RC, 1996, AM J PHYSIOL-HEART C, V270, pH1159, DOI 10.1152/ajpheart.1996.270.4.H1159; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; HUBBARD MJ, 1990, EUR J BIOCHEM, V189, P243, DOI 10.1111/j.1432-1033.1990.tb15483.x; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LINDEMANN JP, 1985, J BIOL CHEM, V260, P4516; MACDOUGALL LK, 1991, EUR J BIOCHEM, V196, P725, DOI 10.1111/j.1432-1033.1991.tb15871.x; MATTIAZZI A, 1994, AM J PHYSIOL, V267, pH812, DOI 10.1152/ajpheart.1994.267.2.H812; NAPOLITANO R, 1992, J MOL CELL CARDIOL, V24, P387, DOI 10.1016/0022-2828(92)93193-N; NEUMANN J, 1993, AM J PHYSIOL, V265, pH257, DOI 10.1152/ajpheart.1993.265.1.H257; NEUMANN J, 1991, CIRC RES, V69, P1450, DOI 10.1161/01.RES.69.6.1450; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STEINER AL, 1972, J BIOL CHEM, V247, P1106; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1982, MOL CELL BIOCHEM, V46, P73; VITTONE L, 1993, MOL CELL BIOCHEM, V124, P33, DOI 10.1007/BF01096379; VITTONE L, 1990, AM J PHYSIOL, V258, pH318, DOI 10.1152/ajpheart.1990.258.2.H318; VITTONE L, 1993, MEDICINA BUENOS A S2, V53, P61; WEGENER AD, 1989, J BIOL CHEM, V264, P11468	29	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33561	33567		10.1074/jbc.271.52.33561	http://dx.doi.org/10.1074/jbc.271.52.33561			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969222	Green Published, hybrid			2022-12-25	WOS:A1996WA71300056
J	Pelton, JG; Torchia, DA; Remington, SJ; Murphy, KP; Meadow, ND; Roseman, S				Pelton, JG; Torchia, DA; Remington, SJ; Murphy, KP; Meadow, ND; Roseman, S			Structures of active site histidine mutants of IIIGlc, a major signal-transducing protein in Escherichia coli - Effects on the mechanism of regulation and phosphoryl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; BACTERIAL PHOSPHOTRANSFERASE SYSTEM; 3-DIMENSIONAL NMR-SPECTROSCOPY; HYDROGEN-BONDING INTERACTIONS; ALPHA-LYTIC PROTEASE; PHOSPHOCARRIER PROTEIN; BACILLUS-SUBTILIS; GLUCOSE PERMEASE; IIA-DOMAIN; SUGAR-TRANSPORT	IIIGlc (also called IIA(Glc)), a major signal-transducing protein in Escherichia coli, is also a phosphorylcarrier in glucose uptake, The crystal and NMR structures of IIIGlc show that His(90), the phosphoryl acceptor, adjoins His(75) in the active site, Glutamine was substituted for His-, giving (IIIGlc)-I-H75Q and (IIIGlc)-I-H90Q, respectively (Presper, K. A., Wong, C.-Y., Liu, L., Meadow, N. D., and Roseman, S. (1989) Proc, Natl. Acad. Sci. U.S.A. 86, 4052-4055), but the mutants showed unexpected properties, (IIIGlc)-I-H90Q loses regulatory functions of IIIGlc, and the phosphoryltransfer rates between Hpr/(IIIGlc)-I-H75Q are 200-fold less than HPr/IIIGlc (Meadow, N. D., and Roseman, S. (1996) J. Biol. Chem. 271, 33440-33445), X-ray crystallography, differential scanning calorimetry, and NMR have now been used to determine the structures of the mutants (phospho-(IIIGlc)-I-H75Q was studied by NMR), The three methods gave completely consistent results. Except for the His to Gin substitutions, the only significant structural changes were in a few hydrogen bonds, (IIIGlc)-I-H90Q contains two structured water molecules (to Gln(90)), which could explain its inability to regulate glycerol kinase. Phospho-IIIGlc contains a chymotrypsin like, hydrogen bond network (Thr(73)-His(75) -O(-)phosphoryl), whereas phospho-(IIIGlc)-I-H75Q contains only one bond (Gln(75)-O--phosphoryl), Hydrogen bonds play an essential role in a proposed mechanism for the phosphoryltransfer reaction.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218; NIDR,BONE RES BRANCH,NIH,BETHESDA,MD 20892; UNIV OREGON,DEPT PHYS,EUGENE,OR 97403; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242	Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Oregon; University of Iowa					NIGMS NIH HHS [GM42618, GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759, R01GM042618] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON B, 1971, J BIOL CHEM, V246, P7023; ANNAND RR, 1996, IN PRESS J AM CHEM S; BACHOVCHIN WW, 1986, BIOCHEMISTRY-US, V25, P7751, DOI 10.1021/bi00371a070; BACHOVCHIN WW, 1978, J AM CHEM SOC, V100, P8041, DOI 10.1021/ja00494a001; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BAX A, 1990, J MAGN RESON, V86, P304, DOI 10.1016/0022-2364(90)90262-8; BLABER M, 1993, BIOCHEMISTRY-US, V32, P11363, DOI 10.1021/bi00093a013; BLOMBERG F, 1977, J AM CHEM SOC, V99, P8149, DOI 10.1021/ja00467a005; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; FAIRBROTHER WJ, 1992, BIOCHEMISTRY-US, V31, P4413, DOI 10.1021/bi00133a005; FAIRBROTHER WJ, 1991, BIOCHEMISTRY-US, V30, P6896, DOI 10.1021/bi00242a013; FAIRBROTHER WJ, 1992, FEBS LETT, V296, P148, DOI 10.1016/0014-5793(92)80367-P; FARRJONES S, 1993, J AM CHEM SOC, V115, P6813, DOI 10.1021/ja00068a044; FEESE M, 1994, P NATL ACAD SCI USA, V91, P3544, DOI 10.1073/pnas.91.9.3544; FERSHT A, 1985, ENZYME STRUCTURE MEC, P152; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Habermann SM, 1996, PROTEIN SCI, V5, P1229, DOI 10.1002/pro.5560050702; HANSEN PE, 1983, ANN REPT NMR SPECTRO, V15, P174; HARBISON G, 1981, J AM CHEM SOC, V103, P4752, DOI 10.1021/ja00406a015; HERZBERG O, 1992, J BIOL CHEM, V267, P24819; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; KALBITZER HR, 1982, BIOCHEMISTRY-US, V21, P2879, DOI 10.1021/bi00541a012; KAPADIA G, 1991, J MOL BIOL, V221, P1079; LEE KH, 1994, PROTEINS, V20, P68, DOI 10.1002/prot.340200108; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; LIVE DH, 1984, J AM CHEM SOC, V106, P1939, DOI 10.1021/ja00319a006; LODI PJ, 1991, BIOCHEMISTRY-US, V30, P6948, DOI 10.1021/bi00242a020; MAES G, 1993, J PHYS CHEM-US, V97, P1818, DOI 10.1021/j100111a017; MARION D, 1989, J MAGN RESON, V85, P393, DOI 10.1016/0022-2364(89)90152-2; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; Meadow ND, 1996, J BIOL CHEM, V271, P33440, DOI 10.1074/jbc.271.52.33440; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MUNOWITZ M, 1982, J AM CHEM SOC, V104, P1192, DOI 10.1021/ja00369a007; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; PELTON JG, 1991, P NATL ACAD SCI USA, V88, P3479, DOI 10.1073/pnas.88.8.3479; PELTON JG, 1992, BIOCHEMISTRY-US, V31, P5215, DOI 10.1021/bi00137a017; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; PELTON JG, 1993, PROTEIN SCI, V2, P543; PERRIN CL, 1994, SCIENCE, V266, P1665, DOI 10.1126/science.266.5191.1665; PETTIGREW DW, 1994, PHOSPHATE IN MICROORGANISMS, P335; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; ROBERTS JD, 1982, J AM CHEM SOC, V104, P3945, DOI 10.1021/ja00378a027; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; ROSEMAN S, 1994, PHOSPHATE MICROORGAN, P151; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Shan SO, 1996, SCIENCE, V272, P97, DOI 10.1126/science.272.5258.97; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VANDIJK AA, 1990, BIOCHEMISTRY-US, V29, P8164, DOI 10.1021/bi00487a026; VANDIJK AA, 1992, BIOCHEMISTRY-US, V31, P9063, DOI 10.1021/bi00152a050; Voet D., 1990, BIOCHEMISTRY-US, P330; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WITANOWSKI M, 1972, TETRAHEDRON, V28, P637, DOI 10.1016/0040-4020(72)84027-4; WORTHYLAKE D, 1991, P NATL ACAD SCI USA, V88, P10382, DOI 10.1073/pnas.88.23.10382; Wuthrich K, 1986, NMR PROTEINS NUCL AC	63	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33446	33456		10.1074/jbc.271.52.33446	http://dx.doi.org/10.1074/jbc.271.52.33446			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969208	hybrid			2022-12-25	WOS:A1996WA71300042
J	Hattori, K; Adachi, H; Matsuzawa, A; Yamamoto, K; Tsujimoto, M; Aoki, J; Hattori, M; Arai, H; Inoue, K				Hattori, K; Adachi, H; Matsuzawa, A; Yamamoto, K; Tsujimoto, M; Aoki, J; Hattori, M; Arai, H; Inoue, K			cDNA cloning and expression of intracellular platelet-activating factor (PAF) acetylhydrolase II - Its homology with plasma PAF acetylhydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; ENDOTHELIAL-CELLS; LIPID-PEROXIDATION; MONOCLONAL-ANTIBODIES; SUBUNIT; IDENTIFICATION; 1-ALKYL-2-ACETYL-SN-GLYCERO-3-PHOSPHOCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPASE-A2; PURIFICATION	Platelet-activating factor (PAF) acetylhydrolase, which inactivates PAF by removing the acetyl group at the sn-2 position, is widely distributed in plasma and tissues, We previously demonstrated that tissue cytosol contains at least two types of PAF acetylhydrolase, isoforms Ib and II, and that isoform Ib is a heterotrimer comprising 45-, 30-, and 29-kDa subunits, whereas isoform II is a 40-kDa monomer. In this study, we isolated cDNA clones of bovine and human PAF acetylhydrolase isoform II, From the longest open reading frame of the cloned cDNAs, both bovine and human PAF acetylhydrolases II are predicted to contain 392 amino acid residues and to exhibit 88% identity with each other at the amino acid level, Both enzymes contain a Gly-X-Ser-X-Gly motif that is characteristic of lipases and serine esterases, Expression of isoform II cDNA in COS7 cells resulted in a marked increase in PAF acetylhydrolase activity, An immunoblot study using an established monoclonal antibody against the bovine enzyme revealed that the recombinant protein exists in the membranous fraction as well as the soluble fraction, Isoform II is expressed most abundantly in the liver and kidney in cattle, but low levels were also observed in other tissues, The amino acid sequence deduced from the cDNA of isoform II had no homology with any subunit of isoform Ib, Interestingly, however, the amino acid sequence of isoform II showed 41% identity with that of plasma PAF acetylhydrolase, Combined with previous data demonstrating that isoform II shows similar substrate specificity to plasma PAF acetylhydrolase, these results indicate that tissue type isoform II and the plasma enzyme may share a common physiologic function.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT HLTH CHEM,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DIV CANC BIOL & MOL IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; RIKEN,INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; University of Tokyo; RIKEN			Hattori, Mitsuharu/F-3859-2010; Matsuzawa, Atsushi/GLU-1387-2022	Hattori, Mitsuharu/0000-0002-0503-4969; Aoki, Junken/0000-0001-9435-1896; Matsuzawa, Atsushi/0000-0001-8303-3905				ADACHI H, 1995, BIOCHEM BIOPH RES CO, V214, P180, DOI 10.1006/bbrc.1995.2272; BLANK ML, 1981, J BIOL CHEM, V256, P175; DAHL CA, 1992, J IMMUNOL, V148, P597; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; EVANS TW, 1987, J APPL PHYSIOL, V63, P479, DOI 10.1152/jappl.1987.63.2.479; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; FEUERSTEIN G, 1983, AM J PHYSIOL, V246, P466; GLENDE EA, 1987, BIOCHEM PHARMACOL, V35, P3301; Grunstein M, 1979, Methods Enzymol, V68, P379; GUAN YH, 1995, J BIOL CHEM, V270, P5412, DOI 10.1074/jbc.270.10.5412; HANAHAN DJ, 1986, ANNREV BIOCH, V55, P43; HATTORI K, 1995, J BIOL CHEM, V270, P22308, DOI 10.1074/jbc.270.38.22308; Hattori M, 1995, J BIOL CHEM, V270, P31345, DOI 10.1074/jbc.270.52.31345; HATTORI M, 1993, J BIOL CHEM, V268, P18748; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; IMAIZUMI TA, 1995, J INTERN MED, V238, P5, DOI 10.1111/j.1365-2796.1995.tb00894.x; ISOLA NR, 1991, BIOTECHNIQUES, V11, P580; Izumi T, 1995, BBA-LIPID LIPID MET, V1259, P317, DOI 10.1016/0005-2760(95)00171-9; KWIATKOWSKI TJ, 1990, NUCLEIC ACIDS RES, V18, P7191, DOI 10.1093/nar/18.23.7191; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASUGI F, 1982, BIOCHEM BIOPH RES CO, V104, P280, DOI 10.1016/0006-291X(82)91971-4; MCINTYRE TM, 1985, J CLIN INVEST, V76, P271, DOI 10.1172/JCI111957; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; ODONNELL SR, 1987, EUR J PHARMACOL, V138, P385, DOI 10.1016/0014-2999(87)90477-8; PRESCOTT SM, 1984, P NATL ACAD SCI-BIOL, V81, P3534, DOI 10.1073/pnas.81.11.3534; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEVANIAN A, 1983, ARCH BIOCHEM BIOPHYS, V223, P441, DOI 10.1016/0003-9861(83)90608-2; SHIMIZU T, 1992, BIOCHEM PHARMACOL, V44, P1001; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SISSON JH, 1987, J IMMUNOL, V138, P3918; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; SNYDER F, 1995, BBA-LIPID LIPID MET, V1254, P231, DOI 10.1016/0005-2760(94)00192-2; SNYDER F, 1987, PLATELET ACTIVATING; SPITZ M, 1986, METHOD ENZYMOL, V121, P33; Stafforini DM, 1996, BBA-LIPID LIPID MET, V1301, P161, DOI 10.1016/0005-2760(96)00040-9; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215; STAFFORINI DM, 1987, J BIOL CHEM, V262, P4222; STEINBRECHER UP, 1989, J LIPID RES, V30, P305; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; STREMLER KE, 1989, J BIOL CHEM, V264, P5331; STREMLER KE, 1991, J BIOL CHEM, V266, P11095; TAMATANI T, 1990, INT IMMUNOL, V2, P165, DOI 10.1093/intimm/2.2.165; TAN KH, 1984, BIOCHEM J, V220, P243, DOI 10.1042/bj2200243; TASUDA M, 1977, JPN J PHARMACOL, V27, P429; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOUQUI L, 1985, BIOCHEM J, V229, P811, DOI 10.1042/bj2290811; UNGEMACH FR, 1987, CHEM PHYS LIPIDS, V45, P171, DOI 10.1016/0009-3084(87)90065-X; VOORN LVD, 1992, FEBS LETT, V307, P131	51	100	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33032	33038		10.1074/jbc.271.51.33032	http://dx.doi.org/10.1074/jbc.271.51.33032			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955149	hybrid			2022-12-25	WOS:A1996VZ37300084
J	Ivanchenko, M; Hassan, A; vanHolde, K; Zlatanova, J				Ivanchenko, M; Hassan, A; vanHolde, K; Zlatanova, J			H1 binding unwinds DNA - Evidence from topological assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED CIRCULAR DNA; TOPOISOMERASE-I; SUPERCOILED DNA; JUNCTION DNA; HISTONES H1; NUCLEOSOMES; SUPERHELICITY; ASSOCIATION; PROTEINS; DOMAINS	The preference of the linker histones to bind to superhelical DNA in comparison with linear or relaxed molecules suggests that these proteins might, in turn, change the twist and/or writhe of DNA molecules upon binding. In order to explore such a possibility, we looked for changes in the linking number of plasmid pBR322 caused by H1 binding, using assays that involve nicking and resealing of DNA strands. Two types of enzymes were used, eukaryotic topoisomerase I and prokaryotic DNA ligase. The results revealed that H1 binding causes unwinding of the DNA, with the unwinding angle being approximately 10 degrees. The globular domain of histone H1 is also capable of unwinding DNA, but to a lesser degree.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; BULGARIAN ACAD SCI,INST GENET,BU-1113 SOFIA,BULGARIA	Oregon State University; Bulgarian Academy of Sciences			Zlatanova, Jordanka/B-3273-2009	Al-Marzouqi, Ahmed/0000-0003-4586-5676	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050276] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50276] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANCHEV T, 1991, BIOCHIM BIOPHYS ACTA, V1073, P230, DOI 10.1016/0304-4165(91)90208-X; BINASTEIN M, 1977, NUCLEIC ACIDS RES, V4, P117, DOI 10.1093/nar/4.1.117; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DEPEW RE, 1975, P NATL ACAD SCI USA, V72, P4275, DOI 10.1073/pnas.72.11.4275; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; Ivanchenko M, 1996, P NATL ACAD SCI USA, V93, P6970, DOI 10.1073/pnas.93.14.6970; IVANCHENKO M, 1996, IN PRESS ELECTROPHOR; JAVAHERIAN K, 1983, NUCLEIC ACIDS RES, V11, P461, DOI 10.1093/nar/11.2.461; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MORSE RH, 1986, NUCLEIC ACIDS RES, V14, P3293, DOI 10.1093/nar/14.8.3293; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; PULLEYBLANK DE, 1975, P NATL ACAD SCI USA, V72, P4280, DOI 10.1073/pnas.72.11.4280; Ray E, 1996, BIOCHEM BIOPH RES CO, V222, P512, DOI 10.1006/bbrc.1996.0775; RICHTER A, 1991, FEBS LETT, V294, P125, DOI 10.1016/0014-5793(91)81357-E; SHEFLIN LG, 1993, BIOCHEMISTRY-US, V32, P3238, DOI 10.1021/bi00064a005; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; STEIN A, 1980, NUCLEIC ACIDS RES, V8, P4803, DOI 10.1093/nar/8.20.4803; TURNA J, 1994, FOLIA MICROBIOL, V39, P105, DOI 10.1007/BF02906803; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; VARGAWEISZ P, 1994, P NATL ACAD SCI USA, V91, P3525, DOI 10.1073/pnas.91.9.3525; VOGEL T, 1976, J BIOL CHEM, V251, P2334; VOGEL T, 1975, P NATL ACAD SCI USA, V72, P2597, DOI 10.1073/pnas.72.7.2597; WATANABE F, 1986, NUCLEIC ACIDS RES, V14, P3573, DOI 10.1093/nar/14.8.3573; ZLATANOVA J, 1995, BIOL STRUCTURE DYNAM, V1, P173	29	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32580	32585		10.1074/jbc.271.51.32580	http://dx.doi.org/10.1074/jbc.271.51.32580			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955084	hybrid			2022-12-25	WOS:A1996VZ37300019
J	Lounsbury, KM; Richards, SA; Carey, KL; Macara, IG				Lounsbury, KM; Richards, SA; Carey, KL; Macara, IG			Mutations within the Ran/TC4 GTPase - Effects on regulatory factor interactions and subcellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN IMPORT; ACTIVATING PROTEIN; CELL-CYCLE; CHROMOSOME CONDENSATION; BINDING DOMAIN; RCC1 PROTEIN; BOUND FORM; RAN; TRANSPORT; RANGAP1	Ran, a member of the Ras superfamily of GTPases, is predominantly localized in the nucleus and is a necessary component in the active transport of proteins through nuclear pores. Disruption of Ran function affects the regulation of mitosis, DNA synthesis, and RNA processing and export. To explore the mechanisms of Ran function, mutants of the Ran GTPase were characterized, several of which are capable of dominantly interfering with nuclear protein import, Unlike wild-type Ran, the putative gain-of-function mutant (G19V Ran) was not sensitive to the exchange factor, RCC1. In addition the G19V Ran and effector domain mutants (L43E and E46G Ran) were not sensitive to the GTPase-activating protein, Fug1. Epitope-tagged G19V Ran and L43E Ran isolated from transfected BHK21 cells were each about 50% GTP-bound, whereas the wild-type and a C-terminal deletion mutant (Delta-DE Ran) were primarily bound to GDP. While G19V Ran interacted with known Ran-binding proteins and with an isolated Ran-binding domain, the T24N Ran did not, and binding by L43E Ran was substantially reduced. Wild-type HA1-tagged Ran expressed in BHK21 cells was nuclear, whereas the G19V, T24N, L43E, and E46G forms of Ran were predominantly localized at the nuclear envelope, and Delta-DE Ran was primarily cytosolic. Similar results were observed when permeabilized BHK21 cells were incubated with extracts of COS cells expressing the mutants. Thus mutations that affect the interaction of Ran with regulatory proteins and effecters can disrupt the normal subcellular localization of Ran, lending support for the current model of Ran-mediated nuclear import.	UNIV VERMONT,CTR COMPREHENS CANC,BURLINGTON,VT 05405	University of Vermont	Lounsbury, KM (corresponding author), UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405, USA.			Carey, Kimberly/0000-0002-0836-8710	NCI NIH HHS [F32CA63801] Funding Source: Medline; NIEHS NIH HHS [EST3207122] Funding Source: Medline; NIGMS NIH HHS [GM50526] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA063801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BURSTEIN ES, 1993, J BIOL CHEM, V268, P22247; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; MELCHIOR F, 1995, J CELL BIOL, V131, P571, DOI 10.1083/jcb.131.3.571; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; Nehrbass U, 1996, SCIENCE, V272, P120, DOI 10.1126/science.272.5258.120; NOVICK P, 1993, CIBA F SYMP, V176, P218; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; REN MD, 1995, MOL CELL BIOL, V15, P2117; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SAITOH H, 1995, J BIOL CHEM, V270, P10658, DOI 10.1074/jbc.270.18.10658; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	44	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32834	32841		10.1074/jbc.271.51.32834	http://dx.doi.org/10.1074/jbc.271.51.32834			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955121	hybrid			2022-12-25	WOS:A1996VZ37300056
J	Thompson, CB; McDonough, AA				Thompson, CB; McDonough, AA			Skeletal muscle Na,K-ATPase alpha and beta subunit protein levels respond to hypokalemic challenge with isoform and muscle type specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+-K+-ATPASE; RAT; EXPRESSION; ALPHA-2-SUBUNIT; DEPLETION; DECREASES; DIAPHRAGM; HINDLIMB; ABSENCE; HEART	During potassium deprivation, skeletal muscle loses K+ to buffer the fall in extracellular K+. Decreased active K+ uptake via the sodium pump, Na,K-ATPase, contributes to the adjustment. Skeletal muscle expresses alpha 1, alpha 2, beta 1, and beta 2 isoforms of the Na,K-ATPase cup heterodimer. This study was directed at testing the hypothesis that K+ loss from muscle during K+ deprivation is a function of decreased expression of specific isoforms expressed in a muscle type-specific pattern. Isoform abundance was measured in soleus, red and white gastrocnemius, extensor digitorum longus, and diaphragm by immunoblot. alpha 2 expression was uniform across control muscles, whereas alpha 1 and beta 1 were twice as high in oxidative (soleus and diaphragm) as in fast glycolytic (white gastrocnemius) muscles, and beta 2 expression was reciprocal: highest in white gastrocnemius and barely detectable in soleus and diaphragm, Following 10 days of potassium deprivation plasma K+ fell from 4.0 to 2.3 mM, and there were distinct responses in glycolytic versus oxidative muscles, In glycolytic white gastrocnemius alpha 2 and beta 2 fell 94 and 70%, respectively; in mixed red gastrocnemius and extensor digitorum longus both fell 60%, and beta 1 fell 25%. In oxidative soleus and diaphragm alpha 2 fell 55 and 30%, respectively, with only minor changes in beta 1. Although decreases in alpha 2 and beta 2 expression are much greater in glycolytic than oxidative muscles during K+ deprivation, both types of muscle lose tissue K+ to the same extent, a 20% decrease, suggesting that multiple mechanisms are in place to regulate the release of skeletal muscle cell K+.	UNIV SO CALIF,SCH MED,DEPT PHYSIOL & BIOPHYS,LOS ANGELES,CA 90033	University of Southern California					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034316] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34316] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARIANO MA, 1973, J HISTOCHEM CYTOCHEM, V21, P51, DOI 10.1177/21.1.51; ARMSTRONG RB, 1984, AM J ANAT, V171, P259, DOI 10.1002/aja.1001710303; AZUMA KK, 1991, AM J PHYSIOL, V260, pC958, DOI 10.1152/ajpcell.1991.260.5.C958; AZUMA KK, 1993, AM J PHYSIOL, V265, pC680, DOI 10.1152/ajpcell.1993.265.3.C680; CLAUSEN T, 1989, KIDNEY INT, V35, P1, DOI 10.1038/ki.1989.1; FAMBROUGH DM, 1994, AM J PHYSIOL, V266, pC579, DOI 10.1152/ajpcell.1994.266.3.C579; GLOOR S, 1987, J CELL BIOL, V104, P1587; GONZALEZMARTINEZ LM, 1994, BIOL CELL, V81, P215, DOI 10.1016/0248-4900(94)90003-5; HSU YM, 1991, J BIOL CHEM, V266, P427; HUNDAL HS, 1992, J BIOL CHEM, V267, P5040; HUNDAL HS, 1983, FEBS LETT, V328, P253; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KASHGARIAN M, 1985, KIDNEY INT, V28, P899, DOI 10.1038/ki.1985.216; KJELDSEN K, 1986, PFLUG ARCH EUR J PHY, V406, P529, DOI 10.1007/BF00583377; KNUDSON CM, 1989, J BIOL CHEM, V264, P1345; Lavoie L, 1996, AM J PHYSIOL-CELL PH, V270, pC1421, DOI 10.1152/ajpcell.1996.270.5.C1421; LINGREL JB, 1994, J BIOL CHEM, V269, P19569; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGYAR CE, 1995, AM J PHYSIOL-CELL PH, V269, pC675, DOI 10.1152/ajpcell.1995.269.3.C675; MARXER A, 1989, J CELL BIOL, V109, P1057, DOI 10.1083/jcb.109.3.1057; MCDONOUGH AA, 1992, ANN NY ACAD SCI, V671, P156; McDonough AA, 1996, ACTA PHYSIOL SCAND, V156, P295, DOI 10.1046/j.1365-201X.1996.194000.x; METZGER JM, 1985, J APPL PHYSIOL, V58, P1085, DOI 10.1152/jappl.1985.58.4.1085; NORGAARD A, 1981, NATURE, V293, P739, DOI 10.1038/293739a0; NORGAARD A, 1985, EUR J PHARMACOL, V113, P373, DOI 10.1016/0014-2999(85)90085-8; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; PRESSLEY TA, 1992, AM J PHYSIOL, V262, pC743, DOI 10.1152/ajpcell.1992.262.3.C743; SELDIN DW, 1989, REGULATION POTASSIUM; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHYJAN AW, 1989, BIOCHEMISTRY-US, V28, P4531, DOI 10.1021/bi00437a002; SIECK GC, 1987, J APPL PHYSIOL, V63, P1076, DOI 10.1152/jappl.1987.63.3.1076; SWEADNER KJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P185, DOI 10.1016/0304-4157(89)90019-1; Talmadge Robert J., 1993, Current Opinion in Rheumatology, V5, P695; URAYAMA O, 1989, J BIOL CHEM, V264, P8271	36	63	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32653	32658		10.1074/jbc.271.51.32653	http://dx.doi.org/10.1074/jbc.271.51.32653			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955095	hybrid			2022-12-25	WOS:A1996VZ37300030
J	Wolf, DA; Wu, D; McKeon, F				Wolf, DA; Wu, D; McKeon, F			Disruption of re-replication control by overexpression of human ORC1 in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; S-PHASE; SACCHAROMYCES-CEREVISIAE; INITIATION; COMPLEX; MITOSIS; GENE; RECOGNITION; ORIGINS; ALPHA	Initiation of DNA replication in Saccharomyces cerevisiae requires the binding of the origin recognition complex (ORC) to autonomously replicating sequences. Hs-ORC1, a recently identified human protein related to yeast Orc1p and Cdc6p/Cdc18p, may be a component of the replication initiation complex in human cells. We have independently isolated the gene for HsORC1 and begun to address its function in eukaryotic DNA replication and its relationship to Cdc18p. Although HsORC1 failed to rescue the temperature-sensitive S. pombe cdc18-K46 strain, overexpression in a wild-type strain led to continuous DNA synthesis in the absence of mitosis. Deletion mutagenesis identified a short N-terminal region of HsORC1 that contains potential phosphorylation sites for cyclin-dependent kinase (CDK) as being sufficient to induce re-replication. In addition, we found that HsORC1 is an efficient substrate for CDKs in vitro. We propose that perturbation of the re-replication control by overexpression of HsORC1 is due to a titration of components involved in inactivating Cdc18p upon initiation of replication.	HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School			Wolf, Dieter/AAE-5890-2021	Wolf, Dieter/0000-0002-3761-1070				BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAVO R, 1985, EMBO J, V4, P655, DOI 10.1002/j.1460-2075.1985.tb03679.x; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Jallepalli PV, 1996, GENE DEV, V10, P541, DOI 10.1101/gad.10.5.541; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MuziFalconi M, 1995, P NATL ACAD SCI USA, V92, P12475, DOI 10.1073/pnas.92.26.12475; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; NAKAMURA H, 1984, EXP CELL RES, V151, P123, DOI 10.1016/0014-4827(84)90362-8; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZWERSCHKE W, 1994, J BIOL CHEM, V269, P23351	26	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32503	32506		10.1074/jbc.271.51.32503	http://dx.doi.org/10.1074/jbc.271.51.32503			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955071	hybrid			2022-12-25	WOS:A1996VZ37300006
J	Good, L; Maggirwar, SB; Harhaj, EW; Sun, SC				Good, L; Maggirwar, SB; Harhaj, EW; Sun, SC			Constitutive dephosphorylation and activation of a member of the nuclear factor of activated T cells, NF-AT1, in tax-expressing and type I human T-cell leukemia virus-infected human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN CORD LEUKOCYTES; HTLV-I; IMMUNOSUPPRESSIVE DRUGS; MOLECULE CD28; C-REL; GENE; FAMILY; TRANSCRIPTION; RETROVIRUS	The tax gene product of the type I human T-cell leukemia virus (HTLV-I) transactivates interleukin-2 (IL-2) gene through activation of an enhancer termed CD28 responsive element (CD28RE). Tax activation of the CD28RE is partially mediated by a member of the nuclear factor of activated T cells, NF-AT1. We have previously shown that NF-AT1 is constitutively active in Jurkat T cells stably transfected with the Tax cDNA, although the underlying molecular mechanism and physiological relevance of this finding remain unclear. In this report, we demonstrate that the active form of NF-AT1 is also present in the nuclei of HTLV-I-transformed T cells that express the Tax protein. Interestingly, the constitutive activation of NF-AT1 in these T cells is associated with its dephosphorylation. Furthermore, the dephosphorylated NF-AT1 can be rapidly re-phosphorylated when the cells are incubated with cyclosporin A, an immunosuppressant inhibiting the serine/threonine phosphatase calcineurin. These results suggest that activation of NF-AT1 in Tax-expressing and HTLV-I-transformed T cells results from its dephosphorylation, which in turn may be due to deregulation of calcineurin.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NCI NIH HHS [R01 CA68471-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1990, MOL ASPECTS CELLULAR, P409; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD D W, 1989, New Biologist, V1, P83; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1054; Curtiss VE, 1996, MOL CELL BIOL, V16, P3567; FRANCHINI G, 1984, P NATL ACAD SCI-BIOL, V81, P6207, DOI 10.1073/pnas.81.19.6207; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GAZDAR AF, 1980, BLOOD, V55, P409; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Good LF, 1996, EMBO J, V15, P3744, DOI 10.1002/j.1460-2075.1996.tb00744.x; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; HIMES SR, 1996, J VIROL, V70, P401; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V365, P352; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Loh C, 1996, MOL CELL BIOL, V16, P3945; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MIYOSHI I, 1981, GANN, V72, P978; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SALAHUDDIN SZ, 1983, VIROLOGY, V129, P51, DOI 10.1016/0042-6822(83)90395-1; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; Wesselborg S, 1996, J BIOL CHEM, V271, P1274, DOI 10.1074/jbc.271.3.1274; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031	52	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1425	1428		10.1074/jbc.272.3.1425	http://dx.doi.org/10.1074/jbc.272.3.1425			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999806	hybrid			2022-12-25	WOS:A1997WD05800004
J	Inocencio, NM; Sucic, JF; Moehring, JM; Spence, MJ; Moehring, TJ				Inocencio, NM; Sucic, JF; Moehring, JM; Spence, MJ; Moehring, TJ			Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-K1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PSEUDOMONAS EXOTOXIN-A; IDENTICAL SUBSTRATE-SPECIFICITY; KEX2-LIKE ENDOPROTEASE; MEDIATED CLEAVAGE; MOUSE FURIN; IDENTIFICATION; EXPRESSION; PROTEASE; GENE	We addressed the question of whether furin is the endoprotease primarily responsible for processing the human immunodeficiency virus type I (HIV-I) envelope protein gp160 in mammalian cells. The furin-deficient Chinese hamster ovary (CHO)-K1 strain RPE.40 processed gp160 as efficiently as wild-type CHO-K1 cells in vivo. Although furin can process gp160 in vitro, this processing is probably not physiologically relevent, because it occurs with very low efficiency. PACE4, a furin homologue, allowed processing of gp160 when both were expressed in RPE.40 cells. Further, PACE4 participated in the activation of a calcium-independent protease activity in RPE.40 cells, which efficiently processed the gp160 precursor in vitro. This calcium independent protease activity was not found in another furin-deficient cell strain, 7.P15, selected from the monkey kidney cell line COS-7.	UNIV VERMONT,DEPT MICROBIOL & MOL GENET,MARKEY CTR MOL GENET,BURLINGTON,VT 05405; UNIV VERMONT,VERMONT CANC CTR,BURLINGTON,VT 05405	University of Vermont; University of Vermont								BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; CREEMERS JWM, 1993, FEBS LETT, V336, P65, DOI 10.1016/0014-5793(93)81610-C; DECROLY E, 1994, J BIOL CHEM, V269, P12240; DEWAR RL, 1989, J VIROL, V63, P2452, DOI 10.1128/JVI.63.6.2452-2456.1989; DEWAR RL, 1989, J VIROL, V63, P129, DOI 10.1128/JVI.63.1.129-136.1989; GU ML, 1995, FEBS LETT, V365, P95, DOI 10.1016/0014-5793(95)00447-H; HAKES DJ, 1991, ENDOCRINOLOGY, V129, P3053, DOI 10.1210/endo-129-6-3053; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; HOSAKA M, 1994, BIOMED RES-TOKYO, V15, P383, DOI 10.2220/biomedres.15.383; INOCENCIO NM, 1994, J BIOL CHEM, V269, P31831; INOCENCIO NM, 1992, J VIROL, V67, P593; KIDO H, 1993, J BIOL CHEM, V268, P13406; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; MCCUNE JM, 1988, CELL, V53, P55, DOI 10.1016/0092-8674(88)90487-4; MOEHRING JM, 1983, INFECT IMMUN, V41, P998, DOI 10.1128/IAI.41.3.998-1009.1983; MOEHRING JM, 1993, J BIOL CHEM, V268, P2590; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; NAGAI Y, 1989, BEHRING I MITT, V89, P35; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; ODA K, 1992, J BIOL CHEM, V267, P17465; OGATA M, 1992, J BIOL CHEM, V267, P25396; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; REHEMTULLA A, 1993, BIOCHEMISTRY-US, V32, P11586, DOI 10.1021/bi00094a015; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; STEINER DF, 1992, J BIOL CHEM, V267, P23435; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; WATSON DG, 1991, J VIROL, V65, P2332, DOI 10.1128/JVI.65.5.2332-2339.1991; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071	35	39	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1344	1348		10.1074/jbc.272.2.1344	http://dx.doi.org/10.1074/jbc.272.2.1344			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995442	hybrid			2022-12-25	WOS:A1997WC04800093
J	Smith, MD; Dawson, SJ; Latchman, DS				Smith, MD; Dawson, SJ; Latchman, DS			Inhibition of neuronal process outgrowth and neuronal specific gene activation by the Brn-3b transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POU-DOMAIN; CELL-LINES; FAMILY; PROTEIN; EXPRESSION; PROMOTER; SNAP-25; DIFFERENTIATION; DISTINCT; ACID	The differentiation of the ND7 neuronal cell line to a nondividing phenotype bearing numerous neurite processes is accompanied by a dramatic increase in the levels of the activating POU family transcription factor Brn-3a and a corresponding fall in the levels of the closely related inhibitory factor Bm-Sb. We have previously shown that the artificial overexpression of Brn-3a in these cells can induce neurite outgrowth and the activation of genes encoding synaptic vesicle proteins in the absence of a differentiation-inducing stimulus. Here we show that overexpression of Brn-3b can reduce process outgrowth and synaptic vesicle gene expression following exposure to a stimulus which would normally induce differentiation. These inhibitory effects are abolished by altering a single amino acid in the POU homeodomain of Bm-Sb to its equivalent in Brn-3a. The converse mutation in Brn-3a allows it to inhibit process outgrowth in response to a differentiation-inducing stimulus. Hence a single amino acid difference results in these closely related factors having opposite effects and allows the balance between them to regulate differentiation.	UNIV COLL & MIDDLESEX SCH MED, DEPT MOL PATHOL, MED MOL BIOL UNIT, LONDON W1P 6DB, ENGLAND	University of London; University College London				Dawson, Sally/0000-0002-4421-2043				BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dawson SJ, 1996, BIOCHEM J, V314, P439, DOI 10.1042/bj3140439; Dawson SJ, 1996, J BIOL CHEM, V271, P11631, DOI 10.1074/jbc.271.20.11631; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; LAKIN ND, 1995, J BIOL CHEM, V270, P15858, DOI 10.1074/jbc.270.26.15858; Latchman DS, 1996, INT J BIOCHEM CELL B, V28, P965, DOI 10.1016/1357-2725(96)00039-8; LATCHMAN DS, 1995, EUKARYOTIC TRANSCRIP; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; MILTON NGN, 1995, J BIOL CHEM, V270, P15143, DOI 10.1074/jbc.270.25.15143; Milton NGN, 1996, BIOCHEM J, V317, P419, DOI 10.1042/bj3170419; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; MORRIS PJ, 1996, IN PRESS MOL BRAIN R; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; SMITH MD, 1996, IN PRESS MOL CELL BI; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; [No title captured]	33	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1382	1388		10.1074/jbc.272.2.1382	http://dx.doi.org/10.1074/jbc.272.2.1382			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995448	hybrid			2022-12-25	WOS:A1997WC04800099
J	Elnitski, L; Miller, W; Hardison, R				Elnitski, L; Miller, W; Hardison, R			Conserved E boxes function as part of the enhancer in hypersensitive site 2 of the beta-globin locus control region - Role of basic helix-loop-helix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; PHYLOGENETIC FOOTPRINTING REVEALS; TRANSCRIPTION FACTOR NF-E2; LEUCINE ZIPPER PROTEIN; TRANSGENIC MICE; ERYTHROID-DIFFERENTIATION; GENE-EXPRESSION; ERYTHROLEUKEMIA-CELLS; CHROMATIN STRUCTURE; ACTIVATION REGION	The human beta-globin gene cluster is regulated in part by a distal locus control region that is required for opening a chromatin domain in erythroid cells and enhancing expression of the beta-like globin genes at the correct developmental stages. One part of the locus control region, called hypersensitive site 2 (HS2), functions as a strong enhancer. Matches to the consensus binding sites for basic helix-loop-helix (bHLH) proteins (E boxes) are well conserved within the HS2 core. We show that mutations of the HS2 core that alter an invariant E box cause a 3.5-fold reduction in enhancement of expression of an E-globin reporter gene in transiently transfected K562 cells, both before and after induction. Mutations of the HS2 core that alter a less-highly conserved E box cause a more modest reduction in enhancement. Footprint analysis shows binding of erythroid nuclear proteins in vitro to the invariant E box as well as an adjacent CAC/GTG box. Probes containing the E box regions form sequence-specific complexes with proteins from both K562 and MEL nuclear extracts; these are disrupted by the same mutations that decrease enhancement, Some of these latter complexes contain known bHLH proteins, as revealed by specific loss of individual complexes when treated with antibodies against TAL1 and USF. Interaction between the E boxes and the bHLH proteins, as well as other binding proteins, could account for the role of these sites in enhancement by HS2.	PENN STATE UNIV, DEPT BIOCHEM & MOL BIOL, ALTHOUSE LAB 206, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, DEPT COMP SCI & ENGN, UNIVERSITY PK, PA 16802 USA; PENN STATE UNIV, CTR GENE REGULAT, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park			Hardison, Ross C/G-1142-2010; Elnitski, Laura/AAD-3595-2021	Hardison, Ross C/0000-0003-4084-7516; Elnitski, Laura/0000-0003-1065-019X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027635] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM005773, R01LM005110] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK27635] Funding Source: Medline; NLM NIH HHS [R01 LM05110, R01 LM05773] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; Chao K M, 1994, J Comput Biol, V1, P271, DOI 10.1089/cmb.1994.1.271; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DHAR V, 1990, MOL CELL BIOL, V10, P4324, DOI 10.1128/MCB.10.8.4324; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, PHILOS T ROY SOC B, V339, P183, DOI 10.1098/rstb.1993.0015; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; Gumucio DL, 1996, MOL PHYLOGENET EVOL, V5, P18, DOI 10.1006/mpev.1996.0004; GUMUCIO DL, 1991, JH S CONT M, P277; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HARDISON R, 1993, DNA SEQUENCE, V4, P163, DOI 10.3109/10425179309015629; HARDISON R, 1995, MOL BIOL HEMOGLOBIN, P405; HARDISON RC, 1997, TRANSGENIC SWINE HUN; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; Jackson JD, 1996, J BIOL CHEM, V271, P11871, DOI 10.1074/jbc.271.20.11871; Jackson JD, 1996, NUCLEIC ACIDS RES, V24, P4327, DOI 10.1093/nar/24.21.4327; LAM L, 1996, J BIOL CHEM, V270, pR30; LI QL, 1990, P NATL ACAD SCI USA, V87, P8207, DOI 10.1073/pnas.87.21.8207; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; Miller J.H., 1972, EXPT MOL GENETICS; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; MOON AM, 1991, BLOOD, V77, P2272; MOON AM, 1990, P NATL ACAD SCI USA, V87, P7693, DOI 10.1073/pnas.87.19.7693; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; OSADA H, 1995, P NATL ACAD SCI USA, V92, P9585, DOI 10.1073/pnas.92.21.9585; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REDDY PMS, 1993, MOL CELL BIOL, V13, P1093, DOI 10.1128/MCB.13.2.1093; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SLIGHTOM J, 1997, IN PRESS GENOMICS, V39; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; THOMPSON JP, 1991, J BIOL CHEM, V266, P2549; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VISVADER J, 1991, ONCOGENE, V6, P187; YANT SR, 1995, NUCLEIC ACIDS RES, V23, P4353, DOI 10.1093/nar/23.21.4353; Yoo J, 1996, BLOOD, V87, P2558, DOI 10.1182/blood.V87.6.2558.bloodjournal8762558; [No title captured]	68	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					369	378						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995271				2022-12-25	WOS:A1997WA56400058
J	Lu, PJ; Chen, CS				Lu, PJ; Chen, CS			Selective recognition of phosphatidylinositol 3,4,5-trisphosphate by a synthetic peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE-BINDING; SIGNAL TRANSDUCTION; 3-KINASE; PHOSPHORYLATION; SEQUENCE; SITE; IDENTIFICATION; TRISPHOSPHATE; NEUROGRANIN	The present study takes a novel approach to explore the mode of action of phosphoinositide 3-kinase lipid products by identifying a synthetic peptide W-NG(28-43) (WAAKIQASFRGHMARKK) that displays discriminative affinity with phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3). This PtdIns(3,4,5)P-3-binding peptide was discovered by a gel filtration-based binding assay and exhibits a high degree of stereochemical selectivity in phosphoinositide recognition. It forms a 1:1 complex with PtdIns(3,4,5)P-3 with K-d of 2 mu M but binds phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) and phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P-2) with substantially lower affinity (5- and 40-fold, respectively) despite the largely shared structural motifs with PtdIns(3,4,5)P-3. Other phospholipids examined, including phosphatidylserine, phosphatidylcholine, phosphatidylinositol, and phosphatidylethanolamine, show low or negligible affinity with the peptide. Several lines of evidence indicate that this phosphoinositide-peptide interaction is not due to nonspecific electrostatic interactions or phospholipid aggregation, and requires a cooperative action among the hydrophobic and basic residues to exert the selective recognition. CD data suggest that the peptide acquires an ordered structure upon binding to PtdIns(3,4,5)P-3. Further, we demonstrate that PtdIns(3,4,5)P-3 enhances the phosphorylation rate of this binding peptide by protein kinase C (PKC)-alpha in a dose-dependent manner. In view of the findings that this stimulatory effect is not noted with other PKC peptide substrates lacking affinity with PtdIns(3,4,5)P-3 and that PKC-alpha is not susceptible to PtdIns(3,4,5)P-3 activation, the activity enhancement is thought to result from the substrate concentrating effect of the D-3 phosphoinositide, i.e. the presence of PtdIns(3,4,5)P-3 allows the peptide to bind to the same vesicles/micelles to which PKC is bound. Moreover, it is noteworthy that neurogranin, the full-length protein of W-NG(28-43) and a relevant PKC substrate in the forebrain, binds PtdIns(3,4,5)P-3 with high affinity. Taken together, it is plausible that, in addition to PKC activation, PtdIns(3,4,5)P-3 provides an alternative mechanism to regulate PRC activity in vivo by recruiting and concentrating its target proteins at the interface to facilitate the subsequent PKC phosphorylation.	UNIV KENTUCKY,COLL PHARM,DIV MED CHEM & PHARMACEUT,ASTECC FACIL,LEXINGTON,KY 40506	University of Kentucky					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM047916] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47916] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUDIER J, 1991, J BIOL CHEM, V266, P229; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; COUGHLIN SR, 1989, SCIENCE, V243, P1191; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; EBERLE M, 1990, J BIOL CHEM, V265, P16725; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukami K, 1996, J BIOL CHEM, V271, P2646, DOI 10.1074/jbc.271.5.2646; GERENDASY DD, 1994, J MOL NEUROSCI, V5, P133, DOI 10.1007/BF02736729; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; JANMEY PA, 1992, J BIOL CHEM, V267, P11818; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; LU PJ, 1994, BIOCHEMISTRY-US, V33, P11586, DOI 10.1021/bi00204a021; MAHONEY CW, 1995, BIOCHEMISTRY-US, V34, P3446, DOI 10.1021/bi00010a037; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SIMOES AP, 1995, BIOCHEMISTRY-US, V34, P5113, DOI 10.1021/bi00015a023; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WENNSTROM S, 1994, ONCOGENE, V9, P651; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1992, J BIOL CHEM, V267, P14616	35	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					466	472						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995284				2022-12-25	WOS:A1997WA56400071
J	Robertson, MA; Woodside, M; Foskett, JK; Orlowski, J; Grinstein, S				Robertson, MA; Woodside, M; Foskett, JK; Orlowski, J; Grinstein, S			Muscarinic agonists induce phosphorylation-independent activation of the NHE-1 isoform of the Na+/H+ antiporter in salivary acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; MOLECULAR-CLONING; FUNCTIONAL EXPRESSION; TRANSPORT MECHANISMS; INTRACELLULAR PH; PAROTID ACINI; SECRETION; CALCIUM; INHIBITOR; PROTEINS	Cholinergic agonists stimulate isotonic fluid secretion in the parotid gland. This process is driven by the apical exit of Cl-, which enters the cells partly via Cl-/HCO3- exchange across the basolateral membrane. Acidification of the cytosol by the extrusion of HCO3- is prevented by the concomitant activation of the Na+/H+ exchanger (NHE), which is directly activated by cholinergic stimulation. Multiple isoforms of the NHE have been described in mammalian cells, but the particular isoform(s) present in salivary glands and their mechanism of activation have not been defined. Reverse transcriptase-polymerase chain reaction with isoform-specific primers was used to establish that NHE-1 and NHE-2, but not NHE-3 or NHE-4, are expressed in parotid glands. The presence of NHE-1 was confirmed by immunoblotting and immunofluorescence, which additionally demonstrated that this isoform is abundant in the basolateral membrane of acinar cells. The predominant role of NHE-1 in carbachol-induced Na+/H+ exchange was established pharmacologically using HOE694, an inhibitor with differential potency toward the individual isoforms. Because muscarinic agonists induce stimulation of protein kinases in acinar cells, we assessed the role of phosphorylation in the activation of the antiport. Immunoprecipitation experiments revealed that, although NHE-1 was phosphorylated in the resting state, no further phosphorylation occurred upon treatment with carbachol. Similar phosphopeptide patterns were observed in control and carbachol-treated samples. Together, these findings indicate that NHE-1, the predominant isoform of the antiporter in the basolateral membrane of acinar cells, is activated during muscarinic stimulation by a phosphorylation-independent event. Other processes, such as association of Ca2+-calmodulin complexes to the cytosolic domain of the antiporter, may be responsible for the activation of Na+/H+ exchange.	HOSP SICK CHILDREN,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McGill University			Foskett, Kevin/R-2549-2019	Orlowski, John/0000-0001-7371-175X; Foskett, J. Kevin/0000-0002-8854-0268				BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BURNS KD, 1991, AM J PHYSIOL, V261, pF607, DOI 10.1152/ajprenal.1991.261.4.F607; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNGMING T, 1993, P NATL ACAD SCI USA, V90, P9110; COHEN ME, 1990, P NATL ACAD SCI USA, V87, P8990, DOI 10.1073/pnas.87.22.8990; COLLINS JF, 1993, P NATL ACAD SCI USA, V90, P3938, DOI 10.1073/pnas.90.9.3938; Cook D. I., 1994, P1061; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; DISSING S, 1990, AM J PHYSIOL, V259, pG1044, DOI 10.1152/ajpgi.1990.259.6.G1044; FOSKETT JK, 1988, AM J PHYSIOL, V255, pC566, DOI 10.1152/ajpcell.1988.255.4.C566; FOSKETT JK, 1989, SCIENCE, V244, P1582, DOI 10.1126/science.2500708; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRINSTEIN S, 1985, J GEN PHYSIOL, V85, P765, DOI 10.1085/jgp.85.5.765; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LAU KR, 1989, AM J PHYSIOL, V256, pC288, DOI 10.1152/ajpcell.1989.256.2.C288; LEE SI, 1991, AM J PHYSIOL, V261, pG111, DOI 10.1152/ajpgi.1991.261.1.G111; MANGANEL M, 1989, J MEMBRANE BIOL, V111, P191, DOI 10.1007/BF01871782; MANGANEL M, 1990, J BIOL CHEM, V265, P4284; MELVIN JE, 1988, J BIOL CHEM, V263, P19564; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PIRANI D, 1987, PFLUG ARCH EUR J PHY, V408, P178, DOI 10.1007/BF00581349; ROBERTSON MA, 1994, AM J PHYSIOL, V267, pC146, DOI 10.1152/ajpcell.1994.267.1.C146; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; TURNER RJ, 1993, CRIT REV ORAL BIOL M, V4, P385, DOI 10.1177/10454411930040031801; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WANG Z, 1993, J BIOL CHEM, V268, P11925; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	34	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					287	294						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995260				2022-12-25	WOS:A1997WA56400047
J	Tikoo, R; CasacciaBonnefil, P; Chao, MV; Koff, A				Tikoo, R; CasacciaBonnefil, P; Chao, MV; Koff, A			Changes in cyclin-dependent kinase 2 and p27(kip1) accompany glial cell differentiation of central glia-4 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTE DEVELOPMENT INVITRO; PROGENITOR-CELL; TGF-BETA; INHIBITOR; SIGNALS; SURVIVAL; ARREST; LINE; G1	The generation of different glial cell types in the central nervous system depends upon a wide variety of proliferative and differentiative signals. Here we report that changes in the levels of cyclin-dependent kinase 2 (CDK2) and the cell cycle inhibitor p27(kip1) accompany the differentiation of central glia-4 (CG-4) progenitor cells to an astrocytic cell phenotype in the presence of fetal calf serum. Although a decrease in CDK2 levels was observed in both oligodendrocyte and astrocyte cells derived from CG-4 cells, a striking increase in the levels of p27 was observed during the differentiation of astrocyte cells. In astrocyte cell extracts, inhibition of CDK2 activity could be overcome with exogenously added cy clin E. Furthermore, depletion of p27 from astrocyte extracts lowered the amount of cyclin E required for CDK2 activation. Taken together, these results suggest that the inhibitory action of p27 upon cyclin E-CDK2 may prevent entry of cells into the S phase and regulate the progression of CG-4 cells toward an astrocytic lineage.	CORNELL UNIV,COLL MED,DEPT NEUROL & NEUROSCI,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021	Cornell University; Memorial Sloan Kettering Cancer Center	Tikoo, R (corresponding author), CORNELL UNIV,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,1300 YORK AVE,NEW YORK,NY 10021, USA.			Chao, Moses/0000-0002-6969-3744; Koff, Andrew/0000-0003-3271-3067	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM052597, R01GM052597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS021072, R01NS021072] Funding Source: NIH RePORTER; NICHD NIH HHS [HD232315] Funding Source: Medline; NIGMS NIH HHS [GM52597] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, DEVELOPMENT, V118, P283; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; KOFF A, 1993, SCIENCE, V260, P536, DOI 10.1126/science.8475385; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LILLIEN LE, 1990, NEURON, V4, P525, DOI 10.1016/0896-6273(90)90110-2; LOUIS JC, 1992, J NEUROSCI RES, V31, P193, DOI 10.1002/jnr.490310125; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TEMPLE S, 1985, NATURE, V313, P223, DOI 10.1038/313223a0; TONTSCH U, 1994, P NATL ACAD SCI USA, V91, P11616, DOI 10.1073/pnas.91.24.11616	16	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					442	447						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995281				2022-12-25	WOS:A1997WA56400068
J	Kovalsky, OI; Grossman, L; Ahn, B				Kovalsky, OI; Grossman, L; Ahn, B			The topodynamics of incision of UV-irradiated covalently closed DNA by the Escherichia coli Uvr(A)BC endonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; UVRABC ENDONUCLEASE; TOPOISOMERASE-I; SUPERCOILED DOMAINS; (A)BC EXCINUCLEASE; MICROCOCCUS-LUTEUS; PROTEIN COMPLEXES; POLYMERASE-I; HELICASE-II; DAMAGED DNA	The Escherichia coli Uvr(A)BC endonuclease (Uvr(A)BC) initiates nucleotide excision repair of a large variety of DNA damages. The damage recognition and incision steps by the Uvr(A)BC is a complex process utilizing an ATP-dependent DNA helix-tracking activity associated with the UvrA(2)B(1) complex. The latter activity leads to the generation of highly positively supercolied DNA in the presence of E. coli topoisomerase I in vitro. Such highly positively supercolied DNA, containing ultraviolet irradiation-induced photoproducts (uvDNA), is resistant to the incision by Uvr(A)BC, whereas the negatively supercolied and relaxed forms of the uvDNA are effectively incised. The E. coli gyrase can contribute to the above reaction by abolishing the accumulation of highly positively supercolied uvDNA thereby restoring Uvr(A)BC-catalyzed incision. Eukaryotic (calf thymus) topoisomerase I is able to substitute for gyrase in restoring this Uvr(A)BC-mediated incision reaction. The inability of Uvr(A)BC to incise highly positively supercolied uvDNA results from the failure of the formation of UvrAB-dependent obligatory intermediates associated with the DNA conformational change. In contrast to Uvr(A)BC, the Micrococcus luteus UV endonuclease efficiently incises uvDNA regardless of its topological state. The in vitro topodynamic system proposed in this study may provide a simple model for studying a topological aspect of nucleotide excision repair and its interaction with other DNA topology related processes in E. coli.			Kovalsky, OI (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOCHEM, 615 N WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022846, R37GM022846] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 22846] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn BC, 1996, J BIOL CHEM, V271, P21462, DOI 10.1074/jbc.271.35.21462; Ahn BC, 1996, J BIOL CHEM, V271, P21453, DOI 10.1074/jbc.271.35.21453; BACKENDORF C, 1989, NUCLEIC ACIDS RES, V17, P10337, DOI 10.1093/nar/17.24.10337; BERTRANDBURGGRAF E, 1991, J MOL BIOL, V219, P27, DOI 10.1016/0022-2836(91)90854-Y; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; CIARROCCHI G, 1982, J MOL BIOL, V155, P177, DOI 10.1016/0022-2836(82)90445-4; CRUMPLIN GC, 1981, CARCINOGENESIS, V2, P157, DOI 10.1093/carcin/2.2.157; FRANKKAMENETSKI.MD, 1990, DNA TOPOLOGY ITS BIO, P185; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P218; GARTENBERG MR, 1992, P NATL ACAD SCI USA, V89, P11461, DOI 10.1073/pnas.89.23.11461; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GRAFSTROM RH, 1982, J BIOL CHEM, V257, P13465; GROSSMAN L, 1993, J BIOL CHEM, V268, P16871; HAYS JB, 1978, P NATL ACAD SCI USA, V75, P4125, DOI 10.1073/pnas.75.9.4125; HIASA H, 1994, J BIOL CHEM, V269, P16371; HIASA H, 1994, J BIOL CHEM, V269, P32655; KOO HS, 1991, P NATL ACAD SCI USA, V88, P1212, DOI 10.1073/pnas.88.4.1212; KOVALSKY OI, 1994, J BIOL CHEM, V269, P27421; KOVALSKY OI, 1990, NUCLEIC ACIDS RES, V18, P2801, DOI 10.1093/nar/18.9.2801; KOZYAVKIN SA, 1990, EUR J BIOCHEM, V191, P105, DOI 10.1111/j.1432-1033.1990.tb19099.x; LIN JJ, 1992, MOL MICROBIOL, V6, P2219, DOI 10.1111/j.1365-2958.1992.tb01398.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; MAZUR SJ, 1991, BIOCHEMISTRY-US, V30, P4432, DOI 10.1021/bi00232a009; MELON I, 1981, NATURE, V342, P95; MUNN MM, 1991, J BIOL CHEM, V266, P24748; OH EY, 1989, NUCLEIC ACIDS RES, V17, P4145, DOI 10.1093/nar/17.11.4145; OH EY, 1986, NUCLEIC ACIDS RES, V14, P8557, DOI 10.1093/nar/14.21.8557; ORREN DK, 1992, J BIOL CHEM, V267, P780; PEDRINI AM, 1983, P NATL ACAD SCI-BIOL, V80, P1787, DOI 10.1073/pnas.80.7.1787; PURDY MA, 1976, ANTIMICROB AGENTS CH, V10, P182, DOI 10.1128/AAC.10.1.182; SELBY CP, 1994, MICROBIOL REV, V58, P317, DOI 10.1128/MMBR.58.3.317-329.1994; SIMON TJ, 1974, BIOCHIM BIOPHYS ACTA, V349, P271, DOI 10.1016/0005-2787(74)90089-6; SNOWDEN A, 1991, J MOL BIOL, V220, P19, DOI 10.1016/0022-2836(91)90378-J; STERNGLANZ R, 1981, P NATL ACAD SCI-BIOL, V78, P2747, DOI 10.1073/pnas.78.5.2747; THIAGALINGAM S, 1993, J BIOL CHEM, V268, P18382; VANHOUTEN B, 1990, MICROBIOL REV, V54, P18, DOI 10.1128/MMBR.54.1.18-51.1990; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WANG JC, 1993, CURR OPIN GENET DEV, V3, P764, DOI 10.1016/S0959-437X(05)80096-6; WANG JC, 1982, COLD SPRING HARB SYM, V47, P85, DOI 10.1101/SQB.1983.047.01.011; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WANG JC, 1992, TRANSCRIPTIONAL REGU, V2, P1253; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P2567, DOI 10.1093/nar/14.6.2567; YEUNG AT, 1986, NUCLEIC ACIDS RES, V14, P8535, DOI 10.1093/nar/14.21.8535	47	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33236	33241		10.1074/jbc.271.52.33236	http://dx.doi.org/10.1074/jbc.271.52.33236			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969181	hybrid			2022-12-25	WOS:A1996WA71300015
J	Minambres, B; MartinezBlanco, H; Olivera, ER; Garcia, B; Diez, B; Barredo, JL; Moreno, MA; Schleissner, C; Salto, F; Luengo, JM				Minambres, B; MartinezBlanco, H; Olivera, ER; Garcia, B; Diez, B; Barredo, JL; Moreno, MA; Schleissner, C; Salto, F; Luengo, JM			Molecular cloning and expression in different microbes of the DNA encoding Pseudomonas putida U phenylacetyl-CoA ligase - Use of this gene to improve the rate of benzylpenicillin biosynthesis in Penicillium chrysogenum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; DIRECT ENZYMATIC-SYNTHESIS; PROTEIN N-MYRISTOYLATION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BIOCHEMICAL-CHARACTERIZATION; SEQUENCE DETERMINATION; FUNCTIONAL EXPRESSION; ACID ACYLTRANSFERASE; ASPERGILLUS-NIDULANS	The gene encoding phenylacetyl-CoA ligase (pcl), the first enzyme of the pathway involved in the aerobic catabolism of phenylacetic acid in Pseudomonas putida U, has been cloned, sequenced, and expressed in two different microbes. In both, the primary structure of the protein was studied, and after genetic manipulation, different recombinant proteins were analyzed. The pcl gene, which was isolated from P. putida U by mutagenesis with the transposon Tn5, encodes a 48-kDa protein corresponding to the phenylacetyl-CoA ligase previously purified by us (Martinez-Blanco, H., Reglero, A. Rodriguez-Aparicio, L. B., and Luengo, J. M. (1990) J. Biol. Chem. 265, 7084-7090). Expression of the pcl gene in Escherichia coli leads to the appearance of this enzymatic activity, and cloning and expression of a 10.5-kb DNA fragment containing this gene confer this bacterium with the ability to grow in chemically defined medium containing phenylacetic acid as the sole carbon source. The appearance of phenylacetyl-CoA ligase activity in all of the strains of the fungus Penicillium chrysogenum transformed with a construction bearing this gene was directly related to a significant increase in the quantities of benzylpenicillin accumulated in the broths (between 1.8- and 2.2-fold higher), indicating that expression of this bacterial gene (pcl) helps to increase the pool of a direct biosynthetic precursor, phenylacetyl-CoA This report describes the sequence of a phenylacetyl-CoA ligase for the first time and provides direct evidence that the expression in P. chrysogenum of a heterologous protein (involved in the catabolism of a penicillin precursor) is a useful strategy for improving the biosynthetic machinery of this fungus.	UNIV LEON,DEPT BIOQUIM & BIOL MOL,FAC VET,E-24007 LEON,SPAIN; UNIV LEON,FAC BIOL,E-24007 LEON,SPAIN; ANTIBIOT SA LEON,LEON,SPAIN	Universidad de Leon; Universidad de Leon			Olivera, Elias Rodriguez/Q-1166-2019; OLIVERA, ELIAS RODRIGUEZ/H-6385-2016; Luengo, Jose M./E-1935-2016	Olivera, Elias Rodriguez/0000-0003-2315-8524; OLIVERA, ELIAS RODRIGUEZ/0000-0003-2315-8524; Luengo, Jose M./0000-0002-4984-6256; Martinez Blanco, Honorina/0000-0003-4591-2321; Minambres Rodriguez, Baltasar/0000-0003-4590-4911; Moreno Valle, Miguel Angel/0000-0002-1419-6898				ABE T, 1992, J BIOCHEM-TOKYO, V111, P123, DOI 10.1093/oxfordjournals.jbchem.a123707; Abraham EP, 1991, 50 YEARS PENICILLIN, P7; AHARONOWITZ Y, 1993, BIO-TECHNOL, V11, P807, DOI 10.1038/nbt0793-807; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; BARREDO JL, 1989, CURR GENET, V16, P453, DOI 10.1007/BF00340725; BARREDO JL, 1989, GENE, V83, P291, DOI 10.1016/0378-1119(89)90115-7; BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; Birch P R, 1992, DNA Seq, V2, P319, DOI 10.3109/10425179209030965; BLACK PN, 1992, J BIOL CHEM, V267, P25513; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONNERTON IF, 1990, MOL MICROBIOL, V4, P451, DOI 10.1111/j.1365-2958.1990.tb00611.x; DAGLEY S, 1975, ESSAYS BIOCHEM, V11, P81; DEVIRGILIO C, 1992, YEAST, V8, P1043, DOI 10.1002/yea.320081207; DIEZ B, 1990, J BIOL CHEM, V265, P16358; DRISCOLL JR, 1992, J BACTERIOL, V174, P5063, DOI 10.1128/JB.174.15.5063-5071.1992; DURONIO RJ, 1992, J CELL BIOL, V117, P515, DOI 10.1083/jcb.117.3.515; EGGEN RIL, 1991, J BACTERIOL, V173, P6383, DOI 10.1128/jb.173.20.6383-6389.1991; EICHLER K, 1994, MOL MICROBIOL, V13, P775, DOI 10.1111/j.1365-2958.1994.tb00470.x; FERNANDEZCANON JM, 1989, J ANTIBIOT, V42, P1398, DOI 10.7164/antibiotics.42.1398; FERNANDEZVALVERDE M, 1993, APPL ENVIRON MICROB, V59, P1149; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; FUJINO T, 1992, J BIOCHEM-TOKYO, V111, P197, DOI 10.1093/oxfordjournals.jbchem.a123737; FULLMER CS, 1979, J BIOL CHEM, V254, P7208; GARRE V, 1994, MOL GEN GENET, V244, P278, DOI 10.1007/BF00285455; GHOSH B, L09229 AC EMBL; GIBSON J, 1994, J BACTERIOL, V176, P634, DOI 10.1128/jb.176.3.634-641.1994; GRUNDY FJ, 1993, MOL MICROBIOL, V10, P259, DOI 10.1111/j.1365-2958.1993.tb01952.x; JOHNSON DR, 1994, J BIOL CHEM, V269, P18037; KONOMI T, 1979, BIOCHEM J, V184, P427, DOI 10.1042/bj1840427; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; LUENGO JM, 1986, BIO-TECHNOL, V4, P44, DOI 10.1038/nbt0186-44; LUENGO JM, 1986, J ANTIBIOT, V39, P1565, DOI 10.7164/antibiotics.39.1565; LUENGO JM, 1979, J GEN MICROBIOL, V115, P207, DOI 10.1099/00221287-115-1-207; LUENGO JM, 1986, J ANTIBIOT, V39, P1754, DOI 10.7164/antibiotics.39.1754; LUENGO JM, 1995, J ANTIBIOT, V48, P1195, DOI 10.7164/antibiotics.48.1195; MARTINEZBLANCO H, 1990, FEMS MICROBIOL LETT, V72, P113; MARTINEZBLANCO H, 1990, J BIOL CHEM, V265, P7084; MARTINEZBLANCO H, 1993, GENE, V130, P265, DOI 10.1016/0378-1119(93)90429-7; MINAMBRES B, 1996, Patent No. 9600664; MORENO MA, 1987, ANAL BIOCHEM, V164, P559; OLIVERA ER, 1994, EUR J BIOCHEM, V221, P375, DOI 10.1111/j.1432-1033.1994.tb18749.x; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PRIEFERT H, 1992, J BACTERIOL, V174, P6590, DOI 10.1128/JB.174.20.6590-6599.1992; Ratledge C., 1994, BIOCH MICROBIAL DEGR; RODRIGUEZAPARICIO LB, 1991, BIOCHIM BIOPHYS ACTA, V1073, P431, DOI 10.1016/0304-4165(91)90153-8; Sambrook J., 2002, MOL CLONING LAB MANU; SAMSON SM, 1985, NATURE, V318, P191, DOI 10.1038/318191a0; SANCHEZ F, 1987, GENE, V51, P97, DOI 10.1016/0378-1119(87)90479-3; SANCHEZ F, 1987, Patent No. 235951; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFFER JE, 1994, U15977 AC EMBL; SCHLEISSNER C, 1994, J BACTERIOL, V176, P7667, DOI 10.1128/JB.176.24.7667-7676.1994; SCHMITZ A, 1992, APPL ENVIRON MICROB, V58, P4068, DOI 10.1128/AEM.58.12.4068-4071.1992; SELVARAJ G, 1983, J BACTERIOL, V156, P1292, DOI 10.1128/JB.156.3.1292-1300.1983; SHARMA V, 1994, L35031 AC EMBL; SMITH DJ, 1989, MOL GEN GENET, V216, P492, DOI 10.1007/BF00334395; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; UHLMANN A, 1993, PLANT PHYSIOL, V102, P1147, DOI 10.1104/pp.102.4.1147; VANBEILEN JB, 1992, MOL MICROBIOL, V6, P3121; WHITEMAN PA, 1990, FEBS LETT, V262, P342, DOI 10.1016/0014-5793(90)80224-7; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHAO Y, 1990, NUCLEIC ACIDS RES, V18, P6144, DOI 10.1093/nar/18.20.6144	66	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33531	33538		10.1074/jbc.271.52.33531	http://dx.doi.org/10.1074/jbc.271.52.33531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969218	hybrid			2022-12-25	WOS:A1996WA71300052
J	Zhang, SY; Coso, OA; Lee, CH; Gutkind, JS; Simonds, WF				Zhang, SY; Coso, OA; Lee, CH; Gutkind, JS; Simonds, WF			Selective activation of effector pathways by brain-specific G protein beta(5)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; SIGNALING PATHWAY; KINASE ACTIVATION; ADENYLYL CYCLASE; ALPHA-SUBUNIT; BINDING; STIMULATION; EXPRESSION	While multiple G protein beta and gamma subunit isoforms have been identified, the implications of this potential diversity of beta gamma heterodimers for signaling through beta gamma-regulated effector pathways remains unclear. Furthermore the molecular mechanism(s) by which the beta gamma complex modulates diverse mammalian effector molecules is unknown. Effector signaling by the structurally distinct brain-specific beta(5) subunit was assessed by transient cotransfection with gamma(2) in COS cells and compared with beta(1). Transfection of either beta(1) or beta(5) with gamma(2) stimulated the activity of cotransfected phospholipase C-beta(2) (PLC-beta(2)), as previously reported, In contrast, cotransfection of beta(1) but not beta(5) with gamma(2) stimulated the mitogen-activated protein kinase (MAPK) and c-jun N-terminal kinase (JNK) pathways even though the expression of beta(5) in COS cells was evident by immunoblotting. The G protein beta(5) expressed in transfected COS cells was properly folded as its pattern of stable C-terminal proteolytic fragments was identical to that of native brain beta(5). The inability of beta(5) to activate the MAPK and JNK pathways was not overcome by cotransfection with three additional G gamma isoforms. These results suggest it is the G beta subunit which determines the pattern of downstream signaling by the beta gamma complex and imply that the structural features of the beta gamma complex mediating effector regulation may differ among effectors.	NIDDK,METAB RES BRANCH,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,MOL SIGNALLING UNIT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	Gutkind, J. Silvio/0000-0002-5150-4482; 				BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BONIFACINO JS, 1990, SCIENCE, V247, P79, DOI 10.1126/science.2294595; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALI JJ, 1992, J BIOL CHEM, V267, P24023; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; FAURE M, 1994, J BIOL CHEM, V269, P7851; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FISHER KJ, 1992, MOL CELL BIOL, V12, P1585, DOI 10.1128/MCB.12.4.1585; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; MURAKAMI T, 1992, BIOCHEMISTRY-US, V31, P2905, DOI 10.1021/bi00126a009; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARK D, 1992, J BIOL CHEM, V267, P16048; PARK DG, 1993, J BIOL CHEM, V268, P4573; PRONIN AN, 1993, FEBS LETT, V328, P89, DOI 10.1016/0014-5793(93)80971-V; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; RAY K, 1995, J BIOL CHEM, V270, P21765, DOI 10.1074/jbc.270.37.21765; Reichlin M, 1980, Methods Enzymol, V70, P159; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT CJ, 1992, J BIOL CHEM, V267, P13807; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; TOUHARA K, 1995, P NATL ACAD SCI USA, V92, P9284, DOI 10.1073/pnas.92.20.9284; UEDA N, 1994, J BIOL CHEM, V269, P4388; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang SY, 1996, J BIOL CHEM, V271, P20208, DOI 10.1074/jbc.271.33.20208; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	54	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33575	33579		10.1074/jbc.271.52.33575	http://dx.doi.org/10.1074/jbc.271.52.33575			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969224	hybrid			2022-12-25	WOS:A1996WA71300058
J	Gordon, DA; Jamil, H; Gregg, RE; Olofsson, SO; Boren, J				Gordon, DA; Jamil, H; Gregg, RE; Olofsson, SO; Boren, J			Inhibition of the microsomal triglyceride transfer protein blocks the first step of apolipoprotein B lipoprotein assembly but not the addition of bulk core lipids in the second step	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; ENDOPLASMIC-RETICULUM; MCA-RH7777 CELLS; APO-B; ABETALIPOPROTEINEMIA; LIVER; EXPRESSION; SECRETION; COMPLEX; LINE	The microsomal triglyceride transfer protein (MTP) is required for assembly and secretion of the lipoproteins containing apolipoprotein B (apoB): very low density lipoproteins and chylomicrons. Evidence indicates that the subclasses of these lipoproteins that contain apoB-48 are assembled in a distinct two-step process; first a relatively lipid-poor primordial lipoprotein precursor is produced, and then bulk neutral lipids are added to form the core of these spherical particles, To determine if either step is mediated by MTP, a series of clonal cell lines stably expressing apoB-53 and MTP was established in non-lipoprotein producing HeLa cells, MTP activity in these cells was similar to 30%, and apoB secretion was 7-33% of that in HepG2 cells on a molar basis, Despite having robust levels of triglyceride and phospholipid synthesis, these cell lines, as exemplified by HLMB53-59, secreted >90% of the apoB-53 on relatively lipid-poor particles in the density range of 1.063-1.21 g/ml, These results suggested that coexpression of MTP and apoB only reconstituted the first but not the second step in lipoprotein assembly, To extend this observation, additional studies were carried out in McArdle RH-7777 rat hepatoma cells, in which the second step of apoB-48 lipoprotein assembly is well defined, Treatment of these cells with the MTP photoaffinity inhibitor BMS-192951 before pulse labeling with [S-35]methionine/cysteine led to an 85% block of both apoB-48 and apoB-100 but not apoAI secretion, demonstrating inhibition of the first step of lipoprotein assembly, After a 30-min [S-35]methioneine/cysteine pulse labeling and 120 min of chase, all of the nascent apoB-48 was observed to have a density of high density lipoproteins (1.063-1.21 g/ml), indicating that only the first step of lipoprotein assembly had occurred, The addition of oleic acid to the cell culture media activated the second step as evidenced by the conversion of the apoB-48 high density lipoproteins to very low density lipoproteins (d < 1.006 g/ml) during an extended chase period, Inactivation of MTP after completion of the first step, but before stimulation of the second step by the addition of oleic acid, did not block this conversion, Thus, inhibition of MTP did not hinder the addition of bulk core lipid to the primordial lipoprotein precursor particles, indicating that MTP is not required for the second step of apoB-48 lipoprotein assembly.	GOTHENBURG UNIV,DEPT MED BIOCHEM,S-41390 GOTHENBURG,SWEDEN; GOTHENBURG UNIV,WALLENBERG LAB,S-41390 GOTHENBURG,SWEDEN; DAVID J GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94110	University of Gothenburg; University of Gothenburg; University of California System; University of California San Francisco; The J David Gladstone Institutes	Gordon, DA (corresponding author), BRISTOL MYERS SQUIBB CO,DEPT METAB DIS,K23-03,POB 4000,PRINCETON,NJ 08543, USA.							ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; AVIGAN MI, 1984, HEPATOLOGY, V4, P1223, DOI 10.1002/hep.1840040621; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GORDON DA, 1995, CIRCULATION, V92, P362; Havel RJ, 1980, METABOLIC CONTROL DI, P393; Innerarity TL, 1996, J BIOL CHEM, V271, P2353, DOI 10.1074/jbc.271.5.2353; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1995, J LIPID RES, V36, P1073; PATEL SB, 1994, CIRCULATION, V90, P186; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; Sambrook J., 2002, MOL CLONING LAB MANU; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1986, J LIPID RES, V27, P236; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; YAO ZM, 1991, J BIOL CHEM, V266, P3300	27	136	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33047	33053		10.1074/jbc.271.51.33047	http://dx.doi.org/10.1074/jbc.271.51.33047			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955151	hybrid			2022-12-25	WOS:A1996VZ37300086
J	Ptushkina, M; FierroMonti, I; vandenHeuvel, J; Vasilescu, S; Birkenhager, R; Mita, K; McCarthy, JEG				Ptushkina, M; FierroMonti, I; vandenHeuvel, J; Vasilescu, S; Birkenhager, R; Mita, K; McCarthy, JEG			Schizosaccharomyces pombe has a novel eukaryotic initiation factor 4F complex containing a cap-binding protein with the human eIF4E C-terminal motif KSGST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; FACTOR EIF-4E; TRANSLATIONAL INITIATION; SECONDARY STRUCTURE; YEAST; PHOSPHORYLATION; GENES; RECOGNITION; SEQUENCE	Genetic and biochemical analyses mere performed on the cytoplasmic cap-binding complex (eukaryotic initiation factor (eIF) 4F) of Schizosaccharomyces pombe, Genomic and cDNA sequencing of the S. pombe gene (tif1) encoding the cap-binding component eIF4E revealed the presence of two introns in a reading frame of 219 codons. The encoded sequence of 218 amino acids shows a greater degree of identity to the mammalian eIF4E sequence than does its counterpart from Saccharomyces cerevisiae, In particular, unlike its S. cerevisiae counterpart, S.pombe eIF4E has a C-terminal Ser(209) within the motif KSGST that is a site of phosphorylation in hamster and rabbit eIF4E. Of relevance to its potential regulatory role, eIF4E was found to be encoded by an mRNA with a six-nucleotide leader and to be of low abundance in vivo. Cross-linking experiments identified S. pombe eIF4E as the major cap binding protein while a further protein, p36, also showed cap-dependent binding. eIF4A was not associated with the cap-binding complex. While S. pombe eIF4E was shown capable of binding S. cerevisiae p20, an equivalent protein was absent from the eIF4F complex isolated from S. pombe cells. S. pombe 4F therefore shows a remarkable combination of structural and functional properties, some of which it shares with its higher and its lower eukaryotic counterparts.	NATL BIOTECHNOL RES CTR,DEPT GENE EXPRESS,D-38124 BRAUNSCHWEIG,GERMANY; NATL INST RADIOL SCI,GENOME RES GRP,INAGE KU,CHIBA 260,JAPAN	National Institutes for Quantum Science & Technology			Fierro-Monti, Ivo/AAH-3595-2020	/0000-0002-5460-2117				ALTMANN M, 1989, NUCLEIC ACIDS RES, V17, P7520, DOI 10.1093/nar/17.18.7520; ALTMANN M, 1993, EMBO J, V12, P3997, DOI 10.1002/j.1460-2075.1993.tb06077.x; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Guthrie C., 1991, METHOD ENZYMOL, V194, P21; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; HUMPHREY T, 1991, EMBO J, V10, P3503, DOI 10.1002/j.1460-2075.1991.tb04914.x; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; KAUFER NF, 1985, NATURE, V318, P78, DOI 10.1038/318078a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LANG V, 1994, J BIOL CHEM, V269, P6117; LEER RJ, 1984, NUCLEIC ACIDS RES, V12, P6685, DOI 10.1093/nar/12.17.6685; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MERRICK W, 1992, MICROBIOL REV, V56, P219; Miller J.H., 1972, EXPT MOL GENETICS; MINICH WB, 1994, P NATL ACAD SCI USA, V91, P7668, DOI 10.1073/pnas.91.16.7668; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; Rau M, 1996, J BIOL CHEM, V271, P8983, DOI 10.1074/jbc.271.15.8983; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; ROSE MD, 1990, METHODS YEAST GENETI, P126; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEPPE B, 1994, GENE, V143, P201, DOI 10.1016/0378-1119(94)90097-3; SCOTT MG, 1988, BIOCHEM BIOPH RES CO, V155, P1352; SOMMER SS, 1982, CELL, V31, P429, DOI 10.1016/0092-8674(82)90136-2; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P174; Sonenberg Nahum, 1993, Gene Expression, V3, P317; Vasilescu S, 1996, J BIOL CHEM, V271, P7030, DOI 10.1074/jbc.271.12.7030; ZANCHIN NIT, 1995, J BIOL CHEM, V270, P26505, DOI 10.1074/jbc.270.44.26505; ZAPATA JM, 1994, J BIOL CHEM, V269, P18047; ZHANG MQ, 1994, NUCLEIC ACIDS RES, V22, P1750, DOI 10.1093/nar/22.9.1750	45	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32818	32824		10.1074/jbc.271.51.32818	http://dx.doi.org/10.1074/jbc.271.51.32818			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955119	hybrid			2022-12-25	WOS:A1996VZ37300054
J	Villain, P; Mache, R; Zhou, DX				Villain, P; Mache, R; Zhou, DX			The mechanism of GT element-mediated cell type-specific transcriptional control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; CHLOROPLAST DEVELOPMENT; TRANSGENIC TOBACCO; RIBOSOMAL-PROTEIN; SILENCER REGION; NUCLEAR-PROTEIN; GENE-EXPRESSION; RBCS-3A GENE; PLANT GENES; PROMOTER	Promoter studies have revealed that sequences related to the GT-1 binding site, known as GT elements, are conserved in plant nuclear genes of diverse functions, In this work, we addressed the issue of whether GT elements are involved in cell type-specific transcriptional regulation, We found that the inactivation of GT-1 site mediated transcription in roots is correlated with the absence of the GT-1 binding activity in root extracts, In addition, the mutation of the related GT-1 (from the pea rbcs-3A) and the S1F (from the spinach rps1) sites resulted in an increase of their transcriptional activity in roots that contain a distinct GT element-binding factor, referred to as RGTF, Although specific to GT elements, RGTF has a different sequence requirement and a lower sequence specificity than GT-1, Interestingly, RGTF has a higher binding affinity to the mutant GT-1 and S1F sites than to the wild-type sequences, This cor relation suggests that RGTF may have some role in transcriptional regulation in roots, Furthermore, root cellular protein extracts contain an inhibitory activity that prevents GT-1 from binding to DNA. This helps to explain the absence of the GT-1 binding activity in roots in which the gene of GT-1 is expressed, Together, these data suggest that the cell type-specific transcription modulation by GT elements is achieved by using two different strategies.	UNIV GRENOBLE 1,CNRS,UNITE MIXTE RECH 5575,LAB GENET MOL PLANTES,F-38041 GRENOBLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)				Zhou, Dao-Xiu/0000-0002-1540-0598				ANDERSON SL, 1994, PLANT J, V6, P457, DOI 10.1046/j.1365-313X.1994.6040457.x; DEHESH K, 1990, SCIENCE, V250, P1397, DOI 10.1126/science.2255908; DEHESH K, 1992, EMBO J, V11, P4131, DOI 10.1002/j.1460-2075.1992.tb05506.x; EYAL Y, 1995, PLANT CELL, V7, P373, DOI 10.1105/tpc.7.3.373; FLUHR R, 1986, SCIENCE, V232, P1106, DOI 10.1126/science.232.4754.1106; FRANZETTI B, 1992, NUCLEIC ACIDS RES, V20, P4153, DOI 10.1093/nar/20.16.4153; GILMARTIN PM, 1992, PLANT CELL, V4, P839, DOI 10.1105/tpc.4.7.839; GILMARTIN PM, 1990, PLANT CELL, V2, P369, DOI 10.1105/tpc.2.5.369; GREEN PJ, 1988, EMBO J, V7, P4035, DOI 10.1002/j.1460-2075.1988.tb03297.x; GREEN PJ, 1987, EMBO J, V6, P2543, DOI 10.1002/j.1460-2075.1987.tb02542.x; GREEN PJ, 1989, PLANT MOL BIOL MANUA, P1; HARRAK H, 1995, PLANT PHYSIOL, V108, P685, DOI 10.1104/pp.108.2.685; HARRISON MJ, 1991, P NATL ACAD SCI USA, V88, P2515, DOI 10.1073/pnas.88.6.2515; HIRATSUKA K, 1994, PLANT CELL, V6, P1805, DOI 10.1105/tpc.6.12.1805; JEFFERSON RA, 1987, EMBO J, V6, P3901; KUHLEMEIER C, 1988, P NATL ACAD SCI USA, V85, P4662, DOI 10.1073/pnas.85.13.4662; LAGRANGE T, 1993, MOL CELL BIOL, V13, P2614, DOI 10.1128/MCB.13.4.2614; LAM E, 1990, SCIENCE, V248, P471, DOI 10.1126/science.2330508; LAWTON MA, 1991, PLANT MOL BIOL, V16, P235, DOI 10.1007/BF00020555; LI YF, 1995, PLANT MOL BIOL, V28, P595, DOI 10.1007/BF00021186; PERISIC O, 1992, PLANT CELL, V4, P831, DOI 10.1105/tpc.4.7.831; SCHINDLER U, 1990, EMBO J, V9, P3415, DOI 10.1002/j.1460-2075.1990.tb07549.x; SUSEK RE, 1993, CELL, V74, P787, DOI 10.1016/0092-8674(93)90459-4; VILLAIN P, 1994, J BIOL CHEM, V269, P16626; ZHOU DX, 1992, J BIOL CHEM, V267, P23515	25	73	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32593	32598		10.1074/jbc.271.51.32593	http://dx.doi.org/10.1074/jbc.271.51.32593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955086	hybrid			2022-12-25	WOS:A1996VZ37300021
J	SoferLevi, Y; Resnitzky, D				SoferLevi, Y; Resnitzky, D			Apoptosis induced by ectopic expression of cyclin D1 but not cyclin E	ONCOGENE			English	Article						cyclin D1; apoptosis; cell cycle	S-PHASE ENTRY; CELL-CYCLE; PROTEIN; GENE; RB; TRANSITION; LEADS; G(1); RETINOBLASTOMA; FIBROBLASTS	Deregulation of the pRb/E2F pathway leads to disruption of the normal control of the G(1)/S transition, and is associated with transformation. However, recent accumulated evidence suggest that under certain circumstances deregulation of the pRb/E2F pathway can also lead to apoptotic cell death. Apoptosis was shown to be induced by expression of DNA tumor virus oncoproteins, knockout of the rb gene, and expression of E2F from heterologous promoter. Since phosphorylation of pRb by G(1) cyclin-dependent kinases (Cdks) causes its inactivation, we examined whether deregulation of G(1) Cdks, also drives apoptosis. We have used rat fibroblast cell lines capable of expressing cyclin E, cyclin D1, or both, in an inducible manner, through a tetracycline responsive promoter. We show here that ectopic expression of cyclins D1 and E in rat fibroblasts under serum starvation, leads to deregulated entry into S phase, and subsequently to apoptotic cell death. Furthermore, expression of cyclin D1 alone is sufficient to provoke apoptosis, whereas expression of cyclin E alone during serum starvation does not. Moreover, expression of either cyclins D1 and E, and cyclin D1 alone, under serum starvation led to a significant increase in the fraction of hyper-phosphorylated pRb whereas cyclin E expression alone did not. These results demonstrate that expression of cyclin D1 from heterologous promoter leads to apoptosis in serum starved cells, which may be mediated by phosphorylation of pRb.	WEIZMANN INST SCI,DEPT MOL & CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bates S, 1996, CURR OPIN GENET DEV, V6, P12, DOI 10.1016/S0959-437X(96)90004-0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVAN GI, 1995, CURR OPIN CELL BIOL, V7, P825, DOI 10.1016/0955-0674(95)80066-2; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOTOKURA T, 1993, CURR OPIN GENET DEV, V3, P5, DOI 10.1016/S0959-437X(05)80334-X; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Preston GA, 1996, MOL CELL BIOL, V16, P211; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RENZING J, 1995, ONCOGENE, V10, P1865; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Sherr Charles J., 1994, Trends in Cell Biology, V4, P15, DOI 10.1016/0962-8924(94)90033-7; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WYLLIE AH, 1995, CURR OPIN GENET DEV, V5, P97, DOI 10.1016/S0959-437X(95)90060-8	43	104	105	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2431	2437						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957085				2022-12-25	WOS:A1996VX10800016
J	Brader, ML; Kaarsholm, NC; Harnung, SE; Dunn, MF				Brader, ML; Kaarsholm, NC; Harnung, SE; Dunn, MF			Ligand perturbation effects on a pseudotetrahedral Co(II)(His)(3)-ligand site - A magnetic circular dichroism study of the Co(II)-substituted insulin hexamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBONIC-ANHYDRASE-II; BETA-LACTAMASE-II; ACTIVE-SITE; ALLOSTERIC TRANSITION; BACILLUS-CEREUS; COPPER PROTEINS; BINDING; ZINC; PHENOL; RESOLUTION	Magnetic circular dichroism (MCD) spectra of a series of adducts formed by the Co(II)-substituted R-state insulin hexamer are reported, The His-B10 residues in this hexamer form tris imidazole chelates in which pseudotetrahedral Co(II) centers are completed by an exogenous fourth ligand, This study investigates how the MCD signatures of the Co(II) center in this unit are influenced by the chemical and steric characteristics of the fourth ligand, The spectra obtained for the adducts formed with halides, pseudohalides, trichloroacetate, nitrate, imidazole, and 1-methylimidazole appear to be representative of near tetrahedral Co(II) geometries. With bulkier aromatic ligands, more structured spectra indicative of highly distorted Co(II) geometries are obtained, The MCD spectrum of the phenolate adduct is very similar to those of Co(II)-carbonic anhydrase (alkaline form) and Co(II)-beta-lactamase. The MCD spectrum of the Co(II)-R(6)-CN- adduct is very similar to the CN- adduct of Co(II)-carbonic anhydrase. The close similarity of the Co(II)-R(6)-pentafluorophenolate and Co(II)-R(6)-phenolate spectra demonstrates that the Co(II)-carbonic anhydrase like spectral profile is preserved despite a substantial perturbation in the electron withdrawing nature of the coordinated phenolate oxygen atom. We conclude that this type of spectrum must arise from a specific Co(II) coordination geometry common to each of the Co(II) sites in the Co(II)-R(6)-phenolate, Co(II)-R(6)-pentafluorophenolate, Co(II)-beta-lactamase, and the alkaline Co(II)-carbonic anhydrase species, These spectroscopic results are consistent with a trigonally distorted tetrahedral Co(II) geometry (C-3v), an interpretation supported by the pseudotetrahedral Zn(II)(His)(3)(phenolate) center identified in a Zn(II)-R(6) crystal structure (Smith, G. D., and Dodson, G. G. (1992) Biopolymers 32, 441-445).	UNIV CALIF RIVERSIDE,DEPT BIOCHEM,RIVERSIDE,CA 92521; NOVO NORDISK AS,NOVO RES INST,DK-2880 BAGSVAERD,DENMARK; UNIV COPENHAGEN,DEPT CHEM,DK-2100 COPENHAGEN,DENMARK	University of California System; University of California Riverside; Novo Nordisk; University of Copenhagen					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042124] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK42124] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MJ, 1969, NATURE, V224, P491, DOI 10.1038/224491a0; BAKER EN, 1988, PHILOS T ROY SOC B, V319, P369, DOI 10.1098/rstb.1988.0058; BALDWIN GS, 1980, J INORG BIOCHEM, V13, P189, DOI 10.1016/S0162-0134(00)80068-9; BERTINI I, 1978, J AM CHEM SOC, V100, P4873, DOI 10.1021/ja00483a038; BERTINI I, 1986, ZINC ENZYMES PROGR I, V1, P1; BERTINI I, 1983, COORDINATION CHEM ME, P1; BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P7208, DOI 10.1021/bi00370a066; BLOOM CR, 1995, J MOL BIOL, V245, P324, DOI 10.1006/jmbi.1994.0027; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BRADER ML, 1991, TRENDS BIOCHEM SCI, V16, P341; BRADER ML, 1991, BIOCHEMISTRY-US, V30, P6636, DOI 10.1021/bi00241a002; BRADER ML, 1990, J BIOL CHEM, V265, P15666; BRADER ML, 1992, BIOCHEMISTRY-US, V31, P4691, DOI 10.1021/bi00134a023; BRADER ML, 1992, J AM CHEM SOC, V114, P4480, DOI 10.1021/ja00038a006; BRZOVIC PS, 1994, BIOCHEMISTRY-US, V33, P13057, DOI 10.1021/bi00248a015; CHOI WE, 1993, BIOCHEMISTRY-US, V32, P11638, DOI 10.1021/bi00094a021; CISZAK E, 1994, BIOCHEMISTRY-US, V33, P1512, DOI 10.1021/bi00172a030; COLEMAN JE, 1972, J BIOL CHEM, V247, P4718; CORWIN DT, 1987, J CHEM SOC CHEM COMM, V13, P966; DEREWENDA U, 1989, NATURE, V338, P594, DOI 10.1038/338594a0; DIDEBERG O, 1982, NATURE, V299, P469, DOI 10.1038/299469a0; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; FLAMINI A, 1971, INORG CHIM ACTA, V5, P241; HIROSE J, 1984, CHEM PHARM BULL, V32, P2481; HOLT EM, 1970, J AM CHEM SOC, V92, P2721, DOI 10.1021/ja00712a023; KAARSHOLM NC, 1989, BIOCHEMISTRY-US, V28, P4427, DOI 10.1021/bi00436a046; KADEN TA, 1974, INORG CHEM, V13, P2585, DOI 10.1021/ic50141a012; LEVER ABP, 1984, INORGANIC ELECTR SPE, P196; LINDSKOG S, 1963, J BIOL CHEM, V238, P945; LIPPARD SJ, 1994, PRINCIPLES BIOINORGA, P257; MCMILLIN D R, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1339, DOI 10.1073/pnas.71.4.1339; MCMILLIN DR, 1974, P NATL ACAD SCI USA, V71, P4760, DOI 10.1073/pnas.71.12.4760; NAIR SK, 1994, J AM CHEM SOC, V116, P3659, DOI 10.1021/ja00087a086; ROY M, 1989, J BIOL CHEM, V264, P19081; SHI YG, 1993, BIOPHYS J, V64, P749, DOI 10.1016/S0006-3495(93)81435-8; SIMONSSON I, 1982, BIOCHEM BIOPH RES CO, V108, P1406, DOI 10.1016/S0006-291X(82)80063-6; SMITH GD, 1994, P NATL ACAD SCI USA, V91, P8851, DOI 10.1073/pnas.91.19.8851; SMITH GD, 1984, P NATL ACAD SCI-BIOL, V81, P7093, DOI 10.1073/pnas.81.22.7093; SMITH GD, 1992, BIOPOLYMERS, V32, P441, DOI 10.1002/bip.360320422; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; STOCKER W, 1995, CURR OPIN STRUC BIOL, V5, P383, DOI 10.1016/0959-440X(95)80101-4; STORM MC, 1985, BIOCHEMISTRY-US, V24, P1749, DOI 10.1021/bi00328a027; SUTTON BJ, 1987, BIOCHEM J, V248, P181, DOI 10.1042/bj2480181; THOMPSON JS, 1979, J AM CHEM SOC, V101, P4193, DOI 10.1021/ja00509a027; WHITTINGHAM JL, 1995, BIOCHEMISTRY-US, V34, P15553, DOI 10.1021/bi00047a022	46	24	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1088	1094		10.1074/jbc.272.2.1088	http://dx.doi.org/10.1074/jbc.272.2.1088			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995407	hybrid			2022-12-25	WOS:A1997WC04800058
J	Huyer, G; Liu, S; Kelly, J; Moffat, J; Payette, P; Kennedy, B; Tsaprailis, G; Gresser, MJ; Ramachandran, C				Huyer, G; Liu, S; Kelly, J; Moffat, J; Payette, P; Kennedy, B; Tsaprailis, G; Gresser, MJ; Ramachandran, C			Mechanism of inhibition of protein-tyrosine phosphatases by vanadate and pervanadate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; KINASE-ACTIVITY; RAT ADIPOCYTES; HUMAN-PLACENTA; INSULIN; PURIFICATION; RECEPTOR; PHOSPHORYLATION; VANADIUM	Vanadate and pervanadate (the complexes of vanadate with hydrogen peroxide) are two commonly used general protein-tyrosine phosphatase (PTP) inhibitors. These compounds also have insulin-mimetic properties, an observation that has generated a great deal of interest and study. Since a careful kinetic study of the two inhibitors has been lacking, we sought to analyze their mechanisms of inhibition. Our results show that vanadate is a competitive inhibitor for the protein-tyrosine phosphatase PTP1B, with a K-i of 0.38 +/- 0.02 mu M. EDTA, which is known to chelate vanadate, causes an immediate and complete reversal of the inhibition due to vanadate when added to an enzyme assay. Pervanadate, by contrast, inhibits by irreversibly oxidizing the catalytic cysteine of PTP1B, as determined by mass spectrometry. Reducing agents such as dithiothreitol that are used in PTP assays to keep the catalytic cysteine reduced and active were found to convert pervanadate rapidly to vanadate, Under certain conditions, slow time-dependent inactivation by vanadate was observed; since catalase blocked this inactivation, it was ascribed to in situ generation of hydrogen peroxide and subsequent formation of pervanadate. Implications for the use of these compounds as inhibitors and rationalization for some of their in vivo effects are considered.	MERCK FROSST CANADA INC, MERCK FROSST CTR THERAPEUT RES, DEPT BIOCHEM & MOL BIOL, POINTE CLAIRE, PQ H9R 4P8, CANADA; MERCK FROSST CANADA INC, MERCK FROSST CTR THERAPEUT RES, DEPT MED CHEM, POINTE CLAIRE, PQ H9R 4P8, CANADA; CONCORDIA UNIV, DEPT CHEM & BIOCHEM, MONTREAL, PQ H3G 1M8, CANADA	Merck & Company; Merck & Company; Concordia University - Canada			Moffat, Jason/AAC-1110-2020	Moffat, Jason/0000-0002-5663-8586; Tsaprailis, George/0000-0003-1239-2358				Barford D, 1995, CURR OPIN STRUC BIOL, V5, P728, DOI 10.1016/0959-440X(95)80004-2; BARFORD D, 1995, NAT STRUCT BIOL, V2, P1043, DOI 10.1038/nsb1295-1043; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BIEMANN K, 1990, BIOLOGICAL MASS SPECTROMETRY /, P179; BRAUTIGAN DL, 1992, BIOCHIM BIOPHYS ACTA, V1114, P63, DOI 10.1016/0304-419X(92)90007-L; BURLET O, 1995, J AM SOC MASS SPECTR, V6, P242, DOI 10.1016/1044-0305(94)00098-K; BURLET O, 1992, J AM SOC MASS SPECTR, V3, P337, DOI 10.1016/1044-0305(92)87061-3; BUTLER A, 1994, CHEM REV, V94, P625, DOI 10.1021/cr00027a004; CANTLEY LC, 1979, J BIOL CHEM, V254, P1781; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; CHO H, 1991, J AM CHEM SOC, V114, P7296; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; COSTA M, 1977, BIOCHEM BIOPH RES CO, V78, P596, DOI 10.1016/0006-291X(77)90221-2; CRANS DC, 1989, J AM CHEM SOC, V111, P7597, DOI 10.1021/ja00201a049; CRANS DC, 1994, COMMENT INORG CHEM, V16, P1; DEGANI H, 1981, BIOCHEMISTRY-US, V20, P5795, DOI 10.1021/bi00523a023; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GOLDFINE AB, 1995, J CLIN ENDOCR METAB, V80, P3311, DOI 10.1210/jc.80.11.3311; Gresser MJ, 1990, VANADIUM BIOL SYSTEM, P63; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARRISON AT, 1985, J CHEM SOC DALTON, P1173, DOI 10.1039/dt9850001173; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEYLIGER CE, 1985, SCIENCE, V227, P1474, DOI 10.1126/science.3156405; ITOH M, 1992, J BIOL CHEM, V267, P12356; JASWAL JS, 1991, INORG CHEM, V30, P3718, DOI 10.1021/ic00019a030; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; KUSTIN K, 1973, J AM CHEM SOC, V95, P3564, DOI 10.1021/ja00792a017; LEIGHTON B, 1991, BIOCHEM J, V276, P289, DOI 10.1042/bj2760289; LIAO K, 1991, J BIOL CHEM, V266, P6544; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MEI L, 1991, J BIOL CHEM, V266, P16063; MILARSKI KL, 1995, BIOCHEM J, V308, P579, DOI 10.1042/bj3080579; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MISRA HP, 1974, J BIOL CHEM, V249, P2151; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; POSNER BI, 1994, J BIOL CHEM, V269, P4596; POT DA, 1991, J BIOL CHEM, V266, P19688; PRZYBOROWSKI L, 1965, HELV CHIM ACTA, V48, P1556, DOI 10.1002/hlca.19650480716; Sambrook J., 2002, MOL CLONING LAB MANU; Schecter Y., 1990, VANADIUM BIOL SYSTEM, P129; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHAVER A, 1993, INORG CHEM, V32, P3109, DOI 10.1021/ic00066a024; SHECHTER Y, 1990, DIABETES, V39, P1, DOI 10.2337/diabetes.39.1.1; STONE RL, 1994, J BIOL CHEM, V269, P31323; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; TRACEY AS, 1988, J AM CHEM SOC, V110, P5869, DOI 10.1021/ja00225a044; TROTTA PP, 1974, J BIOL CHEM, V249, P1915; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILLSKY GR, 1984, J BIOL CHEM, V259, P3273; Yale JF, 1995, MOL CELL BIOCHEM, V153, P181, DOI 10.1007/BF01075936; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765; ZHAO ZZ, 1993, J BIOL CHEM, V268, P2816; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	68	700	728	2	63	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					843	851		10.1074/jbc.272.2.843	http://dx.doi.org/10.1074/jbc.272.2.843			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995372	hybrid			2022-12-25	WOS:A1997WC04800023
J	Kim, YM; deVera, ME; Watkins, SC; Billiar, TR				Kim, YM; deVera, ME; Watkins, SC; Billiar, TR			Nitric oxide protects cultured rat hepatocytes from tumor necrosis factor-alpha-induced apoptosis by inducing heat shock protein 70 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANOUS SUPEROXIDE-DISMUTASE; IN-VIVO; RADICAL PRODUCTION; MOUSE THYMOCYTES; CELL VIABILITY; LIVER-INJURY; PEROXYNITRITE; CYTOTOXICITY; GLUTATHIONE; SYNTHASE	Nitric oxide (NO) and tumor necrosis factor-alpha (TNF alpha) play important roles in the pathogenesis of liver disease during acute inflammation. The present study was designed to elucidate the effect of NO pre exposure on TNF alpha-induced hepatotoxicity. Pretreatment of primary cultures of rat hepatocytes with the NO donor S-nitroso-N-acetylpenicillamine (SNAP) induced the expression of heat shock protein 70 (HSP70) mRNA and protein, which was associated with thermotolerance and cytoprotection from TNF alpha+actinomycin D-induced hepatotoxicity and apoptosis. SNAP transiently changed the intracellular redox state by inducing glutathione (GSH) oxidation associated with the formation of S-nitrosoglutathione (GSNO). HSP70 mRNA was also induced by the GSH-oxidizing agent diamide and the GSH-conjugating agent N-ethylmaleimide, suggesting that NO induces HSP70 expression through GSH oxidation. The protective effect of SNAP pretreatment on TNF alpha-induced apoptosis correlated with the level of HSP70 expression, SNAP pretreatment inhibited reactive oxygen intermediate generation and lipid peroxidation effects that were reversed by blocking HSP70 expression using an antisense oligonucleotide to HSP70. Finally, endogenous NO formation, induced in hepatocytes stimulated with interferon-gamma and interleukin-1 beta, led to the formation of GSNO and GSSG, induced HSP70, and attenuated TNF alpha-mediated cytotoxicity. These findings demonstrated that NO can induce resistance to TNF alpha-induced hepatotoxicity, possibly through the stimulation of HSP70 expression.	UNIV PITTSBURGH, SCH MED, DEPT PHARMACOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH MED, DEPT CELL BIOL & PHYSIOL, PITTSBURGH, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kim, YM (corresponding author), UNIV PITTSBURGH, SCH MED, DEPT SURG, W1503 BIOMED SCI TOWER, PITTSBURGH, PA 15261 USA.		Watkins, Simon/ABG-2590-2021	Watkins, Simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037753, R01GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM-37753, R01-GM-44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUCOIN MM, 1995, AM J PHYSIOL-HEART C, V268, pH1651, DOI 10.1152/ajpheart.1995.268.4.H1651; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; BAUTISTA AP, 1994, AM J PHYSIOL, V266, pG783, DOI 10.1152/ajpgi.1994.266.5.G783; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; Buege J A, 1978, Methods Enzymol, V52, P302; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Chiao H, 1996, J CLIN INVEST, V97, P2038, DOI 10.1172/JCI118639; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; COSSARIZZA A, 1995, BIOCHEM BIOPH RES CO, V214, P503, DOI 10.1006/bbrc.1995.2315; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; FEHSEL K, 1995, J IMMUNOL, V155, P2858; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GELLER DA, 1995, J IMMUNOL, V155, P4890; GIANOTTI L, 1993, ANN SURG, V217, P644, DOI 10.1097/00000658-199306000-00006; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; HARBRECHT BG, 1994, AM J PHYSIOL, V266, pG1004, DOI 10.1152/ajpgi.1994.266.6.G1004; HARBRECHT BG, 1992, J LEUKOCYTE BIOL, V52, P390, DOI 10.1002/jlb.52.4.390; HARBRECHT BG, 1994, HEPATOLOGY, V20, P1055, DOI 10.1002/hep.1840200439; HARKNESS TAA, 1994, J CELL BIOL, V124, P637, DOI 10.1083/jcb.124.5.637; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HELQVIST S, 1991, DIABETOLOGIA, V34, P150, DOI 10.1007/BF00418268; HEWETT JA, 1993, AM J PHYSIOL, V265, pG1011, DOI 10.1152/ajpgi.1993.265.6.G1011; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUANG LE, 1994, J BIOL CHEM, V269, P30718; IGNARRO LJ, 1989, SEMIN HEMATOL, V26, P63; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JAATTELA M, 1989, EUR J IMMUNOL, V19, P1413, DOI 10.1002/eji.1830190810; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JAATTELA M, 1993, J EXP MED, V177, P231, DOI 10.1084/jem.177.1.231; JACQUIERSARLIN MR, 1994, EXPERIENTIA, V50, P1031, DOI 10.1007/BF01923458; KANNER J, 1991, ARCH BIOCHEM BIOPHYS, V289, P130, DOI 10.1016/0003-9861(91)90452-O; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; KIM YM, 1995, FEBS LETT, V374, P228, DOI 10.1016/0014-5793(95)01115-U; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LEIST M, 1994, J IMMUNOL, V153, P1778; LEIST M, 1995, AM J PATHOL, V146, P1220; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MANNICK JB, 1994, CELL, V79, P1137, DOI 10.1016/0092-8674(94)90005-1; MATTHYS P, 1995, J IMMUNOL, V155, P3823; MEHLEN P, 1995, J IMMUNOL, V154, P363; MERTENS JJWM, 1995, ARCH BIOCHEM BIOPHYS, V320, P51, DOI 10.1006/abbi.1995.1341; MESTRIL R, 1994, BIOCHEM J, V298, P561, DOI 10.1042/bj2980561; MIGLIORATI G, 1992, CELL IMMUNOL, V143, P348, DOI 10.1016/0008-8749(92)90031-J; MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NUSSLER AK, 1994, AM J PHYSIOL, V267, pC394, DOI 10.1152/ajpcell.1994.267.2.C394; REIF DW, 1993, NEUROREPORT, V4, P566, DOI 10.1097/00001756-199305000-00026; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SAUNDERS EL, 1991, ARCH BIOCHEM BIOPHYS, V288, P368, DOI 10.1016/0003-9861(91)90208-Z; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Slater AFG, 1995, BIOCHEM J, V312, P833, DOI 10.1042/bj3120833; SON K, 1995, CANCER RES, V55, P5524; SORGER PK, 1987, EMBO J, V6, P993, DOI 10.1002/j.1460-2075.1987.tb04850.x; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TERENZI F, 1995, J BIOL CHEM, V270, P6017, DOI 10.1074/jbc.270.11.6017; VanRemmen H, 1996, J CELL PHYSIOL, V166, P453; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WHEELER CR, 1990, ANAL BIOCHEM, V184, P193, DOI 10.1016/0003-2697(90)90668-Y; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; YAMAUCHI N, 1989, CANCER RES, V49, P1671	72	483	517	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1402	1411		10.1074/jbc.272.2.1402	http://dx.doi.org/10.1074/jbc.272.2.1402			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995451	hybrid			2022-12-25	WOS:A1997WC04800102
J	Lenhard, B; Filipic, S; Landeka, I; Skrtic, I; Soll, D; WeygandDurasevic, I				Lenhard, B; Filipic, S; Landeka, I; Skrtic, I; Soll, D; WeygandDurasevic, I			Defining the active site of yeast Seryl-tRNA synthetase - Mutations in motif 2 loop residues affect tRNA-dependent amino acid recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; SEQUENCE HOMOLOGY; AMINOACYLATION; BINDING; EVOLUTION; ADENYLATE; SPECIFICITY	The active site of class II aminoacyl-tRNA synthetases contains the motif 2 loop, which is involved in binding of ATP, amino acid, and the acceptor end of tRNA. In order to characterize the active site of Saccharomyces cerevisiae seryl-tRNA synthetase (SerRS), we performed in vitro mutagenesis of the portion of the SES1 gene encoding the motif 2 loop, Substitutions of amino acids conserved in the motif 2 loop of seryl-tRNA synthetases from other sources led to loss of complementation of a yeast SES1 null allele strain by the mutant yeast SES1 genes. Steady-state kinetic analyses of the purified mutant SerRS proteins revealed elevated K-m values for serine and ATP, accompanied by decreases in k(cat) (as expected for replacement of residues involved in aminoacyl-adenylate formation). The differences in the affinities for serine and ATP, in the absence and presence of tRNA are consistent with the proposed conformational changes induced by positioning the 3'-end of tRNA into the active site, as observed recently in structural studies of Thermus thermophilus SerRS (Cusack, S., Yaremchuk, A., and Tukalo, M. (1996) EMBO J. 15, 2834-2842). The crystal structure of this moderately homologous prokaryotic counterpart of the yeast enzyme allowed us to produce a model of the yeast SerRS structure and to place the mutations in a structural context, In conjunction with structural data for T. thermophilus SerRS, the kinetic data presented here suggest that yeast seryl-tRNA synthetase displays tRNA-dependent amino acid recognition.	UNIV ZAGREB,FAC SCI,DEPT CHEM,ZAGREB 10000,CROATIA; YALE UNIV,DEPT MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06520; RUDJER BOSKOVIC INST,ZAGREB 10000,CROATIA	University of Zagreb; Yale University; Rudjer Boskovic Institute				Lenhard, Boris/0000-0002-1114-1509				ASAHARA H, 1994, J MOL BIOL, V236, P738, DOI 10.1006/jmbi.1994.1186; BELRHALI H, 1995, STRUCTURE, V3, P341, DOI 10.1016/S0969-2126(01)00166-6; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOREL F, 1994, NUCLEIC ACIDS RES, V22, P2963, DOI 10.1093/nar/22.15.2963; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; CALENDAR R, 1966, BIOCHEMISTRY-US, V5, P1681, DOI 10.1021/bi00869a033; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Cusack S, 1996, EMBO J, V15, P2834, DOI 10.1002/j.1460-2075.1996.tb00644.x; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; dePouplana LR, 1996, P NATL ACAD SCI USA, V93, P166, DOI 10.1073/pnas.93.1.166; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; ERIANI G, 1995, J MOL EVOL, V40, P499; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Guthrie C, 1991, GUIDE YEAST GENETICS; HARTLEIN M, 1995, J MOL EVOL, V40, P519; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HOUTONDJI C, 1986, BIOCHIMIE, V68, P1071; Ibba M, 1996, P NATL ACAD SCI USA, V93, P6953, DOI 10.1073/pnas.93.14.6953; IBBA M, 1995, NUCL ACIDS S SER, V33, P40; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; LU Y, 1994, J BIOL CHEM, V269, P12137; MOSYAK L, 1993, BIOCHIMIE, V75, P1091, DOI 10.1016/0300-9084(93)90008-G; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NAGEL GM, 1995, J MOL EVOL, V40, P487; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; POTERSZMAN A, 1994, J MOL BIOL, V244, P158, DOI 10.1006/jmbi.1994.1716; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1995, J MOL EVOL, V40, P509; Sever S, 1996, BIOCHEMISTRY-US, V35, P32, DOI 10.1021/bi952103d; SIDORIK LL, 1991, FEBS LETT, V292, P76, DOI 10.1016/0014-5793(91)80838-T; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VINCENT C, 1995, NUCLEIC ACIDS RES, V23, P1113, DOI 10.1093/nar/23.7.1113; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WEYGANDDURASEVI.I, 1993, P NATL ACAD SCI USA, V90, P210; WEYGANDDURASEVIC I, 1993, EUR J BIOCHEM, V214, P869, DOI 10.1111/j.1432-1033.1993.tb17990.x; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; WEYGANDDURASEVIC I, 1990, PERIOD BIOL, V92, P295; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589	48	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1136	1141		10.1074/jbc.272.2.1136	http://dx.doi.org/10.1074/jbc.272.2.1136			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995413	hybrid			2022-12-25	WOS:A1997WC04800064
J	Olivares, L; Aragon, C; Gimenez, C; Zafra, F				Olivares, L; Aragon, C; Gimenez, C; Zafra, F			Analysis of the transmembrane topology of the glycine transporter GLYT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINAL-CORD; N-GLYCOSYLATION; UPTAKE SYSTEMS; EXPRESSION; CLONING; BRAIN; LOCALIZATION; GENE; RECEPTOR; PROTEIN	A theoretical 12-transmembrane segment model based on the hydrophobic moment has been proposed for the transmembrane topology of the glycine transporter GLYT1 and all other members of the sodium- and chloride-dependent transporter family, We tested this model by introducing N-glycosylation sites along the GLYT1 sequence as reporter for an extracellular localization and by an in vitro transcription/translation assay that allows the analysis of the topogenic properties of different segments of the protein, The data reported herein are compatible with the existence of 12 transmembrane segments, but support a rearrangement of the first third of the protein, Contrary to prediction, hydrophobic domain 1 seems not to span the membrane, and the loop connecting hydrophobic domains 2 and 3, formerly believed to be intracellular, appears to be extracellularly located, In agreement with the theoretical model, we provide evidence for the extracellular localization of loops between hydrophobic segments 5 and 6, 7 and 8, 9 and 10, and 11 and 12.	UNIV AUTONOMA MADRID,FAC CIENCIAS,CSIC,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)			Aragon, Carmen/K-9783-2014; Zafra, Francisco/A-6121-2008; Gimenez, Cecilio/K-8027-2014	Aragon, Carmen/0000-0001-8287-9386; Zafra, Francisco/0000-0003-3801-3109; Gimenez, Cecilio/0000-0001-6726-8405				ADAMS RH, 1995, J NEUROSCI, V15, P2524, DOI 10.1523/JNEUROSCI.15-03-02524.1995; Amara S G, 1993, Curr Opin Neurobiol, V3, P337, DOI 10.1016/0959-4388(93)90126-J; AUBERT JP, 1981, ARCH BIOCHEM BIOPHYS, V208, P20, DOI 10.1016/0003-9861(81)90118-1; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; BOROWSKY B, 1993, NEURON, V10, P851, DOI 10.1016/0896-6273(93)90201-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSS M, 1995, J BIOL CHEM, V270, P9197; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; GUASTELLA J, 1992, P NATL ACAD SCI USA, V89, P7189, DOI 10.1073/pnas.89.15.7189; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HART GW, 1979, J BIOL CHEM, V254, P9747; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JOHNSTON GA, 1971, J NEUROCHEM, V18, P1951, DOI 10.1111/j.1471-4159.1971.tb09601.x; JURSKY F, 1995, J NEUROCHEM, V64, P1026; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P627; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KIM KM, 1994, MOL PHARMACOL, V45, P608; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRONQUIST KE, 1978, J SUPRAMOL STR CELL, V8, P51, DOI 10.1002/jss.400080105; KUHAR MJ, 1978, J NEUROCHEM, V31, P251, DOI 10.1111/j.1471-4159.1978.tb12456.x; LIU QR, 1993, J BIOL CHEM, V268, P22802; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; LOGAN WJ, 1972, BRAIN RES, V42, P413, DOI 10.1016/0006-8993(72)90540-9; LUQUE JM, 1995, NEUROSCIENCE, V64, P525, DOI 10.1016/0306-4522(94)00404-S; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; Nirenberg MJ, 1996, J NEUROSCI, V16, P436; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; OLIVARES L, 1994, J BIOL CHEM, V269, P28400; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; SMITH KE, 1992, NEURON, V8, P927, DOI 10.1016/0896-6273(92)90207-T; TATE CG, 1994, J BIOL CHEM, V269, P26303; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; WRIGHT EM, 1992, URR OPIN CELL BIOL, V4, P697; ZAFRA F, 1995, EUR J NEUROSCI, V7, P1342, DOI 10.1111/j.1460-9568.1995.tb01125.x; ZAFRA F, 1995, J NEUROSCI, V15, P3952	40	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1211	1217		10.1074/jbc.272.2.1211	http://dx.doi.org/10.1074/jbc.272.2.1211			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995423	hybrid			2022-12-25	WOS:A1997WC04800074
J	Cal, S; Connolly, BA				Cal, S; Connolly, BA			DNA distortion and base flipping by the EcoRV DNA methyltransferase - A study using interference at dA and T bases and modified deoxynucleoside	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVELY SUPERCOILED DNA; DIETHYL PYROCARBONATE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NUCLEIC-ACID; B-DNA; MODIFICATION METHYLASE; CHEMICAL PROBES; EXCISION-REPAIR; TARGET BASE	The EcoRV DNA methyltransferase introduces a CH3 group at the 6-amino position of the first dA in the duplex sequence d(GATATC), It has previously been reported that the methylase contacts the four phosphates (pNpNpGpA) at, and preceding, the 5'-end of the recognition sequence as well as the single dG in this sequence (Szczelkun, M, D,, Jones, H., and Connolly, B, A, (1995) Biochemistry 34, 10734-10743), To study the possible role of the dA and T bases within the ATAT sequence, interference studies have been carried out using diethylpyrocarbonate and osmium tetroxide, The methylase bound very strongly to hemimethylated oligonucleotides modified at the second AT, of the ATAT sequence, in the unmethylated strand of the duplex, This probably arises because these modifications facilitate DNA distortion that follows the binding of the nucleic acid to the protein, Oligonucleotides containing modified bases at both the target dA base and its complementary T were used to determine whether this dA methylase flips out its target base in a similar manner to that observed for dC DNA methylases, In binary EcoRV methylase-DNA complexes, analogues that weakened the base pair caused an increase in affinity between the protein and the nucleic acid, In contrast, in ternary EcoRV methylase-DNA-sinefungin (an analogue of the natural co factor, S-adenosyl-L-methionine (AdoMet)) complexes, only small differences in affinity were observed between the normal dA-T base pair and the analogues, These results are almost identical to those seen with DNA dC methylases (Klimasauskas, S,, and Roberts R, J, (1995) Nucleic Acid Res, 23, 1388-1395; Yang, S, A., Jiang-Cheng, S,, Zingg, J, M,, Mi, S,, and Jones, P, A, (1995) Nucleic Acids Res, 23, 1380-1387) and support a base-flipping mechanism for DNA dA methylases.	UNIV NEWCASTLE,DEPT BIOCHEM & GENET,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND	Newcastle University - UK								Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; CALLADINE CR, 1982, J MOL BIOL, V161, P343, DOI 10.1016/0022-2836(82)90157-7; CONNOLLY BA, 1992, METHOD ENZYMOL, V211, P36; CONNOLLY BA, 1991, OLIGONUCLEOTIDES ANA, P155; DICKERSON RE, 1983, J MOL BIOL, V166, P419, DOI 10.1016/S0022-2836(83)80093-X; FOX KR, 1990, NUCLEIC ACIDS RES, V16, P3655; HERR W, 1985, P NATL ACAD SCI USA, V82, P8009, DOI 10.1073/pnas.82.23.8009; HEUER C, 1988, J MOL BIOL, V202, P407, DOI 10.1016/0022-2836(88)90274-4; JAPPESEN C, 1988, FEBS LETT, V231, P172; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEONARD NJ, 1971, BIOCHEMISTRY-US, V10, P3335, DOI 10.1021/bi00794a003; LESSER DR, 1993, P NATL ACAD SCI USA, V90, P7548, DOI 10.1073/pnas.90.16.7548; LILLEY DMJ, 1984, EMBO J, V3, P1187, DOI 10.1002/j.1460-2075.1984.tb01949.x; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Manfield I, 1994, Methods Mol Biol, V30, P125; Maxam A.M., 1980, METHODS ENZYMOL, V65, P449; MAZZARELLI JM, 1992, BIOCHEMISTRY-US, V31, P5925, DOI 10.1021/bi00140a032; MCCLELLAN JA, 1987, J MOL BIOL, V197, P707, DOI 10.1016/0022-2836(87)90477-3; MCLELLAN JA, 1994, METHOD MOL BIOL, V30, P97; MEANS GE, 1971, CHEM MODIFICATION PR, P81; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; NEWMAN PC, 1990, BIOCHEMISTRY-US, V29, P9891, DOI 10.1021/bi00494a020; NWOSU VU, 1988, NUCLEIC ACIDS RES, V16, P3705, DOI 10.1093/nar/16.9.3705; PALACEK E, 1992, METHOD ENZYMOL, V212, P305; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PEATTIE DA, 1980, P NATL ACAD SCI-BIOL, V77, P4679, DOI 10.1073/pnas.77.8.4679; PORTUGAL J, 1988, NUCLEIC ACIDS RES, V16, P3655, DOI 10.1093/nar/16.9.3655; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; RUNKEL L, 1986, J MOL BIOL, V189, P487, DOI 10.1016/0022-2836(86)90319-0; Sambrook J., 2002, MOL CLONING LAB MANU; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; SUZUKI M, 1995, NUCLEIC ACIDS RES, V23, P2083, DOI 10.1093/nar/23.12.2083; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10734, DOI 10.1021/bi00034a005; SZCZELKUN MD, 1995, BIOCHEMISTRY-US, V34, P10724, DOI 10.1021/bi00034a004; Taylor J D, 1994, Methods Mol Biol, V30, P263; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WILSON GG, 1992, METHOD ENZYMOL, V216, P259; WISSMANN A, 1991, METHOD ENZYMOL, V208, P365; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	49	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					490	496						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995288				2022-12-25	WOS:A1997WA56400075
J	Saha, N; Banerjee, KK				Saha, N; Banerjee, KK			Carbohydrate-mediated regulation of interaction of Vibrio cholerae hemolysin with erythrocyte and phospholipid vesicle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCAL ALPHA-TOXIN; EL-TOR; CONCANAVALIN-A; MEMBRANE; PROTEINS; PURIFICATION; RECEPTOR; GLYCOPROTEIN; CYTOLYSIN; LECTINS	Vibrio cholerae hemolysin is an extracellular pore-forming monomeric protein with a native molecular weight of about 60,000. In this study, we showed that the hemolysin interacted with immobilized phospholipids and cholesterol and formed oligomers in vesicles constituted from phospholipids alone with a stoichiometry identical to those produced in rabbit erythrocyte membrane. However, the hemolysin bound to glycoproteins with terminal beta 1-galactosyl residues and an association constant of 9.4 x 10(7) M(-1) was estimated for the hemolysin-asialofetuin complex by solid phase binding assay. Oligomerization of the hemolysin in lipid bilayer converted the sugar-binding monomer to a lectin with strong carbohydrate-dependent hemagglutinating activity accompanied by inactivation of hemolytic activity and loss in ability to interact with phospholipids. There was no evidence for erythrocyte surface carbohydrates playing an essential role in interaction of the hemolysin with the cell, However, specific glycoproteins inhibited hemolysis of rabbit erythrocytes as well as interaction of the hemolysin with phospholipid. The results suggest (i) V. cholerae hemolysin is a monomer with distinct domains associated with specific binding to carbohydrates and interaction with lipids, (ii) the pore-forming property depends solely on the protein-lipid interaction with no evidence for involvement of sugars, and (iii) specific sugars can down-regulate the ability of the hemolysin to form pores in lipid bilayers.	NATL INST CHOLERA & ENTER DIS, DIV IMMUNOL & VACCINE DEV, CALCUTTA 700010, W BENGAL, INDIA	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)								Barondes S.H., 1986, LECTINS PROPERTIES F, P467; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BOLDT DH, 1977, BIOCHEM BIOPH RES CO, V74, P208, DOI 10.1016/0006-291X(77)91395-X; BUCKELEW AR, 1971, BIOCHIM BIOPHYS ACTA, V233, P7, DOI 10.1016/0005-2736(71)90352-X; CUATRECA.P, 1973, BIOCHEMISTRY-US, V12, P1312, DOI 10.1021/bi00731a011; Dahlquist F W, 1978, Methods Enzymol, V48, P270; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; GOLDBERG SL, 1984, J BACTERIOL, V160, P239, DOI 10.1128/JB.160.1.239-244.1984; GOLDSTEIN IJ, 1965, BIOCHEMISTRY-US, V4, P876, DOI 10.1021/bi00881a013; HARSHMAN S, 1985, INFECT IMMUN, V48, P114, DOI 10.1128/IAI.48.1.114-118.1985; HONDA T, 1979, INFECT IMMUN, V26, P1020, DOI 10.1128/IAI.26.3.1020-1027.1979; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; ICHINOSE Y, 1987, INFECT IMMUN, V55, P1090, DOI 10.1128/IAI.55.5.1090-1093.1987; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; KAPER JB, 1995, CLIN MICROBIOL REV, V8, P48, DOI 10.1128/CMR.8.1.48; KATO I, 1976, INFECT IMMUN, V13, P289, DOI 10.1128/IAI.13.1.289-291.1976; KRASILNIKOV OV, 1992, BIOCHIM BIOPHYS ACTA, V1111, P7, DOI 10.1016/0005-2736(92)90268-Q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MAHARAJ I, 1980, CAN J MICROBIOL, V26, P524, DOI 10.1139/m80-088; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MORRELL AG, 1972, METHOD ENZYMOL, V28, P205; NICOLSON GL, 1974, INT REV CYTOL, V39, P89, DOI 10.1016/S0074-7696(08)60939-0; OJCIUS DM, 1991, TRENDS BIOCHEM SCI, V16, P225, DOI 10.1016/0968-0004(91)90090-I; RADER AE, 1988, INFECT IMMUN, V56, P1414, DOI 10.1128/IAI.56.6.1414-1419.1988; RICHARDSON CE, 1976, J MOL BIOL, V102, P441, DOI 10.1016/0022-2836(76)90326-0; Segrest J P, 1971, Biochem Biophys Res Commun, V44, P390; ROWE GE, 1994, METHOD ENZYMOL, V235, P657; SAHA N, 1995, J BACTERIOL, V177, P758, DOI 10.1128/jb.177.3.758-764.1995; SANDLIN RC, 1995, INFECT IMMUN, V63, P229, DOI 10.1128/IAI.63.1.229-237.1995; SEN K, 1991, J BACTERIOL, V173, P926, DOI 10.1128/jb.173.2.926-928.1991; SHARON N, 1982, PROTEINS, V5, P1; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; STANLEY PLD, 1993, MOL MICROBIOL, V10, P781, DOI 10.1111/j.1365-2958.1993.tb00948.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARREN L, 1959, J BIOL CHEM, V234, P1971; WILLIAMS SG, 1993, MOL MICROBIOL, V9, P751, DOI 10.1111/j.1365-2958.1993.tb01735.x; YAMAMOTO K, 1984, INFECT IMMUN, V45, P192, DOI 10.1128/IAI.45.1.192-196.1984; ZITZER A, 1995, MED MICROBIOL IMMUN, V184, P37, DOI 10.1007/BF00216788	39	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					162	167						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995242	hybrid			2022-12-25	WOS:A1997WA56400029
J	Nielsen, MD; Chan, GCK; Poser, SW; Storm, DR				Nielsen, MD; Chan, GCK; Poser, SW; Storm, DR			Differential regulation of type I and type VIII Ca2+-stimulated adenylyl cyclases by G(i)-coupled receptors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; DROSOPHILA LEARNING MUTANT; ISLET-ACTIVATING PROTEIN; LONG-TERM POTENTIATION; ADP-RIBOSYLATION; CYCLIC-AMP; RAT-BRAIN; PERTUSSIS TOXIN; SOMATOSTATIN RECEPTORS; HORMONAL-STIMULATION	Coupling of intracellular Ca2+ to cAMP increases may be important for some forms of synaptic plasticity. The type I adenylyl cyclase (I-AC) is a neural-specific, Ca2+. stimulated enzyme that couples intracellular Ca2+ to cAMP increases. Since optimal cAMP levels may be crucial for some types of synaptic plasticity, mechanisms for inhibition of Ca2+-stimulated adenylyl cyclases may also be important for neuroplasticity. Here we report that Ca2+ stimulation of I-AC is inhibited by activation of G(i)-coupled somatostatin and dopamine D(2)L receptors. This inhibition is due primarily to G(i alpha) and not beta gamma subunits since coexpression of beta gamma-binding proteins with I-AC did not affect somatostatin inhibition. However, beta gamma released from G(s) did inhibit I-AC, indicating that the enzyme can be inhibited by beta gamma in vivo. Interestingly, type VIII adenylyl cyclase (VIII-AC), another Ca2+-stimulated adenylyl cyclase, was not inhibited by G(i)-coupled receptors. These data indicate that I-AC and VIII-AC are differentially regulated by G(i)-coupled receptors and provide distinct mechanisms for interactions between the Ca2+ and cAMP signal transduction systems. We propose that I-AC may be particularly important for synaptic plasticity that depends upon rapid and transient cAMP increases, whereas VIII-AC may contribute to transcriptional-dependent synaptic plasticity that is dependent upon prolonged, Ca2+-stimulated cAMP increases.	UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle								ABRAMS TW, 1991, J NEUROSCI, V11, P2655; BACKSAI BJ, 1993, SCIENCE, V260, P222; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BELL GI, 1993, TRENDS NEUROSCI, V16, P34, DOI 10.1016/0166-2236(93)90050-V; BURNS DL, 1983, J BIOL CHEM, V258, P1435; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOI EJ, 1992, BIOCHEMISTRY-US, V31, P6492, DOI 10.1021/bi00143a019; CHOI EJ, 1992, J BIOL CHEM, V267, P12440; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; FEANY MB, 1990, P NATL ACAD SCI USA, V87, P2795, DOI 10.1073/pnas.87.7.2795; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HSIA JA, 1984, J BIOL CHEM, V259, P1086; IMPEY S, 1994, MOL CELL BIOL, V14, P8272, DOI 10.1128/MCB.14.12.8272; Impey S, 1996, NEURON, V16, P973, DOI 10.1016/S0896-6273(00)80120-8; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KATADA T, 1982, J BIOL CHEM, V257, P7210; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAW SF, 1993, J BIOL CHEM, V268, P10721; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; LUTTRELL LM, 1995, J BIOL CHEM, V270, P12984, DOI 10.1074/jbc.270.22.12984; Matthies H, 1990, Adv Exp Med Biol, V268, P359; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; REISINE T, 1995, NEUROSCIENCE, V67, P777, DOI 10.1016/0306-4522(95)00072-Q; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SHEN Y, 1993, J BIOL CHEM, V268, P18200; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; TOTA MR, 1990, MOL PHARMACOL, V37, P950; Tsu RC, 1996, J NEUROSCI, V16, P1317; VILLACRES EC, 1995, J BIOL CHEM, V270, P14352, DOI 10.1074/jbc.270.24.14352; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; WAYMAN GA, 1995, J BIOL CHEM, V270, P21480, DOI 10.1074/jbc.270.37.21480; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WEST RE, 1985, J BIOL CHEM, V260, P4428; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WU ZL, 1995, P NATL ACAD SCI USA, V92, P220, DOI 10.1073/pnas.92.1.220; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; XIA ZG, 1995, BEHAV BRAIN SCI, V18, P429, DOI 10.1017/S0140525X00039194; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; Yan K, 1996, J BIOL CHEM, V271, P17597, DOI 10.1074/jbc.271.30.17597; YOKOYAMA C, 1994, J COMP NEUROL, V344, P121, DOI 10.1002/cne.903440109; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	67	70	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33308	33316		10.1074/jbc.271.52.33308	http://dx.doi.org/10.1074/jbc.271.52.33308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969190	hybrid			2022-12-25	WOS:A1996WA71300024
J	ODay, CL; DalbadieMcFarland, G; Abelson, J				ODay, CL; DalbadieMcFarland, G; Abelson, J			The Saccharomyces cerevisiae Prp5 protein has RNA-dependent ATPase activity with specificity for U2 small nuclear RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SPLICING FACTOR; STRUCTURAL ELEMENT; HELICASE ACTIVITY; HELA-CELLS; YEAST; INVITRO; SNRNP; BINDING; FAMILY	The Saccharomyces cerevisiae protein Prp5 is a member of the ''DEAD box'' family of putative RNA-dependent ATPases and helicases. The protein was purified from Escherichia coli and determined to be an RNA-dependent ATPase. The ATPase activity is 7-fold more specific for full-length U2 than for any of the other small nuclear RNAs or nonspecific RNAs tested. An RNaseH assay in extracts was used to demonstrate that Prp5 mediates an ATP-dependent conformational change in the intact U2 small nuclear ribonucleoprotein. We propose that this conformational change makes the branch point pairing sequence of U2 RNA accessible for pairing with the intron allowing formation of the pre-spliceosome.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032637, R37GM032637] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32637] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CLAUDE A, 1991, J BIOL CHEM, V266, P10358; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GEIDER K, 1981, ANNU REV BIOCHEM, V50, P233, DOI 10.1146/annurev.bi.50.070181.001313; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; MADHANI HD, 1992, ANNU REV GENET, V28, P677; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; Moore M., 1993, RNA WORLD, P303; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; RAY BK, 1985, J BIOL CHEM, V260, P7651; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHUSTER EO, 1988, CELL, V55, P41, DOI 10.1016/0092-8674(88)90007-4; SILICIANO PG, 1991, NUCLEIC ACIDS RES, V19, P6367, DOI 10.1093/nar/19.23.6367; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; WEINER A, 1993, CELL, V72, P1; WEIST D, 1996, J BIOL CHEM, V271, P33268; WELLS SE, 1994, MOL CELL BIOL, V14, P6337, DOI 10.1128/MCB.14.9.6337; Yan D, 1996, MOL CELL BIOL, V16, P818; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521	35	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33261	33267		10.1074/jbc.271.52.33261	http://dx.doi.org/10.1074/jbc.271.52.33261			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969184	hybrid, Green Accepted			2022-12-25	WOS:A1996WA71300018
J	Zou, YZ; Komuro, I; Yamazaki, T; Aikawa, R; Kudoh, S; Shiojima, I; Hiroi, Y; Mizuno, T; Yazaki, Y				Zou, YZ; Komuro, I; Yamazaki, T; Aikawa, R; Kudoh, S; Shiojima, I; Hiroi, Y; Mizuno, T; Yazaki, Y			Protein kinase C, but not tyrosine kinases or Ras, plays a critical role in angiotensin II-induced activation of Raf-1 kinase and extracellular signal-regulated protein kinases in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; S6 PEPTIDE KINASE; GENE-EXPRESSION; MECHANICAL-STRESS; IN-VITRO; SEQUENTIAL ACTIVATION; DEPENDENT PATHWAYS; MAP KINASES; HYPERTROPHY; PHOSPHORYLATION	Angiotensin II (AngII) induces cardiac hypertrophy through activating a variety of protein kinases. In this study, to understand how cardiac hypertrophy develops, we examined AngII-evoked signal transduction pathways leading to the activation of extracellular signal regulated protein kinases (ERKs), which are reportedly critical for the development of cardiac hypertrophy, in cultured cardiac myocytes isolated from neonatal rats. Inhibition of protein kinase C (PKC) with calphostin C or down-regulation of PKC by pretreatment with a phorbol ester for 24 h abolished AngII-induced activation of Raf-1 and ERKs, and addition of a phorbol ester conversely induced a marked increase in the activities of Raf-1 and ERKs. Pretreatment with two chemically and mechanistically dissimilar tyrosine kinase inhibitors, genistein and tyrphostin, did not attenuate AngII-induced activation of ERKs. In contrast, genistein strongly blocked insulin-induced ERK activation in cardiac myocytes. Although pretreatment with manumycin, a Ras farnesyltransferase inhibitor, or over-expression of a dominant negative mutant of Ras inhibited insulin-induced ERK activation, neither affected AngII-induced activation of ERKs. Overexpression of a dominant negative mutant of Raf-1 completely suppressed ERK2 activation by AngII, endothelin-1, and insulin. These results suggest that PKC and Raf-1, but not tyrosine kinases or Ras, are critical for AngII-induced activation of ERKs in cardiac myocytes.	UNIV TOKYO,SCH MED,DEPT MED 3,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,HLTH SERV CTR,TOKYO 113,JAPAN	University of Tokyo; University of Tokyo								ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BAKER KM, 1992, ANNU REV PHYSIOL, V54, P227, DOI 10.1146/annurev.physiol.54.1.227; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; FULLER SJ, 1989, FEBS LETT, V247, P209, DOI 10.1016/0014-5793(89)81336-5; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; ITO H, 1991, CIRC RES, V69, P209, DOI 10.1161/01.RES.69.1.209; IZUMI T, 1991, J BIOL CHEM, V266, P7933; KIKUCHI A, 1992, ONCOGENE, V7, P289; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; LAMORTE VJ, 1994, J BIOL CHEM, V269, P13490; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MANN DL, 1989, CIRC RES, V64, P1079, DOI 10.1161/01.RES.64.6.1079; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PARKER TG, 1991, ANNU REV PHYSIOL, V53, P179; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; Post GR, 1996, FASEB J, V10, P741, DOI 10.1096/fasebj.10.7.8635691; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1995, CIRC RES, V76, P1; SATOH T, 1992, J BIOL CHEM, V267, P24149; Schieffer B, 1996, J BIOL CHEM, V271, P10329, DOI 10.1074/jbc.271.17.10329; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SIMPSON P, 1983, J CLIN INVEST, V72, P732, DOI 10.1172/JCI111023; TERADA Y, 1995, KIDNEY INT, V48, P1801, DOI 10.1038/ki.1995.478; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1995, MOL BIOL CELL, V6, P1479, DOI 10.1091/mbc.6.11.1479; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; TOBE K, 1992, J BIOL CHEM, V267, P21089; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YAO A, 1995, J CLIN INVEST, V96, P69, DOI 10.1172/JCI118081	50	195	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33592	33597		10.1074/jbc.271.52.33592	http://dx.doi.org/10.1074/jbc.271.52.33592			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969227	hybrid			2022-12-25	WOS:A1996WA71300061
J	Gregoire, C; RosinskiChupin, I; Rabillon, J; Alzari, PM; David, B; Dandeu, JP				Gregoire, C; RosinskiChupin, I; Rabillon, J; Alzari, PM; David, B; Dandeu, JP			cDNA cloning and sequencing reveal the major horse allergen Equ c1 to be a glycoprotein member of the lipocalin superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOL-BINDING-PROTEIN; LIGAND CARRIER PROTEINS; GLOBULIN GENE FAMILY; URINARY PROTEIN; MESSENGER-RNAS; BETA-LACTOGLOBULIN; MOUSE; PURIFICATION; EXPRESSION; CHROMATOGRAPHY	The gene encoding the major horse allergen, designated Equus caballus allergen 1 (Equ c1), was cloned from total cDNA of sublingual salivary glands by reverse transcription-polymerase chain reaction using synthetic degenerate oligonucleotides deduced from N-terminal and internal peptide sequences of the glycosylated hair dandruff protein. A recombinant form of the protein, with a polyhistidine tail, was expressed in Escherichia coli and purified by immobilized metal affinity chromatography. The recombinant protein is able to induce a passive cutaneous anaphylaxis reaction in rat, and it behaves similarly to the native Equ c1 in several immunological tests with allergic patients' IgE antibodies, mouse monoclonal antibodies, or rabbit polyclonal IgG antibodies. Amino acid sequence identity of 49-51% with rodent urinary proteins from mice and rats suggests that Equ c1 is a new member of the lipocalin superfamily of hydrophobic ligand-binding proteins that includes several other major allergens. An RNA blot analysis demonstrates the expression of mRNA Equ c1 in liver and in sublingual and submaxillary salivary glands.	INST PASTEUR,DEPT IMMUNOL,UNITE GENET & BIOCHIM DEV,F-75024 PARIS 15,FRANCE; INST PASTEUR,DEPT IMMUNOL,UNITE IMMUNOL STRUCT,F-75024 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gregoire, C (corresponding author), INST PASTEUR,DEPT PHYSIOPATHOL,UNITE IMMUNOALLERGIE,28 RUE DR ROUX,F-75024 PARIS 15,FRANCE.			Alzari, Pedro/0000-0002-4233-1903				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Arruda LK, 1995, J BIOL CHEM, V270, P31196, DOI 10.1074/jbc.270.52.31196; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; CASEY JL, 1995, J IMMUNOL METHODS, V179, P105, DOI 10.1016/0022-1759(94)00278-5; CESKA M, 1972, INT ARCH ALLER A IMM, V43, P427, DOI 10.1159/000230859; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108; DANDEU JP, 1995, J ALLERGY CLIN IMMUN, V95, P348; DANDEU JP, 1993, J CHROMATOGR-BIOMED, V621, P23, DOI 10.1016/0378-4347(93)80072-C; DOLAN KP, 1982, J BIOL CHEM, V257, P13527; DUDLER T, 1995, J IMMUNOL, V155, P2605; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; FRANKE D, 1990, INT ARCH ALLER A IMM, V92, P309, DOI 10.1159/000235195; GAO F, 1989, NUCLEIC ACIDS RES, V17, P4629, DOI 10.1093/nar/17.12.4629; HENZEL WJ, 1988, J BIOL CHEM, V263, P16682; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAMERLING JP, 1975, BIOCHEM J, V151, P491, DOI 10.1042/bj1510491; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORUSSO JR, 1986, J ALLERGY CLIN IMMUN, V78, P928, DOI 10.1016/0091-6749(86)90242-3; LOWENSTEIN H, 1976, INT ARCH ALLER A IMM, V51, P38, DOI 10.1159/000231577; LOWENSTEIN H, 1978, INT ARCH ALLER A IMM, V57, P349, DOI 10.1159/000232124; MACINNES JI, 1986, MOL CELL BIOL, V6, P3563, DOI 10.1128/MCB.6.10.3563; Mantyjarvi R. A., 1996, Journal of Allergy and Clinical Immunology, V97, P212, DOI 10.1016/S0091-6749(96)80335-6; NAGATA A, 1991, P NATL ACAD SCI USA, V88, P4020, DOI 10.1073/pnas.88.9.4020; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; NORTH ACT, 1989, J MOL GRAPHICS, V7, P67, DOI 10.1016/S0263-7855(89)80001-3; OVARY Z, 1975, INT ARCH ALLER A IMM, V48, P16, DOI 10.1159/000231289; PAPIZ MZ, 1986, NATURE, V324, P383, DOI 10.1038/324383a0; PEVSNER J, 1988, SCIENCE, V241, P336, DOI 10.1126/science.3388043; PONTERIUS G, 1973, INT ARCH ALLER A IMM, V44, P679, DOI 10.1159/000230970; REDL B, 1992, J BIOL CHEM, V267, P20282; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMALE H, 1990, NATURE, V343, P366, DOI 10.1038/343366a0; SHAHAN K, 1987, MOL CELL BIOL, V7, P1947, DOI 10.1128/MCB.7.5.1947; SHAHAN K, 1987, MOL CELL BIOL, V7, P1938, DOI 10.1128/MCB.7.5.1938; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; STANWORTH DR, 1957, BIOCHEM J, V65, P582, DOI 10.1042/bj0650582; SULKOWSKI E, 1985, TRENDS BIOTECHNOL, V3, P1, DOI 10.1016/0167-7799(85)90068-X; SUTER F, 1988, BIOL CHEM H-S, V369, P497, DOI 10.1515/bchm3.1988.369.1.497; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TRONIK D, 1987, EMBO J, V6, P983, DOI 10.1002/j.1460-2075.1987.tb04848.x; UNTERMAN RD, 1981, P NATL ACAD SCI-BIOL, V78, P3478, DOI 10.1073/pnas.78.6.3478; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WALLS AF, 1985, J ALLERGY CLIN IMMUN, V75, P242, DOI 10.1016/0091-6749(85)90053-3	54	81	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32951	32959		10.1074/jbc.271.51.32951	http://dx.doi.org/10.1074/jbc.271.51.32951			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955138	Green Published, hybrid			2022-12-25	WOS:A1996VZ37300073
J	Librizzi, MD; Moir, RD; Brenowitz, M; Willis, IM				Librizzi, MD; Moir, RD; Brenowitz, M; Willis, IM			Expression and purification of the RNA polymerase III transcription specificity factor IIIB70 from Saccharomyces cerevisiae and its cooperative binding with TATA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL EXPRESSION; 2ND LARGEST SUBUNIT; DNA INTERACTIONS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FACTOR-TFIIIB; YEAST TFIIIB; MINOR-GROOVE; BOX COMPLEX; GENE	Transcription by RNA polymerase III (pol III) in yeast requires the assembly of an initiation complex comprising the TATA-binding protein (TBP), a 90-kDa polypeptide (TFIIIB90), and a 70-kDA polypeptide (TFIIIB70). TFIIIB70 interacts with TBP, a unique pol III subunit, C34, and the 131-kDa subunit of the pol III-specific complex, TFIIIC. TFIIIB70 was expressed in Escherichia coli and purified to homogeneity. The specific transcription activity of rTFIIIB(70) is 22-58% that of the native yeast and in vitro synthesized factor. However, only a small fraction (0.07-0.32%) of the TFIIIB70 from these sources results in the synthesis of full-length RNA. The data suggest that TFIIIB70 function may be limited by an unfavorable recruitment equilibrium into the preinitiation complex. Quantitative DNase I ''footprint'' titrations of yeast TBP to the adenovirus major late promoter were conducted at a series of constant TFIIIB70 concentrations. A value of -0.7 +/- 0.2 kcal/mol was determined for the cooperative free energy of formation of the TBP . TFIIIB70. DNA complex at concentrations of TFIIIB70 sufficient to partition all of the binding cooperatively to the TBP binding isotherm. A K-d of 44 +/- 23 nM characterizes the TFIIIB70 concentration dependence of the TBP . TFIIIB70 cooperativity. The relationship delta log K/delta log (TFIIIB70) is consistent with the linkage of a single molecule of TFIIIB70 with the TBP-promoter binding reaction.	ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine				Willis, Ian/0000-0001-6599-2395	NIGMS NIH HHS [GM07491, GM51506, GM42728] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051506, R01GM042728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1993, FOOTPRINTING TECHNIQ, P1; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURNOL AF, 1993, NATURE, V362, P475, DOI 10.1038/362475a0; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CHAUSSIVERT N, 1995, J BIOL CHEM, V270, P15353, DOI 10.1074/jbc.270.25.15353; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COLEMAN RA, 1995, J BIOL CHEM, V270, P13850, DOI 10.1074/jbc.270.23.13850; DALMAWEISZHAUSZ DD, 1992, BIOCHEMISTRY-US, V31, P6980, DOI 10.1021/bi00145a016; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; HORIKOSHI M, 1989, NATURE, V341, P299, DOI 10.1038/341299a0; Huang WB, 1996, NUCLEIC ACIDS RES, V24, P1158, DOI 10.1093/nar/24.6.1158; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KASSAVETIS GA, 1994, RAV S MOL C, V3, P107; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OTTONELLO S, 1994, BIOCHEM BIOPH RES CO, V203, P1217, DOI 10.1006/bbrc.1994.2312; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; PETRI V, 1995, BIOCHEMISTRY-US, V34, P9977, DOI 10.1021/bi00031a020; RAMEAU G, 1994, MOL CELL BIOL, V14, P822, DOI 10.1128/MCB.14.1.822; Ruth J, 1996, EMBO J, V15, P1941, DOI 10.1002/j.1460-2075.1996.tb00545.x; SAWADOGO M, 1985, P NATL ACAD SCI USA, V82, P4394, DOI 10.1073/pnas.82.13.4394; SCHMIDT MC, 1989, P NATL ACAD SCI USA, V86, P7785, DOI 10.1073/pnas.86.20.7785; SETHY I, 1995, J BIOL CHEM, V270, P28463; SETHY I, 1995, GENE EXPRESSION, V5, P35; STARR DB, 1995, J MOL BIOL, V250, P434; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG Y, 1995, P NATL ACAD SCI USA, V92, P8606, DOI 10.1073/pnas.92.19.8606; WERNER M, 1993, J BIOL CHEM, V268, P20721; WHITE RJ, 1994, RNA POLYM 3 TRANSCRI, P47; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x; WILLIS IM, 1982, NUCLEIC ACIDS RES, V20, P3725; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4	49	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32695	32701		10.1074/jbc.271.51.32695	http://dx.doi.org/10.1074/jbc.271.51.32695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955101	hybrid			2022-12-25	WOS:A1996VZ37300036
J	Iotsova, V; Crepieux, P; Montpellier, C; Laudet, V; Stehelin, D				Iotsova, V; Crepieux, P; Montpellier, C; Laudet, V; Stehelin, D			TATA-less promoters of some Ets-family genes are efficiently repressed by wild-type p53	ONCOGENE			English	Article						p53; Ets; promoter; repression	TRANSCRIPTIONAL ACTIVATION; BINDING PROTEIN; REGULATORY ELEMENTS; DNA; EXPRESSION; SEQUENCE; GROWTH; INITIATOR; INVITRO; DOMAIN	p53 has been reported to repress a number of TATA-containing promoters in transient transfection assays, TATA-less promoters are generally believed to be refractive to p53 repression. We report here that the TATA-less promoters of Ets-family genes (Ets-1 and Ets-2) are efficiently repressed by wild-type but not mutant p53 in transient co-transfection assays, Moreover, p53 was immunologically detected in protein complexes formed on oligonucleotides from both the TATA-containing and TATA-less promoters, Our data suggest that p53 is involved in the regulation of the expression of both promoter types, most probably by protein-protein interaction, A model for p53 function in promoter repression is proposed.	INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59018 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Crepieux, Pascale/X-3217-2019	MONTPELLIER, Claire/0000-0002-3112-8491				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAKER SJ, 1990, SCIENCE, V249, P913; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; CHEN JH, 1993, ONCOGENE, V8, P133; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Crepieux Pascale, 1993, Gene Expression, V3, P215; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAISST S, 1994, VIROLOGY, V202, P466, DOI 10.1006/viro.1994.1363; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HU SL, 1981, P NATL ACAD SCI-BIOL, V78, P820, DOI 10.1073/pnas.78.2.820; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Iotsova V, 1996, CELL GROWTH DIFFER, V7, P629; IOTSOVA V, 1995, EUR J CELL BIOL, V68, P122; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETH A, 1990, ONCOGENE, V5, P1761; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2335	49	20	21	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2331	2337						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957074				2022-12-25	WOS:A1996VX10800005
J	Li, J; Hu, SX; Perng, GS; Zhou, YL; Xu, K; Zhang, CY; Seigne, J; Benedict, WF; Xu, HJ				Li, J; Hu, SX; Perng, GS; Zhou, YL; Xu, K; Zhang, CY; Seigne, J; Benedict, WF; Xu, HJ			Expression of the retinoblastoma (RB) tumor suppressor gene inhibits tumor cell invasion in vitro	ONCOGENE			English	Article						tumor suppressor gene; retinoblastoma (RB) gene; p53; tumor invasion; inducible gene expression	QUANTITATIVE ASSAY; BASEMENT-MEMBRANE; PROTEIN; CARCINOMA; MATRIX; TRANSCRIPTION; ASSOCIATION; ACTIVATION; GROWTH; CYCLE	To determine if replacement of the retinoblastoma (RE) tumor suppressor gene could inhibit invasion of RB-defective tumor cells, the capacity of tumor cells to migrate or invade was quantitated by the Boyden chamber assay, The studies were done in a diverse group of stable RE-reconstituted human tumor cell lines, including those derived from the osteosarcoma and carcinomas of the lung, breast and bladder, The expression of the exogenous wildtype RE protein in these tumor cell lines was driven by either a constitutively active promoter or an inducible promoter, It was found that significantly more tumor cells from the parental RE-defective cell lines and the RB(-) revertants than from the RE-reconstituted RB(+) cell lines penetrated through the Matrigel (P < 0.001, two-tailed t-test), although both RB(+) and RB(-) cells migrated at approximately the same rate on uncoated polycarbonate filters in the Boyden chambers, Of note, the inhibition of invasiveness of various RE-defective tumor cells by RE replacement was apparently web correlated with suppression of their tumorigenicity in vivo. In contrast, although either functional RE or p53 re-expression effectively suppressed tumor formation in nude mice of the RB(-)/p53(nuII) osteosarcoma cell line, Saos-2, replacement of the wild-type p53 gene had much less impact on their invasiveness as compared to the RE gene, These studies provided an insight into the broader biological basis of the RE-mediated tumor suppression in RE-defective tumor cells.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL ONCOL,THE WOODLANDS,TX 77381; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,THE WOODLANDS,TX 77381; BAYLOR COLL MED,CTR BIOTECHNOL,THE WOODLANDS,TX 77381	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine				Zhou, Yunli/0000-0003-4831-209X	NATIONAL CANCER INSTITUTE [R01CA067274] Funding Source: NIH RePORTER; NCI NIH HHS [CA-67274] Funding Source: Medline; NEI NIH HHS [EY-06195] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBINI A, 1987, CANCER RES, V47, P3239; AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BIGNON YJ, 1993, GENE DEV, V7, P1654, DOI 10.1101/gad.7.9.1654; BROWN PD, 1993, J NATL CANCER I, V85, P574, DOI 10.1093/jnci/85.7.574; Dawson D. W., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P88; FIECK A, 1992, NUCLEIC ACIDS RES, V20, P1785, DOI 10.1093/nar/20.7.1785; Geng Y, 1996, ONCOGENE, V12, P1173; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P3; HART IR, 1978, CANCER RES, V38, P3218; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KARIKO K, 1993, CANCER RES, V53, P3109; KLEIN G, 1990, BIOESSAYS, V12, P347, DOI 10.1002/bies.950120708; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1980, CANCER LETT, V11, P141, DOI 10.1016/0304-3835(80)90105-6; LU YM, 1994, ONCOGENE, V9, P1015; Lu YM, 1996, J IMMUNOL, V156, P2495; NEVINS JR, 1992, SCIENCE, V258, P424; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STARKEY JR, 1984, CANCER RES, V44, P1585; TERANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465; XU HJ, 1991, ONCOGENE, V6, P1139; Xu HJ, 1996, CANCER RES, V56, P2245; XU HJ, 1995, ADV ANAT PATHOL, V2, P213; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	30	39	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2379	2386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957079				2022-12-25	WOS:A1996VX10800010
J	Cooper, DNW; Boulianne, RP; Charlton, S; Farrell, EM; Sucher, A; Lu, BC				Cooper, DNW; Boulianne, RP; Charlton, S; Farrell, EM; Sucher, A; Lu, BC			Fungal galectins, sequence and specificity of two isolectins from Coprinus cinereus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; AMINO-ACID-SEQUENCE; CARBOHYDRATE-RECOGNITION DOMAINS; MYXOBACTERIAL HEMAGGLUTININ; ANIMAL LECTINS; NUCLEOTIDE-SEQUENCE; MYXOCOCCUS-XANTHUS; ENDOGENOUS LECTIN; MOLECULAR-CLONING; MESSENGER-RNA	Galectins are members of a genetically related family of beta-galactoside-binding lectins. At least eight distinct mammalian galectins have been identified. More distantly related, but still conserving amino acid residues critical for carbohydrate-binding, are galectins in chicken, eel, frog, nematode, and sponge. Here we report that galectins are also expressed in a species of fungus, the inky cap mushroom, Coprinus cinereus. Two dimeric galectins are expressed during fruiting body formation which are 83% identical to each other in amino acid sequence and conserve all key residues shared by members of the galectin family. Unlike most galectins, these have no N-terminal post-translational modification and no cysteine residues. We expressed one of these as a recombinant protein and studied its carbohydrate-binding specificity using a novel nonradioactive assay. Binding specificity has been well studied for a number of other galectins, and like many of these, the recombinant C. cinereus galectin shows particular affinity for blood group A structures. These results demonstrate not only that the galectin gene family is evolutionarily much older than previously realized but also that fine specificity for complex saccharide structures has been conserved. Such conservation implies that galectins evolved to perform very basic cellular functions, presumably by interaction with glycoconjugates bearing complex lactoside carbohydrates resembling blood group A.	UNIV GUELPH,DEPT MOL BIOL & GENET,GUELPH,ON N1G 2W1,CANADA; UNIV CALIF SAN FRANCISCO,DEPT ANAT,SAN FRANCISCO,CA 94143	University of Guelph; University of California System; University of California San Francisco	Cooper, DNW (corresponding author), UNIV CALIF SAN FRANCISCO,LANGLEY PORTER PSYCHIAT INST,DEPT PSYCHIAT,CTR NEUROBIOL & PSYCHIAT,SAN FRANCISCO,CA 94143, USA.				NIAMS NIH HHS [AR41459] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR041459] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; AHMED H, 1994, GLYCOBIOLOGY, V4, P545, DOI 10.1093/glycob/4.5.545; BALDAUF SL, 1993, P NATL ACAD SCI USA, V90, P11558, DOI 10.1073/pnas.90.24.11558; BARONDES SH, 1987, METHOD CELL BIOL, V28, P387; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; CHARLTON S, 1992, GENE, V122, P163, DOI 10.1016/0378-1119(92)90044-P; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Cleves AE, 1996, J CELL BIOL, V133, P1017, DOI 10.1083/jcb.133.5.1017; CODINGTON JF, 1976, METHODS CARBOHYDRATE, V7, P226; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COOPER DNW, 1984, DEV BIOL, V105, P59, DOI 10.1016/0012-1606(84)90261-6; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; CRENSHAW RW, 1995, PLANT PHYSIOL, V107, P1465, DOI 10.1104/pp.107.4.1465; CROWLEY TE, 1985, CELL, V43, P633, DOI 10.1016/0092-8674(85)90235-1; CUMSKY MG, 1981, J BIOL CHEM, V256, P2581; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FUKUMORI F, 1990, J BIOCHEM-TOKYO, V107, P190, DOI 10.1093/oxfordjournals.jbchem.a123024; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hanisch FG, 1996, GLYCOBIOLOGY, V6, P321, DOI 10.1093/glycob/6.3.321; HARRISON FL, 1992, J CELL SCI, V101, P635; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; KAWAGISHI H, 1988, FEBS LETT, V277, P99; KAWAGUCHI N, 1986, BIOCHEM BIOPH RES CO, V140, P350, DOI 10.1016/0006-291X(86)91097-1; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; LeGendre N., 1989, PRACTICAL GUIDE PROT, P52; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; LU BC, 1988, EUR J BIOCHEM, V174, P725, DOI 10.1111/j.1432-1033.1988.tb14157.x; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; Moore D., 1995, GROWING FUNGUS, P423; NELSON DR, 1981, J BIOL CHEM, V256, P2589; NORBRINGHERTZ B, 1986, MICROBIAL LECTINS AG, P393; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; ODA Y, 1993, J BIOL CHEM, V268, P5929; ODA Y, 1991, GENE, V99, P279; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; PEMBERTON RT, 1994, MYCOL RES, V98, P277, DOI 10.1016/S0953-7562(09)80455-3; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROMEO JM, 1987, J BACTERIOL, V169, P3801, DOI 10.1128/jb.169.8.3801-3808.1987; Rosen S, 1996, EUR J BIOCHEM, V238, P822, DOI 10.1111/j.1432-1033.1996.0822w.x; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; Su ZZ, 1996, P NATL ACAD SCI USA, V93, P7252, DOI 10.1073/pnas.93.14.7252; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	71	95	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1514	1521		10.1074/jbc.272.3.1514	http://dx.doi.org/10.1074/jbc.272.3.1514			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999822	hybrid			2022-12-25	WOS:A1997WD05800020
J	GrahamLorence, S; Truan, G; Peterson, JA; Falck, JR; Wei, SZ; Helvig, C; Capdevila, JH				GrahamLorence, S; Truan, G; Peterson, JA; Falck, JR; Wei, SZ; Helvig, C; Capdevila, JH			An active site substitution, F87V, converts cytochrome p450 BM-3 into a regio- and stereoselective (14S,15R)-arachidonic acid epoxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-MEGATERIUM; ARACHIDONIC-ACID; FATTY-ACIDS; CRYSTAL-STRUCTURE; SYSTEM	Cytochrome P450 BM-3 catalyzes the high turnover regio and stereoselective metabolism of arachidonic and eicosapentaenoic acids, To map structural determinants of productive active site fatty acid binding, we mutated two amino acid residues, arginine 47 and phenylalanine 87, which flank the surface and heme ends of the enzyme's substrate access channel, respectively. Replacement of arginine 47 with glutamic acid resulted in a catalytically inactive mutant, Replacement of arginine 47 with alanine yielded a protein with reduced substrate binding affinity and arachidonate sp(3) carbon hydroxylation activity (72% of control wild type), On the other hand, arachidonic and eicosapentaenoic acid epoxidation was significantly enhanced (154 and 137%, of control wild type, respectively), As with wild type, the alanine 47 mutant generated (18R)-hydroxyeicosatetraenoic, (14S,15R)-epoxyeicosatrienoic, and (17S,18R)-epoxyeicosatetraenoic acids nearly enantiomerically pure. Replacement of phenylalanine 87 with valine converted cytochrome P450 BM-3 into a reso- and stereoselective arachidonic acid epoxygenase ((14S,15R)-epoxyeicosatrienoic acid, 99% of total products). Conversely, metabolism of eicosapentaenoic acid by the valine 87 mutant yielded a mixture of (14S,15R)- and (17S,18R)-epoxyeicosatetraenoic acids (26 and 69% of total, 94 and 96% optical purity, respectively), Finally, replacement of phenylalanine 87 with tyrosine yielded an inactive protein. We propose that: (a) fatty acid oxidation by P450 BM-3 is incompatible with the presence of residues with negatively charged side chains at the surface opening of the substrate access channel or a polar aromatic side chain in the vicinity of the heme iron; (b) the high turnover regio- and stereoselective metabolism of arachidonic and eicosapentaenoic acids involves charge-dependent anchoring of the fatty acids at the mouth of the access channel by arginine 47, as well as steric gating of the heme-bound oxidant by phenylalanine 87; and (c) substrate binding coordinates, as opposed to oxygen chemistries, are the determining factors responsible for reaction rates, product chemistry, and, thus, catalytic outcome.	VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT MOL GENET, DALLAS, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			; Truan, Gilles/C-7044-2019	Falck, John/0000-0002-9219-7845; Truan, Gilles/0000-0002-3560-8302	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278, R01GM043479] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31278, GM 37922, GM 43479] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; CAPDEVILA JH, 1991, METHOD ENZYMOL, V206, P441; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; Capdevila JH, 1996, J BIOL CHEM, V271, P22663, DOI 10.1074/jbc.271.37.22663; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; Capdevila Jorge H., 1995, P443; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MIURA Y, 1975, BIOCHIM BIOPHYS ACTA, V388, P305, DOI 10.1016/0005-2760(75)90089-2; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; Negishi M, 1996, FASEB J, V10, P683, DOI 10.1096/fasebj.10.7.8635685; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; OMURA T, 1964, J BIOL CHEM, V239, P2370; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; RUETTINGER RT, 1981, J BIOL CHEM, V256, P5728; WEN LP, 1987, J BIOL CHEM, V262, P6676	25	150	170	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1127	1135		10.1074/jbc.272.2.1127	http://dx.doi.org/10.1074/jbc.272.2.1127			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995412	hybrid			2022-12-25	WOS:A1997WC04800063
J	Venema, RC; Ju, H; Zou, R; Ryan, JW; Venema, VJ				Venema, RC; Ju, H; Zou, R; Ryan, JW; Venema, VJ			Subunit interactions of endothelial nitric-oxide synthase - Comparisons to the neuronal and inducible nitric-oxide synthase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; NO SYNTHASE; TETRAHYDROBIOPTERIN; ENZYME; PURIFICATION; IDENTIFICATION; BINDING; BIOSYNTHESIS; ASSOCIATION; MUTAGENESIS	Endothelial nitric-oxide synthase (eNOS) is comprised of two identical subunits. Each subunit has a bidomain structure consisting of an N-terminal oxygenase domain containing heme and tetrahydrobiopterin (BH,) and a C-terminal reductase domain containing binding sites for FAD, FMN, and NADPH. Each subunit is also myristoylated and contains a calmodulin (CaM)-binding site located between the oxygenase and reductase domains. In this study, wild-type and mutant forms of eNOS have been expressed in a baculovirus system, and the quaternary structure of the purified enzymes has been analyzed by low temperature SDS-PAGE. eNOS dimer formation requires incorporation of the heme prosthetic group but does not require myristoylation or CaM or BH, binding. In order to identify domains of eNOS involved in subunit interactions, we have also expressed eNOS oxygenase and reductase domain fusion proteins in a yeast two-hybrid system. Corresponding human neuronal NOS (nNOS) and murine inducible NOS (iNOS) fusion proteins have also been expressed. Comparative analysis of NOS domain interactions shows that subunit association of eNOS and nNOS involves not only head to head interactions of oxygenase domains but also tail to tail interactions of reductase domains and head to tail interactions between oxygenase and reductase domains. In contrast, iNOS subunit association involves only oxygenase domain interactions.	MED COLL GEORGIA, VASC BIOL CTR, DEPT PHARMACOL & TOXICOL, AUGUSTA, GA 30912 USA	University System of Georgia; Augusta University	Venema, RC (corresponding author), MED COLL GEORGIA, VASC BIOL CTR, DEPT PEDIAT, AUGUSTA, GA 30912 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL057201, R01HL057201] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57201] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albakri QA, 1996, J BIOL CHEM, V271, P5414, DOI 10.1074/jbc.271.10.5414; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BALLIGAND JL, 1995, AM J PHYSIOL-HEART C, V268, pH1293, DOI 10.1152/ajpheart.1995.268.3.H1293; BALLIGAND JL, 1995, J BIOL CHEM, V270, P14582, DOI 10.1074/jbc.270.24.14582; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Hellermann GR, 1996, FASEB J, V10, P2525; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEE CM, 1995, J BIOL CHEM, V270, P27403, DOI 10.1074/jbc.270.46.27403; List BM, 1996, BIOCHEM J, V315, P57, DOI 10.1042/bj3150057; LIU JW, 1995, BIOCHEMISTRY-US, V34, P12333, DOI 10.1021/bi00038a029; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; RIVEROSMORENO V, 1995, EUR J BIOCHEM, V230, P52; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; SHETA EA, 1994, J BIOL CHEM, V269, P15147; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; TRACEY WR, 1994, AM J PHYSIOL, V266, pC22, DOI 10.1152/ajpcell.1994.266.1.C22; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; WERNER ER, 1993, P SOC EXP BIOL MED, V203, P1; Xie QW, 1996, P NATL ACAD SCI USA, V93, P4891, DOI 10.1073/pnas.93.10.4891	41	122	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1276	1282		10.1074/jbc.272.2.1276	http://dx.doi.org/10.1074/jbc.272.2.1276			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995432	hybrid			2022-12-25	WOS:A1997WC04800083
J	Abdellatif, M; Schneider, MD				Abdellatif, M; Schneider, MD			An effector-like function of Ras GTPase-activating protein predominates in cardiac muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; GENE-EXPRESSION; GROWTH-FACTORS; SRC HOMOLOGY; SIGNAL TRANSDUCTION; TERMINAL REGION; KINASE DOMAIN; K+ CHANNELS; PC12 CELLS; S6 KINASE	In contrast to familiar role for Ras in proliferation, we and others previously suggested that Ras also mediates hypertrophy, the increase in cell mass characteristic of post-natal ventricular muscle. We showed that activated (G12R) and dominant-negative (S17N) Ha-Ras regulate ''constitutive'' and growth factor-responsive genes equivalently, in both cardiac myocytes and non-cardiac, Mv1Lu cells. Here, we attempt to delineate pathways by which Ras exerts this global effect. The E63K mutation, which impairs binding of guanine nucleotide releasing factor to Ras, alleviated suppression by S17N, consistent with sequestration of exchange factors as the mechanism for inhibition. To compare potential Ras effector proteins, we first engineered G12R/D38N, to abolish binding of Raf and phosphatidylinositol-3-kinase and established that this site was indispensable for augmenting gene expression. To distinguish between inhibition of Ras by Ras GTPase-activating protein (GAP) versus a potential effector function of GAP, we tested the effector domain substitution P34R: this mutation, which abolishes GAP binding, enhanced Ras-dependent transcription in Mv1Lu cells, yet interfered with Ras-dependent expression in ventricular myocytes. To examine the dichotomous role of Ras-GAP predicted from these P34R results, we transfected both cell types with full-length GAP, the C-terminal catalytic domain (cGAP), or N-terminal Src homology domains (nGAP). In Mv1Lu cells, cGAP markedly inhibited both reporter genes, whereas GAP and nGAP had little effect. Antithetically, in ventricular myocytes, GAP and nGAP activated gene expression, whereas cGAP was ineffective. Thus, Ras activates gene expression through differing effecters contingent on cell type, and an effector-like function of GAP predominates in ventricular muscle.	BAYLOR COLL MED, DEPT MED, MOL CARDIOL UNIT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOL PHYSIOL & BIOPHYS, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047567, P01HL049953] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL47567, R01 HL5255, P01 HL49953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF M, 1994, J BIOL CHEM, V269, P15423; ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAND T, 1993, J BIOL CHEM, V268, P11500; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; CHANG JS, 1995, EUR J BIOCHEM, V232, P691; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARK GJ, 1993, P NATL ACAD SCI USA, V90, P4887, DOI 10.1073/pnas.90.11.4887; CORNELL RA, 1994, DEVELOPMENT, V120, P453; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORD SR, 1992, ANAL BIOCHEM, V204, P283, DOI 10.1016/0003-2697(92)90239-4; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUTMANN DH, 1995, DEV DYNAM, V202, P302, DOI 10.1002/aja.1002020309; HIPSKIND RA, 1994, GENE DEV, V8, P1803, DOI 10.1101/gad.8.15.1803; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; Kirshenbaum LA, 1995, TRENDS CARDIOVAS MED, V5, P230, DOI 10.1016/1050-1738(95)00105-0; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KORACICMILIJOVE.B, 1992, MOL CELL BIOL, V12, P292; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; LEMBO D, 1994, J GEN VIROL, V75, P1685, DOI 10.1099/0022-1317-75-7-1685; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PARKER TG, 1990, J CLIN INVEST, V85, P507, DOI 10.1172/JCI114466; PAYNE PA, 1987, P NATL ACAD SCI USA, V84, P8956, DOI 10.1073/pnas.84.24.8956; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SADOSHIMA J, 1995, CIRC RES, V77, P1040, DOI 10.1161/01.RES.77.6.1040; SADOSHIMA J, 1993, EMBO J, V12, P1681, DOI 10.1002/j.1460-2075.1993.tb05813.x; Sadoshima J, 1996, EMBO J, V15, P775, DOI 10.1002/j.1460-2075.1996.tb00413.x; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STONE JC, 1993, MOL CELL BIOL, V13, P7311, DOI 10.1128/MCB.13.12.7311; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; Takano H, 1996, FEBS LETT, V379, P255, DOI 10.1016/0014-5793(95)01523-X; THORBURN A, 1993, J BIOL CHEM, V268, P2244; THORBURN J, 1994, J BIOL CHEM, V269, P30580; THORBURN J, 1994, J CELL BIOL, V126, P1565, DOI 10.1083/jcb.126.6.1565; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAO R, 1995, ONCOGENE, V11, P1607; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1991, J BIOL CHEM, V266, P22222; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	79	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					525	533						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995293				2022-12-25	WOS:A1997WA56400080
J	Bianchini, L; LAllemain, G; Pouyssegur, J				Bianchini, L; LAllemain, G; Pouyssegur, J			The p42/p44 mitogen-activated protein kinase cascade is determinant in mediating activation of the Na+/H+ exchanger (NHE1 isoform) in response to growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; MAMMALIAN-CELLS; HAMSTER FIBROBLASTS; CYTOPLASMIC DOMAIN; ALPHA-THROMBIN; OKADAIC ACID; HEAT-SHOCK; S6 KINASE; IN-VIVO; PHOSPHORYLATION	The ubiquitously expressed Na+/H+ exchanger NHE1 is the target of multiple signaling pathways, including those activated by tyrosine kinase receptors, G protein-coupled receptors, and integrins, The intracellular pathways leading to activation of NHE1 are poorly understood, To gain more insight into these activation pathways, we examined the role of mitogen-activated protein kinases (MAPKs) as potential mediators of NHE1 activation by extracellular stimuli such as growth factors and hyperosmotic stress. Whereas p44 MAPK does not appear to phosphorylate NHE1 in vitro, we found that inhibition of the p42/p44 MAPK signaling by expression of a dominant negative form of p44 MAPK, by expression of the MAP kinase phosphatase MKP-1, or by inhibition of MAPK kinase 1 (MKK1) with the PD 98059 compound reduced by 50-60% NHE1 activation in response to growth factors, This inhibitory effect also was observed in C-terminal NHE1 deletion mutants in which the major phosphorylation sites have been deleted, Furthermore, the use of a CCL39-derived cell line expressing an estradiol-regulated form of oncogenic Raf-1 (CCL39-Delta Raf-1:ER) revealed that the exclusive activation of the Raf --> MKK1 --> p42/p44 MAPK cascade was capable of inducing NHE1 activation to the same extent as potent growth factors like thrombin. Together, our findings demonstrate that the p42/p44 MAPK cascade plays a predominant role in the regulation of NHE1 by growth factors, an action that is mediated via accessory proteins that remain to be identified, In contrast, we found no evidence in favor of the contribution of any MAPK, p42/p44, p38 MAPKs, and Jun kinase, in NHE1 activation by osmotic stress.	UNIV NICE,CNRS,CTR BIOCHIM,F-06108 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur								ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BIANCHINI L, 1995, AM J PHYSIOL-CELL PH, V269, pC998, DOI 10.1152/ajpcell.1995.269.4.C998; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; GRINSTEIN S, 1985, P NATL ACAD SCI USA, V82, P1429, DOI 10.1073/pnas.82.5.1429; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; McSwine RL, 1996, J CELL PHYSIOL, V168, P8; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOOLENAAR WH, 1983, NATURE, V304, P645, DOI 10.1038/304645a0; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARIS S, 1984, J BIOL CHEM, V259, P989; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; POUYSSEGUR J, 1992, ANNU REV PHYSIOL, V54, P195, DOI 10.1146/annurev.ph.54.030192.001211; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TERADA Y, 1994, J BIOL CHEM, V269, P31296; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOURETCRAVIARI V, 1993, BIOCHEM J, V289, P209, DOI 10.1042/bj2890209; WAKABAYASHI S, 1992, P NATL ACAD SCI USA, V89, P2424, DOI 10.1073/pnas.89.6.2424; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583	58	165	169	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					271	279						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995258				2022-12-25	WOS:A1997WA56400045
J	Kang, HA; Lee, KN; Yu, MH				Kang, HA; Lee, KN; Yu, MH			Folding and stability of the Z and S-iiyama genetic variants of human alpha(1)-antitrypsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-SHEET POLYMERIZATION; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; INTRACELLULAR DEGRADATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; PROTEIN; ALPHA-1-ANTITRYPSIN; DISEASE; DEFICIENCY	Z (Glu(342) --> Lys) and S-iiyama (Ser(53) --> Phe) genetic variations of human alpha(1)-antitrypsin (alpha(1)-AT) cause a secretion blockage in the hepatocytes, leading to alpha(1)-AT deficiency in the plasma, Using in vitro folding analysis, we have shown previously that these mutations interfere with the proper folding of polypeptides. To understand the fundamental cause for the secretion defect of the Z and S-iiyama variants of alpha(1)-AT, we investigated in vivo folding and stability of these variant alpha(1)-AT using the secretion system of yeast Saccharomyces cerevisiae, Various thermostable mutations suppressing the folding block of the Z variant in vitro corrected the secretion defect as well as the intracellular degradation in the yeast secretion system, Significantly, the extent of suppression in the secretion defect of Z protein was proportional to the extent of suppression in the folding defect, assuring that the in vivo defect associated with the Z variant is primarily derived from the folding block. In contrast, the folding and secretion efficiency of S-iiyama was not much improved by the same mutations, In addition, none of the rarely secreted S-iiyama alpha(1)-AT carrying the stabilizing mutations for the wild type and Z variant were active, It appears that the major defect in S-iiyama variant is the loss of stability in contrast to the kinetic block of folding in the Z variant.	KOREA ADV INST SCI & TECHNOL,KOREA RES INST BIOSCI & BIOTECHNOL,DIV PROT ENGN,YUSONG 305600,TAEJON,SOUTH KOREA; KOREA ADV INST SCI & TECHNOL,KOREA RES INST BIOSCI & BIOTECHNOL,DIV APPL MICROBIOL,YUSONG 305600,TAEJON,SOUTH KOREA	Korea Advanced Institute of Science & Technology (KAIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)								Carrell RW, 1996, BIOL CHEM H-S, V377, P1; CRYSTAL RG, 1989, TRENDS GENET, V5, P411, DOI 10.1016/0168-9525(89)90200-X; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GRAHAM KS, 1990, J BIOL CHEM, V265, P20463; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Helms LR, 1996, J MOL BIOL, V257, P77, DOI 10.1006/jmbi.1996.0148; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KANG HA, 1993, J BIOL CHEM, V268, P14750; Kang HA, 1996, J BIOTECHNOL, V48, P15, DOI 10.1016/0168-1656(96)01391-0; KIM JH, 1995, J BIOL CHEM, V270, P8597, DOI 10.1074/jbc.270.15.8597; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LE A, 1990, J BIOL CHEM, V265, P14001; LE AQ, 1992, J BIOL CHEM, V267, P1072; LE AQ, 1994, J BIOL CHEM, V269, P7514; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; MATOBA S, 1988, MOL CELL BIOL, V8, P4904, DOI 10.1128/MCB.8.11.4904; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SIDHAR SK, 1995, J BIOL CHEM, V270, P8393, DOI 10.1074/jbc.270.15.8393; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Teckman JH, 1996, J BIOL CHEM, V271, P13215, DOI 10.1074/jbc.271.22.13215; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; WU Y, 1994, P NATL ACAD SCI USA, V91, P9014, DOI 10.1073/pnas.91.19.9014; YU MH, 1995, NAT STRUCT BIOL, V2, P363, DOI 10.1038/nsb0595-363	33	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					510	516						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995291				2022-12-25	WOS:A1997WA56400078
J	Chagnovich, D; Fayos, BE; Cohn, SL				Chagnovich, D; Fayos, BE; Cohn, SL			Differential activity of ELAV-like RNA-binding proteins in human neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AU-RICH ELEMENTS; ANTI-HU ANTIBODY; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; IN-VITRO; C-FOS; N-MYC; EXPRESSION; GENES	Many short-lived mRNAs contain AU-rich instability elements within their 3'-untranslated region. Cellular factors that bind to these elements are thought to play a role in the regulation of mRNA degradation. In the accompanying paper (Chagnovich, D., and Cohn, S. L. (1996) J. Biol. Chem. 271, 33580-33586) we characterized the binding activity of a 40-kDa protein (p40) that interacts with high specificity with at least two AU-rich elements located within the 3'-untranslated region of N-myc. p40 activity correlates with N-myc mRNA stability in subclones of the NBL-W neuroblastoma cells line (W-N and W-S). In an effort to determine the identity of p40 we performed immunoblotting studies, immunoprecipitation experiments, and RNA gel mobility shift assays using antibodies that are directed against known RNA-binding proteins. In this paper we demonstrate that in W-N and W-S cells, p40 activity parallels the expression of embryonic letal abnormal vision (ELAV)-like proteins, and that antibodies directed against this family of RNA-binding proteins recognize p40, We also show that purified ELAV-like proteins (HuD and Hel-N1) bind with high specificity to the same N-myc 3'-untranslated region sequences as p40. Our data indicate that p40 is a member of the ELAV-like family, and suggest that this family of RNA-binding proteins may regulate N-myc mRNA turnover.	NORTHWESTERN UNIV, SCH MED,ROBERT H LAURIE CANC CTR, CHILDRENS MEM HOSP,DIV HEMATOL ONCOL, CHICAGO, IL 60614 USA; NORTHWESTERN UNIV, SCH MED, ROBERT H LAURIE CANC CTR, PROGRAM TUMOR CELL BIOL, CHICAGO, IL 60614 USA; NORTHWESTERN UNIV, SCH MED, ROBERT H LAURIE CANC CTR, DEPT PEDIAT, CHICAGO, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650	NCI NIH HHS [CA51061, 5P30CA60553] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051061, P30CA060553] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Biedler J L, 1988, Prog Clin Biol Res, V271, P265; BIEDLER J L, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P29; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1990, METHOD ENZYMOL, V181, P202; CAMPOS AR, 1985, J NEUROGENET, V2, P197, DOI 10.3109/01677068509100150; Chaconas G, 1980, Methods Enzymol, V65, P75; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHEN CYA, 1995, MOL CELL BIOL, V15, P5777; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; CICCARONE V, 1989, CANCER RES, V49, P219; DALMAU J, 1990, ANN NEUROL, V27, P544, DOI 10.1002/ana.410270515; DALMAU J, 1992, AM J PATHOL, V141, P881; DIGNAM JD, 1990, METHOD ENZYMOL, V182, P194; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1984, J CELL BIOL, V99, pA233, DOI 10.1083/jcb.99.6.1997; FOLEY J, 1991, CANCER RES, V51, P6338; Gao FB, 1996, J CELL SCI, V109, P579; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; HOMYK T, 1985, J NEUROGENET, V2, P309, DOI 10.3109/01677068509102326; HOMYK T, 1980, MOL GEN GENET, V177, P553; HORMIGO A, 1994, J NEUROIMMUNOL, V55, P205, DOI 10.1016/0165-5728(94)90011-6; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; KING PH, 1994, J NEUROSCI, V14, P1943; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LIU J, 1995, NEUROLOGY, V45, P544, DOI 10.1212/WNL.45.3.544; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Michitsch R W, 1988, Prog Clin Biol Res, V271, P103; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; ROBINOW S, 1988, SCIENCE, V242, P1570, DOI 10.1126/science.3144044; ROSS RA, 1983, J NATL CANCER I, V71, P741; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAKAI K, 1994, BIOCHEM BIOPH RES CO, V199, P1200, DOI 10.1006/bbrc.1994.1358; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SZABO A, 1991, CELL, V67, P325, DOI 10.1016/0092-8674(91)90184-Z; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	46	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33587	33591		10.1074/jbc.271.52.33587	http://dx.doi.org/10.1074/jbc.271.52.33587			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969226	hybrid			2022-12-25	WOS:A1996WA71300060
J	Ding, HG; Hidalgo, E; Demple, B				Ding, HG; Hidalgo, E; Demple, B			The redox state of the [2Fe-2S] clusters in SoxR protein regulates its activity as a transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESPONSE REGULON; STRESS REGULON; GENES	SoxR protein is a redox-responsive transcription factor that governs a regulon of oxidative stress and antibiotic resistance genes in Escherichia coli. Purified SoxR contains oxidized [2Fe-2S] clusters and stimulates in vitro transcription of its target gene soxS up to 100-fold. SoxR transcriptional activity, but not DNA binding, is completely dependent on the [2Fe-2S] clusters; apo-SoxR prepared in vitro binds the soxS promoter with unchanged affinity but does not have transcription activity. Thus, modulation of the SoxR [2Fe-2S] clusters was proposed to control the protein's function in transcription. Here, we provide evidence that SoxR with reduced [2Fe-2S] clusters is inactive. Redox titration of purified SoxR revealed a midpoint potential of -285 +/- 10 mV (pH 7.6). In vitro transcription assays showed that SoxR was inactivated when the [2Fe-2S] cluster was reduced (-380 mV), and full activity was restored upon reoxidation (+100 mV). The results suggest that one-electron oxidation and reduction of the [2Fe-2S] cluster regulate SogR transcriptional activity.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOL & CELLULAR TOXICOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health			Hidalgo, Elena/K-2919-2014; Ding, Huangen/AAJ-8550-2020	Hidalgo, Elena/0000-0002-3768-6785; Ding, Huangen/0000-0002-4815-7336	NCI NIH HHS [CA37831] Funding Source: Medline; NIEHS NIH HHS [F32 ES05726] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005726] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMABILECUEVAS CF, 1991, NUCLEIC ACIDS RES, V19, P4479, DOI 10.1093/nar/19.16.4479; DEMPLE B, 1991, ANNU REV GENET, V25, P315, DOI 10.1146/annurev.ge.25.120191.001531; Ding HE, 1996, P NATL ACAD SCI USA, V93, P9449, DOI 10.1073/pnas.93.18.9449; Dutton P L, 1978, Methods Enzymol, V54, P411; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; Hidalgo E, 1996, J BIOL CHEM, V271, P7269, DOI 10.1074/jbc.271.13.7269; HIDALGO E, 1995, J BIOL CHEM, V270, P20908, DOI 10.1074/jbc.270.36.20908; HIDALGO E, 1996, MOL BIOL INTELLIGENC, P433; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LIOCHEV SI, 1992, P NATL ACAD SCI USA, V89, P5892, DOI 10.1073/pnas.89.13.5892; NUNOSHIBA T, 1992, J BACTERIOL, V174, P6054, DOI 10.1128/JB.174.19.6054-6060.1992; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; WU J, 1992, J BACTERIOL, V174, P3915, DOI 10.1128/jb.174.12.3915-3920.1992; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323	15	156	166	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33173	33175		10.1074/jbc.271.52.33173	http://dx.doi.org/10.1074/jbc.271.52.33173			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969171	hybrid, Green Published			2022-12-25	WOS:A1996WA71300005
J	Chambraud, B; Radanyi, C; Camonis, JH; Shazand, K; Rajkowski, K; Baulieu, EE				Chambraud, B; Radanyi, C; Camonis, JH; Shazand, K; Rajkowski, K; Baulieu, EE			FAP48, a new protein that forms specific complexes both immunophilins FKBP59 and FKBP12 - Prevention by the immunosuppressant drugs FK506 and rapamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; TETRATRICOPEPTIDE REPEAT DOMAIN; STEROID-RECEPTOR COMPLEXES; MEDIATED GENE-EXPRESSION; BINDING-PROTEIN; SECONDARY STRUCTURE; CYCLOPHILIN-A; 59-KILODALTON PROTEIN; POLYCLONAL ANTIBODY; MAMMALIAN PROTEIN	We have identified a human gene encoding a 48-kDa protein that specifically interacts with the peptidyl prolyl isomerase FK506-binding protein 59 (FKBP59) and also with the well known FKBP12. FKBP59 and FKBP12 belong to the large family of immunophilins that bind the macrolide immunosuppressant drugs FK506 and rapamycin, The yeast two-hybrid system was used to isolate target proteins that interact with the immunosuppressant drug binding domain of the rabbit FKBP59. The cDNA for an as yet unidentified protein was isolated and cloned from a Jurkat cell library. The cDNA sequence of 1804 base pairs reveals an open reading frame of 417 amino acids. In vitro experiments suggest a direct interaction between FKBP59 and this new target protein. This specific association seems to be restricted to the FKBP family, since it also occurs both in vivo and in vitro with FKBP12 but not with cyclophilin 40. This novel protein was named FKBP-associated protein (FAP48). The formation of the complexes between FKBP59 or FKBP12 and FAP48 is prevented by FK506 and rapamycin in a dose dependent manner. These results suggest that FAP48 shares or overlaps the macrolide binding site on FKBP59 as well as on FKBP12 and therefore may represent a natural common ligand of these immunosuppressant drug receptors.	INSERM,U33,F-94276 LE KREMLIN BICETR,FRANCE; COLL FRANCE,F-94276 LE KREMLIN BICETR,FRANCE; INST CURIE,INSERM,U248,F-75231 PARIS 05,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			RADANYI, Christine/A-8921-2008					ALLEN JB, 1995, TRENDS BIOCHEM SCI, V20, P511, DOI 10.1016/S0968-0004(00)89119-7; BENICHOU S, 1994, J BIOL CHEM, V269, P30073; BIERER BE, 1994, CHEM IMMUNOL, V59, P128; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CHAMBRAUD B, 1993, BIOCHEM BIOPH RES CO, V196, P160, DOI 10.1006/bbrc.1993.2229; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DUMAS JP, 1995, PCR 2 PRACTICAL APPR, P89; DUMONT FJ, 1994, J PHARMACOL EXP THER, V268, P32; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALAT A, 1993, EUR J BIOCHEM, V216, P689, DOI 10.1111/j.1432-1033.1993.tb18189.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Hemenway CS, 1996, J BIOL CHEM, V271, P18527, DOI 10.1074/jbc.271.31.18527; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HOHFELD J, 1995, CELL, V83, P589; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; Kaiser C., 1994, METHODS YEAST GENETI; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEBEAU MC, 1994, BIOCHEM BIOPH RES CO, V203, P750, DOI 10.1006/bbrc.1994.2246; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; LEBIHAN S, 1993, BIOCHEM BIOPH RES CO, V195, P600, DOI 10.1006/bbrc.1993.2088; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MASSOL N, 1992, BIOCHEM BIOPH RES CO, V187, P1330, DOI 10.1016/0006-291X(92)90448-T; NING YM, 1993, J BIOL CHEM, V268, P6073; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; RENOIR JM, 1994, J STEROID BIOCHEM, V48, P101, DOI 10.1016/0960-0760(94)90256-9; Rose M, 1990, LAB COURSE MANUAL ME; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; TAI PKK, 1993, BIOCHEMISTRY-US, V32, P8842, DOI 10.1021/bi00085a015; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1994, BIOCHEMISTRY-US, V33, P10666, DOI 10.1021/bi00201a014; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIEDERRECHT G, 1992, J BIOL CHEM, V267, P21753; Wiederrecht Greg, 1994, Perspectives in Drug Discovery and Design, V2, P57, DOI 10.1007/BF02171737; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; YEM AW, 1992, J BIOL CHEM, V267, P2868; YEM AW, 1993, BIOCHEMISTRY-US, V32, P12571, DOI 10.1021/bi00210a004	59	62	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32923	32929		10.1074/jbc.271.51.32923	http://dx.doi.org/10.1074/jbc.271.51.32923			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955134	hybrid			2022-12-25	WOS:A1996VZ37300069
J	Zeng, FY; Weigel, PH				Zeng, FY; Weigel, PH			Fatty acylation of the rat and human asialoglycoprotein receptors - A conserved cytoplasmic cysteine residue is acylated in all receptor subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSYL RECEPTORS; COENZYME-A; HEPATOCYTES; PROTEINS; PALMITOYLATION; INACTIVATION; IDENTIFICATION; REQUIREMENTS; PALMITATE; PATHWAYS	Functional rat or human asialoglycoprotein receptors (ASGP-Rs) are hetero-oligomeric integral membrane glycoproteins, Rat ASGP-R contains three subunits, designated rat hepatic lectins (RHL) 1, 2, and 3; human ASGP-R contains two subunits, HHL1 and HHL2. Both receptors are covalently modified by fatty acylation (Zeng, F.-Y., Kaphalia, B. S., Ansari, G. A. S., and Weigel, P. H. (1995) J. Biol. Chem. 270, 21382-21381; Zeng, F.-Y., Oka, J. A., and Weigel, P. H. (1996) Biochem, Biophys. Res. Commun, 218, 325-330). We report here that the single Cys residue in the cytoplasmic domain of each RHL or HHL subunit is fatty acylated, The degree of acylation is greater than or equal to 90% per subunit, Deacylation of affinity-purified ASGP-Rs with hydroxylamine results in the spontaneous formation of dimers through reversible disulfide bonds, indicating that deacylation concomitantly generates free thiol groups, Reaction of hydpoxylamine-treated ASGP-R with [C-14]iodoacetamide resulted in the specific incorporation of radioactivity into all RRL and HHL subunits, verifying that fatty acids are attached via thioester linkages, To identify the Cys residue involved in the thioester linkages, C-14-carboxyamidomethylated RHL subunits were separated by SDS-polyacrylamide gel electrophoresis and digested in-gel with trypsin, and the resulting peptides were separated by reverse-phase high performance liquid chromatography, Amino acid sequence of radioactive peptides revealed that Cys(35) in RHL1 and Cys(54) in RHL2 and RHL3 were radiolabeled and, therefore, are fatty acylation sites. Fatty acylation of HHL subunits was analyzed by site-directed mutagenesis. Metabolic labeling of Cos7 cells transfected with wild type HHL1 cDNA resulted in substantial incorporation of [H-3]-palmitate into purified HHL1, In corporation of [H-3]palmitate into a C36S mutant of HHL1 was negligible (similar to 1%) compared with wild type, This result also shows that. Cys(57) within the transmembrane domain of HHL1 is not normally palmitoylated, We conclude that Cys(35) in RHL1, Cys(54) in RHL2 and RHL3, and Cys(36) in HHL1 are fatty acylated, Cys(57) in HHL1 and probably Cys(56) in RHL1 are not palmitoylated.	UNIV OKLAHOMA, HLTH SCI CTR, DEPT BIOCHEM & MOL BIOL, OKLAHOMA CITY, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 49695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACH R, 1988, BIOCHEMISTRY-US, V27, P4227, DOI 10.1021/bi00412a004; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; CRISE B, 1992, J BIOL CHEM, V267, P13593; DRICKAMER K, 1987, KIDNEY INT, V32, pS167; DRICKAMER K, 1984, J BIOL CHEM, V259, P770; FIETE D, 1983, J BIOL CHEM, V258, P817; FUHRER C, 1994, J BIOL CHEM, V269, P3277; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALBERG DF, 1987, J BIOL CHEM, V262, P9828; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; JING SQ, 1990, J BIOL CHEM, V265, P11555; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; KINDBERG GM, 1990, J BIOL CHEM, V265, P8999; KOCH N, 1986, J BIOL CHEM, V261, P3434; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MEDH JD, 1991, J BIOL CHEM, V266, P8771; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OKA JA, 1990, BIOCHEM BIOPH RES CO, V170, P1308, DOI 10.1016/0006-291X(90)90536-V; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; ROSE JK, 1984, P NATL ACAD SCI-BIOL, V81, P2050, DOI 10.1073/pnas.81.7.2050; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS NW, 1988, J NEUROSCI RES, V21, P35, DOI 10.1002/jnr.490210106; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER JT, 1988, J BIOL CHEM, V263, P10534; SAXENA A, 1995, MOL BIOL CELL, V6, P329; SCHWARTZ AL, 1984, J CELL BIOL, V98, P732, DOI 10.1083/jcb.98.2.732; SCHWEIZER A, 1995, J BIOL CHEM, V270, P9638, DOI 10.1074/jbc.270.16.9638; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; VEIT M, 1991, J VIROL, V65, P2491, DOI 10.1128/JVI.65.5.2491-2500.1991; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1986, BIOCHEM BIOPH RES CO, V140, P43, DOI 10.1016/0006-291X(86)91055-7; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; YUK MH, 1995, J BIOL CHEM, V270, P20169, DOI 10.1074/jbc.270.34.20169; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388; Zeng FY, 1996, BIOCHEM BIOPH RES CO, V218, P325, DOI 10.1006/bbrc.1996.0057; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382; Zeng FY, 1996, GLYCOBIOLOGY, V6, P247, DOI 10.1093/glycob/6.3.247	47	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32454	32460		10.1074/jbc.271.50.32454	http://dx.doi.org/10.1074/jbc.271.50.32454			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943311	hybrid			2022-12-25	WOS:A1996VY34000102
J	Lew, J; Coruh, N; Tsigelny, I; Garrod, S; Taylor, SS				Lew, J; Coruh, N; Tsigelny, I; Garrod, S; Taylor, SS			Synergistic binding of nucleotides and inhibitors to cAMP-dependent protein kinase examined by acrylodan fluorescence spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; CATALYTIC SUBUNIT; KINETIC MECHANISM; SKELETAL-MUSCLE; ATP SITE; ACTIVATION; ANALOGS; CREB	We have engineered an acrylodan-modified derivative of the catalytic subunit of cyclic AMP-dependent protein kinase (cAPK) whose fluorescence emission signal has allowed the synergistic binding between nucleotides and physiological inhibitors of cAPK to be examined (Whitehouse, S., and Walsh, D. A. (1983) J. Biol. Chem. 258, 3682-3692). In the presence of the regulatory subunit, R(I), the affinity of cAPK for adenosine, ADP, AMPPNP (adenosine 5'-(beta,gamma-imino)triphosphate), or ATP was 5-, 50, 120-, and 15,000-fold enhanced, while in the presence of the heat-stable inhibitor protein of cAPK (PKI), there was a 3-, 20, 33-, and 2000-fold enhancement in the binding of these nucleotides, respectively. A short inhibitor peptide, PKI-(14-22), enhanced the binding of ADP to the same degree as did full-length PKI (20-fold) but, in contrast, did not significantly enhance the binding of ATP or AMPPNP. The full binding synergism between PKI and either ATP (2000 fold) or AMPPNP (33-fold) to cAPK could, however, be mimicked by a longer peptide, PKI-(5-24), suggesting that the PKI NH2 terminus (residues 5-13) is most likely critical. Since this region is remote from the ATP gamma-phosphate, the binding synergism must arise through an extended network communication mechanism between the PKI NH2 terminus and the ATP binding site.	UNIV CALIF SAN DIEGO, DEPT CHEM & BIOCHEM, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019301, R37GM019301] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beavo J A, 1975, Adv Cyclic Nucleotide Res, V5, P241; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; FRANK DA, 1994, CELL, V79, P5, DOI 10.1016/0092-8674(94)90394-8; GLASS DB, 1989, J BIOL CHEM, V264, P14579; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARTL FT, 1983, BIOCHEMISTRY-US, V22, P2347, DOI 10.1021/bi00279a007; Herberg FW, 1996, BIOCHEMISTRY-US, V35, P2934, DOI 10.1021/bi951647c; HERBERG FW, 1993, BIOCHEMISTRY-US, V32, P14015, DOI 10.1021/bi00213a035; HOPPE J, 1977, EUR J BIOCHEM, V80, P369, DOI 10.1111/j.1432-1033.1977.tb11891.x; HOPPE J, 1978, EUR J BIOCHEM, V90, P427, DOI 10.1111/j.1432-1033.1978.tb12621.x; KARLSSON R, 1994, ACTA CRYSTALLOGR D, V50, P657, DOI 10.1107/S0907444994001939; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KNIGHTON DR, 1993, ACTA CRYSTALLOGR D, V49, P357, DOI 10.1107/S0907444993000502; MADHUSUDAN T, 1994, PROTEIN SCI, V3, P176; MENDELOW M, 1993, J BIOL CHEM, V268, P12289; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; RICHARDSON JM, 1990, J BIOL CHEM, V265, P13635; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TAYLOR SS, 1990, PEPT PROT PHOSPH, P1; TONERWEBB J, 1992, J BIOL CHEM, V267, P25174; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WALSH DA, 1968, J BIOL CHEM, V243, P3763; WEN W, 1994, J BIOL CHEM, V269, P8423; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; ZHENG JH, 1993, ACTA CRYSTALLOGR D, V49, P362, DOI 10.1107/S0907444993000423; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003	37	52	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1507	1513		10.1074/jbc.272.3.1507	http://dx.doi.org/10.1074/jbc.272.3.1507			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999821	hybrid			2022-12-25	WOS:A1997WD05800019
J	Niu, JK; Lawrence, S				Niu, JK; Lawrence, S			Nonphosphorylatable tyrosine surrogates - Implications for protein kinase inhibitor design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTECTED PEPTIDE-FRAGMENTS; SITE SUBSTRATE-SPECIFICITY; SOLID-PHASE SYNTHESIS	Tyrosine-specific protein kinases are known to utilize short synthetic tyrosine-containing peptides as substrates and, as a consequence, a number of inhibitory peptides have been prepared by replacing the tyrosine moiety in these peptides with a nonphosphorylatable phenylalanine residue. Unfortunately, the inhibitory efficacy of these phenylalanine-based peptides is often disappointing. These results demonstrate the need for nonphosphorylatable tyrosine surrogates that enhance enzyme affinity. As a consequence, we prepared nearly two dozen different phenethylamine derivatives, attached them to the C terminus of an active site directed peptide (Glu-Glu-Leu-Leu), and examined their effectiveness as inhibitors of pp60(c-src). Three derivatives exhibit enhanced inhibitory activity (relative to phenethylamine), including para-substituted sulfonamide and guanidino analogs as well as a pentafluoro-containing species. The para-sulfonamide derivative was selected for further study and was found to function as a competitive inhibitor versus variable peptide substrate and as a noncompetitive inhibitor versus variable ATP. In short, the enhanced inhibitory activity of the sulfonamide derivative is not due to the association of this moiety with the ATP binding site. Furthermore, peptides containing the para-guanidino and pentafluoro derivatives of phenylalanine were prepared. These species also display enhanced inhibitory activity toward pp60(c-src) relative to the corresponding phenylalanine-based peptide.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine								ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; COLE PA, 1994, J BIOL CHEM, V269, P30880; DAILE P, 1975, NATURE, V257, P416, DOI 10.1038/257416a0; DAILE P, 1974, BIOCHEM BIOPH RES CO, V61, P852, DOI 10.1016/0006-291X(74)90234-4; DEGRADO WF, 1980, J ORG CHEM, V45, P1295, DOI 10.1021/jo01295a026; EDLUND B, 1977, BIOCHEM BIOPH RES CO, V79, P139, DOI 10.1016/0006-291X(77)90071-7; FERAMISCO JR, 1978, J BIOL CHEM, V253, P8968; FINDEIS MA, 1989, J ORG CHEM, V54, P3478, DOI 10.1021/jo00275a041; GAO JM, 1995, J MED CHEM, V38, P2292, DOI 10.1021/jm00013a005; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; KIM KS, 1993, TETRAHEDRON LETT, V34, P7677, DOI 10.1016/S0040-4039(00)61537-X; KIM MH, 1994, INT J PEPT PROT RES, V44, P457; KWON YG, 1993, J BIOL CHEM, V268, P10713; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; Wang CQ, 1996, BIOCHEMISTRY-US, V35, P1533, DOI 10.1021/bi952435i; YUAN CJ, 1990, J BIOL CHEM, V265, P16205	23	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1493	1499		10.1074/jbc.272.3.1493	http://dx.doi.org/10.1074/jbc.272.3.1493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999819	hybrid			2022-12-25	WOS:A1997WD05800017
J	Bennett, ER; Kanner, BI				Bennett, ER; Kanner, BI			The membrane topology of GAT-1, a (Na++Cl-)-coupled gamma-aminobutyric acid transporter from rat brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE CREVICE; GABA TRANSPORTER; NEUROTRANSMITTER TRANSPORTERS; CYSTEINE-SUBSTITUTION; XENOPUS OOCYTES; RECEPTOR; SODIUM; GLYCOSYLATION; EXPRESSION; IDENTIFICATION	The membrane topology of GAT-1, a sodium and chloride-coupled gamma-aminobutyric acid transporter from rat brain, has been probed using N-glycosylation scanning mutagenesis, Overall, the results support the theoretical 12-transmembrane segment model, This model (based on hydropathy analysis) was originally proposed for GAT-1 and adopted for all other members of the sodium- and chloride dependent neurotransmitter transporter superfamily, However, our data indicate that the loop connecting putative transmembrane domains 2 and 3, which was predicted to be located intracellularly, can be glycosylated in vivo. Furthermore, studies with permeant and impermeant methanesulfonate reagents suggest that cysteine 74, located in the hydrophilic loop connecting transmembrane domains 1 and 2, is intracellular rather than extracellular, We present a model in which the topology deviates from the theoretical one in the amino-terminal third of the transporter. It also contains 12 transmembrane segments, but the highly conserved domain 1 does not form a conventional transmembrane alpha-helix.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem			Bennett, Estelle R/A-5067-2017					AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BENDAHAN A, 1993, FEBS LETT, V318, P41, DOI 10.1016/0014-5793(93)81323-R; BRUSS M, 1995, J BIOL CHEM, V270, P9197; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; HOLMGREN M, 1996, IN PRESS J NEUROPHAR; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; JAVITCH JA, 1994, P NATL ACAD SCI USA, V91, P10355, DOI 10.1073/pnas.91.22.10355; KANNER BI, 1994, FEBS LETT, V356, P191, DOI 10.1016/0014-5793(94)01255-5; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1989, BIOCHEMISTRY-US, V28, P3722, DOI 10.1021/bi00435a015; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KESHET GI, 1995, FEBS LETT, V371, P39, DOI 10.1016/0014-5793(95)00859-8; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MABJEESH NJ, 1992, J BIOL CHEM, V267, P2563; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MCKINNON R, 1995, NEURON, V14, P889; NIRENBERG MJ, 1996, J NEUROSCI, V16, P434; OLAMI Y, 1997, IN PRESS J BIOL CHEM, V272; OLIVARES L, 1995, J BIOL CHEM, V270, P9437, DOI 10.1074/jbc.270.16.9437; Olivares L, 1997, J BIOL CHEM, V272, P1211, DOI 10.1074/jbc.272.2.1211; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; RADIAN R, 1986, J BIOL CHEM, V261, P5437; SCHLOSS P, 1992, FEBS LETT, V307, P76, DOI 10.1016/0014-5793(92)80905-V; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; TAMURA S, 1995, J BIOL CHEM, V270, P28712, DOI 10.1074/jbc.270.48.28712; TATE CG, 1994, J BIOL CHEM, V269, P26303; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; WANG JB, 1995, J NEUROCHEM, V64, P1416; XU M, 1993, J BIOL CHEM, V268, P21505; ZAFRA F, 1995, J NEUROSCI, V15, P3952	39	86	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1203	1210		10.1074/jbc.272.2.1203	http://dx.doi.org/10.1074/jbc.272.2.1203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995422	hybrid			2022-12-25	WOS:A1997WC04800073
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; FUNCTIONAL CONSEQUENCES; CFTR; PROTEASOME; MUTATIONS; ATPASE	There is growing evidence that abnormal protein folding or trafficking (protein kinesis) leads to diseases, We have used P-glycoprotein as a model protein to develop strategies to overcome defects in protein kinesis. Mis-processed mutants of the human P-glycoprotein are retained in the endoplasmic reticulum as core glycosylated biosynthetic intermediates and rapidly degraded. Synthesis of the mutant proteins in the presence of drug substrates or modulators such as capsaicin, cyclosporin, vinblastine, or verapamil, however, resulted in the appearance of a fully glycosylated and functional protein at the cell surface. These effects were dose-dependent and occurred within a few hours after the addition of substrate. The ability to facilitate processing of the misfolded mutants appeared to be independent of the cell lines used and location of the mutation. P-glycoproteins with mutations in transmembrane segments, extracellular or cytoplasmic loops, the nucleotide-binding domains, or the linker region were processed to the fully mature form in the presence of these substrates. These drug substrates or modulators acted as specific chemical chaperones for P-glycoprotein because they were ineffective on the Delta F508 mutant of cystic fibrosis transmembrane conductance regulator. Therefore, one possible strategy to prevent protein misfolding is to carry out synthesis in the presence of specific substrates or modulators of the protein.	UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,MRC,GRP MEMBRANE BIOL,TORONTO,ON M5S 1A8,CANADA	University of Toronto; University of Toronto			Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOOF T, 1994, J BIOL CHEM, V269, P20575; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1995, J BIOL CHEM, V270, P21839, DOI 10.1074/jbc.270.37.21839; Loo TW, 1996, J BIOL CHEM, V271, P15414, DOI 10.1074/jbc.271.26.15414; LOO TW, 1994, J BIOL CHEM, V269, P28683; PRINCE LS, 1993, AM J PHYSIOL, V264, pC491, DOI 10.1152/ajpcell.1993.264.2.C491; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	22	208	218	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					709	712		10.1074/jbc.272.2.709	http://dx.doi.org/10.1074/jbc.272.2.709			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995353	hybrid			2022-12-25	WOS:A1997WC04800004
J	Reinhardt, DP; Ono, RN; Sakai, LY				Reinhardt, DP; Ono, RN; Sakai, LY			Calcium stabilizes fibrillin-1 against proteolytic degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEONATAL MARFAN-SYNDROME; FACTOR-LIKE DOMAINS; AMINO-ACID SEQUENCE; DEPENDENT PROTEIN-S; EGF-LIKE REPEATS; HUMAN FACTOR-IX; DROSOPHILA-NOTCH; EXTRACELLULAR-MATRIX; FIBROBLAST-CULTURES; BINDS CALCIUM	The calcium binding epidermal growth factor (cbEGF)-like domain is a structural motif that is present in many matrix proteins throughout the animal kingdom from invertebrates to mammals, This module has been demonstrated to bind calcium in the micromolar range. However, little is known about the functional consequences of calcium binding to proteins that contain this structural element. We used fibrillin-1, an extracellular matrix protein consisting of similar to 60% cbEGF-like motifs, as a model system to study stabilizing effects of calcium in protease degradation assays. Authentic human fibrillin-1 and recombinant human fibrillin-1 subdomains, spanning the whole molecule, showed significantly slower proteolytic degradation in the presence of CaCl2 than in the presence of EDTA, demonstrating that calcium stabilizes the structure of fibrillin-1 and protects the molecule against proteolytic degradation. Information about cleavage sites protected by calcium was obtained with a new recombinant subdomain, rF17 (Asp(952)-Val(1527)), comprising the longest stretch of cbEGF-like motifs in the center of the fibrillin-1 molecule. The most sensitive sites for trypsin and endoproteinase Glu-C were observed in cbEGF-like motifs 11 (Met(1034) and Asn(1046)), 12 (Ser(1103)), and 17 (Thr(1318)). Since most of the currently known mutations in fibrillin-1 are found within cbEGF-like motifs and are predicted to disrupt calcium binding, we suggest that these mutations render fibrillin-1 more susceptible to proteolytic cleavage, and this might be one of the reasons why these mutations result in Marfan's syndrome.	OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOL BIOL,PORTLAND,OR 97201	Oregon Health & Science University	Reinhardt, DP (corresponding author), SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201, USA.		Reinhardt, Dieter P/A-3102-2008	Reinhardt, Dieter P/0000-0001-6535-9872				ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; BULAJ G, 1995, J MOL BIOL, V247, P701, DOI 10.1006/jmbi.1995.0174; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CORSON GM, 1993, GENOMICS, V17, P476, DOI 10.1006/geno.1993.1350; DAHLBACK B, 1990, J BIOL CHEM, V265, P18481; DAHLBACK B, 1990, J BIOL CHEM, V265, P16082; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; DURKIN ME, 1988, J CELL BIOL, V107, P2749, DOI 10.1083/jcb.107.6.2749; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GANDRILLE S, 1995, BLOOD, V85, P130, DOI 10.1182/blood.V85.1.130.bloodjournal851130; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; GLANVILLE RW, 1994, J BIOL CHEM, V269, P26630; GODFREY M, 1995, AM J PATHOL, V146, P1414; HANDFORD P, 1995, J BIOL CHEM, V270, P6751, DOI 10.1074/jbc.270.12.6751; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; HEWETT DR, 1993, HUM MOL GENET, V2, P475, DOI 10.1093/hmg/2.4.475; KAINULAINEN K, 1994, NAT GENET, V6, P64, DOI 10.1038/ng0194-64; KIELTY CM, 1993, FEBS LETT, V336, P323, DOI 10.1016/0014-5793(93)80829-J; KIELTY CM, 1994, FEBS LETT, V351, P85, DOI 10.1016/0014-5793(94)00818-3; Knott V, 1996, J MOL BIOL, V255, P22, DOI 10.1006/jmbi.1996.0003; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MAYER U, 1995, FEBS LETT, V365, P129, DOI 10.1016/0014-5793(95)00438-F; MORRIS NP, 1986, J BIOL CHEM, V261, P5638; OHLIN AK, 1988, J BIOL CHEM, V263, P7411; PAN TC, 1993, EUR J BIOCHEM, V215, P733, DOI 10.1111/j.1432-1033.1993.tb18086.x; PAN TC, 1993, J CELL BIOL, V123, P1269, DOI 10.1083/jcb.123.5.1269; PEREIRA L, 1993, HUM MOL GENET, V2, P961, DOI 10.1093/hmg/2.7.961; PERSSON E, 1989, J BIOL CHEM, V264, P16897; Putnam EA, 1996, AM J MED GENET, V62, P233, DOI 10.1002/(SICI)1096-8628(19960329)62:3<233::AID-AJMG7>3.0.CO;2-U; PUTNAM EA, 1995, NAT GENET, V11, P456, DOI 10.1038/ng1295-456; RAGHUNATH M, 1994, BIOCHEM J, V302, P889, DOI 10.1042/bj3020889; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; Reinhardt DP, 1996, J BIOL CHEM, V271, P19489, DOI 10.1074/jbc.271.32.19489; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; STENFLO J, 1991, BLOOD, V78, P1637; SUPERTIFURGA A, 1992, J MED GENET, V29, P875, DOI 10.1136/jmg.29.12.875; WANG M, 1995, HUM MOL GENET, V4, P607, DOI 10.1093/hmg/4.4.607; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WU YS, 1995, CHEM BIOL, V2, P91, DOI 10.1016/1074-5521(95)90281-3; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855; ZHANG RZ, 1994, GENOMICS, V22, P425, DOI 10.1006/geno.1994.1404	53	115	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1231	1236		10.1074/jbc.272.2.1231	http://dx.doi.org/10.1074/jbc.272.2.1231			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995426	Green Published, hybrid			2022-12-25	WOS:A1997WC04800077
J	Wong, LM; Myers, SJ; Tsou, CL; Gosling, J; Arai, H; Charo, IF				Wong, LM; Myers, SJ; Tsou, CL; Gosling, J; Arai, H; Charo, IF			Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene - Evidence for the role of the carboxyl-terminal tail in receptor trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DI-LEUCINE MOTIF; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; CHEMOKINE RECEPTOR; CYTOPLASMIC TAIL; MESSENGER-RNA; SITE; CYTOKINE; CLEAVAGE; CELLS	Two forms of the monocyte chemoattractant protein-1 receptors (the type A monocyte chemoattractant protein 1 (MCP-1) receptor CCR-2A and the type B MCP-1 receptor (CCR-2B) have been recently cloned and found to differ only in their terminal carboxyl tails. Here, we report that the two isoforms are alternatively spliced variants of a single MCP-1 receptor gene, Sequencing of the gene revealed that the 47-amino acid carboxyl tail of CCR2B was located in the same exon as the seven transmembrane domains of the receptor, and the 61-amino acid tail of CCR2A was in a downstream exon. Examination of freshly isolated human monocytes by reverse transcriptase polymerase chain reaction revealed that CCR2B was the predominant isoform and that message levels of both CCR2A and CCR2B decreased as the monocytes differentiated into macrophages. In stably transfected cell lines, CCR2B trafficked well to the cell surface, but CCR2A was found predominately in the cytoplasm. Equilibrium binding studies revealed that those CCR2A receptors that successfully trafficked to the cell surface bound MCP-1 with high affinity (K-d = 310 pM), similar to CCR2B. In signaling studies, both CCR2A and CCR2B mediated agonist-dependent calcium mobilization, as well as inhibition of adenylyl cyclase. Creation of chimeras between CCR2A and the human thrombin receptor revealed that the cytoplasmic retention of CCR2A was due to its terminal carboxyl tail. Progressive truncation of the carboxyl tail indicated that a cytoplasmic retention signal(s) was located between residues 316 and 349. These data indicate that the alternatively spliced form of the human MCP-1 receptor (CCR2A) binds MCP-1 with high affinity and is a functional receptor and that expression at the cell surface is controlled by amino acid sequences located in the terminal carboxyl tail.	UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94141; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94141	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Arai, Hidenori/P-9816-2017	Arai, Hidenori/0000-0002-9000-6849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Audran R, 1996, CLIN EXP IMMUNOL, V103, P155, DOI 10.1046/j.1365-2249.1996.d01-4.x; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; DANNER D, 1985, P NATL ACAD SCI USA, V82, P8658, DOI 10.1073/pnas.82.24.8658; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DENHOLM EM, 1995, CYTOKINE, V7, P436, DOI 10.1006/cyto.1995.0059; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; HANEY PM, 1995, J CELL BIOL, V129, P641, DOI 10.1083/jcb.129.3.641; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; HEIN L, 1994, J BIOL CHEM, V269, P27719; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; ISHII K, 1993, J BIOL CHEM, V268, P9780; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; ROGERS J, 1986, MOL CELL BIOL, V6, P4749, DOI 10.1128/MCB.6.12.4749; ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517; SCHALL TJ, 1994, CYTOKINE HDB, P419; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YOSHIMURA T, 1990, J IMMUNOL, V145, P292; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	35	109	120	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1038	1045		10.1074/jbc.272.2.1038	http://dx.doi.org/10.1074/jbc.272.2.1038			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995400	hybrid			2022-12-25	WOS:A1997WC04800051
J	Astier, A; Avraham, H; Manie, SN; Groopman, J; Canty, T; Avraham, S; Freedman, AS				Astier, A; Avraham, H; Manie, SN; Groopman, J; Canty, T; Avraham, S; Freedman, AS			The related adhesion focal tyrosine kinase is tyrosine-phosphorylated after beta 1-integrin stimulation in B cells and binds to p130(cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-LYMPHOBLASTIC CELLS; PROTEIN; PP125(FAK); FIBRONECTIN; ACTIVATION; INTEGRINS; SRC; ALPHA-4-BETA-1; ALPHA-5-BETA-1; ASSOCIATION	Integrin ligation initiates intracellular signaling events, among which are the activation of protein tyrosine kinases. The related adhesion focal tyrosine kinase (RAFTK), also known as PYK2 and CAK beta, is a tyrosine kinase that is homologous to the focal adhesion kinase (FAK) p125(FAK). The structure of RAFTK is similar to p125(FAK) in that it lacks a transmembrane region, does not contain Src homology 2 or 3 domains, and has a proline rich region in its C terminus. Here we report that RAFTK is a target for beta 1-integrin-mediated tyrosine phosphorylation in both transformed and normal human B cells. Ligation of the B cell antigen receptor also induced tyrosine phosphorylation of RAFTK. Phosphorylation of RAFTK following integrin- or B cell antigen receptor-mediated stimulation was decreased by prior treatment of cells with cytochalasin B, indicating that this process was at least partially cytoskeleton-dependent. One of the tyrosine-phosphorylated substrates after integrin stimulation in fibroblasts is p130(cas), which can associate with p125(FAK). RAFTK also interacted constitutively with p130(cas) in B cells, since p130(cas) was detected in RAFTK immunoprecipitates. Although the function of RAFTK remains unknown, these data suggest that RAFTK may have a significant function in integrin-mediated signaling pathways in B cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; HARVARD UNIV,DEACONESS HOSP,SCH MED,DIV HEMATOL & ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Manie, Serge/ABC-8331-2021; Astier, Anne L/A-1641-2008	Astier, Anne L/0000-0002-0144-3431; Avraham, Hava/0000-0002-7545-3640; manie, serge/0000-0002-9168-1977	NCI NIH HHS [CA66996, CA55207] Funding Source: Medline; NHLBI NIH HHS [HL51456] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA066996, R01CA055207] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BRANDO C, 1995, J IMMUNOL, V154, P2005; CHAN PY, 1994, J BIOL CHEM, V269, P20567; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FREEDMAN AS, 1993, J IMMUNOL, V150, P1645; GISMONDI A, 1995, J IMMUNOL, V154, P3128; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; MANIE S, 1996, BLOOD, V88, P1855; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; NOJIMA Y, 1995, CELL IMMUNOL, V161, P8, DOI 10.1006/cimm.1995.1002; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SUMIMOTO SI, 1994, J IMMUNOL, V153, P2488; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	32	193	194	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					228	232						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995252				2022-12-25	WOS:A1997WA56400039
J	Ichinohe, T; Takayama, H; Ezumi, Y; Arai, M; Yamamoto, N; Takahashi, H; Okuma, M				Ichinohe, T; Takayama, H; Ezumi, Y; Arai, M; Yamamoto, N; Takahashi, H; Okuma, M			Collagen-stimulated activation of Syk but not c-Src is severely compromised in human platelets lacking membrane glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; CYTOSKELETAL REORGANIZATION; INTEGRIN ALPHA(IIB)BETA(3); ALPHA(2)BETA(1) INTEGRIN; PHOSPHOLIPASE C-GAMMA-2; SIGNAL-TRANSDUCTION; INDUCED AGGREGATION; PHOSPHORYLATION; ADHESION; RECEPTOR	Activation of circulating platelets by subendothelial collagen is an essential event in vascular hemostasis. In human platelets, two membrane glycoprotein (GP) abnormalities, integrin alpha(2) beta(1) deficiency and GPVI deficiency, have been reported to result in severe hyporesponsiveness to fibrillar collagen. Although it has been well established that integrin alpha(2) beta(1), also known as the GPIa-IIa complex, functions as a primary platelet adhesion receptor for collagen, the mechanism by which GPVI contributes to collagen-platelet interaction has been ill defined to date. However, our recent observation that GPVI cross-linking couples to cyclic AMP-insensitive activation of c-Src and Syk tyrosine kinases suggested a potential role for GPVI in regulating protein-tyrosine phosphorylation by collagen (Ichinohe, T., Takayama, H., Ezumi, Y., Yanagi, S., Yamamura, H., and Okuma, M. (1995) J. Biol. Chem. 270, 28029-28036). To further investigate this hypothesis, here we examined the collagen-induced protein-tyrosine phosphorylation in GPVI-deficient platelets expressing normal amounts of alpha(2) beta(1). In response to collagen, these platelets exhibited alpha(2) beta(1)-dependent c-Src activation accompanied by tyrosine phosphorylation of several substrates including cortactin. In contrast, severe defects were observed in collagen-stimulated Syk activation and tyrosine phosphorylation of phospholipase C-gamma 2, Vav, and focal adhesion kinase, implicating a specific requirement of GPVI for recruiting these molecules to signaling cascades evoked by collagen-platelet interaction.	KYOTO UNIV,GRAD SCH MED,DEPT HEMATOL & ONCOL,SAKYO KU,KYOTO 60601,JAPAN; TOKYO MED COLL,DEPT CLIN PATHOL,TOKYO 160,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT CARDIOVASC RES,TOKYO 113,JAPAN; NIIGATA UNIV,HOSP MED,DIV BLOOD TRANSFUS,NIIGATA 951,JAPAN	Kyoto University; Tokyo Medical University; Tokyo Metropolitan Institute of Medical Science; Niigata University								ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; Asazuma N, 1996, THROMB HAEMOSTASIS, V75, P648; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BLAKE RA, 1996, J BIOL CHEM, V271, P7544; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLARK EA, 1994, J BIOL CHEM, V269, P28859; COLLER BS, 1989, BLOOD, V74, P182; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DANIEL JL, 1994, THROMB HAEMOSTASIS, V71, P353; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; GREENWALT DE, 1992, BLOOD, V80, P1105; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; HIRASAWA N, 1995, J BIOL CHEM, V270, P10960, DOI 10.1074/jbc.270.18.10960; HUANG MM, 1991, P NATL ACAD SCI USA, V83, P852; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ICHINOHE T, 1995, J BIOL CHEM, V270, P28029; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KEHREL B, 1988, BLOOD, V71, P1074; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LIEBENHOFF U, 1993, BIOCHEM J, V295, P41, DOI 10.1042/bj2950041; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; Matsuno K, 1996, BRIT J HAEMATOL, V92, P960, DOI 10.1046/j.1365-2141.1996.422962.x; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1994, BIOCHEM J, V299, P791, DOI 10.1042/bj2990791; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; RYO R, 1992, AM J HEMATOL, V39, P25, DOI 10.1002/ajh.2830390107; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SANTORO SA, 1988, PLATELET MEMBRANE RE, P291; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SIXMA JJ, 1995, THROMB HAEMOSTASIS, V74, P454; SMITH JB, 1993, BIOCHEM BIOPH RES CO, V191, P695, DOI 10.1006/bbrc.1993.1273; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; SUGIYAMA T, 1987, BLOOD, V69, P1712; TAKADA Y, 1989, J CELL BIOL, V109, P397, DOI 10.1083/jcb.109.1.397; TAKAHASHI H, 1995, THROMB HAEMOSTASIS, V74, pA1197; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TAKAYAMA H, 1991, BIOCHEM BIOPH RES CO, V174, P922, DOI 10.1016/0006-291X(91)91506-8; TAKAYAMA H, 1993, BIOCHEM BIOPH RES CO, V194, P472, DOI 10.1006/bbrc.1993.1843; TANDON NN, 1989, J BIOL CHEM, V264, P7576; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; YAMAMOTO N, 1992, BRIT J HAEMATOL, V81, P86, DOI 10.1111/j.1365-2141.1992.tb08177.x	47	129	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					63	68						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995228				2022-12-25	WOS:A1997WA56400015
J	Lounsbury, KM; Macara, IG				Lounsbury, KM; Macara, IG			Ran-binding protein 1 (RanBP1) forms a ternary complex with Ran and karyopherin beta and reduces Ran GTPase-activating protein (RanGAP) inhibition by karyopherin beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEXES; IMPORT SUBSTRATE; RAN/TC4 GTPASE; IDENTIFICATION; INTERACTS; NUCLEOPORINS; DISSOCIATION; SUBUNITS; ENVELOPE; HOMOLOG	The nuclear accumulation of proteins containing nuclear localization signals requires the Ran GTPase and a complex of proteins assembled at the nuclear pore. RanBP1 is a cytosolic Ran-binding protein that inhibits RCC1-stimulated release of GTP from Ran. RanBP1 also promotes the binding of Ran to karyopherin beta (also called importin beta and p97) and is a co-stimulator of RanGAP activity. Yeast karyopherin beta inhibits the GTP hydrolysis by Ran catalyzed by RanGAP. To further define the roles of RanBP1 and karyopherin beta in Ran function, we explored the effects of RanBP1 and karyopherin beta on mammalian proteins known to regulate Ran. Like RanBP1, karyopherin beta prevented the release of GTP from Ran stimulated by RCC1 or EDTA. As with the yeast protein, mammalian karyopherin beta completely blocked RanGAP activity. However, the addition of RanBP1 to this assay partially rescued the inhibited RanGAP activity. Kinetic analysis of the effects on RanGAP activity by karyopherin beta and RanBP1 revealed a combination of competitive and noncompetitive interactions. Solution binding assays confirmed the ability of RanBP1 to associate with Ran and karyopherin beta in a ternary complex, and RanBP1 binding was not competed out by the addition of karyopherin beta. These results demonstrate that RanBP1 and karyopherin beta interact with distinct sites of Ran and suggest that RanBP1 plays an essential role in nuclear transport by permitting RanGAP-mediated hydrolysis of GTP on Ran complexed to karyopherin beta.	UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405; VERMONT REG CANC CTR,BURLINGTON,VT 05405	University of Vermont					NIGMS NIH HHS [GM50526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CUOMO CA, 1994, P NATL ACAD SCI USA, V91, P6156, DOI 10.1073/pnas.91.13.6156; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1996, J BIOL CHEM, V271, P5313, DOI 10.1074/jbc.271.10.5313; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; Lounsbury KM, 1996, J BIOL CHEM, V271, P2357, DOI 10.1074/jbc.271.5.2357; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P7059, DOI 10.1073/pnas.93.14.7059; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; SCHLENSTEDT G, 1995, EMBO J, V14, P5637; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	33	119	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					551	555						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995296				2022-12-25	WOS:A1997WA56400083
J	Parrizas, M; Saltiel, AR; LeRoith, D				Parrizas, M; Saltiel, AR; LeRoith, D			Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGF-I RECEPTOR; PROGRAMMED CELL-DEATH; HEMATOPOIETIC-CELLS; SIGNAL-TRANSDUCTION; PC12 CELLS; 3-KINASE; NEURONS; PURIFICATION; FIBROBLASTS; STIMULATION	The role of insulin-like growth factor 1 (IGF-1) in preventing apoptosis was examined in differentiated PC12 cells, Induction of differentiation was achieved using nerve growth factor, and apoptosis was provoked by serum withdrawal. After 4-6 h of serum deprivation, apoptosis was initiated, concomitant with a 30% decrease in cell number and a 75% decrease in MTT activity, IGF-1 was capable of preventing apoptosis at concentrations as low as 10(-9) M and as early as 4 h. The phosphatidylinositol 3' (PI3')-kinase inhibitors wortmannin (at concentrations of 10(-8) M) and LY294002 (10(-6) M) blocked the effect of IGF-1. The pp70 S6 kinase (pp70(S6K)) inhibitor rapamycin (10(-8) M) was, however, less effective in blocking IGF-1 action. Moreover, stable transfection of a dominant-negative p85 (subunit of PI3'-kinase) construct in PC12 cells enhanced apoptosis provoked by serum deprivation. Interestingly, in the cells overexpressing the dominant-negative p85 protein, IGF-1 was still capable of inhibiting apoptosis, suggesting the existence of a second pathway involved in the IGF-1 effect. Blocking the mitogen-activated protein kinase pathway with the specific mitogen-activated protein kinase/extracellular-response kinase kinase inhibitor PD098059 (10(-5) M) inhibited the IGF-1 effect, When wortmannin and PD098059 mere given together, the effect was synergistic. The results presented here suggest that IGF-1 is capable of preventing apoptosis by activation of multiple signal transduction pathways.	NIDDK, DIABET BRANCH, NIH, BETHESDA, MD 20892 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48105 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pfizer; University of Michigan System; University of Michigan			Parrizas, Marcelina/AAS-3629-2021; Saltiel, Alan/L-3632-2019	Parrizas, Marcelina/0000-0003-1296-8302; Saltiel, Alan/0000-0002-9726-9828				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATISTATOU A, 1993, NEURONAL CELL DEATH, P33; BLAKESLEY VA, 1995, J BIOL CHEM, V270, P2764, DOI 10.1074/jbc.270.6.2764; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CLEMMONS DR, 1992, GROWTH REGULAT, V2, P80; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GALLI C, 1995, J NEUROSCI, V15, P1172; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GOLDRING M B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P301; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HU Q, 1995, SCIENCE, V268; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KATO H, 1993, J BIOL CHEM, V268, P2655; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Minshall C, 1996, J IMMUNOL, V156, P939; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; SCHEID MP, 1995, BIOCHEM J, V312, P159, DOI 10.1042/bj3120159; SEGER R, 1992, J BIOL CHEM, V267, P14373; SELL C, 1995, CANCER RES, V55, P303; STEPHENS L, 1993, EMBO J, V12, P2265, DOI 10.1002/j.1460-2075.1993.tb05880.x; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANEK PG, 1995, BIOTECHNIQUES, V18, P704; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	44	570	588	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					154	161						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995241				2022-12-25	WOS:A1997WA56400028
J	Keyhani, NO; Wang, LX; Lee, YC; Roseman, S				Keyhani, NO; Wang, LX; Lee, YC; Roseman, S			The chitin catabolic cascade in the marine bacterium Vibrio furnissii - Characterization of an N,N'-diacetyl-chitobiose transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; OLIGOSACCHARIDES; DEACETYLASE; CHEMOTAXIS; PROTEIN; PURIFICATION; MECHANISM; MEMBRANE; MALTOSE	The disaccharideN,N'-diacetyl-chitobiose, (GlcNAc)(2), is critical in chitin dissimilation by Vibrio furnissii and, as reported here, is taken up by a specific permease. Since (GlcNAc)(2) is rapidly catabolized by V. furnissii, a non-hydrolyzable thioglycoside analogue was used: methyl beta-N,N'-[H-3]diacetyl-thiochitobioside (Me-[H-3]TCB). Me-TCB and TCB substitute for (GlcNAc)(2) as chemoattractants and inducers of beta-N-acetylglucosaminidase activity. The [H-3]Me-TCB uptake system was induced only by (GlcNAc)(2) and by (GlcNAc)(n) that can be converted to (GlcNAc)(2). The K-m for [H-3]Me-TCB uptake was less than or equal to 1 mu M and was not affected by Na+ or K+, Uptake appeared to be unidirectional, and in 0.4 M sucrose (+/- K+) the cells accumulated [H-3]Me-TCB until it was depleted from the medium, giving an internal concentration of 0.1 M and an internal/external ratio > 1,000. The only effective inhibitors of uptake were: (GlcNAc)(n), n = 2-4 > cellobiose > (GlcNAc)(5). In 50% artificial sea water (or sucrose/Na+), [H-3]Me-TCB accumulation attained a constant steady state level because of efflux, a Na+-dependent process. The physiological implications of these results are considered.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University			Wang, Lai-Xi/E-8755-2019; Keyhani, Nemat O/I-8150-2013; wang, xl/Y-8251-2019; Wang, Lai-Xi/E-8790-2019	Wang, Lai-Xi/0000-0003-4293-5819	NIDDK NIH HHS [DK09970] Funding Source: Medline; NIGMS NIH HHS [GM51215, GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK009970, R37DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051215, R01GM038759, R37GM038759] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; AMANO J, 1989, METHOD ENZYMOL, V179, P261; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; COMB DG, 1958, J BIOL CHEM, V232, P807; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; GAO XD, 1995, J BIOCHEM, V117, P257, DOI 10.1093/jb/117.2.257; GRINIUS LL, 1994, J BIOL CHEM, V269, P29998; JOHN M, 1993, P NATL ACAD SCI USA, V90, P625, DOI 10.1073/pnas.90.2.625; KAFETZOPOULOS D, 1993, P NATL ACAD SCI USA, V90, P8005, DOI 10.1073/pnas.90.17.8005; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; ROSEMAN S, 1956, ANAL CHEM, V28, P1743, DOI 10.1021/ac60119a028; ROSEMAN S, 1957, J BIOL CHEM, V226, P115; ROSEMAN S, 1954, J AM CHEM SOC, V76, P301, DOI 10.1021/ja01630a098; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; STOCK J, 1971, BIOCHEM BIOPH RES CO, V44, P132, DOI 10.1016/S0006-291X(71)80168-7; TSIGOS I, 1995, J BIOL CHEM, V270, P26286, DOI 10.1074/jbc.270.44.26286; Wang LX, 1996, J CHEM SOC PERK T 1, P581, DOI 10.1039/p19960000581; Wang LX, 1995, CARBOHYDR LETT, V1, P185; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260	26	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33409	33413		10.1074/jbc.271.52.33409	http://dx.doi.org/10.1074/jbc.271.52.33409			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969203	hybrid			2022-12-25	WOS:A1996WA71300037
J	Perini, LT; Doherty, EA; Werner, E; Senear, DF				Perini, LT; Doherty, EA; Werner, E; Senear, DF			Multiple specific CytR binding sites at the Escherichia coli deoP2 promoter mediate both cooperative and competitive interactions between CytR and cAMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE ACTIVATOR PROTEIN; LAMBDA-CI REPRESSOR; DNA-BINDING; TRANSCRIPTION ACTIVATION; CRYSTAL-STRUCTURE; GEL-ELECTROPHORESIS; PURINE REPRESSOR; RNA-POLYMERASE; LAC REPRESSOR; CRP COMPLEX	Binding of cAMP receptor protein (CRP) and CytR mediates both positive and negative control of transcription from Escherichia coli deoP2. Transcription is activated by CRP and repressed by a multi protein CRP . CytR . CRP complex. The latter is stabilized by cooperative interactions between CRP and CytR. Similar interactions at the other transcriptional units of the CytR regulon coordinate expression of the transport proteins and enzymes required for nucleoside catabolism. A fundamental question in both prokaryotic and eukaryotic gene regulation is how combinatorial mechanisms of this sort regulate differential expression. To understand the combinatorial control mechanism at deoP2, we have used quantitative footprint and gel shift analysis of CRP and CytR binding to evaluate the distribution of ligation states. By comparison to distributions for other CytR-regulated promoters, we hope to understand the roles of individual states in differential gene expression. The results indicate that CytR binds specifically to multiple sites at deoP2, including both the well recognized CytR site flanked by CRP1 and CRP2 and also sites coincident with CRP1 and CRP2. Binding to these multiple sites yields both cooperative and competitive interactions between CytR and CRP. Based on these findings we propose that CytR functions as a differential modulator of CRP1 versus CRP2-mediated activation. Additional high affinity specific sites are located at deoP1 and near the middle of the 600-base pair sequence separating P1 and P2. Evaluation of the DNA sequence requirement for specific CytR binding suggests that a limited array of contiguous and overlapping CytR sites exists at deoP2. Similar extended arrays, but with different arrangements of overlapping CytR and CRP sites, are found at the other CytR-regulated promoters. We propose that competition and cooperativity in CytR and CRP binding are important to differential regulation of these promoters.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697	University of California System; University of California Irvine				Werner, Erik/0000-0002-6377-9897	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM041465] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41465] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ACKERS GK, 1983, J MOL BIOL, V170, P223, DOI 10.1016/S0022-2836(83)80234-4; BREMER E, 1988, J BACTERIOL, V170, P108, DOI 10.1128/jb.170.1.108-116.1988; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; BRENOWITZ M, 1989, CURRENT PROTOCOLS MO, V2; Brikun I, 1996, J BACTERIOL, V178, P1614, DOI 10.1128/jb.178.6.1614-1622.1996; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CANN JR, 1989, J BIOL CHEM, V264, P17032; CANN JR, 1993, ELECTROPHORESIS, V14, P669, DOI 10.1002/elps.11501401107; CAREY J, 1988, P NATL ACAD SCI USA, V85, P975, DOI 10.1073/pnas.85.4.975; CHOI KY, 1992, J BACTERIOL, V174, P6207, DOI 10.1128/JB.174.19.6207-6214.1992; DALMAWEISZHAUSZ DD, 1992, BIOCHEMISTRY-US, V31, P6980, DOI 10.1021/bi00145a016; DANDANELL G, 1985, EMBO J, V4, P3333, DOI 10.1002/j.1460-2075.1985.tb04085.x; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; Dunn D.B., 1975, HDB BIOCH MOL BIOL N, V1, P65; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; FILES JG, 1976, J BIOL CHEM, V251, P3386; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; GERLACH P, 1991, J BACTERIOL, V173, P5419, DOI 10.1128/jb.173.17.5419-5430.1991; GREENSTEIN D, 1989, CURRENT PROTOCOLS S9, V1; GRONENBORN AM, 1986, BIOCHEM J, V236, P643, DOI 10.1042/bj2360643; GUNASEKERA A, 1990, NUCLEIC ACIDS RES, V18, P6853, DOI 10.1093/nar/18.23.6853; GUNASEKERA A, 1992, J BIOL CHEM, V267, P14713; Hammer-Jespersen K., 1983, METABOLISM NUCLEOTID, P203; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HOLST B, 1992, EMBO J, V11, P3635, DOI 10.1002/j.1460-2075.1992.tb05448.x; JOHNSON AD, 1981, NATURE, V294, P217, DOI 10.1038/294217a0; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; Kristensen HH, 1996, J MOL BIOL, V260, P113, DOI 10.1006/jmbi.1996.0385; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Maniatis T., 1982, MOL CLONING; MARTINUSSEN J, 1989, DNA PROTEIN INTERACT, P31; MERKEL TJ, 1995, J BACTERIOL, V177, P1712, DOI 10.1128/jb.177.7.1712-1718.1995; MOLLEGAARD NE, 1993, J BIOL CHEM, V268, P17471; MUNCHPETERSEN A, 1990, EUR J BIOCHEM, V190, P547, DOI 10.1111/j.1432-1033.1990.tb15608.x; NIU W, 1994, J MOL BIOL, V243, P595, DOI 10.1016/0022-2836(94)90034-5; PEDERSEN H, 1992, J MOL BIOL, V227, P396, DOI 10.1016/0022-2836(92)90896-R; PEDERSEN H, 1991, J BIOL CHEM, V266, P17804; PEDERSEN H, 1995, MOL MICROBIOL, V17, P843, DOI 10.1111/j.1365-2958.1995.mmi_17050843.x; PERINI L, 1995, BIOPHYS J, V68, pA295; Pyles EA, 1996, BIOCHEMISTRY-US, V35, P1162, DOI 10.1021/bi952187q; RASMUSSEN PB, 1993, NUCLEIC ACIDS RES, V21, P879, DOI 10.1093/nar/21.4.879; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; SENEAR DF, 1993, ELECTROPHORESIS, V14, P704, DOI 10.1002/elps.11501401112; SENEAR DF, 1990, BIOCHEMISTRY-US, V29, P6568, DOI 10.1021/bi00480a004; SENEAR DF, 1992, METHOD ENZYMOL, V210, P463; SENEAR DF, 1991, BIOCHEMISTRY-US, V30, P6677, DOI 10.1021/bi00241a007; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SOGAARDANDERSEN L, 1993, CELL, V75, P557, DOI 10.1016/0092-8674(93)90389-8; SOGAARDANDERSEN L, 1991, P NATL ACAD SCI USA, V88, P4921, DOI 10.1073/pnas.88.11.4921; SOGAARDANDERSEN L, 1991, MOL MICROBIOL, V5, P969, DOI 10.1111/j.1365-2958.1991.tb00772.x; SOGAARDANDERSEN L, 1990, MOL MICROBIOL, V4, P1595, DOI 10.1111/j.1365-2958.1990.tb02071.x; SOGAARDANDERSEN L, 1990, J BACTERIOL, V172, P5706, DOI 10.1128/jb.172.10.5706-5713.1990; SOGAARDANDERSEN L, 1991, MOL GEN GENET, V231, P76, DOI 10.1007/BF00293824; TAKAHASHI M, 1989, J MOL BIOL, V207, P783, DOI 10.1016/0022-2836(89)90244-1; USHIDA C, 1990, NUCLEIC ACIDS RES, V18, P6325, DOI 10.1093/nar/18.21.6325; VALENTINHANSEN P, 1991, MOL MICROBIOL, V5, P433, DOI 10.1111/j.1365-2958.1991.tb02126.x; VALENTINHANSEN P, 1987, NATURE, V325, P823; WYMAN J, 1964, ADV PROTEIN CHEM, V19, P223, DOI 10.1016/S0065-3233(08)60190-4; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x	65	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33242	33255		10.1074/jbc.271.52.33242	http://dx.doi.org/10.1074/jbc.271.52.33242			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969182	hybrid			2022-12-25	WOS:A1996WA71300016
J	Zhang, QH; Mosher, DF				Zhang, QH; Mosher, DF			Cross-linking of the NH2-terminal region of fibronectin to molecules of large apparent molecular mass - Characterization of fibronectin assembly sites induced by the treatment of fibroblasts with lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE ALPHA-HELICES; PLASMA FIBRONECTIN; EXTRACELLULAR-MATRIX; CELL-SURFACE; FACTOR-XIII; BINDING; RECEPTOR; PROTEIN; LAYERS; IDENTIFICATION	Cell surface molecules on adherent cells that bind I-125-labeled fibronectin or its 70-kDa N-terminal fragment were identified by cross-linking with factor XIIIa and by photoaffinity labeling. Such cross-linking caused the 70-kDa fragment to become associated irreversibly to cell layers and was greater in cells treated with lysophosphatidic acid, an enhancer of fibronectin assembly and strong modulator of cell shape. Cross-linking of the 70-kDa fragment with factor XIIIa was to molecules that migrated in discontinuous sodium dodecyl sulfate-polyacrylamide gels at the top of the 3.3% stacking gel and near the top of the separating gel. Estimated sizes of these large apparent molecular mass molecules (LAMMs) were >>3 MDa and similar to 3 MDa. The label in 70-kDa fragment conjugated with I-125-sulfosuccinimidyl 2-(p-azidosalicylamido)-1,3'-dithiopropionate was associated with >>3-MDa LAMMs without reduction and with similar to 3-MDa LAMMs after reduction and transfer of the cleavable label. The LAMMs were expressed on monolayer cells shortly after adherence, required both 1% Triton X-100 and 2 M urea for efficient extraction, and were susceptible to digestion with trypsin but not to cathepsin D digestion. Complexes of I-125-70-kDa fragment and LAMMs were also susceptible to limited acid digestion and Glu-C protease digestion but were not cleaved by chondroitin lyase or heparitinase. Neither the uncleaved complexes nor the cleavage products were immunoprecipitated with anti-fibronectin antibodies directed toward epitopes outside the 70-kDa region. Thus, cell surface molecules that are either very large or not dissociated in sodium dodecyl sulfate comprise the labile matrix assembly sites for fibronectin.	UNIV WISCONSIN,DEPT MED,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOMOL CHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NHLBI NIH HHS [HL-21644] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; ALLIO AE, 1988, J CELL PHYSIOL, V135, P459, DOI 10.1002/jcp.1041350313; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BARKALOW FJ, 1994, J BIOL CHEM, V269, P3957; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; BARRY ELR, 1989, J BIOL CHEM, V264, P4179; BARRY ELR, 1990, J BIOL CHEM, V265, P9302; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BLYSTONE SD, 1992, J BIOL CHEM, V267, P3968; BROWN RA, 1994, BIOMATERIALS, V15, P457, DOI 10.1016/0142-9612(94)90225-9; CARTER WG, 1984, J CELL BIOL, V99, P105, DOI 10.1083/jcb.99.1.105; CHECOVICH WJ, 1993, ARTERIOSCLER THROMB, V13, P1662, DOI 10.1161/01.ATV.13.11.1662; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLVIN RB, 1989, FIBRONECTIN, P213; DARRIBERE T, 1992, DEV DYNAM, V194, P63, DOI 10.1002/aja.1001940108; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; EILERTSEN KJ, 1992, J CELL BIOL, V119, P549, DOI 10.1083/jcb.119.3.549; EJIM OS, 1993, BIOMATERIALS, V14, P743, DOI 10.1016/0142-9612(93)90038-4; FOGERTY FJ, 1990, CELL DIFFER DEV, V32, P439, DOI 10.1016/0922-3371(90)90061-Z; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GHOSH P, 1995, NATURE, V378, P457, DOI 10.1038/378457a0; HALLIDAY NL, 1995, EXP CELL RES, V217, P109, DOI 10.1006/excr.1995.1069; Hocking DC, 1996, J CELL BIOL, V133, P431, DOI 10.1083/jcb.133.2.431; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; Hynes RO, 1990, FIBRONECTINS; KOLODNEY MS, 1993, J BIOL CHEM, V268, P23850; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landon, 1977, Methods Enzymol, V47, P145; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCDONAGH RP, 1981, FEBS LETT, V127, P174, DOI 10.1016/0014-5793(81)80198-6; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MOON KY, 1994, J BIOL CHEM, V269, P7651; MORLA A, 1994, NATURE, V367, P193, DOI 10.1038/367193a0; MOSHER DF, 1977, BIOCHIM BIOPHYS ACTA, V491, P205, DOI 10.1016/0005-2795(77)90056-3; MOSHER DF, 1975, J BIOL CHEM, V250, P6614; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1983, ANN NY ACAD SCI, V408, P583, DOI 10.1111/j.1749-6632.1983.tb23275.x; Mosher DF, 1989, FIBRONECTIN; PAN KM, 1994, BIOCHEMISTRY-US, V33, P8255, DOI 10.1021/bi00193a012; PERKINS ME, 1979, CELL, V16, P941, DOI 10.1016/0092-8674(79)90109-0; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; SAKAI K, 1994, J BIOCHEM-TOKYO, V115, P415, DOI 10.1093/oxfordjournals.jbchem.a124353; SANO T, 1995, P NATL ACAD SCI USA, V92, P3180, DOI 10.1073/pnas.92.8.3180; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SINGER II, 1989, FIBRONECTIN, P139; SOMERS CE, 1993, J BIOL CHEM, V268, P22277; SORENSEN P, 1986, J BIOL CHEM, V261, P9094; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; THIERY JP, 1989, FIBRONECTIN, P181; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WILLIAMS EC, 1983, J BIOL CHEM, V258, P5911; WINKLBAUER R, 1991, DEV BIOL, V148, P573, DOI 10.1016/0012-1606(91)90275-8; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; ZHANG QH, 1994, J CELL BIOL, V127, P1447, DOI 10.1083/jcb.127.5.1447	66	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33284	33292		10.1074/jbc.271.52.33284	http://dx.doi.org/10.1074/jbc.271.52.33284			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969187	hybrid			2022-12-25	WOS:A1996WA71300021
J	Zheng, Y; Fischer, DJ; Santos, MF; Tigyi, G; Pasteris, NG; Gorski, JL; Xu, YH				Zheng, Y; Fischer, DJ; Santos, MF; Tigyi, G; Pasteris, NG; Gorski, JL; Xu, YH			The faciogenital dysplasia gene product FGD1 functions as a Cdc42Hs-specific guanine-nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DBL ONCOGENE PRODUCT; GTP-BINDING PROTEINS; ACTIN STRESS FIBERS; CDC42 GTPASES; CELL-CYCLE; RHO; RAC; FILOPODIA; PATHWAY	The Rho family of small GTP-binding proteins plays important roles in the regulation of actin cytoskeleton organization and cell growth. Activation of these GTPases involves the replacement of bound GDP with GTP, a process catalyzed by the Dbl-like guanine-nucleotide exchange factors, all of which seem to share a putative catalytic motif termed the Dbl homology (DH) domain, followed by a pleckstrin homology (PH) domain, Here we have examined the role of a Dbl-like molecule, the faciogenital dysplasia gene product (FGD1), which when mutated in its Dbl homology domain, cosegregates with the developmental disease Aarskog-Scott syndrome. We report that a polypeptide of FGD1 encompassing the DH and PH domains can bind specifically to the Rho family GTPase Cdc42Hs and stimulates the GDP-GTP exchange of the isoprenylated form of Cdc42Hs. Microinjection of this FGD1 polypeptide into Swiss 3T3 fibroblast cells induces the formation of peripheral actin microspikes, similar to that previously observed when cells were injected with a constitutively active form of Cdc42Hs. This effect of FGD1 on actin organization is readily inhibited by coinjection of a dominant-negative mutant of Cdc42Hs. Examination of NIH 3T3 cells expressing the FGD1 fragment revealed that similar to cells expressing Dbl, two independent elements downstream of Cdc42Hs, the Jun NH2-terminal kinase and the p70 S6 kinase, became activated. Hence, our results indicate that FGD1, through its DH and PH domains, acts as a Cdc42Hs-specific guanine-nucleotide exchange factor and suggest that the Cdc42Hs GTPase may have a role in mammalian development.	UNIV TENNESSEE,DEPT PHYSIOL & BIOPHYS,MEMPHIS,TN 38163; UNIV MICHIGAN,DEPT HUMAN GENET,ANN ARBOR,MI 48109	University of Tennessee System; University of Tennessee Health Science Center; University of Michigan System; University of Michigan	Zheng, Y (corresponding author), UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163, USA.		Zheng, Yi/J-7235-2015; Santos, Marinilce F/G-9548-2011	Zheng, Yi/0000-0001-7089-6074; Santos, Marinilce F/0000-0002-3257-3327	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053943] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53943] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CERIONE RA, 1995, METHOD ENZYMOL, V256, P11; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dutartre H, 1996, J CELL SCI, V109, P367; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HART MJ, 1994, J BIOL CHEM, V269, P62; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; PASTERIS NG, 1994, CELL, V79, P669; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	35	128	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33169	33172		10.1074/jbc.271.52.33169	http://dx.doi.org/10.1074/jbc.271.52.33169			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969170	hybrid			2022-12-25	WOS:A1996WA71300004
J	GiraudPanis, MJE; Lilley, DMJ				GiraudPanis, MJE; Lilley, DMJ			T4 endonuclease VII - Importance of a histidine-aspartate cluster within the zinc-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; CLEAVES HOLLIDAY JUNCTIONS; RUVC GENE-PRODUCT; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; RESOLVING ENZYME; PHAGE-LAMBDA; ACTIVE-SITE; DNA; RESOLUTION	The DNA junction-resolving enzyme endonuclease VII of bacteriophage T4 contains a zinc binding region toward the N-terminal end of the primary sequence. In the center of this 39-amino acid section (between residues 38 and 44) lies the sequence HLDHDHE, termed the His-acid cluster. Closely related sequences are found in three other proteins that have similar zinc-binding motifs. We have analyzed the function of these residues by a site-directed mutagenesis approach, modifying single amino acids and studying the properties of the resulting N-terminal protein A fusions. No sequence changes within the His acid cluster led to a change in zinc content of the protein, indicating that these residues are not involved in the coordination of zinc. We found that the N-terminal aspartate residue (Asp-40) and the two histidine residues (His-41 and His-43) within the cluster are essential for junction-cleavage activity of the proteins. However, all sequence variations within this region generate proteins that retain their ability to bind to four-way DNA junctions (with minor changes in binding affinity in some cases) and to distort their global structure in the same manner as active enzymes. We conclude that the process of cleavage can be uncoupled from those of binding to and distortion of the junction. It is probable that some amino acid side chains of the His-acid cluster participate in the phosphodiester cleavage mechanism of endonuclease VII. The essential aspartate residue might be required for coordination of catalytic metal ions.	UNIV DUNDEE,DEPT BIOCHEM,CANC RES CAMPAIGN,NUCLE ACID STRUCT RES GRP,DUNDEE DD1 4HN,SCOTLAND	University of Dundee				Giraud-Panis, Marie-Josephe/0000-0001-7941-2873				BEAUCAGE SL, 1981, TETRAHEDRON LETT, V22, P1859, DOI 10.1016/S0040-4039(01)90461-7; BENNETT RJ, 1993, CELL, V74, P1021, DOI 10.1016/0092-8674(93)90724-5; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BROKER TR, 1971, J MOL BIOL, V60, P131, DOI 10.1016/0022-2836(71)90453-0; CHENG XD, 1994, EMBO J, V13, P3927, DOI 10.1002/j.1460-2075.1994.tb06708.x; CONNOLLY B, 1991, P NATL ACAD SCI USA, V88, P6063, DOI 10.1073/pnas.88.14.6063; COOPER JP, 1987, J MOL BIOL, V198, P711, DOI 10.1016/0022-2836(87)90212-9; DEMASSY B, 1984, COLD SPRING HARB SYM, V49, P715, DOI 10.1101/SQB.1984.049.01.081; DUCKETT DR, 1995, J MOL BIOL, V246, P95, DOI 10.1006/jmbi.1994.0069; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; ELBOROUGH KM, 1990, EMBO J, V9, P2931, DOI 10.1002/j.1460-2075.1990.tb07484.x; GARDEL C, 1990, EMBO J, V9, P3209, DOI 10.1002/j.1460-2075.1990.tb07519.x; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; GIRAUDPANIS MJE, 1995, J MOL BIOL, V252, P596, DOI 10.1006/jmbi.1995.0523; GOUGH GW, 1985, NATURE, V313, P154, DOI 10.1038/313154a0; HATFULL GF, 1993, MOL MICROBIOL, V7, P395, DOI 10.1111/j.1365-2958.1993.tb01131.x; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOLLIDAY R, 1964, GENET RES, V5, P282, DOI 10.1017/S0016672300001233; HUNT JB, 1984, J BIOL CHEM, V259, P4793; HYDE H, 1994, J BIOL CHEM, V269, P5202; IWASAKI H, 1991, EMBO J, V10, P4381, DOI 10.1002/j.1460-2075.1991.tb05016.x; JAYARAM M, 1988, P NATL ACAD SCI USA, V85, P7902, DOI 10.1073/pnas.85.21.7902; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KEMPER B, 1976, J VIROL, V18, P992, DOI 10.1128/JVI.18.3.992-999.1976; KEMPER LB, 1991, EUR JBIOCH, V115, P123; KITTS PA, 1987, NATURE, V329, P346, DOI 10.1038/329346a0; KOSTREWA D, 1995, BIOCHEMISTRY-US, V34, P683, DOI 10.1021/bi00002a036; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUMPKIN OJ, 1982, BIOPOLYMERS, V21, P2315, DOI 10.1002/bip.360211116; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MORIKAWA K, 1995, J MOL BIOL, V249, P360, DOI 10.1006/jmbi.1995.0302; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; PARSONS CA, 1995, NATURE, V374, P375, DOI 10.1038/374375a0; Pohler JRG, 1996, J MOL BIOL, V260, P678; POTTER H, 1976, P NATL ACAD SCI USA, V73, P3000, DOI 10.1073/pnas.73.9.3000; POTTER H, 1978, P NATL ACAD SCI USA, V75, P3698, DOI 10.1073/pnas.75.8.3698; SAITO A, 1995, P NATL ACAD SCI USA, V92, P7470, DOI 10.1073/pnas.92.16.7470; SAMBROOK J, 1989, MOL CLONING LAB MANU, V1, P168; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARPLES GJ, 1991, J BACTERIOL, V173, P7711, DOI 10.1128/jb.173.23.7711-7715.1991; SHARPLES GJ, 1994, EMBO J, V13, P6133, DOI 10.1002/j.1460-2075.1994.tb06960.x; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; STUART D, 1992, J VIROL, V66, P1551, DOI 10.1128/JVI.66.3.1551-1563.1992; SYMINGTON LS, 1985, P NATL ACAD SCI USA, V82, P7247, DOI 10.1073/pnas.82.21.7247; TOMASCHEWSKI J, 1988, THESIS UBOCHUM; WEST SC, 1985, P NATL ACAD SCI USA, V82, P6445, DOI 10.1073/pnas.82.19.6445; White MF, 1996, J MOL BIOL, V257, P330, DOI 10.1006/jmbi.1996.0166; ZUECO J, 1992, ANAL BIOCHEM, V207, P348, DOI 10.1016/0003-2697(92)90023-Z	49	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33148	33155		10.1074/jbc.271.51.33148	http://dx.doi.org/10.1074/jbc.271.51.33148			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955164	hybrid			2022-12-25	WOS:A1996VZ37300099
J	Kahn, RA; Bak, S; Olsen, CE; Svendsen, I; Moller, BL				Kahn, RA; Bak, S; Olsen, CE; Svendsen, I; Moller, BL			Isolation and reconstitution of the heme-thiolate protein obtusifoliol 14 alpha-demethylase from Sorghum bicolor (L.) Moench	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOGENIC GLUCOSIDE DHURRIN; CATALYZING LANOSTEROL 14-ALPHA-DEMETHYLATION; P-HYDROXYPHENYLACETALDEHYDE OXIME; PLANT STEROL BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL EXPRESSION; CYTOCHROME P-450(TYR); ENZYMATIC CLEAVAGE; CANDIDA-ALBICANS; L-TYROSINE	The heme-thiolate (cytochrome P450) enzyme which catalyzes the 14 alpha-demethylation of obtusifoliol has been isolated from microsomes prepared from etiolated seedlings of Sorghum bicolor (L.) Moench. The obtusifoliol 14 alpha-demethylase is a key enzyme in plant sterol biosynthesis and a target for the design of phyla-specific sterol 14 alpha-demethylase inhibitors. Microsomal cytochrome P450s were solubilized by using the detergents Renex 690 and reduced Triton X-100, and the obtusifoliol 14 alpha-demethylase was isolated by DEAE ion exchange and dye affinity column chromatography. The isolated enzyme has an absorption spectrum characteristic for low spin cytochrome P450s and produces a Type I binding spectrum with obtusifoliol as substrate. Binding spectra were not obtained with lanosterol, campesterol, sitosterol, or stigmasterol. Obtusifoliol 14 alpha-demethylase has an apparent molecular mass of 53 kDa and is estimated to constitute approximate to 20% of the total cytochrome P450 content of the microsomal membranes and about 0.2% of the total microsomal protein. Gas chromatography-mass spectrometry analysis of reconstitution experiments with dilauroylphosphatidylcholine micelles containing isolated obtusifoliol 14 alpha-demethylase and sorghum NADPH-cytochrome P450 oxidoreductase demonstrated the conversion of obtusifoliol (4 alpha,14 alpha-dimethyl-5 alpha-ergosta-8,24-(28)-dien-3 beta-ol) to 4 alpha-methyl-5 alpha-ergosta-8,14,24(28)-trien-3 beta-ol, the 14 alpha-demethylated product of obtusifoliol with a double bond introduced at the Delta(14) position. The N-terminal amino acid sequence of the protein is MDLADIPQ/KQQRLMAGXALVV. Five internal sequences were obtained after endoproteinase Lys-C and Glu-C digestion. The fragment AAGAFSYISFGGGRH aligns with the unique heme binding domain of mammalian and yeast sterol 14 alpha-demethylases which belong to the CYP51 family, Therefore it is conceivable that the obtusifoliol 14 alpha-demethylase from plants also belongs to the CYP51 family, the only P450 family so far known to be conserved across the phyla.	ROYAL VET & AGR UNIV,DEPT PLANT BIOL,PLANT BIOCHEM LAB,DK-1871 FREDERIKSBERG C,COPENHAGEN,DENMARK; ROYAL VET & AGR UNIV,DEPT CHEM,DK-1871 FREDERIKSBERG C,COPENHAGEN,DENMARK; CARLSBERG LAB,DEPT CHEM,DK-2500 VALBY,DENMARK	University of Copenhagen; University of Copenhagen			Olsen, Carl E/H-3031-2014; Møller, Birger Lindberg/H-2657-2014; Bak, Soren/H-4404-2014; Møller, Birger Lindberg/GQI-1792-2022	Olsen, Carl E/0000-0002-2275-0596; Møller, Birger Lindberg/0000-0002-3252-3119; Bak, Soren/0000-0003-4100-115X; Møller, Birger Lindberg/0000-0002-3252-3119				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AOYAMA Y, 1994, BIOCHEM BIOPH RES CO, V201, P1320, DOI 10.1006/bbrc.1994.1848; AOYAMA Y, 1992, BIOCHEM BIOPH RES CO, V183, P1266, DOI 10.1016/S0006-291X(05)80327-4; AOYAMA Y, 1984, J BIOL CHEM, V259, P1661; BENVENISTE I, 1986, BIOCHEM J, V235, P365, DOI 10.1042/bj2350365; BENVENISTE P, 1986, ANNU REV PLANT PHYS, V37, P275, DOI 10.1146/annurev.pp.37.060186.001423; BOLWELL GP, 1994, PHYTOCHEMISTRY, V37, P1491, DOI 10.1016/S0031-9422(00)89567-9; CHAPPELL J, 1995, ANNU REV PLANT PHYS, V46, P521, DOI 10.1146/annurev.pp.46.060195.002513; CHEN C, 1988, DNA-J MOLEC CELL BIO, V7, P617, DOI 10.1089/dna.1988.7.617; de Montellano P. R. O., 1995, CYTCOCHROME P450 STR, P245; Durst Francis, 1995, Drug Metabolism and Drug Interactions, V12, P171; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GOAD LJ, 1966, BIOCHEM J, V99, P735, DOI 10.1042/bj0990735; GRAUSEM B, 1995, PLANT J, V7, P761, DOI 10.1046/j.1365-313X.1995.07050761.x; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; GUO DA, 1995, LIPIDS, V30, P203, DOI 10.1007/BF02537823; HALKIER BA, 1989, PLANT PHYSIOL, V90, P1552, DOI 10.1104/pp.90.4.1552; HALKIER BA, 1995, ARCH BIOCHEM BIOPHYS, V322, P369, DOI 10.1006/abbi.1995.1477; HEINTZ R, 1974, J BIOL CHEM, V249, P4267; HITCHCOCK CA, 1989, BIOCHEM J, V263, P573, DOI 10.1042/bj2630573; Jefcoate C R, 1978, Methods Enzymol, V52, P258; KALB VF, 1986, GENE, V45, P237, DOI 10.1016/0378-1119(86)90021-1; KOCH BM, 1995, ARCH BIOCHEM BIOPHYS, V323, P177; LAI MH, 1989, NUCLEIC ACIDS RES, V17, P804, DOI 10.1093/nar/17.2.804; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Nes W. David, 1993, P389; OMURA T, 1964, J BIOL CHEM, V239, P2379; PASCAL S, 1993, J BIOL CHEM, V268, P11639; PATTERSON GW, 1971, ANAL CHEM, V43, P1165, DOI 10.1021/ac60304a015; RAHIER A, 1977, PHYTOCHEMISTRY, V16, P1187, DOI 10.1016/S0031-9422(00)94357-7; RAHIER A, 1986, BIOCHEM BIOPH RES CO, V140, P1064, DOI 10.1016/0006-291X(86)90743-6; RAHIER A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P215, DOI 10.1016/0005-2760(92)90048-Z; REES HH, 1969, BIOCHIM BIOPHYS ACTA, V176, P892, DOI 10.1016/0005-2760(69)90274-4; RUSSELL PT, 1967, J BIOL CHEM, V242, P5802; SENIOR IJ, 1995, PESTIC SCI, V45, P57, DOI 10.1002/ps.2780450109; SIBBESEN O, 1995, J BIOL CHEM, V270, P3506, DOI 10.1074/jbc.270.8.3506; SIBBESEN O, 1994, P NATL ACAD SCI USA, V91, P9740, DOI 10.1073/pnas.91.21.9740; SLOANE DL, 1995, GENE, V161, P243, DOI 10.1016/0378-1119(95)00211-N; SONO H, 1991, BIOCHIM BIOPHYS ACTA, V1078, P388, DOI 10.1016/0167-4838(91)90161-R; SONODA Y, 1993, BIOCHIM BIOPHYS ACTA, V1170, P92; TATON M, 1991, BIOCHEM J, V277, P483, DOI 10.1042/bj2770483; TRZASKOS J, 1986, J BIOL CHEM, V261, P4651; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; YOSHIDA Y, 1984, J BIOL CHEM, V259, P1655; Yoshida Y., 1993, CYTOCHROME P 450, P93	45	42	46	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32944	32950		10.1074/jbc.271.51.32944	http://dx.doi.org/10.1074/jbc.271.51.32944			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955137	hybrid			2022-12-25	WOS:A1996VZ37300072
J	Kanaya, S; Oobatake, M; Liu, YY				Kanaya, S; Oobatake, M; Liu, YY			Thermal stability of Escherichia coli ribonuclease HI and its active site mutants in the presence and absence of the Mg2+ ion - Proposal of a novel catalytic role for Glu(48)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CRYSTAL-STRUCTURE; DIRECTED MUTAGENESIS; MAGNESIUM-ION; BINDING-SITE; METALLOBIOCHEMISTRY; SUBSTITUTIONS; STABILIZATION; ENDONUCLEASE; TRANSITION	Escherichia coli ribonuclease HI, which requires divalent cations (Mg2+ or Mn2+) for activity, was thermostabilized by 2.6-3.0 kcal/mol in the presence of the Mg2+, Mn2+, or Ca2+ ion, probably because the negative charge repulsion around the active site was canceled upon the binding of these metal ions. The dissociation constants were determined to be 0.71 mM for Mg2+, 0.035 mM for Mn2+, and 0.16 mM for Ca2+. Likewise, various active site mutants at Asp(10), Glu(48), Asp(70), or Asp(134) were thermostabilized by 0.4-3.0 kcal/mol in the presence of the Mg2+ ion, suggesting that this ion binds to these mutant proteins as well. The dissociation constants of Mg2+ were determined to be 9.8 mM for D10N, 1.1 mM for E48Q, 18.8 mM for D70N, and 1.8 mm for D134N. Thus, the mutation of Asp(10) or Asp(70) to Asn considerably impairs the Mg2+ binding, whereas the mutation of Glu(48) to Gln or Asp(134) to Asn does not. Comparison of the thermal stability of the mutant proteins with that of the wild-type protein in the absence of the Mg2+ ion suggests that the negative charge repulsion between Asp10 and Asp(70) is responsible for the binding of the metal cofactor. Glu(48) may be required to anchor a water molecule, which functions as a general acid.	PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN									ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; BERKOWER I, 1973, J BIOL CHEM, V248, P5914; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; CASARENO RLB, 1995, J AM CHEM SOC, V117, P11011, DOI 10.1021/ja00149a026; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HIBLER DW, 1987, BIOCHEMISTRY-US, V26, P6278, DOI 10.1021/bi00393a048; Hostomsky Z., 1993, NUCLEASES, V2nd, P341; HUANG HW, 1994, EUR J BIOCHEM, V219, P253, DOI 10.1111/j.1432-1033.1994.tb19936.x; IWAI S, 1995, FEBS LETT, V368, P315, DOI 10.1016/0014-5793(95)00683-Z; JOU RW, 1991, J AM CHEM SOC, V113, P6685, DOI 10.1021/ja00017a056; KANAYA S, 1990, BIOCHEM J, V271, P59, DOI 10.1042/bj2710059; KANAYA S, 1993, J BIOTECHNOL, V28, P117, DOI 10.1016/0168-1656(93)90129-B; KANAYA S, 1989, J BIOL CHEM, V264, P11546; KANAYA S, 1991, J BIOL CHEM, V266, P6038; KANAYA S, 1990, J BIOL CHEM, V265, P4615; KASHIWAGI T, 1996, IN PRESS PROTEIN ENG; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KATAYANAGI K, 1993, J BIOL CHEM, V268, P22092; KIMURA S, 1992, J BIOL CHEM, V267, P21535; Lide D. R., 1994, CRC HDB CHEM PHYSICS, P5; MEIERING EM, 1992, J MOL BIOL, V225, P585, DOI 10.1016/0022-2836(92)90387-Y; Miller J. H., 1972, EXPT MOL GENETICS, P433; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NEEDHAM JV, 1993, BIOCHEMISTRY-US, V32, P3363, DOI 10.1021/bi00064a020; ODA Y, 1991, Journal of Biomolecular NMR, V1, P247, DOI 10.1007/BF01875518; ODA Y, 1993, J BIOL CHEM, V268, P88; ODA Y, 1994, BIOCHEMISTRY-US, V33, P5275, DOI 10.1021/bi00183a034; OOI T, 1987, P NATL ACAD SCI USA, V84, P3086, DOI 10.1073/pnas.84.10.3086; OOI T, 1991, P NATL ACAD SCI USA, V88, P2859, DOI 10.1073/pnas.88.7.2859; OTA M, 1995, J MOL BIOL, V248, P733, DOI 10.1016/S0022-2836(95)99991-4; PACE CN, 1988, BIOCHEMISTRY-US, V27, P3242, DOI 10.1021/bi00409a018; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; UCHIYAMA Y, 1994, J MOL BIOL, V243, P782, DOI 10.1016/0022-2836(94)90047-7; Yamasaki T, 1995, THERMOCHIM ACTA, V267, P379, DOI 10.1016/0040-6031(95)02495-6; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648; ZHANG J, 1982, PROTEIN-STRUCT FUNCT, V13, P87; ZHI W, 1991, BIOCHEMISTRY-US, V30, P9281, DOI 10.1021/bi00102a021	45	69	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32729	32736		10.1074/jbc.271.51.32729	http://dx.doi.org/10.1074/jbc.271.51.32729			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955106	hybrid			2022-12-25	WOS:A1996VZ37300041
J	Meszaros, JG; Karin, NJ; Akanbi, K; FarachCarson, MC				Meszaros, JG; Karin, NJ; Akanbi, K; FarachCarson, MC			Down-regulation of L-type Ca2+ channel transcript levels by 1,25-dihydroxyvitamin D-3 - Osteoblastic cells express L-type alpha(1C) Ca2+ channel isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; RAT OSTEOSARCOMA CELLS; GENE-EXPRESSION; FUNCTIONAL EXPRESSION; MOLECULAR DIVERSITY; SKELETAL-MUSCLE; ION CHANNELS; ACTIVATION; RECEPTOR; HORMONE	Osteoblast Ca2+ channels play a fundamental role in controlling intracellular and systemic Ca2+ homeostasis. A reverse transcription-polymerase chain reaction strategy was used to determine the molecular identity of voltage-sensitive calcium channels present in ROS 17/2.8 osteosarcoma cells. The amino acid sequences encoded by the two resultant PCR products matched the alpha 1(C-a) and the alpha 1(C-d) isoforms. The ability of 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) and structural analogs to modulate expression of voltage-sensitive calcium channel mRNA transcripts was then investigated. ROS 17/2.8 cells were cultured for 48 h in the presence of either 1,25(OH)(2)D-3, 1,24-dihydroxy-22-ene-24-cyclopropyl D-3 (analog BT) or 25-hydroxy-16-ene-23-yne-D-3 (analog AT), and the levels of mRNA encoding alpha(1C) were quantitated using a competitive reverse transcription-polymerase chain reaction assay. We found that 1,25(OH)(2)D-3 and analog BT reduced steady state levels of alpha(1C) mRNA. Conversely, the Ca2+-mobilizing analog AT did not alter steady state levels of voltage-sensitive calcium channel mRNA. Since analog BT, but not analog AT, binds and transcriptionally activates the nuclear receptor for 1,25(OH)(2)D-3, these findings suggest that the down-regulation of voltage-sensitive calcium channel mRNA levels may involve the nuclear receptor.	UNIV TEXAS, DENT BRANCH, DEPT BASIC SCI, HOUSTON, TX 77030 USA	University of Texas System					NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010318] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 10318] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BARRY ELR, 1995, P NATL ACAD SCI USA, V92, P10914, DOI 10.1073/pnas.92.24.10914; BIEL M, 1991, EUR J BIOCHEM, V200, P81, DOI 10.1111/j.1432-1033.1991.tb21051.x; BORTELL R, 1992, P NATL ACAD SCI USA, V89, P6119, DOI 10.1073/pnas.89.13.6119; CAFFREY JM, 1987, SCIENCE, V236, P570, DOI 10.1126/science.2437651; CAFFREY JM, 1989, J BIOL CHEM, V264, P20265; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Duncan RL, 1996, P NATL ACAD SCI USA, V93, P1864, DOI 10.1073/pnas.93.5.1864; FARACHCARSON MC, 1991, ENDOCRINOLOGY, V129, P1876, DOI 10.1210/endo-129-4-1876; GREEN J, 1992, AM J PHYSIOL, V263, pE1070; HANNAH SS, 1994, NUTR REV, V52, P376, DOI 10.1111/j.1753-4887.1994.tb01368.x; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; HORTON WE, 1991, J BIOL CHEM, V266, P24804; IWASHIMA Y, 1993, DIABETES, V42, P948, DOI 10.2337/diabetes.42.7.948; KAWAGUCHI N, 1992, P NATL ACAD SCI USA, V89, P4569, DOI 10.1073/pnas.89.10.4569; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KHOURY R, 1994, ENDOCRINOLOGY, V135, P2446, DOI 10.1210/en.135.6.2446; KOCH WJ, 1990, J BIOL CHEM, V265, P17786; KYEYUNENYOMBI E, 1989, ARCH BIOCHEM BIOPHYS, V275, P363, DOI 10.1016/0003-9861(89)90383-4; LI Q, 1994, J BIOL CHEM, V269, P4934; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MESZAROS JG, 1994, MOL BIOL CELL, V5; MESZAROS JG, 1996, IN PRESS CONNECT TIS; MIKAMI A, 1989, NATURE, V340, P230, DOI 10.1038/340230a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NORMAN AW, 1992, J STEROID BIOCHEM, V41, P231, DOI 10.1016/0960-0760(92)90349-N; PEREZREYES E, 1989, NATURE, V340, P233, DOI 10.1038/340233a0; PEREZREYES E, 1990, J BIOL CHEM, V265, P20430; PUZAS JE, 1981, P SOC EXP BIOL MED, V166, P113; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; YOSHIMOTO Y, 1986, J STEROID BIOCHEM, V25, P905, DOI 10.1016/0022-4731(86)90322-5; YU ASL, 1992, P NATL ACAD SCI USA, V89, P10494, DOI 10.1073/pnas.89.21.10494	37	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32981	32985		10.1074/jbc.271.51.32981	http://dx.doi.org/10.1074/jbc.271.51.32981			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955142	hybrid			2022-12-25	WOS:A1996VZ37300077
J	Pinnaduwage, P; Bruce, BD				Pinnaduwage, P; Bruce, BD			In vitro interaction between a chloroplast transit peptide and chloroplast outer envelope lipids is sequence-specific and lipid class-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IMPORT MACHINERY; MITOCHONDRIAL TARGETING SEQUENCES; ESCHERICHIA-COLI; PRECURSOR PROTEINS; SIGNAL PEPTIDES; CONTACT FORMATION; MEMBRANE-LIPIDS; TRANSLOCATION; PRESEQUENCE; BINDING	Interaction of artificial lipid bilayers (liposomes) with the purified transit peptide (SS-tp) of the precursor form of the small subunit for ribulose-2,5-bisphosphate carboxylase/oxygenase (prSSU) has been studied using a vesicle-disruption assay (calcein dye release) and electron microscopy. Employing purified forms of Escherichia coli-expressed prSSU, mature small subunit, glutathione S-transferase-transit peptide fusion protein, and SS-tp in dye release studies demonstrated that lipid interaction is mediated primarily through the transit peptide. Using chemically synthesized peptides (20-mers), the lipid-interacting domain of the transit peptide was partially mapped to the C-terminal 20 amino acids of the transit peptide. Peptides corresponding to other regions of the transit peptide and control peptides promoted significantly less calcein release. Interaction between the transit peptide and the bilayer was very rapid and could not be resolved by stopped-flow fluorometry with a mixing time of <50 ms. Interaction between the peptides and bilayer was also lipid class-dependent. Disruption occurred only when the bilayer contained the galactolipid monogalactosyldiacylglycerol (MGDG). The extent of bilayer disruption directly correlated with the relative concentration of MGDG in the liposome, with maximum calcein release occurring in 20 mol % MGDG liposomes. Lipid bilayers with greater than 20 mol % MGDG could not be achieved as determined by calcein entrapment. Electron microscopy of the liposomes before and after addition of the transit peptide suggested that the transit peptide induced a dramatic reorganization of lipids, These results are discussed in light of a possible mechanism for the early steps in protein transport that may involve polymorphic changes in the envelope membrane organization to include localized non-bilayer H-II structures.	UNIV TENNESSEE,DEPT BIOCHEM & CELLULAR & MOL BIOL,KNOXVILLE,TN 37996; UNIV TENNESSEE,CTR LEGUME RES,KNOXVILLE,TN 37996	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture				Bruce, Barry/0000-0002-4045-9815				ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BRIGGS MS, 1985, SCIENCE, V228, P1096, DOI 10.1126/science.3158076; BRIGGS MS, 1986, SCIENCE, V233, P206, DOI 10.1126/science.2941862; Bruce B.D., 1994, PLANT MOL BIOL MANUA, VJ1, P1; BRUCE BD, 1994, ADV MOL CEL, V10, P389; BULYCHEV A, 1994, FEBS LETT, V356, P204, DOI 10.1016/0014-5793(94)01259-8; CLINE K, 1984, PLANT PHYSIOL, V75, P675, DOI 10.1104/pp.75.3.675; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; DEMEL RA, 1990, BIOCHIM BIOPHYS ACTA, V1027, P155, DOI 10.1016/0005-2736(90)90079-4; DEVRIJE GJ, 1990, MOL MICROBIOL, V4, P143; ENDO T, 1992, EUR J BIOCHEM, V207, P671, DOI 10.1111/j.1432-1033.1992.tb17094.x; ENDO T, 1988, EMBO J, V7, P1153, DOI 10.1002/j.1460-2075.1988.tb02925.x; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HAGEMAN J, 1990, PLANT CELL, V2, P479, DOI 10.1105/tpc.2.5.479; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; HORNIAK L, 1993, FEBS LETT, V334, P241, DOI 10.1016/0014-5793(93)81720-K; HOYT DW, 1991, J BIOL CHEM, V266, P21693; JOYARD J, 1991, EUR J BIOCHEM, V199, P489, DOI 10.1111/j.1432-1033.1991.tb16148.x; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KEEGSTRA K, 1989, PHOTOSYNTHESIS, P347; KERBER B, 1992, FEBS LETT, V306, P71, DOI 10.1016/0014-5793(92)80840-D; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KILLIAN JA, 1990, EMBO J, V9, P815, DOI 10.1002/j.1460-2075.1990.tb08178.x; KLEIN RR, 1992, PLANT PHYSIOL, V98, P546, DOI 10.1104/pp.98.2.546; LEENHOUTS JM, 1993, FEBS LETT, V327, P172, DOI 10.1016/0014-5793(93)80164-P; LEENHOUTS JM, 1994, MOL MEMBR BIOL, V11, P159, DOI 10.3109/09687689409162234; MAYER A, 1995, EMBO J, V14, P4204, DOI 10.1002/j.1460-2075.1995.tb00094.x; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; PERRY SE, 1991, J BIOL CHEM, V266, P11882; PINNADUWAGE P, 1992, BIOCHEMISTRY-US, V31, P2850, DOI 10.1021/bi00126a002; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; REITVELD AG, 1995, EMBO J, V14, P5506; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SNEL MME, 1995, BIOCHEMISTRY-US, V34, P3605, DOI 10.1021/bi00011a015; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; TOROK Z, 1994, BIOCHEMISTRY-US, V33, P5589; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VANTHOF R, 1995, FEBS LETT, V361, P35, DOI 10.1016/0014-5793(95)00135-V; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; VASILENKO I, 1982, BIOCHIM BIOPHYS ACTA, V685, P144, DOI 10.1016/0005-2736(82)90091-8; VONHEIJNE G, 1991, FEBS LETT, V278, P1, DOI 10.1016/0014-5793(91)80069-F; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; VONHEIJNE G, 1991, PLANT MOL BIOL REP, V9, P104	54	77	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32907	32915		10.1074/jbc.271.51.32907	http://dx.doi.org/10.1074/jbc.271.51.32907			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955132	hybrid			2022-12-25	WOS:A1996VZ37300067
J	Yao, YQ; Yamamoto, K; Nishi, Y; Nogi, Y; Muramatsu, M				Yao, YQ; Yamamoto, K; Nishi, Y; Nogi, Y; Muramatsu, M			Mouse RNA polymerase I 16-kDa subunit able to associate with 40-kDa subunit is a homolog of yeast AC19 subunit of RNA polymerases I and III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SHUTTLE VECTORS; ALPHA-SUBUNIT; GENE; SEQUENCE; DNA; TRANSCRIPTION; PURIFICATION; MUTATIONS	We have previously isolated a mouse RPA40 (mRPA40) cDNA encoding the 40-kDa subunit of mouse RNA polymerase I and demonstrated that mRPA40 is a mouse homolog of the yeast subunit AC40, which is a subunit of RNA polymerases I and III, having a limited homology to bacterial RNA polymerase subunit alpha (Song, C. Z., Hanada, K., Yano, K., Maeda, Y., Yamamoto, K., and Muramatsu, M. (1994) J. Biol. Chem. 269, 26976-26981). In an extension of the study we have now cloned mouse RPA16 (mRPA16) cDNA encoding the 16-kDa subunit of mouse RNA polymerase I by a yeast two-hybrid system using mRPA40 as a bait. The deduced amino acid sequence shows 45% identity to the yeast subunit AC19 of RNA polymerases I and III, known to associate with AC40, and a local similarity to bacterial alpha subunit. We have shown that mRPA40 mutants failed to interact with mRPA16 and that neither mRPA16 nor mRPA40 can interact by itself in the yeast two-hybrid system. These results suggest that higher eukaryotic RNA polymerase I conserves two distinct alpha-related subunits that function to associate with each other in an early stage of RNA polymerase I assembly.	SAITAMA MED SCH,DEPT BIOCHEM,MOROYAMA,SAITAMA 35004,JAPAN	Saitama Medical University								AZUMA Y, 1993, NUCLEIC ACIDS RES, V21, P3749, DOI 10.1093/nar/21.16.3749; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DEQUARDCHABLAT M, 1991, J BIOL CHEM, V266, P15300; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IGARASHI K, 1990, NUCLEIC ACIDS RES, V18, P5945, DOI 10.1093/nar/18.20.5945; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; KOLODZIEJ PA, 1991, MOL CELL BIOL, V11, P4669, DOI 10.1128/MCB.11.9.4669; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; LANZENDORFER M, 1994, SYST APPL MICROBIOL, V16, P656; MANN C, 1987, CELL, V48, P627, DOI 10.1016/0092-8674(87)90241-8; MCKUNE K, 1995, MOL CELL BIOL, V15, P6895; MCKUNE K, 1995, MOL CELL BIOL, V14, P4155; MEEK DW, 1984, NUCLEIC ACIDS RES, V12, P5813, DOI 10.1093/nar/12.14.5813; PATI UK, 1990, J BIOL CHEM, V265, P8400; PATI UK, 1994, GENE, V145, P289, DOI 10.1016/0378-1119(94)90022-1; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; Sentenac A., 1992, TRANSCRIPTIONAL REGU, V1, P27; Sherman F, 1986, LAB COURSE MANUAL ME; SHPAKOVSKI GV, 1995, MOL CELL BIOL, V15, P4702; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONG CZ, 1994, J BIOL CHEM, V269, P26976; THURIAUX P, 1994, MOL CELLULAR BIOL YE, V2, P1; Woychik Nancy A., 1993, Gene Expression, V3, P77; YURA T, 1979, ANNU REV GENET, V13, P59, DOI 10.1146/annurev.ge.13.120179.000423	32	18	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32881	32885		10.1074/jbc.271.51.32881	http://dx.doi.org/10.1074/jbc.271.51.32881			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955128	hybrid			2022-12-25	WOS:A1996VZ37300063
J	Soloway, PD; Alexander, CM; Werb, Z; Jaenisch, R				Soloway, PD; Alexander, CM; Werb, Z; Jaenisch, R			Targeted mutagenesis of Timp-1 reveals that lung tumor invasion is influenced by Timp-1 genotype of the tumor but not by that of the host	ONCOGENE			English	Article						Timp-1; metastasis; proteinase inhibitor; targeted mutant	B16-F10 MELANOMA-CELLS; EMBRYONIC STEM-CELLS; TISSUE INHIBITOR; MATRIX METALLOPROTEINASE; EXPRESSION; COLLAGENASE; LOCALIZATION; PROTEINASES; GELATINASES; SECRETION	Timp-1 has been implicated as a suppressor of tumor metastasis, To study the relative importance of Timp-1 expression by tumor vs host during tumor invasion, three pairs of co-isogenic, tumorigenic cells containing wildtype or mutant Timp-1 alleles were generated, These were used in experimental metastasis assays in wild-type or Timp-1-deficient mice, Timp-1 expression in tumorigenic cells could either increase or decrease tumor invasion of lungs in a tumor cell-specific manner, This suggests that depending on the tumor, Timp-1 can either suppress or potentiate metastasis. Mice deficient for Timp-1 were indistinguishable from wild-type mice in metastasis assays with all tumorigenic cells tested, Although Timp-1 is a secreted protein, and lung produces other Timps, the influence of Timp-1 on lung invasion by the tumorigenic cells tested is cell-autonomous, depending only on Timp-1 genotype of tumor and not that of host.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; UNIV CALIF SAN FRANCISCO,DEPT ANAT,RADIOBIOL & ENVIRONM HLTH LAB,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,PROGRAM DEV BIOL,SAN FRANCISCO,CA 94143	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Soloway, Paul/T-8243-2019	Soloway, Paul/0000-0003-1967-0437	NATIONAL CANCER INSTITUTE [R01CA057621] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015325] Funding Source: NIH RePORTER; NCI NIH HHS [CA57621] Funding Source: Medline; NEI NIH HHS [EY11279] Funding Source: Medline; NIGMS NIH HHS [GM15325] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; CLAVEL C, 1992, B CANCER, V79, P261; DOCHERTY AJ, 1995, NATURE, V318, P66; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HICKS NJ, 1984, INT J CANCER, V33, P835, DOI 10.1002/ijc.2910330620; HOWARD EW, 1991, J BIOL CHEM, V266, P13070; HOYHTYA M, 1994, INT J CANCER, V56, P500, DOI 10.1002/ijc.2910560408; KAN CC, 1985, P NATL ACAD SCI USA, V82, P2282, DOI 10.1073/pnas.82.8.2282; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LECO KJ, 1992, GENE, V117, P209, DOI 10.1016/0378-1119(92)90731-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MAQUAT LE, 1995, RNA, V1, P453; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONSKY WL, 1993, CANCER RES, V53, P3159; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; PONTON A, 1991, CANCER RES, V51, P2138; Sambrook J., 2002, MOL CLONING LAB MANU; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHULTZ RM, 1988, CANCER RES, V48, P5539; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; WANG X, 1994, CANCER RES, V54, P4726; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WELGUS HG, 1983, J BIOL CHEM, V258, P2259; WRIGHT JH, 1994, MOL CARCINOGEN, V10, P207, DOI 10.1002/mc.2940100405; ZUCKER S, 1992, INT J CANCER, V52, P366, DOI 10.1002/ijc.2910520307	34	109	113	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2307	2314						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957071				2022-12-25	WOS:A1996VX10800002
J	Zhang, YN; Dean, WL; Gray, RD				Zhang, YN; Dean, WL; Gray, RD			Cooperative binding of Ca2+ to human interstitial collagenase assessed by circular dichroism, fluorescence, and catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST COLLAGENASE; C-TERMINAL DOMAIN; MATRIX METALLOPROTEINASES; VERTEBRATE COLLAGENASE; ZINC CONTENT; SUBSTRATE; SPECIFICITY; ACTIVATION; IDENTIFICATION; STROMELYSIN-1	Dissociation of Ca2+ from human interstitial collagenase induced either by chelation with EGTA or by dilution resulted in loss of enzyme activity, a red shifted emission maximum from 334 to 340 nm and quenching of protein fluorescence by 10% at 340 nm. Circular dichroism indicated that secondary structure was unaffected by EGTA. Ca2+ binding to the EGTA-treated enzyme as assessed by fluorescence was cooperative (Hill coefficient, 2.9; 50% saturation at 0.4 mM Ca2+). The dependence of catalytic activity on [Ca2+] was also cooperative (Hill coefficient, 1.7-2.0; midpoint [Ca2+], 0.2 mM). The Ca2+-reconstituted protein was indistinguishable from the untreated enzyme by activity and fluorescence measurements. These results demonstrate that removal of Ca2+ from full-length collagenase generates a catalytically incompetent, partially unfolded state with native secondary structure but altered tertiary structure characterized by exposure of at least one tryptophyl residue to a more polar environment.	UNIV LOUISVILLE,SCH MED,DEPT BIOCHEM,LOUISVILLE,KY 40292	University of Louisville					NIADDK NIH HHS [AM 39733] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BODE W, 1993, FEBS LETT, V331, P143; DARLAK K, 1990, J BIOL CHEM, V265, P5199; DAWSON RMC, 1986, DATA BIOCH RES, P404; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRANT GA, 1987, J BIOL CHEM, V262, P5886; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; Hunt L T, 1987, Protein Seq Data Anal, V1, P21; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MURPHY G, 1992, J BIOL CHEM, V267, P9612; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; SELTZER JL, 1977, BIOCHIM BIOPHYS ACTA, V485, P179, DOI 10.1016/0005-2744(77)90205-4; SOLER D, 1994, BIOCHEM BIOPH RES CO, V201, P917, DOI 10.1006/bbrc.1994.1789; SPRINGMAN EB, 1995, BIOCHEMISTRY-US, V34, P15713, DOI 10.1021/bi00048a016; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; SPRULINO JC, 1994, PROTEIN-STRUCT FUNCT, V19, P98; STACK MS, 1989, J BIOL CHEM, V264, P4277; SWANN JC, 1981, BIOCHEM J, V195, P41, DOI 10.1042/bj1950041; TERATO K, 1976, BIOCHIM BIOPHYS ACTA, V445, P753, DOI 10.1016/0005-2744(76)90125-X; WEINGARTEN H, 1985, ANAL BIOCHEM, V147, P437, DOI 10.1016/0003-2697(85)90294-5; WELGUS HG, 1981, J BIOL CHEM, V256, P9511; WILLENBROCK F, 1995, FEBS LETT, V358, P189, DOI 10.1016/0014-5793(94)01421-V; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Zhang YN, 1996, J BIOL CHEM, V271, P8015, DOI 10.1074/jbc.271.14.8015	29	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1444	1447		10.1074/jbc.272.3.1444	http://dx.doi.org/10.1074/jbc.272.3.1444			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999811	hybrid			2022-12-25	WOS:A1997WD05800009
J	Illy, C; Quraishi, O; Wang, J; Purisima, E; Vernet, T; Mort, JS				Illy, C; Quraishi, O; Wang, J; Purisima, E; Vernet, T; Mort, JS			Role of the occluding loop in cathepsin B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY CRYSTAL-STRUCTURE; HUMAN CYSTATIN-C; CYSTEINE PROTEINASES; PROCATHEPSIN-B; PAPAIN; INHIBITORS; SPECIFICITY; ASSOCIATION; RESOLUTION; MECHANISM	Within the lysosomal cysteine protease family, cathepsin B is unique due to its ability to act both as an endopeptidase and a peptidyldipeptidase. This latter capacity to remove C-terminal dipeptides has been attributed to the presence of a 20-residue insertion, termed the occluding loop, that blocks the primed terminus of the active site cleft, Variants of human procathepsin B, where all or part of this element was deleted, were expressed in the yeast Pichia pastoris. A mutant, where the 12 central residues of the occluding loop were deleted, autoprocessed, albeit more slowly than the wild type proenzyme, to yield a mature form of the enzyme with endopeptidase activity comparable with the wildtype cathepsin B, but totally lacking exopeptidase activity, This deletion mutant showed a 40-fold higher affinity for the inhibitor cystatin C, suggesting that the occluding loop normally restricts access of this inhibitor to the active site, In addition, the binding affinity of the cathepsin B propeptide, which is a potent inhibitor of this enzyme, was 50-fold increased, consistent with the finding that the loop reorients on activation of the proenzyme, These results suggest that the endopeptidase activity of cathepsin B is an evolutionary remnant since, as a consequence of its membership in the papain family, the propeptide must be able to bind unobstructed through the full length of the active site cleft.	SHRINERS HOSP CRIPPLED CHILDREN,JOINT DIS LAB,MONTREAL,PQ H3G 1A6,CANADA; MCGILL UNIV,DEPT SURG,MONTREAL,PQ H3G 1A6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,MONTREAL,PQ H4P 2R2,CANADA; INST BIOL STURCT,F-38027 GRENOBLE 1,FRANCE	McGill University; McGill University; McGill University; National Research Council Canada			Vernet, Thierry/G-1118-2012					ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ARONSON NN, 1978, BIOCHEM J, V171, P759, DOI 10.1042/bj1710759; BARRETT AJ, 1988, ISI ATLAS-BIOCHEM, V1, P256; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; FOSANG AJ, 1992, J BIOL CHEM, V267, P19470; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; HASNAIN S, 1992, J BIOL CHEM, V267, P4713; IZQUIERDOMARTIN M, 1992, J AM CHEM SOC, V114, P1527, DOI 10.1021/ja00030a085; JIA ZC, 1995, J BIOL CHEM, V270, P5527, DOI 10.1074/jbc.270.10.5527; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; LEATHERBARROW RJ, 1990, TRENDS BIOCHEM SCI, V15, P455, DOI 10.1016/0968-0004(90)90295-M; LINDAHL P, 1992, BIOCHEM J, V281, P49, DOI 10.1042/bj2810049; LINDAHL P, 1988, BIOCHEMISTRY-US, V27, P5074, DOI 10.1021/bi00414a019; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; MACH L, 1994, J BIOL CHEM, V269, P13030; MORT JS, 1981, J HISTOCHEM CYTOCHEM, V29, P649, DOI 10.1177/29.5.6788835; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; POHL J, 1987, ANAL BIOCHEM, V165, P96, DOI 10.1016/0003-2697(87)90205-3; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Sivaraman J, 1996, ACTA CRYSTALLOGR D, V52, P874, DOI 10.1107/S0907444996001801; STARKEY PM, 1977, PROTEINASES MAMMALIA, P57; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; Turk D, 1996, FEBS LETT, V384, P211, DOI 10.1016/0014-5793(96)00309-2; TURK D, 1995, BIOCHEMISTRY-US, V34, P4791, DOI 10.1021/bi00014a037; VERNET T, 1992, J MOL BIOL, V224, P501, DOI 10.1016/0022-2836(92)91011-D; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7	31	215	224	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1197	1202		10.1074/jbc.272.2.1197	http://dx.doi.org/10.1074/jbc.272.2.1197			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995421	hybrid			2022-12-25	WOS:A1997WC04800072
J	Jiang, GQ; Sladek, FM				Jiang, GQ; Sladek, FM			The DNA binding domain of hepatocyte nuclear factor 4 mediates cooperative, specific binding to DNA and heterodimerization with the retinoid X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR HNF-4; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; ACID RECEPTOR; DIMERIZATION ACTIVITIES; RESPONSE ELEMENTS; CRYSTAL-STRUCTURE; LIGAND-BINDING; DIRECT REPEATS	We recently showed that hepatocyte nuclear factor 4 (HNF-4) defines a unique subclass of nuclear receptors that exist in solution and bind DNA elements as homodimers (Jiang, G., Nepomuceno, L., Hopkins, K., and Sladek, F. M. (1995) Mel. Cell. Biol. 15, 5131-5143). In this study, we show that the dimerization domains of HNF-4 map to both the DNA binding and the ligand binding domain, Whereas the latter is critical for dimerization in solution, the DNA binding domain mediates cooperative, specific binding to direct repeats of AGGTCA separated by one or two nucleotides. Whereas amino acid residues 117-125 (the T-box/third helix region) are insufficient for cooperative homodimerization and high affinity DNA binding, residues 126-142 (encompassing the A-box region) are required. Finally, in contrast to the full-length receptor, the DNA binding domain of HNF-4 is capable of heterodimerizing with that of the retinoid X receptor alpha but not with that of other receptors. These results indicate that the HNF-4 DNA binding domain is distinct from that of other receptors and that the determinants that prevent HNF-4 from heterodimerizing with RXR lie outside the DNA binding domain, presumably in the ligand binding domain.	UNIV CALIF RIVERSIDE, ENVIRONM TOXICOL GRAD PROGRAM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside								AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; GIGUERE V, 1990, MOL CELL BIOL, V10, P2335, DOI 10.1128/MCB.10.5.2335; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KNEGTEL RMA, 1993, ANN NY ACAD SCI, V684, P49, DOI 10.1111/j.1749-6632.1993.tb32270.x; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEE MS, 1993, SCIENCE, V260, P1117, DOI 10.1126/science.8388124; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LINSTEDT AD, 1986, J STEROID BIOCHEM, V24, P677, DOI 10.1016/0022-4731(86)90842-3; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SLADEK FM, 1993, RECEPTOR, V3, P223; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; THOMPSON CC, 1987, SCIENCE, V237, P1610, DOI 10.1126/science.3629259; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WRANGE O, 1989, J BIOL CHEM, V264, P5253; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1994, MOL CELL BIOL, V14, P4311, DOI 10.1128/MCB.14.6.4311; ZHANG XK, 1993, RECEPTOR, V3, P183; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	44	71	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1218	1225		10.1074/jbc.272.2.1218	http://dx.doi.org/10.1074/jbc.272.2.1218			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995424	hybrid			2022-12-25	WOS:A1997WC04800075
J	Naik, SM; Shibagaki, N; Li, LJ; Quinlan, KL; Paxton, LL; Caughman, SW				Naik, SM; Shibagaki, N; Li, LJ; Quinlan, KL; Paxton, LL; Caughman, SW			Interferon gamma-dependent induction of human intercellular adhesion molecule-1 gene expression involves activation of a distinct STAT protein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-BINDING PROTEIN; TRANSCRIPTION FACTOR ISGF3; IFN-GAMMA; TYROSINE PHOSPHORYLATION; ALPHA-INTERFERON; RESPONSE ELEMENT; SIGNAL TRANSDUCTION; INVITRO ACTIVATION; REGULATORY FACTOR; PROMOTER	In response to interferon gamma (IFN gamma), intercellular adhesion molecule-1 (ICAM-1) is expressed on human keratinocytes, a cell type that is critically involved in cutaneous inflammation. An ICAM-1 5' regulatory region palindromic response element, pI gamma RE, has been shown to confer IFN gamma-dependent transcription enhancement. By electrophoretic mobility shift assays (EMSA), pI gamma RE forms a distinct complex with proteins from IFN gamma-treated human keratinocytes, termed gamma response factor (GRF). Binding of GRF is tyrosine phosphorylation-dependent, and mutations of pI gamma RE that disrupt the palindromic sequence or alter its spatial relationship abrogate GRF binding. Supershift EMSAs using antibodies to characterized STAT proteins suggest that GRF contains a Stat1 alpha-like protein; however, non-ICAM-1 IFN gamma-responsive elements (REs) known to bind Stat1 alpha homodimers fail to compete for GRF binding in EMSA, and pI gamma RE does not cross compete with these REs that complex with homodimeric stat1 alpha. The pI gamma RE GRF complex also displays a distinctly different electrophoretic mobility compared to that of IFN gamma REs complexed to homodimeric Stat1 alpha. These findings indicate that a distinct complex containing a Stat1 alpha-like protein mediates IFN gamma-induced ICAM-1 gene transcription and identifies a subset of IFN gamma-responsive genes that appear to be regulated by this complex.	EMORY UNIV,SCH MED,DEPT DERMATOL,EMORY SKIN DIS RES CORE CTR,ATLANTA,GA 30322	Emory University				Knicely, Kimberly/0000-0001-7794-3996	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR042687] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 42687, AR 41206] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; BOYCE ST, 1985, J TISSUE CULTURE MET, V9, P83; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAUGHMAN SW, 1992, J INVEST DERMATOL, V98, pS61, DOI 10.1111/1523-1747.ep12462226; CAUGHMAN SW, 1991, PROG DERMATOL, V25, P1; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DEGITZ K, 1991, J BIOL CHEM, V266, P14024; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DOUGHERTY GJ, 1988, EUR J IMMUNOL, V18, P35, DOI 10.1002/eji.1830180107; DUSTIN ML, 1986, J IMMUNOL, V137, P245; FELDMAN GM, 1994, J BIOL CHEM, V269, P10747; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; GUYER NB, 1995, J IMMUNOL, V155, P3472; HARROCH S, 1993, J BIOL CHEM, V268, P9092; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; PEARSE RN, 1991, P NATL ACAD SCI USA, V88, P11305, DOI 10.1073/pnas.88.24.11305; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	45	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1283	1290		10.1074/jbc.272.2.1283	http://dx.doi.org/10.1074/jbc.272.2.1283			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995433	hybrid			2022-12-25	WOS:A1997WC04800084
J	Prowse, DM; Bolgan, L; Molnar, A; Dotto, GP				Prowse, DM; Bolgan, L; Molnar, A; Dotto, GP			Involvement of the Sp3 transcription factor in induction of p2(Cip1/WAF1) in keratinocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; DEPENDENT KINASES; BINDING PROTEINS; GENE-EXPRESSION; GROWTH; CELLS; SUPPRESSION; P300; P21; P53	The cyclin-dependent kinase inhibitor p21 is induced in several in vitro terminal differentiation systems as well as in differentiating tissues in vivo. To determine the mechanism responsible for p21 induction during differentiation of mouse primary keratinocytes, we performed a deletion analysis of the p21 promoter. The minimal region of the p21 promoter required for its induction in keratinocyte differentiation consists of a contiguous stretch of 78 base pairs, which contains a GC-rich region as well as the TATA box. We determined that transcription factors Spl and Sp3, present in primary keratinocyte nuclear extracts, bind the GC region concomitantly. Expression studies established that both Spl and Sp3 activate the p21 promoter, but showed that only Sp3 overexpression enhances promoter inducibility during differentiation. Furthermore, disruption of the GC-rich region dramatically decreases transcription factor binding as well as promoter activity and inducibility upon differentiation. The overexpression of either Spl or Sp3 restores the basal activity of the disrupted promoter, but only Sp3 can restore its inducibility. These findings show that both Spl and Sp3 can contribute to the basal activity of the p21 promoter, and establish Sp3 as a specific transcription factor involved in the induction of p21 promoter during keratinocyte differentiation.	MASSACHUSETTS GEN HOSP EAST, CBRC, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, DIABET RES LAB, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University					NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039190] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038] Funding Source: Medline; NIAMS NIH HHS [AR39190] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FILVAROFF E, 1994, J BIOL CHEM, V269, P21735; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JIANG HP, 1994, ONCOGENE, V9, P3397; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Liu Y, 1996, CANCER RES, V56, P31; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Missero C, 1996, MOL CELL DIFFER, V4, P1; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHAO ZM, 1995, ONCOGENE, V11, P493; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242	39	126	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1308	1314		10.1074/jbc.272.2.1308	http://dx.doi.org/10.1074/jbc.272.2.1308			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995437	hybrid			2022-12-25	WOS:A1997WC04800088
J	Trub, T; Frantz, JD; Miyazaki, M; Band, H; Shoelson, SE				Trub, T; Frantz, JD; Miyazaki, M; Band, H; Shoelson, SE			The role of a lymphoid-restricted, Grb2-like SH3-SH2-SH3 protein in T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SH3 DOMAIN; NUCLEOTIDE EXCHANGE FACTOR; GRB2 ADAPTER PROTEIN; C-CBL PROTOONCOGENE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MOLECULAR-CLONING; ANTIGEN RECEPTOR; BINDING-PROTEIN; DYNAMIN BINDS	We have characterized an SH3-SH2-SH3 linker protein that is prominently expressed in lymphoid tissues, This protein has 58% sequence identity to Grb2, An identical protein called Grap has been found in hematopoietic cells, In Jurkat cells, T cell receptor activation leads to the association of Grap with phosphoproteins p36/38 and, to a lesser degree, Shc. This interaction is mediated by the Grap SH2 domain, which has similar binding specificity to the Grb2 SH2 domain, Grap also associates via its SH3 domains with Sos, the Ras guanine nucleo tide exchange factor; with dynamin, a GTPase involved in membrane protein trafficking; and with Sam68, a nuclear RNA-binding protein that serves as a substrate of Src kinases during mitosis, T cell activation effects an increase in Grap association with p36/38, Shc, Sos, and dynamin, Sam68 binding is constitutive, Phospholipase C-gamma 1 and Fyn are also found in activated Grap signaling complexes, although these interactions may not be direct, We conclude that Grap is a prominent component of lymphocyte receptor signaling, Based on the known functions of bound effector molecules, Grap-mediated responses to antigen challenge may include endocytosis of the T cell receptor, cellular proliferation, and regulated entry into the cell cycle.	HARVARD UNIV, SCH MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DIV RHEUMATOL & IMMUNOL, LYMPHOCYTE BIOL SECT, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DIV RHEUMATOL & IMMUNOL, DEPT MED, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital			Miyazaki, Masaya/F-8520-2012	Miyazaki, Masaya/0000-0003-4031-7224	NIAMS NIH HHS [AR36308] Funding Source: Medline; NIDDK NIH HHS [DK45943, DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK045943] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS MD, 1995, NATURE, V377, P3; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Courtneidge Sara A., 1994, Trends in Cell Biology, V4, P345, DOI 10.1016/0962-8924(94)90074-4; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DIETRICH J, 1994, EMBO J, V13, P2156, DOI 10.1002/j.1460-2075.1994.tb06492.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; GOUDREAU N, 1994, NAT STRUCT BIOL, V1, P898, DOI 10.1038/nsb1294-898; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; Lock P, 1996, CELL, V84, P23, DOI 10.1016/S0092-8674(00)80989-7; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPITS H, 1983, HYBRIDOMA, V2, P423, DOI 10.1089/hyb.1983.2.423; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VOGEL LB, 1993, MOL CELL BIOL, V13, P7408, DOI 10.1128/MCB.13.12.7408; Wang ZX, 1996, SCIENCE, V272, P1935, DOI 10.1126/science.272.5270.1935; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	73	87	87	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					894	902		10.1074/jbc.272.2.894	http://dx.doi.org/10.1074/jbc.272.2.894			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995379	hybrid			2022-12-25	WOS:A1997WC04800030
J	Kim, DH; Chang, JH; Lee, KH; Lee, HY; Kim, SJ				Kim, DH; Chang, JH; Lee, KH; Lee, HY; Kim, SJ			Mechanism of E1A-induced transforming growth factor-beta (TGF-beta) resistance in mouse keratinocytes involves repression of TGF-beta type II receptor transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CYCLIN-A; MICROSATELLITE INSTABILITY; PROMOTER REGION; CANCER CELLS; E1A PROTEINS; GENE; EXPRESSION; FACTOR-BETA-1; INHIBITION; DIFFERENTIATION	Cellular transformation driven by the E1A oncogene is associated with the development of cellular resistance to the growth inhibitory effects of transforming growth factor-beta (TGF-beta). We demonstrate that development of resistance occurs simultaneously with decreased expression of TGF-beta type II receptor (TGF-beta RII) mRNA and protein, To determine whether changes in transcriptional regulation are responsible for the decreased receptor expression in E1A-transformed cells, a series of mobility shift assays was performed utilizing nuclear extracts from E1A-transformed and untransformed murine keratinocytes using radiolabeled positive regulatory elements (PRE1 and PRE2) of the TGF-beta RII promoter. The results from these assays suggest that E1A-transformed cells express markedly lower levels of nuclear proteins that bind specifically to PRE1 and PRE2, Transfection of both E1A-transformed and untransformed cell lines with a series of mutant promoter constructs confirmed that both PREs contribute significantly to basal expression of TGF-beta RII and that inactivation of either element leads to markedly reduced promoter activity. We conclude that development of TGF-beta resistance in E1A-transformed cells is achieved in part through transcriptional down-regulation of the TGF-beta RII gene and that this down-regulation is the result of decreased expression of unidentified transcription factor complexes that interact with PRE1 and PRE2.	NCI, CHEMOPREVENT LAB, NATL INST HLTH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AKUSJARVI G, 1986, ADENOVIRUS DNA VIRAL, V8, P53; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; CARUSO M, 1993, ONCOGENE, V8, P267; DOERFLER W, 1991, ADV VIRUS RES, V39, P89; GIORDANO A, 1991, ONCOGENE, V6, P481; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KIM SJ, 1989, J BIOL CHEM, V264, P402; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; MANNING AM, 1991, ONCOGENE, V6, P1471; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; MAYOL X, 1993, ONCOGENE, V6, P481; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOUSTAKAS A, 1993, J BIOL CHEM, V268, P22215; MYEROFF LL, 1995, CANCER RES, V55, P5545; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11576, DOI 10.1073/pnas.91.24.11576; PARK K, 1994, CANCER RES, V54, P6087; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REISS M, 1987, CANCER RES, V47, P6705; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TAIPALE J, 1994, CELL GROWTH DIFFER, V5, P1309; TRENTIN JJ, 1962, SCIENCE, V137, P835, DOI 10.1126/science.137.3533.835; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					688	694						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995313				2022-12-25	WOS:A1997WA56400100
J	Sosnowski, BA; Gonzalez, AM; Chandler, LA; Buechler, YJ; Pierce, GF; Baird, A				Sosnowski, BA; Gonzalez, AM; Chandler, LA; Buechler, YJ; Pierce, GF; Baird, A			Targeting DNA to cells with basic fibroblast growth factor (FGF2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERPES-SIMPLEX VIRUS; RECEPTOR-MEDIATED ENDOCYTOSIS; RESPIRATORY EPITHELIAL-CELLS; FACTOR-SAPORIN MITOTOXIN; GENE-TRANSFER; HEPARAN-SULFATE; PROTEOLYTIC DEGRADATION; BINDING; EXPRESSION; DELIVERY	Ligand-mediated targeting of DNA was validated by condensing a plasmid DNA encoding the beta-galactosidase (beta-gal) gene with a basic fibroblast growth factor (FGF2) that was first chemically conjugated to polylysine (K). The conditions that gave optimal binding of this FGF2 to DNA also generated the highest level of beta-gal expression when added to FGF2 target cells like COS-1, 3T3, baby hamster kidney (BHK), or endothelial cells. This beta-gal activity increased in a time- and dose-dependent manner and was dependent on the inclusion of FGF2 in the complex. FGF receptor specificity was demonstrated by competition of the complex with FGF2 and heparin, and by the failure of cytochrome c or histone H1 to mimic the gene-targeting effects of FGF2. The expression of beta-gal was also endosome dependent because chloroquine increased beta-gal expression 8-fold and endosome disruptive peptides increased expression of beta-gal 26-fold. Taken together these findings establish that DNA can be introduced into cells through the high affinity FGF receptor complex, and while its efficiency will require significant enhancements to achieve sustained and elevated transgene expression, the possibility that the technique could be used to deliver DNAs encoding cytotoxic molecules is discussed.			Sosnowski, BA (corresponding author), PRIZM PHARMACEUT, 11035 ROSELLE ST, SAN DIEGO, CA 92121 USA.			Baird, Andrew/0000-0003-0027-9905				ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; AMALRIC F, 1994, BIOCHEM PHARMACOL, V47, P111, DOI 10.1016/0006-2952(94)90443-X; BAIRD A, 1990, NATURE, V348, P344, DOI 10.1038/348344a0; BEHARCOHEN FF, 1995, INVEST OPHTH VIS SCI, V36, P2434; BEHARCOHEN FF, 1995, INVEST OPHTH VIS SCI, V36, P2425; BEITZ JG, 1992, CANCER RES, V52, P227; CASSCELLS W, 1992, P NATL ACAD SCI USA, V89, P7159, DOI 10.1073/pnas.89.15.7159; CHEN JB, 1994, FEBS LETT, V338, P167, DOI 10.1016/0014-5793(94)80357-9; CHEN SY, 1995, GENE THER, V2, P116; CURIEL DT, 1992, AM J RESP CELL MOL, V6, P247, DOI 10.1165/ajrcmb/6.3.247; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FERKOL T, 1993, J CLIN INVEST, V92, P2394, DOI 10.1172/JCI116845; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FITZGERALD D, 1989, J NATL CANCER I, V81, P1455, DOI 10.1093/jnci/81.19.1455; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HARRIS CE, 1993, AM J RESP CELL MOL, V9, P441, DOI 10.1165/ajrcmb/9.4.441; HART SL, 1994, J BIOL CHEM, V269, P12468; HART SL, 1995, GENE THER, V2, P552; HUCKETT B, 1990, BIOCHEM PHARMACOL, V40, P253, DOI 10.1016/0006-2952(90)90686-F; HUD NV, 1995, P NATL ACAD SCI USA, V92, P3581, DOI 10.1073/pnas.92.8.3581; KANER RJ, 1990, SCIENCE, V248, P1410, DOI 10.1126/science.2162560; KREITMAN RJ, 1992, INT J IMMUNOPHARMACO, V14, P465, DOI 10.1016/0192-0561(92)90177-M; LAPPI D A, 1990, Progress in Growth Factor Research, V2, P223, DOI 10.1016/0955-2235(90)90020-K; LAPPI DA, 1994, J BIOL CHEM, V269, P12552; LAPPI DA, 1993, ANAL BIOCHEM, V212, P446, DOI 10.1006/abio.1993.1353; Mattar SG, 1996, J SURG RES, V60, P339, DOI 10.1006/jsre.1996.0054; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; PLANK C, 1994, J BIOL CHEM, V269, P12918; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SHIEH MT, 1991, SCIENCE, V253, P208, DOI 10.1126/science.1649495; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SIEGALL CB, 1991, FASEB J, V5, P2843, DOI 10.1096/fasebj.5.13.1717336; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; WAGNER E, 1991, P NATL ACAD SCI USA, V88, P4255, DOI 10.1073/pnas.88.10.4255; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009; YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YING WB, 1994, CANCER, V74, P848, DOI 10.1002/1097-0142(19940801)74:3<848::AID-CNCR2820740310>3.0.CO;2-J	39	109	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33647	33653		10.1074/jbc.271.52.33647	http://dx.doi.org/10.1074/jbc.271.52.33647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969234	hybrid			2022-12-25	WOS:A1996WA71300068
J	Hartwig, JH; Kung, S; Kovacsovics, T; Janmey, PA; Cantley, LC; Stossel, TP; Toker, A				Hartwig, JH; Kung, S; Kovacsovics, T; Janmey, PA; Cantley, LC; Stossel, TP; Toker, A			D3 phosphoinositides and outside in integrin signaling by glycoprotein IIb-IIIa mediate platelet actin assembly and filopodial extension induced by phorbol 12-myristate 13 acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STRESS FIBERS; F-ACTIN; ESTER; ACTIVATION; 3-KINASE; RHO; CYTOSKELETON; NEUTROPHILS; BINDING	Phorbol 12-myristate 13-acetate (PMA) uncaps a small number of the fast-growing (barbed) ends of actin filaments, thereby eliciting slow actin assembly and extension of filopodia in human blood platelets, These reactions, which also occur in response to immunologic perturbation of the integrin glycoprotein (GP) IIb-IIIa, are sensitive to the phosphoinositide 3-kinase inhibitor wortmannin. Platelets deficient in GPIIb-IIIa integrins or with GPIIb-IIIa function inhibited by calcium chelation or the peptide RGDS have diminished PMA responsiveness. The effects of PMA contrast with thrombin receptor stimulation by greater than or equal to 5 mu M thrombin receptor-activating peptide (TRAP), which causes rapid and massive wortmannin-insensitive actin assembly and lamellar and filopodial extension, However, we show here that wortmannin can inhibit filopod formation if the thrombin receptor is ligated using suboptimal doses (<1 mu M) of TRAP, Phosphatidylinositol 3,4-bisphosphate inhibits actin filament severing and capping by human gelsolin in vitro. The findings implicate D3 polyphosphoinositides and integrin signaling in PMA-mediated platelet stimulation and implicate D3 containing phosphoinositides generated in response to protein kinase C activation and GPITb-IIIa signaling as late-acting intermediates leading to filopodial actin assembly.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,DIV SIGNAL TRANSDUCT,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,DEPT CELL BIOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University	Hartwig, JH (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV EXPT MED,DEPT MED,BOSTON,MA 02115, USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NHLBI NIH HHS [HL 19429] Funding Source: Medline; NIAMS NIH HHS [AR 38910] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890, GM 41890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019429, R37HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890, R37GM041890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1995, MOL BIOL CELL, V6, P97, DOI 10.1091/mbc.6.1.97; AUGER KR, 1989, J BIOL CHEM, V264, P20181; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Barkalow K, 1996, J CELL BIOL, V134, P389, DOI 10.1083/jcb.134.2.389; CARROLL R, 1981, CELL, V30, P385; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; DUGINA VB, 1987, P NATL ACAD SCI USA, V84, P4122, DOI 10.1073/pnas.84.12.4122; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; Gabbeta J, 1996, BLOOD, V87, P1368, DOI 10.1182/blood.V87.4.1368.bloodjournal8741368; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; HARTWIG JH, 1991, J CELL BIOL, V112, P407, DOI 10.1083/jcb.112.3.407; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; HARTWIG JH, 1995, CELL, V82, P1; HOWARD TH, 1987, J CLIN INVEST, V79, P1359, DOI 10.1172/JCI112962; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KRISHNAMURTHI S, 1989, BIOCHEM J, V262, P77, DOI 10.1042/bj2620077; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; Nachmias VT, 1996, FEBS LETT, V378, P258, DOI 10.1016/0014-5793(95)01474-8; NACHMIAS VT, 1988, ADV CELL BIOL, V2, P181; NIU MY, 1994, CELL MOTIL CYTOSKEL, V27, P327, DOI 10.1002/cm.970270405; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; NOLAN RD, 1990, J BIOL CHEM, V265, P2441; Nurden P, 1996, BLOOD, V88, P887, DOI 10.1182/blood.V88.3.887.bloodjournal883887; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P634, DOI 10.1083/jcb.86.2.634; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; SHETERLINE P, 1986, J MUSCLE RES CELL M, V7, P405, DOI 10.1007/BF01753583; TOKER A, 1995, J BIOL CHEM, V270, P29525, DOI 10.1074/jbc.270.49.29525; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VONGILLIGEN G, 1996, BIOCHEM J, V314, P769; WENNSTROM S, 1994, CURR BIOL, V4, P385, DOI 10.1016/S0960-9822(00)00087-7; WHITE JG, 1974, AM J PATHOL, V74, P453; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; YAMAMOTO K, 1990, BIOCHEM BIOPH RES CO, V168, P466, DOI 10.1016/0006-291X(90)92344-Y; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; ZHANG J, 1995, J BIOL CHEM, V270, P22807, DOI 10.1074/jbc.270.39.22807; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZUCKER MB, 1974, J CELL BIOL, V60, P325, DOI 10.1083/jcb.60.2.325	46	112	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32986	32993		10.1074/jbc.271.51.32986	http://dx.doi.org/10.1074/jbc.271.51.32986			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955143	hybrid, Green Published			2022-12-25	WOS:A1996VZ37300078
J	Wu, MS; Biemesderfer, D; Giebisch, G; Aronson, PS				Wu, MS; Biemesderfer, D; Giebisch, G; Aronson, PS			Role of NHE3 in mediating renal brush border Na+-H+ exchange - Adaptation to metabolic acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT NA/H EXCHANGER; MOLECULAR-CLONING; MEMBRANE-VESICLES; ISOFORM; EXPRESSION; KIDNEY; ANTIPORTER; AMILORIDE; PROTEINS	The aims of the present study were to estimate the fraction of renal brush border membrane Na+-H+ exchange activity mediated by the isoform NHE3 and to evaluate whether the increased brush border Na+-H+ exchange observed in metabolic acidosis is due to increased expression of NHE3 protein. Compared with other isoforms, NHE3 is known to have a unique profile of sensitivity to pharmacologic inhibitors, including relative resistance to amiloride analogs and HOE694. We therefore assessed the inhibitor sensitivity of pH gradient-stimulated Na-22 uptake in renal brush border vesicles isolated from normal rats. The I-50 values for amiloride (30 mu M), dimethylamiloride (10 mu M), ethylisopropylamiloride (6 mu M), and HOE694 (>100 mu M) were markedly dissimilar from those reported for NHE1 and NHE2 but were nearly identical to reported values for NHE3, Na+-H+ exchange activity in renal brush border vesicles isolated from rats with 5 days of NH4Cl-induced metabolic acidosis was increased 1.5-fold compared with control rats, with no change in inhibitor sensitivity. Western blot analysis indicated that NHE3 protein expression was greater in brush border membranes from acidotic compared with control rats. We conclude that virtually all measured Na+-H+ exchange activity in brush border membranes from control and acidotic rats is mediated by NHE3 and that metabolic acidosis causes increased expression of renal brush border NHE3 protein.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06520; YALE UNIV,SCH MED,DEPT CELLULAR & MOL PHYSIOL,NEW HAVEN,CT 06520; NATL TAIWAN UNIV HOSP,DEPT INTERNAL MED,TAIPEI 10016,TAIWAN	Yale University; Yale University; National Taiwan University; National Taiwan University Hospital				WU, MING-SHIOU/0000-0002-1674-443X	NIDDK NIH HHS [DK-33793, DK-17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033793, P01DK017433, R01DK033793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIBA T, 1987, J CLIN INVEST, V80, P308, DOI 10.1172/JCI113074; ALPERN RJ, 1996, KIDNEY, P408; Ambuhl PM, 1996, AM J PHYSIOL-RENAL, V271, pF917, DOI 10.1152/ajprenal.1996.271.4.F917; AMEMIYA M, 1995, KIDNEY INT, V48, P1206, DOI 10.1038/ki.1995.404; ARONSON PS, 1982, NATURE, V299, P161, DOI 10.1038/299161a0; ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; Azuma KK, 1996, AM J PHYSIOL-CELL PH, V270, pC585, DOI 10.1152/ajpcell.1996.270.2.C585; BIEMESDERFER D, 1993, AM J PHYSIOL, V265, pF736, DOI 10.1152/ajprenal.1993.265.5.F736; BIEMESDERFER D, 1992, AM J PHYSIOL, V263, pF833, DOI 10.1152/ajprenal.1992.263.5.F833; BIEMESDERFER D, 1995, J AM SOC NEPHROL, V6, P372; CASTLE JD, 1985, J MEMBRANE BIOL, V87, P13; COHN DE, 1983, AM J PHYSIOL, V245, pF217, DOI 10.1152/ajprenal.1983.245.2.F217; COUNILLON L, 1993, MOL PHARMACOL, V44, P1041; FORBUSH B, 1983, ANAL BIOCHEM, V128, P159, DOI 10.1016/0003-2697(83)90356-1; KINSELLA J, 1984, P NATL ACAD SCI-BIOL, V81, P630, DOI 10.1073/pnas.81.2.630; KLANKE CA, 1995, GENOMICS, V25, P615, DOI 10.1016/0888-7543(95)80002-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAHNENSMITH RL, 1985, J BIOL CHEM, V260, P2586; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; PIZZONIA JH, 1994, J AM SOC NEPHROL, V5, P297; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; Szasz G., 1974, METHOD ENZYMAT AN, P715; TSAI CJ, 1984, AM J PHYSIOL, V147, pF339; TSE CM, 1992, J BIOL CHEM, V267, P9340; TSE CM, 1993, J BIOL CHEM, V268, P11917; WANG Z, 1993, J BIOL CHEM, V268, P11925; WU MH, 1995, J AM SOC NEPHROL, V6, P318	27	151	152	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32749	32752		10.1074/jbc.271.51.32749	http://dx.doi.org/10.1074/jbc.271.51.32749			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955109	hybrid			2022-12-25	WOS:A1996VZ37300044
J	Yamazaki, A; Bondarenko, VA; Dua, S; Yamazaki, M; Usukura, J; Hayashi, F				Yamazaki, A; Bondarenko, VA; Dua, S; Yamazaki, M; Usukura, J; Hayashi, F			Possible stimulation of retinal rod recovery to dark state by cGMP release from a cGMP phosphodiesterase noncatalytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; BINDING-SITES; PHOTORECEPTOR PHOSPHODIESTERASE; INHIBITORY SUBUNIT; GTP HYDROLYSIS; MECHANISM; PHOSPHORYLATION; TRANSDUCIN; AFFINITY	Cyclic GMP phosphodiesterase, a key enzyme for phototransduction, contains alpha, beta (P alpha beta), and two gamma (P gamma) subunits, In addition to catalytic sites, P alpha beta has two classes of noncatalytic cGMP binding sites with different affinities (K-d values < 100 nM and >1 mu M). P gamma regulates P alpha beta as an inhibitor of cGMP hydrolysis and as a stimulator of cGMP binding to the high affinity noncatalytic sites. P gamma release from P alpha beta by the GTP-bound alpha subunit of transducin (GTP . T alpha) interrupts these two functions. Here we describe a novel regulation of the P gamma release by [cGMP] and its physiological implication, We isolated P gamma mutants that exhibit abnormally one of these two functions, indicating the distinct domains in P gamma are involved to express these functions, When [cGMP] was high (similar to 5 mu M), P gamma responsible for the inhibition of cGMP hydrolysis was preferentially released, and cGMP hydrolysis activity of P alpha beta was increased about 10 times, When [cGMP] was low (less than similar to 0.5 mu M), P gamma responsible for the stimulation of cGMP binding to the high affinity sites was released, The P gamma release resulted in the decrease of relative affinity of cGMP for the high affinity sites to at least 1/10, followed by the rapid release of cGMP from one of the high affinity sites (apparent t 1/2 = 3.8 s), cGMP (similar to 5 mu M) inhibited the extraction of P alpha beta from rod membranes by a Mg2+-free hypotonic buffer, The inhibition of P alpha beta extraction was not affected by P gamma, suggesting that P alpha beta detects on the order of micromolar [cGMP] using low affinity noncatalytic sites on P alpha beta. Because [cGMP] is similar to 5 mu M in darkness and lowered by photoexcitation and phosphodiesterase concentration is similar to 30 mu M in rod photoreceptors, it is possible that cGMP phosphodiesterase functions to increase cytoplasamic [cGMP] after [cGMP] is reduced to the illuminated level.	WAYNE STATE UNIV, SCH MED, DEPT PHARMACOL, DETROIT, MI 48201 USA; NAGOYA UNIV, SCH MED, DEPT ANAT, NAGOYA, AICHI 466, JAPAN; KOBE UNIV, FAC SCI, DEPT BIOL, KOBE 657, JAPAN	Wayne State University; Nagoya University; Kobe University	Yamazaki, A (corresponding author), WAYNE STATE UNIV, SCH MED, KRESGE EYE INST, DEPT OPHTHALMOL, 4717 ST ANTOINE, DETROIT, MI 48201 USA.			Usukura, Jiro/0000-0003-2286-5403	NATIONAL EYE INSTITUTE [R01EY007546, R01EY009631] Funding Source: NIH RePORTER; NEI NIH HHS [EY09631, EY07546] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; BAYLOR DA, 1987, INVEST OPHTH VIS SCI, V28, P34; Bondarenko VA, 1996, INVEST OPHTH VIS SCI, V37, P1082; COTE RH, 1993, J BIOL CHEM, V268, P17190; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; GILLESPIE PG, 1988, J BIOL CHEM, V263, P8133; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MILLER WH, 1990, INVEST OPHTH VIS SCI, V31, P1664; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SOMLYO AP, 1985, J PHYSIOL-LONDON, V358, P183, DOI 10.1113/jphysiol.1985.sp015547; TING TD, 1991, BIOCHEMISTRY-US, V30, P8996, DOI 10.1021/bi00101a013; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771	22	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32495	32498		10.1074/jbc.271.51.32495	http://dx.doi.org/10.1074/jbc.271.51.32495			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955069	hybrid			2022-12-25	WOS:A1996VZ37300004
J	Pai, LM; Kirkpatrick, C; Blanton, J; Oda, H; Takeichi, M; Peifer, M				Pai, LM; Kirkpatrick, C; Blanton, J; Oda, H; Takeichi, M; Peifer, M			Drosophila alpha-catenin and E-cadherin bind to distinct regions of Drosophila Armadillo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEGMENT POLARITY GENE; CELL-CELL ADHESION; TYROSINE KINASE SUBSTRATE; PROTEIN INTERACTIONS; CYTOPLASMIC DOMAIN; COMPLEX-FORMATION; BETA-CATENIN; APC PROTEIN; PLAKOGLOBIN; HOMOLOG	Adherens junctions are multiprotein complexes mediating cell-cell adhesion and communication, They are organized around a transmembrane cadherin, which binds a set of cytoplasmic proteins required for adhesion and to link the complex to the actin cytoskeleton, Three components of Drosophila adherens junctions, analogous to those in vertebrates, have been identified: Armadillo (homolog of beta-catenin), Drosophila E-cadherin (DE-cadherin), and alpha-catenin. We carried out the first analysis of the interactions between these proteins using in vitro binding assays, the yeast two-hybrid system, and in vivo assays, We identified a 76-amino acid region of Armadillo that is necessary and sufficient for binding alpha-catenin and found that the N-terminal 258 amino acids of alpha-catenin interact with Armadillo, A large region of Armadillo, spanning six central Armadillo repeats, is required for DE-cadherin binding, whereas only 41 amino acids of the DE-cadherin cytoplasmic tail are sufficient for Armadillo binding. Our data complement and extend results obtained in studies of vertebrate adherens junctions, providing a foundation for understanding how junctional proteins assemble and a basis for interpreting existing mutations and creating new ones.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599; KYOTO UNIV,DEPT BIOPHYS,KYOTO 60601,JAPAN	University of North Carolina; University of North Carolina Chapel Hill; Kyoto University			Takeichi, Masatoshi/G-5903-2012; Peifer, Mark/A-1152-2010; Oda, Hiroki/AAC-2559-2019	Takeichi, Masatoshi/0000-0002-9931-3378; Peifer, Mark/0000-0003-1412-3987	NIGMS NIH HHS [GM47857] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047857] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520; ABERLE H, 1994, J CELL SCI, V107, P3655; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRAND AH, 1993, DEVELOPMENT, V118, P401; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Cox RT, 1996, J CELL BIOL, V134, P133, DOI 10.1083/jcb.134.1.133; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; FAGATTO F, 1996, J CELL BIOL, V132, P1105; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JOU T, 1995, J CELL BIOL, V92, P5067; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KIRKPATRICK C, 1995, CURR OPIN GENET DEV, V5, P56, DOI 10.1016/S0959-437X(95)90054-3; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MCCREA PD, 1991, J BIOL CHEM, V266, P4514; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1995, J BIOCHEM-TOKYO, V118, P1077, DOI 10.1093/jb/118.5.1077; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SCHIESTL RH, 1989, CURR GENET, V16, P329; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAPPERT J, 1994, CELL ADHES COMMUN, V2, P319, DOI 10.3109/15419069409014207; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	51	80	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32411	32420		10.1074/jbc.271.50.32411	http://dx.doi.org/10.1074/jbc.271.50.32411			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943306	hybrid, Green Published			2022-12-25	WOS:A1996VY34000097
J	Chiappetta, G; Avantaggiato, V; Visconti, R; Fedele, M; Battista, S; Trapasso, F; Merciai, BM; Fidanza, V; Giancotti, V; Santoro, M; Simeone, A; Fusco, A				Chiappetta, G; Avantaggiato, V; Visconti, R; Fedele, M; Battista, S; Trapasso, F; Merciai, BM; Fidanza, V; Giancotti, V; Santoro, M; Simeone, A; Fusco, A			High level expression of the HMGI (Y) gene during embryonic development	ONCOGENE			English	Article						HMGI proteins; in situ hybridization; development; embryo	GROUP PROTEIN HMG-I(Y); NUCLEAR PROTEINS; THYROID-CELLS; TRANSFORMATION; CDNA; ELEMENTS; SEQUENCE; DNA; RNA	The HMGI protein family includes three proteins, named HMG-I, HMG-Y and HMGI-C, The first two proteins are coded for by the same gene, HMGI (Y), through an alternative splicing mechanism, Their expression is elevated in neoplastic tissues and cells and this overexpression has a causal role in the process of cellular neoplastic transformation, We demonstrate that the HMGI (Y) gene is expressed at very tow levels in normal adult tissues, whereas in embryonic tissues it is expressed at high levels comparable to those detected in neoplastic tissues, Specifically, a very high expression of the HMGI (Y) gene was detected in all embryonic tissues at 8.5 dpc, Then in the following days, even though the gene is expressed essentially in all tissues, an abundant gene expression was restricted to some tissues, These results indicate an important role of the HMGI (Y) gene in development.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; IST NAZL TUMORI,FDN SENATORE PASCALE,I-80131 NAPLES,ITALY; CNR,IST INT GENET & BIOFIS,I-80125 NAPLES,ITALY; UNIV NAPLES,FAC MED & CHIRURG NAPOLI,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,THOMAS JEFFERSON CANC INST,PHILADELPHIA,PA 19107; UNIV TRIESTE,DIPARTIMENTO BIOCHIM BIOFIS & CHIM MACROMOL,I-34127 TRIESTE,ITALY	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; IRCCS Fondazione Pascale; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University; University of Trieste			Fedele, Monica/C-1417-2015; Simeone, Antonio/ABG-5269-2020; Visconti, Roberta/C-5299-2009	Fedele, Monica/0000-0002-9171-1312; Simeone, Antonio/0000-0003-2693-9836; Visconti, Roberta/0000-0001-7613-3801; Fusco, Alfredo/0000-0003-3332-5197				ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BUSSEMAKERS MJG, 1991, CANCER RES, V51, P606; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHIAPPETTA G, 1995, ONCOGENE, V10, P1307; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; Fedele M, 1996, CANCER RES, V56, P1896; FRIEDMANN M, 1993, NUCLEIC ACIDS RES, V21, P4259, DOI 10.1093/nar/21.18.4259; GIANCOTTI V, 1985, CANCER RES, V45, P6051; GIANCOTTI V, 1989, EXP CELL RES, V184, P538, DOI 10.1016/0014-4827(89)90352-2; GIANCOTTI V, 1987, EMBO J, V6, P1981, DOI 10.1002/j.1460-2075.1987.tb02461.x; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; JOHNSON KR, 1988, J BIOL CHEM, V263, P18338; LOVELLBADGE R, 1995, NATURE, V376, P725, DOI 10.1038/376725a0; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; RAM TG, 1993, CANCER RES, V53, P2655; REEVES R, 1990, J BIOL CHEM, V265, P8576; REEVES R, 1991, P NATL ACAD SCI USA, V88, P4005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THEILER K, 1989, HOUSE MOUSE; TMIMI Y, 1993, CANCER RES, V53, P5512; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	30	283	289	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2439	2446						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957086				2022-12-25	WOS:A1996VX10800017
J	Nakamura, T; Jenkins, NA; Copeland, NG				Nakamura, T; Jenkins, NA; Copeland, NG			Identification of a new family of Pbx-related homeobox genes	ONCOGENE			English	Article						Meis; Pbx; Hox; homeobox; transcription	HUMAN PROTOONCOGENE PBX1; DNA-BINDING SPECIFICITY; TRANSLOCATION PROTEIN; MYELOID-LEUKEMIA; LINKAGE MAP; PRE-B; EXTRADENTICLE; MOUSE; MICE; ARABIDOPSIS	The expression of Meis1 (a novel Pbx-related homeobox gene) and either Hoxa7 or Hoxa9 are coactivated by retroviral integration in BXH2 murine myeloid leukemias (T Nakamura, DA Largaespada, JD Shaughnessy Jr, NA Jenkins and NG Copeland (1996) Nature Genet. 12: 149-153). As Pbx proteins are Hox cofactors, which cooperatively bind DNA with Hox proteins to modulate the otherwise similar DNA bind specificities of Hox proteins, these results suggested that Meis1 may function as a cofactor for Hoxa7 and Hoxa9 in the induction of murine myeloid leukemias. By DNA cross-hybridization we have identified two Meis1-related genes, Meis2 and Meis3. Sequence analysis revealed extensive amino acid similarity among the three Meis proteins both within and outside of the homeodomain. Phylogenetic analysis showed that the Meis genes belong to a distinct family of Pbx-related genes. Chromosome mapping studies indicated that Meis2 and Meis3 are unlinked to Meis1 and map to mouse chromosome 2 and 7, respectively. The Meis genes displayed distinct but overlapping patterns of expression in normal tissues and were expressed in some cases of murine myeloid leukemia. The identification of two additional Meis genes identifies a new family of potential Hox cofactors as well as two new potential disease genes.	NCI,FREDERICK CANC RES & DEV CTR,MAMMALIAN GENET LAB,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								Beckler G S, 1995, Methods Mol Biol, V37, P215; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chang CP, 1996, MOL CELL BIOL, V16, P1734; CHENCHIK A, 1995, CLONTECHNIQUES, V10, P5; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKINSON ME, 1990, GENOMICS, V6, P505, DOI 10.1016/0888-7543(90)90480-I; DOCKX J, 1995, PLANT MOL BIOL, V28, P723, DOI 10.1007/BF00021196; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Green EL, 1981, GENETICS PROBABILITY, P77; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HURST HC, 1995, PROTEIN PROFILE, V2, P131; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LAWLER J, 1991, GENOMICS, V11, P587, DOI 10.1016/0888-7543(91)90066-N; Lu Q, 1996, MOL CELL BIOL, V16, P1632; LU QA, 1995, MOL CELL BIOL, V15, P3786; MA HC, 1994, PLANT MOL BIOL, V24, P465, DOI 10.1007/BF00024114; MANAK JR, 1994, DEVELOPMENT, P61; MATSUOKA M, 1993, PLANT CELL, V5, P1039, DOI 10.1105/tpc.5.9.1039; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MITELMAN F, 1994, CATALOG CHROMOSOME A; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSCOW JJ, 1995, MOL CELL BIOL, V15, P5434; MUELLER KJ, 1995, NATURE, V347, P727; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; NEUTEBOOM STC, 1995, P NATL ACAD SCI USA, V92, P9166, DOI 10.1073/pnas.92.20.9166; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PHELAN ML, 1995, MOL CELL BIOL, V15, P3786; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUAEDVLIEG N, 1995, PLANT CELL, V7, P117, DOI 10.1105/tpc.7.1.117; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; REISER L, 1995, CELL, V83, P735, DOI 10.1016/0092-8674(95)90186-8; SIRACUSA LD, 1991, GENETICS, V127, P169; SIRACUSA LD, 1991, GENETICS, V128, P813; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; VOLLBRECHT E, 1991, NATURE, V350, P241, DOI 10.1038/350241a0; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153	52	95	97	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2235	2242						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950991				2022-12-25	WOS:A1996VV14500021
J	Houston, KM; Cushley, W; Harnett, W				Houston, KM; Cushley, W; Harnett, W			Studies on the site and mechanism of attachment of phosphorylcholine to a filarial nematode secreted glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUGH ENDOPLASMIC-RETICULUM; BRUGIA-MALAYI; ACANTHOCHEILONEMA-VITEAE; ONCHOCERCA-GIBSONI; BREFELDIN-A; PRODUCT; ANTIGENS; PROTEINS; GOLGI; OLIGOSACCHARIDES	We have recently shown that the immunomodulatory substance phosphorylcholine (PC) is covalently attached to ES-62, a major secreted protein of the filarial nematode parasite Acanthocheilonema viteae, via an N-linked glycan. Linkage of PC to N-glycans is previously unreported, and hence we have investigated the biochemical events underlying it. PC addition was found by pulse-chase experiments to be a fairly early event during intracellular transport, occurring within 40-60 min of protein synthesis. Biosynthetic labeling/immunoprecipitation experiments revealed that addition of PC to ES-62 was blocked by (i) brefeldin A, an inhibitor of trafficking of newly synthesized proteins from the endoplasmic reticulum (ER) to the Golgi, (ii) 1-deoxynorijirimycin, an inhibitor of glucosidase activity in the ER, and (iii) 1-deoxymannojirimycin, an inhibitor of mannosidase I in the cis Golgi. Swainsonine, an inhibitor of mannosidase II in the medial Golgi, did not affect PC addition. Taken together these data indicate that PC attachment is a post-ER event which is dependent on generation of an appropriate substrate during oligosaccharide processing. Furthermore, they strongly suggest that PC addition takes place in the medial Golgi and that the substrate for addition is the 3-linked branch of Man(5)GlcNAc(3) or Man(3)GLcNAc(3).	UNIV STRATHCLYDE,DEPT IMMUNOL,GLASGOW G4 0NR,LANARK,SCOTLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Strathclyde; University of Glasgow				Harnett, William/0000-0001-9545-9401	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENNETT LG, 1977, CAN J CHEM, V55, P8, DOI 10.1139/v77-002; BRILES EB, 1975, J BACTERIOL, V122, P335, DOI 10.1128/JB.122.1.335-337.1975; BRUNDISH DE, 1968, BIOCHEM J, V110, P573, DOI 10.1042/bj1100573; CARROLL M, 1991, INT J BIOCHEM, V23, P1293, DOI 10.1016/0020-711X(91)90230-K; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FORSYTH KP, 1984, EXP PARASITOL, V58, P41, DOI 10.1016/0014-4894(84)90019-5; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; HARNETT W, 1994, PARASITE, V1, P179, DOI 10.1051/parasite/1994012179; HARNETT W, 1994, INT J PARASITOL, V24, P543, DOI 10.1016/0020-7519(94)90146-5; HARNETT W, 1989, PARASITOLOGY, V99, P229, DOI 10.1017/S0031182000058686; HARNETT W, 1993, EXP PARASITOL, V77, P498, DOI 10.1006/expr.1993.1113; HARNETT W, 1993, J IMMUNOL, V151, P4829; HARNETT W, 1995, PERSPECTIVES NEMATOD, P207; HORNE DS, 1993, J BACTERIOL, V175, P1717, DOI 10.1128/JB.175.6.1717-1722.1993; Houston KM, 1996, J PARASITOL, V82, P320, DOI 10.2307/3284169; LAL RB, 1990, AM J TROP MED HYG, V42, P56, DOI 10.4269/ajtmh.1990.42.56; LEON MA, 1971, BIOCHEMISTRY-US, V10, P1424, DOI 10.1021/bi00784a024; LODISH HF, 1983, NATURE, V304, P80, DOI 10.1038/304080a0; LODISH HF, 1984, J CELL BIOL, V98, P1720, DOI 10.1083/jcb.98.5.1720; MAIZELS RM, 1987, PARASITE IMMUNOL, V9, P49, DOI 10.1111/j.1365-3024.1987.tb00488.x; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; SELKIRK ME, 1990, MOL BIOCHEM PARASIT, V42, P31, DOI 10.1016/0166-6851(90)90110-8; SELKIRK ME, 1993, PARASITOLOGY, V107, P449, DOI 10.1017/S0031182000067810; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; UNKEFER CJ, 1990, J BIOL CHEM, V265, P685; *WHO, 1993, TROP DIS RES PROGR 1, P37; WORMS MJ, 1961, J PARASITOL, V47, P963, DOI 10.2307/3275034; YEWDELL JW, 1989, SCIENCE, V244, P1072, DOI 10.1126/science.2471266	31	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1527	1533		10.1074/jbc.272.3.1527	http://dx.doi.org/10.1074/jbc.272.3.1527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999824	hybrid			2022-12-25	WOS:A1997WD05800022
J	Jiang, HB; Kanost, MR				Jiang, HB; Kanost, MR			Characterization and functional analysis of 12 naturally occurring reactive site variants of serpin-1 from Manduca sexta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR COAGULATION INHIBITOR; PROTEINASE-INHIBITORS; CDNA CLONING; PURIFICATION; SUPERFAMILY; INSECT; SPECIFICITY; HEMOLYMPH	Serpin gene-1 from the tobacco hornworm, Manduca sexta, encodes, through alternative exon usage, 12 reactive site variants (Jiang, H., Wang, Y. and Kanost, M. R., (1994) J. Blot. Chem. 269, 55-58; Jiang, H., Wang, Y., Huang, Y., Mulnix, A. B., Kadel, J., Cole, K., and Kanost, M. R. (1996) J. Biol. Chem. 271, 28017-28023). These 43-kDa proteins differ from each other only in their COOH-terminal 39-46 residues, which include the reactive site. To test the hypothesis that these proteins are proteinase inhibitors of diverse selectivities and to begin to elucidate their physiological functions, we expressed the 12 serpin-1 variants in Escherichia coli. Seven of the variants inhibited mammalian serine proteinases, with association rate constants comparable with those of human serpins. Serpin-1A, with a P-1 Arg residue, inhibited both trypsin and plasmin. Serpin-1B (P-1 Ala) and serpin-1F (P-1 Val) inhibited porcine pancreatic elastase and human neutrophil elastase. Serpin-1H, -1K, and -1Z, all with a Tyr residue at the P-1 position, inhibited chymotrypsin and cathepsin G. Serpin-1I (P-1 Leu) inhibited both elastase and chymotrypsin. Nine of the serpin variants were active as inhibitors of microbial serine proteinases, including subtilisin Carlsberg, proteinase K, and two proteinases secreted by an entomopathogenic fungus, Metarhizium anisopliae. In addition, one of the serpin variants, serpin-1J, strongly inhibited activation of M. sexta hemolymph phenoloxidase, a pathway involving a serine proteinase cascade. This pathway is a component of the defensive response of insects to microbial infection. These results suggest that the products of M. sexta serpin gene-1 may be important in regulating both exogenous and endogenous serine proteinases in hemolymph.	KANSAS STATE UNIV,DEPT BIOCHEM,MANHATTAN,KS 66506	Kansas State University			Jiang, Haobo/A-6519-2008	Kanost, Michael/0000-0002-6827-0061; Jiang, Haobo/0000-0003-1357-1315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041247, R01GM041247, R29GM041247] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41247, R37 GM041247] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHIDA M, 1994, INSECT BIOCHEM MOLEC, V24, P1037, DOI 10.1016/0965-1748(94)90141-4; Ashida M., 1990, P239; BEATTY K, 1980, J BIOL CHEM, V255, P3931; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; CHURCH FC, 1985, P NATL ACAD SCI USA, V82, P6631; HALL M, 1995, P NATL ACAD SCI USA, V92, P7764, DOI 10.1073/pnas.92.17.7764; Jiang H, 1995, INSECT BIOCHEM MOLEC, V25, P1093, DOI 10.1016/0965-1748(95)00042-9; JIANG HB, 1994, J BIOL CHEM, V269, P55; Jiang HB, 1996, J BIOL CHEM, V271, P28017, DOI 10.1074/jbc.271.45.28017; Kanost M.R., 1990, P139; Kanost Michael R., 1996, P155; KANOST MR, 1989, J BIOL CHEM, V264, P965; KANOST MR, 1994, INSECT BIOCHEM MOLEC, V25, P285; KEZDY FJ, 1970, METHOD ENZYMOL, V11, P3; Komiyama T, 1996, PROTEIN SCI, V5, P874; MARSHALL CJ, 1993, PHILOS T ROY SOC B, V342, P101, DOI 10.1098/rstb.1993.0141; MIURA Y, 1995, J BIOL CHEM, V270, P558, DOI 10.1074/jbc.270.2.558; MIURA Y, 1994, J BIOL CHEM, V269, P542; Morisato D, 1995, ANNU REV GENET, V29, P371, DOI 10.1146/annurev.genet.29.1.371; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; SASAKI T, 1991, EUR J BIOCHEM, V202, P255, DOI 10.1111/j.1432-1033.1991.tb16370.x; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHULZE AJ, 1994, J BIOTECHNOL, V32, P231, DOI 10.1016/0168-1656(94)90209-7; SHEFFIELD WP, 1994, FEBS LETT, V339, P147, DOI 10.1016/0014-5793(94)80403-6; STLEGER RJ, 1992, EUR J BIOCHEM, V204, P991, DOI 10.1111/j.1432-1033.1992.tb16721.x; STLEGER RJ, 1995, CAN J BOT, V73, pS1119, DOI 10.1139/b95-367; SUGUMARAN M, 1993, PARASITES PATHOGENS, V1, P317; WILLOTT E, 1994, EUR J CELL BIOL, V64, P451	30	122	135	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1082	1087		10.1074/jbc.272.2.1082	http://dx.doi.org/10.1074/jbc.272.2.1082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995406	hybrid			2022-12-25	WOS:A1997WC04800057
J	Kingma, PS; Osheroff, N				Kingma, PS; Osheroff, N			Apurinic sites are position-specific topoisomerase II poisons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; CLEAVAGE RELIGATION REACTION; STRAND DNA CLEAVAGE; EUKARYOTIC TOPOISOMERASE; ABASIC SITES; DROSOPHILA-MELANOGASTER; DEOXYRIBONUCLEIC-ACID; ANTINEOPLASTIC DRUGS; MOLECULAR-DYNAMICS; SEQUENCE	Many anticancer drugs ''poison'' topoisomerase II by enhancing its double-stranded DNA cleavage activity. To determine whether DNA lesions act as endogenous topoisomerase II poisons, we characterized the effects of position-specific apurinic sites on enzyme activity. Lesions located within the 4-base overhang generated by enzyme-mediated DNA scission stimulated cleavage similar to 10-18-fold without altering the specificity of topoisomerase II. DNA breaks were double-stranded in nature, protein-linked, and readily reversible. In contrast, apurinic sites located immediately outside the cleavage overhang were inhibitory. Thus, apurinic sites, which are the most commonly formed lesion in DNA, are position-specific topoisomerase II poisons. A model is proposed that encompasses the actions of endogenous and exogenous topoisomerase II poisons and provides a pre-existing pathway for the cellular actions of topoisomerase II-targeted anticancer drugs.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, SCH MED, DEPT MED ONCOL, NASHVILLE, TN 37232 USA	Vanderbilt University; Vanderbilt University					NIGMS NIH HHS [GM53960, GM33944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033944] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen A H, 1994, Adv Pharmacol, V29A, P83; ANDERSEN AH, 1991, J BIOL CHEM, V266, P9203; ANDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P6237, DOI 10.1021/bi00441a015; ANDERSON RD, 1994, MUTAT RES-FUND MOL M, V309, P109, DOI 10.1016/0027-5107(94)90048-5; BECK WT, 1994, CANCER CHEMOTH PHARM, V34, pS14, DOI 10.1007/BF00684858; BECK WT, 1993, ADV ENZYME REGUL, V33, P113; Berger JM, 1996, CURR OPIN STRUC BIOL, V6, P84, DOI 10.1016/S0959-440X(96)80099-6; Bigioni M, 1996, BIOCHEMISTRY-US, V35, P153, DOI 10.1021/bi951736p; Burden DA, 1996, J BIOL CHEM, V271, P29238, DOI 10.1074/jbc.271.46.29238; CAPRANICO G, 1992, EUR J CANCER, V28A, P2055, DOI 10.1016/0959-8049(92)90255-Z; CAPRANICO G, 1993, BIOCHEMISTRY-US, V32, P3038, DOI 10.1021/bi00063a015; CAPRANICO G, 1990, NUCLEIC ACIDS RES, V18, P6611, DOI 10.1093/nar/18.22.6611; CHEN AY, 1994, ANNU REV PHARMACOL, V34, P191, DOI 10.1146/annurev.pa.34.040194.001203; COGNET JAH, 1995, J MOL BIOL, V246, P209, DOI 10.1006/jmbi.1994.0077; CORBETT AH, 1991, J BIOL CHEM, V266, P19666; CORBETT AH, 1992, J BIOL CHEM, V267, P683; CORBETT AH, 1993, CHEM RES TOXICOL, V6, P585, DOI 10.1021/tx00035a001; Cozzarelli N.R., 1990, DNA TOPOLOGY ITS BIO; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEVORE R, 1989, ANN INTERN MED, V110, P704, DOI 10.7326/0003-4819-110-9-740; FELIX CA, 1995, CANCER RES, V55, P4287; FELIX CA, 1995, BLOOD, V85, P3250, DOI 10.1182/blood.V85.11.3250.bloodjournal85113250; FERGUSON LR, 1994, ENVIRON MOL MUTAGEN, V24, P245, DOI 10.1002/em.2850240402; FREUDENREICH CH, 1993, EMBO J, V12, P2085, DOI 10.1002/j.1460-2075.1993.tb05857.x; FREUDENREICH CH, 1994, P NATL ACAD SCI USA, V91, P11007, DOI 10.1073/pnas.91.23.11007; FRIEDBERG EC, 1995, DNA REPAIR; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P14998, DOI 10.1074/jbc.270.25.14998; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GALE KC, 1992, J BIOL CHEM, V267, P12090; GERVAIS V, 1995, EUR J BIOCHEM, V228, P279; GOLJER I, 1995, J BIOL CHEM, V270, P22980, DOI 10.1074/jbc.270.39.22980; HIGGINS NP, 1982, NUCLEIC ACIDS RES, V10, P6833, DOI 10.1093/nar/10.21.6833; KALNIK MW, 1988, BIOCHEMISTRY-US, V27, P924, DOI 10.1021/bi00403a013; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; KREUZER KN, 1979, J BACTERIOL, V140, P424, DOI 10.1128/JB.140.2.424-435.1979; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE AN, 1995, EUR J BIOCHEM, V230, P1073, DOI 10.1111/j.1432-1033.1995.tb20658.x; LEE MP, 1992, NUCLEIC ACIDS RES, V20, P5027, DOI 10.1093/nar/20.19.5027; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LIU L, 1994, DNA TOPOISOMERASES T; LIU LF, 1983, J BIOL CHEM, V258, P5365; Lloyd RS, 1993, NUCLEASES, P263; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Macdonald T. L., 1991, DNA TOPOISOMERASES C; MULLER MT, 1988, BIOCHEMISTRY-US, V27, P8369, DOI 10.1021/bi00422a012; NEGRINI M, 1993, CANCER RES, V53, P4489; NETO JBC, 1992, J BIOL CHEM, V267, P19718; NITISS JL, 1994, CANCER CHEMOTH PHARM, V34, pS6, DOI 10.1007/BF00684857; OSHEROFF N, 1989, BIOCHEMISTRY-US, V28, P6157, DOI 10.1021/bi00441a005; OSHEROFF N, 1991, BIOESSAYS, V13, P269, DOI 10.1002/bies.950130603; POMMIER Y, 1991, NUCLEIC ACIDS RES, V19, P5973, DOI 10.1093/nar/19.21.5973; POMMIER Y, 1993, CANCER CHEMOTH PHARM, V32, P103, DOI 10.1007/BF00685611; POMMIER Y, 1994, CANCER INVEST, V12, P530, DOI 10.3109/07357909409021413; Pommier Y., 1996, CANC CHEMOTHERAPY BI, P435; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PURMAL AA, 1994, J BIOL CHEM, V269, P22046; RAAP J, 1987, J BIOMOL STRUCT DYN, V5, P219, DOI 10.1080/07391102.1987.10506391; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; ROBINSON MJ, 1991, BIOCHEMISTRY-US, V30, P1807, DOI 10.1021/bi00221a012; ROSS JA, 1994, J NATL CANCER I, V86, P1678, DOI 10.1093/jnci/86.22.1678; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; SINHA BK, 1995, DRUGS, V49, P11, DOI 10.2165/00003495-199549010-00002; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; SMITH MA, 1993, J NATL CANCER I, V85, P554, DOI 10.1093/jnci/85.7.554; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SUTCLIFFE JG, 1979, COLD SPRING HARB SYM, V43, P77, DOI 10.1101/SQB.1979.043.01.013; TREIBER DK, 1994, P NATL ACAD SCI USA, V91, P5672, DOI 10.1073/pnas.91.12.5672; VASSETZKY YS, 1995, BIOESSAYS, V17, P767, DOI 10.1002/bies.950170906; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681; ZECHIEDRICH EL, 1989, BIOCHEMISTRY-US, V28, P6229, DOI 10.1021/bi00441a014	76	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1148	1155		10.1074/jbc.272.2.1148	http://dx.doi.org/10.1074/jbc.272.2.1148			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995415	hybrid			2022-12-25	WOS:A1997WC04800066
J	Kokoza, VA; Raikhel, AS				Kokoza, VA; Raikhel, AS			Ovarian- and somatic-specific transcripts of the mosquito clathrin heavy chain gene generated by alternative 5'-exon splicing and polyadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; LIGHT-CHAINS; VITELLOGENIN RECEPTOR; MOLECULAR-CLONING; COATED VESICLES; CELL-GROWTH; PROTEIN; REQUIREMENT; SEQUENCE; DICTYOSTELIUM	Insect oocytes are extraordinarily specialized for receptor-mediated endocytosis of yolk protein precursors. The clathrin heavy chain (CHC) is the major structural protein of coated vesicles, the principal organelles of receptor-mediated endocytosis. To understand the role of clathrin in the development of the oocyte's powerful endocytotic machinery we determined the structure of the mosquito chc gene. The gene spans approximately 45 kilobases and its coding region is divided into seven exons, five of which encode the protein. Three distinct mature transcripts of this gene were identified in mosquito tissues, Two of them code isoforms of the CHC polypeptide differing in their NH2-terminal sequences, and are specifically expressed in female germ-line cells. The third transcript has a 3'-untranslated region about 1 kilobase longer than the other variants, and is found only in the somatic cells. Tissue-specific 5'-exon splicing and alternative polyadenylation of the primary transcript combine to give rise to these mRNAs. We identified two alternative promoters, distal and proximal, separated by approximately 10 kilobases involved in tissue-specific regulation of mosquito che gene expression. Our data provide the first molecular evidence for complex structure and regulation of a che gene, in this case occurring at both the transcriptional and post-transcriptional levels.	MICHIGAN STATE UNIV, DEPT ENTOMOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, GENET PROGRAM, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, CELL & MOL BIOL PROGRAM, E LANSING, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI132154, R01AI032154] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-32154] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZINET C, 1993, GENETICS, V134, P1119; BOSE SG, 1988, BIOCHEM BIOPH RES CO, V155, P436, DOI 10.1016/S0006-291X(88)81105-7; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHO WL, 1992, J BIOL CHEM, V267, P21823; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; Deitsch K.W., 1993, Insect Molecular Biology, V2, P205, DOI 10.1111/j.1365-2583.1994.tb00140.x; DHADIALLA TS, 1992, INSECT BIOCHEM MOLEC, V22, P803, DOI 10.1016/0965-1748(92)90107-P; DODGE GR, 1991, GENOMICS, V11, P174, DOI 10.1016/0888-7543(91)90115-U; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAYS AR, 1990, ROUX ARCH DEV BIOL, V199, P114, DOI 10.1007/BF02029559; HU YH, 1993, NEURON, V10, P921, DOI 10.1016/0896-6273(93)90207-8; JACKSON AP, 1988, J BIOL CHEM, V263, P16688; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; Kedra D, 1996, HUM MOL GENET, V5, P625, DOI 10.1093/hmg/5.5.625; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1987, P NATL ACAD SCI USA, V84, P8805, DOI 10.1073/pnas.84.24.8805; LEMMON SK, 1991, J CELL BIOL, V112, P65, DOI 10.1083/jcb.112.1.65; LEMMON SK, 1987, SCIENCE, V238, P504, DOI 10.1126/science.3116672; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; OHALLORAN TJ, 1992, DNA CELL BIOL, V11, P321, DOI 10.1089/dna.1992.11.321; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1987, EMBO J, V6, P2507, DOI 10.1002/j.1460-2075.1987.tb02536.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RAIKHEL AS, 1984, EUR J CELL BIOL, V35, P279; RAO PN, 1987, HEREDITY, V59, P253, DOI 10.1038/hdy.1987.120; ROTHMAN KJ, 1994, SCAND J WORK ENV HEA, V20, P313, DOI 10.5271/sjweh.1391; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sappington TW, 1996, P NATL ACAD SCI USA, V93, P8934, DOI 10.1073/pnas.93.17.8934; SAPPINGTON TW, 1995, INSECT BIOCHEM MOLEC, V25, P807, DOI 10.1016/0965-1748(95)00016-O; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; SILVEIRA LA, 1990, J CELL BIOL, V111, P1437, DOI 10.1083/jcb.111.4.1437; Sirotkin H, 1996, HUM MOL GENET, V5, P617, DOI 10.1093/hmg/5.5.617; STAMM S, 1992, NUCLEIC ACIDS RES, V20, P5097, DOI 10.1093/nar/20.19.5097; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	46	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1164	1170		10.1074/jbc.272.2.1164	http://dx.doi.org/10.1074/jbc.272.2.1164			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995417	hybrid			2022-12-25	WOS:A1997WC04800068
J	Lieberman, BA; Nordeen, SK				Lieberman, BA; Nordeen, SK			DNA intersegment transfer, how steroid receptors search for a target site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSOR-OPERATOR INTERACTION; DIFFUSION-DRIVEN MECHANISMS; PROTEIN-PROTEIN INTERACTIONS; GLUCOCORTICOID RECEPTOR; BINDING DOMAIN; LAC REPRESSOR; ASSOCIATION KINETICS; NUCLEIC-ACIDS; COUPLED DIFFUSION; AMINO-ACIDS	The mammalian nucleus contains 6 billion base pairs of DNA, encoding about 100,000 genes, yet in a given cell steroid hormones induce only a handful of genes, The logistical difficulties faced by steroid receptors or other transcription factors of sorting through this much genetic information is further increased by the density of nuclear DNA (approximately 10-50 mg/ml), Standard models propose that steroid receptors find target elements by repeated cycles of dissociation and reassociation until a high affinity site is found (cycling model) and/or by conducting a one-dimensional search along the DNA (sliding model), A third model proposes that steroid receptors search for target sites in the genome by DNA intersegment transfer, In this model, receptor dimers bind nonspecific DNA sequences and search for a target site by binding a second strand of DNA before dissociating from the first, in effect moving through the genome like Tarzan swinging from vine to vine, This model has the advantage that a high concentration of DNA favors, rather than hinders, the search, The intersegment transfer model predicts, in contrast to the cycling and sliding models, that the dissociation rate of receptor from DNA is highly dependent on DNA concentration, We have employed the purified DNA binding domain fragment from the rat glucocorticoid receptor to perform equilibrium and kinetic studies of the DNA dependence of receptor DNA dissociation, We find receptor dissociation from DNA to be highly dependent on the concentration of DNA in solution, in agreement with the intersegment transfer model, We also find that this interaction is primarily electrostatic, because DNA-like polyanion chains (e.g. heparin and polyglutamate) can mediate the transfer, These studies provide evidence that direct DNA transfer aids the target site search conducted by steroid receptors in their role as inducible transcription factors.	UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOL BIOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037061] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37061] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALROY I, 1992, NUCLEIC ACIDS RES, V20, P1045, DOI 10.1093/nar/20.5.1045; ARCHER TK, 1990, P NATL ACAD SCI USA, V87, P7560, DOI 10.1073/pnas.87.19.7560; BARKLEY MD, 1981, BIOCHEMISTRY-US, V20, P3833, DOI 10.1021/bi00516a026; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P13463, DOI 10.1021/bi00212a011; BERG OG, 1982, TRENDS BIOCHEM SCI, V7, P52, DOI 10.1016/0968-0004(82)90075-5; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; BERG OG, 1977, BIOPHYS CHEM, V7, P33, DOI 10.1016/0301-4622(77)87012-9; BERG OG, 1978, BIOPHYS CHEM, V8, P271, DOI 10.1016/0301-4622(78)80010-6; BERG OG, 1976, BIOPHYS CHEM, V4, P367, DOI 10.1016/0301-4622(76)80017-8; BERG OG, 1986, BIOPOLYMERS, V25, P811, DOI 10.1002/bip.360250506; BERG OG, 1984, BIOPOLYMERS, V23, P1869, DOI 10.1002/bip.360231005; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; Berkhout B, 1996, J BIOL CHEM, V271, P1837, DOI 10.1074/jbc.271.4.1837; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DAHLMANWRIGHT K, 1993, J STEROID BIOCHEM, V45, P239, DOI 10.1016/0960-0760(93)90338-W; DAHLMANWRIGHT K, 1992, J STEROID BIOCHEM, V41, P249, DOI 10.1016/0960-0760(92)90351-I; Dahlquist F W, 1978, Methods Enzymol, V48, P270; FREEDMAN LP, 1988, CELL, V54, P444, DOI 10.1016/0092-8674(88)90063-3; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; HEITMAN J, 1992, BIOESSAYS, V14, P445, DOI 10.1002/bies.950140704; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUNDBACK T, 1993, BIOCHEMISTRY-US, V32, P5074, DOI 10.1021/bi00070a015; LUNDBACK T, 1994, BIOCHEMISTRY-US, V33, P5955, DOI 10.1021/bi00185a037; MANNING GS, 1972, BIOPOLYMERS, V11, P937, DOI 10.1002/bip.1972.360110502; MOMANY FA, 1975, J PHYS CHEM-US, V79, P2361, DOI 10.1021/j100589a006; RECORD MT, 1976, BIOPOLYMERS, V15, P893, DOI 10.1002/bip.1976.360150507; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHTER PH, 1974, BIOPHYS CHEM, V2, P255, DOI 10.1016/0301-4622(74)80050-5; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; RUUSALA T, 1992, P NATL ACAD SCI USA, V89, P4903, DOI 10.1073/pnas.89.11.4903; Sambrook J., 2002, MOL CLONING LAB MANU; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VANTILBORG MAA, 1995, J MOL BIOL, V247, P689, DOI 10.1016/S0022-2836(05)80148-2; von Smoluchowski M, 1917, Z PHYS CHEM-STOCH VE, V92, P129; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6948, DOI 10.1021/bi00527a029	43	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1061	1068		10.1074/jbc.272.2.1061	http://dx.doi.org/10.1074/jbc.272.2.1061			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995403	hybrid			2022-12-25	WOS:A1997WC04800054
J	Matsui, H; Johnson, LG; Randell, SH; Boucher, RC				Matsui, H; Johnson, LG; Randell, SH; Boucher, RC			Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; CYSTIC-FIBROSIS; IN-VITRO; PHAGOCYTOSIS; ENDOCYTOSIS; FIBROBLASTS; ADENOVIRUS; THERAPY; VECTOR; MICE	The target cells for gene therapy of cystic fibrosis lung disease are the well differentiated cells that line airway lumens. Employing cultures of airway epithelial cells that grow like ''islands'' and exhibit a continuum of cellular differentiation, we studied the mechanisms that render well differentiated cells more difficult to transfect with cationic liposomes than poorly differentiated cells. The poorly differentiated cells at the edge of the islands were transfectable with liposome-DNA complexes (pCMV beta:LipofectACE = 1:5 (w/w)), whereas the more differentiated cells in the center of the islands were not. Evaluation of the steps leading to lipid-mediated transfection revealed that edge cells bound more liposome-DNA complexes, in part due to a more negative surface charge (as measured by cationized ferritin binding), and that edge cells internalized more liposome-DNA complexes than central cells. Edge cells exhibited receptor-mediated endocytosis of LDL, pinocytosis of 10-nm microspheres, and phagocytosis of 2-mu m microspheres, whereas central cells were only capable of receptor-mediated endocytosis. Cytochalasin B, which inhibited pinocytosis by 65% and phagocytosis by 93%, decreased edge cell liposome DNA complex entry by 50%, Potassium depletion, which decreased phagocytosis by >90% but had no effect on pinocytosis, inhibited edge cell liposome-DNA complex entry by 71%. These results indicate that liposome-DNA complexes enter edge cells via phagocytosis and that this pathway is not detectable in central cells. In conclusion, both reduced negative surface charge and absence of phagocytosis internalization pathways in relatively differentiated cells may explain differentiation dependent decrements in cationic liposome-mediated gene transfer in airway epithelia.			Matsui, H (corresponding author), UNIV N CAROLINA,CYST FIBROSIS PULM RES & TREATMENT CTR,7129 THRUSTON BOWLES BLDG,CB 7248,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [HL51818] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGGELER J, 1982, J CELL BIOL, V94, P613, DOI 10.1083/jcb.94.3.613; ANDERSON JM, 1995, AM J PHYSIOL, V269, pG469; BARAK LS, 1981, J CELL BIOL, V90, P595, DOI 10.1083/jcb.90.3.595; BARTHEL F, 1993, DNA CELL BIOL, V12, P553, DOI 10.1089/dna.1993.12.553; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; CAPLEN NJ, 1995, NAT MED, V1, P39, DOI 10.1038/nm0195-39; CLAASSEN E, 1992, J IMMUNOL METHODS, V147, P231, DOI 10.1016/S0022-1759(12)80013-5; DUPUIT F, 1995, HUM GENE THER, V6, P1185, DOI 10.1089/hum.1995.6.9-1185; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; GRUBB BR, 1994, NATURE, V371, P802, DOI 10.1038/371802a0; GUSTAFSSON J, 1995, BBA-BIOMEMBRANES, V1235, P305, DOI 10.1016/0005-2736(95)80018-B; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; HOLMEN SL, 1995, IN VITRO CELL DEV, V30, P347; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; ISBERG RR, 1995, TRENDS CELL BIOL, V5, P120, DOI 10.1016/S0962-8924(00)88962-X; KAARTINEN L, 1993, IN VITRO CELL DEV-AN, V29A, P481, DOI 10.1007/BF02639383; KING CA, 1977, FEBS LETT, V73, P59, DOI 10.1016/0014-5793(77)80015-X; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; Lechner J F, 1985, J TISSUE CULT METHOD, V9, P43; LEVENTIS R, 1990, BIOCHIM BIOPHYS ACTA, V1023, P124, DOI 10.1016/0005-2736(90)90017-I; LOGAN JJ, 1995, GENE THER, V2, P38; NICOLAU C, 1982, BIOCHIM BIOPHYS ACTA, V721, P185, DOI 10.1016/0167-4889(82)90067-2; PRATTEN MK, 1986, BIOCHIM BIOPHYS ACTA, V881, P307, DOI 10.1016/0304-4165(86)90020-6; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SOEIRO MNC, 1994, J SUBMICR CYTOL PATH, V26, P121; SORSCHER EJ, 1994, HUM GENE THER, V5, P1259, DOI 10.1089/hum.1994.5.10-1259; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; TAKESHITA S, 1994, J CLIN INVEST, V93, P652, DOI 10.1172/JCI117017; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; TRIVEDI RA, 1995, J NEUROCHEM, V64, P2230; WILLIAMS MC, 1984, P NATL ACAD SCI-BIOL, V81, P6054, DOI 10.1073/pnas.81.19.6054; WU R, 1985, AM REV RESPIR DIS, V132, P311; YOSHIMURA K, 1991, NUCLEIC ACIDS RES, V20, P3323; YU XY, 1994, ENVIRON HEALTH PERSP, V102, P1068, DOI 10.2307/3431994; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3	39	164	169	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1117	1126		10.1074/jbc.272.2.1117	http://dx.doi.org/10.1074/jbc.272.2.1117			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995411	hybrid, Green Published			2022-12-25	WOS:A1997WC04800062
J	DelVillar, K; Mitsuzawa, H; Yang, WL; Sattler, I; Tamanoi, F				DelVillar, K; Mitsuzawa, H; Yang, WL; Sattler, I; Tamanoi, F			Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAS PROTEINS; BETA-SUBUNIT; METAL REQUIREMENTS; KINETIC MECHANISM; ESCHERICHIA-COLI; PEPTIDE-BINDING; GENE-PRODUCT; CDNA CLONING; YEAST	Protein farnesyltransferase (FTase), a heterodimer enzyme consisting of alpha and beta subunits, catalyzes the addition of farnesyl groups to the C termini of proteins such as Ras, In this paper, we report that the protein substrate specificity of yeast FTase can be switched to that of a closely related enzyme, geranylgeranyltransferase type I (GGTase I) by a single amino acid change at one of the three residues: Ser-159, Tyr-362, or Tyr-366 of its beta-subunit, Dpr1. All three Dpr1 mutants can function as either FTase or GGTase I beta subunit in vivo, although some differences in efficiency were observed, These results point to the importance of two distinct regions (one at 159 and the other at 362 and 366) of Dpr1 for the recognition of the protein substrate, Analysis of the protein, after site directed mutagenesis was used to change Ser-159 to all possible amino acids, showed that either asparagine or aspartic acid at this position allowed FTase beta to function as GGTase I beta. A similar site directed mutagenesis study on Tyr-362 showed that leucine, methionine, or isoleucine at this position also resulted in the ability of mutant FTase beta to function as GGTase I beta, Interestingly, in both position 159 and 362 substitutions, amino acids that could change the protein substrate specificity had similar van der Waals volumes. Biochemical characterization of the S159N and Y362L mutant proteins showed that their k(cat)/K-m values for GGTase I substrate are increased about 20-fold compared with that of the wild type protein, These results demonstrate that the conversion of the protein substrate specificity of FTase to that of GGTase I can be accomplished by introducing a distinct size amino acid at either of the two residues, 159 and 362.	UNIV CALIF LOS ANGELES, INST MOL BIOL, DEPT MICROBIOL & MOL GENET, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [R01CA041996] Funding Source: NIH RePORTER; NCI NIH HHS [CA41996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSS J, 1996, CHEM BIOL, V2, P787; CAPLIN BE, 1994, BBA-PROTEIN STRUCT M, V1205, P39, DOI 10.1016/0167-4838(94)90089-2; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Creighton T. E., 1993, PROTEINS STRUCTURES; DIAZ M, 1993, EMBO J, V12, P5245, DOI 10.1002/j.1460-2075.1993.tb06220.x; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FINEGOLD AA, 1992, THESIS U CHICAGO; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOMEZ R, 1993, BIOCHEM J, V289, P25, DOI 10.1042/bj2890025; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HE B, 1991, P NATL ACAD SCI USA, V88, P11373, DOI 10.1073/pnas.88.24.11373; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KOHL NE, 1991, J BIOL CHEM, V266, P18884; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; MAYER ML, 1992, J BIOL CHEM, V267, P20589; MAYER MP, 1993, GENE, V132, P41, DOI 10.1016/0378-1119(93)90512-2; MITSUZAWA H, 1995, P NATL ACAD SCI USA, V92, P1704, DOI 10.1073/pnas.92.5.1704; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P5410, DOI 10.1128/MCB.8.12.5410; OHYA Y, 1991, J BIOL CHEM, V266, P12356; OMER CA, 1993, BIOCHEMISTRY-US, V32, P5167, DOI 10.1021/bi00070a028; QADOTA H, 1992, YEAST, V8, P735, DOI 10.1002/yea.320080906; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; TRUEBLOOD CE, 1993, MOL CELL BIOL, V13, P4260, DOI 10.1128/MCB.13.7.4260; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; YING WL, 1994, J BIOL CHEM, V269, P470; YOKOYAMA K, 1995, BIOCHEMISTRY-US, V34, P1344, DOI 10.1021/bi00004a029; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; ZHANG FL, 1994, J BIOL CHEM, V269, P3175; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	50	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					680	687						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995312				2022-12-25	WOS:A1997WA56400099
J	OConnell, MA; Gerber, A; Keller, W				OConnell, MA; Gerber, A; Keller, W			Purification of human double-stranded RNA-specific editase 1 (hRED1) involved in editing of brain glutamate receptor B pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DEAMINASE; MESSENGER-RNA; IN-VITRO; GLUR-B; MOLECULAR-CLONING; SUBUNIT; PERMEABILITY; EXPRESSION; CONVERSION; CHANNELS	RNAs encoding subunits of glutamate-gated ion channel receptors are posttranscriptionally modified by RNA editing and alternative splicing. The change in amino acid sequence caused by RNA editing can affect both the kinetics and the permeability of the ion channel receptors to cations. Here, we report the purification of a 90-kDa double-stranded RNA-specific adenosine deaminase from HeLa cell nuclear extract that specifically edits the glutamine codon at position 586 in the pre-mRNA of the glutamate receptor B subunit. Site-specific deamination of an adenosine to an inosine converts the glutamine codon to that of arginine. Recently, a gene encoding a double-stranded-specific editase (RED1) was cloned from a rat brain cDNA library. Antibodies generated against the deaminase domain of its human homolog specifically recognized and inhibited the activity of the 90-kDa enzyme, indicating that we have purified hRED1 the human homolog of rat RED1. This enzyme is distinct from double-stranded RNA-specific adenosine deaminase which we and others have previously purified and cloned.	UNIV BASEL, BIOCTR, DEPT CELL BIOL, CH-4056 BASEL, SWITZERLAND	University of Basel			OConnell, Mary Anne/G-4740-2015; O'Connell, Mary Anne/U-7693-2019	OConnell, Mary Anne/0000-0003-3844-6174; O'Connell, Mary Anne/0000-0003-3844-6174				BASILIO C, 1962, P NATL ACAD SCI USA, V48, P613, DOI 10.1073/pnas.48.4.613; BASS BL, 1995, CURR BIOL, V5, P598, DOI 10.1016/S0960-9822(95)00119-9; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CIABARRA AM, 1995, J NEUROSCI, V15, P6498; Dabiri GA, 1996, EMBO J, V15, P34, DOI 10.1002/j.1460-2075.1996.tb00331.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hurst SR, 1995, RNA, V1, P1051; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Kung SS, 1996, MOL BRAIN RES, V35, P119; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; OCONNELL MA, 1994, P NATL ACAD SCI USA, V91, P10596, DOI 10.1073/pnas.91.22.10596; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Portmann S, 1996, CHEM BIOL, V3, P173, DOI 10.1016/S1074-5521(96)90260-4; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; Seeburg PH, 1996, J NEUROCHEM, V66, P1; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; Skuse GR, 1996, NUCLEIC ACIDS RES, V24, P478, DOI 10.1093/nar/24.3.478; STEITZ TA, 1993, RNA WORLD, P219; SUCHER NJ, 1995, J NEUROSCI, V15, P6509; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	38	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					473	478						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995285				2022-12-25	WOS:A1997WA56400072
J	PoteetSmith, CE; Shabb, JB; Francis, SA; Corbin, JD				PoteetSmith, CE; Shabb, JB; Francis, SA; Corbin, JD			Identification of critical determinants for autoinhibition in the pseudosubstrate region of type I alpha cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; AMINO-ACID-SEQUENCE; BACTERIOPHAGE-T7 RNA-POLYMERASE; CYCLIC-NUCLEOTIDE ANALOGS; HEAT-STABLE INHIBITOR; REGULATORY SUBUNIT; CATALYTIC SUBUNIT; BOVINE HEART; BINDING-SITES; ADENOSINE 3'-5'-MONOPHOSPHATE	The consensus substrate site for cAMP-dependent protein kinase (PKA) is Arg-Arg-Xaa-Ser(P)-Xaa and the autoinhibitory domain of the PKA type I alpha regulatory subunit (RI subunit) contains a similar sequence, Arg(92)-Arg-Arg-Arg-Gly-Ala-Ile-Ser-Ala-Glu. The italicized amino acids form a putative pseudosubstrate site (Ser is replaced with Ala), which together with adjacent residues could competitively inhibit substrate phosphorylation by the PHA catalytic subunit (C subunit). The present studies determine the contributions of Arg(92-95), Ile(98), and Glu(101) to inhibitory potency. Amino-terminal truncation of RI subunit through Arg(92) (Delta 1-92) or Arg(93) (Delta 1-93) had no detectable effect on inhibition of C subunit. Truncation through Arg(94) (Delta 1-94), or point mutation of Arg(95) within truncated mutants (Delta 1-93.R95A or Delta 1-92.R95A), caused a dramatic reduction in inhibitory potency. Truncation through Arg(95) (Delta 1-95) had a greater effect than did replacement or deletion of Arg(94) or Arg(95) alone. Using full-length RI subunit, the inhibitory potency was reduced by replacing Ile(98) with Ala, Gly, or Gln, but not by replacing it with Val. The inhibitory potency of RI subunit was unchanged when Glu(101) was replaced with Ala or Gln. It is concluded that Arg(94), Arg(95) and, to a lesser extent, Ile(98) are vital constituents of PKA autoinhibition by type I alpha R subunit.	VANDERBILT UNIV,DEPT MOL PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; UNIV N DAKOTA,SCH MED,DEPT BIOCHEM & MOL BIOL,GRAND FORKS,ND 58202	Vanderbilt University; University of North Dakota Grand Forks					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 40029] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; BOISSEL JP, 1988, J BIOL CHEM, V263, P8443; BRAMSON HN, 1985, J BIOL CHEM, V260, P5452; BUECHLER YJ, 1993, J BIOL CHEM, V268, P16495; BUECHLER YJ, 1991, J BIOL CHEM, V266, P3491; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; BUILDER SE, 1981, PROTEIN PHOSPHORYLAT, P33; CHAU V, 1980, BIOCHEMISTRY-US, V19, P924, DOI 10.1021/bi00546a016; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHESSA G, 1983, EUR J BIOCHEM, V135, P609, DOI 10.1111/j.1432-1033.1983.tb07695.x; COBB CE, 1987, J BIOL CHEM, V262, P16566; CONNELLY PA, 1986, J BIOL CHEM, V261, P2325; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CORBIN JD, 1978, J BIOL CHEM, V253, P3997; CORBIN JD, 1975, J BIOL CHEM, V250, P218; CORBIN JD, 1988, METHOD ENZYMOL, V159, P74; CORBIN JD, 1977, J BIOL CHEM, V252, P3854; CORBIN JD, 1981, J BIOL CHEM, V256, P1671; Dills W L, 1979, Adv Cyclic Nucleotide Res, V10, P199; DILLS WL, 1975, BIOCHEM BIOPH RES CO, V62, P70, DOI 10.1016/S0006-291X(75)80406-2; DILLS WL, 1976, BIOCHEMISTRY-US, V15, P3724, DOI 10.1021/bi00662a013; DOSKELAND SO, 1984, J BIOL CHEM, V259, P2291; GIBBS CS, 1992, J BIOL CHEM, V267, P4806; GLASS DB, 1989, J BIOL CHEM, V264, P8802; GRANOT J, 1981, BIOCHEMISTRY-US, V20, P602, DOI 10.1021/bi00506a024; GRANOT J, 1980, J BIOL CHEM, V255, P4569; HEMMINGS HC, 1984, J BIOL CHEM, V259, P4486; HOFMANN F, 1980, J BIOL CHEM, V255, P1559; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KUNKEL TA, 1994, CURRENT PROTOCOLS MO; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MURPHY BJ, 1993, J BIOL CHEM, V268, P27355; Nimmo H G, 1977, Adv Cyclic Nucleotide Res, V8, P145; OGREID D, 1989, EUR J BIOCHEM, V181, P19; PARKER PJ, 1981, FEBS LETT, V123, P332, DOI 10.1016/0014-5793(81)80321-3; RANGELALDAO R, 1977, J BIOL CHEM, V252, P7140; RANNELS SR, 1983, METHOD ENZYMOL, V99, P55; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P5732, DOI 10.1073/pnas.82.17.5732; SHABB JB, 1995, PROTEIN SCI, V4, P2100, DOI 10.1002/pro.5560041015; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SHABB JB, 1990, J BIOL CHEM, V265, P16031; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1994, CURRENT PROTOCOLS MO; THOMPSON WJ, 1991, PHARMACOL THERAPEUT, V51, P13, DOI 10.1016/0163-7258(91)90039-O; TITANI K, 1984, BIOCHEMISTRY-US, V23, P4193, DOI 10.1021/bi00313a028; TSUZUKI J, 1978, BIOCHEMISTRY-US, V17, P2961, DOI 10.1021/bi00608a004; WALSH DA, 1973, ENZYMES, P555; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; WOLFE L, 1990, ACTIVATION DESENSITI, P133; YEAMAN SJ, 1977, BIOCHEM J, V162, P411, DOI 10.1042/bj1620411; ZETTERQVIST O, 1976, BIOCHEM BIOPH RES CO, V70, P696, DOI 10.1016/0006-291X(76)90648-3; ZETTERQVIST O, 1982, FEBS LETT, V139, P287, DOI 10.1016/0014-5793(82)80872-7; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	59	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					379	388						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995272				2022-12-25	WOS:A1997WA56400059
J	Wiest, DK; ODay, CL; Abelson, J				Wiest, DK; ODay, CL; Abelson, J			In vitro studies of the Prp9 center dot Prp11 center dot Prp21 complex indicate a pathway for U2 small nuclear ribonucleoprotein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; EUKARYOTIC INITIATION-FACTORS; SPLICING FACTOR; SACCHAROMYCES-CEREVISIAE; STRUCTURAL ELEMENT; SNRNP BINDING; YEAST PRP9; PROTEIN; SPLICEOSOME; PRESPLICEOSOME	Pre-mRNA splicing takes place on a large ribonucleoprotein particle, the spliceosome which contains the five small nuclear ribonucleoproteins (snRNPs), U1, U2, U4, U5, and U6. In Saccharomyces cerevisiae the mRNA splicing factors, Prp9, Prp11, and Prp21, are necessary for addition of the U2 snRNP to the pre-mRNA in an early step of spliceosome assembly. This paper describes a study of interactions between these proteins and their role in spliceosome assembly. The proteins were expressed in Escherichia coli. Prp9 and Prp11 were purified by metal affinity chromatography. Prp21 was purified using a solubilization/renaturation protocol. We have combined these separately purified proteins and present direct evidence of a Prp9 . Prp11 . Prp21 protein complex that is functional in in vitro splicing assays. Characteristics of this Prp9 . Prp11 . Prp21 complex were further investigated using proteins synthesized in vitro. In addition, we found that Prp9, Prp11, and Prp21 influence the structure of the U2 snRNP in a manner that alters the accessibility of the branch point pairing region of the U2 snRNA to oligonucleotide- directed RNaseH cleavage. We present a model, based on the data presented here and in the accompanying paper, for a combined role of Prp9, Prp11, Prp21, and Prp5 in activating the U2 snRNP for assembly into the pre-spliceosome.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM32637] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032637, R01GM032637] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOVICH N, 1990, MOL CELL BIOL, V10, P6417, DOI 10.1128/MCB.10.12.6417; ABRAMSON RD, 1988, J BIOL CHEM, V263, P6016; ARENAS JE, 1993, P NATL ACAD SCI USA, V90, P6771, DOI 10.1073/pnas.90.14.6771; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BEHRENS SE, 1993, P NATL ACAD SCI USA, V90, P8229, DOI 10.1073/pnas.90.17.8229; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1993, SCIENCE, V262, P105, DOI 10.1126/science.8211113; BROSI R, 1993, SCIENCE, V262, P102, DOI 10.1126/science.8211112; BROSI R, 1993, J BIOL CHEM, V268, P17640; CHANG TH, 1988, MOL CELL BIOL, V8, P2379, DOI 10.1128/MCB.8.6.2379; CHIARA MD, 1994, P NATL ACAD SCI USA, V91, P6403, DOI 10.1073/pnas.91.14.6403; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; GOSS DJ, 1987, BIOCHEMISTRY-US, V26, P1551, DOI 10.1021/bi00380a009; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; HODGES PE, 1994, CURR BIOL, V4, P264, DOI 10.1016/S0960-9822(00)00061-0; KRAMER A, 1994, NUCLEIC ACIDS RES, V22, P5223, DOI 10.1093/nar/22.24.5223; LEGRAIN P, 1990, EMBO J, V9, P2775, DOI 10.1002/j.1460-2075.1990.tb07465.x; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1994, ANNU REV GENET, V28, P677; MCPHEETERS DS, 1989, GENE DEV, V3, P2124, DOI 10.1101/gad.3.12b.2124; MILBURN SC, 1990, EMBO J, V9, P2783, DOI 10.1002/j.1460-2075.1990.tb07466.x; MIRAGLIA L, 1991, P NATL ACAD SCI USA, V88, P7061, DOI 10.1073/pnas.88.16.7061; Moore M., 1993, RNA WORLD, P303; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; RAY BK, 1985, J BIOL CHEM, V260, P7651; RUBY SW, 1991, TRENDS GENET, V7, P79; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; STAKNIS D, 1994, MOL CELL BIOL, V14, P2994, DOI 10.1128/MCB.14.5.2994; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WELLS SE, 1994, MOL CELL BIOL, V14, P6337, DOI 10.1128/MCB.14.9.6337; Yan D, 1996, MOL CELL BIOL, V16, P818; ZAVANELLI MI, 1994, MOL CELL BIOL, V14, P1689, DOI 10.1128/MCB.14.3.1689; ZAVANELLI MI, 1991, GENE DEV, V5, P2521, DOI 10.1101/gad.5.12b.2521	38	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33268	33276		10.1074/jbc.271.52.33268	http://dx.doi.org/10.1074/jbc.271.52.33268			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969185	hybrid, Green Accepted			2022-12-25	WOS:A1996WA71300019
J	Bottger, V; Bottger, A; Howard, SF; Picksley, SM; Chene, P; GarciaEcheverria, C; Hochkeppel, HK; Lane, DP				Bottger, V; Bottger, A; Howard, SF; Picksley, SM; Chene, P; GarciaEcheverria, C; Hochkeppel, HK; Lane, DP			Identification of novel mdm2 binding peptides by phage display	ONCOGENE			English	Article						mdm2; hdm2; p53; phage display library; peptide inhibitors	TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MONOCLONAL-ANTIBODIES; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; SYNTHETIC PEPTIDES; EPITOPE LIBRARY; P53; LIGANDS; PROTEIN	The oncogene mdm2 and its human homologue hdm2 bind to the tumour suppressor protein p53 and inactivate its function as a transcription factor. This has been implied as a possible mechanism for cancer development in several tumours including human sarcomas. The mdm2-p53 interaction is therefore a much persued target for the development of anti-cancer drugs. In order to find novel high affinity ligands for hdm2 which would interfere with its binding to p53 we screened phage display peptide libraries for mdm2 binding phage. We found a series of 12 and 15mer peptides which interact strongly with hdm2. The peptide sequences show striking homology with the previously established mdm2 binding site on p53, confirming that the peptide defined (18)TFSDLW(23) region is crucial for the interaction but that contact between the two molecules extends to position L(26) On p53. Free synthetic peptides derived from the phage selected sequences proved to be up to 100 times stronger inhibitors of the p53-mdm2 interaction than the p53 derived wt-peptide in several ELISA-assays. This illustrates the potency of phage display libraries in the search for new peptide based lead structures designed to mimic or inhibit therapeutically important protein-protein interactions.	UNIV DUNDEE, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; CIBA GEIGY AG, CH-4002 BASEL, SWITZERLAND	University of Dundee; Novartis			Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545; Bottger, Angelika/0000-0003-3273-9558				BOTTGER V, 1995, J MOL BIOL, V247, P932, DOI 10.1006/jmbi.1995.0191; BOTTGER V, 1994, J MOL BIOL, V235, P61, DOI 10.1016/S0022-2836(05)80013-0; CHAN S, 1987, MOL CELL PROBE, V1, P73, DOI 10.1016/0890-8508(87)90008-9; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LENG P, 1995, ONCOGENE, V10, P1275; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SNYDER LC, 1987, SOMAT CELL MOLEC GEN, V13, P235; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	28	178	196	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2141	2147						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950981				2022-12-25	WOS:A1996VV14500011
J	Taki, T; Hayashi, Y; Taniwaki, M; Seto, M; Ueda, R; Hanada, R; Suzukawa, K; Yokota, J; Morishita, K				Taki, T; Hayashi, Y; Taniwaki, M; Seto, M; Ueda, R; Hanada, R; Suzukawa, K; Yokota, J; Morishita, K			Fusion of the MLL gene with two different genes, AF-6 and AF-5 alpha, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia	ONCOGENE			English	Article						AF-5 alpha; complex chromosomal translocation; infant leukemia; topoisomerase II recognition site-like sequence	ACUTE LYMPHOBLASTIC-LEUKEMIA; YEAST ARTIFICIAL CHROMOSOME; BREAKPOINT CLUSTER REGION; TUMOR-SUPPRESSOR PROTEIN; ACUTE MYELOID LEUKEMIAS; IN-SITU HYBRIDIZATION; DNA TOPOISOMERASE-II; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; SEPTATE JUNCTIONS	We analysed a complex translocation involving chromosomes 5, 6, 8 and 11 in a case of infant leukemia. Molecular analysis of the MLL gene revealed that MLL was fused with two different genes, AF-6 on chromosome 6q27 and AF-5 alpha. AF-5 alpha, the 11th partner gene fused with MLL, is a novel gene mapped to chromosome 5q12, which encodes a 31 kDa protein of 269 amino acids and contains possible nuclear targeting sequence, potential leucine zipper dimerization motif and an alpha-helical coiled-coil domain. In situ hybridization and molecular cloning analyses demonstrated that two different types of chromosomal recombination had occurred in the cells. One was a three-way translocation among chromosomes 6, 8 and 11, and the other was an insertion of a chromosome 5-derived segment into the breakpoint of chromosomes 8 and 11. Accordingly, the karyotype was defined as del(5)(q11.2q12), der(6)t(6;8) (q27;q11.2), der(8)(8pter-->8q11.2::5q11.2-->5q12::11q23-->11qter), der(11)t(6;11) (q27;q23). Thus, the MLL gene created two different fusion mRNAs, since the chromosome 11 split into two different chromosomes 5 and 6. This is the first report demonstrating fusion of the MLL gene with two different genes by a complex translocation.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, FAC MED, DEPT PEDIAT, BUNKYO KU, TOKYO 113, JAPAN; HAMAMATSU UNIV SCH MED, DEPT PEDIAT, HAMAMATSU, SHIZUOKA 43131, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT INTERNAL MED 3, KAMIGYO KU, KYOTO 602, JAPAN; AICHI CANC CTR, RES INST, LAB CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; SAITAMA CHILDRENS MED CTR, DIV HEMATOL ONCOL, IWATSUKI, SAITAMA 339, JAPAN	National Cancer Center - Japan; University of Tokyo; Hamamatsu University School of Medicine; Kyoto Prefectural University of Medicine; Aichi Cancer Center; Saitama Children's Medical Center				Suzukawa, Kazumi/0000-0001-9904-3905				BEVERLOO HB, 1995, CANCER RES, V55, P4220; CHEN CS, 1993, BLOOD, V81, P2386; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1995, CANCER RES, V55, P4287; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUNGER SP, 1993, BLOOD, V81, P3197; IIDA S, 1993, ONCOGENE, V8, P3085; KEARNEY L, 1992, BLOOD, V80, P1659; KODURU PRK, 1993, ONCOGENE, V8, P3239; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCKEITHAN TW, 1992, P NATL ACAD SCI USA, V89, P4923, DOI 10.1073/pnas.89.11.4923; MORISHITA K, 1990, ONCOGENE, V5, P963; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEGRINI M, 1993, CANCER RES, V53, P4489; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PRASAD R, 1993, CANCER RES, V53, P5624; PUI CH, 1995, LEUKEMIA, V9, P762; RUBNITZ JE, 1994, BLOOD, V84, P570; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	40	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2121	2130						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950979				2022-12-25	WOS:A1996VV14500009
J	Debry, P; Nash, EA; Neklason, DW; Metherall, JE				Debry, P; Nash, EA; Neklason, DW; Metherall, JE			Role of multidrug resistance P-glycoproteins in cholesterol esterification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE SPHINGOMYELIN; HMG-COA REDUCTASE; HUMAN-FIBROBLASTS; ACYL-COA; INTRACELLULAR CHOLESTEROL; CULTURED FIBROBLASTS; STEROID-HORMONES; GENE LEADS; RAT-LIVER; CELLS	Cholesterol esterification, catalyzed by acyl-CoA:cholesterol acyltransferase (ACAT), plays a central role in cellular cholesterol homeostasis and in physiologic processes that lead to coronary heart disease. Although ACAT resides in the endoplasmic reticulum (ER), the cholesterol substrate for esterification originates in the plasma membrane and must be transported to the ER for esterification. Progesterone inhibits esterification, possibly by blocking the transport of cholesterol to the ER. Recent studies suggest that progesterone acts by inhibiting the activity of one or more of the multidrug-resistant (MDR) P-glycoproteins. In the current manuscript, we demonstrate that progesterone's ability to inhibit esterification is not mediated through the progesterone receptor. We evaluate a series of steroid hormones and find a strong correlation between a steroid hormone's hydrophobicity and its ability to inhibit both cholesterol esterification and MDR catalyzed drug efflux. We also find that cholesterol esterification is inhibited by nonsteroidal MDR inhibitors, and that this inhibition specifically affects the esterification of cholesterol derived from the plasma membrane. MDR inhibitors also inhibit cholesterol esterification in a wide range of cultured human cell lines. These observations suggest that MDR activity normally functions in a general process of intracellular cholesterol transport.	UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,ECCLES PROGRAM HUMAN MOL BIOL & GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah					NHGRI NIH HHS [HG00042-01] Funding Source: Medline	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALTUVIA S, 1993, J BIOL CHEM, V268, P27127; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; DOOLITTLE GM, 1982, BIOCHEMISTRY-US, V21, P674, DOI 10.1021/bi00533a014; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FIELD FJ, 1995, J LIPID RES, V36, P1533; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUPTA AK, 1991, J LIPID RES, V32, P125; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1994, J BIOL CHEM, V269, P29371; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LING V, 1992, CANCER-AM CANCER SOC, V69, P2603, DOI 10.1002/1097-0142(19920515)69:10<2603::AID-CNCR2820691034>3.0.CO;2-E; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; PORN MI, 1995, BIOCHEM J, V308, P269; QIAN XD, 1990, J BIOL CHEM, V265, P18753; RAO US, 1994, BIOCHEM PHARMACOL, V48, P287, DOI 10.1016/0006-2952(94)90099-X; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SUCKLING KE, 1982, BIOCHIM BIOPHYS ACTA, V710, P154, DOI 10.1016/0005-2760(82)90145-X; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; YANG CPH, 1989, J BIOL CHEM, V264, P782	34	126	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1026	1031		10.1074/jbc.272.2.1026	http://dx.doi.org/10.1074/jbc.272.2.1026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995398	hybrid			2022-12-25	WOS:A1997WC04800049
J	Dorahy, DJ; Thorne, RF; Fecondo, JV; Burns, GF				Dorahy, DJ; Thorne, RF; Fecondo, JV; Burns, GF			Stimulation of platelet activation and aggregation by a carboxyl-terminal peptide from thrombospondin binding to the integrin-associated protein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; LEUKOCYTE RESPONSE INTEGRIN; GPIIB-IIIA; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; ADHESION; IDENTIFICATION; CALCIUM; DOMAIN; RADIOIMMUNOASSAY	Thrombospondin, a major secretory product of the alpha-granules of activated platelets, is a large trimeric glycoprotein that plays an important role in platelet aggregation, On resting platelets, thrombospondin binds to a single receptor in a cation-independent manner, but upon platelet activation it binds at least two further, distinct receptors that are both dependent upon divalent cations, Each of these receptors on the platelet surface binds to different regions of the thrombospondin molecule, and such binding may be responsible for the multifunctional role of thrombospondin in aggregation, We show here that a peptide from the carboxyl terminus of thrombospondin, RFYVVMWK, directly and specifically induces the activation and aggregation of washed human platelets from different donors at concentrations of 5-25 mu M. At lower concentrations the peptide synergizes with suboptimal concentrations of ADP to induce aggregation, Peptide affinity chromatography and immunoprecipitation with a monoclonal antibody were used to identify the receptor for the carboxyl terminal peptide as the integrin-associated protein, The integrin-associated protein remained bound to the RFYVVMWK-containing peptide column when washed with a scrambled peptide in the presence of 5 mM EDTA, indicating a divalent cation-independent association, It is suggested that integrin-associated protein is the primary receptor for thrombospondin on the surface of resting platelets and is implicated in potentiating the platelet aggregation response.	UNIV NEWCASTLE, FAC MED & HLTH SCI, CANC RES UNIT, CALLAGHAN, NSW 2308, AUSTRALIA; SWINBURNE UNIV TECHNOL, SCH CHEM SCI, HAWTHORN, VIC 3122, AUSTRALIA	University of Newcastle; Swinburne University of Technology								AIKEN ML, 1990, BLOOD, V76, P2501; AIKEN ML, 1986, J CLIN INVEST, V78, P1713, DOI 10.1172/JCI112767; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BALE MD, 1985, J BIOL CHEM, V260, P7502; BERNDT MC, 1993, PLATELETS, V4, P190, DOI 10.3109/09537109309013216; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Craig KL, 1996, BIOCHEM J, V314, P937, DOI 10.1042/bj3140937; DAWES J, 1983, THROMB RES, V29, P569, DOI 10.1016/0049-3848(83)90212-8; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GAO AG, 1994, J BIOL CHEM, V269, P29650; GARTNER TK, 1984, THROMB RES, V33, P19; GARTNER TK, 1984, BIOCHEM BIOPH RES CO, V124, P290, DOI 10.1016/0006-291X(84)90950-1; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Huang E. M., 1986, BIOCH PLATELETS, P1; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JAFFE EA, 1982, NATURE, V295, P246, DOI 10.1038/295246a0; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322; KEHREL B, 1991, BIOCHEM BIOPH RES CO, V179, P985, DOI 10.1016/0006-291X(91)91915-Y; KOSFELD MD, 1993, J BIOL CHEM, V268, P8808; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LAWLER J, 1986, BLOOD, V67, P1197; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; Mazurov A V, 1992, Platelets, V3, P181, DOI 10.3109/09537109209013181; MCPHERSON J, 1981, J BIOL CHEM, V256, P1330; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; PHILLIPS DR, 1980, J BIOL CHEM, V255, P1629; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; ROSALES C, 1992, J IMMUNOL, V149, P2759; SAGLIO SD, 1982, BLOOD, V59, P162; SCHNOLZER M, 1992, SCIENCE, V256, P221, DOI 10.1126/science.1566069; SCHWARTZ MA, 1993, J BIOL CHEM, V268, P19931; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; SENIOR RM, 1992, J CLIN INVEST, V90, P2251, DOI 10.1172/JCI116111; TSAO PW, 1995, J BIOL CHEM, V270, P23747, DOI 10.1074/jbc.270.40.23747; TUSZYNSKI GP, 1988, BLOOD, V72, P109; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; WOLFF R, 1986, J BIOL CHEM, V261, P6840; ZHOU MJ, 1993, J EXP MED, V178, P1165, DOI 10.1084/jem.178.4.1165	45	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1323	1330		10.1074/jbc.272.2.1323	http://dx.doi.org/10.1074/jbc.272.2.1323			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995439	hybrid			2022-12-25	WOS:A1997WC04800090
J	Kirley, TL				Kirley, TL			Complementary DNA cloning and sequencing of the chicken muscle Ecto-ATPase - Homology with the lymphoid cell activation antigen CD39	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIZZARD SMOOTH-MUSCLE; MG-ATPASE; POLYVINYLIDENE DIFLUORIDE; SKELETAL-MUSCLE; ENZYMATIC DIGESTION; TOXOPLASMA-GONDII; ADHESION MOLECULE; SEARCH TOOL; PROTEINS; GLYCOPROTEIN	The ecto ATPase from chicken gizzard (smooth muscle) was solubilized, and the 66-kDa cell membrane ecto-ATPase protein was purified, The protein was then subjected to both enzymatic and chemical cleavage, and the resultant peptides were purified by reverse phase high pressure liquid chromatography and sequenced, Several of these internal peptide sequences were used to design oligonucleotides to screen a chicken muscle library to identify the cDNA encoding the ecto-ATPase. Two overlapping partial clones were sequenced, yielding the complete coding region and a long 3'-untranslated sequence, The deduced amino acid sequence is in agreement with the N-terminal and peptide sequences obtained from the purified protein, The chicken muscle ecto-ATPase is a slightly basic (predicted pI = 7.93) 494-amino acid protein (54.4 kDa), containing a single transmembrane domain at each end of the protein. The majority of the protein is predicted to be extracellular, making it a Type Ia plasma membrane protein, There are four putative N-glycosylation sites, a single potential cAMP/cGMP-dependent protein kinase phosphorylation site, as well as a single putative tyrosine kinase phosphorylation site, Analysis of the sequence using the BLAST programs demonstrated homology with other ecto-ATPases and ecto-apyrases, including those from the parasitic protozoan Toxoplasma gondii, potato tubers, and garden pea, as well as a guanosine diphosphohydrolase from yeast, However, the most striking homology observed was to the human and mouse lymphoid cell activation antigen 39 (CD39), a molecule now known to have apyrase activity, The chicken ecto-ATPase showed considerable amino acid sequence homology with CD39 over the entire length of the sequence, excluding about 30-40 amino acids at the extreme ends of the protein (which include the two membrane-spanning helices), The sequence homology between the gizzard ecto-ATPase and CD39 was confirmed by Western blots demonstrating immunocross-reactivity between mono- and polyclonal antibodies raised against the chicken ecto-ATPase and two commercially available monoclonal antibodies against the human CD39 protein, The results suggest that the muscle ecto ATPase may be involved in cell adhesion, since the highly homologous CD39 protein is involved in homotypic adhesion of activated B lymphocytes.			Kirley, TL (corresponding author), UNIV CINCINNATI,COLL MED,DEPT PHARMACOL & CELL BIOPHYS,231 BETHESDA AVE,CINCINNATI,OH 45267, USA.			Kirley, Terence/0000-0002-6211-1414	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038576, K04AR001841] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR38576, K04 AR01841] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASAI T, 1995, J BIOL CHEM, V270, P11391, DOI 10.1074/jbc.270.19.11391; BERMUDES D, 1994, J BIOL CHEM, V269, P29252; CHAMPAGNE DE, 1995, P NATL ACAD SCI USA, V92, P694, DOI 10.1073/pnas.92.3.694; CUNNINGHAM HB, 1993, ARCH BIOCHEM BIOPHYS, V303, P32, DOI 10.1006/abbi.1993.1252; DZHANDZHUGAZYAN K, 1993, FEBS LETT, V336, P279, DOI 10.1016/0014-5793(93)80820-K; FERNANDEZ J, 1994, ANAL BIOCHEM, V218, P112, DOI 10.1006/abio.1994.1148; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; Handa M, 1996, BIOCHEM BIOPH RES CO, V218, P916, DOI 10.1006/bbrc.1996.0162; KANSAS GS, 1991, J IMMUNOL, V146, P2235; KIRLEY TL, 1984, BIOCHEM BIOPH RES CO, V125, P767, DOI 10.1016/0006-291X(84)90605-3; KITTEL A, 1994, CELL BIOL INT, V18, P875, DOI 10.1006/cbir.1994.1124; KNOWLES AF, 1995, BIOCHEM BIOPH RES CO, V207, P529, DOI 10.1006/bbrc.1995.1220; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SH, 1989, J BIOL CHEM, V264, P14408; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOULTON MP, 1986, J BIOL CHEM, V261, P2244; PLESNER L, 1995, INT REV CYTOL, V158, P141; Robson SC, 1996, TRANSPLANT P, V28, P536; SABORIDO A, 1991, J BIOL CHEM, V266, P23490; Stout JG, 1995, BIOCHEM MOL BIOL INT, V36, P927; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; Stout JG, 1996, BIOCHEMISTRY-US, V35, P8289, DOI 10.1021/bi960563g; STOUT JG, 1995, J BIOL CHEM, V270, P11845, DOI 10.1074/jbc.270.20.11845; STOUT JG, 1994, BIOCHEM MOL BIOL INT, V33, P1091; STOUT JG, 1994, BIOCHEM MOL BIOL INT, V32, P745; STROBEL R, 1993, ANN NY ACAD SCI, V671, P487; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang TF, 1996, J BIOL CHEM, V271, P9898, DOI 10.1074/jbc.271.17.9898; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	32	111	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1076	1081		10.1074/jbc.272.2.1076	http://dx.doi.org/10.1074/jbc.272.2.1076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995405	hybrid			2022-12-25	WOS:A1997WC04800056
J	Tauchi, T; Miyazawa, K; Feng, GS; Broxmeyer, HE; Toyama, K				Tauchi, T; Miyazawa, K; Feng, GS; Broxmeyer, HE; Toyama, K			A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE-ACTIVITY; PHOSPHOTYROSINE PHOSPHATASE; PHILADELPHIA-CHROMOSOME; C-ABL; TRANSFORMATION; RAS; ONCOGENE; CELLS; ACTIVATION	BCR-ABL is a chimeric oncoprotein that exhibits deregulated tyrosine kinase activity and is implicated in the pathogenesis of Philadelphia chromosome (Phl)positive leukemia, We have previously shown SH2-containing phosphotyrosine phosphatase SHP-2 forms stable complexes with BCR-ABL and Grb2 in BCR-ABL-transformed cells (Tauchi, T., Feng, G. S., Shen, R., Song, H. Y., Donner, D., Pawson, T., and Broxmeyer, H. E. (1994) J. Biol, Chem, 269, 15381-15387), To elucidate the structural requirement of BCR-ABL for the interactions with SH2-containing signaling molecules, we examined a series of BCR-ABL mutants which include the Grb2 binding site-deleted BCR-ABL (1-63 BCR/ABL), the tetramerization domain deleted BCR-ABL (64-509 BCR/ABL), and the SH2 domain-deleted BCR-ABL (BCR/ABL Delta SH2). These BCR-ABL mutants were previously shown to reduce the transforming activity in fibroblasts, We found that the tetramerization domain-deleted BCR-ABL did not induce the tyrosine phosphorylation of SHP-2 and the interactions of BCR-ABL, SHP-2, and Grb2. In vitro kinase assays have also shown that the tetramerization domain-deleted BCR-ABL mutant did not phosphorylate GST-SHP-2 in vitro, SHP-2 was co immunoprecipitated with phosphatidylinositol 3-kinase in BCR/ABL p210-transformed cells; however, this interaction was not observed in the tetramerization domain-deleted BCR-ABL mutant, Therefore the tetramerization domain of BCR ABL is essential for interactions of these downstream molecules.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT BIOCHEM & MOL BIOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,DEPT MICROBIOL & IMMUNOL,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Tauchi, T (corresponding author), TOKYO MED COLL,DEPT INTERNAL MED 1,SHINJUKU KU,6-7-1 NISHISHINJUKU,TOKYO 160,JAPAN.				NCI NIH HHS [R37 CA36464] Funding Source: Medline; NHLBI NIH HHS [R01 HL46549, R01 HL54037] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036464] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054037, R01HL046549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; FEINSTEIN E, 1991, ONCOGENE, V4, P1477; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HEITERKAMP N, 1985, NATURE, V315, P758; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MANDANAS RA, 1993, BLOOD, V82, P1838; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MCWIRTER JR, 1993, EMBO J, V12, P1533; MCWIRTER JR, 1991, MOL CELL BIOL, V11, P1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TAUCHI T, 1995, INT J HEMATOL, V61, P105; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	28	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1389	1394		10.1074/jbc.272.2.1389	http://dx.doi.org/10.1074/jbc.272.2.1389			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995449	hybrid			2022-12-25	WOS:A1997WC04800100
J	Wilson, BA; Zhu, XJ; Ho, MF; Lu, L				Wilson, BA; Zhu, XJ; Ho, MF; Lu, L			Pasteurella multocida toxin activates the inositol triphosphate signaling pathway in Xenopus oocytes via G(q)alpha-coupled phospholipase c-beta 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE HYDROLYSIS; THYROTROPIN-RELEASING-HORMONE; M1 MUSCARINIC RECEPTOR; G-PROTEINS STIMULATE; G-ALPHA-Q; POTENT MITOGEN; DERMONECROTIC TOXIN; ESCHERICHIA-COLI; BINDING PROTEINS	Pasteurella multocida toxin (PMT) has been hypothesized to cause activation of a GTP-binding protein (G-protein)-coupled phosphatidylinositol-specific phospholipase C (PLC) in intact cells. We used voltage-clamped Xenopus oocytes to test for direct PMT-mediated stimulation of PLC by monitoring the endogenous Ca2+-dependent Cl- current. Injection of PMT induced an inward, two component Cl- current, similar to that evoked by injection of IP3 through intracellular Ca2+ mobilization and Ca2+ influx through voltage-gated Ca2+ channels. These PMT-induced currents were blocked by specific inhibitors of Ca2+ and Cl- channels, removal of extracellular Ca2+, or chelation of intracellular Ca2+. Specific antibodies directed against an N-terminal, but not a C-terminal, peptide of PMT inhibited the toxin-induced currents, implicating that the N terminus of PMT is important for toxin activity. Injection with specific antibodies against PLC beta 1, PLC beta 2, PLC beta 3, or PLC beta 1 identified PLC beta 1 as the primary mediator of the PMT-induced Cl- currents. Injection with guanosine 5'-O-(2-(thio)diphosphate), antibodies to the common GTP-binding region of G-protein alpha subunits, or antibodies to different regions of G-protein beta subunits established the involvement of a G-protein alpha subunit in PMT-activation of PLC beta 1. Injection with specific antibodies against the cu-subunits of G(q/11), G(s/olf), G(i/o/t/z), or G(i-1/i-2/i-3) isoforms confirmed the involvement of G(q/11)alpha. Preinjection of oocytes with pertussis toxin enhanced the PMT response. Overexpression of G(q) alpha in oocytes could enhance the PMT response by 30-fold to more than 300-fold, whereas introduction of antisense G(q) alpha cRNA reduced the response by 7-fold. The effects of various specific antibodies on the PMT response were reproduced in oocytes overexpressing G(q) alpha.	WRIGHT STATE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,DAYTON,OH 45435	Wright State University Dayton	Wilson, BA (corresponding author), WRIGHT STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DAYTON,OH 45435, USA.		Ho, Mengfei/Q-6844-2019	Ho, Mengfei/0000-0002-8315-8158	NATIONAL EYE INSTITUTE [R01EY015281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038396, R01AI038396] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY015281] Funding Source: Medline; NIAID NIH HHS [R29 AI038396, AI38396] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI A, 1993, FEBS LETT, V315, P340, DOI 10.1016/0014-5793(93)81190-B; CHRISP CE, 1991, AM J VET RES, V52, P56; DASCAL N, 1985, J PHYSIOL-LONDON, V366, P299, DOI 10.1113/jphysiol.1985.sp015799; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DECKMYN H, 1993, NEWS PHYSIOL SCI, V8, P61; DELISLE S, 1991, CELL CALCIUM, V12, P217, DOI 10.1016/0143-4160(91)90022-7; DIETRICH A, 1994, EUR J BIOCHEM, V219, P171, DOI 10.1111/j.1432-1033.1994.tb19927.x; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; DOMINICK MA, 1988, VET PATHOL, V25, P17, DOI 10.1177/030098588802500103; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FAURE M, 1994, J BIOL CHEM, V269, P7851; FELIX R, 1992, INFECT IMMUN, V60, P4984, DOI 10.1128/IAI.60.12.4984-4988.1992; FOGED NT, 1992, APMIS, V100, P1; GILLO B, 1987, J PHYSIOL-LONDON, V392, P349, DOI 10.1113/jphysiol.1987.sp016784; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTTRIDGE KL, 1995, P NATL ACAD SCI USA, V92, P1297, DOI 10.1073/pnas.92.5.1297; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; HUFF RM, 1986, J BIOL CHEM, V261, P1105; JHON DY, 1993, J BIOL CHEM, V268, P6654; KAMP EM, 1988, AM J VET RES, V49, P1844; KATZ A, 1995, P NATL ACAD SCI USA, V92, P1998, DOI 10.1073/pnas.92.6.1998; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; LIPINSKY D, 1992, FEBS LETT, V307, P237, DOI 10.1016/0014-5793(92)80775-C; LU L, 1991, Cellular Physiology and Biochemistry, V1, P251, DOI 10.1159/000154613; MARTIN TFJ, 1991, BIOCHEM J, V280, P753, DOI 10.1042/bj2800753; Mullan PB, 1996, INFECT IMMUN, V64, P959, DOI 10.1128/IAI.64.3.959-965.1996; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; NEER EJ, 1994, PROTEIN SCI, V3, P3; OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814; PARK DG, 1993, J BIOL CHEM, V268, P4573; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER I, 1986, PROC R SOC SER B-BIO, V228, P307, DOI 10.1098/rspb.1986.0057; PARKER I, 1987, PROC R SOC SER B-BIO, V231, P27, DOI 10.1098/rspb.1987.0033; PETTIT RK, 1993, LAB INVEST, V69, P94; QUICK MW, 1994, J BIOL CHEM, V269, P30164; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; ROSS EM, 1993, LIFE SCI, V52, P413, DOI 10.1016/0024-3205(93)90296-F; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; SCHNABEL P, 1993, EUR J BIOCHEM, V217, P1109, DOI 10.1111/j.1432-1033.1993.tb18343.x; SHAW K, 1992, BIOCHEMISTRY-US, V31, P6347, DOI 10.1021/bi00142a026; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STADDON JM, 1992, J BIOL CHEM, V267, P25239; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; TAKAI Y, 1995, TRENDS BIOL SCI, V20, P217; TAYLOR SJ, 1991, FEBS LETT, V286, P214, DOI 10.1016/0014-5793(91)80976-A; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	64	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1268	1275		10.1074/jbc.272.2.1268	http://dx.doi.org/10.1074/jbc.272.2.1268			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995431	hybrid			2022-12-25	WOS:A1997WC04800082
J	Ancsin, JB; Kisilevsky, R				Ancsin, JB; Kisilevsky, R			Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COMPONENTS; HEPARAN-SULFATE PROTEOGLYCAN; HIGH-DENSITY LIPOPROTEIN; A GENE-EXPRESSION; COLLAGEN TYPE-IV; ALZHEIMERS-DISEASE; STRUCTURAL CHARACTERIZATION; TRANSCRIPTIONAL REGULATION; EXTRACELLULAR-MATRIX; MULTIDOMAIN PROTEIN	Serum amyloid A isoforms, apoSAA1 and apoSAA2, are acute-phase proteins of unknown function and can be precursors of amyloid AA peptides (AA) found in animal and human amyloid deposits. These deposits are often a complication of chronic inflammatory disorders and are associated with a local disturbance in basement membrane (BM). In the course of trying to understand the pathogenesis of this disease laminin, a major BM glycoprotein, has been discovered to bind saturably, and with high affinity to murine acute-phase apoSAA. This interaction involves a single class of binding sites, which are ionic in nature, conformation-dependent, and possibly involve sulfhydryls. Binding activity was significantly enhanced by Zn2+, an effect possibly mediated through Cys-rich zinc finger-like sequences on laminin. Collagen type TV also bound apoSAA but with lower affinity. Unexpectedly, no binding was detected for perlecan, a BM proteoglycan previously implicated in AA fibrillogenesis, although a low affinity interaction cannot be excluded. Entactin, another BM protein that functions to cross-link the BM matrix and is normally complexed with laminin, could inhibit laminin-apoSAA binding suggesting apoSAA does not bind to normal BM. Since laminin binds apoSAA with high affinity and has previously been shown to codeposit with AA amyloid fibrils, we postulate that laminin interacts with apoSAA and facilitates nucleation events leading to fibrillogenesis. This work also provides further support for the hypothesis that a disturbance in BM metabolism contributes to the genesis of amyloid. The specificity and avidity of the laminin-apoSAA interaction also implies that it may be a normal event occurring during the inflammatory process, which mediates one or more of the functions recently proposed for apoSAA.	QUEENS UNIV,KINGSTON GEN HOSP,SYL & MOLLY APPS RES CTR,DEPT PATHOL,KINGSTON,ON K7L 3N6,CANADA	Queens University - Canada								AILLES L, 1993, LAB INVEST, V69, P443; Ancsin JB, 1996, J BIOL CHEM, V271, P6845, DOI 10.1074/jbc.271.12.6845; AUMAILLEY M, 1989, EUR J BIOCHEM, V184, P241, DOI 10.1111/j.1432-1033.1989.tb15013.x; AUMAILLEY M, 1994, KIDNEY INT, V47, P4; AXELRAD MA, 1982, LAB INVEST, V47, P139; BADOLATO R, 1994, J EXP MED, V180, P203, DOI 10.1084/jem.180.1.203; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; BENDITT EP, 1979, P NATL ACAD SCI USA, V76, P4092, DOI 10.1073/pnas.76.8.4092; BENDITT EP, 1977, P NATL ACAD SCI USA, V74, P4025, DOI 10.1073/pnas.74.9.4025; BENSON MD, 1979, J IMMUNOL, V122, P2077; BERG JM, 1990, J BIOL CHEM, V265, P6513; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; CARLIN B, 1981, J BIOL CHEM, V256, P5209; CHUNG AE, 1993, KIDNEY INT, V43, P13, DOI 10.1038/ki.1993.4; COETZEE GA, 1986, J BIOL CHEM, V261, P9644; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; DAVIDSON JM, 1992, INFLAMMATION BASIC P, P809; DEBEER MC, 1993, J BIOL CHEM, V268, P20606; DZIADEK M, 1989, AM J ANAT, V184, P298, DOI 10.1002/aja.1001840405; DZIADEK M, 1995, EXPERIENTIA, V51, P901, DOI 10.1007/BF01921740; DZIADEK M, 1985, EMBO J, V4, P2513, DOI 10.1002/j.1460-2075.1985.tb03964.x; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; ENGEL J, 1981, J MOL BIOL, V150, P97, DOI 10.1016/0022-2836(81)90326-0; FOX JW, 1991, EMBO J, V10, P3137, DOI 10.1002/j.1460-2075.1991.tb04875.x; FRASER PE, 1992, J NEUROCHEM, V59, P1531, DOI 10.1111/j.1471-4159.1992.tb08470.x; GOLDBERGER G, 1987, J IMMUNOL, V138, P3967; GOLDSMITH MR, 1979, ANAL BIOCHEM, V99, P33, DOI 10.1016/0003-2697(79)90041-1; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HOFFMAN JS, 1982, J BIOL CHEM, V257, P510; HORIGUCHI Y, 1992, J INVEST DERMATOL, V99, P12, DOI 10.1111/1523-1747.ep12611384; HUANG JH, 1990, MOL CELL BIOL, V10, P3619, DOI 10.1128/MCB.10.7.3619; HUSBY G, 1994, AMYLOID, V1, P119, DOI 10.3109/13506129409148635; HUSBY G, 1973, NATURE, V244, P362, DOI 10.1038/244362a0; KISILEVSKY R, 1989, NEUROBIOL AGING, V10, P499, DOI 10.1016/0197-4580(89)90109-7; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; KISILEVSKY R, 1994, BAILLIERE CLIN RHEUM, V8, P613, DOI 10.1016/S0950-3579(05)80118-9; KISILEVSKY R, 1992, LAB INVEST, V66, P778; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; LEVARTOWSKY D, 1991, AMYLOID AND AMYLOIDOSIS 1990, P129; LEVIN M, 1973, J EXP MED, V138, P373, DOI 10.1084/jem.138.2.373; LI X, 1992, NUCLEIC ACIDS RES, V20, P4765, DOI 10.1093/nar/20.18.4765; LINKE RP, 1991, BIOCHEM BIOPH RES CO, V176, P1100, DOI 10.1016/0006-291X(91)90397-P; LOWELL CA, 1986, J BIOL CHEM, V261, P8453; LYON AW, 1991, LAB INVEST, V64, P785; MANN K, 1989, EMBO J, V8, P65, DOI 10.1002/j.1460-2075.1989.tb03349.x; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MCADAM KPWJ, 1976, J EXP MED, V144, P1121, DOI 10.1084/jem.144.4.1121; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; NARINDRASORASAK S, 1992, LAB INVEST, V67, P643; NARINDRASORASAK S, 1991, J BIOL CHEM, V266, P12878; NEL AE, 1988, BIOCHEM J, V255, P29, DOI 10.1042/bj2550029; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; PAULSSON M, 1988, J BIOL CHEM, V263, P5425; PAULSSON M, 1987, EUR J BIOCHEM, V166, P11, DOI 10.1111/j.1432-1033.1987.tb13476.x; PAULSSON M, 1986, EUR J BIOCHEM, V156, P467, DOI 10.1111/j.1432-1033.1986.tb09605.x; PERLMUTTER LS, 1991, J NEUROSCI RES, V30, P673, DOI 10.1002/jnr.490300411; PHILLIPS DR, 1988, BLOOD, V71, P831; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; PRECIADOPATT L, 1994, EUR J BIOCHEM, V223, P35, DOI 10.1111/j.1432-1033.1994.tb18963.x; PRUZANSKI W, 1995, BIOCHEM J, V309, P461, DOI 10.1042/bj3090461; SASAKI M, 1987, J BIOL CHEM, V262, P17111; SASAKI M, 1987, P NATL ACAD SCI USA, V84, P935, DOI 10.1073/pnas.84.4.935; SASAKI M, 1988, J BIOL CHEM, V263, P16536; SCHULTZ R T, 1985, American Journal of Pathology, V119, P127; SHAINKINKESTENBAUM R, 1991, SCAND J IMMUNOL, V34, P179, DOI 10.1111/j.1365-3083.1991.tb01535.x; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SKINNER M, 1983, PREP BIOCHEM, V12, P461; SNOW AD, 1991, J HISTOCHEM CYTOCHEM, V39, P1321, DOI 10.1177/39.10.1940305; SNOW AD, 1985, LAB INVEST, V53, P37; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; TURNELL W, 1986, MOL BIOL MED, V3, P387; UHLAR CM, 1994, GENOMICS, V19, P228, DOI 10.1006/geno.1994.1052; WESTERMARK GT, 1992, BIOCHEM BIOPH RES CO, V182, P27, DOI 10.1016/S0006-291X(05)80107-X; WOODROW SI, 1994, AMYLOID AMYLOIDOSIS, P195; WU CY, 1988, BIOCHEMISTRY-US, V27, P8780, DOI 10.1021/bi00424a014; XU LL, 1995, J IMMUNOL, V155, P1184; YAMAGUCHI H, 1992, AM J PATHOL, V141, P249; YAMAMOTO K, 1985, P NATL ACAD SCI USA, V82, P2915, DOI 10.1073/pnas.82.9.2915; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; YURCHENCO PD, 1990, J BIOL CHEM, V265, P3981; YURCHENCO PD, 1992, J CELL BIOL, V117, P1119, DOI 10.1083/jcb.117.5.1119; ZIMLICHMAN S, 1990, J LAB CLIN MED, V116, P180	87	34	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					406	413						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995276				2022-12-25	WOS:A1997WA56400063
J	Liu, YC; Elly, C; Langdon, WY; Altman, A				Liu, YC; Elly, C; Langdon, WY; Altman, A			Ras-dependent, Ca2+-stimulated activation of nuclear factor of activated T cells by a constitutively active Cbl mutant in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-CBL; PROTEIN PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGEN RECEPTOR; TYROSINE PHOSPHORYLATION; SH3 DOMAIN; INTERLEUKIN-2 PROMOTER; SENSITIVE ACTIVATION; SIGNAL-TRANSDUCTION; EGF STIMULATION	T cell receptor (TCR) stimulation induces rapid tyrosine phosphorylation of cellular proteins, including Cbl, a protooncogene product whose function remains unclear. As a first step toward elucidating the function of Cbl in TCR-initiated signaling, we evaluated the ability of wild-type Cbl or a transforming Cbl mutant (70Z/3) to induce transcriptional activation of a nuclear factor of activated T cells (NFAT) element derived from the interleukin 2 (IL2) promoter in transiently cotransfected Jurkat-TAg T cells. 70Z/3, but not Cbl, caused NFAT activation which was significantly enhanced by stimulation with calcium ionophore, and was drastically reduced by cyclosporin A pretreatment. A point mutation of a potential phosphatidylinositol 3-kinase (PI3-K) binding site (Y(731)EAM to Y(731)EAC) in 70Z/3 disrupted the association of PI3-K with 70Z/3, but did not reduce the induction of NFAT activity, suggesting that the interaction between Cbl and PI3-K is not required in the 70Z/3 mediated induction of NFAT. Additional mapping studies indicated that defined deletions of C-terminal 70Z/3 sequences affected to a variable degree its ability to stimulate NFAT activity. Strikingly, deletion of 346 C-terminal residues augmented this activity, whereas removal of 20 additional residues abolished it. Coexpression of dominant negative Ras abrogated the basal or ionomycin stimulated, 70Z/3-mediated NFAT activation, suggesting a functional Ras is required for this activation. These results implicate Cbl in Ras-dependent signaling pathways which lead to NFAT activation.	LA JOLLA INST ALLERGY & IMMUNOL, DIV CELL BIOL, SAN DIEGO, CA 92121 USA; UNIV WESTERN AUSTRALIA, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA	La Jolla Institute for Immunology; University of Western Australia				LIU, YUN-CAI/0000-0002-0996-7109				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LIU YC, 1993, P NATL ACAD SCI USA, V90, P8957, DOI 10.1073/pnas.90.19.8957; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSTELIN T, 1994, IMMUNITY, V1, P351, DOI 10.1016/1074-7613(94)90065-5; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; WOODROW MA, 1993, J IMMUNOL, V150, P3853; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					168	173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995243				2022-12-25	WOS:A1997WA56400030
J	Ma, JY; Qian, R; Rausa, FM; Colley, KJ				Ma, JY; Qian, R; Rausa, FM; Colley, KJ			Two naturally occurring alpha 2,6-sialyltransferase forms with a single amino acid change in the catalytic domain differ in their catalytic activity and proteolytic processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; NH2-TERMINAL SIGNAL ANCHOR; TISSUE-SPECIFIC EXPRESSION; WHEAT-GERM AGGLUTININ; DARBY CANINE KIDNEY; HAMSTER OVARY CELLS; GOLGI-APPARATUS; TERMINAL GLYCOSYLATION; SIALIC-ACID; LINKED OLIGOSACCHARIDES	The alpha 2,6-sialyltransferase (ST) is a Golgi glycosyltransferase that adds sialic acid residues to glycoprotein N-linked oligosaccharides. Here we show that two forms of alpha 2,6-sialyltransferase are expressed by the liver and are encoded by two different RNAs that differ by a single nucleotide, The ST tyr possesses a Tyr at amino acid 123, whereas the ST cys possesses a Cys at this position. The ST tyr is more catalytically active than the ST cys; however, both are functional when introduced into tissue culture cells, The proteolytic processing and turnover of the ST tyr and ST cys proteins differ dramatically, The ST cys is retained intact in COS-1 cells, whereas the ST tyr is rapidly cleaved and secreted, Analysis of the N-linked oligosaccharides of these proteins demonstrates that both proteins enter the late Golgi. However, differences in ST tyr and ST cys proteolytic processing may be related to differences in their localization, because ST tyr but not ST cys is expressed at low levels on the cell surface, The possibility that the ST tyr is cleaved in a post-Golgi compartment is supported by the observation that a 20 degrees C temperature block, which stops protein transport in the trans Golgi network, blocks both cleavage and secretion of the ST tyr.	UNIV ILLINOIS,COLL MED,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Qian, Rui/GQB-5129-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048134, R01GM048134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE M, 1995, HYPERTENSION, V26, P891, DOI 10.1161/01.HYP.26.6.891; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARTHOLOMEW BA, 1973, J BIOL CHEM, V248, P5751; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; BERGER EG, 1981, J HISTOCHEM CYTOCHEM, V29, P364, DOI 10.1177/29.3.6787115; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; COLLEY KJ, 1997, IN PRESS GLYCOBIOLOG; DAGOSTARO G, 1989, EUR J BIOCHEM, V183, P211, DOI 10.1111/j.1432-1033.1989.tb14915.x; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; DENNIS JW, 1987, CANCER METAST REV, V5, P185, DOI 10.1007/BF00046998; DIMENT S, 1988, J BIOL CHEM, V263, P6901; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ERIKSON AH, 1989, J CELL BIOCHEM, V40, P117; FULLER SD, 1985, EMBO J, V4, P297, DOI 10.1002/j.1460-2075.1985.tb03629.x; GLEESON PA, 1994, GLYCOCONJUGATE J, V11, P381, DOI 10.1007/BF00731273; GOLDSTEIN IJ, 1975, BIOCHIM BIOPHYS ACTA, V405, P53, DOI 10.1016/0005-2795(75)90313-X; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HATHAWAY H J, 1991, Glycobiology, V1, P211, DOI 10.1093/glycob/1.2.211; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOMA FL, 1993, J BIOL CHEM, V268, P12609; HUDGIN RL, 1971, CAN J BIOCHEM CELL B, V49, P829, DOI 10.1139/o71-117; IGLESIAS JL, 1982, EUR J BIOCHEM, V123, P247, DOI 10.1111/j.1432-1033.1982.tb19760.x; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KELM S, 1996, GLYCOCONJUGATE J, V13, P1; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAMMERS G, 1988, BIOCHEM J, V256, P623, DOI 10.1042/bj2560623; LARSEN RD, 1989, P NATL ACAD SCI USA, V86, P8227, DOI 10.1073/pnas.86.21.8227; LEE EU, 1989, J BIOL CHEM, V264, P13848; LOW SH, 1994, J BIOL CHEM, V269, P1985; Ma JY, 1996, J BIOL CHEM, V271, P7758, DOI 10.1074/jbc.271.13.7758; MATLIN KS, 1983, CELL, V34, P233, DOI 10.1016/0092-8674(83)90154-X; MAYORGA LS, 1989, J BIOL CHEM, V264, P5392; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MILLER RL, 1987, METHOD ENZYMOL, V138, P527; MURESAN V, 1982, J HISTOCHEM CYTOCHEM, V30, P938, DOI 10.1177/30.9.6897073; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAULSON JC, 1977, J BIOL CHEM, V252, P2356; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; PETERS BP, 1979, BIOCHEMISTRY-US, V18, P5505, DOI 10.1021/bi00591a038; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RATNAM S, 1981, BIOCHIM BIOPHYS ACTA, V673, P435, DOI 10.1016/0304-4165(81)90475-X; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1988, EUR J CELL BIOL, V46, P105; ROTH J, 1982, J CELL BIOL, V92, P223; RUSSO RN, 1992, J BIOL CHEM, V267, P9241; Sawyer W H, 1976, Eur J Immunol, V5, P507; SCHNEIKERT J, 1995, J BIOL CHEM, V270, P17736, DOI 10.1074/jbc.270.30.17736; SCOTT J, 1995, CELL, V81, P833, DOI 10.1016/0092-8674(95)90002-0; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SMITH PL, 1994, J BIOL CHEM, V269, P15162; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; STROUS GJAM, 1982, J BIOL CHEM, V257, P7623; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAATJES DJ, 1988, J BIOL CHEM, V263, P6302; TARENTINO AL, 1974, J BIOL CHEM, V249, P818; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	73	60	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					672	679						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995311				2022-12-25	WOS:A1997WA56400098
J	Misra, UK; GonzalezGronow, M; Gawdi, G; Pizzo, SV				Misra, UK; GonzalezGronow, M; Gawdi, G; Pizzo, SV			Up-regulation of the alpha(2)-macroglobulin signaling receptor on rheumatoid synovial fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; MURINE PERITONEAL-MACROPHAGES; INTRACELLULAR CALCIUM; ALPHA-2-MACROGLOBULIN RECEPTOR; ALPHA(2)M RECEPTORS; FAST FORMS; THAPSIGARGIN; LIGATION; CELLS; ARTHRITIS	In the present study, we demonstrate that the alpha(2)-macroglobulin (alpha(2)M) signaling receptor is up-regulated on rheumatoid synovial fibroblasts. In rheumatoid cells, I-125-alpha(2)M-methylamine bound to two sites; namely, one of high affinity (K-d similar to 52 pM) and the second of lower affinity (K-d similar to 9.7 nM). In normal synovial fibroblasts only one site for I-125-alpha(2)M-methylamine (K-d similar to 5.36 nM) was present. Receptor-associated protein did not inhibit the binding of alpha(2)M-methylamine to the high affinity binding sites, but it caused a 70-80% reduction in its binding to low affinity binding sites establishing its identity as the low density lipoprotein receptor-related protein/alpha(2)M receptor. Binding of alpha(2)M-methylamine to rheumatoid but not normal synovial fibroblasts caused a rapid rise in inositol 1,4,5-trisphosphate synthesis with a peak reached within 10 s of ligand exposure. Concomitantly, rheumatoid but not normal cells showed a rise in intracellular Ca2+. Pretreatment of rheumatoid cells with Receptor-associated protein or pertussis toxin did not affect the alpha(2)M-methylamine-induced increase in intracellular Ca2+. These are characteristic properties of ligation by alpha(2)M-methylamine of the alpha(2)M signaling receptor but not the lipoprotein receptor-related protein/alpha(2)M receptor. Binding of alpha(2)M-methylamine to rheumatoid synovial fibroblasts significantly increased the synthesis of DNA compared with normal synovial fibroblasts treated similarly.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University					NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29589] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABE S, 1973, J BIOCHEM-TOKYO, V73, P897, DOI 10.1093/oxfordjournals.jbchem.a130153; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BROMMER EJP, 1992, ANN RHEUM DIS, V51, P965, DOI 10.1136/ard.51.8.965; CHARLESWORTH A, 1994, J BIOL CHEM, V269, P32528; CHU CT, 1994, LAB INVEST, V71, P792; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1400; GONZALEZGRONOW M, 1994, J BIOL CHEM, V269, P4360; GONZALEZGRONOW M, 1993, J BIOL CHEM, V268, P20791; HOFFMAN M, 1988, AGENTS ACTIONS, V25, P360, DOI 10.1007/BF01965043; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; KUMMER JA, 1992, ARTHRITIS RHEUM, V35, P884; LEE KM, 1993, J BIOL CHEM, V268, P9945; MCDONALD JA, 1986, J CLIN INVEST, V78, P1237, DOI 10.1172/JCI112707; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; MISRA UK, 1994, ANN NY ACAD SCI, V737, P486, DOI 10.1111/j.1749-6632.1994.tb44347.x; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; Misra UK, 1996, J CELL BIOCHEM, V61, P39, DOI 10.1002/(SICI)1097-4644(19960401)61:1<39::AID-JCB6>3.3.CO;2-8; NEWCOMB TG, 1993, CELL CALCIUM, V14, P539, DOI 10.1016/0143-4160(93)90075-H; PRESCOTT SM, 1990, J BIOL CHEM, V265, P17381; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; SALVESEN G, 1993, HEMOSTASIS THROMBOSE, P241; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SNYDER F, 1995, BIOCHEM J, V305, P689, DOI 10.1042/bj3050689; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; UHING RJ, 1991, BIOCHIM BIOPHYS ACTA, V1093, P115, DOI 10.1016/0167-4889(91)90111-A; VENABLE ME, 1993, J LIPID RES, V34, P691; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; WEINBERG JB, 1993, CLIN HEMATOLOGY, P267; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	38	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					497	502						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995289				2022-12-25	WOS:A1997WA56400076
J	Lalowski, M; Golabek, A; Lemere, CA; Selkoe, DJ; Wisniewski, HM; Beavis, RC; Frangione, B; Wisniewski, T				Lalowski, M; Golabek, A; Lemere, CA; Selkoe, DJ; Wisniewski, HM; Beavis, RC; Frangione, B; Wisniewski, T			The ''nonamyloidogenic'' p3 fragment (amyloid beta 17-42) is a major constituent of Down's syndrome cerebellar preamyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMER-TYPE DEMENTIA; BETA-PROTEIN; APOLIPOPROTEIN-E; SENILE PLAQUES; A-BETA; FIBRIL FORMATION; SYNDROME BRAIN; IN-VITRO; NEUROFIBRILLARY TANGLES; CEREBROSPINAL-FLUID	Down's syndrome (DS) patients show accelerated Alzheimer's disease (AD) neuropathology, which consists of preamyloid lesions followed by the development of neuritic plaques and neurofibrillary tangles. The major constituents of preamyloid and neuritic plaques are amyloid beta (A beta) peptides. Preamyloid lesions are defined as being A beta immunoreactive lesions, which unlike neuritic plaque amyloid are Congo red-negative and largely nonfibrillar ultrastructurally. DS patients can develop extensive preamyloid deposits in the cerebellum, without neuritic plaques; hence, DS cerebellums are a source of relatively pure preamyloid. We biochemically characterized the composition of DS preamyloid and compared it to amyloid in the neuritic plaques and leptomeninges in the same patients. We found that A beta 17-42 or p3 is a major A beta peptide of DS cerebellar preamyloid. This 26-residue peptide is also present in low quantities in neuritic plaques. We suggest that preamyloid can now be defined biochemically as lesions in which a major AP peptide is p3.	NYU, MED CTR, DEPT NEUROL, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, CTR NEUROL DIS, BOSTON, MA 02115 USA; NEW YORK STATE INST BASIC RES DEV DISABIL, STATEN ISL, NY 10314 USA	New York University; New York University; New York University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Institute for Basic Research in Developmental Disabilities			Lalowski, Maciej/AAB-4151-2019; Wisniewski, Thomas/Q-6525-2019	Lalowski, Maciej/0000-0002-3683-4096; Wisniewski, Thomas/0000-0002-3379-8966	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG005891, R01AG005891, R01AG008721] Funding Source: NIH RePORTER; NIA NIH HHS [AG05891, AG08721] Funding Source: Medline; NINDS NIH HHS [NS30455] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Beavis RC, 1996, J AM SOC MASS SPECTR, V7, P107, DOI 10.1016/1044-0305(95)00592-7; BUSH AI, 1994, SCIENCE, V265, P1464, DOI 10.1126/science.8073293; Castano EM, 1996, J BIOL CHEM, V271, P32185, DOI 10.1074/jbc.271.50.32185; CHECLER F, 1995, J NEUROCHEM, V65, P1431; CLEMENTS A, 1993, NEUROSCI LETT, V161, P17, DOI 10.1016/0304-3940(93)90129-9; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; CRYSTAL HA, 1993, ANN NEUROL, V34, P566, DOI 10.1002/ana.410340410; CUMMINGS BJ, 1993, NEUROBIOL AGING, V14, P547, DOI 10.1016/0197-4580(93)90038-D; DAVIES L, 1988, NEUROLOGY, V38, P1688, DOI 10.1212/WNL.38.11.1688; DELAERE P, 1990, NEUROSCI LETT, V116, P87, DOI 10.1016/0304-3940(90)90391-L; DYRKS T, 1992, J BIOL CHEM, V267, P18210; EVANS KC, 1995, P NATL ACAD SCI USA, V92, P763, DOI 10.1073/pnas.92.3.763; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOREVIC PD, 1986, J NEUROPATH EXP NEUR, V45, P647, DOI 10.1097/00005072-198611000-00004; GOWING E, 1994, J BIOL CHEM, V269, P10987; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Higgins LS, 1996, AM J PATHOL, V149, P585; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; HILBICH C, 1992, J MOL BIOL, V228, P1; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1988, BRAIN RES, V474, P100, DOI 10.1016/0006-8993(88)90673-7; KIDA E, 1995, BRAIN RES, V685, P211, DOI 10.1016/0006-8993(95)00482-6; KIDA E, 1995, NEUROSCI LETT, V193, P105, DOI 10.1016/0304-3940(95)11678-P; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; Lemere CA, 1996, NEUROBIOL DIS, V3, P16, DOI 10.1006/nbdi.1996.0003; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Mann DMA, 1996, AM J PATHOL, V148, P1257; MANN DMA, 1989, NEUROBIOL AGING, V10, P397, DOI 10.1016/0197-4580(89)90073-0; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MILLER DL, 1993, ARCH BIOCHEM BIOPHYS, V301, P41, DOI 10.1006/abbi.1993.1112; MORI H, 1992, J BIOL CHEM, V267, P17082; Morris JC, 1996, NEUROLOGY, V46, P707, DOI 10.1212/WNL.46.3.707; MOTTE J, 1989, ACTA NEUROPATHOL, V77, P535, DOI 10.1007/BF00687256; NAIKI H, 1991, LAB INVEST, V65, P104; NASLUND J, 1995, NEURON, V15, P219, DOI 10.1016/0896-6273(95)90079-9; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; PRELLI F, 1988, J NEUROCHEM, V51, P648, DOI 10.1111/j.1471-4159.1988.tb01087.x; ROHER AE, 1993, P NATL ACAD SCI USA, V90, P10836, DOI 10.1073/pnas.90.22.10836; ROHER AE, 1993, J BIOL CHEM, V268, P3072; SAIDO TC, 1995, NEURON, V14, P457, DOI 10.1016/0896-6273(95)90301-1; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1986, J NEUROCHEM, V46, P1820; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SNOW AD, 1987, LAB INVEST, V56, P120; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; TABATON M, 1994, BIOCHEM BIOPH RES CO, V200, P1598, DOI 10.1006/bbrc.1994.1634; TAGLIAVINI F, 1988, NEUROSCI LETT, V93, P191, DOI 10.1016/0304-3940(88)90080-8; Teller JK, 1996, NAT MED, V2, P93, DOI 10.1038/nm0196-93; TIMMERS WF, 1990, NEUROSCI LETT, V118, P223, DOI 10.1016/0304-3940(90)90632-J; Tjernberg LO, 1996, J BIOL CHEM, V271, P8545, DOI 10.1074/jbc.271.15.8545; TOMIYAMA T, 1994, J BIOL CHEM, V269, P10205; UEDA K, 1994, BRAIN RES, V639, P240, DOI 10.1016/0006-8993(94)91736-1; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; WISNIEWSKI HM, 1994, DEV BRAIN DYSFUNCT, V7, P330; Wisniewski HM, 1996, NEUROPATH APPL NEURO, V22, P3, DOI 10.1046/j.1365-2990.1996.1698016.x; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P337, DOI 10.1007/BF00688170; WISNIEWSKI HM, 1990, KEY TOP BRAIN RES, P151; WISNIEWSKI T, 1995, LANCET, V345, P956, DOI 10.1016/S0140-6736(95)90701-7; WISNIEWSKI T, 1995, LANCET, V346, P1366, DOI 10.1016/S0140-6736(95)92379-9; Wisniewski T, 1996, BIOCHEM J, V313, P575, DOI 10.1042/bj3130575; Wisniewski T, 1996, ACTA NEUROBIOL EXP, V56, P267; WISNIEWSKI T, 1994, NEUROBIOL AGING, V15, P143, DOI 10.1016/0197-4580(94)90105-8; WISNIEWSKI T, 1991, BIOCHEM BIOPH RES CO, V179, P1247, DOI 10.1016/0006-291X(91)91706-I; WISNIEWSKI T, 1994, AM J PATHOL, V145, P1030; Wisniewski T, 1996, NEUROREPORT, V7, P667, DOI 10.1097/00001756-199601310-00068; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YAMAGUCHI H, 1991, ACTA NEUROPATHOL, V82, P13, DOI 10.1007/BF00310918; YAMAGUCHI H, 1995, AMYLOID, V2, P7, DOI 10.3109/13506129509031882; YAMAZAKI T, 1991, ACTA NEUROPATHOL, V81, P540, DOI 10.1007/BF00310135; YANG FS, 1994, NEUROREPORT, V5, P2117, DOI 10.1097/00001756-199410270-00032; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	86	112	116	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33623	33631		10.1074/jbc.271.52.33623	http://dx.doi.org/10.1074/jbc.271.52.33623			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969231	hybrid			2022-12-25	WOS:A1996WA71300065
J	AbuSoud, HM; Rousseau, DL; Stuehr, DJ				AbuSoud, HM; Rousseau, DL; Stuehr, DJ			Nitric oxide binding to the heme of neuronal nitric-oxide synthase links its activity to changes in oxygen tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SKELETAL-MUSCLE; CAROTID-BODY; NO	Neuronal nitric-oxide synthase (NOS-1) is a hemeprotein that generates NO and citrulline from L-arginine, O-2, and NADPH. During catalysis, a majority of NOS-1 binds self-generated NO and converts to a ferrous-NO complex, which causes it to operate at a fraction of its maximum possible activity during the steady state (Abu-Soud, H, M,, Wang, J,, Rousseau, D, L,, Fukuto, J,, Ignarro, L, J., and Stuehr, D, J, (1995) J. Biol, Chem, 270, 22997-23006), To examine how NO complex formation affects the O-2 response of NOS-1, me measured rates of NO synthesis and NADPH oxidation versus O-2 concentration in the presence and absence of L-arginine, In the absence of L-arginine, NOS-1 catalyzed simple O-2 reduction, and its heme iron displayed a typical affinity for O-2 (estimated K-m O-2 less than or equal to 40 mu M, saturation at similar to 100 mu M). In the presence of L-arginine, the rates of NO synthesis and NADPH oxidation were proportional to the O-2 concentration over a much broader range (estimated KmO2 similar to 400 mu M, saturation at similar to 800 mu M), indicating that ferrous-NO complex formation altered the O-2 response of NOS-1, Stopped-flow experiments revealed that the rate of ferrous-NO complex formation was relatively independent of the O-2 concentration between 100 and 700 mu M, while the rate of complex breakdown was directly proportional to O-2 concentration. We conclude that the O-2 sensitivity of the ferrous-NO complex governs the O-2 response of NOS-1 and thus its activity during the steady state, This enables NOS-1 to couple its rate of NO synthesis to the O-2 concentration throughout the physiologic range.	CLEVELAND CLIN FDN, RES INST, DEPT IMMUNOL, CLEVELAND, OH 44195 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT PHYSIOL & BIOPHYS, BRONX, NY 10461 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Cleveland Clinic Foundation; Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048714, R01GM051491] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48714, GM51491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; ANDO N, 1981, J BIOCHEM-TOKYO, V70, P557; ANTONINI E, 1965, PHYSIOL REV, V45, P123, DOI 10.1152/physrev.1965.45.1.123; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; Estabrook R W, 1977, Adv Exp Med Biol, V78, P19; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GRIMES PA, 1995, J AUTONOM NERV SYST, V54, P80, DOI 10.1016/0165-1838(95)00006-J; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; JONES DP, 1978, J BIOL CHEM, V253, P4874; KLATT P, 1993, J BIOL CHEM, V268, P14781; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; POU S, 1992, J BIOL CHEM, V267, P24173; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; VANDERKOOI JM, 1991, AM J PHYSIOL, V260, pC1131, DOI 10.1152/ajpcell.1991.260.6.C1131; VINCENT SR, 1994, PROG NEUROBIOL, V42, P129, DOI 10.1016/0301-0082(94)90023-X; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	27	116	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32515	32518		10.1074/jbc.271.51.32515	http://dx.doi.org/10.1074/jbc.271.51.32515			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955074	hybrid			2022-12-25	WOS:A1996VZ37300009
J	Mosley, B; DeImus, C; Friend, D; Boiani, N; Thoma, B; Park, LS; Cosman, D				Mosley, B; DeImus, C; Friend, D; Boiani, N; Thoma, B; Park, LS; Cosman, D			Dual oncostatin M (OSM) receptors - Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; COLONY-STIMULATING FACTOR; AIDS-KAPOSIS-SARCOMA; EXPRESSION CLONING; GROWTH-FACTOR; MOLECULAR-CLONING; TRANSCRIPTIONAL ACTIVATION; HEMATOPOIETIN RECEPTOR; TRANSDUCER GP130	Oncostatin M (OSM) is a cytokine whose structural and functional features are similar to other members of the interleukin (IL)-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor (LIF), granulocyte colony-stimulating factor, ciliary neurotrophic factor, and cardiotrophin-1), many of which utilize gp130 as a common receptor subunit. A biologically active OSM receptor has been previously described that consists of a heterodimer of leukemia inhibitory factor receptor (LIFR) and gp130. This LIFR gp130 complex is also a functional receptor for LIF. We have cloned and characterized an alternative subunit (OSMR beta) for an OSM receptor complex (a heterodimer of gp130 and OSMR beta) that is activated by OSM but not by LIF. The signaling capability of specific receptor subunit combinations was analyzed by independent assays measuring cell proliferation or induction of acute phase protein synthesis. Our results demonstrate that both LIF and OSM cause tyrosine phosphorylation and activation of the gp130 LIFR combination, but the gp130 . OSMR beta complex is activated by OSM only. OSM-induced cellular responses, initiated through low affinity binding to gp130, are mediated by two heterodimeric receptor complexes that utilize alternative signal transducing subunits that confer different cytokine specificities to the receptor complex.			Mosley, B (corresponding author), IMMUNEX CORP,51 UNIV ST,SEATTLE,WA 98101, USA.							BAUMANN H, 1990, MOL CELL BIOL, V10, P5967, DOI 10.1128/MCB.10.11.5967; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BENSI G, 1985, EMBO J, V4, P119, DOI 10.1002/j.1460-2075.1985.tb02325.x; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; BROWN TJ, 1987, J IMMUNOL, V139, P2977; BROWN TJ, 1990, MOL BIOL CARDIOVASC, V131, P195; BRUCE AG, 1992, J IMMUNOL, V149, P1271; CAI J, 1994, AM J PATHOL, V145, P74; CHUA AO, 1994, J IMMUNOL, V153, P128; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DU XX, 1994, BLOOD, V83, P2023; FANSLOW WC, 1992, J IMMUNOL, V149, P655; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GROVE RI, 1993, P NATL ACAD SCI USA, V90, P823, DOI 10.1073/pnas.90.3.823; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JEFFERY E, 1993, CYTOKINE, V5, P107, DOI 10.1016/1043-4666(93)90048-A; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; Kushner I., 1993, ACUTE PHASE PROTEINS; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LIU JW, 1992, J BIOL CHEM, V267, P16763; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MALIK N, 1989, MOL CELL BIOL, V9, P2847, DOI 10.1128/MCB.9.7.2847; MILES SA, 1992, SCIENCE, V255, P1432, DOI 10.1126/science.1542793; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; MORRONE G, 1988, J BIOL CHEM, V263, P12554; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MURAKAMIMORI K, 1995, J CLIN INVEST, V96, P1319, DOI 10.1172/JCI118167; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PETERS M, 1995, FEBS LETT, V372, P177, DOI 10.1016/0014-5793(95)00972-C; RADKA SF, 1993, J IMMUNOL, V150, P5195; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOOLTINK H, 1992, FEBS LETT, V314, P280, DOI 10.1016/0014-5793(92)81489-9; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SPORENO E, 1994, J BIOL CHEM, V269, P10991; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; THOMA B, 1994, J BIOL CHEM, V269, P6215; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZIEGLER SF, 1993, MOL CELL BIOL, V13, P2384, DOI 10.1128/MCB.13.4.2384	63	325	338	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32635	32643		10.1074/jbc.271.51.32635	http://dx.doi.org/10.1074/jbc.271.51.32635			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8999038	hybrid			2022-12-25	WOS:A1996VZ37300028
J	Shapiro, MJ; Trejo, J; Zeng, DW; Coughlin, SR				Shapiro, MJ; Trejo, J; Zeng, DW; Coughlin, SR			Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking - Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ACTIVATION; MECHANISM; CELLS; SEQUESTRATION; SPECIFICITY; CLONING; KINASES; MUTANT	The G protein-coupled thrombin receptor is activated by an irreversible proteolytic mechanism and, perhaps as a result, exhibits an unusual trafficking pattern in the cell. Naive receptors tonically cycle between the cell surface and a protected intracellular pool, whereas receptors cleaved and activated at the cell surface internalize and move to lysosomes. Toward understanding how these trafficking events are regulated, we examined a series of receptor mutants. A receptor with alanine substitutions at all potential phosphorylation sites in the cytoplasmic tail failed to display agonist-triggered internalization but, like wild type receptor, displayed robust signaling, tonic cycling, and localization to both the cell surface and an intracellular pool. A truncation mutant that lacked most of the cytoplasmic tail also signaled robustly, lacked phosphorylation, and was defective in agonist-triggered internalization. However, in contrast to the specific phosphorylation site mutant, the truncation mutant did not display tonic cycling and localized exclusively to the cell surface. An analysis of a series of truncation mutants localized residues important for receptor trafficking to a 10-amino acid stretch in its cytoplasmic tail. These data suggest that phosphorylation may trigger internalization of activated thrombin receptors but that a second phosphorylation-independent signal mediates tonic internalization of naive receptors. They further suggest that maintenance of the intracellular pool of naive thrombin receptors requires tonic receptor internalization.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				TREJO, JOANN/0000-0003-4405-6228	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRASS LF, 1991, J BIOL CHEM, V266, P958; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CHEN J, 1994, J BIOL CHEM, V269, P16041; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; Harlow E., 1988, ANTIBODIES LAB MANUA; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; HOXIE JA, 1993, J BIOL CHEM, V268, P13756; HUNG DT, 1992, J CLIN INVEST, V89, P444, DOI 10.1172/JCI115604; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MORO O, 1993, J BIOL CHEM, V268, P6862; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; TSUGA H, 1994, J BIOL CHEM, V269, P32522; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0	29	114	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32874	32880		10.1074/jbc.271.51.32874	http://dx.doi.org/10.1074/jbc.271.51.32874			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955127	hybrid			2022-12-25	WOS:A1996VZ37300062
J	Sippel, CJ; Shen, TX; Perlmutter, DH				Sippel, CJ; Shen, TX; Perlmutter, DH			Site-directed mutagenesis within an ectoplasmic ATPase consensus sequence abrogates the cell aggregating properties of the rat liver canalicular bile acid transporter ecto-ATPase cell CAM 105 and carcinoembryonic antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; ADHESION; PROTEIN; FAMILY; CDNA; DNA	Recent studies of the rat liver canalicular bile acid transporter/ecto-ATPase/cell CAM 105 (CBATP), a member of the carcinoembryonic antigen (CEA) supergene family, indicate that it is a multifunctional protein possessing bile acid efflux, ecto ATPase, and intercellular aggregating properties, Cheung et al. (Cheung, P. H., Luo, W., Qiu, Y., Zhang, K. E., Millron, P., Lin, S. H. (1993) J. Biol. Chem. 268, 24303-24310) have shown that the amino-terminal Ig V-like domain of this protein is required for its aggregating properties, much like the homologous amino-terminal domain of CEA is required for its aggregating properties, The amino-terminal domains of both CBATP and CEA include a consensus ATPase sequence, Site-directed mutagenesis within this ATPase consensus sequence completely eliminates the ecto-ATPase activity of CBATP (Sippel, C. J., McCollum, M., Perlmutter, D. H. (1994) J. Biol. Chem. 269, 2820-2826). In this study we examined the possibility that it is this ATPase consensus sequence which is required for the cell aggregating properties of CBATP and CEA and whether there is a relationship between ATPase, aggregating, and bile acid efflux activities, For this we used a baculovirus vector to express in Sf9 cells wild type as well as mutant and chimeric CBATP and CEA molecules, The results indicate that Arg-98 in the ATPase consensus sequence of CBATP and the corresponding residue of CEA are essential for the aggregating properties of these molecules, Moreover Arg-98 is essential for CBATP to interact with itself, CEA to interact with itself, and CBATP to interact with CEA. However, the role of Arg-98 in aggregation is distinct from its role in ecto-ATPase activity and the aggregating properties cannot be attributed to a change in ATP metabolism in the pericellular milieu.	WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047084] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HD07409] Funding Source: Medline; NIDDK NIH HHS [1R01 DK47084] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNETT T, 1988, Genomics, V3, P59, DOI 10.1016/0888-7543(88)90160-7; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CHEUNG PH, 1993, J BIOL CHEM, V268, P6139; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; KAMARCK ME, 1987, P NATL ACAD SCI USA, V84, P5350, DOI 10.1073/pnas.84.15.5350; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OIKAWA S, 1991, J BIOL CHEM, V266, P7995; PERLMUTTER DH, 1988, J BIOL CHEM, V263, P16499; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SIPPEL CJ, 1994, J BIOL CHEM, V269, P2820; SIPPEL CJ, 1990, AM J PHYSIOL, V258, pG728, DOI 10.1152/ajpgi.1990.258.5.G728; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; YIH LH, 1991, CELL BIOL INT REP, V15, P253, DOI 10.1016/0309-1651(91)90157-E; ZHOU H, 1993, J CELL BIOL, V122, P951, DOI 10.1083/jcb.122.4.951	20	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33095	33104		10.1074/jbc.271.51.33095	http://dx.doi.org/10.1074/jbc.271.51.33095			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955157	hybrid			2022-12-25	WOS:A1996VZ37300092
J	Bae, YS; Kang, SW; Seo, MS; Baines, IC; Tekle, E; Chock, PB; Rhee, SG				Bae, YS; Kang, SW; Seo, MS; Baines, IC; Tekle, E; Chock, PB; Rhee, SG			Epidermal growth factor (EGF)-induced generation of hydrogen peroxide - Role in EGF receptor-mediated tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SMOOTH-MUSCLE CELLS; PHOSPHOLIPASE C-II; SIGNAL-TRANSDUCTION; AUTOPHOSPHORYLATION SITES; HUMAN-FIBROBLASTS; POINT MUTATION; BINDING-SITES; OXYGEN; H2O2	Recent evidence indicates that reactive oxygen species (ROS) may function as intracellular messengers in receptor signaling pathways. The possible role of ROS in epidermal growth factor (EGF) signaling was therefore investigated. Stimulation of A431 human epidermoid carcinoma cells with EGF resulted in a transient increase in the intracellular concentration of ROS, measured with the oxidation-sensitive fluorescent probe 2',7'-dichlorofluorescin diacetate and laser-scanning confocal microscopy. The predominant ROS produced appeared to be H2O2, because the EGF-induced increase in fluorescence was completely abolished by incorporation of catalase into the cells by electroporation. The elimination of H2O2 by catalase also inhibited the EGF-induced tyrosine phosphorylation of various cellular proteins including the EGF receptor and phospholipase C-gamma 1. The dependence of H2O2 production on the intrinsic tyrosine kinase activity of the EGF receptor and the autophosphorylation sites located in its COOH-terminal tail was investigated. EGF failed to induce H2O2 generation in cells expressing a kinase-inactive EGF receptor. However, normal H2O2 generation was observed in cells expressing a mutant receptor from which the 126 COOH-terminal amino acids had been deleted to remove four (out of the total of five) autophosphorylation sites. These results suggest that EGF-induced H2O2 formation requires the kinase activity but probably not the autophosphorylation sites of the EGF receptor and that inhibition of protein tyrosine phosphatase activity by H2O2 may be required for EGF-induced protein tyrosine phosphorylation to be manifested.	NHLBI,CELL SIGNALING LAB,NIH,BETHESDA,MD 20892; NHLBI,CELL BIOL LAB,NIH,BETHESDA,MD 20892; NHLBI,BIOCHEM LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BASS DA, 1983, J IMMUNOL, V130, P1910; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; JONES SA, 1994, FEBS LETT, V355, P178, DOI 10.1016/0014-5793(94)01201-6; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, MOL CELL BIOL, V10, P435, DOI 10.1128/MCB.10.2.435; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; MAY JM, 1979, J BIOL CHEM, V254, P9017; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUKHERJEE SP, 1978, BIOCHEM PHARMACOL, V27, P2589, DOI 10.1016/0006-2952(78)90332-5; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROBERTSON FM, 1990, CANCER RES, V50, P6062; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SELVA E, 1993, J BIOL CHEM, V268, P2250; SOLER C, 1994, J BIOL CHEM, V269, P12320; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STONE RL, 1994, J BIOL CHEM, V269, P3123; SUH PG, 1988, J BIOL CHEM, V263, P14497; SULLIVAN SG, 1994, FREE RADICAL BIO MED, V16, P399, DOI 10.1016/0891-5849(94)90042-6; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TEKLE E, 1991, P NATL ACAD SCI USA, V88, P4230, DOI 10.1073/pnas.88.10.4230; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; THELEN M, 1993, PHYSIOL REV, V73, P797, DOI 10.1152/physrev.1993.73.4.797; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; YIM MB, 1994, J BIOL CHEM, V269, P1621; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	50	1042	1066	1	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					217	221		10.1074/jbc.272.1.217	http://dx.doi.org/10.1074/jbc.272.1.217			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995250				2022-12-25	WOS:A1997WA56400037
J	Brosh, RM; Matson, SW				Brosh, RM; Matson, SW			A point mutation in Escherichia coli DNA helicase II renders the enzyme nonfunctional in two DNA repair pathways - Evidence for initiation of unwinding from a nick in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UVRD GENE-PRODUCT; RECBC ENZYME; DIRECTED MUTAGENESIS; MISMATCH CORRECTION; EXCISION-REPAIR; POLYMERASE-I; CIRCULAR DNA; FULLY DUPLEX; MECHANISMS; PROTEINS	Biosynthetic errors and DNA damage introduce mismatches and lesions in DNA that can lead to mutations, These abnormalities are susceptible to correction by a number of DNA repair mechanisms, each of which requires a distinct set of proteins. Escherichia coli DNA helicase II has been demonstrated to function in two DNA repair pathways, methyl-directed mismatch repair and UvrABC-mediated nucleotide excision repair. To define further the role of UvrD in DNA repair a site-specific mutant was characterized. The mutation, uvrDQ251E, resides within helicase motif III, a conserved segment of amino acid homology found in a superfamily of prokaryotic and eukaryotic DNA helicases. The UvrD-Q251E protein failed to complement the mutator and ultraviolet light-sensitive phenotypes of a uvrD deletion strain indicating that the mutant protein is inactive in both mismatch repair and excision repair. Biochemical characterization revealed a significant defect in the ability of the mutant enzyme to initiate unwinding at a nick. The elongation phase of the unwinding reaction was nearly normal, Together, the biochemical and genetic data provide evidence that UvrD-Q251E is dysfunctional because the mutant protein fails to initiate unwinding at the nick(s) used to initiate excision and subsequent repair synthesis. These results provide direct evidence to support the notion that helicase II initiates unwinding from a nick in vivo in mismatch repair and excision repair.	UNIV N CAROLINA, DEPT BIOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CURRICULUM GENET & MOL BIOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033476] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33476] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELMONEM M, 1977, EUR J BIOCHEM, V79, P33, DOI 10.1111/j.1432-1033.1977.tb11780.x; ABDELMONEM M, 1977, EUR J BIOCHEM, V79, P39, DOI 10.1111/j.1432-1033.1977.tb11781.x; ARTHUR HM, 1983, GENE, V25, P309, DOI 10.1016/0378-1119(83)90235-4; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; CARON PR, 1985, P NATL ACAD SCI USA, V82, P4925, DOI 10.1073/pnas.82.15.4925; CHAO KL, 1990, J BIOL CHEM, V265, P1067; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GLASSNER BJ, 1994, RADIAT RES, V139, P24, DOI 10.2307/3578728; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; GRILLEY M, 1990, MUTAT RES, V236, P253, DOI 10.1016/0921-8777(90)90009-T; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HUSAIN I, 1985, P NATL ACAD SCI USA, V82, P6774, DOI 10.1073/pnas.82.20.6774; KAISERROGERS K, 1991, THESIS U N CAROLINA; KARU AE, 1972, P NATL ACAD SCI USA, V69, P2855, DOI 10.1073/pnas.69.10.2855; KUHN B, 1979, J BIOL CHEM, V254, P1343; KUMURA K, 1984, J BIOL CHEM, V259, P1560; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1987, J BIOL CHEM, V262, P2066; MATSON SW, 1986, J BIOL CHEM, V261, P169; MATSON SW, 1983, J BIOL CHEM, V258, P4009; MATSON SW, 1994, BIOESSAYS, V16, P13, DOI 10.1002/bies.950160103; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; MODRICH P, 1989, J BIOL CHEM, V264, P6597; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MUSKAVITCH KMT, 1982, J BIOL CHEM, V257, P2641; NAKAYAMA K, 1983, MOL GEN GENET, V192, P391, DOI 10.1007/BF00392180; ORREN DK, 1992, J BIOL CHEM, V267, P780; RICHET E, 1976, J BIOL CHEM, V251, P808; RUNYON GT, 1989, J BIOL CHEM, V264, P17502; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P602, DOI 10.1021/bi00053a028; RUNYON GT, 1990, P NATL ACAD SCI USA, V87, P6383, DOI 10.1073/pnas.87.16.6383; RUNYON GT, 1993, BIOCHEMISTRY-US, V32, P4128, DOI 10.1021/bi00066a039; SANCAR A, 1994, SCIENCE, V266, P1954, DOI 10.1126/science.7801120; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SIEGEL EC, 1983, MOL GEN GENET, V191, P397, DOI 10.1007/BF00425753; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WASHBURN BK, 1991, J BACTERIOL, V173, P2569, DOI 10.1128/jb.173.8.2569-2575.1991; WESSEL R, 1990, EUR J BIOCHEM, V192, P695, DOI 10.1111/j.1432-1033.1990.tb19278.x; WILLETTS N, 1986, ESCHERICHIA COLI SAL, P1110; WILLETTS NS, 1969, J BACTERIOL, V100, P923, DOI 10.1128/JB.100.2.923-934.1969; ZOLLER MJ, 1991, RECOMBINANT DNA METH, P537	58	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					572	579						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995299				2022-12-25	WOS:A1997WA56400086
J	Fu, GK; Smith, MJ; Markovitz, DM				Fu, GK; Smith, MJ; Markovitz, DM			Bacterial protease lon is a site-specific DNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI K-12; VIRUS TYPE-2 ENHANCER; ION GENE; MYXOCOCCUS-XANTHUS; CAPR PROTEIN; CLONING; PROTEOLYSIS; DEGRADATION; SEQUENCE	The product of the Escherichia coli lon gene is the ATP-dependent Lon protease, Lon contributes to the regulation of several important cellular functions, including radiation resistance, cell division, filamentation, capsular polysaccharide production, lysogeny of certain bacteriophages, and proteolytic degradation of certain regulatory and abnormal proteins, Lon homologues are also found in several widely divergent bacteria, as well as in the mitochondria of yeast and humans, E. coli Lon has long been known to bind to DNA, but this interaction has not been further characterized and has generally been assumed to be nonspecific, We now demonstrate that E. coli Lon can bind to a TG-rich DNA promoter element in a sequence specific manner, This finding is based on the results of experiments employing SouthWestern blotting, protein purification, ''shift-shift'' electrophoretic mobility shift assays, electrophoretic mobility shift assays using in vitro transcribed and translated Lon, and DNase footprinting, Site-specific DNA binding is likely to be an additional important biochemical characteristic of the multifaceted Lon protease.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV INFECT DIS,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT EPIDEMIOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NIAID NIH HHS [AI36885, AI303924] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUCHANAN CE, 1973, J BACTERIOL, V114, P891, DOI 10.1128/JB.114.2.891-893.1973; BUKHARI AI, 1973, NATURE-NEW BIOL, V243, P238, DOI 10.1038/newbio243238a0; CHARETTE MF, 1982, J MOL BIOL, V162, P503, DOI 10.1016/0022-2836(82)90541-1; CHARETTE MF, 1984, J BACTERIOL, V158, P195, DOI 10.1128/JB.158.1.195-201.1984; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; CLARK NM, 1993, J VIROL, V67, P5522, DOI 10.1128/JVI.67.9.5522-5528.1993; Coward C, 1995, DEV BIOL STAND, V85, P481; DOWNS D, 1986, J BACTERIOL, V165, P193, DOI 10.1128/jb.165.1.193-197.1986; EASTGATE JA, 1995, J BACTERIOL, V177, P932, DOI 10.1128/jb.177.4.932-937.1995; Fu GK, 1996, J BIOL CHEM, V271, P19599, DOI 10.1074/jbc.271.32.19599; GAYDA RC, 1985, J BACTERIOL, V162, P271, DOI 10.1128/JB.162.1.271-275.1985; GOFF SA, 1984, P NATL ACAD SCI-BIOL, V81, P6647, DOI 10.1073/pnas.81.21.6647; GOFF SA, 1985, CELL, V41, P587, DOI 10.1016/S0092-8674(85)80031-3; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1978, J BACTERIOL, V133, P844, DOI 10.1128/JB.133.2.844-851.1978; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HILFINGER JM, 1993, J VIROL, V67, P4448, DOI 10.1128/JVI.67.7.4448-4453.1993; HUA SS, 1974, P NATL ACAD SCI USA, V71, P507, DOI 10.1073/pnas.71.2.507; ITO K, 1992, J BACTERIOL, V174, P2281, DOI 10.1128/JB.174.7.2281-2287.1992; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; MACKIE G, 1972, J BIOL CHEM, V247, P2973; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; PHILLIPS TA, 1984, J BACTERIOL, V159, P283, DOI 10.1128/JB.159.1.283-287.1984; RIETHDORF S, 1994, J BACTERIOL, V176, P6158; SCHMIDT R, 1994, J BACTERIOL, V176, P6528, DOI 10.1128/JB.176.21.6528-6537.1994; SCHOEMAKER JM, 1981, J BACTERIOL, V147, P46, DOI 10.1128/JB.147.1.46-56.1981; STORTS DR, 1988, J BACTERIOL, V170, P1541, DOI 10.1128/jb.170.4.1541-1547.1988; Suzuki CK, 1995, METHOD ENZYMOL, V260, P486, DOI 10.1016/0076-6879(95)60160-0; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Teichmann U, 1996, J BIOL CHEM, V271, P10137, DOI 10.1074/jbc.271.17.10137; TOJO N, 1993, J BACTERIOL, V175, P2271, DOI 10.1128/JB.175.8.2271-2277.1993; TOJO N, 1993, J BACTERIOL, V175, P4545, DOI 10.1128/JB.175.14.4545-4549.1993; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; ZEHNBAUER BA, 1980, J BACTERIOL, V143, P852, DOI 10.1128/JB.143.2.852-863.1980; ZEHNBAUER BA, 1981, P NATL ACAD SCI-BIOL, V78, P2043, DOI 10.1073/pnas.78.4.2043	42	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					534	538						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995294				2022-12-25	WOS:A1997WA56400081
J	Benkirane, N; Guichard, G; Briand, JP; Muller, S				Benkirane, N; Guichard, G; Briand, JP; Muller, S			Exploration of requirements for peptidomimetic immune recognition - Antigenic and immunogenic properties of reduced peptide bond pseudopeptide analogues of a histone hexapeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETRO-INVERSO-PEPTIDOMIMETICS; CROSS-REACTIVITY; CLASS-I; ANTIBODIES; SPECIFICITY; BINDING; ANTAGONISTS; CHROMATIN; RECEPTOR; PROBES	We present a detailed analysis of the antigenic and immunogenic properties of a series of very stable peptidomimetics of a model hexapeptide corresponding to the C-terminal residues 130-135 of histone H3. Five pseudopeptide analogues of the natural sequence IRGERA were synthesized by systematically replacing, in each analogue, one peptide bond at a time by a reduced peptide bond Psi(CH2-NH). Three important features of the resulting analogues were examined. First, the analogues were tested in a biosensor system for their ability to bind monoclonal antibodies generated against the parent natural peptide, and their kinetic rate constants were measured. The results show that reduced peptide bond analogues can very efficiently mimic the parent peptide. The position of reduced bonds which were deleterious for the binding was found to depend on the antibody tested, and one monoclonal antibody recognized all five analogues. The equilibrium affinity constant toward reduced peptide bond analogues of four antibodies of IgG(1) isotype induced against the parent hexapeptide was higher (up to 670 times) with certain analogues than toward the homologous peptide. Second, immunogenic properties of the five analogues were studied, and it was found that polyclonal antibodies induced against analogues in which Psi(CH2-NH) bonds were introduced between residues 130-131, 131-132, and 132-133 (R1-R2, R2-R3, and R3-R4) crossreacted strongly with the cognate protein H3. Third, we tested the protease resistance of analogues. Altogether, the results provide a strong support for the potent applicability of reduced peptide bond pseudopeptides as components of synthetic vaccines and open a new field for the development of immunomodulatory agents.	CNRS,INST BIOL MOL & CELLULAIRE,UPR 9021,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Muller, Sylviane/J-5319-2014; Benkirane-Jessel, Nadia/H-6438-2016; GUICHARD, Gilles/I-3858-2016	GUICHARD, Gilles/0000-0002-2584-7502; Benkirane-Jessel, Nadia/0000-0003-3059-3559				ALMOUDALLAL Z, 1982, EMBO J, V1, P1005, DOI 10.1002/j.1460-2075.1982.tb01285.x; Appella E, 1995, Biomed Pept Proteins Nucleic Acids, V1, P177; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BENKIRANE N, 1995, J BIOL CHEM, V270, P11921, DOI 10.1074/jbc.270.20.11921; BRIAND JP, 1995, J BIOL CHEM, V270, P20686, DOI 10.1074/jbc.270.35.20686; FAUCHERE JL, 1992, ADV DRUG RES, V23, P128; FRIEDE M, 1993, MOL IMMUNOL, V30, P539, DOI 10.1016/0161-5890(93)90028-A; GUICHARD G, 1995, J BIOL CHEM, V270, P26057, DOI 10.1074/jbc.270.44.26057; GUICHARD G, 1994, PEPTIDE RES, V7, P308; GUICHARD G, 1994, P NATL ACAD SCI USA, V91, P9765, DOI 10.1073/pnas.91.21.9765; Guichard G, 1996, J MED CHEM, V39, P2030, DOI 10.1021/jm9509511; HARPER M, 1987, MOL IMMUNOL, V24, P97, DOI 10.1016/0161-5890(87)90081-2; HILL CM, 1994, J IMMUNOL, V152, P2890; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; LEBAN JJ, 1993, P NATL ACAD SCI USA, V90, P1922, DOI 10.1073/pnas.90.5.1922; MARRAUD M, 1993, BIOPOLYMERS, V33, P1135, DOI 10.1002/bip.360330715; MERRIFIELD RB, 1995, P NATL ACAD SCI USA, V92, P3449, DOI 10.1073/pnas.92.8.3449; MICHALON P, 1993, EUR J BIOCHEM, V216, P387, DOI 10.1111/j.1432-1033.1993.tb18156.x; MULLER S, 1995, PEPTIDE RES, V8, P138; MULLER S, 1988, SYNTHETIC POLYPEPTID, P45; PAPADOULI I, 1993, EUR J BIOCHEM, V211, P227, DOI 10.1111/j.1432-1033.1993.tb19890.x; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RAMMENSEE HG, 1995, CURR OPIN IMMUNOL, V7, P85, DOI 10.1016/0952-7915(95)80033-6; SAUNAL H, 1996, IN PRESS IMMUNOCHEMI, V2; SLOANLANCASTER J, 1995, CURR OPIN IMMUNOL, V7, P103, DOI 10.1016/0952-7915(95)80035-2; Verdoliva A, 1995, J BIOL CHEM, V270, P30422, DOI 10.1074/jbc.270.51.30422	28	23	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33218	33224		10.1074/jbc.271.52.33218	http://dx.doi.org/10.1074/jbc.271.52.33218			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969178	hybrid			2022-12-25	WOS:A1996WA71300012
J	Horazdovsky, BF; Cowles, CR; Mustol, P; Holmes, M; Emr, SD				Horazdovsky, BF; Cowles, CR; Mustol, P; Holmes, M; Emr, SD			A novel RING finger protein, Vps8p, functionally interacts with the small GTPase, Vps21p, to facilitate soluble vacuolar protein localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; LYSOSOME-LIKE VACUOLE; SACCHAROMYCES-CEREVISIAE; CARBOXYPEPTIDASE-Y; PREVACUOLAR COMPARTMENT; SORTING RECEPTOR; BINDING PROTEIN; GENE; MEMBRANE; MUTANTS	Genetic analyses of vacuolar protein sorting in Saccharomyces cerevisiae have uncovered a large number of mutants (vps) that missort and secrete soluble vacuolar hydrolases. Here we report the characterization of the gene product affected in one of these mutants, Vps8p. Polyclonal antiserum raised against a trpE-Vps8 fusion protein specifically detects a 134-kDa protein in labeled yeast cell extracts. Subcellular fractionation studies demonstrate that Vps8p is distributed between a low speed membrane pellet fraction and a high speed membrane pellet fraction. The lack of a hydrophobic domain in Vps8p suggests that Vps8p peripherally associates with a membrane(s). This association was found to depend on the function of Vps21p, a member of the Rab/Ypt/Sec4 family of small GTPases. In vps21 null mutant cells, Vps8p is found in the cytosol. In addition, overexpression of Vps21p partially suppresses a vps8 null mutant, indicating that Vps8p and Vps21p functionally interact. Vps8p contains a C-terminal cysteine-rich region that conforms to the H2 variant of the RING finger Zn2+ binding motif. Truncation of this C-terminal region partially compromises Vps8p function, While vps8 null mutant strains missort and secrete soluble vacuolar hydrolases, the integral vacuolar membrane protein, alkaline phosphatase (ALP), is sorted to the vacuole and matured normally. In addition, when vps8 mutants are combined with endocytic or late secretory pathway mutants (end3 or sec1, respectively), ALP is still delivered to the vacuole. These observations indicate that ALP is sorted to the vacuole in a Vps8p-independent manner, possibly via an alternative vesicle carrier.	UNIV CALIF SAN DIEGO, SCH MED, DIV CELLULAR & MOL MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, SCH MED, HOWARD HUGHES MED INST, LA JOLLA, CA 92093 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032703] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-32703] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BANTA LM, 1988, J CELL BIOL, V107, P1369, DOI 10.1083/jcb.107.4.1369; Becherer KA, 1996, MOL BIOL CELL, V7, P579, DOI 10.1091/mbc.7.4.579; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; Burd CG, 1996, MOL CELL BIOL, V16, P2369; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; COWLES CR, 1994, J CELL SCI, V107, P3449; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; DULIC V, 1989, EMBO J, V8, P1349, DOI 10.1002/j.1460-2075.1989.tb03515.x; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JONES EW, 1977, GENETICS, V85, P23; KLEID DG, 1981, SCIENCE, V214, P1125, DOI 10.1126/science.6272395; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; Miller J.H., 1972, EXPT MOL GENETICS; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PARAVICINI G, 1992, MOL BIOL CELL, V3, P415, DOI 10.1091/mbc.3.4.415; PERLMAN R, 1993, P NATL ACAD SCI USA, V90, P5474, DOI 10.1073/pnas.90.12.5474; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; PIPER RC, 1994, EUR J CELL BIOL, V65, P305; RAYMOND CK, 1990, J CELL BIOL, V111, P877, DOI 10.1083/jcb.111.3.877; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Rieder SE, 1996, MOL BIOL CELL, V7, P985, DOI 10.1091/mbc.7.6.985; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROBINSON JS, 1991, MOL CELL BIOL, V11, P5813, DOI 10.1128/MCB.11.12.5813; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Sherman F, 1979, METHODS YEAST GENETI; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGERKRUGER B, 1994, J CELL BIOL, V125, P283, DOI 10.1083/jcb.125.2.283; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VATER CA, 1992, J CELL BIOL, V119, P773, DOI 10.1083/jcb.119.4.773; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; VIDA TA, 1993, J CELL BIOL, V121, P1245, DOI 10.1083/jcb.121.6.1245; VIDA TA, 1990, J CELL BIOL, V111, P2871, DOI 10.1083/jcb.111.6.2871; VOLGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615; WEISMAN LS, 1992, J BIOL CHEM, V267, P618; WOOLFORD CA, 1990, GENETICS, V125, P739; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	67	67	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33607	33615		10.1074/jbc.271.52.33607	http://dx.doi.org/10.1074/jbc.271.52.33607			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969229	hybrid			2022-12-25	WOS:A1996WA71300063
J	Meadow, ND; Roseman, S				Meadow, ND; Roseman, S			Rate and equilibrium constants for phosphoryltransfer between active site histidines of Escherichia coli HPr and the signal transducing protein IIIGlc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; SALMONELLA-TYPHIMURIUM; SUGAR-TRANSPORT; PHOSPHOCARRIER PROTEIN; ENZYME-I; PHOSPHOENOLPYRUVATE; PYRUVATE	The bacterial phosphoenolpyruvate:glycose phosphotransferase system (PTS) plays a central role in catabolizing many sugars; regulation is effected by phosphorylation of PTS proteins, In Escherichia coli, the phosphoryltransfer sequence for glucose uptake is: PEP --> Enzyme I(His(191)) --> HPr(His(15)) --> IIIGlc(His(90)) --> IIGlc(Cys(421)) --> glucose, A rapid quench method has now been developed for determining the rate and equilibrium constants of these reactions. The method was validated by control experiments, and gave the following results for phosphoryltransfer between the following protein pairs. For phospho-HPr/ IIIGlc (and HPr/phospho-IIIGlc), k(1), = 6.1 x 10(7) m(-1) s(-1), k(-1), = 4.7 x 10(7); for the mutant (IIIGlc)-I-H75Q in place of IIIGlc, k(1) 2.8 x 10(5) M(-1) s(-1), k(-1) = 2.3 x 10(5), The derived K-eq values agreed with the K-eq obtained without use of the rapid quench apparatus, K-eq for both reactions is 1-1.5. The rate of phosphoryltransfer between HPr and wild type IIIGlc is close to a diffusion-controlled process, while the reactions involving the mutant (IIIGlc)-I-H75Q are 200-fold slower, These rate differences are explained by an hypothesis for the mechanism of phosphoryltransfer between HPr and IIIGlc based on the structures of mutant and wild type proteins (see Pelton et al, (Pelton, J. G., Torchia, D. A., Remington, S. J., Murphy, K. P., Meadow, N. D., and Roseman, S. (1996) J. Biol. Chem. 271, 33446-33456)).	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NIGMS NIH HHS [GM38759] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038759, R37GM038759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KS, 1991, J BIOL CHEM, V266, P8020; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; Fersht A., 1985, ENZYME STRUCTURE MEC, V2nd, P123; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; FROEHLICH JP, 1976, ANAL BIOCHEM, V73, P331, DOI 10.1016/0003-2697(76)90178-0; GUTTFREUND H, 1969, METHOD ENZYMOL, V16, P229; HANSEN RE, 1988, J PHYS CHEM-US, V92, P2189, DOI 10.1021/j100319a022; Hiromi K., 1979, KINETICS FAST ENZYME; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATTOO RL, 1983, CAN J BIOCHEM CELL B, V61, P29, DOI 10.1139/o83-005; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; Pelton JG, 1996, J BIOL CHEM, V271, P33446, DOI 10.1074/jbc.271.52.33446; PELTON JG, 1991, BIOCHEMISTRY-US, V30, P10043, DOI 10.1021/bi00105a032; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; PRESPER KA, 1989, P NATL ACAD SCI USA, V86, P4052, DOI 10.1073/pnas.86.11.4052; Reddy P, 1991, Protein Expr Purif, V2, P179, DOI 10.1016/1046-5928(91)90069-U; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; ROSEMAN S, 1990, J BIOL CHEM, V265, P2993; ROSEMAN S, 1994, PHOSPHATE MICROORGAN, P151; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SHEVELL DE, 1988, J BACTERIOL, V170, P3294, DOI 10.1128/jb.170.7.3294-3296.1988; WAYGOOD EB, 1985, BIOCHEMISTRY-US, V24, P6938, DOI 10.1021/bi00345a028; WAYGOOD EB, 1979, ANAL BIOCHEM, V95, P293, DOI 10.1016/0003-2697(79)90219-7; WEIGEL N, 1982, J BIOL CHEM, V257, P4461	30	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33440	33445		10.1074/jbc.271.52.33440	http://dx.doi.org/10.1074/jbc.271.52.33440			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969207	hybrid			2022-12-25	WOS:A1996WA71300041
J	Sax, CM; Salamon, C; Kays, WT; Guo, J; Yu, FSX; Cuthbertson, RA; Piatigorsky, J				Sax, CM; Salamon, C; Kays, WT; Guo, J; Yu, FSX; Cuthbertson, RA; Piatigorsky, J			Transketolase is a major protein in the mouse cornea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WERNICKE-KORSAKOFF SYNDROME; ADENYLATE-CYCLASE ACTIVITY; LENS CRYSTALLINS; ALDEHYDE DEHYDROGENASE; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; HUMAN-ERYTHROCYTES; EYE; EPITHELIUM; EXPRESSION	Earlier experiments in this laboratory identified a highly expressed 65-68-kDa protein in both mouse and human corneas (Cuthbertson, R. A., Tomarev, S. I., and Piatigorsky J. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 4004-4008). Here, we demonstrate that this protein is transketolase (TKT; EC 2.2.1.1), an enzyme in the nonoxidative branch of the pentose-phosphate pathway, based on peptide and cDNA isolation and sequence analysis of mouse cornea protein and RNA samples, respectively. While expressed at low levels in a number of tissues, the 2.1-kilobase TKT mRNA was expressed at a 50-fold higher level in the adult mouse cornea. The area of most abundant expression was localized to the cornea epithelial cell layer by in situ hybridization. Western blot analysis confirmed TKT protein abundance in the cornea and indicated that TKT may comprise as much as 10% of the total soluble protein of the adult mouse cornea. Soluble cornea extracts exhibited a correspondingly high level of TKT enzymatic activity. TKT expression increased progressively through cornea maturation, as shown by Northern blot, in situ hybridization, Western blot, and enzymatic analyses. TKT mRNA and protein were expressed at low levels in the cornea prior to eye opening, while markedly increased levels were observed after eye opening. Taken together, these observations suggest that TKT may be a cornea enzyme-crystallin, and suggest that the crystallin paradigm and concept of gene sharing, once thought to be restricted to the lens, apply to other transparent ocular tissues.	HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02114	Harvard University; Harvard Medical School; Schepens Eye Research Institute	Sax, CM (corresponding author), NEI,MOL & DEV BIOL LAB,NIH,MSC 2730,BETHESDA,MD 20892, USA.				NATIONAL EYE INSTITUTE [R01EY010869] Funding Source: NIH RePORTER; NEI NIH HHS [EY10869] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ABEDINIA M, 1992, BIOCHEM BIOPH RES CO, V183, P1159, DOI 10.1016/S0006-291X(05)80312-2; ALVES AMCR, 1994, J BACTERIOL, V176, P6827, DOI 10.1128/JB.176.22.6827-6835.1994; Atalla L R, 1990, CLAO J, V16, pS30; ATALLA LR, 1988, CURR EYE RES, V7, P1023, DOI 10.3109/02713688809015149; ATALLA LR, 1989, CURR EYE RES, V8, P229; BAILEY AL, 1994, BRIT J NUTR, V72, P111, DOI 10.1079/BJN19940014; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; BERNACCHIA G, 1995, EMBO J, V14, P610, DOI 10.1002/j.1460-2075.1995.tb07037.x; BHUYAN KC, 1977, BIOCHIM BIOPHYS ACTA, V497, P641, DOI 10.1016/0304-4165(77)90284-7; BHUYAN KC, 1978, BIOCHIM BIOPHYS ACTA, V542, P28, DOI 10.1016/0304-4165(78)90229-5; BLASS JP, 1977, NEW ENGL J MED, V297, P1367, DOI 10.1056/NEJM197712222972503; Boesch JS, 1996, J BIOL CHEM, V271, P5150; CALINGASAN NY, 1995, J NEUROCHEM, V64, P1034; Camhi S L, 1995, New Horiz, V3, P170; COOPER DL, 1991, GENE, V98, P201, DOI 10.1016/0378-1119(91)90174-A; CROUCH R, 1978, EXP EYE RES, V27, P503, DOI 10.1016/0014-4835(78)90135-5; CUTHBERTSON RA, 1992, P NATL ACAD SCI USA, V89, P4004, DOI 10.1073/pnas.89.9.4004; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; DEJONG WW, 1989, TRENDS BIOCHEM SCI, V14, P365, DOI 10.1016/0968-0004(89)90009-1; DELAYE M, 1983, NATURE, V302, P415, DOI 10.1038/302415a0; EISINGER J, 1992, J ADV MED, V5, P105; ESCRIBANO J, 1994, J CELL PHYSIOL, V160, P511, DOI 10.1002/jcp.1041600314; GEROSKI DH, 1978, EXP EYE RES, V26, P611, DOI 10.1016/0014-4835(78)90095-7; GIPSON IK, 1982, INVEST OPHTH VIS SCI, V23, P269; GREEN K, 1995, OPHTHALMIC RES, V27, P143, DOI 10.1159/000267860; Guo J., 1996, Investigative Ophthalmology and Visual Science, V37, pS354; HEINRICH PC, 1971, HELV CHIM ACTA, V54, P2658, DOI 10.1002/hlca.19710540829; HIMMO SD, 1988, PREP BIOCHEM, V18, P261, DOI 10.1080/00327488808062528; HOLMES RS, 1990, GENET RES, V56, P258; JUNG EH, 1993, FASEB J, V7, pA838; KINOSHITA JH, 1955, SCIENCE, V122, P72, DOI 10.1126/science.122.3158.72-a; KINOSHITA JH, 1954, ARCH BIOCHEM BIOPHYS, V53, P9, DOI 10.1016/0003-9861(54)90228-3; Klyce SD., 1988, CORNEA, P3; KOCHETOV GA, 1982, METHOD ENZYMOL, V90, P209; KUHLMAN RE, 1959, ARCH BIOCHEM BIOPHYS, V85, P29, DOI 10.1016/0003-9861(59)90443-6; KUHLMAN RE, 1958, AM J OPHTHALMOL, V46, P47, DOI 10.1016/0002-9394(58)90034-5; LAND MF, 1988, CONTEMP PHYS, V29, P435, DOI 10.1080/00107518808222601; LAND MF, 1992, ANNU REV NEUROSCI, V15, P1, DOI 10.1146/annurev.ne.15.030192.000245; LONDSALE D, 1980, AM J CLIN NUTR, V33, P205; MARTIN PR, 1993, ALCOHOL CLIN EXP RES, V17, P31, DOI 10.1111/j.1530-0277.1993.tb00722.x; MASTERSON E, 1978, BIOCHIM BIOPHYS ACTA, V542, P372, DOI 10.1016/0304-4165(78)90368-9; MASTERSON E, 1978, INVEST OPHTH VIS SCI, V17, P449; MITCHELL J, 1995, CORNEA, V14, P266, DOI 10.1097/00003226-199505000-00007; MUKHERJEE AB, 1987, J CLIN INVEST, V79, P1039, DOI 10.1172/JCI112916; Nishida K, 1996, INVEST OPHTH VIS SCI, V37, P1800; NIXON PF, 1984, EUR J CLIN INVEST, V14, P278, DOI 10.1111/j.1365-2362.1984.tb01181.x; Pham X. T., 1996, Investigative Ophthalmology and Visual Science, V37, pS353; PIATIGORSKY J, 1993, DEV DYNAM, V196, P267, DOI 10.1002/aja.1001960408; PIATIGORSKY J, 1988, P NATL ACAD SCI USA, V85, P3479, DOI 10.1073/pnas.85.10.3479; PIATIGORSKY J, 1989, CELL, V57, P197, DOI 10.1016/0092-8674(89)90956-2; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; PIATIGORSKY J, 1992, ADV DEV BIOCH, V1, P211; RACKER E, 1961, ENZYMES, P397; RINGVOLD A, 1980, ACTA OPHTHALMOL, V58, P63; Salamon C., 1996, Investigative Ophthalmology and Visual Science, V37, pS354; Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155; Schimmer BP, 1996, J BIOL CHEM, V271, P4993; SCHIMMER BP, 1984, CAN J BIOCHEM CELL B, V62, P601, DOI 10.1139/o84-080; SHEU KFR, 1988, ARCH NEUROL-CHICAGO, V45, P841, DOI 10.1001/archneur.1988.00520320027010; TAKEUCHI T, 1986, BIOCHIM BIOPHYS ACTA, V872, P24, DOI 10.1016/0167-4838(86)90143-3; TAKEUCHI T, 1984, CLIN CHEM, V30, P658; TOMBACCINI D, 1994, EXP MOL PATHOL, V60, P140, DOI 10.1006/exmp.1994.1013; WATANABE H, 1993, INVEST OPHTH VIS SCI, V34, P327; WATT VM, 1981, J BIOL CHEM, V256, P1365; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403; WOOD T, 1985, PENTOSE PHOSPHATE PA; ZIESKE JD, 1992, DEV BIOL, V151, P18, DOI 10.1016/0012-1606(92)90209-Y; Zigman S., 1985, OCULAR LENS STRUCTUR, P301	71	69	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33568	33574		10.1074/jbc.271.52.33568	http://dx.doi.org/10.1074/jbc.271.52.33568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969223	hybrid			2022-12-25	WOS:A1996WA71300057
J	Lembo, D; RicciardiCastagnoli, P; Alber, G; Ozmen, L; Landolfo, S; Bluthmann, H; Dembic, Z; Kotenko, SV; Cook, JR; Pestka, S; Garotta, G				Lembo, D; RicciardiCastagnoli, P; Alber, G; Ozmen, L; Landolfo, S; Bluthmann, H; Dembic, Z; Kotenko, SV; Cook, JR; Pestka, S; Garotta, G			Mouse macrophages carrying both subunits of the human interferon-gamma (IFN-gamma) receptor respond to human IFN-gamma but do not acquire full protection against viral cytopathic effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNE INTERFERON; ACCESSORY FACTOR; EXTRACELLULAR DOMAIN; MOLECULAR-CLONING; SIGNAL TRANSDUCER; HUMAN-CELLS; EXPRESSION; GENE; CDNA; SENSITIVITY	Studies of hamster-human and mouse human somatic fibroblast hybrids and transfected mouse fibroblasts have demonstrated that signaling through the human interferon-gamma receptor (hu-IFN-gamma R) requires the formation of a complex consisting of ligand (IFN-gamma), a ligand binding receptor chain (IFN-gamma R1), and a signal transducing receptor chain (IFN-gamma R2). To date, the ability of this receptor complex to transduce the full repertoire of biological signals has been difficult to assess due to the limited number of activities that IFN-gamma can exert on fibroblasts. The current report assesses the ability of hu-IFN-gamma R chains to transduce signals in the absence of background human gene products by expressing hu-IFN-gamma R2 in a transformed macrophage cell line (F10/96) derived from a hu-IFN-gamma R1 transgenic mouse. Our results indicate that F10/96 clones expressing both human receptor proteins bind hu-IFN-gamma with an affinity comparable to that of human cells. Binding of either human or mouse IFN-gamma to its respective receptor elicits classic IFN-gamma responses such as up-regulation of major histocompatibility complex antigens, enhanced expression of IRF-1, and increased production of NO2- radicals, interleukin-6, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor. However, hu-IFN-gamma could not fully protect the clones from cytopathic effects of encephalomyocarditis virus and vesicular stomatitis virus while mo-IFN-gamma could. These results demonstrate that while co-expression of hu-IFN-gamma R1 and hu-IFN-gamma R2 is necessary and sufficient for most IFN-gamma-induced responses, it is not sufficient to confer a generalized antiviral state. These findings further suggest that additional species specific accessory factor(s) are necessary for full signaling potential through the IFN-gamma receptor complex. The nature and potential role of such factors in IFN-gamma R signaling is discussed.	CNR,CTR IMMUNOGENET & EXPTL ONCOL,I-10126 TURIN,ITALY; F HOFFMANN LA ROCHE & CO LTD,CH-4070 BASEL,SWITZERLAND; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ 08854; CNR,CTR CELLULAR & MOL PHARMACOL,I-20129 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); Roche Holding; Rutgers State University New Brunswick; Rutgers State University Medical Center; Consiglio Nazionale delle Ricerche (CNR)			Dembic, Zlatko/A-1833-2008	Dembic, Zlatko/0000-0002-9970-6497; Lembo, David/0000-0002-0969-100X	NATIONAL CANCER INSTITUTE [R01CA052363, R01CA046465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52363, R01 CA46465] Funding Source: Medline; NIAID NIH HHS [R01 AI36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUET M, 1988, CELL, V55, P273, DOI 10.1016/0092-8674(88)90050-5; Bach EA, 1996, MOL CELL BIOL, V16, P3214; BASU MT, 1988, P NATL ACAD SCI USA, V85, P6282, DOI 10.1073/pnas.85.17.6282; BLALOCK JE, 1980, CELL IMMUNOL, V49, P390, DOI 10.1016/0008-8749(80)90041-6; COFANO F, 1990, J BIOL CHEM, V265, P4064; COOK JR, 1994, J BIOL CHEM, V269, P7013; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DING AH, 1988, J IMMUNOL, V141, P2407; DOEBELI H, 1988, J BIOTECHNOL, V7, P199; ESPEVIK T, 1986, J IMMUNOL METHODS, V95, P99, DOI 10.1016/0022-1759(86)90322-4; Familletti P C, 1981, Methods Enzymol, V78, P387; GAROTTA G, 1990, J BIOL CHEM, V265, P6908; GIBBS VC, 1991, MOL CELL BIOL, V11, P5860, DOI 10.1128/MCB.11.12.5860; GRAY PW, 1989, P NATL ACAD SCI USA, V86, P8497, DOI 10.1073/pnas.86.21.8497; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAMMERLING U, 1995, J PHARMACEUT BIOMED, V13, P9, DOI 10.1016/0731-7085(94)00128-O; HEMMI S, 1989, P NATL ACAD SCI USA, V86, P9901, DOI 10.1073/pnas.86.24.9901; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HEMMI S, 1992, P NATL ACAD SCI USA, V89, P2737, DOI 10.1073/pnas.89.7.2737; HIBINO Y, 1992, J BIOL CHEM, V267, P3741; HOGAN B, 1986, MANIPULATING MOUSE E; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; JUNG V, 1990, J BIOL CHEM, V265, P1827; JUNG V, 1987, P NATL ACAD SCI USA, V84, P4151, DOI 10.1073/pnas.84.12.4151; KALINA U, 1993, J VIROL, V67, P1702, DOI 10.1128/JVI.67.3.1702-1706.1993; KOTENKO SV, 1995, J BIOL CHEM, V270, P20915, DOI 10.1074/jbc.270.36.20915; KOTENKO SV, 1994, J INTERFERON RES, V14, pS93; KUMAR CS, 1988, J BIOL CHEM, V263, P13493; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MUNRO S, 1989, P NATL ACAD SCI USA, V86, P9248, DOI 10.1073/pnas.86.23.9248; PAGLIA P, 1993, J EXP MED, V178, P1893, DOI 10.1084/jem.178.6.1893; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; RASHIDBAIGI A, 1986, P NATL ACAD SCI USA, V83, P384, DOI 10.1073/pnas.83.2.384; SASSANO M, 1994, ONCOGENE, V9, P1473; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STONEWOLFF DS, 1984, P NATL ACAD SCI USA, V84, P4767; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TYRING S, 1982, INT J CANCER, V30, P59, DOI 10.1002/ijc.2910300111; WHEELOCK EF, 1965, SCIENCE, V149, P310, DOI 10.1126/science.149.3681.310	41	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32659	32666		10.1074/jbc.271.51.32659	http://dx.doi.org/10.1074/jbc.271.51.32659			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955096	hybrid			2022-12-25	WOS:A1996VZ37300031
J	Tanimoto, K; Yoshida, E; Mita, S; Nibu, Y; Murakami, K; Fukamizu, A				Tanimoto, K; Yoshida, E; Mita, S; Nibu, Y; Murakami, K; Fukamizu, A			Human activin beta A gene - Identification of novel 5' exon, functional promoter, and enhancers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROID-DIFFERENTIATION FACTOR; FOLLICLE-STIMULATING-HORMONE; SIGNAL-TRANSDUCTION PATHWAYS; FSH-RELEASING PROTEIN; AMP RESPONSE ELEMENT; RAT GRANULOSA-CELLS; DNA-BINDING PROTEIN; ALPHA-INHIBIN GENE; CYCLIC-AMP; TRANSCRIPTION FACTORS	On the basis of cDNA cloning, primer extension, and transfection experiments, we identified a novel 5' exon of the human activin beta A subunit gene, and found its enhancer and promoter regions as well as multiple transcription start sites. A series of deletion and mutation analyses of the enhancer sequences defined the 45-base pair core region (DR-1 core) containing two short elements with similarity to AP-1 (12-O-tetradecanoylphorbol-13- acetate response element; TRE) and CREB/ATF (cyclic AMP response element; CRE) binding sites, both of which were necessary for full enhancer activity. Gel shift and antibody supershift assays using DR-1 core region revealed the formation of two specific DNA-protein complexes, one of which could be partially dissociated by a competing oligonucleotide containing a single copy of the consensus TRE, but the other of which contained neither CREB/ATF nor AP-1 as major components. Although 12-O-tetradecanoylphorbol-13-acetate and cAMP induced the activin enhancer/promoter-driven CAT activity, such drug induction was obscured when either the TRE- or CRE-like elements were mutated in the native promoter context. Our results demonstrate that the promoter and enhancer regions identified here are essential for maintaining the efficient promoter activity of the human activin beta A subunit gene.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012; Nibu, Yutaka/J-4136-2019; Tanimoto, Keiji/B-2600-2014	fukamizu, akiyoshi/0000-0002-8786-6020; Nibu, Yutaka/0000-0002-4696-7503; Tanimoto, Keiji/0000-0003-1971-6546				ALBANO RM, 1993, DEVELOPMENT, V117, P711; ALBISTON AL, 1990, MOL CELL ENDOCRINOL, V68, P121, DOI 10.1016/0303-7207(90)90184-A; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ASASHIMA M, 1990, ROUX ARCH DEVEL BIOL, V188, P123; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; DYKEMA JC, 1994, ENDOCRINOLOGY, V135, P702, DOI 10.1210/en.135.2.702; ETO Y, 1987, BIOCHEM BIOPH RES CO, V142, P1095, DOI 10.1016/0006-291X(87)91528-2; FENG ZM, 1989, MOL ENDOCRINOL, V3, P1914, DOI 10.1210/mend-3-12-1914; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HALL SH, 1988, MOL ENDOCRINOL, V2, P55; HASHIMOTO M, 1990, BIOCHEM BIOPH RES CO, V173, P193, DOI 10.1016/S0006-291X(05)81040-X; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HSUEH AJW, 1987, P NATL ACAD SCI USA, V84, P5082, DOI 10.1073/pnas.84.14.5082; HUANG JD, 1993, GENE DEV, V7, P694, DOI 10.1101/gad.7.4.694; HUTCHINSON LA, 1987, BIOCHEM BIOPH RES CO, V146, P1405, DOI 10.1016/0006-291X(87)90806-0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IP YT, 1991, CELL, V64, P439; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KRUYT FA, 1992, NUCLEIC ACIDS RES, V18, P7357; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MASON AJ, 1989, MOL ENDOCRINOL, V3, P1352, DOI 10.1210/mend-3-9-1352; MASON AJ, 1986, BIOCHEM BIOPH RES CO, V135, P957, DOI 10.1016/0006-291X(86)91021-1; MASON AJ, 1987, HUMAN INHIBIN ACTIVI, P77; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NERLOV C, 1992, EMBO J, V11, P4573, DOI 10.1002/j.1460-2075.1992.tb05559.x; PEI L, 1991, MOL ENDOCRINOL, V5, P521, DOI 10.1210/mend-5-4-521; RODGERS RJ, 1991, J MOL ENDOCRINOL, V6, P87, DOI 10.1677/jme.0.0060087; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SHANNON MF, 1988, P NATL ACAD SCI USA, V85, P674, DOI 10.1073/pnas.85.3.674; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANLEY E, 1985, EMBO J, V4, P2569, DOI 10.1002/j.1460-2075.1985.tb03972.x; STEWART AG, 1986, FEBS LETT, V206, P329, DOI 10.1016/0014-5793(86)81006-7; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; SUGINO H, 1988, BIOCHEM BIOPH RES CO, V153, P281, DOI 10.1016/S0006-291X(88)81219-1; Tanimoto K, 1991, DNA Seq, V2, P103, DOI 10.3109/10425179109039678; TANIMOTO K, 1992, BIOCHEM BIOPH RES CO, V182, P773, DOI 10.1016/0006-291X(92)91799-V; TANIMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V302, P409, DOI 10.1006/abbi.1993.1232; TANIMOTO K, 1994, EXP CELL RES, V211, P408, DOI 10.1006/excr.1994.1105; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; TSUJI T, 1988, BIOTECHNOL BIOENG, V31, P675, DOI 10.1002/bit.260310708; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; VANDENEIJNDENVANRAAIJ AJM, 1990, NATURE, V345, P732, DOI 10.1038/345732a0; VERRI A, 1990, NUCLEIC ACIDS RES, V18, P5775, DOI 10.1093/nar/18.19.5775; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; YING SY, 1988, ENDOCR REV, V9, P267, DOI 10.1210/edrv-9-2-267; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	63	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32760	32769		10.1074/jbc.271.51.32760	http://dx.doi.org/10.1074/jbc.271.51.32760			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955111	hybrid			2022-12-25	WOS:A1996VZ37300046
J	Zhang, LT; JacksonMachelski, E; Gordon, JI				Zhang, LT; JacksonMachelski, E; Gordon, JI			Biochemical studies of Saccharomyces cerevisiae myristoyl-coenzyme A Protein N-myristoyltransferase mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CANDIDA-ALBICANS; ACID AUXOTROPHY; CRYPTOCOCCUS-NEOFORMANS; SUBSTRATE-SPECIFICITY; YEAST GENES; COA; TRANSFERASE; STABILITY; ANALOGS	Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (Nmt1p) is an essential 455-residue, monomeric enzyme that catalyzes the transfer of myristate from myristoyl-CoA to the NH2-terminal Gly residue of cellular proteins, Nmt1p has an ordered Bi Bi reaction mechanism with binding of myristoyl-CoA occurring before binding of peptide substrates, To define residues important for function, the polymerase chain reaction was used to generate random mutations in the NMT1 gene, A colony color sectoring assay was used to screen a library of 52,000 transformants for nmt1 alleles encoding enzymes with reduced activity, nmt1 alleles were identified that produced temperature sensitive (ts) growth arrest due to substitutions affecting eight residues conserved in orthologous Nmts: Asn(102), Ala(202), Cys(217), Ser(328), Val(395), Asn(404), Leu(420), and Asn(426). Ala(202) --> Thr, Cys(217) --> Arg, Ser(328) --> Pro, Asn(404) --> Tyr, and Asn(426) --> Ile produced the most severe ts phenotype, Their effects on the functional properties of the enzyme's myristoyl CoA and peptide binding sites were defined by purifying each mutant from Escherichia coli and conducting in vitro kinetic analyses with acyl-CoA and peptide substrates and with two competitive inhibitors: S-(2-oxo)pentadecyl-CoA, a nonhydrolyzable myristoyl-CoA analog, and SC-58272, a peptidomimetic derived from the NH2-terminal sequence of an Nmt1p substrate (ADP-ribosylation factor-2, Arf2p), None of the substitutions affect the enzyme's acyl chain length selectivity, When compared with wild type Nmt1p, Cys(217) --> Arg produces 3- and 6-fold increases in K-i for SC-58272 at 24 and 37 degrees C but no change in K-i for S-(2-oxo)pentadecyl-CoA, indicating that the substitution selectively affects Nmt1p's peptide binding site. Asn(426) --> Ile selectively perturbs the myristoyl-CoA binding site, resulting in the most pronounced reduction in affinity for S-(2-oxo)pentadecyl-CoA (12- and 20-fold), Ala(202) --> Thr, which confers the most severe ts phenotype, provides an example of a substitution that affects both sites, producing 3- and 6-fold increases in the K-i for S-(2-oxo)pentadecyl-CoA and 6- and 9-fold increases in the K-i for SC-58272 at 24 and 37 degrees C. An N-myristoylation-dependent change in the electrophoretic mobility of Arf1p was used to assay the effects of the mutants on cellular levels of protein N-myristoylation under a variety of growth conditions. The ts growth arrest produced by nmt1 alleles correlates with a reduction in myristoyl-Arf1p to less than or equal to 50% of total cellular Arf1p.	WASHINGTON UNIV, SCH MED, DEPT MOL BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIAID NIH HHS [AI38200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BHATNAGAR RS, 1994, J BIOL CHEM, V269, P11045; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BRYANT ML, 1991, P NATL ACAD SCI USA, V88, P2055, DOI 10.1073/pnas.88.6.2055; CHOW M, 1993, LIPID MODIFICATION P, P59; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; DEVADAS B, 1992, J BIOL CHEM, V267, P7224; DEVADAS B, 1995, J MED CHEM, V38, P1837, DOI 10.1021/jm00011a001; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; DURONIO RJ, 1991, J CELL BIOL, V113, P1313, DOI 10.1083/jcb.113.6.1313; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; FELSTED RL, 1995, J NATL CANCER I, V87, P1571, DOI 10.1093/jnci/87.21.1571; HARPER DR, 1993, J GEN VIROL, V74, P1181, DOI 10.1099/0022-1317-74-6-1181; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON DR, 1994, P NATL ACAD SCI USA, V91, P10158, DOI 10.1073/pnas.91.21.10158; JOHNSON DR, 1993, J BIOL CHEM, V268, P483; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KNOLL LJ, 1992, J BIOL CHEM, V267, P5366; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KS, 1993, MOL CELL BIOL, V13, P5843, DOI 10.1128/MCB.13.9.5843; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LODGE JK, 1994, J BIOL CHEM, V269, P2996; LODGE JK, 1994, P NATL ACAD SCI USA, V91, P12008, DOI 10.1073/pnas.91.25.12008; LU TB, 1994, J BIOL CHEM, V269, P5346; MAGNUSON BA, 1995, J NATL CANCER I, V87, P1630, DOI 10.1093/jnci/87.21.1630; MEYER KH, 1974, J BACTERIOL, V117, P345, DOI 10.1128/JB.117.2.345-350.1974; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NADLER MJS, 1993, BIOCHEMISTRY-US, V32, P9250, DOI 10.1021/bi00086a034; PAIGE LA, 1989, J MED CHEM, V32, P1665, DOI 10.1021/jm00128a001; PESECKIS SM, 1994, J BIOL CHEM, V269, P30888; Rose MD., 1990, METHODS YEAST GENETI; Rudnick D.A., 1992, LIPID MODIFICATION P, P37; RUDNICK DA, 1992, J BIOL CHEM, V267, P23852; RUDNICK DA, 1993, ADV ENZYMOL RAMB, V67, P375; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; SIKORSKI RS, 1989, GENETICS, V122, P19; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; WEINBURG RA, 1995, MOL MICROBIOL, V16, P241, DOI 10.1111/j.1365-2958.1995.tb02296.x; WIEGAND RC, 1992, J BIOL CHEM, V267, P8591; ZHU DH, 1995, J BIOL CHEM, V270, P24831, DOI 10.1074/jbc.270.42.24831	49	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33131	33140		10.1074/jbc.271.51.33131	http://dx.doi.org/10.1074/jbc.271.51.33131			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955162	hybrid			2022-12-25	WOS:A1996VZ37300097
J	Chung, SW; Chen, H; Wong, PMC				Chung, SW; Chen, H; Wong, PMC			Activation of quiescent ABL-transduced hemopoietic stem cells	ONCOGENE			English	Article						ABL; hematopoietic stem cells	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PRIMITIVE HEMATOPOIETIC PROGENITORS; CHRONIC MYELOCYTIC-LEUKEMIA; TYROSINE KINASE-ACTIVITY; BCR-ABL; ABELSON VIRUS; V-ABL; PHILADELPHIA-CHROMOSOME; AUTOCRINE MECHANISM	Chronic myelogenous leukemia (CML) is a hemopoietic stem cell disorder in which an activated ABL oncogene is expressed and has been shown to play an important role in disease pathogenesis. A mouse model has been established in which hemopoietic stem cells (HSCs) transduced with a retrovirus vector carrying an activated ABL oncogene can be analysed. Using this model, we now report that abl-transduced HSCs can be quiescent without causing a disease for an extended period of time. Recipient mice were able to survive more than one treatment of 5-fluorouracil (5-FU) at a dose that normally eliminates cycling hemopoietic progenitor cells; subsequently, transduced HSCs could become activated and undergo clonal expansion, resulting in abl-induced leukemic development. The disease developed in these mice was transplantable. Upon engraftment into secondary mice, previously unidentified abl-transduced HSC clones appeared. These data suggest the presence of an abl-suppressive mechanism in HSCs and have important implications to the pathogenesis of stem cell diseases and leukemic clonal evolution.	TEMPLE UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Chung, SW (corresponding author), TEMPLE UNIV,SCH MED,DEPT BIOCHEM,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140, USA.				NHLBI NIH HHS [HL46547] Funding Source: Medline; NIDDK NIH HHS [DK41298] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046547] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041298] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEDI A, 1993, BLOOD, V81, P2898; BRECHER G, 1993, P NATL ACAD SCI USA, V90, P6028, DOI 10.1073/pnas.90.13.6028; BRETCHER G, 1988, EXP HEMATOL, V16, P627; CHUNG SW, 1988, BLOOD, V71, P973; CHUNG SW, 1986, BLOOD, V68, P1074; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1585, DOI 10.1073/pnas.88.4.1585; CHUNG SW, 1995, ONCOGENE, V10, P1261; CHUNG SW, 1994, ONCOGENE, V9, P3527; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COULOMBEL L, 1983, NEW ENGL J MED, V308, P1493, DOI 10.1056/NEJM198306233082502; CRONKITE EP, 1987, EXP HEMATOL, V16, P627; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DUBE ID, 1984, BLOOD, V63, P1172; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; FIORETOS T, 1994, BLOOD, V83, P3441; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; HADGSON GS, 1979, NATURE, V281, P381; HAN XD, 1991, P NATL ACAD SCI USA, V88, P10129, DOI 10.1073/pnas.88.22.10129; Hariharan I K, 1988, Oncogene Res, V3, P387; HUMPHRIES RK, 1988, EXP HEMATOL, V16, P774; KEATING A, 1994, BLOOD, V83, P1744, DOI 10.1182/blood.V83.7.1744.bloodjournal8371744; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANEUVILLE P, 1992, BLOOD, V80, P1788; LANEUVILLE P, 1991, ONCOGENE, V6, P275; LEBIEN TW, 1979, NEW ENGL J MED, V301, P144, DOI 10.1056/NEJM197907193010307; LERNER C, 1990, EXP HEMATOL, V18, P114; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; NOWELL PC, 1960, SCIENCE, V132, P1497; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; POIRIER Y, 1989, J VIROL, V63, P2088, DOI 10.1128/JVI.63.5.2088-2098.1989; ROVERA G, 1987, ONCOGENE, V1, P29; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SCOTT M, 1991, P NATL ACAD SCI USA, V88, P6505; SIRARD C, 1994, BLOOD, V83, P1575; SOKAL JE, 1980, BLOOD, V56, P1072; SPOONCER E, 1994, LEUKEMIA, V8, P620; VANZANT G, 1984, J EXP MED, V159, P679, DOI 10.1084/jem.159.3.679; VERFAILLIE CM, 1992, BLOOD, V79, P1003; VOGT M, 1987, ONCOGENE RES, V2, P49; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WONG PMC, 1989, MOL CELL BIOL, V9, P798, DOI 10.1128/MCB.9.2.798; WONG PMC, 1987, GENE DEV, V1, P358, DOI 10.1101/gad.1.4.358; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P851	53	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2397	2405						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957081				2022-12-25	WOS:A1996VX10800012
J	Adachi, Y; Matsubara, S; Pedraza, C; Ozawa, M; Tsutsui, J; Takamatsu, H; Noguchi, H; Akiyama, T; Muramatsu, T				Adachi, Y; Matsubara, S; Pedraza, C; Ozawa, M; Tsutsui, J; Takamatsu, H; Noguchi, H; Akiyama, T; Muramatsu, T			Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1)	ONCOGENE			English	Article						Wilms' tumor; WT1; midkine	ACID-RESPONSIVE GENE; GROWTH-DIFFERENTIATION FACTOR; EMBRYONAL CARCINOMA-CELLS; ZINC FINGER PROTEIN; FACTOR-II GENE; FACTOR-A-CHAIN; MOUSE EMBRYOGENESIS; KIDNEY DEVELOPMENT; CHLORAMPHENICOL ACETYLTRANSFERASE; TERATOCARCINOMA SYSTEM	Midkine (MK) is a heparin-binding growth factor which is strongly expressed during the midgestation period of mouse embryogenesis. Wilms' tumor is an embryonal kidney malignancy in infants, and WT1 has been identified as its tumor suppressor gene. The high expression level of MK in all Wilms' tumor specimens so far examined and the presence of two WT1 elements (5-GCGGGGGCG-3') in the human MK promoter region led us to examine the possible role of the WT1 gene product in the regulation of MK gene expression. A gel shift assay verified the complex formation between the WT1 gene product and WT1 consensus sequence of MK gene. DNase1 footprint analysis also demonstrated that the downstream WT1 element was protected from DNase1 cleavage by the addition of the WT1 protein. The human MK promoter fused with the chloramphenicol acetyltransferase gene (phMK2.3kCAT) was cotransfected with an effector plasmid containing the WT1 gene into several cell lines. Transient transfection assays showed suppression of the MK promoter by WT1 co-transfection in recipient cells; deletion of the WT1 binding site abolished the suppression. The evidence reported in this study indicates that MK gene is a newly identified WT1 target gene.	KAGOSHIMA UNIV,FAC MED,DEPT PEDIAT SURG,KAGOSHIMA 890,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,DEPT BIOCHEM,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Kagoshima University; Osaka University; Nagoya University	Adachi, Y (corresponding author), KAGOSHIMA UNIV,FAC MED,DEPT BIOCHEM,8-35-1 SAKURAGAOKA,KAGOSHIMA 890,JAPAN.							ARIDOME K, 1995, JPN J CANCER RES, V86, P655, DOI 10.1111/j.1349-7006.1995.tb02449.x; BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899; BRENNER B, 1992, ONCOGENE, V7, P1431; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1993, J PEDIATR-US, V123, P673, DOI 10.1016/S0022-3476(05)80839-X; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRAIZER GE, 1987, J CELL PHYSIOL, V133, P169, DOI 10.1002/jcp.1041330122; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; FUJISAWASEHARA A, 1986, NUCLEIC ACIDS RES, V14, P1465; GANSLER T, 1989, AM J PATHOL, V135, P961; GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V; GARVIN AJ, 1993, AM J PATHOL, V142, P375; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P227; HANAOKA K, 1991, DIFFERENTIATION, V48, P183, DOI 10.1111/j.1432-0436.1991.tb00256.x; HARBOMEL P, 1984, CELL, V39, P653; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KADOMATSU K, 1990, J CELL BIOL, V110, P607, DOI 10.1083/jcb.110.3.607; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; KIM DW, 1990, GENE, V91, P217, DOI 10.1016/0378-1119(90)90091-5; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LEISENRING WM, 1994, CANCER RES, V54, P4680; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUBARA S, 1994, J BIOCHEM-TOKYO, V115, P1088, DOI 10.1093/oxfordjournals.jbchem.a124462; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; MURAMATSU T, 1993, INT J DEV BIOL, V37, P183; NAKAMOTO M, 1992, J BIOCHEM-TOKYO, V112, P346, DOI 10.1093/oxfordjournals.jbchem.a123903; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEDRAZA C, 1995, J BIOCHEM-TOKYO, V117, P845; PEEBLES PT, 1978, PEDIATR RES, V12, P485, DOI 10.1203/00006450-197804001-00732; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; REEVE AE, 1985, NATURE, V317, P258, DOI 10.1038/317258a0; RYAN G, 1995, DEVELOPMENT, V121, P867; SAWAI S, 1991, NEW BIOL, V3, P861; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; TOMOMURA M, 1990, J BIOL CHEM, V265, P10765; TSUTSUI J, 1993, CANCER RES, V53, P1281; UEHARA K, 1992, J BIOCHEM-TOKYO, V111, P563, DOI 10.1093/oxfordjournals.jbchem.a123797; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999	53	53	60	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2197	2203						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950987				2022-12-25	WOS:A1996VV14500017
J	Molinari, M; Okorokov, AL; Milner, J				Molinari, M; Okorokov, AL; Milner, J			Interaction with damaged DNA induces selective proteolytic cleavage of p53 to yield 40 kDa and 35 kDa fragments competent for sequence-specific DNA binding	ONCOGENE			English	Article						p53; damaged DNA; DNA binding proteolysis	WILD-TYPE P53; ACTIVATED PROTEIN-KINASE; TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; CRYSTAL-STRUCTURE; SINGLE STRANDS; GROWTH ARREST; NUCLEIC-ACIDS; CELL-CYCLE; CONFORMATION	The p53 protein binds sites of primary DNA damage via its C-terminus. This interaction in some way activates sequence-specific binding (via the central core domain) and transactivation of p53 target genes. We now show that interaction with non-specific DNA, but not specific DNA targets, induces selective proteolysis of p53 to give a 40 kDa fragment, comprising the core plus C-terminus, and a 35 KDa conformationally intact core domain. Proteolytic cleavage was limited and yielded roughly equivalent proportions of full length p53 and the 40 kDa and 35 kDa fragments. Significantly, both 40 kDa and 35 kDa products were activated for sequence-specific DNA binding. Similar p53-related products were induced by exposure of cells to DNA damage. We propose that some functions of p53 can be activated by proteolytic processing and that this may be important in the cellular response to DNA damage.	UNIV YORK,DEPT BIOL,YCRC P53 RES GRP,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK				Okorokov, Andrei/0000-0003-2477-3254				BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BAYLE JH, 1995, P NATL ACAD SCI USA, V92, P5729, DOI 10.1073/pnas.92.12.5729; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRAIN R, 1994, ONCOGENE, V9, P1775; CANMAN CE, 1995, SEMIN CANCER BIOL, V6, P17, DOI 10.1006/scbi.1995.0003; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FAN SJ, 1995, CANCER RES, V55, P1649; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1994, ONCOGENE, V9, P299; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HESKETH R, 1995, ONCOGENE FACTS BOOK; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HUANG L, 1996, IN PRESS P NATL ACAD, V96; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, CURR BIOL, V5, P1210, DOI 10.1016/S0960-9822(95)00238-7; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KIM B, 1993, CELL, V73, P1165, DOI 10.1016/0092-8674(93)90645-7; KURIYAN J, 1995, STRUCTURE, V3, P135, DOI 10.1016/S0969-2126(01)00143-5; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1990, ONCOGENE, V5, P1683; MOLINARI M, 1995, ONCOGENE, V10, P1849; MUMMENBRAUER T, 1996, IN PRESS CELL; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAILLARD S, 1993, PROTEINS, V15, P330, DOI 10.1002/prot.340150310; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	54	47	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2077	2086						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950974				2022-12-25	WOS:A1996VV14500004
J	Wolf, MJ; Wang, J; Turk, J; Gross, RW				Wolf, MJ; Wang, J; Turk, J; Gross, RW			Depletion of intracellular calcium stores activates smooth muscle cell calcium-independent phospholipase A(2) - A novel mechanism underlying arachidonic acid mobilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROTID ACINAR-CELLS; CA2+ STORES; INOSITOL PHOSPHATE; CYCLOPIAZONIC ACID; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; THAPSIGARGIN; RELEASE; OSCILLATIONS; HOMEOSTASIS	Herein we present multiple lines of evidence which demonstrate that depletion of internal calcium stores is both necessary and sufficient for the activation of calcium-independent phospholipase A(2) during arginine vasopressin (AVP)-mediated mobilization of arachidonic acid in A-10 smooth muscle cells. First, AVP-induced [H-3]arachidonic acid release was independent of increases in cytosolic calcium yet was decreased by pharmacological inhibition of the release of calcium ion from internal stores. Second, thapsigargin induced the dramatic release of [H-3]arachidonic acid from A-10 cells at a similar rate as the AVP induced release of arachidonic acid, and the release of arachidonic acid by either AVP or thapsigargin was entirely inhibited by (E)-6-(bromomethylene)-3-(1-naphthalenyl)-2H-tetrahydropyran-2-one (BEL). Third, the magnitude of thapsigargin-induced [H-3]arachidonic acid release was entirely independent of alterations in cytosolic calcium concentration. Fourth, A23187 resulted in the BEL-inhibitable release of [H-3]arachidonic acid from A-10 cells even when ionophore-induced increases in cytosolic calcium were completely prevented by calcium chelators. Fifth, pretreatment of A-10 cells with a calmodulin antagonist (N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide, HCl) resulted in the time-dependent decrease of subsequent thapsigarsn-induced [H-3]arachidonic acid release. Collectively, these results identify a novel paradigm which links alterations in calcium homeostasis to the calmodulin-mediated regulation of calcium-independent phospholipase A(2) through the depletion of internal calcium stores.	WASHINGTON UNIV,SCH MED,DEPT MED,DIV BIOORGAN CHEM & MOL PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT LAB MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MASS SPECTROMETRY RESOURCE,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			WOLF, MATTHEW/AHC-5201-2022; wolf, matthew/C-2315-2008	Wolf, Matthew/0000-0001-8004-4852	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057278] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL57278-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALONSO F, 1986, BIOCHIM BIOPHYS ACTA, V878, P273, DOI 10.1016/0005-2760(86)90156-6; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; CARNEY DH, 1985, CELL, V42, P479, DOI 10.1016/0092-8674(85)90105-9; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; FOSKETT JK, 1992, AM J PHYSIOL, V262, pC656, DOI 10.1152/ajpcell.1992.262.3.C656; FOSKETT JK, 1991, J BIOL CHEM, V266, P2778; GRILLONE LR, 1988, J BIOL CHEM, V263, P2658; GROSS RW, 1993, BIOCHEMISTRY-US, V32, P327, DOI 10.1021/bi00052a041; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; HIMPENS B, 1995, J VASC RES, V32, P207, DOI 10.1159/000159095; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEHMAN JJ, 1993, J BIOL CHEM, V268, P20713; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASON MJ, 1991, J BIOL CHEM, V266, P20856; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PHAIR RD, 1988, CELL CALCIUM, V9, P275, DOI 10.1016/0143-4160(88)90008-5; PIETROBON D, 1990, EUR J BIOCHEM, V193, P599, DOI 10.1111/j.1432-1033.1990.tb19378.x; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; PUTNEY JW, 1987, TRENDS PHARMACOL SCI, V8, P481, DOI 10.1016/0165-6147(87)90043-5; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; REMBOLD CM, 1992, HYPERTENSION, V20, P129, DOI 10.1161/01.HYP.20.2.129; ROE MW, 1993, J BIOL CHEM, V268, P9953; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; STASSEN FL, 1988, MOL PHARMACOL, V31, P259; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THATRUP O, 1990, P NATL ACAD SCI USA, V87, P2466; TSE A, 1994, J PHYSIOL-LONDON, V477, P511, DOI 10.1113/jphysiol.1994.sp020212; UFRETVINCENTY CA, 1995, J BIOL CHEM, V270, P26790, DOI 10.1074/jbc.270.45.26790; WALDRON RT, 1994, J BIOL CHEM, V269, P11927; Wolf MJ, 1995, FEBS LETT, V377, P358, DOI 10.1016/0014-5793(95)01371-7; Wolf MJ, 1996, J BIOL CHEM, V271, P20989, DOI 10.1074/jbc.271.35.20989; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	45	108	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1522	1526		10.1074/jbc.272.3.1522	http://dx.doi.org/10.1074/jbc.272.3.1522			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999823	hybrid			2022-12-25	WOS:A1997WD05800021
J	Zong, CS; Chan, JLK; Yang, SK; Wang, LH				Zong, CS; Chan, JLK; Yang, SK; Wang, LH			Mutations of Ros differentially effecting signal transduction pathways leading to cell growth versus transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; PROTEIN-TYROSINE KINASE; PROTOONCOGENE C-ROS; ACTIN STRESS FIBERS; SARCOMA VIRUS UR2; INSULIN-RECEPTOR; ONCOGENIC TRANSFORMATION; DROSOPHILA-MELANOGASTER; FACTOR STIMULATION; FOCAL ADHESIONS	The signaling functions of the oncogenic protein-tyrosine kinase v-Ros were studied by systematically mutating the tyrosine residues in its cytoplasmic domain. The carboxyl mutation of Tyr-564 produces the most pronounced inhibitory effect on v-Ros autophosphorylation and interaction with phospholipase C gamma. A cluster of 3 tyrosine residues, Tyr-414, Tyr-418, and Tyr-419, within the PTK domain of v-Ros plays an important role in modulating its kinase activity. The mutant F419 and the mutant DI, deleting 6-amino acids near the catalytic loop, retain wild type protein tyrosine kinase and mitogenic activities, but have dramatically reduced oncogenicity. Both mutant proteins are able to phosphorylate or activate components in the Ras/microtubule-associated protein kinase signaling pathway. However, F419 mutant protein is unable to phosphorylate insulin receptor substrate 1 (IRS-1) or promote association of IRS-1 with phosphatidylinositol 3-kinase. This tyrosine residue in the context of the NDYY motif may define a novel recognition site for IRS-1. Both F419 and DI mutants display impaired ability to induce tyrosine phosphorylation of a series of cytoskeletal and cell-cell interacting proteins. Thus the F419 and DI mutations define v-Ros sequences important for cytoskeleton signaling, the impairment of which correlates with the reduced cell transforming ability.	CUNY MT SINAI SCH MED, DEPT MICROBIOL, NEW YORK, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACKER JM, 1992, J BIOL CHEM, V267, P1367; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN JM, 1991, ONCOGENE, V6, P257; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUMBINER BM, 1993, J CELL SCI, P155; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; JONG SMJ, 1987, ONCOGENE RES, V1, P7; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P1350; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; WANG HCR, 1989, J VIROL, V63, P291, DOI 10.1128/JVI.63.1.291-302.1989; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; ZONG CS, 1994, P NATL ACAD SCI USA, V91, P10982, DOI 10.1073/pnas.91.23.10982	43	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1500	1506		10.1074/jbc.272.3.1500	http://dx.doi.org/10.1074/jbc.272.3.1500			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999820	hybrid			2022-12-25	WOS:A1997WD05800018
J	Moro, O; Lerner, EA				Moro, O; Lerner, EA			Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLY LUTZOMYIA-LONGIPALPIS; PACAP-LIKE NEUROPEPTIDE; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; SALIVARY-GLANDS; POLYPEPTIDE; CLONING; TRANSMISSION; DROSOPHILA; INHIBITOR	Maxadilan is a potent vasodilator peptide isolated from salivary gland lysates of the sand fly Lutzomyia longipalpis, a vector of leishmaniasis. The peptide aids the fly in obtaining blood from the skin of its vertebrate hosts but the mammalian receptor through which this insect ligand acts was unknown. We demonstrate that maxadilan is an agonist of the type I receptor for pituitary adenylate cyclase activating peptide, a neuropeptide with vascular activity. This surprising observation is a unique example of convergent evolution from a functional standpoint as these two peptides do not share significant sequence homology.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,DEPT DERMATOL,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042005] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR42005-01] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; ARIMURA A, 1992, REGUL PEPTIDES, V37, P286; BREIMER LH, 1988, BIOCHEM J, V255, P377, DOI 10.1042/bj2550377; GREVELINK SA, 1993, P NATL ACAD SCI USA, V90, P9155, DOI 10.1073/pnas.90.19.9155; GREVELINK SA, 1995, J PHARMACOL EXP THER, V272, P33; HEIMBROOK DC, 1988, J BIOL CHEM, V263, P7016; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; KLOOG Y, 1988, SCIENCE, V242, P268, DOI 10.1126/science.2845579; LERNER EA, 1992, J BIOL CHEM, V267, P1062; LERNER EA, 1991, J BIOL CHEM, V266, P11234; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MORO O, 1995, BIOCHEM BIOPH RES CO, V216, P234, DOI 10.1006/bbrc.1995.2615; MORO O, 1997, IN PRESS INSECT BIOC; NONG YH, 1989, J IMMUNOL, V143, P45; PISEGNA JR, 1993, P NATL ACAD SCI USA, V90, P6345, DOI 10.1073/pnas.90.13.6345; Qureshi AA, 1996, AM J TROP MED HYG, V54, P665, DOI 10.4269/ajtmh.1996.54.665; RIBEIRO JMC, 1989, SCIENCE, V243, P212, DOI 10.1126/science.2783496; RIBEIRO JMC, 1987, ANNU REV ENTOMOL, V32, P463, DOI 10.1146/annurev.en.32.010187.002335; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; ROBBERECHT P, 1988, FEBS LETT, V228, P351, DOI 10.1016/0014-5793(88)80030-9; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; WAXMAN L, 1990, SCIENCE, V248, P593, DOI 10.1126/science.2333510; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0; ZHONG Y, 1995, NEURON, V14, P527, DOI 10.1016/0896-6273(95)90309-7	26	162	173	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					966	970		10.1074/jbc.272.2.966	http://dx.doi.org/10.1074/jbc.272.2.966			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995389	hybrid			2022-12-25	WOS:A1997WC04800040
J	Davidson, JM; LuValle, PA; Zoia, O; Quaglino, D; Giro, MG				Davidson, JM; LuValle, PA; Zoia, O; Quaglino, D; Giro, MG			Ascorbate differentially regulates elastin and collagen biosynthesis in vascular smooth muscle cells and skin fibroblasts by pretranslational mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN-MESSENGER-RNA; STIMULATED LIPID-PEROXIDATION; HUMAN DERMAL FIBROBLASTS; EPIDERMAL GROWTH-FACTOR; CHICK TENDON COLLAGEN; INCREASES TYPE-I; GENE-EXPRESSION; PROLINE HYDROXYLATION; EXTRACELLULAR-MATRIX; LYSYL HYDROXYLASE	Ascorbate contributes to several metabolic processes including efficient hydroxylation of hydroxyproline in elastin, collagen, and proteins with collagenous domains, yet hydroxyproline in elastin has no known function. Prolyl hydroxylation is essential for efficient collagen production; in contrast, ascorbate has been shown to decrease elastin accumulation in vitro and to alter morphology of elastic tissues in vivo, Ascorbate doses that maximally stimulated collagen production (10-200 mu M) antagonized elastin biosynthesis in vascular smooth muscle cells and skin fibroblasts, depending on a com bination of dose and exposure time. Diminished elastin production paralleled reduced elastin mRNA levels, while collagen I and III mRNAs levels increased. We compared the stability of mRNAs for elastin and collagen I with a constitutive gene after ascorbate supplementation or withdrawal. Ascorbate decreased elastin mRNA stability, while collagen I mRNA was stabilized to a much greater extent. Ascorbate withdrawal decreased collagen I mRNA stability markedly (4.9-fold), while elastin mRNA became more stable. Transcription of elastin was reduced 72% by ascorbate exposure. Differential effects of ascorbic acid on collagen I and elastin mRNA abundance result from the combined, marked stabilization of collagen mRNA, the lesser stability of elastin mRNA, and the significant repression of elastin gene transcription.	UNIV MODENA, DIPARTIMENTO SCI BIOMED, SEZ PATOL GEN, I-41100 MODENA, ITALY; DEPT VET AFFAIRS MED CTR, NASHVILLE, TN 37212 USA; UNIV UTAH, SCH MED, DEPT PATHOL, SALT LAKE CITY, UT 84132 USA	Universita di Modena e Reggio Emilia; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Utah System of Higher Education; University of Utah	Davidson, JM (corresponding author), VANDERBILT UNIV, SCH MED, DEPT PATHOL, C-3321 MCN, NASHVILLE, TN 37232 USA.		Quaglino, Daniela/A-9381-2010	Quaglino, Daniela/0000-0002-4302-5078	NIGMS NIH HHS [GM37387] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037387] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCAIN FJ, 1994, J BIOENERG BIOMEMBR, V26, P393, DOI 10.1007/BF00762780; ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; BARONE LM, 1985, BIOCHIM BIOPHYS ACTA, V840, P245, DOI 10.1016/0304-4165(85)90125-4; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BERGETHON PR, 1989, BIOCHEM J, V258, P279, DOI 10.1042/bj2580279; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1985, BIOCHEMISTRY-US, V24, P2698, DOI 10.1021/bi00332a016; BLANCK TJJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P259, DOI 10.1016/0003-9861(75)90031-4; BUCKLEY A, 1988, METHOD ENZYMOL, V163, P674; CHOJKIER M, 1989, J BIOL CHEM, V264, P16957; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; DARR D, 1993, ARCH BIOCHEM BIOPHYS, V307, P331, DOI 10.1006/abbi.1993.1596; DAVIDSON JM, 1985, J BIOL CHEM, V260, P1901; DAVIDSON JM, 1981, METHOD CELL BIOL, V23, P119, DOI 10.1016/S0091-679X(08)61495-8; DECLERCK YA, 1980, BIOCHEM J, V186, P217, DOI 10.1042/bj1860217; DUNN DM, 1982, BIOCHEMISTRY-US, V21, P4195, DOI 10.1021/bi00261a001; FARIS B, 1984, BIOCHIM BIOPHYS ACTA, V797, P71, DOI 10.1016/0304-4165(84)90383-0; FAZIO MJ, 1988, LAB INVEST, V58, P270; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FRANCESCHI RT, 1992, NUTR REV, V50, P65; FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843; FRISCH SM, 1985, MOL CELL BIOL, V5, P253, DOI 10.1128/MCB.5.1.253; GEESIN JC, 1988, J INVEST DERMATOL, V90, P420, DOI 10.1111/1523-1747.ep12460849; GEESIN JC, 1991, ARCH BIOCHEM BIOPHYS, V289, P6, DOI 10.1016/0003-9861(91)90434-K; GEESIN JC, 1991, ARCH BIOCHEM BIOPHYS, V290, P127, DOI 10.1016/0003-9861(91)90598-D; GEESIN JC, 1990, ARCH BIOCHEM BIOPHYS, V278, P350, DOI 10.1016/0003-9861(90)90270-9; GIRO MG, 1984, COLLAGEN REL RES, V4, P21; HOROWITZ S, 1989, J BIOL CHEM, V264, P7092; HOUGLUM KP, 1991, AM J CLIN NUTR, V54, pS1141, DOI 10.1093/ajcn/54.6.1141s; JIMENEZ S, 1973, BIOCHEM BIOPH RES CO, V52, P106, DOI 10.1016/0006-291X(73)90960-1; KAHARI VM, 1992, LAB INVEST, V66, P580; KAO WWY, 1976, ARCH BIOCHEM BIOPHYS, V173, P638, DOI 10.1016/0003-9861(76)90301-5; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1980, ENZYMOLOGY POST TRAN, P53; KURATA S, 1991, J BIOL CHEM, V266, P9997; KURATA SI, 1993, EXP CELL RES, V206, P63, DOI 10.1006/excr.1993.1121; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Lind J., 1753, TREATISE SCURVY; LYONS BL, 1984, NUCLEIC ACIDS RES, V12, P2569, DOI 10.1093/nar/12.5.2569; MAGUIRE MC, 1994, BIOCHEM SOC T, V22, pS51, DOI 10.1042/bst022051s; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MISKULIN M, 1986, BIOCHEMISTRY-US, V25, P1408, DOI 10.1021/bi00354a033; MURAD S, 1981, P NATL ACAD SCI-BIOL, V78, P2879, DOI 10.1073/pnas.78.5.2879; MURAD S, 1981, BIOCHEM BIOPH RES CO, V101, P868, DOI 10.1016/0006-291X(81)91830-1; MURAD S, 1983, J INVEST DERMATOL, V81, P158, DOI 10.1111/1523-1747.ep12543573; MYLLYLA R, 1984, J BIOL CHEM, V259, P5403; Parks William C., 1993, V6, P133; PETERKOF.B, 1972, ARCH BIOCHEM BIOPHYS, V152, P318, DOI 10.1016/0003-9861(72)90221-4; PHILLIPS CL, 1992, ARCH BIOCHEM BIOPHYS, V295, P397, DOI 10.1016/0003-9861(92)90533-3; PHILLIPS CL, 1994, J INVEST DERMATOL, V103, P228, DOI 10.1111/1523-1747.ep12393187; QUAGLINO D, 1991, EUR J CELL BIOL, V54, P18; RODBARD D, 1971, PRINCIPLES COMPETITI, P158; ROSENBLO.J, 1973, ARCH BIOCHEM BIOPHYS, V158, P478, DOI 10.1016/0003-9861(73)90539-0; ROSENBLOOM J, 1976, FEBS LETT, V65, P246, DOI 10.1016/0014-5793(76)80490-5; ROWE LB, 1983, MOL CELL BIOL, V3, P241, DOI 10.1128/MCB.3.2.241; RUCKMAN JL, 1994, MATRIX BIOL, V14, P135, DOI 10.1016/0945-053X(94)90003-5; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDELL LJ, 1988, CONNECT TISSUE RES, V17, P11, DOI 10.3109/03008208808992790; SCHEIN J, 1977, ARCH BIOCHEM BIOPHYS, V183, P416, DOI 10.1016/0003-9861(77)90376-9; SCHWARZ RI, 1985, J BIOL CHEM, V260, P3045; SCOTTBURDEN T, 1979, BIOCHEM BIOPH RES CO, V91, P739, DOI 10.1016/0006-291X(79)91942-9; TAJIMA S, 1982, BIOCHEM BIOPH RES CO, V106, P632, DOI 10.1016/0006-291X(82)91157-3; Tajima Shingo, 1995, Keio Journal of Medicine, V44, P140; UITTO J, 1976, ARCH BIOCHEM BIOPHYS, V173, P187, DOI 10.1016/0003-9861(76)90249-6; UITTO J, 1979, J INVEST DERMATOL, V72, P1, DOI 10.1111/1523-1747.ep12530093; URRY DW, 1979, BIOCHEM BIOPH RES CO, V90, P194, DOI 10.1016/0006-291X(79)91608-5; VENESSMEEHAN KA, 1991, AM J RESP CELL MOL, V5, P516, DOI 10.1165/ajrcmb/5.6.516; WHITE BA, 1982, J BIOL CHEM, V257, P8569; YOON K, 1985, ARCH BIOCHEM BIOPHYS, V241, P684, DOI 10.1016/0003-9861(85)90595-8; ZERN MA, 1985, EXP CELL RES, V160, P307, DOI 10.1016/0014-4827(85)90178-8; ZHANG MC, 1995, J CLIN INVEST, V95, P986, DOI 10.1172/JCI117808	74	115	120	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					345	352						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995268	hybrid			2022-12-25	WOS:A1997WA56400055
J	Kinsella, MG; Tsoi, CK; Jarvelainen, HT; Wight, TN				Kinsella, MG; Tsoi, CK; Jarvelainen, HT; Wight, TN			Selective expression and processing of biglycan during migration of bovine aortic endothelial cells - The role of endogenous basic fibroblast growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; DERMATAN SULFATE PROTEOGLYCANS; FACTOR-BETA; PLASMINOGEN-ACTIVATOR; I COLLAGEN; DECORIN; FIBRONECTIN; INHIBITION; MOLECULE; CULTURE	Repair of the vascular lumenal surface after injury requires a controlled endothelial cell response that includes cell migration, proliferation, and remodeling of the extracellular matrix. These cellular processes are modulated by growth factors that are released or activated following cell injury. When endothelial cell migration is stimulated in response to monolayer wounding in vitro, cells increase synthesis of small leucine-rich dermatan sulfate proteoglycans (PGs) (Kinsella, M. G., and Wight, T. N. (1986) J. Cell Biol. 102, 679-687), However, the identity of the PGs that are increased during cell migration and the factors that affect this modulation have not been identified. We now report that basic fibroblast growth factor (bFGF) is responsible for the transient increase of [S-35]sulfate incorporation into PGs following monolayer wounding. SDS-polyacrylamide gel electrophoresis analysis revealed that bFGF-treated and wounded cultures increase both biglycan core protein synthesis and biglycan proteolytic processing, which results in the accumulation of a similar to 20-kDa N-terminal biglycan fragment in the culture media. Biglycan RNA steady-state levels also selectively increase 2- to 3-fold after wounding or bFGF treatment. Finally, immunocytochemical staining localizes biglycan to the tips and edges of lamellopodia on migrating cells, indicating that biglycan is found at loci at which the formation and dissolution of adhesion plaques occurs, consistent with hypotheses that predict involvement of biglycan in the control of cell migration, Taken together, these results suggest that release of endogenous bFGF is primarily responsible for altered biglycan expression, synthesis, and proteolytic processing as endothelial cells migrate after wounding.			Kinsella, MG (corresponding author), UNIV WASHINGTON,DEPT PATHOL,BOX 357470,SEATTLE,WA 98195, USA.				FIC NIH HHS [F05TW04222] Funding Source: Medline; NHLBI NIH HHS [HL18645] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [F05TW004222] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; BIDANSET DJ, 1992, J CELL BIOL, V118, P1523, DOI 10.1083/jcb.118.6.1523; Bjerrum O. J., 1986, ANAL ELECTROPHORESIS; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUCHMAN JR, 1990, J INVEST DERMATOL, V94, pS7, DOI 10.1111/1523-1747.ep12874973; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GROSS JL, 1982, J CELL BIOL, V95, P974, DOI 10.1083/jcb.95.3.974; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; KINSELLA MG, 1990, J BIOL CHEM, V265, P17891; KINSELLA MG, 1986, J CELL BIOL, V102, P679, DOI 10.1083/jcb.102.3.679; KINSELLA MG, 1988, J BIOL CHEM, V263, P19222; KLEBANOFF SJ, 1993, AM J PATHOL, V143, P907; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; KU PT, 1995, J CELL BIOCHEM, V58, P328, DOI 10.1002/jcb.240580307; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; Maniatis T., 1982, MOL CLONING; MCGUIRE PG, 1993, DEVELOPMENT, V118, P931; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MURDOCH AD, 1992, J BIOL CHEM, V267, P8544; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; ROBERTS AB, 1989, AM REV RESPIR DIS, V140, P1126, DOI 10.1164/ajrccm/140.4.1126; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAITO H, 1968, J BIOL CHEM, V243, P1536; SAKU T, 1989, J BIOL CHEM, V264, P3514; SATO Y, 1989, J CELL BIOL, V109, P309, DOI 10.1083/jcb.109.1.309; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; SCOTT JE, 1981, BIOCHEM J, V197, P213, DOI 10.1042/bj1970213; TAN EML, 1991, LAB INVEST, V64, P474; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VOSS B, 1986, J HISTOCHEM CYTOCHEM, V34, P1013, DOI 10.1177/34.8.2426331; WASTESON A, 1973, BIOCHEM J, V136, P1069, DOI 10.1042/bj1361069; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; WINNEMOLLER M, 1992, EUR J CELL BIOL, V59, P47; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0	47	93	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					318	325						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995264				2022-12-25	WOS:A1997WA56400051
J	Schmedtje, JF; Ji, YS; Liu, WL; DuBois, RN; Runge, MS				Schmedtje, JF; Ji, YS; Liu, WL; DuBois, RN; Runge, MS			Hypoxia induces cyclooxygenase-2 via the NF-kappa B p65 transcription factor in human vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR GENE; NUCLEAR FACTOR; INDUCIBLE CYCLOOXYGENASE; PHORBOL ESTER; MESSENGER-RNA; EXPRESSION; ACTIVATION; LIPOPOLYSACCHARIDE; PHOSPHORYLATION; CLONING	The inducible cyclooxygenase, COX-2, has been associated with vascular inflammation and cellular proliferation, We have discovered that hypoxia increases expression of the COX-2 gene in human vascular endothelial cells in culture independent of other stimuli. Western analysis of human umbilical vein endothelial cells (HUVEC) revealed a greater than 4-fold induction of protein by hypoxia (1% O-2), The steady-state level of COX-2 mRNA was correspondingly elevated by both Northern blot and reverse transcriptase-polymerase chain reaction analysis. Using electrophoretic mobility shift assays with antibody supershifting, we also found that hypoxia causes increased binding of NF-kappa B p65 (Rel A) to the one out of the two NF-kappa B consensus elements in the COX-2 promoter which is closest to the transcription start site of the COX-2 gene. Transfection of an immortalized human microvascular endothelial cell line (HMEC-1) with mutation reporter gene constructs and HUVEC with both mutation and deletion reporter gene constructs suggested that transcription of the COX-2 gene was enhanced by hypoxia. In transcription factor decoy experiments, hypoxic HUVEC were exposed in culture to 20 mu M of the same NF-kappa B element found to bind NF-kappa B protein, The wild type transcription factor decoy prevented hypoxic induction of COX-2, presumably by binding with cytoplasmic p65; however, mutated or scrambled oligonucleotides did not prevent the increase in COX-2 protein expression by hypoxia. Thus, the intracellular signaling mechanism that leads to induction of COX-2 by hypoxia includes binding of p65 to the relatively 3' NF-kappa B consensus element in the COX-2 upstream promoter region in human vascular endothelial cells.	VANDERBILT UNIV, MED CTR, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	Schmedtje, JF (corresponding author), UNIV TEXAS, MED BRANCH,DEPT MED,SEALY CTR MOL CARDIOL, 301 UNIV BLVD, RT 1064, GALVESTON, TX 77555 USA.		DuBois, Raymond N./AAX-8869-2020		NHLBI NIH HHS [P01 HL48667] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048667] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BAZAN NG, 1994, P NATL ACAD SCI USA, V91, P5252, DOI 10.1073/pnas.91.12.5252; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COLLINS T, 1993, LAB INVEST, V68, P499; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; DUBOIS RN, 1994, AM J PHYSIOL, V266, pG822; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; EVETT GE, 1993, ARCH BIOCHEM BIOPHYS, V306, P169, DOI 10.1006/abbi.1993.1496; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; FARBER HW, 1990, EXP CELL RES, V191, P27, DOI 10.1016/0014-4827(90)90031-5; FINKENZELLER G, 1995, BIOCHEM BIOPH RES CO, V208, P432, DOI 10.1006/bbrc.1995.1356; FUSTER V, 1993, CIRCULATION, V87, P659, DOI 10.1161/01.CIR.87.2.659; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; HABIB A, 1993, J BIOL CHEM, V268, P23448; HEMPEL SL, 1994, J BIOL CHEM, V269, P32979; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KOONG AC, 1994, CANCER RES, V54, P1425; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LEE SH, 1992, J BIOL CHEM, V267, P25934; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; LU XJ, 1995, P NATL ACAD SCI USA, V92, P7961, DOI 10.1073/pnas.92.17.7961; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; MICHELS C, 1993, AM J PHYSIOL, V264, pC866, DOI 10.1152/ajpcell.1993.264.4.C866; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; Munroe DG, 1995, J INFLAMM, V45, P260; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Planas AM, 1995, NEUROSCI LETT, V200, P187, DOI 10.1016/0304-3940(95)12108-G; Pratico D, 1996, J BIOL CHEM, V271, P8919, DOI 10.1074/jbc.271.15.8919; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; RUPEC RA, 1995, EUR J BIOCHEM, V234, P632, DOI 10.1111/j.1432-1033.1995.632_b.x; Schmedtje JF, 1996, BIOCHEM BIOPH RES CO, V220, P687, DOI 10.1006/bbrc.1996.0465; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Sharma HW, 1996, ANTICANCER RES, V16, P61; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRIBBLE DL, 1990, BIOCHEM PHARMACOL, V39, P729, DOI 10.1016/0006-2952(90)90152-B; Verrier E, 1996, J CARDIOVASC PHARM, V27, pS26; WEKSLER BB, 1982, CARDIOVASCULAR PHARM, P137; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	47	603	623	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					601	608						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995303				2022-12-25	WOS:A1997WA56400090
J	Wang, JC; Gebre, AK; Anderson, RA; Parks, JS				Wang, JC; Gebre, AK; Anderson, RA; Parks, JS			Amino acid residue 149 of lecithin:cholesterol acyltransferase determines phospholipase A(2) and transacylase fatty acyl specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEINS; APOLIPOPROTEIN A-I; PLASMA LECITHIN; POSITIONAL SPECIFICITY; CATALYTIC MECHANISM; MICELLAR COMPLEXES; SN-2 POSITION; PHOSPHATIDYLCHOLINE; RAT; REACTIVITY	Human LCAT prefers phosphatidylcholine (PC) with sn-1-palmitoyl-2-oleoyl PC (POPC) as substrate for cholesteryl ester synthesis, whereas rat LCAT (which is 92% similar in amino acid sequence) prefers sn-1-palmitoyl-2-arachidonoyl PC (PAPC), Six recombinant human LCAT cDNA clones were constructed with unique clusters of rat sequence substitutions in the human background spanning the region encoding amino acids 121-296, Media from transfected COS cells expressing each of the constructs were assayed for LCAT cholesterol esterification (CE) or phospholipase A(2) (PLA(2)) activity using substrate particles containing POPC or PAPC, The PAPC/POPC CE activity ratio of the cluster 1 construct (amino acids 149-158) was 1.3, resembling rat LCAT, whereas cluster 2-5 clones produced CE activity ratios <0.3, unchanged from human LCAT, The cluster 6 clone (Y292H/W294F) had an intermediate ratio (0.6), Similar results were observed for LCAT PLA(2) activity, In additional studies, position 149 of human LCAT was changed to the rat sequence (hE149A) and compared to a triple mutation containing the remainder of the cluster 1 changes (G151R/E154D/R158Q), CE and PLA(2) activity ratio for the hE149A construct was >1.7, similar to rat LCAT, whereas the triple mutation construct retained a ratio similar to human LCAT (<0.6). Thus, a single amino acid substitution (E149A) was sufficient to alter the fatty acyl specificity of human LCAT to that of rat LCAT, with an increase in activity toward PAPC, This is the first example of a point mutation in an enzyme with PLA(2) activity that results in an increase in activity toward arachidonic acid.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT COMPARAT MED,WINSTON SALEM,NC 27157; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT INTERNAL MED,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center					NHLBI NIH HHS [HL 49373, HL 54176, HL 47864] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047864, R01HL054176, P01HL049373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKITA EM, 1993, J IMMUNOL METHODS, V160, P207, DOI 10.1016/0022-1759(93)90179-B; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AUERBACH BJ, 1990, J LIPID RES, V31, P738; AUERBACH BJ, 1989, J BIOL CHEM, V264, P10264; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABIAK J, 1986, J LIPID RES, V27, P1304; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOLIN DJ, 1994, J BIOL CHEM, V269, P7429; CZARNECKA H, 1993, J BIOL CHEM, V268, P19334; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EVANS RW, 1987, BIOCHEM J, V245, P455, DOI 10.1042/bj2450455; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FISKE HC, 1925, J BIOL CHEM, V66, P357; GLOMSET JA, 1970, J CLIN INVEST, V49, P1827, DOI 10.1172/JCI106400; GLOMSET JA, 1968, J LIPID RES, V9, P155; GROVE D, 1991, LIPIDS, V26, P416, DOI 10.1007/BF02536066; HAMILTON RL, 1976, J CLIN INVEST, V58, P667, DOI 10.1172/JCI108513; HAMMAD S, 1992, J LIQ CHROMATOGR, V15, P2005, DOI 10.1080/10826079208020874; HIDA Y, 1993, BIOSCI BIOTECH BIOCH, V57, P1111, DOI 10.1271/bbb.57.1111; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIU M, 1995, J LIPID RES, V36, P1813; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATZ CE, 1982, J BIOL CHEM, V257, P4541; MATZ CE, 1982, J BIOL CHEM, V257, P4535; MCLEAN J, 1986, P NATL ACAD SCI USA, V83, P2335, DOI 10.1073/pnas.83.8.2335; MERONI G, 1990, NUCLEIC ACIDS RES, V18, P5308, DOI 10.1093/nar/18.17.5308; Miller KR, 1996, J LIPID RES, V37, P551; PARKS JS, 1992, J LIPID RES, V33, P879; PARKS JS, 1979, J BIOL CHEM, V254, P6716; PARKS JS, 1989, J BIOL CHEM, V264, P2545; PARKS JS, 1993, J LIPID RES, V34, P779; PORTMAN OW, 1964, ARCH BIOCHEM BIOPHYS, V105, P532, DOI 10.1016/0003-9861(64)90048-7; POWNALL HJ, 1987, J BIOL CHEM, V262, P9033; POWNALL HJ, 1985, BIOCHIM BIOPHYS ACTA, V833, P456, DOI 10.1016/0005-2760(85)90103-1; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SGOUTAS DS, 1972, BIOCHEMISTRY-US, V11, P293, DOI 10.1021/bi00752a022; SUBBAIAH PV, 1994, BBA-LIPID LIPID MET, V1215, P150, DOI 10.1016/0005-2760(94)90104-X; SUBBAIAH PV, 1992, BIOCHIM BIOPHYS ACTA, V1128, P83, DOI 10.1016/0005-2760(92)90261-S; SUBBAIAH PV, 1994, BIOCHEMISTRY-US, V33, P13259, DOI 10.1021/bi00249a012; THORNBURG JT, 1995, J LIPID RES, V36, P277; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	44	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					280	286						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995259				2022-12-25	WOS:A1997WA56400046
J	Avdi, NJ; Winston, BW; Russel, M; Young, SK; Johnson, GL; Worthen, GS				Avdi, NJ; Winston, BW; Russel, M; Young, SK; Johnson, GL; Worthen, GS			Activation of MEKK by formyl-methionyl-leucyl-phenylalanine in human neutrophils - Mapping pathways for mitogen-activated protein kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MAP KINASE; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; MAMMALIAN-CELLS; POTENTIAL ROLE; GROWTH-FACTOR; WORTMANNIN; INHIBITION	Mechanisms of neutrophil activation in response to chemoattractants remain incompletely understood,.We have recently reported a Ras-mediated c-Raf pathway leading to the activation of mitogen activated protein (MAP) kinase in human neutrophils stimulated with the chemoattractant formyl-Met-Leu-Phe (FMLP). However, concern that Raf activation may not fully account for the early FMLP-mediated human neutrophil responses prompted us to investigate the activation of MAP kinase/ERK kinase (MEK) by MEK kinase (MEKK). In cell lysates we identified protein species at 180, 160, 110, 72, and 54 kDa with a monoclonal antibody to MEKK, Activation of MEKK was determined on immunoprecipitates from FMLP-stimulated neutrophils by in vitro kinase assay, which utilized both MEK1 and MEK2 as substrates. It was rapid, detectable at 30 s and reaching a plateau at 5 min, and it was inhibited in a dose-dependent fashion by a specific phosphatidylinositol 3-kinase inhibitor, wortmannin. Partial inhibition by pertussis toxin was observed. We were unable to show inhibition of the MEKK response by GF 109203X, a protein kinase C-specific inhibitor. These data indicate that in neutrophils activation of MEKK in addition to Raf may under-lie stimulation of MAP kinase and other MAP kinase homologues by FMLP.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80206	National Jewish Health; National Jewish Health; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NHLBI NIH HHS [HL-40784, HL-34303] Funding Source: Medline; NIGMS NIH HHS [GM-30324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303, P50HL040784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BLUMER KJ, 1994, P NATL ACAD SCI USA, V91, P4925, DOI 10.1073/pnas.91.11.4925; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOULAY F, 1990, BIOCHEMISTRY-US, V29, P11123, DOI 10.1021/bi00502a016; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FERBY IM, 1994, J BIOL CHEM, V269, P30485; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HASLETT C, 1985, AM J PATHOL, V119, P101; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAUDANNA C, 1993, BIOCHEM BIOPH RES CO, V190, P935, DOI 10.1006/bbrc.1993.1139; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; OKADA T, 1994, J BIOL CHEM, V269, P3563; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PELECH SL, 1993, CURR BIOL, V3, P513, DOI 10.1016/0960-9822(93)90043-N; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANDBORG RR, 1988, LAB INVEST, V59, P300; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P1059, DOI 10.1073/pnas.72.3.1059; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WINSTON BW, 1995, P NATL ACAD SCI USA, V92, P1614, DOI 10.1073/pnas.92.5.1614; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WORTHEN GS, 1988, J IMMUNOL, V140, P3553	51	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33598	33606		10.1074/jbc.271.52.33598	http://dx.doi.org/10.1074/jbc.271.52.33598			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969228	hybrid			2022-12-25	WOS:A1996WA71300062
J	Corthesy, B; Kaufmann, M; Phalipon, A; Peitsch, M; Neutra, MR; Kraehenbuhl, JP				Corthesy, B; Kaufmann, M; Phalipon, A; Peitsch, M; Neutra, MR; Kraehenbuhl, JP			A pathogen-specific epitope inserted into recombinant secretory immunoglobulin A is immunogenic by the oral route	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL EPITOPES; SHIGELLA-FLEXNERI; CHOLERA-TOXIN; EPITHELIAL-CELLS; IG RECEPTOR; DIMERIC IGA; HELA-CELLS; DOMAIN-I; TOLERANCE; RABBIT	Oral administration of rabbit secretory IgA (sIgA) to adult BALB/c mice induced IgA(+), IgM(+), and IgG(+) lymphoblasts in the Peyer's patches, whose fusion with myeloma cells resulted in hybridomas producing IgA, IgM, and IgG1 antibodies to the secretory component (SC). This suggests that SC could serve as a vector to target protective epitopes into mucosal lymphoid tissue and elicit an immune response. We tested this concept by inserting a Shigella flexneri invasin B epitope into SC. which, following reassociation with IgA, was delivered orally to mice. To identify potential insertion sites at the surface of SC, we constructed a molecular model of the first and second Ig-like domains of rabbit SC. A surface epitope recognized by an SC-specific antibody was mapped to the loop connecting the E and F beta strands of domain I. This 8-amino acid sequence was replaced by a 9-amino acid linear epitope from S. flexneri invasin B. We found that cellular trafficking of recombinant SC produced in mammalian CV-1 cells was drastically altered and resulted in a 50-fold lower rate of secretion, However, purification of chimeric SC could be achieved by Ni2+-chelate affinity chromatoraphy. Both wild type and chimeric SC bound to dimeric IgA, but not to monomeric IgA, Reconstituted sIgA carrying the invasin B epitope within the SC moiety triggers the appearance of seric and salivary invasin B-specific antibodies. Thus, neo-antigenized sIgA can serve as a mucosal vaccine delivery system inducing systemic and mucosal immune responses.	INST BIOCHIM,CH-1066 EPALINGES,SWITZERLAND; INST PASTEUR,UNITE PATHOGENIE MICROBIENNE MOL,F-75724 PARIS 15,FRANCE; GLAXO INST MOL BIOL SA,CH-1228 PLAN LES OUATES,SWITZERLAND; CHILDRENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Corthesy, B (corresponding author), INST SUISSE RECH EXPT CANC,CHEM BOVERESSES 155,CH-1066 EPALINGES,SWITZERLAND.		Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				BAKOS MA, 1994, MOL IMMUNOL, V31, P165, DOI 10.1016/0161-5890(94)90088-4; BANTING G, 1989, FEBS LETT, V254, P177, DOI 10.1016/0014-5793(89)81034-8; BARZU S, 1993, INFECT IMMUN, V61, P3825, DOI 10.1128/IAI.61.9.3825-3831.1993; BAUDRY B, 1987, J GEN MICROBIOL, V133, P3403; BERTHOLET C, 1985, P NATL ACAD SCI USA, V82, P2096, DOI 10.1073/pnas.82.7.2096; COYNE RS, 1994, J BIOL CHEM, V269, P31620; DEITCHER DL, 1986, MOL CELL BIOL, V6, P2712, DOI 10.1128/MCB.6.7.2712; FRUTIGER S, 1988, J BIOL CHEM, V263, P8120; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; HAMMARSTROM V, 1993, LANCET, V341, P1036, DOI 10.1016/0140-6736(93)91136-A; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HANLY CW, 1987, J IMMUNOL, V139, P1597; Hanson L A, 1993, Pediatr Allergy Immunol, V4, P16; HARLOW F, 1988, ANTIBODIES LAB MANUA; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HUSBY S, 1994, J IMMUNOL, V152, P4663; KNIGHT KL, 1974, J IMMUNOL, V112, P877; KRAJCI P, 1991, HUM GENET, V87, P642, DOI 10.1007/BF00201717; KUHN LC, 1983, J BIOL CHEM, V258, P6653; Lullau E, 1996, J BIOL CHEM, V271, P16300, DOI 10.1074/jbc.271.27.16300; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LYCKE N, 1990, J IMMUNOL, V145, P3316; LYCKE N, 1990, NEW GENERATION VACCI, P217; MA JKC, 1990, INFECT IMMUN, V58, P3407, DOI 10.1128/IAI.58.10.3407-3414.1990; MAURELLI AT, 1985, INFECT IMMUN, V49, P164, DOI 10.1128/IAI.49.1.164-171.1985; MCGHEE JR, 1992, VACCINE, V10, P75, DOI 10.1016/0264-410X(92)90021-B; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; Neutra Marian R., 1994, P685; PHALIPON A, 1992, INFECT IMMUN, V60, P1919, DOI 10.1128/IAI.60.5.1919-1926.1992; PIERRE P, 1992, EUR J IMMUNOL, V22, P3179, DOI 10.1002/eji.1830221223; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; ROY MJ, 1987, CELL TISSUE RES, V248, P645, DOI 10.1007/BF00216495; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1990, J CELL BIOL, V110, P987, DOI 10.1083/jcb.110.4.987; SOLARI R, 1985, J BIOL CHEM, V260, P1141; Solari R., 1987, The mammary gland. Development, regulation, and function., P269; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; WEINER HL, 1994, P NATL ACAD SCI USA, V91, P10762, DOI 10.1073/pnas.91.23.10762; WELTZIN R, 1994, ANTIMICROB AGENTS CH, V38, P2785, DOI 10.1128/AAC.38.12.2785; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673	42	40	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33670	33677		10.1074/jbc.271.52.33670	http://dx.doi.org/10.1074/jbc.271.52.33670			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969237	hybrid			2022-12-25	WOS:A1996WA71300071
J	Croze, E; RussellHarde, D; Wagner, TC; Pu, HF; Pfeffer, LM; Perez, HD				Croze, E; RussellHarde, D; Wagner, TC; Pu, HF; Pfeffer, LM; Perez, HD			The human type I interferon receptor - Identification of the interferon beta-specific receptor-associated phosphoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; ALPHA/BETA RECEPTOR; SIGNALING PATHWAY; IFNAR CHAIN; SUBUNIT; PROTEIN; EXPRESSION; CLONING; BINDING; KINASE	We used specific antibodies recognizing the receptor 1 (IFNAR1) and the recently cloned receptor 2.2 (IFNAR2.2) chains of the human type I interferon receptor complex to demonstrate that the interferon beta (IFN-beta)-specific receptor-associated phosphoprotein is IFNAR2.2 and not an unknown or additional receptor component. Immunoprecipitation experiments demonstrated that IFNAR2.2 is present in Daudi cells as a cell surface protein of approximately 90-100 kDa, which is tyrosine-phosphorylated and associated with IFNAR1, upon stimulation of cells with IFN-beta. IFNAR2.2 was not detected associated with IFNAR1 in cells stimulated with IFN-alpha, suggesting differences in receptor interaction between the two type I interferons, Both IFNAR1 and IFNAR2.2 undergo tyrosine phosphorylation upon induction by either IFN-alpha or IFN-beta. Therefore, it is unclear as to why IFNAR2.2 is not detectable in IFNAR1 immunoprecipitates in IFN-beta-treated cells. These data suggest that, although IFN-alpha and IFN-beta may utilize similar receptor chains, they interact with IFNAR1 and IFNAR2.2 in different ways.	BERLEX BIOSCI,DEPT CELL & MOL BIOL,RICHMOND,CA 94804; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804; UNIV TENNESSEE,DEPT PATHOL,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center	Croze, E (corresponding author), BERLEX BIOSCI,DEPT PROT BIOCHEM & BIOPHYS,15049 SAN PABLO AVE,RICHMOND,CA 94804, USA.		Eishingdrelo, Haifeng/R-8426-2019	Eishingdrelo, Haifeng/0000-0001-7205-1008; Pfeffer, Lawrence/0000-0003-2809-1234				ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; Bach EA, 1996, MOL CELL BIOL, V16, P3214; COHEN B, 1995, MOL CELL BIOL, V15, P4208; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; LI X, 1996, IN PRESS MOL CELL BI; LUTFALLA G, 1995, EMBO J, V14, P5100, DOI 10.1002/j.1460-2075.1995.tb00192.x; Means RT, 1996, EXP HEMATOL, V24, P204; MERLIN G, 1985, J GEN VIROL, V66, P1149, DOI 10.1099/0022-1317-66-5-1149; NOVICK D, 1995, J LEUKOCYTE BIOL, V57, P712, DOI 10.1002/jlb.57.5.712; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; RANI S, 1996, J BIOL CHEM, V271, P22878; ROSENBLUM MG, 1990, J INTERFERON RES, V10, P141, DOI 10.1089/jir.1990.10.141; RUSSELLHARDE D, 1995, J BIOL CHEM, V270, P26033, DOI 10.1074/jbc.270.44.26033; RUSSELLHARDE D, 1995, J INTERF CYTOK RES, V15, P31, DOI 10.1089/jir.1995.15.31; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERFERON CYTOKIN, V15, P7271; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x	30	75	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33165	33168		10.1074/jbc.271.52.33165	http://dx.doi.org/10.1074/jbc.271.52.33165			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969169	hybrid			2022-12-25	WOS:A1996WA71300003
J	Goetz, TL; Lloyd, TL; Griswold, MD				Goetz, TL; Lloyd, TL; Griswold, MD			Role of E box and initiator region in the expression of the rat follicle-stimulating hormone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; TRANSCRIPTION FACTOR USF; SERTOLI CELLS; C-MYC; LUTEINIZING-HORMONE; PROMOTER ACTIVITY; BINDING PROTEINS; GENE-EXPRESSION; DNA-BINDING; TFII-I	The promoter for the rat follicle-stimulating hormone receptor (FSHR) gene contains a conserved consensus E box sequence and an initiator-like region (InR) sequence. Deletion analysis and transient transfections showed that a 114-base pair region (-143 to -30) that encompasses the E box and the InR was sufficient for greater than 75% of promoter function. DNase I footprint analysis showed that the E box and InR were protected by nuclear proteins from rat Sertoli cells, and the E box region was shown by electrophoretic mobility shift assays (EMSA) to be a site of Sertoli protein interactions. Mutations in the E box disrupted these interactions and reduced FSHR promoter activity. Co-transfection of the inhibitor of DNA binding (Id) with an FSHR/luciferase construct into mouse Sertoli 1 cells reduced FSHR promoter activity. Using EMSA, the upstream stimulatory factor was shown to be a component of the complexes that interacted with the E box in the FSHR promoter. Binding of proteins from rat Sertoli cells to the InR was demonstrated using EMSA. Also, an oligonucleotide that represented the sequence of the terminal deoxynucleotidyltransferase InR displaced the complexes at the FSHR InR. Mutations in the InR resulted in a significant reduction of FSHR promoter activity.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD010808] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD010808] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10808] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Burke TW, 1996, GENE DEV, V10, P711, DOI 10.1101/gad.10.6.711; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GROMOLL J, 1994, MOL CELL ENDOCRINOL, V102, P93, DOI 10.1016/0303-7207(94)90102-3; HALL SH, 1991, ENDOCRINOLOGY, V129, P1243, DOI 10.1210/endo-129-3-1243; HECKERT LL, 1992, MOL ENDOCRINOL, V6, P70, DOI 10.1210/me.6.1.70; Higuchi R., 1990, PCR PROTOCOLS GUIDE; HUHTANIEMI IT, 1992, MOL CELL ENDOCRINOL, V88, P55, DOI 10.1016/0303-7207(92)90009-U; JACKSON SM, 1995, MOL ENDOCRINOL, V9, P278, DOI 10.1210/me.9.3.278; KARL AF, 1990, METHOD ENZYMOL, V190, P71; KOJI T, 1988, HISTOCHEM J, V20, P551, DOI 10.1007/BF01002609; LIM K, 1995, MOL CELL ENDOCRINOL, V111, P51, DOI 10.1016/0303-7207(95)03543-G; LINDER CC, 1994, ENDOCRINE, V2, P957; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MCGUINNESS MP, 1994, BIOL REPROD, V51, P116, DOI 10.1095/biolreprod51.1.116; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; OUTRAM SV, 1994, J BIOL CHEM, V269, P26525; PARMENTIER M, 1989, SCIENCE, V246, P1620, DOI 10.1126/science.2556796; PESCHON JJ, 1992, MOL ENDOCRINOL, V6, P1403, DOI 10.1210/me.6.9.1403; ROY AL, 1994, INDIAN J BIOCHEM BIO, V31, P14; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; Sharma S, 1996, J BIOL CHEM, V271, P2294, DOI 10.1074/jbc.271.4.2294; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; THEMMEN APN, 1994, MOL CELL ENDOCRINOL, V100, P15, DOI 10.1016/0303-7207(94)90272-0; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447	37	57	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33317	33324		10.1074/jbc.271.52.33317	http://dx.doi.org/10.1074/jbc.271.52.33317			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969191	hybrid			2022-12-25	WOS:A1996WA71300025
J	Miller, MC; Resnick, JB; Smith, BT; Lovett, CM				Miller, MC; Resnick, JB; Smith, BT; Lovett, CM			The Bacillus subtilis dinR gene codes for the analogue of Escherichia coli LexA - Purification and characterization of the DinR protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; SOS-INDUCING SIGNAL; RECA PROTEIN; DEPENDENT CLEAVAGE; SEQUENCE ANALYSIS; REPRESSOR; DAMAGE; INDUCTION; SYSTEM; REPAIR	The Bacillus subtilis dinR gene encodes a 23-kDa protein that shares about 34% homology with the Escherichia coli LexA protein, We have purified the dinR gene product to near homogeneity, and we describe its activities, The purified DinR protein binds specifically to the promoter regions of three B. subtilis SOS genes: dinB, dinC, and recA, Electrophoretic mobility of DinR-promoter complexes in each case is identical to that of promoters bound by the B, subtilis SOS repressor (Lovett, et al., (1993) J. Bacteriol. 175, 6842-6849), Analysis of hydroxyl radical footprints of DinR bound to the dinC promoter indicates that DinR interacts with one side of the DNA providing access to the consensus operator site (5'-GAACN(4)GTTC-3') within two adjacent major grooves, Consistent with its proposed role as a transcriptional repressor, purified DinR displaces B, subtilis RNA polymerase from the recA promoter and represses transcription of the recA gene in vitro, We also show that purified DinR protein undergoes general base-catalyzed autodigestion as well as RecA-mediated cleavage at the peptide bond between Ala-91 and Gly-92, Corresponding to its cleavage by activated RecA following DNA damage, the level of DinR is significantly reduced in RecA(+) B, subtilis cells following exposure to mitomycin C, Thus, the DinR protein is structurally and functionally analogous to the E, coli LexA protein, and accordingly, we propose renaming the protein B, subtilis LexA.	WILLIAMS COLL,DEPT CHEM,WILLIAMSTOWN,MA 01267	Williams College				Smith, Bradley T/0000-0003-4261-8071				ALONSO JC, 1990, NUCLEIC ACIDS RES, V18, P6771, DOI 10.1093/nar/18.23.6771; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BRENT R, 1981, P NATL ACAD SCI-BIOL, V78, P4204, DOI 10.1073/pnas.78.7.4204; CHEO DL, 1991, J BACTERIOL, V173, P1696, DOI 10.1128/jb.173.5.1696-1703.1991; CHEO DL, 1993, J BACTERIOL, V175, P5907, DOI 10.1128/JB.175.18.5907-5915.1993; CRAIG NL, 1980, NATURE, V283, P26, DOI 10.1038/283026a0; Dubnau David, 1993, P555; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; GARRIGA X, 1992, MOL GEN GENET, V236, P125, DOI 10.1007/BF00279651; HAIJEMA BJ, 1996, THESIS U GRONINGEN; HARRIS WJ, 1971, MOL GEN GENET, V113, P316, DOI 10.1007/BF00272332; HORII T, 1981, CELL, V27, P515, DOI 10.1016/0092-8674(81)90393-7; HURSTEL S, 1988, EMBO J, V7, P269, DOI 10.1002/j.1460-2075.1988.tb02809.x; HURSTEL S, 1988, EMBO J, V5, P793; KARU AE, 1982, MOL GEN GENET, V185, P275, DOI 10.1007/BF00330798; KIM B, 1992, SCIENCE, V255, P203, DOI 10.1126/science.1553548; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1985, P NATL ACAD SCI USA, V82, P2301, DOI 10.1073/pnas.82.8.2301; LITTLE JW, 1980, P NATL ACAD SCI-BIOL, V77, P3225, DOI 10.1073/pnas.77.6.3225; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LOVE PE, 1984, J BACTERIOL, V160, P910, DOI 10.1128/JB.160.3.910-920.1984; LOVE PE, 1985, P NATL ACAD SCI USA, V82, P6201, DOI 10.1073/pnas.82.18.6201; LOVETT CM, 1993, J BACTERIOL, V175, P6842, DOI 10.1128/jb.175.21.6842-6849.1993; LOVETT CM, 1989, J BACTERIOL, V171, P2318, DOI 10.1128/jb.171.5.2318-2322.1989; LOVETT CM, 1988, J BACTERIOL, V170, P1467, DOI 10.1128/jb.170.4.1467-1474.1988; LOVETT CM, 1985, J BIOL CHEM, V260, P3305; LOVETT CM, 1994, J BACTERIOL, V176, P4914, DOI 10.1128/jb.176.16.4914-4923.1994; MORAN CP, 1990, MOL BIOL METHODS BAC, P276; PHIZICKY EM, 1981, CELL, V25, P259, DOI 10.1016/0092-8674(81)90251-8; RAYMONDDENISE A, 1991, J BACTERIOL, V173, P7084, DOI 10.1128/jb.173.22.7084-7091.1991; ROLAND KL, 1990, J BIOL CHEM, V265, P12828; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; SLILATY SN, 1986, BIOCHEMISTRY-US, V25, P6866, DOI 10.1021/bi00370a020; SLILATY SN, 1987, P NATL ACAD SCI USA, V84, P3987, DOI 10.1073/pnas.84.12.3987; TAKAHASHI M, 1986, FEBS LETT, V196, P215, DOI 10.1016/0014-5793(86)80249-6; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WERTMAN KF, 1985, J BACTERIOL, V163, P376, DOI 10.1128/JB.163.1.376-384.1985; WOJCIECHOWSKI MF, 1991, J BACTERIOL, V173, P6475; YASBIN RE, 1977, MOL GEN GENET, V153, P211, DOI 10.1007/BF00264738; YASBIN RE, 1980, GENE, V12, P155, DOI 10.1016/0378-1119(80)90026-8; YASBIN RE, 1992, MOL MICROBIOL, V6, P1263, DOI 10.1111/j.1365-2958.1992.tb00847.x	45	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33502	33508		10.1074/jbc.271.52.33502	http://dx.doi.org/10.1074/jbc.271.52.33502			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969214	hybrid			2022-12-25	WOS:A1996WA71300048
J	Uetz, P; Fumagalli, S; James, D; Zeller, R				Uetz, P; Fumagalli, S; James, D; Zeller, R			Molecular interaction between limb deformity proteins (formins) and Src family kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; C-SRC; OVEREXPRESSER CELLS; SH3 DOMAINS; WW DOMAIN; GENE; LOCALIZATION; ASSOCIATION; FIBROBLASTS; EMBRYO	Ld proteins (formins) are encoded by the limb deformity (ld) gene and define a family of related gene products regulating establishment of embryonic polarity. In this study we establish that chicken and murine Ld proteins interact directly with Src family kinases (c-Src and c-Fyn). Specific binding is mediated by the proline-rich domain present in Ld proteins and the ligand binding surface of the Src SH3 domain. Co-immunoprecipitation of Ld and c-Src proteins from transfected cells shows that these proteins associate in vivo. Immunolocalization and biochemical fractionation of fibroblasts confirms the predominant nuclear localization of Ld proteins, but unexpectedly identifies a population of Ld proteins associated to cellular membranes. This population of Ld proteins co-localizes with membrane-associated c-Src proteins at both plasma and perinuclear membranes. These studies indicate that the morphoregulatory Ld proteins interact with signal transduction cascades by association to membrane-bound Src family kinases.	EUROPEAN MOL BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			FUMAGALLI, Stefano/C-2914-2019; Uetz, Peter/A-7119-2012; James, Dominic/G-6435-2016; Zeller, Rolf/C-2610-2013	Uetz, Peter/0000-0001-6194-4927; James, Dominic/0000-0002-0452-2178; Zeller, Rolf/0000-0002-3186-7403; Fumagalli, Stefano/0000-0001-5832-8680				Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CASTRILLON DH, 1994, DEVELOPMENT, V120, P3367; CHAN DC, 1995, DEVELOPMENT, V121, P3151; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DELAPOMPA JL, 1995, DEV DYNAM, V204, P156, DOI 10.1002/aja.1002040206; EMMONS S, 1995, GENE DEV, V9, P2482, DOI 10.1101/gad.9.20.2482; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; Erpel T, 1996, J BIOL CHEM, V271, P16807, DOI 10.1074/jbc.271.28.16807; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANDI P, 1993, EMBO J, V12, P3061, DOI 10.1002/j.1460-2075.1993.tb05975.x; Haramis AG, 1995, DEVELOPMENT, V121, P4237; Harlow E., 1988, ANTIBODIES LAB MANUA; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JACKSONGRUSBY L, 1992, GENE DEV, V6, P29, DOI 10.1101/gad.6.1.29; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kawakatsu H, 1996, J BIOL CHEM, V271, P5680, DOI 10.1074/jbc.271.10.5680; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIEBL EC, 1992, ONCOGENE, V7, P2417; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MAAS R, 1994, DEV DYNAM, V199, P214, DOI 10.1002/aja.1001990306; MAAS RL, 1991, NATURE, V346, P853; MARHOUL JF, 1995, GENETICS, V139, P537; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MONSEAU L, 1996, DEVELOPMENT, V122, P2109; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; REDMOND T, 1992, CELL GROWTH DIFFER, V3, P567; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH SE, 1993, NUCLEIC ACIDS RES, V21, P1581, DOI 10.1093/nar/21.7.1581; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14; VOGT TF, 1993, P NATL ACAD SCI USA, V90, P5554, DOI 10.1073/pnas.90.12.5554; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; ZELLER R, 1989, GENE DEV, V3, P1481, DOI 10.1101/gad.3.10.1481; ZHAN X, 1994, J BIOL CHEM, V269, P20221	49	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33525	33530		10.1074/jbc.271.52.33525	http://dx.doi.org/10.1074/jbc.271.52.33525			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969217	hybrid			2022-12-25	WOS:A1996WA71300051
J	Chen, CF; Li, S; Chen, YM; Chen, PL; Sharp, ZD; Lee, WH				Chen, CF; Li, S; Chen, YM; Chen, PL; Sharp, ZD; Lee, WH			The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; LOCATION SIGNALS; BINDING PROTEIN; DNA-BINDING; IDENTIFICATION; GENE; DIFFERENTIATION; TRANSLOCATION; NUCLEOPLASMIN; EXPRESSION	The BRCA1 gene product is a nuclear phosphoprotein that is aberrantly localized in the cytoplasm of most breast cancer cells. In an attempt to elucidate the potential mechanism for the nuclear transport of BRCA1 protein, three regions of highly charged, basic residues, (503)KRKRRP(508), (606)PKKNRLRRKS(615), and (KKKKYN656)-K-651, were identified as potential nuclear localization signals (NLSs). These three regions were subsequently mutated to (503)KLP(508), (607)KLS(615), and (651)KLN(656), respectively. Wild-type and mutated proteins were tagged with the flag epitope, expressed in human DU145 cells, and detected with the M2 monoclonal antibody. In DU145 cells, the KLP mutant completely fails to localize in nuclei, whereas the KLS mutant is mostly cytoplasmic with occasional nuclear localization. The KLN protein is always located in nuclei. Consistently, hSRP1 alpha (importin-alpha), a component of the NLS receptor complex, was identified in a yeast two-hybrid screen using BRCA1 as the bait. The specificity of the interaction between BRCA1 and importin-alpha was further demonstrated by showing that the (503)KRKRRP(508) and (606)PKKNRLRRKS(615) regions, but not (KKKKYN656)-K-651, are critical for this interaction. To determine if the cytoplasmic mislocation of endogenous BRCA1 in breast cancer cells is due to a deficiency of the cells, wild-type BRCA1 protein tagged with the flag epitope was ectopically expressed in six breast cancer cell lines. The analysis demonstrated that, in all six, this protein localized in the cytoplasm of these cells. In contrast, expression of the construct in four non-breast cancer cell lines resulted in nuclear localization. These data support the possibility that the mislocation of the BRCA1 protein in breast cancer cells may be due to a defect in the cellular machinery involved in the NLS receptor-mediated pathway of nuclear import.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,DEPT MOL MED,SAN ANTONIO,TX 78245	University of Texas System; University of Texas Health San Antonio			LI, SHANG/HII-4989-2022	Chen, Chi-Fen/0000-0002-6391-821X; LI, SHANG/0000-0002-6226-3362	NATIONAL CANCER INSTITUTE [R01CA058318] Funding Source: NIH RePORTER; NCI NIH HHS [CA58318] Funding Source: Medline; PHS HHS [P50-58183] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chen YM, 1996, SCIENCE, V272, P125, DOI 10.1126/science.272.5258.125; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; GOWAN LC, 1996, NAT GENET, V12, P191; GREENSPAN D, 1988, J VIROL, V62, P3020, DOI 10.1128/JVI.62.8.3020-3026.1988; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; LIANG XH, 1993, ONCOGENE, V8, P2645; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MORIN N, 1989, MOL CELL BIOL, V9, P4372, DOI 10.1128/MCB.9.10.4372; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; Wilson CA, 1996, NAT GENET, V13, P264, DOI 10.1038/ng0796-264	38	174	184	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32863	32868		10.1074/jbc.271.51.32863	http://dx.doi.org/10.1074/jbc.271.51.32863			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955125	hybrid			2022-12-25	WOS:A1996VZ37300060
J	Zimrin, AB; Pepper, MS; McMahon, GA; Nguyen, F; Montesano, R; Maciag, T				Zimrin, AB; Pepper, MS; McMahon, GA; Nguyen, F; Montesano, R; Maciag, T			An antisense oligonucleotide to the notch ligand jagged enhances fibroblast growth factor-induced angiogenesis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYRIN-LIKE REPEATS; INVITRO; EXPRESSION; NEUROGENESIS; PROTEINS; CELLS	Angiogenesis, or the formation of new blood vessels, plays a central role in a number of physiologic and pathologic conditions, including wound healing, dia betic retinopathy, and solid tumor growth, and endothelial cells can be induced to mimic this process in vitro. Using a modification of the differential display method (Zimrin, A. B., Villeponteau, B., and Maciag, T. (1995) Biochem, Biophys, Res. Commun. 213, 630-638), we isolated the human homolog of the Jagged ligand for the Notch receptor from human endothelial cells exposed to fibrin and demonstrate that the Jagged transcript, but not the Notch 1 or Notch 2 transcripts, are up-regulated by fibrin, Interestingly, the addition of an antisense Jagged oligomer to bovine microvascular endothelial cells grown on a collagen gel resulted in a marked increase in invasion and tube formation in the underlying gel in response to fibroblast growth factor. In contrast, no effect was observed on vascular endothelial growth factor-induced angiogenesis under identical conditions, These data suggest that Jagged-Notch signaling is able to regulate fibroblast growth factor-induced endothelial cell migration in vitro, an early event during angiogenesis in vivo.	AMER RED CROSS, JEROME H HOLLAND LAB, DEPT MOL BIOL, ROCKVILLE, MD 20855 USA; UNIV GENEVA, MED CTR, DEPT MORPHOL, CH-1211 GENEVA, SWITZERLAND	American Red Cross; University of Geneva			Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32348, HL02646] Funding Source: Medline; NIA NIH HHS [AG07450] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Axelrod JD, 1996, SCIENCE, V271, P1826, DOI 10.1126/science.271.5257.1826; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; HUBBARD EJ, 1976, SCIENCE, V273, P112; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; LINDSELL CE, 1995, CELL, V80, P909, DOI 10.1016/0092-8674(95)90294-5; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; MONTESANO R, 1985, CELL, V42, P469, DOI 10.1016/0092-8674(85)90104-7; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MONTESANO R, 1994, FRONTIERS ENDOCRINOL, P43; NYE JS, 1995, CURR BIOL, V5, P966, DOI 10.1016/S0960-9822(95)00189-8; NYE JS, 1994, DEVELOPMENT, V120, P2421; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; SCANLON KJ, 1995, FASEB J, V9, P1288, DOI 10.1096/fasebj.9.13.7557018; Uyttendaele H, 1996, DEVELOPMENT, V122, P2251; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; ZIMRIN AB, 1995, BIOCHEM BIOPH RES CO, V213, P630, DOI 10.1006/bbrc.1995.2178	26	126	141	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32499	32502		10.1074/jbc.271.51.32499	http://dx.doi.org/10.1074/jbc.271.51.32499			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955070	hybrid			2022-12-25	WOS:A1996VZ37300005
J	Abarzua, P; LoSardo, JE; Gubler, ML; Spathis, R; Lu, YA; Felix, A; Neri, A				Abarzua, P; LoSardo, JE; Gubler, ML; Spathis, R; Lu, YA; Felix, A; Neri, A			Restoration of the transcription activation function to mutant p53 in human cancer cells	ONCOGENE			English	Article						mutant p53; DNA binding; pegylated peptide; transcription activation; SW480 cells	WILD-TYPE P53; DNA-BINDING FUNCTION; P53-MEDIATED G(1) ARREST; SOLID-PHASE SYNTHESIS; INDUCED APOPTOSIS; GENE-EXPRESSION; GROWTH ARREST; PROTEIN; SEQUENCE; MUTATIONS	The p53 tumor suppressor gene product is a sequence-specific transcription activator frequently mutated in a variety of human malignancies. Typically, tumor-derived p53 missense mutants are defective in DNA binding and this is likely to result in a failure to active p53-regulated genes. Hence, restoring function to mutant p53 represents an attractive target to develop a novel cancer chemotherapeutic agent. We now show that a small chemically modified peptide derived from p53 restores sequence-specific DNA binding to a subset of p53 mutants. Moreover, when microinjected into human colon carcinoma cells this peptide restores the transcription activation function to endogenous mutant p53 protein. This is the first example showing that a small peptide molecule can reverse the effect of several inactivating missense mutations and restore protein function.			Abarzua, P (corresponding author), HOFFMANN LA ROCHE INC,ROCHE RES CTR,NUTLEY,NJ 07110, USA.							ABARZUA P, 1995, CANCER RES, V55, P3490; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALL PA, 1993, ONCOGENE, V8, P203; HARRIS CC, 1993, SCIENCE, V262, P1980, DOI 10.1126/science.8266092; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LU YA, 1994, INT J PEPT PROT RES, V43, P127; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEIENHOFER J, 1979, INT J PEPT PROT RES, V13, P35; NIEWOLIK D, 1995, ONCOGENE, V10, P881; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	48	68	71	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2477	2482						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957091				2022-12-25	WOS:A1996VX10800022
J	Mumberg, D; Haas, K; Moroy, T; Niedenthal, R; Hegemann, JH; Funk, M; Muller, R				Mumberg, D; Haas, K; Moroy, T; Niedenthal, R; Hegemann, JH; Funk, M; Muller, R			Uncoupling of DNA replication and cell cycle progression by human cyclin E	ONCOGENE			English	Article						cyclin E; DNA-replication; Saccharomyces cerevisiae; oncogene co-operation; ras oncogene	SACCHAROMYCES-CEREVISIAE; G1 CYCLIN; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; SIGNAL-TRANSDUCTION; POTENTIAL MEDIATOR; DEPENDENT KINASES; DIVISION CYCLE; BUDDING YEAST	The G(1)-specific D- and E-type cyclins are among the most crucial factors controlling cell cycle progression in mammalian cells and are therefore thought to play an important role in tumorigenisis, D-type cyclins have indeed been shown to be endowed with an oncogenic potential, Here, we report that the ectopic expression of human cyclin E, but not cyclin D1, deregulates DNA synthesis in both yeast and mammalian cells, In yeast, induction of DNA synthesis by cyclin E occurs even under conditions of cell cycle arrest in G(1) or G(2)/M, indicating an uncoupling of DNA replication from cell cycle progression, In rat embryo fibroblasts, the cooperative action of Ras and cyclin E induces transformation, These cells, in contrast to those transformed by Ras and cyclin D1, show aberrant levels of DNA synthesis, Since cyclin E is commonly overexpressed in a variety of human tumors, these findings may point to a link between the uncontrolled proliferation and the genomic instability typically seen in malignant tumors, Furthermore they reveal significant differences in the functional properties of cyclin E and D1.	UNIV MARBURG, INST MOL BIOL & TUMORFORSCH, D-35033 MARBURG, GERMANY; UNIV GIESSEN, INST MIKROBIOL & MOL BIOL, D-35392 GIESSEN, GERMANY	Philipps University Marburg; Justus Liebig University Giessen			Müller, Rolf/L-4997-2016; Moroy, Tarik/D-9923-2011	Müller, Rolf/0000-0003-3339-4248; Funk, Martin/0000-0003-2721-4036				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BASCO RD, 1995, MOL CELL BIOL, V15, P5030; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KERJAN P, 1986, NUCLEIC ACIDS RES, V14, P7861, DOI 10.1093/nar/14.20.7861; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOVEC H, 1994, ONCOGENE, V9, P323; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SEWING A, 1993, J CELL SCI, V104, P545; SIKORSKI RS, 1989, GENETICS, V122, P19; SPRAGUE GF, 1991, TRENDS GENET, V7, P393, DOI 10.1016/0168-9525(91)90262-O; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIMMEL A, 1994, ONCOGENE, V9, P995; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2	48	23	25	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2493	2497						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957094				2022-12-25	WOS:A1996VX10800025
J	Rosenberg, JE; Lisle, DK; Burwick, JA; Ueki, K; vonDeimling, A; Mohrenweiser, HW; Louis, DN				Rosenberg, JE; Lisle, DK; Burwick, JA; Ueki, K; vonDeimling, A; Mohrenweiser, HW; Louis, DN			Refined deletion mapping of the chromosome 19q glioma tumor suppressor gene to the D19S412-STD interval	ONCOGENE			English	Article						chromosome 19; D19S745; glioma; tumor suppressor gene	REGION; ASTROCYTOMAS; CANDIDATE; 19Q13.3; MAP	Allelic loss of chromsome 19q occurs frequently in malignant gliomas, suggesting the presence of a chromosome 19q glioma tumor suppressor gene, Deletion mapping studies have delineated a 3.5 Mb candidate region between D19S219 and HRC, Cloned sequences from the proximal 425 kb of this interval, however, have not shown tumor-specific alterations, To refine the location of the tumor suppressor gene further, we conducted loss of heterozygosity studies on 191 malignant gliomas using nine PCR-based polymorphisms, These included the previously identified and physically mapped markers D19S219, DM, D19S112, HRC and the recently physically mapped polymorphisms at D19S412, STD, D19S596 and GYS. In addition, we isolated a novel microsatellite polymorphism that maps 400 kb telomeric to D19S112, Oligodendroglial tumors showed frequent loss of heterozygosity in all grades, and typically displayed allelic loss at all studied markers, Astrocytomas, however, showed frequent loss primarily in anaplastic astrocytomas and displayed deletion breakpoints within the candidate region, Deletion mapping revealed a minimal region of overlap between D19S412 and STD, a distance of 900 kb, These data suggest that the D19S412-STD interval represents the most likely location for a chromsome 19q glioma tumor suppressor gene involved in astrocytoma, and perhaps oligodendroglioma, tumorigenesis.	MASSACHUSETTS GEN HOSP,DEPT PATHOL NEUROPATHOL,NEUROSURG SERV,MOL NEUROONCOL LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; UNIV HOSP,INST NEUROPATHOL,BONN,GERMANY; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Bonn; United States Department of Energy (DOE); Lawrence Livermore National Laboratory			von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X	NATIONAL CANCER INSTITUTE [R01CA057683, R01CA069285] Funding Source: NIH RePORTER; NCI NIH HHS [CA 69285, CA 57683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; DUROCHER F, 1995, GENOMICS, V29, P781, DOI 10.1006/geno.1995.9935; ELBEIN SC, 1994, DIABETES, V43, P1061, DOI 10.2337/diabetes.43.8.1061; GORDON LA, 1995, GENOMICS, V30, P187, DOI 10.1006/geno.1995.9886; Kleihues P, 1993, HISTOLOGICAL TYPING; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LOUIS DN, 1992, AM J PATHOL, V141, P777; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RUBIO MP, 1994, CANCER RES, V54, P4760; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; VONDEIMLING A, 1992, CANCER RES, V52, P4277; VONDEIMLING A, 1994, CANCER RES, V54, P1397; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; YONG WH, 1995, J NEUROPATH EXP NEUR, V54, P622, DOI 10.1097/00005072-199509000-00002; YONG WH, 1995, GENOMICS, V29, P533, DOI 10.1006/geno.1995.9972	16	78	79	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2483	2485						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957092				2022-12-25	WOS:A1996VX10800023
J	Eliopoulos, AG; Dawson, CW; Mosialos, G; Floettmann, JE; Rowe, M; Armitage, RJ; Dawson, J; Zapata, JM; Kerr, DJ; Wakelam, MJO; Reed, JC; Kieff, E; Young, LS				Eliopoulos, AG; Dawson, CW; Mosialos, G; Floettmann, JE; Rowe, M; Armitage, RJ; Dawson, J; Zapata, JM; Kerr, DJ; Wakelam, MJO; Reed, JC; Kieff, E; Young, LS			CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr virus-encoded LMP1: Involvement of TRAF3 as a common mediator	ONCOGENE			English	Article						CD40; TNF alpha; Fas; LMP1; TRAF3; epithelial	LATENT MEMBRANE-PROTEIN; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; BCL-2 HOMOLOG BAK; CD40 LIGAND; ACTIVATION MOLECULE; CYTOPLASMIC DOMAIN; INDUCED APOPTOSIS; IMMUNE-RESPONSES; DRUG-RESISTANCE	CD40, a member of the tumour necrosis factor receptor family, is expressed on the surface of B lymphocytes where its ligation provides a potent survival signal. CD40 is also expressed in basal epithelial cells and in a number of different carcinomas where its function remains unknown. We observed that contrary to the studies in normal B cells, CD40 Ligation in carcinoma cell lines and in normal primary epithelial cells resulted in growth inhibition and enhanced susceptibility to apoptosis induced by anti-neoplastic drugs, TNF-alpha, Fas and ceramide. This effect was also observed in CD40-transfected Rat-1 fibroblasts. The expression of Bcl-2 did not affect growth inhibition induced by CD40 ligation in epithelial cells but the Epstein - Barr Virus-encoded latent membrane protein 1 (LMP1) blocked the effect. Whilst transient expression of LMP-1 resulted in the inhibition of epithelial cell growth, this effect was not observed with a LMP1 mutant lacking the binding domain for TRAF3, a protein which may mediate signal transduction by interacting with the cytoplasmic domains of both CD40 and LMP1. Transient expression of TRAF3 also inhibited epithelial cell growth, whilst expression of a dominant-negative TRAF3 partially blocked the inhibitory effect of CD40 ligation and of transient LMP1 expression. These results suggest that CD40 regulates epithelial cell growth in a manner mimicked by LMP1 and implicate TRAF3 as a common mediator in the transduction of the growth inhibitory signals generated via the CD40 and LMP1 pathways.	UNIV BIRMINGHAM,SCH MED,CRC,INST CANC STUDIES,BIRMINGHAM B15 2TJ,AL,ENGLAND; HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOL GENET,BOSTON,MA 02115; UNIV WALES COLL MED,DEPT MED,CARDIFF CF4 4XN,S GLAM,WALES; IMMUNEX RES & DEV CORP,DEPT CELLULAR IMMUNOL,SEATTLE,WA 98101; BURNHAM INST,CANC RES CTR,LA JOLLA,CA 92037	University of Birmingham; Harvard University; Harvard Medical School; Cardiff University; Sanford Burnham Prebys Medical Discovery Institute			ELIOPOULOS, ARISTIDES/ABI-6632-2020; Zapata, Juan M/J-6304-2014; ELIOPOULOS, ARISTIDES/R-9449-2018; Rowe, Martin/B-2880-2009; Young, Lawrence S/B-7213-2009	ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Zapata, Juan M/0000-0002-0110-0009; ELIOPOULOS, ARISTIDES/0000-0002-6403-6761; Rowe, Martin/0000-0003-4139-7326; Young, Lawrence S/0000-0003-3919-4298; Wakelam, Michael/0000-0003-4059-9276	NCI NIH HHS [CA-69381] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA069381] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1993, EUR J IMMUNOL, V23, P2326, DOI 10.1002/eji.1830230941; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CALLARD RE, 1993, IMMUNOL TODAY, V14, P559, DOI 10.1016/0167-5699(93)90188-Q; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FLOETTMANN JE, IN PRESS VIROLOGY; FUNAKOSHI S, 1994, BLOOD, V83, P2787, DOI 10.1182/blood.V83.10.2787.2787; GONZALEZ AL, 1995, TRENDS GENET, V11, P216, DOI 10.1016/S0168-9525(00)89051-4; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAMMER AC, 1995, J IMMUNOL, V154, P4996; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2366; HORNER AA, 1995, J EXP MED, V181, P1239, DOI 10.1084/jem.181.3.1239; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ITOH N, 1993, J IMMUNOL, V151, P621; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; KATIRA A, 1995, LEUKOCYTE TYPING, V5; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MORIMOTO H, 1993, CANCER RES, V53, P2591; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PENG M, 1992, ONCOGENE, V7, P1775; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; RUBY J, 1995, NAT MED, V1, P437, DOI 10.1038/nm0595-437; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; Schulze-Osthoff Klaus, 1994, Trends in Cell Biology, V4, P421, DOI 10.1016/0962-8924(94)90102-3; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAMENKOVIC I, 1989, EMBO J, V8, P1403, DOI 10.1002/j.1460-2075.1989.tb03521.x; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG LS, 1989, INT J CANCER, V43, P786, DOI 10.1002/ijc.2910430508	58	190	199	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2243	2254						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950992				2022-12-25	WOS:A1996VV14500022
J	Patel, HV; Vyas, AA; Vyas, KA; Liu, YS; Chiang, CM; Chi, LM; Wu, WG				Patel, HV; Vyas, AA; Vyas, KA; Liu, YS; Chiang, CM; Chi, LM; Wu, WG			Heparin and heparan sulfate bind to snake cardiotoxin - Sulfated oligosaccharides as a potential target for cardiotoxin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; NAJA-NAJA-ATRA; VENOM; GLYCOSAMINOGLYCANS; IDENTIFICATION; PROTEOGLYCANS; ACTIVATION; MEMBRANES; PROTEINS; LIGAND	Cardiotoxins (CTXs) from cobra venom show cytotoxicity toward several cell types. They cause systolic heart arrest and severe tissue necrosis. Their interaction with phospholipids is established but by itself fails to explain the specificity of these toxins; other component(s) of membrane must, therefore, intervene to direct them toward their target. We herein show, for the first time, that sulfated glycosaminoglycans, heparin, heparan sulfate (HS), chondroitin sulfate (CS), and dermatan sulfate (DS), interact with CTX A3, a major component of Taiwan cobra venom, by use of affinity chromatography, circular dichroism, absorbance, and fluorescence intensity and anisotropy measurements. The relative strength of binding, determined by the NaCl concentration required to dissociate the CTX-glycosaminoglycan complex, varied as follows: heparin > DS > CS > HS. In physiological buffer (8 mM Na2HPO4, 2.7 mM KCl, 1.8 mM KH2PO4, 138 mM NaCl, pH 7.4), however, only heparin and HS bound to CTX, with respective dissociation constants of 1.4 and 16 mu M, while CS and DS failed to exhibit well defined binding behavior, as indicated by fluorescence measurements. We estimate that CTX makes 3-4 ionic contacts with heparin based on a salt-dependent binding study and that similar to 40% of binding free energy is derived from purely electrostatic interactions under physiological conditions. Sulfated pentasaccharide may be sufficient to bind to CTX. We also found that heparin accentuates the penetration of CTX into phospholipid membranes as analyzed by Langmuir monolayer measurement. In view of these results we propose that heparin-like moieties of the cell surface may modulate the action of CTX.	NATL TSING HUA UNIV, DEPT LIFE SCI, HSINCHU 30043, TAIWAN	National Tsing Hua University			Vyas, Kavita/GRJ-4578-2022					BATENBURG AM, 1985, BIOCHEMISTRY-US, V24, P7101, DOI 10.1021/bi00346a013; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BOCK PE, 1980, BIOCHEM J, V191, P769, DOI 10.1042/bj1910769; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Chiang CM, 1996, BIOCHEMISTRY-US, V35, P9177, DOI 10.1021/bi960077t; Chiang CM, 1996, BIOCHEMISTRY-US, V35, P9167, DOI 10.1021/bi952823k; CHIAPPINELLI VA, 1993, NATURAL SYNTHETIC NE, P65; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; CONDREA E, 1974, EXPERIENTIA, V30, P121, DOI 10.1007/BF01927688; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DICCIANNI MB, 1991, BIOCHEMISTRY-US, V30, P9090, DOI 10.1021/bi00101a026; Dufton M.J., 1991, P259; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FALLER B, 1992, BIOCHEMISTRY-US, V31, P8285, DOI 10.1021/bi00150a023; Fukuda M, 1994, MOL GLYCOBIOLOGY; HANDIN RI, 1976, J BIOL CHEM, V251, P4273; Harvey A.L., 1991, HDB NATURAL TOXINS, V5, P85; IVERIUS PH, 1972, J BIOL CHEM, V247, P2607; IVERIUS PH, 1971, BIOCHEM J, V124, P677, DOI 10.1042/bj1240677; JAHNKE W, 1994, J MOL BIOL, V240, P445, DOI 10.1006/jmbi.1994.1460; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEE CY, 1979, SNAKE VENOM HDB EXPT, V52; LOMONTE B, 1994, BIOCHEM PHARMACOL, V47, P1509, DOI 10.1016/0006-2952(94)90525-8; LOMONTE B, 1994, J BIOL CHEM, V269, P29867; MACH H, 1993, BIOCHEMISTRY-US, V32, P5480, DOI 10.1021/bi00071a026; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; OLSON ST, 1991, J BIOL CHEM, V266, P6342; OLSON ST, 1991, J BIOL CHEM, V266, P6353; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REES B, 1993, CHEM RES TOXICOL, V6, P385, DOI 10.1021/tx00034a001; REYNERTSON R, 1983, J BIOL CHEM, V258, P7449; SINGHAL AK, 1993, BIOCHEMISTRY-US, V32, P8036, DOI 10.1021/bi00082a026; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; TU T., 1959, JOUR FORMOSAN MED ASSOC, V58, P182; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WU WG, 1993, FASEB J, V7, pA1235; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451	45	64	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1484	1492		10.1074/jbc.272.3.1484	http://dx.doi.org/10.1074/jbc.272.3.1484			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999818	hybrid			2022-12-25	WOS:A1997WD05800016
J	Liu, CE; Ames, GFL				Liu, CE; Ames, GFL			Characterization of transport through the periplasmic histidine permease using proteoliposomes reconstituted by dialysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT GALACTOSE TRANSPORT; ESCHERICHIA-COLI; BINDING-PROTEIN; SALMONELLA-TYPHIMURIUM; CYSTIC-FIBROSIS; FUNCTIONAL RECONSTITUTION; MEMBRANE-COMPONENTS; MALTOSE TRANSPORT; MULTIDRUG-RESISTANCE; ATP HYDROLYSIS	The superfamily of traffic ATPases (ABC transporters) includes bacterial periplasmic transport systems (permeases) and various eukaryotic transporters. The histidine permease of Salmonella typhimurium and Escherichia coli is composed of a membrane-bound complex containing four subunits and of a soluble receptor, the substrate binding protein (HisJ), and is energized by ATP. The permease was previously reconstituted into proteoliposomes by a detergent dilution method (1). Here we extensively characterize the properties of this permease after reconstitution into proteoliposomes by dialysis and encapsulation of ATP or other reagents by freeze-thawing. We show that histidine transport depends entirely on both ATP and liganded HisJ, with apparent K-m values of 8 mM and 8 mu M, respectively, and is affected by pH, temperature, and salt concentration. Transport is irreversible and accumulation reaches a plateau at which point transport ceases. The permease is inhibited by ADP and by high concentrations of internal histidine. The inhibition by histidine implies that the membrane-bound complex HisQ/M/P carries a substrate-binding site. The reconstituted permease activity corresponds to about 40-70% turnover rate of the in vivo rate of transport.	UNIV CALIF BERKELEY,DEPT MOL & CELL BIOL,DIV BIOCHEM & MOL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley					NIDDK NIH HHS [DK12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBUDKAR SV, 1986, J BIOL CHEM, V261, P9083; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GF, 1992, FASEB J, V6, P2660, DOI 10.1096/fasebj.6.9.1377140; AMES GF, 1964, ARCH BIOCHEM BIOPHYS, V104, P1, DOI 10.1016/S0003-9861(64)80028-X; Ames GFL, 1996, J BIOL CHEM, V271, P14264, DOI 10.1074/jbc.271.24.14264; AMES GFL, 1970, P NATL ACAD SCI USA, V66, P1096, DOI 10.1073/pnas.66.4.1096; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOOS W, 1996, CELLULAR MOL BIOL, P1175; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; DRIESSEN AJM, 1990, P NATL ACAD SCI USA, V87, P3107, DOI 10.1073/pnas.87.8.3107; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; HAUSER H, 1981, BIOCHIM BIOPHYS ACTA, V650, P21, DOI 10.1016/0304-4157(81)90007-1; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HOSHINO T, 1992, J BIOL CHEM, V267, P21313; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOSHI AK, 1989, J BIOL CHEM, V264, P2126; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVER JE, 1972, J BIOL CHEM, V247, P4317; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; Racker E, 1979, Methods Enzymol, V55, P699; RICHARME G, 1992, BIOCHIM BIOPHYS ACTA, V1104, P201, DOI 10.1016/0005-2736(92)90151-B; RICHARME G, 1993, J BIOL CHEM, V268, P9473; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985	41	47	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					859	866		10.1074/jbc.272.2.859	http://dx.doi.org/10.1074/jbc.272.2.859			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995374	hybrid			2022-12-25	WOS:A1997WC04800025
J	Strauss, PR; Beard, WA; Patterson, RA; Wilson, SH				Strauss, PR; Beard, WA; Patterson, RA; Wilson, SH			Substrate binding by human apurinic/apyrimidinic endonuclease indicates a Briggs-Haldane mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; APURINIC APYRIMIDINIC ENDONUCLEASE; EXONUCLEASE-III; REPAIR; CDNA; EXPRESSION; SIMULATION; RESIDUES; SEQUENCE; EXCISION	Apurinic/apyrimidinic endonuclease (AP endo) makes a single nick 5' to a DNA abasic site, We have characterized this reaction by steady-state and transient-state kinetics with purified human AP endo, which had been expressed in Escherichia coli, The substrate was a 49-base pair oligonucleotide with an abasic site at position 21. This substrate was generated by treating a 49-mer duplex oligonucleotide with a single G/U located at position 21 with uracil-DNA glycosylase. The enzymatic products of the AP endo nicking reaction were a 20-mer with a hydroxyl group at the 3'-terminus and a 28-mer with a phosphodeoxyribose at the 5'-terminus. To obtain maximal enzymatic activity, it was necessary to stabilize the abasic site during treatment with uracil-DNA glycosylase with a reducing agent, Otherwise, a 20-mer with phosphoribose at the 3'-terminus resulted from beta-elimination. In agreement with others, K-m and k(cat) were 100 nar and 10 s(-1), respectively. Heat treatment of the abasic site-containing 49-mer without enzyme also resulted in conversion to the beta-elimination product, The resultant heat degradation product was an efficient inhibitor of AP endo with a K-i of 30 nM. The enzyme required divalent cation (Mg2+) for activity, but bound substrate DNA in the absence of Mg2+. Electrophoretic mobility shift assays indicated that AP endo bound tightly to DNA containing an abasic site and formed a 1:1 complex at low enzyme concentrations, The association and dissociation rate constants for substrate binding to AP endo were determined by using a challenge assay to follow AP endo-substrate complex formation, Heat degradation product together with heparin served as an effective trap for free enzyme, The results are consistent with a Briggs-Haldane mechanism where k(om) and k(off) are 5 x 10(7) M(-1) s(-1) and 0.04 s(-1), respectively (K-d = 0.8 nM), k(cat) is 10 s(-1), and product release is very rapid (i.e. k(off,product) >> 10 s(-1)). This scheme is in excellent agreement with the measured steady-state kinetic parameters.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; ARES INC,RANDOLPH,MA 02368	University of Texas System; University of Texas Medical Branch Galveston			Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NIEHS NIH HHS [ES06492, ES06776] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006492] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILLY V, 1989, BIOCHEM J, V259, P761, DOI 10.1042/bj2590761; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; BAYLEY CR, 1961, J CHEM SOC, P1903, DOI 10.1039/jr9610001903; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG XB, 1992, NUCLEIC ACIDS RES, V20, P4591, DOI 10.1093/nar/20.17.4591; CHENG XB, 1992, NUCLEIC ACIDS RES, V20, P370, DOI 10.1093/nar/20.2.370; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; PRASAD R, 1994, J BIOL CHEM, V269, P18096; Rickwood D., 1990, GEL ELECTROPHORESIS; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SEKI S, 1991, J BIOL CHEM, V266, P20797; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; WACHSSTOCK DH, 1994, BIOPHYS J, V67, P1260, DOI 10.1016/S0006-3495(94)80598-3; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23	24	139	145	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1302	1307		10.1074/jbc.272.2.1302	http://dx.doi.org/10.1074/jbc.272.2.1302			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995436	hybrid			2022-12-25	WOS:A1997WC04800087
J	Welham, MJ; Bone, H; Levings, M; Learmonth, L; Wang, LM; Leslie, KB; Pierce, JH; Schrader, JW				Welham, MJ; Bone, H; Levings, M; Learmonth, L; Wang, LM; Leslie, KB; Pierce, JH; Schrader, JW			Insulin receptor substrate-2 is the major 170-kDa protein phosphorylated on tyrosine in response to cytokines in murine lymphohemopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; INTERLEUKIN-4 RECEPTOR; COMMON ELEMENTS; GROWTH-HORMONE; IL-4 RECEPTOR; T-LYMPHOCYTES; ACTIVATION	Insulin receptor substrate 1 (IRS-1), and its structural relative IRS-2, are both phosphorylated on tyrosine following treatment of cells with interleukin-4 (IL-4) and insulin. We have investigated whether both IRS-I and IRS-P are expressed in murine lymphohemopoietic cells. T and B lymphocytes and macrophages from primary cultures expressed only IRS-2, which became phosphorylated on tyrosine following stimulation with both IL-4 and insulin. Likewise, the murine myeloid cell line FD-5 expressed only IRS-2, which was tyrosine phosphorylated in response to IL-4 and insulin, as well as interleukin-3 and granulocyte-macrophage colony stimulating factor. Neither IRS-1 nor IRS-S were expressed at detectable levels in primary bone marrow mast cells although these cells do respond to IL-4. Moreover, a factor-dependent lymphocyte cell line, CT.4S, which grows continuously in IL-4, did not express detectable levels of IRS-1 or IRS-2. IRS-2 from FD-5 cells stimulated with either IL-4 or insulin bound to glutathione S-transferase fusion proteins of the p85 subunit of phosphoinositol 3'-kinase, Grb2, and Syp, paralleling reported associations of IRS-1 with these molecules and indicating phosphorylation of the corresponding residues on IRS-2.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER,BC V6T 1Z3,CANADA; NIH,CELL & MOL BIOL LAB,BETHESDA,MD 20892	University of British Columbia; National Institutes of Health (NIH) - USA	Welham, MJ (corresponding author), UNIV BATH,SCH PHARM & PHARMACOL,PHARMACOL GRP,CALVERTON DOWN,BATH BA2 7AY,AVON,ENGLAND.			Levings, Megan/0000-0002-0305-5790				ANDERSSON J, 1972, EUR J IMMUNOL, V2, P349, DOI 10.1002/eji.1830020410; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; GOLD MR, 1994, J BIOL CHEM, V269, P5403; HULI J, 1989, J IMMUNOL, V142, P800; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1995, J BIOL CHEM, V270, P28527, DOI 10.1074/jbc.270.48.28527; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TURNER B, 1991, P NATL ACAD SCI USA, V88, P1227, DOI 10.1073/pnas.88.4.1227; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATTS JD, 1993, J IMMUNOL, V151, P6862; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; WHITE MF, 1994, J BIOL CHEM, V269, P1; YIN TG, 1994, J BIOL CHEM, V269, P26614	36	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1377	1381		10.1074/jbc.272.2.1377	http://dx.doi.org/10.1074/jbc.272.2.1377			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995447	hybrid			2022-12-25	WOS:A1997WC04800098
J	Hirai, A; Nakamura, S; Noguchi, Y; Yasuda, T; Kitagawa, M; Tatsuno, I; Oeda, T; Tahara, K; Terano, T; Narumiya, S; Kohn, LD; Saito, Y				Hirai, A; Nakamura, S; Noguchi, Y; Yasuda, T; Kitagawa, M; Tatsuno, I; Oeda, T; Tahara, K; Terano, T; Narumiya, S; Kohn, LD; Saito, Y			Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27(Kip1) and facilitate the progression from G(1) to S phase in growth-stimulated rat FRTL-5 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; ADP-RIBOSYLTRANSFERASE; CYCLE PROGRESSION; GENE-PRODUCT; 3T3 CELLS; INHIBITOR; ACTIVATION; PROTEIN; KINASE; PROLIFERATION	Cyclin-dependent kinase (Cdk) enzymes are activated for entry into the S phase of the cell cycle. Elimination of Cdk inhibitor protein p27(Kip1) during the G(1) to S phase is required for the activation process. An inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase prevents its elimination and leads to G(1) arrest. Mevalonate and its metabolite, geranylgeranyl pyrophosphate, but not farnesyl pyrophosphate, restore the inhibitory effect of pravastatin on the degradation of p27 and allow Cdk2 activation. By the addition of geranylgeranyl pyrophosphate, Rho small GTPase(s) are geranylgeranylated and translocated to membranes during G(1)/S progression. The restoring effect of geranylgeranyl pyrophosphate is abolished with botulinum C3 exoenzyme, which specifically inactivates Rho. These results indicate (i) among mevalonate metabolites, geranylgeranyl pyrophosphate is absolutely required for the elimination of p27 followed by Cdk2 activation; (ii) geranylgeranylated Rho small GTPase(s) promote the degradation of p27 during G(1)/S transition in FRTL-5 cells.	OKAYAMA UNIV,SCH MED,INST CELLULAR & MOL BIOL,DEPT CELL CHEM,OKAYAMA 700,JAPAN; MERCK RES LABS,BANYU TSUKUBA RES INST,TSUKUBA,IBARAKI 30026,JAPAN; CHIBA MUNICIPAL HOSP,DEPT INTERNAL MED,CHUO KU,CHIBA 260,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN; NIDDK,METAB RES BRANCH,CELL REGULAT SECT,NIH,BETHESDA,MD 20892	Okayama University; Merck & Company; Kyoto University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hirai, A (corresponding author), CHIBA UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,1-8-1 INOHANA CHO,CHIBA 260,JAPAN.							Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CHAKRABARTI R, 1991, J BIOL CHEM, V266, P12216; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRAI A, 1994, J CLIN INVEST, V94, P2215, DOI 10.1172/JCI117583; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; ORTIZ MB, 1995, J CELL PHYSIOL, V162, P139, DOI 10.1002/jcp.1041620117; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; TSUJITA Y, 1986, BIOCHIM BIOPHYS ACTA, V877, P50, DOI 10.1016/0005-2760(86)90117-7; TURNER JE, 1995, J CELL BIOL, V128, P1145, DOI 10.1083/jcb.128.6.1145; Yamamoto K, 1996, ENDOCRINOLOGY, V137, P2036, DOI 10.1210/en.137.5.2036; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	32	199	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					13	16						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995216				2022-12-25	WOS:A1997WA56400003
J	Jiang, WN; Hou, Y; Inouye, M				Jiang, WN; Hou, Y; Inouye, M			CspA, the major cold-shock protein of Escherichia coli, is an RNA chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID BINDING-PROTEINS; Y-BOX PROTEINS; MESSENGER-RNA; DNA; IDENTIFICATION; TRANSCRIPTION; FAMILY; CS7.4; GENE; TRANSLATION	CspA, the major cold-shock protein of Escherichia coli, is dramatically induced during the cold-shock response, The amino acid sequence of CspA shows 43% identity to the ''cold-shock domain'' of the eukaryotic Y-box protein family, which interacts with RNA and DNA to regulate their functions, Here, we demonstrate that CspA binds to RNA as a chaperone, First, CspA cooperatively binds to heat-denatured single stranded RNA if it is larger than 74 bases, causing a supershift in gel electrophoresis. A minimal concentration of CspA at 2.7 x 10(-5) M is absolutely required for this cooperative binding, which is sufficiently lower than the estimated cellular concentration of CspA (10(-4) M) in cold shocked cells, No specific RNA sequences for CspA binding were identified, indicating that it has a broad sequence specificity for its binding, When the 142-base 5'-untranslated region of the cspA mRNA was used as a substrate for ribonucleases A and T1, the addition of CspA significantly stimulated RNA hydrolysis by preventing the formation of RNase-resistant bands due to stable secondary structures in the 5'-untranslated region, These results indicate that binding of CspA to RNA destabilizes RNA secondary structures to make them susceptible to ribonucleases, We propose that CspA functions as an RNA chaperone to prevent the formation of secondary structures in RNA molecules at low temperature, Such a function may be crucial for efficient translation of mRNAs at low temperatures and may also have an effect on transcription.	RUTGERS STATE UNIV,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Brandi A, 1996, MOL MICROBIOL, V19, P231, DOI 10.1046/j.1365-2958.1996.362897.x; CHATTERJEE S, 1993, J BIOCHEM, V114, P663, DOI 10.1093/oxfordjournals.jbchem.a124234; Etchegaray JP, 1996, GENES CELLS, V1, P171, DOI 10.1046/j.1365-2443.1996.d01-231.x; Goldenberg D, 1996, MOL MICROBIOL, V19, P241, DOI 10.1046/j.1365-2958.1996.363898.x; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; JIANG WN, 1993, J BACTERIOL, V175, P5824, DOI 10.1128/JB.175.18.5824-5828.1993; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; Jones PG, 1996, P NATL ACAD SCI USA, V93, P76, DOI 10.1073/pnas.93.1.76; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LEE CG, 1992, J BIOL CHEM, V267, P4398; LEE SJ, 1994, MOL MICROBIOL, V11, P833, DOI 10.1111/j.1365-2958.1994.tb00361.x; MUSSO RE, 1989, GENE, V85, P205, DOI 10.1016/0378-1119(89)90482-4; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; RANJAN M, 1993, GENE DEV, V7, P1725, DOI 10.1101/gad.7.9.1725; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SCHEFFNER M, 1989, CELL, V57, P955, DOI 10.1016/0092-8674(89)90334-6; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; TAFURI SR, 1992, NEW BIOL, V4, P349; TANABE H, 1992, J BACTERIOL, V174, P3867, DOI 10.1128/jb.174.12.3867-3873.1992; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WOLFFE AP, 1992, NEW BIOL, V4, P290; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	29	499	517	2	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					196	202						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995247				2022-12-25	WOS:A1997WA56400034
J	LealPinto, E; Tao, WJ; Rappaport, J; Richardson, M; Knorr, BA; Abramson, RG				LealPinto, E; Tao, WJ; Rappaport, J; Richardson, M; Knorr, BA; Abramson, RG			Molecular cloning and functional reconstitution of a urate transporter/channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVILLUS MEMBRANE-VESICLES; AMINOHIPPURATE TRANSPORT; SECONDARY STRUCTURE; BINDING PROTEIN; ION CHANNELS; LECTIN; SEQUENCE; EXPRESSION; URICASE; ACID	Maintenance of urate homeostasis requires urate efflux from mate-producing cells with subsequent renal and gastrointestinal excretion, The molecular basis for urate transport, however, has not been identified. A novel full-length cDNA encoding a 322-amino acid protein, designated UAT (urate transporter), has been cloned from a rat renal cDNA library by antibody screening, UAT mRNA transcripts that approximate 1.55 kilobases are present, but differentially expressed in various rat tissues, Recombinant UAT protein that was expressed from the cloned cDNA in Escherichia coli and purified via immobilized metal affinity chromatography has been functionally reconstituted as a highly selective urate transporter/channel in planar lipid bilayers, The IgG fraction of the polyclonal antibody that was used to select the UAT clone from the cDNA library, but not nonimmune IgG, blocked mate channel activity. Based on the wide tissue distribution of the mRNA for UAT we propose that UAT provides the molecular basis for mate flux across cell membranes, allowing urate that is formed during purine metabolism to efflux from cells and serving as an electrogenic transporter that plays an important role in renal and gastrointestinal urate excretion.			LealPinto, E (corresponding author), CUNY MT SINAI SCH MED,DEPT MED,DIV NEPHROL,NEW YORK,NY 10029, USA.							ABRAMSON RG, 1985, AM J PHYSIOL, V248, pF574, DOI 10.1152/ajprenal.1985.248.4.F574; ABRAMSON RG, 1982, AM J PHYSIOL, V242, pF158, DOI 10.1152/ajprenal.1982.242.2.F158; ABRAMSON RG, 1990, BASIC PRINCIPLES TRA, V3, P115; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BLOMSTEDT JW, 1980, J CLIN INVEST, V65, P931, DOI 10.1172/JCI109748; BRIGGS JP, 1977, AM J PHYSIOL, V233, pF373, DOI 10.1152/ajprenal.1977.233.5.F373; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; EMMERSON BT, 1978, URIC ACID HDB EXPT P, V51, P287; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUGGINO SE, 1983, AM J PHYSIOL, V244, pF612, DOI 10.1152/ajprenal.1983.244.6.F612; GUGGINO SE, 1985, J CLIN INVEST, V76, P543, DOI 10.1172/JCI112004; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Hruban Z, 1969, MICROBODIES RELATED; KAHN AM, 1983, AM J PHYSIOL, V244, pF56, DOI 10.1152/ajprenal.1983.244.1.F56; KAHN AM, 1983, AM J PHYSIOL, V245, pF151, DOI 10.1152/ajprenal.1983.245.2.F151; KAHN AM, 1985, AM J PHYSIOL, V249, pF654, DOI 10.1152/ajprenal.1985.249.5.F654; KNORR BA, 1994, KIDNEY INT, V45, P727, DOI 10.1038/ki.1994.97; KNORR BA, 1994, J BIOL CHEM, V269, P6759; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEALPINTO E, 1995, J MEMBRANE BIOL, V146, P123; Lehninger AL, 1993, PRINCIPLES BIOCH, P688; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAHLER HR, 1956, SCIENCE, V124, P705, DOI 10.1126/science.124.3225.705; ODA Y, 1993, J BIOL CHEM, V268, P5929; OELERT H, 1969, PFLUG ARCH EUR J PHY, V307, P178, DOI 10.1007/BF00592083; PORDY WT, 1987, AM J PHYSIOL, V253, pF702, DOI 10.1152/ajprenal.1987.253.4.F702; Sambrook J., 2002, MOL CLONING LAB MANU; SANKARAM MB, 1994, BIOPHYS J, V67, P105, DOI 10.1016/S0006-3495(94)80459-X; SANSOM MSP, 1991, PROG BIOPHYS MOL BIO, V55, P139, DOI 10.1016/0079-6107(91)90004-C; SONNENBERG H, 1968, PFLUGERS ARCH, V286, P171; SORENSEN LEIF BOGE, 1960, SCANDINAVIAN JOUR CLIN AND LAB INVEST, V12, P1; SORENSON LB, 1978, URIC ACID HDB EXPT P, V51, P325; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; WILCOX WR, 1972, MED BIOL ENG, V10, P522, DOI 10.1007/BF02474201; Zagury J.-F., 1996, Cellular Pharmacology, V3, P97	43	64	68	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					617	625						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995305				2022-12-25	WOS:A1997WA56400092
J	Lee, YS; Hwang, DS				Lee, YS; Hwang, DS			Occlusion of RNA polymerase by oligomerization of DnaA protein over the dnaA promoter of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION ORIGIN; CHROMOSOMAL REPLICATION; NUCLEOTIDE-SEQUENCE; AUTO-REGULATION; GENE; INITIATION; TRANSCRIPTION; COMPLEX; INVOLVEMENT; EXPRESSION	DnaA protein, the initiator protein for initiation of Escherichia coli chromosomal replication, has been shown to repress its own expression from two dnaA promoters, 1P and 2P. The sequence-specific binding of DnaA protein to the DnaA box, located between the two promoters, results in subsequent oligomerization of DnaA protein. Upon increasing the concentration of DnaA protein, the oligomerization proceeds to both dnaA promoters from the DnaA box and inhibits RNA polymerase binding to both promoters. This results in the repression of transcription, suggesting that the extent of oligomerization of DnaA proteins over two dnaA promoters contributes to the autoregulation of expression of the dnaA gene. When the two dnaA promoters were bound and repressed by DnaA protein, the interaction of RNA polymerase with IciA protein, which is a specific inhibitor of initiation of in vitro E. coli chromosomal replication, appeared to dissociate the oligomerized DnaA proteins from the 1P promoter and allowed RNA polymerase to be loaded for its transcription.	SEOUL NATL UNIV,INST MOL BIOL & GENET,SEOUL 151742,SOUTH KOREA; SEOUL NATL UNIV,DEPT MICROBIOL,SEOUL 151742,SOUTH KOREA	Seoul National University (SNU); Seoul National University (SNU)								ATLUNG T, 1985, MOL GEN GENET, V200, P442, DOI 10.1007/BF00425729; ATLUNG T, 1984, MOL GEN GENET, V197, P125, DOI 10.1007/BF00327932; AUGUSTIN LB, 1994, J BACTERIOL, V176, P378, DOI 10.1128/JB.176.2.378-387.1994; BRAMHILL D, 1988, CELL, V54, P915, DOI 10.1016/0092-8674(88)90102-X; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BRAUN RE, 1985, CELL, V40, P159, DOI 10.1016/0092-8674(85)90319-8; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; CROOKE E, 1993, J MOL BIOL, V233, P16, DOI 10.1006/jmbi.1993.1481; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FULLER RS, 1983, P NATL ACAD SCI-BIOL, V80, P5817, DOI 10.1073/pnas.80.19.5817; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANSEN EB, 1982, NUCLEIC ACIDS RES, V10, P7373, DOI 10.1093/nar/10.22.7373; HANSEN FG, 1987, EMBO J, V6, P255, DOI 10.1002/j.1460-2075.1987.tb04747.x; HANSEN FG, 1982, EMBO J, V1, P1043, DOI 10.1002/j.1460-2075.1982.tb01294.x; HIROTA Y, 1970, J MOL BIOL, V53, P369, DOI 10.1016/0022-2836(70)90072-0; HWANG DS, 1992, J BIOL CHEM, V267, P23087; HWANG DS, 1990, CELL, V63, P325, DOI 10.1016/0092-8674(90)90165-B; HWANG DS, 1992, J BIOL CHEM, V267, P2209; HWANG DS, 1990, J BIOL CHEM, V265, P19244; HWANG DS, 1992, J BIOL CHEM, V267, P23083; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; Kornberg A., 1992, DNA REPLICATION; KUCHERER C, 1986, MOL GEN GENET, V205, P115, DOI 10.1007/BF02428040; Lee YS, 1996, MOL MICROBIOL, V19, P389, DOI 10.1046/j.1365-2958.1996.485902.x; Papavassiliou AG., 1994, DNA-protein interactions, P43, DOI 10.1385/0-89603-256-6:43; Sambrook J., 2002, MOL CLONING LAB MANU; SAMITT CE, 1989, EMBO J, V8, P989, DOI 10.1002/j.1460-2075.1989.tb03462.x; SCHAEFER C, 1988, GENE, V73, P347, DOI 10.1016/0378-1119(88)90499-4; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SCHAUS NA, 1981, ICN UCLA S MOL CELL, V22, P315; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; TESFASELASE F, 1992, MOL GEN GENET, V231, P256, DOI 10.1007/BF00279799; VANDENBERG EA, 1985, NUCLEIC ACIDS RES, V13, P1829, DOI 10.1093/nar/13.6.1829; VONMEYENBURG K, 1987, ESCHERICHIA COLI SAL, V2, P1555; WANG QP, 1989, J BIOL CHEM, V264, P7338; WANG QP, 1987, MOL GEN GENET, V209, P518, DOI 10.1007/BF00331158; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025	39	28	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					83	88						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995231				2022-12-25	WOS:A1997WA56400018
J	Lima, WF; BrownDriver, V; Fox, M; Hanecak, R; Bruice, TW				Lima, WF; BrownDriver, V; Fox, M; Hanecak, R; Bruice, TW			Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; GENE-EXPRESSION; NUCLEIC-ACIDS; IN-VITRO; SECONDARY STRUCTURE; INVITRO SELECTION; INHIBITION; RIBOZYME; OLIGODEOXYNUCLEOTIDES; CLEAVAGE	We describe our initial application of a biochemical strategy, comprising combinatorial screening and rational optimization, which directly identifies oligonucleotides with maximum affinity (per unit length), specificity, and rates of hybridization to structurally preferred sites on folded RNA, to the problem of design of antisense oligonucleotides active against the hepatitis C virus (HCV), A fully randomized sequence DNA oligonucleotide (10-mer) library was equilibrated with each of two folded RNA fragments (200 and 370 nucleotides (nt)), together spanning the 5' 440 nt of an HCV transcript (by overlapping 130 nt), which were varied over a range of concentrations, The equilibrations were performed in solution under conditions determined to preserve RNA structure and to limit all RNA-DNA library oligonucleotide interactions to 1:1 stoichiometry. Subsequent Escherichia coli RNase H (endoribonuclease H: EC 3.1.26.4) cleavage analysis identified two preferred sites of highest affinity heteroduplex hybridization. The lengths and sequences of different substitute chemistry oligonucleotides complementary to these sites were rationally optimized using an iterative and quantitative analysis of binding affinity and specificity, Thus, DNA oligonucleotides that hybridized with the same affinity to the preferred sites in the folded RNA fragments found by screening as to short (less than or equal to 25 nt) RNA complements were identified but were found to vary in length (10-18 nt) from site to site. Phosphorothioate (P=S) and 2'-fluoro (2'-F) uniformly substituted oligonucleotides also were found, which hybridized optimally to these sites, supporting the design of short (10-15-nt) and maximally specific oligonucleotides that are more nuclease-resistant (via P=S) and have higher affinity (via 2'-F) than DNA. Finally, the affinities of DNA and uniform 2'-F-, P=S-substituted 10-20-mer oligonucleotide complements for the best hybridization site, from HCV nt 355 to nt 364-374, closely corresponded to antisense mechanism inhibition activities in an in vitro translation assay and in a human cell-based HCV core protein expression assay, respectively, These results validate our strategy for the selection of hybridization-optimized and biologically active antisense oligonucleotides targeting HCV RNA and support the potential for utility in further applications.	ISIS PHARMACEUT,DEPT RES MED CHEM,CARLSBAD,CA 92008; ISIS PHARMACEUT,DEPT MOL CELLULAR & STRUCT BIOL,CARLSBAD,CA 92008; ISIS PHARMACEUT,DEPT INFECT DIS,CARLSBAD,CA 92008	Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc; Isis Pharmaceuticals Inc								ALT M, 1995, HEPATOLOGY, V22, P707; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BROWN EA, 1992, NUCLEIC ACIDS RES, V20, P5041, DOI 10.1093/nar/20.19.5041; BUKH J, 1992, P NATL ACAD SCI USA, V89, P4942, DOI 10.1073/pnas.89.11.4942; CAMPBELL TB, 1995, RNA, V1, P598; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; CHANG KY, 1994, P NATL ACAD SCI USA, V91, P8705, DOI 10.1073/pnas.91.18.8705; Chastain M, 1993, ANTISENSE RES APPL, P55; CHETVERIN AB, 1994, BIO-TECHNOL, V12, P1093, DOI 10.1038/nbt1194-1093; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CLOAD ST, 1991, J AM CHEM SOC, V113, P6324, DOI 10.1021/ja00016a089; CLOAD ST, 1993, J AM CHEM SOC, V115, P5005, DOI 10.1021/ja00065a008; COHEN JS, 1994, SCI AM, V271, P76, DOI 10.1038/scientificamerican1294-76; DAVIS P, 1996, METHODS MOL CELLULAR, V40, P23; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEMESMAEKER A, 1995, CURR OPIN STRUC BIOL, V5, P343, DOI 10.1016/0959-440X(95)80096-4; ECKER DJ, 1992, SCIENCE, V257, P958, DOI 10.1126/science.1502560; ECKER DJ, 1993, NUCLEIC ACIDS RES, V21, P1853, DOI 10.1093/nar/21.8.1853; Ecker DJ, 1993, ANTISENSE RES APPL, P387; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FRANCOIS JC, 1994, NUCLEIC ACIDS RES, V22, P3943, DOI 10.1093/nar/22.19.3943; FRANKEL AD, 1991, CELL, V67, P1041, DOI 10.1016/0092-8674(91)90282-4; FRAUENDORF A, 1994, BIOORG MED CHEM LETT, V4, P1019, DOI 10.1016/S0960-894X(01)80673-9; FREIER SM, 1993, ANTISENSE RES APPL, P67; FROEHLER BC, 1993, TETRAHEDRON LETT, V34, P1003, DOI 10.1016/S0040-4039(00)77476-4; GRIFFEY RH, 1994, ACS SYM SER, V580, P212; Hanecak R, 1996, J VIROL, V70, P5203, DOI 10.1128/JVI.70.8.5203-5212.1996; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HERSCHLAG D, 1994, EMBO J, V13, P2913, DOI 10.1002/j.1460-2075.1994.tb06586.x; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; JAEGER JA, 1993, ANNU REV BIOCHEM, V62, P255; Jaroszewski J W, 1993, Antisense Res Dev, V3, P339; Jones JT, 1996, NAT MED, V2, P643, DOI 10.1038/nm0696-643; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; LADBURY J, 1994, BIO-TECHNOL, V12, P1083, DOI 10.1038/nbt1194-1083; LIEBER A, 1995, MOL CELL BIOL, V15, P540, DOI 10.1128/MCB.15.1.540; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MIZUTANI T, 1995, BIOCHEM BIOPH RES CO, V212, P906, DOI 10.1006/bbrc.1995.2055; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PUROHIT P, 1994, NATURE, V370, P659, DOI 10.1038/370659a0; RICHARDSON PL, 1991, J AM CHEM SOC, V113, P5109, DOI 10.1021/ja00013a083; RITTNER K, 1993, NUCLEIC ACIDS RES, V21, P1381, DOI 10.1093/nar/21.6.1381; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; ROSEN CA, 1990, AIDS, V4, P499, DOI 10.1097/00002030-199006000-00002; SOUTHERN EM, 1994, NUCLEIC ACIDS RES, V22, P1368, DOI 10.1093/nar/22.8.1368; STEIN CA, 1994, ANTISENSE RES DEV, V4, P67, DOI 10.1089/ard.1994.4.67; SZAKIEL G, 1993, ANTISENSE RES DEV, V3, P45; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Ueno T, 1993, Hum Cell, V6, P126; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; Wagner RW, 1996, NAT BIOTECHNOL, V14, P840, DOI 10.1038/nbt0796-840; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; WAKITA T, 1994, J BIOL CHEM, V269, P14205; WANG CY, 1995, RNA, V1, P526; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; WEIDNER DA, 1994, ONCOL RES, V6, P237; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; WUPONG S, 1994, PHARM TECH, V18, P102	62	129	153	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					626	638						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995306				2022-12-25	WOS:A1997WA56400093
J	Berka, V; Chen, PF; Tsai, AL				Berka, V; Chen, PF; Tsai, AL			Spatial relationship between L-arginine and heme binding sites of endothelial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXY-L-ARGININE; L-THIOCITRULLINE; SELECTIVE-INHIBITION; CRYSTAL-STRUCTURE; RESOLUTION; MECHANISM; IMIDAZOLE; POTENT	Binding of L-arginine and imidazole to the endothelial nitric-oxide synthase (eNOS) was characterized by direct heme spectral perturbation, L-Arginine is competitive with imidazole for binding to eNOS. Both equilibrium binding and kinetic binding were measured at 4 and 23 degrees C for these two ligands. K-d (imidazole) is 60 mu M and 110 mu M, K-on (imidazole) is 2.5 x 10(5) M(-1) s(-1) and 1.2 x 10(6) M(-1) s(-1), k(off) (imidazole) is 11.8 s(-1) and 116 s(-1) at 4 and 23 degrees C, respectively. Corresponding values for L-arginine are calculated from the data of binding competition with imidazole and computer modeling. K-d (L-arginine) is 0.5 mu M and 2.0 mu M, k(on) (L-arginine) is 2 x 10(5) M(-1) s(-1) and 8 x 10(5) M(-1) s(-1), k(off) (L-arginine) is 0.08 s(-1) and 1.6 s(-1) at 4 and 23 degrees C, respectively. It is suggested that binding of both ligands occurs through the same access channel to the heme site based on their similarly slow association rate constants. A series of potential heme ligands and amino acid analogs of L-arginine were evaluated for their binding and their effect on the heme structure. All ligands besides cyanide tested for binding inhibition are competitive with either L-arginine or imidazole. The space for the distal heme ligand was estimated to be similar to 6.3 x 6.7 Angstrom by three groups of rigid planar ligands: imidazole, pyridine, and pyrimidine. Results of the thiazole and amino acid ligand series permitted the conclusion that the guanidine group of L-arginine is critical for its binding affinity and its specific orientation relative to the heme. Such a specific conformation is essential for the oxygenase mechanism of eNOS.	UNIV TEXAS,SCH MED,DEPT INTERNAL MED,DIV HEMATOL,HOUSTON,TX 77225	University of Texas System					NIGMS NIH HHS [GM44911] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; CHEN PF, 1994, J BIOL CHEM, V269, P25062; FREY C, 1994, J BIOL CHEM, V269, P26083; FREY C, 1996, FASEB J, V10, pA1399; FURFINE ES, 1994, J BIOL CHEM, V269, P26677; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; Griffin B. W., 1979, PORPHYRINS, V7, P333; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; KERWIN JF, 1995, J MED CHEM, V38, P4343, DOI 10.1021/jm00022a001; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; KORTH HG, 1994, J BIOL CHEM, V269, P17776; MARLETTA MA, 1993, ADV EXP MED BIOL, V338, P281; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MAYER B, 1994, FEBS LETT, V350, P199, DOI 10.1016/0014-5793(94)00766-7; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3683; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SALERNO JC, 1995, J BIOL CHEM, V270, P27423, DOI 10.1074/jbc.270.46.27423; SALERNO JC, 1984, J AM CHEM SOC, V106, P2156, DOI 10.1021/ja00319a041; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; Tsai AL, 1996, J BIOL CHEM, V271, P32563, DOI 10.1074/jbc.271.51.32563; WOLFF DJ, 1993, J BIOL CHEM, V268, P9425	26	45	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33293	33300		10.1074/jbc.271.52.33293	http://dx.doi.org/10.1074/jbc.271.52.33293			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969188	hybrid			2022-12-25	WOS:A1996WA71300022
J	Giuffre, A; Sarti, P; DItri, E; Buse, G; Soulimane, T; Brunori, M				Giuffre, A; Sarti, P; DItri, E; Buse, G; Soulimane, T; Brunori, M			On the mechanism of inhibition of cytochrome c oxidase by nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGEN; RESPIRATION; BINDING	The mechanism of inhibition of cytochrome (cyt) c oxidase by nitric oxide (NO) has been investigated by stopped flow transient spectroscopy and singular value decomposition analysis, Following the time course of cyt c oxidation at different O-2/NO ratios, we observed that the onset of inhibition: (i) is fast and at a high NO concentration is complete during the first turnover; (ii) is sensitive to the O-2/NO ratio; and (iii) is independent of incubation time of the oxidized enzyme with NO, Analysis of the reaction kinetics and computer simulations support the conclusion that inhibition occurs via binding of NO to a turnover intermediate with a partially reduced cyt a(3)-Cu-B binuclear center, The inhibited enzyme has the optical spectrum typical of NO bound to reduced cyt a(3). Reversal of inhibition in the presence of O-2 does not involve a direct reaction of O-2 with NO while bound at the binuclear center, since recovery of activity occurs at the rate of NO dissociation (k = 0.13 s(-1)), as determined in the absence of O-2 using hemoglobin as a NO scavenger, We propose that removal of NO from the medium is associated with reactivation of the enzyme via a relatively fast thermal dissociation of NO from the reduced cyt a(3)-Cu-B center.	UNIV ROMA LA SAPIENZA,DIPARTIMENTO SCI BIOCHIM A ROSSI FANELLI,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR MOL BIOL,I-00185 ROME,ITALY; UNIV CAGLIARI,INST BIOL CHEM,I-09125 CAGLIARI,ITALY; RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Cagliari; RWTH Aachen University			Sarti, Paolo/D-2946-2009; Giuffrè, Alessandro/K-4341-2015	Giuffrè, Alessandro/0000-0001-5301-0681; Brunori, Maurizio/0000-0002-7795-1635; Sarti, Paolo/0000-0002-8219-4827				Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BLACKMORE RS, 1991, J BIOL CHEM, V266, P19245; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; MALATESTA F, 1995, BIOPHYS CHEM, V54, P1, DOI 10.1016/0301-4622(94)00117-3; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; SOULIMANE T, 1995, EUR J BIOCHEM, V227, P588, DOI 10.1111/j.1432-1033.1995.tb20429.x; STEVENS TH, 1979, P NATL ACAD SCI USA, V76, P3320, DOI 10.1073/pnas.76.7.3320; TAKEHARA Y, 1995, ARCH BIOCHEM BIOPHYS, V323, P27, DOI 10.1006/abbi.1995.0005; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VERKHOVSKY MI, 1994, BIOCHEMISTRY-US, V33, P3079, DOI 10.1021/bi00176a042; VERKHOVSKY MI, 1992, BIOCHEMISTRY-US, V31, P11860, DOI 10.1021/bi00162a026; YONETANI T, 1972, J BIOL CHEM, V247, P2447; ZHAO XJ, 1994, BIOCHEM BIOPH RES CO, V204, P537, DOI 10.1006/bbrc.1994.2492	23	122	123	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33404	33408		10.1074/jbc.271.52.33404	http://dx.doi.org/10.1074/jbc.271.52.33404			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969202	hybrid			2022-12-25	WOS:A1996WA71300036
J	Mehta, KD; Chang, RX; Underwood, J; Wise, J; Kumar, A				Mehta, KD; Chang, RX; Underwood, J; Wise, J; Kumar, A			Identification of a novel cis-acting element participating in maximal induction of the human low density lipoprotein receptor gene transcription in response to low cellular cholesterol levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGATION-MEDIATED PCR; RNA POLYMERASE-II; IN-VIVO; PROMOTER; ACTIVATION; BINDING; PROTEIN; CELLS; EXPRESSION; PATHWAY	In this paper, we present both in vivo and in vitro evidence for the presence of a novel cis-acting regulatory element that is required for maximal induction of the human low density lipoprotein (LDL) receptor gene following depletion of cellular sterols in HepG2 cells. First, in vivo dimethyl sulfate footprinting of the human LDL receptor promoter before and after transcriptional induction in HepG2 cells revealed protection from -145 to -126, 5'-GAGCTTCACGGGTTAAAAAG-3' (referred to as FP1 site). Second, transient transfections of HepG2 cells with promoter luciferase reporter constructs containing the FP1 site resulted in significant enhancement (approximately 375%) of reporter gene expression in response to low levels of sterols compared with parallel plasmid without the FP1 site. In addition, this response was markedly attenuated on nucleotide substitutions within the FP1 site. Third, by electrophoretic mobility shift assays, the FP1 sequence was found to bind protein(s) from HepG2 nuclear extracts in a sequence-specific manner. In vitro binding of the FP1 mutants paralleled the results obtained for their in vivo transcription. On the basis of competition profiles, the FP1-binding factor is different from the known transcription factors binding to the AT-rich CArG and GArC motifs. Further more, the FP1-binding protein is not specific to HepG2 cells because nuclear factor(s) with the same specificity was observed in nuclear extracts of non-hepatic HeLa cells. We conclude that transcriptional induction of the LDL receptor gene in response to sterol depletion is mediated, in part, by an highly conserved novel cis-acting element through the binding of specific nuclear protein(s).	UNIV ARKANSAS MED SCI HOSP,COLL MED,DEPT MED,LITTLE ROCK,AR 72205	University of Arkansas System; University of Arkansas Medical Sciences	Mehta, KD (corresponding author), UNIV ARKANSAS MED SCI HOSP,COLL MED,DEPT BIOCHEM & MOL BIOL,4301 W MARKHAM,LITTLE ROCK,AR 72205, USA.							AUWERX JH, 1989, MOL CELL BIOL, V9, P2298, DOI 10.1128/MCB.9.6.2298; AUWERX JH, 1989, P NATL ACAD SCI USA, V86, P1133, DOI 10.1073/pnas.86.4.1133; BASHEERUDDIN K, 1995, ARTERIOSCL THROM VAS, V15, P1248, DOI 10.1161/01.ATV.15.8.1248; BECKER PB, 1987, CELL, V51, P435, DOI 10.1016/0092-8674(87)90639-8; BECKERANDRE M, 1993, METHOD ENZYMOL, V218, P420; BISHOP R, 1993, J LIPID RES, V33, P551; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chang R, 1996, BIOCHEM BIOPH RES CO, V218, P733, DOI 10.1006/bbrc.1996.0130; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUTHBERT JA, 1990, J LIPID RES, V31, P2067; DAWSON PA, 1988, J BIOL CHEM, V263, P3372; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELLSWORTH JL, 1995, J LIPID RES, V36, P383; ELLSWORTH JL, 1988, J CELL PHYSIOL, V135, P213, DOI 10.1002/jcp.1041350208; GARRITY PA, 1992, P NATL ACAD SCI USA, V89, P1021, DOI 10.1073/pnas.89.3.1021; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HOFFER MJV, 1993, BIOCHEM BIOPH RES CO, V191, P880, DOI 10.1006/bbrc.1993.1299; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KRONE W, 1988, J LIPID RES, V29, P1663; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; LLOYD DB, 1995, J BIOL CHEM, V270, P25812, DOI 10.1074/jbc.270.43.25812; MABLY JD, 1993, J BIOL CHEM, V268, P476; MAZZONE T, 1990, J BIOL CHEM, V265, P5145; MAZZONE T, 1989, J BIOL CHEM, V264, P1787; MEHTA KD, 1991, J BIOL CHEM, V266, P10406; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; NICHOLSON AC, 1992, J BIOL CHEM, V267, P25982; RIGAUD G, 1991, CELL, V67, P977, DOI 10.1016/0092-8674(91)90370-E; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SCHNEIDER MD, 1992, BASIC RES CARDIOL, V87, P33; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SORCITHOMAS M, 1989, J BIOL CHEM, V264, P9039; STOPECK AT, 1993, J BIOL CHEM, V268, P17489; Streicher R, 1996, J BIOL CHEM, V271, P7128, DOI 10.1074/jbc.271.12.7128; SUDHOF TC, 1987, CELL, V48, P1061, DOI 10.1016/0092-8674(87)90713-6; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; WADE DP, 1989, EUR J BIOCHEM, V181, P727, DOI 10.1111/j.1432-1033.1989.tb14784.x; WALSH K, 1987, J BIOL CHEM, V262, P9429; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	45	24	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33616	33622		10.1074/jbc.271.52.33616	http://dx.doi.org/10.1074/jbc.271.52.33616			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969230	hybrid			2022-12-25	WOS:A1996WA71300064
J	Rossi, EA; McNeer, RR; PriceSchiavi, SA; VandenBrande, JMH; Komatsu, M; Thompson, JF; Carraway, CAC; Fregien, NL; Carraway, KL				Rossi, EA; McNeer, RR; PriceSchiavi, SA; VandenBrande, JMH; Komatsu, M; Thompson, JF; Carraway, CAC; Fregien, NL; Carraway, KL			Sialomucin complex, a heterodimeric glycoprotein complex - Expression as a soluble, secretable form in lactating mammary gland and colon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEINS; FAT-GLOBULE-MEMBRANE; ADENOCARCINOMA CELLS; MOLECULAR-CLONING; MUCIN; MILK; DIFFERENTIATION; MICROVILLI; COMPONENT; P185(NEU)	Ascites 13762 rat mammary adenocarcinoma cells express abundantly on their cell surfaces a heterodimeric glycoprotein complex composed of a sialomucin ascites sialoglycoprotein (ASGP)-1 and a transmembrane subunit ASGP-2, The latter, which contains two epidermal growth factor-like domains, binds the receptor tyrosine kinase p185(neu), suggesting that the complex is bifunctional as well as heterodimeric. Immunoblot analyses using monoclonal antibodies prepared against the complex demonstrate high levels of expression in rat lactating mammary gland and colon, Immunolocalization studies with anti-ASGP-2 indicate that ASGP-2 is present in these two tissues in the apical regions of secretory epithelial cells, Both mammary gland and colon contain a soluble, secretable form of ASGP-2, which is not found in the ascites cells; milk and mammary gland also have the membrane form. Immunoblot analyses using a COOH-terminal-specific polyclonal antibody indicate that the soluble form of ASGP-2 is missing its COOH-terminal domains, Both the soluble and membrane forms of ASGP-2 are similar to the membrane-associated form from the 13762 adenocarcinoma with respect to M(r), antigenicity, and association with ASGP-1. The presence of ASGP-1 in milk suggests that it is a candidate for the uncharacterized high M(r) milk mucin, MUCX, ASGP-2 expression is up-regulated in mammary gland during pregnancy, because it is undetectable in virgin and early pregnant rats but abundant in the gland from late pregnant and lactating animals. However, compared with the lactating mammary gland, the 13762 ascites cells overexpress ASGP-2 by more than 100-fold, which may contribute to their malignancy. These combined results indicate that sialomucin complex is a unique secreted product in the mammary gland and colon, whose behavior is different from that in the mammary ascites tumors, and which may play important roles in mammary and intestinal physiology.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT PEDIAT,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOL BIOL,MIAMI,FL 33101	University of Miami; University of Miami; University of Miami				Komatsu, Masanobu/0000-0001-7548-137X	NATIONAL CANCER INSTITUTE [P30CA014395, R01CA052498] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498, CA 14395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BINGHAM EW, 1992, COMP BIOCHEM PHYS B, V102, P213, DOI 10.1016/0305-0491(92)90113-6; BUCHHEIM W, 1988, PEDIATRICS, V81, P141; BURDON T, 1991, J BIOL CHEM, V266, P6909; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1992, J CELL SCI, V103, P299; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1995, TRENDS GLYCOSCI GLYC, V7, P31, DOI 10.4052/tigg.7.31; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; HARLOW E, 1988, ANTIBODIES LAB MANUA, P150; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; HULL SR, 1984, J BIOL CHEM, V259, P4866; KITCHEN BJ, 1974, BIOCHIM BIOPHYS ACTA, V356, P257, DOI 10.1016/0005-2736(74)90266-1; KOLDOVSKY O, 1989, J NUTR, V119, P1543, DOI 10.1093/jn/119.11.1543; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; MORIARTY J, 1990, CANCER RES, V50, P6800; Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3; PHILLIPS TE, 1992, AM J PHYSIOL, V262, pG327, DOI 10.1152/ajpgi.1992.262.2.G327; SCHROTEN H, 1992, J PEDIATR GASTR NUTR, V15, P150, DOI 10.1097/00005176-199208000-00009; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SHIMIZU M, 1986, BIOCHEM J, V233, P725, DOI 10.1042/bj2330725; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; WU K, 1994, J BIOL CHEM, V269, P11950; WU K, 1994, ONCOGENE, V9, P3139	31	108	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33476	33485		10.1074/jbc.271.52.33476	http://dx.doi.org/10.1074/jbc.271.52.33476			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969211	hybrid			2022-12-25	WOS:A1996WA71300045
J	Schemidt, RA; Brauning, CK; Bouvier, A; Brusilow, WSA				Schemidt, RA; Brauning, CK; Bouvier, A; Brusilow, WSA			Localization of a conformational energy-coupling determinant near the C terminus of the beta subunit of the F1F0-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING ATPASE; ESCHERICHIA-COLI; BACILLUS-MEGATERIUM; SYNTHASE; MECHANISM; CONSTRUCTION	Escherichia coli mutants in the beta subunit of the F1F0-ATPase can be complemented with the beta subunit from the obligate aerobe Bacillus megaterium, It has been shown that cells carrying such hybrid ATPases have an unusual energy-coupling phenotype, Although they are able to grow on minimal succinate medium, and therefore carry a functional ATP synthase, they are defective in the ability to grow anaerobically, indicating some defect in ATP-driven proton pumping (Scarpetta, M., Hawthorne, C. A., and Brusilow, W. S. A. (1991) J. Biol. Chem. 266, 18567-18572), In this study, chimeric beta subunits were constructed consisting of the E. coli or the B. megaterium beta subunit carrying the C-terminal 18% of the other's beta subunit, The phenotypes of an E. coli beta mutant complemented with these chimeric subunits showed that the energy-coupling defect was located in this C-terminal region, The E. coli beta subunit carrying the B. megaterium C-terminal region displayed the energy-coupling defect, while the B. megaterium beta subunit carrying the E. coli C-terminal region did not, In ATP-dependent fluorescence quenching assays, membranes isolated from cells displaying the energy-coupling defect also pumped protons less well than membranes isolated from cells that were able to grow anaerobically, These results demonstrate that the C terminus of the beta subunit is involved in the conformational coupling pathway, which, through the polypeptide backbone of the beta subunit, physically links ATP synthesis or hydrolysis to the energy of proton translocation.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOL BIOL,DETROIT,MI 48201	Wayne State University								ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRUSILOW WSA, 1989, J BIOL CHEM, V264, P1528; BRUSILOW WSA, 1994, J BIOL CHEM, V269, P7285; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COX GB, 1986, BIOCHIM BIOPHYS ACTA, V849, P62, DOI 10.1016/0005-2728(86)90096-4; COX GB, 1984, BIOCHIM BIOPHYS ACTA, V768, P201, DOI 10.1016/0304-4173(84)90016-8; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; GUNSALUS RP, 1982, P NATL ACAD SCI-BIOL, V79, P320, DOI 10.1073/pnas.79.2.320; Harold F. M., 1996, ESCHERICHIA COLI SAL, P283; LEE RSF, 1991, BIOCHEMISTRY-US, V30, P6842, DOI 10.1021/bi00242a006; MATTEN SR, 1995, J BIOL CHEM, V270, P1489, DOI 10.1074/jbc.270.4.1489; Miller J. H., 1972, EXPT MOL GENETICS, P433; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SCARPETTA MA, 1991, J BIOL CHEM, V266, P18567; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11	20	4	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33390	33393		10.1074/jbc.271.52.33390	http://dx.doi.org/10.1074/jbc.271.52.33390			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969200	hybrid			2022-12-25	WOS:A1996WA71300034
J	Kamata, H; Tanaka, C; Yagisawa, H; Matsuda, S; Gotoh, Y; Nishida, E; Hirata, H				Kamata, H; Tanaka, C; Yagisawa, H; Matsuda, S; Gotoh, Y; Nishida, E; Hirata, H			Suppression of nerve growth factor-induced neuronal differentiation of PC12 cells - N-acetylcysteine uncouples the signal transduction from Ras to the mitogen-activated protein kinase cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; KAPPA-B ACTIVATION; MAP KINASE; SUPEROXIDE-DISMUTASE; TRANSCRIPTION FACTOR; PARKINSONS-DISEASE; OXIDATIVE STRESS; PLASMA-MEMBRANE; RAF-1; GENE	The cellular redox state is thought to play an important role in a wide variety cellular signaling pathways. Here, we investigated the involvement of redox regulation in the nerve growth factor (NGF) signaling pathway and neuronal differentiation in PC12 cells. N acetyl-L-cysteine (NAG), which acts as a reductant in cells both by its direct reducing activity and by increasing the synthesis of the cellular antioxidant glutathione, inhibited neuronal differentiation induced by NGF or by the expression of oncogenic ras in PC12 cells. NAC suppressed NGF-induced c-fos gene expression and AP-1 activation. These results suggest that neuronal differentiation and NGF signaling are subject to regulation by the cellular redox state. NAC also suppressed the NGF-induced activation of mitogen-activated protein kinases (MAPKs) and decreased the amount of tyrosine phosphorylation of MAPKs. The suppression of MAPK by NAC was independent of glutathione synthesis. In parallel with the suppression of MAPK, the activation of MAPK kinase kinase activity was also suppressed in the presence of NAG. In contrast, NGF-induced activation of has was not inhibited by NAG. The inhibitory effect of NAC on the MAPK cascade was independent of transcription and translation. Thus, NAC suppresses NGF-induced neuronal differentiation by uncoupling the signal transduction from Ras to the MAP kinase cascade in PC12 cells.	KYOTO UNIV, INST VIRUS RES, KYOTO 60601, JAPAN	Kyoto University	Kamata, H (corresponding author), HIMEJI INST TECHNOL, FAC SCI, DEPT LIFE SCI, HIMEJI, HYOGO 67812, JAPAN.		Kamata, Hideaki/N-3907-2017					ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FUKUDA M, 1995, ONCOGENE, V11, P239; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JENNER P, 1992, NEUROLOGY, V42, P2241, DOI 10.1212/WNL.42.12.2241; Kamata H, 1996, NEUROSCI LETT, V212, P179, DOI 10.1016/0304-3940(96)12806-8; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MOLDEUS P, 1994, METHOD ENZYMOL, V234, P482; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUROYA K, 1992, ONCOGENE, V7, P277; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; SAMPATH D, 1994, J NEUROCHEM, V62, P2476; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; SUZUKI YJ, 1994, J IMMUNOL, V153, P5008; TAGAYA Y, 1989, EMBO J, V8, P757, DOI 10.1002/j.1460-2075.1989.tb03436.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	65	86	87	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33018	33025		10.1074/jbc.271.51.33018	http://dx.doi.org/10.1074/jbc.271.51.33018			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955147	hybrid			2022-12-25	WOS:A1996VZ37300082
J	Semenza, GL; Jiang, BH; Leung, SW; Passantino, R; Concordet, JP; Maire, P; Giallongo, A				Semenza, GL; Jiang, BH; Leung, SW; Passantino, R; Concordet, JP; Maire, P; Giallongo, A			Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROPOIETIN GENE; ENDOTHELIAL GROWTH-FACTOR; FACTOR-I; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; COOPERATIVE BINDING; INSULIN GENE; 3' ENHANCER; CELLS; DNA	Hypoxia-inducible factor 1 (HIF-1) is a basic helix-loop-helix transcription factor which is expressed when mammalian cells are subjected to hypoxia and which activates transcription of genes encoding erythropoietin, vascular endothelial growth factor, and other pro teins that are important for maintaining oxygen homeostasis. Previous studies have provided indirect evidence that HIF-1 also regulates transcription of genes encoding glycolytic enzymes, In this paper we characterize hypoxia response elements in the promoters of the ALDA, ENO1, and Ldha genes, We demonstrate that HIF-1 plays an essential role in activating transcription via these elements and show that although absolutely necessary, the presence of a HIF-1 binding site alone is not sufficient to mediate transcriptional responses to hypoxia, Analysis of hypoxia response elements in the ENO1 and Ldha gene promoters revealed that each contains two functionally-essential HIF-1 sites arranged as direct and inverted repeats, respectively. Our data establish that functional hypoxia-response elements consist of a pair of contiguous transcription factor binding sites at least one of which contains the core sequence 5'-RCGTG-3' and is recognized by HIF-1. These results provide further evidence that the coordinate transcriptional activation of genes encoding glycolytic enzymes which occurs in hypoxic cells is mediated by HIF-1.	JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,CTR MED GENET,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21287; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY; INST COCHIN GENET MOL,F-75014 PARIS,FRANCE	Johns Hopkins University; Johns Hopkins University; Consiglio Nazionale delle Ricerche (CNR); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Maire, Pascal/E-6339-2016; Giallongo, Agata/ABD-1103-2020; passantino, rosa/C-3993-2015; concordet, jean-paul/C-3417-2015	Giallongo, Agata/0000-0001-9998-4481; passantino, rosa/0000-0001-6598-2664; Jiang, Bing-Hua/0000-0003-4526-2031; Concordet, Jean-Paul/0000-0001-8924-4316; Maire, Pascal/0000-0001-7795-0029	NHLBI NIH HHS [HL55338] Funding Source: Medline; NIDDK NIH HHS [R01 DK39869] Funding Source: Medline; Telethon [416] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK I, 1993, BLOOD, V82, P704; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; Brizel DM, 1996, CANCER RES, V56, P941; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONCORDET JP, 1991, NUCLEIC ACIDS RES, V19, P4173, DOI 10.1093/nar/19.15.4173; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADAN A, 1993, P NATL ACAD SCI USA, V90, P3928, DOI 10.1073/pnas.90.9.3928; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; ROBIN ED, 1984, J CELL PHYSIOL, V118, P287, DOI 10.1002/jcp.1041180311; SCHAEFER S, 1995, J MOL CELL CARDIOL, V27, P2167, DOI 10.1016/S0022-2828(95)91407-2; SCHUSTER SJ, 1989, BLOOD, V73, P13; SCHWICKERT G, 1995, CANCER RES, V55, P4757; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SRERE P, 1994, TRENDS BIOCHEM SCI, V19, P519, DOI 10.1016/0968-0004(94)90048-5; STEIN I, 1995, MOL CELL BIOL, V15, P5363; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; VANOVERSCHELDE JLJ, 1993, CIRCULATION, V87, P1513, DOI 10.1161/01.CIR.87.5.1513; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wang GL, 1996, REDOX REP, V2, P89, DOI 10.1080/13510002.1996.11747034; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WEBSTER KA, 1987, MOL CELL BIOCHEM, V77, P19; WEBSTER KA, 1990, J CELL PHYSIOL, V142, P566, DOI 10.1002/jcp.1041420316; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	48	1297	1345	6	85	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32529	32537		10.1074/jbc.271.51.32529	http://dx.doi.org/10.1074/jbc.271.51.32529			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955077	hybrid			2022-12-25	WOS:A1996VZ37300012
J	Wilkie, N; Morton, C; Ng, LL; Boarder, MR				Wilkie, N; Morton, C; Ng, LL; Boarder, MR			Stimulated mitogen-activated protein kinase is necessary but not sufficient for the mitogenic response to angiotensin II - A role for phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SPONTANEOUSLY HYPERTENSIVE RATS; BETA-GAMMA-SUBUNITS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; INDEPENDENT PATHWAYS; DEPENDENT ACTIVATION; CARDIAC FIBROBLASTS; MESANGIAL CELLS; MAP KINASES	Activation of the mitogen-activated protein kinase (MAPK) cascade has been widely associated with cell proliferation; previous studies have shown that angiotensin II (AII), acting on 7-transmembrane G protein coupled receptors, stimulates the MAPK pathway. In this report we investigate whether the MAPK pathway is required for the mitogenic response to AII stimulation of vascular smooth muscle cells derived from the hypertensive rat (SHR-VSM), AII stimulates the phosphorylation of MAPK, as determined by Western blot specific for the tyrosine 204 phosphorylated form of the protein. This MAPK phosphorylation was inhibited by the presence of the inhibitor of MAPK kinase activation, PD 098059, Using a peptide kinase assay shown to measure the p42 and p44 isoforms of MAPK, the stimulated response to AII was inhibited by PD 098059 with an IC50 of 15.6 +/- 1.6 mu M. The AII stimulation of [H-3]thymidine incorporation was inhibited by PD 098059 with an IC50 of 17.8 +/- 3.1 mu M. PD 098059 had no effect on AII-stimulated phospholipase C or phospholipase D (PLD) activity, When the SHR-VSM cells were stimulated with phorbol ester, there was an activation of MAPK similar in size and duration to the response to AII, but there was no significant enhancement of [H-3]thymidine incorporation, There was also no activation of PLD by phorbol ester, while ATI produced a robust PLD response, Diversion of the product of the PLD reaction by 1-butanol caused a partial loss of the [H-3]thymidine response; this did not occur with tertiary butanol, which did not interfere with the PLD reaction, These results show that in these cells the MAPK cascade is required but not sufficient for the mitogenic response to AII, and suggest that the full mitogenic response requires both MAPK in conjunction with other signaling components, one of which is PLD.	UNIV LEICESTER,DEPT CELL PHYSIOL & PHARMACOL,LEICESTER LE1 9HN,LEICS,ENGLAND; UNIV LEICESTER,DEPT MED,LEICESTER LE1 9HN,LEICS,ENGLAND	University of Leicester; University of Leicester				Ng, Leong/0000-0002-6553-5749	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BAINES RJ, 1996, IN PRESS HYPERTENSIO; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOARDER MR, NEUROPROTOCOLS, V3, P157; BOOZ GW, 1995, ANN NY ACAD SCI, V752, P158, DOI 10.1111/j.1749-6632.1995.tb17419.x; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BUNKENBURG B, 1992, HYPERTENSION, V20, P746, DOI 10.1161/01.HYP.20.6.746; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIES JE, 1991, CLIN SCI, V80, P506; DUFF JL, 1995, CARDIOVASC RES, V30, P511, DOI 10.1016/0008-6363(95)00088-7; FAURE M, 1994, J BIOL CHEM, V269, P7851; FORCE T, 1991, J BIOL CHEM, V266, P6650; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HAYSTEAD TA, 1992, FEBS LETT, V13, P17; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; Jahan H, 1996, EUR J PHARMACOL, V295, P261, DOI 10.1016/0014-2999(95)00653-2; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KONDO T, 1992, J BIOL CHEM, V267, P23609; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; Mii S, 1996, AM J PHYSIOL-HEART C, V270, pH142, DOI 10.1152/ajpheart.1996.270.1.H142; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MORTON C, 1995, BRIT J PHARMACOL, V115, P361, DOI 10.1111/j.1476-5381.1995.tb15886.x; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OSANAI T, 1992, HYPERTENSION, V19, P446, DOI 10.1161/01.HYP.19.5.446; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAQUET JL, 1990, J HYPERTENS, V8, P565, DOI 10.1097/00004872-199006000-00010; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; PURKISS JR, 1992, BIOCHEM J, V287, P31, DOI 10.1042/bj2870031; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SCHEIFFER B, 1996, J BIOL CHEM, V271, P10329; SUNG CP, 1994, J PHARMACOL EXP THER, V271, P429; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0	41	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32447	32453		10.1074/jbc.271.50.32447	http://dx.doi.org/10.1074/jbc.271.50.32447			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943310	hybrid			2022-12-25	WOS:A1996VY34000101
J	Locher, KP; Rosenbusch, JP				Locher, KP; Rosenbusch, JP			Modeling ligand-gated receptor activity - FhuA-mediated ferrichrome efflux from lipid vesicles triggered by phage T5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; REVERSE-PHASE EVAPORATION; IRON TRANSPORT; OUTER-MEMBRANE; ACETYLCHOLINE-RECEPTOR; PERIPLASMIC FHUD; PROTEIN; TONB; PORIN; RESOLUTION	An in vitro assay of iron-ferrichrome translocation across the FhuA protein of outer membranes from Escherichia coli has been devised. Upon reconstitution into large lipid vesicles, bacteriophage T5 binds to this polyvalent receptor, triggering a conformational change that resulted in channel opening. This facilitates the translocation of an iron(III)-siderophore, without the complexities involved in the in vivo process. Efflux of Fe-55(III)-ferrichrome across FhuA channels was determined quantitatively by monitoring the release of trapped radioactivity. The assay is rapid, reliable, and specific, because other bacteriophages, such as Phi 80, fail to trigger channel opening of the FhuA receptor.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel								BENDET I J, 1963, Adv Virus Res, V10, P65; Bonhivers M, 1996, EMBO J, V15, P1850, DOI 10.1002/j.1460-2075.1996.tb00535.x; Boulanger P, 1996, BIOCHEMISTRY-US, V35, P14216, DOI 10.1021/bi9608673; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; CHANGEUX JP, 1995, BIOCHEM SOC T, V23, P195, DOI 10.1042/bst0230195; COULTON JW, 1983, J BACTERIOL, V156, P1315, DOI 10.1128/JB.156.3.1315-1321.1983; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FECKER L, 1983, J BACTERIOL, V156, P1301, DOI 10.1128/JB.156.3.1301-1314.1983; GARAVITO RM, 1986, METHOD ENZYMOL, V125, P309; GUERINOT ML, 1994, ANNU REV MICROBIOL, V48, P743, DOI 10.1146/annurev.mi.48.100194.003523; HANTKE K, 1975, FEBS LETT, V49, P301, DOI 10.1016/0014-5793(75)80771-X; HOLLOMAN WK, 1973, J BIOL CHEM, V248, P8114; JEANTEUR D, 1994, P NATL ACAD SCI USA, V91, P10675, DOI 10.1073/pnas.91.22.10675; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KLEBBA PE, 1993, J BIOENERG BIOMEMBR, V25, P603; KOEBNIK R, 1993, J BACTERIOL, V175, P826, DOI 10.1128/JB.175.3.826-839.1993; KOSTER W, 1990, J BIOL CHEM, V265, P21407; KREUSCH A, 1994, PROTEIN SCI, V3, P58; LOCHER KP, 1997, THESIS U BASEL BASEL; Lou KL, 1996, J BIOL CHEM, V271, P20669, DOI 10.1074/jbc.271.34.20669; Marie D, 1996, APPL ENVIRON MICROB, V62, P1649, DOI 10.1128/AEM.62.5.1649-1655.1996; MENICHI B, 1983, J BACTERIOL, V154, P130, DOI 10.1128/JB.154.1.130-138.1983; NAU CD, 1989, J BACTERIOL, V171, P1041, DOI 10.1128/jb.171.2.1041-1047.1989; NEILANDS JB, 1981, ANNU REV BIOCHEM, V50, P715, DOI 10.1146/annurev.bi.50.070181.003435; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; POSTLE K, 1990, MOL MICROBIOL, V4, P2019, DOI 10.1111/j.1365-2958.1990.tb00561.x; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Saint N, 1996, BIOCHEM BIOPH RES CO, V223, P118, DOI 10.1006/bbrc.1996.0855; SCHENKMAN S, 1984, J BIOL CHEM, V259, P7570; Schertler G. F. X., 1992, CURR OPIN STRUC BIOL, V2, P534, DOI DOI 10.1016/0959-440X(92)90083-J; SCHIRMER T, 1995, SCIENCE, V267, P512, DOI 10.1126/science.7824948; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; WEAVER CA, 1980, J BACTERIOL, V143, P1513, DOI 10.1128/JB.143.3.1513-1518.1980; WEISS MS, 1991, FEBS LETT, V280, P379, DOI 10.1016/0014-5793(91)80336-2	38	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1448	1451		10.1074/jbc.272.3.1448	http://dx.doi.org/10.1074/jbc.272.3.1448			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999812	hybrid			2022-12-25	WOS:A1997WD05800010
J	Wolfgang, CL; Zhang, ZP; Gabriel, JL; Pieringer, RA; Soprano, KJ; Soprano, DR				Wolfgang, CL; Zhang, ZP; Gabriel, JL; Pieringer, RA; Soprano, KJ; Soprano, DR			Identification of sulfhydryl-modified cysteine residues in the ligand binding pocket of retinoic acid receptor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOCORTICOID RECEPTOR; CRYSTAL-STRUCTURE; STEROID BINDING; ALPHA; DOMAIN; GAMMA; ISOFORMS; PURIFICATION; MUTAGENESIS; EXPRESSION	The diverse biological functions of retinoic acid (RA) are mediated through retinoic acid receptors (RARs) and retinoid X receptors. RARs contain a high affinity binding site for RA which is sensitive to treatment with sulfhydryl modification reagents. In an attempt to identify which Cys residues are important for this loss of binding, we created three site-specific RAR beta mutants: C228A, C258A, and C267A. The affinity for RA of all three mutant receptors was in the range of that of the wild type protein, suggesting that none of these Cys residues are critical for RA binding, Rather, these modified Cys residue(s) function to sterically hinder RA binding; however, the modified Cys residues critical for the inhibition of binding differ depending on the reagent employed. Only modification of Cys(228) is necessary to inhibit RA binding when RAR beta is modified by reagents which transfer large bulky groups while both Cys(228) and Cys(267) must be modified when a small functional group is transferred. These data suggest that both Cys(228) and Cys(267) but not Cys(258) lie in the ligand binding pocket of RAR beta. However, Cys(228) lies closer to the opening of the RAR beta ligand binding pocket whereas Cys(267) lies more deeply buried.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NICHD NIH HHS [HD01076] Funding Source: Medline; NIDDK NIH HHS [DK44517] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENBROOK D, 1988, NATURE, V333, P444; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; DALLERY N, 1993, BIOCHEMISTRY-US, V32, P12428, DOI 10.1021/bi00097a022; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; DEGANI Y, 1970, J AM CHEM SOC, V92, P6969; DUKOH S, 1981, ANAL BIOCHEM, V116, P211; GABER BP, 1968, Q REP SULFUR CHEM, V3, P317; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GUDAS L, 1994, RETINOIDS, P453; HARRISON RW, 1983, BIOCHIM BIOPHYS ACTA, V759, P1, DOI 10.1016/0304-4165(83)90181-2; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; JOSHI S, 1981, J BIOL CHEM, V256, P1112; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LEVIN AA, 1992, NATURE, V355, P369; LUPISELLA JA, 1995, J BIOL CHEM, V270, P24884, DOI 10.1074/jbc.270.42.24884; Mangelsdorf David J., 1994, P319; MILLER NR, 1988, J BIOL CHEM, V263, P15217; NISHIMURA JS, 1975, ARCH BIOCHEM BIOPHYS, V170, P461, DOI 10.1016/0003-9861(75)90141-1; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; ROBERTSON KA, 1992, MOL CELL BIOL, V12, P3743, DOI 10.1128/MCB.12.9.3743; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SANI BP, 1990, ARCH BIOCHEM BIOPHYS, V283, P107, DOI 10.1016/0003-9861(90)90619-A; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHEN S, 1993, MECH DEVELOP, V40, P177, DOI 10.1016/0925-4773(93)90075-9; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P766, DOI 10.1021/bi00675a019; STANCATO LF, 1993, BIOCHEMISTRY-US, V32, P3729, DOI 10.1021/bi00065a027; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAIRIS N, 1995, J BIOL CHEM, V270, P18380, DOI 10.1074/jbc.270.31.18380; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; VANAMAN TC, 1970, J BIOL CHEM, V245, P3565; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	38	15	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					746	753		10.1074/jbc.272.2.746	http://dx.doi.org/10.1074/jbc.272.2.746			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995359	hybrid			2022-12-25	WOS:A1997WC04800010
J	Riddell, DR; Graham, A; Owen, JS				Riddell, DR; Graham, A; Owen, JS			Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway - Implications for vascular disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN-BLOOD PLATELETS; CYCLIC-AMP; SELECTIVE-INHIBITION; ADENYLATE-CYCLASE; CORONARY-ARTERY; HEART-DISEASE; BONE-MARROW; MICE; ATHEROSCLEROSIS	We have previously reported that plasma apolipoprotein (ape) E-containing high density lipoprotein particles have a potent anti-platelet action, apparently by occupying saturable binding sites in the cell surface. Here we show that purified apoE (10-50 mu g/ml), complexed with phospholipid vesicles (dimyristoylphosphatidylcholine, DMPC), suppresses platelet aggregation induced by ADP, epinephrine, or collagen. This effect was not due to sequestration of cholesterol from platelet membranes; apoE . DMPC chemically modified with cyclohexanedione (cyclohexanedione-apoE . DMPC) did not inhibit aggregation but nevertheless removed similar amounts of cholesterol as untreated complexes, about 2% during the aggregation period. Rather we found that apoE influenced intracellular platelet signaling. Thus, apoE . DMPC markedly increased cGMP in ADP-stimulated platelets which correlated with the resulting inhibition of aggregation (r = 0.85; p < 0.01, n = 10), whereas cyclohexanedione-apoE DMPC vesicles had no effect, One important cellular mechanism for up-regulation of cGMP is through stimulation of nitric oxide (NO) synthase, the NO generated by conversion of L-arginine to L-citrulline, binds to and activates guanylate cyclase. This signal transduction pathway was implicated by the finding that NO synthase inhibitors of distinct structural and functional types all reversed the anti-platelet action of apoE, whereas a selective inhibitor of soluble guanylate cyclase, 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (100 nM), had a similar reversing action. Direct confirmation that apoE stimulates NO synthase was obtained by use of L-[H-3]arginine; platelets pretreated with apoE DMPC produced markedly more L-[H-3]citrulline (0.71 +/- 0.1 pmol/h/10(9) platelets) than controls (0.18 +/- 0.03; p < 0.05). In addition, hemoglobin which avidly binds NO also suppressed the anti-aggregatory effect, indicating that apoE stimulated sufficient production of NO by platelets for extracellular release to occur. We conclude that apoE inhibits platelet aggregation through the L-arginine:NO signal transduction pathway.	UNIV LONDON,ROYAL FREE HOSP,SCH MED,DEPT MED,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School			Owen, James/C-5908-2009; Owen, James S./AAP-8628-2020					ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; COULDERE R, 1993, STROKE, V24, P661; DESAI K, 1989, J LIPID RES, V30, P831; DESAI K, 1989, LANCET, V1, P693; ELWOOD PC, 1991, CIRCULATION, V83, P38, DOI 10.1161/01.CIR.83.1.38; FAZIO S, 1993, J CLIN INVEST, V92, P1497, DOI 10.1172/JCI116728; FISCH A, 1995, EUR J PHARM-MOLEC PH, V289, P455, DOI 10.1016/0922-4106(95)90154-X; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARVEY EP, 1994, J BIOL CHEM, V269, P26669; GENEST JJ, 1991, ATHEROSCLEROSIS, V90, P149, DOI 10.1016/0021-9150(91)90109-G; GIANTURCO SH, 1983, J BIOL CHEM, V258, P4526; GILLETT MPT, 1992, LIPOPROTEIN ANAL PRA, P189; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; HARMONY JAK, 1995, ATHEROSELEROSIS, V10, P675; HASLAM RJ, 1975, MOL PHARMACOL, V11, P528; HAYNES DH, 1993, PLATELETS, V4, P231, DOI 10.3109/09537109309013223; HEEMSKERK JWM, 1994, PLATELETS, V5, P295, DOI 10.3109/09537109409006439; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; HIGASHIHARA M, 1991, FEBS LETT, V282, P82, DOI 10.1016/0014-5793(91)80449-D; HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571; IGNARRO LJ, 1991, BIOCHEM PHARMACOL, V41, P485, DOI 10.1016/0006-2952(91)90618-F; Innerarity T L, 1986, Methods Enzymol, V129, P542; INNERARITY TL, 1979, J BIOL CHEM, V254, P4186; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KELLY ME, 1994, CELL IMMUNOL, V159, P124, DOI 10.1006/cimm.1994.1302; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; Mahley Robert W., 1995, Current Opinion in Lipidology, V6, P86, DOI 10.1097/00041433-199504000-00005; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAHLEY RW, 1990, CURRENT OPINION LIPI, V1, P87; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P960, DOI 10.1006/bbrc.1993.1914; MAURICE DH, 1990, MOL PHARMACOL, V37, P671; MELLION BT, 1981, BLOOD, V57, P946; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; Moro MA, 1996, P NATL ACAD SCI USA, V93, P1480, DOI 10.1073/pnas.93.4.1480; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1990, BRIT J PHARMACOL, V101, P325, DOI 10.1111/j.1476-5381.1990.tb12709.x; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SALVEMINI D, 1990, BRIT J PHARMACOL, V101, P991, DOI 10.1111/j.1476-5381.1990.tb14194.x; SHATTIL SJ, 1975, J CLIN INVEST, V55, P636, DOI 10.1172/JCI107971; SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; TATESON JE, 1977, PROSTAGLANDINS, V13, P389, DOI 10.1016/0090-6980(77)90019-3; THAULOW E, 1991, CIRCULATION, V84, P613, DOI 10.1161/01.CIR.84.2.613; TROVATI M, 1994, DIABETES, V43, P1015, DOI 10.2337/diabetes.43.8.1015; VALLANCE P, 1994, J ROY COLL PHYS LOND, V28, P209; VANE JR, 1990, NEW ENGL J MED, V323, P27; WILSON HM, 1993, CLIN CHIM ACTA, V220, P175, DOI 10.1016/0009-8981(93)90046-7	51	163	171	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					89	95						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995232				2022-12-25	WOS:A1997WA56400019
J	Yasumoto, K; Yokoyama, K; Takahashi, K; Tomita, Y; Shibahara, S				Yasumoto, K; Yokoyama, K; Takahashi, K; Tomita, Y; Shibahara, S			Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOCYTE-SPECIFIC TRANSCRIPTION; LOOP-HELIX PROTEINS; HEME OXYGENASE GENE; HUMAN HOMOLOG; RETINOBLASTOMA PROTEIN; MOLECULAR-BASIS; BROWN LOCUS; DNA-BINDING; MOUSE; EXPRESSION	Tyrosinase, tyrosinase-related protein-1 (TRP-1), and TRP-2 are the enzymes involved in melanin biosynthesis and are preferentially expressed in pigment cells. Their human gene promoters share the 11-base pair M box containing a CATGTG motif, which was shown here to be bound in vitro by microphthalmia-associated transcription factor (MITF). Transient cotransfection analysis showed that MITF overexpression increased the expression of a reporter gene under the control of the human tyrosinase or TRP-1 gene promoter but not the TRP-2 promoter. The promoter activation caused by MITF is dependent on each CATGTG motif of the distal enhancer element, the IM box, and the initiator E box of the tyrosinase gene and the TRP-1 M box. Furthermore, a truncated MITF lacking the carboxyl-terminal 125 amino acid residues transactivated the tyrosinase promoter less efficiently than did MITF, suggesting that MIF's carboxyl terminus contains a transcriptional activation domain, but unexpectedly such a truncated MITF remarkably transactivated the TRP-2 gene promoter. These results suggest that MITF is sufficient to direct pigment cell-specific transcription of the tyrosinase and TRP-1 genes but not the TRP-2 gene.	TOHOKU UNIV,SCH MED,DEPT APPL PHYSIOL & MOL BIOL,AOBA KU,SENDAI,MIYAGI 98077,JAPAN; AKITA UNIV,SCH MED,DEPT DERMATOL,AKITA 010,JAPAN	Tohoku University; Akita University			Shibahara, Shigeki/M-3644-2014; Takahashi, Kazuhiro/A-4887-2010	Takahashi, Kazuhiro/0000-0001-8943-1875; Yasumoto, Ken-ichi/0000-0002-8090-1161				ARTANDI SE, 1995, NUCLEIC ACIDS RES, V23, P3865, DOI 10.1093/nar/23.19.3865; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; BOUCHARD B, 1994, EUR J BIOCHEM, V219, P127, DOI 10.1111/j.1432-1033.1994.tb19922.x; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; HASUMI K, 1978, CANCER-AM CANCER SOC, V42, P2675, DOI 10.1002/1097-0142(197812)42:6<2675::AID-CNCR2820420624>3.0.CO;2-G; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HUGHES MJ, 1993, J BIOL CHEM, V268, P20687; INOUE S, 1987, BIOCHEM PHARMACOL, V36, P3537, DOI 10.1016/0006-2952(87)90340-6; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JACKSON IJ, 1992, EMBO J, V11, P527, DOI 10.1002/j.1460-2075.1992.tb05083.x; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; MURAOSA Y, 1993, MOL CELL BIOL, V13, P7881, DOI 10.1128/MCB.13.12.7881; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; SATO M, 1990, EUR J BIOCHEM, V188, P231, DOI 10.1111/j.1432-1033.1990.tb15394.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SHIBAHARA S, 1989, EUR J BIOCHEM, V179, P557, DOI 10.1111/j.1432-1033.1989.tb14583.x; SHIBATA K, 1992, J BIOL CHEM, V267, P20584; SHIBATA K, 1992, BIOCHEM BIOPH RES CO, V184, P568, DOI 10.1016/0006-291X(92)90627-W; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; TAKEDA A, 1989, BIOCHEM BIOPH RES CO, V162, P984, DOI 10.1016/0006-291X(89)90770-5; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; TSUKAMOTO K, 1992, EMBO J, V11, P519, DOI 10.1002/j.1460-2075.1992.tb05082.x; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494; YAVUZER U, 1995, ONCOGENE, V10, P123; YOKOYAMA K, 1994, J BIOL CHEM, V269, P27080; YOKOYAMA K, 1994, BBA-GENE STRUCT EXPR, V1217, P317, DOI 10.1016/0167-4781(94)90292-5; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	43	310	329	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					503	509						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995290				2022-12-25	WOS:A1997WA56400077
J	Bouma, CL; Roseman, S				Bouma, CL; Roseman, S			Sugar transport by the marine chitinolytic bacterium Vibrio furnissii - Molecular cloning and analysis of the mannose/glucose permease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; AMINO-ACID-SEQUENCE; PHAGE-LAMBDA-DNA; PHOSPHOTRANSFERASE SYSTEM; SALMONELLA-TYPHIMURIUM; MANNOSE-PERMEASE; OPERON; PROTEINS; GLUCOSE; GENES	We have previously reported that the chitin catabolic cascade in Vibrio furnissii involves multiple signal transducing systems, and that mono- and disaccharide chemoreceptors/transporters are essential components of some of these systems, This and the accompanying papers (Bouma, C. L., and Roseman, S. (1996) J. Biol. Chem 271, 33457-33467; Keyhani, N. O., Wang, L.-X., Lee, Y. C., and Roseman, S. (1996) J. Biol. Chem. 271, 33409-33413) describe some of the sugar transporters, A 13-kilobase pair fragment of V. furnissii DNA was found to impart a Glc(+), Man(+) phenotype to Escherichia coli ptsG ptsM mutants, and encodes the mannose transporter, ptsM, of the phosphoenolpyruvate:glycose phosphotransferase system. Unlike the E. coli mannose permease, V. furnissii IIMan is inactive with GlcNAc and Fru, and is encoded by four genes rather than three, The gene order is manXYZM, where the product of manY corresponds to IIPMan, manZ to the mannose receptor IIBMan, and manX and manW to the single E. coli gene, manX (which encodes IIIMan, viz. IIA(Man)). Thus, in V. furnissii, the E. coli manX equivalent comprises two genes, which are separated in the genome by two other genes of the ptsM complex. Two additional open reading frames were detected in the V. furnissii DNA fragment, One encodes a GlcNAc-6-P deacetylase, and the other is similar to aldolase.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NIGMS NIH HHS [GM38759, GM07321, GM51215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759, R01GM051215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEFOUNDER PR, 1989, MOL MICROBIOL, V3, P723, DOI 10.1111/j.1365-2958.1989.tb00221.x; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BOUMA CL, 1987, P NATL ACAD SCI USA, V84, P930, DOI 10.1073/pnas.84.4.930; Bouma CL, 1996, J BIOL CHEM, V271, P33457, DOI 10.1074/jbc.271.52.33457; CURTIS SJ, 1975, J BACTERIOL, V122, P1189, DOI 10.1128/JB.122.3.1189-1199.1975; ELLIOTT J, 1978, MOL GEN GENET, V161, P1, DOI 10.1007/BF00266608; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1987, J BIOL CHEM, V262, P5238; FERENCI T, 1971, FEBS LETT, V13, P12; GIBSON JL, 1991, J BIOL CHEM, V266, P14646; JONESMORTIMER MC, 1980, J GEN MICROBIOL, V117, P369; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; Kushner SR, 1978, GENET ENG N Y, P17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T, 1982, MOL CLONING LABORATO, P68; MAO QC, 1995, J BIOL CHEM, V270, P5258, DOI 10.1074/jbc.270.10.5258; MARTINVERSTRAETE I, 1990, J MOL BIOL, V214, P657, DOI 10.1016/0022-2836(90)90284-S; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MITCHELL C, 1992, MOL MICROBIOL, V6, P1345, DOI 10.1111/j.1365-2958.1992.tb00855.x; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NOBELMANN B, 1995, BBA-GENE STRUCT EXPR, V1262, P69, DOI 10.1016/0167-4781(95)00053-J; PERI KG, 1990, BIOCHEM CELL BIOL, V68, P123, DOI 10.1139/o90-017; POSTMA PW, 1993, MICROBIOL REV, V57, P534; ROSEMAN S, 1959, FED PROC, V18, P984; SAFFEN DW, 1987, J BIOL CHEM, V262, P16241; SAIER MH, 1992, J BACTERIOL, V174, P1433, DOI 10.1128/jb.174.5.1433-1438.1992; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SPRENGER GA, 1984, J BACTERIOL, V157, P39, DOI 10.1128/JB.157.1.39-45.1984; STOCK JB, 1982, J BIOL CHEM, V257, P4543; STOLZ B, 1993, J BIOL CHEM, V268, P27094; WAYGOOD EB, 1982, METHOD ENZYMOL, V90, P423; WEHMEIER UF, 1992, J BACTERIOL, V174, P7784, DOI 10.1128/JB.174.23.7784-7790.1992; WILLIAMS N, 1986, P NATL ACAD SCI USA, V83, P8934, DOI 10.1073/pnas.83.23.8934; WOHRL BM, 1990, MOL MICROBIOL, V45, P1557; YU C, 1991, J BIOL CHEM, V266, P24260; YU C, 1993, J BIOL CHEM, V268, P24276	39	32	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33468	33475		10.1074/jbc.271.52.33468	http://dx.doi.org/10.1074/jbc.271.52.33468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969210	hybrid			2022-12-25	WOS:A1996WA71300044
J	Lu, J; Kobayashi, R; Brill, SJ				Lu, J; Kobayashi, R; Brill, SJ			Characterization of a high mobility group 1/2 homolog in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP CHROMOSOMAL-PROTEINS; SINGLE-STRANDED-DNA; RNA POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; HMG-BOX; NUCLEAR-PROTEIN; BINDING MOTIF; CHROMATIN; GENE	A 35-kDa polypeptide belonging to the high mobility group family of proteins was purified from the yeast Saccharomyces cerevisiae on the basis of its association with a DNA helicase activity. Amino acid sequence alignment suggests that this protein, Hmo1p, is related to the HMG1/2 class of chromatin-associated proteins. Consistent with this prediction, the Hmo1 protein immunolocalizes to the nucleus, binds single stranded DNA, and unwinds DNA in the presence of eukaryotic DNA topoisomerase I. While the purified protein has no DNA helicase activity on its own, immunoprecipitation experiments confirm that Hmo1p associates with a 5' to 3' DNA helicase activity in nuclear extracts. The in vivo role of the protein was investigated by constructing an hmo1 deletion mutant. This strain has a severe growth defect, reduced plasmid stability, and chromatin that is hypersensitive to micrococcal nuclease digestion. Taken together, the data indicate that HMO1 is likely to be the homolog of HMG1/2 in higher cells and that it plays an important role in genome maintenance.	RUTGERS STATE UNIV, DEPT MOL BIOL & BIOCHEM, CTR ADV BIOTECHNOL & MED, PISCATAWAY, NJ 08855 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	Rutgers State University New Brunswick; Cold Spring Harbor Laboratory								BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BROSIUS J, 1992, METHOD ENZYMOL, V216, P469; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUSTIN M, 1979, CELL, V16, P181, DOI 10.1016/0092-8674(79)90199-5; CARON F, 1979, P NATL ACAD SCI USA, V76, P4265, DOI 10.1073/pnas.76.9.4265; CERTA U, 1984, NUCLEIC ACIDS RES, V12, P7975, DOI 10.1093/nar/12.21.7975; COSTIGAN C, 1994, MOL CELL BIOL, V14, P2391, DOI 10.1128/MCB.14.4.2391; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; FISHER RP, 1992, J BIOL CHEM, V267, P3358; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; ISACKSON PJ, 1979, J BIOL CHEM, V254, P5569; ISACKSON PJ, 1980, BIOCHEMISTRY-US, V19, P4466, DOI 10.1021/bi00560a013; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; JAVAHERIAN K, 1978, SCIENCE, V199, P1345, DOI 10.1126/science.628842; Johns E.W., 1982, HMG CHROMOSOMAL PROT, P1; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KOLODRUBETZ D, 1988, FEBS LETT, V238, P175, DOI 10.1016/0014-5793(88)80251-5; KOLODRUBETZ D, 1990, J BIOL CHEM, V265, P3234; KUEHL L, 1980, J BIOL CHEM, V255, P1090; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LOHR D, 1977, BIOCHEMISTRY-US, V16, P463, DOI 10.1021/bi00622a020; LOHR D, 1979, P NATL ACAD SCI USA, V76, P4285, DOI 10.1073/pnas.76.9.4285; NORRIS D, 1988, SCIENCE, V242, P759, DOI 10.1126/science.2847314; PETERS EH, 1979, J BIOL CHEM, V254, P3358; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Rose M. D., 1990, METHODS YEAST GENETI, P97; SEO YS, 1991, J BIOL CHEM, V266, P13161; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; SIKORSKI RS, 1989, GENETICS, V122, P19; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TREMETHICK DJ, 1986, J BIOL CHEM, V261, P6986; TREMETHICK DJ, 1988, NUCLEIC ACIDS RES, V16, P11107, DOI 10.1093/nar/16.23.11107; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VIDALI G, 1977, CELL, V12, P409, DOI 10.1016/0092-8674(77)90117-9; WEBER S, 1980, BIOCHEMISTRY-US, V19, P2236, DOI 10.1021/bi00551a037; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WOOD ER, 1987, J BIOL CHEM, V262, P15269	46	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33678	33685		10.1074/jbc.271.52.33678	http://dx.doi.org/10.1074/jbc.271.52.33678			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969238	hybrid			2022-12-25	WOS:A1996WA71300072
J	Mattagajasingh, SN; Misra, HP				Mattagajasingh, SN; Misra, HP			Mechanisms of the carcinogenic chromium(VI)-induced DNA-protein cross-linking and their characterization in cultured intact human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	10th International Conference on Methods in Protein Structure Analysis	SEP 08-13, 1994	SNOWBIRD, UT	Int Symp Immunobiol Protein & Peptides Inc			NUCLEAR MATRIX; MAMMALIAN-CELLS; HYDROGEN-PEROXIDE; CHROMIUM BINDING; TOPOISOMERASE-II; ACTIN ANTIBODIES; HELA-CELLS; REDUCTION; CHROMATE; GLUTATHIONE	DNA-protein complexes (DPCs) were induced in human leukemic T-lymphocyte MOLT4 cells by treatment with potassium chromate. DPCs were isolated by ultra centrifugal sedimentation in the presence of 2% SDS and 5 M urea. The complexes were analyzed by two-dimensional SDS-polyacrylamide gel electrophoresis. Three acidic proteins of 74, 44, and 42 kDa and a basic protein of 51 kDa were primarily complexed to DNA following 25 mu M chromate treatment. Higher concentrations of chromate cross-linked many other proteins to DNA. Amino acid sequencing and immunoblotting studies indicated that the acidic 44-kDa protein could be nuclear beta-actin, Lectin and aminoglycoside nucleotidyltransferase were also found to cross-link with DNA by chromate treatment. The composition and stability of the DPCs were studied using nucleases, proteinase K, and disruptive chemicals. Pretreatment. of cells with antioxidants inhibited the formation of DPCs, measured as K+-SDS precipitable DPCs, indicating the involvement of oxidative mechanisms. Because chromate causes certain nuclear proteins to form complexes with DNA and the complexes are resistant to treatments such as 2% SDS and 5 M urea, but disruptable under gel electrophoretic conditions, chromium could be used as a cross-linking agent for the identification of other proteins, such as transcription factors, that transiently interact with DNA.	VIRGINIA POLYTECH INST & STATE UNIV,VIRGINIA MARYLAND REG COLL VET MED,BLACKSBURG,VA 24061	Virginia Polytechnic Institute & State University								ARSLAN P, 1987, BIOCHIM BIOPHYS ACTA, V931, P10, DOI 10.1016/0167-4889(87)90044-9; BANJAR ZM, 1983, BIOCHEM BIOPH RES CO, V114, P767, DOI 10.1016/0006-291X(83)90847-1; BANJAR ZM, 1984, BIOCHEMISTRY-US, V23, P1921, DOI 10.1021/bi00304a005; BEDINGER P, CELL, V34, P115; BOUCK NP, 1989, CHEM RES TOXICOL, V2, P1, DOI 10.1021/tx00007a001; BOULIKAS T, 1986, BIOCHEM CELL BIOL, V64, P474, DOI 10.1139/o86-066; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS JA, 1988, CANCER RES, V48, P6484; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHIU SM, 1986, RADIAT RES, V107, P24, DOI 10.2307/3576847; COHEN M, 1990, BIOL EFFECTS HEAVY M, V2, P19; COHEN MD, 1992, MUTAT RES, V269, P141, DOI 10.1016/0027-5107(92)90169-3; CONNETT PH, 1983, STRUCT BOND, V54, P93; COSMA GN, 1988, MUTAT RES, V201, P161, DOI 10.1016/0027-5107(88)90122-4; De Flora S, 1989, LIFE CHEM REPORTS, V7, P169; EAGLY JM, 1984, EMBO J, V3, P2363; EARLEY JE, 1965, TRANSITION METAL CHE, V1, P33; FABIANEK J, 1968, CLIN CHEM, V14, P456; FORNACE AJ, 1981, CHEM-BIOL INTERACT, V36, P345, DOI 10.1016/0009-2797(81)90077-6; GABIUS HJ, 1986, LECTINS, V5, P237; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P977, DOI 10.1021/bi00456a020; GRUNICKE H, 1973, CANCER RES, V33, P1048; HAMILTON JW, 1989, MOL CARCINOGEN, V2, P274, DOI 10.1002/mc.2940020508; JENNETTE KW, 1981, ENV HLTH PERSPECT, V40, P223; JONES P, 1991, ARCH BIOCHEM BIOPHYS, V286, P652, DOI 10.1016/0003-9861(91)90095-Z; KAUFMANN SH, 1981, EXP CELL RES, V132, P105, DOI 10.1016/0014-4827(81)90088-4; KAWANISHI S, 1986, J BIOL CHEM, V261, P5952; KOLBBACHOFEN V, 1986, LECTINS BIOL BIOCH C, P197; KORTENKAMP A, 1989, MUTAT RES, V216, P19, DOI 10.1016/0165-1161(89)90019-8; KORTENKAMP A, 1991, CARCINOGENESIS, V12, P1143, DOI 10.1093/carcin/12.6.1143; KOSTER A, 1985, TOXICOL ENVIRON CHEM, V10, P307, DOI 10.1080/02772248509360968; KUYKENDALL JR, 1993, TOXICOL APPL PHARM, V123, P283, DOI 10.1006/taap.1993.1247; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESKO SA, 1982, BIOCHEMISTRY-US, V21, P5010, DOI 10.1021/bi00263a026; Lis H., 1986, LECTINS PROPERTIES F, P293; Lis H, 1986, LECTINS PROPERTIES F, P265; LIU LF, 1983, J BIOL CHEM, V258, P5365; Maniatis T., 1982, MOL CLONING; MARGOLIS SA, 1988, BIOCHEMISTRY-US, V27, P6353, DOI 10.1021/bi00417a024; MATTAGAJASINGH SN, 1995, MOL CELL BIOCHEM, V142, P61, DOI 10.1007/BF00928914; Mattagajasingh SN, 1997, TOX SUBST MECH, V16, P63, DOI 10.1080/107691897229801; Mattagajasingh SN, 1995, METHODS IN PROTEIN STRUCTURE ANALYSIS, P295; MATTAGAJASINGH SN, 1994, J PROTEIN CHEM, V13, P449; MATTAGAJASINGH SN, 1993, FASEB J, V7, P469; Miller C A 3rd, 1989, Mol Toxicol, V2, P11; MILLER CA, 1988, MOL CARCINOGEN, V1, P125; MILLER CA, 1991, CARCINOGENESIS, V12, P269, DOI 10.1093/carcin/12.2.269; Nieboer E., 1988, CHROMIUM NATURAL HUM, V20, P21; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OLEINICK N L, 1987, British Journal of Cancer, V55, P135; ONO H, 1981, J TOXICOL ENV HEALTH, V8, P947, DOI 10.1080/15287398109530129; PATIERNO SR, 1985, CHEM-BIOL INTERACT, V55, P75, DOI 10.1016/S0009-2797(85)80121-6; PETERS KE, 1982, EUR J BIOCHEM, V129, P221, DOI 10.1111/j.1432-1033.1982.tb07043.x; RUNGGER D, 1979, NATURE, V282, P320, DOI 10.1038/282320a0; SAMMONS DW, 1981, ELECTROPHORESIS, V2, P135, DOI 10.1002/elps.1150020303; SCHEER U, 1984, CELL, V39, P111, DOI 10.1016/0092-8674(84)90196-X; SHI XL, 1989, BIOCHEM BIOPH RES CO, V163, P627, DOI 10.1016/0006-291X(89)92183-9; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V277, P342, DOI 10.1016/0003-9861(90)90589-Q; SHI XL, 1990, ARCH BIOCHEM BIOPHYS, V281, P90, DOI 10.1016/0003-9861(90)90417-W; STANDEVEN AM, 1991, CHEM RES TOXICOL, V4, P616, DOI 10.1021/tx00024a003; STEIN GS, 1979, CHROMOSOMAL PROTEINS; SUGDEN KD, 1992, BIOCHEMISTRY-US, V31, P11626, DOI 10.1021/bi00161a049; SUGIYAMA M, 1986, MOL PHARMACOL, V29, P606; SUGIYAMA M, 1992, PHOTOCHEM PHOTOBIOL, V56, P31, DOI 10.1111/j.1751-1097.1992.tb09598.x; TRASK DK, 1984, EMBO J, V3, P671, DOI 10.1002/j.1460-2075.1984.tb01865.x; TSAPAKOS MJ, 1983, CHEM-BIOL INTERACT, V46, P265, DOI 10.1016/0009-2797(83)90034-0; WEDRYCHOWSKI A, 1986, J BIOL CHEM, V261, P3370; WEDRYCHOWSKI A, 1985, J BIOL CHEM, V260, P7150; ZHITKOVICH A, 1992, CARCINOGENESIS, V13, P1485, DOI 10.1093/carcin/13.8.1485	69	37	41	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33550	33560		10.1074/jbc.271.52.33550	http://dx.doi.org/10.1074/jbc.271.52.33550			11	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969221	hybrid			2022-12-25	WOS:A1996WA71300055
J	Haddad, EB; Rousell, J; Lindsay, MA; Barnes, PJ				Haddad, EB; Rousell, J; Lindsay, MA; Barnes, PJ			Synergy between tumor necrosis factor alpha and interleukin 1 beta in inducing transcriptional down-regulation of muscarinic M(2) receptor gene expression - Involvement of protein kinase A and ceramide pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; MESSENGER-RNA; HUMAN FIBROBLASTS; CELL-LINE; TNF-ALPHA; ACTIVATION; CYTOKINES; BETA; MEDIATORS; IL-1	Stimulation of HEL 299 cells with tumor necrosis factor alpha (TNF-alpha) or interleukin 1 beta (IL-1 beta) had no effect on M(2) muscarinic receptor expression, However, the combination of Obese two cytokines markedly down-regulated muscarinic M(2) receptor protein and mRNA expression and uncoupled M(2) receptors from adenylyl cyclase, There was no effect of TNF-alpha and IL-1 beta on the m2 muscarinic receptor mRNA stability, and nuclear run on assays showed reduced m2 receptor gene transcription, Sequential cytokine addition suggests that the synergy involves postreceptor events, Although the cAMP-dependent protein kinase inhibitor H8 provided a significant protection against receptor down-regulation, the protein kinase C inhibitor GF109203X had no effect. The ceramide analog C-2-ceramide (N-acetylsphingosine) was without effect on m2 receptor expression, However, a strong synergistic effect was demonstrated when cells were treated with the combination of C-2-ceramide and TNF-alpha or IL-1 beta. TNF-alpha and/or IL-1 beta combination also activated the 46- and 55-kDa c-Jun NH2-terminal protein kinases and to a lesser extent p42 and p44 mitogen-activated protein kinase isoforms, Cycloheximide abolished the TNF-alpha and IL-1 beta effect, suggesting that de novo protein synthesis is required for receptor down-regulation, These results suggest that the TNF-alpha and IL-1 beta synergize to induce transcriptional down regulation of the M(2) muscarinic receptor, which seems to be mediated through activation of both ceramide and cAMP-dependent protein kinase pathways, Furthermore, these results suggest that M(2) receptor expression is under the control of a cytokine network.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,NATL HEART & LUNG INST,DEPT THORAC MED,LONDON SW3 6LY,ENGLAND	Imperial College London				Barnes, Peter/0000-0002-5122-4018; Lindsay, Mark/0000-0003-4807-5506				AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BARKER JNWN, 1990, J CLIN INVEST, V85, P605, DOI 10.1172/JCI114481; BARNES PJ, 1994, AM J RESP CRIT CARE, V150, pS42, DOI 10.1164/ajrccm/150.5_Pt_2.S42; BARNES PJ, 1993, LIFE SCI, V52, P521, DOI 10.1016/0024-3205(93)90310-Y; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BIRD TA, 1991, J BIOL CHEM, V266, P22661; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEDID M, 1989, J IMMUNOL, V142, P4301; CORONEOSE, 1996, BIOCHEM J, V316, P13; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153; ELIAS JA, 1990, J IMMUNOL, V145, P161; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRYER AD, 1993, LIFE SCI, V52, P529, DOI 10.1016/0024-3205(93)90311-P; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GUY GR, 1991, J BIOL CHEM, V266, P14343; Haddad EB, 1996, MOL PHARMACOL, V49, P781; HADDAD EB, 1995, BRIT J PHARMACOL, V116, P2027, DOI 10.1111/j.1476-5381.1995.tb16407.x; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HORIKOSHI T, 1995, FEBS LETT, V363, P141, DOI 10.1016/0014-5793(95)00299-O; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Koto H, 1996, J CLIN INVEST, V98, P1780, DOI 10.1172/JCI118977; KWON OJ, 1994, IMMUNOLOGY, V81, P389; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAULEDERKIND SJF, 1995, J EXP MED, V182, P599, DOI 10.1084/jem.182.2.599; MARTIN M, 1988, TRENDS PHARMACOL SCI, V9, P171, DOI 10.1016/0165-6147(88)90033-8; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461, DOI 10.1152/jappl.1989.67.6.2461; MIZEL SB, 1989, FASEB J, V3, P2379, DOI 10.1096/fasebj.3.12.2676681; NOGAMI M, 1994, AM J PHYSIOL, V266, pL187, DOI 10.1152/ajplung.1994.266.2.L187; OHMORI Y, 1995, J IMMUNOL, V154, P5235; PATEL HJ, 1995, AM J RESP CRIT CARE, V152, P872, DOI 10.1164/ajrccm.152.3.7663798; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; ROUSELL J, 1995, J BIOL CHEM, V270, P7213, DOI 10.1074/jbc.270.13.7213; Rousell J, 1996, MOL PHARMACOL, V49, P629; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P6802; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TSUJIMOTO M, 1986, J IMMUNOL, V136, P2441; VILCEK J, 1991, J BIOL CHEM, V266, P7313; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	49	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32586	32592		10.1074/jbc.271.51.32586	http://dx.doi.org/10.1074/jbc.271.51.32586			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955085	hybrid			2022-12-25	WOS:A1996VZ37300020
J	Mackenzie, B; Loo, DDF; PanayotovaHeiermann, M; Wright, EM				Mackenzie, B; Loo, DDF; PanayotovaHeiermann, M; Wright, EM			Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; ELECTROGENIC PROPERTIES; VOLTAGE-CLAMP; TRANSPORT; HETEROGENEITY; KINETICS; CELLS	The Na+-dependent, low affinity glucose transporter SGLT2 cloned from pig kidney is 76% identical (at the amino acid level) to its high affinity homologue SGLT1. Using two-microelectrode voltage clamp, we have characterized the presteady-state and steady-state kinetics of SGLT2 expressed in Xenopus oocytes. The kinetic properties of the steady-state sugar evoked currents as a function of external Na+ and alpha-methyl-D-glucopyranoside (alpha MG) concentrations were consistent with an ordered, simultaneous transport model in which Na+ binds first. Na+ binding was voltage-dependent and saturated with hyperpolarizing voltages. Phlorizin was a potent inhibitor of the sugar-evoked currents (K-i(Pz) approximate to 10 mu M) and blocked an inward Na+ current in the absence of sugar. SGLT2 exhibited Na+-dependent presteady-state currents with time constants 3-7 ms. Charge movements were described by Boltzmann relations with apparent valence approximate to 1 and maximal charge transfer approximate to 11 nC, and were reduced by the addition of sugar or phlorizin. The differences between SGLT1 and SGLT2 were that (i) the apparent affinity constant (K-0.5) for alpha MG (approximate to 3 mM) was an order of magnitude higher for SGLT2; (ii) SGLT2 excluded galactose, suggesting discrete sugar binding; (iii) K-0.5 for Na+ was lower in SGLT2; and (iv) the Hill coefficient for Nat was 1 for SGLT2 but 2 for SGLT1. Simulations of the six-state kinetic model previously proposed for SGLT1 indicated that many of the kinetic properties observed in SGLT2 are expected by simply reducing the Na+/glucose coupling from 2 to 1.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Mackenzie, Bryan/0000-0002-9661-8838	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19567] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRNIR B, 1991, PFLUG ARCH EUR J PHY, V418, P79, DOI 10.1007/BF00370455; BROWN GC, 1995, BIOPHYS CHEM, V54, P181, DOI 10.1016/0301-4622(94)00132-4; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KONG CT, 1993, J BIOL CHEM, V268, P1509; LAUGER P, 1986, J MEMBRANE BIOL, V91, P275, DOI 10.1007/BF01868820; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; Mackenzie B, 1996, J BIOL CHEM, V271, P5430, DOI 10.1074/jbc.271.10.5430; OHTA T, 1990, MOL CELL BIOL, V10, P6491, DOI 10.1128/MCB.10.12.6491; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PANAYOTOVAHEIERMANN M, 1995, J BIOL CHEM, V270, P27099, DOI 10.1074/jbc.270.45.27099; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; TURNER RJ, 1982, J MEMBRANE BIOL, V70, P37, DOI 10.1007/BF01871587; TURNER RJ, 1982, AM J PHYSIOL, V242, pF406, DOI 10.1152/ajprenal.1982.242.4.F406; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	20	110	125	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32678	32683		10.1074/jbc.271.51.32678	http://dx.doi.org/10.1074/jbc.271.51.32678			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955098	hybrid			2022-12-25	WOS:A1996VZ37300033
J	Moreau, S; Davies, MJ; Mathieu, C; Herouart, D; Puppo, A				Moreau, S; Davies, MJ; Mathieu, C; Herouart, D; Puppo, A			Leghemoglobin-derived radicals - Evidence for multiple protein-derived radicals and the initiation of peribacteroid membrane damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; FRENCH-BEAN NODULES; HYDROGEN-PEROXIDE; ROOT-NODULES; SPIN; IDENTIFICATION; HYDROPEROXIDES; SENESCENCE; OXIDATION; TYR-103	Reaction of H2O2 with ferric leghemoglobin (metLb, the monomeric, oxygen-carrying, heme protein from root nodules of nitrogen-fixing plants) has been previously shown to generate an iron(IV) oxo (ferryl) species and at least one protein radical, The latter has been suggested to be a tyrosine-derived phenoxyl radical present at Tyr-133 in the soybean protein and Tyr-138 in the lupin protein. To obtain further information on these protein radicals and their potential interaction with the physiologically important peribacteroid membrane (which surrounds the microsymbiont in vivo), EPR spin trapping studies have been carried out with soybean metLb. Evidence has been obtained for at least two additional protein derived radicals in addition to the phenoxyl radical; these radicals are transient and reactive in nature, These species are carbon-centered, and at least one is a tertiary species ((.)CR(1)R(2)R(3)); these radicals may be side chain- or alpha-carbon-derived, their exact sites have not been determined, Some of these radicals are on the protein surface and may be key intermediates in the formation of protein dimers. These radicals have been shown to be capable of reacting with peribacteroid membrane fractions, with the consequent generation of lipid-derived radicals. The formation of such radicals may result in the depletion of membrane antioxidants and the initiation of lipid peroxidation, This transfer of damage from the heme center via the protein surface to neighboring membranes may be of considerable biological significance; the destruction of this membrane is one of the earliest observable events in root nodule senescence and is associated with the loss of nitrogen-fixing activity.	UNIV NICE,CNRS,URA 1114,LAB BIOL VEGETALE & MICROBIOL,F-06108 NICE 2,FRANCE; UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of York - UK			Davies, Michael/GWV-2527-2022; Davies, Michael J/H-4939-2011; mathieu, chantal/ABD-5505-2021; Davies, Michael/AGX-9184-2022	Davies, Michael J/0000-0002-5196-6919; mathieu, chantal/0000-0002-4055-5233; Davies, Michael/0000-0002-5196-6919; Norman, Christel/0000-0002-9305-9292				ARUTYUNYAN EG, 1980, SOV PHYS-CRYSTALLOGR, V25, P43; Bergersen F. J., 1980, Nitrogen fixation. Proceedings of the Phytochemical Society of Europe Symposium, Sussex, September, 1979 [Stewart, W. D. P., Gallon, J. R. (Editors)]., P139; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; DALTON DA, 1986, P NATL ACAD SCI USA, V83, P3811, DOI 10.1073/pnas.83.11.3811; Davies Michael J., 1993, Biochemical Society Transactions, V21, p87S; DAVIES MJ, 1991, FREE RADICAL RES COM, V15, P111, DOI 10.3109/10715769109049131; DAVIES MJ, 1992, BIOCHEM J, V281, P197, DOI 10.1042/bj2810197; DAVIES MJ, 1993, BIOCHIM BIOPHYS ACTA, V1202, P182, DOI 10.1016/0167-4838(93)90003-A; DAVIES MJ, 1993, RES CHEM INTERMEDIAT, V19, P669, DOI 10.1163/156856793X00307; DOMIGAN NM, 1988, ARCH BIOCHEM BIOPHYS, V264, P564, DOI 10.1016/0003-9861(88)90322-0; GREENLEY TL, 1992, BIOCHIM BIOPHYS ACTA, V1116, P192, DOI 10.1016/0304-4165(92)90116-C; HERRADA G, 1989, J GEN MICROBIOL, V135, P3165; HERRADA G, 1993, FEBS LETT, V326, P33, DOI 10.1016/0014-5793(93)81755-O; HOGG N, 1994, ARCH BIOCHEM BIOPHYS, V314, P39, DOI 10.1006/abbi.1994.1409; JOB D, 1980, EUR J BIOCHEM, V107, P491; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; KELMAN DJ, 1992, FREE RADICAL RES COM, V16, P27, DOI 10.3109/10715769209049156; MASON RP, 1980, J BIOL CHEM, V255, P5019; MOREAU S, 1995, BBA-PROTEIN STRUCT M, V1251, P17, DOI 10.1016/0167-4838(95)00087-B; PAGANGA G, 1992, FEBS LETT, V303, P154, DOI 10.1016/0014-5793(92)80508-E; PLADYS D, 1988, PLANT SCI, V56, P99, DOI 10.1016/0168-9452(88)90021-0; PUPPO A, 1987, ELECTROPHORESIS, V8, P212, DOI 10.1002/elps.1150080408; PUPPO A, 1991, PLANT PHYSIOL, V96, P826, DOI 10.1104/pp.96.3.826; PUPPO A, 1988, PLANTA, V173, P405, DOI 10.1007/BF00401028; PUPPO A, 1981, PLANT SCI LETT, V22, P353, DOI 10.1016/0304-4211(81)90081-X; RAO SI, 1993, J BIOL CHEM, V268, P803; SULLIVAN AB, 1966, J ORG CHEM, V31, P2811, DOI 10.1021/jo01347a018; TEW D, 1988, J BIOL CHEM, V263, P17880; VUKPAVLOVIC S, 1976, INT J PEPT PROT RES, V8, P427; WILKS A, 1992, J BIOL CHEM, V267, P8827	30	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32557	32562		10.1074/jbc.271.51.32557	http://dx.doi.org/10.1074/jbc.271.51.32557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955081	hybrid			2022-12-25	WOS:A1996VZ37300016
J	Wei, X; Peterson, DL				Wei, X; Peterson, DL			Expression, purification, and characterization of an active RNase H domain of the hepatitis B viral polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; MUTATIONAL ANALYSIS; DNA-SYNTHESIS; SEQUENCE; PROTEINS; GENOME	The replication of the hepatitis B viral DNA genome proceeds through a pregenomic RNA intermediate, This pregenomic RNA subsequently serves as the template for the formation of the viral DNA by the reverse transcriptase activity of the viral P gene product. The P gene product is believed to be a multifunctional enzyme with DNA-dependent DNA polymerase, RNA-dependent DNA polymerase, and RNase H activities. Detailed biochemical studies of this protein have not been performed because of the inability to obtain sufficient amounts of the enzyme from the virus and by the inability to produce the enzyme in heterologous expression systems. The RNase H activity is essential for viral replication and is believed to be responsible for the degradation of the RNA pregenomic intermediate as well as for generating the short RNA primer that is required for DNA second strand synthesis. We have assembled an expression vector which directs the synthesis of a protein that corresponds to the putative RNase H domain of the P gene product and having a carboxyl-terminal polyhistidine tag to facilitate purification, The protein has been expressed in Escherichia coli and purified to yield 1-2 mg of protein/liter of culture. This protein has RNase H activity as defined by its ability to degrade the RNA component of RNA-DNA hybrids but not the DNA component. The RNase H has a basic optimum pH, is active only in the presence of reducing agents, and is dependent on the presence of divalent cations, with magnesium being preferred over manganese.	VIRGINIA COMMONWEALTH UNIV,DEPT BIOCHEM & MOL BIOPHYS,RICHMOND,VA 23298	Virginia Commonwealth University								BEUGASSAT A, 1987, J BACTERIOL, V169, P751; BLAIN SW, 1995, J VIROL, V69, P4440, DOI 10.1128/JVI.69.7.4440-4452.1995; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CROUCH RJ, 1982, NUCLEASES, P221; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; KHUDYAKOV YE, 1988, FEBS LETT, V243, P115; LIEN JM, 1986, J VIROL, V57, P229, DOI 10.1128/JVI.57.1.229-236.1986; NAKAMURA H, 1991, NUCLEIC ACIDS RES, V19, P1817, DOI 10.1093/nar/19.8.1817; OBERHAUS SM, 1995, J VIROL, V69, P5697, DOI 10.1128/JVI.69.9.5697-5704.1995; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; ROBINSON WS, 1982, VIRAL HEPATITIS, P57; STARNES MC, 1989, J BIOL CHEM, V264, P7073; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SZMUNESS W, 1981, HEPATOLOGY, V1, P377, DOI 10.1002/hep.1840010502; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; TOH H, 1983, NATURE, V305, P827, DOI 10.1038/305827a0; WAINHOBSON S, 1984, ADV HEPATITIS RES, P49; WINTERSBERGER U, 1990, PHARMACOL THERAPEUT, V48, P259, DOI 10.1016/0163-7258(90)90083-E	22	18	19	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32617	32622		10.1074/jbc.271.51.32617	http://dx.doi.org/10.1074/jbc.271.51.32617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955090	hybrid			2022-12-25	WOS:A1996VZ37300025
J	Chen, S; Knox, R; Wu, K; Deng, PSK; Zhou, DJ; Bianchet, MA; Amzel, LM				Chen, S; Knox, R; Wu, K; Deng, PSK; Zhou, DJ; Bianchet, MA; Amzel, LM			Molecular basis of the catalytic differences among DT-diaphorase of human, rat, and mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD(P)H-QUINONE ACCEPTOR OXIDOREDUCTASE; COLON-CARCINOMA CELLS; INDUCED DNA DAMAGE; MITOMYCIN-C; ESCHERICHIA-COLI; SENSITIVITY; METABOLISM; MECHANISM; NAD(P)H; CYTOTOXICITY	DT-diaphorase (EC 1.6.99.2), also referred to as NAD(P)H:(quinone-acceptor) oxidoreductase, is involved in the reductive activation process of several cytotoxic antitumor quinones and nitrobenzenes. It has been observed in our and other laboratories that the rat enzyme is significantly more effective in activating these drugs than the human and mouse enzymes. These results indicate that the available cytotoxic drugs are better substrates for the rat enzyme and are not the most ideal prodrugs for activation by DT-diaphorase in human tumors. In this study, using site-directed mutagenesis to replace residues in the rat enzyme with the human sequences and residues in the human enzyme with the rat sequences, we have found that residue 104 (Tyr in the rat enzyme and Gln in the human and mouse enzymes) is an important residue responsible for the catalytic differences between the rat and the human (and mouse) enzymes. With an exchange of a single amino acid, the rat mutant Y104Q behaved like the wildtype human enzyme, and the human mutant Q104Y behaved like the wild-type rat enzyme in their ability to reductively activate the cytotoxic drug CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). The study also confirms the conclusion of the x-ray structural analysis of rat enzyme that residue 130 (Thr in the rat enzyme and Ala in the human and mouse enzymes) is positioned near the binding region of the nicotinamide portion of NAD(P)H. This structural information is very important for designing suitable drugs and approaches for human cancer chemotherapy mediated by DT diaphorase.	INST CANC RES, CRC, CTR CANC THERAPEUT, SUTTON SM2 5NG, SURREY, ENGLAND; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOPHYS & BIOPHYS CHEM, BALTIMORE, MD 21205 USA	University of London; Institute of Cancer Research - UK; Johns Hopkins University	Chen, S (corresponding author), CITY HOPE NATL MED CTR, BECKMAN RES INST, DIV IMMUNOL, 1450 E DUARTE RD, DUARTE, CA 91010 USA.		Bianchet, Mario a/K-2131-2015	Bianchet, Mario a/0000-0001-9032-7549; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM45540] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEALL HD, 1994, CANCER RES, V54, P3196; BOLAND MP, 1991, BIOCHEM PHARMACOL, V41, P867, DOI 10.1016/0006-2952(91)90190-G; CHEN HH, 1992, BIOCHEM J, V284, P855, DOI 10.1042/bj2840855; CHEN S, 1994, PROTEIN SCI, V3, P51; CHEN S, 1993, ARCH BIOCHEM BIOPHYS, V302, P72, DOI 10.1006/abbi.1993.1182; CHEN S, 1995, MOL PHARMACOL, V47, P934; CHEN SU, 1994, PROTEIN SCI, V3, P1296, DOI 10.1002/pro.5560030816; IYANAGI T, 1987, CHEM SCRIPTA, V27A, P31; IYANAGI T, 1970, BIOCHIM BIOPHYS ACTA, V216, P282, DOI 10.1016/0005-2728(70)90220-3; KASAHARA K, 1994, INT J CANCER, V59, P204, DOI 10.1002/ijc.2910590211; KUEHL BL, 1995, BRIT J CANCER, V72, P555, DOI 10.1038/bjc.1995.373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; LIN AJ, 1972, J MED CHEM, V15, P1247, DOI 10.1021/jm00282a011; LIU XF, 1990, MOL PHARMACOL, V37, P911; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; SIEGEL D, 1990, CANCER RES, V50, P7483; SIEGEL D, 1990, CANCER RES, V50, P7293; SINGH SV, 1995, CANCER LETT, V95, P49, DOI 10.1016/0304-3835(95)03864-S; WALTON MI, 1991, CANCER COMMUN, V3, P199, DOI 10.3727/095535491820873164; XU BH, 1994, BRIT J CANCER, V69, P242, DOI 10.1038/bjc.1994.46	21	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1437	1439		10.1074/jbc.272.3.1437	http://dx.doi.org/10.1074/jbc.272.3.1437			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999809	hybrid			2022-12-25	WOS:A1997WD05800007
J	Booth, BL; Pugh, BF				Booth, BL; Pugh, BF			Identification and characterization of a nuclease specific for the 3' end of the U6 small nuclear RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III TRANSCRIPTION; POL-III; SJOGRENS SYNDROME; BINDING PROTEIN; RIBOSOMAL-RNA; GENES; ANTIBODIES; INVITRO; EXTRACT	The U6 small nuclear RNA is post-transcriptionally processed by the addition and removal of nontemplate uridylates (Us) at its 3' end prior to incorporation into the U4 . U6 small nuclear ribonucleoprotein complex. An enzyme responsible for removing Us from the U6 3' end has not been previously identified. Here we biochemically isolate and characterize an exonuclease activity from HeLa cells that removes template and nontemplate 3'-nucleotides specifically from U6 RNA. We also report the isolation of an inhibitor of this U6 nuclease. U6 nuclease rapidly removes the four terminal 3' Us found in the human U6 coding sequence in a magnesium-dependent manner. Mutagenesis studies on the U6 RNA define regions essential for processing. U6 nuclease recognizes specific sequences on both strands near the base of the major intramolecular stem loop of the U6 RNA. The preprocessed 3' Us form part of the base of the stem loop, but neither specific sequences nor secondary structure at the four terminal nucleotides are required to achieve processing.	PENN STATE UNIV,CTR GENE REGULAT,DEPT BIOCHEM & MOL BIOL,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NIGMS NIH HHS [GM47855] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIZUKI M, 1977, J CLIN INVEST, V59, P264, DOI 10.1172/JCI108637; ALSPAUGH MA, 1975, J CLIN INVEST, V55, P1067, DOI 10.1172/JCI108007; BERNUES J, 1993, EMBO J, V12, P3573, DOI 10.1002/j.1460-2075.1993.tb06031.x; BINDEREIF A, 1990, EMBO J, V9, P251, DOI 10.1002/j.1460-2075.1990.tb08102.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EPSTEIN P, 1980, J BIOL CHEM, V255, P8901; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GOTTLIEB EL, 1989, EMBO J, V8, P841, DOI 10.1002/j.1460-2075.1989.tb03445.x; HENDRICK JP, 1981, MOL CELL BIOL, V1, P1135; HIRAI H, 1988, J BIOCHEM-TOKYO, V104, P991, DOI 10.1093/oxfordjournals.jbchem.a122597; JACKSON AJ, 1995, MOL CELL BIOL, V15, P94, DOI 10.1128/MCB.15.1.94; JAGADEESWARAN P, 1981, CELL, V26, P141, DOI 10.1016/0092-8674(81)90296-8; LEE DI, 1989, J BIOCHEM-TOKYO, V105, P526, DOI 10.1093/oxfordjournals.jbchem.a122700; LUND E, 1992, SCIENCE, V255, P327, DOI 10.1126/science.1549778; MARAIA RJ, 1992, MOL CELL BIOL, V12, P1500, DOI 10.1128/MCB.12.4.1500; MARAIA RJ, 1994, MOL CELL BIOL, V14, P2147, DOI 10.1128/MCB.14.3.2147; Pugh B F, 1995, Methods Mol Biol, V37, P349; REDDY R, 1987, J BIOL CHEM, V262, P75; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TERNS MP, 1992, MOL CELL BIOL, V12, P3032, DOI 10.1128/MCB.12.7.3032; VANARSDELL SW, 1981, CELL, V26, P11, DOI 10.1016/0092-8674(81)90028-3; WALDSCHMIDT R, 1991, EMBO J, V10, P2595, DOI 10.1002/j.1460-2075.1991.tb07801.x; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WILLIS IM, 1993, EUR J BIOCHEM, V212, P1, DOI 10.1111/j.1432-1033.1993.tb17626.x	26	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					984	991		10.1074/jbc.272.2.984	http://dx.doi.org/10.1074/jbc.272.2.984			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995392	hybrid			2022-12-25	WOS:A1997WC04800043
J	Brumell, JH; Chan, CK; Butler, J; Borregaard, N; Siminovitch, KA; Grinstein, S; Downey, GP				Brumell, JH; Chan, CK; Butler, J; Borregaard, N; Siminovitch, KA; Grinstein, S; Downey, GP			Regulation of Src homology 2-containing tyrosine phosphatase 1 during activation of human neutrophils - Role of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL PHOSPHATASE; ELECTROPERMEABILIZED HUMAN-NEUTROPHILS; MOTH-EATEN MICE; PHOSPHOTYROSINE PHOSPHATASE; PLASMA-MEMBRANE; SH2 DOMAIN; CATALYTIC ACTIVITY; LEUKEMIA-CELLS; PHOSPHORYLATION; RECEPTOR	The tyrosine phosphorylation of several proteins induced in neutrophils by soluble and particulate stimuli is thought to be crucial for initiating antimicrobial responses. Although activation of tyrosine kinases is thought to mediate this event, the role of tyrosine phosphatases in the initiation and modulation of neutrophil responses remains largely undefined. We investigated the role of Src homology 2-containing tyrosine phosphatase 1 (SHP-1; also known as protein tyrosine phosphatase 1C (PTP1C), hematopoetic cell phosphatase, PTP-N6, and SHPTP-1), a phosphatase expressed primarily in hemopoietic cells, in the activation of human neutrophils. SHP-1 mRNA and protein were detected in these cells, and the enzyme was found to be predominantly localized to the cytosol in unstimulated cells. Following stimulation with neutrophil agonists such as phorbol ester, chemotactic peptide, or opsonized zymosan, a fraction of the phosphatase redistributed to the cytoskeleton. Agonist treatment also induced significant decreases (30-60%) in SHP-1 activity, which correlated temporally with increases in the cellular phosphotyrosine content, Phosphorylation of SHP-1 on serine residues was associated with the inhibition of its enzymatic activity, suggesting a causal relationship. Accordingly, both the agonist-evoked phosphorylation of SHP-1 and the inhibition of its catalytic activity were blocked by treatment with bisindolylmaleimide I, a potent and specific inhibitor of protein kinase C (PKC) activity. Immunoprecipitated SHP-1 was found to be phosphorylated efficiently by purified PKC in vitro. Such phosphorylation also caused a decrease in the phosphatase activity of SHP-1. Together, these data suggest that inhibition of SHP-1 by PKC-mediated serine phosphorylation plays a role in facilitating the accumulation of tyrosine phosphorylated proteins following neutrophil stimulation. These findings provide a new link between the PKC and tyrosine phosphorylation branches of the signaling cascade that triggers antimicrobial responses in human neutrophils.	UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON M5S 1A8,CANADA; HOSP SICK CHILDREN,RES INST,DIV CELL BIOL,TORONTO,ON M5G 1X8,CANADA; RIGSHOSP,GRANULOCYTE RES LAB,DEPT HAEMATOL L,DK-2100 COPENHAGEN,DENMARK; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; TORONTO GEN HOSP,DIV RESP,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Rigshospitalet; University of Copenhagen; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital			Siminovitch, Katherine/K-1475-2013	Downey, Gregory P/0000-0003-3253-5862				ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ASAHI M, 1993, J BIOL CHEM, V268, P23334; BERKOW RL, 1990, BLOOD, V75, P2445; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BERTON G, 1994, J CELL BIOL, V126, P1111, DOI 10.1083/jcb.126.4.1111; BIGNON JS, 1994, CLIN IMMUNOL IMMUNOP, V73, P168, DOI 10.1006/clin.1994.1185; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P318; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRUMELL JH, 1994, AM J PHYSIOL-CELL PH, V267, pC1574, DOI 10.1152/ajpcell.1994.267.6.C1574; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; CUI Y, 1994, J IMMUNOL, V152, P5420; Edwards S.L., 1994, BIOCH PHYSL NEUTROPH; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FISHER EH, 1991, SCIENCE, V253, P401; GAUDRY M, 1992, J LEUKOCYTE BIOL, V51, P103, DOI 10.1002/jlb.51.2.103; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; GRINSTEIN S, 1994, J BIOL CHEM, V269, P19313; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; KANSHA M, 1993, BIOCHIM BIOPHYS ACTA, V1179, P189, DOI 10.1016/0167-4889(93)90140-K; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOBAYASHI K, 1995, J BIOCHEM, V117, P1156, DOI 10.1093/oxfordjournals.jbchem.a124838; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; KRAFT AS, 1987, BLOOD, V70, P356; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LLOYDS D, 1994, BIOCHEM PHARMACOL, V48, P15, DOI 10.1016/0006-2952(94)90218-6; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MCGREGOR PE, 1994, BIOCHEM BIOPH RES CO, V198, P359, DOI 10.1006/bbrc.1994.1050; MEI L, 1994, J BIOL CHEM, V269, P12254; MITSUYAMA T, 1993, FEBS LETT, V322, P280, DOI 10.1016/0014-5793(93)81586-O; MOHN H, 1995, BIOCHEM J, V309, P657; OKAMURA M, 1995, CURR OPIN IMMUNOL, V7, P312; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; PULIDO R, 1989, FEBS LETT, V249, P337, DOI 10.1016/0014-5793(89)80654-4; PULIDO R, 1992, CLIN EXP IMMUNOL, V87, P329; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TRACHMAN JD, 1995, CR ACAD SCI III-VIE, V318, P367; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; UCHIDA T, 1993, J BIOL CHEM, V268, P11845; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; YETTER A, 1995, J BIOL CHEM, V270, P18179, DOI 10.1074/jbc.270.31.18179; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007; ZOR U, 1993, BIOCHEM J, V295, P879, DOI 10.1042/bj2950879	65	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					875	882		10.1074/jbc.272.2.875	http://dx.doi.org/10.1074/jbc.272.2.875			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995376	hybrid			2022-12-25	WOS:A1997WC04800027
J	Hsu, YM; Lucci, J; Su, LH; Ehrenfels, B; Garber, E; Thomas, D				Hsu, YM; Lucci, J; Su, LH; Ehrenfels, B; Garber, E; Thomas, D			Heteromultimeric complexes of CD40 ligand are present on the cell surface of human T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; HYPER-IGM SYNDROME; LINKED IMMUNOGLOBULIN DEFICIENCY; DEPENDENT HELPER FUNCTION; SOLUBLE FORM; DEFECTIVE EXPRESSION; ELEVATED IGM; B-CELLS; TNF; ACTIVATION	CD40 ligand (CD40L), a 33-kDa type II membrane glycoprotein expressed primarily on activated CD4(+) T lymphocytes, is responsible for the helper function of T cells on resting B cells in a non-antigen dependent, non-major histocompatability complex-restricted fashion, Interaction of CD40L with its receptor CD40 induces proliferation of and isotype switching in B lymphocytes. Recently we solved the x-ray structure of recombinant soluble CD40L and showed that, similar to other members of the tumor necrosis factor family, CD40L indeed exists as a trimer. We now report that, under normal physiological conditions, CD40L molecules exist as heteromultimeric complexes. These CD40L complexes, made of the full length and smaller fragments of CD40L, are present on the cell surface of T lymphocytes and are capable of interacting with CD40 molecule, A prominent fragment with a mass of 31 kDa accounts for as much as half of the CD40L on the surface of Jurkat cells. N-terminal sequence data revealed that this fragment lacks the cytoplasmic tail. A minor 18-kDa fragment of CD40L was also characterized which lacks the cytoplasmic tail, transmembrane region, and stalk region of the extracellular domain. The presence of CD40L heteromultimeric variants implies an additional regulation of the functional activity of this ligand complex.	BIOGEN INC,DEPT MOL GENET,CAMBRIDGE,MA 02142; BIOGEN INC,DEPT IMMUNOL & INFLAMMAT,CAMBRIDGE,MA 02142	Biogen; Biogen	Hsu, YM (corresponding author), BIOGEN INC,DEPT PROT ENGN,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.							ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; *APPL BIOS, 1987, MOD 470A PROT PEPT S; ARMITAGE RJ, 1992, EUR J IMMUNOL, V22, P2071, DOI 10.1002/eji.1830220817; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CASAMAYORPALLEJA M, 1995, J EXP MED, V181, P1293, DOI 10.1084/jem.181.4.1293; CASTLE BE, 1993, J IMMUNOL, V151, P1777; CLEVELAND DW, 1983, NATURE, V305, P738, DOI 10.1038/305738a0; COVEY LR, 1994, MOL IMMUNOL, V31, P471, DOI 10.1016/0161-5890(94)90066-3; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; FARRAH T, 1992, NATURE, V358, P26, DOI 10.1038/358026b0; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEDERMAN S, 1994, J IMMUNOL, V152, P2163; LEDERMAN S, 1992, J IMMUNOL, V149, P3817; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; MACCHI P, 1995, AM J HUM GENET, V56, P898; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NOBUHIKO K, 1995, J EXP MED, V182, P1777; PARKER DC, 1993, ANNU REV IMMUNOL, V11, P331, DOI 10.1146/annurev.immunol.11.1.331; Pietravalle F, 1996, J BIOL CHEM, V271, P5965, DOI 10.1074/jbc.271.11.5965; RAMESH N, 1993, INT IMMUNOL, V5, P769, DOI 10.1093/intimm/5.7.769; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SPRIGGS MK, 1992, J EXP MED, V176, P1543, DOI 10.1084/jem.176.6.1543; TANAKA M, 1995, EMBO J, V14, P1129, DOI 10.1002/j.1460-2075.1995.tb07096.x; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; YELLIN MJ, 1994, J IMMUNOL, V152, P598; YELLIN MJ, 1991, J IMMUNOL, V147, P3389	42	47	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					911	915		10.1074/jbc.272.2.911	http://dx.doi.org/10.1074/jbc.272.2.911			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995381	hybrid			2022-12-25	WOS:A1997WC04800032
J	Baudler, M; Duschl, J; Winkler, C; Schartl, M; Altschmied, J				Baudler, M; Duschl, J; Winkler, C; Schartl, M; Altschmied, J			Activation of transcription of the melanoma inducing Xmrk oncogene by a GC box element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; BINDING-PROTEINS; GENE-EXPRESSION; PROMOTER REGION; XIPHOPHORUS; DROSOPHILA; PLATYFISH; CLONING; DNA; SP1	Melanoma formation in Xiphophorus is caused by overexpression of the Xmrk gene. The promoter region of the Xmrk oncogene differs strikingly from the corresponding proto-oncogenic sequences and was acquired in the course of a nonhomologous recombination with another gene locus, D. In order to identify regulatory elements leading to the strong transcriptional activation of Xmrk in melanoma tissue and to contribute to an understanding of the role the regulatory locus R might play in suppressing the tumor phenotype in wild-type Xiphophorus, we performed functional analysis of the Xmrk oncogene promoter. Transient transfections in melanoma and nonmelanoma cells revealed the existence of a potent positive regulatory element positioned close to the transcriptional start site, Contained within this promoter segment is a GC-rich sequence identical to the binding site described for human Sp1. In vitro binding studies and biochemical characterizations demonstrated the existence of GC-binding proteins in fish that share immunological properties with members of the human Sp family of transcription factors and appear to be involved in the high transcriptional activation of the Xmrk oncogene. Since the identified cis element is functional in both melanoma and nonmelanoma cells, additional silencer elements suppressing Xmrk expression in nonpigment cells must exist, thereby suggesting a negative regulatory function for the genetically defined R locus.	UNIV WURZBURG, THEODOR BOVERI INST BIOSCI, BIOCTR, D-97074 WURZBURG, GERMANY	University of Wurzburg			Winkler, Christoph/G-4822-2012	Winkler, Christoph/0000-0003-4688-6241; Schartl, Manfred/0000-0001-9882-5948				ADAM D, 1993, SCIENCE, V259, P816, DOI 10.1126/science.8430335; ADAM D, 1991, ONCOGENE, V6, P73; AHUJA MR, 1976, PROG EXP TUMOR RES, V20, P380; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRONNER G, 1994, NATURE, V369, P664, DOI 10.1038/369664a0; Chestier A, 1992, DNA Seq, V2, P325, DOI 10.3109/10425179209030966; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, V22, P743; CRABB DW, 1987, ANAL BIOCHEM, V163, P88, DOI 10.1016/0003-2697(87)90096-0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWZER CEA, 1991, MOL CELL BIOL, V11, P5701, DOI 10.1128/MCB.11.11.5701; DYNAN WS, 1989, TRENDS GENET, V5, P35, DOI 10.1016/0168-9525(89)90016-4; Fornzler D, 1996, GENOME RES, V6, P102, DOI 10.1101/gr.6.2.102; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; FRIEND SH, 1993, SCIENCE, V259, P774, DOI 10.1126/science.8430329; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUHN C, 1979, IN VITRO CELL DEV B, V15, P537, DOI 10.1007/BF02618156; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI XL, 1994, EMBO J, V13, P400, DOI 10.1002/j.1460-2075.1994.tb06274.x; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; MAUELER W, 1988, ONCOGENE, V2, P421; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; NEHLIN JO, 1990, EMBO J, V9, P2891, DOI 10.1002/j.1460-2075.1990.tb07479.x; Papavassiliou A G, 1994, Methods Mol Biol, V30, P43; SCHARTL M, 1995, TRENDS GENET, V11, P185, DOI 10.1016/S0168-9525(00)89041-1; SCHARTL M, 1990, GENETICS, V126, P1083; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; SUEN TC, 1990, MOL CELL BIOL, V10, P6306, DOI 10.1128/MCB.10.12.6306; WAKAMATSU Y, 1981, CANCER RES, V41, P679; WIMMER EA, 1993, NATURE, V366, P690, DOI 10.1038/366690a0; WINKLER C, 1994, ONCOGENE, V9, P1517; WINKLER C, 1991, MOL GEN GENET, V226, P129, DOI 10.1007/BF00273596; WITTBRODT J, 1992, EMBO J, V11, P4239, DOI 10.1002/j.1460-2075.1992.tb05518.x; WITTBRODT J, 1989, NATURE, V341, P415, DOI 10.1038/341415a0; WOOLCOCK BW, 1994, CELL GROWTH DIFFER, V5, P575; YANAGIDA A, 1990, MOL CELL BIOL, V10, P1470, DOI 10.1128/MCB.10.4.1470	44	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					131	137						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995238				2022-12-25	WOS:A1997WA56400025
J	Huang, CK; Zhan, LJ; Ai, YX; Jongstra, J				Huang, CK; Zhan, LJ; Ai, YX; Jongstra, J			LSP1 is the major substrate for mitogen-activated protein kinase-activated protein kinase 2 in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-SPECIFIC PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; HEAT-SHOCK PROTEINS; MAPKAP KINASE-2; CA-2+-BINDING PROTEIN; MAMMALIAN-CELLS; PHOSPHORYLATION; ACTIN; IDENTIFICATION; CYTOSKELETON	In intact cells, mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 is rapidly activated by various cytokines, stresses, and chemotactic factors. The small heat shock protein p27 has been shown to be a substrate for MAPKAP kinase 2. Recently, we identified a novel substrate, designated p60, for MAPKAP kinase 2 in human neutrophils (Zu, Y.-L., Ai, Y., Gilchrist, A., Labadia, M. E., Sha'afi, R, I., and Huang, C.-K. (1996) Blood 87, 5287-5296). To further understand the signaling pathway of MAPKAP kinase 2, we have purified p60 from a heat-treated neutrophil lysate by DEAE-cellulose chromatography and SDS-polyacrylamide gel electrophoresis. Microsequencing of five peptides derived from purified p60 indicates that p60 is lymphocyte-specific protein 1 (LSP1). Furthermore antibodies specific for human and mouse LSP1 react with human and mouse p60. The sequence of human LSP1 indicates two serine residues at positions 204 and 252 as potential phosphorylation sites. The amino acid sequences surrounding these two sites are in agreement with the consensus sequence (Xaa-Xaa-Hyd-Xaa-Arg-Xaa-Xaa-Ser-Xaa-Xaa) for phosphorylation by MAPKAP kinase 2. Both serine residues in human LSP1 and the corresponding conserved serine residues in mouse LSP1 are in the basic C-terminal F-actin binding domain. Various fusion proteins of wild type and truncated mouse LSP1 with glutathione S-transferase were tested for their capacity to be phosphorylated by MAPKAP kinase 2. The results indicate that LSP1 is a substrate for MAPKAP kinase 2 in vitro and that the phosphorylation sites are located in the basic C-terminal domain of LSP1. Because both the small heat shock proteins and LSP1 are F-actin binding proteins, these results suggest a role for MAPKAP kinase 2 in the regulation of cytoskeletal structure or function.	UNIV TORONTO,DEPT IMMUNOL,TORONTO,ON M5T 2S8,CANADA; TORONTO HOSP,RES INST,ARTHRIT CTR,RES UNIT,TORONTO,ON M5T 2S8,CANADA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Huang, CK (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PATHOL,FARMINGTON,CT 06030, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020943] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20943] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BENNAN L, 1996, CARCINOGENESIS, V17, P101; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Carballo E, 1996, J IMMUNOL, V156, P1709; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COSCO OA, 1995, CELL, V81, P1137; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; ENGEL K, 1995, J BIOL CHEM, V270, P27213, DOI 10.1074/jbc.270.45.27213; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HOWARD T, 1994, BLOOD, V83, P231; JONGSTRA J, 1994, MOL IMMUNOL, V31, P1125, DOI 10.1016/0161-5890(94)90026-4; JONGSTRA J, 1988, J IMMUNOL, V141, P3999; JONGSTRABILEN J, 1992, J CELL BIOL, V118, P1443, DOI 10.1083/jcb.118.6.1443; JONGSTRABILEN J, 1990, J IMMUNOL, V144, P1104; KADIYALA RK, 1990, EUR J IMMUNOL, V20, P2417; KLEIN DP, 1989, MOL CELL BIOL, V9, P3043, DOI 10.1128/MCB.9.7.3043; KLEIN DP, 1990, J IMMUNOL, V145, P2967; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Labadia ME, 1996, J LEUKOCYTE BIOL, V59, P116, DOI 10.1002/jlb.59.1.116; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI Y, 1995, J IMMUNOL, V155, P3563; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; Sen J, 1996, J IMMUNOL, V156, P4535; Sithanandam G, 1996, MOL CELL BIOL, V16, P868; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VOTJEK AB, 1995, CELL, V82, P527; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zu YL, 1996, BLOOD, V87, P5287, DOI 10.1182/blood.V87.12.5287.bloodjournal87125287; ZU YL, 1995, J BIOL CHEM, V270, P202, DOI 10.1074/jbc.270.1.202	42	101	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					17	19		10.1074/jbc.272.1.17	http://dx.doi.org/10.1074/jbc.272.1.17			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995217	hybrid			2022-12-25	WOS:A1997WA56400004
J	Kimura, T; Ohnuma, M; Sawai, T; Yamaguchi, A				Kimura, T; Ohnuma, M; Sawai, T; Yamaguchi, A			Membrane topology of the transposon 10-encoded metal-tetracycline/H+ antiporter as studied by site-directed chemical labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RESISTANCE PROTEIN; NUCLEOTIDE-SEQUENCE; H+ ANTIPORTER; TN10; GENE; EFFLUX; MOTIF; DETERMINANTS; PERMEASE	The transposon (Tn) 10-encoded metal-tetrarcycline/H+ antiporter (Tn10-TetA) is predicted to have a membrane topology involving 12 transmembrane domains on the basis of the hydropathy profile of its sequence and the results of limited proteolysis; however, the experimental results of limited proteolysis are not enough to confirm the topology because proteases cannot gain access from the periplasmic side (Eckert, B., and Beck, C. F. (1989) J. Biol. Chem. 264, 11663-11670). One or two cysteine residues were introduced into each predicted hydrophilic loop or the N-terminal segment of Tn10-TetA by site directed mutagenesis, and then the topology of the protein was determined by examining whether labeling of the introduced Cys residue by membrane-permeant [C-14]N-ethylmaleimide ([C-14]NEM) was prevented by preincubation of intact cells with the membrane-impermeant maleimide, 4-acetamido-4'-maleimidylstilbene-2,2'-disulfonic acid (AMS). The binding of [C-14]NEM to the S36C (loop 1-2), L97C (loop 3-4), S156C (loop 5-6), R238C (loop 7-8), S296C (loop 9-10), Y357C, and D365C (loop 10-11) mutants was completely blocked by pretreatment with AMS, indicating that these residues are located on the periplasmic surface, In contrast, [C-14]NEM binding to the S4C (N-terminal segment), S65C (loop 2-3), D120C (loop 4-5), S199C and S201C (loop 6-7), T270C (loop 8-9), and S328C (loop 10-11) mutants was not affected by pretreatment with AMS, indicating that these residues are on the cytoplasmic surface, These results for the first time thoroughly confirm the 12-transmembrane topology of the metal-tetracycline/H+ antiporter.	OSAKA UNIV,FAC PHARMACEUT SCI,SUITA,OSAKA 565,JAPAN; CHIBA UNIV,FAC PHARMACEUT SCI,DIV MICROBIAL CHEM,CHIBA 260,JAPAN	Osaka University; Chiba University	Kimura, T (corresponding author), OSAKA UNIV,INST SCI & IND RES,DEPT CELL MEMBRANE BIOL,8-1 MIHOGAOKA,IBARAKI,OSAKA 567,JAPAN.		Kimura-Someya, Tomomi/C-4169-2017	Kimura-Someya, Tomomi/0000-0003-2232-1801				ALLARD JD, 1992, J BIOL CHEM, V267, P17809; ECKERT B, 1989, J BIOL CHEM, V264, P11663; HENDERSON PJF, 1990, J BIOENERG BIOMEMBR, V22, P525, DOI 10.1007/BF00762961; HENDERSON PJF, 1990, PHILOS T ROY SOC B, V326, P391, DOI 10.1098/rstb.1990.0020; HILLEN W, 1983, NUCLEIC ACIDS RES, V11, P525, DOI 10.1093/nar/11.2.525; JESSENMARSHALL AE, 1995, J BIOL CHEM, V270, P16251, DOI 10.1074/jbc.270.27.16251; KANEKO M, 1985, FEBS LETT, V193, P194, DOI 10.1016/0014-5793(85)80149-6; KIMURA T, 1996, IN PRESS BIOCHEMISTR; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MCMURRY L, 1980, P NATL ACAD SCI-BIOL, V77, P3974, DOI 10.1073/pnas.77.7.3974; MOYED HS, 1983, J BACTERIOL, V155, P549, DOI 10.1128/JB.155.2.549-556.1983; NEYFAKH AA, 1992, ANTIMICROB AGENTS CH, V36, P484, DOI 10.1128/AAC.36.2.484; NGUYEN TT, 1983, GENE, V25, P83, DOI 10.1016/0378-1119(83)90170-1; PHILIPSON L, 1978, CELL, V13, P189, DOI 10.1016/0092-8674(78)90149-6; SEOL W, 1992, BIOCHEMISTRY-US, V31, P3550, DOI 10.1021/bi00128a032; SOMEYA Y, 1995, BIOCHEMISTRY-US, V34, P7, DOI 10.1021/bi00001a002; STOKER NG, 1982, GENE, V18, P335, DOI 10.1016/0378-1119(82)90172-X; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; YAMAGUCHI A, 1992, BIOCHEMISTRY-US, V31, P8344, DOI 10.1021/bi00150a031; YAMAGUCHI A, 1993, J BIOL CHEM, V268, P6496; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P4809; YAMAGUCHI A, 1991, FEBS LETT, V282, P415, DOI 10.1016/0014-5793(91)80527-A; YAMAGUCHI A, 1990, FEBS LETT, V265, P17, DOI 10.1016/0014-5793(90)80872-G; YAMAGUCHI A, 1990, J BIOL CHEM, V265, P15525; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P19155; YAMAGUCHI A, 1992, J BIOL CHEM, V267, P7490; YAMAGUCHI A, 1994, J BIOCHEM-TOKYO, V115, P958, DOI 10.1093/oxfordjournals.jbchem.a124445; YAMAMOTO T, 1981, J BACTERIOL, V145, P808, DOI 10.1128/JB.145.2.808-813.1981; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	30	53	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					580	585						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995300				2022-12-25	WOS:A1997WA56400087
J	Krueger, KM; Daaka, Y; Pitcher, JA; Lefkowitz, RJ				Krueger, KM; Daaka, Y; Pitcher, JA; Lefkowitz, RJ			The role of sequestration in G protein-coupled receptor resensitization - Regulation of beta(2)-adrenergic receptor dephosphorylation by vesicular acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; SUBCELLULAR-DISTRIBUTION; SUBSTANCE-P; DESENSITIZATION; PHOSPHORYLATION; TRANSFERRIN; ENDOCYTOSIS; MEMBRANE; KINASES	G protein-coupled receptor kinases phosphorylate the agonist occupied conformation of G protein-coupled receptors in the plasma membrane, leading to their desensitization, Receptor resensitization requires receptor dephosphorylation, a process which is mediated by a plasma and vesicular membrane-associated form of PP-2A. We present evidence that, like receptor phosphorylation, receptor dephosphorylation is tightly regulated, requiring a specific receptor conformation induced by vesicular acidification. In vitro, spontaneous dephosphorylation of phosphorylated receptors is observed only at acidic pH. Furthermore, in intact cells upon agonist stimulation, phosphorylated receptors traffic fi om the plasma membrane to vesicles where they become physically associated with the phosphatase and dephosphorylated. Treatment of cells with NH4Cl, which disrupts the acidic pH found in endosomal vesicles, blocks association of the receptors with the phosphatase and blocks receptor dephosphorylation. These findings suggest that a conformational change in the receptor induced by acidification of the endosomal vesicles is the key determinant regulating receptor dephosphorylation and resensitization.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020		NHLBI NIH HHS [HL16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BASU SK, 1981, CELL, V24, P493, DOI 10.1016/0092-8674(81)90340-8; BEAUMELLE B, 1992, J BIOL CHEM, V267, P11525; DAUTRYVARSAT A, 1983, P NATL ACAD SCI-BIOL, V80, P2258, DOI 10.1073/pnas.80.8.2258; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Garland AM, 1996, MOL PHARMACOL, V49, P438; GRADY EF, 1995, MOL BIOL CELL, V6, P509, DOI 10.1091/mbc.6.5.509; GRUENBERG J, 1989, ANNU REV CELL BIOL, V5, P453; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; KASSIS S, 1986, J CYCLIC NUCL PROT, V11, P35; KIM CM, 1993, RECEPTOR, V3, P39; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; LI M, 1995, BIOCHEMISTRY-US, V34, P1988, DOI 10.1021/bi00006a020; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SIBLEY DR, 1986, P NATL ACAD SCI USA, V83, P9408, DOI 10.1073/pnas.83.24.9408; SJODIN L, 1992, J RECEPTOR RES, V12, P323, DOI 10.3109/10799899209074799; STEIN BS, 1984, J BIOL CHEM, V259, P4762; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; YU SS, 1993, J BIOL CHEM, V268, P337	31	297	301	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					5	8						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995214				2022-12-25	WOS:A1997WA56400001
J	Vasudevan, G; McDonald, MJ				Vasudevan, G; McDonald, MJ			Spectral demonstration of semihemoglobin formation during CN-Hemin incorporation into human apohemoglobins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMOGLOBIN SUBUNITS; SELF-ASSOCIATION; KINETICS; ALPHA; GLOBIN; BETA; RECONSTITUTION; FLUORESCENCE; BINDING; MYOGLOBIN	The incorporation of CN-hemin into three human adult apohemoglobin species (apohemoglobin, alpha-apohemoglobin, and apohemoglobin modified at its beta 93 sulfhydryl with p-hydroxymercuribenzoate) has been monitored at micromolar concentrations in 0.05 M potassium phosphate buffer, pH 7.0, at 10 degrees C, In all cases, Soret spectral blue shifts accompanied CN-protohemoglobin but not CN-deuterohemoglobin formation. This finding in conjunction with isofocusing studies provided evidence of a CN-protosemi-alpha-hemoglobin intermediate, the formation of which appeared to be a direct consequence of CN-protohemin-alpha heme pocket interactions, The kinetics of full reconstitution of CN-protohemoglobin and CN-deuterohemoglobin revealed four distinct phases that apparently correlated with heme insertion (Phase I), local structural rearrangement (Phase II), global conformational response (Phase III), and irreversible histidine iron bond formation (Phase IV). These phases exhibited rates of 7.8-22 x 10(7) M(-1) s(-1), 0.19-0.23 s(-1), 0.085-0.12 s(-1) and 0.008-0.012 s(-1), respectively. Partial (50%) reconstitution with CN-protohemin, in contrast, revealed only three kinetic phases (with Phase III missing) of heme incorporation into native and p-hydroxymercuribenzoate-modified apohemoglobin, Furthermore, the absence of Phase III slowed the rate of proximal bond formation, These findings support the premise that irreversible assembly of CN-protosemi-alpha-hemoglobin is deterred by the presence of a heme-free beta partner, the consequence of which may be that intermolecular heme transfer is encouraged under conditions of heme deficiency in vivo.	UNIV LOWELL,COLL ARTS & SCI,DEPT CHEM,BIOCHEM PROGRAM,LOWELL,MA 01854	University of Massachusetts System; University of Massachusetts Lowell					NHLBI NIH HHS [HL 38456] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038456] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERS GK, 1985, ANNU REV BIOCHEM, V54, P597, DOI 10.1146/annurev.bi.54.070185.003121; Ascoli F, 1981, Methods Enzymol, V76, P72; BENESCH RE, 1995, J BIOL CHEM, V270, P13785, DOI 10.1074/jbc.270.23.13785; BENESCH RE, 1990, J BIOL CHEM, V265, P14881; BOYER PD, 1954, J AM CHEM SOC, V76, P4331, DOI 10.1021/ja01646a025; Bucci E, 1981, Methods Enzymol, V76, P97; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CASSOLY R, 1971, EUR J BIOCHEM, V19, P514, DOI 10.1111/j.1432-1033.1971.tb01343.x; CHU AH, 1979, J BIOL CHEM, V254, P3772; CURRELL DL, 1972, BIOCHIM BIOPHYS ACTA, V263, P82, DOI 10.1016/0005-2795(72)90161-4; FERMI G, 1981, ATLAS MOL STRUCTURES, V2; FRIEDMAN FK, 1979, ANNU REV BIOCHEM, V48, P217, DOI 10.1146/annurev.bi.48.070179.001245; Gattoni M, 1996, J BIOL CHEM, V271, P10130, DOI 10.1074/jbc.271.17.10130; GIBSON QH, 1963, J BIOL CHEM, V238, P1384; GIBSON QH, 1960, BIOCHEM J, V77, P328, DOI 10.1042/bj0770328; ISHIMORI K, 1988, BIOCHEMISTRY-US, V27, P4747, DOI 10.1021/bi00413a025; JAVAHERI.K, 1968, J MOL BIOL, V37, P1, DOI 10.1016/0022-2836(68)90069-7; JOSHI AA, 1994, J BIOL CHEM, V269, P8549; KAWAMURAKONISHI Y, 1992, EUR BIOPHYS J BIOPHY, V21, P85; KAWAMURAKONISHI Y, 1988, EUR J BIOCHEM, V170, P589, DOI 10.1111/j.1432-1033.1988.tb13738.x; KAWAMURAKONISHI Y, 1985, J BIOCHEM-TOKYO, V98, P1181, DOI 10.1093/oxfordjournals.jbchem.a135384; Koetzle T. F., 1993, MOL STRUCTURES BIOL, P164; KOMAR AA, 1993, FEBS LETT, V326, P261, DOI 10.1016/0014-5793(93)81803-8; LAU PW, 1976, J BIOL CHEM, V251, P6838; LEUTZINGER Y, 1981, P NATL ACAD SCI-BIOL, V78, P780, DOI 10.1073/pnas.78.2.780; LINDQVIST L, 1978, PHOTOCHEM PHOTOBIOL, V28, P417, DOI 10.1111/j.1751-1097.1978.tb07728.x; Manning LR, 1996, PROTEIN SCI, V5, P775; MCDONALD MJ, 1981, J BIOL CHEM, V256, P6487; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MCDONALD MJ, 1974, J BIOL CHEM, V249, P3161; MOULTON DP, 1994, BIOCHEM BIOPH RES CO, V199, P1278, DOI 10.1006/bbrc.1994.1369; OMALLEY SM, 1994, J PROTEIN CHEM, V13, P585, DOI 10.1007/BF01890456; OMALLEY SM, 1994, BIOCHEM BIOPH RES CO, V200, P384, DOI 10.1006/bbrc.1994.1460; OTON J, 1981, J BIOL CHEM, V256, P7248; PARK RY, 1989, BIOCHEM BIOPH RES CO, V162, P522, DOI 10.1016/0006-291X(89)92028-7; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; ROSE MY, 1983, J BIOL CHEM, V258, P4298; SCHAAD O, 1993, CR ACAD SCI III-VIE, V316, P564; SHAEFFER JR, 1973, J BIOL CHEM, V248, P7473; TURCI SM, 1985, J CHROMATOGR, V343, P168, DOI 10.1016/S0378-4347(00)84581-8; WAKS M, 1973, J BIOL CHEM, V248, P6462; WHITAKER TL, 1995, BIOCHEMISTRY-US, V34, P8221, DOI 10.1021/bi00026a002; WINTERHA.KH, 1969, BRIT J HAEMATOL, V16, P523, DOI 10.1111/j.1365-2141.1969.tb00434.x; WINTERHALTER KH, 1971, BIOCHEMISTRY-US, V10, P3790, DOI 10.1021/bi00796a023; YEE S, 1991, FEBS LETT, V290, P119, DOI 10.1016/0014-5793(91)81240-9	45	25	27	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					517	524						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995292				2022-12-25	WOS:A1997WA56400079
J	Muriaux, D; DeRocquigny, H; Roques, BP; Paoletti, J				Muriaux, D; DeRocquigny, H; Roques, BP; Paoletti, J			NCp7 activates HIV-1(Lai) RNA dimerization by converting a transient loop-loop complex into a stable dimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEOCAPSID PROTEIN NCP7; MOLONEY MURINE LEUKEMIA; TERMINAL ZINC-FINGER; PRIMER TRANSFER-RNA; GENOMIC RNA; IN-VITRO; AUTOCOMPLEMENTARY SEQUENCE; REVERSE TRANSCRIPTION; ANNEALING ACTIVITIES	Nucleocapsid protein 7 (NCp7), the human immunodeficiency virus type 1 (HTV-1) nucleocapsid protein, was shown to strongly potentiate the dimerization of the retroviral genomic RNA. This process involves the inter action of two retroviral RNA monomer subunits near their 5'-ends. A region located upstream from the splice donor site was recently identified as being responsible for the formation of dimeric HIV-1 RNA. This region appeared to be confined within a stem-loop structure, with an autocomplementary sequence in the loop. In an in vitro study of spontaneous dimer formation, we reported that the 77-402 RNA transcript forms two distinct dimers differing in their thermostability: D37 and D55. We identified D37 as a ''kissing'' complex structure, formed via a loop-loop interaction between the two monomers, and D55 as a double stranded structure involving all nucleotides of the stem loop via canonical base pairing. In this report, we have characterized the role of NCp7 in the HIV-1(Lai) RNA dimerization process by using in vitro dimerization assays with RNA transcripts of different lengths and dimer thermal dissociation. Our results show that the nucleocapsid protein NCp7 activates RNA dimerization very likely through interaction with the kissing complex and converts it into a stable dimer. Furthermore, this NCp7-prometed conversion only occurs if the 240-280 stem loop structure is present in HIV-1(Lai) RNA molecules and contains the autocomplementary G(257)CGCGC(262) sequence. This study suggests that, under physiological conditions, an NCp7-mediated RNA conformational change is involved in the maturation of the HIV-1 RNA dimer.	INST GUSTAVE ROUSSY,CNRS,URA 147,UNITE BIOCHIM,F-94805 VILLEJUIF,FRANCE; UNIV PARIS 05,CNRS,URA D1500,INSERM,U266,DEPT PHARACOCHIM MOL & STRUCT,F-75006 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite								ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; AWANG G, 1993, BIOCHEMISTRY-US, V32, P11453, DOI 10.1021/bi00093a024; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BENDER W, 1978, J VIROL, V25, P888, DOI 10.1128/JVI.25.3.888-896.1978; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERKHOUT B, 1993, FASEB J, V7, P181, DOI 10.1096/fasebj.7.1.8422965; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; COFFIN JM, 1984, RNA TUMOR VIRUSES, V1, P261; COVEY SN, 1986, NUCLEIC ACIDS RES, V14, P623, DOI 10.1093/nar/14.2.623; DANNULL J, 1994, EMBO J, V13, P1525, DOI 10.1002/j.1460-2075.1994.tb06414.x; DARLIX JL, 1993, CR ACAD SCI III-VIE, V316, P763; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEMENE H, 1994, BIOCHEMISTRY-US, V33, P11707, DOI 10.1021/bi00205a006; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; Dickson C., 1985, RNA TUMOR VIRUSES, P513; EGUSHI Y, 1990, CELL, V60, P199; FENG YX, 1995, J VIROL, V69, P2486, DOI 10.1128/JVI.69.4.2486-2490.1995; FU W, 1994, J VIROL, V68, P5013, DOI 10.1128/JVI.68.8.5013-5018.1994; Girard PM, 1996, BIOCHEMISTRY-US, V35, P8705, DOI 10.1021/bi952454s; GIRARD PM, 1995, BIOCHEMISTRY-US, V34, P9785, DOI 10.1021/bi00030a016; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; KHAN R, 1992, J BIOL CHEM, V267, P6689; LAPADATTAPOLSKY M, 1995, NUCLEIC ACIDS RES, V23, P2434, DOI 10.1093/nar/23.13.2434; LAPADATTAPOLSKY M, 1993, NUCLEIC ACIDS RES, V21, P831, DOI 10.1093/nar/21.4.831; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; Maniatis T., 1982, MOL CLONING; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MASSIE HR, 1965, P NATL ACAD SCI USA, V54, P1641, DOI 10.1073/pnas.54.6.1641; MELY Y, 1991, BIOPOLYMERS, V31, P899, DOI 10.1002/bip.360310709; MELY Y, 1994, BIOCHEMISTRY-US, V33, P12085, DOI 10.1021/bi00206a011; MERIC C, 1988, J VIROL, V62, P3328; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MORELLET N, 1994, J MOL BIOL, V235, P287, DOI 10.1016/S0022-2836(05)80033-6; MURIAUX D, 1995, J BIOL CHEM, V270, P8209, DOI 10.1074/jbc.270.14.8209; Muriaux D, 1996, BIOCHEMISTRY-US, V35, P5075, DOI 10.1021/bi952822s; MURTI KG, 1981, J VIROL, V37, P411, DOI 10.1128/JVI.37.1.411-419.1981; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; PRIEL E, 1995, FEBS LETT, V362, P59, DOI 10.1016/0014-5793(95)00208-Q; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; SOUTH TL, 1993, PROTEIN SCI, V2, P3; STOLTZFUS CM, 1975, J VIROL, V16, P1161, DOI 10.1128/JVI.16.5.1161-1170.1975; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TURNER DH, 1982, ANN REV BIOPHYS BIOP; YOU JC, 1994, J BIOL CHEM, V269, P31491; ZUCKER M, 1989, SCIENCE, V244, P48	55	158	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33686	33692		10.1074/jbc.271.52.33686	http://dx.doi.org/10.1074/jbc.271.52.33686			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969239	hybrid			2022-12-25	WOS:A1996WA71300073
J	Koch, J; Gartner, S; Li, CM; Quintern, LE; Bernardo, K; Levran, O; Schnabel, D; Desnick, RJ; Schuchman, EH; Sandhoff, K				Koch, J; Gartner, S; Li, CM; Quintern, LE; Bernardo, K; Levran, O; Schnabel, D; Desnick, RJ; Schuchman, EH; Sandhoff, K			Molecular cloning and characterization of a full-length complementary DNA encoding human acid ceramidase - Identification of the first molecular lesion causing Farber disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; LONG-CHAIN BASES; INHIBITION; BIOSYNTHESIS; SIGNAL; CELLS; SPHINGANINE; CLEAVAGE	Human acid ceramidase ((AC) N-acylsphingosine amidohydrolase, EC 3.5.1.23) hydrolyzes the sphingolipid ceramide into sphingosine and free fatty acid, Ceramide is an essential component of all sphingolipids and an important cell-signaling molecule, Moreover, an inherited deficiency of AC activity leads to the lysosomal storage disorder known as Farber disease, Human AC was purified from urine, and 117 amino acid residues were determined by microsequencing. Degenerative oligonucleotide probes were then constructed and used to screen for human fibroblast and pituitary cDNA libraries, Several partial cDNA clones were obtained, and two of these were combined to construct a full-length cDNA containing a 17-base pair (bp) 5'-untranslated sequence, a 1185-bp open reading frame encoding 395 amino acids, a 1110-bp 3'-untranslated sequence, and an 18-bp poly(A) tail. Transient expression of the full-length cDNA in COS-1 cells led to a 10-fold increase in AC activity, In addition, biosynthetic studies carried out in the transfected cells demonstrated that 13-kDa (alpha) and 40-kDa (beta) AC subunits were derived from a common 55-kDa precursor encoded by the full length cDNA. This protein pattern was identical to that seen in normal human skin fibroblasts, A homoallelic point mutation (T222K) was also identified in the AC gene of a patient suffering from Farber disease, further confirming the authenticity of the full-length cDNA.	UNIV BONN,INST ORGAN CHEM & BIOCHEM,D-53121 BONN,GERMANY; CUNY MT SINAI SCH MED,DEPT HUMAN GENET,NEW YORK,NY 10029	University of Bonn; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Levran, Orna/H-2772-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD028607] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028607] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 28607] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; GATT S, 1963, J BIOL CHEM, V238, P3131; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; KAN CC, 1993, TRENDS GLYCOSCI GLYC, V5, P99; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVADE T, 1995, J NEUROL SCI, V134, P108, DOI 10.1016/0022-510X(95)00231-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERRILL AH, 1986, J BIOL CHEM, V261, P2610; MOSER HW, 1995, METABOLIC MOL BASES, P2589; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TOPPET M, 1978, ACTA PAEDIATR SCAND, V67, P113, DOI 10.1111/j.1651-2227.1978.tb16287.x; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG E, 1991, J BIOL CHEM, V266, P14486; WILSON E, 1986, J BIOL CHEM, V261, P2616; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0	21	193	211	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33110	33115		10.1074/jbc.271.51.33110	http://dx.doi.org/10.1074/jbc.271.51.33110			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955159	hybrid			2022-12-25	WOS:A1996VZ37300094
J	Russell, SJ; Sathyanarayana, UG; Johnston, SA				Russell, SJ; Sathyanarayana, UG; Johnston, SA			Isolation and characterization of SUG2 - A novel ATPase family component of the yeast 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAT-BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; GAL4 PROTEIN; GALACTOSE; ACTIVATION; GENE; TRANSFORMATION; DEGRADATION; MEDIATOR; REGULON	Using a genetic strategy designed to find proteins involved in the function of the Saccharomyces cerevisiae transcriptional activator GAL4, we isolated mutants in two genes which rescue a class of gal4 activation domain mutants. One of these genes, SUG1, encodes a member of a large family of putative ATPases, the (C) under bar onserved (A) under bar TPase containing (D) under bar omain (CAD) proteins (also known as AAA proteins) that are involved in a wide variety of cellular functions. Subsequently, SUG1 was identified as a subunit of the 26 S proteasome. We have now cloned the gene defined by the second complementation group. SUG2 encodes an essential 49-kDa protein that is also a member of the CAD family and is 43% identical to SUG1. The mutation in sug2-1, like that in sug1-1, is found in the CAD near the highly conserved ATPase motif. We present biochemical and genetic evidence that SUG2 is associated in vivo with SUG1 and is a novel CAD protein subunit of the 26 S proteasome. With its highly con served mammalian homologs, human p42 and ground squirrel CADp44, SUG2 defines a new class of proteasomal CAD proteins.	UNIV TEXAS, SW MED CTR,DEPT INTERNAL MED, GRAD PROGRAM BIOCHEM & MOL BIOL,MOL CARDIOL LABS, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, GRAD PROGRAM BIOCHEM & MOL BIOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AKIYAMA K, 1995, FEBS LETT, V363, P151, DOI 10.1016/0014-5793(95)00304-R; Bauer VW, 1996, GENE, V181, P63, DOI 10.1016/S0378-1119(96)00463-5; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; Fujiwara T, 1996, FEBS LETT, V387, P184, DOI 10.1016/0014-5793(96)00489-9; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HILL DE, 1988, NUCLEIC ACIDS RES, V16, P9253, DOI 10.1093/nar/16.19.9253; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Johnston M., 1992, MOL CELLULAR BIOL YE, P193; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; JOHNSTON SA, 1987, CELL, V50, P143, DOI 10.1016/0092-8674(87)90671-4; KEW OM, 1976, J BACTERIOL, V125, P33, DOI 10.1128/JB.125.1.33-41.1976; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEUTHER KK, 1992, SCIENCE, V256, P1333, DOI 10.1126/science.1598579; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MA CP, 1994, J BIOL CHEM, V269, P3539; MAMROUDKIDRON E, 1994, FEBS LETT, V356, P162, DOI 10.1016/0014-5793(94)01260-1; MATSUMOTO K, 1980, J BACTERIOL, V141, P508, DOI 10.1128/JB.141.2.508-527.1980; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; OHANA B, 1993, P NATL ACAD SCI USA, V90, P138, DOI 10.1073/pnas.90.1.138; PETERS JM, 1994, J BIOL CHEM, V269, P7709; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SALMERON JM, 1990, GENETICS, V125, P21; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SHERMAN F, 1991, GUIDE YEAST GENETICS, P13; SIKORSKI RS, 1989, GENETICS, V122, P19; SPANG A, 1995, J CELL BIOL, V128, P863, DOI 10.1083/jcb.128.5.863; Swaffield JC, 1996, NATURE, V379, P658, DOI 10.1038/379658a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	47	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32810	32817		10.1074/jbc.271.51.32810	http://dx.doi.org/10.1074/jbc.271.51.32810			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955118	hybrid			2022-12-25	WOS:A1996VZ37300053
J	Spahn, CMT; Remme, J; Schafer, MA; Nierhaus, KH				Spahn, CMT; Remme, J; Schafer, MA; Nierhaus, KH			Mutational analysis of two highly conserved UGG sequences of 23 S rRNA from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; FUNCTIONAL TRANSFER-RNAS; RIBOSOMAL-RNA; PEPTIDYLTRANSFERASE ACTIVITY; A-SITES; P-SITES; MUTAGENESIS; SUBUNIT; INVIVO; RECONSTITUTION	The 23 S-type rRNA contains two phylogenetically conserved UGG sequences, which have the potential to bind the universal CCA-3'-ends of tRNAs at the ribosomal peptidyltransferase center by base pairing. The first two positions, UG, of these sequences at the helix-loop 80 (U2249G2250) and helix-loop 90 (Psi 2580G2581) and some related nucleotides were tested by site-directed mutagenesis for their involvement in ribosomal function, i.e. peptidyltransferase. The plasmid derived mutated 23 S rRNA comprised about 50% of the total 23 S rRNA, None of the single mutations caused an assembly defect, and all 50 S subunits carrying an altered 23 S rRNA could freely exchange with the pools of 70S ribosomes and polysomes, The mutations at the helix-loop 80 region hardly affected bacterial growth. However, mutations at the helix 90 caused severe growth effects and severely impaired the in vitro protein synthesis, showing that this 23 S rRNA region is of high importance for ribosomal function.	AG RIBOSOMEN, MAX PLANCK INST MOL GENET, D-14195 BERLIN, GERMANY; TARTU STATE UNIV, INST MOL & CELL BIOL, EE-2400 TARTU, ESTONIA	Max Planck Society; University of Tartu			Remme, Jaanus/L-1830-2019; Remme, Jaanus/A-4614-2011	Remme, Jaanus/0000-0002-4011-6580; Remme, Jaanus/0000-0002-4011-6580				Ausubel FM, 1991, CURRENT PROTOCOLS MO; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; BARTETZKO A, 1988, METHOD ENZYMOL, V164, P650; BILGIN N, 1994, J MOL BIOL, V235, P813, DOI 10.1006/jmbi.1994.1041; BOURD SB, 1983, EUR J BIOCHEM, V135, P465, DOI 10.1111/j.1432-1033.1983.tb07674.x; BRIMACOMBE R, 1995, EUR J BIOCHEM, V230, P365; CHLADEK S, 1985, ANGEW CHEM, V97, P377; COOPERMAN BS, 1990, RIBOSOME, P491; CUNDLIFFE E, 1990, RIBOSOME, P479; DOUTHWAITE S, 1993, TRANSLATIONAL APPARATUS, P339; EGEBJERG J, 1990, RIBOSOME, P168; FRANCESCHI FJ, 1990, J BIOL CHEM, V265, P16676; GOURSE RL, 1983, CELL, V32, P1347, DOI 10.1016/0092-8674(83)90315-X; GREGORY ST, 1994, NUCLEIC ACIDS RES, V22, P279, DOI 10.1093/nar/22.3.279; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; GUTELL RR, 1993, TRANSLATIONAL APPARATUS, P477; HAMPL H, 1981, J BIOL CHEM, V256, P2284; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEWICKI BTU, 1993, J MOL BIOL, V231, P581, DOI 10.1006/jmbi.1993.1311; LIEBERMAN KR, 1994, J BIOL CHEM, V269, P16163; LIU MS, 1994, P NATL ACAD SCI USA, V91, P10389, DOI 10.1073/pnas.91.22.10389; MADEN BEH, 1968, J MOL BIOL, V35, P333, DOI 10.1016/S0022-2836(68)80028-2; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; NOLLER HF, 1993, J BACTERIOL, V175, P5297, DOI 10.1128/JB.175.17.5297-5300.1993; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; PESTKA S, 1970, ARCH BIOCHEM BIOPHYS, V136, P89, DOI 10.1016/0003-9861(70)90330-9; PORSE BT, 1995, J MOL BIOL, V249, P1, DOI 10.1006/jmbi.1995.0276; RHEINBERGER HJ, 1990, EUR J BIOCHEM, V193, P643, DOI 10.1111/j.1432-1033.1990.tb19382.x; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SAARMA U, 1992, NUCLEIC ACIDS RES, V20, P3147, DOI 10.1093/nar/20.12.3147; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZE H, 1982, EMBO J, V1, P609, DOI 10.1002/j.1460-2075.1982.tb01216.x; SIGMUND CD, 1988, METHOD ENZYMOL, V164, P673; Spahn CMT, 1996, J BIOL CHEM, V271, P32857, DOI 10.1074/jbc.271.51.32857; STADE K, 1994, NUCLEIC ACIDS RES, V22, P1394, DOI 10.1093/nar/22.8.1394; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; TAKEMOTO C, 1995, BIOCHIMIE, V77, P104, DOI 10.1016/0300-9084(96)88112-0; TAMURA K, 1994, FEBS LETT, V353, P173, DOI 10.1016/0014-5793(94)01038-2; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; THOMPSON J, 1988, J MOL BIOL, V203, P457, DOI 10.1016/0022-2836(88)90012-5; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; ULBRICH B, 1978, ARCH BIOCHEM BIOPHYS, V190, P149, DOI 10.1016/0003-9861(78)90262-X; WAGNER EGH, 1982, EUR J BIOCHEM, V122, P193, DOI 10.1111/j.1432-1033.1982.tb05866.x; WELCH M, 1995, BIOCHEMISTRY-US, V34, P385, DOI 10.1021/bi00002a001; [No title captured]	52	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32849	32856		10.1074/jbc.271.51.32849	http://dx.doi.org/10.1074/jbc.271.51.32849			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955123	hybrid			2022-12-25	WOS:A1996VZ37300058
J	Takahashi, A; Musy, PY; Martins, LM; Poirier, GG; Moyer, RW; Earnshaw, WC				Takahashi, A; Musy, PY; Martins, LM; Poirier, GG; Moyer, RW; Earnshaw, WC			CrmA/SPI-2 inhibition of an endogenous ICE-related protease responsible for lamin A cleavage and apoptotic nuclear fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; INTERLEUKIN-1-BETA CONVERTING-ENZYME; POLY(ADP-RIBOSE) POLYMERASE; ICE/CED-3 PROTEASE; MAMMALIAN HOMOLOG; CRMA GENE; CED-3; INDUCTION; PROTEINASE; ENCODES	CrmA, a poxvirus gene product with a serpin-like structure, blocks a variety of apoptotic death events in cultured cells. Based on the ability of CrmA to inhibit the interleukin-1 beta converting enzyme in vitro, it has been speculated that interleukin-1 beta converting enzyme-related proteases (caspases) essential for apoptosis are the cellular targets of CrmA. Here we found that rabbit-pox virus CrmA/SPI-2 inhibits the cleavage of lamin A mediated by a caspase in our cell-free system of apoptosis. In the presence of CrmA/SPI-2, nuclear apoptosis in vitro was blocked at an intermediate stage after collapse of the chromatin against the nuclear periphery and before nuclear shrinkage and disintegration into apoptotic body-like fragments. Using N-(acetyltyrosinylvalinyl-N-epsilon-biotinyllysyl) aspartic acid [(2,6-dimethylbenzoyl) oxy] methyl ketone, which derivatizes the active forms of caspases, we could show that one of five caspases active in the extracts is inhibited both by CrmA/SPI-2 and by a peptide spanning the lamin A apoptotic cleavage site. These results reveal that CrmA/SPI-2 can inhibit a caspase responsible both for lamin A cleavage and for the nuclear disintegration characteristic of apoptosis.	UNIV EDINBURGH,INST CELL & MOL BIOL,EDINBURGH EH9 3JR,MIDLOTHIAN,SCOTLAND; UNIV FLORIDA,COLL MED,DEPT MOL GENET & MICROBIOL,GAINESVILLE,FL 32610; UNIV LAVAL,RES CTR,CTR HOSP,DEPT MOL ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA	University of Edinburgh; State University System of Florida; University of Florida; Laval University			Earnshaw, William/AAY-7438-2020	Poirier, Guy/0000-0002-4869-1424; Earnshaw, William/0000-0002-7191-0621	NATIONAL CANCER INSTITUTE [R01CA069008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI015722, R01AI015722] Funding Source: NIH RePORTER; NCI NIH HHS [CA69008] Funding Source: Medline; NIAID NIH HHS [AI 15722] Funding Source: Medline; Wellcome Trust [073915] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		ALI AN, 1994, VIROLOGY, V202, P305, DOI 10.1006/viro.1994.1347; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; ELMES ME, 1977, J PATHOL, V123, P219, DOI 10.1002/path.1711230404; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; KAUFMANN SH, 1989, CANCER RES, V49, P5870; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOSS B, 1990, NATURE, V348, P91, DOI 10.1038/348091a0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; UCKER DS, 1992, J IMMUNOL, V149, P1583; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	32	62	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32487	32490		10.1074/jbc.271.51.32487	http://dx.doi.org/10.1074/jbc.271.51.32487			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955067	hybrid			2022-12-25	WOS:A1996VZ37300002
J	Calogero, A; Cuomo, L; DOnofrio, M; deGrazia, U; Spinsanti, P; Mercola, D; Faggioni, A; Frati, L; Adamson, ED; Ragona, G				Calogero, A; Cuomo, L; DOnofrio, M; deGrazia, U; Spinsanti, P; Mercola, D; Faggioni, A; Frati, L; Adamson, ED; Ragona, G			Expression of Egr-1 correlates with the transformed phenotype and the type of viral latency in EBV genome positive lymphoid cell lines	ONCOGENE			English	Article						Egr-1; EBV; lymphoid cell lines	EPSTEIN-BARR-VIRUS; ZINC FINGER GENE; TRANSCRIPTION FACTOR; BURKITTS-LYMPHOMA; B-LYMPHOCYTES; INVITRO INFECTION; RESPONSE GENES; CROSS-LINKING; WILMS-TUMOR; LUNG-CANCER	In this paper we have investigated the role of Egr-1 in B cell growth regulation by examining the gene expression in a panel of B cell lines, including both EBV genome negative and EBV carrying cell lines. Egr-1 expression correlates with the cellular phenotype and the specific pattern of viral latency established within the individual cell lines. Thus, constitutive activation of Egr-1 gene is invariably associated with unrestricted expression of viral latent genes in all group III EBV genome carrying cell lines. In contrast, Egr-1 expression is abrogated in group I Burkitt tumor cells, irrespective of the EBV genome carrying status. Activated viral gene expression associated with phenotypic conversion of group I cell lines in to group II or III restores the Egr-1 gene expression. Several forms of EGR-1 protein are found within the different groups of cell lines, and the binding activity to DNA consensus sequences was investigated. Finally, time course analysis of Egr-1 expression during the early steps of EBV infection in vitro demonstrated that Egr-1 is upregulated within minutes from the initial interaction with the B lymphocyte.	IRCCS, IST NEUROL MEDITERRANEO, POZZILLI, ITALY; UNIV ROMA LA SAPIENZA, DIPARTIMENTO MED SPERIMENTALE & PATOL, I-00185 ROME, ITALY; SIDNEY KIMMEL CANC CTR, SAN DIEGO, CA USA; BURNHAM INST, SAN DIEGO, CA USA	IRCCS Neuromed; Sapienza University Rome			de Grazia, Ugo/K-1307-2016; Frati, Luigi/ABI-7437-2020; mercola, dan/L-4182-2013; calogero, antonella/U-5418-2019	de Grazia, Ugo/0000-0001-8648-0372; mercola, dan/0000-0002-0281-9840; calogero, antonella/0000-0002-3322-2916				Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BOULTWOOD J, 1994, GENOMICS, V19, P425, DOI 10.1006/geno.1994.1090; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CIRONE M, 1995, CANCER LETT, V89, P125, DOI 10.1016/0304-3835(94)03663-4; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; EHLINHENRIKSSON B, 1987, INT J CANCER, V39, P211, DOI 10.1002/ijc.2910390215; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; GREGORY CD, 1992, REV MED VIROL, V2, P205, DOI 10.1002/rmv.1980020405; GUALANDI G, 1992, J VIROL, V66, P5677, DOI 10.1128/JVI.66.9.5677-5681.1992; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HUANG RP, 1994, ONCOGENE, V9, P1367; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUANG RP, 1995, CANCER RES, V55, P5054; KLAUS SJ, 1993, MOL IMMUNOL, V30, P1553, DOI 10.1016/0161-5890(93)90463-L; KLEIN G, 1972, INT J CANCER, V10, P44, DOI 10.1002/ijc.2910100108; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LEBEAU MM, 1993, P NATL ACAD SCI USA, V90, P5484, DOI 10.1073/pnas.90.12.5484; Lenoir G M, 1985, IARC Sci Publ, P309; LEVIN WJ, 1995, ONCOGENE, V11, P1261; LEVIN WJ, 1994, CHEST, V106, pS372, DOI 10.1378/chest.106.6.372S; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; Maltzman JS, 1996, MOL CELL BIOL, V16, P2283; Masucci Maria G., 1994, Trends in Microbiology, V2, P125, DOI 10.1016/0966-842X(94)90599-1; MCMAHON SB, 1995, J EXP MED, V181, P417, DOI 10.1084/jem.181.1.417; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; Mitchell R L, 1986, Symp Fundam Cancer Res, V39, P99; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; MONROE JG, 1993, ADV MOL CELL IMMUN B, V1, P1; MURRAY RJ, 1988, J VIROL, V62, P894, DOI 10.1128/JVI.62.3.894-901.1988; Nemerow G R, 1990, Adv Cancer Res, V54, P273, DOI 10.1016/S0065-230X(08)60814-3; PIECHACZYK M, 1994, CRIT REV ONCOL HEMAT, V17, P93, DOI 10.1016/1040-8428(94)90021-3; RAGONA G, 1986, CELL BIOL INT REP, V10, P315, DOI 10.1016/0309-1651(86)90002-0; RAGONA G, 1991, DNA CELL BIOL, V10, P61, DOI 10.1089/dna.1991.10.61; REEDMAN BM, 1973, INT J CANCER, V11, P499, DOI 10.1002/ijc.2910110302; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; ROONEY CM, 1984, INT J CANCER, V34, P339, DOI 10.1002/ijc.2910340310; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAKIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P1686, DOI 10.1073/pnas.88.5.1686; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIVEDI P, 1995, ONCOGENE, V11, P505; WILSON RE, 1993, ONCOGENE, V8, P3229; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; ZALANI S, 1995, J VIROL, V69, P3816, DOI 10.1128/JVI.69.6.3816-3823.1995	52	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2105	2112						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950977				2022-12-25	WOS:A1996VV14500007
J	Grunewald, SM; Kunzmann, S; Schnarr, B; Ezernieks, J; Sebald, W; Duschl, A				Grunewald, SM; Kunzmann, S; Schnarr, B; Ezernieks, J; Sebald, W; Duschl, A			A murine interleukin-4 antagonistic mutant protein completely inhibits interleukin-4-induced cell proliferation, differentiation, and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-GAMMA-CHAIN; STIMULATORY FACTOR-I; B-CELLS; HIGH-AFFINITY; IGE SYNTHESIS; CDNA CLONE; MOUSE; IL-4; RESPONSES; BINDING	We characterize here a highly efficient antagonist for interleukin-4 (IL-4) in the mouse system. In this double mutant of the murine IL-4 protein, both glutamine 116 and tyrosine 119 were substituted by aspartic acid residues. This variant (QY) bound with similar affinity to the IL-4 receptor alpha subunit as wild type IL-4 without inducing cellular responses. In contrast, QY completely inhibited in a dose-dependent manner the IL-4-induced proliferation of lipopolysaccharide stimulated murine splenic B-cells, of the murine T cell line CTLL-2, and of the murine pre-B-cell line BA/F3. QY also inhibited the IL-4-stimulated up regulation of CD23 expression by lipopolysaccharide-stimulated murine splenic B-cells and abolished tyrosine phosphorylation of the transcription factor Stat6 and the tyrosine kinase Jak3 in IL-4-stimulated BA/F3 cells. Selective inhibition of IL-4 may be beneficial in T-helper cell type 2-dominated diseases, like type I hypersensitivity reactions or helminthic infections. The QY mutant could be an attractive tool to study in vivo the therapeutic potential of IL-4 antagonists in mouse systems.	THEODOR BOVERI INST BIOWISSENSCH BIOZENTRUM,D-97074 WURZBURG,GERMANY				Duschl, Albert/E-5872-2011	Duschl, Albert/0000-0002-7034-9860				AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; BONSCH D, 1995, J BIOL CHEM, V270, P8452, DOI 10.1074/jbc.270.15.8452; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Duschl A, 1992, Eur Cytokine Netw, V3, P97; DUSCHL A, 1995, EUR J BIOCHEM, V228, P305; DUSCHL A, 1995, BEHRING I MITT, V96, P87; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; GESSNER A, 1995, IMMUNOBIOLOGY, V194, P168; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; Lischke A, 1996, ANAL BIOCHEM, V236, P322, DOI 10.1006/abio.1996.0173; MALISZEWSKI CR, 1994, P SOC EXP BIOL MED, V206, P233; MORRISON BW, 1992, J BIOL CHEM, V267, P11957; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOSMANN TR, 1987, J IMMUNOL, V138, P1813; MULLER T, 1994, NAT STRUCT BIOL, V1, P674, DOI 10.1038/nsb1094-674; MULLER T, 1994, J MOL BIOL, V237, P424; MULLER W, 1991, EUR J IMMUNOL, V21, P921, DOI 10.1002/eji.1830210410; PAUL WE, 1991, BLOOD, V77, P1859; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCOTT P, 1991, IMMUNOL TODAY, V12, P346, DOI 10.1016/0167-5699(91)90063-Y; Shen BJ, 1996, EUR J BIOCHEM, V240, P252, DOI 10.1111/j.1432-1033.1996.0252h.x; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; TONY HP, 1994, EUR J BIOCHEM, V225, P659, DOI 10.1111/j.1432-1033.1994.00659.x; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	38	39	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1480	1483		10.1074/jbc.272.3.1480	http://dx.doi.org/10.1074/jbc.272.3.1480			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999817	hybrid			2022-12-25	WOS:A1997WD05800015
J	Namchuk, M; Lindsay, L; Turck, CW; Kanaani, J; Baekkeskov, SS				Namchuk, M; Lindsay, L; Turck, CW; Kanaani, J; Baekkeskov, SS			Phosphorylation of serine residues 3, 6, 10, and 13 distinguishes membrane anchored from soluble glutamic acid decarboxylase 65 and is restricted to glutamic acid decarboxylase 65 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; STIFF-MAN SYNDROME; GEL-ELECTROPHORESIS; DISTINCT FORMS; BRAIN; RAT; SEPARATION; GABA; GAD; AUTOANTIBODIES	GAD65, the smaller isoform of the gamma-aminobutyric acid-synthesizing enzyme glutamic acid decarboxylase is detected as an alpha/beta doublet of distinct mobility on SDS-polyacrylamide gel electrophoresis. Glutamic acid decarboxylase (GAD) 65 is reversibly anchored to the membrane of synaptic vesicles in neurons and synaptic like microvesicles in pancreatic beta-cells. Here we demonstrate that GAD65 alpha but not beta is phosphorylated in vivo and in vitro in several cell types. Phosphorylation is not the cause of the alpha/beta heterogeneity but represents a unique post-translational modification of GAD65 alpha. Two-dimensional protein analyses identified five phosphorylated species of three different charges, which are likely to represent mono-, di-, and triphosphorylated GAD65 alpha in different combinations of phosphorylated serines. Phosphorylation of GAD65 alpha was located at serine residues 3, 6, 10, and 13, shown to be mediated by a membrane bound kinase, and distinguish the membrane anchored, and soluble forms of the enzyme. Phosphorylation status does not affect membrane anchoring of GAD65, nor its K-m or V-max for glutamate. The results are consistent with a model in which GAD65 alpha and -beta constitute the two subunits of the native GAD65 dimer, only one of which, alpha, undergoes phosphorylation following membrane anchoring, perhaps to regulate specific aspects of GAD65 function in the synaptic vesicle membrane.	UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Baekkeskov, Steinunn/0000-0003-0878-3188	NIDDK NIH HHS [DK41822] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041822] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AANSTOOT HJ, 1994, DIABETOLOGIA, V37, P917, DOI 10.1007/BF00400948; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BAEKKESKOV S, 1989, DIABETES, V38, P1133, DOI 10.2337/diabetes.38.9.1133; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BAO J, 1995, J BIOL CHEM, V270, P6464, DOI 10.1074/jbc.270.12.6464; Bao Jun, 1994, Journal of Biomedical Science, V1, P237, DOI 10.1007/BF02253308; BAXTER CF, 1976, GABA NERVOUS SYSTEM, P61; BAXTER CF, 1970, HDB NEUROCHEMISTRY, V3, P289; BLINDERMANN JM, 1978, EUR J BIOCHEM, V86, P143, DOI 10.1111/j.1432-1033.1978.tb12293.x; BONZELIUS F, 1994, J CELL BIOL, V127, P1603, DOI 10.1083/jcb.127.6.1603; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BU DF, 1992, P NATL ACAD SCI USA, V89, P2115, DOI 10.1073/pnas.89.6.2115; CHRISTGAU S, 1991, J BIOL CHEM, V266, P21257; CHRISTGAU S, 1992, J CELL BIOL, V118, P309, DOI 10.1083/jcb.118.2.309; COOPER JA, 1991, METHOD ENZYMOL, V201, P251; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; ITOH M, 1981, NEUROCHEM RES, V6, P1283, DOI 10.1007/BF00964349; KARLSEN AE, 1992, DIABETES, V41, P1355, DOI 10.2337/diabetes.41.10.1355; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KIM J, 1994, J EXP MED, V180, P595, DOI 10.1084/jem.180.2.595; KIM J, 1993, DIABETES, V42, P1799, DOI 10.2337/diabetes.42.12.1799; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; Leatherbarrow R. J., 1992, GRAFIT VERSION 3 0; LEGAY F, 1987, J NEUROCHEM, V48, P1022, DOI 10.1111/j.1471-4159.1987.tb05620.x; MARTIN DL, 1991, J NEUROSCI, V11, P2725; MILLER LP, 1980, BRAIN RES BULL, V5, P89, DOI 10.1016/0361-9230(80)90014-3; OKADA Y, 1976, SCIENCE, V194, P620, DOI 10.1126/science.185693; PAN YCE, 1982, INT J PEPT PROT RES, V20, P177; PORTER TG, 1984, J NEUROCHEM, V43, P1464, DOI 10.1111/j.1471-4159.1984.tb05409.x; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; RICHTER W, 1993, P NATL ACAD SCI USA, V90, P2832, DOI 10.1073/pnas.90.7.2832; ROBERTS E, 1986, BENZODIAZEPINE GABA; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHI YG, 1994, J CELL BIOL, V124, P927, DOI 10.1083/jcb.124.6.927; Shi YG, 1995, INT CONGR SER, V1100, P111; SMITH J, 1995, CURRENT PROTOCOLS MO, V2; SOLIMENA M, 1994, J CELL BIOL, V126, P331, DOI 10.1083/jcb.126.2.331; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; SPINK DC, 1985, BIOCHEM J, V231, P695, DOI 10.1042/bj2310695; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x	45	61	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1548	1557		10.1074/jbc.272.3.1548	http://dx.doi.org/10.1074/jbc.272.3.1548			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999827	hybrid			2022-12-25	WOS:A1997WD05800025
J	Dittmer, F; Pohlmann, R; vonFigura, K				Dittmer, F; Pohlmann, R; vonFigura, K			The phosphorylation pattern of oligosaccharides in secreted procathepsin D is glycosylation site-specific and independent of the expression of mannose 6-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL-ENZYMES; DIRECTED MUTAGENESIS; TARGETED DISRUPTION; LIGAND INTERACTIONS; PROTEIN; DETERMINANTS; RECOGNITION; DEFICIENT; CELLS; AMINO	Mammalian cells contain two types of mannose 6-phosphate receptors (MPR), MPRs 46 and 300, that contribute with variable efficiency to the sorting of individual lysosomal proteins. To evaluate the role of phosphorylated oligosaccharides for the sorting efficiency by either of the two receptors, the structure of phosphorylated oligosaccharides on lysosomal proteins escaping sorting in cells lacking MPR 46 and/or MPR 300 was analyzed. Procathepsin D was chosen as a model because it is sorted efficiently via MPR 300 and poorly via MPR 46 and contains a distinct and highly heterogenous mixture of phosphorylated oligosaccharides at either of its two N glycosylation sites, Both MPRs 46 and 300 were found to have a minor but distinct preference for forms of procathepsin D and other lysosomal proteins containing oligosaccharides with two phosphomonoesters. However, the phosphorylation of oligosaccharides in procathepsin D and other lysosomal proteins that escape sorting in control cells or in cells lacking MPR 46 and/or MPR 300 was strikingly similar, and oligosaccharides with two phosphomonoesters represented the major oligosaccharide species. We conclude from these results that the position of the position of the phosphate groups, the structure of the underlying oligosaccharide, and/or the polypeptide backbone of lysosomal proteins have major roles in determining the affinity to MPRs.	UNIV GOTTINGEN,BIOCHEM ABT 2,D-37073 GOTTINGEN,GERMANY	University of Gottingen								CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CONNER GE, 1989, BIOCHEM J, V263, P601, DOI 10.1042/bj2630601; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GIESELMANN V, 1992, J BIOL CHEM, V267, P13262; GOLDBERG DE, 1981, J BIOL CHEM, V258, P3159; HOFLACK B, 1987, J BIOL CHEM, V262, P123; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MunierLehmann H, 1996, J BIOL CHEM, V271, P15166, DOI 10.1074/jbc.271.25.15166; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; SHIPLEY JM, 1993, J BIOL CHEM, V268, P12193; SONDERFELDFRESKO S, 1989, J BIOL CHEM, V264, P7692; TONG PY, 1989, J BIOL CHEM, V264, P7962; TONG PY, 1989, J BIOL CHEM, V264, P7970; VARKI A, 1983, J BIOL CHEM, V258, P2808; VARKI A, 1980, J BIOL CHEM, V255, P847; WAHEED A, 1988, EMBO J, V7, P2351, DOI 10.1002/j.1460-2075.1988.tb03079.x; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEITZ G, 1992, J BIOL CHEM, V267, P10039	26	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					852	858		10.1074/jbc.272.2.852	http://dx.doi.org/10.1074/jbc.272.2.852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995373	hybrid			2022-12-25	WOS:A1997WC04800024
J	McGowan, KM; Police, S; Winslow, JB; Pekala, PH				McGowan, KM; Police, S; Winslow, JB; Pekala, PH			Tumor necrosis factor-alpha regulation of glucose transporter (GLUT1) mRNA turnover - Contribution of the 3'-untranslated region of the GLUT1 message	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA TURNOVER; 3' UNTRANSLATED REGION; PROTEIN-CODING REGION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; SEQUENCE; BRAIN; STABILIZATION; DEGRADATION; DETERMINANT	In the current study we report on the contribution of the GLUT1 3'-untranslated region (UTR) to the stability of the GLUT1 mRNA. To facilitate these investigations, a hybrid construct was prepared by insertion of the GLUT1 3'-UTR into a normally stable reporter gene coding for preproinsulin, The GLUT1 3'-UTR conferred lability to the otherwise long lived construct and transferred an ability to be stabilized in response to treatment with the cytokine, tumor necrosis factor-alpha (TNF), The destabilizing element has been mapped to a region located between bases 2242 and 2347 of the GLUT1 3'-UTR; this same region also mediates the stabilization response to TNF, In vitro RNA protein binding assays using protein extracts from control and TNF-treated cells demonstrated that two proteins, one of 37 kDa and the other of 40 kDa, recognized sequence elements within the stability-determining region and were up-regulated in response to TNF treatment, The RNA-binding activity of these proteins coincides with the stabilization of the GLUT1 message, suggesting that they may be involved in regulation of the turnover of this message.	E CAROLINA UNIV,SCH MED,DEPT BIOCHEM,GREENVILLE,NC 27858	University of North Carolina; East Carolina University					NIGMS NIH HHS [GM32892] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032892] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1993, J BIOL CHEM, V268, P19161; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; BEUTLER B, 1992, AM J MED SCI, V303, P129, DOI 10.1097/00000441-199202000-00015; BINDER R, 1994, EMBO J, V13, P1969, DOI 10.1002/j.1460-2075.1994.tb06466.x; BOADO RJ, 1993, J NEUROCHEM, V60, P2290, DOI 10.1111/j.1471-4159.1993.tb03516.x; BREWER G, 1990, METHOD ENZYMOL, V181, P202; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHEN CYA, 1992, MOL CELL BIOL, V12, P5748, DOI 10.1128/MCB.12.12.5748; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FEINBERG AP, 1985, ANAL BIOCHEM, V132, P6; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUNKEL TA, 1994, METHOD ENZYMOL, V104, P125; MAHER F, 1990, BIOCHEM BIOPH RES CO, V171, P210, DOI 10.1016/0006-291X(90)91378-6; MAHER F, 1994, FASEB J, V8, P1003, DOI 10.1096/fasebj.8.13.7926364; MCCALL AL, 1982, P NATL ACAD SCI-BIOL, V79, P5406, DOI 10.1073/pnas.79.17.5406; McGowan K, 1996, BIOCHEM BIOPH RES CO, V221, P42, DOI 10.1006/bbrc.1996.0541; MCGOWAN KM, 1995, PHARMACOL THERAPEUT, V66, P465, DOI 10.1016/0163-7258(95)00007-4; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; PARDRIDGE WM, 1990, DIABETES, V39, P1040, DOI 10.2337/diabetes.39.9.1040; PRYHUBER GS, 1994, AM J PHYSIOL, V267, pL16, DOI 10.1152/ajplung.1994.267.1.L16; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; Sambrook J., 2002, MOL CLONING LAB MANU; SANDOUK T, 1993, ENDOCRINOLOGY, V133, P352, DOI 10.1210/en.133.1.352; SCOTTO L, 1993, MOL CELL BIOL, V13, P3588, DOI 10.1128/MCB.13.6.3588; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHETTY M, 1992, AM J PHYSIOL, V262, pC527, DOI 10.1152/ajpcell.1992.262.2.C527; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; WHITE MK, 1994, ONCOL REP, V1, P17; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232	36	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1331	1337		10.1074/jbc.272.2.1331	http://dx.doi.org/10.1074/jbc.272.2.1331			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995440	hybrid			2022-12-25	WOS:A1997WC04800091
J	Methot, N; Rom, E; Olsen, H; Sonenberg, N				Methot, N; Rom, E; Olsen, H; Sonenberg, N			The human homologue of the yeast Prt1 protein is an integral part of the eukaryotic initiation factor 3 complex and interacts with p170	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATION INITIATION; FACTOR EIF-3; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; RABBIT RETICULOCYTES; BINDING-PROTEIN; CROSS-LINKING; PURIFICATION; SEQUENCE; SUBUNIT	Eukaryotic initiation factor 3 (eIF3) is a large multisubunit complex that stabilizes the ternary complex, eIF2 . GTP . tRNA(i)(Met), and promotes mRNA binding to the 40 S ribosomal subunit. eIF3 also functions as a ribosome subunit anti-association factor. The molecular mechanisms by which eIF3 exerts these functions are poorly understood. We describe here the cloning of the cDNA encoding the human homologue of the yeast eIF3 subunit Prt1. The human PRT1 cDNA encodes a protein of predicted molecular mass of 98.9 kDa that migrates at 116 kDa on SDS polyacrylamide gels. Human and yeast Prt1 share 31% identity and 50% similarity at the amino acid level. The homology is distributed throughout the entire protein, except for the amino terminus, and is particularly high in the central portion of the protein, which contains a putative RNA recognition motif. hPrt1 is recognized by an antibody raised against eIF3, and an affinity-purified antibody to recombinant hPrt1 recognizes a protein migrating at 116 kDa in a purified eIF3 preparation. Far Western analysis shows that hPrt1 interacts directly with the p170 subunit of eIF3. Mapping studies identify the RNA recognition motif as the region required for association with p170. Taken together, these experiments demonstrate that hPrt1 is a component of eIF3. Our data, combined with those of Hershey and co-workers, suggest that mammalian eIF3 is composed of at least 10 subunits: p170, p116 (hPrt1), p110, p66, p48, p47, p44, p40, p36, and p35.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; HUMAN GENOME SCI INC,ROCKVILLE,MD 20850	McGill University; McGill University; GlaxoSmithKline; Human Genome Sciences Inc								ADAMS MD, 1995, NATURE, V377, P3; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; BEHLKE J, 1986, EUR J BIOCHEM, V157, P523, DOI 10.1111/j.1432-1033.1986.tb09698.x; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; Benne R, 1979, Methods Enzymol, V60, P15; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; DANAIE P, 1995, J BIOL CHEM, V270, P4288, DOI 10.1074/jbc.270.9.4288; EVANS DRH, 1995, MOL CELL BIOL, V15, P4525; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FEINBERG B, 1982, J BIOL CHEM, V257, P846; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GOUMANS H, 1980, BIOCHIM BIOPHYS ACTA, V608, P39, DOI 10.1016/0005-2787(80)90131-8; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; HANICJOYCE PJ, 1987, J BIOL CHEM, V262, P2845; HANNIG EM, 1995, BIOESSAYS, V17, P915, DOI 10.1002/bies.950171103; HARTWELL LH, 1968, J BACTERIOL, V96, P1664, DOI 10.1128/JB.96.5.1664-1671.1968; HARTWELL LH, 1969, P NATL ACAD SCI USA, V62, P468, DOI 10.1073/pnas.62.2.468; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; MENGOD G, 1985, BIOCHIM BIOPHYS ACTA, V825, P169, DOI 10.1016/0167-4781(85)90101-0; Merrick WC., 1996, TRANSLATION CONTROL, P31; METHOT N, 1994, MOL CELL BIOL, V14, P2307, DOI 10.1128/MCB.14.4.2307; Methot N, 1996, MOL CELL BIOL, V16, P5328; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; SAFER B, 1976, P NATL ACAD SCI USA, V73, P2584, DOI 10.1073/pnas.73.8.2584; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WESTERMANN P, 1984, NUCLEIC ACIDS RES, V12, P8887, DOI 10.1093/nar/12.23.8887	43	65	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1110	1116		10.1074/jbc.272.2.1110	http://dx.doi.org/10.1074/jbc.272.2.1110			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995410	hybrid			2022-12-25	WOS:A1997WC04800061
J	Pierce, KL; Baily, TJ; Hoyer, PB; Gil, DW; Woodward, DF; Regan, J				Pierce, KL; Baily, TJ; Hoyer, PB; Gil, DW; Woodward, DF; Regan, J			Cloning of a carboxyl-terminal isoform of the prostanoid FP receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EP3 SUBTYPE; PROSTAGLANDIN E(2); MOLECULAR-CLONING; CORPUS-LUTEUM; 2 ISOFORMS; EXPRESSION; CDNA; TAIL; STIMULATION; INHIBITION	An FP prostanoid receptor isoform, which appears to arise from alternative mRNA splicing, has been cloned from a mid cycle ovine large cell corpus luteum library. The isoform, named the FPB receptor, is identical to the original isoform, the FPA, throughout the seven transmembrane domains, but diverges nine amino acids into the carboxyl terminus. In contrast to FPA, whose carboxyl terminus continues for another 46 amino acids beyond the nine shared residues, the FPB terminates after only one amino acid. The FPA isoform appears to arise by the failure to utilize a potential splice site, while a 3.2-kilobase pair intron is spliced out from the FP gene to generate the FPB isoform mRNA. The two isoforms have indistinguishable radioligand binding properties, but seem to differ in functional coupling to phosphatidylinositol hydrolysis. Thus, in COS-7 cells transiently transfected with either the FPA or the FPB receptor cDNAs, prostaglandin F-2 alpha stimulates inositol phosphate accumulation to the same absolute maximum, but the basal level of inositol phosphate accumulation is approximately 1.3-fold higher in cells transfected with the FPB as compared with cells transfected with the FPA isoform. Using the polymerase chain reaction, mRNA encoding the FPB isoform was identified in the ovine corpus luteum.	UNIV ARIZONA,DEPT PHYSIOL,TUCSON,AZ 85721; ALLERGAN PHARMACEUT INC,DEPT BIOL SCI,IRVINE,CA 92713	University of Arizona; AbbVie; Allergan	Pierce, KL (corresponding author), UNIV ARIZONA,COLL PHARM,DEPT PHARMACOL & TOXICOL,TUCSON,AZ 85721, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026778] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY009355] Funding Source: NIH RePORTER; NEI NIH HHS [EY09355] Funding Source: Medline; NICHD NIH HHS [HD26778, HD00907] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; AN SZ, 1994, BIOCHEMISTRY-US, V33, P14496, DOI 10.1021/bi00252a016; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; GRAVES PE, 1995, ENDOCRINOLOGY, V136, P3430, DOI 10.1210/en.136.8.3430; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MCCRACKEN JA, 1970, J CLIN ENDOCR METAB, V30, P544, DOI 10.1210/jcem-30-4-544; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Negishi M, 1996, FEBS LETT, V386, P165, DOI 10.1016/0014-5793(96)00354-7; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NEGISHI M, 1993, J BIOL CHEM, V268, P26067; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PIERCE KL, 1995, TRENDS PHARMACOL SCI, V16, P253, DOI 10.1016/S0165-6147(00)89035-5; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REGAN JW, 1994, BRIT J PHARMACOL, V112, P377, DOI 10.1111/j.1476-5381.1994.tb13082.x; REGAN JW, 1994, MOL PHARMACOL, V46, P213; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; SCHMID A, 1995, EUR J BIOCHEM, V228, P23, DOI 10.1111/j.1432-1033.1995.tb20223.x; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W	24	83	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					883	887		10.1074/jbc.272.2.883	http://dx.doi.org/10.1074/jbc.272.2.883			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995377	hybrid			2022-12-25	WOS:A1997WC04800028
J	Lecroisey, A; Martineau, P; Hofnung, M; Delepierre, M				Lecroisey, A; Martineau, P; Hofnung, M; Delepierre, M			NMR studies on the flexibility of the poliovirus C3 linear epitope inserted into different sites of the maltose-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-TRANSPORT; ESCHERICHIA-COLI; IMMUNOGENICITY; MACROMOLECULES; PURIFICATION; RECOGNITION; EXPRESSION; ANTIBODIES; RESOLUTION; RESIDUES	A set of permissive positions that tolerate insertions/deletions without major deleterious consequences for the binding activity of the protein was previously identified in the maltose-binding protein, The C3 epitope from poliovirus VP1 protein ((93)DNPASTTNKDK(103)) was inserted into eight of these positions and two nonpermissive control sites, NMR studies were performed on the MalE protein, the insertion/deletion mutants, and the C3MalE hybrids to selectively determine the flexible regions in these proteins. Comparison of the C3 epitope mobility in the different hybrid proteins indicates that, whatever its insertion site and independently from the specific sequences of its linkers, the epitope is mostly flexible, The vector protein was shown to unfold partially only in the two C3MalE hybrids that correspond to nonpermissive positions, For one of them (insertion at site 339), both sides of the insert are flexible, and at most one side for all the other hybrids, This result correlates with the antigenicity data on the inserted epitope (Martineau, P., Leclerc, C., and Hofnung, M. (1997) Mol. Immunol, in press.	INST PASTEUR,CNRS URA 1444,UNITE PROGRAMMAT MOL & TOXICOL GENET,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lecroisey, A (corresponding author), INST PASTEUR,CNRS URA 1129,LAB RESONANCE MAGNET NUCL,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		Martineau, Pierre/N-4386-2017	Martineau, Pierre/0000-0002-7993-7183				ARNON R, 1969, P NATL ACAD SCI USA, V62, P163, DOI 10.1073/pnas.62.1.163; AUSUBEL FM, 1993, CURRENT PROTOCOLS MO, P451; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEDOUELLE H, 1988, EUR J BIOCHEM, V171, P541, DOI 10.1111/j.1432-1033.1988.tb13823.x; BETTON JM, 1993, FEBS LETT, V325, P34, DOI 10.1016/0014-5793(93)81409-S; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DUPLAY P, 1987, J MOL BIOL, V194, P663, DOI 10.1016/0022-2836(87)90243-9; DUPLAY P, 1984, J BIOL CHEM, V259, P606; FERENCI T, 1978, FEBS LETT, V94, P213, DOI 10.1016/0014-5793(78)80940-5; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HOFNUNG M, 1988, B I PASTEUR, V86, P95; HOGLE JM, 1985, SCIENCE, V229, P1358, DOI 10.1126/science.2994218; JARDETZKY O, 1981, NMR MOL BIOL, P448; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LECLERC C, 1990, J IMMUNOL, V144, P3174; MARTINEAU P, 1991, BIO-TECHNOL, V9, P170, DOI 10.1038/nbt0291-170; MARTINEAU P, 1992, GENE, V113, P35, DOI 10.1016/0378-1119(92)90667-E; MARTINEAU P, 1990, J MOL BIOL, V214, P337, DOI 10.1016/0022-2836(90)90165-I; MILLER JH, 1972, EXPT MOL GENETICS, P11724; OCALLAGHAN D, 1990, RES MICROBIOL, V141, P963, DOI 10.1016/0923-2508(90)90136-E; RODSETH L, 1992, THESIS RICE U; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; STAHL S, 1989, J IMMUNOL METHODS, V124, P43, DOI 10.1016/0022-1759(89)90184-1; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; VUILLEMIER S, 1992, STRUCTURE ANTIGENS, P79; WIEN MW, 1995, NAT STRUCT BIOL, V2, P232, DOI 10.1038/nsb0395-232; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P17; WYCHOWSKI C, 1983, EMBO J, V2, P2019, DOI 10.1002/j.1460-2075.1983.tb01694.x	32	9	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					362	368						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995270				2022-12-25	WOS:A1997WA56400057
J	RodriguezLopez, JN; Smith, AT; Thorneley, RNF				RodriguezLopez, JN; Smith, AT; Thorneley, RNF			Effect of distal cavity mutations on the binding and activation of oxygen by ferrous horseradish peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; LIGAND-BINDING; COMPOUND-I; LIGNIN PEROXIDASE; HYDROGEN-PEROXIDE; CARBON-MONOXIDE; HEME POCKET; KINETICS; SITE; MYOGLOBIN	Mutations have been introduced at residues Arg-38 or His-42 in horseradish peroxidase isoenzyme C (HRPC) in order to probe the role of these key distal residues in the reaction of ferrous HRPC with dioxygen, The association and dissociation rate constants for dioxygen binding to His-42 --> Leu, His-42 --> Arg, Arg-38 --> Leu, Arg-38 --> Lys, Arg-38 --> Ser, and Arg-38 --> Gly variants have been measured using stopped-flow spectrophotometry, Replacement of His-42 by Leu or Arg increases the oxygen binding rate constant by less than an order of magnitude, whereas changing the polar distal Arg-38 causes increases of more than 2 orders, These results demonstrate that His-42 and Arg-38 impede the binding of dioxygen to ferrous HRPC, presumably by steric and/or electrostatic interactions in the distal heme cavity. Recombinant HRPC oxyperoxidase reverted slowly to the ferric state with no spectrophotometrically detectable intermediates and with an apparent first-order rate constant of 9.0 x 10(-3) s(-1), which is essentially the same as that for the native, glycosylated enzyme, This reaction was accelerated when His-42 was replaced by Leu or Arg (k(decay) = 0.10 and 0.07 s(-1), respectively) presumably due to the loss of the hydrogen bond between the His-42 imidazole and the bound dioxygen. Substitution of Arg-38 by Leu, Lys, or Gly also produced a less stable oxyperoxidase (k(decay) = 0.22, 0.20, and 0.58 s(-1) respectively), However, with the Arg-38 --> Ser variant, a transient intermediate, proposed to be a ferric-superoxide complex, was detected by rapid-scan stopped-flow spectrophotometry during the conversion of oxyperoxidase to the ferric state, This variant also exhibits an unusually high affinity for dioxygen, It is proposed that Arg-38 interacts with the bound dioxygen to promote superoxide character, thereby stabilizing the oxyperoxidase state and making the binding of dioxygen to ferrous HRPC essentially irreversible, We conclude that Arg-38 and His-42 not only promote the heterolytic cleavage of bound hydrogen peroxide to form compound I but also decrease the lability of the ferrous enzyme-dioxygen complex in order to suppress the formation of the inactive ferrous state.	JOHN INNES CTR PLANT SCI RES,NITROGEN FIXAT LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND; UNIV SUSSEX,DEPT BIOCHEM,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Sussex			Neptuno, Jose/F-5012-2016	Rodriguez-Lopez, Jose Neptuno/0000-0001-6863-1173; Smith, Andrew/0000-0002-0926-1878				BAECK HK, 1992, J AM CHEM SOC, V114, P718; BAECK HK, 1989, BIOCHEMISTRY-US, V28, P5714; BALASUBRAMANIAN S, 1993, P NATL ACAD SCI USA, V90, P4718, DOI 10.1073/pnas.90.10.4718; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; CREIGHTON TE, 1983, PROTEINS STRUCTURES, P242; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; ERMAN JE, 1992, J AM CHEM SOC, V114, P6592, DOI 10.1021/ja00042a068; Furhop J., 1975, PORPHYRINS METALLOPO, P757; Gazaryan IG, 1996, BIOCHEM J, V313, P841, DOI 10.1042/bj3130841; HENRIKSEN A, 1995, ACTA CRYSTALLOGR D, V51, P121, DOI 10.1107/S0907444994008723; KEILIN D, 1951, BIOCHEM J, V49, P88, DOI 10.1042/bj0490088; MEUNIER B, 1995, BIOCHEMISTRY-US, V34, P14687, DOI 10.1021/bi00045a009; MILLER MA, 1992, BIOCHEMISTRY-US, V31, P2789, DOI 10.1021/bi00125a020; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MIMS MP, 1983, J BIOL CHEM, V258, P4219; MYLRAJAN M, 1990, BIOCHEMISTRY-US, V29, P9617, DOI 10.1021/bi00493a016; NILSSON O, 1993, PLANT J, V3, P681, DOI 10.1111/j.1365-313X.1993.00681.x; PARKHURST LJ, 1980, BIOCHEMISTRY-US, V19, P2688, DOI 10.1021/bi00553a023; PEISACH J, 1968, J BIOL CHEM, V243, P1871; PHELPS CF, 1974, BIOCHEM J, V141, P265, DOI 10.1042/bj1410265; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SMERDON SJ, 1995, BIOCHEMISTRY-US, V34, P8715, DOI 10.1021/bi00027a022; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; SMITH AT, 1990, J BIOL CHEM, V265, P13335; SMITH AT, 1993, PLANT PEROXIDASES BI, P159; SMULEVICH G, 1994, BIOCHEMISTRY-US, V33, P7398, DOI 10.1021/bi00189a046; TAMURA M, 1972, J BIOCHEM-TOKYO, V71, P311, DOI 10.1093/oxfordjournals.jbchem.a129768; Tsaprailis G., 1995, ADV INORG CHEM, V43, P79; TUCKER PW, 1978, P NATL ACAD SCI USA, V75, P1076, DOI 10.1073/pnas.75.3.1076; VANWART HE, 1985, J BIOL CHEM, V260, P8372; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; WARIISHI H, 1990, J BIOL CHEM, V265, P2070; WELINDER KG, 1985, EUR J BIOCHEM, V151, P497, DOI 10.1111/j.1432-1033.1985.tb09129.x; WELINDER KG, 1977, EUR J BIOCHEM, V73, P353, DOI 10.1111/j.1432-1033.1977.tb11325.x; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; WITTENBERG BA, 1968, J BIOL CHEM, V243, P1863; WITTENBERG JB, 1967, J BIOL CHEM, V242, P626; [No title captured]	42	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					389	395						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995273				2022-12-25	WOS:A1997WA56400060
J	Liu, XD; McCarron, RC; Nordin, JH				Liu, XD; McCarron, RC; Nordin, JH			A cysteine protease that processes insect vitellin - Purification and partial characterization of the enzyme and the proenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLATTELLA-GERMANICA VITELLIN; YOLK DEGRADATION; CATHEPSIN-B; TICK EGGS; PAPAIN PRECURSOR; SUGGESTED ROLE; BOMBYX-MORI; PROTEINASE; ACIDIFICATION; OOCYTES	A cysteine protease that initiates degradation of vitellin (Vt) in the orthopteran Blattella germanica, and its proprotease precursor, were purified from yolk and partially characterized. The protease, purified 300-fold, contains three peptides of M(r) 27,000, 29,000, and 31,000, A comparison of the purified enzyme's action pattern on Vt in vivo and in vitro confirmed its role in Vt processing, Protease deficient yolk (day 0 postovulation) contained peptides of M(r) 35,500, 37,000, 39,000, and 41,000, which were absent from yolk with protease activity, These were replaced by three peptides of approximately M(r) 29,000, at days 2-3, the same time in development that protease expression and acidification of yolk granules occur (Nordin, J. H., Beaudoin, E. L., and Liu, X. (1991) Arch, Insect Biochem. Physiol. 18, 177-192), Acidification of purified proprotease converted it to three peptides of approximately M(r) 29,000 with cysteine protease activity, This conversion also required participation of a cysteine protease. Activated proprotease had the same pH activity profile, susceptibility to inhibitors, and cathepsin classification (L) as the protease, These results indicate that the Vt-processing protease is derived from a proprotease, which is activated in vivo by a developmentally regulated decrease in intragranular pH.	UNIV MASSACHUSETTS,DEPT BIOCHEM & MOL BIOL,AMHERST,MA 01003; UNIV MASSACHUSETTS,GRAD PROGRAM MOL & CELLULAR BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								ARMANT DR, 1986, DEV BIOL, V113, P342, DOI 10.1016/0012-1606(86)90169-7; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BOROVSKY D, 1988, ARCH INSECT BIOCHEM, V8, P249, DOI 10.1002/arch.940080406; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKLEHURST K, 1973, NATURE-NEW BIOL, V242, P167, DOI 10.1038/newbio242167a0; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTTERS TD, 1981, BIOCHIM BIOPHYS ACTA, V640, P655, DOI 10.1016/0005-2736(81)90096-1; CHEN JS, 1995, J CELL BIOCH S, V215; CULLEN BM, 1992, BIOCHEM J, V283, P461, DOI 10.1042/bj2830461; DELEPELAIRE P, 1989, J BIOL CHEM, V264, P9083; Dunn BM., 1989, PROTEOLYTIC ENZYMES, P57; FAGOTTO F, 1994, J CELL BIOL, V125, P1047, DOI 10.1083/jcb.125.5.1047; FAGOTTO F, 1994, J CELL SCI, V107, P3325; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P237, DOI 10.1002/arch.940140404; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P217, DOI 10.1002/arch.940140403; FAGOTTO F, 1991, DEV GROWTH DIFFER, V33, P57; FAUSTO AM, 1994, DEV GROWTH DIFFER, V36, P197; GIORGI F, 1994, J INSECT PHYSIOL, V40, P1077, DOI 10.1016/0022-1910(94)90061-2; IKEDA M, 1990, INSECT BIOCHEM, V20, P725, DOI 10.1016/0020-1790(90)90087-B; KONIG R, 1988, INSECT BIOCHEM, V18, P395, DOI 10.1016/0020-1790(88)90055-8; KUNKEL JG, 1966, J INSECT PHYSIOL, V12, P227, DOI 10.1016/0022-1910(66)90137-5; KUNKEL JG, 1976, J INSECT PHYSIOL, V22, P809, DOI 10.1016/0022-1910(76)90248-1; KUNKEL JG, 1985, COMPREHENSIVE INSECT, V1, P83; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU X, 1994, FASEB J, V8, pA1374; MALLYA SK, 1992, J CELL BIOL, V117, P1211, DOI 10.1083/jcb.117.6.1211; MEDINA M, 1989, INSECT BIOCHEM, V19, P687, DOI 10.1016/0020-1790(89)90105-4; MEDINA M, 1988, ARCH BIOCHEM BIOPHYS, V263, P355, DOI 10.1016/0003-9861(88)90646-7; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NAGAO E, 1987, J LIPID RES, V28, P450; NEURATH H, 1984, SCIENCE, V224, P355; NORDIN JH, 1991, ARCH INSECT BIOCHEM, V18, P177, DOI 10.1002/arch.940180306; NORDIN JH, 1990, ARCH INSECT BIOCHEM, V15, P119, DOI 10.1002/arch.940150302; NORDIN JH, 1990, MOL INSECT SCI, P341; NUSSENZVEIG RH, 1992, ARCH INSECT BIOCHEM, V21, P253, DOI 10.1002/arch.940210402; Postlethwait J H, 1985, Dev Biol (N Y 1985), V1, P85; PURCELL JP, 1988, ARCH INSECT BIOCHEM, V8, P39, DOI 10.1002/arch.940080105; PURCELL JP, 1988, ARCH INSECT BIOCHEM, V9, P237, DOI 10.1002/arch.940090307; RAIKHEL AS, 1992, ANNU REV ENTOMOL, V37, P217, DOI 10.1146/annurev.en.37.010192.001245; RIBOLLA PEM, 1993, INSECT BIOCHEM MOLEC, V23, P217, DOI 10.1016/0965-1748(93)90002-A; RIBOLLA PEM, 1995, INSECT BIOCHEM MOLEC, V25, P1011, DOI 10.1016/0965-1748(95)00036-U; RICH DH, 1986, BIOCHEM J, V235, P731, DOI 10.1042/bj2350731; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SCHWARTZ LM, 1990, NEURON, V5, P411, DOI 10.1016/0896-6273(90)90080-Y; STORELLA JR, 1979, AM ZOOL, V19, P999; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; UDVARDY A, 1993, J BIOL CHEM, V268, P9055; VERNET T, 1991, J BIOL CHEM, V266, P21451; VERNET T, 1990, J BIOL CHEM, V265, P16661; WILDE CG, 1990, J BIOL CHEM, V265, P2038; WOJCHOWSKI DM, 1986, DEV BIOL, V116, P422, DOI 10.1016/0012-1606(86)90143-0; YAMAMOTO Y, 1993, COMP BIOCHEM PHYS B, V106, P35, DOI 10.1016/0305-0491(93)90004-O; YAMAMOTO Y, 1994, J INSECT PHYSIOL, V40, P447, DOI 10.1016/0022-1910(94)90163-5; YAMASHITA M, 1990, COMP BIOCHEM PHYS B, V96, P247, DOI 10.1016/0305-0491(90)90371-Y	57	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33344	33351		10.1074/jbc.271.52.33344	http://dx.doi.org/10.1074/jbc.271.52.33344			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969194	hybrid			2022-12-25	WOS:A1996WA71300028
J	Bhat, R; Weaver, JA; Wagner, C; Bodwell, JE; Bresnick, E				Bhat, R; Weaver, JA; Wagner, C; Bodwell, JE; Bresnick, E			ATP depletion affects the phosphorylation state, ligand binding, and nuclear transport of the 4 S polycyclic aromatic hydrocarbon-binding protein in rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE N-METHYLTRANSFERASE; HIGH-AFFINITY BINDING; GLUCOCORTICOID RECEPTORS; DNA-BINDING; DEPENDENT PHOSPHORYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; HORMONE-BINDING; LIVER CYTOSOL; C-JUN	In the rat, cytochrome P4501A1 gene expression is thought to be regulated by several trans-acting factors including the 4 S polycyclic aromatic hydrocarbon (PAH)-binding protein, Phosphorylation and dephosphorylation have been suggested to influence the function of many cytosolic receptors and transcription factors, The ATP level within H4IIE rat hepatoma cells could be depleted by treatment with sodium azide or 2,4-dinitrophenol; restoration of the original ATP levels occurred with addition of glucose to the cell culture, ATP depletion reduced the phosphate content of the 4 S protein by similar to 25-30%, which lowered the binding of benzo[a]pyrene (B[a]P) to the 4 S protein by >60%. This effect could not be reversed by the addition of ATP to the binding reaction mixtures, Alkaline phosphatase treatment of the purified 4 S protein in a cell-free system also reduced the B[a]P binding to the protein, Cells treated with a protein phosphatase inhibitor, okadaic acid, and a protein kinase inhibitor, staurosporin, affected the B[a]P binding of the 4 S protein positively and negatively, respectively,, These data suggested that phosphorylation is involved in the interaction of the 4 S protein with the PAH. The nuclear translocation of the predominantly cytosolic binding protein has been investigated after ligand binding, Western blots with the immunopurified 4 S PAH binding protein from cytosolic and nuclear lysates showed significant differences in the distribution of the 4 S receptor between cytosolic and nuclear compartments in control and ATP-depleted cells, Ligand binding stimulated the movement of the receptor into the nucleus, which was completely blocked by reducing the intracellular ATP concentration, These findings provide new information on the role of ATP and phosphorylation on the interaction of B[a]P with 4 S PAH-binding protein and its nuclear translocation.	UNIV MASSACHUSETTS, MED CTR, DEPT MOL PHARMACOL & TOXICOL, WORCESTER, MA 01655 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; DARTMOUTH COLL, HITCHCOCK MED CTR, SCH MED, DEPT PHYSIOL, HANOVER, NH 03756 USA	University of Massachusetts System; University of Massachusetts Worcester; Vanderbilt University; Dartmouth College					NCI NIH HHS [CA36105] Funding Source: Medline; NIDDK NIH HHS [DK45337] Funding Source: Medline; NIEHS NIH HHS [ES03980] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003980] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; BOHMANN D, 1990, CANCER CELL-MON REV, V2, P337; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; COLLINS S, 1984, MOL PHARMACOL, V26, P353; CONNEY AH, 1967, PHARMACOL REV, V19, P317; COOK RJ, 1984, P NATL ACAD SCI-BIOL, V81, P3631, DOI 10.1073/pnas.81.12.3631; FISCHBECK KH, 1984, EXP NEUROL, V83, P577, DOI 10.1016/0014-4886(84)90125-0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GIBBONS JA, 1992, CHEM-BIOL INTERACT, V83, P203, DOI 10.1016/0009-2797(92)90098-6; GIBBONS JA, 1990, TOXICOLOGIST, V10, P193; GILLETTE JR, 1974, ANNU REV PHARMACOL, V14, P271, DOI 10.1146/annurev.pa.14.040174.001415; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; HEINTZ NH, 1981, CANCER RES, V41, P1794; HOLDER GM, 1981, CANCER RES, V41, P4408; HOUSER WH, 1986, ARCH BIOCHEM BIOPHYS, V251, P361, DOI 10.1016/0003-9861(86)90083-4; HOUSER WH, 1985, BIOCHEMISTRY-US, V24, P7839, DOI 10.1021/bi00347a050; HOUSER WH, 1987, ARCH BIOCHEM BIOPHYS, V259, P215, DOI 10.1016/0003-9861(87)90488-7; HU LM, 1994, J BIOL CHEM, V269, P6571; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MENDEL DB, 1990, PROG CLIN BIOL RES, V322, P97; MENDEL DB, 1986, NATURE, V324, P478, DOI 10.1038/324478a0; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MYLIN LM, 1990, MOL CELL BIOL, V10, P4623, DOI 10.1128/MCB.10.9.4623; NEBERT DW, 1988, GENES ENCODING DRUG, P45; NIELSEN CJ, 1977, P NATL ACAD SCI USA, V74, P1398, DOI 10.1073/pnas.74.4.1398; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; OGAWA H, 1982, J BIOL CHEM, V257, P3447; ORTI E, 1989, J BIOL CHEM, V264, P9728; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAHA A, 1994, J BIOL CHEM, V269, P5750; RAHA A, 1995, ARCH BIOCHEM BIOPHYS, V322, P395, DOI 10.1006/abbi.1995.1480; RHIS HP, 1991, EMBO J, V10, P633; SLOMAN JC, 1976, BIOCHIM BIOPHYS ACTA, V428, P403, DOI 10.1016/0304-4165(76)90048-9; SONG O, 1990, GENE DEV, V5, P741; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; TIERNEY B, 1980, ARCH BIOCHEM BIOPHYS, V200, P513, DOI 10.1016/0003-9861(80)90383-5; TIERNEY B, 1983, ARCH BIOCHEM BIOPHYS, V225, P826, DOI 10.1016/0003-9861(83)90095-4; WAGNER C, 1989, J BIOL CHEM, V264, P9638; XU LC, 1990, BIOCHEM PHARMACOL, V40, P1399; ZYTKOVICZ TH, 1982, CANCER RES, V42, P4387	52	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32551	32556		10.1074/jbc.271.51.32551	http://dx.doi.org/10.1074/jbc.271.51.32551			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955080	hybrid			2022-12-25	WOS:A1996VZ37300015
J	Li, JZ; Smithgall, TE				Li, JZ; Smithgall, TE			Co-expression with BCR induces activation of the FES tyrosine kinase and phosphorylation of specific N-terminal BCR tyrosine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; ABL ONCOGENE; HEMATOPOIETIC-CELLS; GENE-PRODUCT; SH2 DOMAIN; RAS; TRANSFORMATION; ONCOPROTEINS; ASSOCIATION; FIBROBLASTS	The human BCR gene encodes a protein with serine/threonine kinase activity and regulatory domains for the small G-proteins RAC and CDC42. Previous work in our laboratory has established that BCR is a substrate for c-FES, a non-receptor tyrosine kinase linked to myeloid growth and differentiation. Tyrosine phosphorylation led to the association of BCR with the RAS guanine nucleotide exchange complex GRB2-SOS in vivo via the GRB2 SH2 domain, linking BCR to RAS signaling (Maru, Y., Peters, K. L., Afar, D. E. H., Shibuya, M., Witte, O. N., and Smithgall, T. E. (1995) Mol. Cell. Biol. 15, 835- 842). In the present study, we demonstrate that BCR Tyr-246 and at least one of the closely spaced tyrosine residues, Tyr-279, Tyr-283, and Tyr-289 (3Y cluster), are phosphorylated by FES both in vitro and in P-32(i)-labeled cells. Mutagenesis of BCR Tyr-177 to Phe completely abolished FES-induced BCR binding to the GRB2 SH2 domain, identifying Tyr-177 as an additional phosphorylation site for FES. Co-expression of BCR and FES in human 293T cells stimulated the tyrosine autophosphorylation of FES. By contrast, tyrosine phosphorylation of BCR by FES suppressed BCR serine/threonine kinase activity toward the 14-3-3 protein and BCR substrate, BAP-1. These data show that tyrosine phosphorylation by FES affects the interaction of BCR with multiple signaling partners and suggest a general role for BCR in non-receptor protein-tyrosine kinase regulation and signal transduction.	UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NCI NIH HHS [CA58667, P30 CA36727] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058667, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREER PA, 1988, MOL CELL BIOL, V8, P578, DOI 10.1128/MCB.8.2.578; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HJERMSTAD SJ, 1993, BIOCHEMISTRY-US, V32, P10519, DOI 10.1021/bi00090a031; HJERMSTAD SJ, 1993, ONCOGENE, V8, P2283; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MARU Y, 1995, MOL CELL BIOL, V15, P835; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CANCER SURV, V15, P37; TIMMONS MS, 1989, ONCOGENE, V4, P559; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X	31	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32930	32936		10.1074/jbc.271.51.32930	http://dx.doi.org/10.1074/jbc.271.51.32930			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955135	hybrid			2022-12-25	WOS:A1996VZ37300070
J	Sahni, M; Zhou, XM; Bakiri, L; Schlessinger, J; Baron, R; Levy, JB				Sahni, M; Zhou, XM; Bakiri, L; Schlessinger, J; Baron, R; Levy, JB			Identification of a novel 135-kDa Grb2-binding protein in osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; SRC HOMOLOGY-3 DOMAINS; DNA-BINDING PROTEIN; C-CBL PROTOONCOGENE; EXPRESS HIGH-LEVELS; SH3 DOMAINS; SIGNAL TRANSDUCTION	The tyrosine kinase receptor for macrophage colony-stimulating factor and the non-receptor tyrosine kinase c-Src play critical roles in osteoclast differentiation and function, Since the ubiquitously expressed adaptor protein Grb2 plays an important role in several tyrosine kinase signal transduction pathways, we used a filter binding assay to identify osteoclast proteins that bind to Grb2. In osteoclasts, there were three major Grb2-binding proteins, two of which, mSos and c-Cbl (p120), have been previously identified as Grb2-binding proteins in many cell types, The third protein, p135, had a restricted pattern of expression and was present at high levels in authentic osteoclasts and osteoclast-like cells formed in an in vitro co-culture system, In addition to binding Grb2 in the filter binding assay, p135 was isolated in complexes with endogenous Grb2 from osteoclast cell extracts, The association of p135 and Grb2 was dependent on an intact Src homology 3 domain and furthermore, was shown to preferentially interact with the N-terminal Src homology 3 domain of Grb2, which is similar to the interaction of mSos and Grb2 in other cell types, p135 was not recognized by antibodies against several known Grb2-binding proteins and thus may be a novel Grb2-binding protein.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT ORTHOPED, NEW HAVEN, CT 06510 USA; ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA; NYU, MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA	Yale University; Yale University; Takeda Pharmaceutical Company Ltd; Takeda Oncology; New York University			Bakiri, Latifa/AAP-1674-2020; Bakiri, Latifa/N-5780-2014	bakiri, latifa/0000-0002-6300-2420	NIAMS NIH HHS [1F33AR08261-01, 5-R01-AR42927-01-02] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042927, F33AR008261] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AKATSU T, 1992, J BONE MINER RES, V7, P1297; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HOFSTETTER W, 1992, P NATL ACAD SCI USA, V89, P9637, DOI 10.1073/pnas.89.20.9637; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; KATO I, 1991, J BONE MINER RES  S1, V6, pS197; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TAKAHASHI N, 1991, J BONE MINER RES, V6, P977; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1992, FEBS LETT, V313, P85, DOI 10.1016/0014-5793(92)81190-W; TEZUKA K, 1992, BIOCHEM BIOPH RES CO, V186, P911, DOI 10.1016/0006-291X(92)90832-6; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WEIR EC, 1993, J BONE MINER RES, V8, P1507; WIKTORJEDRZEJCZAK W, 1982, J EXP MED, V156, P1516, DOI 10.1084/jem.156.5.1516; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	44	8	8	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33141	33147		10.1074/jbc.271.51.33141	http://dx.doi.org/10.1074/jbc.271.51.33141			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955163	hybrid			2022-12-25	WOS:A1996VZ37300098
J	Blaszyk, H; Hartmann, A; Tamura, Y; Saitoh, S; Cunningham, JM; McGovern, RM; Schroeder, JJ; Schaid, DJ; Ii, K; Monden, Y; Morimoto, T; Komaki, K; Sasa, M; Hirata, K; Okazaki, M; Kovach, JS; Sommer, SS				Blaszyk, H; Hartmann, A; Tamura, Y; Saitoh, S; Cunningham, JM; McGovern, RM; Schroeder, JJ; Schaid, DJ; Ii, K; Monden, Y; Morimoto, T; Komaki, K; Sasa, M; Hirata, K; Okazaki, M; Kovach, JS; Sommer, SS			Molecular epidemiology of breast cancers in northern and southern Japan: The frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations	ONCOGENE			English	Article						Japan; molecular epidemiology; p53; breast cancer	TUMOR-SUPPRESSOR GENE; FACTOR-IX GENE; CPG DINUCLEOTIDES; CARCINOMAS; WOMEN; ETIOLOGY; PROTEIN; RATES	Comparison of acquired mutations in the p53 tumor suppressor gene can illuminate factors contributing to carcinogenesis among cancer cohorts. Japan has an ethnically homogeneous population with a low incidence of breast cancer. Previously we reported an unusual frequency, allelic status, and clustering of mutations in breast cancers from the northern part of the main Japanese island. To extend these findings, exons 2-11 and adjacent intronic sequences were analysed in tumors of women from northern (Hokkaido) and southern (Tokushima) Japan. The frequency of breast cancers with p53 gene mutations in the Hokkaido group is the highest reported (81%) while that in Tokushima (28%) is similar to most other populations. Thirteen of the 19 mutations (68.4%) in the Hokkaido cohort were heterozygous, an unusually high frequency for p53 mutations in any tumor type. There were three missense mutations at codon 175, a known hotspot for alterations in the p53 gene, and three missense mutations at codon 179, a rare site for p53 changes. In addition, the patterns of p53 gene mutation differed between the two Japanese cohorts (P=0.04). The multiple differences in acquired p53 mutations suggest unsuspected biological differences among breast cancers in northern and southern Japan. In addition, the high frequency of p53 mutations in breast cancers from Hokkaido predicted a poorer prognosis for this population which was confirmed on examination of mortality data.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT ONCOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT LAB MED & PATHOL,ROCHESTER,MN 55905; HIROSAKI UNIV,SCH MED,DEPT INTERNAL MED 1,HIROSAKI,AOMORI 036,JAPAN; UNIV TOKUSHIMA,SCH MED,DEPT PATHOL 1,TOKUSHIMA 770,JAPAN; SAPPORO MED UNIV,DEPT SURG 1,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Hirosaki University; Tokushima University; Sapporo Medical University					NATIONAL CANCER INSTITUTE [R01CA056881] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA56881, CA15086] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; BLASZYK H, 1995, BIOTECHNIQUES, V18, P256; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BORRESEN AL, 1992, CANCER RES, V52, P3234; BOTTEMA CDK, 1993, HUM GENET, V91, P496; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; CALEFFI M, 1994, CANCER, V73, P2147, DOI 10.1002/1097-0142(19940415)73:8<2147::AID-CNCR2820730820>3.0.CO;2-5; CHIBA I, 1990, ONCOGENE, V5, P1603; COLEMAN MP, 1993, IARC SCI PUBL, V121, P1; COLES C, 1992, CANCER RES, V52, P5291; COOPER DN, 1990, HUM GENET, V85, P55; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DeVries EMG, 1996, HUM MUTAT, V7, P202, DOI 10.1002/(SICI)1098-1004(1996)7:3<202::AID-HUMU4>3.3.CO;2-5; GLEBOV OK, 1994, CANCER RES, V54, P3703; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hartmann A, 1996, BRIT J CANCER, V73, P896, DOI 10.1038/bjc.1996.179; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTMANN A, 1995, J CLIN INVEST, V95, P686, DOI 10.1172/JCI117714; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; JONES PA, 1991, CANCER RES, V51, P3617; KETTERLING RP, 1994, AM J HUM GENET, V54, P831; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; KUROISHI T, 1994, CANC MORTALITY MORBI, P96; MAZARS R, 1992, CANCER RES, V52, P3918; MOLES JP, 1993, ONCOGENE, V8, P583; SAITOH S, 1994, ONCOGENE, V9, P2869; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SASA M, 1993, BREAST CANCER RES TR, V27, P247, DOI 10.1007/BF00665694; SHIELDS PG, 1991, JAMA-J AM MED ASSOC, V266, P681, DOI 10.1001/jama.266.5.681; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; SOMMER SS, 1990, NATURE, V346, P22, DOI 10.1038/346022b0; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; Sommer Steve S., 1994, P214; SOUSSI T, 1990, ONCOGENE, V5, P945; STEMMERMANN GN, 1991, BREAST CANCER RES TR, V18, pS67, DOI 10.1007/BF02633531; THORLACIUS S, 1993, CANCER RES, V53, P1637; TOMINAGA S, 1995, CANCER LETT, V90, P75, DOI 10.1016/0304-3835(94)03680-H; TOMINAGA S, 1993, GANN TOKEI HAKUSHO R, P86; TOMINAGA S, 1994, CANC MORTALITY MORBI, P120; TORNALETTI S, 1995, ONCOGENE, V10, P1493; TSUDA H, 1993, JPN J CANCER RES, V84, P394, DOI 10.1111/j.1349-7006.1993.tb00149.x; UMEKITA Y, 1994, JPN J CANCER RES, V85, P825, DOI 10.1111/j.1349-7006.1994.tb02954.x	48	21	21	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2159	2166						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950983				2022-12-25	WOS:A1996VV14500013
J	Marra, G; Chang, CL; Laghi, LA; Chauhan, DP; Young, D; Boland, CR				Marra, G; Chang, CL; Laghi, LA; Chauhan, DP; Young, D; Boland, CR			Expression of human MutS homolog 2 (hMSH2) protein in resting and proliferating cells	ONCOGENE			English	Article						hMSH2; protein expression; cell cycle; DNA mismatch repair	NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; SACCHAROMYCES-CEREVISIAE; MICROSATELLITE INSTABILITY; COLORECTAL-CANCER; MUTATIONS; GENE; YEAST; MSH2; RECOMBINATION	The hMSH2 protein plays an important role in the DNA mismatch repair system. Since this system is involved in the correction of errors that occur during DNA replication, we studied the expression of hMSH2 protein in resting and DNA-replicating cells, as well as through the cell cycle in cell types with different growth characteristics. Using Western blot analysis, we showed that hMSH2 protein was detectable in resting peripheral blood lymphocytes and thymocytes. However, when these cells were induced to proliferate, the protein level increased at least 12-fold. In cell-cycle dependent expression studies we chose two DNA mismatch repair proficient cell lines (HEL and HeLa-S3), and flow cytometry was used to monitor cell-cycle progression. At every phase in the cell cycle, the steady-state level of hMSH2 was higher than in resting lymphocytes or thymocytes, and only minor variations of expression level were observed through the cell cycle. In particular, a two to fourfold decrease in hMSH2 expression occurred at G(1) in HEL and at early S phase in HeLa-S3, but higher expression levels resumed during the replicative and postreplicative phases of the cell cycle. Interestingly, hMSH2 protein expression decreased fourfold when HEL cells were induced to differentiate along the megakaryocyte lineage, when continuous DNA replication occurs without mitosis. These results suggest that a basal level of hMSH2 protein expression is necessary for resting and differentiated cells, and that increased hMSH2 protein expression is required when DNA replication is activated and followed by mitosis.	UNIV CALIF SAN DIEGO, DEPT MED, DIV GASTROENTEROL, LA JOLLA, CA 92093 USA; UNIV MICHIGAN, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; UNIV CALIF SAN DIEGO, CTR CANC, CORE FLOW CYTOMETRY FACIL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of California System; University of California San Diego			Chang, Christina/B-9650-2009; Laghi, Luigi/GZM-5831-2022	Laghi, Luigi/0000-0003-4187-1059				ALANI E, 1994, GENETICS, V137, P19; BICKNELL DC, 1994, P NATL ACAD SCI USA, V91, P4751, DOI 10.1073/pnas.91.11.4751; BISHOP DK, 1989, P NATL ACAD SCI USA, V86, P3713, DOI 10.1073/pnas.86.10.3713; BISHOP DK, 1987, NATURE, V328, P362, DOI 10.1038/328362a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Carethers JM, 1996, J CLIN INVEST, V98, P199, DOI 10.1172/JCI118767; CHANG CL, 1988, J BACTERIOL, V170, P4015, DOI 10.1128/jb.170.9.4015-4022.1988; CHI NW, 1994, J BIOL CHEM, V269, P29984; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAWN MT, 1995, CANCER RES, V55, P3721; HOLLINGSWORTH NM, 1995, GENE DEV, V9, P1728, DOI 10.1101/gad.9.14.1728; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; KRAMER B, 1989, MOL CELL BIOL, V9, P4432, DOI 10.1128/MCB.9.10.4432; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Leach FS, 1996, CANCER RES, V56, P235; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LIU B, 1994, CANCER RES, V54, P4590; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LOEB LA, 1994, CANCER RES, V54, P5059; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NEW L, 1993, MOL GEN GENET, V239, P97, DOI 10.1007/BF00281607; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; REENAN RAG, 1992, GENETICS, V132, P963; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELVA EM, 1995, GENETICS, V139, P1175; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; TANNERGARD P, 1995, CANCER RES, V55, P6092; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TURKA LA, 1991, J IMMUNOL, V146, P1428; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WILSON TM, 1995, CANCER RES, V55, P5146	52	70	70	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2189	2196						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950986				2022-12-25	WOS:A1996VV14500016
J	Nishii, K; Kabarowski, JHS; Gibbons, DL; Griffiths, SD; Titley, I; Wiedemann, LM; Greaves, MF				Nishii, K; Kabarowski, JHS; Gibbons, DL; Griffiths, SD; Titley, I; Wiedemann, LM; Greaves, MF			ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block	ONCOGENE			English	Article						apoptosis; BCR-ABL; phosphorylation; cdc2; cell cycle; leukaemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; PROTEIN-TYROSINE KINASE; HAMSTER OVARY CELLS; INDUCED APOPTOSIS; DNA-DAMAGE; ANTICANCER AGENTS; P34CDC2 KINASE; G2 ARREST; DEATH; PHOSPHORYLATION	Using a temperature-sensitive mutant of the p210 BCR-ABL gene, transfected into a growth factor-dependent cell line (BaF3), we show that transient BCR-ABL kinase expression increases single cell and clonogenic resistance to apoptosis arising from genotoxic damage induced by ionizing radiation and VP-16/etoposide. This effect is achieved in the absence of any detectable changes in the levels of BCL-2, BAX or BCL-x proteins and is independent of proliferative, MAP kinase-dependent effects of BCR-ABL kinase. In contrast to parental cells that transiently arrest in G(2) and then apoptose, p210 BaF3 cells show a pronounced and sustained G(2) arrest following radiation coupled with enhanced phosphorylation of cdc2. A cell cycle block in early M phase induced by the mitotic spindle poison, nocodazole, does not provide protection from apoptosis. Reversal of G(2) arrest by caffeine abolishes the protective effect of BCR-ABL kinase. These data provide further insight into the transforming properties of BCR-ABL and are relevant to the clinical intransigence of Ph-positive leukaemias.	INST CANC RES, LEUKAEMIA RES FUND CTR, LONDON SW3 6JB, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Wiedemann, Leanne/E-3316-2010	Wiedemann, Leanne/0000-0002-0964-4676				AFAR DEH, 1995, P NATL ACAD SCI USA, V92, P9540, DOI 10.1073/pnas.92.21.9540; AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ALLEN PB, 1992, MOL GENETICS HAEMATO, P897; BEDI A, 1994, BLOOD, V83, P2038; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; CHAPMAN RS, 1994, CANCER RES, V54, P5131; CHAPMAN RS, 1995, MOL PHARMACOL, V48, P334; CHEN G, 1995, J EXP MED, V181, P2295, DOI 10.1084/jem.181.6.2295; CHENG HC, 1991, J BIOL CHEM, V266, P17919; CLARK SS, 1989, MOL DIAGNOSTICS HUMA, P15; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CRIST W, 1990, BLOOD, V76, P489; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; EVANS CA, 1995, J CELL SCI, V108, P2591; EVANS CA, 1993, CANCER RES, V53, P1735; FARRELL PJ, 1977, CELL, V11, P187, DOI 10.1016/0092-8674(77)90330-0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREAVES MF, 1993, BRIT J CANCER, V67, P413, DOI 10.1038/bjc.1993.81; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HERMANS A, 1989, CANCER CEL, V7, P21; HERZINGER T, 1995, ONCOGENE, V11, P2151; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KHARBANDA S, 1994, CANCER RES, V54, P1412; LOCK RB, 1990, CANCER RES, V50, P3761; LOCK RB, 1990, CANCER RES, V50, P3767; MA A, 1995, P NATL ACAD SCI USA, V92, P4763, DOI 10.1073/pnas.92.11.4763; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; McKenna WG, 1996, ONCOGENE, V12, P237; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; ONGKEKO W, 1995, J CELL SCI, V108, P2897; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; PALUMBO GJ, 1990, CANCER RES, V50, P1917; PALUMBO GJ, 1991, LEUKEMIA RES, V15, P847, DOI 10.1016/0145-2126(91)90469-A; PINKEL D, 1987, CANCER, V59, P1683, DOI 10.1002/1097-0142(19870515)59:10<1683::AID-CNCR2820591002>3.0.CO;2-G; POWELL SN, 1995, CANCER RES, V55, P1643; PROCTOR SJ, 1994, BRIT J HAEMATOL, V88, P229, DOI 10.1111/j.1365-2141.1994.tb05011.x; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; ROBERTS WM, 1994, LANCET, V343, P331, DOI 10.1016/S0140-6736(94)91166-5; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SANTUCCI MA, 1993, INT J RADIAT ONCOL, V26, P831, DOI 10.1016/0360-3016(93)90498-K; SECKERWALKER LM, 1991, LEUKEMIA, V5, P196; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843	58	87	93	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2225	2234						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950990				2022-12-25	WOS:A1996VV14500020
J	Schmitt, F; Oakeley, EJ; Jost, JP				Schmitt, F; Oakeley, EJ; Jost, JP			Antibiotics induce genome-wide hypermethylation in cultured Nicotiana tabacum plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DNA HYPERMETHYLATION; DRUG-RESISTANCE; METHYLATION; TOBACCO; CELLS; DIFFERENTIATION; EXPRESSION; RNA	Plant genomic DNA methylation was analyzed by an improved SssI methyltransferase assay and by genomic sequencing with sodium bisulfite. Kanamycin, hygromycin, and cefotaxime (also called Claforan) are commonly used as selective agents for the production of transgenic plants. These antibiotics caused DNA hypermethylation in tobacco plants grown in vitro, which was both time- and dose-dependent. An exposure of the plantlets to 500 mg/liter cefotaxime for 1 month caused the de novo methylation of 3 x 10(7) CpG sites/haploid genome of 3.5 x 10(9) base pairs. It occurred in high, moderate, and low repetitive DNA and was not reversible upon the removal of the antibiotics. Reversion was only observed in progeny grown in the absence of drugs. Analysis of the promoter regions of two single-copy genes, an auxin-binding protein gene and the class I chitinase gene, showed the hypermethylation to be heterogeneous but biased toward CpGs. The hypermethylation of the class I chitinase and the auxin-binding protein promoters was not a consequence of a drug-induced gene amplification.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Friedrich Miescher Institute for Biomedical Research								BENNETT MD, 1976, PHILOS T R SOC B, V274, P227, DOI 10.1098/rstb.1976.0044; Bestor TH, 1996, NAT GENET, V12, P363, DOI 10.1038/ng0496-363; BESTOR TH, 1984, MOL CELL BIOL, V4, P1800, DOI 10.1128/MCB.4.9.1800; BRITTEN RJ, 1968, SCIENCE, V161, P529, DOI 10.1126/science.161.3841.529; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; FINNEGAN EJ, 1994, BIOTECHNOLOGY, V12, P883; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GATZ C, 1991, MOL GEN GENET, V227, P229, DOI 10.1007/BF00259675; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; LOSCHIAVO F, 1989, THEOR APPL GENET, V77, P325, DOI 10.1007/BF00305823; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; MEYER P, 1994, MOL GEN GENET, V243, P390, DOI 10.1007/BF00280469; NYCE J, 1986, NUCLEIC ACIDS RES, V14, P4353, DOI 10.1093/nar/14.10.4353; NYCE J, 1989, CANCER RES, V49, P5829; NYCE J, 1993, P NATL ACAD SCI USA, V90, P2960, DOI 10.1073/pnas.90.7.2960; PHILLIPS RL, 1994, P NATL ACAD SCI USA, V91, P5222, DOI 10.1073/pnas.91.12.5222; RAIZIS AM, 1995, ANAL BIOCHEM, V226, P161, DOI 10.1006/abio.1995.1204; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH SS, 1994, PROG NUCLEIC ACID RE, V49, P65; SORENSEN MB, 1990, LAB GUIDE IN VIVO ST, P35; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VANBUUREN M, 1992, MOL GEN GENET, V232, P460, DOI 10.1007/BF00266251; VOGELILANGE R, 1994, PLANT J, V5, P273, DOI 10.1046/j.1365-313X.1994.05020273.x; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Young A., 1991, FOCUS, V13, P137	29	77	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1534	1540		10.1074/jbc.272.3.1534	http://dx.doi.org/10.1074/jbc.272.3.1534			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999825	hybrid			2022-12-25	WOS:A1997WD05800023
J	Asano, K; Kinzy, TG; Merrick, WC; Hershey, JWB				Asano, K; Kinzy, TG; Merrick, WC; Hershey, JWB			Conservation and diversity of eukaryotic translation initiation factor eIF3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; AMINO-ACID-SEQUENCE; RABBIT RETICULOCYTES; GEL-ELECTROPHORESIS; HELA-CELLS; YEAST; RNA; COMPLEX; SUBUNIT; CLONING	The largest of the mammalian translation initiation factors, eIF3, consists of at least eight subunits ranging in mass from 35 to 170 kDa. eIF3 binds to the 40 S ribosome in an early step of translation initiation and promotes the binding of methionyl tRNA(i) and mRNA. We report the cloning and characterization of human cDNAs encoding two of its subunits, p110 and p36. It was found that the second slowest band during polyacrylamide gel electrophresis of eIF3 subunits in sodium dodecyl sulfate contains two proteins: p110 and p116. Analysis of the cloned cDNA encoding p110 indicates that its amino acid sequence is 31% identical to that of the yeast protein, Nip1. The p116 cDNA was cloned and characterized as a human homolog of yeast Prt1, as described elsewhere (Methot, N., Rom, E., Olsen, H., and Sonenberg, N. (1997) J. Biol. Chem. 272, 1110-1116). p36 is a WD40 repeat protein, which is 46% identical to the p39 subunit of yeast eIF3 and is identical to TRIP-1, a phosphorylation substrate of the TGF-beta type II receptor. The p116, p110, and p36 subunits localize on 40 S ribosomes in cells active in translation and co-immunoprecipitate with affinity-purified antibodies against the p170 subunit, showing that these proteins are integral components of eIF3. Although p36 and p116 have homologous protein subunits in yeast eIF3, the p110 homolog, Nip1, is not detected in yeast eIF3 preparations. The results indicate both conservation and diversity in eIF3 between yeast and humans.	LAWRENCE LIVERMORE NATL LAB,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Case Western Reserve University					NIGMS NIH HHS [GM26796, GM22135, GM36467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022135, R01GM026796, R01GM036467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BENNE R, 1978, J BIOL CHEM, V253, P3078; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BROWNLUEDI ML, 1982, BIOCHEMISTRY-US, V21, P4202, DOI 10.1021/bi00261a002; CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DUNCAN R, 1983, J BIOL CHEM, V258, P7228; GARCIABARRIO MT, 1995, GENE DEV, V9, P1781, DOI 10.1101/gad.9.14.1781; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; GU ZY, 1992, P NATL ACAD SCI USA, V89, P10355, DOI 10.1073/pnas.89.21.10355; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; HARTWELL LH, 1968, P NATL ACAD SCI USA, V62, P468; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; KASPERAITIS MAM, 1995, FEBS LETT, V365, P47, DOI 10.1016/0014-5793(95)00427-B; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; Merrick WC., 1996, TRANSLATION CONTROL, P31; Methot N, 1996, MOL CELL BIOL, V16, P5328; Methot N, 1997, J BIOL CHEM, V272, P1110, DOI 10.1074/jbc.272.2.1110; MEYER LJ, 1982, BIOCHEMISTRY-US, V21, P4206, DOI 10.1021/bi00261a003; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; MOLDAVE K, 1988, GENETICS TRANSLATION, P271; NARANDA T, 1994, J BIOL CHEM, V269, P32286; Naranda T, 1996, MOL CELL BIOL, V16, P2307; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NYGARD O, 1982, NUCLEIC ACIDS RES, V10, P1327, DOI 10.1093/nar/10.4.1327; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; SHARP NA, 1989, ONCOGENE, V4, P1043; Silhavy T.J., 1984, EXPT GENE FUSIONS; SOARES MB, 1994, P NATL ACAD SCI USA, V91, P9228, DOI 10.1073/pnas.91.20.9228; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; TABER S, 1985, P NATL ACAD SCI USA, V82, P1074; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248; YOUNG RA, 1983, SCIENCE, V222, P778, DOI 10.1126/science.6356359	43	121	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1101	1109		10.1074/jbc.272.2.1101	http://dx.doi.org/10.1074/jbc.272.2.1101			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995409	hybrid			2022-12-25	WOS:A1997WC04800060
J	Ciaccia, AV; Willemze, AJ; Church, FC				Ciaccia, AV; Willemze, AJ; Church, FC			Heparin promotes proteolytic inactivation by thrombin of a reactive site mutant (L444R) of recombinant heparin cofactor II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ARG CHLOROMETHYLKETONE; MOLECULAR WEIGHT HEPARIN; HUMAN ALPHA-THROMBIN; PROTEIN-C INHIBITOR; ANTITHROMBIN-III; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; ANTI-THROMBIN; HINGE REGION; HUMAN-PLASMA	A heparin cofactor II (HCII) mutant with an Arg substituted for Leu(444) the P1 position (L444R-rHCII) was previously found to have altered proteinase specificity (Derechin, V. M., Blinder, M. A., and Tollefsen, D. M. (1990) J. Biol. Chem. 265, 5623-5628). The present study characterizes the effect of glycosaminoglycans on the substrate versus inhibitor activity of L444R-rHCII. Heparin increased the stoichiometry of inhibition of L444R-rHCII with alpha-thrombin (compared with minus glycosaminoglycan) but decreased it with R93A,R97A,R101A0-thrombin, a mutant thrombin that does not bind glycosaminoglycans. Dermatan sulfate decreased the stoichiometry of inhibition of L444R-rHCII with both proteinases. SDS-polyacrylamide gel electrophoresis showed no proteolysis of L444R-rHCII when incubated with R93A,R97A,R101A-thrombin in the absence or the presence of glycosaminoglycan or with alpha-thrombin and dermatan sulfate. In contrast, greater than 75% of the L444R-rHCII was converted to a lower molecular weight form when incubated with alpha-thrombin/heparin. A time course of alpha-thrombin inhibition by L444R-rHCII/heparin showed a rapid but transient inhibition with approximately 80% of the alpha-thrombin activity being regained after 6 h of incubation. In contrast, all other combinations of inhibitor, proteinase, and glycosaminoglycan resulted in complete and sustained inhibition of the proteinase, Heparin fragments of 8-20 polysaccharides in length rapidly accelerated L444R-rHCII inhibition of both alpha-thrombin and R93A,R97A,R101A-thrombin. After extended incubations, R93A,R97A,R101A-thrombin was completely inhibited by L444R-rHCII with all the heparin fragments, but approximately 30-50% of alpha-thrombin activity remained with fragments long enough to bridge HCII-thrombin. These results collectively indicate that ternary complex formation, mediated by heparin, increases L444R-rHCII inactivation by alpha-thrombin.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT LAB MED & PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine				Sontag, Angelina/0000-0003-4012-4537	NHLBI NIH HHS [HL-32656] Funding Source: Medline; NIGMS NIH HHS [5T32-GM-07040-19] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007040] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN RC, 1991, BLOOD, V77, P2185; BJORK I, 1992, J BIOL CHEM, V267, P1976; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1992, PROTEIN SCI, V1, P426; CARLSTROM AS, 1977, THROMB RES, V11, P785, DOI 10.1016/0049-3848(77)90107-4; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1994, TRENDS CARDIOVAS MED, V4, P140, DOI 10.1016/1050-1738(94)90066-3; CHURCH FC, 1995, MOL BASIS THROMBOSIS, P379; Ciaccia AV, 1995, PROTEIN EXPRES PURIF, V6, P806, DOI 10.1006/prep.1995.0012; COOPER ST, 1995, BBA-PROTEIN STRUCT M, V1246, P29, DOI 10.1016/0167-4838(94)00185-J; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DANIELSSON A, 1980, FEBS LETT, V119, P241, DOI 10.1016/0014-5793(80)80262-6; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; GETTINS PGW, 1993, BIOCHEMISTRY-US, V32, P8385, DOI 10.1021/bi00084a001; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI, P48; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; INHORN RC, 1986, BIOCHEM BIOPH RES CO, V137, P431, DOI 10.1016/0006-291X(86)91228-3; JORDAN R, 1979, J BIOL CHEM, V254, P2902; JORDAN RE, 1980, J BIOL CHEM, V255, P73; KIM YS, 1989, THROMB RES, V53, P55, DOI 10.1016/0049-3848(89)90115-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1978, BIOCHEM J, V175, P691, DOI 10.1042/bj1750691; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; MATHESON NR, 1991, J BIOL CHEM, V266, P13489; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1985, J BIOL CHEM, V260, P153; OLSON ST, 1983, FED PROC, V42, P1861; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PATSTON PA, 1994, THROMB HAEMOSTASIS, V72, P166; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHECHTER NM, 1993, J BIOL CHEM, V268, P23626; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; SIE P, 1988, BIOCHIM BIOPHYS ACTA, V966, P188, DOI 10.1016/0304-4165(88)90111-0; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TOLLEFSEN DM, 1992, ADV EXP MED BIOL, V313, P167; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1993, J PROTEIN CHEM, V12, P677, DOI 10.1007/BF01024926; YE J, 1994, J BIOL CHEM, V269, P17965	51	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					888	893		10.1074/jbc.272.2.888	http://dx.doi.org/10.1074/jbc.272.2.888			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995378	Green Published, hybrid			2022-12-25	WOS:A1997WC04800029
J	Silva, JC; Townsend, CA				Silva, JC; Townsend, CA			Heterologous expression, isolation, and characterization of versicolorin B synthase from Aspergillus parasiticus - A key enzyme in the aflatoxin B-1 biosynthetic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-OXIDASE GENE; SACCHAROMYCES-CEREVISIAE; MANDELONITRILE LYASE; ESCHERICHIA-COLI; CDNA CLONING; YEAST; SECRETION; PROTEINS; SEQUENCE; NIGER	Aflatoxin B-1 is a potent environmental carcinogen produced by certain strains of Aspergillus. Central to the biosynthesis of this mycotoxin is the reaction catalyzed by versicolorin B synthase (VBS) in which a racemic substrate, versiconal hemiacetal, is cyclized to an optically active product whose absolute configuration is crucial to the interaction of aflatoxin B-1 with DNA. Attempted over-production of VBS in Escherichia coli led principally to protein aggregated into inclusion bodies but also small amounts of soluble but catalytically inactive enzyme. Comparisons to wild-type VBS by SDS-polyacrylamide gel electrophoresis and after N glycosidase F treatment revealed that extensive glycosylation accounted for the mass discrepancy (7,000 +/- 1,500 Da) between the native and bacterially expressed proteins, Several over-expression systems in Saccharomyces cerevisiae were surveyed in which one that incorporated a secretion signal was found most successful. VBS of indistinguishable mass on SDS-polyacrylamide gel electrophoresis and kinetic properties from the wild-type enzyme could be obtained in 50-100-fold greater amounts and whose catalytic behavior has been examined. The translated protein sequence of VBS showed three potential N-glycosylation sites (Asn-Xaa-Ser/Thr) consistent with the modifications observed above and unexpectedly revealed extensive homology to the ADP-binding region prominently conserved in the glucose-methanol-choline (GMC) family of flavoenzymes. Over production of VBS in yeast marks the first aflatoxin biosynthetic enzyme to be so obtained and opens the way to direct study of the enzymology of this complex biosynthetic pathway.	JOHNS HOPKINS UNIV, DEPT CHEM, BALTIMORE, MD 21218 USA	Johns Hopkins University					NIEHS NIH HHS [ES01670] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES001670] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAKER D, 1988, CELL, V54, P335, DOI 10.1016/0092-8674(88)90196-1; BANKS TE, 1969, J BIOL CHEM, V244, P6323; BARWALD KR, 1978, FEBS LETT, V90, P255, DOI 10.1016/0014-5793(78)80380-9; BHATNAGAR D, 1991, HDB APPL MYCOLOGY MY, P255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROBST SW, 1994, CAN J CHEM, V72, P200, DOI 10.1139/v94-031; CAVENER DR, 1992, J MOL BIOL, V223, P811, DOI 10.1016/0022-2836(92)90992-S; Cleland W W, 1979, Methods Enzymol, V63, P103; DUTTON MF, 1988, MICROBIOL REV, V52, P274, DOI 10.1128/MMBR.52.2.274-295.1988; EATON DL, 1994, ANNU REV PHARMACOL, V34, P135, DOI 10.1146/annurev.pa.34.040194.001031; FENG GH, 1995, J BACTERIOL, V177, P6246, DOI 10.1128/jb.177.21.6246-6254.1995; FREDERICK KR, 1990, J BIOL CHEM, V265, P3793; HARRIS AL, 1991, NATURE, V350, P377, DOI 10.1038/350377a0; HARRIS CC, 1991, CANCER RES, V51, pS5023; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HATA Y, 1991, AGR BIOL CHEM TOKYO, V55, P941, DOI 10.1080/00021369.1991.10870734; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HINNEN A, 1978, P NATL ACAD SCI USA, V75, P1929, DOI 10.1073/pnas.75.4.1929; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORNG JS, 1990, MOL GEN GENET, V224, P294, DOI 10.1007/BF00271564; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; INNIS MA, 1985, SCIENCE, V228, P21, DOI 10.1126/science.228.4695.21; IYER RS, 1994, J AM CHEM SOC, V116, P1603, DOI 10.1021/ja00084a001; IYER RS, 1994, J AM CHEM SOC, V116, P8863, DOI 10.1021/ja00099a001; JACKSON DA, 1972, P NATL ACAD SCI USA, V69, P2904, DOI 10.1073/pnas.69.10.2904; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORNS MS, 1979, J BIOL CHEM, V254, P2145; Kaiser C., 1994, METHODS YEAST GENETI; KELLER NP, 1995, APPL ENVIRON MICROB, V61, P3628, DOI 10.1128/AEM.61.10.3628-3632.1995; KRIECHBAUM M, 1989, FEBS LETT, V255, P63, DOI 10.1016/0014-5793(89)81061-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUBLE H, 1994, PROTEINS, V19, P343, DOI 10.1002/prot.340190410; LEE LS, 1975, J AGR FOOD CHEM, V23, P1132, DOI 10.1021/jf60202a011; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; Lundblad R.L., 1991, CHEM REAGENTS PROTEI; Mahanti N, 1996, APPL ENVIRON MICROB, V62, P191, DOI 10.1128/AEM.62.1.191-195.1996; Maniatis T., 1982, MOL CLONING; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MARSTON FAO, 1990, METHOD ENZYMOL, V182, P264; McGuire SM, 1996, BIOCHEMISTRY-US, V35, P11470, DOI 10.1021/bi960924s; MCGUIRE SM, 1989, J AM CHEM SOC, V111, P8308, DOI 10.1021/ja00203a058; MCGUIRE SM, 1993, BIOORG MED CHEM LETT, V3, P653, DOI 10.1016/S0960-894X(01)81247-6; MELNICK LM, 1990, J BIOL CHEM, V265, P801; Miles E W, 1977, Methods Enzymol, V47, P431; MOIR DT, 1987, GENE, V56, P209, DOI 10.1016/0378-1119(87)90138-7; MOIR DT, 1991, METHOD ENZYMOL, V194, P491; PAPA KE, 1982, J GEN MICROBIOL, V128, P1345; PAPA KE, 1978, MYCOLOGIA, V70, P766, DOI 10.2307/3759356; PAPA KE, 1984, CAN J MICROBIOL, V30, P68, DOI 10.1139/m84-012; RITTER JK, 1991, BIOCHEMISTRY-US, V30, P11430, DOI 10.1021/bi00112a009; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SCHEIN CH, 1989, BIO-TECHNOL, V7, P1141; SEGEL IH, 1975, ENZYME KINETICS, P18; SHIBUYA I, 1992, BIOSCI BIOTECH BIOCH, V56, P174, DOI 10.1271/bbb.56.174; Silva JC, 1996, J BIOL CHEM, V271, P13600, DOI 10.1074/jbc.271.23.13600; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SKORY CD, 1992, APPL ENVIRON MICROB, V58, P3527, DOI 10.1128/AEM.58.11.3527-3537.1992; SMITH DF, 1979, NUCLEIC ACIDS RES, V6, P487, DOI 10.1093/nar/6.2.487; SMITH RA, 1985, SCIENCE, V229, P1219, DOI 10.1126/science.3939723; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TABOR S, 1990, CURRENT PROTOCOLS MO; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TATSUMI H, 1989, MOL GEN GENET, V219, P33, DOI 10.1007/BF00261154; TOWNSEND CA, 1992, ENVIR SCI R, V44, P141; TRAIL F, 1995, APPL ENVIRON MICROB, V61, P2665, DOI 10.1128/AEM.61.7.2665-2673.1995; TURNER BG, 1991, BIOTECHNOL BIOENG, V37, P869, DOI 10.1002/bit.260370911; VARGO D, 1981, J BIOL CHEM, V256, P6027; Vennesland B., 1981, CYANIDE BIOL, DOI [10.1086/413208, DOI 10.1086/413208]; VIDALCROS A, 1994, EUR J BIOCHEM, V219, P985, DOI 10.1111/j.1432-1033.1994.tb18581.x; Watanabe CMH, 1996, CHEM BIOL, V3, P463, DOI 10.1016/S1074-5521(96)90094-0; WHITTINGTON H, 1990, CURR GENET, V18, P531, DOI 10.1007/BF00327024; XU LL, 1986, ARCH BIOCHEM BIOPHYS, V250, P322, DOI 10.1016/0003-9861(86)90733-2; YABE K, 1993, APPL ENVIRON MICROB, V59, P2493, DOI 10.1128/AEM.59.8.2493-2500.1993; YEMM RS, 1986, ARCH BIOCHEM BIOPHYS, V247, P440, DOI 10.1016/0003-9861(86)90604-1; YU JJ, 1993, APPL ENVIRON MICROB, V59, P3564, DOI 10.1128/AEM.59.11.3564-3571.1993; YU JJ, 1995, APPL ENVIRON MICROB, V61, P2365, DOI 10.1128/AEM.61.6.2365-2371.1995	76	19	22	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					804	813		10.1074/jbc.272.2.804	http://dx.doi.org/10.1074/jbc.272.2.804			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995367	hybrid			2022-12-25	WOS:A1997WC04800018
J	Starace, DM; Knox, BE				Starace, DM; Knox, BE			Activation of transducin by a Xenopus short wavelength visual pigment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VERTEBRATE PHOTORECEPTORS; MOLECULAR-PROPERTIES; CHICKEN GREEN; COLOR-VISION; RHODOPSIN; CONE; IODOPSIN; BINDING; ROD; RECEPTORS	Phototransduction in cones differs significantly from that in rods in sensitivity, kinetics, and recovery following exposure to light. The contribution that the visual pigment makes in determining the cone response was investigated biochemically by expressing a Xenopus violet cone opsin (VCOP) cDNA in COS1 cells and assaying the light dependent activation of transducin. Light exposed VCOP stimulated [S-35]guanosine 5'-(gamma-thio)triphosphate nucleotide exchange on bovine rod transducin in a time dependent manner with a half-time for activation of 0.75 min, similar to that of bovine rhodopsin. In exhaustive binding assays, VCOP and rhodopsin activity showed similar concentration dependence with half-maximal activation occurring at 0.02 mol of pigment/mol of transducin. Although VCOP was able to activate as many as 12 transducins per photoisomerization, rhodopsin catalyzed significantly more. When assays were performed with lambda > 420 nm illumination, VCOP exhibited rapid regeneration and high affinity for the photoregenerated 11-cis-retinal. Recycling of the chromophore and reactivation of the pigment resulted in multiple activations of transducin, whereas a maximum of 1 transducin per VCOP was activated under brief illumination. The decay of the active species formed following photobleaching was complete in <5 min, similar to 10-fold faster than that of rhodopsin. In vitro, VCOP activated rod transducin with kinetics and affinity similar to those of rhodopsin, but the active conformation decayed more rapidly and the apoprotein regenerated more efficiently with VCOP than with rhodopsin. These properties of the violet pigment may account for much of the difference in response kinetics between rods and cones.	SUNY HLTH SCI CTR,DEPT BIOCHEM & MOL BIOL,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT OPHTHALMOL,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NEI NIH HHS [EY09409] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009409, R55EY009409] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBURY ML, 1994, SOC GEN PHY, V49, P235; Batni S, 1996, J BIOL CHEM, V271, P3179, DOI 10.1074/jbc.271.6.3179; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; FUKADA Y, 1990, BIOCHEMISTRY-US, V29, P10102, DOI 10.1021/bi00495a013; FUKADA Y, 1982, FEBS LETT, V149, P117, DOI 10.1016/0014-5793(82)81084-3; FUKADA Y, 1989, FEBS LETT, V246, P69, DOI 10.1016/0014-5793(89)80255-8; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HESS RF, 1989, J PHYSIOL-LONDON, V417, P123, DOI 10.1113/jphysiol.1989.sp017794; HUBBARD R, 1966, J BIOL CHEM, V241, P1814; HUBBARD R, 1952, J GEN PHYSIOL, V36, P415; HURLEY JB, 1992, J BIOENERG BIOMEMBR, V24, P219, DOI 10.1007/BF00762680; IMAI H, 1995, BIOCHEMISTRY-US, V34, P10525, DOI 10.1021/bi00033a026; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KNOX B E, 1991, Biophysical Journal, V59, p328A; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; MCNAUGHTON PA, 1990, PHYSIOL REV, V70, P847, DOI 10.1152/physrev.1990.70.3.847; Miller James L., 1994, Current Opinion in Neurobiology, V4, P488, DOI 10.1016/0959-4388(94)90048-5; NATHANS J, 1992, BIOCHEMISTRY-US, V31, P4923, DOI 10.1021/bi00136a001; OKADA T, 1994, BIOCHEMISTRY-US, V33, P4940, DOI 10.1021/bi00182a024; PERRY RJ, 1991, J PHYSIOL-LONDON, V433, P561, DOI 10.1113/jphysiol.1991.sp018444; REITNER A, 1991, NATURE, V352, P798, DOI 10.1038/352798a0; SHICHIDA Y, 1994, BIOCHEMISTRY-US, V33, P9040, DOI 10.1021/bi00197a002; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; VANAKEN T, 1986, METHOD ENZYMOL, V125, P27; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P12444; YOKOYAMA S, 1995, MOL BIOL EVOL, V12, P53, DOI 10.1093/oxfordjournals.molbev.a040190; YOSHIZAWA T, 1994, BIOPHYS CHEM, V50, P17, DOI 10.1016/0301-4622(94)85016-X	30	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1095	1100		10.1074/jbc.272.2.1095	http://dx.doi.org/10.1074/jbc.272.2.1095			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995408	hybrid			2022-12-25	WOS:A1997WC04800059
J	Chan, JLK; Lai, M; Wang, LH				Chan, JLK; Lai, M; Wang, LH			Effect of dimerization on signal transduction and biological function of oncogenic Ros, insulin, and insulin-like growth factor I receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; SARCOMA VIRUS UR2; PHOSPHOTYROSINE-DEPENDENT INTERACTION; TRANSMEMBRANE REGION; LIVING CELLS; EGF RECEPTOR; NPEY MOTIF; PROTEIN; DOMAIN; SUBSTRATE-1	The avian sarcoma virus UR2 codes for an oncogenic Gag-Ros fusion protein-tyrosine kinase (PTK), We have previously derived two retroviruses, T6 and NM1, coding for oncogenic Gag-insulin receptor and Gag-insulinlike growth factor I receptor (IGFR) fusion proteins, respectively, The Gag-IGFR fusion protein dimerizes, whereas Gag-Ros does not, To identify sequences affecting dimerization and the effect of dimerization on signaling and biological functions, we generated recombinants exchanging the extracellular and transmembrane sequences among the three fusion receptors, The presence of multiple cysteines in the Gag sequence appears to preclude dimerization, since deletion of the 3' cysteine residue allows for dimerization. Most of the chimeric receptors retain high PTK activity and induce transformation regardless of their configuration on the cell surface, UT, a UR2/T6 chimera, retained mitogenic activity but has a markedly reduced transforming ability, while UN7, a UR2/NM1 recombinant, which also harbors Y950F and F951S mutations in IGFR, exhibits dramatic reductions in both activities, All of the fusion receptors can phosphorylate insulin receptor substrate 1 and activate PI 3-kinase. UT protein induces Shc phosphorylation, whereas UN7 protein does not, but both are unable to activate mitogen-activated protein kinase, Our results show that overexpressed oncogenic Gag-fusion receptors do not require dimerization for their signaling and transforming functions and that the extracellular and transmembrane sequences of a receptor PTK can affect its specific substrate interactions.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NATIONAL CANCER INSTITUTE [R01CA055054] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BRANDTRAUF PW, 1995, J PROTEIN CHEM, V14, P33, DOI 10.1007/BF01902842; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARLBERG K, 1994, MOL BIOL CELL, V5, P81, DOI 10.1091/mbc.5.1.81; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; COCHET C, 1988, J BIOL CHEM, V263, P3290; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; GULLICK WJ, 1992, EMBO J, V11, P43, DOI 10.1002/j.1460-2075.1992.tb05025.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; JONG SMJ, 1987, ONCOGENE RES, V1, P7; JONG SMJ, 1992, J VIROL, V66, P4909, DOI 10.1128/JVI.66.8.4909-4918.1992; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KWATRA MM, 1992, BIOCHIM BIOPHYS ACTA, V1134, P178, DOI 10.1016/0167-4889(92)90042-A; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEE JS, 1993, J BIOL CHEM, V268, P4092; LI W, 1991, MOL CELL BIOL, V11, P3756, DOI 10.1128/MCB.11.7.3756; LIU DL, 1992, J VIROL, V66, P374, DOI 10.1128/JVI.66.1.374-385.1992; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P2117; POON B, 1991, P NATL ACAD SCI USA, V88, P877, DOI 10.1073/pnas.88.3.877; REIDEL H, 1989, EMBO J, V8, P2943; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V51, P660; SHOELSON SE, 1991, BIOCHEMISTRY-US, V30, P7740, DOI 10.1021/bi00245a010; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SOROKIN A, 1995, ONCOGENE, V11, P1531; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; STERNBERG MJE, 1990, PROTEIN ENG, V3, P245, DOI 10.1093/protein/3.4.245; TARTAREDECKERT S, 1995, J BIOL CHEM, V270, P23456, DOI 10.1074/jbc.270.40.23456; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WEINER DB, 1989, ONCOGENE, V4, P1175; XIONG Q, 1996, MOL CELL BIOL, V271, P160; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; ZONG CS, 1994, P NATL ACAD SCI USA, V91, P10982, DOI 10.1073/pnas.91.23.10982	52	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					146	153						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995240				2022-12-25	WOS:A1997WA56400027
J	Kuno, K; Kanada, N; Nakashima, E; Fujiki, F; Ichimura, F; Matsushima, K				Kuno, K; Kanada, N; Nakashima, E; Fujiki, F; Ichimura, F; Matsushima, K			Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SNAKE-VENOM METALLOPROTEINASES; EXPERIMENTAL CANCER CACHEXIA; CROTALUS-ATROX VENOM; AMINO-ACID-SEQUENCE; SPERM-EGG FUSION; COLON-26 ADENOCARCINOMA; FACTOR-ALPHA; I REPEATS; CELL	A cellular disintegrin and metalloproteinase (ADAM) is a new family of genes with structural homology to the snake venom metalloproteinases and disintegrins. We screened genes which were selectively expressed in the cachexigenic colon 26 adenocarcinoma subline in vivo. It was found that one novel cDNA clone, identified as a cachexigenic tumor selective gene, encodes a cysteine-rich protein which shows a sequence similarity to that of both the snake venom metalloproteinases and thrombospondins. We named this cDNA clone A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS-1). ADAMTS1 consists of six domains, 1) a pro- and 2) a metalloproteinase, 3) a disintegrin-like, 4) a thrombospondin (TSP) homologous domain containing TSP type I motif, 5) a spacer region, and 6) COOH-terminal TSP submotifs. Unlike other ADAMs, ADAMTS-1 does not possess a transmembrane domain and is a putative secretory protein. Therefore, ADAMTS-1 is a new type of ADAM family protein with TSP type I motifs. We demonstrated that the TSP homologous domain containing the TSP type I motif of ADAMTS-1 is functional for binding to heparin. ADAMTS-1 mRNA could be induced by stimulating colon 26 cells with an inflammatory cytokine, interleukin-1, in vitro. Moreover, intravenous administration of lipopolysaccharide in mice selectively induced ADAMTS-1 mRNA in kidney and heart. These data suggest that ADAM-TS-1 may be a gene whose expression is associated with various inflammatory processes as well as development of cancer cachexia.	KANAZAWA UNIV,CANC RES INST,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,DEPT PHARMACOL,KANAZAWA,ISHIKAWA 920,JAPAN; KANAZAWA UNIV,HOSP PHARM,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Kanazawa University; Kanazawa University			KUNO, Kouji/D-8439-2015					ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BECK SA, 1987, CANCER RES, V47, P5919; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BJARNASON JB, 1988, BIOL CHEM H-S, V369, P121; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1991, J BIOL CHEM, V266, P12821; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; FUJIMOTOOUCHI K, 1995, INT J CANCER, V61, P522, DOI 10.1002/ijc.2910610416; FUJIOKA N, 1995, J LEUKOCYTE BIOL, V58, P90, DOI 10.1002/jlb.58.1.90; GELIN J, 1991, CANCER RES, V51, P415; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; GRAMS F, 1993, FEBS LETT, V335, P76, DOI 10.1016/0014-5793(93)80443-X; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HITE LA, 1992, BIOCHEMISTRY-US, V31, P6203, DOI 10.1021/bi00142a005; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANGSTEIN HN, 1991, HEMATOL ONCOL CLIN N, V5, P103, DOI 10.1016/S0889-8588(18)30457-X; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MASUNO H, 1981, CANCER RES, V41, P284; MATTHY P, 1991, INT J CANCER, V9, P77; MILPETZ F, 1995, TRENDS BIOCHEM SCI, V20, P204, DOI 10.1016/S0968-0004(00)89009-X; MOLDAWER LL, 1987, CLIN PHYSIOL, V7, P263, DOI 10.1111/j.1475-097X.1987.tb00169.x; MORI M, 1991, CANCER RES, V51, P6656; NIEWIAROWSKI S, 1994, SEMIN HEMATOL, V31, P289; NORTON JA, 1987, CRC CR REV ONCOL-HEM, V7, P289, DOI 10.1016/S1040-8428(87)80003-3; OLIFF A, 1987, CELL, V50, P555, DOI 10.1016/0092-8674(87)90028-6; PERRY ACF, 1992, BIOCHEM J, V286, P671, DOI 10.1042/bj2860671; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RANDOLPH A, 1992, PROTEIN SCI, V1, P590, DOI 10.1002/pro.5560010505; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SENFTLEBEN A, 1994, DEV GROWTH DIFFER, V36, P49; SHANNON JD, 1989, J BIOL CHEM, V264, P11575; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; TANAKA Y, 1990, CANCER RES, V50, P2290; TISDALE MJ, 1991, BRIT J CANCER, V63, P337, DOI 10.1038/bjc.1991.80; Todorov P, 1996, NATURE, V379, P739, DOI 10.1038/379739a0; TRACEY KJ, 1988, J EXP MED, V167, P1211, DOI 10.1084/jem.167.3.1211; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YASUMOTO K, 1995, CANCER RES, V55, P921; YONEDA T, 1993, CANCER RES, V53, P737; YOSHIDA S, 1990, INT IMMUNOL, V2, P585, DOI 10.1093/intimm/2.6.585	50	403	461	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					556	562						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995297	hybrid			2022-12-25	WOS:A1997WA56400084
J	Leeb, T; Mathis, SA; LeebLundberg, LMF				Leeb, T; Mathis, SA; LeebLundberg, LMF			The sixth transmembrane domains of the human B1 and B2 bradykinin receptors are structurally compatible and involved in discriminating between subtype-selective agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-BASIS; PHARMACOLOGICAL CHARACTERIZATION; BETA-2-ADRENERGIC RECEPTORS; SPECIES SELECTIVITY; EXPRESSION CLONING; SUBSTANCE-P; BINDING; SPECIFICITY; ANTAGONISTS; AFFINITY	In order to investigate the molecular basis for the ability of the human B1 and B2 bradykinin (BK) receptor subtypes to discriminate between subtype-selective ligands, we constructed chimeric proteins in which the sixth transmembrane domains (TM-VI) of these receptors were exchanged, The pharmacological profiles of the constructs were analyzed by radioligand binding in particulate preparations of transiently transfected HEK293 cells using the agonist [H-3]des-Arg(10)-kallidin and the antagonist [H-3]NPC17731. The ability of these constructs to transmit an intracellular signal was measured in transiently transfected A10 cells, a vascular smooth muscle cell line, by single cell Ca2+ imaging. Substitution of B1 TM-VI into the B2 receptor (B2(B1VI)) dramatically reduced the affinity of the B2-selective agonist BK, whereas the affinity of the B2-selective antagonist NPC17731 was unaltered. High affinity BK binding was fully regained when two residues, Tyr(259) and Ala(263), near the extracellular surface of TM-VI in B2(B1VI), were replaced with the corresponding residues in the wild-type B2 receptor, which are Phe(259) and Thr(263). The construct B1(B2VI), produced by substitution of B2 TM-VI into the B1 receptor, did not support high affinity binding of the B1-selective agonist des-Arg(10)-kallidin. In contrast to BK and des-Arg(10)-kallidin, the binding of the less subtype-selective agonist kallidin showed little sensitivity to TM-VI exchange. These results show that TM-VI in the human B1 and B2 BK receptor subtypes, although only 36% identical, are structurally compatible. Furthermore, this domain contributes significantly to the ability of these receptors to discriminate between the subtype-selective agonists BK and des-Arg(10)-kallidin.	UNIV TEXAS, HLTH SCI CTR, DEPT BIOCHEM, SAN ANTONIO, TX 78284 USA	University of Texas System; University of Texas Health San Antonio			Leeb, Tosso/G-3187-2014	Leeb, Tosso/0000-0003-0553-4880	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041659, R29GM041659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbdAlla S, 1996, J BIOL CHEM, V271, P27382, DOI 10.1074/jbc.271.44.27382; ALI SA, 1995, BIOTECHNIQUES, V18, P746; Bachvarov DR, 1995, J PHARMACOL EXP THER, V275, P1623; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; DIXON RAF, 1989, PROTEINS, V6, P267, DOI 10.1002/prot.340060309; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; FONG TM, 1992, J BIOL CHEM, V267, P25664; FREEDMAN R, 1992, RECENT PROGR KININS, P487; FRIELLE T, 1988, P NATL ACAD SCI USA, V85, P9494, DOI 10.1073/pnas.85.24.9494; GETHER U, 1993, NATURE, V362, P345, DOI 10.1038/362345a0; GETHER U, 1993, P NATL ACAD SCI USA, V90, P6194, DOI 10.1073/pnas.90.13.6194; Herzig MCS, 1996, J BIOL CHEM, V271, P29746, DOI 10.1074/jbc.271.47.29746; HERZIG MCS, 1995, J BIOL CHEM, V270, P20591, DOI 10.1074/jbc.270.35.20591; HESS JF, 1994, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOCK FJ, 1991, BRIT J PHARMACOL, V102, P769, DOI 10.1111/j.1476-5381.1991.tb12248.x; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; Kyle D. J., 1995, CURR PHARM DESIGN, V1, P233; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; KYLE DJ, 1991, J MED CHEM, V34, P2649, DOI 10.1021/jm00112a047; KYLE DJ, 1991, J MED CHEM, V34, P1230, DOI 10.1021/jm00107a052; MACNEIL T, 1995, BBA-GENE STRUCT EXPR, V1264, P223, DOI 10.1016/0167-4781(95)00152-7; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; Mathis SA, 1996, MOL PHARMACOL, V50, P128; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCINTYRE P, 1993, MOL PHARMACOL, V44, P346; MENKE JG, 1994, J BIOL CHEM, V269, P21583; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; Pesquero JB, 1996, BIOCHEM BIOPH RES CO, V220, P219, DOI 10.1006/bbrc.1996.0384; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; REGOLI D, 1980, PHARMACOL REV, V32, P1; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SCHWARTZ TW, 1995, CURR PHARM DESIGN, V1, P355; STEWART JM, 1991, BRADYKININ ANTAGONIS, P51; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; TROPEA MM, 1993, J PHARMACOL EXP THER, V264, P930; VAVREK RJ, 1985, PEPTIDES, V6, P161, DOI 10.1016/0196-9781(85)90033-6; Wirth K J, 1992, Agents Actions Suppl, V38 ( Pt 2), P406; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024	44	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					311	317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995263				2022-12-25	WOS:A1997WA56400050
J	Mackie, GA; Genereaux, JL; Masterman, SK				Mackie, GA; Genereaux, JL; Masterman, SK			Modulation of the activity of RNase E in vitro by RNA sequences and secondary structures 5' to cleavage sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN S20; ESCHERICHIA-COLI; MESSENGER-RNA; UNTRANSLATED REGION; RIBONUCLEASE-E; INVITRO; SPECIFICITY; DEGRADATION; OVEREXPRESSION; RECOGNITION	The endoribonuclease RNase E is believed to initiate the degradation of many mRNAs in Escherichia coli, yet the mechanism by which it recognizes cleavage sites is poorly understood. We have prepared derivatives of the mRNA encoding ribosomal protein S20 which contain a single major RNase E cleavage site at residues 300/301 preceded by variable 5' extensions. Three of these RNAs are cleaved in vitro with significantly reduced efficiencies relative to the intact S20 mRNA by both crude RNase E and pure Rne protein (endonuclease component of RNase E). In all three substrates as well as in the full-length mRNA the major cleavage site itself remains single-stranded. One such substrate (t84D) contains a 5' stem-loop structure characterized by three noncanonical A-G pairs. Removal or denaturation of the stem restores efficient cleavage at the major RNase E site, The other two contain single-stranded 5'-termini but apparently lack cleavage sites near the termini. Our data show that sensitivity to RNase E can be influenced by distant structural motifs in the RNA and also suggest a model in which the initial recognition and cleavage of a substrate near its 5' end facilitates sequential cleavages at more distal sites. The model implies that RNase E contains at least a dimer of the Rne subunit and that the products of the first cleavage are retained by Rne prior to the second cleavage.			Mackie, GA (corresponding author), UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,DH COPP BLDG,2146 HLTH SCI MALL,VANCOUVER,BC V6T 1Z3,CANADA.							BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHEN LH, 1991, J BACTERIOL, V173, P4578, DOI 10.1128/jb.173.15.4578-4586.1991; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HANSEN MJ, 1994, MOL MICROBIOL, V12, P707, DOI 10.1111/j.1365-2958.1994.tb01058.x; IWAI S, 1992, NUCLEIC ACIDS RES, V20, P6465, DOI 10.1093/nar/20.24.6465; Kaberdin VR, 1996, J BIOL CHEM, V271, P13103, DOI 10.1074/jbc.271.22.13103; KRAMER A, 1984, CELL, V38, P299, DOI 10.1016/0092-8674(84)90551-8; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Sambrook J., 2002, MOL CLONING LAB MANU; TARASEVICIENE L, 1995, J BIOL CHEM, V270, P26391, DOI 10.1074/jbc.270.44.26391; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; Turner DH, 1996, CURR OPIN STRUC BIOL, V6, P299, DOI 10.1016/S0959-440X(96)80047-9; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WOESE CR, 1983, MICROBIOL REV, V47, P621, DOI 10.1128/MMBR.47.4.621-669.1983; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					609	616						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995304				2022-12-25	WOS:A1997WA56400091
J	Chitlaru, E; Roseman, S				Chitlaru, E; Roseman, S			Molecular cloning and characterization of a novel beta-N-acetyl-D-glucosaminidase from Vibrio furnissii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CHITIN OLIGOSACCHARIDES; MARINE-BACTERIA; DNA; GLUCOSIDASE; SEQUENCES; PURIFICATION; PROTEIN; STRAIN	The accompanying papers (Keyhani, N. O., and Roseman, S. (1996) J. Biol. Chem. 271, 33414-33424; Keyhani, N. O., and Roseman, S. (1996) J. Biol. Chem. 271, 33425- 33432) describe two unique beta-N-acetylglucosaminidases from Vibrio furnissii. A third, ExoII, is reported here. The gene, exoII, was cloned into Escherichia coli, sequenced, and ExoII purified to apparent homogeneity (36 kDa). The molecular weight and N-terminal 16 amino acids of the protein conform to the predicted sequence. ExoII exhibited unique substrate specificity. It rapidly cleaved p-nitrophenyl and 4-methylumbelliferyl beta-GlcNAc, was slightly active with p-nitrophenyl-beta-GalNAc, and was inactive with all other GlcNAc derivatives tested, including N,N'-diacetylchitobiose and (GlcNAc)(n), n = 3-6. Unlike GlcNAc (K-i, 210 mu M), (GlcNAc)(n) are poor inhibitors of ExoII. The predicted protein sequence is unique among beta-N-acetylglucosaminidases excepting Cht60, recently cloned hom a marine Alteromonas (Tsujibo, H., Fujimoto, K., Tanno, H., Miyamoto, K., Imada, C., Okami, Y., and Inamori, Y. (1994) Gene (Amst.) 146, 111-115). Cht60, a chitobiase, is 26.9% identical to ExoII in a 182-amino acid overlap, but the two enzymes differ in substrate specificity and other properties. ExoII shares similarity with five bacterial and yeast beta-glucosidases, up to 44% identity in the 25-amino acid catalytic domain. By analogy, ExoII mag play a role in signal transduction between invertebrate hosts and V. furnissii.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NIGMS NIH HHS [GM51215] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1995, CURRENT PROTOCOLS MO, V1; BARNETT CC, 1991, BIO-TECHNOL, V9, P562, DOI 10.1038/nbt0691-562; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BAUSE E, 1980, BIOCHIM BIOPHYS ACTA, V626, P459, DOI 10.1016/0005-2795(80)90142-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTLE LA, 1992, J BACTERIOL, V174, P1478, DOI 10.1128/jb.174.5.1478-1486.1992; DONG DLY, 1994, J BIOL CHEM, V269, P19321; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; KAMST E, 1995, J BACTERIOL, V177, P6282, DOI 10.1128/jb.177.21.6282-6285.1995; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LIN JJ, 1992, BIOTECHNIQUES, V12, P718; Morgan WTJ, 1934, BIOCHEM J, V28, P988, DOI 10.1042/bj0280988; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; Osborn M J, 1974, Methods Enzymol, V31, P642; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; TSUJIBO H, 1994, GENE, V146, P111, DOI 10.1016/0378-1119(94)90843-5; WAITE JH, 1990, COMP BIOCHEM PHYS B, V97, P19, DOI 10.1016/0305-0491(90)90172-P; WAITE JH, 1984, METHOD ENZYMOL, V107, P397; YU C, 1991, J BIOL CHEM, V266, P24260	25	56	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33433	33439		10.1074/jbc.271.52.33433	http://dx.doi.org/10.1074/jbc.271.52.33433			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969206	hybrid			2022-12-25	WOS:A1996WA71300040
J	Puzianowska-Kuznicka, M; Wong, JM; Kanamori, A; Shi, YB				Puzianowska-Kuznicka, M; Wong, JM; Kanamori, A; Shi, YB			Functional characterization of a mutant thyroid hormone receptor in Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; TRANSCRIPTIONAL ACTIVATION; AMPHIBIAN METAMORPHOSIS; RESPONSE ELEMENTS; ONCOGENE PRODUCT; GENE-EXPRESSION; DIRECT REPEATS; X RECEPTORS; BETA; REPRESSION	Thyroid hormone plays a causative role during frog metamorphosis, and its effect is mediated by thyroid hormone receptors (TRs), To investigate the function of Xenopus TRs, we have recently developed a thyroid hormone dependent in vivo transcription system by introducing TRs and RXRs (9-cis-retinoic acid receptors) into Xenopus oocytes. Interestingly, using this system, we have found that the TR alpha B cloned previously is defective in transcriptional activation compared with TR alpha A, In vitro DNA binding experiments show that TR alpha B . RXR heterodimers have drastically reduced affinity for a thyroid hormone response element, Site-directed mutagenesis shows that two of the seven amino acid residues that differ between TR alpha A and TR alpha B are responsible for the defect in TR alpha B function. These two residues affect the DNA binding by both TR . RXR heterodimers and TR homodimers, In contrast, heterodimer formation with RXRs is not affected as demonstrated by coimmunoprecipitation and dominant-transcriptional inhibition experiments, By cDNA and genomic DNA sequence analysis, we have demonstrated that the residues, which affect TR alpha B function when mutated, are identical between the wild type TR alpha B and TR alpha A, Thus, our experiments have discovered the first amphibian TR mutant, The DNA binding and transcription activation functions of the mutant are discussed in relation to the recently published TR crystal structure.	NICHHD, MOL EMBRYOL LAB, NIH, BETHESDA, MD 20892 USA; NATL RES INST AQUACULTURE, TAMAKI, MIE 51904, JAPAN	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Japan Fisheries Research & Education Agency (FRA)				KANAMORI, AKIRA/0000-0002-4311-8143; Wong, Jiemin/0000-0002-5311-842X; Shi, Yun-Bo/0000-0002-6330-0639; Puzianowska-Kuznicka, Monika/0000-0001-5295-3848				ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BLUMBERG B, 1992, P NATL ACAD SCI USA, V89, P2321, DOI 10.1073/pnas.89.6.2321; BROOKS AR, 1989, NUCLEIC ACIDS RES, V17, P9395, DOI 10.1093/nar/17.22.9395; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Dodd M.H.I., 1976, P467; ELICEIRI BP, 1994, J BIOL CHEM, V269, P24459; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; Gilbert L, 1981, METAMORPHOSIS PROBLE; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; GRAUPNER G, 1989, NATURE, V340, P653, DOI 10.1038/340653a0; ISHIZUYAOKA A, 1991, IN VITRO CELL DEV B, V27, P853; KAWAHARA A, 1991, DEVELOPMENT, V112, P933; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEE Y, 1993, J BIOL CHEM, V268, P2021; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARKLEW S, 1994, BBA-GENE STRUCT EXPR, V1218, P267, DOI 10.1016/0167-4781(94)90177-5; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; RANJAN M, 1994, J BIOL CHEM, V269, P24699; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SHI YB, 1994, FEBS LETT, V355, P61, DOI 10.1016/0014-5793(94)01173-7; SHI YB, 1990, GENE DEV, V4, P1107, DOI 10.1101/gad.4.7.1107; SHI YB, 1992, J BIOL CHEM, V267, P733; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; UPPALURI R, 1995, MOL CELL BIOL, V15, P1499; WANG Z, 1993, J BIOL CHEM, V268, P16270; WONG JM, 1995, J BIOL CHEM, V270, P18479, DOI 10.1074/jbc.270.31.18479; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; YAOITA Y, 1990, GENE DEV, V4, P1917, DOI 10.1101/gad.4.11.1917; YAOITA Y, 1990, P NATL ACAD SCI USA, V87, P7090, DOI 10.1073/pnas.87.18.7090; YEN PM, 1994, TRENDS ENDOCRIN MET, V5, P65, DOI 10.1016/1043-2760(94)90004-3; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1414, DOI 10.1002/j.1460-2075.1994.tb06395.x; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	42	10	10	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33394	33403		10.1074/jbc.271.52.33394	http://dx.doi.org/10.1074/jbc.271.52.33394			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969201	hybrid			2022-12-25	WOS:A1996WA71300035
J	Simpson, PB; Russell, JT				Simpson, PB; Russell, JT			Mitochondria support inositol 1,4,5-trisphosphate-mediated Ca2+ waves in cultured oligodendrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM-CONCENTRATION; ENDOPLASMIC-RETICULUM; PHOSPHOINOSITIDE HYDROLYSIS; RAT OLIGODENDROCYTES; ASTROCYTES; CELLS; RECEPTORS; NEURONS; AGONIST; LOCALIZATION	We have examined the spatial and temporal nature of Ca2+ signals activated via the phosphoinositide pathway in oligodendrocytes and the cellular specializations underlying oligodendrocyte Ca2+ response characteristics. Cultured cortical oligodendrocytes were incubated with fluo 3 or fura 2, and digital video fluorescence microscopy was used to study the effect of methacholine on [Ca2+](i). Single peaks, oscillations, and steady-state plateau [Ca2+](i) elevations were evoked by increasing agonist concentration. The peaks and oscillations were found to be Ca2+ wave fronts, which propagate via distinct amplification regions in the cell where the kinetics of Ca2+ release (amplitude and rate of rise of response) are elevated. Staining with 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolecarbocyanine iodide (JC-1) and 3,3'-dihexyloxacarbocyanine iodide revealed that mitochondria are found in groups of three or more in oligodendrocyte processes and that the groups are distributed with considerable distance separating them. Cross-correlation analysis showed a high degree of correlation between sites where mitochondria are present and peaks in the amplitude and rate of rise of the Ca2+ response. Intramitochondrial Ca2+ concentration, measured using rhod 2, increased upon treatment with methacholine. Methacholine also evoked a rapid change in mitochondrial membrane potential as measured by the J-aggregate fluorescence of JC-1. Pretreatment with the mitochondrial inhibitors carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (1 mu M, 2 min) or antimycin (2 mu g/ml, 2 min) altered the methacholine-evoked Ca2+ response in most cells studied, responses being either markedly potentiated or inhibited. The results of this study demonstrate that stimulation of phosphoinositide-coupled muscarinic acetylcholinoceptors activates propagating Ca2+ wave fronts in oligodendrocytes and that the characteristics of these waves are dependent on mitochondrial location and function.	NICHHD,LCMN,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Simpson, Peter/0000-0003-0364-2685				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BINDOKAS VP, 1995, J NEUROSCI, V15, P6999; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; COHEN RI, 1994, EUR J NEUROSCI, V6, P1213, DOI 10.1111/j.1460-9568.1994.tb00620.x; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; FATATIS A, 1992, GLIA, V5, P95, DOI 10.1002/glia.440050203; FRIEL DD, 1994, J NEUROSCI, V14, P4007; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; HEYTLER PG, 1981, INHIBITORS MITOCHOND, P199; HOLTZCLAW LA, 1995, J NEUROSCI RES, V42, P124, DOI 10.1002/jnr.490420114; INAGAKI N, 1991, NEUROSCI LETT, V128, P257, DOI 10.1016/0304-3940(91)90274-W; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; KASTRITSIS CH, 1993, GLIA, V8, P106, DOI 10.1002/glia.440080206; KIEDROWSKI L, 1995, MOL PHARMACOL, V47, P140; KIRISCHUK S, 1995, NEUROREPORT, V6, P737, DOI 10.1097/00001756-199503270-00008; KRIEGLER S, 1993, J NEUROSCI, V13, P4229, DOI 10.1523/jneurosci.13-10-04229.1993; LAROCCA JN, 1987, BRAIN RES, V436, P357, DOI 10.1016/0006-8993(87)91679-9; MASSA PT, 1984, J NEUROSCI, V4, P3128; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Meucci O, 1996, J NEUROSCI, V16, P519; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; NIXON GF, 1994, J MUSCLE RES CELL M, V15, P682, DOI 10.1007/BF00121075; Oppenheim A. V., 1975, DIGITAL SIGNAL PROCE; PENDE M, 1994, P NATL ACAD SCI USA, V91, P3215, DOI 10.1073/pnas.91.8.3215; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; RANSCHT B, 1982, P NATL ACAD SCI-BIOL, V79, P2709, DOI 10.1073/pnas.79.8.2709; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; RITCHIE T, 1987, LIFE SCI, V41, P31, DOI 10.1016/0024-3205(87)90553-4; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROTH BJ, 1995, CELL CALCIUM, V17, P53, DOI 10.1016/0143-4160(95)90102-7; SHAO Y, 1995, CELL CALCIUM, V17, P187, DOI 10.1016/0143-4160(95)90033-0; Simpson P. B., 1995, Society for Neuroscience Abstracts, V21, P1129; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; TAKEDA M, 1995, GLIA, V14, P225, DOI 10.1002/glia.440140308; TAKEI K, 1992, J NEUROSCI, V12, P489; TERASAKI M, 1992, J CELL SCI, V101, P315; VASILIEV JM, 1978, INT REV CYTOL, V50, P159; WHITE RJ, 1995, J NEUROSCI, V15, P1318; WILLARS GB, 1995, BRIT J PHARMACOL, V114, P1133, DOI 10.1111/j.1476-5381.1995.tb13325.x; YAGODIN SV, 1994, J NEUROBIOL, V25, P265, DOI 10.1002/neu.480250307	46	137	139	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33493	33501		10.1074/jbc.271.52.33493	http://dx.doi.org/10.1074/jbc.271.52.33493			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969213				2022-12-25	WOS:A1996WA71300047
J	Colville, CA; Molday, RS				Colville, CA; Molday, RS			Primary structure and expression of the human beta-subunit and related proteins of the rod photoreceptor cGMP-gated channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CATION CHANNEL; FUNCTIONAL EXPRESSION; GENE STRUCTURE; ION CHANNELS; CELLS; PURIFICATION; MODULATION; FAMILY; CDNA	The full-length cDNA for the beta-subunit of the human rod photoreceptor cyclic nucleotide-gated channel has been shown to encode a 1251-amino acid (similar to 140 kDa) polypeptide which, like its bovine counterpart, has an unusual bipartite structure. The C-terminal part corresponds to the previously reported ''subunit 2'' of the human rod channel and contains the structural features of other cyclic nucleotide-gated channel subunits including six putative membrane spanning segments, a cyclic nucleotide binding domain, a voltage sensor motif, and a pore region. The N-terminal part contains the human homolog of the bovine glutamic acid-rich protein called GARP. Western blots indicate that both the native and heterologously expressed human beta subunit migrate anomalously as a 220-kDa polypeptide by SDS-gel electrophoresis. Two other GARP variants, full-length GARP (f-GARP) and truncated GARP (t-GARP), are also present in human, bovine, and rat rod outer segments and migrate as 120-140- and 55-62-kDa polypeptides, respectively. The bovine f-GARP and t-GARP cDNAs code for proteins containing 590 amino acids and 299 amino acids, respectively. The first 571 amino acids of f-GARP and the first 291 amino acids of t-GARP are identical to the corresponding N-terminal amino acid sequence of the bovine beta-subunit. The two GARP variants, themselves, are not tightly associated with the rod channel. These results indicate that mammalian rod outer segments contain three alternatively spliced variants of GARP, one of which constitutes the N-terminal part of the rod channel beta-subunit.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOL BIOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia					NATIONAL EYE INSTITUTE [R01EY002422] Funding Source: NIH RePORTER; NEI NIH HHS [EY 02422] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1992, P NATL ACAD SCI USA, V89, P10262, DOI 10.1073/pnas.89.21.10262; ARDELL MD, 1995, GENOMICS, V28, P32, DOI 10.1006/geno.1995.1102; Biel M, 1996, J BIOL CHEM, V271, P6349, DOI 10.1074/jbc.271.11.6349; BIEL M, 1994, P NATL ACAD SCI USA, V91, P3505, DOI 10.1073/pnas.91.9.3505; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COOK NJ, 1987, P NATL ACAD SCI USA, V84, P585, DOI 10.1073/pnas.84.2.585; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; KAUPP UB, 1995, CURR OPIN NEUROBIOL, V5, P434, DOI 10.1016/0959-4388(95)80002-6; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; MOLDAY RS, 1987, J CELL BIOL, V105, P2589, DOI 10.1083/jcb.105.6.2589; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUGIMOTO Y, 1991, P NATL ACAD SCI USA, V88, P3116, DOI 10.1073/pnas.88.8.3116; WEYAND I, 1994, NATURE, V368, P859, DOI 10.1038/368859a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZUFALL F, 1994, ANNU REV BIOPH BIOM, V23, P577, DOI 10.1146/annurev.bb.23.060194.003045	22	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32968	32974		10.1074/jbc.271.51.32968	http://dx.doi.org/10.1074/jbc.271.51.32968			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955140	hybrid			2022-12-25	WOS:A1996VZ37300075
J	Ermakova, OV; Frappier, L; Schildkraut, CL				Ermakova, OV; Frappier, L; Schildkraut, CL			Role of the EBNA-1 protein in pausing of replication forks in the Epstein-Barr virus genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN EBNA-1; ORIGIN-BINDING-PROTEIN; DNA HELICASE ACTIVITY; RIBOSOMAL-RNA GENES; LARGE TUMOR-ANTIGEN; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; TERMINATOR PROTEIN; LATENT ORIGIN; POLAR CONTRAHELICASE	We have previously shown that replication forks stall at a family of repeated sequences (FR) within the Epstein-Barr virus latent origin of replication oriP, both in a small plasmid and in the intact Epstein-Barr virus genome, Each of the 20 repeated sequences within the FR contains a binding site for Epstein-Barr nuclear antigen 1 (EBNA-1), the only viral protein required for latent replication. We showed that the EBNA-1 protein enhances the accumulation of paused replication forks at the FR. In this study, we have investigated a series of truncated EBNA-1 proteins to determine the portion of the EBNA-1 protein that is responsible for pausing of forks at the FR, Two-dimensional agarose gel electrophoresis was performed on the products of in vitro replication reactions in the presence of full-length EBNA-1 or proteins with various deletions to assess the extent of fork pausing at the FR. We conclude that a portion of the DNA binding domain is important for fork pausing, We also present evidence indicating that phosphorylation of the EBNA-1 protein or EBNA-1-truncated derivatives is not essential for pausing, To investigate the mechanism of EBNA-1-mediated pausing of replication forks, we asked whether EBNA-1 could inhibit the DNA unwinding activity of replicative helicases, We found that EBNA-1, when bound to the FR, inhibits DNA unwinding in vitro by SV40 T antigen and Escherichia coli dnaB helicases in an orientation-independent manner.	ALBERT EINSTEIN COLL MED, DEPT CELL BIOL CH 416, NEW YORK, NY 10461 USA; MCMASTER UNIV, INST MOL BIOL & BIOTECHNOL, CANC RES GRP, HAMILTON, ON L8N 3Z5, CANADA	Yeshiva University; McMaster University			Ermakova, Olga/K-5712-2019; Ermakova, Olga/Z-2037-2018	Ermakova, Olga/0000-0001-8365-4904; Ermakova, Olga/0000-0001-8365-4904	NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045751] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA13330] Funding Source: Medline; NIGMS NIH HHS [R01 GM45751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBINDER RF, 1991, J VIROL, V65, P1466, DOI 10.1128/JVI.65.3.1466-1478.1991; AMIN AA, 1992, J BIOL CHEM, V267, P18612; BARWELL JA, 1995, J BIOL CHEM, V270, P20556, DOI 10.1074/jbc.270.35.20556; Bochkarev A, 1996, CELL, V84, P791, DOI 10.1016/S0092-8674(00)81056-9; BOCHKAREV A, 1995, CELL, V83, P39, DOI 10.1016/0092-8674(95)90232-5; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CARRIGAN CM, 1991, J MOL BIOL, V222, P197, DOI 10.1016/0022-2836(91)90206-L; CHEN MR, 1994, VIROLOGY, V205, P486, DOI 10.1006/viro.1994.1669; CHEN MR, 1993, J VIROL, V67, P4875, DOI 10.1128/JVI.67.8.4875-4885.1993; Deshpande AM, 1996, SCIENCE, V272, P1030, DOI 10.1126/science.272.5264.1030; DHAR V, 1991, MOL CELL BIOL, V11, P6268, DOI 10.1128/MCB.11.12.6268; FILUTOWICZ M, 1994, PROG NUCLEIC ACID RE, V48, P239, DOI 10.1016/S0079-6603(08)60857-0; FRAPPIER L, 1991, P NATL ACAD SCI USA, V88, P10875, DOI 10.1073/pnas.88.23.10875; FRAPPIER L, 1992, J VIROL, V66, P1786, DOI 10.1128/JVI.66.3.1786-1790.1992; FRAPPIER L, 1991, J BIOL CHEM, V266, P7819; FRAPPIER L, 1994, J BIOL CHEM, V269, P1057; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GOLDSMITH K, 1993, J VIROL, V67, P3418, DOI 10.1128/JVI.67.6.3418-3426.1993; GREENFEDER SA, 1992, MOL CELL BIOL, V12, P4056, DOI 10.1128/MCB.12.9.4056; HARRISON S, 1994, J VIROL, V68, P1913, DOI 10.1128/JVI.68.3.1913-1925.1994; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HEARING JC, 1985, VIROLOGY, V145, P105; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HILL TM, 1992, ANNU REV MICROBIOL, V46, P603, DOI 10.1146/annurev.micro.46.1.603; HSIEH DJ, 1993, EMBO J, V12, P4933, DOI 10.1002/j.1460-2075.1993.tb06187.x; KAUL S, 1994, P NATL ACAD SCI USA, V91, P11143, DOI 10.1073/pnas.91.23.11143; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KRYSAN PJ, 1989, MOL CELL BIOL, V9, P1026, DOI 10.1128/MCB.9.3.1026; Laine A, 1995, J BIOL CHEM, V270, P30914, DOI 10.1074/jbc.270.52.30914; LANGLEY DB, 1993, MOL MICROBIOL, V10, P771, DOI 10.1111/j.1365-2958.1993.tb00947.x; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1989, J BACTERIOL, V171, P3564, DOI 10.1128/jb.171.6.3564-3567.1989; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LITTLE RD, 1995, MOL CELL BIOL, V15, P2893; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MACALLISTER T, 1990, P NATL ACAD SCI USA, V87, P2828, DOI 10.1073/pnas.87.7.2828; MACKEY D, 1995, J VIROL, V69, P6199, DOI 10.1128/JVI.69.10.6199-6208.1995; MATSON SW, 1986, J BIOL CHEM, V261, P169; MIDDLETON T, 1994, J VIROL, V68, P4067, DOI 10.1128/JVI.68.6.4067-4071.1994; MIRON A, 1994, P NATL ACAD SCI USA, V91, P6438, DOI 10.1073/pnas.91.14.6438; Mohanty BK, 1996, EMBO J, V15, P2530, DOI 10.1002/j.1460-2075.1996.tb00610.x; NORDSTROM K, 1990, CELL, V63, P1121, DOI 10.1016/0092-8674(90)90405-4; OH SJ, 1991, J VIROL, V65, P514, DOI 10.1128/JVI.65.1.514-519.1991; PLATT THK, 1993, J VIROL, V67, P1739, DOI 10.1128/JVI.67.3.1739-1745.1993; POLVINOBODNAR M, 1988, NUCLEIC ACIDS RES, V16, P3415, DOI 10.1093/nar/16.8.3415; RAWLINS DR, 1985, CELL, V42, P859, DOI 10.1016/0092-8674(85)90282-X; REISMAN D, 1986, MOL CELL BIOL, V6, P3838, DOI 10.1128/MCB.6.11.3838; REISMAN D, 1985, MOL CELL BIOL, V5, P1822, DOI 10.1128/MCB.5.8.1822; SAHOO T, 1995, EMBO J, V14, P619, DOI 10.1002/j.1460-2075.1995.tb07038.x; SMITH MT, 1994, J MOL BIOL, V241, P335, DOI 10.1006/jmbi.1994.1510; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SU W, 1991, P NATL ACAD SCI USA, V88, P10870, DOI 10.1073/pnas.88.23.10870; Summers H, 1996, J VIROL, V70, P1228, DOI 10.1128/JVI.70.2.1228-1231.1996; WEISENDANGER B, 1995, NUCLEIC ACIDS RES, V22, P5038; WEN LT, 1989, J VIROL, V63, P3315, DOI 10.1128/JVI.63.8.3315-3322.1989; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YATES JL, 1988, CANCER CELL, V6, P197; ZHANG SJ, 1994, P NATL ACAD SCI USA, V91, P2843, DOI 10.1073/pnas.91.7.2843	67	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33009	33017		10.1074/jbc.271.51.33009	http://dx.doi.org/10.1074/jbc.271.51.33009			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955146	hybrid			2022-12-25	WOS:A1996VZ37300081
J	Kolko, M; DeCoster, MA; deTurco, EBR; Bazan, NG				Kolko, M; DeCoster, MA; deTurco, EBR; Bazan, NG			Synergy by secretory phospholipase A(2) and glutamate on inducing cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-INDEPENDENT PHOSPHOLIPASE-A2; PLATELET-ACTIVATING-FACTOR; MAST-CELLS; RAT-BRAIN; SYNAPTIC TRANSMISSION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; CEREBRAL-CORTEX; BINDING SITES; NMDA-RECEPTOR	Secretory and cytosolic phospholipases A(2) (sPLA(2) and cPL(2)) may contribute to the release of arachidonic acid and other bioactive lipids, which are modulators of synaptic function. In primary cortical neuron cultures, neurotoxic cell death and [H-3]arachidonate metabolism was studied after adding glutamate and sPLA(2) from bee venom. sPLA(2), at concentrations eliciting low neurotoxicity (less than or equal to 100 ng/ml), induced a decrease of [H-3]arachidonate-phospholipids and preferential reesterification of the fatty acid into triacylglycerols. Free [H-3]arachidonic acid accumulated at higher enzyme concentrations, below those exerting highest toxicity. Synergy in neurotoxicity and [H-3]arachidonate release was observed when low, nontoxic (10 ng/ml, 0.71 nm), or mildly toxic (25 ng/ml, 1.78 nM) concentrations of sPLA(2) were added together with glutamate (80 mu M). A similar synergy was observed with the sPLA(2) OS2, from Taipan snake venom. The NMDA receptor antagonist MK-801 blocked glutamate effects and partially inhibited sPLA(2) OS2 but not sPLA(2) from bee venom-induced arachidonic acid release. Thus, the synergy with glutamate and very low concentrations of exogenously added sPLA(2) suggests a potential role for this enzyme in the modulation of glutamatergic synaptic function and of excitotoxicity.	LOUISIANA STATE UNIV,CTR NEUROSCI,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,DEPT OPHTHALMOL,NEW ORLEANS,LA 70112	Louisiana State University System; Louisiana State University System			DeCoster, Mark/AAF-5224-2020; Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Kolko, Miriam/0000-0001-8697-0734	NINDS NIH HHS [NS23002] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023002] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; BALSINDE J, 1994, P NATL ACAD SCI USA, V91, P11060, DOI 10.1073/pnas.91.23.11060; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAZAN NG, 1991, LIPIDS, V26, P1236, DOI 10.1007/BF02536539; BAZAN NG, 1995, NATURE, V374, P501, DOI 10.1038/374501a0; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1994, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1994, P3; BAZAN NG, 1992, NEUROCHEMICAL CORREL, P321; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLAPP LE, 1995, BRAIN RES, V693, P101, DOI 10.1016/0006-8993(95)00720-B; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DECOSTER MA, 1994, INT J DEV NEUROSCI, V12, P227, DOI 10.1016/0736-5748(94)90044-2; DECOSTER MA, 1992, NEUROREPORT, V3, P773, DOI 10.1097/00001756-199209000-00013; DENNING GM, 1983, J LIPID RES, V24, P933; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DOUCET JP, 1990, MOL NEUROBIOL, V6, P27; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; FOLCH J, 1957, J BIOL CHEM, V226, P497; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FRANDSEN A, 1990, INT J DEV NEUROSCI, V8, P209, DOI 10.1016/0736-5748(90)90013-R; FUJIMORI Y, 1992, J BIOCHEM-TOKYO, V111, P54, DOI 10.1093/oxfordjournals.jbchem.a123718; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; KATO K, 1994, NATURE, V367, P179; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; KIM DK, 1995, BIOCHEM J, V310, P83, DOI 10.1042/bj3100083; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; Klette KL, 1995, BRAIN RES, V704, P31, DOI 10.1016/0006-8993(95)01103-X; KOLKO M, 1996, FASEB; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V117, P217; LAMBEAU G, 1990, J BIOL CHEM, V265, P9526; LAMBEAU G, 1989, J BIOL CHEM, V264, P11503; LAMBEAU G, 1995, J BIOL CHEM, V270, P5534, DOI 10.1074/jbc.270.10.5534; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAURITZEN I, 1994, BRAIN RES, V651, P353, DOI 10.1016/0006-8993(94)90719-6; LAZAREWICZ JW, 1992, ADV EXP MED BIOL, V318, P73; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; Matsuzawa A, 1996, BIOCHEM J, V318, P701, DOI 10.1042/bj3180701; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; NAKATANI Y, 1994, J IMMUNOL, V153, P796; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKA S, 1991, J BIOL CHEM, V266, P9956; OREGAN MH, 1995, NEUROSCI LETT, V185, P191, DOI 10.1016/0304-3940(95)11259-Y; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; PIERIK AJ, 1988, BIOCHIM BIOPHYS ACTA, V962, P345, DOI 10.1016/0005-2760(88)90264-0; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Reddy ST, 1996, J BIOL CHEM, V271, P186, DOI 10.1074/jbc.271.1.186; RORDORF G, 1991, J NEUROSCI, V11, P1829; ROSS BM, 1995, J NEUROCHEM, V64, P2213; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SANTOS FF, 1996, INT OPHTHALMOL, V29, P149; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SIESJO BK, 1982, J NEUROCHEM, V39, P796, DOI 10.1111/j.1471-4159.1982.tb07962.x; SPECTOR AA, 1985, J LIPID RES, V26, P1015; STEPHENSON DT, 1994, BRAIN RES, V637, P97, DOI 10.1016/0006-8993(94)91221-1; UMEMURA A, 1992, J NEUROSURG, V76, P648, DOI 10.3171/jns.1992.76.4.0648; UPRETI GC, 1980, J MEMBRANE BIOL, V55, P113, DOI 10.1007/BF01871153; VANDENBOSCH H, 1980, BIOCHIM BIOPHYS ACTA, V604, P191; YANG HC, 1994, BIOCHEM J, V299, P91, DOI 10.1042/bj2990091; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I	66	84	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32722	32728		10.1074/jbc.271.51.32722	http://dx.doi.org/10.1074/jbc.271.51.32722			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955105	hybrid			2022-12-25	WOS:A1996VZ37300040
J	Pinto, M; Lobe, CG				Pinto, M; Lobe, CG			Products of the grg (Groucho-related gene) family can dimerize through the amino-terminal Q domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-ENHANCER; MOLECULAR CHARACTERIZATION; NEGATIVE REGULATOR; SEX DETERMINATION; BHLH PROTEINS; C-MYC; SPLIT; NEUROGENESIS; HAIRY; LOCUS	The murine grg (Groucho-related gene) products are believed to interact with transcription factors and repress transcription, thereby regulating cell proliferation and differentiation. Most proteins in the grg family contain all of the domains found in the Drosophila Groucho protein, including the S/P (Ser-Pro-rich) domain required for interaction with transcription factors and the WD40 domain, which is thought to interact with other proteins. However, at least two Grg proteins contain only the amino-terminal Q (glutamine-rich) domain. We examined whether the Q domain is used for dimerization between Grg proteins, using the yeast two-hybrid system and binding assays with glutathione S-transferase fusion proteins. We found that Grg proteins are able to dimerize through the Q domain and that dimerization requires a core of 50 amino acids. Surprisingly, the dimerization does not require the leucine zipper located within the Q domain.	MCMASTER UNIV, INST MOL BIOL, CANC RES GRP, HAMILTON, ON L8S 4K1, CANADA; MCMASTER UNIV, DEPT BIOCHEM, HAMILTON, ON L8S 4K1, CANADA; MCMASTER UNIV, DEPT MED SCI, HAMILTON, ON L8S 4K1, CANADA	McMaster University; McMaster University; McMaster University								AKAZAWA C, 1992, J BIOL CHEM, V267, P21879; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; Campos-Ortega J A, 1990, Adv Genet, V27, P403; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; DAWSON SR, 1995, MOL CELL BIOL, V15, P6923; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FALCONE D, 1991, MOL CELL BIOL, V11, P2656, DOI 10.1128/MCB.11.5.2656; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FORTINI ME, 1993, CELL, V75, P1245, DOI 10.1016/0092-8674(93)90611-S; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; ISHIBASHI M, 1993, EUR J BIOCHEM, V215, P645, DOI 10.1111/j.1432-1033.1993.tb18075.x; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; Leon C, 1997, DEV DYNAM, V208, P11, DOI 10.1002/(SICI)1097-0177(199701)208:1<11::AID-AJA2>3.0.CO;2-4; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; MIYASAKA H, 1993, EUR J BIOCHEM, V216, P343, DOI 10.1111/j.1432-1033.1993.tb18151.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SASAI Y, 1992, GENE DEV, V6, P2620, DOI 10.1101/gad.6.12b.2620; SCHMIDT CJ, 1993, J BIOL CHEM, V268, P25681; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TATA F, 1993, DEVELOPMENT, P139	28	74	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33026	33031		10.1074/jbc.271.51.33026	http://dx.doi.org/10.1074/jbc.271.51.33026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955148	hybrid			2022-12-25	WOS:A1996VZ37300083
J	Spahn, CMT; Schafer, MA; Krayevsky, AA; Nierhaus, KH				Spahn, CMT; Schafer, MA; Krayevsky, AA; Nierhaus, KH			Conserved nucleotides of 23 S rRNA located at the ribosomal peptidyltransferase center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; ALLOSTERIC 3-SITE MODEL; TRANSFER-RNA; ELONGATION CYCLE; MESSENGER-RNA; P-SITES; THIOSTREPTON; MUTAGENESIS; VIOMYCIN	Two nucleotides of the 23 S rRNA gene were mutated; the nucleotides correspond to the first two positions of the universally conserved sequence Psi GG2582 at the peptidyltransferase ring of 23 S rRNA. The ribosomes containing the altered 23 S rRNA were analyzed. Previously, it was shown that ribosomal assembly was indistinguishable from that in wild-type cells, that the flow of the corresponding 50 S subunit into the polysome fraction was not restricted, but that the ribosomes were strongly impaired in poly(Phe) synthesis (C. M. T. Spahn, J. Remme, M. A. Schafer, and K. H. Nierhaus (1996) J. Biol. Chem. 271, 32849-32856). Here we apply assay systems exclusively testing the puromycin reaction of ribosomes carrying plasmid-born rRNA, a dipeptide assay using the minimal P site donor pA(fMet) and a translocation system not depending on the puromycin reaction. The mutations in helix 90 exclusively abolish or severely impair the ribosome capability to catalyze AcPhe-puromycin formation, A possible explanation of these observations is that G2581 and Psi 2580 (and possibly also G2582) are part of the binding site of C75 of peptidyl-tRNA in the P site. The results suggest that in this case, however, such an interaction would disobey canonical base pairing.	AG RIBOSOMEN,MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; RUSSIAN ACAD SCI,VA ENGELHARDT MOL BIOL INST,MOSCOW 117984,RUSSIA	Max Planck Society; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS								AREVALO MA, 1988, J BIOL CHEM, V263, P58; BAKIN A, 1994, BIOCHEMISTRY-US, V33, P13457; BEYER D, 1994, J BIOL CHEM, V269, P30713; CERNA J, 1973, FEBS LETT, V37, P188; CERNA J, 1975, FEBS LETT, V58, P94, DOI 10.1016/0014-5793(75)80233-X; CHLADEK S, 1985, ANGEW CHEM, V97, P377; GNIRKE A, 1989, J BIOL CHEM, V264, P7291; GUTELL RR, 1993, NUCLEIC ACIDS RES, V21, P3055, DOI 10.1093/nar/21.13.3055; HAUSNER TP, 1988, J BIOL CHEM, V263, P13103; Krayevsky A A, 1979, Prog Nucleic Acid Res Mol Biol, V23, P1; KUTAY UR, 1990, BIOCHIM BIOPHYS ACTA, V1050, P193, DOI 10.1016/0167-4781(90)90165-X; LIEBERMAN KR, 1994, J BIOL CHEM, V269, P16163; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MONRO RE, 1968, P NATL ACAD SCI USA, V61, P1042, DOI 10.1073/pnas.61.3.1042; NIERHAUS KH, 1993, MOL MICROBIOL, V9, P661, DOI 10.1111/j.1365-2958.1993.tb01726.x; OCONNOR M, 1993, EMBO J, V12, P2559, DOI 10.1002/j.1460-2075.1993.tb05911.x; PORSE BT, 1995, J MOL BIOL, V249, P1, DOI 10.1006/jmbi.1995.0276; QUIGGLE K, 1980, FEBS LETT, V118, P172, DOI 10.1016/0014-5793(80)80212-2; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Spahn CMT, 1996, J BIOL CHEM, V271, P32849, DOI 10.1074/jbc.271.51.32849; STEBBINSBOAZ B, 1991, J MOL BIOL, V217, P93, DOI 10.1016/0022-2836(91)90614-C; THOMPSON J, 1988, J MOL BIOL, V203, P457, DOI 10.1016/0022-2836(88)90012-5; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298	24	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32857	32862		10.1074/jbc.271.51.32857	http://dx.doi.org/10.1074/jbc.271.51.32857			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955124	hybrid			2022-12-25	WOS:A1996VZ37300059
J	Steiner, H; Kispal, G; Zollner, A; Haid, A; Neupert, W; Lill, R				Steiner, H; Kispal, G; Zollner, A; Haid, A; Neupert, W; Lill, R			Heme binding to a conserved Cys-Pro-Val motif is crucial for the catalytic function of mitochondrial heme lyases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROMES; YEAST SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; APOCYTOCHROME-C; CELLULAR FACTOR; 2 STEPS; IMPORT; PROTEINS; BIOGENESIS; TRANSLOCATION	Covalent attachment of heme to the apoforms of mitochondrial cytochromes c and c(1) requires the activity of cytochrome c heme lyase (CCHL) and cytochrome c(1) heme lyase (CC(1)HL), respectively, The two enzymes differ in their cytochrome specificity, but they are related in sequence, and both contain conserved Cys-Pro-Val (CPV) motifs, By using various in vitro assays we investigated whether heme can bind directly to heme lyases and whether the CPV motif may be involved in heme binding, Heme stabilized CC(1)HL, as a model protein, in a folded, protease-resistant conformation, stimulated the refolding of CC(1)HL after urea denaturation, and inhibited the import of the CC(1)HL precursor into mitochondria, These effects were not observed with a point mutant, CC(1)HL(SPV), in which cysteine was replaced by serine, and with CC(1)HL(Delta CPV), in which the motif was deleted, These results show that heme lyases can bind heme directly, and they identify the CPV sequence as a structural element important for this interaction. The phenotype of a yeast mutant expressing CC(1)HL(SPV) is in good agreement with such a role of the CPV motif, The mutant cells accumulate the heme-free intermediate form of cytochrome c(1) and display a severe deficiency in the hole form. We suggest that the CPV motif forms a crucial part of the substrate binding site for heme.	TECH UNIV MUNCHEN WEIHENSTEPHAN, INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL, D-80336 MUNICH, GERMANY; TECH UNIV MUNCHEN WEIHENSTEPHAN, INST MIKROBIOL & GENET, D-80638 MUNICH, GERMANY	Technical University of Munich; Technical University of Munich				Lill, Roland/0000-0002-8345-6518				BLOM J, 1993, MOL CELL BIOL, V13, P7364, DOI 10.1128/MCB.13.12.7364; CREUSOT F, 1988, J MOL BIOL, V204, P263, DOI 10.1016/0022-2836(88)90574-8; DAUM G, 1982, J BIOL CHEM, V257, P3075; DRYGAS ME, 1989, J BIOL CHEM, V264, P17897; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; DUMONT ME, 1988, J BIOL CHEM, V263, P15928; DUMONT ME, 1996, ADV MOL CELL BIOL; FYTLOVICH S, 1993, EMBO J, V12, P1209, DOI 10.1002/j.1460-2075.1993.tb05762.x; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GONZALES DH, 1990, J BIOENERG BIOMEMBR, V22, P753; Guthrie C, 1991, GUIDE YEAST GENETICS; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Lill R, 1996, CURR OPIN CELL BIOL, V8, P505, DOI 10.1016/S0955-0674(96)80028-7; LILL R, 1996, P NATO ASI CELL BIOL, P137; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; MAYER A, 1993, J CELL BIOL, V121, P1233, DOI 10.1083/jcb.121.6.1233; NICHOLSON DW, 1989, P NATL ACAD SCI USA, V86, P4340, DOI 10.1073/pnas.86.12.4340; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; Ranu R S, 1979, Methods Enzymol, V60, P459; ROBERTSON DE, 1994, NATURE, V368, P425, DOI 10.1038/368425a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMITT M, 1995, EMBO J, V14, P3434, DOI 10.1002/j.1460-2075.1995.tb07349.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLLNER T, 1991, METHOD CELL BIOL, V34, P345; STEINER H, 1995, J BIOL CHEM, V270, P22842, DOI 10.1074/jbc.270.39.22842; THONYMEYER L, 1994, BBA-BIOENERGETICS, V1187, P260, DOI 10.1016/0005-2728(94)90123-6; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; VARGAS C, 1993, ANAL BIOCHEM, V209, P323, DOI 10.1006/abio.1993.1127; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHANG L, 1994, J BIOL CHEM, V269, P14643; ZOLLNER A, 1994, CURR GENET, V25, P291, DOI 10.1007/BF00351480; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	42	86	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32605	32611		10.1074/jbc.271.51.32605	http://dx.doi.org/10.1074/jbc.271.51.32605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955088	hybrid			2022-12-25	WOS:A1996VZ37300023
J	Tsumoto, K; Ogasahara, K; Ueda, Y; Watanabe, K; Yutani, K; Kumagai, I				Tsumoto, K; Ogasahara, K; Ueda, Y; Watanabe, K; Yutani, K; Kumagai, I			Role of salt bridge formation in antigen-antibody interaction - Entropic contribution to the complex between hen egg white lysozyme and its monoclonal antibody HyHEL10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-FOLDING THERMODYNAMICS; BINDING; ENTHALPY; RESIDUES; DNA; RECOGNITION; EXPRESSION; HYDRATION; REGIONS; SURFACE	For elucidation of the role of salt bridge formation in the antigen-antibody complex, the interaction between hen egg white lysozyme (HEL) and its monoclonal antibody HyHEL10, the structure of which has been well characterized and forms one salt bridge (Lys97 of HEL and Asp32 of HyHEL10 heavy chain variable region (VH)), was investigated, Asp32 of VH was substituted with Ala, Asn, or Glu by site-directed mutagenesis, and the interaction between HEL and the mutant fragments of the variable region of light chain was investigated by inhibition of the enzymatic activity of HEL and isothermal titration calorimetry, Inhibition assay indicated that these mutations lowered the inhibition only slightly, Thermodynamic study indicated that the negative enthalpic change in the interaction between each of the mutant variable regions of light chain and HEL was significantly increased, although the association constant was slightly decreased, suggesting that these mutations increased the entropy change upon antigen-antibody binding, These results indicate that the role of salt bridge formation in the Hy HyHEL10-HEL interaction is to lower the entropic loss due to binding. In the mutant proteins, the numbers of residues that were perturbed structurally on binding increased, suggesting that the salt bridge suppresses excess structural movement of the antibody upon binding.	TOHOKU UNIV, GRAD SCH ENGN, DEPT BIOCHEM & ENGN, AOBA KU, SENDAI, MIYAGI 98077, JAPAN; OSAKA UNIV, INST PROT RES, SUITA, OSAKA 565, JAPAN; UNIV TOKYO, GRAD SCH ENGN, DEPT CHEM & BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	Tohoku University; Osaka University; University of Tokyo								BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; Bode W, 1991, CURR OPIN STRUC BIOL, V1, P45, DOI 10.1016/0959-440X(91)90010-Q; BRADEN BC, 1994, J MOL BIOL, V243, P767, DOI 10.1016/0022-2836(94)90046-9; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5172, DOI 10.1021/bi00183a022; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONNELLY PR, 1994, P NATL ACAD SCI USA, V91, P1964, DOI 10.1073/pnas.91.5.1964; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Imoto T., 1972, ENZYMES, V7, P665; ITO W, 1993, J BIOL CHEM, V268, P16639; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; MAENAKA K, 1995, J MOL BIOL, V247, P281, DOI 10.1006/jmbi.1994.0139; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1995, PROTEINS, V21, P83, DOI 10.1002/prot.340210202; NOVOTNY J, 1989, BIOCHEMISTRY-US, V28, P4735, DOI 10.1021/bi00437a034; NOVOTNY J, 1991, MOL IMMUNOL, V28, P201, DOI 10.1016/0161-5890(91)90062-O; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; RAMAN CS, 1995, BIOCHEMISTRY-US, V34, P5831, DOI 10.1021/bi00017a015; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SMITHGILL SJ, 1987, J MOL BIOL, V194, P713, DOI 10.1016/0022-2836(87)90249-X; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TORIGOE H, 1995, J BIOL CHEM, V270, P22218, DOI 10.1074/jbc.270.38.22218; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; TSUMOTO K, 1994, BIOCHEM BIOPH RES CO, V201, P546, DOI 10.1006/bbrc.1994.1736; UEDA Y, 1993, GENE, V129, P129; WALLS PH, 1992, J MOL BIOL, V228, P277, DOI 10.1016/0022-2836(92)90506-F; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	41	50	50	4	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32612	32616		10.1074/jbc.271.51.32612	http://dx.doi.org/10.1074/jbc.271.51.32612			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955089	hybrid			2022-12-25	WOS:A1996VZ37300024
J	Lam, LT; Bresnick, EH				Lam, LT; Bresnick, EH			A novel DNA-binding protein, HS2NF5, interacts with a functionally important sequence of the human beta-globin locus control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; DOMINANT CONTROL REGION; LOOP-HELIX PROTEINS; TRANSGENIC MICE; ERYTHROLEUKEMIA-CELLS; CHROMATIN STRUCTURE; ERYTHROID-CELLS; GENE-EXPRESSION; LEUCINE-ZIPPER; RECEPTOR	We have identified a previously unreported DNA-binding protein, HS2NF5, which interacts with a conserved sequence within hypersensitive site II (HS2) of the human beta-globin locus control region. A minimal DNA recognition sequence of TGTTCTCA was defined. The binding site for HS2NF5 overlaps an E box, which is a preferred recognition site in vitro for the erythroid-specific transcription factor TAL1 (SCL). No evidence for TAL1 (SCL) binding was found using nuclear extracts from K562 and MEL erythroleukemia cells. Mutations that prevent HS2NF5 binding reduce the enhancer activity of HS2 by 40 and 38% in transient and stable transfection assays, respectively. Analytical gel filtration and velocity centrifugation studies revealed a Stokes' radius of 23.0 Angstrom and an s(20,w) of 3.45 for HS2NF5. Based on these parameters, a native molecular mass of 34,679 Da was calculated. An ultraviolet light cross-linking assay was used to cross-link HS2NF5 to a minimal oligonucleotide. The cross-linking results are consistent with a protein of 33,396-38,309 Da. We propose that HS2NF5 is a novel DNA-binding protein that modulates the transcriptional activation property of the beta-globin locus control region.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050107, R37DK050107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50107] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; BRESNICK EH, 1994, J BIOL CHEM, V269, P21110; Cantor C.R., 1980, BIOPHYS CHEM; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; ELNITSKI L, 1997, IN PRESS J BIOL CHEM; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FELSENFELD G, 1995, MOL BIOL HEMOGLOBIN, P1; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FURUKAWA T, 1994, BLOOD, V83, P1412; GAMETCHU B, 1984, ENDOCRINOLOGY, V114, P274, DOI 10.1210/endo-114-1-274; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; Hug BA, 1996, MOL CELL BIOL, V16, P2906; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Lam LT, 1995, BIOCHEMISTRY-US, V34, P16347, DOI 10.1021/bi00050a015; LISTER J, 1995, J BIOL CHEM, V270, P17939, DOI 10.1074/jbc.270.30.17939; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MOON AM, 1991, BLOOD, V77, P2272; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; PRASAD KSS, 1995, J BIOL CHEM, V270, P11603, DOI 10.1074/jbc.270.19.11603; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	34	29	29	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32421	32429		10.1074/jbc.271.50.32421	http://dx.doi.org/10.1074/jbc.271.50.32421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943307	hybrid			2022-12-25	WOS:A1996VY34000098
J	Rokaw, MD; West, M; Johnson, JP				Rokaw, MD; West, M; Johnson, JP			Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-TRANSPORT; CHANNEL RYANODINE RECEPTOR; FK506-BINDING PROTEIN; ACTIVATION; VASOPRESSIN; CALCIUM; PHOSPHORYLATION; CHEMISTRY; SUBSTRATE; PEPTIDE	Rapamycin and FK506 have unique cellular effects despite the fact that they bind to the same set of immunophilins, the FK506 binding proteins (FKBP). We have previously reported that rapamycin (RAP) stimulates sodium transport in A6 cells. FK506 did not stimulate sodium transport but did inhibit the stimulation seen in RAP-treated cells. Since FKBP12 has been shown to have sequence homology with an endogenous inhibitor of protein kinase C (PKC) and PKC inhibition has been shown to increase Na+ channel activity in A6 cells, studies to determine the effect of RAP on PKC activity and its relationship to sodium transport were performed. Here we report that RAP stimulates sodium transport, and the effect is not additive to that seen with a cell-permeant inhibitor of PKC alpha and -beta subtypes. RAP significantly inhibits endogenous PKC activity in A6 cells both in membrane and cytosolic preparations. There is a strong correlation between the degree of inhibition of PKC activity and the stimulation of sodium transport by RAP, RAP has no effect on Na+/K+-ATPase activity over this time course. Purified recombinant FKBP12 with or without FK506 has no effect on PKC activity when incubated with a rat brain-derived PKC preparation of known activity. By contrast, RAP plus FKBP12 significantly inhibits PKC activity. RAP plus FKBP12 inhibits the PKC alpha and not the -beta subtype. The results demonstrate inhibition of PKC activity by RAP and not FK506 through its binding to FKBP12. The inhibition of PKC activity by RAP stimulates sodium transport in A6. The results therefore imply the existence of an endogenous RAP-like ligand which when bound to FKBP12 could regulate Na+ channel activity through this mechanism.	VET AFFAIRS MED CTR,PITTSBURGH,PA 15213	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Rokaw, MD (corresponding author), UNIV PITTSBURGH,SCH MED,LAB EPITHELIAL CELL BIOL,RENAL ELECTROLYTE DIV,RM 939,SCAIFE HALL,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047874] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47874] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1987, KIDNEY INT, V31, P521, DOI 10.1038/ki.1987.31; BANG H, 1995, P NATL ACAD SCI USA, V92, P3435, DOI 10.1073/pnas.92.8.3435; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; CALVO V, 1992, P NATL ACAD SCI USA, V89, P7571, DOI 10.1073/pnas.89.16.7571; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARDY J, 1995, P NATL ACAD SCI USA, V92, P56, DOI 10.1073/pnas.92.1.56; COLLINS JH, 1991, BIOCHEM BIOPH RES CO, V178, P1288, DOI 10.1016/0006-291X(91)91033-9; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; FARRAR YJK, 1991, BIOCHEM BIOPH RES CO, V180, P694, DOI 10.1016/S0006-291X(05)81121-0; FESCHENKO MS, 1995, J BIOL CHEM, V270, P14072, DOI 10.1074/jbc.270.23.14072; Frindt G, 1996, AM J PHYSIOL-RENAL, V270, pF371, DOI 10.1152/ajprenal.1996.270.2.F371; GOEBL MG, 1991, CELL, V64, P1051, DOI 10.1016/0092-8674(91)90258-Z; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; MARUNAKA Y, 1991, AM J PHYSIOL, V260, pC1071, DOI 10.1152/ajpcell.1991.260.5.C1071; MATSUMOTO PS, 1993, AM J PHYSIOL, V264, pC246, DOI 10.1152/ajpcell.1993.264.1.C246; MIDDLETON JP, 1993, J BIOL CHEM, V268, P15958; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; Prat AG, 1996, J BIOL CHEM, V271, P18045, DOI 10.1074/jbc.271.30.18045; PRAT AG, 1993, AM J PHYSIOL, V265, pC224, DOI 10.1152/ajpcell.1993.265.1.C224; Rokaw MD, 1996, J BIOL CHEM, V271, P4491; Rokaw MD, 1996, AM J PHYSIOL-CELL PH, V271, pC194, DOI 10.1152/ajpcell.1996.271.1.C194; RUFF VA, 1992, J BIOL CHEM, V267, P21285; RUFF VA, 1992, IMMUNOL INVEST, V21, P259, DOI 10.3109/08820139209072263; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SHAEFFER J, 1992, KIDNEY INT, V41, P255; SIERKIERKA JJ, 1990, J BIOL CHEM, V265, P21011; TAYLOR A, 1979, AM J PHYSIOL, V236, pF505, DOI 10.1152/ajprenal.1979.236.6.F505; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; YANASE M, 1986, AM J PHYSIOL, V250, pC517, DOI 10.1152/ajpcell.1986.250.3.C517	34	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32468	32473		10.1074/jbc.271.50.32468	http://dx.doi.org/10.1074/jbc.271.50.32468			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943313	hybrid			2022-12-25	WOS:A1996VY34000104
J	Tatematsu, K; Nakayama, J; Danbara, M; Shionoya, S; Sato, H; Omine, M; Ishikawa, F				Tatematsu, K; Nakayama, J; Danbara, M; Shionoya, S; Sato, H; Omine, M; Ishikawa, F			A novel quantitative 'stretch PCR assay', that detects a dramatic increase in telomerase activity during the progression of myeloid leukemias	ONCOGENE			English	Article						telomerase; leukemia; progression; PCR	HUMAN-LYMPHOCYTES; CELLS; IMMORTALITY; TRANSFORMATION; LENGTH; CANCER; EVENT	Telomerase activation is important for carcinogenesis. However, the timing and magnitude of the activation during cancer development are unknown. In this study, a new PCR-based method for measuring telomerase activity was developed and shown to be very useful for quantitative analysis of human telomerase. Using this assay, blood or bone marrow cells from healthy donors, and patients with chronic myelogenous leukemia (CML) and acute myelogenous leukemia (AML) were examined as to their relative activity. Telomerase activity present in normal peripheral blood cells was generally very low. However, significant activity was detected occasionally in samples derived from younger healthy donors. Striking telomerase activation was observed at the time of the blastic crisis in CML: no samples from chronic phase cases showed significant activity, while all cases with a well established crisis showed strong activity. Most AML cases were telomerase-positive. Quantitative analyses revealed that the relative titer varied among the AML patients, from as low as found in normal cells to as high as found in cell lines. However, a tendency that the activity was higher in relapsed cases than in fresh ones was suggested. In summary, telomerase was activated during the progression of the clinical stages in leukemias. This observation suggests that shortened telomeres and increased telomerase activity might be necessary for cancer cells to undergo clonal evolution towards more malignant phenotypes in advanced stages.	TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 226,JAPAN; KITASATO UNIV,SCH MED,DEPT INTERNAL MED,SAGAMIHARA,KANAGAWA 228,JAPAN; TEIKYO UNIV,SCH MED,DEPT INTERNAL MED 4,TAKATSU KU,KAWASAKI,KANAGAWA 213,JAPAN; SHOWA UNIV,FUJIGAOKA HOSP,SCH MED,DEPT HEMATOL,AOBA KU,YOKOHAMA,KANAGAWA 227,JAPAN	Tokyo Institute of Technology; Kitasato University; Teikyo University; Showa University			Ishikawa, Fuyuki/AAU-4056-2021; Nakayama, Jun-ichi/C-6003-2011	Ishikawa, Fuyuki/0000-0002-5580-2305; Nakayama, Jun-ichi/0000-0002-5597-8239				ADAMSON DJA, 1992, CANCER GENET CYTOGEN, V61, P204, DOI 10.1016/0165-4608(92)90088-P; BECKERANDRE M, 1993, METHOD ENZYMOL, V218, P420; BEDI A, 1994, BLOOD, V83, P2038; BEDNAREK A, 1995, CANCER RES, V55, P4566; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; CLARKSON B, 1993, LEUKEMIA, V7, P1683; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1995, TELOMERES, P265; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; FERRE F, 1994, POLYM CHAIN REACTION, P67; FIALKOW PJ, 1967, P NATL ACAD SCI USA, V58, P1468, DOI 10.1073/pnas.58.4.1468; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1993, COLD SPRING HARB SYM, V58, P719, DOI 10.1101/SQB.1993.058.01.079; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; HARLEY CB, 1994, COLD SPRING HARB SYM, V64, P1; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA K, 1995, J IMMUNOL, V155, P3711; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; MORIN GB, 1991, NATURE, V353, P454, DOI 10.1038/353454a0; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NEWBOLD RF, 1982, NATURE, V299, P633, DOI 10.1038/299633a0; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OHYASHIKI K, 1994, CANCER GENET CYTOGEN, V78, P64, DOI 10.1016/0165-4608(94)90047-7; PAITYSZEK MA, 1995, METHODS CELL SCI, V17, P1; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH HS, 1987, JNCI-J NATL CANCER I, V78, P611; TAKAUCHI K, 1994, JPN J CANCER RES, V85, P127, DOI 10.1111/j.1349-7006.1994.tb02071.x; VAZIRI H, 1993, AM J HUM GENET, V52, P661; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	33	127	138	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2265	2274						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950994				2022-12-25	WOS:A1996VV14500024
J	Davidson, D; Chow, LML; Veillette, A				Davidson, D; Chow, LML; Veillette, A			Chk, a Csk family tyrosine protein kinase, exhibits Csk-like activity in fibroblasts, but not in an antigen-specific T-cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; RETROVIRAL VECTORS; MOLECULAR-CLONING; GENE-TRANSFER; SRC; IDENTIFICATION; ACTIVATION; P50(CSK); RECEPTOR; LYMPHOCYTES	The Csk family of tyrosine protein kinases comprises two members named Csk and Chk. These enzymes phosphorylate the carboxyl-terminal tyrosine of Src-related kinases in vitro, thereby repressing their activity. Csk has been found to be necessary for normal embryonic development, and to be a potent negative regulator of antigen receptor signaling in T-lymphocytes. As the functions of Chk in mammalian cells are not known, we examined its ability to carry out Csk-like functions in vivo. Like p50(csk), Chk reduced the elevated phosphotyrosine levels and the augmented activity of Src family kinases in Csk-deficient fibroblasts. Contrary to Csk, however, Chk was inefficient at repressing antigen receptor-induced signals in a T-cell line (BI-141). We also noted that Chk, but not Csk, failed to stably associate with cellular membranes following addition of a membrane targeting signal to its amino terminus. This observation suggested that Chk may contain dominant targeting sequences disallowing its recruitment to cellular membranes. Hence, these data demonstrate that Chk can mediate some, but not all, Csk related functions in vivo. Moreover, they suggest that the ''restricted'' function of Chk may relate at least in part to its inability to be recruited to certain cellular locales.	MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ H3G 1Y6,CANADA; MONTREAL GEN HOSP,DEPT MED,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL,PQ H3G 1A4,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University				Chow, Lionel/0000-0001-8447-063X				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; AVRAHAM S, 1995, J BIOL CHEM, V270, P1833, DOI 10.1074/jbc.270.4.1833; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; Chow L M, 1995, Semin Immunol, V7, P207, DOI 10.1006/smim.1995.0026; CHOW LML, 1994, ONCOGENE, V9, P3437; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Cloutier JF, 1996, EMBO J, V15, P4909, DOI 10.1002/j.1460-2075.1996.tb00871.x; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; Coligan JKA, 1991, CURRENT PROTOCOLS IM; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DAVIDSON D, 1994, J BIOL CHEM, V269, P10956; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; HAMAGUCHI I, 1994, ONCOGENE, V9, P3371; HORAK ID, 1990, ONCOGENE, V5, P597; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KUO SS, 1994, J NEUROSCI RES, V38, P705, DOI 10.1002/jnr.490380613; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MCVICAR DW, 1994, ONCOGENE, V9, P2037; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NADA S, 1994, ONCOGENE, V9, P3571; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; SAKANO S, 1994, ONCOGENE, V9, P1155; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; STAERZ UD, 1985, J IMMUNOL, V134, P3994; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAMAJI Y, 1995, P NATL ACAD SCI USA, V92, P6274, DOI 10.1073/pnas.92.14.6274	36	42	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1355	1362		10.1074/jbc.272.2.1355	http://dx.doi.org/10.1074/jbc.272.2.1355			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995444	hybrid			2022-12-25	WOS:A1997WC04800095
J	Kuang, B; Rubenstein, PA				Kuang, B; Rubenstein, PA			Beryllium fluoride and phalloidin restore polymerizability of a mutant yeast actin (V266G,L267G) with severely decreased hydrophobicity in a subdomain 3/4 loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND DIVALENT-CATION; F-ACTIN; SACCHAROMYCES-CEREVISIAE; ATP HYDROLYSIS; STRUCTURAL DYNAMICS; BUDDING YEAST; NH2 TERMINUS; ADP-ACTIN; PHOSPHATE; FILAMENT	Holmes proposed that in F-actin, hydrophobic residues in a subdomain 3/4 loop interact with a hydrophobic pocket on the opposing strand resulting in helix stabilization, We have determined how a decreased hydrophobicity of this plug affects yeast actin function. Cells harboring only the V266G, V266D, V266F, L267G, L269D, or L269K actins appear normal, although V266G cells display an altered budding pattern, However, V266G,L267G (GG) double mutant cells are cold sensitive with randomly oriented thick actin assemblies seen in rhodamine phalloidin-stained GG cells, V266D actin polymerizes slower than wild-type actin at room temperature, At 4 degrees C, not only is polymerization slowed, but there is also an effect on critical concentration, However, the polymerization defects are milder than those associated with substitution of Asp for the neighboring Leu(267). Purified GG-actin does not polymerize in vitro alone or in the presence of wildtype F-actin seeds, GG-actin polymerization can be restored by larger amounts of wild-type actin, beryllium fluoride, or phalloidin at room temperature, although at 4 degrees C only phalloidin is effective, These results suggest that the diminished hydrophobicity of the plug in GG actin leads to filament destabilization. However, the V266D actin results require a modification of the original Holmes filament model.	UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA	University of Iowa					NIGMS NIH HHS [GM33689] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; CARLIER MF, 1986, J BIOL CHEM, V261, P785; CARLIER MF, 1988, J BIOL CHEM, V263, P817; CHEN X, 1993, J CELL BIOL, V123, P1185, DOI 10.1083/jcb.123.5.1185; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COOK RK, 1991, J BIOL CHEM, V266, P16825; COOK RK, 1993, J BIOL CHEM, V268, P2410; COOKE R, 1975, BIOCHEMISTRY-US, V14, P3250, DOI 10.1021/bi00685a035; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; ESTES JE, 1992, J MUSCLE RES CELL M, V13, P272, DOI 10.1007/BF01766455; HEGRI G, 1992, PROTEIN SCI, V1, P132; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KARPOVA TS, 1995, J CELL BIOL, V131, P1483, DOI 10.1083/jcb.131.6.1483; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MENDELSON RA, 1994, J MOL BIOL, V240, P138, DOI 10.1006/jmbi.1994.1428; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MONCMAN CL, 1993, CELL MOTIL CYTOSKEL, V25, P73, DOI 10.1002/cm.970250109; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; NELLEN W, 1981, Journal of Molecular and Applied Genetics, V1, P239; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; ORLOVA A, 1995, J MOL BIOL, V245, P598, DOI 10.1006/jmbi.1994.0049; ORLOVA A, 1995, J MOL BIOL, V245, P582, DOI 10.1006/jmbi.1994.0048; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; ORLOVA A, 1994, BIOPHYS J, V66, P276, DOI 10.1016/S0006-3495(94)80791-X; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; ROBZYK K, 1992, NUCLEIC ACIDS RES, V20, P3790, DOI 10.1093/nar/20.14.3790; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1995, J STRUCT BIOL, V115, P186, DOI 10.1006/jsbi.1995.1043; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; STRZELECKAGOLASZEWSKA H, 1993, EUR J BIOCHEM, V211, P731, DOI 10.1111/j.1432-1033.1993.tb17603.x; TIRION MM, 1995, BIOPHYS J, V68, P5, DOI 10.1016/S0006-3495(95)80156-6; TOBACMAN LS, 1983, J BIOL CHEM, V258, P3207; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779	44	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1237	1247		10.1074/jbc.272.2.1237	http://dx.doi.org/10.1074/jbc.272.2.1237			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995427	Green Published, hybrid			2022-12-25	WOS:A1997WC04800078
J	Wu, SY; Kaufman, RJ				Wu, SY; Kaufman, RJ			A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; BINDING DOMAIN; INTERFERON ACTION; MESSENGER-RNAS; IN-VIVO; MALIGNANT TRANSFORMATION; P68 KINASE; DAI; MECHANISM; CELLS	Binding of double-stranded RNA (dsRNA) to PKR induces autophosphorylation and activation. However, the requirement for dsRNA in promoting dimerization and the requirement for dimerization in PKR activation are controversial, We have studied the dsRNA binding and dimerization requirements for the activation of PKR in vivo. Go-expression and immunoprecipitation experiments detected an interaction between the K296P mutant and a bacteriophage T7-epitope-tagged K64E mutant of dsRNA binding domain. In contrast, the K64E/K296P double mutant did not form a detectable dimer with the wild-type dsRNA binding domain. These results support that dimerization of intact PKR with the isolated dsRNA binding domain requires dsRNA binding activity. Expression of the isolated PKR kinase domain (residues 228-551) reduced translation of the reporter mRNA even in the presence of PKR inhibitors. Furthermore, the isolated kinase domain (residues 228-551) undergoes autophosphorylation and sequentially trans-phosphorylates both mutant K296P PKR and wild-type eIF-2 alpha in vitro. In contrast, the isolated kinase domain (residues 264-551) lacking the third basic region was not active. These observations lead us to propose that the dsRNA binding domains on intact PKR inhibit kinase activity and that dsRNA binding to intact PKR induces a conformational change to expose dimerization sites within the dsRNA binding domain thereby promoting dimerization and facilitating trans-phosphorylation and activation.	UNIV MICHIGAN,CTR MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160				BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; MARCUS PI, 1988, J GEN VIROL, V69, P1637, DOI 10.1099/0022-1317-69-7-1637; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993; TIWARI RK, 1988, MOL CELL BIOL, V8, P4289, DOI 10.1128/MCB.8.10.4289; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	45	147	181	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1291	1296		10.1074/jbc.272.2.1291	http://dx.doi.org/10.1074/jbc.272.2.1291			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995434	hybrid			2022-12-25	WOS:A1997WC04800085
J	Lee, BS; Krits, I; CraneZelkovic, MK; Gluck, SL				Lee, BS; Krits, I; CraneZelkovic, MK; Gluck, SL			A novel transcription factor regulates expression of the vacuolar H+-ATPase B2 subunit through AP-2 sites during monocytic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITES; PROTON PUMP; V-ATPASES; PROMOTER ACTIVITY; GENE-EXPRESSION; CYTOPLASMIC PH; MESSENGER-RNA; DNA-BINDING; CELLS; PROTEIN	During monocyte-to-macrophage differentiation, the cellular content of vacuolar H+-ATPase (V-ATPase) in creases more than 4-fold, We have shown previously that amplified expression of the B2 subunit of the V-ATPase occurs solely by increased transcription, and that the 5'-untranslated region of the B2 gene, containing multiple consensus binding sites for the transcription factors AP-2 and Sp1, is required for this expression. The present study demonstrates that AP-2 binding sequences are essential for increased transcription from the B2 promoter during monocyte-macrophage differentiation and that AP-2, expressed exogenously in THP-1 and other cells, activates transcription from the B2 promoter. In mobility shift assays, a nuclear factor from THP-1 and U-937 cells was identified that binds to several AP-2 response elements within the B2 promoter, but does not react with AP-2 antibodies, and has a DNA sequence binding affinity profile that differs from AP-2. These findings suggest that a novel AP-2-like transcription factor is responsible for V-ATPase B subunit amplification during monocyte differentiation.	WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,GEORGE M OBRIEN CTR KIDNEY & UROL DIS,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)	Lee, BS (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV RENAL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.		Lee, Beth S/E-9578-2010	Lee, Beth S/0000-0002-1468-6387	NIAMS NIH HHS [AR32087] Funding Source: Medline; NIDDK NIH HHS [DK38848, DK09976] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK009976, R01DK038848] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADLER V, 1995, J CELL PHYSIOL, V164, P26, DOI 10.1002/jcp.1041640105; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Barahmandpour F, 1996, CURR TOP MICROBIOL, V211, P121; BERNASCONI P, 1990, J BIOL CHEM, V265, P17428; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BUETTNER R, 1993, MOL CELL BIOL, V13, P41474; CHEN HM, 1993, J BIOL CHEM, V268, P8230; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; Lee BS, 1996, AM J PHYSIOL-CELL PH, V270, pC382, DOI 10.1152/ajpcell.1996.270.1.C382; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; MACKMAN N, 1991, J EXP MED, V174, P1517, DOI 10.1084/jem.174.6.1517; MANOLSON MF, 1992, J EXP BIOL, V172, P105; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; MOSER M, 1995, DEVELOPMENT, V121, P2779; MYERS M, 1993, J BIOL CHEM, V268, P9184; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PHILIPP J, 1994, DEV BIOL, V165, P602, DOI 10.1006/dbio.1994.1279; RHOADES KL, 1995, CELL IMMUNOL, V161, P125, DOI 10.1006/cimm.1995.1016; ROBERTS MS, 1988, J VIROL, V62, P4307, DOI 10.1128/JVI.62.11.4307-4320.1988; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; Simon MC, 1996, CURR TOP MICROBIOL, V211, P113; SUHDHOF TC, 1989, P NATL ACAD SCI USA, V86, P6067; SUPEK F, 1992, ANN NY ACAD SCI, V671, P284, DOI 10.1111/j.1749-6632.1992.tb43803.x; SWALLOW CJ, 1990, SURGERY, V108, P363; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TSUCHIYA S, 1982, CANCER RES, V42, P1530; WANG SY, 1988, J BIOL CHEM, V263, P17638; WANG ZQ, 1990, J BIOL CHEM, V265, P21957; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZINN K, 1986, CELL, V45, P611, DOI 10.1016/0092-8674(86)90293-X	50	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					174	181						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995244				2022-12-25	WOS:A1997WA56400031
J	MurakamiMurofushi, K; Nishikawa, K; Hirakawa, E; Murofushi, H				MurakamiMurofushi, K; Nishikawa, K; Hirakawa, E; Murofushi, H			Heat stress induces a glycosylation of membrane sterol in myxoamoebae of a true slime mold, Physarum polycephalum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORIFERASTEROL GLUCOSYLTRANSFERASE; UDP-GLUCOSE; DIFFERENTIATION; EXPRESSION; MONOGLUCOSIDE	To know the very early events occurring after heat shock, the changes of membrane lipids were examined. Heat stress induced the production of a certain glycolipid in the myxoamoebae of Physarum polycephalum in a few minutes. The purified glycolipid was determined to be a poriferasterol monoglucoside by structural studies that was previously reported to be expressed during the differentiation of Physarum cells from haploid myxoamoebae to diploid plasmodia (Murakami-Murofushi, K., Nakanzura, K., Ohta, J., Suzuki, M., Suzuki, A, Murofushi, H., and Yokota, T. (1987) J. Biol. Chem. 262, 16719-16723). The activity of UDP-glucose:poriferasterol glucosyltransferase (Murakami-Murofushi, K., and Ohta, J. (1989) Biochim. Biophys. Acta 992, 412-415) was also expressed rapidly after heat shock. Thus, the activation of sterol glucosyltransferase and the production of sterol-glucoside were considered to be important events that were involved in the signal transduction system to induce some succeeding heat-shock responses, such as the synthesis of heat-shock proteins.	OCHANOMIZU UNIV,FAC SCI,DEPT BIOL,TOKYO 112,JAPAN; UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN	Ochanomizu University; University of Tokyo								BUSH PB, 1972, PLANT PHYSIOL, V50, P69, DOI 10.1104/pp.50.1.69; EVANS FJ, 1972, J PHARM PHARMACOL, V24, P645, DOI 10.1111/j.2042-7158.1972.tb09077.x; GRUNWALD C, 1971, PLANT PHYSIOL, V48, P653, DOI 10.1104/pp.48.5.653; LEPAGE M, 1964, J LIPID RES, V5, P587; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCCULLOUGH CHR, 1978, J GEN MICROBIOL, V106, P297; MIMURA K, 1991, Natural Science Report of the Ochanomizu University, V42, P49; MOMOSE T, 1963, ANAL CHEM, V35, P1751, DOI 10.1021/ac60204a062; MURAKAMIMUROFUSHI K, 1984, CELL STRUCT FUNCT, V9, P311, DOI 10.1247/csf.9.311; MURAKAMIMUROFUSHI K, 1987, CELL STRUCT FUNCT, V12, P519, DOI 10.1247/csf.12.519; MURAKAMIMUROFUSHI K, 1987, J BIOL CHEM, V262, P16719; MURAKAMIMUROFUSHI K, 1989, BIOCHIM BIOPHYS ACTA, V992, P412, DOI 10.1016/0304-4165(89)90108-6; MURAKAMIMUROFUSHI K, 1990, P JPN ACAD B-PHYS, V66, P197, DOI 10.2183/pjab.66.197; RADIN NS, 1955, J BIOL CHEM, V217, P789; Schlesinger M. J., 1982, HEAT SHOCK BACTERIA; SHIMADA Y, 1992, CELL STRUCT FUNCT, V17, P301, DOI 10.1247/csf.17.301; SMITH PF, 1969, LIPIDS, V4, P331, DOI 10.1007/BF02531002; WOJCIECHOWSKI ZA, 1979, BIOCHIM BIOPHYS ACTA, V570, P363, DOI 10.1016/0005-2744(79)90156-6; WOJCIECHOWSKI ZA, 1976, PHYTOCHEMISTRY, V15, P1681, DOI 10.1016/S0031-9422(00)97452-1; WOJCIECHOWSKI ZA, 1977, PHYTOCHEMISTRY, V16, P911, DOI 10.1016/S0031-9422(00)86691-1	20	38	39	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					486	489						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995287				2022-12-25	WOS:A1997WA56400074
J	Quirk, S; Do, BT				Quirk, S; Do, BT			Cloning, purification, and characterization of the Shigella boydii dGTP triphosphohydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYGUANOSINE TRIPHOSPHATE TRIPHOSPHOHYDROLASE; GENE 1.2 PROTEIN; ESCHERICHIA-COLI; BINDING; BACTERIOPHAGE-T7	The nucleotide sequence of the Shigella boydii dgt gene, which encodes the enzyme deoxyguanosine triphosphate triphosphohydrolase (dGTPase, EC 3.1.5.1), has been determined. The 1515-nucleotide Shigella dgt open reading frame has been subcloned into a T7 RNA polymerase-based expression vector. The resulting expressed protein has been purified to homogeneity using a novel single-day chromatographic regime. The protocol includes ion exchange, affinity, and hydrophobic interaction chromatography. The purified 505-amino acid (59.4 kDa) protein exists in solution as a heat-stable homotetramer, and enzymatic assays reveal that the expressed enzyme is fully active. Substrate specificity can be explained by the array of potential hydrogen bond donors/accepters displayed on the base moiety of the (deoxy)nucleoside triphosphate. Shigella dGTPase can be inhibited by the addition of stoichiometric amounts of reducing agents. The loss of activity is both time and concentration-dependent and is accompanied by a decrease in the thermal stability of the enzyme, Shigella dGTPase in the fully reduced form is destabilized by 1.8 kcal/mol compared with the oxidized form. Hence, disulfide bonds play a pivotal role in the maintenance of dGTPase stability and enzymatic functionality, Initial Shigella dGTPase protein crystals have been formed.			Quirk, S (corresponding author), GEORGIA INST TECHNOL,SCH CHEM & BIOCHEM,ATHENS,GA 30332, USA.			Quirk, Stephen/0000-0002-4497-1023	NCI NIH HHS [R29CA6798101A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA067981] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1960, J BIOL CHEM, V235, P769; BEAUCHAMP BB, 1988, P NATL ACAD SCI USA, V85, P2563, DOI 10.1073/pnas.85.8.2563; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Giege R, 1992, CRYSTALLIZATION NUCL, P82; HUBER HE, 1988, J BIOL CHEM, V263, P13549; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KORNBERG SR, 1958, J BIOL CHEM, V233, P159; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; Morrison D A, 1979, Methods Enzymol, V68, P326; NAKAI H, 1990, J BIOL CHEM, V265, P4411; Ochman H, 1987, ESCHERICHIA COLI SAL, P1649; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; QUIRK S, 1989, MOL MICROBIOL, V3, P1391, DOI 10.1111/j.1365-2958.1989.tb00121.x; QUIRK S, 1990, GENE, V89, P13, DOI 10.1016/0378-1119(90)90200-B; QUIRK S, 1991, J BACTERIOL, V173, P6665, DOI 10.1128/jb.173.21.6665-6669.1991; SAITO H, 1981, J VIROL, V37, P343, DOI 10.1128/JVI.37.1.343-351.1981; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SETO D, 1988, J BIOL CHEM, V263, P1494; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; WURGLER SM, 1993, J BIOL CHEM, V268, P20046; WURGLER SM, 1990, P NATL ACAD SCI USA, V87, P2740, DOI 10.1073/pnas.87.7.2740	24	2	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					332	336						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995266				2022-12-25	WOS:A1997WA56400053
J	Wang, Z; Sachs, MS				Wang, Z; Sachs, MS			Arginine-specific regulation mediated by the Neurospora crassa arg-2 upstream open reading frame in a homologous, cell-free in vitro translation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; LEADER PEPTIDE; REPRESSION; EXPRESSION; YEAST; INITIATION; STABILITY; ARGININE; GENE	Translational control mediated by an upstream open reading frame (uORF) in the 5'-leader of the Neurospora crassa arg-2 mRNA was reconstituted in a homologous, cell-free in vitro translation system. A cell-free N. crassa system was developed that required the presence of cap and poly(A) on RNA for maximal translation and that was amino acid-dependent. The 24-codon arg-2 uORF, when placed in the 5'-leader region of capped and adenylated synthetic luciferase RNAs, conferred Arg-specific negative regulation in this system. Improving the uORF translation initiation context decreased luciferase production and only slightly increased the magnitude of Arg-specific regulation. Mutation of uORF Asp codon 12 to Asn, which eliminates Arg-specific regulation in vivo, eliminated regulation in vitro. Elimination of the uORF translation initiation codon also eliminated Arg-specific regulation. Arg-specific regulation in vitro appeared to be reversible. Control of RNA stability did not appear to be a primary component of Arg-specific regulation in vitro. Comparison of the effects of adding Arg to in vitro translation reactions with adding compounds related to Arg indicated that Arg-specific translational regulation was specific for L-arginine.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM BIOCHEM & MOL BIOL, PORTLAND, OR 97291 USA					Sachs, Matthew/0000-0001-9891-9223	NIGMS NIH HHS [GM 47498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047498, R01GM047498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDISON R, 1987, J BIOL CHEM, V262, P17031; Cao JH, 1996, MOL CELL BIOL, V16, P603; Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CRABEEL M, 1990, MOL CELL BIOL, V10, P1226, DOI 10.1128/MCB.10.3.1226; CURLE CA, 1988, CURR GENET, V13, P401, DOI 10.1007/BF00365661; DAMIANI RD, 1993, P NATL ACAD SCI USA, V90, P8244, DOI 10.1073/pnas.90.17.8244; DELBECQ P, 1994, MOL CELL BIOL, V14, P2378, DOI 10.1128/MCB.14.4.2378; DEVCHAND M, 1988, CURR GENET, V13, P323, DOI 10.1007/BF00424426; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; Freitag M, 1996, GENETICS, V142, P117; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GEBALLE AP, 1996, TRANSLATIONAL CONTRO, P173; GERSTEL B, 1992, MOL MICROBIOL, V6, P2339, DOI 10.1111/j.1365-2958.1992.tb01409.x; GROEBE DR, 1988, NUCLEIC ACIDS RES, V16, P11725, DOI 10.1093/nar/16.24.11725; Hershey JWB, 1996, TRANSLATIONAL CONTRO; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; LUO ZG, 1995, MOL CELL BIOL, V15, P5235; Luo ZL, 1996, J BACTERIOL, V178, P2172, DOI 10.1128/jb.178.8.2172-2177.1996; OLIVEIRA CC, 1993, NUCLEIC ACIDS RES, V21, P5316, DOI 10.1093/nar/21.23.5316; ORBACH MJ, 1990, J BIOL CHEM, V265, P10981; PAROLA AL, 1994, J BIOL CHEM, V269, P4497; RUAN HJ, 1994, J BIOL CHEM, V269, P17905; SACHS MS, 1989, MOL CELL BIOL, V9, P566, DOI 10.1128/MCB.9.2.566; SACHS MS, 1991, DEV BIOL, V148, P117, DOI 10.1016/0012-1606(91)90322-T; SACHS MS, 1996, MYCOTA, V3, P315; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SZCZESNASKORUPA E, 1981, EUR J BIOCHEM, V121, P163, DOI 10.1111/j.1432-1033.1981.tb06445.x; TARUN SZ, 1995, GENE DEV, V9, P2997, DOI 10.1101/gad.9.23.2997; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	38	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					255	261						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995256				2022-12-25	WOS:A1997WA56400043
J	Keyhani, NO; Roseman, S				Keyhani, NO; Roseman, S			The chitin catabolic cascade in the marine bacterium Vibrio furnissii - Molecular cloning, isolation, and characterization of a periplasmic chitodextrinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CIRCULANS WL-12; ESCHERICHIA-COLI; ENCODING GENE; EXPRESSION; SEQUENCE; DEGRADATION; OLIGOSACCHARIDES; ENDOCHITINASE; PURIFICATION; CHEMOTAXIS	Chitin catabolism in Vibrio furnissii comprises several signal transducing systems and many proteins, Two of these enzymes are periplasmic and convert chitin oligosaccharides to GlcNAc and (GlcNAc)(2), One of these unique enzymes, a chitodextrinase, designated EndoI, is described here. The protein, isolated from a recombinant Escherichia coli clone, exhibited (via SDS-polyacrylamide gel electrophoresis) two enzymatically active, close running bands (similar to mass of 120 kDa) with identical N-terminal sequences, The chitodextrinase rapidly cleaved chitin oligosaccharides, (GlcNAc)(4) to (GlcNAc)(2), and (GlcNAc)(5.6) to (GlcNAc)(2) and (GlcNAc)(3), EndoI was substrate inhibited in the millimolar range and was inactive with chitin, glucosamine oligosaccharides, glycoproteins, and glycopeptides containing (GlcNAc)(2). The sequence of the cloned gene indicates that it encodes a 112,690-kDa protein (1046 amino acids), Both proteins lacked the predicted N-terminal 31 amino acids, corresponding to a consensus prokaryotic signal peptide. Thus, E, coli recognizes and processes this V, furnissii signal sequence, Although inactive with chitin, the predicted amino acid sequence of EndoI displayed similarities to many chitinases, with 8 amino acids completely conserved in 10 or more of the homologous proteins, There was, however, no ''consensus'' chitin-binding domain in EndoI.	JOHNS HOPKINS UNIV, DEPT BIOL, BALTIMORE, MD 21218 USA; JOHNS HOPKINS UNIV, MCCOLLUM PRATT INST, BALTIMORE, MD 21218 USA	Johns Hopkins University; Johns Hopkins University			Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM51215, GM07321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1982, MOL CLONING LAB MANU; AUSUBEL FM, 1996, CURRENT PROTOCOLS S, V1; BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BLAISEAU PL, 1992, GENE, V120, P243, DOI 10.1016/0378-1119(92)90099-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CABIB E, 1988, METHOD ENZYMOL, V161, P424; Cleland W W, 1979, Methods Enzymol, V63, P500; Danulat E., 1986, P241; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; FUHRMAN JA, 1992, P NATL ACAD SCI USA, V89, P1548, DOI 10.1073/pnas.89.5.1548; GORBUNOFF MJ, 1990, METHOD ENZYMOL, V182, P329; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HARPSTER MH, 1989, NUCLEIC ACIDS RES, V17, P5395, DOI 10.1093/nar/17.13.5395; HAYES CK, 1994, GENE, V138, P143, DOI 10.1016/0378-1119(94)90797-8; HISHINUMA F, 1984, NUCLEIC ACIDS RES, V12, P7581, DOI 10.1093/nar/12.19.7581; HOROWITZ ST, 1957, J AM CHEM SOC, V79, P5046, DOI 10.1021/ja01575a059; JONES JDG, 1986, EMBO J, V5, P467, DOI 10.1002/j.1460-2075.1986.tb04235.x; KAMEI K, 1989, J BIOCHEM-TOKYO, V105, P979, DOI 10.1093/oxfordjournals.jbchem.a122791; Keyhani NO, 1996, J BIOL CHEM, V271, P33425, DOI 10.1074/jbc.271.52.33425; KURANDA MJ, 1987, P NATL ACAD SCI USA, V84, P2585, DOI 10.1073/pnas.84.9.2585; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; PEGG GF, 1988, METHOD ENZYMOL, V161, P484; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; ROBBINS PW, 1988, J BIOL CHEM, V263, P443; ROFFEY PE, 1990, CURR MICROBIOL, V21, P329, DOI 10.1007/BF02092100; ROSEMAN S, 1956, ANAL CHEM, V28, P1743, DOI 10.1021/ac60119a028; ROWE CA, 1995, THESIS J HOPKINS U B; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TRACEY M. V., 1957, REVS PURE AND APPL CHEM, V7, P1; TSUJIBO H, 1994, GENE, V146, P111, DOI 10.1016/0378-1119(94)90843-5; *US BIOCH CORP, 1993, PROT DNA SEQ SEQ V 2; VOET D, 1990, BIOCHEMISTRY-US, P367; WATANABE T, 1992, J BACTERIOL, V174, P408, DOI 10.1128/jb.174.2.408-414.1992; WATANABE T, 1994, J BACTERIOL, V176, P4465, DOI 10.1128/JB.176.15.4465-4472.1994; WATANABE T, 1990, J BACTERIOL, V172, P4017, DOI 10.1128/jb.172.7.4017-4022.1990; WATANABE T, 1990, J BIOL CHEM, V265, P15659; YU C, 1993, J BIOL CHEM, V268, P9405; YU C, 1991, J BIOL CHEM, V266, P24260; Zechmeister L, 1939, ENZYMOLOGIA, V7, P165; Zechmeister L, 1939, ENZYMOLOGIA, V7, P170; ZHU BCR, 1992, J BIOCHEM-TOKYO, V112, P163, DOI 10.1093/oxfordjournals.jbchem.a123857	45	81	87	3	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33414	33424		10.1074/jbc.271.52.33414	http://dx.doi.org/10.1074/jbc.271.52.33414			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969204	hybrid			2022-12-25	WOS:A1996WA71300038
J	Sviridov, D; Pyle, LE; Fidge, N				Sviridov, D; Pyle, LE; Fidge, N			Efflux of cellular cholesterol and phospholipid to apolipoprotein A-I mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE; ACYLTRANSFERASE ACTIVATION; ENDOPLASMIC-RETICULUM; HDL-PARTICLES; CELLS; PROTEIN; BINDING; TRANSPORT; MUTAGENESIS	Human plasma apolipoprotein A-I (apoA-I) and recombinant full-length proapoA-I (apoA-I-(-6-243)) as well as four truncated forms of proapoA-I were used as accepters to study cholesterol and phospholipid efflux from HepG2 cells. Efflux of both cholesterol and phospholipid to the lipid-free plasma apoA-I was twice that of apoA-I-(-6-243). When apoA-I was incorporated into reconstituted high density lipoprotein, cholesterol efflux increased, phospholipid efflux decreased and the difference between plasma apoA-I and apoA-I-(-6-243) disappeared. Truncation of recombinant apoA-I to residues 222 (apoA-I-(-6-222)) and 210 (apoA-I-(-6-210)) resulted in a 70-95% decrease in their ability to promote the efflux of both intracellular and plasma membrane cholesterol. Further truncation to residues 150 (apoA-I-(-6-150)) and 135 (apoA-I-(-6-135)) fully restored the ability of apoA-I to promote cholesterol efflux. Phospholipid efflux closely paralleled the efflux of cholesterol. Interaction of I-125-labeled apoA-I with the cells was similar for apoA-I-(-6-243), apoA-I-(-6-222), and apoA-I(-6-210), but slightly higher for apoA-I-(-6-150) and apoA-I-(-6-135). When complexed with phospholipid, all forms except apoA-I-(-6-210) formed discoidal reconstituted high density lipoprotein particles. When the same amounts of free or lipid-associated apoA-I were compared, association of apoA-I with phospholipid increased cholesterol efflux and decreased phospholipid efflux, and the difference in the ability of different mutants to promote cholesterol and phospholipid efflux disappeared. We conclude that the capacity of lipid-free apoA-I to promote cholesterol efflux is related to its ability to mobilize cellular phospholipid, which apparently involves a region around residues 222-243. A second lipid-binding region is exposed when the carboxy-terminal half of apoA-I is absent.			Sviridov, D (corresponding author), BAKER MED RES INST,COMMERCIAL RD,POB 348,PRAHRAN,VIC 3181,AUSTRALIA.		Sviridov, Dmitri/E-7943-2010					ALLAN CM, 1993, BIOCHEM J, V290, P449, DOI 10.1042/bj2900449; BANKA CL, 1994, J BIOL CHEM, V269, P10288; Barter Philip, 1993, Current Opinion in Lipidology, V4, P210, DOI 10.1097/00041433-199306000-00006; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1982, J BIOL CHEM, V257, P955; FIELDING PE, 1994, BIOCHEMISTRY-US, V33, P6981, DOI 10.1021/bi00188a030; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; Forte Trudy M., 1994, Current Opinion in Lipidology, V5, P354, DOI 10.1097/00041433-199410000-00007; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HOLVOET P, 1995, BIOCHEMISTRY-US, V34, P13334, DOI 10.1021/bi00041a009; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; JONAS A, 1989, J BIOL CHEM, V264, P4818; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; MATZ CE, 1982, J BIOL CHEM, V257, P4535; McGuire KA, 1996, J LIPID RES, V37, P1519; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; MINNICH A, 1992, J BIOL CHEM, V267, P16553; MORRISON JR, 1990, ANAL BIOCHEM, V186, P145, DOI 10.1016/0003-2697(90)90588-Z; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Pyle LE, 1996, BIOCHEMISTRY-US, V35, P12046, DOI 10.1021/bi9609073; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; Rye KA, 1996, J BIOL CHEM, V271, P4243; SCHMIDT HHJ, 1995, J BIOL CHEM, V270, P5469, DOI 10.1074/jbc.270.10.5469; SEGREST JP, 1992, J LIPID RES, V33, P141; SorciThomas MG, 1996, J LIPID RES, V37, P673; SVIRIDOV D, 1995, BBA-LIPID LIPID MET, V1256, P210, DOI 10.1016/0005-2760(95)00028-B; SVIRIDOV D, 1995, J LIPID RES, V36, P1887; Sviridov D, 1996, BIOCHEMISTRY-US, V35, P189, DOI 10.1021/bi9507544; URBANI L, 1990, J BIOL CHEM, V265, P1919; WESTMAN J, 1993, SCAND J CLIN LAB INV, V53, P773, DOI 10.3109/00365519309086488; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	40	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33277	33283		10.1074/jbc.271.52.33277	http://dx.doi.org/10.1074/jbc.271.52.33277			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969186	hybrid			2022-12-25	WOS:A1996WA71300020
J	Chu, DS; Pishvaee, B; Payne, GS				Chu, DS; Pishvaee, B; Payne, GS			The light chain subunit is required for clathrin function in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SECRETORY PATHWAY; HEAVY-CHAIN; COATED VESICLES; MEMBRANE-PROTEINS; GOLGI-COMPLEX; CELL-GROWTH; IDENTIFICATION; ENDOCYTOSIS; RETENTION; TRANSPORT	Clathrin, a multimeric protein involved in intracellular protein trafficking, is composed of three heavy chains (Chc) and three light chains (Clc), Upon disruption (clc1 Delta) of the single Clc-encoding gene (CLC1) in yeast, the steady state protein levels of Chc decreased 5-10-fold compared with wild type cells; consequently, phenotypes exhibited by clc1 Delta cells may result indirectly from the loss of Chc as opposed to the absence of Clc, As an approach to directly examine Clc function, clc1 Delta strains were generated that carry a multicopy plasmid containing the clathrin heavy chain gene (CHC1), resulting in levels of Chc 5-10-fold elevated over wild-type levels, As with deletion of CHC1, deletion of CLC1 results in defects in growth, receptor-mediated endocytosis, and maturation of the mating pheromone alpha-factor, However, elevated Chc expression in clc1 Delta cells partially suppresses the growth and alpha-factor maturation defects displayed by clc1 Delta cells alone, Biochemical analyses indicate that trimerization and assembly of Chc are perturbed in the absence of Clc, resulting in vesiculation defects, Our results demonstrate that the light chain subunit of clathrin is required for efficient Chc trimerization, proper formation of clathrin coats, and the generation of clathrin-coated vesicles.	UNIV CALIF LOS ANGELES, DEPT BIOL CHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039040] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 07185, GM39040] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRODSKY FM, 1991, TRENDS BIOCHEM SCI, V16, P208, DOI 10.1016/0968-0004(91)90087-C; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DELUCAFLAHERTY C, 1990, CELL, V62, P875, DOI 10.1016/0092-8674(90)90263-E; DULIC V, 1991, METHOD ENZYMOL, V194, P697; HILL BL, 1988, J BIOL CHEM, V263, P5499; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON SK, 1988, J CELL BIOCHEM, V36, P329, DOI 10.1002/jcb.240360403; LISANTI MP, 1982, EUR J BIOCHEM, V125, P463, DOI 10.1111/j.1432-1033.1982.tb06706.x; LIU SH, 1995, CELL, V83, P257, DOI 10.1016/0092-8674(95)90167-1; MUELLER SC, 1984, J CELL BIOL, V98, P341, DOI 10.1083/jcb.98.1.341; NATHKE I, 1990, J BIOL CHEM, V265, P18621; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; PAYNE GS, 1988, J CELL BIOL, V106, P1453, DOI 10.1083/jcb.106.5.1453; PAYNE GS, 1989, SCIENCE, V245, P1358, DOI 10.1126/science.2675311; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PHAN HL, 1994, EMBO J, V13, P1706, DOI 10.1002/j.1460-2075.1994.tb06435.x; RAD MR, 1995, J CELL SCI, V108, P1605; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHRODER S, 1991, J BIOL CHEM, V266, P7910; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; SEEGER M, 1992, J CELL BIOL, V118, P531, DOI 10.1083/jcb.118.3.531; Sherman F., 1974, METHODS YEAST GENETI; SILVEIRA LA, 1990, J CELL BIOL, V111, P1437, DOI 10.1083/jcb.111.4.1437; SILVEIRA LA, 1990, THESIS U CALIFORNIA; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; TAN PK, 1993, J CELL BIOL, V123, P1707, DOI 10.1083/jcb.123.6.1707; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; UNGEWICKELL E, 1991, J BIOL CHEM, V266, P12710; Wilsbach Kathleen, 1993, Trends in Cell Biology, V3, P426, DOI 10.1016/0962-8924(93)90031-U; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x	35	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33123	33130		10.1074/jbc.271.51.33123	http://dx.doi.org/10.1074/jbc.271.51.33123			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955161	hybrid			2022-12-25	WOS:A1996VZ37300096
J	Gruber, G; Capaldi, RA				Gruber, G; Capaldi, RA			The trapping of different conformations of the Escherichia coli F-1 ATPase by disulfide bond formation - Effect of nucleotide binding affinities of the catalytic sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; EPSILON-SUBUNIT; NONCATALYTIC SITES; OXIDATIVE-PHOSPHORYLATION; CRYOELECTRON MICROSCOPY; GAMMA-SUBUNIT; BETA-SUBUNIT; DIRECT PROBE; F1-ATPASE; FLUORESCENCE	Two mutants of the Escherichia coli F-1 ATPase, beta Y331W:E381C/epsilon S108C and alpha S411C/beta Y331W/epsilon S108C, have been used to relate nucleotide binding in catalytic sites with different interactions of the stalk-forming subunits gamma and epsilon at the alpha(3) beta(3) subunit domain, Essentially full yield cross-linking between beta + gamma and beta + epsilon, or between alpha + gamma and alpha + epsilon was obtained in these mutants by Cu2+-induced disulfide bond formation, thereby trapping the enzyme in states with the small subunits interacting either with beta or alpha subunits, The presence of the Trp for beta Tyr-331 in both mutants allowed direct measurement of nucleotide occupancy of catalytic sites. Before cross-linking, Mg2+-ATP could be bound in all three catalytic sites in both mutants with a K-d of around 0.1 mu M for the highest affinity site and K-d values of approximately 2 mu M and 30-40 mu M for the second and third sites, respectively, In the absence of Mg2+, ATP also bound in all three catalytic sites but with a single low affinity (above 100 mu M) in both mutants, Cu2+-induced cross-linking of ECF(1) from the mutant beta Y331W:E381C/epsilon S108C had very little effect on nucleotide binding, The binding affinities of the three catalytic sites for Mg2+ ATP were not significantly altered from those obtained before cross-linking, and the enzyme still switched between cooperative binding and equal binding affinities of the three catalytic sites (when Mg2+ was absent). When the gamma and epsilon subunits were cross-linked to alpha subunits, ATP binding in the highest affinity catalytic site was dramatically altered, This site became closed so that nucleotide (ATP or ADP) that had been bound into it prior to cross-linking was trapped and could not exchange out. Also, ATP or ADP could not enter this site, although empty, once the enzyme had been cross-linked, Finally, cross-linking of the gamma and epsilon to the alpha subunits prevented the switching between cooperative binding and the state where the three catalytic sites are equivalent, We argue that the conformation of the enzyme in which the small subunits are at alpha subunits occurs during functioning of the enzyme in the course of the rotation of gamma and epsilon subunits within the alpha(3) beta(3) hexamer and that this may be the activated state for ATP synthesis.	UNIV OREGON, INST MOL BIOL, EUGENE, OR 97403 USA	University of Oregon					NHLBI NIH HHS [HL24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BOYER D, 1993, BIOCHIM BIOPHYS ACTA, V1440, P215; CAPALDI RA, 1994, NAT STRUCT BIOL, V1, P660, DOI 10.1038/nsb1094-660; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V87, P9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; Gruber G, 1996, BIOCHEMISTRY-US, V35, P3875, DOI 10.1021/bi952949h; HAUGHTON MA, 1995, J BIOL CHEM, V270, P20568, DOI 10.1074/jbc.270.35.20568; LAEMMLI UK, 1970, BIOCHEMISTRY-US, V9, P4620; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Tang CL, 1996, J BIOL CHEM, V271, P3018, DOI 10.1074/jbc.271.6.3018; TURINA P, 1992, J BIOL CHEM, V268, P6978; WEBER J, 1994, J BIOL CHEM, V269, P20462; WEBER J, 1994, J BIOL CHEM, V269, P11261; WEBER J, 1993, J BIOL CHEM, V268, P20126; WISE JG, 1981, J BIOL CHEM, V256, P383; WISE JG, 1985, BIOCHEMISTRY-US, V24, P6949, DOI 10.1021/bi00345a030; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609; Zhou YT, 1996, BBA-BIOENERGETICS, V1275, P96, DOI 10.1016/0005-2728(96)00056-4	32	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32623	32628		10.1074/jbc.271.51.32623	http://dx.doi.org/10.1074/jbc.271.51.32623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955091	hybrid			2022-12-25	WOS:A1996VZ37300026
J	Hamelryck, TW; Poortmans, F; Goossens, A; Angenon, G; VanMontagu, M; Wyns, L; Loris, R				Hamelryck, TW; Poortmans, F; Goossens, A; Angenon, G; VanMontagu, M; Wyns, L; Loris, R			Crystal structure of arcelin-5, a lectin-like defense protein from Phaseolus vulgaris	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED CARBOHYDRATE; 3-DIMENSIONAL STRUCTURES; LEGUME LECTINS; BINDING SITE; SEED PROTEIN; DATA-BANK; RESOLUTION; DISACCHARIDES; SPECIFICITY; MANNOSE	In the seeds of the legume plants, a class of sugar-binding proteins with high structural and sequential identity is found, generally called the legume lectins. The seeds of the common bean (Phaseolus vulgaris) contain, besides two such lectins, a lectin-like defense protein called arcelin, in which one sugar binding loop is absent. Here we report the crystal structure of arcelin-5 (Arc5), one of the electrophoretic variants of arcelin, solved at a resolution of 2.7 Angstrom. The R factor of the refined structure is 20.6%, and the free R factor is 27.1%. The main difference between Arc5 and the legume lectins is the absence of the metal binding loop. The bound metals are necessary for the sugar binding capabilities of the legume lectins and stabilize an Ala-Asp cis-peptide bond. Surprisingly, despite the absence of the metal binding site in Arc5, this cis-peptide bond found in all legume lectin structures is still present, although the Asp residue has been replaced by a Tyr residue. Despite the high identity between the different legume lectin sequences, they show a broad range of quaternary structures. The structures of three different dimers and three different tetramers have been solved. Arc5 crystallized as a monomer, bringing the number of known quaternary structures to seven.	VLAAMSE INSTELLING TECHNOL ONDERZOEK, B-2400 MOL, BELGIUM; STATE UNIV GHENT VIB, GENET LAB, B-9000 GHENT, BELGIUM	VITO; Flanders Institute for Biotechnology (VIB); Ghent University	Hamelryck, TW (corresponding author), FREE UNIV BRUSSELS VIB, LAB ULTRASTRUCT, PAARDENSTR 65, B-1640 RHODE ST GENESE, BELGIUM.		Loris, Remy/GPG-0894-2022; Angenon, Geert/O-3127-2019; Angenon, Geert/A-1960-2015; Hamelryck, Thomas/A-3923-2012	Angenon, Geert/0000-0001-8177-4961; Angenon, Geert/0000-0001-8177-4961; Hamelryck, Thomas/0000-0003-2917-3602; Loris, Remy/0000-0002-8862-3338				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANERJEE R, 1994, P NATL ACAD SCI USA, V91, P227, DOI 10.1073/pnas.91.1.227; BECKER JW, 1975, J BIOL CHEM, V250, P1513; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; BOUWSTRA JB, 1990, EUR J BIOCHEM, V190, P113, DOI 10.1111/j.1432-1033.1990.tb15553.x; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; Delbaere L.T.J., 1989, T AM CRYSTALLOGR ASS, V25, P65; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DIAZ CL, 1989, NATURE, V338, P579, DOI 10.1038/338579a0; EINSPAHR H, 1986, J BIOL CHEM, V261, P6518; GOOSSENS A, 1994, EUR J BIOCHEM, V225, P787, DOI 10.1111/j.1432-1033.1994.0787b.x; Hamelryck TW, 1996, J BIOL CHEM, V271, P20479, DOI 10.1074/jbc.271.34.20479; HARTWECK LM, 1991, PLANT PHYSIOL, V97, P204, DOI 10.1104/pp.97.1.204; HENNIG M, 1995, J MOL BIOL, V254, P237, DOI 10.1006/jmbi.1995.0614; HERZBERG O, 1991, PROTEINS, V11, P223, DOI 10.1002/prot.340110307; IMBERTY A, 1991, GLYCOCONJUGATE J, V8, P456, DOI 10.1007/BF00769847; IMBERTY A, 1990, GLYCOCONJUGATE J, V7, P27, DOI 10.1007/BF01050401; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KORNEGAY J, 1993, CROP SCI, V33, P589, DOI 10.2135/cropsci1993.0011183X003300030034x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORIS R, 1993, BIOCHEMISTRY-US, V32, P8772, DOI 10.1021/bi00085a007; McDonald I, 1993, HBPLUS COMPUTER PROG; MIRKOV TE, 1994, PLANT MOL BIOL, V26, P1103, DOI 10.1007/BF00040692; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OSBORN TC, 1988, SCIENCE, V240, P207, DOI 10.1126/science.240.4849.207; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PFLUGRATH JW, 1989, MADNESS MANUAL FAST; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	35	33	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32796	32802		10.1074/jbc.271.51.32796	http://dx.doi.org/10.1074/jbc.271.51.32796			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955116	hybrid			2022-12-25	WOS:A1996VZ37300051
J	Jezek, P; Costa, ADT; Vercesi, AE				Jezek, P; Costa, ADT; Vercesi, AE			Evidence for anion-translocating plant uncoupling mitochondrial protein in potato mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; FREE FATTY-ACIDS; OXIDATIVE-PHOSPHORYLATION; ALTERNATIVE OXIDASE; TRANSPORT; METABOLISM; SENESCENCE; INHIBITION; MECHANISM; CHANNEL	Transport properties of plant mitochondria from potato tubers were investigated using the swelling technique and membrane potential measurements. Proton-dependent swelling of fatty acid-depleted mitochondria in potassium acetate with valinomycin was possible only in the presence of fatty acids (linoleic acid and 12-(4-azido-2-nitrophenylamino) do decanoic acid) and was inhibited by various purine nucleotides including ATP, GDP, and GTP. Swelling representing uptake of hexanesulfonate was also inhibited by purine nucleotides. Also, the membrane potential of fatty acid-depleted potato mitochondria energized by succinate declined upon the addition of linoleic acid or 12-(4-azido-2-nitrophenylamino)dodecanoic acid, and this decrease was prevented by ATP and other purine nucleotides. These transport activities are identical to those reported for brown adipose tissue mitochondria and related to the uncoupling protein; therefore, we ascribed them to the plant mitochondrial uncoupling protein (PUMP). A major difference between plant and mammalian uncoupling protein is that PUMP transports small hydrophilic anions such as Cl- very slowly, if at all. We suggest that PUMP may play an important role in plant physiology, where a regulated uncoupling and thermogenesis can proceed during fruit and seed development.	UNIV ESTADUAL CAMPINAS, UNICAMP, DEPT BIOQUIM, BR-13083970 CAMPINAS, SP, BRAZIL; ACAD SCI CZECH REPUBL, INST PHYSIOL, DEPT MEMBRANE TRANSPORT BIOPHYS, CR-14220 PRAGUE 4, CZECH REPUBLIC	Universidade Estadual de Campinas; Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences			Vercesi, Aníbal E/C-8767-2012; Jezek, Petr/B-9264-2012; Costa, Alexandre Augusto da/HCJ-0140-2022	Jezek, Petr/0000-0002-2720-9395; Costa, Alexandre Augusto da/0000-0001-7558-5435; Dias Tavares Costa, Alexandre/0000-0001-8434-2152; Vercesi, Anibal Eugenio/0000-0001-6671-7125				BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BIALE JB, 1981, RECENT ADV BIOCH FRU, P1, DOI DOI 10.1111/J.1365-313X.2007.03170.X; BONNER WD, 1967, METHOD ENZYMOL, V10, P126; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; DAY DA, 1995, J BIOENERG BIOMEMBR, V27, P379, DOI 10.1007/BF02110000; DAY DA, 1980, BIOCH PLANTS, V2, P197; GALLIARD T, 1980, BIOCH PLANTS, V4, P85; GARDESTROM P, 1995, J BIOENERG BIOMEMBR, V27, P415, DOI 10.1007/BF02110004; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; HOLDEN MJ, 1989, PLANT PHYSIOL, V91, P1296, DOI 10.1104/pp.91.4.1296; JEZEK P, 1988, J BIOENERG BIOMEMBR, V20, P603, DOI 10.1007/BF00768922; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1994, J BIOL CHEM, V269, P26184; JEZEK P, 1995, FEBS LETT, V361, P303, DOI 10.1016/0014-5793(95)00201-J; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KRAB K, 1995, J BIOENERG BIOMEMBR, V27, P387, DOI 10.1007/BF02110001; MOORE AL, 1995, J BIOENERG BIOMEMBR, V27, P367, DOI 10.1007/BF02109999; MOORE AL, 1994, BBA-BIOENERGETICS, V1187, P145, DOI 10.1016/0005-2728(94)90101-5; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; PETRUSSA E, 1992, FEBS LETT, V307, P267, DOI 10.1016/0014-5793(92)80692-A; Ruzicka M, 1996, FEBS LETT, V382, P239, DOI 10.1016/0014-5793(96)00161-5; SCHONFELD P, 1996, IN PRESS EUR J BIOCH; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; SMART CM, 1994, NEW PHYTOL, V126, P419, DOI 10.1111/j.1469-8137.1994.tb04243.x; SOBOLL S, 1985, BIOCHIM BIOPHYS ACTA, V807, P245, DOI 10.1016/0005-2728(85)90255-5; SOOLE KL, 1995, J BIOENERG BIOMEMBR, V27, P397, DOI 10.1007/BF02110002; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; WANNER L, 1991, PLANT SCI, V78, P199, DOI 10.1016/0168-9452(91)90199-I; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y	32	74	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32743	32748						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955108				2022-12-25	WOS:A1996VZ37300043
J	Magana, MM; Osborne, TF				Magana, MM; Osborne, TF			Two tandem binding sites for sterol regulatory element binding proteins are required for sterol regulation of fatty-acid synthase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; COENZYME-A REDUCTASE; DNA-BINDING; RECEPTOR GENE; TRANSCRIPTION; IDENTIFICATION; SEQUENCE; DIFFERENTIATION; SPECIFICITY; MOTIF	We previously reported that sterol regulation of the rat fatty-acid synthase was lost when the DNA sequence between -73 and -43 of the promoter was deleted from a luciferase reporter construct (Bennett, M. K., Lopez, J. M., Sanchez, H. B., and Osborne, T. F. (1995) J. Biol. Chem. 270, 25578-25583). We also showed that there was a binding site for sterol regulatory element binding protein-1 (SREBP-1) in this region that contains a palindromic E-box motif (5'-CANNTG-3'). This is the consensus recognition element for basic helix-loop-helix leucine zipper containing proteins such as the SREBPs. However, the SREBPs are unique basic-helix-loop helix leucine zipper proteins that not only bind to a subset of E-boxes but also to the direct repeat SRE-1 element of the low density lipoprotein receptor promoter as well as to variant sites present in the promoters for key enzymes of both cholesterol and fatty acid biosynthesis. Based on the sequence of the variant SREBP recognition sites in these other promoters, we noted there was more than one potential recognition site for SREBP within the -73 to -43 interval of the fatty-acid synthase promoter. In the present studies we have systematically mutated these potential SREBP sites and have analyzed the consequences on sterol regulation, activation by exogenously supplied SREBPs, and binding by SREBPs in vitro. The results clearly show that the E-box element is not the SREBP recognition site in this region. Rather, there are two independent SREBP binding sites that flank the E-box, and both are required for maximal sterol regulation and activation by transfected SREBP protein.	UNIV CALIF IRVINE,DEPT MOL BIOL & BIOCHEM,IRVINE,CA 92697	University of California System; University of California Irvine					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUAN GM, 1995, J BIOL CHEM, V270, P21958, DOI 10.1074/jbc.270.37.21958; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MOUSTAID N, 1993, BIOCHEM J, V292, P767, DOI 10.1042/bj2920767; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OSBORNE TF, 1991, J BIOL CHEM, V266, P13947; OSBORNE TF, 1987, P NATL ACAD SCI USA, V84, P3614, DOI 10.1073/pnas.84.11.3614; Osborne TF, 1995, CRIT REV EUKAR GENE, V5, P317, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.50; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; SMITH JR, 1990, J BIOL CHEM, V265, P2306; SMITH JR, 1988, J BIOL CHEM, V263, P18480; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WANG XD, 1993, J BIOL CHEM, V268, P14497; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yokoyama C., 1993, CELL, V75, P185	34	268	275	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32689	32694		10.1074/jbc.271.51.32689	http://dx.doi.org/10.1074/jbc.271.51.32689			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955100	hybrid			2022-12-25	WOS:A1996VZ37300035
J	Thomas, SR; Witting, PK; Stocker, R				Thomas, SR; Witting, PK; Stocker, R			3-hydroxyanthranilic acid is an efficient, cell-derived co-antioxidant for alpha-tocopherol, inhibiting human low density lipoprotein and plasma lipid peroxidation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; ALBUMIN-BOUND BILIRUBIN; HUMAN-BLOOD PLASMA; VITAMIN-E; MEDIATED PEROXIDATION; TRYPTOPHAN-METABOLITES; CINNABARINIC ACID; METHYL LINOLEATE; OXIDATION; ATHEROSCLEROSIS	alpha-Tocopherol (alpha-TSH) can promote lipid peroxidation in human low density lipoprotein (LDL) unless co-antioxidants are present that eliminate the chain-carrying alpha-tocopheroxyl radical (alpha-TO.) (Bowry, V. W., Mohr, D., Cleary, J., and Stocker, R. (1995) J. Biol. Chem. 270, 5756-5763). Interferon-gamma inhibits human monocyte/macrophage-facilitated LDL lipid peroxidation via induction of cellular tryptophan degradation and production and release of 3-hydroxyanthranilic acid (3HAA) (Christen, S., Thomas, S.R., Garner, B., and Stocker, R. (1994) J. Clin. Invest. 93, 2149-2158). We now report on the mechanism of antioxidant action of 3HAA. 3HAA directly reduced alpha-TO. in UV-exposed micellar dispersions of alpha-TOH or in LDL incubated with soybean 15-lipoxygenase (SLO), as assessed by electron paramagnetic resonance spectroscopy. 3HAA did not inhibit SLO enzyme activity. Anthranilic acid, which lacks the phenoxyl group, was incapable of reducing alpha-TO.. 3HAA dose-dependently inhibited the peroxidation of surface phospholipids and core cholesteryl esters in LDL exposed to SLO, peroxyl radicals (ROO(.)), or Cu2+; oxidants that convert alpha-TOH to alpha-TO.. In all cases, sparing of LDL's alpha-TOH, but not ubiquinol-10 (CoQ(10)H(2)), was observed until the majority of 3HAA was consumed. Addition of 3HAA or ascorbate prevented further consumption of alpha-TOH and accumulation of lipid hydroperoxides when added to aqueous or lipophilic ROO(.)-oxidizing LDL after complete and partial consumption of CoQ(10)H(2) and alpha-TOH, respectively. In contrast, addition of urate, an efficient ROO(.) scavenger incapable of scavenging alpha-TO., did not efficiently inhibit ongoing lipid peroxidation. Oxidation of 3HAA-supplemented human plasma by aqueous ROO(.) resulted in the successive consumption of ascorbate, CoQ(10)H(2), 3HAA, bilirubin, alpha-TOH, alpha-TOH, and urate. Lipid peroxidation was prevented as long as ascorbate, CoQ(10)H(2), and 3HAA were present, but subsequently proceeded as a free-radical chain reaction concomitant with alpha-TOH, bilirubin, and urate immediately and as efficiently as did ascorbate. These findings demonstrate that 3HAA is a highly efficient co-antioxidant for plasma lipid peroxidation by virtue of its ability to interact with alpha-TO. in lipoproteins. Since interferon-gamma is the principal inducer of tryptophan degradation and release of 3HAA by monocytes/macrophages, this may represent a localized extracellular antioxidant defense against LDL oxidation in inflammation.	HEART RES INST, BIOCHEM UNIT, SYDNEY, NSW 2050, AUSTRALIA	University of Sydney; Heart Research Institute			Stocker, Roland/AAV-4489-2021; Witting, Paul/L-9786-2019; Witting, Paul/ABD-2053-2020	Witting, Paul/0000-0003-2237-7004				BARAN H, 1990, J NEUROCHEM, V55, P738, DOI 10.1111/j.1471-4159.1990.tb04553.x; BEHRENS WA, 1987, ANAL BIOCHEM, V165, P102, DOI 10.1016/0003-2697(87)90206-5; BISBY RH, 1991, FEBS LETT, V290, P205, DOI 10.1016/0014-5793(91)81260-F; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BOWRY VW, 1993, J AM CHEM SOC, V115, P6029, DOI 10.1021/ja00067a019; BOWRY VW, 1995, J BIOL CHEM, V270, P5756, DOI 10.1074/jbc.270.11.5756; BOWRY VW, 1992, BIOCHEM J, V288, P341, DOI 10.1042/bj2880341; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; BURTON GW, 1986, ACCOUNTS CHEM RES, V19, P194, DOI 10.1021/ar00127a001; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211; CHRISTEN S, 1992, BIOCHEMISTRY-US, V31, P8090, DOI 10.1021/bi00149a045; CHRISTEN S, 1992, ANAL BIOCHEM, V200, P273, DOI 10.1016/0003-2697(92)90465-J; CHRISTEN S, 1990, P NATL ACAD SCI USA, V87, P2506, DOI 10.1073/pnas.87.7.2506; DIEBERROTHENEDER M, 1991, J LIPID RES, V32, P1325; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FRUEBIS J, 1994, J CLIN INVEST, V94, P392, DOI 10.1172/JCI117334; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; HANSSON GK, 1989, AM J PATHOL, V135, P169; HIRAKU Y, 1995, CARCINOGENESIS, V16, P349, DOI 10.1093/carcin/16.2.349; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; KAGAN VE, 1992, J LIPID RES, V33, P385; KALYANARAMAN B, 1990, BIOCHIM BIOPHYS ACTA, V1035, P286, DOI 10.1016/0304-4165(90)90090-J; MAO SJT, 1991, ARTERIOSCLER THROMB, V11, P1266, DOI 10.1161/01.ATV.11.5.1266; MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P; NEUZIL J, 1994, J BIOL CHEM, V269, P16712; NEUZIL J, 1996, IN PRESS FREE RADICA; NIKI E, 1984, J BIOL CHEM, V259, P4177; NIKI E, 1986, B CHEM SOC JPN, V59, P471, DOI 10.1246/bcsj.59.471; PADGETT EL, 1992, BIOCHEM BIOPH RES CO, V186, P775, DOI 10.1016/0006-291X(92)90813-Z; REAVEN PD, 1993, ARTERIOSCLER THROMB, V13, P601, DOI 10.1161/01.ATV.13.4.601; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rubbo H, 1995, ARCH BIOCHEM BIOPHYS, V324, P15, DOI 10.1006/abbi.1995.9935; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SCHLEGEL JU, 1969, J UROLOGY, V101, P317, DOI 10.1016/S0022-5347(17)62335-8; SPARROW CP, 1992, J CLIN INVEST, V89, P1885, DOI 10.1172/JCI115793; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; STOCKER R, 1990, METHOD ENZYMOL, V186, P301; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; Thomas SR, 1996, ARTERIOSCL THROM VAS, V16, P687, DOI 10.1161/01.ATV.16.5.687; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; Waldeck AR, 1996, CHEM RES TOXICOL, V9, P954, DOI 10.1021/tx960057s; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WITTING PK, 1995, FEBS LETT, V375, P45, DOI 10.1016/0014-5793(95)01172-B; Witting PK, 1996, J LIPID RES, V37, P853; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; YOSHIDA R, 1979, P NATL ACAD SCI USA, V76, P4084, DOI 10.1073/pnas.76.8.4084; YOSHIDA Y, 1994, BBA-GEN SUBJECTS, V1200, P85, DOI 10.1016/0304-4165(94)90121-X	53	74	76	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32714	32721		10.1074/jbc.271.51.32714	http://dx.doi.org/10.1074/jbc.271.51.32714			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955104	hybrid			2022-12-25	WOS:A1996VZ37300039
J	Gelderloos, JA; Anderson, SM				Gelderloos, JA; Anderson, SM			Over-expression of protein tyrosine phosphatase 1 (PTP1) alters IL-3-dependent growth and tyrosine phosphorylation	ONCOGENE			English	Article						IL-3; signal transduction; protein tyrosine phosphatase; tyrosine kinase	COLONY-STIMULATING FACTOR; RECEPTOR-LIKE PROTEIN; MYELOID CELL-LINES; GM-CSF RECEPTOR; INTERLEUKIN-3 RECEPTOR; SIGNAL-TRANSDUCTION; KINASE PP56LCK; HUMAN-PLACENTA; BETA-SUBUNIT; STEEL FACTOR	Interleukin-3 (IL-3) is a hematopoietic growth factor receptor which stimulates the proliferation of multilineage progenitor cells, It is known that IL-3 stimulates tyrosine phosphorylation while transducing a mitogenic signal. The signal transduction pathways activated by the IL-3 receptor, however, are not fully understood, In this study a protein tyrosine phosphatase has been overexpressed in the IL-3 dependent, murine myeloid progenitor cell line, 32D c13 in order to test whether altering the levels of tyrosine phosphorylation would change IL-3 stimulated proliferation, These cells were transfected with a metal-inducible expression vector containing a rat cDNA encoding PTP1. A low basal level of rat PTP1 message and protein was detected in cells transfected with the PTP1 vector, and zinc treatment resulted in a three- to fourfold increase in the amount of PTP1 message, protein and catalytic activity, Over-expression of PTP1 resulted in a two- to threefold decrease in IL-3 stimulated proliferation, Cells over-expressing PTP1 also exhibited decreased levels of tyrosine phosphorylation; phosphorylation of the IL-3 receptor beta subunit and the She protein were both dramatically decreased, Thus, PTP1 over-expression negatively modulated IL-3 signal transduction. To identify potential substrates of PTP1, 32D c13 cells were transfected with a catalytically inactive PTP1 mutant, PTP1(C/S). Three tyrosine-phosphorylated proteins of MW 140, 79 and 69 k coprecipitated with PTP1(C/S). We believe that the 140 kDa protein represents the beta subunit of the IL-3 receptor, In addition, a GST-fusion protein containing active PTP1 dephosphorylated the beta-subunit in an in vitro assay, By immunofluorescent microscopy over-expressed PTP1(C/S) co-localized largely with calnexin, an endoplasmic reticulum-associated protein, Immunofluorescent microscopy also indicated that PTP1(C/S) and the beta subunit co-localized at discrete sites at the plasma membrane and around a cytoplasmic organelle where most of the beta subunit was located, These observations suggest PTP1 over-expression may downregulate the growth response to IL-3 through dephosphorylation of the IL-3 receptor, perhaps in an intracellular compartment, thereby inhibiting propagation of the IL-3 mitogenic signal.	SUNY STONY BROOK, PROGRAM MOL & CELLULAR BIOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PATHOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								ANDERSON SM, 1995, J IMMUNOL, V155, P1660; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CIRCIRELLI MF, 1990, P NATL ACAD SCI USA, V87, P5514; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; CYSTER JG, 1995, IMMUNITY, V2, P13, DOI 10.1016/1074-7613(95)90075-6; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; ERWIN JL, 1992, ONCOGENE, V7, P1101; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; GUAN KL, 1990, P NATL ACAD SCI USA, V87, P1501, DOI 10.1073/pnas.87.4.1501; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; IHLE JN, 1982, J IMMUNOL, V129, P1377; IHLE JN, 1982, IMMUNOL REV, V63, P5, DOI 10.1111/j.1600-065X.1982.tb00409.x; ISCOVE NN, 1982, J CELL PHYSIOL, P65; ISFORT R, 1988, J BIOL CHEM, V263, P19203; ISFORT RJ, 1988, P NATL ACAD SCI USA, V85, P7982, DOI 10.1073/pnas.85.21.7982; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; KAMPS MP, 1988, ONCOGENE, V2, P305; KANAKURA Y, 1990, BLOOD, V76, P706; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOYASU S, 1987, EMBO J, V6, P3979, DOI 10.1002/j.1460-2075.1987.tb02740.x; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; LINNEKIN D, 1990, BIOCHEM J, V271, P317, DOI 10.1042/bj2710317; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORLA AO, 1988, MOL CELL BIOL, V8, P2214, DOI 10.1128/MCB.8.5.2214; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; OKUDA K, 1992, BLOOD, V79, P2880; OSTERGAARD HL, 1990, J EXP MED, V172, P347, DOI 10.1084/jem.172.1.347; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; RAINES MA, 1992, BLOOD, V79, P3350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1992, J BIOL CHEM, V267, P2537; SHULTZ LD, 1984, AM J PATHOL, V116, P179; SHULTZ LD, 1983, EXP HEMATOL, V11, P667; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SORENSEN P, 1989, J BIOL CHEM, V264, P19253; SORENSEN PHB, 1989, BLOOD, V73, P406; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOJO A, 1987, EXP CELL RES, V171, P16, DOI 10.1016/0014-4827(87)90247-3; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1990, MOL CELL BIOL, V10, P458, DOI 10.1128/MCB.10.2.458; TORIGOE T, 1992, BLOOD, V80, P617; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; ZHAO ZZ, 1995, J BIOL CHEM, V270, P11765, DOI 10.1074/jbc.270.20.11765	64	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2367	2378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957078				2022-12-25	WOS:A1996VX10800009
J	Badiani, PA; Kioussis, D; Swirsky, DM; Lampert, IA; Weston, K				Badiani, PA; Kioussis, D; Swirsky, DM; Lampert, IA; Weston, K			T-cell lymphomas in v-Myb transgenic mice	ONCOGENE			English	Article						Myb; T cell; lymphoma; transgenic mice	MURINE HEMATOPOIETIC-CELLS; RECEPTOR-DELTA-ENHANCER; C-MYB; LEUKEMIA-VIRUS; PROTO-ONCOGENE; ANTISENSE OLIGODEOXYNUCLEOTIDES; INSERTIONAL MUTAGENESIS; PROMONOCYTIC LEUKEMIAS; GENE-EXPRESSION; RAPID INDUCTION	v-Myb, the transforming protein of avian myeloblastosis virus, causes acute myeloid leukemia in chickens. Similarly, truncation and rearrangement of the c-myb proto-oncogene to yield a v-Myb-like protein leads to myeloid and B cell lymphomas in chickens and mice, and may be a factor in a number of human cancers. To study the effects of deregulation of v-Myb on T cell development, we have generated lines of transgenic mice in which the v-Myb oncoprotein is expressed in a T-cell-specific fashion. Analysis of T cell development in the v-Myb transgenic mice shows that ectopic expression of v-Myb affects the ratio of helper to cytotoxic T cells, by increasing the number of CD4(+) helper cells, and inhibits thymic involution, such that mature animals have elevated numbers of thymocytes and circulating mature T cells. In a significant proportion of older animals, high grade T cell lymphomas develop, demonstrating that v-Myb is oncogenic in T cells.	INST CANC RES, CRC, CTR CELLULAR & MOL BIOL, LONDON SW3 6JB, ENGLAND; NATL INST MED RES, LAB MOL IMMUNOL, LONDON NW7 1AA, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HISTOPATHOL, LONDON W12 0NN, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC National Institute for Medical Research; Imperial College London; Imperial College London								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BERNS A, 1989, INT J CANCER, P22; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; Bies J, 1996, ONCOGENE, V12, P355; BLICK M, 1984, BLOOD, V64, P1234; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BORN W, 1985, P NATL ACAD SCI USA, V82, P2925, DOI 10.1073/pnas.82.9.2925; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CALABRETTA B, 1991, CANCER RES, V51, P4505; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALNAN BJ, 1995, IMMUNITY, V3, P273; CHURILLA AM, 1989, J EXP MED, V170, P105, DOI 10.1084/jem.170.1.105; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRAO P, 1995, ONCOGENE, V11, P1631; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HOGAN B, 1986, MANIPULATING MOUSE E; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; JACOBS SM, 1994, CANCER GENET CYTOGEN, V75, P31, DOI 10.1016/0165-4608(94)90212-7; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LAOUAR Y, 1994, J IMMUNOL, V153, P3948; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1995, ONCOGENE, V11, P525; PRUDHOMME GJ, 1991, J IMMUNOL, V147, P3314; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMARDA J, 1994, ONCOGENE, V9, P237; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STRASSER A, 1993, ONCOGENE, V8, P1; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; TESCH H, 1992, LEUKEMIA RES, V16, P265, DOI 10.1016/0145-2126(92)90064-E; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	70	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2205	2212						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950988				2022-12-25	WOS:A1996VV14500018
J	Billon, N; vanGrunsven, LA; Rudkin, BB				Billon, N; vanGrunsven, LA; Rudkin, BB			The CDK inhibitor p21(WAF1/Cip1) is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells	ONCOGENE			English	Article						NGF; PC12; p21(WAF1/Cip1); p300; E1A; cell cycle; differentiation	NERVE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; TERMINAL DIFFERENTIATION; TRANSCRIPTIONAL ADAPTER; REQUIRES BINDING; CYCLE ARREST; P21; PROTEIN; EXPRESSION; INDUCTION	The block of cell proliferation elicited by the addition of nerve growth factor (NGF) to exponentially-growing PC12 cells results, in part, from the inhibition of cyclin D1-associated kinase activity by p2l(WAF1/ClP1). NGF treatment of PC12 cells provokes the accumulation of p21 mRNA, due to transcriptional activation of the p21 promoter in a p53-independent manner. Transient expression of a mutated form of the adenovirus E1A protein (E1A dCR2), which retains its capacity to bind the transcriptional co-activator p300, completely abolishes the NGF-mediated stimulation of p21 promoter activity. This phenomenon can be reversed by ectopic expression of p300, suggesting that p300 is necessary for the induction of p21 by NGF. In addition, stable expression of E1A dCR2 in PC12 cells results in the inhibition of the NGF response, i.e. it prevents activation of the p21 promoter, cell cycle arrest, and neuronal differentiation. The signalling pathway from the TrkA receptor via the MAP kinase pathway is not altered in these cells. Together, these data indicate that p300 could play a pivotal role in the triggering of the anti-mitogenic effect of NGF and of neuronal differentiation.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOL LAB,DIFFERENTIAT & CELL CYCLE GRP,UMR 49 CNRS,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)			van Grunsven, Leo/E-5839-2010	van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Avantaggiati ML, 1996, EMBO J, V15, P2236, DOI 10.1002/j.1460-2075.1996.tb00577.x; BANNISTER AJ, 1995, EMBO J, V14, P4790; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CASILLAS AM, 1993, BIOCHEM J, V290, P545, DOI 10.1042/bj2900545; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Dubois PM, 1996, J IMMUNOL, V156, P1356; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LUNDBLAD JR, 1995, NATURE, V374, P83; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P3489, DOI 10.1073/pnas.88.8.3489; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Savatier P, 1996, ONCOGENE, V12, P309; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; SLACK RS, 1995, ONCOGENE, V10, P19; Smits PHM, 1996, ONCOGENE, V12, P1529; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; vanGrunsven LA, 1996, ONCOGENE, V12, P1347; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZENG X, 1996, ONCOGENE, V12, P1557	53	66	67	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2047	2054						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950971				2022-12-25	WOS:A1996VV14500001
J	Brizzi, MF; Dentelli, P; Lanfrancone, L; Rosso, A; Pelicci, PG; Pegoraro, L				Brizzi, MF; Dentelli, P; Lanfrancone, L; Rosso, A; Pelicci, PG; Pegoraro, L			Discrete protein interactions with the Grb2/c-Cbl complex in SCF- and TPO-mediated myeloid cell proliferation	ONCOGENE			English	Article						c-Cbl; thrombopoietin; stem cell factor; cell proliferation; signal transduction	COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-3 DOMAIN; C-CBL PROTOONCOGENE; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; ANTIGEN RECEPTOR; SH3 DOMAINS; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING	Hemopoietic cell proliferation is mediated by nontyrosine and tyrosine kinases that signal via uncommon and common sets of downstream effector molecules including the Grb2/c-Chl. In the present study we evaluated tyrosine phosphorylation of c-Cbl and the interaction of the Grb2/c-Cbl complex with signaling proteins upon activation of non-tyrosine (c-Mpl) and tyrosine kinase (c-Kit) receptors leading to myeloid cell proliferation. By using the growth factor dependent M-07e cell line, we found that both c-Mpl and c-Kit ligands, namely: SCF and TPO, induce c-Cbl tyrosine phosphorylation. In these cells the adaptor protein Grb2 constitutively binds a substantial fraction of c-Cbl through the N-terminal SH3 domain. In vitro experiments showed that the stable Grb2/c-Cbl complex interacts, through the Grb2 SH2 domain, with the SCF-activated c-Kit. By contrast stimulation with TPO leads to the formation of a Grb2 complex containing JAK2. In vitro and in vivo experiments support the hypothesis that Grb2 mediates the association of c-Kit with c-Cbl. Moreover we found that, upon SCF stimulation, the Grb2/c-Cbl complex recruits She, probably via Grb2. By contrast the Ras exchanger factor (Sos1) was not detected in anti-c-Cbl immunoprecipitates suggesting that Grb2/Sos1 and Grb2/c-Cbl are present in different complexes. Taken together our results demonstrate that c-Cbl plays an important role in coupling both tyrosine and non-tyrosine kinase receptors to downstream effector molecules and that different signaling molecules interact with Grb2/c-Cbl complex when non-tyrosine or tyrosine kinase receptors are activated.	UNIV TURIN,DIPARTIMENTO MED INTERNA,I-10126 TURIN,ITALY; IST EUROPEO ONCOL,DIPARTIMENTO ONCOL SPERIMENTALE,I-20141 MILAN,ITALY	University of Turin; IRCCS European Institute of Oncology (IEO)			Pelicci, Pier Giuseppe/AAL-6572-2020; Lanfrancone, Luisa/AAC-8671-2019; Brizzi, Maria Felice/J-7882-2016	Lanfrancone, Luisa/0000-0002-4523-3815; 				AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLECHMAN JM, 1993, J BIOL CHEM, V268, P4399; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEV S, 1992, J BIOL CHEM, V267, P10866; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MIKI H, 1994, J BIOL CHEM, V269, P5489; MIYAZAWA K, 1991, EXP HEMATOL, V19, P1110; Montrucchio G, 1996, BLOOD, V87, P2762, DOI 10.1182/blood.V87.7.2762.bloodjournal8772762; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; MYERS M, 1995, TRENDS BIOCHEM SCI, V19, P289; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SASAKI K, 1995, BIOCHEM BIOPH RES CO, V216, P338, DOI 10.1006/bbrc.1995.2629; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG XY, 1995, J BIOL CHEM, V270, P27999; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZSEBO KM, 1990, CELL, V63, P195, DOI 10.1016/0092-8674(90)90300-4	55	31	33	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2067	2076						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950973				2022-12-25	WOS:A1996VV14500003
J	Xu, F				Xu, F			Effects of redox potential and hydroxide inhibition on the pH activity profile of fungal laccases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHENOL OXIDASES; ELECTRON-TRANSFER; OXIDATION; MECHANISM; REDUCTION; ENZYMES; PLANTS	The electronic absorption spectrum, susceptibility to fluoride inhibition, redox potential, and substrate turnover of several fungal laccases have been explored as a function of pH. The laccases showed a single spectrally detectable acid-base transition at pH 6-9 and a fluoride inhibition that diminished by increased pH (indicating a competition with hydroxide inhibition). Relatively small changes in the redox potentials (less than or equal to 0.1 V) of laccase were observed over the pH 2.7-11. Under the catalysis of laccase, the apparent oxidation rates (k(cat) and k(cat)/K-m) of two nonphenolic substrates, potassium ferrocyanide and 2,2'-azinobis-(3-ethylbenzthiazoline-6-sulfonic acid), decreased monotonically as the pH increased. In contrast, the apparent oxidation rates (k(cat) and k(cat)/K-m) of three 2,6-dimethoxyphenols (whose pK(alpha) values range from 7.0 to 8.7) exhibited bell-shaped pH profiles whose maxima were distinct for each laccase but independent of the substrate, By correlating these pH dependences, it is proposed that the balance of two opposing effects, one generated by the redox potential difference between a reducing substrate and the type 1 copper of laccase (which correlates to the electron transfer rate and is favored for a phenolic substrate by higher pH) and another generated by the binding of a hydroxide anion to the type 2/type 3 coppers of laccase (which inhibits the activity at higher pH), contributes to the pH activity profile of the fungal laccases.			Xu, F (corresponding author), NOVO NORDISK BIOTECH,1445 DREW AVE,DAVIS,CA 95616, USA.							ANDREASSON LE, 1979, BIOCHIM BIOPHYS ACTA, V568, P145, DOI 10.1016/0005-2744(79)90282-1; BOLLAG JM, 1984, APPL ENVIRON MICROB, V48, P849, DOI 10.1128/AEM.48.4.849-854.1984; BOURBONNAIS R, 1992, APPL MICROBIOL BIOT, V36, P823, DOI 10.1007/BF00172202; FARVER O, 1978, P NATL ACAD SCI USA, V75, P5245, DOI 10.1073/pnas.75.11.5245; FARVER O, 1984, COPPER PROTEINS COPP, P184; FUKUSHIMA Y, 1995, APPL ENVIRON MICROB, V61, P872, DOI 10.1128/AEM.61.3.872-876.1995; HANSEN FB, 1984, BIOCHEMISTRY-US, V23, P2049, DOI 10.1021/bi00304a026; HOFFMANN P, 1977, ARCH MICROBIOL, V112, P111, DOI 10.1007/BF00446663; JOVANOVIC SV, 1991, J PHYS CHEM-US, V95, P10824, DOI 10.1021/j100179a054; KOUDELKA GB, 1985, J BIOL CHEM, V260, P5561; MAYER AM, 1987, PHYTOCHEMISTRY, V26, P11; MAYER AM, 1979, PHYTOCHEMISTRY, V18, P193, DOI 10.1016/0031-9422(79)80057-6; MESSERSCHMIDT A, 1994, ADV INORG CHEM, V63, P121; NAKAMURA T, 1958, BIOCHIM BIOPHYS ACTA, V30, P44, DOI 10.1016/0006-3002(58)90239-7; NAKI A, 1982, BIOCHEMISTRY-US, V46, P1344; OMURA T, 1961, J BIOCHEM, V50, P264, DOI 10.1093/oxfordjournals.jbchem.a127442; PEYRATOUT CS, 1994, ARCH BIOCHEM BIOPHYS, V314, P405, DOI 10.1006/abbi.1994.1460; REINHAMMAR B, 1981, METAL IONS BIOL COPP, V3, P109; REINHAMMAR BR, 1972, BIOCHIM BIOPHYS ACTA, V275, P245, DOI 10.1016/0005-2728(72)90045-X; ROSENBERG RC, 1976, J AM CHEM SOC, V98, P6364, DOI 10.1021/ja00436a049; SARIASLANI FS, 1989, CRIT REV BIOTECHNOL, V9, P171, DOI 10.3109/07388558909036736; SOLOMON EI, 1992, CHEM REV, V92, P541; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; TOLLIN G, 1993, BIOCHIM BIOPHYS ACTA, V1183, P309, DOI 10.1016/0005-2728(93)90232-5; Wahleithner JA, 1996, CURR GENET, V29, P395, DOI 10.1007/BF02208621; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Xu F, 1996, BBA-PROTEIN STRUCT M, V1292, P303, DOI 10.1016/0167-4838(95)00210-3; YAROPOLOV AI, 1994, APPL BIOCHEM BIOTECH, V49, P257, DOI 10.1007/BF02783061; Yaver DS, 1996, APPL ENVIRON MICROB, V62, P834, DOI 10.1128/AEM.62.3.834-841.1996	29	345	359	2	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					924	928		10.1074/jbc.272.2.924	http://dx.doi.org/10.1074/jbc.272.2.924			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995383	hybrid			2022-12-25	WOS:A1997WC04800034
J	Deng, L; Shuman, S				Deng, L; Shuman, S			Transcription termination by vaccinia RNA polymerase entails recognition of specific phosphates in the nascent RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Vaccinia virus RNA polymerase terminates transcription downstream of a UUUUUNU signal in the nascent RNA. Transduction of the RNA signal to the elongating polymerase requires a termination factor (vaccinia termination factor/capping enzyme) and is coupled to the hydrolysis of ATP. It was shown previously that incorporation of 5-bromouracil or 5-iodouracil within the UUUUUNU element abolishes termination by preventing factor-dependent release of the nascent chain from the polymerase elongation complex. Here, we report that termination is prevented by phosphorothioate substitution at UMP residues in the nascent RNA. In contrast, phosphorothioate substitution at AMP, CMP, and GMP nucleotides does not inhibit termination. Thus, the action of a eukaryotic termination factor entails recognition of the nucleotide bases and the phosphate groups of the target sequence in nascent RNA.			Deng, L (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM42498] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042498] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Deng L, 1996, J BIOL CHEM, V271, P19556, DOI 10.1074/jbc.271.32.19556; DENG L, UNPUB; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; HAGLER J, 1994, J BIOL CHEM, V269, P10050; HAGLER J, 1993, J BIOL CHEM, V268, P2166; HEIDENREICH O, 1993, FASEB J, V7, P90, DOI 10.1096/fasebj.7.1.7678566; LUO Y, 1995, J VIROL, V69, P3852, DOI 10.1128/JVI.69.6.3852-3856.1995; LUO Y, 1991, VIROLOGY, V185, P432, DOI 10.1016/0042-6822(91)90793-B; SHUMAN S, 1987, J BIOL CHEM, V262, P12372; SHUMAN S, 1988, J BIOL CHEM, V263, P6220; YUEN L, 1987, P NATL ACAD SCI USA, V84, P6417, DOI 10.1073/pnas.84.18.6417	11	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					695	698						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995314				2022-12-25	WOS:A1997WA56400101
J	Hirschman, JE; DeZutter, GS; Simonds, WF; Jenness, DD				Hirschman, JE; DeZutter, GS; Simonds, WF; Jenness, DD			The G beta gamma complex of the yeast pheromone response pathway - Subcellular fractionation and protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; SIGNAL TRANSDUCTION PATHWAY; ALPHA-FACTOR PHEROMONE; TRIMERIC-G-PROTEINS; SACCHAROMYCES-CEREVISIAE; MATING-PHEROMONE; ADAPTIVE RESPONSE; BINDING PROTEIN; SUBUNIT; GENE	Genetic evidence suggests that the yeast STE4 and STE18 genes encode G beta and G gamma subunits, respectively, that the G beta gamma complex plays a positive role in the pheromone response pathway, and that its activity is subject to negative regulation by the G alpha subunit (product of the GPA1 gene) and to positive regulation by cell-surface pheromone receptors, However, as yet there is no direct biochemical evidence for a G beta gamma protein complex associated with the plasma membrane, We found that the products of the STE4 and STE18 genes are stably associated with plasma membrane as well as with internal membranes and that 30% of the protein pool is not tightly associated with either membrane fraction, A slower-migrating, presumably phosphorylated, form of Ste4p is enriched in the non-membrane fraction, The Ste4p and Ste18p proteins that had been extracted from plasma membranes with detergent were found to cosediment as an 8 S particle under low salt conditions and as a 6 S particle in the presence of 0.25 M NaCl; the Ste18p in these fractions was precipitated with anti-Ste4p antiserum, Under the conditions of our assay, Gpa1p was not associated with either particle. The levels of Ste4p and Ste18p accumulation in mutant cells provided additional evidence for a G beta gamma complex. Ste18p failed to accumulate in ste4 mutant cells, and Ste4p showed reduced levels of accumulation and an increased rate of turnover in ste18 mutant cells. The gpa1 mutant blocked stable association of Ste4p with the plasma membrane, and the ste18 mutant blocked stable association of Ste4p with both plasma membranes and internal membranes, The membrane distribution of Ste4p was unaffected by the ste2 mutation or by down-regulation of the cell-surface receptors, These results indicate that at least 40% of Ste4p and Ste18p are part of a G beta gamma complex at the plasma membrane and that stable association of this complex with the plasma membrane requires the presence of G alpha.	UNIV MASSACHUSETTS, SCH MED, DEPT MOL GENET & MICROBIOL, WORCESTER, MA 01655 USA; NIDDK, MDB, NIH, BETHESDA, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)					NIGMS NIH HHS [GM34719] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034719] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akada R, 1996, GENETICS, V143, P103; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BROWN PJ, 1993, J BIOL CHEM, V268, P6668; CLARK KL, 1993, MOL CELL BIOL, V13, P1; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Coleman DE, 1996, TRENDS BIOCHEM SCI, V21, P41, DOI 10.1016/S0968-0004(96)80176-9; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; Coria R, 1996, YEAST, V12, P41; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; HARTWELL LH, 1980, J CELL BIOL, V85, P811, DOI 10.1083/jcb.85.3.811; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; JAHNG KY, 1988, MOL CELL BIOL, V8, P2484, DOI 10.1128/MCB.8.6.2484; JENNESS DD, 1987, MOL CELL BIOL, V7, P1311, DOI 10.1128/MCB.7.4.1311; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; Kao LR, 1996, MOL CELL BIOL, V16, P168; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MACKAY V, 1974, GENETICS, V76, P255; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P5410, DOI 10.1128/MCB.8.12.5410; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Pryciak PM, 1996, MOL CELL BIOL, V16, P2614; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RENSDOMIANO S, 1995, FASEB J, V9, P1059, DOI 10.1096/fasebj.9.11.7649405; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; SONG J, 1996, J BIOL CHEM, V271; SPAIN BH, 1995, J BIOL CHEM, V270, P25435, DOI 10.1074/jbc.270.43.25435; SPRAGUE GF, 1981, J MOL BIOL, V153, P305, DOI 10.1016/0022-2836(81)90280-1; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STONE DE, 1991, GENE DEV, V5, P1969, DOI 10.1101/gad.5.11.1969; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WHITEWAY M, 1994, MOL CELL BIOL, V14, P3223, DOI 10.1128/MCB.14.5.3223; WHITEWAY M, 1992, BIOCHEM CELL BIOL, V70, P1230, DOI 10.1139/o92-169; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; WHITEWAY MS, 1994, GENETICS, V137, P967; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; XU J, 1995, P NATL ACAD SCI USA, V92, P2086, DOI 10.1073/pnas.92.6.2086; ZHANG M, 1993, MOL MICROBIOL, V9, P813, DOI 10.1111/j.1365-2958.1993.tb01740.x; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246	68	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					240	248						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995254				2022-12-25	WOS:A1997WA56400041
J	Bengtsson, T; Redegren, K; Strosberg, AD; Nedergaard, J; Cannon, B				Bengtsson, T; Redegren, K; Strosberg, AD; Nedergaard, J; Cannon, B			Down-regulation of beta(3) adrenoreceptor gene expression in brown fat cells is transient and recovery is dependent upon a short-lived protein factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR MESSENGER-RNA; SMOOTH-MUSCLE CELLS; COLD-ACCLIMATED HAMSTERS; TERM AGONIST EXPOSURE; ADIPOSE-TISSUE; BETA(3)-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; UNCOUPLING PROTEIN; BETA-3-ADRENERGIC RECEPTOR; MOLECULAR CHARACTERIZATION	The regulation of the expression of the beta(3) adrenoreceptor gene was examined in the brown adipose tissue of intact mice and in murine brown fat primary cell cultures, Both in vivo and in vitro, high levels of beta(3) receptor mRNA were observed. Acute cold exposure of mice resulted in a marked and rapid down-regulation of beta(3) gene expression; this down-regulation was, however, transient, Similarly, in brown fat cell cultures, norepinephrine addition led to down-regulation of beta(3) gene expression, with a lag phase of 30 min and with an apparent half-life of beta(3) mRNA of similar to 30 min, This down-regulation was stimulated via the beta(3) receptors themselves and mediated via cAMP; the apparent affinity of norepinephrine was extremely high (<1 nM), The degradation rate after actinomycin was identical to that after norepinephrine and was not affected by the presence of norepinephrine; thus, the down-regulation was due to cessation of transcription but not to an increased rate of degradation, Notably, inhibition of protein synthesis by cycloheximide also led to down-regulation. The norepinephrine induced doum-regulation was transient; spontaneous recovery occurred after similar to 18 h and was not due to depletion of adrenergic agent, Recovery did not occur in the presence of cycloheximide. After recovery, the cells showed a functional desensitization of the down-regulation process itself (EC(50) now similar to 10 similar to 10 nM). It is concluded that a down-regulated state cannot explain the functional desensitization of beta(3) adrenergic responsiveness observed in brown fat cells isolated from cold-acclimated animals (i.e. physiologically chronically adrenergically stimulated brown fat cells); since the beta(3) receptor is not subject to desensitization via phosphorylation processes, no satisfactory explanation for the functional desensitization exists as yet, A model is presented for the down-regulation/recovery process, involving the participation of a phosphorylatable short-lived transcription factor.	UNIV PARIS 07,F-75014 PARIS,FRANCE; LAB IMMUNOPHARMACOL MOL,CNRS,UPR 0415,F-75014 PARIS,FRANCE	UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Bengtsson, T (corresponding author), STOCKHOLM UNIV,ARRHENIUS LAB F3,WENNER GREN INST,S-10691 STOCKHOLM,SWEDEN.		Nedergaard, Jan/A-1706-2010; Nedergaard, Jan/Q-8286-2019; Cannon, Barbara/B-3089-2016	Cannon, Barbara/0000-0001-6594-2363; Nedergaard, Jan/0000-0003-2070-1587				BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BRONNIKOV G, 1992, J BIOL CHEM, V267, P2006; CANNON B, 1994, THERMAL BALANCE HLTH, P87; CARTER DA, 1993, ENDOCRINOLOGY, V133, P2263, DOI 10.1210/en.133.5.2263; CHAO J, 1994, AM J PHYSIOL, V267, pC969; CHEN X, 1994, EUR J PHARM-MOLEC PH, V267, P175, DOI 10.1016/0922-4106(94)90169-4; COLLINS S, 1989, P NATL ACAD SCI USA, V86, P4853, DOI 10.1073/pnas.86.13.4853; COLLINS S, 1991, ANNU REV PHYSIOL, V53, P497, DOI 10.1146/annurev.physiol.53.1.497; DALLAIRE F, 1995, BRIT J PHARMACOL, V114, P275, DOI 10.1111/j.1476-5381.1995.tb13223.x; EMORINE LJ, 1989, SCIENCE, V245, P1118, DOI 10.1126/science.2570461; FEVE B, 1994, P NATL ACAD SCI USA, V91, P5677, DOI 10.1073/pnas.91.12.5677; FEVE B, 1995, J BIOL CHEM, V270, P10952, DOI 10.1074/jbc.270.18.10952; GALITZKY J, 1993, AM J PHYSIOL, V264, pE403, DOI 10.1152/ajpendo.1993.264.3.E403; GRANNEMAN JG, 1995, AM J PHYSIOL-CELL PH, V268, pC1040; GRANNEMAN JG, 1994, ENDOCRINOLOGY, V135, P1025, DOI 10.1210/en.135.3.1025; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; GRANNEMAN JG, 1995, CELL SIGNAL, V7, P9, DOI 10.1016/0898-6568(94)00066-K; HADCOCK JR, 1988, P NATL ACAD SCI USA, V85, P5021, DOI 10.1073/pnas.85.14.5021; HADCOCK JR, 1993, J NEUROCHEM, V60, P1, DOI 10.1111/j.1471-4159.1993.tb05816.x; HANSEN ES, 1986, BIOSCIENCE REP, V6, P31, DOI 10.1007/BF01145176; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HOUGH C, 1990, BIOCHEM BIOPH RES CO, V170, P46, DOI 10.1016/0006-291X(90)91238-N; HU ZW, 1993, MOL PHARMACOL, V44, P1105; ISHIZAKA N, 1994, BBA-GENE STRUCT EXPR, V1218, P173, DOI 10.1016/0167-4781(94)90007-8; IZZO NJ, 1990, P NATL ACAD SCI USA, V87, P6268, DOI 10.1073/pnas.87.16.6268; JACOBSSON A, 1994, AM J PHYSIOL-REG I, V267, pR999, DOI 10.1152/ajpregu.1994.267.4.R999; KLAUS S, 1995, MOL CELL ENDOCRINOL, V109, P189, DOI 10.1016/0303-7207(95)03502-X; KOPECKY J, 1990, J BIOL CHEM, V265, P22204; KUROSHIMA A, 1991, J THERM BIOL, V16, P109, DOI 10.1016/0306-4565(91)90007-O; KWASTWELFELD J, 1993, J BIOL CHEM, V268, P19581; LEVIN BE, 1986, J PHARMACOL EXP THER, V236, P681; MARULLO S, 1995, BIOCHEM SOC T, V23, P126, DOI 10.1042/bst0230126; MOHELL N, 1989, BIOCHEM J, V261, P401, DOI 10.1042/bj2610401; MUZZIN P, 1994, MOL PHARMACOL, V46, P357; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; MUZZIN P, 1992, FEBS LETT, V298, P162, DOI 10.1016/0014-5793(92)80046-J; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NANTEL F, 1994, J BIOL CHEM, V269, P13148; NECHAD M, 1987, AM J PHYSIOL, V253, pC889, DOI 10.1152/ajpcell.1987.253.6.C889; NECHAD M, 1983, EXP CELL RES, V149, P105, DOI 10.1016/0014-4827(83)90384-1; Nechad M., 1986, BROWN ADIPOSE TISSUE; NEDERGAARD J, 1982, AM J PHYSIOL, V242, pC250, DOI 10.1152/ajpcell.1982.242.3.C250; NEDERGAARD J, 1994, OBESITY IN EUROPE 93, P73; PICO C, 1994, BIOCHEM J, V302, P81, DOI 10.1042/bj3020081; PUIGSERVER P, 1992, BIOCHEM J, V284, P393, DOI 10.1042/bj2840393; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; REVELLI JP, 1992, BIOCHEM J, V286, P743, DOI 10.1042/bj2860743; REVELLI JP, 1993, J MOL ENDOCRINOL, V10, P193, DOI 10.1677/jme.0.0100193; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; ROHTWELL N, 1985, AM JPHYSL, V248, pE397; SAKURAI T, 1992, BIOCHEM BIOPH RES CO, V186, P342, DOI 10.1016/S0006-291X(05)80813-7; SVARTENGREN J, 1982, EUR J BIOCHEM, V128, P481; SVOBODA P, 1993, BIOCHEM J, V295, P655, DOI 10.1042/bj2950655; THOMAS RF, 1992, P NATL ACAD SCI USA, V89, P4490, DOI 10.1073/pnas.89.10.4490; THONBERG H, 1994, J BIOL CHEM, V269, P33179; UNELIUS L, 1993, AM J PHYSIOL, V265, pC1340, DOI 10.1152/ajpcell.1993.265.5.C1340; UNELIUS L, 1990, AM J PHYSIOL, V258, pC818, DOI 10.1152/ajpcell.1990.258.5.C818; WILSON C, 1984, PFLUGERS ARCH, V373, P189; YOUNG JB, 1982, J CLIN INVEST, V69, P1061, DOI 10.1172/JCI110541	60	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33366	33375		10.1074/jbc.271.52.33366	http://dx.doi.org/10.1074/jbc.271.52.33366			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969197	hybrid			2022-12-25	WOS:A1996WA71300031
J	Chagnovich, D; Cohn, SL				Chagnovich, D; Cohn, SL			Binding of a 40-kDa protein to the N-myc 3'-untranslated region correlates with enhanced N-myc expression in human neuroblastoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; HUMAN NEURO-BLASTOMA; AU-RICH ELEMENTS; CELL-LINE; NEGATIVE AUTOREGULATION; GENE-EXPRESSION; DEGRADATION; SEQUENCE; AMPLIFICATION; AUUUA	Subclones of neuronal (N) and non neuronal (S) cells established from neuroblastoma tumors cultured in vitro differ in their growth characteristics and N-myc expression. N (W-N) cells derived from the NBL-W cell line express 5-fold higher levels of N-myc mRNA and 10-12-fold higher levels of protein than S cells (W-S), despite having the same N-myc copy number. This study demonstrates that the steady-state levels of N-myc are largely determined by differences in N-myc mRNA stability. The half-life of N-myc mRNA in the W-N cells is similar to 35 min compared with similar to 6 min in the W-S cells. Turnover of labile mRNAs is thought to be mediated in part by the interactions of trans-acting factors with elements within the 3'-untranslated region. RNA UV cross-linking assays using W-N cell lysate demonstrate abundant quantities of a protein complex that is 40 kDa in size (p40) that binds to the N-myc 3'-untranslated region, p40 is barely detectable in W-S cells. We have mapped two distinct regions within the 3'-UTR that specifically bind p40 (base pairs 5694-5715 and 6465-6482). Analysis of nine additional neuroblastoma cell lines shows that p40 activity correlates with enhanced expression of N-myc. p40 activity is also detected in 5 of 19 primary neuroblastomas, and activity is associated with clinically aggressive disease. In the accompanying study, we identify p40 as a member of the embryonic lethal abnormal vision (ELAV)-like family of RNA binding proteins. Our studies suggest that ELAV-like proteins may play a role in the regulation of N-myc mRNA turnover and thereby modulate the steady-state levels of N-myc expression and tumor cell phenotype.	NORTHWESTERN UNIV, SCH MED,ROBERT H LURIE CANC CTR,CHILDRENS MEM HOSP, DIV HEMATOL ONCOL, CHICAGO, IL 60614 USA; NORTHWESTERN UNIV, SCH MED, ROBERT H LURIE CANC CTR, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, ROBERT H LURIE CANC CTR, PROGRAM TUMOR CELL BIOL, CHICAGO, IL 60611 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Robert H. Lurie Comprehensive Cancer Center			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650	NCI NIH HHS [5P30CA60553, CA51061] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553, R29CA051061] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMY CM, 1987, CANCER RES, V47, P6310; BABISS LE, 1990, MOL CELL BIOL, V10, P6700, DOI 10.1128/MCB.10.12.6700; BERNSTEIN P, 1989, MOL CELL BIOL, V9, P659, DOI 10.1128/MCB.9.2.659; BERNSTEIN P, 1989, TRENDS BIOCHEM SCI, V14, P373, DOI 10.1016/0968-0004(89)90011-X; Biedler J L, 1988, Prog Clin Biol Res, V271, P265; BIEDLER J L, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P29; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHAGNOVICH D, 1996, J BIOL CHEM, V271; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCARONE V, 1989, CANCER RES, V49, P219; Cleveland J L, 1988, Oncogene Res, V3, P357; COHN SL, 1990, ONCOGENE, V5, P1821; COHN SL, 1995, CANCER RES, V55, P721; COHN SL, 1990, AM J PATHOL, V136, P1043; CORNAGLIAFERRARIS P, 1990, PEDIATR RES, V27, P1, DOI 10.1203/00006450-199001000-00001; FOLEY J, 1991, CANCER RES, V51, P6338; GOOD PJ, 1995, P NATL ACAD SCI USA, V92, P4557, DOI 10.1073/pnas.92.10.4557; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; IKEGAKI N, 1986, P NATL ACAD SCI USA, V83, P5929, DOI 10.1073/pnas.83.16.5929; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; MACHIN GA, 1982, NEUROBLASTOMA CLIN B, P195; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MCSWINEKENNICK RL, 1991, J BIOL CHEM, V266, P15135; Michitsch R W, 1988, Prog Clin Biol Res, V271, P103; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RAJ NBK, 1993, FASEB J, V7, P702, DOI 10.1096/fasebj.7.8.8500695; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SADEE W, 1987, CANCER RES, V47, P5207; SCHMIDT ML, 1994, CELL GROWTH DIFFER, V5, P171; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SCHWAB M, 1991, ADV ENZYME REGUL, V31, P329, DOI 10.1016/0065-2571(91)90021-D; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SLEIGHT BJ, 1993, ANTICANCER RES, V13, P2031; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1987, MOL CELL BIOL, V7, P4266, DOI 10.1128/MCB.7.12.4266; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WADA RK, 1992, ONCOGENE, V7, P711; Weston J A, 1970, Adv Morphog, V8, P41; WHITTEMORE LA, 1990, MOL CELL BIOL, V10, P1329, DOI 10.1128/MCB.10.4.1329; XU L, 1993, ONCOGENE, V8, P2547; XU L, 1995, ONCOGENE, V11, P1865; YOUNG JL, 1975, J PEDIATR-US, V86, P254, DOI 10.1016/S0022-3476(75)80484-7; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	54	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33580	33586		10.1074/jbc.271.52.33580	http://dx.doi.org/10.1074/jbc.271.52.33580			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969225	hybrid			2022-12-25	WOS:A1996WA71300059
J	Liu, J; Tse, AGD; Chang, HC; Liu, JH; Wang, JH; Hussey, RE; Chishti, Y; Rheinhold, B; Spoerl, R; Nathenson, SG; Sacchettini, JC; Reinherz, EL				Liu, J; Tse, AGD; Chang, HC; Liu, JH; Wang, JH; Hussey, RE; Chishti, Y; Rheinhold, B; Spoerl, R; Nathenson, SG; Sacchettini, JC; Reinherz, EL			Crystallization of a deglycosylated T cell receptor (TCR) complexed with an anti-TCR Fab fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; HETERODIMERS; RECOGNITION; EXPRESSION; PROTEINS; CHAIN; OLIGOSACCHARIDES; GLYCOSYLATION	A strategy to overexpress T cell receptors (TCRs) in Lec3.2.8.1 cells has been developed using the ''Velcro'' leucine zipper sequence to facilitate alpha-beta pairing. Upon secretion in culture media, the VSV-8-specific/H2-K-b-restricted N15 TCR could be readily immunopurified using the anti-leucine zipper monoclonal antibody 2H11, with a yield of 5-10 mg/liter. Mass spectrometry analysis revealed that all attached glycans were GlcNAc(2)-Man(5). Following Superdex 200 gel filtration to remove aggregates, wild-type N15 or N15(s), a C183S variant lacking the unpaired cysteine at amino acid residue 183 in the C beta domain, was thrombin-cleaved and endoglycosidase H-digested, and the two derivatives were termed iN15 Delta(H) and N15(s) Delta(H), respectively, and sized by Superdex 75 chromatography to high purity. N-terminal and C-terminal microsequencing analysis showed the expected unique termini of N15 alpha and beta subunits. Nevertheless, neither protein crystallized under a wide range of conditions. Subsequently, we produced a Fab fragment of the murine TCR C beta-specific hamster monoclonal antibody H57 and complexed the Fab fragment with iN15 Delta(H) and N15(s) Delta(H). Both N15(s) Delta(H)-Fab[H57] and iN15 Delta(H)-Fab[H57] complexes crystallize, with the former diffracting to 2.8-Angstrom resolution. These findings show that neither intact glycans nor the conserved and partially exposed Cys-183 is required for protein stability. Furthermore, our results suggest that the H57 Fab fragment aids in the crystallization of TCRs by altering their molecular surface and/or stabilizing inherent conformational mobility.	DANA FARBER CANC INST,IMMUNOBIOL LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Boston University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NIAID NIH HHS [AI39098, AI19807] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039098, R37AI019807, R01AI019807, R56AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BILL J, 1990, J MOL CELL IMMUNOL, V4, P269; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLAVERIE JM, 1989, IMMUNOL TODAY, V10, P10, DOI 10.1016/0167-5699(89)90058-3; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; HOO WFS, 1992, P NATL ACAD SCI USA, V89, P4759, DOI 10.1073/pnas.89.10.4759; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Kabat EA, 1991, SEQUENCES PROTEINS I; Kovari LC, 1995, STRUCTURE, V3, P1291, DOI 10.1016/S0969-2126(01)00266-0; KUBO RT, 1989, J IMMUNOL, V142, P2736; KURODA K, 1990, VIROLOGY, V174, P418, DOI 10.1016/0042-6822(90)90095-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LINSLEY KB, 1994, ANAL BIOCHEM, V219, P207, DOI 10.1006/abio.1994.1259; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P82; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; NOVOTNY J, 1991, P NATL ACAD SCI USA, V88, P8646, DOI 10.1073/pnas.88.19.8646; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; OSHEA EK, 1993, CURR BIOL, V3, P658, DOI 10.1016/0960-9822(93)90063-T; PAREKH RB, 1987, EMBO J, V6, P1233, DOI 10.1002/j.1460-2075.1987.tb02359.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SLANETZ AE, 1991, EUR J IMMUNOL, V21, P179, DOI 10.1002/eji.1830210127; STANLEY P, 1989, MOL CELL BIOL, V9, P377, DOI 10.1128/MCB.9.2.377; WARD ES, 1992, J MOL BIOL, V224, P885, DOI 10.1016/0022-2836(92)90455-S; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WILLIAMS PJ, 1991, BIOCHIM BIOPHYS ACTA, V1075, P1456; WULFING C, 1995, IMMUNOLOGIST, V3, P59	38	32	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33639	33646		10.1074/jbc.271.52.33639	http://dx.doi.org/10.1074/jbc.271.52.33639			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969233	hybrid			2022-12-25	WOS:A1996WA71300067
J	Osman, N; McKenzie, IFC; Mouhtouris, E; Sandrin, MS				Osman, N; McKenzie, IFC; Mouhtouris, E; Sandrin, MS			Switching amino-terminal cytoplasmic domains of alpha(1,2)fucosyltransferase and alpha(1,3)galactosyltransferase alters the expression of H substance and Gal alpha(1,3)Gal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; SPECIFY GOLGI RETENTION; GDP-L-FUCOSE; TRANSMEMBRANE DOMAIN; SIGNAL ANCHOR; ENDOPLASMIC-RETICULUM; FLANKING SEQUENCES; UDP-GAL; LOCALIZATION; APPARATUS	When alpha(1,2)fucosyltransferase cDNA is expressed in cells that normally express large amounts of the terminal carbohydrate Gal alpha(1,3)Gal, and therefore the alpha(1,3)galactosyltransferase (GT), the Gal alpha(1,3)Gal almost disappears, indicating that the presence of the alpha(1,2)fucosyltransferase (HT) gene/enzyme alters the synthesis of Gal alpha(1,3)Gal. A possible mechanism to account for these findings is enzyme location within the Golgi apparatus. We examined the effect of Golgi localization by exchanging the cytoplasmic tails of HT and GT; if Golgi targeting signals are contained within the cytoplasmic tail sequences of these enzymes then a ''tail switch'' would permit GT first access to the substrate and thereby reverse the observed dominance of HT. Two chimeric glycosyltransferase proteins were constructed and compared with the normal glycosyltransferases after transfection into COS cells. The chimeric enzymes showed K-m values and cell surface carbohydrate expression comparable with normal glycosyltransferases. Coexpression of the two chimeric glycosyltransferases resulted in cell surface expression of Gal alpha(1,3)Gal, and virtually no HT product was expressed. Thus the cytoplasmic tail of HT determines the temporal order of action, and therefore dominance, of these two enzymes.	AUSTIN HOSP, AUSTIN RES INST, IMMUNOGENET MOL LAB, MELBOURNE, VIC 3084, AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health								AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; DAHDAL RY, 1993, J BIOL CHEM, V268, P26310; GLEESON PA, 1994, GLYCOCONJ J, V11, P391; HARTELSCHENK S, 1991, BIOCHIM BIOPHYS ACTA, V1115, P108, DOI 10.1016/0304-4165(91)90019-D; HAYES CE, 1974, J BIOL CHEM, V249, P1904; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KAPPELER F, 1994, J BIOL CHEM, V269, P6279; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; MATSUMOT.I, 1969, BIOCHIM BIOPHYS ACTA, V194, P180, DOI 10.1016/0005-2795(69)90193-7; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sandrin Mauro S., 1994, Xenotransplantation, V1, P81, DOI 10.1111/j.1399-3089.1994.tb00053.x; SANDRIN MS, 1995, NAT MED, V1, P1261, DOI 10.1038/nm1295-1261; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SMITH DF, 1990, J BIOL CHEM, V265, P6225; TANG BL, 1992, J BIOL CHEM, V267, P10122; TEASDALE RD, 1992, J BIOL CHEM, V267, P4084; VANDENEIJNDEN DH, 1983, EUR J BIOCHEM, V134, P523; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245	34	46	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33105	33109		10.1074/jbc.271.51.33105	http://dx.doi.org/10.1074/jbc.271.51.33105			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955158	hybrid			2022-12-25	WOS:A1996VZ37300093
J	Fuhrer, C; Hall, ZW				Fuhrer, C; Hall, ZW			Functional interaction of Src family kinases with the acetylcholine receptor in C2 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; TORPEDO ELECTRIC ORGAN; SIGNAL-TRANSDUCTION; DELTA-SUBUNIT; GROWTH-FACTOR; GENE-PRODUCT; MUSCLE-CELLS; PHOSPHORYLATION; AGRIN; DYSTROPHIN	Tyrosine phosphorylation of the beta subunit of the acetylcholine receptor (AChR) has been postulated to play a role in AChR clustering during development of the neuromuscular junction. me have investigated the mechanism of this phosphorylation in mammalian C2 myotubes and report that the tyrosine kinase Src binds and phosphorylates glutathione S-transferase fusion proteins containing the N-terminal half of the cytoplasmic loop of the beta subunit. No binding occurs to the related kinases Fyn or Yes or to the corresponding regions from the gamma and delta subunits. Furthermore, AChRs affinity-isolated from C2 myotubes using alpha-bungarotoxin-Sepharose mere specifically associated with Src and Fyn and had tyrosine-phosphorylated beta subunits. We suggest that AChRs are initially phosphorylated by Src and subsequently bind Fyn in a phosphotyrosine-dependent manner. These interactions are likely to play an important role in construction of the specialized postsynaptic membrane during synaptogenesis.	UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; NIMH, SECT SYNAPT MECHANISMS, CELL BIOL LAB, BETHESDA, MD 20892 USA	University of California System; University of California San Francisco; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)				Fuhrer, Christian/0000-0001-8216-8883				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BAKER LP, 1992, J CELL SCI, V102, P543; BUONANNO A, 1989, J BIOL CHEM, V264, P7611; CAMBIER JC, 1994, CURR OPIN GENET DEV, V4, P55, DOI 10.1016/0959-437X(94)90091-4; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; COOKE M P, 1989, New Biologist, V1, P66; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Ferns M, 1996, J CELL BIOL, V132, P937, DOI 10.1083/jcb.132.5.937; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GORDON H, 1993, J NEUROSCI, V13, P586; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KEFALAS P, 1995, INT J BIOCHEM CELL B, V27, P551, DOI 10.1016/1357-2725(95)00024-J; MEIER T, 1995, J CELL BIOL, V131, P441, DOI 10.1083/jcb.131.2.441; NEF P, 1984, P NATL ACAD SCI-BIOL, V81, P7975, DOI 10.1073/pnas.81.24.7975; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENG HB, 1991, NEURON, V6, P237; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; PLEIMAN CM, 1994, P NATL ACAD SCI USA, V91, P4268, DOI 10.1073/pnas.91.10.4268; QU Z, 1994, J NEUROSCI, V14, P6834; QU ZC, 1990, NEURON, V4, P367, DOI 10.1016/0896-6273(90)90049-L; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIBAHARA S, 1985, EUR J BIOCHEM, V146, P15, DOI 10.1111/j.1432-1033.1985.tb08614.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; STROUD RM, 1985, ANNU REV CELL BIOL, V1, P317, DOI 10.1146/annurev.cb.01.110185.001533; SUDOL M, 1986, MOL CELL BIOL, V6, P2839, DOI 10.1128/MCB.6.8.2839; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; SUPERTIFURGA G, 1995, FEBS LETT, V369, P62, DOI 10.1016/0014-5793(95)00636-N; SWOPE SL, 1995, ANN NY ACAD SCI, V757, P197, DOI 10.1111/j.1749-6632.1995.tb17476.x; SWOPE SL, 1993, J BIOL CHEM, V268, P25152; SWOPE SL, 1994, J BIOL CHEM, V269, P29817; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; WAGNER K, 1991, J BIOL CHEM, V266, P23784; Wagner K R, 1991, Curr Opin Neurobiol, V1, P65, DOI 10.1016/0959-4388(91)90011-U; WAGNER KR, 1994, J NEUROCHEM, V62, P1947; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WALLACE BG, 1991, NEURON, V6, P869, DOI 10.1016/0896-6273(91)90227-Q; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; YU XM, 1994, MOL PHARMACOL, V46, P964	55	81	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32474	32481		10.1074/jbc.271.50.32474	http://dx.doi.org/10.1074/jbc.271.50.32474			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943314	Green Published, hybrid			2022-12-25	WOS:A1996VY34000105
J	Kaufmann, AM; Lichtner, RB; Schirrmacher, V; Khazaie, K				Kaufmann, AM; Lichtner, RB; Schirrmacher, V; Khazaie, K			Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumour metastasis	ONCOGENE			English	Article						EGF receptor; retroviral gene transfer; mammary carcinoma; proliferation; apoptosis; metastasis	EPIDERMAL-GROWTH-FACTOR; HUMAN-BREAST-CANCER; CARCINOMA-CELLS; TRANSGENIC MICE; TGF-ALPHA; EXPRESSION; GENES; ACTIVATION; STIMULATION; FIBROBLASTS	The low metastatic MTC (13762NF) rat mammary adenocarcinoma cell line is devoid of epidermal growth factor receptor (EGFR). To test for a link between expression of EGFR and the ability of tumour cells to metastasise from their orthotopic site (spontaneous metastasis), stable subclones of this line (S+) that had been retrovirally transduced to express an ectopic full length HER1 were established and characterised, Proliferation, survival, and response to TGF-alpha were investigated and related to the tumorigenic growth and metastatic properties of the cells, S+ clones responded in vitro to ligand stimulation by growth inhibition and apoptosis, Upon orthotopic inoculation into the mammary fat pad of nude (nu/nu) mice, S+ clones showed retarded growth and apoptosed in situ, while MTC cells or neo(R) control cells showed no signs of apoptosis, Yet, S+ cells exhibited more spontaneous metastasis than the MTC parental cells or neo(R) control cells, Spontaneous metastasis requires cellular detachment (primary site) as well as attachment (secondary site) and growth in target organs, Neither the HER1 mediated increased ECM adhesion nor its negative effect on growth potential explains the observed effect, This is the first direct demonstration of the potential of EGFR to promote spontaneous metastasis of mammary adenocarcinoma cells from their orthotopic site.	GERMAN CANC RES CTR, DIV TUMOR IMMUNOL, D-69120 HEIDELBERG, GERMANY; SCHERING AG, RES LABS, D-13342 BERLIN, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Schering AG				Kaufmann, Andreas/0000-0001-7732-3009				ARMSTRONG DK, 1994, CANCER RES, V54, P5280; BATTAGLIA F, 1988, EUR J CANCER CLIN ON, V24, P1685, DOI 10.1016/0277-5379(88)90068-5; Behrens J, 1992, Semin Cell Biol, V3, P169; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; Birchmeier W, 1991, CURR OPIN CELL BIOL, V3, P832, DOI 10.1016/0955-0674(91)90057-6; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; CASTELLANI R, 1994, CANCER, V73, P344, DOI 10.1002/1097-0142(19940115)73:2<344::AID-CNCR2820730218>3.0.CO;2-Y; DEAN C, 1994, INT J CANCER, P103; DELARUE JC, 1988, BREAST CANC RES TREA, V11; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HART IR, 1991, BRIT J CANCER, V63, P9, DOI 10.1038/bjc.1991.4; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; KAUFMANN AM, 1994, INT J ONCOL, V4, P1149; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KHAZAIE K, 1991, ONCOGENE, V6, P21; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KLIJN JGM, 1994, BREAST CANCER RES TR, V29, P73, DOI 10.1007/BF00666183; KOENDERS PG, 1991, CANCER RES, V51, P4544; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LICHTNER RB, 1995, ONCOGENE, V10, P1823; LICHTNER RB, 1992, J BIOL CHEM, V267, P11872; LICHTNER RB, 1988, J CELL PHYSIOL, V137, P285, DOI 10.1002/jcp.1041370211; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARSHALLHEYMAN H, 1994, ONCOGENE, V9, P3655; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MODJTAHEDI H, 1994, CANCER RES, V54, P1695; MORONI MC, 1992, J BIOL CHEM, V267, P2714; NERI A, 1982, J NATL CANCER I, V68, P507; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOLSON GL, 1992, ONCOGENE, V7, P1127; NICOLSON GL, 1984, EXP CELL RES, V150, P3, DOI 10.1016/0014-4827(84)90696-7; OSTEROP APRM, 1994, BIOCHEMISTRY-US, V33, P7453, DOI 10.1021/bi00189a053; OZAWA S, 1987, INT J CANCER, V40, P706, DOI 10.1002/ijc.2910400523; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAINSBURY JRC, 1987, LANCET, V1, P1398; SAINSBURY JRC, 1985, LANCET, V1, P364; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SCHIRRMACHER V, 1985, ADV CANCER RES, V43, P1, DOI 10.1016/S0065-230X(08)60942-2; STERN DF, 1987, SCIENCE, V235, P321, DOI 10.1126/science.3492043; TOI M, 1991, EUR J CANCER, V27, P977, DOI 10.1016/0277-5379(91)90262-C; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207	50	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2349	2358						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957076				2022-12-25	WOS:A1996VX10800007
J	Wang, MH; MonteroJulian, FA; Dauny, I; Leonard, EJ				Wang, MH; MonteroJulian, FA; Dauny, I; Leonard, EJ			Requirement of phosphatidylinositol-3 kinase for epithelial cell migration activated by human macrophage stimulating protein	ONCOGENE			English	Article						MSP; RON; PI-3 kinase; migration	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; MET PROTOONCOGENE PRODUCT; HA-RAS MUTATION; TYROSINE KINASE; FACTOR-RECEPTOR; SIGNAL TRANSDUCTION; MOLECULAR-CLONING; 3-KINASE; FAMILY	Macrophage stimulating protein (MSP) is a ligand for the RON receptor protein tyrosine kinase. Activation of RON in murine resident macrophages results in cell shape change and migration. We studied cell movement induced by MSP in different types of human epithelial cells and the possible role of phosphatidylinositol-3 (PI-3) kinase in RON-mediated signal transduction. We observed specific and saturable binding of I-125-MSP to RON on several epithelial cell lines. In addition to activation and phosphorylation of RON, MSP also induced tyrosine phosphorylation of the PI-3 kinase p85 subunit in a time-dependent manner, with a peak at 15 min. Moreover, phosphorylated RON formed complex with PI-3 kinase in both HK-NOC keratinocyte and RON cDNA-transfected MDCK cells. An in vitro protein interaction assay confirmed that PI-3 kinase from a lysate of MSP-activated cells bound to pure RON protein. MSP, at a concentration range of 1 to 5 nM, induced migration of three epithelial cell lines. This effect was inhibited by wortmannin, a specific inhibitor for PI-3 kinase, with an IC50 of 10 nM. MSP-induced shape change in murine resident peritoneal macrophages was also abolished by wortmannin. These data suggest that activation of PI-3 kinase is required for MSP-induced epithelial cell migration. The stimulation by MSP of epithelial cell movement may have implications for tissue repair, wound healing, and tumor metastasis.	NCI,IMMUNOBIOL LAB,IMMUNOPATHOL SECT,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,NIH,FREDERICK,MD 21702; IMMUNOTECH SA,ANTIBODY DEPT,MARSEILLE 9,FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ANDO Y, 1993, J CELL PHYSIOL, V156, P487, DOI 10.1002/jcp.1041560308; Banu N, 1996, J IMMUNOL, V156, P2933; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROXMEYER HE, 1996, IN PRESS ANN HEMATOL; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HAMMACHER A, 1989, EMBO J, V8, P2489, DOI 10.1002/j.1460-2075.1989.tb08385.x; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEONARD EJ, 1976, EXP CELL RES, V102, P434, DOI 10.1016/0014-4827(76)90065-3; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; VARTICOVSKI L, 1994, BBA-MOL BASIS DIS, V1226, P1, DOI 10.1016/0925-4439(94)90051-5; VILLA LL, 1992, MOL CARCINOGEN, V6, P5, DOI 10.1002/mc.2940060103; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1996, IN PRESS EXP CELL RE; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; YANO H, 1993, J BIOL CHEM, V268, P25846; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461	50	80	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2167	2175						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950984				2022-12-25	WOS:A1996VV14500014
J	Brondello, JM; Brunet, A; Pouyssegur, J; McKenzie, FR				Brondello, JM; Brunet, A; Pouyssegur, J; McKenzie, FR			The dual specificity mitogen-activated protein kinase phosphatase-1 and -2 are induced by the p42/p44(MAPK) cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; MAP KINASE; TYROSINE-PHOSPHATASE; HEAT-SHOCK; FIBROBLAST PROLIFERATION; MAMMALIAN-CELLS; ENCODED PROTEIN; GROWTH-FACTORS; IN-VIVO; EXPRESSION	Mitogen-activated protein (MAP) kinase phosphatase-1 (MKP-1) and MKP-2 are two members of a recently described family of dual specificity phosphatases that are capable of dephosphorylating p42/p44(MAPK). Overexpression of MKP-1 or MKP-2 inhibits MAP kinase-dependent intracellular signaling events and fibroblast proliferation. By using specific antibodies that recognize endogenous MKP-1 and MKP-2 in CCL39 cells, we show that MKP-1 and MKP-2 are not expressed in quiescent cells, but are rapidly induced following serum addition, with protein detectable as early as 30 min (MKP-1) or 60 min (MKP-2). Serum induction of MKP-1 and MKP-2 is sustained, with protein detectable up to 14 h after serum addition. Induction of MKP-1 and, to a lesser extent, MKP-2 temporally correlates with p42/p44(MAPK) inactivation. To analyze the contribution of the MAP kinase cascade to MKP-1 and MKP-2 induction, we examined CCL39 cells transformed with either v-ras or a constitutively active direct upstream activator of MAP kinase, mitogen-activated protein kinase kinase-l (MKK-1; MKK-1(SD/SD) mutant). In both cell models, MKP-1 and MKP-2 are constitutively expressed, with MKP-2 being prevalent. In addition, in CCL39 cells expressing an estradiol-inducible Delta Raf-1::ER chimera, activation of Raf alone is sufficient to induce MKP-1 and MKP-2. The role of the MAP kinase cascade in MKP induction was highlighted by the MKK-1 inhibitor PD 098059, which blunted both the activation of p42/p44(MAPK); and the induction of MKP-1 and MKP-2. However, the MAP kinase cascade is not absolutely required for the induction of MKP-1, as this phosphatase, but not MKP-2, was induced to detectable levels by agents that stimulate protein-kinases A and C. Thus, activation of the p42/p44(MAPK) cascade promotes the induction of MKP-1 and MKP-2, which may then attenuate p42/p44(MAPK)-dependent events in an inhibitory feedback loop.	UNIV NICE,CTR BIOCHIM,CNRS,UMR 134,F-06108 NICE 02,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Brondello, Jean-Marc/U-8232-2017	Brondello, Jean-Marc/0000-0001-5991-3945				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ASHWORTH A, 1992, ONCOGENE, V7, P2555; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BRUNET A, 1994, ONCOGENE, V9, P3379; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Degols G, 1996, MOL CELL BIOL, V16, P2870; DEGROOT RP, 1993, MOL ENDOCRINOL, V7, P145, DOI 10.1210/me.7.2.145; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dixon JE, 1995, ANN NY ACAD SCI, V766, P18, DOI 10.1111/j.1749-6632.1995.tb26644.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GERONDAKIS S, 1994, GENOMICS, V24, P182, DOI 10.1006/geno.1994.1598; GROOM LA, 1996, EMBO J, V15, P101; Grumont RJ, 1996, MOL CELL BIOL, V16, P2913; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; King AG, 1995, ONCOGENE, V11, P2553; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KWAK SP, 1995, J BIOL CHEM, V270, P1156, DOI 10.1074/jbc.270.3.1156; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LEWIS T, 1995, J CELL SCI, V108, P2885; MAGUN BE, 1995, CELL GROWTH DIFFER, V6, P891; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; McKenzie FR, 1996, J BIOL CHEM, V271, P13476, DOI 10.1074/jbc.271.23.13476; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Mourey RJ, 1996, J BIOL CHEM, V271, P3795; Muda M, 1996, J BIOL CHEM, V271, P4319; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Sugimoto T, 1996, J BIOL CHEM, V271, P544, DOI 10.1074/jbc.271.1.544; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU G, 1995, J BIOL CHEM, V275, P12665; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	74	316	323	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1368	1376		10.1074/jbc.272.2.1368	http://dx.doi.org/10.1074/jbc.272.2.1368			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995446	hybrid			2022-12-25	WOS:A1997WC04800097
J	Cote, GJ; Huang, ESC; Jin, W; Morrison, RS				Cote, GJ; Huang, ESC; Jin, W; Morrison, RS			Sequence requirements for regulated RNA splicing of the human fibroblast growth factor receptor-1 alpha exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERM-LINE MUTATIONS; MESSENGER-RNA; STRUCTURAL DOMAINS; HUMAN ASTROCYTOMAS; RET PROTOONCOGENE; CANCER; EXPRESSION; TISSUES; GENE; FAMILIES	Progression of astrocytes from a benign to a malignant phenotype is accompanied by a change in the RNA processing of the fibroblast growth factor receptor 1 (FGFR-1) gene. The level of a high affinity form of the FGFR-1 is dramatically elevated as a result of alpha-exon skipping during RNA splicing. In this paper we have been able to duplicate this tumor-specific RNA processing pathway by transfection of a chimeric minigene containing a 4-kilobase fragment of the human FGFR-1 gene (including the alpha-exon) into a variety of cell lines, In a transfected human astrocytoma cell line, alpha-exon skipping was consistently observed for RNA transcripts derived from both the chimeric minigene and endogenous gene expression. This exon skipping phenotype was dependent on the size of the flanking intron as deletions which reduced the introns to less than similar to 350 base pairs resulted in enhanced alpha-exon inclusion, Increased exon inclusion was not sequence-specific as exon skipping could be restored with insertion of nonspecific sequence. Cell-specific exon recognition was maintained with a 375-nucleotide sequence inclusive and flanking the alpha-exon, provided that intron size was maintained. These results identify the minimal cis-regulatory sequence requirements for exclusion of FGFR-1 alpha-exon in astrocytomas.	UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	Cote, GJ (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,ENDOCRINOL SECT,1515 HOLCOMBE BLVD,BOX 15,HOUSTON,TX 77030, USA.				NCI NIH HHS [CA67946, 2P30-CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067946, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLACK DL, 1995, RNA, V1, P763; BURGER PC, 1991, SURGICAL PATHOLOGY N, P193; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; DAFFADA AAI, 1995, CANCER RES, V55, P288; DELGATTO F, 1995, MOL CELL BIOL, V15, P4825; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; Fernig David G., 1994, Progress in Growth Factor Research, V5, P353, DOI 10.1016/0955-2235(94)00007-8; FREBOURG T, 1995, AM J HUM GENET, V56, P608; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FU XD, 1995, RNA, V1, P663; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GOTTELAND M, 1995, MOL CELL ENDOCRINOL, V112, P1, DOI 10.1016/0303-7207(95)03576-S; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; HALL NR, 1994, EUR J CANCER, V30A, P1550, DOI 10.1016/0959-8049(94)00326-Z; HARADA T, 1995, BIOCHEM BIOPH RES CO, V205, P1057; HARADA Y, 1995, J BIOCHEM-TOKYO, V118, P780, DOI 10.1093/oxfordjournals.jbchem.a124980; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HUGHES SE, 1993, LAB INVEST, V69, P173; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAWAGISHI J, 1995, GENOMICS, V30, P224, DOI 10.1006/geno.1995.9883; LOU H, 1995, MOL CELL BIOL, V15, P7135; LOU H, 1994, MOL ENDOCRINOL, V8, P1618, DOI 10.1210/me.8.12.1618; MCKEEHAN WL, 1994, MOL REPROD DEV, V39, P69, DOI 10.1002/mrd.1080390112; MIURA Y, 1995, J BIOL CHEM, V270, P26840, DOI 10.1074/jbc.270.45.26840; MIYAKI M, 1995, J MOL MED-JMM, V73, P515; MORRISON RS, 1994, J NEURO-ONCOL, V18, P207, DOI 10.1007/BF01328955; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NAKAMURA M, 1995, J BIOL CHEM, V270, P30102, DOI 10.1074/jbc.270.50.30102; Neuhausen SL, 1996, AM J HUM GENET, V58, P271; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; Peleg Sara, 1993, P343; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; SLUYSER M, 1994, CRIT REV ONCOGENESIS, V5, P539; STEFANIK DF, 1991, CANCER RES, V51, P5760; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG F, 1995, J BIOL CHEM, V270, P10222, DOI 10.1074/jbc.270.17.10222; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WRIGHT JA, 1993, CRIT REV ONCOGENESIS, V4, P473; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAZAKI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P37, DOI 10.1016/0167-4781(93)90266-G	45	17	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1054	1060		10.1074/jbc.272.2.1054	http://dx.doi.org/10.1074/jbc.272.2.1054			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995402	hybrid			2022-12-25	WOS:A1997WC04800053
J	Guo, HM; Zucker, S; Gordon, MK; Toole, BP; Biswas, C				Guo, HM; Zucker, S; Gordon, MK; Toole, BP; Biswas, C			Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; INTERSTITIAL COLLAGENASE; INHIBITOR COMPLEXES; MOUSE BASIGIN; TUMOR; EXPRESSION; CANCER; STROMELYSIN; LOCALIZATION; FIBROBLASTS	Many of the tumor-associated matrix metalloproteinases that are implicated in metastasis are produced by stromal fibroblasts within or surrounding the tumor in response to stimulation by factors produced by tumor cells. In this study we transfected Chinese hamster ovary cells with putative cDNA for human extracellular matrix metalloproteinase inducer (EMMPRIN), a transmembrane glycoprotein that is attached to the surface of many types of malignant human tumor cells and that has previously been implicated in stimulation of matrix metalloproteinase production in fibroblasts. We show that these transfected cells synthesize EMMPRIN that is extensively post-translationally processed; this recombinant EMMPRIN stimulates human fibroblast production of interstitial collagenase, stromelysin-1, and gelatinase A (72-kDa type IV collagenase). We propose that EMMPRIN regulates matrix metalloproteinase production during tumor invasion and other processes involving tissue remodeling.	TUFTS UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02111; VET AFFAIRS MED CTR,DEPT RES,NORTHPORT,NY 11768; VET AFFAIRS MED CTR,DEPT MED,NORTHPORT,NY 11768	Tufts University; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [R01CA038817] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38817] Funding Source: Medline; NEI NIH HHS [EY 09056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BISWAS C, 1995, CANCER RES, V55, P434; BISWAS C, 1984, CANCER LETT, V24, P201, DOI 10.1016/0304-3835(84)90137-X; BISWAS C, 1987, CELL MEMBRANES METHO, P341; COOKSLEY S, 1990, MATRIX, V10, P285, DOI 10.1016/S0934-8832(11)80183-6; DeCastro R, 1996, J INVEST DERMATOL, V106, P1260, DOI 10.1111/1523-1747.ep12348959; ELLIS SM, 1989, CANCER RES, V49, P3385; GRAY ST, 1992, AM J PATHOL, V141, P301; GUIRGUIS R, 1990, J OCCUP ENVIRON MED, V32, P846, DOI 10.1097/00043764-199009000-00017; KASINRERK W, 1992, J IMMUNOL, V149, P847; KATAOKA H, 1993, CANCER RES, V53, P3154; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; MONSKY WL, 1993, CANCER RES, V53, P3159; MURAOKA K, 1993, INT J CANCER, V55, P19, DOI 10.1002/ijc.2910550105; NABESHIMA K, 1991, ARCH BIOCHEM BIOPHYS, V285, P90, DOI 10.1016/0003-9861(91)90332-D; POLETTE M, 1993, INVAS METAST, V13, P31; POULSOM R, 1992, AM J PATHOL, V141, P389; PYKE C, 1992, CANCER RES, V52, P1336; SASAGURI Y, 1992, AM J PATHOL, V141, P611; SEULBERGER H, 1992, NEUROSCI LETT, V140, P93, DOI 10.1016/0304-3940(92)90690-9; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; ZUCKER S, 1994, B I PASTEUR, V92, P284; ZUCKER S, 1987, CANCER RES, V47, P1608; ZUCKER S, 1994, ANN NY ACAD SCI, V732, P248, DOI 10.1111/j.1749-6632.1994.tb24740.x	25	276	314	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					24	27						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995219				2022-12-25	WOS:A1997WA56400006
J	HadzopoulouCladaras, M; Kistanova, E; Evagelopoulou, C; Zeng, SY; Cladaras, C; Ladias, JAA				HadzopoulouCladaras, M; Kistanova, E; Evagelopoulou, C; Zeng, SY; Cladaras, C; Ladias, JAA			Functional domains of the nuclear receptor hepatocyte nuclear factor 4''	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HNF-4; THYROID-HORMONE RECEPTOR; APO-B GENE; INTESTINAL TRANSCRIPTION; PROMOTER ELEMENTS; MAMMALIAN-CELLS; CO-REPRESSOR; DNA; SUPERFAMILY; EXPRESSION	The hepatocyte nuclear factor 4 (HNF-4) is a member of the nuclear receptor superfamily and participates in the regulation of several genes involved in diverse metabolic pathways and developmental processes. To date, the functional domains of this nuclear receptor have not been identified, and it is not known whether its transcriptional activity is regulated by a ligand or other signals. In this report, we show that HNF-4 contains two transactivation domains, designated AF-1 and AF-2, which activate transcription in a cell type-independent manner. AF-1 consists of the extreme N-terminal 24 amino acids and functions as a constitutive autonomous activator of transcription. This short transactivator belongs to the class of acidic activators, and it is predicted to adopt an amphipathic alpha-helical structure. In contrast, the AF-2 transactivator is complex, spanning the 128-366 region of HNF-4, and it cannot be further dissected without impairing activity. The 360-366 region of HNF-4 contains a motif that is highly conserved among transcriptionally active nuclear receptors, and it is essential for AF-2 activity, but it is not necessary for dimerization and DNA binding of HNF-4. Thus, HNF-4 deletion mutants lacking the 361-465 region bind efficiently to DNA as homo- and heterodimers and behave as dominant negative mutants. Remarkably, the full transactivation potential of AF-2 is inhibited by the region spanning residues 371-465 (region F). The inhibitory effect of region F on the HNF-4 AF-2 activity is a unique feature among members of the nuclear receptor superfamily, and we propose that it defines a distinct regulatory mechanism of transcriptional activation by HNF-4.	HARVARD UNIV,SCH MED,NEW ENGLAND DEACONESS HOSP,DEPT MED,HEMATOL ONCOL DIV,GENE REGULAT LAB,BOSTON,MA 02215	Harvard University; Harvard Medical School	HadzopoulouCladaras, M (corresponding author), BOSTON UNIV,SCH MED,CARDIOVASC INST,SECT MOL GENET,DEPT MED & BIOCHEM,700 ALBANY ST,BOSTON,MA 02118, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043909, R01HL056104, R01HL052666] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56104, HL52666, HL43909] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CARTER ME, 1993, J BIOL CHEM, V268, P13805; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FOLKERS GE, 1995, J BIOL CHEM, V270, P23552, DOI 10.1074/jbc.270.40.23552; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; HADZOPOULOUCLADARAS M, 1993, BIOCHEMISTRY-US, V32, P9657, DOI 10.1021/bi00088a018; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HATA S, 1995, BBA-GENE STRUCT EXPR, V1260, P55, DOI 10.1016/0167-4781(94)00177-5; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KTISTAKI E, 1994, NUCLEIC ACIDS RES, V22, P4689, DOI 10.1093/nar/22.22.4689; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1994, J BIOL CHEM, V269, P5944; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; LEDUARIN B, 1995, EMBO J, V14, P2020; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKSHATRI H, 1994, J BIOL CHEM, V269, P890; OGAMI K, 1990, J BIOL CHEM, V265, P9808; ONATE SA, 1995, SCIENCE, V270, P1354; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; ZHONG WM, 1993, EMBO J, V12, P537, DOI 10.1002/j.1460-2075.1993.tb05685.x	48	125	125	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					539	550						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995295				2022-12-25	WOS:A1997WA56400082
J	Zhang, R; Ducy, P; Karsenty, G				Zhang, R; Ducy, P; Karsenty, G			1,25-dihydroxyvitamin D-3 inhibits Osteocalcin expression in mouse through an indirect mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D; GENE-EXPRESSION; PARATHYROID-HORMONE; RETINOIC ACID; COLLAGEN PROMOTER; RESPONSE ELEMENTS; OSTEOPONTIN GENE; THYROID-HORMONE; MESSENGER-RNA; OSTEO-SARCOMA	1,25-Dihydroxyvitamin D-3 (1,25-(OH)(2)D-3), a key regulator of mineral metabolism, regulates the expression of several genes that are expressed in osteoblasts. In particular, in rat and human osteoblasts, 1,25-(OH)(2)D-3 increases the expression of Osteocalcin by interacting, through a hormone-receptor complex, with a vitamin D-responsive element present in the promoter of the genes. Here we show that in mouse, 1,25-(OH)(2)D-3 inhibits the expression of both osteocalcin genes, OG1 and OG2. This inhibition was observed in primary osteoblast cultures and in the whole animal. From sequence inspection, DNA transfection experiments, and DNA binding assays, we could not identify a functional vitamin D-responsive element in the promoter of OG2 or in the first 3.3 kilobases of the OG1 promoter. However, we show that 1,25-(OH)(2)D-3 treatment of primary osteoblasts abolishes the binding of OSF2, an osteoblast-specific activator of transcription that binds to OSE2, a critical osteoblast specific cis-acting element present in OG1 and OG2 promoters. Consistent with these DNA binding data, a mutation in OSE2 in the OG2 promoter abrogated the inhibitory effect of 1,25-(OH)(2)D-3 treatment on this promoter activity. This study illustrates that 1,25-(OH)(2)D-3 can play different roles in the expression of the same gene in various species and indicates that this regulation in mouse occurs through an indirect mechanism, 1,25-(OH)(2)D-3 acting on a gene genetically located upstream of Osteocalcin.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011290] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41059] Funding Source: Medline; NIDCR NIH HHS [DE/AR-11290] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BALSAN S, 1986, J CLIN INVEST, V77, P1661, DOI 10.1172/JCI112483; BROESS M, 1995, J CELL BIOCHEM, V57, P440, DOI 10.1002/jcb.240570310; BROWN T, 1987, CURRENT PROTOCOLS MO, V1; CARLBERG C, 1995, EUR J BIOCHEM, V231, P517, DOI 10.1111/j.1432-1033.1995.0517d.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Geoffroy V, 1995, J BIOL CHEM, V270, P30973, DOI 10.1074/jbc.270.52.30973; HARRIS SE, 1994, J BONE MINER RES, V9, P389; HORLEIN AJ, 1995, NATURE, V377, P394; IKEDA T, 1992, BIOCHEM BIOPH RES CO, V189, P1231, DOI 10.1016/0006-291X(92)92336-V; ISHIDA H, 1993, ENDOCRINOLOGY, V132, P61, DOI 10.1210/en.132.1.61; JOHANNES FJ, 1992, TRENDS GENET, V8, P48; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LIAN J, 1989, P NATL ACAD SCI USA, V86, P1143, DOI 10.1073/pnas.86.4.1143; LIAN JB, 1992, J CELL BIOCHEM, V49, P37, DOI 10.1002/jcb.240490108; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MERRIMAN HL, 1995, BIOCHEMISTRY-US, V34, P13125, DOI 10.1021/bi00040a025; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; NODA M, 1989, J CELL BIOL, V108, P713, DOI 10.1083/jcb.108.2.713; OLDBERG A, 1986, P NATL ACAD SCI USA, V83, P8819, DOI 10.1073/pnas.83.23.8819; OLDBERG A, 1989, J CELL BIOL, V109, P3183, DOI 10.1083/jcb.109.6.3183; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; OZONO K, 1990, J BIOL CHEM, V265, P21881; PRICE PA, 1980, J BIOL CHEM, V255, P1660; REICHEL H, 1989, NEW ENGL J MED, V320, P980, DOI 10.1056/NEJM198904133201506; RIDALL AL, 1995, ANN NY ACAD SCI, V760, P59, DOI 10.1111/j.1749-6632.1995.tb44620.x; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; SILVER J, 1986, J CLIN INVEST, V78, P1296, DOI 10.1172/JCI112714; STERN PH, 1980, PHARMACOL REV, V32, P47; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; SZTAJNKRYCER MD, 1994, J BONE MINER RES SB, V9, P235; TAMURA M, 1994, J CELL BIOL, V126, P773, DOI 10.1083/jcb.126.3.773; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y	40	86	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					110	116						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995235	hybrid			2022-12-25	WOS:A1997WA56400022
J	Uhl, MA; Miller, JF				Uhl, MA; Miller, JF			Central role of the BvgS receiver as a phosphorylated intermediate in a complex two-component phosphorelay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDETELLA-PERTUSSIS; ESCHERICHIA-COLI; SIGNAL-TRANSDUCTION; VIRULENCE FACTORS; BACTERIAL CHEMOTAXIS; BACILLUS-SUBTILIS; SENSOR PROTEIN; GENE; BRONCHISEPTICA; SPORULATION	Two-component systems use phosphorylation reactions to regulate stimulus/response pathways. In Bordetella pertussis, a human respiratory pathogen, the infectious cycle of the organism is controlled by the BvgAS two-component system. BvgS has similarities to sensor and response regulator components and is an autophosphorylating kinase that phosphorylates BvgA. BvgA, a response regulator, is a DNA-binding protein that activates virulence gene transcription. Three phosphorylated BvgS domains, the transmitter, receiver, and C terminus, are essential for signal transduction. We now demonstrate that the BvgS transmitter is sufficient for autophosphorylation but is unable to phosphorylate the C terminus or BvgA. The BvgS receiver regulates several phenotypes: dephosphorylation of both the BvgS transmitter and C terminus as well as transfer of a phosphoryl group from the transmitter to the C terminus. Our results indicate that BvgAS signal transduction initiates with autophosphorylation of the transmitter followed by phosphotransfer to the receiver. The phosphorylated receiver can donate to the C terminus or to water. The phosphorylated C terminus is then able to transfer the phosphoryl group to BvgA.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, INST MOL BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI031548, R01AI038417] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38417, AI31548, AI07323] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akerley BJ, 1996, TRENDS MICROBIOL, V4, P141, DOI 10.1016/0966-842X(96)10024-X; AKERLEY BJ, 1995, CELL, V80, P611, DOI 10.1016/0092-8674(95)90515-4; AKERLEY BJ, 1992, J BACTERIOL, V174, P980, DOI 10.1128/jb.174.3.980-990.1992; ARICO B, 1989, P NATL ACAD SCI USA, V86, P6671, DOI 10.1073/pnas.86.17.6671; BEIER D, 1995, J MOL BIOL, V248, P596, DOI 10.1006/jmbi.1995.0245; BOUCHER PE, 1995, J BACTERIOL, V177, P6486, DOI 10.1128/jb.177.22.6486-6491.1995; BOUCHER PE, 1994, J MOL BIOL, V241, P363, DOI 10.1006/jmbi.1994.1513; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GIARDINA PC, 1995, J BACTERIOL, V177, P6058, DOI 10.1128/jb.177.21.6058-6063.1995; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1993, J BIOL CHEM, V268, P23972; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MILLER JF, 1989, J BACTERIOL, V171, P6345, DOI 10.1128/jb.171.11.6345-6348.1989; OHLSEN KL, 1994, P NATL ACAD SCI USA, V91, P1756, DOI 10.1073/pnas.91.5.1756; PEREGO M, 1994, CELL, V79, P1047, DOI 10.1016/0092-8674(94)90035-3; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; ROY CR, 1991, J BACTERIOL, V173, P2385, DOI 10.1128/JB.173.7.2385-2392.1991; ROY CR, 1989, J BACTERIOL, V171, P6338, DOI 10.1128/jb.171.11.6338-6344.1989; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Steffen P, 1996, EMBO J, V15, P102, DOI 10.1002/j.1460-2075.1996.tb00338.x; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; STIBITZ S, 1991, J BACTERIOL, V173, P4288, DOI 10.1128/JB.173.14.4288-4296.1991; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; TSUSUKI M, 1995, MOL MICROBIOL, V18, P953; Uhl MA, 1996, EMBO J, V15, P1028, DOI 10.1002/j.1460-2075.1996.tb00440.x; UHL MA, 1994, P NATL ACAD SCI USA, V91, P1163, DOI 10.1073/pnas.91.3.1163; Uhl MA, 1995, 2 COMPONENT SIGNAL T, P333; VOLZ K, 1993, BIOCHEMISTRY-US, V32, P11741, DOI 10.1021/bi00095a001; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WEISS AA, 1983, INFECT IMMUN, V42, P33, DOI 10.1128/IAI.42.1.33-41.1983; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919	36	84	87	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33176	33180		10.1074/jbc.271.52.33176	http://dx.doi.org/10.1074/jbc.271.52.33176			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969172	hybrid			2022-12-25	WOS:A1996WA71300006
J	Roy, B; Reisman, D				Roy, B; Reisman, D			Positive and negative regulatory elements in the murine p53 promoter	ONCOGENE			English	Article						p53 expression; transcription; promoter	TUMOR-SUPPRESSOR GENE; WILD-TYPE P53; HELIX-LOOP-HELIX; TRANSCRIPTIONAL REPRESSION; PROTEIN; EXPRESSION; ANTIGEN; CELLS; TRANSFORMATION; BINDING	In order to understand the basis for regulated as well as de-regulated expression of the p53 tumor suppressor gene, we have focused on characterizing the transcriptional regulation of the p53 gene. Here we present evidence for the existence of two additional upstream regulatory elements in the murine p53 promoter. One of these sites maps to a region between -296 to -270 and the second one between -255 to -226 relative to the major transcription initiation site. These two sites are referred to as binding sites for PBF I and II, respectively. Nucleotide bases that have been found to be critical for the binding of nuclear factors to these sites are 5'-AGA-3' (-282 to -280) in binding site I and 5'-ACAG-3' (-246 to -243) in binding site II. Mutational analyses in conjunction with transient transfection assays indicated that the factor that binds to the region between -245 to -242 (PBF II) plays a positive regulatory role p53 promoter activity. This was demonstrated by the observation that promoter mutations that abolished binding to this site, showed a decreased level of activity as compared to the wild type promoter. In analogous experiments, mutational anlayses and transient transfection assays indicated that the factor that binds to the region between -282 to -280 (PBF I) plays a negative regulatory role in p53 promoter activity. This was demonstrated by the observation that promoter mutations that abolished binding to this site, showed an increased level of activity as compared to the wild type promoter.	UNIV S CAROLINA,DEPT BIOL SCI,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL CANCER INSTITUTE [R29CA059986] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA59986] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Balint E, 1996, CANCER RES, V56, P1648; BEINZTADMOR B, 1985, EMBO J, V4, P3209; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GINSBERG D, 1990, ONCOGENE, V5, P1285; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OLTIVAI ZN, 1993, CELL, V74, P609; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PROKOCIMER M, 1994, BLOOD, V84, P2391; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1993, NUCLEIC ACIDS RES, V21, P345, DOI 10.1093/nar/21.2.345; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STUART ET, 1995, EMBO J, V14, P5638, DOI 10.1002/j.1460-2075.1995.tb00251.x; UITTENBOGAARD MN, 1995, J BIOL CHEM, V270, P28503, DOI 10.1074/jbc.270.48.28503; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU HY, 1994, J BIOL CHEM, V269, P20067; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	43	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2359	2366						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957077				2022-12-25	WOS:A1996VX10800008
J	ZerfassThome, K; Zwerschke, W; Mannhardt, B; Tindle, R; Botz, JW; JansenDurr, P				ZerfassThome, K; Zwerschke, W; Mannhardt, B; Tindle, R; Botz, JW; JansenDurr, P			Inactivation of the cdk inhibitor p27(KIP1) by the human papillomavirus type 16 E7 oncoprotein	ONCOGENE			English	Article						cdk2; cyclin A; cyclin E; HPV-16 E7; p27(KIP1)	HIGH-EFFICIENCY TRANSFORMATION; DEPENDENT KINASE INHIBITOR; GROWTH-FACTOR-BETA; HUMAN CYCLIN-E; CELL-CYCLE; HUMAN KERATINOCYTES; PHASE-TRANSITION; PROTEIN; GENE; ADENOVIRUS-E1A	Expression of the E7 oncogene of HPV-16 induces S phase entry of mammalian cells in the presence of antiproliferative signals. In particular, E7 can bypass G(0)/G(1) arrest in response to both serum withdrawal and loss of cell adhesion, two experimental conditions in which cell cycle progression is accompanied by elevated levels of the cdk inhibitor p27(KIP1). We show here that E7 can antagonize the ability of p27(KIP1) block cyclin E-associated kinase in vitro and to inhibit transcription from the cyclin A gene in transfection experiments. E7 associates with p27(KIP1) both in a reconstituted in vitro system and in extracts of mammalian cells, and association requires the C-terminal part of E7. The interaction between p27(KIP1) and E7 can also be demonstrated in a yeast two hybrid system. The data suggest that the ability of E7 to override certain forms of G(0)/G(1) arrest is mediated in part by binding to and subsequent inactivation of the cdk inhibitor p27(KIP1).	DEUTSCH KREBSFORSCHUNGSZENTRUM, FORSCH SCHWERPUNKT ANGEW TUMORVIROL, ABT 620, D-69120 HEIDELBERG, GERMANY; PRINCESS ALEXANDRA HOSP, LIONS HUMAN IMMUNOL LABS, BRISBANE, QLD 4102, AUSTRALIA	Helmholtz Association; German Cancer Research Center (DKFZ)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429; Zwerschke, Werner/0000-0003-1137-2953				BANKS L, 1990, ONCOGENE, V5, P833; BANKS L, 1990, ONCOGENE, V5, P1383; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCOLINI F, 1994, ONCOGENE, V9, P2633; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MATSUMOTO K, 1990, J CELL PHYSIOL, V145, P95, DOI 10.1002/jcp.1041450114; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MIN SY, 1992, ONCOGENE, V7, P1531; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNGER K, 1989, J VIROL, V63, P4417; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PHELPS WC, 1992, J VIROL, V66, P2418, DOI 10.1128/JVI.66.4.2418-2427.1992; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Schulze A, 1996, MOL CELL BIOL, V16, P4632; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245; Zwerschke W, 1996, ONCOGENE, V12, P213	41	276	297	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2323	2330						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957073				2022-12-25	WOS:A1996VX10800004
J	Bond, J; Haughton, M; Blaydes, J; Gire, V; WynfordThomas, D; Wyllie, F				Bond, J; Haughton, M; Blaydes, J; Gire, V; WynfordThomas, D; Wyllie, F			Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence	ONCOGENE			English	Article						p53; senescence; immortalisation; transactivation; beta-galactosidase; DNA damage	HUMAN-DIPLOID FIBROBLASTS; DNA-BINDING FUNCTION; EPITHELIAL-CELLS; MUTANT P53; MAMMALIAN-CELLS; HUMAN CANCER; IMMORTALIZATION; EXPRESSION; PROTEIN; DAMAGE	Wild-type p53 is necessary for the growth arrest of human diploid fibroblasts (HDF) (and many other cell types) at the end of their proliferative lifespan. Although p53 may actively mediate senescence, possibly in response to telomere erosion, it is however equally possible that it is merely a permissive factor required for response to some other inducer. To address this question, we have generated stable transfectants of early passage HDF, represented here by clone LacZ21, in which expression of a beta-galactosidase reporter construct reflects p53 transactivation activity. During continuous passage, the proportion of beta-gal positive LacZ21 cells remained below 2% for 25 population doublings (pd), first became significantly increased after 29 pd, and thereafter increased rapidly, reaching a maximum of 88% in fully-senescent cells (32 pd), which exceeded the response observed following an optimum dose (20 J/m(2)) of u.v. radiation. Correspondingly, the proportion of cells incorporating bromodeoxyuridine (BrdU) (initially 45-50%) began to fall at 29 pd and thereafter dropped rapidly to below 1% by pd 32. There was therefore a near-perfect reciprocal relationship between reporter construct expression and DNA synthesis as cells approached senescence. Furthermore, a dominant-negative p53 mutant (introduced by retroviral transduction) rescued LacZ21 cells from senescence and generated colonies with extended lifespan in which beta-gal expression was totally abolished. These data, although not excluding the need for other p53 functions, strongly suggest that p53-mediated transactivation of growth regulatory genes is a direct trigger, rather than a permissive factor, for cellular senescence.	UNIV WALES COLL MED,DEPT PATHOL,CANC RES CAMPAIGN,THYROID TUMOR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University			Blaydes, Jeremy/AAC-6939-2019; Gire, Veronique/N-7553-2017; Gire, Véronique/AAC-2218-2020	Blaydes, Jeremy/0000-0001-8525-0209; Gire, Veronique/0000-0002-9009-2185				AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BLAYDES JP, 1995, ONCOGENE, V10, P307; BOND JA, 1994, ONCOGENE, V9, P1885; BOND JA, 1995, CANCER RES, V55, P2404; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; FRIEDRICH VL, 1993, J NEUROSCI RES, V36, P88, DOI 10.1002/jnr.490360110; GUDAS J, 1995, ONCOGENE, V11, P253; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOPEZLARRAZA D, 1990, MUTAT RES, V232, P57, DOI 10.1016/0027-5107(90)90110-P; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; RENZING J, 1995, ONCOGENE, V10, P1865; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SHAY JW, 1993, ONCOGENE, V8, P1407; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119	37	126	130	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2097	2104						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950976				2022-12-25	WOS:A1996VV14500006
J	Ahmad, M; Srinivasula, SM; Wang, LJ; Litwack, G; FernandesAlnemri, T; Alnemri, ES				Ahmad, M; Srinivasula, SM; Wang, LJ; Litwack, G; FernandesAlnemri, T; Alnemri, ES			Spodoptera frugiperda caspase-1, a novel insect death protease that cleaves the nuclear immunophilin FKBP46, is the target of the baculovirus antiapoptotic protein p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; GENE; INHIBITION; MOTIF	Employing the degenerate primer-dependent polymerase chain reaction approach used recently to clone human Mch2, we have identified and cloned the insect Spodoptera frugiperda target of the baculovirus antiapoptotic protein p35. This protein named Sf caspase-1 belongs to the family of caspases and is highly related to human Mch3 and CPP32 in sequence and specific activity. The proenzyme of Sf caspase-1 is 299 amino acids in length and can undergo autocatalytic processing in Escherichia coli to an active enzyme heterocomplex. Autoprocessing occurs at Asp-28, Asp-184, and Asp-195 to generate the large p19/p18 and small p12 subunits. Sf caspase-1 is able to induce apoptosis in Sf9 cells and is capable of cleaving p35 to similar sized fragments as observed with extracts from p35 null mutant baculovirus-infected Sf9 cells. Sf caspase-1 activity is potently inhibited by p35, suggesting that it is an important target of this antiapoptotic protein. Finally, the Sf9 nuclear immunophilin FKBP46 was identified as a death-associated substrate for Sf caspase-1.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,KIMMEL CANC INST,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,CTR APOPTOSIS RES,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOL PHARMACOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University; Jefferson University			Alnemri, Emad S/B-4526-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35035] Funding Source: Medline; NIA NIH HHS [AG 13487] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ALNEMRI ES, 1994, J BIOL CHEM, V269, P30828; ALNEMRI ES, 1996, IN PRESS J CELL BIOC, V62; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Srinivasula SM, 1996, J BIOL CHEM, V271, P27099, DOI 10.1074/jbc.271.43.27099; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	25	136	150	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1421	1424		10.1074/jbc.272.3.1421	http://dx.doi.org/10.1074/jbc.272.3.1421			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999805	hybrid			2022-12-25	WOS:A1997WD05800003
J	Atfi, A; Djelloul, S; Chastre, E; Davis, RR; Gespach, C				Atfi, A; Djelloul, S; Chastre, E; Davis, RR; Gespach, C			Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor beta-mediated signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; TGF-BETA; C-JUN; TRANSDUCTION PATHWAYS; RAS SUPERFAMILY; FAMILY; INHIBITION; MECHANISM; CASCADES; RECEPTOR	Transforming growth factor beta (TGF-beta) is a multifunctional factor that induces a wide variety of cellular processes which affect growth and differentiation. TGF-beta exerts its effects through a heteromeric complex between two transmembrane serine/threonine kinase receptors, the type I and type II receptors. However, the intracellular signaling pathways through which TGF-beta receptors act to generate cellular responses remain largely undefined. Here, we report that TGF-beta initiates a signaling cascade leading to stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) activation. Expression of dominant-interfering forms of various components of the SAPK/JNK signaling pathways including Rho-like GTPases, mitogen-activated protein kinase (MAPK) kinase kinase 1 (MEKK1), MAPK kinase 4 (MKK4), SAPK/JNK, and c-Jun abolishes TGF-beta-mediated signaling. Therefore, the SAPK/JNK activation contributes to TGF-beta signaling.	CHU ST ANTOINE, HOP ST ANTOINE, INST FED RECH, INSERM, U55, F-75571 PARIS 12, FRANCE; UNIV MASSACHUSETTS, SCH MED, DEPT BIOCHEM & MOL BIOL, PROGRAM MOL MED, WORCESTER, MA 01605 USA; UNIV MASSACHUSETTS, SCH MED, HOWARD HUGHES MED INST, WORCESTER, MA 01605 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester			CHASTRE, Eric/L-8446-2018	CHASTRE, Eric/0000-0002-8993-1228				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ATFI A, 1994, J BIOL CHEM, V269, P30688; Atfi A, 1995, P NATL ACAD SCI USA, V92, P12110, DOI 10.1073/pnas.92.26.12110; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALL A, 1995, OPIN CELL BIOL, V5, P265; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HITMARSH AJ, 1996, IN PRESS J MOL MED; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; LI L, 1990, J BIOL CHEM, V265, P1556; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAPP UR, 1994, ONCOGENE, V9, P3493; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798	40	261	268	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1429	1432		10.1074/jbc.272.3.1429	http://dx.doi.org/10.1074/jbc.272.3.1429			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999807	hybrid			2022-12-25	WOS:A1997WD05800005
J	HendricksTaylor, LR; Motto, DG; Zhang, J; Siraganian, RP; Koretzky, GA				HendricksTaylor, LR; Motto, DG; Zhang, J; Siraganian, RP; Koretzky, GA			SLP-76 is a substrate of the high affinity IgE receptor-stimulated protein tyrosine kinases in rat basophilic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION PROTEIN; RI CROSS-LINKING; T-CELL; ANTIGEN RECEPTOR; IMMUNOGLOBULIN-E; SIGNAL-TRANSDUCTION; 2H3 CELLS; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; HISTAMINE-RELEASE	Stimulation of the IgE high affinity receptor on rat basophilic leukemia RBL-2H3 cells results in activation of protein tyrosine kinases and rapid tyrosine phosphorylation of several substrates, many of which remain unidentified. In this report, we demonstrate that the Grb2 adapter protein, when expressed as a glutathione S-transferase fusion protein, associates with four tyrosine-phosphorylated molecules (116, 76, 36, and 31 kDa) from lysates of stimulated RBL-2H3 cells, We show further that the 76-kDa protein is SLP-76, a hematopoietic cell-specific protein first identified as a Grb2-binding protein in T cells, Upon stimulation of the high affinity receptor for IgE, SLP 76 undergoes rapid tyrosine phosphorylation and associates with two additional tyrosine phosphoproteins of 62 and 130 kDa via the SH2 domain of SLP-76. Additional studies demonstrate that the SLP-76 SH2 domain also binds a protein kinase from stimulated RBL-2H3 cell lysates. Furthermore, the phosphorylation of SLP-76 requires Syk activity but is not dependent on Ca+2 mobilization, These data, together with our previous work documenting its role in T cell activation, suggest that SLP-76 and the proteins with which it associates may play a fundamental role in coupling signaling events in multiple cell types in the immune system.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52246; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52246; UNIV IOWA,COLL MED,GRAD PROGRAM IMMUNOL,IOWA CITY,IA 52246; NIDR,NIH,IMMUNOL LAB,BETHESDA,MD 20892	University of Iowa; University of Iowa; University of Iowa; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)			Koretzky, Gary/AAU-5381-2021		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053256] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM 53256] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMCZEWSKI M, 1994, CHEM IMMUNOL, V59, P173; BEAVEN MA, 1984, J BIOL CHEM, V259, P7129; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1992, IMMUNOL TODAY, V13, P195, DOI 10.1016/0167-5699(92)90152-W; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; BUDAY L, 1994, J BIOL CHEM, V269, P9019; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EISEMAN E, 1992, NATURE, V355, P78; Fang N, 1996, J IMMUNOL, V157, P3769; FUKAMACHI H, 1993, INT ARCH ALLERGY IMM, V102, P15, DOI 10.1159/000236546; HAMAWY MM, 1994, J IMMUNOL, V153, P4655; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kimura T, 1996, J BIOL CHEM, V271, P27962, DOI 10.1074/jbc.271.44.27962; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; MINOGUCHI K, 1994, J BIOL CHEM, V269, P16902; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Motto DG, 1996, MOL CELL BIOL, V16, P2823; PAOLINI R, 1995, J EXP MED, V181, P247, DOI 10.1084/jem.181.1.247; PAOLINI R, 1992, P NATL ACAD SCI USA, V89, P10733, DOI 10.1073/pnas.89.22.10733; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PARK DJ, 1991, J BIOL CHEM, V266, P24237; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SWIETER M, 1995, J BIOL CHEM, V270, P21902, DOI 10.1074/jbc.270.37.21902; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	49	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1363	1367		10.1074/jbc.272.2.1363	http://dx.doi.org/10.1074/jbc.272.2.1363			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995445	hybrid			2022-12-25	WOS:A1997WC04800096
J	Jo, H; Sipos, K; Go, YM; Law, R; Rong, J; McDonald, JM				Jo, H; Sipos, K; Go, YM; Law, R; Rong, J; McDonald, JM			Differential effect of shear stress on extracellular signal-regulated kinase and N-terminal Jun kinase in endothelial cells - G(i)2- and G beta/gamma-dependent signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR-B-CHAIN; HAMSTER OVARY CELLS; GROWTH-FACTOR; MAP KINASE; TRANSCRIPTION FACTORS; TRANSDUCTION PATHWAY; CAROTID BIFURCATION; ADHESION MOLECULE-1; NUCLEOTIDE-BINDING	Shear stress differentially regulates production of many vasoactive factors at the level of gene expression in endothelial cells that may be mediated by mitogen-activated protein kinases, including extracellular signal-regulated kinase (ERK) and N-terminal Jun kinase (JNK). Here we show, using bovine aortic endothelial cells (BAEC), that shear stress differentially regulates ERK and JNK by mechanisms involving G(i2) and pertussis toxin (PTx)-insensitive G-protein-dependent pathways, respectively. Shear activated ERK with a rapid, biphasic time course (maximum by 5 min and basal by 30-min shear exposure) and force dependence (minimum and maximum at 1 and 10 dyn/cm(2) shear stress, respectively). PTx treatment prevented shear-dependent activation of ERK1/2, consistent with a G(i)-dependent mechanism. In contrast, JNK activity was maximally turned on by a threshold level of shear force (0.5 dyn/cm(2) or higher) with a much slower and prolonged time course (requiring at least 30 min to 4 h) than that of ERK. Also, PTx had no effect on shear-dependent activation of JNK, To further define the shear-sensitive ERK and JNK pathways, vectors expressing hemagglutinin epitope-tagged ERK (HA-ERK) or HA-JNK were cotransfected with other vectors by using adenovirus-polylysine in BAEC. Expression of the mutant alpha(i2)(G203), antisense Ga-i2 and a dominant negative Ras (N17Ras) prevented shear-dependent activation of HA-ERK, while that of alpha(i2)(G204) and antisense alpha(i3), did not, Expression of a G beta/gamma scavenger, the carboxyl terminus of beta-adrenergic receptor kinase (beta ARK-ct), and N17Ras inhibited shear-dependent activation of HA-JNK. Treatment of BAEC with genistein prevented shear-dependent activation of ERK and JNK, indicating the essential role of tyrosine kinase(s) in both ERK and JNK pathways. These results provide evidence that 1) G(i2)-protein, Ras, and tyrosine kinase(s) are upstream regulators of shear dependent activation of ERK and 2) that shear-dependent activation of JNK is regulated by mechanisms involving G beta/gamma, Has, and tyrosine kinase(s).			Jo, H (corresponding author), UNIV ALABAMA,DEPT PATHOL,DIV MOL & CELLULAR PATHOL,G019C VOLKER HALL,BIRMINGHAM,AL 35294, USA.		Sipos, Katalin/B-5242-2015; Jo, Hanjoong/L-6216-2019	Sipos, Katalin/0000-0002-6706-2682; Jo, Hanjoong/0000-0003-1833-372X	NHLBI NIH HHS [HL53601] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL053601] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER V, 1992, J BIOL CHEM, V267, P17001; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Coso OA, 1996, J BIOL CHEM, V271, P3963; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DESHANE J, 1995, GYNECOL ONCOL, V59, P8, DOI 10.1006/gyno.1995.1260; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; FAURE M, 1994, J BIOL CHEM, V269, P7851; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HSIEH HJ, 1992, J CELL PHYSIOL, V150, P552, DOI 10.1002/jcp.1041500316; HSIEH HJ, 1993, J CELL PHYSIOL, V154, P143, DOI 10.1002/jcp.1041540118; Ishida T, 1996, CIRC RES, V79, P310, DOI 10.1161/01.RES.79.2.310; JO H, 1991, AM J PHYSIOL, V260, pH1992, DOI 10.1152/ajpheart.1991.260.6.H1992; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; KUCHAN MJ, 1994, AM J PHYSIOL, V267, pC753, DOI 10.1152/ajpcell.1994.267.3.C753; Kuo WL, 1996, MOL CELL BIOL, V16, P1458; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAN QX, 1994, BIOCHEM BIOPH RES CO, V201, P950, DOI 10.1006/bbrc.1994.1794; LIAO JK, 1992, CIRC RES, V70, P1018, DOI 10.1161/01.RES.70.5.1018; LIU YF, 1994, J BIOL CHEM, V269, P13880; LOZIER JN, 1994, HUM GENE THER, V5, P313, DOI 10.1089/hum.1994.5.3-313; MALEK AM, 1993, J CLIN INVEST, V92, P2013, DOI 10.1172/JCI116796; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MITCHELL FM, 1995, BIOCHEM J, V309, P381, DOI 10.1042/bj3090381; MITSUMATA M, 1993, AM J PHYSIOL, V265, pH3, DOI 10.1152/ajpheart.1993.265.1.H3; MORITA T, 1993, J CLIN INVEST, V92, P1705; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OHNO M, 1993, CIRCULATION, V88, P193, DOI 10.1161/01.CIR.88.1.193; OHTSUKA A, 1993, BIOCHEM BIOPH RES CO, V193, P303, DOI 10.1006/bbrc.1993.1624; OSAWA S, 1991, J BIOL CHEM, V266, P4673; Pearce MJ, 1996, BIOCHEM BIOPH RES CO, V218, P500, DOI 10.1006/bbrc.1996.0089; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; SLEPAK VZ, 1993, J BIOL CHEM, V268, P21889; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; WINITZ S, 1994, J BIOL CHEM, V269, P1889; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502	55	235	237	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1395	1401		10.1074/jbc.272.2.1395	http://dx.doi.org/10.1074/jbc.272.2.1395			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995450	hybrid			2022-12-25	WOS:A1997WC04800101
J	Karlsson, OP; Dahlqvist, A; Vikstrom, S; Wieslander, A				Karlsson, OP; Dahlqvist, A; Vikstrom, S; Wieslander, A			Lipid dependence and basic kinetics of the purified 1,2-diacylglycerol 3-glucosyltransferase from membranes of Acholeplasma laidlawii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; ACYL-CHAIN-LENGTH; PROTEIN-KINASE-C; ESCHERICHIA-COLI; BILAYER-MEMBRANES; PHASE-EQUILIBRIA; STRAIN-A; ACTIVATION; PHOSPHATIDYLSERINE; DIACYLGLYCEROLS	UDP-glucose: 1,2-diacylglycerol 3-glucosyltransferase (EC 2.4.1.157), catalyzes the transfer of glucose from UDP-glucose to diacylglycerol (DAG) to yield monoglucosyldiacylglycerol (MGlcDAG) and UDP, MGlcDAG is the first glucolipid along the glucolipid pathway, and a major (nonbilayer-prone) lipid in the single membrane of Acholeplasma laidlawii, MGlcDAG is further glucosylated to give the major diglucosyldiacylglycerol (DGlcDAG), The bilayer fractions of these lipids are crucial for the metabolic maintenance of phase equilibria close to a potential bilayer-nonbilayer transition and a nearly constant spontaneous curvature, The glucolipid syntheses are also balanced against the phosphatidylglycerol pathway, competing for the common minor precursor phosphatidic acid, to retain a constant lipid surface charge density, The 1,2-diacylglycerol 3-glucosyltransferase was purified to homogeneity from detergent solubilized A. laidlawii cells by three column chromatography methods (enrichment approximate to 9 000 x), and identified as a minor 40 kDa protein by using SDS-polyacrylamide gel electrophoresis. In CHAPS detergent, mixed micelles, a cooperative dependence on anionic lipids for activity was confirmed, Dependence of the enzyme on UDP-glucose followed Michaelis-Menten kinetics while the other hydrophobic substrate dioleoylglycerol stimulated the enzyme by an activating potentially cooperative mechanism, Physiological concentrations of the activator lipid dioleoyl-phosphatidylglycerol influenced the turnover number of the enzyme but not the interaction with UDP glucose, as inferred from variable and constant values of the apparent V-max and K-m, respectively, Dipalmitoylglycerol was a better substrate than the oleoyl species, supporting earlier in vivo and crude enzyme data, The responses of the purified 1,2-diacylglycerol 3-glucosyltransferase indicated that (i) the regulatory features of the MGlcDAG synthesis is held by the catalytic enzyme itself, and (ii) this strongly corroborates the ''homeostasis'' model for lipid bilayer properties in A, laidlawii proposed earlier.			Karlsson, OP (corresponding author), UMEA UNIV, DEPT BIOCHEM, S-90187 UMEA, SWEDEN.							CHRISTIANSSON A, 1985, J BIOL CHEM, V260, P3984; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5881, DOI 10.1021/bi00238a011; CORNELL RB, 1991, BIOCHEMISTRY-US, V30, P5873, DOI 10.1021/bi00238a010; DAHLQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1105, P131, DOI 10.1016/0005-2736(92)90171-H; DAHLQVIST A, 1995, BIOCHEMISTRY-US, V34, P13381, DOI 10.1021/bi00041a015; DAHLQVIST A, 1995, THESIS UMEA U UMEA; EISENBERG M, 1979, BIOCHEMISTRY-US, V18, P5213, DOI 10.1021/bi00590a028; EPAND RM, 1991, BIOSCIENCE REP, V11, P59, DOI 10.1007/BF01118606; FOHT PJ, 1995, BIOCHEMISTRY-US, V34, P13811, DOI 10.1021/bi00042a012; GOLDBERG EM, 1994, BIOPHYS J, V66, P382, DOI 10.1016/S0006-3495(94)80788-X; GOLDFINE H, 1993, GENETICS MOL BIOL AN, P354; Gruner S. M., 1992, STRUCTURE BIOL MEMBR, P211; HAUKSSON JB, 1995, BBA-LIPID LIPID MET, V1258, P1, DOI 10.1016/0005-2760(95)00074-M; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HJELMSTAD RH, 1991, BIOCHEMISTRY-US, V30, P1731, DOI 10.1021/bi00221a001; ISRAELACHVILI JN, 1991, INTERMOLECULAR SURFA, P366; Karlsson OP, 1996, BIOCHEMISTRY-US, V35, P10094, DOI 10.1021/bi9602876; KARLSSON OP, 1994, J BIOL CHEM, V269, P23484; LINDBLOM G, 1986, BIOCHEMISTRY-US, V25, P7502, DOI 10.1021/bi00371a037; MANNOCK DA, 1990, BIOCHEMISTRY-US, V29, P7790, DOI 10.1021/bi00486a003; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; MCLAUGHLIN S, 1981, J GEN PHYSIOL, V77, P445, DOI 10.1085/jgp.77.4.445; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MULLER K, 1981, BIOCHEMISTRY-US, V20, P404, DOI 10.1021/bi00505a028; NYSTROM S, 1992, EUR J BIOCHEM, V204, P231, DOI 10.1111/j.1432-1033.1992.tb16629.x; OSTERBERG F, 1995, BBA-LIPID LIPID MET, V1257, P18, DOI 10.1016/0005-2760(95)00042-B; RIETVELD AG, 1993, J BIOL CHEM, V268, P12427; RILFORS L, 1994, BIOCHEMISTRY-US, V33, P6110, DOI 10.1021/bi00186a010; Rilfors L, 1993, Subcell Biochem, V20, P109; Saha SK, 1996, BIOSCI BIOTECH BIOCH, V60, P111; Schurholz T, 1996, BIOPHYS CHEM, V58, P87, DOI 10.1016/0301-4622(95)00088-7; SHIBUYA I, 1992, PROG LIPID RES, V31, P245, DOI 10.1016/0163-7827(92)90010-G; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; SMALL DM, 1986, HDB LIPID RES, V4, P345; SMITH PF, 1969, J BACTERIOL, V99, P480, DOI 10.1128/JB.99.2.480-486.1969; THURMOND RL, 1994, BIOCHEMISTRY-US, V33, P13178, DOI 10.1021/bi00249a004; WALSH JP, 1986, J BIOL CHEM, V261, P5062; WIESLANDER A, 1995, EUR J BIOCHEM, V227, P734, DOI 10.1111/j.1432-1033.1995.tb20196.x; WIESLANDER A, 1986, BIOCHEMISTRY-US, V25, P7511, DOI 10.1021/bi00371a038	41	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					929	936		10.1074/jbc.272.2.929	http://dx.doi.org/10.1074/jbc.272.2.929			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995384	hybrid			2022-12-25	WOS:A1997WC04800035
J	Helvig, C; Alayrac, C; Mioskowski, C; Koop, D; Poullain, D; Durst, F; Salaun, JP				Helvig, C; Alayrac, C; Mioskowski, C; Koop, D; Poullain, D; Durst, F; Salaun, JP			Suicide inactivation of cytochrome P450 by midchain and terminal acetylenes - A mechanistic study of inactivation of a plant lauric acid omega-hydroxlyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTHETIC HEME ALKYLATION; UNSATURATED FATTY-ACIDS; ACTIVE-SITE; HELIANTHUS-TUBEROSUS; SUBSTRATE-ANALOGS; VICIA-SATIVA; OLEIC-ACID; HYDROXYLASE; MICROSOMES; INDUCTION	Incubation of Vicia sativa microsomes, containing cytochrome P450-dependent lauric acid omega-hydroxylase (omega-LAH), with [1-C-14]11-dodecynoic acid (11-DDYA) generates a major metabolite characterized as 1,12-dodecandioic acid, In addition to time- and concentration-dependent inactivation of lauric acid and 11-DDYA oxidation, irreversible binding of 11-DDYA (200 pmol of 11-DDYA bound/mg of microsomal protein) at a saturating concentration of 11-DDYA was observed. SDS-polyacrylamide gel electrophoresis analysis showed that 30% of the label was associated with several protein bands of about 53 kDa, The presence of beta-mercaptoethanol in the incubate reduces 1,12-dodecandioic acid formation and leads to a polar metabolite resulting from the interaction of oxidized 11-DDYA with the nucleophile, Although the alkylation of proteins was reduced, the lauric acid omega-hydroxylase activity was not restored, suggesting an active site-directed inactivation mechanism, Similar results were obtained when reconstituted mixtures of cytochrome P450 from family CYP4A from rabbit liver were incubated With 11-DDYA, In contrast, both 11- and 10-DDYA resulted in covalent labeling of the cytochrome P450 2B4 protein and irreversible inhibition of activity, These results demonstrate that acetylenic analogues of substrate are efficient mechanism based inhibitors and that a correlation between the position of the acetylenic bond in the inhibitor and the regiochemistry of cytochromes P450 oxygenation is essential for enzyme inactivation.	DEPT ENZYMOL CELLULAIRE & MOL,CNRS,INST BIOL MOL PLANTES,F-67083 STRASBOURG,FRANCE; FAC PHARM,LAB SYNTHESE BIOORGAN,CNRS URA 1386,F-67048 STRASBOURG,FRANCE; OREGON HLTH SCI UNIV,SCH MED,DEPT PHARMACOL,PORTLAND,OR 97201; CEA,SERV MOL MARQUEES,F-91191 GIF SUR YVETTE,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Oregon Health & Science University; CEA; UDICE-French Research Universities; Universite Paris Saclay								ALAYRAC C, 1992, SYNLETT, V1, P73; BELL DR, 1993, BIOCHEM J, V294, P173, DOI 10.1042/bj2940173; BOLWELL GP, 1994, PHYTOCHEMISTRY, V37, P1491, DOI 10.1016/S0031-9422(00)89567-9; CAJACOB CA, 1988, J BIOL CHEM, V263, P18640; CAJACOB CA, 1986, BIOCHEMISTRY-US, V25, P4705, DOI 10.1021/bi00364a038; Coon M J, 1978, Methods Enzymol, V52, P109; DEMONTELLANO PRO, 1982, BIOCHEMISTRY-US, V21, P1331, DOI 10.1021/bi00535a035; DURST F, 1992, BIOCHEM SOC T, V20, P353, DOI 10.1042/bst0200353; GIBSON GG, 1982, BIOCHEM J, V203, P161, DOI 10.1042/bj2030161; HANSEN L, 1986, PHYTOCHEMISTRY, V25, P285, DOI 10.1016/S0031-9422(00)85468-0; Helvig C, 1996, PESTIC BIOCHEM PHYS, V54, P161, DOI 10.1006/pest.1996.0020; HIRAKURA K, 1994, PHYTOCHEMISTRY, V35, P963, DOI 10.1016/S0031-9422(00)90648-4; KAWASHIMA H, 1994, J BIOCHEM, V116, P74, DOI 10.1093/oxfordjournals.jbchem.a124506; KUNZE KL, 1983, J BIOL CHEM, V258, P4202; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAETHEM RM, 1992, J BIOL CHEM, V267, P5552; LAETHEM RM, 1992, J PHARMACOL EXP THER, V262, P433; LESOT A, 1992, PLANT PHYSIOL, V100, P1406, DOI 10.1104/pp.100.3.1406; LOPEZGARCIA MP, 1994, BIOCHEMISTRY-US, V33, P166, DOI 10.1021/bi00167a022; MILLER JP, 1994, BIOCHEMISTRY-US, V33, P807, DOI 10.1021/bi00169a023; MUERHOFF AS, 1989, J BIOL CHEM, V264, P749; NAGAHISA A, 1983, J BIOL CHEM, V258, P6721; OMURA T, 1964, J BIOL CHEM, V239, P2379; ORTON TC, 1982, DRUG METAB DISPOS, V10, P110; PALMA JM, 1991, ARCH BIOCHEM BIOPHYS, V287, P68, DOI 10.1016/0003-9861(91)90389-Z; PINOT F, 1993, PLANT PHYSIOL, V102, P1313, DOI 10.1104/pp.102.4.1313; PINOT F, 1994, BIOCHEM BIOPH RES CO, V198, P795, DOI 10.1006/bbrc.1994.1114; PINOT F, 1992, BIOCHEM BIOPH RES CO, V184, P183, DOI 10.1016/0006-291X(92)91176-Q; REICH NO, 1986, BIOCHEM PHARMACOL, V35, P1227, DOI 10.1016/0006-2952(86)90264-9; ROBERTS ES, 1994, BIOCHEMISTRY-US, V33, P3766, DOI 10.1021/bi00178a037; ROBESON DJ, 1980, PHYTOCHEMISTRY, V19, P2359, DOI 10.1016/S0031-9422(00)91027-6; SALAUN JP, 1984, ARCH BIOCHEM BIOPHYS, V232, P1, DOI 10.1016/0003-9861(84)90515-0; SALAUN JP, 1986, LIPIDS, V21, P776, DOI 10.1007/BF02535411; SALAUN JP, 1988, ARCH BIOCHEM BIOPHYS, V260, P540, DOI 10.1016/0003-9861(88)90479-1; SALAUN JP, 1993, PLANT PHYSIOL BIOCH, V31, P285; SALAUN JP, 1992, FEBS LETT, V303, P109, DOI 10.1016/0014-5793(92)80499-7; SHIRANE N, 1993, BIOCHEMISTRY-US, V32, P13732, DOI 10.1021/bi00212a044; WEISSBART D, 1992, BIOCHIM BIOPHYS ACTA, V1124, P135, DOI 10.1016/0005-2760(92)90089-E; YOSHIMURA R, 1990, J BIOCHEM, V108, P544, DOI 10.1093/oxfordjournals.jbchem.a123239; ZOU AP, 1994, J PHARMACOL EXP THER, V268, P474	40	27	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					414	421						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995277				2022-12-25	WOS:A1997WA56400064
J	Tachias, K; Madison, EL				Tachias, K; Madison, EL			Converting tissue type plasminogen activator into a zymogen - Important role of Lys(156)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ONE-CHAIN; STREPTOKINASE; FIBRIN; RESISTANT; CLEAVAGE; EFFICIENT; INHIBITOR; COMPLEXES; VARIANTS	In stark contrast to most other members of the chymotrypsin family of serine proteases, tissue type plasminogen activator (t-PA) is not synthesized and secreted as a true zymogen. Instead, single-chain t-PA exhibits very significant catalytic activity, Consequently, the zymogenicity, or ratio of the catalytic efficiencies of the mature, two-chain enzyme and the single-chain precursor, is only 3-9 for t-PA. Both we and others have previously proposed that Lys1(56) may contribute directly to this exceptional property of t-PA by forming interactions that selectively stabilize the active conformation of the single chain enzyme. To test this hypothesis we created variants of t-PA in which Lys(156) was replaced by a tyrosine residue. As predicted, the K156Y mutation selectively suppressed the activity of the single-chain enzyme and thereby substantially enhanced the enzyme's zymogenicity. In addition, however, this mutation produced a very dramatic increase in the ability of single chain t-PA to discriminate among distinct fibrin co-factors. Compared with wild type t-PA, one of the variants characterized in this study, t-PA/R15E,K156Y, possessed substantially enhanced response to and selectivity among fibrin co-factors, resistance to inhibition by plasminogen activator inhibitor type 1, and significantly increased zymogenicity. The combination of these properties, and the maintenance of full activity in the presence of fibrin, suggest that the R15E,K156Y mutations may extend the therapeutic range of t-PA.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052475, P01HL031950] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL31950, R01 HL52475] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATTY K, 1980, J BIOL CHEM, V255, P3931; BENNETT WF, 1991, J BIOL CHEM, V266, P5191; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1995, THROMB HAEMOSTASIS, V74, P167; DAVIDSON DJ, 1990, BIOCHEMISTRY-US, V29, P3585, DOI 10.1021/bi00466a023; GERTLER A, 1974, BIOCHEMISTRY-US, V13, P1302, DOI 10.1021/bi00703a038; HEMKER HC, 1975, BIOCHIM BIOPHYS ACTA, V379, P180, DOI 10.1016/0005-2795(75)90020-3; HENDRIX H, 1983, J BIOL CHEM, V258, P3637; HOLMES WE, 1987, BIOCHEMISTRY-US, V26, P5133, DOI 10.1021/bi00390a036; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAMBA B, 1996, J MOL BIOL, V258, P117; LIJNEN HR, 1992, FIBRINOLYSIS, V6, P33, DOI 10.1016/0268-9499(92)90045-J; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1990, THROMB RES S10, V57, P45; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MADISON EL, 1993, SCIENCE, V262, P419, DOI 10.1126/science.8211162; MADISON EL, 1994, FIBRINOLYSIS, V8, P221, DOI 10.1016/0268-9499(94)90720-X; NEINABER VL, 1992, BIOCHEMISTRY-US, V31, P3852; PAONI NF, 1993, PROTEIN ENG, V6, P529, DOI 10.1093/protein/6.5.529; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RANBY M, 1982, THROMB RES, V27, P175, DOI 10.1016/0049-3848(82)90197-9; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; REDDY KNN, 1988, ENZYME, V40, P79, DOI 10.1159/000469149; ROBINSON NC, 1973, BIOCHEMISTRY-US, V12, P420, DOI 10.1021/bi00727a010; SCHICK LA, 1973, BIOCHEMISTRY-US, V12, P4315, DOI 10.1021/bi00746a003; SILVERBERG M, 1982, BLOOD, V60, P64; Smith JW, 1995, J BIOL CHEM, V270, P30486, DOI 10.1074/jbc.270.51.30486; STRANDBERG L, 1995, J BIOL CHEM, V270, P23444, DOI 10.1074/jbc.270.40.23444; SUMMARIA L, 1974, J BIOL CHEM, V249, P4760; Tachias K, 1996, J BIOL CHEM, V271, P28749, DOI 10.1074/jbc.271.46.28749; TACHIAS K, 1995, J BIOL CHEM, V270, P18319, DOI 10.1074/jbc.270.31.18319; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	36	27	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					28	31						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995220				2022-12-25	WOS:A1997WA56400007
J	Cappiello, M; Voltarelli, M; Cecconi, I; Vilardo, PG; Dal Monte, M; Marini, I; DelCorso, A; Wilson, DK; Quiocho, FA; Petrash, JM; Mura, U				Cappiello, M; Voltarelli, M; Cecconi, I; Vilardo, PG; Dal Monte, M; Marini, I; DelCorso, A; Wilson, DK; Quiocho, FA; Petrash, JM; Mura, U			Specifically targeted modification of human aldose reductase by physiological disulfides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; GLUTATHIONE; INHIBITION; RESIDUES; IDENTIFICATION; QUANTITATION; INVOLVEMENT; ACTIVATION; MECHANISM	Aldose reductase is inactivated by physiological disulfides such as GSSG and cystine. To study the mechanism of disulfide-induced enzyme inactivation, we examined the rate and extent of enzyme inactivation using wild-type human aldose reductase and mutants containing cysteine-to-serine substitutions at positions 80 (C80S), 298 (C298S), and 303 (C303S). The mild-type, C80S, and C303S enzymes lost >80% activity following incubation with GSSG, whereas the C298S mutant was not affected. Loss of activity correlated with enzyme thiolation. The binary enzyme-NADP(+) complex was less susceptible to enzyme thiolation than the apoenzyme. These results suggest that thiolation of human aldose reductase occurs predominantly at Cys-298. Energy minimization of a hypothetical enzyme complex modified by glutathione at Cys-298 revealed that the glycyl carboxylate of glutathione may participate in a charged interaction with His-110 in a manner strikingly similar to that involving the carboxylate group of the potent aldose reductase inhibitor Zopolrestat. In contrast to what was observed with GSSG and cystine, cystamine inactivated the wild-type enzyme as well as all three cysteine mutants. This suggests that cystamine-induced inactivation of aldose reductase does not involve modification of cysteines exclusively at position 80, 298, or 303.	UNIV PISA, DIPARTIMENTO FISIOL & BIOCHIM, I-56100 PISA, ITALY; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; WASHINGTON UNIV, SCH MED,DEPT OPHTHALMOL & VISUAL SCI, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED,DEPT GENET, ST LOUIS, MO 63110 USA; UNIV MODENA, DIPARTIMENTO SCI BIOMED, I-41100 MODENA, ITALY	University of Pisa; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Washington University (WUSTL); Washington University (WUSTL); Universita di Modena e Reggio Emilia			Cappiello, Mario/L-3877-2019	DEL CORSO, ANTONELLA/0000-0003-3165-6128	NEI NIH HHS [EY05856, EY02687] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY002687, R01EY005856, R55EY005856, R23EY005856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BHATNAGAR A, 1992, MOL PHARMACOL, V42, P917; BHATNAGAR A, 1989, MOL PHARMACOL, V36, P825; BIRLOUEZARAGON I, 1989, CURR EYE RES, V8, P449, DOI 10.3109/02713688909000025; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BOHREN KM, 1993, ENZYMOLOGY MOL BIOL, V4, P267; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR SYSTEM CRYSTAL; CAPPIELLO M, 1994, EXP EYE RES, V58, P491, DOI 10.1006/exer.1994.1042; CAPPIELLO M, 1995, BIOCHEM BIOPH RES CO, V207, P775, DOI 10.1006/bbrc.1995.1254; DECK LM, 1991, J MED CHEM, V34, P3301, DOI 10.1021/jm00115a021; DELCORSO A, 1990, INT CONGR SER, V913, P195; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; DELCORSO A, 1989, ARCH BIOCHEM BIOPHYS, V270, P604, DOI 10.1016/0003-9861(89)90543-2; DELCORSO A, 1989, J BIOL CHEM, V264, P17653; DELCORSO A, 1987, BIOCHEM BIOPH RES CO, V148, P369, DOI 10.1016/0006-291X(87)91120-X; DVORNIK D, 1987, ALDOSE REDUCTASE INH, P69; EHRIG T, 1994, BIOCHEMISTRY-US, V33, P7157, DOI 10.1021/bi00189a019; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GIANNESSI M, 1993, ARCH BIOCHEM BIOPHYS, V300, P423, DOI 10.1006/abbi.1993.1057; Grimshaw CE, 1996, ARCH BIOCHEM BIOPHYS, V327, P89, DOI 10.1006/abbi.1996.0096; GRIMSHAW CE, 1989, BIOCHEMISTRY-US, V28, P5343, DOI 10.1021/bi00439a006; KADOR PF, 1985, J MED CHEM, V28, P841, DOI 10.1021/jm00145a001; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; KINOSHITA JH, 1986, AM J OPHTHALMOL, V102, P685, DOI 10.1016/0002-9394(86)90394-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU S, 1989, ARCH BIOCHEM BIOPHYS, V275, P112, DOI 10.1016/0003-9861(89)90355-X; LIU SQ, 1993, BIOCHIM BIOPHYS ACTA, V1164, P268, DOI 10.1016/0167-4838(93)90258-S; LIU SQ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P329, DOI 10.1016/0167-4838(92)90256-D; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; PETRASH JM, 1994, DIABETES, V43, P955, DOI 10.2337/diabetes.43.8.955; SMAR MW, 1992, J MED CHEM, V35, P1117, DOI 10.1021/jm00084a017; SRIVASTAVA SK, 1989, MAILLARD REACTION AG, P171; TARLE I, 1993, J BIOL CHEM, V268, P25687; THOMAS JA, 1986, ANAL BIOCHEM, V157, P32, DOI 10.1016/0003-2697(86)90192-2; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; Varma S D, 1980, Curr Top Eye Res, V3, P91; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	40	62	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33539	33544		10.1074/jbc.271.52.33539	http://dx.doi.org/10.1074/jbc.271.52.33539			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969219	hybrid			2022-12-25	WOS:A1996WA71300053
J	Keyhani, NO; Roseman, S				Keyhani, NO; Roseman, S			The chitin catabolic cascade in the marine bacterium Vibrio furnissii - Molecular cloning, isolation, and characterization of a periplasmic beta-N-acetylglucosaminidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; ALPHA-SUBUNIT; HUMAN ENZYME; CDNA; ACETYLHEXOSAMINIDASE; HEXOSAMINIDASE; N,N'-DIACETYLCHITOBIASE; HOMOLOGY; HARVEYI; GENE	We have described some steps in chitin catabolism by Vibrio furnissii, and proposed that chitin oligosaccharides are hydrolyzed in the periplasmic space to GlcNAc and (GlcNAc)(2). Since (GlcNAc)(2) is an important inducer in the cascade, it must resist hydrolysis in the periplasm. Known V. furnissii periplasmic hydrolases comprise an endoenzyme (Keyhani, N. O. and Roseman, S. (1996) J. Biol. Chem. 271, 33414-33424), and the beta-N-acetylglucosaminidase, ExoI, reported here. ExoI was isolated from a recombinant strain of Escherichia coli, and hydrolyzes aryl-beta-GlcNAc, aryl-beta-GalNAc, and chitin oligosaccharides. No other beta-GlcNAc glycosides were cleaved. The pH optimum was 7.0 for (GlcNAc)(n), n = 3-6, but 5.8 for (GlcNAc)(2). At the pH of sea water (8.0-8.3), the enzymatic activity with (GlcNAc)(2) is virtually undetectable. These results explain the stability of (GlcNAc)(2) in the periplasmic space. The cloned beta-GlcNAcidase gene, exoI, encodes a 69,377-kDa protein (611 amino acids); the predicted N-terminal 20 amino acid residues matched those of the isolated protein, The protein amino acid sequence displays significant homologies to the alpha- and beta-chains of human hexosaminidase despite their marked differences in substrate specificities and pH optima.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University			Keyhani, Nemat O/I-8150-2013		NIGMS NIH HHS [GM51215, GM07321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051215] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1996, CURRENT PROTOCOLS S, V1; BAPAT B, 1988, FEBS LETT, V237, P191, DOI 10.1016/0014-5793(88)80199-6; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; Bouma CL, 1996, J BIOL CHEM, V271, P33468, DOI 10.1074/jbc.271.52.33468; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chitlaru E, 1996, J BIOL CHEM, V271, P33433, DOI 10.1074/jbc.271.52.33433; EDMAN P, 1949, ARCH BIOCHEM, V22, P475; GRAHAM TR, 1988, J BIOL CHEM, V263, P16823; JANNATIPOUR M, 1987, J BACTERIOL, V169, P3785, DOI 10.1128/jb.169.8.3785-3791.1987; Keyhani NO, 1996, J BIOL CHEM, V271, P33414, DOI 10.1074/jbc.271.52.33414; Keyhani NO, 1996, J BIOL CHEM, V271, P33409, DOI 10.1074/jbc.271.52.33409; KORNELUK RG, 1986, J BIOL CHEM, V261, P8407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morgan WTJ, 1934, BIOCHEM J, V28, P988, DOI 10.1042/bj0280988; NEOTE K, 1988, GENOMICS, V3, P279, DOI 10.1016/0888-7543(88)90116-4; PERRIN DD, 1987, BUFFERS PH METAL ION, P128; REISSIG JL, 1955, J BIOL CHEM, V217, P959; ROSEMAN S, 1951, J BIOL CHEM, V191, P607; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOMERVILLE CC, 1993, P NATL ACAD SCI USA, V90, P6751, DOI 10.1073/pnas.90.14.6751; SOTOGIL RW, 1989, J BIOL CHEM, V264, P14778; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; *US BIOCH CORP, 1993, PROT DNA SEQ SEQ V 2; WALKER P. G., 1966, P155; YU C, 1991, J BIOL CHEM, V266, P24260; ZHU BCR, 1992, J BIOCHEM-TOKYO, V112, P163, DOI 10.1093/oxfordjournals.jbchem.a123857	27	81	89	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33425	33432		10.1074/jbc.271.52.33425	http://dx.doi.org/10.1074/jbc.271.52.33425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969205	hybrid			2022-12-25	WOS:A1996WA71300039
J	Rigotti, A; Edelmann, ER; Seifert, P; Iqbal, SN; DeMattos, RB; Temel, RE; Krieger, M; Williams, DL				Rigotti, A; Edelmann, ER; Seifert, P; Iqbal, SN; DeMattos, RB; Temel, RE; Krieger, M; Williams, DL			Regulation by adrenocorticotropic hormone of the in vivo expression of scavenger receptor class B type I (SR-BI), a high density lipoprotein receptor, in steroidogenic cells of the murine adrenal gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTERYL LINOLEYL ETHER; APOPROTEIN-A-I; SELECTIVE UPTAKE; PLASMA-LIPOPROTEINS; RAT; ESTERS; INVIVO; METABOLISM; HEPATOCYTES; TRANSPORT	The class B, type I scavenger receptor, SR-BI, binds high density lipoprotein (HDL) and can mediate selective uptake of HDL cholesteryl esters by cultured cells. The high levels of expression of SR-BI in steroidogenic tissues and the importance of selective uptake from HDL as a source of cholesterol for steroidogenesis raised the possibility that SR-BI may participate in cholesterol delivery to steroidogenic tissues in vivo. We have used immunoblotting and immunohistochemical methods to show that SR-BI is specifically expressed in a distinctive pattern on the surfaces of steroid-producing cells in the murine adrenal gland's cortex and that its expression in vivo is induced by adrenocorticotropic hormone and suppressed by glucocorticoids. Thus, expression of SR-BI protein is coordinately regulated with adrenal steroidogenesis. These data provide strong support for the hypothesis that SR-BI is a physiologically relevant HDL receptor that provides substrate cholesterol for steroid hormone synthesis.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOVASC,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; SUNY STONY BROOK,MED CTR,DEPT PHARMACOL SCI,STONY BROOK,NY 11794	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Krieger, Marco/AAE-8611-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052212, P01HL041484] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41484, HL/GM49039, HL52212] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; ANDERSEN JM, 1978, J BIOL CHEM, V253, P9024; ANDERSEN JM, 1981, J BIOL CHEM, V256, P7362; BURGESS LH, 1992, ENDOCRINOLOGY, V131, P1261, DOI 10.1210/en.131.3.1261; FOJO SS, 1987, HORM METAB RES, V19, P648, DOI 10.1055/s-2007-1011900; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDBERG DI, 1991, J CLIN INVEST, V87, P331, DOI 10.1172/JCI114991; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GREEN SR, 1991, J LIPID RES, V32, P667; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; GWYNNE JT, 1976, P NATL ACAD SCI USA, V73, P4329, DOI 10.1073/pnas.73.12.4329; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; GWYNNE JT, 1980, J BIOL CHEM, V255, P875; HANDA RJ, 1994, HORM BEHAV, V28, P464, DOI 10.1006/hbeh.1994.1044; HIGASHIJIMA M, 1987, ENDOCRINOL JAPON, V34, P635; ILLINGWORTH DR, 1982, J CLIN ENDOCR METAB, V54, P27, DOI 10.1210/jcem-54-1-27; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KNECHT TP, 1989, BIOCHIM BIOPHYS ACTA, V1002, P365, DOI 10.1016/0005-2760(89)90351-2; KOVANEN PT, 1980, J BIOL CHEM, V255, P5591; KOVANEN PT, 1979, J BIOL CHEM, V254, P5498; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; LAUE L, 1987, J CLIN ENDOCR METAB, V64, P531, DOI 10.1210/jcem-64-3-531; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nussdorfer G G, 1986, Int Rev Cytol, V98, P1; PIETERS MN, 1994, BBA-MOL BASIS DIS, V1225, P125, DOI 10.1016/0925-4439(94)90069-8; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; REAVEN E, 1989, J LIPID RES, V30, P1551; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; RINNINGER F, 1988, J LIPID RES, V29, P1179; RINNINGER F, 1987, J LIPID RES, V28, P1313; STEIN Y, 1983, BIOCHIM BIOPHYS ACTA, V752, P98, DOI 10.1016/0005-2760(83)90237-0; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLIAMS DL, 1995, J LIPID RES, V36, P745	41	201	240	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33545	33549		10.1074/jbc.271.52.33545	http://dx.doi.org/10.1074/jbc.271.52.33545			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969220	hybrid			2022-12-25	WOS:A1996WA71300054
J	Kim, YW; Wang, HY; Sures, I; Lammers, R; Martell, KJ; Ullrich, A				Kim, YW; Wang, HY; Sures, I; Lammers, R; Martell, KJ; Ullrich, A			Characterization of the PEST family protein tyrosine phosphatase BDP1	ONCOGENE			English	Article						protein tyrosine phosphatase; PEST sequence; growth factor receptor phosphatase	CHROMOSOMAL LOCALIZATION; HUMAN-PLACENTA; GENE; CLONING; SEQUENCES; REGION; CELLS; CAP	Using a polymerase chain reaction (PCR) amplication strategy, we identified a novel protein tyrosine phosphatase (PTPase) designated Brain Derived Phosphatase (BDP1). The full length sequence encoded an open reading frame of 459 amino acids with no transmembrane domain and had a calculated molecular weight of 50 kDa. The predicted amino acid sequence contained a PEST motif and accordingly, BDP1 shared the greatest homology with members of the PTP-PEST family. When transiently expressed in 293 cells BDP1 hydrolyzed p-Nitrophenylphosphate, confirming it as a functional protein tyrosine phosphatase. Northern blot analysis indicated that BDP1 was expressed not only in brain, but also in colon and several different tumor-derived cell lines. Furthermore, BDP1 was found to differentially dephosphorylate autophosphorylated tyrosine kinases which are known to be overexpressed in tumor tissues.	MAX PLANCK INST BIOCHEM,DEPT MOL BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Wang, Hongyang/B-1340-2010					BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BROWNSHIMER S, 1990, P NATL ACAD SCI USA, V87, P5148, DOI 10.1073/pnas.87.13.5148; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; MALISSEN M, 1983, SCIENCE, V221, P750, DOI 10.1126/science.6410508; MARTELL KJ, 1994, GENOMICS, V22, P462, DOI 10.1006/geno.1994.1411; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCHLESSINGER J, 1992, CELL, V9, P383; SELICOF A, 1993, J BIOL CHEM, V268, P13448; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; TAKEKAWA M, 1994, FEBS LETT, V339, P222, DOI 10.1016/0014-5793(94)80420-6; TAKEKAWA M, 1992, BIOCHEM BIOPH RES CO, V189, P1223, DOI 10.1016/0006-291X(92)92335-U; TONKS NK, 1988, J BIOL CHEM, V263, P6731; TONKS NK, 1988, J BIOL CHEM, V263, P6722; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WILKS M, 1994, J HOSP INFECT, V28, P231, DOI 10.1016/0195-6701(94)90105-8; YANG Q, 1993, J BIOL CHEM, V268, P6622; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	26	25	32	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2275	2279						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950995				2022-12-25	WOS:A1996VV14500025
J	Zhan, QM; Alamo, I; Yu, K; Boise, LH; Cherney, B; Tosato, G; OConnor, PM; Fornace, AJ				Zhan, QM; Alamo, I; Yu, K; Boise, LH; Cherney, B; Tosato, G; OConnor, PM; Fornace, AJ			The apoptosis-associated gamma-ray response of BCL-X(L) depends on normal p53 function	ONCOGENE			English	Article						BCL-X(L); p53; apoptosis; ionizing radiation	TUMOR-SUPPRESSOR P53; CELL-CYCLE; BCL-X; ATAXIA-TELANGIECTASIA; CANCER-CELLS; DNA-DAMAGE; BAX GENE; IN-VIVO; C-MYC; EXPRESSION	We have investigated the effect of DNA damage on the expression of BCL-X, a member of the BCL-2 family. BCL-X mRNA levels were found to increase upon exposure human cells to ionizing radiation (IR). The Bcl-X(L) protein, but not Bcl-X(S), was identified to be induced by IR. Like BAX, another member of the BCL-2 family and a p53-regulated gene, the induction of BCL-X(L) was dependent on normal p53 function and required that cells have an apoptosis-susceptible phenotype. The induction of BCL-X(L) was rapid, transient and dose-dependent. The mRNA level peaked at 4 h and returned to baseline by 24 h post-irradiation. In agreement with the increased transcript level, Bcl-X(L) protein level was also observed to increase in cells with wild-type p53 where IR triggered apoptosis. In addition, a survey of the BCL-X(L) mRNA basal levels in human cells with known apoptotic responses showed that low basal levels of BCL-X(L) mRNA in cells were highly correlated with a strong ability of cells to undergo IR-induced apoptosis. On the other hand, high levels of basal BCL-X(L) were correlated,vith the resistance of cells to IR-induced apoptosis regardless of p53 status. These results indicate that BCL-2 and BCL-X(L) behave differently in response to DNA damage treatment even though they both are able to protect cells from p53-mediated apoptosis; along with down-regulation of BCL-2, BCL-X(L) was up-regulated by IR in human cells with wild-type p53 and susceptibility to IR-induced apoptosis. We speculate that the physiological function of increased BCL-X(L) protein would be expected to probably limit the severity and length of BAX effect in order to maintain a proper threshold for apoptosis and to complete cell cycle arrest activated by p53.	UNIV CHICAGO,GWEN KNAPP CTR LUPUS & IMMUNOL,CHICAGO,IL 60637; US FDA,CTR BIOL,BETHESDA,MD 20892	University of Chicago; US Food & Drug Administration (FDA)	Zhan, QM (corresponding author), NCI,MOL PHARMACOL LAB,DIV BASIC SCI,ROOM 5C09,BLDG 37,BETHESDA,MD 20892, USA.		Boise, Lawrence/AAD-2314-2019; Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Boise, Lawrence/0000-0001-9436-8815; Tosato, Giovanna/0000-0003-1663-3227				BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN S, 1996, UNPUB; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORNACE AJ, 1980, BIOCHIM BIOPHYS ACTA, V607, P432, DOI 10.1016/0005-2787(80)90153-7; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HALDAR S, 1994, CANCER RES, V54, P2095; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SCHOTT AF, 1995, ONCOGENE, V11, P1389; SCOTT WL, 1993, CELL, V74, P957; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SMITH ML, 1995, ONCOGENE, V10, P1053; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHAN QM, 1995, INT J ONCOL, V6, P937	35	71	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2287	2293						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950997				2022-12-25	WOS:A1996VV14500027
J	Yedovitzky, M; MochlyRosen, D; Johnson, JA; Gray, MO; Ron, D; Abramovitch, E; Cerasi, E; Nesher, R				Yedovitzky, M; MochlyRosen, D; Johnson, JA; Gray, MO; Ron, D; Abramovitch, E; Cerasi, E; Nesher, R			Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN-SECRETION; INTRACELLULAR RECEPTOR; ARACHIDONIC-ACID; ACTIVATION; ISLETS; LOCALIZATION; ISOZYMES; RELEASE; ALPHA; CA-2+	The protein kinase C (PKC) family consists of 11 isoenzymes. Following activation, each isoenzyme translocates and binds to a specific receptor for (a) under bar ctivated (C) under bar (k) under bar inase (RACK) (Mochly-Rosen, D. (1995) Science 268, 247-251) that provides an anchoring site in close proximity to the isoenzyme's specific substrate. Pancreatic islet cells contain at least six PKC isoenzymes (Knutson, K. L., and Hoenig, M. (1994) Endocrinology 135, 881-886). Although PKC activation enhances insulin release, the specific function of each isoenzyme is unknown. Here we show that following stimulation with glucose, alpha PKC and epsilon PKC translocate to the cell's periphery, while delta PKC and zeta PKC translocate to perinuclear sites. beta C2-4, a peptide derived from the RACK1 binding site in the C2 domain of beta PKC, inhibits translocation of alpha PKC and reduces insulin response to glucose. Likewise, epsilon V1-2, an epsilon PKC derived peptide containing the site for its specific RACK, inhibits translocation of epsilon PKC and reduces insulin response to glucose. Inhibition of islet-glucose metabolism with mannoheptulose blocks translocation of both alpha PKC and epsilon PKC and diminishes insulin response to glucose while calcium-free buffer inhibits translocation of alpha PKC but not epsilon PKC and lowers insulin response by 50%. These findings illustrate the unique ability of specific translocation inhibitors to elucidate the isoenzyme-specific functions of PKC in complex signal transduction pathways.	HEBREW UNIV JERUSALEM,HADASSAH MED CTR,DEPT ENDOCRINOL & METAB,IL-91120 JERUSALEM,ISRAEL; STANFORD UNIV,SCH MED,DEPT MOL PHARMACOL,STANFORD,CA 94305	Hebrew University of Jerusalem; Hadassah University Medical Center; Stanford University				Mochly-Rosen, Daria/0000-0002-6691-8733	NHLBI NIH HHS [HL43380] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043380] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BALDASSARE JJ, 1992, J BIOL CHEM, V267, P15585; BONEH A, 1988, BIOCHEM CELL BIOL, V66, P262, DOI 10.1139/o88-035; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DISATNIK MH, 1994, EXP CELL RES, V210, P287, DOI 10.1006/excr.1994.1041; DISATNIK MH, 1994, CELL GROWTH DIFFER, V5, P873; GANESAN S, 1992, J CELL BIOL, V119, P313, DOI 10.1083/jcb.119.2.313; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; JOHNSON JA, 1996, IN PRESS CIRC RES; JONES PM, 1993, J ENDOCRINOL, V137, P7, DOI 10.1677/joe.0.1370007; KAISER N, 1988, ENDOCRINOLOGY, V123, P834, DOI 10.1210/endo-123-2-834; KILEY SC, 1990, MOL ENDOCRINOL, V4, P59, DOI 10.1210/mend-4-1-59; KNUTSON KL, 1994, ENDOCRINOLOGY, V135, P881, DOI 10.1210/en.135.3.881; KOMATSU M, 1995, P NATL ACAD SCI USA, V92, P10728, DOI 10.1073/pnas.92.23.10728; MISRA UK, 1987, BIOCHEM BIOPH RES CO, V145, P760, DOI 10.1016/0006-291X(87)91030-8; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; NESHER R, 1985, DIABETOLOGIA, V28, P233; NESHER R, 1994, INSULIN SECRETION PA, P411; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHOJI M, 1986, BIOCHEM BIOPH RES CO, V135, P1144, DOI 10.1016/0006-291X(86)91047-8; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; ZAWALICH WS, 1991, BIOCHEM J, V279, P807, DOI 10.1042/bj2790807; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X	33	156	171	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1417	1420		10.1074/jbc.272.3.1417	http://dx.doi.org/10.1074/jbc.272.3.1417			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999804	hybrid			2022-12-25	WOS:A1997WD05800002
J	Abousalham, A; Liossis, C; OBrien, L; Brindley, DN				Abousalham, A; Liossis, C; OBrien, L; Brindley, DN			Cell-permeable ceramides prevent the activation of phospholipase D by ADP-ribosylation factor and RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING-PROTEIN; TUMOR-NECROSIS-FACTOR; PHOSPHATIDIC-ACID; HL-60 CELLS; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; DNA-SYNTHESIS; PHOSPHATIDYLCHOLINE BREAKDOWN; QUANTITATIVE MEASUREMENT	The mechanism of inhibition of phospholipase D (PLD) by ceramides was determined using granulocytes differentiated from human promyelocytic leukemic (HL-60) cells. In a cell free system, hydrolysis of phosphatidylcholine by membrane-bound PLD depended upon phosphatidylinositol 4,5-bisphosphate, guanosine 5'-3-O-(thio)triphosphate) (GTP gamma S), and cytosolic factors including ADP-ribosylating factor (ARF) and RhoA. C-2(N-acetyl-), C-8-(N-octanoyl-), and long-chain ceramides, but not dihydro-C-2-ceramide inhibited PLD activity. Apyrase or okadaic acid did not modify the inhibition of PLD by ceramides, indicating that the effect in the cell-free system was unlikely to be dependent upon a ceramide-stimulated kinase or phosphoprotein phosphatases. C-2- and C-8-ceramides prevented the GTP gamma S-induced translocation of ARF1 and RhoA from the cytosol to the membrane fraction. In whole cells, C-2-ceramide, but not dihydro-C-2-ceramide, inhibited the stimulation of PLD by N-formylmethionylleucylphenylalanine and decreased the amounts of ARF1, RhoA, CDC42, Rab4, and protein kinase C-alpha and -beta(1) that were associated with the membrane fraction, but did not alter the distribution of protein kinase C-epsilon and -zeta. It is concluded that one mechanism by which ceramides prevent the activation of PLD is inhibition of the translocation to membranes of G-proteins and protein kinase C isoforms that are required for PLD activity.	UNIV ALBERTA,DEPT BIOCHEM,SIGNAL TRANSDUCT LABS,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA	University of Alberta			ABOUSALHAM, Abdelkarim/Q-4487-2019; abousalham, abdelkarim/A-4363-2018	abousalham, abdelkarim/0000-0002-8020-4294				ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; BALLARD MP, 1993, FEBS LETT, V334, P13; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOURGOIN S, 1995, J BIOL CHEM, V270, P3172, DOI 10.1074/jbc.270.7.3172; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindley DN, 1996, CHEM PHYS LIPIDS, V80, P45, DOI 10.1016/0009-3084(96)02545-5; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHEN CS, 1995, J BIOL CHEM, V270, P13291, DOI 10.1074/jbc.270.22.13291; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GOLDKORN T, 1991, J BIOL CHEM, V266, P16092; GOMEZMUNOZ A, 1995, J BIOL CHEM, V270, P26318, DOI 10.1074/jbc.270.44.26318; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Han JS, 1996, J BIOL CHEM, V271, P11163, DOI 10.1074/jbc.271.19.11163; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; JONES GA, 1993, J BIOL CHEM, V268, P20845; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LOPEZ I, 1995, J BIOL CHEM, V270, P19465, DOI 10.1074/jbc.270.33.19465; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; Martin A, 1996, J BIOL CHEM, V271, P17397, DOI 10.1074/jbc.271.29.17397; MARTIN A, 1993, J BIOL CHEM, V268, P23924; MARTIN A, 1994, SIGNAL ACTIVATED PHO, P139; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MURAYAMA T, 1987, J BIOL CHEM, V262, P5522; NAKAMURA T, 1994, J BIOL CHEM, V269, P18384; Nakamura Y, 1996, J IMMUNOL, V156, P256; NEWBY AC, 1975, BIOCHEM J, V146, P625, DOI 10.1042/bj1460625; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PATERSON A, 1991, BIOCHEM J, V280, P829, DOI 10.1042/bj2800829; PREISS J, 1986, J BIOL CHEM, V261, P8597; PREISS JE, 1987, METHOD ENZYMOL, V141, P294; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; Sherman LA, 1996, ENDOCRINOLOGY, V137, P266, DOI 10.1210/en.137.1.266; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; VENABLE ME, 1994, J BIOL CHEM, V269, P26040; Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800; VONMOLLARD GF, 1994, TRENDS BIOCHEM SCI, V19, P164, DOI 10.1016/0968-0004(94)90278-X; Waggoner DW, 1996, J BIOL CHEM, V271, P16506, DOI 10.1074/jbc.271.28.16506; YOUNES A, 1992, J BIOL CHEM, V267, P842	68	98	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1069	1075		10.1074/jbc.272.2.1069	http://dx.doi.org/10.1074/jbc.272.2.1069			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995404	hybrid			2022-12-25	WOS:A1997WC04800055
J	Anderson, SM; Burton, EA; Koch, BL				Anderson, SM; Burton, EA; Koch, BL			Phosphorylation of Cbl following stimulation with interleukin-3 and its association with Grb2, Fyn, and phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE FAMILY; GAMMA SIGNAL-TRANSDUCTION; C-CBL; GM-CSF; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; PROTEIN PRODUCT; HIGH-AFFINITY; BETA-SUBUNIT	We have demonstrated that a 120-kDa protein, identified as Cbl, becomes rapidly phosphorylated on tyrosine residues following stimulation of factor-dependent cells with interleukin-3 (IL-3). Little or no phosphorylation of Cbl was observed in the absence of IL-3 stimulation and phosphorylation is maximal by 20-30 min after IL-3 stimulation. Association of Cbl with Grb2 was noted in unstimulated cells, and the amount of Cbl associated with Grb2 increased following IL-3 stimulation. The p85 subunit of phosphatidylinositol 3-kinase was constitutively associated with Cbl. Approximately 10% of the PI kinase activity present in anti-phosphotyrosine immunoprecipitates was present in anti-Cbl immunoprecipitates of IL-3-stimulated cells. The constitutive association of Cbl with Fyn was also observed, Cbl was observed to bind to bacterial fusion proteins encoding the unique, SH3, and SH2 domains of Fyn, Hck, and Lyn. The SH2 domain of Fyn alone was able to bind Cbl to nearly the same extent as did the fusion protein encoding the unique, SH3, and SH2 domains. This was not the case for the SH2 domain of Hck, however, as binding of the Hck fusion protein to Cbl appeared to require multiple domains. The binding of the fusion proteins to Cbl occurred regardless of whether Cbl was tyrosine-phosphorylated or not, and the binding could not be disrupted by the addition of 30 mM free phosphotyrosine. These data suggest the unexpected conclusion that the Fyn SH2 domain may bind to Cbl in a phosphotyrosine-independent manner.			Anderson, SM (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PATHOL, BOX B216, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NCI NIH HHS [CA46934] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1995, J IMMUNOL, V155, P1660; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Levkowitz G, 1996, ONCOGENE, V12, P1117; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; Raffel GD, 1996, J BIOL CHEM, V271, P4640; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ribon V, 1996, MOL CELL BIOL, V16, P45; Sattler M, 1996, ONCOGENE, V12, P839; Smit L, 1996, ONCOGENE, V13, P381; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					739	745		10.1074/jbc.272.2.739	http://dx.doi.org/10.1074/jbc.272.2.739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995358	hybrid			2022-12-25	WOS:A1997WC04800009
J	Duperray, A; Languino, LR; Plescia, J; McDowall, A; Hogg, N; Craig, AG; Berendt, AR; Altieri, DC				Duperray, A; Languino, LR; Plescia, J; McDowall, A; Hogg, N; Craig, AG; Berendt, AR; Altieri, DC			Molecular identification of a novel fibrinogen binding site on the first domain of ICAM-1 regulating leukocyte-endothelium bridging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; IMMUNOGLOBULIN-LIKE DOMAINS; PLASMODIUM-FALCIPARUM; TRANSENDOTHELIAL MIGRATION; TYROSINE PHOSPHORYLATION; HUMAN RHINOVIRUS; RECEPTOR; LFA-1; MAC-1; CELLS	Binding of fibrinogen to intercellular adhesion molecule 1 (ICAM-1) enhances leukocyte adhesion to endothelium by acting as a bridging molecule between the two cell types, Here, a panel of four monoclonal antibodies (mAbs) to ICAM-1 was used to dissect the structure-function requirements of this recognition. All four mAbs bound to ICAM-1 transfectants and immunoprecipitated and immunoblotted ICAM-1 from detergent-solubilized JY lymphocyte extracts. Functionally, mAbs 1G12 and 2D5 inhibited binding of I-125-fibrinogen to ICAM-1-transfectants and abrogated the enhancing effect of fibrinogen on mononuclear cell adhesion to endothelium and transendothelial migration. In contrast, mAbs 3D6 and 6E6 did not affect ICAM-1 recognition of fibrinogen. With respect to other ligands, mAbs 1G12 and 2D5 completely inhibited attachment of Plasmodium falciparum-infected erythrocytes to immobilized recombinant ICAM-1-Fc, whereas they had no effect on LFA-1-dependent T cell binding to ICAM-1-Fc. Conversely, mAbs 3D6 and 6E6 completely abolished LFA-1 binding to ICAM-1-Fc. Epitope assignment using ICAM-1 chimeras and receptor mutants revealed that the fibrinogen-blocking mAbs 1G12 and 2D5 reacted with domain 1 of ICAM-1, and their binding was disrupted by 97 and 70% by mutations of D26 and P70, respectively, whereas mAbs 3D6 and 6E6 bound to domain 2 of ICAM-1. By recognizing a site distinct from that of beta(2) integrins Mac-1 or LFA-1, fibrinogen binding to ICAM-1 may provide an alternative pathway of intercellular adhesion and/or modulate integrin-dependent adherence during inflammation and vascular injury.	YALE UNIV, SCH MED, BOYER CTR MOL MED, MOL CARDIOBIOL PROGRAM, NEW HAVEN, CT 06536 USA; YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA; CEA, HEMATOL LAB, DEPT BIOL MOL & STRUCT, INSERM, U217, F-38054 GRENOBLE 9, FRANCE; YALE UNIV, SCH MED, BOYER CTR MOL MED, DEPT PATHOL, NEW HAVEN, CT 06536 USA; IMPERIAL CANC RES FUND, LEUKOCYTE ADHES LAB, LONDON WC2A 3PX, ENGLAND; JOHN RADCLIFFE HOSP, INST MOL MED, MOL PARASITOL GRP, OXFORD OX3 9DU, ENGLAND	Yale University; Yale University; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Yale University; Cancer Research UK; University of Oxford			Duperray, Alain/E-8428-2012	Duperray, Alain/0000-0002-2719-252X; McDowall, Alison/0000-0003-2018-1462; Craig, Alister/0000-0003-0914-6164	NATIONAL CANCER INSTITUTE [R29CA071870] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054131, R37HL054131, R01HL043773] Funding Source: NIH RePORTER; NCI NIH HHS [CA71870] Funding Source: Medline; NHLBI NIH HHS [HL43773, HL54131] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; BINI A, 1989, ARTERIOSCLEROSIS, V9, P109, DOI 10.1161/01.ATV.9.1.109; CARLOS TM, 1994, BLOOD, V84, P2068; CHIRATHAWORN C, 1995, J IMMUNOL, V155, P5479; CRAIG AG, 1995, LEUKOCYTE TYPING, V5, P1554; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUPLAA C, 1993, EUR J CLIN INVEST, V23, P474, DOI 10.1111/j.1365-2362.1993.tb00793.x; DURIEUTRAUTMANN O, 1994, J BIOL CHEM, V269, P12536; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Hicks RCJ, 1996, NATURE, V379, P818, DOI 10.1038/379818a0; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; LANGUINO LR, 1993, CELL, V73, P1423, DOI 10.1016/0092-8674(93)90367-Y; MCCLELLAND A, 1991, P NATL ACAD SCI USA, V88, P7993, DOI 10.1073/pnas.88.18.7993; MCCOURT PAG, 1994, J BIOL CHEM, V269, P30081; OCKENHOUSE CF, 1992, CELL, V68, P63, DOI 10.1016/0092-8674(92)90206-R; POBER JS, 1986, J IMMUNOL, V137, P1893; POSTON RN, 1992, AM J PATHOL, V140, P665; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Shetty S, 1996, THROMB HAEMOSTASIS, V75, P782; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SLIGH JE, 1993, P NATL ACAD SCI USA, V90, P8529, DOI 10.1073/pnas.90.18.8529; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sriramarao P, 1996, BLOOD, V88, P3416, DOI 10.1182/blood.V88.9.3416.bloodjournal8893416; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; Stewart MP, 1996, J IMMUNOL, V156, P1810; TURNER GDH, 1994, AM J PATHOL, V145, P1057; vandeStolpe A, 1996, THROMB HAEMOSTASIS, V75, P182; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0	35	100	106	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					435	441						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995280				2022-12-25	WOS:A1997WA56400067
J	Grant, ER; Bacskai, BJ; Pleasure, DE; Pritchett, DB; Gallagher, MJ; Kendrick, SJ; Kricka, LJ; Lynch, DR				Grant, ER; Bacskai, BJ; Pleasure, DE; Pritchett, DB; Gallagher, MJ; Kendrick, SJ; Kricka, LJ; Lynch, DR			N-methyl-D-aspartate receptors expressed in a nonneuronal cell line mediate subunit-specific increases in free intracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; RAT HIPPOCAMPAL-NEURONS; CENTRAL NERVOUS-SYSTEM; AMINO-ACID RECEPTORS; NMDA RECEPTOR; GLUTAMATE NEUROTOXICITY; MOLECULAR CHARACTERIZATION; RECOMBINANT AEQUORIN; TARGETED AEQUORIN; MAMMALIAN-CELLS	N-methyl-D-aspartate (NMDA) receptors can mediate cell death in neurons and in non-neuronal cells that express recombinant NMDA receptors. In neurons, increases in intracellular calcium correlate with NMDA receptor-mediated death, supporting a key role for loss of cellular calcium homeostasis in excitotoxic cell death, In the present study, free intracellular calcium concentrations were examined in response to activation of recombinant NMDA receptors expressed in human embryonic kidney 293 cells. Intracellular calcium was measured in transfected cell populations by cotransfection with the calcium-sensitive, bioluminescent protein aequorin and by single cell imaging with the fluorescent calcium indicator fluo-3. Agonist application to NR1/2A or NR1/2B-transfected cells elicited robust rises in intracellular calcium. NR1/2A responses were inhibited by the noncompetitive antagonists MK-801 and dextromethorphan and were dependent on extracellular calcium but not on intracellular calcium stores. In contrast, no detectable intracellular calcium responses were observed in NR1/2C-transfected cells, These findings indicate that NMDA receptors in the absence of other neuron-specific factors can mediate increases in intracellular calcium with subunit specificity and extracellular calcium dependence.	UNIV PENN, SCH MED, CHILDRENS SEASHORE HOUSE, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CHILDRENS SEASHORE HOUSE, DEPT NEUROL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CHILDRENS SEASHORE HOUSE, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, CHILDRENS SEASHORE HOUSE, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania			Bacskai, Brian/AAE-9583-2021		NIDA NIH HHS [DA07130] Funding Source: Medline; NINDS NIH HHS [NS01789-01] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN DG, 1978, NATURE, V273, P509, DOI 10.1038/273509a0; ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; ANEGAWA NJ, 1995, J NEUROCHEM, V64, P2004; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1994, J BIOLUM CHEMILUM, V9, P177, DOI 10.1002/bio.1170090312; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/jphysiol.1995.sp020738; Casado M, 1996, J PHYSIOL-LONDON, V490, P391, DOI 10.1113/jphysiol.1996.sp021153; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; COBBOLD PH, 1980, NATURE, V285, P441, DOI 10.1038/285441a0; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gallagher MJ, 1996, J BIOL CHEM, V271, P9603, DOI 10.1074/jbc.271.16.9603; GARTHWAITE G, 1986, NEUROSCIENCE, V18, P437, DOI 10.1016/0306-4522(86)90164-8; Grimwood S, 1996, J NEUROCHEM, V66, P2239; Grimwood S, 1996, J NEUROCHEM, V66, P2589; HAHN JS, 1988, P NATL ACAD SCI USA, V85, P6556, DOI 10.1073/pnas.85.17.6556; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; INOUYE S, 1985, P NATL ACAD SCI USA, V82, P3154, DOI 10.1073/pnas.82.10.3154; ISHII T, 1993, J BIOL CHEM, V268, P2836; JOHANSEN FF, 1983, ACTA NEUROPATHOL, V61, P135, DOI 10.1007/BF00697393; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; Kendrick SJ, 1996, J NEUROCHEM, V67, P608; KNIGHT MR, 1993, J CELL BIOL, V121, P83, DOI 10.1083/jcb.121.1.83; Krupp J., 1995, Society for Neuroscience Abstracts, V21, P79; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LOVINGER DM, 1995, J PHARMACOL EXP THER, V274, P164; LYNCH DR, 1995, J NEUROCHEM, V64, P1462; LYSKO PG, 1989, BRAIN RES, V499, P258, DOI 10.1016/0006-8993(89)90773-7; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MEDINA I, 1995, J PHYSIOL-LONDON, V482, P567, DOI 10.1113/jphysiol.1995.sp020540; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORI H, 1992, NATURE, V358, P673, DOI 10.1038/358673a0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; PERRIER ML, 1995, NEUROPHARMACOLOGY, V34, P35, DOI 10.1016/0028-3908(94)00130-K; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; PRITCHETT DB, 1989, SCIENCE, V245, P1389, DOI 10.1126/science.2551039; PULSINELLI WA, 1985, PROG BRAIN RES, V63, P29; RANDALL RD, 1992, J NEUROSCI, V12, P1882; RIDGWAY EB, 1967, BIOCHEM BIOPH RES CO, V29, P229, DOI 10.1016/0006-291X(67)90592-X; RIDGWAY EB, 1977, P NATL ACAD SCI USA, V74, P623, DOI 10.1073/pnas.74.2.623; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; SEGAL M, 1992, J PHYSIOL-LONDON, V448, P655, DOI 10.1113/jphysiol.1992.sp019063; SHEU YA, 1993, ANAL BIOCHEM, V209, P343, DOI 10.1006/abio.1993.1132; SHIMOMURA O, 1995, BIOCHEM BIOPH RES CO, V211, P359, DOI 10.1006/bbrc.1995.1821; SHIMOMURA O, 1989, BIOCHEM J, V261, P913, DOI 10.1042/bj2610913; SHIMOMURA O, 1990, BIOCHEM J, V270, P309, DOI 10.1042/bj2700309; SHIMOMURA O, 1991, CELL CALCIUM, V12, P635, DOI 10.1016/0143-4160(91)90060-R; SIMPSON PB, 1993, J NEUROCHEM, V61, P760; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TYMIANSKI M, 1993, NEURON, V11, P221, DOI 10.1016/0896-6273(93)90180-Y; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WATKINS NJ, 1995, BIOCHEM J, V306, P865, DOI 10.1042/bj3060865; WILLIAMS K, 1991, MOL PHARMACOL, V40, P774	73	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					647	656						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995308				2022-12-25	WOS:A1997WA56400095
J	Hadari, YR; Haring, HU; Zick, Y				Hadari, YR; Haring, HU; Zick, Y			p75, a member of the heat shock protein family, undergoes tyrosine phosphorylation in response to oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR KINASE; INSULINOMIMETIC AGENTS H2O2; ADHERENS-TYPE JUNCTIONS; CHAIN BINDING-PROTEIN; SIGNAL-TRANSDUCTION; INTACT-CELLS; PHOSPHATIDYLINOSITOL 3'-KINASE; RAT ADIPOCYTES; VANADATE; IRS-1	The combination of H2O2 and vanadate generates aqueous peroxovanadium (pV) species, which are effective cell-permeable oxidants, and potent inhibitors of protein-tyrosine phosphatases. As a result, treatment of intact cells with pV compounds significantly enhances protein Tyr phosphorylation. Here we demonstrate that treatment of intact rat hepatoma Fao cells with pV markedly enhances Tyr phosphorylation of a 75-kDa protein, termed pp75. Amino-terminal sequencing of pp75 revealed that this protein is a member of the 70-75-kDa heat shock protein family, which includes PBP-74, glucose-related protein (GRP)-75, and mortalin. Tyr phosphorylation of pp75 is selective, because other proteins that belong to the heat shock protein 70 family, such as GRP-72, Bip (GRP-78), and HSC-70 fail to undergo Tyr phosphorylation when cells are treated with pV. Our findings suggest that heat shock proteins such as pp75 may undergo tyrosine phosphorylation when intact cells are subjected to oxidative stress induced by pV compounds.	WEIZMANN INST SCI, DEPT MOL CELL BIOL, IL-76100 REHOVOT, ISRAEL; UNIV TUBINGEN, MED KLIN & POLIKLIN, ABT 4, D-72076 TUBINGEN, GERMANY	Weizmann Institute of Science; Eberhard Karls University of Tubingen			Zick, Yehiel/K-1479-2012					BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BOHEN SP, 1995, SCIENCE, V268, P1303, DOI 10.1126/science.7761850; CHRETIEN P, 1988, J CELL PHYSIOL, V137, P157, DOI 10.1002/jcp.1041370119; De Maio A, 1995, New Horiz, V3, P198; DOMANICO SZ, 1993, MOL CELL BIOL, V13, P3598, DOI 10.1128/MCB.13.6.3598; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAHAM J, 1984, CENTRIFUGATION PRACT, P168; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1993, MOL CELL ENDOCRINOL, V97, P9, DOI 10.1016/0303-7207(93)90206-Y; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1991, METHOD ENZYMOL, V201, P44; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HELLERHARRISON RA, 1995, J BIOL CHEM, V270, P24442, DOI 10.1074/jbc.270.41.24442; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; Jurivich D.A., 1994, BIOL HEAT SHOCK PROT, P417; KADOTA S, 1987, J BIOL CHEM, V262, P8252; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; MASSA SM, 1995, J NEUROSCI RES, V40, P807, DOI 10.1002/jnr.490400612; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; PIEDIMONTE G, 1988, J CELL BIOCHEM, V36, P91, DOI 10.1002/jcb.240360110; POSNER BI, 1994, J BIOL CHEM, V269, P4596; PUMFORD NR, 1993, CHEM RES TOXICOL, V6, P609, DOI 10.1021/tx00035a004; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SHAVER A, 1993, INORG CHEM, V32, P3109, DOI 10.1021/ic00066a024; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SNOEK M, 1994, IMMUNOGENETICS, V40, P159, DOI 10.1007/BF00188181; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TRACEY AS, 1986, P NATL ACAD SCI USA, V83, P609, DOI 10.1073/pnas.83.3.609; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1994, CELL STRUCT FUNCT, V19, P1, DOI 10.1247/csf.19.1; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZICK Y, 1990, BIOCHEMISTRY-US, V29, P10240, DOI 10.1021/bi00496a013	58	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					657	662						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995309				2022-12-25	WOS:A1997WA56400096
J	Soengas, MS; Mateo, CR; Rivas, G; Salas, M; Acuna, KU; Gutierrez, C				Soengas, MS; Mateo, CR; Rivas, G; Salas, M; Acuna, KU; Gutierrez, C			Structural features of phi 29 single-stranded DNA-binding protein .2. Global conformation of phi 29 single-stranded DNA-binding protein and the effects of complex formation on the protein and the single-stranded DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIRCULAR-DICHROISM; GENE-V; FILAMENTOUS BACTERIOPHAGE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NUCLEIC ACID; REPLICATION; FLUORESCENCE; ULTRACENTRIFUGATION; DECONVOLUTION	The strand-displacement mechanism of Bacillus subtilis phage phi 29 DNA replication occurs through replicative intermediates with high amounts of single-stranded DNA (ssDNA). These ssDNA must be covered by the viral ssDNA-binding protein, phi 29 SSB, to be replicated in vivo. To understand the characteristics of phi 29 SSB-ssDNA complex that could explain the requirement of phi 29 SSB, we have (i) determined the hydrodynamic behavior of phi 29 SSB in solution and (ii) monitored the effect of complex formation on phi 29 SSB and ssDNA secondary structure. Based on its translational frictional coefficient (3.5 +/- 0.1) x 10(8) gs(-1), and its rotational correlation time, 7.0 +/- 0.5 ns, phi 29 SSB was modeled as a nearly spherical ellipsoid of revolution. The axial ratio (p = a/b) could range from 0.8 to 1.0 (oblate model, a < b) or 1.0 to 3.2 (prolate model, a > b). Far-UV CD spectra, indicated that phi 29 SSB is highly organized within a wide range of temperatures (15 to 50 degrees C), being mainly constituted by beta-sheet elements (similar to 50%, at pH 7). Complex formation with ssDNA, although inducing minimal changes on the global conformation of phi 29 SSB, had a clear stabilizing effect against pH and temperature increase of the solution samples. On the other hand, phi 29 SSB binding leads to non-conservative changes of the near-UV CD spectra of ssDNA, which are consistent with different nearest-neighbor interactions of the nucleotide bases upon complex formation. The above results will be compared to those reported for other SSBs and discussed in terms of the functional roles of phi 29 SSB.	AUTONOMOUS UNIV MADRID,CSIC,CTR BIOL MOL SEVERO OCHOA,E-28049 MADRID,SPAIN; CSIC,INST QUIM FIS ROCASOLANO,E-28006 MADRID,SPAIN; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)			Soengas, Maria S/H-6455-2015; Rivas, German/AFL-7528-2022; Rivas, German/AAG-7458-2022; Salas, Margarita/J-9873-2014; Mateo, C. Reyes/ABF-8920-2020; Gutierrez, Crisanto/ABH-8782-2020	Soengas, Maria S/0000-0003-0612-6299; Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Salas, Margarita/0000-0001-5939-3441; Mateo, C. Reyes/0000-0002-2085-1676; Gutierrez, Crisanto/0000-0001-8905-8222	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5RO1 GM 27242-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMA NCM, 1983, J MOL BIOL, V163, P47, DOI 10.1016/0022-2836(83)90029-3; ANDERSON RA, 1975, BIOCHEMISTRY-US, V14, P5485, DOI 10.1021/bi00696a017; BALEY P, 1980, INTRO SPECTROSCOPY B, P148; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; Cantor C.R., 1980, BIOPHYSICAL CHEM 2; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; CASASFINET JR, 1993, BIOCHEMISTRY-US, V32, P9735, DOI 10.1021/bi00088a028; CATLIN JC, 1975, BIOPOLYMERS, V14, P51, DOI 10.1002/bip.1975.360140105; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; DAY LA, 1973, BIOCHEMISTRY-US, V12, P5329, DOI 10.1021/bi00750a017; DEWEY TG, 1980, BIOCHEMISTRY-US, V19, P1681, DOI 10.1021/bi00549a025; FOLKERS PJM, 1994, J MOL BIOL, V236, P229, DOI 10.1006/jmbi.1994.1132; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; FOLMER RHA, 1994, J MOL BIOL, V240, P341, DOI 10.1006/jmbi.1994.1449; GOLDBERG RJ, 1953, J PHYS CHEM-US, V57, P194, DOI 10.1021/j150503a014; GRYZYNSKI I, 1991, BIOPHYS CHEM, V39, P69; GUTIERREZ C, 1991, J MOL BIOL, V222, P983, DOI 10.1016/0022-2836(91)90589-X; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HIRS CHW, 1973, METHODS ENZYMOL D, V27, P675; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; KIM YT, 1994, J BIOL CHEM, V269, P5270; KIM YT, 1992, J BIOL CHEM, V267, P15032; KNEALE GG, 1992, CURR OPIN STRUC BIOL, V2, P124; KORNBERG A, 1992, DNA REPLICATION, P323; Kowalczykowski S.C., 1981, ENZYMES, V14, P373; LAKOWICZ JR, 1986, BIOPHYS CHEM, V24, P97, DOI 10.1016/0301-4622(86)80002-3; Laue T., 1993, ANAL ULTRACENTRIFUGA, P90; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; MATEO CR, 1991, EUR BIOPHYS J, V20, P41; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; MONTEJO JM, 1992, BIOCHEMISTRY-US, V31, P7580, DOI 10.1021/bi00148a020; OLSTHOORN CSM, 1980, EUR J BIOCHEM, V106, P85; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Perrin F, 1936, J PHYS-PARIS, V7, P1, DOI 10.1051/jphysrad:01936007010100; POWELL MD, 1993, BIOCHEMISTRY-US, V32, P12538, DOI 10.1021/bi00097a034; PRASAD BVV, 1987, J MOL BIOL, V193, P579; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PROVENCHER SW, 1984, DAO7 EMBL; RILEY M, 1966, J MOL BIOL, V20, P359, DOI 10.1016/0022-2836(66)90069-6; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1995, FEMS MICROBIOL REV, V17, P73; Salas Margarita, 1993, P843; SALSTROM JS, 1971, J MOL BIOL, V61, P489, DOI 10.1016/0022-2836(71)90061-1; SANG BC, 1989, BIOCHEMISTRY-US, V28, P9502, DOI 10.1021/bi00450a038; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SOENGAS MS, 1994, J MOL BIOL, V239, P213, DOI 10.1006/jmbi.1994.1364; Soengas MS, 1997, J BIOL CHEM, V272, P295; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; STAFFORD WF, 1978, BIOCHEMISTRY-US, V17, P607, DOI 10.1021/bi00597a008; STEEL C, 1991, J PHYS CHEM-US, V95, P10713, DOI 10.1021/j100179a037; STUIVER MH, 1992, J MOL BIOL, V255, P999; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VANHOLDE KE, 1985, PHYSICAL BIOCH, P225; WAHL PH, 1983, NATO ASCI SERIES A, V69; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YANG JT, 1986, METHOD ENZYMOL, V130, P208	67	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					303	310						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995262				2022-12-25	WOS:A1997WA56400049
J	Hansra, G; Bornancin, F; Whelan, R; Hemmings, BA; Parker, PJ				Hansra, G; Bornancin, F; Whelan, R; Hemmings, BA; Parker, PJ			12-O-tetradecanoylphorbol-13-acetate-induced dephosphorylation of protein kinase C alpha correlates with the presence of a membrane-associated protein phosphatase 2A heterotrimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOWN-REGULATION; PHORBOL-ESTER; CELLS; ACTIVATION; PHOSPHORYLATION; PURIFICATION; SPECIFICITY; SUBUNIT; LEADS; GAMMA	Protein kinase C signaling is desensitized through a combination of dephosphorylation and proteolysis in intact cells. The process of dephosphorylation is analyzed here, as well as its relationship to degradation. It is established for protein kinase C alpha that dephosphorylation occurs in a membrane compartment following activation and temporally preceding significant degradation. The phosphatase responsible for the dephosphorylation appears to be a heterotrimeric type 2A phosphatase, which is shown to be in part constitutively membrane associated. Consistent with a role for this activity, okadaic acid is shown to inhibit the phorbol ester-induced dephosphorylation of protein kinase C that occurs in intact cells. Furthermore, phorbol ester-induced down-regulation of protein kinase C alpha is shown not to be dependent on the rate of dephosphorylation, indicating that these desensitizing pathways may operate in parallel.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Cancer Research UK; Friedrich Miescher Institute for Biomedical Research			Parker, Peter j/D-5192-2013; Bornancin, Frederic/AAA-2888-2021	Bornancin, Frederic/0000-0002-0152-6720; parker, peter/0000-0002-6218-2933				ALEXANDER DR, 1992, BIOCHEM J, V288, P69, DOI 10.1042/bj2880069; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DENT P, 1995, SCIENCE, V269, P1657; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FAVRE B, 1994, J BIOL CHEM, V269, P16311; GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KILEY SC, 1991, J BIOL CHEM, V266, P23761; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; PALMER RH, 1995, BIOCHEM J, V309, P315, DOI 10.1042/bj3090315; PEARS C, 1991, FEBS LETT, V284, P120, DOI 10.1016/0014-5793(91)80776-Y; PEARS C, 1992, BIOCHEM J, V283, P515, DOI 10.1042/bj2830515; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; STABEL S, 1991, METHOD ENZYMOL, P670; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; WERA S, 1995, J BIOL CHEM, V270, P21374, DOI 10.1074/jbc.270.36.21374; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	31	90	91	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32785	32788		10.1074/jbc.271.51.32785	http://dx.doi.org/10.1074/jbc.271.51.32785			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955114	hybrid			2022-12-25	WOS:A1996VZ37300049
J	Reynafarje, BD; Pedersen, PL				Reynafarje, BD; Pedersen, PL			ATP synthase - Conditions under which all catalytic sites of the F-1 moiety are kinetically equivalent in hydrolyzing ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; NUCLEOTIDE-BINDING; OXIDATIVE-PHOSPHORYLATION; RAT-LIVER; ADENINE-NUCLEOTIDES; F1 MOIETY; MECHANISM; F1-ATPASE; SUBUNIT	Conditions have been reported under which the F-1 moiety of bovine heart ATP synthase catalyzes the hydrolysis of ATP by an apparently cooperative mechanism in which the slow rate of hydrolysis at a single catalytic site (unisite catalysis) is enhanced more than 10(6)-fold when ATP is added in excess to occupy one or both of the other two catalytic sites (multisite catalysis) (Cross, R. L., Grubmeyer, C., and Penefsky, H. S. (1982) J, Biol, Chem, 257, 12101-12105). In the novel studies reported here, and in contrast to the earlier report, we have (a) monitored the kinetics of ATP hydrolysis of F-1 by using nucleotide-depleted preparations and a highly sensitive chemiluminescent assay; (b) followed the reaction immediately upon addition of F-1 to ATP, rather than after prior incubation with ATP; and (c) used a reaction medium with P-i as the only buffer, The following observations were noted, First, regardless of the source of enzyme, bovine or rat, and catalytic conditions (unisite or multisite), the rates of hydrolysis depend on ATP concentration to the first power, Second, the first order rate constant for ATP hydrolysis remains relatively constant under both unisite and multisite conditions declining only slightly at high ATP concentration, Third, the initial rates of ATP hydrolysis exhibit Michaelis-Menten kinetic behavior with a single V-max exceeding 100 mu mol of ATP hydrolyzed per min/mg of F-1 (turnover number = 635 s(-1)) and a single K-m for ATP of about 57 mu M. Finally, the reaction is inhibited markedly by low concentrations of ADP, It is concluded that, under the conditions described here, all catalytic sites that participate in the hydrolysis of ATP within the F-1 moiety of mitochondrial ATP synthase function in a kinetically equivalent manner.			Reynafarje, BD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.				NCI NIH HHS [CA 10951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA010951, R01CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADOLFSEN R, 1976, ARCH BIOCHEM BIOPHYS, V172, P425, DOI 10.1016/0003-9861(76)90094-1; Aflalo C, 1988, Prog Clin Biol Res, V273, P337; ALLISON WS, 1992, J BIOENERG BIOMEMBR, V24, P469, DOI 10.1007/BF00762364; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1979, MEMBRANE BIOENERGETI, P451; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V12, P186; CATTERALL WA, 1971, J BIOL CHEM, V246, P4987; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1982, J BIOL CHEM, V257, P2874; DELUCA M, 1974, BIOCHEMISTRY-US, V13, P921, DOI 10.1021/bi00702a015; ESCH FS, 1978, J BIOL CHEM, V253, P6100; FILLINGAME RH, 1992, J BIOENERG BIOMEMBR, V24, P485, DOI 10.1007/BF00762366; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GARRETT NE, 1975, J BIOL CHEM, V250, P6640; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; KNOWLES AF, 1972, J BIOL CHEM, V247, P6617; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; PEDERSEN PL, 1995, J BIOL CHEM, V270, P1775, DOI 10.1074/jbc.270.4.1775; PEDERSEN PL, 1993, J BIOL CHEM, V268, P9937; PEDERSEN PL, 1981, J BIOL CHEM, V256, P1362; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; WEBER J, 1993, J BIOL CHEM, V268, P20126	27	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32546	32550		10.1074/jbc.271.51.32546	http://dx.doi.org/10.1074/jbc.271.51.32546			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955079	hybrid			2022-12-25	WOS:A1996VZ37300014
J	Sood, AK; Buller, RE				Sood, AK; Buller, RE			Genomic instability in ovarian cancer: A reassessment using an arbitrarily primed polymerase chain reaction	ONCOGENE			English	Article						ovarian cancer; genomic instability; replication error	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; GENETIC INSTABILITY; REPEATED SEQUENCES; MISMATCH REPAIR; ALU REPEATS; CELL-LINES; DNA; MUTATIONS; TUMORS	Traditional polymerase chain reaction (PCR) amplification of multiple microsatellite markers to detect microsatellite instability (MI) is labor intensive and may be marker dependent, An arbitrarily primed polymerase chain reaction (AP-PCR) is a modification of PCR that generates a genomic DNA fingerprint using a single, arbitrarily chosen primer which is useful in the detection of somatic genetic alterations, We hypothesize that AP-PCR of an AluI DNA restriction digest, which we term Alu/AP-PCR, identifies genomic instability as well, In order to test this hypothesis, we correlated Alu/AP-PCR fingerprints with analyses of traditional PCR amplified microsatellite markers using paired germline and tumor DNA samples obtained from 68 patients with ovarian cancer, The microsatellite markers tested included dinucleotide, trinucleotide, and tetranucleotide repeats. We found that MI is more common in ovarian cancer than previously thought, We estimate a minimum incidence of MI at 37% based on the 10 traditional markers we tested, to an incidence of 53% based upon our Alu/AP-PCR analysis, All cases of MI were associated with an abnormal Alu/AP-PCR banding pattern, Both MI, detected by polymorphic markers (P=0.03), and an abnormal Alu/MAP-PCR pattern (P=0.01) were significantly associated with the occurrence of a second primary malignancy in the same patient. In addition, abnormal Alu/AP-PCR patterns were associated with higher grade lesions (P=0.02), and family history of cancer (P=0.009), These findings suggest: (1) MI may play an important role in ovarian carcinogenesis, and (2) Alu/AP-PCR is a novel technique for identification of genomic instability.	UNIV IOWA HOSP & CLIN, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, IOWA CITY, IA 52242 USA; UNIV IOWA HOSP & CLIN, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ARCOT SS, 1995, GENOMICS, V29, P136, DOI 10.1006/geno.1995.1224; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BOYER JC, 1995, CANCER RES, V55, P6063; BULLER RE, 1995, GYNECOL ONCOL, V58, P368, DOI 10.1006/gyno.1995.1244; Cass I., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P544; CHARLIEU JP, 1992, NUCLEIC ACIDS RES, V20, P1333, DOI 10.1093/nar/20.6.1333; DESOUZA AP, 1994, GENOMICS, V19, P391, DOI 10.1006/geno.1994.1079; HAN HJ, 1993, CANCER RES, V53, P5087; HOUCK CM, 1979, J MOL BIOL, V132, P289, DOI 10.1016/0022-2836(79)90261-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACOBS IJ, 1993, CANCER RES, V53, P1218; KOLODNER RD, 1995, CANCER RES, V55, P242; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LOEB LA, 1991, CANCER RES, V51, P3075; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MUTA H, 1990, CANCER, V77, P265; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PALOMBO F, 1994, NATURE, V367, P417, DOI 10.1038/367417a0; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PEROLAT P, 1994, J CLIN MICROBIOL, V32, P1949, DOI 10.1128/JCM.32.8.1949-1957.1994; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Skilling JS, 1996, ONCOGENE, V13, P117; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WEBER JL, 1989, AM J HUM GENET, V44, P388; WELSH J, 1990, NUCLEIC ACIDS RES, V18, P7213, DOI 10.1093/nar/18.24.7213; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YANGFENG TL, 1992, INT J CANCER, V52, P575, DOI 10.1002/ijc.2910520414; YULUG IG, 1995, GENOMICS, V27, P544, DOI 10.1006/geno.1995.1090	35	55	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	1996	13	11					2499	2504						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957095				2022-12-25	WOS:A1996VX10800026
J	Gavin, DK; Gupta, KC				Gavin, DK; Gupta, KC			Efficient hammerhead ribozymes targeted to the polycistronic Sendai virus P/C mRNA - Structure-function relationships	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NONSTRUCTURAL C-PROTEINS; T7 RNA-POLYMERASE; MESSENGER-RNA; TRANSLATION INITIATION; TYPE-1 EXPRESSION; GENE SUPPRESSION; MAMMALIAN-CELLS; VACCINIA VIRUS; CLEAVAGE	The Sendai virus polycistronic P/C mRNA encodes the P and C proteins from alternate overlapping reading frames. To determine the functions of these proteins in virus replication, hammerhead ribozymes were targeted to cleave the 5'-untranslated region of the P/C mRNA. Both cell-free and intracellular assays were employed to determine ribozyme efficacy. To appropriately compare activities between cell-free and intracellular assays, identical ribozymes were synthesized in vitro as well as expressed in cells. Ribozyme parameters, namely hybridization arm length (HAL) and nonhybridizing extraneous sequences (NES), were found to have rate determining properties. In cell-free reactions, ribozymes with 13-mer HAL were up to 10-fold more efficient than those with 9-mer HAL. Ribozymes with 9-mer HAL were relatively ineffective in transfected cells. Minimizing the number of NES increased ribozyme efficiency in vitro. However, ribozymes with minimal NES were essentially inert intracellularly. The NES at the termini of the most effective intracellular ribozyme, Rz13st (similar to 95% inhibition of the p gene expression), were predicted to fold into stem-loop structures. These structures most likely increase ribozyme stability as evidenced by the 8-fold higher resistance to ribonuclease T2 digestion of Rz13st compared with Rz13B. Our results suggest that when designing effective intracellular ribozymes, parameters that enhance formation of productive ribozyme:substrate duplexes and that increase RNA stability should be optimized.			Gavin, DK (corresponding author), RUSH MED COLL, DEPT MICROBIOL IMMUNOL, 1653 W CONGRESS PKWY, CHICAGO, IL 60612 USA.				NIAID NIH HHS [AI30517] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030517] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BYRAPPA S, 1995, VIROLOGY, V208, P408, DOI 10.1006/viro.1995.1169; CAMERON FH, 1989, P NATL ACAD SCI USA, V86, P9139, DOI 10.1073/pnas.86.23.9139; CANTOR GH, 1993, P NATL ACAD SCI USA, V90, P10932, DOI 10.1073/pnas.90.23.10932; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHOWRIRA BM, 1994, J BIOL CHEM, V269, P25856; COTTEN M, 1989, EMBO J, V8, P3861, DOI 10.1002/j.1460-2075.1989.tb08564.x; CURRAN J, 1992, VIROLOGY, V189, P647, DOI 10.1016/0042-6822(92)90588-G; DENMAN RB, 1993, NUCLEIC ACIDS RES, V21, P4119, DOI 10.1093/nar/21.17.4119; DILLON PJ, 1989, J VIROL, V63, P974, DOI 10.1128/JVI.63.2.974-977.1989; DROPULIC B, 1992, J VIROL, V66, P1432; EFRAT S, 1994, P NATL ACAD SCI USA, V91, P2051, DOI 10.1073/pnas.91.6.2051; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FEDOR MJ, 1990, P NATL ACAD SCI USA, V87, P1668, DOI 10.1073/pnas.87.5.1668; Fersht A., 1985, ENZYME STRUCTURE MEC; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOODCHILD J, 1991, ARCH BIOCHEM BIOPHYS, V284, P386, DOI 10.1016/0003-9861(91)90313-8; Gupta KC, 1996, BIOCHEMISTRY-US, V35, P1223, DOI 10.1021/bi9520646; GUPTA KC, 1988, J BIOL CHEM, V263, P8553; GUPTA KC, 1987, J BIOL CHEM, V262, P7492; GUPTA KC, 1992, BIOTECHNIQUES, V12, P226; HASELOFF J, 1988, NATURE, V334, P585, DOI 10.1038/334585a0; HEIDENREICH O, 1992, J BIOL CHEM, V267, P1904; HENDRICKS DD, 1993, VIROLOGY, V197, P471, DOI 10.1006/viro.1993.1615; HERSCHLAG D, 1991, P NATL ACAD SCI USA, V88, P6921, DOI 10.1073/pnas.88.16.6921; HORIKAMI SM, 1992, J VIROL, V66, P4901, DOI 10.1128/JVI.66.8.4901-4908.1992; KINGSBURY D W, 1991, P507; LEE SW, 1995, GENE THER, V2, P377; LHUILLIER PJ, 1992, EMBO J, V11, P4411, DOI 10.1002/j.1460-2075.1992.tb05541.x; MEHDI H, 1990, GENE, V91, P173, DOI 10.1016/0378-1119(90)90085-6; OJWANG JO, 1992, P NATL ACAD SCI USA, V89, P10802, DOI 10.1073/pnas.89.22.10802; PATWARDHAN S, 1988, J BIOL CHEM, V263, P4907; Perriman R, 1993, Antisense Res Dev, V3, P253; PORTNER A, 1986, VIRUS RES, V6, P109, DOI 10.1016/0168-1702(86)90043-2; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SCANLON KJ, 1994, P NATL ACAD SCI USA, V91, P11123, DOI 10.1073/pnas.91.23.11123; SIOUD M, 1994, NUCLEIC ACIDS RES, V22, P5571, DOI 10.1093/nar/22.25.5571; TAIRA K, 1991, NUCLEIC ACIDS RES, V19, P5125, DOI 10.1093/nar/19.19.5125; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VIDAL S, 1990, EMBO J, V9, P2017, DOI 10.1002/j.1460-2075.1990.tb08330.x; XING Z, 1992, J VIROL, V66, P1361, DOI 10.1128/JVI.66.3.1361-1369.1992; ZHENG X, 1993, J VIROL, V67, P1840, DOI 10.1128/JVI.67.4.1840-1847.1993; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	46	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1461	1472		10.1074/jbc.272.3.1461	http://dx.doi.org/10.1074/jbc.272.3.1461			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999815	hybrid			2022-12-25	WOS:A1997WD05800013
J	Mizuno, T; Yoshihara, Y; Inazawa, J; Kagamiyama, H; Mori, K				Mizuno, T; Yoshihara, Y; Inazawa, J; Kagamiyama, H; Mori, K			CDNA cloning and chromosomal localization of the human telencephalin and its distinctive interaction with lymphocyte function-associated antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; OUTGROWTH-PROMOTING ACTIVITY; IMMUNOGLOBULIN SUPERFAMILY; MONOCLONAL-ANTIBODY; MEMBRANE GLYCOPROTEIN; ICAM-1; EXPRESSION; INTEGRIN; RECEPTOR; BINDING	We have isolated cDNA encoding human telencephalin (TLN), a brain segment-specific neuronal adhesion molecule. Human TLN comprises an NH2-terminal signal peptide, an extracellular region with nine Ig-like domains, a single transmembrane region, and a COOH-terminal cytoplasmic tail. The NH2-terminal five Ig-like domains of TLN were closely related to those of intercellular adhesion molecules (ICAMs)-1 and -3. The TLN gene was mapped to the human chromosome 19p13.2, where the ICAM-1, -3, and -4 (LW) genes are located. Furthermore, we observed lymphocyte function-associated antigen-1 (LFA-1)-mediated adhesion of HL-60 cells on recombinant TLN protein, as well as on ICAM-1. However, the interaction of TLN with LFA-1 on HL 60 cells was divalent cation-independent and phorbol 12-myristate 13-acetate stimulation-independent. We conclude that TLN is a unique neuronal member of ICAM subgroup of the Ig superfamily and propose a novel type of interaction between the Ig superfamily molecule and integrin, which does not require the activation of integrin. TLN on the surface of telencephalic neurons may be a target molecule in the brain for LFA-1-expressing microglia and leukocytes in physiological or pathological conditions.	OSAKA BIOSCI INST, DEPT NEUROSCI, SUITA, OSAKA 565, JAPAN; OSAKA MED COLL, DEPT BIOCHEM, TAKATSUKI, OSAKA 569, JAPAN; KYOTO PREFECTURAL UNIV MED, KAMIGYO KU, KYOTO 602, JAPAN; RIKEN, FRONTIER RES PROGRAM, LAB NEURONAL RECOGNIT MOL, WAKO, SAITAMA 35101, JAPAN	Osaka Medical College; Kyoto Prefectural University of Medicine; RIKEN			Yoshihara, Yoshihiro/N-6481-2015	Yoshihara, Yoshihiro/0000-0002-0319-7166; Mori, Kensaku/0000-0001-7853-9370				AKIYAMA H, 1990, J NEUROIMMUNOL, V30, P81, DOI 10.1016/0165-5728(90)90055-R; BAILLY P, 1994, P NATL ACAD SCI USA, V91, P5306, DOI 10.1073/pnas.91.12.5306; Bailly P, 1995, EUR J IMMUNOL, V25, P3316, DOI 10.1002/eji.1830251217; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; BOSSY D, 1994, GENOMICS, V23, P712, DOI 10.1006/geno.1994.1565; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BRUMMENDORF T, 1994, PROTEIN PROFILE, V1, P951; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; GENNARINI G, 1989, J CELL BIOL, V109, P775, DOI 10.1083/jcb.109.2.775; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; HOLNESS CL, 1995, J BIOL CHEM, V270, P877, DOI 10.1074/jbc.270.2.877; HONG X, 1992, J IMMUNOL, V149, P2650; HORLEY KJ, 1989, EMBO J, V8, P2889, DOI 10.1002/j.1460-2075.1989.tb08437.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IMAMURA K, 1990, NEUROSCI LETT, V119, P118, DOI 10.1016/0304-3940(90)90770-A; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LALLIER T, 1992, J CELL BIOL, V119, P1335, DOI 10.1083/jcb.119.5.1335; LANDIS RC, 1994, J CELL BIOL, V126, P529, DOI 10.1083/jcb.126.2.529; LEWIS M, 1988, ANN HUM GENET, V52, P137, DOI 10.1111/j.1469-1809.1988.tb01089.x; LI R, 1993, J BIOL CHEM, V268, P17513; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LUB M, 1995, IMMUNOL TODAY, V16, P479, DOI 10.1016/0167-5699(95)80031-X; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORI K, 1987, P NATL ACAD SCI USA, V84, P3921, DOI 10.1073/pnas.84.11.3921; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MURAKAMI F, 1991, NEUROSCI RES, V11, P141, DOI 10.1016/0168-0102(91)90052-Z; MURPHY PM, 1993, CELL, V72, P823, DOI 10.1016/0092-8674(93)90571-7; Nemerow Glen R., 1994, Trends in Cell Biology, V4, P52, DOI 10.1016/0962-8924(94)90010-8; NISHIMURA Y, 1987, CANCER RES, V47, P999; OKA S, 1990, NEUROSCIENCE, V35, P93, DOI 10.1016/0306-4522(90)90124-M; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; PIMENTA AF, 1995, NEURON, V15, P287, DOI 10.1016/0896-6273(95)90034-9; ROPERS HH, 1991, GENET PRIOR REP, V1, P524; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; SMITH MEF, 1990, J CLIN PATHOL, V43, P893, DOI 10.1136/jcp.43.11.893; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; STREIT WJ, 1995, SCI AM, V273, P54, DOI 10.1038/scientificamerican1195-54; STRUYK AF, 1995, J NEUROSCI, V15, P2141, DOI 10.1523/JNEUROSCI.15-03-02141.1995; SWANSON LW, 1995, TRENDS NEUROSCI, V18, P471, DOI 10.1016/0166-2236(95)92766-J; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; VAZEUX R, 1992, NATURE, V360, P485, DOI 10.1038/360485a0; VERMOTDESROCHES C, 1995, EUR J IMMUNOL, V25, P2460, DOI 10.1002/eji.1830250908; VONDERHEIDE RH, 1994, J CELL BIOL, V125, P215, DOI 10.1083/jcb.125.1.215; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YOSHIHARA Y, 1994, NEURON, V12, P541, DOI 10.1016/0896-6273(94)90211-9; YOSHIHARA Y, 1994, NEUROSCI RES, V21, P119, DOI 10.1016/0168-0102(94)90153-8; YOSHIHARA Y, 1995, J NEUROBIOL, V28, P51, DOI 10.1002/neu.480280106; YOSHIHARA Y, 1994, NEURON, V13, P415, DOI 10.1016/0896-6273(94)90357-3; YOSHIHARA Y, 1991, NEUROSCI RES, V10, P83, DOI 10.1016/0168-0102(91)90033-U	63	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1156	1163		10.1074/jbc.272.2.1156	http://dx.doi.org/10.1074/jbc.272.2.1156			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995416	hybrid			2022-12-25	WOS:A1997WC04800067
J	Ahmed, A; Yao, PC; Brant, AM; Peter, GJ; Harper, AA				Ahmed, A; Yao, PC; Brant, AM; Peter, GJ; Harper, AA			Electrogenic L-histidine transport in neutral and basic amino acid transporter (NBAT)-expressing Xenopus laevis oocytes - Evidence for two functionally distinct transport mechanisms induced by NBAT expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY; CLONING; SYSTEM; CYSTINURIA; CURRENTS; GENE; CDNA; RBAT; RNA	We have investigated the neutral and basic amino acid transporter (NBAT)-induced transport of L-histidine in Xenopus laevis oocytes. Transport of L-histidine (pH 7.5) was electrogenic and Na+-dependent with a 14-fold increase in L-histidine- (1 mM) evoked current (I-His = -14.7 +/- 1.5 nA) in NBAT-expressing oocytes compared with native (water-injected or uninjected) oocytes (-1.0 +/- 0.2 nA); the Na+-dependent histidine transport showed a stoichiometry of 1:1 (histidine:sodium). I-His was stereospecific at pH 7.5 and saturable in both NaCl and tetramethylammonium chloride media. L-Histidine (1 mM) at pH 8.5, at which histidine is uncharged, evoked an Na+-independent outward current (11 +/- 1.2 nA) in NBAT-expressing oocytes. The total inward 0.1 mM I-His increased from -9 +/- 0.8 nA at pH 7.5 to -19 +/- 2.6 nA at pH 6.5, at which histidine is predominantly cationic. The increase in I-His from pH 7.5 to 6.5 was found to be almost entirely due to the Na+-independent component. At pH 7.5, L-histidine weakly inhibited the Na+-independent L-arginine uptake; however, this inhibition was much stronger (>90%) at pH 6.5, L-Histidine transport, at pH 7.5, is stimulated by NBAT expression, but unlike L-phenylalanine or L-arginine transport, L-histidine transport is Na+-dependent and stereoselective. The induction of Na+-dependent L-histidine transport in NBAT-expressing oocytes provides new evidence that NBAT stimulates functionally distinct amino acid transporters including Na+-dependent L-histidine and Na+-independent L-arginine and L-phenylalanine transporters. The parallel induction of two different mechanisms argues that NBAT is not an amino acid transporter itself but, instead, is a transport-activating protein for a range of amino acid translocases.			Ahmed, A (corresponding author), UNIV DUNDEE,DEPT ANAT & PHYSIOL,DUNDEE DD1 4HN,SCOTLAND.		Harper, Alexander/A-4688-2010	Ahmed, Aamir/0000-0001-7405-5336				AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; BERTRAN J, 1994, CELL PHYSIOL BIOCHEM, V4, P217, DOI 10.1159/000154728; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BUSCH AE, 1994, J BIOL CHEM, V269, P25581; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; Coady MJ, 1996, J MEMBRANE BIOL, V149, P1, DOI 10.1007/s002329900001; KANAI Y, 1994, FASEB J, V8, P1450; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MARKOVICH D, 1993, J BIOL CHEM, V268, P1362; Miyamoto K, 1996, J BIOL CHEM, V271, P16758, DOI 10.1074/jbc.271.28.16758; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; MOSCKOVITZ R, 1993, P NATL ACAD SCI USA, V90, P4022, DOI 10.1073/pnas.90.9.4022; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; WANG Y, 1995, FEBS LETT, V368, P389, DOI 10.1016/0014-5793(95)00685-3; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596; YAN N, 1994, P NATL ACAD SCI USA, V91, P7548, DOI 10.1073/pnas.91.16.7548	21	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					125	130						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995237				2022-12-25	WOS:A1997WA56400024
J	Chang, JY				Chang, JY			A two-stage mechanism for the reductive unfolding of disulfide-containing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC TRYPSIN-INHIBITOR; RIBONUCLEASE-A; SCRAMBLED HIRUDINS; MULTIPLE PATHWAYS; ALPHA-LACTALBUMIN; FOLDING PATHWAYS; STABILITY; BONDS; PRINCIPLES; KINETICS	Reductive unfolding of disulfide-containing proteins can be experimentally dissected into two distinct stages. In the presence of denaturant and thiol catalyst, native proteins unfold by reshuffling their native disulfides and convert to a mixture of scrambled structures. Subsequent reduction of the disulfide bonds of scrambled proteins requires only mild concentration of reductant (0.2-0.5 mM reduced dithiothreitol) and undergoes intermediates that consist of highly heterogeneous disulfide isomers. These properties have been characterized with three cystine-containing proteins, namely hirudin, tick anticoagulant peptide (TAP), and bovine ribonuclease A. In the cases of hirudin and TAP, most intermediates observed during the oxidative folding were found to exist along the pathway of reductive unfolding as well.			Chang, JY (corresponding author), CIBA GEIGY LTD,PHARMACEUT RES LABS,K-121,104,CH-4002 BASEL,SWITZERLAND.							ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BOERNSEN KO, 1990, CHIMIA, V44, P412; CHANG JY, 1991, ANAL BIOCHEM, V197, P52, DOI 10.1016/0003-2697(91)90354-V; CHANG JY, 1995, J BIOL CHEM, V270, P11992, DOI 10.1074/jbc.270.20.11992; Chang JY, 1996, BIOCHEMISTRY-US, V35, P11702, DOI 10.1021/bi9606915; CHANG JY, 1995, J BIOL CHEM, V270, P25661; CHANG JY, 1990, J BIOL CHEM, V265, P22159; CHANG JY, 1994, BIOCHEM J, V300, P643, DOI 10.1042/bj3000643; CHANG JY, 1993, FEBS LETT, V336, P53, DOI 10.1016/0014-5793(93)81607-2; CHATRENET B, 1993, J BIOL CHEM, V268, P20988; Creighton T E, 1986, Methods Enzymol, V131, P83; CREIGHTON TE, 1988, P NATL ACAD SCI USA, V85, P5082, DOI 10.1073/pnas.85.14.5082; CREIGHTON TE, 1984, METHOD ENZYMOL, V107, P305; CREIGHTON TE, 1984, J MOL BIOL, V179, P497, DOI 10.1016/0022-2836(84)90077-9; CREIGHTON TE, 1979, J MOL BIOL, V129, P411, DOI 10.1016/0022-2836(79)90504-7; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DILL KA, 1995, PROTEIN SCI, V4, P561; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3677, DOI 10.1021/bi00065a022; FERSHT AR, 1993, FEBS LETT, V325, P5, DOI 10.1016/0014-5793(93)81405-O; HABER E, 1962, J BIOL CHEM, V237, P1839; HOLLECKER M, 1983, J MOL BIOL, V168, P409, DOI 10.1016/S0022-2836(83)80026-6; HOURY WA, 1995, NAT STRUCT BIOL, V2, P495, DOI 10.1038/nsb0695-495; JAENICKE R, 1990, PROTEIN STRUCTURE PR, P191; JOHNSON RE, 1978, BIOCHEMISTRY-US, V17, P1479, DOI 10.1021/bi00601a019; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; KRESS LF, 1967, J BIOL CHEM, V242, P4925; KUWAJIMA K, 1990, BIOCHEMISTRY-US, V29, P8240, DOI 10.1021/bi00488a007; LEHLE K, 1994, J MOL BIOL, V239, P276, DOI 10.1006/jmbi.1994.1367; Lehle K, 1996, NAT BIOTECHNOL, V14, P476, DOI 10.1038/nbt0496-476; LI YJ, 1995, NAT STRUCT BIOL, V2, P489, DOI 10.1038/nsb0695-489; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MENDOZA JA, 1994, BIOCHEMISTRY-US, V33, P1143, DOI 10.1021/bi00171a013; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RICHARDS FM, 1991, SCI AM, P34; SARDANA M, 1991, J BIOL CHEM, V266, P13560; SCHERAGA HA, 1984, ADV BIOPHYS, V18, P21, DOI 10.1016/0065-227X(84)90005-4; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P27; SUN XJ, 1989, J BIOL CHEM, V264, P11288; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; VILLAFRANCA JE, 1983, SCIENCE, V222, P782, DOI 10.1126/science.6356360; WANKYNG L, 1968, BIOCHEM BIOPH RES CO, V31, P467; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; WELLS JA, 1986, J BIOL CHEM, V261, P6564; WETZEL R, 1987, TRENDS BIOCHEM SCI, V12, P478, DOI 10.1016/0968-0004(87)90234-9	46	59	61	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					69	75						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995229				2022-12-25	WOS:A1997WA56400016
J	Deng, LY; Anderson, JS				Deng, LY; Anderson, JS			Biosynthesis of teichuronic acid in the bacterial cell wall - Purification and characterization of the glucosyltransferase of Micrococcus luteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BOUND GLUCOSYLTRANSFERASE; GROUP-B STREPTOCOCCI; STAPHYLOCOCCUS-AUREUS; ESCHERICHIA-COLI; VIRULENCE FACTOR; GENE-CLUSTER; POLYSACCHARIDE; CAPSULE; IDENTIFICATION; PEPTIDOGLYCAN	This report describes what is, to our knowledge, the first purification to near homogeneity of an enzyme involved in the biosynthesis of the teichuronic acid of Micrococcus luteus cell walls. The glucosyltransferase of M, luteus, which participates in the biosynthesis of teichuronic acid, was solubilized from cytoplasmic membrane fragments by extraction with buffer solutions containing the detergents Thesit (dodecyl alcohol polyoxyethylene ether; 1 mg/ml) and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (0.5 mg/ml). The detergent-solubilized enzyme was purified 150-fold, with a recovery of 13% by adsorbent column chromatography, ion-exchange chromatography, gel filtration, and preparative nondenaturing gradient polyacrylamide gel electrophoresis. On the basis of its mobility on native gradient gel, the glucosyltransferase was estimated to have a molecular mass of 440 kDa. The purified native enzyme was a multisubunit protein consisting of subunits of two sizes; their molecular masses were determined to be 52.5 and 54 kDa, respectively, by observation of the mobility of the protein bands in sodium dodecyl sulfate-polyacrylamide gel electrophoresis, The isoelectric point of the enzyme was similar to 5.	UNIV MINNESOTA,COLL BIOL SCI,DEPT BIOCHEM,ST PAUL,MN 55108	University of Minnesota System; University of Minnesota Twin Cities				Deng, Lingyi Lynn/0000-0002-1906-8457	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI008295, R01AI008295] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-08295] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		COHEN JL, 1991, J BACTERIOL, V173, P4271, DOI 10.1128/JB.173.14.4271-4276.1991; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DOLPH PJ, 1988, J BACTERIOL, V170, P865, DOI 10.1128/jb.170.2.865-871.1988; DZANDU JK, 1984, P NATL ACAD SCI-BIOL, V81, P1733, DOI 10.1073/pnas.81.6.1733; GASSNER GT, 1990, J BACTERIOL, V172, P2273, DOI 10.1128/jb.172.5.2273-2279.1990; GLUCKSMANN MA, 1993, J BACTERIOL, V175, P7045, DOI 10.1128/jb.175.21.7045-7055.1993; HASE S, 1977, J BIOCHEM-TOKYO, V81, P1181; HASE S, 1972, J BIOCHEM, V72, P1117, DOI 10.1093/oxfordjournals.jbchem.a129999; HILDEBRANDT K M, 1988, P151; HILDEBRANDT KM, 1990, J BACTERIOL, V172, P5160, DOI 10.1128/jb.172.9.5160-5164.1990; HUBERMAN M, 1979, BIOCHIM BIOPHYS ACTA, V547, P230, DOI 10.1016/0005-2728(79)90006-9; JOHNSON GL, 1984, ARCH BIOCHEM BIOPHYS, V235, P679, DOI 10.1016/0003-9861(84)90244-3; JOHNSON SD, 1981, BIOCHEMISTRY-US, V20, P4781, DOI 10.1021/bi00519a039; KAO CC, 1991, J BACTERIOL, V173, P7841, DOI 10.1128/jb.173.24.7841-7847.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN WS, 1994, J BACTERIOL, V176, P7005, DOI 10.1128/JB.176.22.7005-7016.1994; MARTIN TR, 1992, J INFECT DIS, V165, P306, DOI 10.1093/infdis/165.2.306; MELAUGH W, 1992, J BIOL CHEM, V267, P13434; OSBORN MJ, 1962, P NATL ACAD SCI USA, V48, P1831, DOI 10.1073/pnas.48.10.1831; PAGE RL, 1972, J BIOL CHEM, V247, P2471; ROBBINS PW, 1967, SCIENCE, V158, P1536, DOI 10.1126/science.158.3808.1536; ROTHBLAT GH, 1964, BIOCHIM BIOPHYS ACTA, V84, P340, DOI 10.1016/0926-6542(64)90060-5; RUBENS CE, 1993, MOL MICROBIOL, V8, P843, DOI 10.1111/j.1365-2958.1993.tb01631.x; SAXENA IM, 1994, J BACTERIOL, V176, P5735, DOI 10.1128/JB.176.18.5735-5752.1994; SHIMAMURA A, 1994, J BACTERIOL, V176, P4845, DOI 10.1128/jb.176.16.4845-4850.1994; SHIRO H, 1994, J INFECT DIS, V169, P1042, DOI 10.1093/infdis/169.5.1042; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STARK NJ, 1977, J BIOL CHEM, V252, P3466; THERISOD H, 1986, P NATL ACAD SCI USA, V83, P7236, DOI 10.1073/pnas.83.19.7236; TRAXLER CI, 1982, J BACTERIOL, V150, P649, DOI 10.1128/JB.150.2.649-656.1982; WEISSBORN AC, 1991, J BIOL CHEM, V266, P8062; WESSELS MR, 1989, P NATL ACAD SCI USA, V86, P8983, DOI 10.1073/pnas.86.22.8983; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WESTON A, 1977, FEBS LETT, V76, P195, DOI 10.1016/0014-5793(77)80150-6	35	5	5	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					479	485						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995286				2022-12-25	WOS:A1997WA56400073
J	Gustafsson, CM; Myers, LC; Li, Y; Redd, MJ; Lui, M; ErdjumentBromage, H; Tempst, P; Kornberg, RD				Gustafsson, CM; Myers, LC; Li, Y; Redd, MJ; Lui, M; ErdjumentBromage, H; Tempst, P; Kornberg, RD			Identification of Rox3 as a component of mediator and RNA polymerase II holoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL REGULATOR; YEAST; GENES; SIN4; EXPRESSION; RGR1; PROTEIN	Yeast Rox3 protein, implicated by genetic evidence in both negative and positive transcriptional regulation, is identified as a mediator subunit by peptide sequence determination and is shown to copurify and co immunoprecipitate with RNA polymerase II holoenzyme.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOL BIOL, NEW YORK, NY 10021 USA	University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center	Gustafsson, CM (corresponding author), STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA.			Gustafsson, Claes/0000-0003-3531-8468	NCI NIH HHS [5 P30CA08748] Funding Source: Medline; NIGMS NIH HHS [GM36659, GM37049-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659, R01GM037049] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BROWN TA, 1995, J BACTERIOL, V177, P6836, DOI 10.1128/jb.177.23.6836-6843.1995; CARLSON M, 1984, GENETICS, V107, P19; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; Evangelista CC, 1996, GENETICS, V142, P1083; FASSLER JS, 1991, MOL GEN GENET, V230, P310, DOI 10.1007/BF00290682; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; JIANG YW, 1995, GENETICS, V140, P103; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JIANG YW, 1995, GENETICS, V140, P47; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LAZ TM, 1984, P NATL ACAD SCI-BIOL, V81, P4475, DOI 10.1073/pnas.81.14.4475; Li Y, 1996, METHOD ENZYMOL, V273, P172; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; NOGI Y, 1983, CURR GENET, V2, P115; PILLAR TM, 1991, CURR GENET, V20, P185, DOI 10.1007/BF00326230; ROSENBLUMVOS LS, 1991, MOL CELL BIOL, V11, P5639, DOI 10.1128/MCB.11.11.5639; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; Song WJ, 1996, MOL CELL BIOL, V16, P115; SUZUKI Y, 1988, MOL CELL BIOL, V8, P4991, DOI 10.1128/MCB.8.11.4991; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T	28	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					48	50						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995225				2022-12-25	WOS:A1997WA56400012
J	George, A; Bannon, L; Sabsay, B; Dillon, JW; Malone, J; Veis, A; Jenkins, NA; Gilbert, DJ; Copeland, NG				George, A; Bannon, L; Sabsay, B; Dillon, JW; Malone, J; Veis, A; Jenkins, NA; Gilbert, DJ; Copeland, NG			The carboxyl-terminal domain of phosphophoryn contains unique extended triplet amino acid repeat sequences forming ordered carboxyl-phosphate interaction ridges that may be essential in the biomineralization process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE DENTIN PHOSPHOPHORYN; RAT INCISOR DENTIN; IMPERFECTA TYPE-II; PHOSPHOPROTEIN; LOCALIZATION; PROTEINS; LOCUS; GENE; ORGANIZATION; INDUCTION	Phosphophoryns (PPs), a family of Asp and Ser(P)-rich dentin proteins, are considered to be archetypal regulators of several aspects of extracellular matrix (ECM) biomineralization. We have cloned a rat incisor PP gene, Dmp2, from our odontoblast cDNA library and localized it to mouse chromosome 5q21 within 2 centimorgans of Dmp1, another tooth-specific ECM protein. The carboxyl-terminal region of Dmp2 protein (60 residue % Ser, 31 residue % Asp) is divided into two domains, one with unique repetitive blocks of [DSS](n,3 less than or equal to 14), the other with [SD](m = 2,3). Conformational analysis shows the phosphorylated form of the [DS*S*](n) repeats to have a unique structure with well defined ridges of phosphates and carboxyls available for counter ion binding. The [S*D](m) domains have different phosphate and carboxylate interaction edges and thus different calcium ion and apatite surface binding properties. These two domains and the colocalization of Dmp1 and Dmp2 genes at a position equivalent to the dentinogenesis imperfecta type II location on human 4q21 all suggest that the PPs are indeed involved in some aspect of ECM mineralization.	NORTHWESTERN UNIV,CHICAGO,IL 60611; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,NIH,FREDERICK,MD 21702	Northwestern University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				GEORGE, ANNE/0000-0002-9008-7642	NIDCR NIH HHS [DE 01374, DE 07201] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE001374] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALPIN HM, 1995, GENOMICS, V30, P347; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BESSEY OA, 1946, J BIOL CHEM, V164, P321; BUTLER WT, 1993, ARCH BIOCHEM BIOPHYS, V225, P178; Chang SR, 1996, CALCIFIED TISSUE INT, V59, P149, DOI 10.1007/s002239900101; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CROSBY AH, 1995, AM J HUM GENET, V57, P832; CROSBY AH, 1995, GENOMICS, V27, P155, DOI 10.1006/geno.1995.1018; CROSSLEY MA, 1996, J DENT RES, V75, P154; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DIMUZIO MT, 1978, CALC TISS RES, V25, P169, DOI 10.1007/BF02010765; Falini G, 1996, SCIENCE, V271, P67, DOI 10.1126/science.271.5245.67; FUREDIMILHOFER H, 1994, CONNECT TISSUE RES, V30, P251, DOI 10.3109/03008209409015041; GEORGE A, 1994, J HISTOCHEM CYTOCHEM, V42, P1527, DOI 10.1177/42.12.7983353; GEORGE A, 1993, J BIOL CHEM, V268, P12624; GOOLD RD, 1993, HUM MOL GENET, V2, P1271, DOI 10.1093/hmg/2.8.1271; Green EL, 1981, GENETICS PROBABILITY, P77; HEUER AH, 1992, SCIENCE, V255, P1098, DOI 10.1126/science.1546311; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; LINDE A, 1989, CALCIFIED TISSUE INT, V44, P286, DOI 10.1007/BF02553763; Lowenstam HA, 1989, BIOMINERALIZATION; MACDOUGALL M, 1992, BIOCHEM J, V287, P651, DOI 10.1042/bj2870651; MACDOUGALL M, 1992, AM J HUM GENET, V50, P190; Rabie AM, 1995, CONNECT TISSUE RES, V31, P197, DOI 10.3109/03008209509010811; RAHIMA M, 1988, CALCIFIED TISSUE INT, V42, P104, DOI 10.1007/BF02556342; RAHIMA M, 1988, J HISTOCHEM CYTOCHEM, V36, P153, DOI 10.1177/36.2.3335773; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; STETLERSTEVENSON WG, 1986, CALCIFIED TISSUE INT, V38, P135, DOI 10.1007/BF02556873; STETLERSTEVENSON WG, 1983, BIOCHEMISTRY-US, V22, P4326, DOI 10.1021/bi00287a025; TRAUB W, 1992, MATRIX, V12, P197, DOI 10.1016/S0934-8832(11)80062-4; Veis A., 1982, BIOMINERALIZATION BI, P273	32	169	178	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32869	32873		10.1074/jbc.271.51.32869	http://dx.doi.org/10.1074/jbc.271.51.32869			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955126				2022-12-25	WOS:A1996VZ37300061
J	Kagoshima, H; Akamatsu, Y; Ito, Y; Shigesada, K				Kagoshima, H; Akamatsu, Y; Ito, Y; Shigesada, K			Functional dissection of the alpha and beta subunits of transcription factor PEBP2 and the redox susceptibility of its DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; NUCLEAR FACTOR; RUNT DOMAIN; POLYOMAVIRUS ENHANCER; VIRUS ENHANCERS; GENE; PROTEIN; AML1; EXPRESSION	The mouse transcription factor PEEPS is a heterodimer of two subunits: a DNA binding subunit alpha and its partner subunit beta. The alpha subunit shares a region of high homology, termed the Punt domain, with the products of the Drosophila melanogaster segmentation gene runt and the human acute myeloid leukemia-related gene AML1. To study the molecular basis for the DNA binding and heterodimerization functions of this factor, we constructed series of deletions of the alpha and beta subunits and examined their activities by electrophoretic mobility shift and affinity column assays. The minimal functional region of the alpha subunit for DNA binding and dimerization was shown to coincide with the Punt domain. On the other hand, the region of the beta subunit required for heterodimerization was localized to the N-terminal 135 amino acids. Furthermore, it was found that the DNA binding activity of the Punt domain is regulated by a reduction/oxidization (redox) mechanism and that its reductively activated state, which is extremely labile, is stabilized by the beta subunit. These findings add a new layer to the mechanism and significance of the regulatory interplay between the two subunits of PEBP2.	KYOTO UNIV,BIOCHEM LAB,DEPT MOL BIOL & GENET,SAKYO KU,KYOTO 606,JAPAN; KYOTO UNIV,LAB CELL REGULAT,DEPT VIRAL ONCOL,INST VIRUS RES,KYOTO 606,JAPAN	Kyoto University; Kyoto University								ABATE C, 1990, CELL GROWTH DIFFER, V1, P455; AKAMATSU Y, 1996, IN PRESS GENE AMST; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; Golling G, 1996, MOL CELL BIOL, V16, P932; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; LEIDEN JM, 1992, IMMUNOL TODAY, V13, P22, DOI 10.1016/0167-5699(92)90200-Q; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NG L, 1993, NUCLEIC ACIDS RES, V21, P5831, DOI 10.1093/nar/21.25.5831; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; OKUNO H, 1993, ONCOGENE, V8, P695; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SATAKE M, 1988, ONCOGENE, V3, P69; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEKI S, 1991, J BIOL CHEM, V266, P20797; SHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735; SNYDER GH, 1981, BIOCHEMISTRY-US, V20, P6509, DOI 10.1021/bi00526a001; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	46	85	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33074	33082		10.1074/jbc.271.51.33074	http://dx.doi.org/10.1074/jbc.271.51.33074			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955155	hybrid			2022-12-25	WOS:A1996VZ37300090
J	Kubler, E; Dohlman, HG; Lisanti, MP				Kubler, E; Dohlman, HG; Lisanti, MP			Identification of triton X-100 insoluble membrane domains in the yeast Saccharomyces cerevisiae - Lipid requirements for targeting of heterotrimeric G-protein subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; CAVEOLAE MEMBRANE; PLASMA-MEMBRANE; LINKED PROTEIN; GAMMA-SUBUNIT; CELL-SURFACE; ASSOCIATION; INTERNALIZATION; REDISTRIBUTION; PURIFICATION	Low density Triton X-100 insoluble (LDTI) membrane domains are found in most mammalian cell types. Previous biochemical and immunolocalization studies have revealed the presence of G-protein coupled receptors and heterotrimeric G-protein subunits (G(alpha) and G(beta gamma) subunits) within these structures, implicating mammalian LDTI membrane domains in G-protein coupled signaling. Here, we present biochemical evidence that similar LDTI structures exist in a genetically tractable organism, the yeast Saccharomyces cerevisiae. Yeast LDTI membranes were purified based on the known biochemical properties of mammalian LDTI membranes: (i) their Triton X-100 insolubility; and (ii) their discrete buoyant density in sucrose gradients. As with purified mammalian LDTI membranes, these yeast LDTI membranes harbor the subunits of the heterotrimeric G-proteins (G(alpha) and G(beta gamma) subunits). Other plasma membrane marker proteins (the plasma membrane H+-ATPase and a GPI-linked protein Gas1p) are preferentially excluded from these purified fractions. Mutational and genetic analyses were performed to define the requirements for the targeting of G-protein subunits to these yeast membrane domains, We find that the targeting of G(alpha) is independent of myristoylation, whereas targeting of G(gamma) requires prenylation. Perhaps surprisingly, the targeting of G(beta) to this membrane domain did not require coexpression of G(gamma). It should now be possible to dissect the function of LDTI membrane domains using yeast as a model genetic system.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06520 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Yale University			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; CLARK KL, 1993, MOL CELL BIOL, V13, P1; DOHLMAN HG, 1993, P NATL ACAD SCI USA, V90, P9688, DOI 10.1073/pnas.90.20.9688; GOLDBERG RI, 1987, J CELL PHYSIOL, V133, P203, DOI 10.1002/jcp.1041330202; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; KURJAN J, 1992, ANNU REV BIOCHEM, V61, P1097; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MONTESANO R, 1982, NATURE, V296, P651, DOI 10.1038/296651a0; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHENOYSCARIA AM, 1994, J CELL BIOL, V126, P353, DOI 10.1083/jcb.126.2.353; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song JP, 1996, J BIOL CHEM, V271, P20273, DOI 10.1074/jbc.271.34.20273; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; TRAVIS J, 1993, SCIENCE, V262, P1208, DOI 10.1126/science.8235646; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635	36	81	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32975	32980		10.1074/jbc.271.51.32975	http://dx.doi.org/10.1074/jbc.271.51.32975			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955141	hybrid			2022-12-25	WOS:A1996VZ37300076
J	Soloviev, MM; Brierley, MJ; Shao, ZY; Mellor, IR; Volkova, TM; Kamboj, R; Ishimaru, H; Sudan, H; Harris, J; Foldes, RL; Grishin, EV; Usherwood, PNR; Barnard, EA				Soloviev, MM; Brierley, MJ; Shao, ZY; Mellor, IR; Volkova, TM; Kamboj, R; Ishimaru, H; Sudan, H; Harris, J; Foldes, RL; Grishin, EV; Usherwood, PNR; Barnard, EA			Functional expression of a recombinant unitary glutamate receptor from Xenopus, which contains N-methyl-D-aspartate (NMDA) and non-NMDA receptor subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; PROTEIN-KINASE-C; SPLICE VARIANTS; BINDING; ANTAGONISTS; CHANNEL; SEQUENCE; CLONING; POLYAMINES; NEURONS	A cDNA encoding a 100-kDa subunit (XenNR1) of the N-methyl D-aspartate (NMDA) glutamate receptor type has been cloned from Xenopus central nervous system, When XenNR1 is coexpressed in a mammalian cell line with a recently cloned 51-kDa non NMDA receptor subunit (XenU1), also from Xenopus, it forms a functional unitary receptor exhibiting the pharmacological properties characteristic of both NMDA and non-NMDA receptors, Firstly, XenU1 can replace NR2 subunits, in complementing XenNR1 to introduce the ligand binding properties of a complete NMDA receptor, Second, responses to both NMDA and non-NMDA receptor agonists and antagonists were obtained in patch-clamp recordings from the cotransfected cells, but no significant responses were recorded when the cells were singly transfected, Third, from solubilized cell membranes from the cotransfected cells, an antibody to the NR1 subunit coprecipitated the binding sites of the non-NMDA receptor subunit, The unitary glutamate receptor has a unique set of properties that denote intersubunit interaction, including a glycine requirement for the responses to non-NMDA as well as to NMDA receptor agonists and voltage-dependent block by Mg2+ of the non-NMDA agonist responses.	ROYAL FREE HOSP,SCH MED,MOL NEUROBIOL UNIT,LONDON NW3 2PF,ENGLAND; UNIV NOTTINGHAM,DEPT LIFE SCI,NOTTINGHAM NG7 2RD,ENGLAND; ALLELIX BIOPHARMACEUT INC,MISSISSAUGA,ON L4V 1V7,CANADA; ASAHI CHEM IND CO LTD,FUJI,SHIZUOKA,JAPAN; SHEMYAKIN & OVCHINNIKOV INST BIORGAN CHEM,MOSCOW 117871,RUSSIA	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Nottingham; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences				Mellor, Ian/0000-0002-8332-5155; Harris, John/0000-0001-7815-5385; Soloviev, Mikhail/0000-0002-3235-1134	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRACKLEY PTH, 1993, J PHARMACOL EXP THER, V265, P910; CIK M, 1993, BIOCHEM J, V296, P877, DOI 10.1042/bj2960877; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; FOLDES RL, 1993, GENE, V131, P293, DOI 10.1016/0378-1119(93)90309-Q; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GRIMWOOD S, 1995, J NEUROCHEM, V64, P525; HENLEY JM, 1989, J NEUROCHEM, V52, P31, DOI 10.1111/j.1471-4159.1989.tb10894.x; HENLEY JM, 1992, P NATL ACAD SCI USA, V89, P4806, DOI 10.1073/pnas.89.11.4806; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOO KH, 1994, RECEPTOR CHANNEL, V2, P327; ISHIMARU H, 1996, RECEPTOR CHANNEL, V4, P33; KERRY CJ, 1993, MOL PHARMACOL, V44, P142; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LYNCH DR, 1994, MOL PHARMACOL, V45, P540; MARIN P, 1993, NEUROPHARMACOLOGY, V32, P29, DOI 10.1016/0028-3908(93)90126-N; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MERY PF, 1992, PFLUG ARCH EUR J PHY, V420, P529, DOI 10.1007/BF00374629; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; SEEBURG PH, 1993, TRENDS PHARMACOL SCI, V14, P297, DOI 10.1016/0165-6147(93)90047-N; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SIGEL E, 1984, J BIOL CHEM, V259, P7219; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VLACHOVA V, 1987, J PHYSIOL-LONDON, V386, P425, DOI 10.1113/jphysiol.1987.sp016542; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WONG LA, 1993, MOL PHARMACOL, V44, P504	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32572	32579		10.1074/jbc.271.51.32572	http://dx.doi.org/10.1074/jbc.271.51.32572			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955083	hybrid			2022-12-25	WOS:A1996VZ37300018
J	Oka, K; Kobayashi, K; Sullivan, M; Martinez, J; Teng, BB; IshimuraOka, K; Chan, L				Oka, K; Kobayashi, K; Sullivan, M; Martinez, J; Teng, BB; IshimuraOka, K; Chan, L			Tissue-specific inhibition of apolipoprotein B mRNA editing in the liver by adenovirus-mediated transfer of a dominant negative mutant APOBEC-1 leads to increased low density lipoprotein in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; MOLECULAR-CLONING; CATALYTIC SUBUNIT; PROTEIN; GENE; ENZYME; MUTAGENESIS; EXPRESSION; EVOLUTION; FACTOR(S)	APOBEC-1 is a catalytic subunit of an apolipoprotein B (apoB) mRNA editing enzyme complex. In humans it is expressed only in the intestine, whereas in mice it is expressed in both the Liver and intestine. APOBEC-1 exists as a spontaneous homodimer (Lau, P. P., Zhu, H. -J., Baldini, A., Charnsangavej, C., and Chan, L. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 8522-8526). We tested the editing activity and dimerization potential of three different mouse APOBEC-1 mutants using in vitro editing activity assay and immunoprecipitation in the presence of epitope-tagged APOBEC-1. One catalytically inactive mutant, mu1 (H61K/C93S/C96S), that retains its capacity to dimerize with wild-type APOBEC-1 was found to inhibit the editing activity of the latter and was thus a dominant negative mutant. Two other inactive mutants that dimerized poorly with APOBEC-1 failed to inhibit its activity. Intravenous injection of a mu1 adenovirus, Admu1, in C57BL/6J mice in vivo resulted in liver-specific expression of mu1 mRNA. On days 4 and 9 after virus injection, endogenous hepatic apoB mRNA editing was 23.3 +/- 5.0 and 36.8 +/- 5.7%, respectively, compared with 65.3 +/- 11 and 71.3 +/- 5.2%, respectively, for luciferase adenovirus-treated animals. Plasma apoB-100 accounted for 95 and 93% of total plasma apoB in Admu1 animals on days 4 and 9, respectively, compared with 78 and 72% in luciferase adenovirus animals. Plasma cholesterol on day 9 was 98 +/- 17 mg/dl in the mu1-treated animals, substantially higher than phosphate-buffered saline-treated (57 +/- 9 mg/dl) or luciferase-treated (71 +/- 12 mg/dl) controls. Fast protein liquid chromatography analysis of mouse plasma showed that the intermediate density/low density lipoprotein fractions in the animals treated with the dominant negative mutant adenovirus were much higher than those in controls. We conclude that active APOBEC-1 functions as a dimer and its activity is inhibited by a dominant negative mutant. Furthermore, apoB mRNA editing determines the availability of apoB-100, which in turn limits the amount of intermediate density/low density lipoprotein that can be formed in mice. Liver-specific inhibition of apoB mRNA editing is an important component of any strategy to enhance the value of mice as a model for human lipoprotein metabolism.	BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030; ARS,CHILDRENS NUTR RES CTR,USDA,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; United States Department of Agriculture (USDA)	Oka, K (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Kobayashi, Kunihisa/V-9554-2019	Kobayashi, Kunihisa/0000-0002-7741-846X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056668] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56668, HL51586] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; CHAN L, 1995, SCI MED, V2, P68; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chien KR, 1996, J CLIN INVEST, V97, P901, DOI 10.1172/JCI118512; COLE TG, 1988, BIOCOMMUNIQUE, V4, P4; DRISCOLL DM, 1994, J BIOL CHEM, V269, P19843; Gerard RD, 1996, CURR OPIN LIPIDOL, V7, P105, DOI 10.1097/00041433-199604000-00010; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HADJIAGAPIOU C, 1994, NUCLEIC ACIDS RES, V22, P1874, DOI 10.1093/nar/22.10.1874; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hirano K, 1996, J BIOL CHEM, V271, P9887, DOI 10.1074/jbc.271.17.9887; Kobayashi K, 1996, J BIOL CHEM, V271, P6852, DOI 10.1074/jbc.271.12.6852; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Morrison JR, 1996, P NATL ACAD SCI USA, V93, P7154, DOI 10.1073/pnas.93.14.7154; Nakamuta M, 1996, J BIOL CHEM, V271, P25981, DOI 10.1074/jbc.271.42.25981; NAKAMUTA M, 1995, J BIOL CHEM, V270, P13042, DOI 10.1074/jbc.270.22.13042; Paigen Beverly, 1994, Current Opinion in Lipidology, V5, P258, DOI 10.1097/00041433-199408000-00003; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; TENG BB, 1992, J BIOL CHEM, V267, P21265; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725	24	35	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1456	1460		10.1074/jbc.272.3.1456	http://dx.doi.org/10.1074/jbc.272.3.1456			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999814	hybrid			2022-12-25	WOS:A1997WD05800012
J	Phoenix, P; Raymond, MA; Masse, E; Drolet, M				Phoenix, P; Raymond, MA; Masse, E; Drolet, M			Roles of DNA topoisomerases in the regulation of R-loop formation in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RNA-POLYMERASE; SUPERHELICAL TURNS; GYRASE INHIBITORS; PLASMID DNA; I MUTANTS; TRANSCRIPTION; TEMPLATE; REGIONS; DOMAINS	We have recently found that stable R-loop formation occurs in vivo and in vitro when a portion of the Escherichia coli rrnB operon is transcribed preferentially in its physiological orientation. Our results also suggested that the formation of such structures was more frequent in topA mutants and was sensitive to the template DNA supercoiling level. In the present report we investigated in greater detail the involvement of DNA topoisomerases in this process. By using an in vitro transcription system with phage RNA polymerases, we found that hypernegative supercoiling of plasmid DNAs in the presence of DNA gyrase is totally abolished by RNase H, suggesting that extensive R-looping occurs during transcription in the presence of DNA gyrase. When RNase A is present, significant hypernegative supercoiling occurs only when the 567-base pair rrnB HindIII fragment is transcribed in its physiological orientation. This result suggests that more stable R-loops are being produced in this orientation. Our results also suggest that DNA gyrase can participate in the process of R-loop elongation. The strong transcription-induced relaxing activity of E. coli DNA topoisomerase I is shown to efficiently counteract the effect of DNA gyrase and thus inhibit extensive R-looping. In addition, we found that an R-looped plasmid DNA is a better substrate for relaxation by E. coli DNA topoisomerase I as compared with a non-R-looped substrate.	UNIV MONTREAL,DEPT MICROBIOL & IMMUNOL,MONTREAL,PQ H3C 3J7,CANADA	Universite de Montreal			Drolet, Marc/M-1328-2019					CHAMPOUX JJ, 1975, BIOCHEMISTRY-US, V14, P307, DOI 10.1021/bi00673a017; DRLICA K, 1992, MOL MICROBIOL, V6, P425, DOI 10.1111/j.1365-2958.1992.tb01486.x; DROLET M, 1995, P NATL ACAD SCI USA, V92, P3526, DOI 10.1073/pnas.92.8.3526; DROLET M, 1994, J BIOL CHEM, V269, P2068; Drolet M, 1994, Adv Pharmacol, V29A, P135; FLEISCHMANN G, 1984, P NATL ACAD SCI-BIOL, V81, P6958, DOI 10.1073/pnas.81.22.6958; FRANCO RJ, 1989, J BACTERIOL, V171, P6573, DOI 10.1128/jb.171.12.6573-6579.1989; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GILMOUR DS, 1986, CELL, V44, P401, DOI 10.1016/0092-8674(86)90461-7; KIRKEGAARD K, 1985, J MOL BIOL, V185, P625, DOI 10.1016/0022-2836(85)90075-0; KROEGER PE, 1992, BIOCHEMISTRY-US, V31, P2492, DOI 10.1021/bi00124a008; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; Menzel R, 1994, Adv Pharmacol, V29A, P39; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Nitiss J L, 1994, Adv Pharmacol, V29A, P103; PARADA CA, 1989, J BIOL CHEM, V264, P15120; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; RICHARDSON JP, 1975, J MOL BIOL, V98, P565, DOI 10.1016/S0022-2836(75)80087-8; ROSE KM, 1988, CHROMOSOMA, V96, P411, DOI 10.1007/BF00303034; Sambrook J., 2002, MOL CLONING LAB MANU; SINDEN RR, 1981, P NATL ACAD SCI-BIOL, V78, P224, DOI 10.1073/pnas.78.1.224; STEWART AF, 1990, CELL, V60, P141; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; WANG JC, 1974, J MOL BIOL, V87, P797, DOI 10.1016/0022-2836(74)90085-0; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; ZHANG H, 1988, P NATL ACAD SCI USA, V85, P1060, DOI 10.1073/pnas.85.4.1060	31	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1473	1479		10.1074/jbc.272.3.1473	http://dx.doi.org/10.1074/jbc.272.3.1473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999816	hybrid			2022-12-25	WOS:A1997WD05800014
J	Farazi, T; Leichman, J; Harris, T; Cahoon, M; Hedstrom, L				Farazi, T; Leichman, J; Harris, T; Cahoon, M; Hedstrom, L			Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5'-monophosphate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSINE 5'-MONOPHOSPHATE DEHYDROGENASE; HUMAN IMP DEHYDROGENASE; TRITRICHOMONAS-FETUS; ESCHERICHIA-COLI; GENE; CELLS; AMPLIFICATION; CLONING; PURIFICATION; SEQUENCE	Mycophenolic acid (MPA) is a potent and specific inhibitor of mammalian inosine-monophosphate dehydrogenases (IMPDH); most microbial IMPDHs are not sensitive to MPA. MPA-resistant mutants of human IMPDH type II were isolated in order to identify the structural features that determine the species selectivity of MPA, Three mutant IMPDHs were identified with decreased affinity for MPA. The mutation of Gln(277) --> Arg causes a 9-fold increase in the K-i of MPA, a 5-6 fold increase in the K-m values for IMP and NAD, and a 3-fold decrease in k(cat) relative to wild type, The mutation of Ala(462) --> Thr causes a 3-fold increase in the K-i for MPA, a 2.5-fold increase in the K-m for NAD, and a 1.5 fold increase in k(cat). The combination of these two mutations does not increase the K-i for MPA, but does increase the K-m for NAD 3-fold relative to Q277R and restores k(cat) to wild type levels, Q277R/A462T is the first human IMPDH mutant with increased K-i for MPA and wild type activity. The third mutant IMPDH contains two mutations, Phe(465) --> Ser and Asp(470) --> Gly. K-i for MPA is increased 3-fold in this mutant enzyme, and K-m for IMP is also increased 3-fold, while the K-m for NAD and k(cat) are unchanged, Thus increases in the K-i for MPA do not correlate with changes in K-m for either IMP or NAD, nor to changes in k(cat). All four of these mutations are in regions of the IMPDH that differ in mammalian and microbial enzymes, and thus can be structural determinants of MPA selectivity.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University								ALLISON AC, 1993, ANN NY ACAD SCI, V696, P63; AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; ANTONINO LC, 1994, BIOCHEMISTRY-US, V33, P1753, DOI 10.1021/bi00173a018; BECK JT, 1994, EXP PARASITOL, V78, P101, DOI 10.1006/expr.1994.1010; CARR SF, 1993, J BIOL CHEM, V268, P27286; COHEN MB, 1987, SOMAT CELL MOLEC GEN, V13, P627, DOI 10.1007/BF01534483; COLLART FR, 1992, CANCER RES, V52, P5826; COLLART FR, 1988, J BIOL CHEM, V263, P15769; COLLART FR, 1987, MOL CELL BIOL, V7, P3328, DOI 10.1128/MCB.7.9.3328; DECLERCQ E, 1993, ADV VIRUS RES, V42, P1, DOI 10.1016/S0065-3527(08)60082-2; Fleming MA, 1996, BIOCHEMISTRY-US, V35, P6990, DOI 10.1021/bi9607416; Franklin TJ, 1996, CANCER RES, V56, P984; FRANKLIN TJ, 1969, BIOCHEM J, V113, P515, DOI 10.1042/bj1130515; GLESNE DA, 1994, BIOCHEM BIOPH RES CO, V205, P537, DOI 10.1006/bbrc.1994.2698; GRECO WR, 1979, J BIOL CHEM, V254, P2104; HAGER PW, 1995, BIOCHEM PHARMACOL, V49, P1323, DOI 10.1016/0006-2952(95)00026-V; HEDSTROM L, 1990, BIOCHEM PHARMACOL, V39, P151, DOI 10.1016/0006-2952(90)90659-9; HEDSTROM L, 1992, SCIENCE, V255, P1249, DOI 10.1126/science.1546324; HEDSTROM L, 1990, BIOCHEMISTRY-US, V29, P849, DOI 10.1021/bi00456a001; HUETEPEREZ JA, 1995, BIOCHEMISTRY-US, V34, P13889, DOI 10.1021/bi00042a021; HUPE DJ, 1986, J BIOL CHEM, V261, P8363; IKEGAMI T, 1987, LIFE SCI, V40, P2277, DOI 10.1016/0024-3205(87)90064-6; KANZAKI N, 1990, NUCLEIC ACIDS RES, V18, P6710, DOI 10.1093/nar/18.22.6710; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIGHTFOOT T, 1994, BBA-GENE STRUCT EXPR, V1217, P156, DOI 10.1016/0167-4781(94)90029-9; Link JO, 1996, J AM CHEM SOC, V118, P2091, DOI 10.1021/ja9534056; MORRISON JF, 1969, BIOCHIM BIOPHYS ACTA, V185, P269, DOI 10.1016/0005-2744(69)90420-3; NAGAI M, 1992, CANCER RES, V52, P258; NATSUMEDA Y, 1990, J BIOL CHEM, V265, P5292; NIJKAMP HJJ, 1967, BIOCHIM BIOPHYS ACTA, V145, P31, DOI 10.1016/0005-2787(67)90651-X; ROBINS RK, 1982, NUCLEOS NUCLEOT, V1, P35, DOI 10.1080/07328318208079400; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHEIDEL LM, 1991, VIROLOGY, V181, P490, DOI 10.1016/0042-6822(91)90881-B; Sintchak MD, 1996, CELL, V85, P921, DOI 10.1016/S0092-8674(00)81275-1; TIEDEMAN AA, 1985, NUCLEIC ACIDS RES, V13, P1303, DOI 10.1093/nar/13.4.1303; ULLMAN B, 1983, J BIOL CHEM, V258, P523; VERHAM R, 1987, MOL BIOCHEM PARASIT, V24, P1, DOI 10.1016/0166-6851(87)90110-1; Wang W, 1996, BIOCHEMISTRY-US, V35, P95, DOI 10.1021/bi951499q; WEBER G, 1983, CANCER RES, V43, P3466; WILSON K, 1991, J BIOL CHEM, V266, P1665; WILSON K, 1994, J BIOL CHEM, V269, P28979; Wu John C., 1994, Perspectives in Drug Discovery and Design, V2, P185, DOI 10.1007/BF02171743; WU TW, 1973, CAN J BIOCHEM CELL B, V51, P1391, DOI 10.1139/o73-182; ZIMMERMANN AG, 1995, J BIOL CHEM, V270, P6808, DOI 10.1074/jbc.270.12.6808	44	42	45	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					961	965		10.1074/jbc.272.2.961	http://dx.doi.org/10.1074/jbc.272.2.961			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995388	hybrid			2022-12-25	WOS:A1997WC04800039
J	Bulens, F; Merchiers, P; IbanezTallon, I; DeVriese, A; Nelles, L; Claessens, F; Belayew, A; Collen, D				Bulens, F; Merchiers, P; IbanezTallon, I; DeVriese, A; Nelles, L; Claessens, F; Belayew, A; Collen, D			Identification of a multihormone responsive enhancer far upstream from the human tissue-type plasminogen activator gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; HORMONE-RECEPTOR SUPERFAMILY; DNA-BINDING SPECIFICITY; RETINOIC ACID; GLUCOCORTICOID RECEPTOR; TRANSCRIPTIONAL SYNERGISM; STRUCTURAL DETERMINANTS; REGULATORY ELEMENTS; FUNCTIONAL-ANALYSIS; STEROID-RECEPTORS	A 2.4-kilobase (kb) DNA fragment, located 7.1 kb up-stream from the human tissue-type plasminogen activator (t-PA) gene (t-PA2.4), acts as an enhancer which is activated by glucocorticoids, progesterone, androgens, and mineralocorticoids. Transient expression of t-PA-chloramphenicol acetyltransferase reporter constructs in HT1080 human fibrosarcoma cells identified a glucocorticoid responsive unit with four functional binding sites for the glucocorticoid receptor, located between bp -7,501 and -7,974. The region from bp -7,145 to -9,578 (t-PA2.4) was found to confer a cooperative induction by dexamethasone and all-trans-retinoic acid (RA) to its homologous and a heterologous promoter, irrespective of its orientation. The minimal enhancer, defined by progressive deletion analysis, comprised the region from -7.1 to -8.0 kb (t-PA0.9) and encompassed the glucocorticoid responsive unit and the previously identified RA-responsive element located at -7.3 kb (Bulens, F., Ibanez-Tallon, I., Van Acker, P., De Vriese, A., Nelles, L., Belayew, A., and Collen, D. (1995) J. Biol. Chem. 270, 7167-7175). The amplitude of the synergistic response to dexamethasone and RA increased by reducing the distance between the enhancer and the proximal t-PA promoter. The synergistic interaction was also observed between the aldosterone and the RA receptors. It is postulated that the t-PA0.9 enhancer might play a role in the hormonal regulation of the expression of human t-PA in vivo.	CATHOLIC UNIV LEUVEN,CTR MOL & VASC BIOL,B-3000 LOUVAIN,BELGIUM	KU Leuven			BELAYEW, Alexandra/D-5205-2013; Claessens, Frank/M-8565-2016	BELAYEW, Alexandra/0000-0001-5115-2424; Claessens, Frank/0000-0002-8676-7709				ARCHER TK, 1995, J STEROID BIOCHEM, V53, P421, DOI 10.1016/0960-0760(95)00088-H; AUDOUINCHEVALLIER I, 1995, J STEROID BIOCHEM, V52, P321, DOI 10.1016/0960-0760(94)00184-N; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BELCH JJF, 1986, Q J MED, V58, P19; BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1; BULENS F, 1995, J BIOL CHEM, V270, P7167, DOI 10.1074/jbc.270.13.7167; BULENS F, 1992, J CARDIOVASC PHARM, V19, P508, DOI 10.1097/00005344-199204000-00006; BULENS F, 1992, FIBRINOLYSIS, V6, P243, DOI 10.1016/0268-9499(92)90077-U; BULENS F, 1991, EUR J BIOCHEM, V195, P235, DOI 10.1111/j.1432-1033.1991.tb15699.x; CARMELIET P, 1995, THROMB HAEMOSTASIS, V74, P429; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLAESSENS F, 1993, BIOCHEM BIOPH RES CO, V191, P688, DOI 10.1006/bbrc.1993.1272; COLLEN D, 1991, BLOOD, V78, P3114; COLLEN D, 1988, CIRCULATION, V77, P731, DOI 10.1161/01.CIR.77.4.731; DEY A, 1994, MOL CELL BIOL, V14, P8191, DOI 10.1128/MCB.14.12.8191; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; HENDERSON BR, 1992, FEBS LETT, V809, P130; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; JIA XC, 1990, MOL CELL ENDOCRINOL, V68, P143; KITABAYASHI I, 1992, EMBO J, V11, P167, DOI 10.1002/j.1460-2075.1992.tb05039.x; KOOISTRA T, 1991, THROMB HAEMOSTASIS, V65, P565; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MEDCALF RL, 1990, J BIOL CHEM, V265, P14618; MYAUCHI A, 1995, ENDOCR J, V42, P57; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; RELLA C, 1993, THROMB RES, V69, P209, DOI 10.1016/0049-3848(93)90046-Q; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; THEURING F, 1995, FIBRINOLYSIS, V9, P277, DOI 10.1016/S0268-9499(95)80016-6; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THOMPSON EA, 1991, EUR J BIOCHEM, V201, P627, DOI 10.1111/j.1432-1033.1991.tb16323.x; TRUSS M, 1992, J STEROID BIOCHEM, V43, P365, DOI 10.1016/0960-0760(92)90071-P; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; VANBENNEKUM AM, 1993, AM J PHYSIOL, V264, pR931, DOI 10.1152/ajpregu.1993.264.5.R931; VANGIEZEN JJJ, 1994, BLOOD COAGUL FIBRIN, V5, P249, DOI 10.1097/00001721-199404000-00015; WAN YJY, 1994, LAB INVEST, V70, P547; WANG C, 1989, ENDOCRINOLOGY, V124, P1595, DOI 10.1210/endo-124-4-1595; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	47	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					663	671						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995310				2022-12-25	WOS:A1997WA56400097
J	Hennecke, J; Spleiss, C; Glockshuber, R				Hennecke, J; Spleiss, C; Glockshuber, R			Influence of acidic residues and the kink in the active-site helix on the properties of the disulfide oxidoreductase DsbA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOND FORMATION INVIVO; FORMATION IN-VIVO; ESCHERICHIA-COLI; CYSTEINE RESIDUES; PHENOTYPIC SELECTION; EFFICIENT CATALYSIS; CRYSTAL-STRUCTURE; REDOX PROPERTIES; ISOMERASE DSBA; THIOREDOXIN	The catalytic disulfide bond Cys(30)-Cys(33) of the disulfide oxidoreductase DsbA from Escherichia coli is located at the amino terminus of an alpha-helix, which has a kink caused by insertion of a tripeptide (residues 38-40). The oxidative force of DsbA (E'(0) = -125 mV) mainly results from the low pK(a) of 3.4 of its Cys(30) thiol. To investigate the role of the kink and the electrostatic contribution of Glu(37) and Glu(38) to the redox properties of DsbA, we have characterized a series of DsbA variants (Delta 38-40, Delta 38-40/H41P, E37Q, E38Q, and E37Q/E38Q). In contrast to theoretical predictions, the redox potentials of the variants are almost unchanged, and the pK(a) values of Cys(30) do not differ by more than 0.5 units from that of DsbA wild type. All variants show the same in vivo activity and dependence of redox potential on ionic strength as the wild type. The mutations have no influence on the polypeptide specificity of the protein, which is independent of the isoelectric point of the polypeptide substrate and most pronounced at acidic pH. We conclude that neither the kink. in the active-site helix nor Glu(37) and Glu(38) are critical for the physical properties of DsbA.	ETH HONGGERBERG,INST MOL BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DARBY NJ, 1995, BIOCHEMISTRY-US, V34, P3576, DOI 10.1021/bi00011a012; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Frech C, 1996, EMBO J, V15, P392, DOI 10.1002/j.1460-2075.1996.tb00369.x; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GRIFFEY RH, 1985, BIOCHEMISTRY-US, V24, P817, DOI 10.1021/bi00325a001; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIN TY, 1989, BIOCHEMISTRY-US, V28, P5282, DOI 10.1021/bi00438a054; MARKWARDT F, 1967, H-S Z PHYSIOL CHEM, V348, P1381, DOI 10.1515/bchm2.1967.348.1.1381; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; OTTO A, 1991, EUR J BIOCHEM, V202, P67, DOI 10.1111/j.1432-1033.1991.tb16345.x; Pace C N, 1986, Methods Enzymol, V131, P266; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PRESCOTT LM, 1990, MICROBIOLOGY, P122; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; ROST N, 1964, NATURE, V201, P185; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SANCHO J, 1992, BIOCHEMISTRY-US, V31, P2253, DOI 10.1021/bi00123a006; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SERRANO L, 1989, NATURE, V342, P296, DOI 10.1038/342296a0; SZAJEWSKI RP, 1980, J AM CHEM SOC, V102, P2011, DOI 10.1021/ja00526a042; TANFORD C, 1956, J AM CHEM SOC, V78, P5287, DOI 10.1021/ja01601a036; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALTER S, 1995, J MOL BIOL, V252, P133, DOI 10.1006/jmbi.1995.0480; Warwicker J, 1996, FEBS LETT, V385, P105, DOI 10.1016/0014-5793(96)00358-4; Weichsel A, 1996, STRUCTURE, V4, P735, DOI 10.1016/S0969-2126(96)00079-2; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; WUNDERLICH M, 1993, BIOCHEMISTRY-US, V32, P12251, DOI 10.1021/bi00096a039; WUNDERLICH M, 1995, J MOL BIOL, V247, P28, DOI 10.1006/jmbi.1995.0119; XIA TH, 1992, PROTEIN SCI, V1, P310; XIA TH, 1991, J MOL BIOL, V221, P1311; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P5202, DOI 10.1021/bi00183a025; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; ZAPUN A, 1994, BIOCHEMISTRY-US, V33, P1907, DOI 10.1021/bi00173a038	51	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					189	195						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995246				2022-12-25	WOS:A1997WA56400033
J	Huang, CC; Casey, PJ; Fierke, CA				Huang, CC; Casey, PJ; Fierke, CA			Evidence for a catalytic role of zinc in protein farnesyltransferase - Spectroscopy of Co2+-farnesyltransferase indicates metal coordination of the substrate thiolate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS FARNESYLATION; INHIBITORS; COBALT; COMPLEXES; BINDING; REPAIR; PROBE; ADA	Protein farnesyltransferase (FTase) is a zinc metalloenzyme that catalyzes the addition of a farnesyl isoprenoid to a conserved cysteine in peptide or protein substrates. We have substituted the essential Zn2+ in FTase with Co2+ to investigate the function of the metal polyhedron using optical absorption spectroscopy. The catalytic activity of FTase is unchanged by the substitution of cobalt for zinc, The absorption spectrum of Co2+. FTase displays a thiolate-Co2+ charge transfer band (epsilon(320) = 1030 M(-1) cm(-1)) consistent with the coordination of one cysteine side chain and also ligand field bands (epsilon(560) = 140 M(-1) cm(-1)) indicative of a pentacoordinate or distorted tetrahedral metal geometry. Most importantly, the ligand-metal charge transfer band displays an increased intensity (epsilon(320) = 1830 M(-1) cm(-1)) in the ternary complex of FTase isoprenoid peptide substrate indicative of the formation of a second Co2+-thiolate bond as cobalt coordinates the thiolate of the peptide substrate. A similar increase in the ligand-metal charge transfer band in a product complex indicates that the sulfur atom of the farnesylated peptide also coordinates the metal. Transient kinetics demonstrate that thiolate cobalt metal coordination also occurs in an active FTase . FPP . peptide substrate complex and that the rate constant for the chemical step is 17 s(-1). These data provide evidence that the zinc ion plays an important catalytic role in FTase, most likely by activation of the cysteine thiol of the protein substrate for nucleophilic attack on the isoprenoid.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MOL CANC BIOL, DURHAM, NC 27710 USA	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040602, R01GM040602, R01GM046372] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40602, GM46372] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertini I, 1984, Adv Inorg Biochem, V6, P71; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Cassidy PB, 1996, J AM CHEM SOC, V118, P8761, DOI 10.1021/ja961214c; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; CORWIN DT, 1987, INORG CHEM, V26, P3079, DOI 10.1021/ic00266a001; CORWIN DT, 1988, INORG CHIM A-BIOINOR, V151, P5, DOI 10.1016/S0020-1693(00)83473-8; DANCHIN A, 1973, J BIOL CHEM, V248, P3241; DAWSON RMC, 1986, DATA BIOCH RES, P404; DOLENCE JM, 1995, P NATL ACAD SCI USA, V92, P5008, DOI 10.1073/pnas.92.11.5008; ELDER RC, 1978, INORG CHEM, V17, P1296, DOI 10.1021/ic50183a039; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; Fu HW, 1996, J BIOL CHEM, V271, P28541, DOI 10.1074/jbc.271.45.28541; FURFINE ES, 1995, BIOCHEMISTRY-US, V34, P6857, DOI 10.1021/bi00020a032; GARCIA AM, 1993, J BIOL CHEM, V268, P18415; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Gonzalez JC, 1996, BIOCHEMISTRY-US, V35, P12228, DOI 10.1021/bi9615452; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; LINDOY LF, 1974, INORG CHEM, V13, P2494, DOI 10.1021/ic50140a037; MANNE V, 1995, DRUG DEVELOP RES, V34, P121, DOI 10.1002/ddr.430340205; MARET W, 1993, METHOD ENZYMOL, V226, P52; MAY SW, 1978, BIOCHEMISTRY-US, V17, P3333, DOI 10.1021/bi00609a025; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Myers L C, 1994, Chem Biol, V1, P91, DOI 10.1016/1074-5521(94)90046-9; MYERS LC, 1993, SCIENCE, V261, P1164, DOI 10.1126/science.8395079; MYERS LC, 1995, J AM CHEM SOC, V117, P10749, DOI 10.1021/ja00148a020; PODLAHA J, 1973, COLLECT CZECH CHEM C, V38, P1730, DOI 10.1135/cccc19731730; RAJANIKANTH B, 1984, INDIAN J CHEM B, V23, P1043; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SALGADO J, 1995, EUR J BIOCHEM, V231, P358, DOI 10.1111/j.1432-1033.1995.tb20708.x; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SHI YG, 1993, BIOPHYS J, V64, P749, DOI 10.1016/S0006-3495(93)81435-8; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; WILKER JJ, 1995, J AM CHEM SOC, V117, P8682, DOI 10.1021/ja00138a031; Zhang FL, 1996, BIOCHEMISTRY-US, V35, P8166, DOI 10.1021/bi960574+; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	38	138	142	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					20	23						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995218				2022-12-25	WOS:A1997WA56400005
J	Ling, BN; Zuckerman, JB; Lin, CM; Harte, BJ; McNulty, KA; Smith, PR; Gomez, LM; Worrell, RT; Eaton, DC; Kleyman, TR				Ling, BN; Zuckerman, JB; Lin, CM; Harte, BJ; McNulty, KA; Smith, PR; Gomez, LM; Worrell, RT; Eaton, DC; Kleyman, TR			Expression of the cystic fibrosis phenotype in a renal amphibian epithelial cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PROTEIN-KINASE-C; NA+ CHANNELS; SODIUM-CHANNELS; CHLORIDE CHANNELS; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGININE-VASOPRESSIN; AIRWAY EPITHELIA; CFTR; A6	Mutations in a Cl- channel (cystic fibrosis transmembrane conductance regulator or CFTR) are responsible for the cystic fibrosis (CF) phenotype, Increased Na+ transport rates are observed in CF airway epithelium, and recent studies suggest that this is due to an increase in Na+ channel open probability (P-o), The Xenopus renal epithelial cell line, A6, expresses both cAMP-activated 8-picosiemen (pS) Cl- channels and amiloride-sensitive 4-pS Na+ channels, and provides a model system for examining the interactions of CFTR and epithelial Na+ channels, A6 cells express CFTR mRNA, as demonstrated by reverse transcriptase-polymerase chain reaction and partial sequence analysis, A phosphorothioate antisense oligonucleotide, complementary to the 5' end of the open reading frame of Xenopus CFTR, was used to inhibit functional expression of CFTR in A6 cells, Parallel studies utilized the corresponding sense oligonucleotide as a control, CFTR protein expression was markedly reduced in cells incubated with the antisense oligonucleotide. Incubation of A6 cells with the antisense oligonucleotide led to inhibition of forskolin-activated amiloride-insensitive short circuit current (I-sc), After a 30-min exposure to 10 mu M forskolin, 8-pS Cl- channel activity was detected in only 1 of 31 (3%) cell-attached patches on cells treated with antisense oligonucleotide, compared to 5 of 19 (26%) patches from control cells, A shift in the single-channel current-voltage relationship derived from antisense-treated cells was also consistent with a reduction in Cl- reabsorption, Both amiloride-sensitive I-sc and Na+ channel P-o were significantly increased in antisense-treated, forskolin-stimulated A6 cells, when compared with forskolin-stimulated controls, These data suggest that the regulation of Na+ channels by CFTR is not limited to respiratory epithelia and to epithelial cells in culture overexpressing CFTR and epithelial Na+ channels.	DEPT VET AFFAIRS,MED CTR,PHILADELPHIA,PA 19104; DEPT VET AFFAIRS MED CTR,ATLANTA,GA 30322; EMORY UNIV,DIV RENAL,ATLANTA,GA 30322; EMORY UNIV,DEPT MED,ATLANTA,GA 30322; EMORY UNIV,DEPT PHYSIOL,ATLANTA,GA 30322; EMORY UNIV,CTR CELL & MOL SIGNALING,ATLANTA,GA 30322; UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; ALLEGHENY UNIV HLTH SCI,DEPT PHYSIOL,PHILADELPHIA,PA 19129	Emory University; Emory University; Emory University; Emory University; University of Pennsylvania; University of Pennsylvania; Drexel University			Zuckerman, Jonathan/AAU-1857-2020	Eaton, Douglas/0000-0002-2686-6692; Zuckerman, Jonathan/0000-0002-8190-9210	NIDDK NIH HHS [P30-DK47757, K08-DK02111, R01-DK37963] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963, K08DK002111, P30DK047757] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; Bao H.-F., 1996, FASEB Journal, V10, pA137; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BOUCHER RC, 1991, ADV EXP MED BIOL, V290, P105; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; CHALFANT ML, 1993, AM J PHYSIOL, V264, pC1480, DOI 10.1152/ajpcell.1993.264.6.C1480; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colquhoun D, 1983, SINGLE CHANNEL RECOR, P191; CoupayeGerard B, 1996, AM J PHYSIOL-CELL PH, V271, pC1639, DOI 10.1152/ajpcell.1996.271.5.C1639; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; DISSER J, 1991, ADV EXP MED BIOL, V290, P133; DUSZYK M, 1989, CAN J PHYSIOL PHARM, V67, P1362, DOI 10.1139/y89-217; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; Gallego MS, 1996, AM J PHYSIOL-RENAL, V271, pF451, DOI 10.1152/ajprenal.1996.271.2.F451; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; JOHNSON LG, 1995, J CLIN INVEST, V95, P1377, DOI 10.1172/JCI117789; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; KEMENDY AE, 1992, AM J PHYSIOL, V263, pC825, DOI 10.1152/ajpcell.1992.263.4.C825; KLEYMAN TR, 1994, AM J PHYSIOL, V266, pF506, DOI 10.1152/ajprenal.1994.266.3.F506; KOKKO KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1414, DOI 10.1152/ajpcell.1994.267.5.C1414; KOPELMAN H, 1993, J CLIN INVEST, V91, P1253, DOI 10.1172/JCI116289; KRAUSS RD, 1992, AM J PHYSIOL, V263, pC1147; LING BN, 1994, J CLIN INVEST, V93, P829, DOI 10.1172/JCI117037; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LING BN, 1992, J CLIN INVEST, V90, P1328, DOI 10.1172/JCI115998; MA H, 1996, J AM SOC NEPHROL, V9, P1284; Ma HP, 1996, AM J PHYSIOL-RENAL, V270, pF798, DOI 10.1152/ajprenal.1996.270.5.F798; MARUNAKA Y, 1990, AM J PHYSIOL, V258, pC352, DOI 10.1152/ajpcell.1990.258.2.C352; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLANGER LE, 1994, KIDNEY INT, V45, P1070, DOI 10.1038/ki.1994.143; Schreiber M, 1996, KIDNEY INT, V49, P82, DOI 10.1038/ki.1996.11; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tucker Stephen J., 1992, Human Molecular Genetics, V1, P77, DOI 10.1093/hmg/1.2.77; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785	50	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					594	600						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995302				2022-12-25	WOS:A1997WA56400089
J	Kurumizaka, H; Aihara, H; Ikawa, S; Kashima, T; Bazemore, LR; Kawasaki, K; Sarai, A; Radding, CM; Shibata, T				Kurumizaka, H; Aihara, H; Ikawa, S; Kashima, T; Bazemore, LR; Kawasaki, K; Sarai, A; Radding, CM; Shibata, T			A possible role of the C-terminal domain of the RecA protein - A gateway model for double-stranded DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSED CIRCULAR DNA; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; SUPERHELICAL DNA; MEIOTIC CELLS; D-LOOPS; COMPLEXES; EXCHANGE	According to the crystal structure, the RecA protein has a domain near the C terminus consisting of amino acid residues 270-328 (from the N terminus). Our model building pointed out the possibility that this domain is a part of ''gateway'' through which double-stranded DNA finds a path for direct contact with single-stranded DNA within a presynaptic RecA filament in the search for homology. To test this possible function of the domain, we made mutant RecA proteins by site-directed single (or double, in one case) replacement of 2 conserved basic amino acid residues and 5 among 9 nonconserved basic amino acid residues in the domain. Replacement of either of the 2 conserved amino acid residues caused deficiencies in repair of W-damaged DNA, an in vivo function of RecA protein, whereas the replacement of most (except one) of the tested nonconserved ones gave little or no effect. Purified mutant RecA proteins showed no (or only slight) deficiencies in the formation of presynaptic filaments as assessed by various assays. However, presynaptic filaments of both proteins that had replacement of a conserved amino acid residue had significant defects in binding to and pairing with duplex DNA (secondary binding). These results are consistent with our model that the conserved amino acid residues in the C-terminal domain have a direct role in double-stranded DNA binding and that they constitute a part of a gateway for homologous recognition.	RIKEN,INST PHYS & CHEM RES,CELLULAR & MOL BIOL LAB,WAKO,SAITAMA 35101,JAPAN; SAITAMA UNIV,GRAD SCH SCI & ENGN,URAWA,SAITAMA 338,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT BIOPHYS & BIOCHEM,TOKYO 113,JAPAN; YALE UNIV,SCH MED,DEPT GENET & MOL BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,GENE BANK,TSUKUBA,IBARAKI 305,JAPAN	RIKEN; Saitama University; University of Tokyo; Yale University; RIKEN				Kurumizaka, Hitoshi/0000-0001-7412-3722	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033504] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM33504] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI N, 1992, J BIOL CHEM, V267, P3514; BEATTIE KL, 1977, J MOL BIOL, V116, P783, DOI 10.1016/0022-2836(77)90271-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYANT FR, 1985, P NATL ACAD SCI USA, V82, P297, DOI 10.1073/pnas.82.2.297; CHOW SA, 1985, P NATL ACAD SCI USA, V82, P5646, DOI 10.1073/pnas.82.17.5646; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DASGUPTA C, 1981, CELL, V25, P507, DOI 10.1016/0092-8674(81)90069-6; DICAPUA E, 1989, BIOCHEMISTRY-US, V28, P3287, DOI 10.1021/bi00434a025; DYKSTRA CC, 1990, J BIOL CHEM, V265, P10968; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; GARDNER RV, 1995, EUR J BIOCHEM, V233, P419, DOI 10.1111/j.1432-1033.1995.419_2.x; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; IKAWA S, 1989, J BIOL CHEM, V264, P21167; IKEDA M, 1992, J BIOL CHEM, V267, P6291; JAIN SK, 1995, J BIOL CHEM, V270, P4943, DOI 10.1074/jbc.270.9.4943; KAHN R, 1984, J BIOL CHEM, V259, P7495; KAWASHIMA H, 1984, MOL GEN GENET, V193, P288, DOI 10.1007/BF00330682; KOLODNER R, 1987, P NATL ACAD SCI USA, V84, P5560, DOI 10.1073/pnas.84.16.5560; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURUMIZAKA H, 1994, J BIOL CHEM, V269, P3068; KURUMIZAKA H, 1994, NUCLEIC ACIDS RES, V22, P3387, DOI 10.1093/nar/22.16.3387; LIU SK, 1993, J BACTERIOL, V175, P6518, DOI 10.1128/jb.175.20.6518-6529.1993; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUISIDELUCA C, 1995, J BACTERIOL, V177, P566, DOI 10.1128/jb.177.3.566-572.1995; MAKINO O, 1985, J BIOL CHEM, V260, P5402; MALKOV VV, 1995, J BIOL CHEM, V270, P30230; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; MENETSKI JP, 1990, J MOL BIOL, V211, P845, DOI 10.1016/0022-2836(90)90078-Z; MOORE SP, 1990, J BIOL CHEM, V265, P11108; Morimatsu K, 1995, EUR J BIOCHEM, V234, P695, DOI 10.1111/j.1432-1033.1995.695_a.x; MULLER B, 1991, J MOL BIOL, V221, P131, DOI 10.1016/0022-2836(91)90810-S; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; OGAWA T, 1979, COLD SPRING HARB SYM, V43, P909, DOI 10.1101/SQB.1979.043.01.099; RAO BJ, 1993, J MOL BIOL, V229, P328, DOI 10.1006/jmbi.1993.1038; RAO BJ, 1993, P NATL ACAD SCI USA, V90, P6646, DOI 10.1073/pnas.90.14.6646; Rehrauer WM, 1996, J BIOL CHEM, V271, P11996, DOI 10.1074/jbc.271.20.11996; ROBERTS JW, 1979, COLD SPRING HARB SYM, V43, P917, DOI 10.1101/SQB.1979.043.01.100; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; SANDER M, 1991, P NATL ACAD SCI USA, V88, P6780, DOI 10.1073/pnas.88.15.6780; SHIBATA T, 1984, COLD SPRING HARB SYM, V49, P541, DOI 10.1101/SQB.1984.049.01.061; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P5100, DOI 10.1073/pnas.76.10.5100; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHIBATA T, 1982, J BIOL CHEM, V257, P3981; SHIBATA T, 1980, P NATL ACAD SCI-BIOL, V77, P2606, DOI 10.1073/pnas.77.5.2606; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; STASIAK A, 1984, COLD SPRING HARB SYM, V49, P561, DOI 10.1101/SQB.1984.049.01.063; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUGINO A, 1988, P NATL ACAD SCI USA, V85, P3683, DOI 10.1073/pnas.85.11.3683; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; Voloshin ON, 1996, SCIENCE, V272, P868, DOI 10.1126/science.272.5263.868; WEINSTOCK GM, 1979, P NATL ACAD SCI USA, V76, P126, DOI 10.1073/pnas.76.1.126; WITTUNG P, 1994, J BIOL CHEM, V269, P5799; YU X, 1992, J MOL BIOL, V227, P334, DOI 10.1016/0022-2836(92)90702-L	59	66	67	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33515	33524		10.1074/jbc.271.52.33515	http://dx.doi.org/10.1074/jbc.271.52.33515			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969216	hybrid			2022-12-25	WOS:A1996WA71300050
J	Tompa, P; Baki, A; Schad, E; Friedrich, P				Tompa, P; Baki, A; Schad, E; Friedrich, P			The Calpain cascade - mu-Calpain activates m-Calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEASE; SUBUNIT AUTOLYSIS; PROTEINS; MUSCLE; PURIFICATION; INVOLVEMENT; SENSITIVITY; CALPASTATIN; CA-2+; IONS	m-Calpain, which usually requires near-millimolar Ca2+ for activation, undergoes autolysis at 25 mu M Ca2+ in the presence of mu-calpain, m-Calpain in itself exhibits no sign of autolysis around this Ca2+ concentration. Half-maximal rate of the reaction occurs at 30 mu M Ca2+, showing that it is mu-calpain that catalyzes the limited proteolysis of m-calpain in an intermolecular reaction (''heterolysis''). This heterolytic step is accompanied by the activation of m-calpain: mu- and m-calpain preincubated together at 25 mu M Ca2+ show significantly higher activity than the sum of activities of mu- and m-calpains preincubated separately, m-Calpain is sensitized to Ca2+ by mu-calpain-mediated activation: the half-maximal value of 160 mu M for activation is lowered to 64 mu M, which is similar to the shift found in m-calpain autoactivation. We suggest that these in vitro observations are relevant in vivo and the calpain cascade may play an important role in coordinating the functioning of calpains in living cells.	HUNGARIAN ACAD SCI,BIOL RES CTR,INST ENZYMOL,H-1518 BUDAPEST,HUNGARY	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences								Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; BROWN N, 1993, FEBS LETT, V322, P65, DOI 10.1016/0014-5793(93)81112-D; CONG JY, 1989, J BIOL CHEM, V264, P10096; COOLICAN SA, 1986, J BIOL CHEM, V261, P4170; COOLICAN SA, 1984, J BIOL CHEM, V259, P1627; DEMARTINO GN, 1986, J BIOL CHEM, V261, P2047; INOMATA M, 1988, J BIOL CHEM, V263, P19783; INOMATA M, 1995, BBA-BIOMEMBRANES, V1235, P107, DOI 10.1016/0005-2736(94)00326-K; INOMATA M, 1986, BIOCHEM BIOPH RES CO, V138, P638, DOI 10.1016/S0006-291X(86)80544-7; INOMATA M, 1983, J BIOCHEM-TOKYO, V93, P291, DOI 10.1093/oxfordjournals.jbchem.a134166; KARLSSON JO, 1985, BIOCHEM J, V231, P201, DOI 10.1042/bj2310201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MELLGREN RL, 1994, BIOCHEM BIOPH RES CO, V204, P544, DOI 10.1006/bbrc.1994.2493; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MURACHI T, 1981, BIOCHEM INT, V2, P651; PINTER M, 1992, BIOCHEMISTRY-US, V31, P8201, DOI 10.1021/bi00150a012; PONTREMOLI S, 1988, P NATL ACAD SCI USA, V85, P1740, DOI 10.1073/pnas.85.6.1740; RICE RH, 1971, J BIOL CHEM, V246, P831; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SAIDO TC, 1994, FEBS LETT, V346, P263, DOI 10.1016/0014-5793(94)00487-0; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P275, DOI 10.1093/oxfordjournals.jbchem.a133463; Suzuki K., 1990, INTRACELLULAR CALCIU, P25; TOMPA P, 1995, ANAL BIOCHEM, V228, P287, DOI 10.1006/abio.1995.1352; YOSHIMURA N, 1983, J BIOL CHEM, V258, P8883	29	49	49	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33161	33164		10.1074/jbc.271.52.33161	http://dx.doi.org/10.1074/jbc.271.52.33161			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969168	hybrid			2022-12-25	WOS:A1996WA71300002
J	Ahmed, H; Pohl, J; Fink, NE; Strobel, F; Vasta, GR				Ahmed, H; Pohl, J; Fink, NE; Strobel, F; Vasta, GR			The primary structure and carbohydrate specificity of a beta-galactosyl-binding lectin from toad (Bufo arenarum Hensel) ovary reveal closer similarities to the mammalian galectin-1 than to the galectin from the clawed frog Xenopus laevis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; TUNICATE DIDEMNUM-CANDIDUM; BOVINE HEART-MUSCLE; FULL-LENGTH CDNA; S-TYPE LECTINS; PHYSICOCHEMICAL CHARACTERIZATION; SECONDARY-STRUCTURE; COMBINING SITE; ANIMAL LECTINS; PROTEIN	The detailed characterization of a galectin from the toad (Bufo arenarum Hensel) ovary in its primary structure, carbohydrate specificity, and overall biochemical properties has provided novel information pertaining to structural and evolutionary aspects of the galectin family. The lectin consists of identical single-chain polypeptide subunits composed of 134 amino acids (calculated mass, 14,797 daltons), and its N-terminal residue, alanine, is N-acetylated. When compared to the sequences of known galectins, the B. arenarum galectin exhibited the highest identity (48% for the whole molecule and 77% for the carbohydrate recognition domain (CRD)) with the bovine spleen galectin-1, but surprisingly less identity (38% for the whole molecule and 47% for the CRD) with a galectin from Xenopus laevis skin (Marschal, P., Herrmann, J., Leffler, H., Barondes, S. H., and Cooper, D. N. W. (1992) J. Biol. Chem. 267, 12942-12949). Unlike the X. laevis galectin, the binding activity of the B. arenarum galectin for N-acetyllactosamine, the human blood group A tetrasaccharide and Gal beta 1,3GalNAc relative to lactose, was in agreement with that observed for the galectin-1 subgroup and those galectins having ''conserved'' (type I) CRDs (Ahmed, H., and Vasta, G. R. (1994) Glycobiology 4, 545-549). Moreover, the toad galectin shares three of the six cysteine residues that are conserved in all mammalian galectins-1, but not in the galectins from X. laevis, fish, and invertebrates described so far. Based on the homologies of the B. arenarum galectin with the bovine spleen galectin-1 and X. laevis skin galectin, it should be concluded that within the galectin family the correlation between conservation of primary structure and phylogenetic distances among the source species may not be a direct one as proposed elsewhere (Hirabayashi, J., and Kasai, K. (1993) Glycobiology 3, 297-304). Furthermore, galectins with conserved (type I) CRDs, represented by the B. arenarum ovary galectin, and those with ''variable'' (type II) CRDs, represented by the X. laevis 16-kDa galectin, clearly constitute distinct subgroups in the extant amphibian taxa and may have diverged early in the evolution of chordate lineages.	UNIV MARYLAND, CTR MARINE BIOTECHNOL, INST BIOTECHNOL, BALTIMORE, MD 21202 USA; EMORY UNIV, WINSHIP CANC CTR, MICROCHEM FAC, ATLANTA, GA 30322 USA; EMORY UNIV, DEPT CHEM, ATLANTA, GA 30322 USA	University System of Maryland; University of Maryland Baltimore; Emory University; Emory University								ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; AHMED H, 1992, Journal of Molecular Recognition, V5, P1, DOI 10.1002/jmr.300050102; Ahmed H, 1996, J BIOCHEM, V120, P1007; AHMED H, 1994, ANN NY ACAD SCI, V712, P315, DOI 10.1111/j.1749-6632.1994.tb33581.x; AHMED H, 1994, GLYCOBIOLOGY, V4, P545, DOI 10.1093/glycob/4.5.545; ALLEN HJ, 1990, J CELL BIOCHEM, V43, P43, DOI 10.1002/jcb.240430105; ALLEN HJ, 1992, COMP BIOCHEM PHYS B, V103, P313, DOI 10.1016/0305-0491(92)90297-5; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; Colnot C, 1996, BIOCHEM SOC T, V24, P141, DOI 10.1042/bst0240141; DECABUTTI NEF, 1987, FEBS LETT, V223, P330, DOI 10.1016/0014-5793(87)80314-9; ELOLA MT, 1987, BRAZ J MED BIOL RES, V20, P749; Fontana A, 1986, PRACTICAL PROTEIN CH, P67; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; Hirabayashi J, 1996, J BIOL CHEM, V271, P2497, DOI 10.1074/jbc.271.5.2497; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; HIRABAYASHI J, 1989, BIOCHIM BIOPHYS ACTA, V1008, P85, DOI 10.1016/0167-4781(89)90173-5; HUFLEJT ME, 1993, J BIOL CHEM, V268, P26712; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEVI G, 1981, J BIOL CHEM, V256, P5735; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MARSCHAL P, 1994, GLYCOBIOLOGY, V4, P297, DOI 10.1093/glycob/4.3.297; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; MILOS NC, 1990, ANAT EMBRYOL, V182, P319, DOI 10.1007/BF02433492; MURAMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1116, P129, DOI 10.1016/0304-4165(92)90109-8; NISHIHARA T, 1986, BIOCHEMISTRY-US, V25, P6013, DOI 10.1021/bi00368a027; ODA Y, 1993, J BIOL CHEM, V268, P5929; OZEKI Y, 1991, BIOCHEM BIOPH RES CO, V178, P407, DOI 10.1016/0006-291X(91)91828-Z; PAROUTAUD P, 1987, P NATL ACAD SCI USA, V84, P6345, DOI 10.1073/pnas.84.18.6345; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Pohl J, 1994, Methods Mol Biol, V36, P107; ROBERSON MM, 1980, P NATL ACAD SCI-BIOL, V77, P3460, DOI 10.1073/pnas.77.6.3460; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SAKAKIBARA F, 1979, CANCER RES, V39, P1347; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SHET MS, 1989, BIOCHIM BIOPHYS ACTA, V991, P465, DOI 10.1016/0304-4165(89)90074-3; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TRACEY BM, 1992, J BIOL CHEM, V267, P10342; VASTA GR, 1986, J BIOL CHEM, V261, P9174; VASTA GR, 1986, J BIOL CHEM, V261, P9182; WELLNER D, 1990, P NATL ACAD SCI USA, V87, P1947, DOI 10.1073/pnas.87.5.1947; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G	57	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33083	33094		10.1074/jbc.271.51.33083	http://dx.doi.org/10.1074/jbc.271.51.33083			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955156	hybrid			2022-12-25	WOS:A1996VZ37300091
J	Diouri, M; KeyvaniAmineh, H; Geoghegan, KF; Weber, JM				Diouri, M; KeyvaniAmineh, H; Geoghegan, KF; Weber, JM			Cleavage efficiency by adenovirus protease is site-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 PROTEINASE; SEQUENCE; PEPTIDE; ACTIVATION; CELLS; HEXON; DNA; VI	The adenovirus protease cleaves consensus sequences (M/I/L)XGX-G and (M/I/L)XGG-X. Using purified recombinant protease, we showed that a peptide bearing the GX-G site was hydrolyzed more rapidly than a peptide bearing the GG-X site, The GX-G site was also preferentially cleaved on viral protein pVI which bears both sites of cleavage. Evidence is presented that suggests a biological role for this differential cleavage efficiency.	UNIV SHERBROOKE,FAC MED,DEPT MICROBIOL,SHERBROOKE,PQ J1H 5N4,CANADA; PFIZER INC,DIV CENT RES,DEPT MOL SCI,GROTON,CT 06340	University of Sherbrooke; Pfizer				Keyvani, Hossein/0000-0002-6528-7861				CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; Chiocca S, 1996, J VIROL, V70, P2939, DOI 10.1128/JVI.70.5.2939-2949.1996; CHROBOCZEK J, 1992, VIROLOGY, V186, P280, DOI 10.1016/0042-6822(92)90082-Z; COTTEN M, 1995, VIROLOGY, V213, P494, DOI 10.1006/viro.1995.0022; DAVISON AJ, 1993, J MOL BIOL, V234, P1308, DOI 10.1006/jmbi.1993.1687; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; Diouri M, 1996, VIROLOGY, V224, P510, DOI 10.1006/viro.1996.0557; DIOURI M, 1995, PROTEIN PEPTIDE LETT, V6, P363; FREIMUTH P, 1993, VIROLOGY, V193, P348, DOI 10.1006/viro.1993.1131; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; HOUDE A, 1990, GENE, V88, P269, DOI 10.1016/0378-1119(90)90042-P; KEYVANIAMINEH H, 1995, J BIOL CHEM, V270, P23250, DOI 10.1074/jbc.270.40.23250; KEYVANIAMINEH H, 1995, VIRUS RES, V37, P87, DOI 10.1016/0168-1702(95)00018-L; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; MATTHEWS DA, 1995, J GEN VIROL, V76, P1959, DOI 10.1099/0022-1317-76-8-1959; MATTHEWS DA, 1994, J GEN VIROL, V75, P3365, DOI 10.1099/0022-1317-75-12-3365; McGrath WJ, 1996, VIROLOGY, V217, P131, DOI 10.1006/viro.1996.0100; RANCOURT C, 1995, VIROLOGY, V209, P167, DOI 10.1006/viro.1995.1240; SONG BW, 1995, GENE, V152, P279, DOI 10.1016/0378-1119(94)00657-E; SUDHANSHU V, 1996, VIROLOGY, V220, P186; TIHANYI K, 1993, J BIOL CHEM, V268, P1780; TREMBLAY ML, 1983, BIOCHIM BIOPHYS ACTA, V743, P239, DOI 10.1016/0167-4838(83)90220-0; Weber J M, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P227; WEBER JM, 1994, J GEN VIROL, V75, P141, DOI 10.1099/0022-1317-75-1-141; WEBSTER A, 1994, J VIROL, V68, P7292, DOI 10.1128/JVI.68.11.7292-7300.1994; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; WEBSTER A, 1989, J GEN VIROL, V70, P3215, DOI 10.1099/0022-1317-70-12-3215	27	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32511	32514		10.1074/jbc.271.51.32511	http://dx.doi.org/10.1074/jbc.271.51.32511			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955073	hybrid			2022-12-25	WOS:A1996VZ37300008
J	Garlatti, M; Aggerbeck, M; Bouguet, J; Barouki, R				Garlatti, M; Aggerbeck, M; Bouguet, J; Barouki, R			Contribution of a nuclear factor 1 binding site to the glucocorticoid regulation of the cytosolic aspartate aminotransferase gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; TRANSCRIPTION FACTORS; FACTOR-I; DNA-BINDING; MMTV PROMOTER; HOUSEKEEPING GENE; MESSENGER-RNAS; RAT HEPATOMA; CELL-LINES	Two regions of the cAspAT gene promoter mediate the glucocorticoid regulation of this gene in the Fao hepatoma cell line, The proximal region was localized by deletion studies and stable transfections in the Fao cells to the sequence -553/-398, This region includes the glucocorticoid-responsive element (GRE) A sequence, which consists of two overlapping GREs and which can mediate the glucocorticoid regulation of a heterologous promoter, DNase I footprinting studies have shown that a site 80 base pairs upstream of the GRE A was protected by liver and brain nuclear extracts (site P-8). The binding was displaced by an excess of an oligonucleotide containing a typical NF1 binding site and by NF1-specific antibodies, In electrophoretic mobility shift assay using the P-8 oligonucleotide as a probe, several complexes were formed, Most complexes were common to liver and brain but were less abundant when testis extracts were used, At least one complex was specific to the liver, All complexes, with the exception of two, were competed for by the NF1 oligonucleotide. Furthermore, the sequence of the P-8 site showed a 7/9-base pair homology with a typical NF1 site, A mutation of the P-8 site, which prevents the binding of NF1-like proteins to it, considerably decreases the regulation of the cAspAT promoter fragment by glucocorticoids. Surprisingly, the basal activity of the mutant promoter was increased 2-fold, Thus, the regulation of the cAspAT gene promoter is mediated by a regulatory unit comprising the GRE A and a NF1-binding site.			Garlatti, M (corresponding author), HOP HENRI MONDOR,INSERM,U99,F-94010 CRETEIL,FRANCE.							AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; ANANIA FA, 1995, HEPATOLOGY, V21, P1640, DOI 10.1002/hep.1840210624; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAROUKI R, 1989, EUR J BIOCHEM, V186, P79, DOI 10.1111/j.1432-1033.1989.tb15180.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUGGEMEIER U, 1990, EMBO J, V9, P2233, DOI 10.1002/j.1460-2075.1990.tb07393.x; BUETTI E, 1989, NUCLEIC ACIDS RES, V17, P3065, DOI 10.1093/nar/17.8.3065; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; GARLATTI M, 1994, MOL CELL BIOL, V14, P8007, DOI 10.1128/MCB.14.12.8007; GARLATTI M, 1993, J BIOL CHEM, V268, P6567; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; HAYES JJ, 1992, BIOESSAYS, V14, P597, DOI 10.1002/bies.950140905; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PAVEPREUX M, 1988, J BIOL CHEM, V263, P17459; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; RIGAUD G, 1991, CELL, V67, P1; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8	41	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32629	32634		10.1074/jbc.271.51.32629	http://dx.doi.org/10.1074/jbc.271.51.32629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955092	hybrid			2022-12-25	WOS:A1996VZ37300027
J	Gilday, D; Gannon, M; Yutzey, K; Bader, D; Rifkind, AB				Gilday, D; Gannon, M; Yutzey, K; Bader, D; Rifkind, AB			Molecular cloning and expression of two novel avian cytochrome p450 1A enzymes induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO LIVER; STENOTOMUS-CHRYSOPS; HYDROCARBON; IDENTIFICATION; PURIFICATION; HYDROXYLASE; SEQUENCE; MUTATION; GENES; SCUP	Transcriptional regulation by the aryl hydrocarbon receptor, for which the environmental toxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is the most potent ligand, leads in mammalian liver to the induction of genes for two distinct cytochrome P450 (CYP)1A enzymes, CYP1A1 and -1A2, Fish seem to have only one CYP1A enzyme. CYP1A enzymes have been regarded as injurious largely because of their ability to activate chemical carcinogens, We report here the cloning and sequencing of cDNAs for two catalytically distinct TCDD-induced CYP enzymes in chick embryo liver. One mediates classic CYP1A1 activities. The other has some -1A2 like activities and is also responsible for TCDD-induced arachidonic acid epoxygenation, a much more conspicuous effect in liver of chicks than of mammalian species. Amino acid sequence analysis shows that although each chick enzyme can be classified in the CYP1A family, both are more like CYP1A1 than -1A2, and neither can be said to be directly orthologous to CYP1A1 or -1A2. Phylogenetic analysis shows that the two chick enzymes form a separate branch in the CYP1A family tree distinct from mammalian CYP1A1 and -1A2 and from fish CYP1A enzymes, The findings suggest that CYP1A progenitors split into two CYP enzymes with some parallel functions independently in two evolutionary lines, evidence for convergent evolution in the CYP1A family. Northern analysis shows that the chick enzymes have a different tissue distribution from CYP1A1 and -1A2. Polymerase chain reaction and in situ hybridization data show that both chick enzymes are expressed in response to TCDD even before organ morphogenesis. The findings further suggest that beyond their role in activating carcinogens, CYP1A enzymes have conferred evolutionary and developmental advantages, perhaps as defenses in maintaining homeostatic responses to toxic chemicals.	CORNELL UNIV, COLL MED, DEPT PHARMACOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT CELL BIOL, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; Cornell University; Cornell University			Gannon, Maureen A/F-9060-2012	Yutzey, Katherine/0000-0002-1444-7124	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003606] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34318] Funding Source: Medline; NIEHS NIH HHS [ES-03606] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BERNDTSON AK, 1994, ARCH BIOCHEM BIOPHYS, V310, P187, DOI 10.1006/abbi.1994.1156; BLACK SD, 1987, ADV ENZYMOL RAMB, V60, P35; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CARROLL RL, 1988, VERTEBRATE PALEONTOL; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEES JH, 1982, CANCER RES, V42, P1423; EDWARDS RJ, 1993, BIOCHEM PHARMACOL, V46, P213, DOI 10.1016/0006-2952(93)90406-M; GANNON M, 1995, DEVELOPMENT, V121, P2439; GEOURJON C, 1993, COMPUT APPL BIOSCI, V9, P87; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HAMILTON JW, 1983, P NATL ACAD SCI-BIOL, V80, P3372, DOI 10.1073/pnas.80.11.3372; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; MCNULTY SE, 1995, BIOCHEM BIOPH RES CO, V212, P165, DOI 10.1006/bbrc.1995.1951; MORRISON HG, 1995, BIOCHEM J, V308, P97, DOI 10.1042/bj3080097; MURTI JR, 1991, BIOCHEM BIOPH RES CO, V175, P928, DOI 10.1016/0006-291X(91)91654-U; NAKAI K, 1992, J BIOL CHEM, V267, P19503; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; Raner GM, 1996, MOL PHARMACOL, V49, P515; RIFKIND AB, 1994, J BIOL CHEM, V269, P3387; RIFKIND AB, 1995, ARCH BIOCHEM BIOPHYS, V320, P380, DOI 10.1016/0003-9861(95)90023-3; RYAN DE, 1980, J BIOL CHEM, V255, P7941; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SESARDIC D, 1990, BRIT J CLIN PHARMACO, V29, P651, DOI 10.1111/j.1365-2125.1990.tb03686.x; STEGEMAN JJ, 1991, TOXICOL APPL PHARM, V110, P486, DOI 10.1016/0041-008X(91)90049-K; STRAUSS WM, 1994, CURRENT PROTOCOLS MO, V1; SUTTER TR, 1994, J BIOL CHEM, V269, P13092	32	115	119	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					33054	33059		10.1074/jbc.271.51.33054	http://dx.doi.org/10.1074/jbc.271.51.33054			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955152	hybrid			2022-12-25	WOS:A1996VZ37300087
J	Lee, KP; Carlson, LM; Woodcock, JB; Ramachandra, N; Schultz, TL; Davis, TA; Lowe, JB; Thompson, CB; Larsen, RD				Lee, KP; Carlson, LM; Woodcock, JB; Ramachandra, N; Schultz, TL; Davis, TA; Lowe, JB; Thompson, CB; Larsen, RD			Molecular cloning and characterization of CFT1, a developmentally regulated avian alpha(1,3)-fucosyltransferase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; ELAM-1-DEPENDENT CELL-ADHESION; CARBOHYDRATE ANTIGEN; FUCOSYL-TRANSFERASE; EMBRYONIC ANTIGEN; ALPHA(1,3)-FUCOSYL-TRANSFERASE GENE; DIFFERENTIAL EXPRESSION; DETERMINES EXPRESSION; MONOCLONAL-ANTIBODY	Although coordinate expression of carbohydrate epitopes during development is well described, mechanisms which regulate this expression remain largely unknown. In this study we demonstrate that developing chicken B cells express the Lewis(x) terminal oligosaccharide structure in a stage-specific manner. To examine regulation of this expression, we have cloned and expressed the chicken alpha(1,3)-fucosyltransferase gene involved in Lewis(x) biosynthesis, naming it chicken fucosyltransferase 1 (CFT1), CFT1 is characterized by a single long open reading frame of 356 amino acids encoding a type II transmembrane glycoprotein. The domain structure and predicted amino acid sequence are highly conserved between CFT1 and mammalian Fuc-TIV genes (52.8% and 46.3% identity to mouse and human respectively). In vitro CFT1 fucosyltransferase activity utilizes LacNAc > 3'sialyl-LacNAc accepters with almost no utilization of other neutral type II (lactose, 2-fucosyllactose), or type I (lacto-N-biose I) accepters, CFT1-transfected cells make cell surface Lewis(x) (COS-7) and Lewis(x) + VIM-2 structures (Chinese hamster ovary). CFT1 gene expression is tissue-specific and includes embryonic thymus and bursa. Furthermore, expression of the CFT1 gene and cell surface Lewis(x) structures are closely linked during B cell development. These findings reveal the evolutionary conservation between nonmammalian and mammalian alpha(1,3)-fucosyltransferase genes and demonstrate a role for fucosyltransferase gene regulation in the developmental expression of oligosaccharide structures.	UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; NIAID, NIH, BETHESDA, MD 20892 USA; GLYCOMED INC, ALAMEDA, CA 94501 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOL GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, GWENN KNAPP CTR LUPUS & IMMUNOL RES, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Lee, KP (corresponding author), USN, MED RES INST,IMMUNE CELL BIOL PROGRAM,RM 228, BLDG 18, 8901 WISCONSIN AVE, BETHESDA, MD 20889 USA.							BROWN DG, 1993, HISTOCHEM J, V25, P452, DOI 10.1007/BF00157810; CIVIN CI, 1990, EXP HEMATOL, V18, P461; DEVRIES T, 1992, HISTOCHEM J, V24, P761, DOI 10.1007/BF01046347; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FALK P, 1994, AM J PHYSIOL, V266, pG987, DOI 10.1152/ajpgi.1994.266.6.G987; FEIZI T, 1991, TRENDS BIOCHEM SCI, V16, P84, DOI 10.1016/0968-0004(91)90038-W; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; FENDERSON BA, 1992, APMIS, V100, P109; FLARIS NA, 1995, BRAIN RES, V678, P99, DOI 10.1016/0006-8993(95)00173-N; FLOWER RLP, 1981, J IMMUNOL METHODS, V46, P347, DOI 10.1016/0022-1759(81)90320-3; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GHERI G, 1993, HISTOL HISTOPATHOL, V8, P351; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; GOOI HC, 1981, NATURE, V292, P156, DOI 10.1038/292156a0; HENRY CBS, 1995, MICROVASC RES, V49, P201, DOI 10.1006/mvre.1995.1016; ITAI S, 1990, CANCER RES, V50, P7603; JESSELL TM, 1990, ANNU REV NEUROSCI, V13, P227, DOI 10.1146/annurev.ne.13.030190.001303; KANAI Y, 1992, J VET MED SCI, V54, P297, DOI 10.1292/jvms.54.297; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LEDOUARIN NM, 1984, AM J ANAT, V170, P261, DOI 10.1002/aja.1001700305; LEE KP, 1990, J IMMUNOL, V145, P344; LIU CK, 1983, EXP HEMATOL, V11, P738; LOVELESS W, 1990, DEVELOPMENT, V108, P97; LOWE JB, 1993, BAILLIERE CLIN HAEM, V6, P465, DOI 10.1016/S0950-3536(05)80155-6; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MALMI R, 1990, HISTOCHEMISTRY, V94, P387; MANN PL, 1992, MECH AGEING DEV, V62, P47, DOI 10.1016/0047-6374(92)90143-2; MARANI E, 1992, HISTOCHEM J, V24, P852, DOI 10.1007/BF01046357; MASTELLER EL, 1995, DEVELOPMENT, V121, P1657; MASTELLER EL, 1995, J IMMUNOL, V155, P5550; MAYLIEPFENNINGER MF, 1994, ARCH BIOCHEM BIOPHYS, V311, P469, DOI 10.1006/abbi.1994.1264; METCALFE WK, 1990, DEVELOPMENT, V110, P491; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MURAMATSU T, 1988, J CELL BIOCHEM, V36, P1, DOI 10.1002/jcb.240360102; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; OHMORI K, 1993, BLOOD, V82, P2797; PALOJOKI E, 1995, EUR J IMMUNOL, V25, P2544, DOI 10.1002/eji.1830250921; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PROUTY SM, 1993, J COMP NEUROL, V332, P444, DOI 10.1002/cne.903320406; ROBERTS C, 1991, DEVELOPMENT, V112, P959; RUDLAND PS, 1991, J CELL PHYSIOL, V146, P222, DOI 10.1002/jcp.1041460206; SASAKI K, 1994, J BIOL CHEM, V269, P14730; SCHWARTING GA, 1992, J NEUROBIOL, V23, P120, DOI 10.1002/neu.480230203; SCOTT SA, 1993, DEV BRAIN RES, V75, P175, DOI 10.1016/0165-3806(93)90021-2; SKACEL PO, 1991, BLOOD, V78, P1452; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Streit A, 1996, J NEUROCHEM, V66, P834; THORPE SJ, 1988, DEVELOPMENT, V102, P193; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YOSHIHARA Y, 1991, J CELL BIOL, V115, P731, DOI 10.1083/jcb.115.3.731	61	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32960	32967		10.1074/jbc.271.51.32960	http://dx.doi.org/10.1074/jbc.271.51.32960			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955139	hybrid			2022-12-25	WOS:A1996VZ37300074
J	Lill, H; Hensel, F; Junge, W; Engelbrecht, S				Lill, H; Hensel, F; Junge, W; Engelbrecht, S			Cross-linking of engineered subunit delta to (alpha beta)(3) in chloroplast F-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; BINDING CHANGE MECHANISM; COUPLING FACTOR; ADENOSINE-TRIPHOSPHATASE; TRANSLOCATING ATPASE; THYLAKOID MEMBRANE; CATALYTIC SITES; EPSILON-SUBUNIT; SYNTHASE; PHOTOPHOSPHORYLATION	Ser --> Cys mutations were introduced into subunit delta of spinach chloroplast F0F1-ATPase (CF0CF1) by site-directed mutagenesis. The engineered delta subunits were overexpressed in Escherichia coli, purified, and reassembled with spinach chloroplast F-1-ATPase (CF1) lacking the delta subunit (CF1(-delta)). By modification with eosin-5-maleimide, it was shown that residues 10, 57, 82, 160, and 166 were solvent accessible in isolated CF1 and all but residue 166 also in membrane-bound CF0CF1. Modification of the engineered delta subunit with photolabile cross-linkers, binding of delta to CF1(-delta), and photolysis yielded the same SDS gel pattern of cross-link products in the presence or absence of ADP, phosphate, and ATP and both in soluble CF1 and in CF0CF1. By chemical hydrolysis of cross-linked CF1, it was shown that delta(S10C) was cross-linked within the N-terminal 62 residues of subunit beta. delta(S57C), delta(S82C), and delta(S166C) were cross-linked within the N-terminal 192 residues of subunit alpha. Crosslinking affected neither ATP hydrolysis by soluble CF1 nor its ability to reassemble with CF0 and to structurally reconstitute ATP synthesis. Functional reconstitution, however, seemed to be impaired.	UNIV OSNABRUCK, FACHBEREICH BIOL CHEM, D-49069 OSNABRUCK, GERMANY	University Osnabruck				Lill, H./0000-0001-9336-5428				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; BERZBORN RJ, 1989, Z NATURFORSCH C, V44, P480; BOYER PD, 1989, FASEB J, V3, P2164, DOI 10.1096/fasebj.3.10.2526771; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BRAGG PD, 1986, BIOCHIM BIOPHYS ACTA, V851, P385, DOI 10.1016/0005-2728(86)90075-7; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; DIMROTH P, 1987, MICROBIOL REV, V51, P320, DOI 10.1128/MMBR.51.3.320-340.1987; DIMROTH P, 1990, PHILOS T ROY SOC B, V326, P465, DOI 10.1098/rstb.1990.0025; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1980, J BIOL CHEM, V255, P6891; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; ENGELBRECHT S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P379, DOI 10.1016/0005-2728(90)90072-C; ENGELBRECHT S, 1989, EUR J BIOCHEM, V181, P485, DOI 10.1111/j.1432-1033.1989.tb14750.x; ENGELBRECHT S, 1987, FEBS LETT, V219, P321, DOI 10.1016/0014-5793(87)80244-2; ENGELBRECHT S, 1990, EUR J BIOCHEM, V189, P193, DOI 10.1111/j.1432-1033.1990.tb15476.x; ENGELBRECHT S, 1988, EUR J BIOCHEM, V172, P213, DOI 10.1111/j.1432-1033.1988.tb13875.x; ENGELBRECHT S, 1989, EUR J BIOCHEM, V179, P117, DOI 10.1111/j.1432-1033.1989.tb14528.x; ENGELBRECHT S, 1991, Z NATURFORSCH C, V46, P759; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; HUNDAL T, 1983, FEBS LETT, V162, P5, DOI 10.1016/0014-5793(83)81038-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNGE W, 1989, ANN NY ACAD SCI, V574, P268; KRAUSE I, 1987, ELEKTROPHORESEFORUM, P382; LEBEL D, 1978, ANAL BIOCHEM, V85, P86, DOI 10.1016/0003-2697(78)90277-4; LILL H, 1988, J BIOL CHEM, V263, P14518; LILL H, 1993, BIOCHIM BIOPHYS ACTA, V1144, P278, DOI 10.1016/0005-2728(93)90112-S; MEANS GE, 1971, CHEM MODIFICATION PR, P112; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; NELSON N, 1979, CATION FLUX BIOMEMBR, P409; POLLE A, 1986, BIOCHIM BIOPHYS ACTA, V848, P257, DOI 10.1016/0005-2728(86)90199-4; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SHOSHAN V, 1973, EUR J BIOCHEM, V37, P355, DOI 10.1111/j.1432-1033.1973.tb02994.x; Stark G R, 1977, Methods Enzymol, V47, P129; STEINEMANN D, 1994, BBA-BIOENERGETICS, V1187, P354, DOI 10.1016/0005-2728(94)90009-4; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013	48	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32737	32742		10.1074/jbc.271.51.32737	http://dx.doi.org/10.1074/jbc.271.51.32737			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955107	hybrid			2022-12-25	WOS:A1996VZ37300042
J	Loijens, JC; Anderson, RA				Loijens, JC; Anderson, RA			Type I phosphatidylinositol-4-phosphate 5-kinases are distinct members of this novel lipid kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; CA2+-ACTIVATED SECRETION; PHOSPHOINOSITIDE KINASES; 4-PHOSPHATE 5-KINASE; PHOSPHATIDIC-ACID; MAST-CELLS; 4,5-BISPHOSPHATE; ACTIVATION; BINDING; RHO	Phosphatidylinositol-4-phosphate 5-kinases (PIP5K) synthesize phosphatidylinositol-4,5-bisphosphate, a key precursor in phosphoinositide signaling that also regulates some proteins and cellular processes directly. Two distinct PIP5Ks have been characterized in erythrocytes, the 68 kDa type I (PIP5KI) and 53-kDa type II (PIP5KII) isoforms. Using peptide sequences from the erythroid 68-kDa PIP5KI, we have isolated cDNAs encoding PIP5KI alpha from human brain. Partial cDNAs obtained for a second isoform, PIP5KI beta, established that the human STM7 gene encoded a previously unrecognized PIP5KI. However, the peptide sequences demonstrated that erythroid PIP5KI corresponded to PIP5KI alpha. Recombinant, bacterially expressed PIP5KI alpha possessed PIP5K activity and was immunoreactive with erythroid PIP5KI antibodies. By Northern analysis, PIP5KI alpha and PIP5KI beta had wide tissue distributions, but their expression levels differed greatly. PIP5KIs had homology to the kinase domains of PIP5KII alpha, yeast Mss4p and Fab1p, and a new Caenorhabditis elegans Fab1-like protein identified in the data base. These new isoforms have refined the sequence requirements for PIP5K activity and, potentially, regulation of these enzymes. Furthermore, the limited homology between PLP5KIs and PIP5KII alpha, which was almost exclusively within the kinase domain core, provided a molecular basis for distinction between type I and II PIP5Ks.	UNIV WISCONSIN,SCH MED,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,PROGRAM MOL & CELLULAR BIOL,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison				Anderson, Richard/0000-0001-6265-8359	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051968, R29GM038906, R01GM038906] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51968, GM38906] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; CARVAJAL JJ, 1995, HUM MOL GENET, V4, P1411, DOI 10.1093/hmg/4.8.1411; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCHET C, 1991, J BIOL CHEM, V266, P637; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Harlow E., 1988, ANTIBODIES LAB MANUA; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LING LE, 1989, J BIOL CHEM, V264, P5080; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; MORITZ A, 1990, J NEUROCHEM, V54, P351, DOI 10.1111/j.1471-4159.1990.tb13322.x; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Sambrook J., 2002, MOL CLONING LAB MANU; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	38	176	184	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32937	32943		10.1074/jbc.271.51.32937	http://dx.doi.org/10.1074/jbc.271.51.32937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955136	hybrid			2022-12-25	WOS:A1996VZ37300071
J	Todd, MC; Xiang, RH; Garcia, DK; Kerbacher, KE; Moore, SL; Hensel, CH; Liu, P; Siciliano, MJ; Kok, K; vandenBerg, A; Veldhuis, P; Buys, CHCM; Killary, AM; Naylor, SL				Todd, MC; Xiang, RH; Garcia, DK; Kerbacher, KE; Moore, SL; Hensel, CH; Liu, P; Siciliano, MJ; Kok, K; vandenBerg, A; Veldhuis, P; Buys, CHCM; Killary, AM; Naylor, SL			An 80 Kb P1 clone from chromosome 3p21.3 suppresses tumor growth in vivo	ONCOGENE			English	Article						tumor suppressor gene; small cell lung cancer; human chromosome 3; positional cloning; homozygous deletion	CELL LUNG-CANCER; POLYMERASE CHAIN-REACTION; SHORT ARM; HOMOZYGOUS DELETION; DNA-SEQUENCE; ALLELIC LOSS; OVARIAN-CANCER; CARCINOMA; LINE; GENE	High frequencies of allelic loss on the short arm of chromosome 3 in small cell lung cancer (SCLC) and a number of other tumors suggest the existence of a tumor suppressor gene(s) within the deleted regions. Two small cell lung cancer lines, NCI H740 and GLC20, have been described which have homozygous deletions in the region 3p21.3. The deleted region overlaps with a 2 Mb fragment of human DNA present in the interspecies hybrid HA(3)BB9F, that suppresses tumor formation by mouse A9 fibrosarcoma cells. Human sequences from this cell hybrid were isolated using inter Alu PCR. From this starting point, a P1 contig was developed for the region of 450 Kb that is common to the homozygous deletions seen in the SCLC lines NCI H740 and GLC20 and is also present in HA(3)BB9F, the suppressed A9 hybrid. Individual P1 clones were assayed for their ability to suppress the tumorigenicity of the mouse fibrosarcoma cell line A9 as assayed by injection of transfected A9 cells into athymic nude mice. The introduction of one of the P1 clones into A9 cells resulted in suppression of tumor growth whereas two other P1 clones from the contig failed to suppress tumor formation in athymic nude mice. These data functionally delimit a tumor suppressor locus to a region of 80 kb within a P1 clone at 3p21.3.	UNIV TEXAS,HLTH SCI CTR,DEPT CELLULAR & STRUCT BIOL,SAN ANTONIO,TX 78284; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; MD ANDERSON CANC INST,DEPT MOL GENET,HOUSTON,TX 77030; MD ANDERSON CANC INST,DEPT LAB MED,HOUSTON,TX 77030; UNIV GRONINGEN,DEPT MED GENET,GRONINGEN,NETHERLANDS	University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Groningen			van den Berg, Anke/H-1718-2011; Liu, Paul/A-7976-2012; todd, martin/I-4143-2015	van den Berg, Anke/0000-0002-8894-2638; Liu, Paul/0000-0002-6779-025X; Moore, Shanna/0000-0001-5578-8868	NCI NIH HHS [CA54174, CA56626] Funding Source: Medline; PHS HHS [H600470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056626, P30CA054174] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; DALY MC, 1993, ONCOGENE, V8, P1721; DEVILEE P, 1989, GENOMICS, V5, P554, DOI 10.1016/0888-7543(89)90023-2; EHLEN T, 1990, ONCOGENE, V5, P219; ELNAGGAR AK, 1993, CANCER, V72, P881, DOI 10.1002/1097-0142(19930801)72:3<881::AID-CNCR2820720337>3.0.CO;2-Q; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; HANSEN MF, 1987, P NATL ACAD SCI USA, V84, P9059; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; JONES MH, 1992, ONCOGENE, V7, P1631; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1994, CANCER RES, V54, P4183; KOVACS G, 1989, CANCER RES, V49, P651; KOVACS G, 1988, P NATL ACAD SCI USA, V85, P1571, DOI 10.1073/pnas.85.5.1571; KRAUS C, 1994, GENOMICS, V23, P272, DOI 10.1006/geno.1994.1493; KRAYEV AS, 1980, NUCLEIC ACIDS RES, V8, P1201, DOI 10.1093/nar/8.6.1201; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LATIF F, 1992, CANCER RES, V52, P1451; LEACH RJ, 1994, GENOMICS, V24, P549, DOI 10.1006/geno.1994.1665; LEDBETTER SA, 1990, GENOMICS, V6, P475, DOI 10.1016/0888-7543(90)90477-C; LIDEREAU R, 1989, J NATL CANCER I, V81, P1815; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; LIU P, 1993, CANCER GENET CYTOGEN, V65, P93, DOI 10.1016/0165-4608(93)90213-6; LOTHE RA, 1989, GENOMICS, V5, P134, DOI 10.1016/0888-7543(89)90097-9; LUPTON SD, 1991, MOL CELL BIOL, V11, P3374, DOI 10.1128/MCB.11.6.3374; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; POPESCU NC, 1988, CANCER RES, V48, P142; RABBITTS P, 1989, GENE CHROMOSOME CANC, V1, P95, DOI 10.1002/gcc.2870010115; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RIMESSI P, 1994, ONCOGENE, V9, P3467; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; SHIMIZU M, 1990, ONCOGENE, V5, P185; SINGER MF, 1985, TRENDS BIOCHEM SCI, V10, P119, DOI 10.1016/0968-0004(85)90271-3; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VANDENBERG A, IN PRESS CYTOGENET C; WANG LM, 1988, BIOTECHNIQUES, V6, P839; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YANGFENG TL, 1993, INT J CANCER, V54, P546, DOI 10.1002/ijc.2910540405; YOKOTA J, 1989, CANCER RES, V49, P3598; YOKOTA J, 1988, ONCOGENE, V3, P471; YOSHIDA MA, 1994, MOL CARCINOGEN, V9, P114, DOI 10.1002/mc.2940090303; ZBAR B, 1987, NATURE, V327, P721, DOI 10.1038/327721a0	56	52	56	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2387	2396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957080				2022-12-25	WOS:A1996VX10800011
J	Byrne, JL; Paterson, HF; Marshall, CJ				Byrne, JL; Paterson, HF; Marshall, CJ			p21Ras activation by the guanine nucleotide exchange factor Sos, requires the Sos/Grb2 interaction and a second ligand-dependent signal involving the Sos N-terminus	ONCOGENE			English	Article						hSos; Grb2; p21Ras; signal transduction	NERVE GROWTH-FACTOR; GRB2 ADAPTER PROTEIN; PC12 CELLS; KINASE ACTIVATION; RAS; MEMBRANE; DIFFERENTIATION; MICROINJECTION; TRANSDUCTION; SEVENLESS	It has been suggested that a key event in growth factor-induced p21Ras activation by the guanine nucleotide exchange factor Sos, is the recruitment of Sos to the plasma membrane by its interaction with the adaptor protein Grb2. However, other evidence argues that the sub cellular localisation of Sos is independent of Grb2, and that the Sos/Grb2 interaction can be dispensed with for p21Ras activation. To clarify the role of the Sos/Grb2 interaction in ligand-stimulated p21Ras activation, we have utilised the observation that overexpression of the Sos C-terminal domain can effectively inhibit p21Ras-dependent signalling in three different mammalian systems. We have shown that concurrent expression of Grb2, but not SH2 or SH3 domain mutants of Grb2, or the alternative adaptor protein Nck, can rescue this inhibitory effect: of the C-terminus. This shows that the Grb2/Sos interaction is required to mediate growth factor-dependent activation of p21Ras, and requires the presence of intact SH2 and SH3 domains of Grb2. This approach was also used for a functional analysis of Sos which revealed that growth factor dependent signals are transmitted through both the N-terminal and C-terminal domains.	INST CANC RES,CHESTER BEATTY LABS,CANC RES CAMPAIGN,CTR CELL & MOL BIOL,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Byrne, Jenny/0000-0002-9381-1851				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DICKSON B, 1994, CURR OPIN GENET DEV, V4, P64, DOI 10.1016/0959-437X(94)90092-2; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HU Q, 1995, MOL CELL BIOL, V88, P189; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; PRONK GJ, 1993, J BIOL CHEM, V268; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; STACEY DW, 1984, NATURE, V310, P508, DOI 10.1038/310508a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294	39	38	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2055	2065						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950972				2022-12-25	WOS:A1996VV14500002
J	Besnard, M; Martinac, B; Ghazi, A				Besnard, M; Martinac, B; Ghazi, A			Voltage-dependent porin-like ion channels in the archaeon Haloferax volcanii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATCH-CLAMP; ESCHERICHIA-COLI; CELL-WALL; ACTIVATED CHANNELS; OUTER MEMBRANES; GIANT LIPOSOMES; PERMEABILITY; GLYCOPROTEIN; PROTEIN; LAYER	Membrane vesicles isolated from the cell envelope of the archaebacterium Haloferax volcanii were either reconstituted in giant liposomes and examined by the patch-clamp technique or were fused into planar lipid bilayers. In addition, cell envelope proteins were solubilized by detergent and reconstituted in azolectin liposomes, which were then fused into planar lipid bilayers. Independently of the technique used the predominant channel activity encountered exhibited the following characteristics. Channels were open at all voltages in the range approximately -120 to +120 mV and exhibited frequent fast transitions to closed levels of different amplitudes. At voltages greater than 120 mV the channels tended to close in a manner characterized by large, slow transitions of variable amplitudes. The tendency to close at high membrane potentials was much stronger at one polarity. The channel gating pattern was complex exhibiting a range of subconductances of 10-300 picosiemens in symmetric 100 mM KCl. These electrophysiological characteristics are comparable with those of bacterial and mitochondrial porins, suggesting that the archaeal channels may belong to the general class of porin channels. Some channels showed preference for K+, whereas the others preferred Cl-, suggesting the existence of at least two types of porin-like channels in H. volcanii.	UNIV PARIS 11,LAB BIOMEMBRANE,CNRS,URA 1116,F-91405 ORSAY,FRANCE; UNIV WESTERN AUSTRALIA,DEPT PHARMACOL,NEDLANDS,WA 6907,AUSTRALIA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Western Australia			Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082				BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BERRIER C, 1992, FEBS LETT, V306, P251, DOI 10.1016/0014-5793(92)81011-A; Berrier C, 1996, J MEMBRANE BIOL, V151, P175, DOI 10.1007/s002329900068; BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BLAUROCK AE, 1976, J CELL BIOL, V71, P1, DOI 10.1083/jcb.71.1.1; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 1992, IONIC CHANNELS EXCIT; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; KESSEL M, 1988, EMBO J, V7, P1549, DOI 10.1002/j.1460-2075.1988.tb02974.x; LECHNER J, 1987, J BIOL CHEM, V262, P9724; LECHNER J, 1989, ANNU REV BIOCHEM, V58, P173, DOI 10.1146/annurev.bi.58.070189.001133; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; NIEDERWEIS M, 1995, J BACTERIOL, V177, P5716, DOI 10.1128/jb.177.19.5716-5718.1995; NIKAIDO H, 1994, J BIOL CHEM, V269, P3905; NIKAIDO H, 1993, MOL MICROBIOL, V8, P1025, DOI 10.1111/j.1365-2958.1993.tb01647.x; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; SUKHAREV SI, 1993, BIOPHYS J, V65, P1; SUMPER M, 1990, J BACTERIOL, V172, P7111, DOI 10.1128/jb.172.12.7111-7118.1990; SZABO I, 1992, BIOCHIM BIOPHYS ACTA, V1112, P29, DOI 10.1016/0005-2736(92)90250-P; SZABO I, 1993, J MEMBRANE BIOL, V131, P203, DOI 10.1007/BF02260109; TRIAS J, 1994, MOL MICROBIOL, V14, P283, DOI 10.1111/j.1365-2958.1994.tb01289.x; TRIAS J, 1992, SCIENCE, V258, P1479, DOI 10.1126/science.1279810; TRIAS JQ, 1993, J BIOL CHEM, V268, P6234; WOESE CR, 1994, MICROBIOL REV, V58, P1; ZORATTI M, 1988, FEBS LETT, V240, P105, DOI 10.1016/0014-5793(88)80348-X	30	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					992	995		10.1074/jbc.272.2.992	http://dx.doi.org/10.1074/jbc.272.2.992			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995393	hybrid			2022-12-25	WOS:A1997WC04800044
J	Gao, JJ; Morrison, DC; Parmely, TJ; Russell, SW; Murphy, WJ				Gao, JJ; Morrison, DC; Parmely, TJ; Russell, SW; Murphy, WJ			An interferon-gamma-activated site (GAS) is necessary for full expression of the mouse iNOS gene in response to interferon-gamma and lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; EPIDERMAL GROWTH-FACTOR; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; MACROPHAGES; INDUCTION; CALMODULIN; STAT; ENDOTHELIUM	Mouse macrophages can be stimulated by interferon (IFN)-gamma and bacterial lipopolysaccharide (LPS) to pro duce nitric oxide (NO) as the result of expression of the inducible NO synthase (iNOS; EC 1.14.13.39) gene. The iNOS gene promoter contains a candidate gamma-interferon-activated site (GAS). In transfection studies reported here, it was demonstrated that a luciferase reporter-gene construct, containing four synthetic copies of the iNOS GAS, was inducible when transfected macrophages were stimulated with either IFN-gamma, LPS, or a combination of the two. Consistent with this finding were other transfection analyses, which showed that responsiveness of the intact iNOS promoter to these same agents was significantly reduced when two conserved nucleotide positions within the GAS were mutated. Oligonucleotide probes, which mimicked the iNOS GAS, formed a complex with proteins that appeared in the nuclei of IFN-gamma or IFN-gamma + LPS treated macrophages within 30 min of stimulation, as shown by electrophoretic mobility shift assay. LPS alone also caused the the appearance of a nuclear protein capable of binding the iNOS GAS-containing oligonucleotide; however, in contrast to binding induced by IFN-gamma, approximately 2 h of stimulation with LPS were required. The protein bound to the iNOS GAS containing oligonucleotide reacted specifically with an antibody raised against Stat1 alpha, regardless of the stimulus used. These data collectively support the conclusion that binding of Stat1 alpha to the iNOS promoter's GAS is required for optimal induction of the iNOS gene by IFN-gamma and LPS.	UNIV KANSAS,MED CTR,WILKINSON LAB CANC RES,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT LAB MED & PATHOL,KANSAS CITY,KS 66160; UNIV KANSAS,MED CTR,DEPT MICROBIOL MOL GENET & IMMUNOL,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center					NATIONAL CANCER INSTITUTE [P01CA054474] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA54474] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLEY EW, 1994, J ENDOTOXIN RES, V1, P235; BACON CM, 1995, P NATL ACAD SCI USA, V92, P7307, DOI 10.1073/pnas.92.16.7307; BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINBLOOM DS, 1995, ARTHRITIS RHEUM-US, V38, P877, DOI 10.1002/art.1780380702; FUJIHARA M, 1994, J BIOL CHEM, V269, P12773; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; LIU RH, 1995, MUTAT RES-REV GENET, V339, P73, DOI 10.1016/0165-1110(95)90004-7; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MUROI M, 1993, J BIOL CHEM, V268, P19534; MURPHY WJ, 1996, IN PRESS J ENDOTOXIN; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; PACE JL, 1994, J ENDOTOXIN RES, V1, P227; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; REIN T, 1994, NUCLEIC ACIDS RES, V22, P3033, DOI 10.1093/nar/22.15.3033; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SEEGERT D, 1994, J BIOL CHEM, V269, P8590; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; ZHANG XO, 1994, INFECT IMMUN, V62, P33, DOI 10.1128/IAI.62.1.33-40.1994; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	38	258	264	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1226	1230		10.1074/jbc.272.2.1226	http://dx.doi.org/10.1074/jbc.272.2.1226			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995425	hybrid			2022-12-25	WOS:A1997WC04800076
J	Langnaese, K; Beesley, PW; Gundelfinger, ED				Langnaese, K; Beesley, PW; Gundelfinger, ED			Synaptic membrane glycoproteins gp65 and gp55 are new members of the immunoglobulin superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSKELETON-ASSOCIATED POLYPEPTIDE; CELL-SURFACE GLYCOPROTEIN; RAT-BRAIN; POSTSYNAPTIC DENSITIES; MOUSE BASIGIN; ENRICHED GLYCOPROTEINS; MONOCLONAL-ANTIBODY; ADHESION MOLECULES; NEURAL RETINA; ANTIGEN	Glycoproteins gp65 and gp55 are major components of synaptic membranes prepared from rat forebrain. Both are recognized by the monoclonal antibody SMgp65. We have used SMgp65 to screen a rat brain cDNA expression library. Two sets of overlapping cDNAs that contain open reading frames of 397 and 281 amino acids were isolated. The deduced proteins are members of the immunoglobulin (Ig) superfamily containing three and two Ig domains, respectively. The common part has similar to 40% sequence identity with neurothelin/basigin. The identity of the proteins as gp65 and gp55 was confirmed by production of new antisera against a common recombinant protein fragment. These antisera immunoprecipitate gp65 and gp55. Furthermore, expression of gp65 and gp55 cDNAs in human 293 cells treated with tunicamycin results in the production of unglycosylated core proteins of identical size to deglycosylated gp65 and gp55. Northern analysis revealed that gp65 transcripts are brain-specific, whereas gp55 is expressed in most tissues and cell lines examined. The tissue distribution was confirmed at the protein level though the pattern of glycosylation of gp55 varies between tissues. In situ hybridization experiments with a common and a gp65 specific probe suggest differential expression of gp65 and gp55 transcripts in the rat brain.	FED INST NEUROBIOL,DEPT NEUROCHEM & MOL BIOL,D-39008 MAGDEBURG,GERMANY; UNIV LONDON,ROYAL HOLLOWAY & BEDFORD NEW COLL,DIV BIOCHEM,SCH BIOL SCI,EGHAM TW20 0EX,SURREY,ENGLAND	University of London; Royal Holloway University London					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTRUDA F, 1989, GENE, V85, P445, DOI 10.1016/0378-1119(89)90438-1; BAHR BA, 1992, BIOCHEM J, V281, P137, DOI 10.1042/bj2810137; BEESLEY PW, 1987, BRAIN RES, V408, P65, DOI 10.1016/0006-8993(87)90359-3; BEESLEY PW, 1995, J NEUROCHEM, V64, P2288; BISWAS C, 1995, CANCER RES, V55, P434; BRUMMENDORF T, 1995, PROTEIN PROFILE, V2, P963; BURGIN KE, 1990, J NEUROSCI, V10, P1788; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOHERTY P, 1995, J NEUROBIOL, V26, P437, DOI 10.1002/neu.480260315; FADOOL JM, 1993, J NEUROCHEM, V60, P1354, DOI 10.1111/j.1471-4159.1993.tb03296.x; FADOOL JM, 1993, DEV DYNAM, V196, P252, DOI 10.1002/aja.1001960406; FOSSUM S, 1991, EUR J IMMUNOL, V21, P671, DOI 10.1002/eji.1830210320; GLOOR S, 1992, GENE, V120, P307, DOI 10.1016/0378-1119(92)90111-2; GURD JW, 1980, CAN J BIOCHEM CELL B, V58, P941, DOI 10.1139/o80-129; GURD JW, 1989, NEUROBIOLOGY GLYCOCO, P219; HILL I, 1989, BIOCHEM SOC T, V17, P770, DOI 10.1042/bst0170770; HILL IE, 1988, BRAIN RES, V461, P27, DOI 10.1016/0006-8993(88)90722-6; KANEKURA T, 1991, CELL STRUCT FUNCT, V16, P23, DOI 10.1247/csf.16.23; KASINRERK W, 1992, J IMMUNOL, V149, P847; KISTNER U, 1993, J BIOL CHEM, V268, P4580; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLERC N, 1989, J COMP NEUROL, V280, P197, DOI 10.1002/cne.902800204; MAYER U, 1993, EMBO J, V12, P1879, DOI 10.1002/j.1460-2075.1993.tb05836.x; MIYAUCHI T, 1991, J BIOCHEM-TOKYO, V110, P770, DOI 10.1093/oxfordjournals.jbchem.a123657; MIYAUCHI T, 1990, J BIOCHEM-TOKYO, V107, P316, DOI 10.1093/oxfordjournals.jbchem.a123045; MIYAUCHI T, 1995, J BIOCHEM-TOKYO, V118, P717, DOI 10.1093/oxfordjournals.jbchem.a124971; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; PERSOHN E, 1989, J COMP NEUROL, V288, P92, DOI 10.1002/cne.902880108; PURVES D, 1985, PRINCIPLES NEURAL DE; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROSALES C, 1995, BBA-REV CANCER, V1242, P77, DOI 10.1016/0304-419X(95)00005-Z; Sambrook J., 2002, MOL CLONING LAB MANU; SCHLOSSHAUER B, 1991, DEVELOPMENT, V113, P129; SCHLOSSHAUER B, 1995, EUR J CELL BIOL, V68, P159; SCHLOSSHAUER B, 1990, J CELL BIOL, V110, P1261, DOI 10.1083/jcb.110.4.1261; SEULBERGER H, 1990, EMBO J, V9, P2151, DOI 10.1002/j.1460-2075.1990.tb07384.x; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; Steward O, 1987, PROG BRAIN RES <D>, V71, P267; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WILLMOTT T, 1992, J NEUROCHEM, V58, P2037, DOI 10.1111/j.1471-4159.1992.tb10944.x; WILLMOTT T, 1994, NEUROSCIENCE, V58, P115, DOI 10.1016/0306-4522(94)90159-7; WILLMOTT TG, 1991, NEUROSCIENCE, V44, P627, DOI 10.1016/0306-4522(91)90083-Z; WISDEN W, 1994, IN SITU HYBRIDIZATIO, P9	47	60	63	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					821	827		10.1074/jbc.272.2.821	http://dx.doi.org/10.1074/jbc.272.2.821			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995369	hybrid			2022-12-25	WOS:A1997WC04800020
J	Le, F; Groshan, K; Zeng, XP; Richelson, E				Le, F; Groshan, K; Zeng, XP; Richelson, E			Characterization of the genomic structure, promoter region, and a tetranucleotide repeat polymorphism of the human neurotensin receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; BETA-2-ADRENERGIC RECEPTOR; TRANSCRIPTION FACTORS; NUCLEOTIDE-SEQUENCE; PARKINSONS-DISEASE; HIGH-AFFINITY; SUBSTANCE-P; EXPRESSION; CLONING; ORGANIZATION	In the present study, we have cloned the human neurotensin receptor (NTR) gene, determined its structure, demonstrated that its promoter is functional in transfection experiments, and identified the start site of transcription and a tetranucleotide repeat polymorphism that locates at less than 3 kilobase pairs from the gene. The gene contains three introns, all in the coding regions, Several differences in genomic clones and previously characterized cDNA sequences are reconciled, The 5' regulatory region, which is rich in presumptive transcription factors, can drive luciferase expression in transfected CHO-K1 cells, Stepwise 5' deletions identify a positive modulator between -782 and -1309 and a negative modulator between -1309 and -1563. Southern blot analyses demonstrate a single copy gene for the NTR, The tetranucleotide repeat polymorphism is highly informative with at least 23 alleles and might serve as a very useful marker for genetic study of the relationship between the NTR and neuropsychiatric disorders.	MAYO CLIN JACKSONVILLE, LAB NEUROPSYCHOPHARMACOL, JACKSONVILLE, FL 32224 USA	Mayo Clinic			Richelson, Elliott/A-9407-2012		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH027692] Funding Source: NIH RePORTER; NIMH NIH HHS [MH27692] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; BOLDENWATSON C, 1993, J NEUROCHEM, V61, P1141, DOI 10.1111/j.1471-4159.1993.tb03631.x; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN K, 1992, MOL BRAIN RES, V14, P20, DOI 10.1016/0169-328X(92)90005-V; CHINAGLIA G, 1990, NEUROSCIENCE, V39, P351, DOI 10.1016/0306-4522(90)90273-7; Cusack B, 1996, J BIOL CHEM, V271, P15054, DOI 10.1074/jbc.271.25.15054; CUSACK B, 1995, J BIOL CHEM, V270, P18359, DOI 10.1074/jbc.270.31.18359; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DEUTCH AY, 1992, ANN NY ACAD SCI, V668, P232, DOI 10.1111/j.1749-6632.1992.tb27353.x; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GARVER DL, 1991, AM J PSYCHIAT, V148, P484; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; HERSHEY AD, 1991, J BIOL CHEM, V266, P4366; HOSODA K, 1992, J BIOL CHEM, V267, P18797; INOUE A, 1989, J BIOL CHEM, V264, P14954; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; KOBILKA BK, 1987, J BIOL CHEM, V262, P7321; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LAURENT P, 1994, MAMM GENOME, V5, P303, DOI 10.1007/BF00389545; LE F, 1994, J AFFECT DISORDERS, V32, P187, DOI 10.1016/0165-0327(94)90017-5; LE F, 1992, J NEUROCHEM, V59, P1309, DOI 10.1111/j.1471-4159.1992.tb08442.x; Le F, 1996, BIOCHEM BIOPH RES CO, V223, P461, DOI 10.1006/bbrc.1996.0916; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NATHANS J, 1984, P NATL ACAD SCI-BIOL, V81, P4851, DOI 10.1073/pnas.81.15.4851; Nemeroff C B, 1989, J Neuropsychiatry Clin Neurosci, V1, P16; Nemeroff C B, 1985, Prog Clin Biol Res, V192, P333; Pang YP, 1996, J BIOL CHEM, V271, P15060, DOI 10.1074/jbc.271.25.15060; QUIRION R, 1992, ANN NY ACAD SCI, V668, P109, DOI 10.1111/j.1749-6632.1992.tb27343.x; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SEYFRIED CE, 1992, GENOMICS, V13, P832, DOI 10.1016/0888-7543(92)90162-L; SHABTAI F, 1993, J MED GENET, V30, P171, DOI 10.1136/jmg.30.2.171; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SPRENGER H, 1994, J IMMUNOL, V153, P2524; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; SUNAHARA RK, 1990, NATURE, V347, P80, DOI 10.1038/347080a0; TAKAHASHI K, 1992, EUR J BIOCHEM, V204, P1025, DOI 10.1111/j.1432-1033.1992.tb16724.x; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TIENARI P, 1994, BRIT J PSYCHIAT, V164, P20, DOI 10.1192/S0007125000292696; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; VANTOL HHM, 1991, NATURE, V350, P610, DOI 10.1038/350610a0; VANWIJNEN AJ, 1987, NUCLEIC ACIDS RES, V15, P1679, DOI 10.1093/nar/15.4.1679; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WATSON M, 1993, MAYO CLIN PROC, V68, P1043, DOI 10.1016/S0025-6196(12)60896-9; WOLF SS, 1995, J NEURAL TRANSM-GEN, V102, P55, DOI 10.1007/BF01276565; YAMADA M, 1994, MOL PHARMACOL, V46, P470; YAMADA M, 1995, NEUROSCIENCE, V64, P405, DOI 10.1016/0306-4522(94)00395-L	52	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1315	1322		10.1074/jbc.272.2.1315	http://dx.doi.org/10.1074/jbc.272.2.1315			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995438	hybrid			2022-12-25	WOS:A1997WC04800089
J	Ma, YZ; Taylor, EW				Ma, YZ; Taylor, EW			Kinetic mechanism of a monomeric kinesin construct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED ATP HYDROLYSIS; MOTOR DOMAIN; MICROTUBULE	The kinetic mechanism is analyzed for a monomeric human kinesin construct K332. In the absence of microtubules, the rate constants of the ATPase cycle are very similar to dimeric human kinesin K379 and whole kinesin sin from bovine brain. The microtubule-activated ATPase is 60 s(-1) at 20 degrees C; K-m(Mt) is 5 mu M; dissociation constants in the presence of ATP and ADP are 9 mu M and 16 mu M, respectively, The values of dissociation constants are 5 times larger than for K379. Binding of K332 to microtubules increased the rate of the hydrolysis step from 7 s(-1) to greater than 200 s(-1) and the 2'-(3')-O-(N-methylanthraniloyl) (mant) ADP dissociation step from 0.02 s(-1) to greater than 100 s(-1). At higher ionic strength, more than one ATP is hydrolyzed before dissociation of MtK332 (small processivity). Data are fitted to the kinetic scheme. [GRAPHICS] SCHEME 1 Approximate values of rate constants are k(1) = 500 s(-1), k(2) greater than or equal to 200 s(-1), k(3)k(4)/(k(3) + k(4)) = 100 s(-1), k(dis) = 80 +/- 10 s(-1). Two experiments to measure k(4) gave 110 s(-1) from the maximum rate of dissociation of mant ADP for reaction of K . ADP with microtubules and 300 s(-1) from extrapolation to zero concentration of rate of binding of mant ADP to MtK. It is proposed that mant ADP dissociation is a two-step process. In the simple scheme, k(4) is the effective rate of the two-step release of ADP, k(4) = 150 s(-1) to 200 s(-1), and k(3) = 150 s(-1) to 200 s(-1) to account for the steady state rate.	UNIV CHICAGO,DEPT MOL GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago					NIGMS NIH HHS [GM 51858] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1994, J BIOL CHEM, V269, P16508; HUANG TG, 1994, J BIOL CHEM, V269, P16502; Jiang W., 1996, Biophysical Journal, V70, pA43; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; Rosenfeld SS, 1996, J BIOL CHEM, V271, P9473, DOI 10.1074/jbc.271.16.9473; SADHU A, 1992, J BIOL CHEM, V267, P11352; SHRIVER JW, 1981, BIOCHEMISTRY-US, V20, P2004, DOI 10.1021/bi00510a041; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; YOUNG EC, 1995, J BIOL CHEM, V270, P3926, DOI 10.1074/jbc.270.8.3926	19	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					717	723		10.1074/jbc.272.2.717	http://dx.doi.org/10.1074/jbc.272.2.717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995355	hybrid			2022-12-25	WOS:A1997WC04800006
J	Shi, JP; Friedman, S; Maciag, T				Shi, JP; Friedman, S; Maciag, T			A carboxyl-terminal domain in fibroblast growth factor (FGF)-2 inhibits FGF-1 release in response to heat shock in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; FACTOR-I; NUCLEAR-LOCALIZATION; SUBCELLULAR FATE; SEQUENCE; BINDING; EXPRESSION; IDENTIFICATION; TRANSLATION; INITIATION	The fibroblast growth factor (FGF) prototypes, FGF-1 and FGF-2, lack a signal sequence, but both contain a nuclear localization sequence. We prepared a series of FGF-1 deletion mutants fused to the reporter gene, beta-galactosidase (beta-gal) and determined that a domain between residues 83 and 154 is responsible for FGF-1 cytosol retention in NIH 3T3 cells. Using a series of FGF-beta-gal chimeric proteins prepared by the shuffling of cassette-formatted synthetic FGF prototype genes, we were able to demonstrate that the nuclear localization sequence from the 5'-CUG region of FGF-2 is not able to direct the nuclear association of FGF-1 due to its inability to repress the function of the FGF-1 cytosol retention domain. We also observed that while the FGF-1:beta-gal chimera was released in response to heat shock, the FGF-2:beta-gal protein was not. Further, replacement of the FGF-1 cytosol retention domain with the corresponding domain from FGF-2 repressed the release of the chimeric protein. These data suggest that the specificity of the stress-induced secretion pathway for FGF-1 involves a carboxyl-terminal domain that is absent in FGF-2 and that the FGF-1 secretion pathway does not restrict the release of high molecular weight forms of FGF-1.	AMER RED CROSS,JEROME H HOLLAND LAB,DEPT BIOL MOL,ROCKVILLE,MD 20855	American Red Cross					NHLBI NIH HHS [HL54710, HL32348, HL35627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348, R01HL035627, P01HL054710] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; ENGLEKA KA, 1992, J BIOL CHEM, V267, P11307; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOROUGH R, 1991, BIOCHIM BIOPHYS ACTA, V1090, P293, DOI 10.1016/0167-4781(91)90192-O; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; IMAMURA T, 1995, BBA-MOL CELL RES, V1266, P124, DOI 10.1016/0167-4889(95)00009-H; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LIN HJL, 1992, J VIROL, V66, P5443, DOI 10.1128/JVI.66.9.5443-5452.1992; MACH H, 1995, BIOCHEMISTRY-US, V34, P9913, DOI 10.1021/bi00031a013; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	25	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1142	1147		10.1074/jbc.272.2.1142	http://dx.doi.org/10.1074/jbc.272.2.1142			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995414	hybrid			2022-12-25	WOS:A1997WC04800065
J	Band, CJ; Posner, BI				Band, CJ; Posner, BI			Phosphatidylinositol 3'-kinase nad p70(s6k) are required for insulin but not bisperoxovanadium 1,10-phenanthroline (bpV(phen)) inhibition of insulin-like growth factor binding protein gene expression - Evidence for MEK-independent activation of mitogen-activated protein kinase by bpV(phen)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; IRS-1 SIGNALING SYSTEM; H4IIE HEPATOMA-CELLS; DNA-SYNTHESIS; PHOSPHOINOSITIDE 3-KINASE; PEROXOVANADIUM COMPOUNDS; MAP KINASE; S6 KINASE; FACTOR-I; STIMULATION	The hormonal regulation of insulin-like growth factor binding protein (IGFBP)-1 and -4 mRNA was compared in serum-free primary rat hepatocyte cultures. The combination of dexamethasone and glucagon (Dex/Gluc) strongly increased IGFBP-1 and IGFBP-4 mRNA levels. Insulin suppressed Dex/Gluc-stimulated IGFBP-1 but not IGFBP-4 mRNA levels. In contrast, the peroxovanadium compound, bisperoxovanadium 1,10-phenanthroline (bpV(phen)), completely abrogated Dex/Gluc induction of both IGFBP mRNA species. Wortmannin and rapamycin blocked the inhibitory effect of insulin but not that of bpV(phen) on Dex/Gluc-stimulated IGFBP mRNA. Thus, although phosphatidylinositol 3'-kinase and p70(s6k) are necessary for insulin-mediated transcriptional inhibition of the IGFBP-1 gene, a signaling pathway, independent of phosphatidyloinositol 3'-kinase and p70(S6k), is activated by bpV(phen) and mediates IGFBP-1 as well as IGFBP-4 mRNA inhibition. Mitogen-activated protein (MAP) kinase activity induced by insulin was suppressed to below basal levels in the presence of Dex/Gluc, whereas in response to bpV(phen), MAP kinase activity was high and unaffected by Dex/Gluc, consistent with a role of MAP kinases in bpV(phen)-mediated inhibition of IGFBP mRNA. The specific MAP kinase kinase (MEK) inhibitor, PD98059, inhibited insulin but not bpV(phen)-stimulated MAP kinase activity, suggesting that MAP kinases can be activated in a MEK-independent fashion. Peroxovanadium compounds are strong inhibitors of tyrosine phosphatases, which may inhibit specific tyrosine/threonine phosphatases involved in the negative regulation of MAP kinases.	MCGILL UNIV,POLYPEPTIDE HORMONE LAB,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 2B2,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3A 2B2,CANADA	McGill University; McGill University; McGill University			Posner, Barry/B-6733-2008					ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bach LA, 1995, DIABETES REV, V3, P38; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BARENTON B, 1988, ENDOCRINOLOGY, V122, P2499, DOI 10.1210/endo-122-6-2499; Bevan AP, 1995, MOL CELL BIOCHEM, V153, P49, DOI 10.1007/BF01075918; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; GAO L, 1993, BIOCHEM BIOPH RES CO, V190, P1053, DOI 10.1006/bbrc.1993.1155; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KACHRA Z, 1991, ENDOCRINOLOGY, V128, P1723, DOI 10.1210/endo-128-4-1723; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHAN MN, 1989, J BIOL CHEM, V264, P12931; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MELOCHE S, 1995, J CELL PHYSIOL, V163, P577, DOI 10.1002/jcp.1041630319; Mendez R, 1996, MOL CELL BIOL, V16, P2857; Muda M, 1996, J BIOL CHEM, V271, P4319; MURPHY LJ, 1990, MOL ENDOCRINOL, V4, P329, DOI 10.1210/mend-4-2-329; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; OKADA T, 1994, J BIOL CHEM, V269, P3568; ORLOWSKI CC, 1991, MOL ENDOCRINOL, V5, P1180, DOI 10.1210/mend-5-8-1180; Osawa H, 1996, J BIOL CHEM, V271, P16690, DOI 10.1074/jbc.271.28.16690; POSNER BI, 1994, J BIOL CHEM, V269, P4596; POWELL DR, 1991, J BIOL CHEM, V266, P18868; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Proud CG, 1996, TRENDS BIOCHEM SCI, V21, P181, DOI 10.1016/0968-0004(96)10016-5; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SHIMASAKI S, 1990, MOL ENDOCRINOL, V4, P1451, DOI 10.1210/mend-4-10-1451; SHIMASAKI S, 1991, Progress in Growth Factor Research, V3, P243, DOI 10.1016/0955-2235(91)90003-M; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUB DS, 1994, MOL ENDOCRINOL, V8, P794; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; SUWANICHKUL A, 1993, J BIOL CHEM, V268, P9730; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORNKVIST A, 1994, J BIOL CHEM, V269, P13919; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; UNTERMAN TG, 1991, ENDOCRINOLOGY, V128, P2693, DOI 10.1210/endo-128-6-2693; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YALE JF, 1995, DIABETES, V44, P1274, DOI 10.2337/diabetes.44.11.1274; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634	69	54	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					138	145						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995239				2022-12-25	WOS:A1997WA56400026
J	Gregori, L; Hainfeld, JF; Simon, MN; Goldgaber, D				Gregori, L; Hainfeld, JF; Simon, MN; Goldgaber, D			Binding of amyloid beta protein to the 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; MULTICATALYTIC PROTEINASE; NEUROFIBRILLARY TANGLES; PROTEOLYTIC ACTIVITY; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; UBIQUITIN; DEGRADATION; CELL; SUBSTRATE	Neurodegenerative disorders of aging are characterized by the intraneuronal accumulation of ubiquitin conjugates into tangles and inclusions. Ubiquitin conjugates are degraded by cellular particles known as proteasomes. We have previously shown that amyloid beta protein (A beta) inhibits proteasomal activity and thereby blocks ubiquitin conjugate degradation. In the present studies, we found that A beta binds the 20 S proteasome and forms a proteasome-A beta complex. The complex was detected by Western blot with anti-A beta antibodies. Using a 1.4 nm Nanogold-labeled A beta, we visualized proteasome-A beta complexes by scanning transmission electron microscopy (STEM). Analysis of the side-on oriented proteasome-A beta complexes revealed a single gold particle, corresponding to one gold-labeled A beta, in the middle portion of the proteasome. On end-on views of proteasome-A beta complexes, gold was detected within the area delimited by the proteasome circular projection. Both STEM views are consistent with A beta localization inside the proteasome along the peptide channel. Direct interaction of A beta with the inner catalytic compartment of the proteasome may explain the generation of ubiquitin-containing lesions in Alzheimer's disease and other neurodegenerative disorders. In addition, detection of Nanogold-labeled peptide inside the 20 S eukaryotic proteasome suggests that conformational constraints for protein degradation in eukaryotic proteasomes are different from those in archaebacteria proteasomes.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	United States Department of Energy (DOE); Brookhaven National Laboratory	Gregori, L (corresponding author), SUNY STONY BROOK,SCH MED,HLTH SCI CTR T10,DEPT PSYCHIAT & BEHAV SCI,STONY BROOK,NY 11794, USA.							ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; GREGORI L, 1995, J BIOL CHEM, V270, P19702, DOI 10.1074/jbc.270.34.19702; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; KWAK S, 1991, NEUROSCI LETT, V128, P21, DOI 10.1016/0304-3940(91)90751-E; LOWE J, 1990, NEUROPATH APPL NEURO, V16, P281, DOI 10.1111/j.1365-2990.1990.tb01263.x; MARTIN BL, 1995, J BIOL CHEM, V270, P26727, DOI 10.1074/jbc.270.45.26727; MORI H, 1987, SCIENCE, V235, P1641, DOI 10.1126/science.3029875; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PERRY G, 1992, AM J PATHOL, V140, P283; PODLISNY MB, 1995, J BIOL CHEM, V270, P9564, DOI 10.1074/jbc.270.16.9564; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SAHASRABUDHE S, 1995, ALZHEIMERS DIS PROMI; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SPILLANTINI MG, 1990, P NATL ACAD SCI USA, V87, P3947, DOI 10.1073/pnas.87.10.3947; TANAKA K, 1992, NEW BIOL, V4, P173; TURNER SR, 1996, J BIOL CHEM, V271, P8966; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WALL JS, 1986, ANNU REV BIOPHYS BIO, V15, P355; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; ZWICKL P, 1992, BIOCHEMISTRY-US, V31, P964, DOI 10.1021/bi00119a004	30	129	131	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					58	62						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995227				2022-12-25	WOS:A1997WA56400014
J	Lardans, A; Gillham, NW; Boynton, JE				Lardans, A; Gillham, NW; Boynton, JE			Site-directed mutations at residue 251 of the photosystem II D1 protein of Chlamydomonas that result in a nonphotosynthetic phenotype and impair D1 synthesis and accumulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBICIDE-RESISTANT MUTANTS; THYLAKOID MEMBRANE; BINDING PROTEIN; Q(B) POCKET; WILD-TYPE; IN-VIVO; CHLOROPLAST; SUBUNIT; LIGHT; REINHARDTII	In Cyanobacteria and Chlamydomonas reinhardtii, substitution of valine for alanine at position 251 of the photosystem II D1 protein in the loop between trans membrane helices IV and V confers resistance to herbicides that reduce photosystem II function and increases sensitivity to photoinhibition. Using site-directed mutagenesis and chloroplast transformation in Chlamydomonas we have examined further the role of residue 251 in relation to D1 structure, function, and photosynthetic performance. Of the 12 different amino acid substitutions for Ala(251) introduced at this position, five (Arg, Asp, Gln, Glu, and His) resulted in a nonphotosynthetic phenotype. Transformants with the Arg(251) substitution synthesize a normal sized 32-kDa D1 protein with greatly reduced stability. The Gln, Glu, His, and Asp transformants make a 33-34-kDa form of the D1 protein of varying stability as well as an immunologically related polypeptide of 24-25 kDa corresponding to the N-terminal portion of D1 that is unstable and appears to be an aborted D1 translation product. All mutant forms of the D1 protein are intrinsic to the thylakoids. In contrast to previous studies in Cyanobacteria showing that residues in the IV-V loop can be mutated or deleted without loss of photosynthetic competence, our results suggest that Ala(251) has a key role in the structure and function of the IV-V loop region.	DUKE UNIV,DEPT BOT,DEV CELL & MOL BIOL GRP,DURHAM,NC 27708; DUKE UNIV,DEPT ZOOL,DEV CELL & MOL BIOL GRP,DURHAM,NC 27708	Duke University; Duke University			Baillet, Anita/R-6217-2018					ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; ASTIER C, 1993, Z NATURFORSCH C, V48, P199; BARBATO R, 1995, J BIOL CHEM, V270, P24032, DOI 10.1074/jbc.270.41.24032; BARBER J, 1994, J PLANT PHYSL, V22, P201; BOYNTON JE, 1993, METHOD ENZYMOL, V217, P510; BREYTON C, 1994, J BIOL CHEM, V269, P7597; CRITCHLEY C, 1994, PHYSIOL PLANTARUM, V92, P188, DOI 10.1111/j.1399-3054.1994.tb06670.x; CROFTS AR, 1993, Z NATURFORSCH C, V48, P259; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; ELICH TD, 1992, J BIOL CHEM, V267, P3523; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; ERICKSON JM, 1989, PLANT CELL, V1, P361, DOI 10.1105/tpc.1.3.361; ETIENNE AL, 1993, PHOTOSYNTH RES, V38, P387, DOI 10.1007/BF00046765; GREENBERG BM, 1987, EMBO J, V6, P2865, DOI 10.1002/j.1460-2075.1987.tb02588.x; GREER KL, 1986, PLANT PHYSIOL, V82, P114, DOI 10.1104/pp.82.1.114; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HEIFETZ PB, 1995, THESIS DUKE U DURHAM; JOHANNINGMEIER U, 1987, FEBS LETT, V211, P221, DOI 10.1016/0014-5793(87)81440-0; KIM JM, 1991, J BIOL CHEM, V266, P14931; KLESS H, 1994, BIOCHEMISTRY-US, V33, P10501, DOI 10.1021/bi00200a035; KLESS H, 1995, J MOL BIOL, V246, P120, DOI 10.1006/jmbi.1994.0071; KRAUSE GH, 1988, PHYSIOL PLANTARUM, V74, P566, DOI 10.1111/j.1399-3054.1988.tb02020.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERS A, 1992, J BIOL CHEM, V267, P17494; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MATTOO AK, 1989, CELL, V56, P241, DOI 10.1016/0092-8674(89)90897-0; MULLET JE, 1990, P NATL ACAD SCI USA, V87, P4038, DOI 10.1073/pnas.87.11.4038; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; Narusaka Y, 1996, PLANT SCI, V115, P261, DOI 10.1016/0168-9452(96)04393-2; OHAD N, 1992, PLANT CELL, V4, P273, DOI 10.1105/tpc.4.3.273; OHAD N, 1990, Z NATURFORSCH C, V45, P402; PALOMARES R, 1993, EUR J BIOCHEM, V217, P345, DOI 10.1111/j.1432-1033.1993.tb18252.x; PEREWOSKA I, 1994, PLANT PHYSIOL, V104, P235, DOI 10.1104/pp.104.1.235; PRZIBILLA E, 1991, PLANT CELL, V3, P169, DOI 10.1105/tpc.3.2.169; RINTAMAKI E, 1995, PLANTA, V195, P379, DOI 10.1007/BF00202595; Rintamaki E, 1996, J BIOL CHEM, V271, P14870, DOI 10.1074/jbc.271.25.14870; Sambrook J., 2002, MOL CLONING LAB MANU; SAYRE RT, 1986, CELL, V47, P601, DOI 10.1016/0092-8674(86)90624-0; SCHMIDT RJ, 1985, MOL CELL BIOL, V5, P1093, DOI 10.1128/MCB.5.5.1093; SCHWENGERERGER C, 1993, FEBS LETT, V329, P43, DOI 10.1016/0014-5793(93)80189-2; SMITH TA, 1994, J CELL BIOL, V126, P365, DOI 10.1083/jcb.126.2.365; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; TREBST A, 1986, Z NATURFORSCH C, V41, P240; Tyystjarvi T, 1996, PHOTOSYNTH RES, V47, P111, DOI 10.1007/BF00016174; YU JJ, 1993, J BIOL CHEM, V268, P7407	45	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					210	216						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995249				2022-12-25	WOS:A1997WA56400036
J	Lee, TT; Worby, C; Dixon, JE; Colman, RF				Lee, TT; Worby, C; Dixon, JE; Colman, RF			Identification of His(141) in the active site of Bacillus subtilis adenylosuccinate lyase by affinity labeling with 6-(4-bromo-2,3-dioxobutyl)thioadenosine 5'-monophosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE INHIBITORY SITE; MUSCLE PYRUVATE-KINASE; DUCK DELTA-CRYSTALLIN; ESCHERICHIA-COLI; GLUTAMATE-DEHYDROGENASE; 6-<(4-BROMO-2,3-DIOXOBUTYL)THIO>-6-DEAMINOADENOSINE 5'-DIPHOSPHATE; PURIFICATION; CLONING; ENZYMES; GENE	Adenylosuccinate lyase of Bacillus subtilis is inactivated by 25-400 mu M 6-(4-bromo-2,3-dioxobutyl)thioadenosine 5'-monophosphate (6-BDB-TAMP) at pH 7.0 and 25 degrees C. The initial inactivation rate constant exhibits nonlinear dependence on the concentration of 6-BDB-TAMP, implying there is reversible formation of enzyme reagent complex (K-I = 30 +/- 4 mu M) prior to irreversible modification (k(max) = 0.139 +/- 0.005 min(-1)). The tetrameric enzyme incorporates about 1 mol of 6-BDB-[P-32]TAMP per mol of enzyme subunit concomitant with complete inactivation. Protection against inactivation and incorporation of [P-32]reagent is provided by adenylosuccinate or a combination of AMP and fumarate, whereas either AMP or fumarate alone is much less effective. These observations suggest that 6-BDB-TAMP targets the adenylosuccinate-binding site. Hydrolyzed 6-BDB-TAMP is a competitive inhibitor with respect to adenylosuccinate in the catalytic reaction and also decreases the rate of inactivation by 6-BDB-TAMP. These results account for the decrease in the inactivation rate as the reaction of 6-BDB-TAMP with the enzyme proceeds. Purification by chromatography on dihydroxyboryl-agarose and high performance liquid chromatography of the tryptic digest of inactivated enzyme yields a single radioactive peptide, Thr(140)-Phe(150), as determined by gas-phase sequencing. Modified His(141) is the reaction product of 6-BDB-TAMP and adenylosuccinate lyase, We conclude that 6-BDB-TAMP functions as a reactive adenylosuccinate analog in modifying His(141) in the substrate-binding site of adenylosuccinate lyase, where it may serve as a general base accepting a proton from the succinyl group during catalysis.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Delaware; University of Michigan System; University of Michigan					NIDDK NIH HHS [R01 DK 18849] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018849] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIMI J, 1990, J BIOL CHEM, V265, P9011; ANNAMALAI AE, 1979, ANAL BIOCHEM, V99, P85, DOI 10.1016/0003-2697(79)90046-0; BARNES LB, 1975, INT J BIOCHEM, V6, P497, DOI 10.1016/0020-711X(75)90030-0; BATRA SP, 1984, BIOCHEMISTRY-US, V23, P4940, DOI 10.1021/bi00316a018; BATRA SP, 1986, BIOCHEMISTRY-US, V25, P3508, DOI 10.1021/bi00360a005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIDGER WA, 1968, J BIOL CHEM, V243, P644; BRIDGER WA, 1969, CAN J BIOCHEM CELL B, V47, P665, DOI 10.1139/o69-102; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CARTER CE, 1956, J BIOL CHEM, V222, P17; CASEY PJ, 1987, BIOCHEM J, V246, P263, DOI 10.1042/bj2460263; CHIOU SH, 1991, BIOCHEM INT, V25, P705; COLMAN RF, 1984, BIOCHEMISTRY-US, V23, P3281, DOI 10.1021/bi00309a025; COLMAN RF, 1990, ENZYMES, V19, P283; DECAMP DL, 1989, J BIOL CHEM, V264, P8430; EBBOLE DJ, 1987, J BIOL CHEM, V262, P8274; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gite SU, 1996, BIOCHEMISTRY-US, V35, P2658, DOI 10.1021/bi952640y; GROVES WE, 1968, ANAL BIOCHEM, V22, P195, DOI 10.1016/0003-2697(68)90307-2; HATCH MD, 1966, BIOCHEM J, V98, P198, DOI 10.1042/bj0980198; Havir E. A., 1973, ENZYMES, V7, P75; HE B, 1992, J BACTERIOL, V174, P130, DOI 10.1128/jb.174.1.130-136.1992; IDA N, 1984, J BIOCHEM-TOKYO, V96, P1315, DOI 10.1093/oxfordjournals.jbchem.a134959; JAEKEN J, 1984, LANCET, V2, P1058; KARSTEN WE, 1991, ARCH BIOCHEM BIOPHYS, V287, P60, DOI 10.1016/0003-9861(91)90388-Y; KEENAN RW, 1982, J BIOL CHEM, V257, P4817; LEE HJ, 1993, BIOCHEM J, V293, P537, DOI 10.1042/bj2930537; LEE HJ, 1992, BIOCHEM J, V283, P597, DOI 10.1042/bj2830597; LEE TT, 1996, FASEB J, V10, pA1101; MILLER RW, 1959, J BIOL CHEM, V234, P1806; Moe OA, 1996, BIOCHEMISTRY-US, V35, P9024, DOI 10.1021/bi960426j; OZTURK DH, 1992, BIOCHEMISTRY-US, V31, P10544, DOI 10.1021/bi00158a018; PATEJUNAS G, 1995, EXP EYE RES, V61, P151, DOI 10.1016/S0014-4835(05)80034-X; Penefsky H S, 1979, Methods Enzymol, V56, P527; PINTO RM, 1983, J BIOL CHEM, V258, P2513; Ratner S, 1972, ENZYMES, P167; Redinbo MR, 1996, PROTEIN SCI, V5, P786; SIMPSON A, 1994, NAT STRUCT BIOL, V1, P724, DOI 10.1038/nsb1094-724; STONE RL, 1993, J BIOL CHEM, V268, P19710; STONE RL, 1992, NAT GENET, V1, P59, DOI 10.1038/ng0492-59; VOLLMER SH, 1994, J BIOL CHEM, V269, P8082; WEAVER TM, 1995, NAT STRUCT BIOL, V2, P654, DOI 10.1038/nsb0895-654; WILLIAMS SE, 1992, BIOCHEMISTRY-US, V31, P9768, DOI 10.1021/bi00155a033; WISTOW G, 1987, SCIENCE, V236, P1554, DOI 10.1126/science.3589669; WISTOW GJ, 1990, GENE, V96, P263, DOI 10.1016/0378-1119(90)90262-P; WONG LJC, 1995, GENOMICS, V28, P341, DOI 10.1006/geno.1995.1152; WOODWARD DO, 1966, J BIOL CHEM, V241, P580	47	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					458	465						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995283				2022-12-25	WOS:A1997WA56400070
J	McCarter, JD; Burgoyne, DL; Miao, SC; Zhang, SQ; Callahan, JW; Withers, SG				McCarter, JD; Burgoyne, DL; Miao, SC; Zhang, SQ; Callahan, JW; Withers, SG			Identification of Glu-268 as the catalytic nucleophile of human lysosomal beta-galactosidase precursor by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSIDASE INHIBITORS; GLUCOSIDASE; MECHANISM; FLUORIDES	Human lysosomal beta-galactosidase catalyzes the hydrolysis of beta-galactosides via a double displacement mechanism involving a covalent glycosyl enzyme intermediate. By use of the slow substrate 2,4-dinitrophenyl-2-deoxy-2-fluoro- beta-D-galactopyranoside, a glycosyl enzyme intermediate has been trapped on the enzyme. This has allowed the catalytic nucleophile to be identified as Glu-268 by peptic and tryptic digestion of the inactivated enzyme followed by high performance liquid chromatography-electrospray ionization tandem mass spectrometry of the peptide mixture. This glutamic acid is fully conserved in a sequence-related family of enzymes (Family 35), consistent with its essential role.	UNIV BRITISH COLUMBIA,DEPT CHEM,VANCOUVER,BC V6T 1Z1,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON M5G 1X8,CANADA	University of British Columbia; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto								BAUSE E, 1974, H-S Z PHYSIOL CHEM, V355, P438, DOI 10.1515/bchm2.1974.355.1.438; DAGROSA RM, 1992, BIOCHEM J, V285, P833, DOI 10.1042/bj2850833; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; MCCARTER JD, 1993, CARBOHYD RES, V249, P77, DOI 10.1016/0008-6215(93)84061-A; MCCARTER JD, 1994, BIOCHEM J, V301, P343, DOI 10.1042/bj3010343; OkamuraOho Y, 1996, BIOCHEM J, V313, P787, DOI 10.1042/bj3130787; OSHIMA A, 1991, AM J HUM GENET, V49, P1091; Oshima M., 1995, METABOLIC MOL BASES, V2, P2785; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; WITHERS SG, 1988, J BIOL CHEM, V263, P7929; ZHANG SQ, 1994, BIOCHEM J, V304, P281, DOI 10.1042/bj3040281	13	36	36	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					396	400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995274				2022-12-25	WOS:A1997WA56400061
J	Musser, SM; Fann, YC; Gurbiel, RJ; Hoffman, BM; Chan, SI				Musser, SM; Fann, YC; Gurbiel, RJ; Hoffman, BM; Chan, SI			Q-band electron nuclear double resonance (ENDOR) and X-band EPR of the sulfobetaine 12 heat-treated cytochrome c oxidase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMUS-THERMOPHILUS; COPPER CENTER; SPECTROSCOPIC CHARACTERIZATION; PARACOCCUS-DENITRIFICANS; REDUCTASE CONTAINS; QUINOL OXIDASE; SITE; PROTEINS; SUBUNIT; DOMAIN	Heat treatment of the bovine cytochrome c oxidase complex in the zwitterionic detergent sulfobetaine 12 (SE-12) results in loss of subunit III and the appearance of a type II copper center as characterized by electron paramagnetic resonance (EPR) spectroscopy. Previous authors (Nilsson, T., Copeland, R. A., Smith, P. A., and Chan, S. I. (1988) Biochemistry 27, 8254-8260) have interpreted this type II copper center as a modified version of the Cu-A site. By using electron nuclear double resonance spectroscopy, it is found that the Cu-A proton and nitrogen resonances remain present in the SB-12 heat-treated enzyme and that three new nitrogen resonances appear having hyperfine coupling constants consistent with histidine ligation, These hyperfine coupling constants correlate well with those recently found for the Cu-B histidines from the cytochrome aa(3)-600 quinol oxidase from Bacillus subtilis (Fann, Y. C., Ahmed, I., Blackburn, N. J., Boswell, J. S., Verkhovskaya, M. L., Hoffman, B. M., and Wikstrom, M. (1995) Biochemistry 34, 10245-10255), In addition, the total EPR-detectable copper concentration per enzyme molecule approximately doubles upon SE-12 heat treatment. Finally, the observed type II copper EPR spectrum is virtually indistinguishable from the EPR spectrum of Cu-B of the as-isolated cytochrome bo(3) complex from Escherichia coli, These data indicate that the type II copper species that appears results from a breaking of the strong antiferromagnetic coupling of the heme a(3)-Cu-B binuclear center.	CALTECH,ARTHUR AMOS NOYES LAB CHEM PHYS,DIV CHEM & CHEM ENGN,PASADENA,CA 91125; NORTHWESTERN UNIV,DEPT CHEM & BIOCHEM,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT MOL BIOL,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT CELLULAR BIOL,EVANSTON,IL 60208	California Institute of Technology; Northwestern University; Northwestern University; Northwestern University					NHLBI NIH HHS [HL13531] Funding Source: Medline; NIGMS NIH HHS [GM22432] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL013531, R37HL013531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022432, R37GM022432] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHOLINE WE, 1992, EUR J BIOCHEM, V209, P875, DOI 10.1111/j.1432-1033.1992.tb17360.x; BEINERT H, 1980, BIOCHIM BIOPHYS ACTA, V591, P458, DOI 10.1016/0005-2728(80)90176-0; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BLAIR DF, 1985, J AM CHEM SOC, V107, P7389, DOI 10.1021/ja00311a029; CARITHERS RP, 1981, J BIOL CHEM, V256, P7967; CHAN SI, 1978, FRONTIERS BIOL ENERG, V2, P883; CHAN SI, 1979, CYTOCHROME OXIDASE, P177; CLINE J, 1983, J BIOL CHEM, V258, P5124; FANN YC, 1995, BIOCHEMISTRY-US, V34, P10245, DOI 10.1021/bi00032a019; FEE JA, 1995, BIOCHEM BIOPH RES CO, V212, P77, DOI 10.1006/bbrc.1995.1938; GELLES J, 1985, BIOCHEMISTRY-US, V24, P3963, DOI 10.1021/bi00336a025; HARTZELL CR, 1974, BIOCHIM BIOPHYS ACTA, V368, P318, DOI 10.1016/0005-2728(74)90178-9; HOFFMAN BM, 1994, J MAGN RESON SER A, V110, P52, DOI 10.1006/jmra.1994.1180; HOFFMAN BM, 1993, BIOL MAGN RESON, V13, P151; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; KELLY M, 1993, J BIOL CHEM, V268, P16781; KRONECK PMH, 1988, FEBS LETT, V242, P70, DOI 10.1016/0014-5793(88)80987-6; LAPPALAINEN P, 1993, J BIOL CHEM, V268, P26416; LARSEN RW, 1989, BIOCHEMISTRY-US, V28, P6418, DOI 10.1021/bi00441a039; LI PM, 1988, BIOCHEMISTRY-US, V27, P7538, DOI 10.1021/bi00419a054; Musser SM, 1995, ADV ENZYMOL RAMB, V71, P79; MUSSER SM, 1997, IN PRESS BIOCHEMISTR; NILSSON T, 1988, BIOCHEMISTRY-US, V27, P8254, DOI 10.1021/bi00421a040; OERTLING WA, 1994, BIOCHEMISTRY-US, V33, P3128, DOI 10.1021/bi00176a048; REINHAMMAR B, 1980, J BIOL CHEM, V255, P5000; SCOTT RA, 1989, P NATL ACAD SCI USA, V86, P4082, DOI 10.1073/pnas.86.11.4082; SURERUS KK, 1992, P NATL ACAD SCI USA, V89, P3195, DOI 10.1073/pnas.89.8.3195; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; VANDEROOST J, 1992, EMBO J, V11, P3209, DOI 10.1002/j.1460-2075.1992.tb05398.x; WERST MM, 1991, J AM CHEM SOC, V113, P1533, DOI 10.1021/ja00005a011; ZICKERMANN V, 1995, EUR J BIOCHEM, V234, P686, DOI 10.1111/j.1432-1033.1995.686_b.x	31	6	6	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					203	209						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995248				2022-12-25	WOS:A1997WA56400035
J	Primm, TP; Walker, KW; Gilbert, HF				Primm, TP; Walker, KW; Gilbert, HF			Facilitated protein aggregation - Effects of calcium on the chaperone and anti-chaperone activity of protein disulfide-isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER ALCOHOL-DEHYDROGENASE; ENDOPLASMIC-RETICULUM; PEPTIDE BINDING; LYSOZYME; BIP; CATALYSIS; SECRETION; ALBUMIN; BONDS; SITES	Protein disulfide-isomerase (PDI) catalyzes the formation and isomerization of disulfides during oxidative protein folding in the eukaryotic endoplasmic reticulum. At high concentrations, it also serves as a chaperone and inhibits aggregation. However, at lower concentrations, PDI can display the unusual ability to facilitate aggregation, termed anti-chaperone activity (Puig, A., and Gilbert, H. F. (1994) J. Biol. Chem. 269, 7764-7771). Under reducing conditions (10 mM dithiothreitol) and at a low concentration (0.1-0.3 mu M) relative to the unfolded protein substrate, PDI facilitates aggregation of alcohol dehydrogenase (11 mu M) that has been denatured thermally or chemically. But at higher concentrations (>0.8 mu M), PDI inhibits aggregation under the same conditions, With denatured citrate synthase, PDI does not facilitate aggregation, but higher concentrations do inhibit aggregation. Anti-chaperone behavior is associated with the appearance of both PDI and substrate proteins in insoluble complexes, while chaperone behavior results in the formation of large (>500 kDa) but soluble complexes that contain both proteins. Physiological concentrations of calcium and magnesium specifically increase the apparent rate of PDI dependent aggregation and shift the chaperone activity to higher PDI concentrations. However, calcium has no effect on the K-m or V-max for PDI-catalyzed oxidative folding, suggesting that the interactions that lead to chaperone/anti-chaperone behavior are distinct from those required for catalytic activity. To account for this unusual behavior of a folding catalyst, a model with analogy to classic immunoprecipitation is proposed; multivalent interactions between PDI and a partially aggregated protein stimulate further aggregate formation by non-covalently cross-linking smaller aggregates. However, at high ratios of PDI to substrate, cross-linking may be inhibited by saturation of the sites with PDI. The effects of PDI concentration on substrate aggregation and the modulation of the behavior by physiological levels of calcium may have implications for the involvement of PDI in protein folding, aggregation, and retention in the endoplasmic reticulum.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040379] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40379] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; CAI H, 1994, J BIOL CHEM, V269, P24550; CANNON DJ, 1969, BIOCHEM BIOPH RES CO, V35, P403, DOI 10.1016/0006-291X(69)90513-0; CHENG SY, 1987, J BIOL CHEM, V262, P11221; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; DORNER AJ, 1987, J CELL BIOL, V105, P2665, DOI 10.1083/jcb.105.6.2665; DORNER AJ, 1988, J CELL BIOL, V123, P1355; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GERSCHITZ J, 1978, EUR J BIOCHEM, V87, P591, DOI 10.1111/j.1432-1033.1978.tb12411.x; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert H F, 1991, Protein Expr Purif, V2, P194, DOI 10.1016/1046-5928(91)90071-P; GILBERT HF, 1989, BIOCHEMISTRY-US, V28, P7298, DOI 10.1021/bi00444a023; Gilbert HF, 1994, MECH PROTEIN FOLDING, P104; Guthapfel R, 1996, J BIOL CHEM, V271, P2663, DOI 10.1074/jbc.271.5.2663; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HILLSON DA, 1984, METHOD ENZYMOL, V107, P281; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; JAKOB U, 1995, J BIOL CHEM, V270, P14412, DOI 10.1074/jbc.270.24.14412; KIM PS, 1993, J BIOL CHEM, V268, P4873; King J, 1996, FASEB J, V10, P57, DOI 10.1096/fasebj.10.1.8566549; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBECHE D, 1994, BIOCHEM BIOPH RES CO, V202, P556, DOI 10.1006/bbrc.1994.1964; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MACER DRJ, 1988, J CELL SCI, V91, P61; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1993, J BIOL CHEM, V268, P19210; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; OTSU M, 1994, J BIOL CHEM, V269, P6874; PAL MK, 1994, INDIAN J BIOCHEM BIO, V31, P109; PUIG A, 1994, J BIOL CHEM, V269, P25889; PUIG A, 1994, J BIOL CHEM, V269, P7764; PUIG A, 1994, J BIOL CHEM, V269, P19128; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; ROBINSON AS, 1995, BIOTECHNOL PROGR, V11, P171, DOI 10.1021/bp00032a009; ROBINSON AS, 1994, BIO-TECHNOL, V12, P381, DOI 10.1038/nbt0494-381; SCHWALLER MD, 1994, FASEB J, V8, pA1386; SONG JL, 1995, EUR J BIOCHEM, V231, P312, DOI 10.1111/j.1432-1033.1995.tb20702.x; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; TSIBRIS JCM, 1989, J BIOL CHEM, V264, P13967; WANG Z, 1992, PROTEIN SCI, V1, P522; WEST SM, 1990, BIOCHIM BIOPHYS ACTA, V1037, P332, DOI 10.1016/0167-4838(90)90034-D; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WILTON DC, 1990, BIOCHEM J, V270, P163, DOI 10.1042/bj2700163; ZAPUN A, 1995, PROTEIN-STRUCT FUNCT, V14, P10	49	88	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33664	33669		10.1074/jbc.271.52.33664	http://dx.doi.org/10.1074/jbc.271.52.33664			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969236	hybrid			2022-12-25	WOS:A1996WA71300070
J	Shyur, LF; Aleshin, AE; Honzatko, RB; Fromm, HJ				Shyur, LF; Aleshin, AE; Honzatko, RB; Fromm, HJ			Biochemical properties of mutant and wild-type fructose-1,6-bisphosphatases are consistent with the coupling of intra- and intersubunit conformational changes in the T- and R-state transition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT LIVER FRUCTOSE-1,6-BISPHOSPHATASE; PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; SITE-DIRECTED MUTAGENESIS; FRUCTOSE 2,6-BISPHOSPHATE; PORCINE FRUCTOSE-1,6-BISPHOSPHATASE; BINDING-SITE; AMP; BISPHOSPHATASE; MECHANISM; 1,6-BISPHOSPHATASE	The significance of interactions between AMP domains in recombinant porcine fructose-1,6-bisphosphatase (FBPase) is explored by site-directed mutagenesis and kinetic characterization of homogeneous preparations of mutant enzymes. Mutations of Lys(42) ILe(190), and Gly(191) do not perturb the circular dichroism spectra, but have significant effects on ligand binding and mechanisms of cooperativity. The K-m for fructose 1,6-bisphosphate and the K-i for the competitive inhibitor, fructose a,g-bisphosphate, decreased by as much as 4- and 8-fold, respectively, in the Q32L, K42E, K42T, I190T, and G191A mutants relative to the wild-type enzyme, Q32L, unlike the other four mutants, exhibited a 1.7-fold increase in K-cat. Mg2+ binding is sigmoidal for the five mutants as well as for the wild-type enzyme, but the Mg2+ affinities were decreased (3-22-fold) in mutant FBPases. With the exception of Q32L (8-fold increase), the 50% inhibiting concentrations of AMP for K42E, K42T, I190T, and G191A were increased over 2,000-fold (>10 mM) relative to the wild-type enzyme. Most importantly, a loss of AMP cooperativity was found with K42E, K42T, I190T, and G191A. In addition, the mechanism of AMP inhibition with respect to Mg2+ was changed from competitive to noncompetitive for K42T, I190T, and G191A FBPases. Structural modeling and kinetic studies suggest that Lys(42), ILe(190), and Gly(191) are located at the pivot point of intersubunit conformational changes that energetically couple the Mg2+-binding site to the AMP domain of FBPase.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON VA, 1993, BIOCHEM BIOPH RES CO, V192, P511, DOI 10.1006/bbrc.1993.1445; CHEN M, 1994, J BIOL CHEM, V269, P5554; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1991, BIOCHEMISTRY-US, V30, P4412, DOI 10.1021/bi00232a007; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P10035; LIU F, 1988, J BIOL CHEM, V263, P9122; LIU F, 1990, J BIOL CHEM, V265, P7401; MARCUS F, 1982, P NATL ACAD SCI-BIOL, V79, P7161, DOI 10.1073/pnas.79.23.7161; MCGRANE MM, 1983, J BIOL CHEM, V258, P445; NIMMO HG, 1975, EUR J BIOCHEM, V58, P575, DOI 10.1111/j.1432-1033.1975.tb02408.x; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1981, J BIOL CHEM, V256, P3619; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; SHYUR LF, 1995, ARCH BIOCHEM BIOPHYS, V319, P123, DOI 10.1006/abbi.1995.1273; Shyur LF, 1996, J BIOL CHEM, V271, P3005, DOI 10.1074/jbc.271.6.3005; Shyur LF, 1996, BIOCHEMISTRY-US, V35, P7492, DOI 10.1021/bi960367+; SIANO DB, 1975, ARCH BIOCHEM BIOPHYS, V170, P587, DOI 10.1016/0003-9861(75)90154-X; STONE SR, 1980, BIOCHEMISTRY-US, V19, P620, DOI 10.1021/bi00545a003; TAKETA K, 1965, J BIOL CHEM, V240, P651; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; TEJWANI GA, 1983, ADV ENZYMOL RELAT AR, V59, P315; Ulm E H, 1975, Methods Enzymol, V42, P369; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4307, DOI 10.1021/bi00013a020; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755; ZHANG YP, 1993, BIOCHEMISTRY-US, V32, P1844, DOI 10.1021/bi00058a019	32	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33301	33307		10.1074/jbc.271.52.33301	http://dx.doi.org/10.1074/jbc.271.52.33301			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969189	hybrid			2022-12-25	WOS:A1996WA71300023
J	Yi, JZ; Nemeria, N; McNally, A; Jordan, F; Machado, RS; Guest, JR				Yi, JZ; Nemeria, N; McNally, A; Jordan, F; Machado, RS; Guest, JR			Effect of substitutions in the thiamin diphosphate-magnesium fold on the activation of the pyruvate dehydrogenase complex from Escherichia coli by cofactors and substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTI-ENZYME COMPLEX; MULTIENZYME COMPLEX; LIPOAMIDE DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; BIFUNCTIONAL ARSENOXIDE; REGULATORY PROPERTIES; ZYMOMONAS-MOBILIS; BINDING-SITE; INHIBITION	The homotropic regulation of the Escherichia coli pyruvate dehydrogenase multienzyme complex (PDHc) by its coenzyme thiamin diphosphate and its substrate pyruvate was re-examined with complexes containing three and one lipoyl domains per E2 chain, and several variants of the latter, containing substitutions in the putative thiamin diphosphate fold of E1 (G231A G231S, C259S, C259N, and N258Q). It was found that all of the E1 variants ants had significantly reduced specific activities, as reported elsewhere (Russell, G. C., Machado, R. S., and Guest, J. R. (1992) Biochem. J. 287, 611-619). In addition, extensive kinetic studies were performed in an attempt to determine the effects of the amino acid substitutions on the Hill coefficients with respect to thiamin diphosphate and pyruvate. All but one of the variants were incapable of being saturated with thiamin diphosphate, even at concentrations > 5 mM. Most importantly, the striking activation lag phase lasting for many seconds in the parental complexes containing three and one lipoyl domains per E2 chain was totally eliminated in the variants. Furthermore, activation by the coenzyme was localized to the E1 subunit, because resolved E1 exhibits virtually the same behavior during the activation lag phase as does the complex. In the parental complexes two distinct lag phases could be resolved, the duration of both decreases with increasing ThDP concentration. A mechanism that is consistent with all of the kinetic data on the parental complexes involves rapid equilibration of the first ThDP with the E1 dimer, followed by a slow conformational equilibration, that in turn is followed by slow addition of the second ThDP to form the fully activated dimer. When the diphosphate site is badly impaired, the binding affinity is very much reduced, this perhaps eliminates the slow step leading to the activated dimer form of the E1.	RUTGERS STATE UNIV,DEPT CHEM,NEWARK,NJ 07102; UNIV SHEFFIELD,DEPT MOL BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND	Rutgers State University Newark; Rutgers State University New Brunswick; University of Sheffield					NIGMS NIH HHS [GM-50380] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON SR, 1984, BIOCHEMISTRY-US, V23, P1269, DOI 10.1021/bi00301a039; ADAMSON SR, 1981, BIOCHEMISTRY-US, V20, P3418, DOI 10.1021/bi00515a018; ALI MS, 1995, J BIOL CHEM, V270, P4570, DOI 10.1074/jbc.270.9.4570; ANNAN N, 1989, J AM CHEM SOC, V111, P8895, DOI 10.1021/ja00206a019; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; BERNASCONI CF, 1976, RELAXATION KINETICS, P24; BISSWANG.H, 1974, EUR J BIOCHEM, V48, P377, DOI 10.1111/j.1432-1033.1974.tb03779.x; BISSWANGER H, 1971, EUR J BIOCHEM, V24, P376, DOI 10.1111/j.1432-1033.1971.tb19696.x; BISSWANGER H, 1980, BIOCHEM BIOPH RES CO, V95, P513, DOI 10.1016/0006-291X(80)90814-1; BREMER J, 1969, EUR J BIOCHEM, V8, P535, DOI 10.1111/j.1432-1033.1969.tb00559.x; CANDY JM, 1994, BIOCHEM J, V300, P7, DOI 10.1042/bj3000007; CRAIG DW, 1980, J BIOL CHEM, V255, P5769; DEGRAAFHESS AC, 1982, FEBS LETT, V143, P261, DOI 10.1016/0014-5793(82)80112-9; DIEFENBACH RJ, 1992, FEBS LETT, V296, P95, DOI 10.1016/0014-5793(92)80411-9; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; EGAN RM, 1981, J BIOL CHEM, V256, P4877; ELEY MH, 1972, ARCH BIOCHEM BIOPHYS, V152, P655, DOI 10.1016/0003-9861(72)90262-7; FLOURNOY DS, 1989, BIOCHEMISTRY-US, V28, P9594, DOI 10.1021/bi00451a007; GUNSALUS IC, 1954, MECHANISM ENZYME ACT, P545; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HORN F, 1983, J BIOL CHEM, V258, P6912; HUBNER G, 1996, BIOCH PHYSL THIAMIN, P243; JACKSON RH, 1983, J BIOL CHEM, V258, P1857; KLUGER R, 1977, J AM CHEM SOC, V99, P4504, DOI 10.1021/ja00455a052; KOCHETOV GA, 1970, BIOCHEM BIOPH RES CO, V41, P1134, DOI 10.1016/0006-291X(70)90203-2; KOIKE M, 1960, J BIOL CHEM, V235, P1924; KOROCHKINA L G, 1991, Biokhimiya, V56, P1840; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDQUIST Y, 1992, EMBO J, V11, P3273; LOWE PN, 1983, BIOCHEMISTRY-US, V22, P150, DOI 10.1021/bi00270a022; LOWE PN, 1984, BIOCHEMISTRY-US, V23, P91, DOI 10.1021/bi00296a015; Massy V, 1963, ENZYMES, V7, P275; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19736, DOI 10.1074/jbc.270.34.19736; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; RUSSELL GC, 1992, BIOCHEM J, V287, P611, DOI 10.1042/bj2870611; SCHELLENBERGER A, 1965, H-S Z PHYSIOL CHEM, V343, P189; SCHONBRUNNHANEBECK E, 1990, BIOCHEMISTRY-US, V29, P4880, DOI 10.1021/bi00472a018; SCHWARTZ ER, 1968, BIOCHEM BIOPH RES CO, V31, P495, DOI 10.1016/0006-291X(68)90504-4; SCHWARTZ ER, 1970, BIOCHEMISTRY-US, V9, P1434, DOI 10.1021/bi00808a019; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P155, DOI 10.1111/j.1432-1033.1983.tb07441.x; STEPHENS PE, 1983, EUR J BIOCHEM, V135, P519, DOI 10.1111/j.1432-1033.1983.tb07683.x; STEPHENS PE, 1983, EUR J BIOCHEM, V133, P481, DOI 10.1111/j.1432-1033.1983.tb07490.x; STEVENSON KJ, 1978, BIOCHEMISTRY-US, V17, P2189, DOI 10.1021/bi00604a026; SUMEGI B, 1983, EUR J BIOCHEM, V136, P347, DOI 10.1111/j.1432-1033.1983.tb07748.x; VOGEL O, 1971, EUR J BIOCHEM, V18, P103, DOI 10.1111/j.1432-1033.1971.tb01220.x	47	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33192	33200		10.1074/jbc.271.52.33192	http://dx.doi.org/10.1074/jbc.271.52.33192			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969175	hybrid			2022-12-25	WOS:A1996WA71300009
J	Mege, D; DiBartolo, V; Germain, V; Tuosto, L; Michel, F; Acuto, O				Mege, D; DiBartolo, V; Germain, V; Tuosto, L; Michel, F; Acuto, O			Mutation of tyrosines 492/493 in the kinase domain of ZAP-70 affects multiple T-cell receptor signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TANDEM SH2 DOMAINS; ANTIGEN RECEPTOR; ZETA-CHAIN; ACTIVATION MOTIF; ADAPTER PROTEIN; GRB2; PHOSPHORYLATION; COMPLEX; FAMILY; SITES	The protein-tyrosine kinase ZAP-70 is implicated, together with the Src kinase p56(lck), in controlling the early steps of the T-cell antigen receptor (TCR) signaling cascade. To help elucidate further the mechanism by which ZAP-70 regulates these initial events, we used a dominant-negative mutant approach. We overexpressed in the Jurkat T-cell line ZAP-70 mutated on Tyr-492 and Tyr-493 in the putative regulatory loop of its kinase domain. This mutant inhibited TCR induced activation of nuclear factor of activated T cells by interfering with both intracellular calcium increase and Ras-regulated activation of extracellular signal-regulated kinases. Moreover, TCR-induced phosphorylation of pp36-38, thought to play a role upstream of these pathways, was found to be reduced. In contrast, overexpression of wildtype ZAP-70 induced constitutive activation of nuclear factor of activated T cells. The ZAP-70 mutant studied here could be phosphorylated on tyrosine when associated to the TCR zeta chain and was able to bind p56(lck). This result demonstrates that Tyr-492 and Tyr-493 are not responsible for the Src homology domain a-mediated association of p56(lck) with ZAP-70. Our data are most consistent with a model in which recruitment to the TCR allows ZAP-70 autophosphorylation and binding to p56(lck), which in turn phosphorylates Tyr-492 and/or Tyr-493 with consequent up-regulation of the ZAP-70 kinase activity. ZAP-70 will then be able to effectively control phosphorylation of its substrates and lead to gene activation.	INST PASTEUR,DEPT IMMUNOL,MOL IMMUNOL UNIT,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Tuosto, Loretta/F-7017-2011; Di Bartolo, Vincenzo/AAL-6834-2020	Tuosto, Loretta/0000-0001-9056-4077; Di Bartolo, Vincenzo/0000-0002-5453-947X; Michel, Frederique/0000-0002-3524-2232				ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1995, ONCOGENE, V10, P1141; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DANIELIAN S, 1989, EUR J IMMUNOL, V19, P2183, DOI 10.1002/eji.1830191202; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HANKS SK, 1995, PROTEIN KINASE FACTS, V1, P7; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KOYASU S, 1994, P NATL ACAD SCI USA, V91, P6693, DOI 10.1073/pnas.91.14.6693; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, MOL CELL BIOL, V16, P2823; NEL AE, 1990, J IMMUNOL, V144, P2683; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; OSMAN N, 1995, J BIOL CHEM, V270, P13981, DOI 10.1074/jbc.270.23.13981; QIAN BD, 1996, J EXP MED, V183, P611; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SHALLER MD, 1994, MOL CELL BIOL, V14, P1680; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Straus DB, 1996, J BIOL CHEM, V271, P9976, DOI 10.1074/jbc.271.17.9976; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOME M, 1995, J EXP MED, V181, P1997, DOI 10.1084/jem.181.6.1997; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517	58	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32644	32652		10.1074/jbc.271.51.32644	http://dx.doi.org/10.1074/jbc.271.51.32644			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955094	hybrid			2022-12-25	WOS:A1996VZ37300029
J	Taylor, TC; Fothergill, MD; Andersson, I				Taylor, TC; Fothergill, MD; Andersson, I			A common structural basis for the inhibition of ribulose 1,5-bisphosphate carboxylase by 4-carboxyarabinitol 1,5-bisphosphate and xylulose 1,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; X-RAY; 2-CARBOXY-D-ARABINITOL 1,5-BISPHOSPHATE; CRYSTAL-STRUCTURE; OXYGENASE; CATALYSIS; PROTEIN; ACTIVATION; PHOSPHOGLYCOLATE	Ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco) catalyzes the carboxylation of ribulose 1,5-bisphosphate. The reaction catalyzed by Rubisco involves several steps, some of which can occur as partial reactions, forming intermediates that can be isolated. Analogues of these intermediates are potent inhibitors of the enzyme. We have studied the interactions with the enzyme of two inhibitors, xylulose 1,5-bisphosphate and 4-carboxyarabinitol 1,5-bisphosphate, by x-ray crystallography. Crystals of the complexes were formed by co-crystallization under activating conditions. In addition, 4-carboxyarabinitol 1,5-bisphosphate was soaked into preformed activated crystals of the enzyme. The result of these experiments was the release of the activating CO2 molecule as well as the metal ion from the active site when the inhibitors bound to the enzyme. Comparison with the structure of an activated complex of the enzyme indicates that the structural basis for the release of the activator groups is a distortion of the metal binding site due to the different geometry of the C-3 hydroxyl of the inhibitors. Both inhibitors induce closure of active site loops despite the inactivated state of the enzyme. Xylulose 1,5-bisphosphate binds in a hydrated form at the active site.	SWEDISH UNIV AGR SCI, DEPT BIOL MOL, S-75124 UPPSALA, SWEDEN	Swedish University of Agricultural Sciences								ANDERSSON I, 1983, J BIOL CHEM, V258, P4088; Andersson I, 1996, J MOL BIOL, V259, P160, DOI 10.1006/jmbi.1996.0310; ANDERSSON I, 1984, J MOL BIOL, V172, P363, DOI 10.1016/S0022-2836(84)80033-9; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1973, BIOCHEMISTRY-US, V12, P11, DOI 10.1021/bi00725a003; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARCENA JA, 1983, BIOCHEM INT, V7, P755; BOLDEN TD, 1983, BIOCHEM INT, V6, P93; BOWES G, 1971, BIOCHEM BIOPH RES CO, V45, P716, DOI 10.1016/0006-291X(71)90475-X; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 1; CLELAND WW, 1990, BIOCHEMISTRY-US, V29, P3194, DOI 10.1021/bi00465a006; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAING WA, 1976, BIOCHEM J, V159, P563, DOI 10.1042/bj1590563; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORIMER GH, 1976, BIOCHEMISTRY-US, V15, P529, DOI 10.1021/bi00648a012; LORIMER GH, 1973, NATURE, V243, P359, DOI 10.1038/243359a0; LORIMER GH, 1987, PLANT MOL BIOL, P21; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; MCCURRY SD, 1977, J BIOL CHEM, V252, P8344; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEWMAN J, 1994, STRUCTURE, V2, P495, DOI 10.1016/S0969-2126(00)00050-2; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SCHLOSS JV, 1988, J BIOL CHEM, V263, P4145; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; YOKOTA A, 1991, PLANT CELL PHYSIOL, V32, P755; ZHANG KYJ, 1994, PROTEIN SCI, V3, P64; ZHU GH, 1991, PLANT PHYSIOL, V97, P1354, DOI 10.1104/pp.97.4.1354; ZHU GH, 1991, PLANT PHYSIOL, V97, P1348, DOI 10.1104/pp.97.4.1348	34	27	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32894	32899		10.1074/jbc.271.51.32894	http://dx.doi.org/10.1074/jbc.271.51.32894			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955130	hybrid			2022-12-25	WOS:A1996VZ37300065
J	Wang, JT; Gralla, JD				Wang, JT; Gralla, JD			The transcription initiation pathway of sigma 54 mutants that bypass the enhancer protein requirement - Implications for the mechanism of activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRATION HOST FACTOR; ESCHERICHIA-COLI COMPONENTS; RNA-POLYMERASE; KLEBSIELLA-PNEUMONIAE; PROMOTER; NTRC; GLNA; SIGMA-54-HOLOENZYME; ASSOCIATION; COMPLEXES	In vitro transcription, DNase I footprinting, and abortive initiation assays were used to characterize transcription using mutant forms of sigma 54 shown previously to bypass certain enhancer requirements in vitro. The holoenzymes containing these sigma mutants produce low levels of open complexes at both the glnAp2 and glnHp2 promoters. The open complexes are unusual in that they are destroyed by heparin. Enhancer protein and ATP convert them into a stable heparin-resistant state. The enhancer response occurs over a similar range of NtrC concentration as occurs with the wildtype holoenzyme, indicating that the activation determinants have been largely preserved within these mutants. One-round transcription assays show that the mutant holoenzymes can be driven to transcribe both promoters without NtrC. The unstable opening induced by these mutations apparently serves as a conduit that can shuttle templates into transcriptionally competent complexes. The results lead to a model in which activation occurs in two steps. First, the enhancer complex overcomes an inhibitory effect of the sigma 54 leucine patch and unlocks the melting activity of the holoenzyme. Second, different sigma 54 determinants are used to drive stabilization of the open complexes, allowing the full transcription potential to be realized.	UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOL BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35754] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUCK M, 1992, MOL MICROBIOL, V6, P1625, DOI 10.1111/j.1365-2958.1992.tb00887.x; CANNON WV, 1990, NUCLEIC ACIDS RES, V18, P1693, DOI 10.1093/nar/18.7.1693; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; CLAVERIEMARTIN F, 1992, J MOL BIOL, V227, P996, DOI 10.1016/0022-2836(92)90516-M; CLAVERIEMARTIN F, 1991, P NATL ACAD SCI USA, V88, P1631, DOI 10.1073/pnas.88.5.1631; COLLADOVIDES J, 1991, MICROBIOL REV, V55, P371, DOI 10.1128/MMBR.55.3.371-394.1991; DAYTON CJ, 1984, J BIOL CHEM, V259, P1616; FENG JL, 1992, J BACTERIOL, V174, P6061, DOI 10.1128/JB.174.19.6061-6070.1992; GOBER JW, 1990, GENE DEV, V4, P1494, DOI 10.1101/gad.4.9.1494; GRALLA JD, 1991, CELL, V66, P415, DOI 10.1016/0092-8674(81)90001-5; HAWLEY DK, 1980, P NATL ACAD SCI-BIOL, V77, P6381, DOI 10.1073/pnas.77.11.6381; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; HSIEH M, 1993, THESIS U CALIFORNIA; HSIEH ML, 1994, J BIOL CHEM, V269, P373; HUNT TP, 1985, P NATL ACAD SCI USA, V82, P8453, DOI 10.1073/pnas.82.24.8453; KUSTU S, 1991, TRENDS BIOCHEM SCI, V16, P397, DOI 10.1016/0968-0004(91)90163-P; MAGASANIK B, 1993, J CELL BIOCHEM, V51, P34, DOI 10.1002/jcb.240510108; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MOORE JB, 1993, J BACTERIOL, V175, P2692, DOI 10.1128/JB.175.9.2692-2701.1993; MORRIS L, 1994, J BIOL CHEM, V269, P11563; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POPHAM D, 1991, J BIOL CHEM, V266, P19510; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; REITZER LJ, 1989, J BACTERIOL, V171, P5512, DOI 10.1128/jb.171.10.5512-5522.1989; SASSEDWIGHT S, 1991, METHOD ENZYMOL, V208, P146; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHAUDER B, 1987, GENE, V52, P279, DOI 10.1016/0378-1119(87)90054-0; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; TINTUT Y, 1995, GENE DEV, V9, P2305, DOI 10.1101/gad.9.18.2305; TINTUT Y, 1995, J BIOL CHEM, V270, P24392, DOI 10.1074/jbc.270.41.24392; WANG JT, 1995, SCIENCE, V270, P992, DOI 10.1126/science.270.5238.992; WEDEL A, 1995, GENE DEV, V9, P2042, DOI 10.1101/gad.9.16.2042; WEISS DS, 1991, CELL, V67, P155, DOI 10.1016/0092-8674(91)90579-N	34	29	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32707	32713		10.1074/jbc.271.51.32707	http://dx.doi.org/10.1074/jbc.271.51.32707			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955103	hybrid			2022-12-25	WOS:A1996VZ37300038
J	Yip, TT; VandeWater, J; Gershwin, ME; Coppel, RL				Yip, TT; VandeWater, J; Gershwin, ME; Coppel, RL			Cryptic antigenic determinants on the extracellular pyruvate dehydrogenase complex mimeotope found in primary biliary cirrhosis - A probe by affinity mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROLIPOAMIDE ACETYLTRANSFERASE; MONOCLONAL-ANTIBODIES; LIMITED PROTEOLYSIS; EPITHELIAL-CELLS; HUMAN AUTOANTIBODIES; PROTEIN ANTIGEN; BINDING DOMAIN; COMPONENT; VIRUS; AUTOANTIGEN	Affinity mass spectrometry (AMS) was used to evaluate the structural diversity of the E2 component of pyruvate dehydrogenase complex (PDC) in normal and diseased liver cells, including those from patients with the autoimmune disease primary biliary cirrhosis (PBC). Two different antibodies to PDC-E2, the immunodominant mitochondrial autoantigen in patients with PBC, were used. AMS was performed directly on frozen liver sections and purified bile duct epithelial cells. Mass spectrometric signals associated with the molecular recognition of PBC-specific antigenic determinants were enhanced by an in situ enzyme-linked signal amplification process. Samples from patients with PBC gave strong positive signals for the antigen(s) recognized by the monoclonal antibody C355.1. Conversely, tissues from normal and disease controls showed only a minimal signal. AMS was used to identify specific antigenic determinants within the E2 component of PDC for comparison with unknown antigenic determinants observed by affinity capture with C355.1 monoclonal antibody from PBC samples. PDC components bound to C355.1 were mapped and identified by mass before dissociation from the E2 component. A similar approach was used to identify unknown antigenic determinants associated with PBC. We believe AMS may be an important new approach with wide application to the identification of molecules associated with a number of disease states.	UNIV CALIF DAVIS, SCH MED, DIV RHEUMATOL ALLERGY & CLIN IMMUNOL, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, SCH MED, DEPT FOOD SCI & TECHNOL, DAVIS, CA 95616 USA; MONASH UNIV, DEPT MICROBIOL, CLAYTON, VIC 3168, AUSTRALIA; MOL ANALYT SYST, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis; Monash University			Coppel, Ross L/A-6626-2008	Coppel, Ross L/0000-0002-4476-9124	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R41GM051658] Funding Source: NIH RePORTER; NIGMS NIH HHS [R41GM 51658] Funding Source: Medline; PHS HHS [39588, 50977] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BENJAMIN DC, 1984, ANNU REV IMMUNOL, V2, P67, DOI 10.1146/annurev.iy.02.040184.000435; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; CHA S, 1993, P NATL ACAD SCI USA, V90, P2527, DOI 10.1073/pnas.90.6.2527; CHA S, 1994, HEPATOLOGY, V20, P574, DOI 10.1002/hep.1840200305; COPPEL RL, 1995, IMMUNOL REV, V144, P17, DOI 10.1111/j.1600-065X.1995.tb00064.x; DOIG P, 1993, J MOL BIOL, V233, P753, DOI 10.1006/jmbi.1993.1550; EISENBERG RJ, 1982, J VIROL, V41, P478, DOI 10.1128/JVI.41.2.478-488.1982; GAUSS C, 1990, ENVIRON HEALTH PERSP, V88, P57; HARRIS DP, 1995, EUR J IMMUNOL, V25, P3173, DOI 10.1002/eji.1830251128; HUTCHENS TW, 1993, RAPID COMMUN MASS SP, V7, P576, DOI 10.1002/rcm.1290070703; HUTCHENS TW, 1994, PROTEIN SCI S1, V3, P81; HUTCHENS TW, 1993, PROTEIN SCI, V2, P92; JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757; JOPLIN R, 1995, J PATHOL, V176, P381, DOI 10.1002/path.1711760409; JOPLIN R, 1989, IN VITRO CELL DEV B, V25, P1189; JOPLIN RE, 1994, HEPATOLOGY, V19, P1375, DOI 10.1002/hep.1840190610; LESSARD IAD, 1995, BIOCHEM J, V306, P727, DOI 10.1042/bj3060727; LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227; MacSween R N, 1981, Semin Liver Dis, V1, P282, DOI 10.1055/s-2008-1040732; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19736, DOI 10.1074/jbc.270.34.19736; MCNALLY AJ, 1995, J BIOL CHEM, V270, P19744, DOI 10.1074/jbc.270.34.19744; MOELLING K, 1980, J VIROL, V33, P680, DOI 10.1128/JVI.33.2.680-688.1980; MOUDGIL KD, 1994, CLIN IMMUNOL IMMUNOP, V73, P283, DOI 10.1006/clin.1994.1200; PAPAC DI, 1994, PROTEIN SCI, V3, P1485, DOI 10.1002/pro.5560030914; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PONS G, 1988, P NATL ACAD SCI USA, V85, P1422, DOI 10.1073/pnas.85.5.1422; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P2221; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROCHE TE, 1989, ANN NY ACAD SCI, V573, P168, DOI 10.1111/j.1749-6632.1989.tb14994.x; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.immunol.11.1.729; SHESHBERADARAN H, 1988, P NATL ACAD SCI USA, V85, P1, DOI 10.1073/pnas.85.1.1; SUCKAU D, 1990, P NATL ACAD SCI USA, V87, P9848, DOI 10.1073/pnas.87.24.9848; SURH CD, 1990, J IMMUNOL, V144, P2647; SVOBODA M, 1991, J CHROMATOGR-BIOMED, V562, P403, DOI 10.1016/0378-4347(91)80595-4; TSUNEYAMA K, 1995, HEPATOLOGY, V21, P1031, DOI 10.1016/0270-9139(95)90251-1; VANDEWATER J, 1988, J IMMUNOL, V141, P2321; VANDEWATER J, 1993, J CLIN INVEST, V91, P2653, DOI 10.1172/JCI116504; YIP TT, 1992, P 40 ASMS C MASS SPE, P1915	39	33	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32825	32833		10.1074/jbc.271.51.32825	http://dx.doi.org/10.1074/jbc.271.51.32825			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955120	hybrid			2022-12-25	WOS:A1996VZ37300055
J	Mayo, LD; Berberich, SJ				Mayo, LD; Berberich, SJ			Wild-type p53 protein is unable to activate the mdm-2 gene during F9 cell differentiation	ONCOGENE			English	Article						mdm-2; p53; F9 cellular differentiation	DNA-BINDING; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; TUMOR-SUPPRESSOR; EXPRESSION; SEQUENCE; ONCOGENE; CYCLE; CHECKPOINT; GROWTH	In this study, we set out to assess whether the p53 protein affects mdm-2 gene expression as F9 embryonal carcinoma cells differentiate into parietal endoderm cells. It was previously reported that F9 cells possess abundant levels of wild-type p53 and upon induction to differentiate, p53 mRNA and protein levels decrease (Oren et at, 1982; Deny et al., 1985). We demonstrate that while p53 mRNA and protein levels decrease as F9 cells differentiate, mdm-2 mRNA and protein expression remains constitutive. Using RNA primer extension assays, we determined that the mdm-2 mRNA expression is not directed by p53 in either F9 embryonal (undifferentiated) or parietal endoderm (differentiated) cells. However, p53 protein does stimulate mdm-2 mRNA expression in response to u.v. irradiation. The inability of p53 to transactivate mdm-2 in undamaged F9 cells was not the result of latent pools as p53 sequence specific DNA binding activity was observed using electrophoretic mobility shift assays. Our results suggest that, in F9 cells, the p53:Mdm-2 autoregulatory loop is confined to pathways governing DNA damage.	WRIGHT STATE UNIV,DEPT BIOCHEM & MOL BIOL,DAYTON,OH 45435	Wright State University Dayton								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BERBERICH S, 1994, ONCOGENE, V9, P1469; BERBERICH S, 1992, ONCOGENE, V7, P775; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHUANG SE, 1994, BIOTECHNIQUES, V17, P634; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P4279; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER J, 1994, ONCOGENE, V9, P3321; OREN M, 1982, MOL CELL BIOL, V2, P443, DOI 10.1128/MCB.2.4.443; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; Shaw P, 1996, ONCOGENE, V12, P921; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x	41	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2315	2321						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957072				2022-12-25	WOS:A1996VX10800003
J	Rousseau, D; Gingras, AC; Pause, A; Sonenberg, N				Rousseau, D; Gingras, AC; Pause, A; Sonenberg, N			The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth	ONCOGENE			English	Article						malignant transformation; cap binding protein; translation inhibitors	CAP-BINDING-PROTEIN; EUKARYOTIC INITIATION FACTOR-4E; RAT EMBRYO FIBROBLASTS; 5' NONCODING REGION; TRANSLATION INITIATION; MALIGNANT TRANSFORMATION; SECONDARY STRUCTURE; ADIPOSE-TISSUE; FACTOR 4E; PHOSPHORYLATION	Initiation in eukaryotes is the rate limiting step of translation. The binding of the mRNA to the 40S ribosomal subunit, which is mediated by the mRNA cap structure, is a key target for control of protein synthesis. The cap binding protein, eIF4E, is the most limiting of all initiation factors and its overexpression in NIH3T3 cells causes malignant transformation. 4E-binding protein 1 (BP1) and 4E-BP2 are small proteins that bind to eIF4E and inhibit translation, Here, 4E-BPs were expressed in cells transformed by eIF4E or by v-src to determine the effect of 4E-BPs on cell growth and tumorigenicity. We show that 4E-BPs cause a significant reversion of the transformed phenotype. Thus, we demonstrate that the eIF4E-binding proteins act as negative regulators of cell growth. We propose that 4E-BPs are members of a class of negative regulators of cell growth acting on the translation machinery of the cell.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,CTR CANC,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; McGill University			Gingras, Anne-Claude/ABA-8341-2020; Gingras, Anne-Claude/E-9982-2010	Gingras, Anne-Claude/0000-0002-6090-4437; Gingras, Anne-Claude/0000-0002-6090-4437				AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELSHAM G J, 1980, Biochemical Society Transactions, V8, P382; BELSHAM GJ, 1982, BIOCHEM J, V204, P345, DOI 10.1042/bj2040345; BLACKSHEAR PJ, 1982, BIOCHEM J, V204, P817, DOI 10.1042/bj2040817; BLACKSHEAR PJ, 1983, BIOCHEM J, V214, P11, DOI 10.1042/bj2140011; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BROOKS RF, 1977, CELL, V12, P311, DOI 10.1016/0092-8674(77)90209-4; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; FREDERICKSON RM, 1991, MOL CELL BIOL, V11, P2896, DOI 10.1128/MCB.11.5.2896; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUANG J, 1991, CELL, V65, P271, DOI 10.1016/0092-8674(91)90161-Q; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; MADER S, 1995, MOL CELL BIOL, V15, P4990; Mathews M. B., 1996, TRANSLATIONAL CONTRO, P1; Merrick WC., 1996, TRANSLATION CONTROL, P31; MORRIS DR, 1995, PROG NUCLEIC ACID RE, V51, P339, DOI 10.1016/S0079-6603(08)60883-1; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEGG AE, 1988, CANCER RES, V48, P759; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; RINKERSCHAEFFER CW, 1992, J BIOL CHEM, V267, P10659; RINKERSCHAEFFER CW, 1993, INT J CANCER, V55, P841, DOI 10.1002/ijc.2910550525; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; SHANTZ LM, 1994, CANCER RES, V54, P2313; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245	38	201	214	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2415	2420						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957083				2022-12-25	WOS:A1996VX10800014
J	Cahill, MA; Peter, ME; Kischkel, FC; Chinnaiyan, AM; Dixit, VM; Krammer, PH; Nordheim, A				Cahill, MA; Peter, ME; Kischkel, FC; Chinnaiyan, AM; Dixit, VM; Krammer, PH; Nordheim, A			CD95 (APO-1/Fas) induces activation of SAP kinases downstream of ICE-like proteases	ONCOGENE			English	Article						CD95 (APO-1/FAS); DISC; MAP kinase; apoptosis; signal transduction	TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; INTERLEUKIN-1-BETA CONVERTING-ENZYME; FACTOR RECEPTOR SUPERFAMILY; ACTIN STRESS FIBERS; PROTEIN-KINASE; INDUCED APOPTOSIS; FAS ANTIGEN; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS	Triggering of CD95 (APO-1/Pas) on different T- and B-cell lines resulted in the induction of a number of kinases (35 kDa, 38 kDa, 46 kDa and 54 kDa) that phosphorylate c-Jun and to a lesser extent Histone H1. Activation of these kinases was independent of protein biosynthesis and preceded apoptotic DNA degradation. The kinase activation pattern was specific for CD95 triggering since a variety of physical or chemical inducers of T- and B-cell apoptosis activated different kinases. The kinase activities at 46 and 54 kDa contained members of the stress-activated family of protein kinases (JNK/SAPK). Activation of the CD95-specific set of kinases was prevented by treating cells with the ICE-inhibiting peptide N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl-ketone (zVAD-fmk) or by overexpression of the cow pox virus serpin CrmA. However, despite inhibition of ICE-like proteases the death signal was readily initiated at the cell membrane since a CD95 death-inducing signaling complex (DISC) was formed. Thus, our results demonstrate that ICE-like proteases in the CD95 pathway function downstream of the DISC but upstream of SAP kinases.	HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY; GERMAN CANC RES CTR,DIV IMMUNOGENET,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY; UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109	Hannover Medical School; Helmholtz Association; German Cancer Research Center (DKFZ); University of Michigan System; University of Michigan			dixit, vishva m/A-4496-2012; CAHILL, Michael/J-8035-2012	dixit, vishva m/0000-0001-6983-0326; CAHILL, Michael/0000-0002-8593-8844; Peter, Marcus Ernst/0000-0003-3216-036X				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; BENHAMOU LE, 1990, EUR J IMMUNOL, V20, P1405, DOI 10.1002/eji.1830200630; Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; BERTRAND R, 1994, EXP CELL RES, V211, P314, DOI 10.1006/excr.1994.1093; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hess S, 1996, J EXP MED, V183, P159, DOI 10.1084/jem.183.1.159; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KANEKO Y, 1994, CANCER LETT, V79, P147, DOI 10.1016/0304-3835(94)90253-4; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRAMMER PH, 1994, IMMUNOL REV, V142, P175, DOI 10.1111/j.1600-065X.1994.tb00889.x; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAHTI JM, 1995, MOL CELL BIOL, V15, P1; Latinis KM, 1996, BLOOD, V87, P871, DOI 10.1182/blood.V87.3.871.bloodjournal873871; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIJAWAKI T, 1992, J IMMUNOL, V149, P3753; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; Peter ME, 1996, CELL DEATH DIFFER, V3, P161; PETER ME, 1995, INT IMMUNOL, V7, P1873, DOI 10.1093/intimm/7.11.1873; PETER ME, 1995, CELL DEATH DIFFER, P163; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; SCHULZEOSTHOFF K, 1996, IN PRESS CELL DEATH, V3; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SKOWRONSKI EW, 1996, IN PRESS CELL GROWTH; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WESTWICK JK, 1995, J BIOL CHEM, V270, P22689, DOI 10.1074/jbc.270.39.22689; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901; ZINCK R, 1995, MOL CELL BIOL, V15, P4930; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	76	123	124	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2087	2096						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950975				2022-12-25	WOS:A1996VV14500005
J	Lee, SH; Fujita, N; Mashima, T; Tsuruo, T				Lee, SH; Fujita, N; Mashima, T; Tsuruo, T			Interleukin-7 inhibits apoptosis of mouse malignant T-lymphoma cells by both suppressing the CPP32-like protease activation and inducing the Bcl-2 expression	ONCOGENE			English	Article						interleukin-7; Bcl-2; ICE-family proteases; apoptosis; T-lymphoma	NODE STROMAL CELLS; DEATH GENE CED-3; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; IL-1-BETA-CONVERTING ENZYME; MONOCLONAL-ANTIBODIES; MURINE INTERLEUKIN-7; ICE/CED-3 PROTEASE; CONVERTING-ENZYME; MAMMALIAN HOMOLOG	Mouse malignant T-lymphoma CS-21 cells grow in vitro in the presence of CA-12 lymph node stromal cells, but they undergo apoptotic cell death when separated from CA-12 stromal cells. In the course of examining the nursing effects of CA-12 stromal cells, we found that these cells provided some soluble factors that suppressed CS-21 cell apoptosis. We recently found that cysteine was an antiapoptotic soluble factor. In this report, we identify interleukin-7 (IL-7) as another antiapoptotic soluble factor secreted by CA-12 stromal cells. Although the activity of CPP32-like protease was increased in induction of CS-21 cell apoptosis, the addition of IL-7 suppressed the activity. The expression of Bcl-2 protein was down-regulated when CS-21 cells were cultured alone, but the addition of IL-7 recovered the expression of Bcl-2. These results indicate that CA-12 stromal cells inhibit CS-21 cell apoptosis by producing IL-7, which leads to the suppression of CPP32-like protease activation and the expression of Bcl-2 protein.	UNIV TOKYO,INST MOL & CELLULAR BIOSCI,BIOMED RES LAB,BUNKYO KU,TOKYO 113,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; Japanese Foundation for Cancer Research			Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264; Lee, Sang-Han/0000-0002-2343-7315				BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORZILLO GV, 1992, ONCOGENE, V7, P869; Boulakia CA, 1996, ONCOGENE, V12, P529; CARSON WE, 1994, P NATL ACAD SCI USA, V91, P7553, DOI 10.1073/pnas.91.16.7553; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DUKE RC, 1986, LYMPHOKINE RES, V5, P289; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FUJITA N, 1993, CANCER RES, V53, P5022; FUJITA N, 1995, CELL GROWTH DIFFER, V6, P355; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HANAOKA K, 1995, CANCER RES, V55, P2186; HERNANDEZCASELLES T, 1995, HUM IMMUNOL, V43, P181, DOI 10.1016/0198-8859(94)00168-P; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KATAOKA S, 1993, EXP CELL RES, V207, P271, DOI 10.1006/excr.1993.1193; KERR JFR, 1974, J CELL SCI, V14, P571; KINOSHITA T, 1995, ONCOGENE, V10, P2207; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEE SH, 1995, BIOCHEM BIOPH RES CO, V213, P837, DOI 10.1006/bbrc.1995.2205; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Monney L, 1996, BIOCHEM BIOPH RES CO, V221, P340, DOI 10.1006/bbrc.1996.0597; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NEITO MA, 1989, J IMMUNOL, V143, P4166; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SAKATA T, 1990, J LEUKOCYTE BIOL, V48, P205, DOI 10.1002/jlb.48.3.205; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Shimizu S, 1996, ONCOGENE, V12, P2251; SQUIER MKT, 1995, J LEUKOCYTE BIOL, V57, P2, DOI 10.1002/jlb.57.1.2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; TSURUO T, 1988, CLIN EXP METASTAS, V6, P141, DOI 10.1007/BF01784845; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	58	25	25	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2131	2139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950980				2022-12-25	WOS:A1996VV14500010
J	Wang, LC; Li, Y; Yan, HG				Wang, LC; Li, Y; Yan, HG			Structure-function relationships of cellular retinoic acid-binding proteins - Quantitative analysis of the ligand binding properties of the wild-type proteins and site-directed mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P2 MYELIN PROTEIN; TRANSPORT PROTEINS; MOLECULAR-CLONING; ESCHERICHIA-COLI; NEONATAL RAT; FATTY-ACID; PURIFICATION; EXPRESSION; NMR; SPECTROSCOPY	It has been suggested that electrostatic interactions are critical for binding of retinoic acid by cellular retinoic acid-binding proteins (CRABP-I and CRABP-II). However, the roles of two conserved arginine residues (Arg-111 and Arg-131 in CRABP-I; Arg-111 and Arg-132 in CRABP-II) that interact with the carboxyl group of retinoic acid have not been evaluated. A novel competitive binding assay has been developed for measuring the relative dissociation constants of the site-directed mutants of CRABPs. Arg-111 and Arg-132 of CRABP-II were replaced with methionine by site-directed mutagenesis. The relative dissociation constants of R111M and R132M (K-d (R111M)/K-d (CRABP-II) and K-d (R132M)/K-d (CRABP-II)) were determined to be 40-45 and 6-8, respectively. The ring protons of the aromatic residues of the wild-type CRABP-II and the two mutants were sequentially assigned by two-dimensional homonuclear NMR in conjunction with three-dimensional heteronuclear NMR. Detailed analysis of the nuclear Overhauser effect spectroscopy spectra of the proteins indicated that the conformations of the two mutants are highly similar to that of the wild-type CRABP-II. These results taken together showed that Arg-111 and Arg-132 are important for binding retinoic acid but contribute to the binding energy only by similar to 2.2 and 1.2 kcal/mol, respectively. In addition, the relative dissociation constant of CRABP-II and CRABP-I (K-d (CRABP-II)/K-d (CRABP-I)) was determined to be 2-3, in close agreement with that calculated using the apparent K-d values determined under the same conditions by fluorometric titrations.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University								ASTROM A, 1991, J BIOL CHEM, V266, P17662; BAILEY JS, 1988, J BIOL CHEM, V263, P9326; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P5521; CHEN LX, 1995, J BIOL CHEM, V270, P4518, DOI 10.1074/jbc.270.9.4518; COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; DALY AK, 1988, BIOCHIM BIOPHYS ACTA, V965, P118, DOI 10.1016/0304-4165(88)90046-3; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FOGH K, 1993, ARCH BIOCHEM BIOPHYS, V300, P751, DOI 10.1006/abbi.1993.1104; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; JONES TA, 1988, EMBO J, V7, P1597, DOI 10.1002/j.1460-2075.1988.tb02985.x; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Mangelsdorf David J., 1994, P319; NORRIS AW, 1994, BBA-PROTEIN STRUCT M, V1209, P10, DOI 10.1016/0167-4838(94)90130-9; Ong David E., 1994, P283; ONG DE, 1978, J BIOL CHEM, V253, P4551; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; STUDIER FW, 1987, METHOD ENZYMOL, P60; SZUTS EZ, 1991, ARCH BIOCHEM BIOPHYS, V287, P297, DOI 10.1016/0003-9861(91)90482-X; THOMPSON JR, 1995, J MOL BIOL, V252, P433, DOI 10.1006/jmbi.1995.0509; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; ZHANG JH, 1992, PROTEINS, V13, P87, DOI 10.1002/prot.340130202; [No title captured]	31	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 17	1997	272	3					1541	1547		10.1074/jbc.272.3.1541	http://dx.doi.org/10.1074/jbc.272.3.1541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WD058	8999826	hybrid			2022-12-25	WOS:A1997WD05800024
J	Collins, BE; Yang, LJS; Mukhopadhyay, G; Filbin, MT; Kiso, M; Hasegawa, A; Schnaar, RL				Collins, BE; Yang, LJS; Mukhopadhyay, G; Filbin, MT; Kiso, M; Hasegawa, A; Schnaar, RL			Sialic acid specificity of myelin-associated glycoprotein binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; THIN-LAYER CHROMATOGRAPHY; O-LINKED OLIGOSACCHARIDES; E-SELECTIN; GANGLIOSIDES; GLYCOSPHINGOLIPIDS; SIALOADHESIN; CLONING; LIGANDS; FAMILY	Myelin associated glycoprotein (MAG), a nervous system cell adhesion molecule, is an I-type lectin that binds to sialylated glycoconjugates, including gangliosides bearing characteristic structural determinants (Yang, L. J.-S., Zeller, C. B., Shaper, N. L., Kiso, M., Hasegawa, A., Shapiro, R. E., and Schnaar, R. L. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 814-818). Two cell adhesion systems, COS-1 monkey kidney fibroblasts transiently transfected to express MAG and Chinese hamster ovary (CHO) cells stably transfected to express MAG, were used to probe the structural specificity of MAG-ganglioside binding. Both cell types bound to the same gangliosides: GQ1b alpha (IV(3)NeuAc),III(6)NuAc,II3(NeuAc)(2)Gg(4)Cer) > GT1b = GD1a > GM3 > GM1, GD1b, and GQ1b (the latter do not support adhesion). Binding was enhanced by pretreatment of MAG-expressing cells with neuraminidase. MAG-expressing Chinese hamster ovary cells bound directly to gangliosides resolved on thin layer chromatograms, allowing detection of MAG binding species in a mixture. The simplest ganglioside ligand for MAG was GM3 bearing N-acetylneuraminic acid, whereas GM3 bearing N-glycolylneuraminic acid did not support adhesion. Chemical modifications of N-acetylneuraminic acid residues (on GD1a) abrogated MAG binding. Mild periodate oxidation of sialic acids to their corresponding seven carbon (or eight-carbon) sialic acid aldehydes abolished MAG binding, as did further conversion to the corresponding primary alcohols. Eliminating the anionic charge by ethyl esterification, amidation, or reduction also abolished MAG-mediated cell adhesion. These data demonstrate that MAG-ganglioside binding is highly specific and defines key carbohydrate structural determinants for MAG-mediated cell adhesion to gangliosides.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; CUNY HUNTER COLL,DEPT BIOL SCI,NEW YORK,NY 10021; GIFU UNIV,DEPT APPL BIOORGAN CHEM,GIFU 50111,JAPAN	Johns Hopkins University; Johns Hopkins University; City University of New York (CUNY) System; Hunter College (CUNY); Gifu University			Schnaar, Ronald L/S-8967-2016	Schnaar, Ronald L/0000-0002-7701-5484	NIGMS NIH HHS [GM07626, GM07309] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007626] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; BLACKBURN CC, 1986, J BIOL CHEM, V261, P2873; BLACKBURN CC, 1983, J BIOL CHEM, V258, P1180; BORRONI E, 1993, DEV BRAIN RES, V71, P247, DOI 10.1016/0165-3806(93)90176-B; BRAESCHANDERSEN S, 1994, J BIOL CHEM, V269, P11783; DAHMS NM, 1983, J NEUROSCI, V3, P806; DeBellard ME, 1996, MOL CELL NEUROSCI, V7, P89, DOI 10.1006/mcne.1996.0007; DELL A, 1994, METHOD ENZYMOL, V230, P108; DEVRIES GH, 1980, J NEUROCHEM, V34, P424, DOI 10.1111/j.1471-4159.1980.tb06613.x; FAHRIG T, 1993, EUR J NEUROSCI, V5, P1118, DOI 10.1111/j.1460-9568.1993.tb00966.x; FREEMAN SD, 1995, BLOOD, V85, P2005, DOI 10.1182/blood.V85.8.2005.bloodjournal8582005; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANDA S, 1984, J BIOCHEM-TOKYO, V95, P1323, DOI 10.1093/oxfordjournals.jbchem.a134738; HOTTA K, 1995, J CARBOHYD CHEM, V14, P491, DOI 10.1080/07328309508005353; JARRELL H, 1992, BIOCHIM BIOPHYS ACTA, V1103, P331, DOI 10.1016/0005-2736(92)90105-U; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; Lee Reiko T., 1994, P23; LI CM, 1994, NATURE, V369, P747, DOI 10.1038/369747a0; Mahoney James A., 1994, P445; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MONTAG D, 1994, NEURON, V13, P229, DOI 10.1016/0896-6273(94)90472-3; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; NATHAN A, 1989, J NEUROCHEM, V53, P88, DOI 10.1111/j.1471-4159.1989.tb07298.x; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; NORGARD KE, 1993, P NATL ACAD SCI USA, V90, P1068, DOI 10.1073/pnas.90.3.1068; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SADOUL R, 1990, J NEUROSCI RES, V25, P1, DOI 10.1002/jnr.490250102; SAITO M, 1986, J NEUROCHEM, V47, P632; SAITO M, 1992, J NEUROCHEM, V58, P83, DOI 10.1111/j.1471-4159.1992.tb09280.x; SALZER JL, 1990, ANN NY ACAD SCI, V605, P302, DOI 10.1111/j.1749-6632.1990.tb42404.x; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P371; SCHNAAR RL, 1994, METHOD ENZYMOL, V230, P348; Schnaar Ronald L., 1994, P425; SCHWAB ME, 1994, NATURE, V371, P658, DOI 10.1038/371658a0; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Sgroi D, 1996, J BIOL CHEM, V271, P18803, DOI 10.1074/jbc.271.31.18803; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SPAGNOL G, 1989, J NEUROSCI RES, V24, P137, DOI 10.1002/jnr.490240203; SPIEGEL S, 1979, P NATL ACAD SCI USA, V76, P5277, DOI 10.1073/pnas.76.10.5277; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P770, DOI 10.1021/bi952461g; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; SVENNERHOLM L, 1994, PROG BRAIN RES, V101, pR11; SWANKHILL P, 1987, ANAL BIOCHEM, V163, P27, DOI 10.1016/0003-2697(87)90088-1; TIEMEYER M, 1990, J BIOL CHEM, V265, P11990; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; TRAPP BD, 1990, ANN NY ACAD SCI, V605, P29, DOI 10.1111/j.1749-6632.1990.tb42378.x; TYRRELL D, 1991, P NATL ACAD SCI USA, V88, P10372, DOI 10.1073/pnas.88.22.10372; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; WALTON KM, 1989, J NEUROCHEM, V52, P1537, DOI 10.1111/j.1471-4159.1989.tb09205.x; Yang LJS, 1996, P NATL ACAD SCI USA, V93, P814, DOI 10.1073/pnas.93.2.814; Yang LJS, 1996, ANAL BIOCHEM, V236, P161, DOI 10.1006/abio.1996.0145; Yu R.K., 1989, NEUROBIOLOGY GLYCOCO, P1; YUEN CT, 1992, BIOCHEMISTRY-US, V31, P9126, DOI 10.1021/bi00153a003; ZHOU B, 1989, J BIOL CHEM, V264, P12272	65	138	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1248	1255		10.1074/jbc.272.2.1248	http://dx.doi.org/10.1074/jbc.272.2.1248			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995428	hybrid			2022-12-25	WOS:A1997WC04800079
J	MacDougall, M; Simmons, D; Luan, XH; Nydegger, J; Feng, J; Gu, TT				MacDougall, M; Simmons, D; Luan, XH; Nydegger, J; Feng, J; Gu, TT			Dentin phosphoprotein and dentin sialoprotein are cleavage products expressed from a single transcript coded by a gene on human chromosome 4 - Dentin phosphoprotein DNA sequence determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-INCISOR DENTIN; IMPERFECTA TYPE-II; PROTEIN; LOCUS; LOCALIZATION; BIOSYNTHESIS; CLONING	Dentin is the major mineralized extracellular matrix of the tooth. The organic components of dentin consist of type I collagen (90%) with 10% noncollagenous proteins, which are also components of bone. Two dentin proteins, dentin sialoprotein and dentin phosphoprotein, have been shown to be tooth-specific being expressed mostly by odontoblast cells. In this study, we screened a mouse molar tooth library for dentin sialoprotein and dentin phosphoprotein cDNA clones. Analysis of the clones resulted in characterization of a 4420-nucleotide cDNA that contained a 940-amino acid open reading frame. The signal peptide and NH2-terminal sequence was 75% homologous to the cDNA sequence of rat dentin sialoprotein. The continued open reading frame, however, contained a RGD sequence followed by a region of repeated aspartic acid and serine residues. This portion of the protein codes for amino acid sequence consistent with that of dentin phosphoprotein. The noncoding region contains three potential polyadenylation signals, two of which were shown to be utilized. Northern blot analysis indicated the presence of two major transcripts of 4.4 and 2.2 kilobases in odontoblasts. Chromosomal mapping localized the gene to hu man chromosome 4. These data suggest that the previously identified dentin extracellular matrix proteins, dentin sialoprotein and dentin phosphoprotein, are expressed as a single cDNA transcript coding for a protein that is specifically cleaved into two smaller polypeptides with unique physical-chemical characteristics. Therefore, we propose that the gene be named dentin sialophosphoprotein. The location of the human dentin sialophosphoprotein gene on chromosome 4 suggests that this gene may be a strong candidate gene for the genetic disease dentinogenesis imperfecta type II.			MacDougall, M (corresponding author), UNIV TEXAS,HLTH SCI CTR,SCH DENT,DEPT PEDIAT DENT,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.		MacDougall, Mary/ABG-8212-2021		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011493, R01DE011658, R01DE009875, R29DE009875] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE11658, DE09875, DE11493] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		APLIN HM, 1995, GENOMICS, V30, P347, DOI 10.1006/geno.1995.9867; Butler W T, 1995, Connect Tissue Res, V33, P59, DOI 10.3109/03008209509016983; BUTLER WT, 1992, MATRIX, V12, P343, DOI 10.1016/S0934-8832(11)80030-2; BUTLER WT, 1995, INT J DEV BIOL, V39, P169; BUTLER WT, 1983, ARCH BIOCHEM BIOPHYS, V255, P178; CROSBY AH, 1995, AM J HUM GENET, V57, P832; CROSBY AH, 1995, GENOMICS, V27, P155, DOI 10.1006/geno.1995.1018; CROSSLEY MA, 1996, J DENT RES, V75, P154; DEVRIES IG, 1986, ARCH ORAL BIOL, V31, P57, DOI 10.1016/0003-9969(86)90114-7; DIMUZIO MT, 1978, J BIOL CHEM, V253, P6845; EVANS JS, 1991, STRUCTURE DESIGN REN, P251; FISHER LW, 1990, J BIOL CHEM, V265, P2347; JONSSON M, 1978, J CHROMATOGR, V157, P235, DOI 10.1016/S0021-9673(00)92338-0; KRIPPNER RD, 1977, J DENT RES, V56, P873, DOI 10.1177/00220345770560072801; KUBOKI Y, 1979, J DENT RES, V58, P1926, DOI 10.1177/00220345790580092001; LECHNER JH, 1981, CHEM BIOL MINERALIZE, P394; LEE SL, 1977, BIOCHEMISTRY-US, V16, P2971, DOI 10.1021/bi00632a026; LINDE A, 1980, J BIOL CHEM, V255, P5931; LINDE A, 1984, DENTIN DENTINOGENESI, V2, P55; Linde Anders, 1993, Critical Reviews in Oral Biology and Medicine, V4, P679; MACDOUGALL M, 1985, BIOCHEM J, V232, P493, DOI 10.1042/bj2320493; MacDougall M, 1995, Connect Tissue Res, V33, P97, DOI 10.3109/03008209509016988; MACDOUGALL M, 1992, BIOCHEM J, V287, P651, DOI 10.1042/bj2870651; MacDougall M, 1996, CYTOGENET CELL GENET, V74, P189, DOI 10.1159/000134410; MACDOUGALL M, 1992, AM J HUM GENET, V50, P190; MATSUKI Y, 1995, J DENT RES, V74, P307, DOI 10.1177/00220345950740010401; MUNKSGAARD EC, 1978, ARCH ORAL BIOL, V23, P583, DOI 10.1016/0003-9969(78)90275-3; RICHARDSON WS, 1978, J BIOL CHEM, V253, P8042; Ritchie H H, 1995, Connect Tissue Res, V33, P73, DOI 10.3109/03008209509016985; RITCHIE HH, 1994, J BIOL CHEM, V269, P3698; SABSAY B, 1991, BIOCHEM J, V276, P699, DOI 10.1042/bj2760699; SHYAMALA V, 1993, PCR PROTOCOLS, P338; VEIS A, 1967, BIOCHEMISTRY-US, V6, P2409, DOI 10.1021/bi00860a017; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V; ZANETTI M, 1981, EUR J BIOCHEM, V113, P541, DOI 10.1111/j.1432-1033.1981.tb05096.x	36	361	395	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					835	842		10.1074/jbc.272.2.835	http://dx.doi.org/10.1074/jbc.272.2.835			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995371	hybrid			2022-12-25	WOS:A1997WC04800022
J	Ruff, SJ; Chen, K; Cohen, S				Ruff, SJ; Chen, K; Cohen, S			Peroxovanadate induces tyrosine phosphorylation of multiple signaling proteins in mouse liver and kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; INSULIN-RECEPTOR KINASE; INSULINOMIMETIC AGENTS H2O2; PHOSPHOTYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; RAT ADIPOCYTES; INTACT-CELLS; BETA-CATENIN; VANADATE	The intraperitoneal injection of a vanadate/H2O2 mixture (peroxovanadate) into mice resulted within minutes in the appearance of numerous tyrosine-phosphorylated proteins in the liver and kidney, These effects are presumably due to the inhibition of phosphotyrosine phosphatase activity, Three of the tyrosine-phosphorylated proteins have been identified as the receptors for epidermal growth factor, insulin, and hepatocyte growth factor. The injection of peroxovanadate also enhanced the tyrosine phosphorylation of many of the proteins known to function downstream of these receptors, including SHC, signal transducer and activator of transcription (Stat) 1 alpha,beta, Stat 3, Stat 5, phospholipase C-gamma, insulin receptor substrate 1, GTPase-activating protein, beta-catenin, gamma-catenin, p120(cas), SHP-1, and SHP-2. The administration of peroxovanadate also induced nuclear translocation of a number of tyrosine-phosphorylated Stat proteins, In addition, the global effects on tyrosine phosphorylation permitted the detection of a number of novel intracellular protein interactions, including an association of Tyk2 with beta-catenin. The in situ administration of peroxovanadate may prove useful in the search for novel tyrosine-phosphorylated proteins and the identification of new interactions between previously identified tyrosine-phosphorylated substrates.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA	Vanderbilt University					NICHD NIH HHS [HD-00700] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BRICHARD SM, 1991, DIABETES METAB, V17, P435; CARPENTER G, 1993, FORUM, V3, P616; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; Crans D.C., 1994, COMMENT INORG CHEM, V16, P35, DOI 10.1080/02603599408035851; CRANS DC, 1994, COMMENT INORG CHEM, V16, P1; CZECH MP, 1974, P NATL ACAD SCI USA, V71, P4173, DOI 10.1073/pnas.71.10.4173; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FANTUS IG, 1989, BIOCHEMISTRY-US, V28, P8864, DOI 10.1021/bi00448a027; Fashena SJ, 1995, CURR BIOL, V5, P1367, DOI 10.1016/S0960-9822(95)00272-7; FEGHALI CA, 1995, BIOCHEM J, V310, P461, DOI 10.1042/bj3100461; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Gronowski AM, 1996, ENDOCRINOLOGY, V137, P55, DOI 10.1210/en.137.1.55; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HADARI YR, 1993, MOL CELL ENDOCRINOL, V97, P9, DOI 10.1016/0303-7207(93)90206-Y; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HEFFETZ D, 1992, BIOCHEM J, V288, P631, DOI 10.1042/bj2880631; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; HINCK L, 1994, TRENDS BIOCHEM SCI, V19, P538, DOI 10.1016/0968-0004(94)90057-4; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; KADOTA S, 1987, BIOCHEM BIOPH RES CO, V147, P259, DOI 10.1016/S0006-291X(87)80115-8; KIM L, 1995, MOL CELL BIOL, V15, P4553; LAMB P, 1994, J INTERFERON RES, V14, P365, DOI 10.1089/jir.1994.14.365; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MAY JM, 1979, J BIOL CHEM, V254, P9017; POSNER BI, 1994, J BIOL CHEM, V269, P4596; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SHECHTER Y, 1993, ENDEAVOUR, V17, P27, DOI 10.1016/0160-9327(93)90008-Q; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; STERN A, 1993, BIOCHEM CELL BIOL, V71, P103, DOI 10.1139/o93-018; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TOURKINE N, 1995, J BIOL CHEM, V270, P20952, DOI 10.1074/jbc.270.36.20952; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; ZHAO Z, 1995, ADV PROT PHOSPHATASE, V9, P297	48	98	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					1263	1267		10.1074/jbc.272.2.1263	http://dx.doi.org/10.1074/jbc.272.2.1263			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995430	hybrid			2022-12-25	WOS:A1997WC04800081
J	Sotiropoulou, G; Anisowicz, A; Sager, R				Sotiropoulou, G; Anisowicz, A; Sager, R			Identification, cloning, and characterization of cystatin M, a novel cysteine proteinase inhibitor, down-regulated in breast cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; EGG-WHITE CYSTATIN; CHICKEN CYSTATIN; SEQUENCE-ANALYSIS; CATHEPSIN-B; EXTRACELLULAR-MATRIX; DIFFERENTIAL DISPLAY; NUCLEOTIDE-SEQUENCE; TUMOR PROGRESSION; MOLECULAR-CLONING	A novel human cystatin gene was identified in a differential display comparison aimed at the isolation of transcriptionally regulated genes involved in invasion and metastasis of breast cancer. Messenger RNAs from primary and metastatic tumor cells isolated from the same patient were compared. A partial cDNA was isolated that was expressed in the primary tumor cell line but not in the metastatic line. The full-length cDNA was cloned and sequenced, and the inferred amino acid sequence was found to encode a novel protein, which we named cystatin M, with 40% homology to human family 2 cystatins and similar overall structure, Cystatin M is expressed by normal mammary cells and a variety of human tissues. The mature cystatin M protein was produced in Escherichia coli as a glutathione S-transferase fusion protein using the pGEX-2T expression system and purified by affinity chromatography. The cystatin M fusion protein displayed inhibitory activity against papain. Native cystatin M protein of approximately 14.5 kDa is secreted and was immunoprecipitated from supernatants of mammary cell cultures using affinity-purified antisera raised against recombinant cystatin M. An N-glycosylated form of cystatin M of 20-22 kDa was co-immunoprecipitated and accounted for about 30-40% of total cystatin M protein. Both forms of native cystatin M also occurred intracellularly. Consistent with the mRNA differential expression, no cystatin M protein was detected in metastatic mammary epithelial tumor cells. Loss of expression of cystatin M is likely associated with the progression of a primary tumor to a metastatic phenotype.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA061253] Funding Source: NIH RePORTER; NCI NIH HHS [CA61253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON M, 1987, J BIOL CHEM, V262, P9688; ABRAHAMSON M, 1987, FEBS LETT, V216, P229, DOI 10.1016/0014-5793(87)80695-6; ABRAHAMSON M, 1991, BIOCHEM J, V273, P621, DOI 10.1042/bj2730621; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1986, BIOCHEM J, V236, P312, DOI 10.1042/bj2360312; Berquin Isabelle M., 1995, Perspectives in Drug Discovery and Design, V2, P371, DOI 10.1007/BF02172031; BJORK I, 1994, BIOCHEM J, V299, P219, DOI 10.1042/bj2990219; BJORK I, 1992, BIOCHEMISTRY-US, V31, P8597, DOI 10.1021/bi00151a029; BJORK I, 1989, BIOCHEMISTRY-US, V28, P1568; BOBEK LA, 1991, BIOCHEM J, V278, P627, DOI 10.1042/bj2780627; BOBEK LA, 1992, CRIT REV ORAL BIOL M, V3, P307, DOI 10.1177/10454411920030040101; BODE W, 1990, BIOL CHEM H-S, V371, P111; BUCK MR, 1992, BIOCHEM J, V282, P273, DOI 10.1042/bj2820273; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; COLELLA R, 1989, J BIOL CHEM, V264, P17164; DIECKMANN T, 1993, J MOL BIOL, V234, P1048, DOI 10.1006/jmbi.1993.1658; ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; GRUBB A, 1984, FEBS LETT, V170, P370, DOI 10.1016/0014-5793(84)81346-0; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; HALL A, 1993, BIOCHEM J, V291, P123, DOI 10.1042/bj2910123; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; JARVINEN M, 1987, ACTA HISTOCHEM, V82, P5; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LAH TT, 1992, INT J CANCER, V50, P36, DOI 10.1002/ijc.2910500109; LAH TT, 1989, BIOCHIM BIOPHYS ACTA, V993, P63, DOI 10.1016/0304-4165(89)90144-X; LIANG L, 1993, NUCLEIC ACIDS RES, V21, P3267; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LINDAHL P, 1994, BIOCHEMISTRY-US, V33, P4384, DOI 10.1021/bi00180a036; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACHLEIDT W, 1989, FEBS LETT, V243, P234, DOI 10.1016/0014-5793(89)80135-8; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; RICH DH, 1988, PROTEINASE INHIBITOR, V12, P153; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SAITOH E, 1989, BIOCHEM BIOPH RES CO, V162, P1324, DOI 10.1016/0006-291X(89)90818-8; SAITOH E, 1987, GENE, V61, P329, DOI 10.1016/0378-1119(87)90196-X; Sambrook J., 2002, MOL CLONING LAB MANU; SLOANE BF, 1994, BIOCH MOL ASPECTS SE, P411; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4	51	138	152	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					903	910		10.1074/jbc.272.2.903	http://dx.doi.org/10.1074/jbc.272.2.903			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995380	hybrid			2022-12-25	WOS:A1997WC04800031
J	Stephens, JM; Lee, J; Pilch, PF				Stephens, JM; Lee, J; Pilch, PF			Tumor necrosis factor-alpha-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE GLUCOSE TRANSPORTER; SKELETAL-MUSCLE; MESSENGER-RNA; TRANSCRIPTIONAL REPRESSION; TYROSINE PHOSPHORYLATION; HEXOSE-TRANSPORT; GENE-EXPRESSION; ADIPOSE-TISSUE; RAT ADIPOCYTES; OBESITY	A number of studies have demonstrated that tumor necrosis factor-alpha (TNF-alpha) is associated with profound insulin resistance in adipocytes and may also play a critical role in the insulin resistance of obesity and non-insulin-dependent diabetes mellitus, Reports on the mechanism of TNF-alpha action have been somewhat contradictory, GLUT4 down-regulation has been implicated as a possible cause of insulin resistance as has been the reduced kinase function of the insulin receptor. Here we examine the effects of tumor necrosis factor on the protein components thought to be involved in insulin-stimulated glucose transport in adipocytes, namely the insulin receptor, its major substrate IRS-1, and the insulin responsive glucose transporter GLUT4. Prolonged exposure (72-96 h) of 3T3-L1 adipocytes to TNF-alpha causes a substantial reduction (>80%) in IRS-1 and GLUT4 mRNA and protein as well as a lesser reduction (>50%) in the amount of the insulin receptor, Nevertheless, the remaining proteins appear to be biochemically indistinguishable from those in untreated adipocytes. Both the insulin receptor and IRS-1 are tyrosine-phosphorylated to the same extent in response to acute insulin stimulation following cellular TNF-alpha exposure. Furthermore, the ability of the insulin receptor to phosphorylate exogenous substrate in the test tube is also normal following its isolation from TNF-alpha-treated cells. These results are confirmed by the reduced but obvious level of insulin-dependent glucose transport and GLUT4 translocation observed in TNF-alpha-treated adipocytes. We conclude that the insulin resistance of glucose transport in 3T3-L1 adipocytes exposed to TNF-alpha for 72-96 h results from a reduced amount in requisite proteins involved in insulin action, These results are consistent with earlier studies indicating that TNF-alpha reduces the transcriptional activity of the GLUT4 gene in murine adipocytes, and reduced mRNA transcription of a number of relevant genes may be the general mechanism by which TNF-alpha causes insulin resistance in adipocytes.	BOSTON UNIV,MED CTR,DEPT BIOCHEM,SCH MED,BOSTON,MA 02118	Boston University			Lee, Jongsoon/AAG-1674-2020; Stephens, Jacqueline M/R-5217-2018	Pilch, Paul/0000-0003-1997-0499; Lee, Jongsoon/0000-0002-0891-5059	NIDDK NIH HHS [DK 30425, DK 44269] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK044269, R01DK030425] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BIRD TA, 1990, J BIOL CHEM, V265, P13578; CLANCY BM, 1990, J BIOL CHEM, V265, P12434; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; CORNELIUS P, 1989, BIOCHEM BIOPH RES CO, V165, P429, DOI 10.1016/0006-291X(89)91088-7; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; FLORESRIVEROS JR, 1993, P NATL ACAD SCI USA, V90, P512, DOI 10.1073/pnas.90.2.512; FONG Y, 1990, CLIN IMMUNOL IMMUNOP, V55, P157, DOI 10.1016/0090-1229(90)90094-7; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; Guo DQ, 1996, J BIOL CHEM, V271, P615, DOI 10.1074/jbc.271.2.615; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JAATTELA M, 1991, LAB INVEST, V64, P724; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; KAESTNER KH, 1989, P NATL ACAD SCI USA, V86, P3150, DOI 10.1073/pnas.86.9.3150; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE SM, 1993, J BIOL CHEM, V268, P19110; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; PEDERSEN O, 1990, DIABETES, V39, P865, DOI 10.2337/diabetes.39.7.865; Peraldi P, 1996, J BIOL CHEM, V271, P13018, DOI 10.1074/jbc.271.22.13018; RICORT JM, 1995, DIABETOLOGIA, V38, P1148, DOI 10.1007/s001250050406; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; SCHECK SH, 1991, DIABETES RES CLIN EX, V16, P111; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; STEPHENS JM, 1991, J BIOL CHEM, V266, P21839; STEPHENS JM, 1992, J BIOL CHEM, V267, P13580; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	41	425	449	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 10	1997	272	2					971	976		10.1074/jbc.272.2.971	http://dx.doi.org/10.1074/jbc.272.2.971			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WC048	8995390	hybrid, Green Published			2022-12-25	WOS:A1997WC04800041
J	Lin, MX; Mirzabekov, T; Kagan, BL				Lin, MX; Mirzabekov, T; Kagan, BL			Channel formation by a neurotoxic prion protein fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-PERMEABLE CHANNELS; BILAYER-MEMBRANES; PEPTIDE; ALPHA	Prions cause neurodegenerative disease in animals and humans. Recently it was shown that a 21-residue fragment of the prion protein (106-126) could be toxic to cultured neurons. We report here that this peptide forms ion-permeable channels in planar lipid bilayer membranes. These channels are freely permeable to common physiological ions, and their formation is significantly enhanced by ''aging'' and/or low pH. We suggest that channel formation is the cytotoxic mechanism of action of amyloidogenic peptides found in prion-related encephalopathies and other amyloidoses. The channels reported here are large enough and nonselective enough to mediate cell death through discharge of cellular membrane potential, changes in ionic homeostasis, and specifically, influx of calcium, perhaps triggering apoptosis.	UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,BRAIN RES INST,DEPT PSYCHIAT,LOS ANGELES,CA 90024; W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Lin, MX (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,BRAIN RES INST,DIV NEUROSCI,LOS ANGELES,CA 90024, USA.		Kagan, Bruce/ABD-7389-2020					ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; FARTHROP DJ, 1991, ARCH TOXICOL, V65, P437; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; KAGAN BL, 1992, SCIENCE, V255, P1427, DOI 10.1126/science.1371890; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAGAN BL, 1994, METHOD ENZYMOL, V235, P699; LASZLO L, 1992, J PATHOL, V166, P333, DOI 10.1002/path.1711660404; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; NGUYEN J, 1995, BIOCHEMISTRY-US, V34, P4186, DOI 10.1021/bi00013a006; ORRENIUS S, 1992, TOXICOL LETT, V64-5, P357, DOI 10.1016/0378-4274(92)90208-2; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523	15	173	176	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					44	47						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995224				2022-12-25	WOS:A1997WA56400011
J	Lowe, ME				Lowe, ME			Colipase stabilized the lid domain of pancreatic triglyceride lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; BINDING; A(2); SITE	Pancreatic lipase is characterized by increased activity against water-insoluble substrates and by dependence on another protein, colipase, for binding to the substrate interface. In most models of pancreatic lipase activity, colipase functions to anchor lipase on the substrate interface. Recent studies of the x-ray crystal structure of the complex between colipase and lipase suggest another function for colipase in maintaining the active conformation of Lipase. We tested this hypothesis by introducing mutations into colipase at position 15, a residue that contacts the lid domain lipase in the open conformation. Multiple mutant colipases were expressed and shown to have decreased activity. To further investigate the function of the interaction between Glu(15) Of colipase and lipase, we examined one mutant, E15R, in detail, This mutant had 175-fold less activity compared with wild-type colipase. Although E15R had decreased activity, it was as effective as wild-type lipase in anchoring lipase to mixed emulsions of bile salt and tributyrin, The importance of the interaction with the lid domain was tested by determining the activity of E15R with lid deletion mutants of lipase. E15R was as active as wild-type colipase with these mutant lipases. These results indicate that Glu(15) is critical for activity of the colipase-lipase complex at an interface and that colipase has a function in lipolysis in addition to anchoring lipase to an interface. We propose that this function is to stabilize the lid domain of lipase in the open conformation, thereby facilitating lipolysis.	WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,DEPT MOL BIOL & PHARMACOL,ST LOUIS,MO 63110	St. Louis Children's Hospital; Washington University (WUSTL)	Lowe, ME (corresponding author), WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,DEPT PEDIAT,1 CHILDRENS PL,ST LOUIS,MO 63110, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042120] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK42120] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELROD J, 1995, TRENDS NEUROSCI, V18, P64; BORGSTROM B, 1984, LIPASES, P152; CANIONI P, 1980, BIOCHIM BIOPHYS ACTA, V621, P29, DOI 10.1016/0005-2795(80)90059-8; COLWELL NS, 1993, INT J BIOCHEM, V25, P885, DOI 10.1016/0020-711X(93)90244-9; EGLOFF MP, 1995, PROTEIN SCI, V4, P44; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; JENNENS ML, 1994, J BIOL CHEM, V269, P25470; LOWE ME, 1992, J BIOL CHEM, V267, P17069; LOWE ME, 1994, PROTEIN EXPRES PURIF, V5, P583, DOI 10.1006/prep.1994.1080; ROSENTHAL MD, 1995, PROSTAG LEUKOTR ESS, V52, P93, DOI 10.1016/0952-3278(95)90004-7; Sambrook J., 2002, MOL CLONING LAB MANU; STERNBY B, 1984, BIOCHIM BIOPHYS ACTA, V789, P159, DOI 10.1016/0167-4838(84)90200-0; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Verger R, 1980, Methods Enzymol, V64, P340; Verger R., 1984, LIPASES, P84	16	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					9	12						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995215				2022-12-25	WOS:A1997WA56400002
J	Soengas, MS; Mateo, CR; Salas, M; Acuna, AU; Gutierrez, C				Soengas, MS; Mateo, CR; Salas, M; Acuna, AU; Gutierrez, C			Structural features of phi 29 single-stranded DNA-binding protein .1. Environment of tyrosines in terms of complex formation with DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; NUCLEIC-ACID INTERACTIONS; GENE-V PROTEIN; ESCHERICHIA-COLI; REPLICATION; RESIDUES; SITE; BACTERIOPHAGE-M13; THERMODYNAMICS; STIMULATION	The single-stranded DNA-binding protein (SSB) of Bacillus subtilis phage phi 29 is absolutely required for viral DNA replication in vivo. About similar to 95% of the intrinsic tyrosine fluorescence of phi 29 SSB is quenched upon binding to ssDNA, making tyrosine residues strong candidates to be directly involved in complex formation with ssDNA. Thus, we have studied the spectroscopic properties of the phi 29 SSB tyrosines (Tyr-50, Tyr-57, and Tyr-76) using steady-state and time-resolved fluorescence measurements. phi 29 SSB tyrosines do not seem to be highly restricted by strong interactions with neighbor residues, as suggested by (i) the high value of the average quantum yield of the phi 29 SSB fluorescence emission (Phi(F) = 0.067 +/- 0.010), (ii) the fast motions of the tyrosine side chains (phi(short) = 0.14 +/- 0.06 ns), and (iii) the lack of tyrosinate emission at neutral pH. Stern-Volmer analysis of the quenching by acrylamide and I- indicates that phi 29 SSB tyrosines are surrounded by a negatively charged environment and located in a relatively exposed protein domain, accessible to the solvent and, likely, to ssDNA. Changes in the intrinsic fluorescence upon ssDNA binding allowed us to determine that temperature has an opposite effect on the thermodynamic parameters Il (intrinsic binding constant) and omega (cooperativity) defining phi 29 SSB-poly(dT) interaction, the effective DNA binding constant, K-eff = K omega, being largely independent of temperature. Altogether, the fluorescent properties of phi 29 SSB tyrosines are consistent with a direct participation in complex formation with ssDNA.	AUTONOMOUS UNIV MADRID, CSIC, CTR BIOL MOL SEVERO OCHOA, E-28049 MADRID, SPAIN; CSIC, INST QUIM FIS ROCASOLANO, E-28006 MADRID, SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)			Gutierrez, Crisanto/ABH-8782-2020; Soengas, Maria S/H-6455-2015; Mateo, C. Reyes/ABF-8920-2020; Salas, Margarita/J-9873-2014	Soengas, Maria S/0000-0003-0612-6299; Salas, Margarita/0000-0001-5939-3441; Gutierrez, Crisanto/0000-0001-8905-8222; Mateo, C. Reyes/0000-0002-2085-1676	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5RO1 GM 27242-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUNA AU, 1984, PHOTOCHEM PHOTOBIOL, V40, P351, DOI 10.1111/j.1751-1097.1984.tb04598.x; ACUNA AU, 1982, BIOPHYS CHEM, V16, P253, DOI 10.1016/0301-4622(82)87008-7; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ALMA NCM, 1983, J MOL BIOL, V163, P47, DOI 10.1016/0022-2836(83)90029-3; BACKLUND BM, 1995, EUR BIOPHYS J, V23, P407, DOI 10.1007/BF00196827; BANDYOPADHYAY PK, 1978, BIOCHEMISTRY-US, V17, P4078, DOI 10.1021/bi00612a032; BLANCO L, 1994, P NATL ACAD SCI USA, V91, P12198, DOI 10.1073/pnas.91.25.12198; BUJALOWSKI W, 1989, J MOL BIOL, V207, P269, DOI 10.1016/0022-2836(89)90455-5; CASASFINET JR, 1993, BIOCHEMISTRY-US, V32, P9735, DOI 10.1021/bi00088a028; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COWGILL RW, 1976, BIOCHEMICAL FLUORESC, V2, P441; DEMAS JN, 1971, J PHYS CHEM-US, V75, P991, DOI 10.1021/j100678a001; DIMICOLI JL, 1974, BIOCHEMISTRY-US, V13, P724, DOI 10.1021/bi00701a014; Eftink M. R., 1991, BIOPHYSICAL BIOCH AS, P1; EFTINK MR, 1991, METHOD BIOCHEM ANAL, V35, P127; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; FOLLENIUS A, 1983, PHOTOCHEM PHOTOBIOL, V38, P373, DOI 10.1111/j.1751-1097.1983.tb02686.x; FOLMER RHA, 1995, EMBO J, V14, P4132, DOI 10.1002/j.1460-2075.1995.tb00087.x; FOLMER RHA, 1994, J MOL BIOL, V240, P341, DOI 10.1006/jmbi.1994.1449; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; GRYCZYNSKI I, 1991, BIOPHYS CHEM, V39, P69, DOI 10.1016/0301-4622(91)85007-D; GUTIERREZ C, 1991, J MOL BIOL, V222, P983, DOI 10.1016/0022-2836(91)90589-X; GUTIERREZ C, 1991, J BIOL CHEM, V266, P2104; HARD T, 1984, BIOCHEMISTRY-US, V28, P396; HERSHBERGER MV, 1976, PHOTOCHEM PHOTOBIOL, V23, P391, DOI 10.1111/j.1751-1097.1976.tb07271.x; HUTNIK CML, 1991, BIOCHEMISTRY-US, V30, P7652, DOI 10.1021/bi00244a038; KELLY RC, 1976, J BIOL CHEM, V251, P7229; KNEALE GG, 1992, CURR OPIN STRUC BIOL, V2, P124; KNIGHT AEW, 1971, SPECTROCHIM ACTA A-M, VA 27, P1223, DOI 10.1016/0584-8539(71)80073-9; KORNBERG A, 1992, DNA REPLICATION, P323; Lakowicz J.R., 1991, TOPICS FLUORESCENCE, V2; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAKOWICZ JR, 1986, BIOPHYS CHEM, V24, P97, DOI 10.1016/0301-4622(86)80002-3; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LOHMAN TM, 1992, METHOD ENZYMOL, V212, P400; Longworth JW, 1971, EXCITED STATES PROTE, P319; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX B, 1977, FEBS LETT, V80, P66, DOI 10.1016/0014-5793(77)80408-0; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; MATEO CR, 1991, EUR BIOPHYS J, V20, P41; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEYER RR, 1990, MICROBIOL REV, V54, P342, DOI 10.1128/MMBR.54.4.342-380.1990; MICHEL B, 1989, P NATL ACAD SCI USA, V86, P4002, DOI 10.1073/pnas.86.11.4002; MOORE SP, 1991, P NATL ACAD SCI USA, V88, P9067, DOI 10.1073/pnas.88.20.9067; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; PLYTE SE, 1991, PROTEIN ENG, V4, P553, DOI 10.1093/protein/4.5.553; PONGOR S, 1985, DNA-J MOLEC CELL BIO, V4, P319, DOI 10.1089/dna.1985.4.319; Priest Fergus G., 1993, P3; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; ROSS JBA, 1992, TOPICS FLUORESCENCE, V3, P1; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; SALAS M, 1995, FEMS MICROBIOL REV, V17, P73; SALSTROM JS, 1971, J MOL BIOL, V61, P489, DOI 10.1016/0022-2836(71)90061-1; SCHWARZ G, 1983, J MOL BIOL, V163, P467, DOI 10.1016/0022-2836(83)90069-4; SEARCY DG, 1988, BIOCHIM BIOPHYS ACTA, V953, P321, DOI 10.1016/0167-4838(88)90041-6; SELA M, 1956, J AM CHEM SOC, V78, P3986, DOI 10.1021/ja01597a032; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; SOENGAS MS, 1994, J MOL BIOL, V239, P213, DOI 10.1006/jmbi.1994.1364; SOENGAS MS, 1995, J MOL BIOL, V253, P517, DOI 10.1006/jmbi.1995.0570; Soengas MS, 1997, J BIOL CHEM, V272, P303; TANFORD C, 1955, J AM CHEM SOC, V77, P6409, DOI 10.1021/ja01629a001; WAHL P, 1977, CHEM PHYS, V22, P245, DOI 10.1016/0301-0104(77)87008-0; WAXMAN E, 1993, BIOCHEMISTRY-US, V32, P3005, DOI 10.1021/bi00063a011; WU PG, 1994, BIOCHEMISTRY-US, V33, P7415, DOI 10.1021/bi00189a048	66	5	5	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					295	302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995261				2022-12-25	WOS:A1997WA56400048
J	Strous, GJ; vanKerkhof, P; Govers, R; Rotwein, P; Schwartz, AL				Strous, GJ; vanKerkhof, P; Govers, R; Rotwein, P; Schwartz, AL			Growth hormone-induced signal transduction depends on an intact ubiquitin system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; EXTRACELLULAR DOMAIN; RECEPTOR; PROTEIN; KINASE; INTERNALIZATION; IDENTIFICATION; ACTIVATION; BINDING; TRANSCRIPTION	The growth hormone receptor (GHR) is a ubiquitinated cell surface protein, Ligand binding and receptor dimerization activate the cytosolic kinase Jak2. This event initiates signal transduction via STAT proteins. Expression of GHR in a Chinese hamster ovary (CHO) cell line, which exhibits a temperature-sensitive defect in ubiquitin conjugation (CHO-ts20), as well as in wild type cells (CHO-E36) has shown that endocytosis of the receptor requires an intact ubiquitin conjugation system (Strous G. J., van Kerkhof, P., Govers, R., Ciechanover A., and Schwartz, A. L. (1996) EMBO J. 15, 3806-3812). We have now examined the requirement for ubiquitin conjugation in growth factor-mediated signal transduction. In CHO-E36 and in CHO-ts20 cells at the permissive temperature, STAT proteins were activated in a growth factor-dependent fashion. However, no activation of STAT proteins was observed at the nonpermissive temperature in CHO-ts20 cells. Neither tyrosine phosphorylation of GHR nor of Jak2 was inhibited at the nonpermissive temperature. When tyrosine phosphorylation was inhibited following treatment with staurosporin, ubiquitination of the receptor proceeded normally, Furthermore, mutation of GHR phenylalanine-327, which prevents GHR endocytosis, inhibited receptor ubiquitination but allowed normal JAK/STAT-mediated signal transduction. Thus, these data provide evidence that the ubiquitin conjugation system is involved in the Jak/STAT signaling pathway, be it not at the initial stage(s) of Jak2 activity.	WASHINGTON UNIV,SCH MED,DEPT MOL BIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Strous, GJ (corresponding author), UNIV UTRECHT,FAC MED,BIOMEMBRANE INST,DEPT CELL BIOL,HEIDELBERGLAAN 100,AZU-H02 314,NL-3584 CX UTRECHT,NETHERLANDS.		Rotwein, Peter/R-5783-2019; Govers, Roland/O-5782-2016	Govers, Roland/0000-0003-1359-5333; van Kerkhof, Peter/0000-0002-8954-2230; Rotwein, Peter/0000-0002-9505-1817	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD020805] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037449] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEVATO G, 1995, J BIOL CHEM, V270, P17210, DOI 10.1074/jbc.270.29.17210; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CIECHANOVER A, 1989, TRENDS BIOCHEM SCI, V14, P483, DOI 10.1016/0968-0004(89)90180-1; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ESHET R, 1984, ACTA ENDOCRINOL-COP, V107, P9, DOI 10.1530/acta.0.1070009; GalchevaGargova Z, 1995, ONCOGENE, V11, P2649; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KILGOUR E, 1994, FEBS LETT, V343, P205, DOI 10.1016/0014-5793(94)80556-3; KULKA RG, 1988, J BIOL CHEM, V263, P15726; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MORI S, 1992, J BIOL CHEM, V267, P6429; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; ROUPAS P, 1988, MOL CELL ENDOCRINOL, V57, P93, DOI 10.1016/0303-7207(88)90037-8; SAITO Y, 1994, MOL CELL ENDOCRINOL, V106, P67, DOI 10.1016/0303-7207(94)90187-2; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; THOMAS MJ, 1995, MOL CELL BIOL, V15, P12, DOI 10.1128/MCB.15.1.12; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0	29	61	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					40	43						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995223				2022-12-25	WOS:A1997WA56400010
J	Zhu, YA; Lambert, K; Corless, C; Copeland, NG; Gilbert, DJ; Jenkins, NA; DAndrea, AD				Zhu, YA; Lambert, K; Corless, C; Copeland, NG; Gilbert, DJ; Jenkins, NA; DAndrea, AD			DUB-2 is a member of a novel family of cytokine-inducible deubiquitinating enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-CELL-LINE; FAT-FACETS GENE; PROTEIN-DEGRADATION; ANTIGEN RECEPTOR; ISOPEPTIDASE-T; TRE ONCOGENE; UBIQUITIN; MECHANISM; PROTEASOMES; ERYTHROPOIETIN	Cytokines regulate cell growth by inducing the expression of specific target genes. We have recently identified a cytokine-inducible, immediate-early gene, DUB-1, that encodes a deubiquitinating enzyme with growth regulatory activity. In the current study, we have isolated a highly related gene, DUB-2, that is induced by interleukin-2. The DUB-2 mRNA was induced in T cells as an immediate-early gene and was rapidly down-regulated. Like DUB-1, the DUB-2 protein had deubiquitinating activity in vitro. When a conserved cysteine residue of DUB-2, required for ubiquitin-specific thiol protease activity, was mutated to serine (C60S), deubiquitinating activity was abolished. DUB-1 and DUB-2 proteins are highly related throughout their primary amino acid sequence except for a hypervariable region at their COOH terminus. Moreover, the DUB genes co-localize to a region of mouse chromosome 7, suggesting that they arose by a tandem duplication of an ancestral DUB gene. Additional DUB genes co-localize to this region, suggesting a larger family of cytokine-inducible DUB enzymes. We propose that different cytokines induce specific DUB genes. Each induced DUB enzyme thereby regulates the degradation or the ubiquitination state of an unknown growth regulatory factor, resulting in a cytokine-specific growth response.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL CANCER INSTITUTE [T32CA009361] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043889] Funding Source: NIH RePORTER; NCI NIH HHS [T32CA09361-16] Funding Source: Medline; NIDDK NIH HHS [R01 DK 43889-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; BOEHM T, 1988, EMBO J, V7, P385, DOI 10.1002/j.1460-2075.1988.tb02825.x; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; FRUH K, 1994, EMBO J, V13, P3236, DOI 10.1002/j.1460-2075.1994.tb06625.x; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; Green E., 1981, GENETICS PROBABILITY, DOI 10.1007/978-1-349-04904-2; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; Hasson T, 1996, GENOMICS, V36, P431, DOI 10.1006/geno.1996.0488; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENTSCH S, 1992, ANNU REV GENET, V26, P177; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; KOUFOS A, 1985, NATURE, V316, P330, DOI 10.1038/316330a0; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LEBEAU MM, 1986, P NATL ACAD SCI USA, V83, P9744; LITTLE MH, 1988, HUM GENET, V79, P186, DOI 10.1007/BF00280564; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; NAKAMURA T, 1992, ONCOGENE, V7, P733; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NOWAK NJ, 1995, CANCER INVEST, V13, P646, DOI 10.3109/07357909509024936; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; SABATH DE, 1990, J BIOL CHEM, V265, P12671; STEIN RL, 1995, BIOCHEMISTRY-US, V34, P12616, DOI 10.1021/bi00039a017; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; ZHYU Y, 1996, MOL CELL BIOL, V16, P4808	53	101	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	1997	272	1					51	57						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA564	8995226				2022-12-25	WOS:A1997WA56400013
J	Hechenberger, M; Schwappach, B; Fischer, WN; Frommer, WB; Jentsch, TJ; Steinmeyer, K				Hechenberger, M; Schwappach, B; Fischer, WN; Frommer, WB; Jentsch, TJ; Steinmeyer, K			A family of putative chloride channels from Arabidopsis and functional complementation of a yeast strain with a CLC gene disruption	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ANION CHANNELS; IRON-LIMITED GROWTH; SACCHAROMYCES-CEREVISIAE; GUARD-CELLS; PLASMA-MEMBRANE; XENOPUS-OOCYTES; VOLTAGE; EXPRESSION; PLANT; CLONING	We have cloned four novel members of the CLC family of chloride channels from Arabidopsis thaliana. The four plant genes are homologous to a recently isolated chloride channel gene from tobacco (CLC-Nt1; Lurin, C., Geelen, D., Barbier-Brygoo, H., Guern, J., and Maurel, C. (1996) Plant Cell 8, 701-711) and are about 30% identical in sequence to the most closely related CLC-6 and CLC-7: putative chloride channels from mammalia. AtCLC transcripts are broadly expressed in the plant. Similarly, antibodies against the AtCLC-d protein detected the protein in all tissues, but predominantly in the silique. AtCLC-a and AtCLC-b are highly homologous to each other (approximate to-87% identity), while being approximate to 50% identical to either AtCLC-c or AtCLC-d. None of the four cDNAs elicited chloride currents when expressed in Xenopus oocytes, either singly or in combination. Among these genes, only AtCLC-d could functionally substitute for the single yeast CLC protein, restoring iron-limited growth of a strain disrupted for this gene. Introduction of disease causing mutations, identified in human CLC genes, abolished this capacity. Consistent with a similar function of both proteins, the green fluorescent protein-tagged AtCLC-d protein showed the identical localization pattern as the yeast ScCLC protein. This suggests that in Arabidopsis AtCLC-d functions as an intracellular chloride channel.	UNIV HAMBURG, CTR MOL NEUROBIOL, D-20246 HAMBURG, GERMANY; UNIV TUBINGEN, INST BOT, D-72076 TUBINGEN, GERMANY	University of Hamburg; Eberhard Karls University of Tubingen			Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Jentsch, Thomas/0000-0002-3509-2553; Schwappach, Blanche/0000-0003-0225-6432				ADACHI S, 1994, J BIOL CHEM, V269, P17677; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BEAVIS AD, 1992, J BIOL CHEM, V267, P3079; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BODE HP, 1995, EUR J BIOCHEM, V228, P337; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; Dangl JL, 1995, CELL, V83, P1071, DOI 10.1016/0092-8674(95)90134-5; EIDE D, 1992, J GEN MICROBIOL, V138, P347, DOI 10.1099/00221287-138-2-347; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; FISHER SE, 1994, HUM MOL GENET, V3, P2053; FROMMER WB, 1995, ANNU REV PLANT PHYS, V46, P419, DOI 10.1146/annurev.pp.46.060195.002223; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GREENE JR, 1993, MOL GEN GENET, V241, P542, DOI 10.1007/BF00279896; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HEDRICH R, 1992, PHILOS T R SOC B, V338, P31, DOI 10.1098/rstb.1992.0126; HEDRICH R, 1990, EMBO J, V9, P3889, DOI 10.1002/j.1460-2075.1990.tb07608.x; HEDRICH R, 1993, EMBO J, V12, P897, DOI 10.1002/j.1460-2075.1993.tb05730.x; HEDRICH R, 1994, PLANT MOL BIOL, V26, P1637, DOI 10.1007/BF00016494; HEDRICH R, 1988, EMBO J, V7, P3661, DOI 10.1002/j.1460-2075.1988.tb03247.x; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Jentsch TJ, 1996, CURR OPIN NEUROBIOL, V6, P303, DOI 10.1016/S0959-4388(96)80112-7; JENTSCH TJ, 1995, J PHYSIOL-LONDON, V482P, pS19; JENTSCH TJ, 1990, NATURE, V348, P510, DOI 10.1038/348510a0; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; KELLER BU, 1989, NATURE, V341, P450, DOI 10.1038/341450a0; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; KOWDLEY GC, 1994, J GEN PHYSIOL, V103, P217, DOI 10.1085/jgp.103.2.217; LINDER B, 1992, FEBS LETT, V313, P27, DOI 10.1016/0014-5793(92)81176-M; Lloyd SE, 1996, NATURE, V379, P445, DOI 10.1038/379445a0; Loison G., 1994, MOL GENETICS YEAST P, P161; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Lurin C, 1996, PLANT CELL, V8, P701, DOI 10.1105/tpc.8.4.701; MALINOWSKA DH, 1995, AM J PHYSIOL-CELL PH, V268, pC191, DOI 10.1152/ajpcell.1995.268.1.C191; MARTEN I, 1991, NATURE, V353, P758, DOI 10.1038/353758a0; MIDDLETON RE, 1994, BIOCHEMISTRY-US, V33, P13189, DOI 10.1021/bi00249a005; MOUNTAIN HA, 1991, YEAST, V7, P873, DOI 10.1002/yea.320070814; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; PLANT PJ, 1994, J MEMBRANE BIOL, V140, P1; POTTOSIN II, 1995, J MEMBRANE BIOL, V148, P143; RAGUZZI F, 1988, FEBS LETT, V231, P253, DOI 10.1016/0014-5793(88)80742-7; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; Sakamoto H, 1996, J BIOL CHEM, V271, P10210, DOI 10.1074/jbc.271.17.10210; SCHONKNECHT G, 1988, NATURE, V336, P589, DOI 10.1038/336589a0; SCHROEDER JI, 1995, PLANT MOL BIOL, V28, P353, DOI 10.1007/BF00020385; SCHROEDER JI, 1992, P NATL ACAD SCI USA, V89, P5025, DOI 10.1073/pnas.89.11.5025; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; Shimbo K, 1995, BIOPHYS J, V69, P1819, DOI 10.1016/S0006-3495(95)80052-4; STEINMEYER K, 1994, EMBO J, V13, P737, DOI 10.1002/j.1460-2075.1994.tb06315.x; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; STEINMEYER K, 1991, NATURE, V354, P304, DOI 10.1038/354304a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; STOLZ J, 1994, PLANT J, V6, P225, DOI 10.1046/j.1365-313X.1994.6020225.x; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TYERMAN SD, 1992, ANNU REV PLANT PHYS, V43, P351, DOI 10.1146/annurev.pp.43.060192.002031; TZOUNOPOULOS T, 1995, BIOPHYS J, V69, P904, DOI 10.1016/S0006-3495(95)79964-7; UCHIDA S, 1993, J BIOL CHEM, V268, P3821; VANSLEGTENHORST MA, 1994, HUM MOL GENET, V3, P547; WADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1101, P296, DOI 10.1016/0005-2728(92)90085-G	65	143	163	2	18	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	1996	271	52					33632	33638		10.1074/jbc.271.52.33632	http://dx.doi.org/10.1074/jbc.271.52.33632			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	WA713	8969232	hybrid			2022-12-25	WOS:A1996WA71300066
J	Banki, K; Hutter, E; Colombo, E; Gonchoroff, NJ; Perl, A				Banki, K; Hutter, E; Colombo, E; Gonchoroff, NJ; Perl, A			Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CELL-DEATH; THYMOCYTE APOPTOSIS; MONOCLONAL-ANTIBODY; NITRIC-OXIDE; FACTOR-ALPHA; OXYGEN; FAS; GENERATION; SUPEROXIDE	Transaldolase (TAL) is a key enzyme of the reversible nonoxidative branch of the pentose phosphate pathway (PPP) that is responsible for the generation of NADPH to maintain glutathione at a reduced state (GSH) and, thus, to protect cellular integrity from reactive oxygen intermediates (ROIs). Formation of ROIs have been implicated in certain types of apoptotic cell death. To evaluate the role of TAL in this process, Jurkat human T cells were permanently transfected with TAL expression vectors oriented in the sense or antisense direction, Overexpression of TAL resulted in a decrease in glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities and NADPH and GSH levels and rendered these cells highly susceptible to apoptosis induced by serum deprivation, hydrogen peroxide, nitric oxide, tumor necrosis factor-alpha, and anti-Fas monoclonal antibody. In addition, reduced levels of TAL resulted in increased glucose 6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase activities and increased GSH levels with inhibition of apoptosis in all five model systems. The effect of TAL expression on susceptibility to apoptosis through regulating the PPP and GSH production is consistent with an involvement of ROIs in each pathway tested. Production of ROIs in Pas-mediated cell death was further substantiated by measurement of intracellular ROI production with oxidation-sensitive fluorescent probes, by the protective effects of GSH precursor, N-acetyl cysteine, free radical spin traps 5,5-dimethyl-1-pyrroline-1-oxide and 3,3,5,5-tetramethyl-1-pyrroline-1-oxide, the antioxidants desferrioxamine, nordihydroguaiaretic acid, and Amytal, and by the enhancing effects of GSH depletion with buthionine sulfoximine, The results provide definitive evidence that TAL has a role in regulating the balance between the two branches of PPP and its overall output as measured by GSH production and thus influences sensitivity to cell death signals.	SUNY HLTH SCI CTR,DEPT MED,COLL MED,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT PATHOL,COLL MED,SYRACUSE,NY 13210; SUNY HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,COLL MED,SYRACUSE,NY 13210	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center			Hutter, Eliza/A-6766-2009	Perl, Andras/0000-0002-5017-1348	NIDDK NIH HHS [R01 DK 49221] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049221] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANKI K, 1994, J BIOL CHEM, V269, P2847; BANKI K, 1994, J EXP MED, V180, P1649, DOI 10.1084/jem.180.5.1649; BANKI K, 1994, AIDS RES HUM RETROV, V10, P303, DOI 10.1089/aid.1994.10.303; BAQUER NZ, 1977, DEV MED CHILD NEUROL, V19, P81; BUROW S, 1987, EUR J CELL BIOL, V43, P128; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; FINKELSTEIN E, 1980, ARCH BIOCHEM BIOPHYS, V200, P1, DOI 10.1016/0003-9861(80)90323-9; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HAMILOS DL, 1985, J IMMUNOL, V135, P2740; HEINRICH PC, 1976, CANCER RES, V36, P3189; HENNET T, 1993, BIOCHEM J, V289, P587, DOI 10.1042/bj2890587; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mayes P., 1993, HARPERS BIOCH, P201; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MERRILL JE, 1993, J IMMUNOL, V151, P2132; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOVELLO F, 1968, BIOCHEM J, V107, P775, DOI 10.1042/bj1070775; Packham G, 1996, J IMMUNOL, V156, P2792; PERL A, 1989, NUCLEIC ACIDS RES, V17, P6841, DOI 10.1093/nar/17.17.6841; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; RUDACK D, 1971, J BIOL CHEM, V246, P1249; RYDSTROM J, 1977, BIOCHIM BIOPHYS ACTA, V463, P155, DOI 10.1016/0304-4173(77)90007-6; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VENKATARAMAN R, 1961, J BIOL CHEM, V236, P1876; WOOD T, 1972, FEBS LETT, V25, P153, DOI 10.1016/0014-5793(72)80474-5; WOOD T, 1985, PENTOSE PHOSPHATE PA; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	44	164	174	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32994	33001		10.1074/jbc.271.51.32994	http://dx.doi.org/10.1074/jbc.271.51.32994			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955144	hybrid			2022-12-25	WOS:A1996VZ37300079
J	GubitosiKlug, RA; Gross, RW				GubitosiKlug, RA; Gross, RW			Fatty acid ethyl esters, nonoxidative metabolites of ethanol, accelerate the kinetics of activation of the human brain delayed rectifier KC channel, Kv1.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; POTASSIUM CHANNELS; ION CHANNELS; HIPPOCAMPAL-NEURONS; ARACHIDONIC-ACID; GENERAL-ANESTHESIA; RAT-BRAIN; CELLS; MECHANISM; LOCALIZATION	Herein we demonstrate that the major metabolites of ethanol in neural tissues, fatty acid ethyl esters, dramatically accelerate the kinetics of the voltage-induced activation of the human brain delayed rectifier potassium channel, Kv1.1. Specifically, the external application of ethyl oleate (20 mu M) to Sf9 cells expressing the recombinant Kv1.1 channel resulted in a decrease in the rise times of the macroscopic current (e.g. from 51.7 +/- 13.1 to 12.8 +/- 3.0 ms at 0 mV for 10-90% rise times) and a 10-mV hyperpolarizing shift (at 0 mV) in the voltage dependence of channel activation, These effects were dose-dependent (half-maximal effect at 7 mu M), saturable and specific (i.e. fatty acid methyl esters were without effect), Although application of either ethanol or oleic acid alone did not result in alterations of the activation kinetics, the concomitant application of ethanol and oleic acid reproduced the effects of fatty acid ethyl esters with a temporal course which paralleled the intracellular accumulation of fatty acid ethyl esters in Sf9 cells, Moreover, application of fatty acid ethyl esters (but not ethanol) to rat hippocampal cells in culture produced similar effects on hippocampal delayed recti fier currents, Collectively, these results demonstrate that pathophysiologically relevant concentrations of metabolites of ethanol, fatty acid ethyl esters, modulate the function of a prototypic neuronal ion channel and thus likely contribute to the pathophysiologic sequelae of ethanol abuse in excitable tissues.	WASHINGTON UNIV, SCH MED, DIV BIOORGAN CHEM & MOL PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)								ANANTHARAM V, 1992, MOL PHARMACOL, V42, P499; BARISH ME, 1986, J PHYSIOL-LONDON, V375, P229, DOI 10.1113/jphysiol.1986.sp016114; BORA PS, 1993, ALCOHOL CLIN EXP RES, V17, P28, DOI 10.1111/j.1530-0277.1993.tb00721.x; CARLEN PL, 1982, SCIENCE, V215, P306, DOI 10.1126/science.7053581; CARLEN PL, 1985, CAN J PHYSIOL PHARM, V63, P831, DOI 10.1139/y85-137; COVARRUBIAS M, 1993, P NATL ACAD SCI USA, V90, P6957, DOI 10.1073/pnas.90.15.6957; COVARRUBIAS M, 1995, J BIOL CHEM, V270, P19408, DOI 10.1074/jbc.270.33.19408; DEITRICH RA, 1989, PHARMACOL REV, V41, P489; DOYLE KM, 1994, J LIPID RES, V35, P428; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; GIVENS B, 1995, BRAIN RES, V688, P27, DOI 10.1016/0006-8993(95)00499-G; GUBITOSIKLUG RA, 1995, J BIOL CHEM, V270, P2885, DOI 10.1074/jbc.270.7.2885; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; HONORE E, 1994, P NATL ACAD SCI USA, V91, P1937, DOI 10.1073/pnas.91.5.1937; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; KAMB A, 1992, METHOD ENZYMOL, V207, P423; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; LANGE LG, 1991, ALCOHOL ALCOHOLISM, P103; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; LAPOSATA EA, 1987, J BIOL CHEM, V262, P4653; MENNERICK S, 1995, J NEUROPHYSIOL, V73, P320, DOI 10.1152/jn.1995.73.1.320; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; MI HY, 1995, J NEUROSCI, V15, P3761; Mitchell DC, 1996, J BIOL CHEM, V271, P19033, DOI 10.1074/jbc.271.32.19033; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PRZYWARA DA, 1993, EUR J PHARM-MOLEC PH, V247, P353, DOI 10.1016/0922-4106(93)90206-O; RAMASWAMI M, 1990, Molecular and Cellular Neuroscience, V1, P214, DOI 10.1016/1044-7431(90)90004-N; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; SCHNEGGENBURGER R, 1992, PFLUG ARCH EUR J PHY, V420, P302, DOI 10.1007/BF00374463; STEFFENSEN SC, 1993, ALCOHOL CLIN EXP RES, V17, P655, DOI 10.1111/j.1530-0277.1993.tb00814.x; TREISTMAN SN, 1991, ANN NY ACAD SCI, V625, P249, DOI 10.1111/j.1749-6632.1991.tb33844.x; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; WU RL, 1992, J NEUROSCI, V12, P2235	39	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32519	32522		10.1074/jbc.271.51.32519	http://dx.doi.org/10.1074/jbc.271.51.32519			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955075	hybrid			2022-12-25	WOS:A1996VZ37300010
J	Lu, Q; Park, HY; Egger, LA; Inouye, M				Lu, Q; Park, HY; Egger, LA; Inouye, M			Nucleoside-diphosphate kinase-mediated signal transduction via histidyl-aspartyl phosphorelay systems in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; BACTERIAL CHEMOTAXIS; TRANSCRIPTIONAL ACTIVATOR; 2-COMPONENT REGULATORS; PHOSPHATASE-ACTIVITIES; FUNCTIONAL-ANALYSIS; MYXOCOCCUS-XANTHUS; TUMOR-METASTASIS; PROTEIN-KINASE; PHOSPHORYLATION	Nucleoside-diphosphate kinase (NDP kinase), a key enzyme in nucleotide metabolism, is also known to be involved in growth and developmental control and tumor metastasis suppression. Interestingly, we find that coexpression of NDP kinase with Taz1, a Tar/EnvZ chimera, in the absence of its native signal, can activate a porin gene ompC-lacZ expression in Escherichia coli. Further studies show that NDP kinase can act as a protein kinase to phosphorylate histidine protein kinases such as EnvZ and CheA which are members of the His-Asp phosphorelay signal transduction systems in E. coli. Instead of ATP, the exclusive phosphodonor for histidine kinases, GTP can be utilized in vitro in the presence of NDP kinase to phosphorylate EnvZ and CheA, which then transfer the phosphoryl group to OmpR and CheY, the respective response regulators. The direct involvement of GTP for the phosphorylation of EnvZ through NDP kinase was further demonstrated by the use of a mutant EnvZ, which lost ability to be autophosphorylated with ATP. Phospho OmpR thus formed can bind specifically to an ompP promoter sequence. These results suggest that NDP kinase may play a physiological role in signal transduction.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMAULA N, 1995, J BACTERIOL, V177, P2524, DOI 10.1128/jb.177.9.2524-2529.1995; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BOMINAAR AA, 1993, EMBO J, V12, P2275, DOI 10.1002/j.1460-2075.1993.tb05881.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; Dutta R, 1996, J BIOL CHEM, V271, P1424, DOI 10.1074/jbc.271.3.1424; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FUKUCHI T, 1993, GENE, V129, P141; GILLESGONZALEZ MA, 1993, J BIOL CHEM, V268, P16293; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HARLOCKER SL, 1995, J BIOL CHEM, V270, P26849, DOI 10.1074/jbc.270.45.26849; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; Hoch JA, 1995, 2 COMPONENT SIGNAL T; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; INOUYE M, 1996, CELL, V85, P13; IZUMIYA H, 1995, J BIOL CHEM, V270, P27859, DOI 10.1074/jbc.270.46.27859; KANAMARU K, 1990, J BIOCHEM-TOKYO, V108, P483, DOI 10.1093/oxfordjournals.jbchem.a123225; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, BIOCHEM BIOPH RES CO, V168, P99, DOI 10.1016/0006-291X(90)91680-Q; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; LU Q, 1995, J MOL BIOL, V254, P337, DOI 10.1006/jmbi.1995.0620; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MCCLEARY WR, 1990, J BACTERIOL, V172, P6661, DOI 10.1128/jb.172.12.6661-6668.1990; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MILLER JH, 1992, SHORT COURSE BACTERI, P59; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; OKABEKADO J, 1995, FEBS LETT, V363, P311, DOI 10.1016/0014-5793(95)00338-A; OLMEDO G, 1990, J MOL BIOL, V215, P359, DOI 10.1016/S0022-2836(05)80357-2; OOSAWA K, 1988, CELL, V53, P89, DOI 10.1016/0092-8674(88)90490-4; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; RAMPERSAUD A, 1991, J BIOL CHEM, V266, P7633; RAY NB, 1992, CURR TOP CELL REGUL, V33, P343; ROBERTS DL, 1994, J BIOL CHEM, V269, P8728; Shankar S, 1996, J BACTERIOL, V178, P1777, DOI 10.1128/jb.178.7.1777-1781.1996; SHANKAR S, 1995, MOL MICROBIOL, V17, P935, DOI 10.1111/j.1365-2958.1995.mmi_17050935.x; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUNG K, 1989, J BIOL CHEM, V264, P4428; Tsuzuki M, 1995, MOL MICROBIOL, V18, P953, DOI 10.1111/j.1365-2958.1995.18050953.x; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	55	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32886	32893		10.1074/jbc.271.51.32886	http://dx.doi.org/10.1074/jbc.271.51.32886			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955129	hybrid			2022-12-25	WOS:A1996VZ37300064
J	Medlock, AE; Dailey, HA				Medlock, AE; Dailey, HA			Human coproporphyrinogen oxidase is not a metalloprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III OXIDASE; HEREDITARY COPROPORPHYRIA; MOLECULAR-CLONING; PURIFICATION; GENE; EXPRESSION	Coproporphyrinogen oxidase (CPO) (EC 1.3.3.3), the antepenultimate enzyme in the heme biosynthetic pathway, catalyzes the conversion of coproporphyrinogen III to protoporphyrinogen IX, Previously, based upon metal analysis and site-directed mutagenesis of purified recombinant enzyme, it has been suggested that CPO contains and requires copper for activity (Kohno, H., Furukawa, T., Tokunaga, R., Taketani, S., and Yoshinaga, T. (1996) Biochim, Biophys, Acta 1292, 156-162), To examine this putative metal site in human CPO, the cDNA encoding human CPO was engineered into an expression vector with a His(6) tag at its amino terminus, and the protein was expressed in Escherichia coli and purified to apparent homogeneity using nickel-nitrolio-triacetic acid resin. Activity of the purified protein was monitored by a coupled fluorometric assay that employed purified protoporphyrinogen oxidase to convert protoporphyrinogen to protoporphyrin, thereby allowing the direct fluorescent determination of protoporphyrin IX produced, CPO has an apparent K-m of 0.6 mu M and an apparent K-cat of 16 min(-1) with coproporphyrinogen III as substrate. Metal analysis of the enzyme was carried out via ultraviolet and visible spectroscopy, inductively coupled plasma atomic emission spectroscopy metal analysis, and electron paramagnetic resonance spectroscopy, The data presented demonstrate that human CPO contains no metal center, that it is not stimulated in vitro by iron or copper, and that addition of these metals to cultures expressing the protein has no effect.	UNIV GEORGIA, DEPT BIOCHEM & MOL BIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, DEPT MICROBIOL, ATHENS, GA 30602 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia				Medlock, Amy/0000-0001-9402-3593	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032303, R56DK032303, R01DK035898] Funding Source: NIH RePORTER; NIDDK NIH HHS [R56 DK032303, DK35898, DK32303] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGARD M, 1989, EUR J BIOCHEM, V181, P417, DOI 10.1111/j.1432-1033.1989.tb14741.x; CAMADRO JM, 1986, EUR J BIOCHEM, V156, P579, DOI 10.1111/j.1432-1033.1986.tb09617.x; Dailey HA, 1996, J BIOL CHEM, V271, P8714, DOI 10.1074/jbc.271.15.8714; Dailey TA, 1996, PROTEIN SCI, V5, P98; DAILY HA, 1990, BIOSYNTHESIS HEME CH, P124; FUHRHOP JH, 1975, PROPHYRINS METALLOPO, P784; FUJITA H, 1994, HUM MOL GENET, V3, P1807, DOI 10.1093/hmg/3.10.1807; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GRANDCHAMP B, 1982, ENZYME, V28, P196, DOI 10.1159/000459102; GRANDCHAMP B, 1978, BIOCHEM J, V176, P97, DOI 10.1042/bj1760097; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; KOHNO H, 1993, J BIOL CHEM, V268, P21359; KONO H, 1996, BIOCHIM BIOPHYS ACTA, V1292, P156; LABBE P, 1985, ANAL BIOCHEM, V149, P248, DOI 10.1016/0003-2697(85)90502-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADSEN O, 1993, PLANT MOL BIOL, V23, P35, DOI 10.1007/BF00021417; MARTASEK P, 1994, HUM MOL GENET, V3, P477, DOI 10.1093/hmg/3.3.477; MARTASEK P, 1994, P NATL ACAD SCI USA, V91, P3024, DOI 10.1073/pnas.91.8.3024; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAKETANI S, 1994, BBA-BIOENERGETICS, V1183, P547, DOI 10.1016/0005-2728(94)90083-3; TROUP B, 1994, J BACTERIOL, V176, P673, DOI 10.1128/jb.176.3.673-680.1994; XU K, 1993, J BACTERIOL, V16, P4990; YOSHINAGA T, 1980, J BIOL CHEM, V255, P4722; YOSHINAGA T, 1980, J BIOL CHEM, V255, P4727; ZAGOREC M, 1988, J BIOL CHEM, V263, P9718	25	49	49	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	1996	271	51					32507	32510		10.1074/jbc.271.51.32507	http://dx.doi.org/10.1074/jbc.271.51.32507			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VZ373	8955072	hybrid			2022-12-25	WOS:A1996VZ37300007
J	Sawyer, ST; Penta, K				Sawyer, ST; Penta, K			Association of JAK2 and STAT5 with erythropoietin receptors - Role of receptor phosphorylation in erythropoietin signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; INDUCED CELL-PROLIFERATION; TYROSINE PHOSPHORYLATION; DNA-BINDING; GROWTH-HORMONE; ACTIVATION; PROTEIN; PROLACTIN; KINASE; INTERLEUKIN-3	Cytokine receptors act at least partially by associating with Janus tyrosine protein kinases at the conserved box one moth of the receptor. These receptor-associated kinases then activate STAT transcription factors through phosphorylation. me found that the 78-kDa erythropoietin receptor (EPOR), a highly modified form of the 66-kDa receptor which is abundant in HCD57 cells, was phosphorylated on serine residues without EPO stimulation, Coprecipitation experiments showed the 78-kDa EPOR but not the more abundant 66-kDa EPOR was associated with JAK2, a Janus protein kinase, in both the presence and absence of EPO. Solubilized 78-kDa EPOR bound to purified, genetically engineered JAK2 better than the 62-76-kDa receptor proteins, and additional phosphorylation of tyrosine residues further increased the binding of the 78-kDa EPOR to JAK2-agarose beads. STAT5 DNA binding was activated by 10-100-fold lower concentrations of EPO in HCD57 cells than in primary erythroid cells, and STATE associated with the EPOR in an EPO dependent manner. These data suggest that phosphorylation of either serine or tyrosine residues of the EPOR can enhance the association of the receptor with JAK2, possibly increasing the sensitivity to EPO.	VANDERBILT UNIV, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	Sawyer, ST (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHARMACOL & TOXICOL, POB 980613, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039781] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK39781] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMEN J, 1992, BLOOD, V80, P1923; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FINBLOOM DS, 1994, MOL CELL BIOL, V14, P2113, DOI 10.1128/MCB.14.3.2113; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HE TC, 1994, J BIOL CHEM, V269, P18291; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KRANTZ SB, 1991, BLOOD, V77, P419; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1994, BLOOD, V84, P1501; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAGAO M, 1995, FEBS LETT, V373, P225, DOI 10.1016/0014-5793(95)01046-H; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; RUI H, 1992, J BIOL CHEM, V267, P24076; RUSCETTI SK, 1990, J VIROL, V64, P1057, DOI 10.1128/JVI.64.3.1057-1062.1990; SAWYER ST, 1994, HEMATOL ONCOL CLIN N, V8, P895, DOI 10.1016/S0889-8588(18)30136-9; SAWYER ST, 1993, P NATL ACAD SCI USA, V90, P6849, DOI 10.1073/pnas.90.14.6849; SPIVAK JL, 1992, EXP HEMATOL, V20, P500; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YI TL, 1995, BLOOD, V85, P87, DOI 10.1182/blood.V85.1.87.bloodjournal85187; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; ZHUANG HM, 1995, J BIOL CHEM, V270, P14500, DOI 10.1074/jbc.270.24.14500; ZHUANG HM, 1994, J BIOL CHEM, V269, P21411; ZHUANG HM, 1994, BIOCHEM BIOPH RES CO, V204, P278, DOI 10.1006/bbrc.1994.2456	43	57	57	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	1996	271	50					32430	32437		10.1074/jbc.271.50.32430	http://dx.doi.org/10.1074/jbc.271.50.32430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	VY340	8943308	hybrid			2022-12-25	WOS:A1996VY34000099
J	Greco, A; Villa, R; Pierotti, MA				Greco, A; Villa, R; Pierotti, MA			Genomic organization of the human NTRK1 gem	ONCOGENE			English	Article						NTRK1 gene; tyrosine kinase receptor; intron exon structure	TRK PROTOONCOGENE; GROWTH-FACTOR; KINASE GENE; RECEPTOR; ONCOGENE; FUSION; MUTATIONS; DOMAIN	The NTRK1 gene encodes one of the receptors for the Nerve Growth Factors and it is located at 1q21-22. Rearrangements of NTRK1 are frequently detected in human papillary thyroid carcinoma and lead to the formation of chimeric oncogenes, similarly to what observed for the other neurotrophin receptor RET. In addition, the two receptor genes are target of point mutations associated with different human diseases. RET is affected by germ line and somatic mutations in MEN2A, MEN2B tumor syndromes and in the abnormal developmental Hirschsprung disease, whereas mutations of NTRK1 have been reported very recently in patients with congenital insensitivity to pain with anidrosis (CIPA). With the aim to provide a tool for searching mutations along the whole NTRK1 gene, we have determined its genomic organization. Our results demonstrated that NTRK1 is contained within 25 Kb of DNA and is organized in 17 exons, one of which is alternatively spliced. The sequence of the 5' flanking region indicates a high content in C/G, the absence of TATA box, the presence of several putative binding sites for Sp1, AP1, AP2, AP3, ATF and GCF transcription factors.			Greco, A (corresponding author), IST NAZL TUMORI,DIV EXPT ONCOL A,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Greco, Angela/C-1953-2017	Greco, Angela/0000-0003-2994-0349; Fontecha, Juliana/0000-0002-2215-7362; Pierotti, Marco Alessandro/0000-0002-7431-8332; Villa, Riccardo/0000-0001-8385-800X				BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARKER PA, 1993, J BIOL CHEM, V268, P15150; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; Indo Y, 1996, NAT GENET, V13, P485, DOI 10.1038/ng0896-485; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MARTINZANCA D, 1990, GENE DEV, V4, P683, DOI 10.1101/gad.4.5.683; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Pasini B, 1996, TRENDS GENET, V12, P138, DOI 10.1016/0168-9525(96)10012-3; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; WEIER HUG, 1995, GENOMICS, V26, P390, DOI 10.1016/0888-7543(95)80226-C	21	47	47	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2463	2466						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957089				2022-12-25	WOS:A1996VX10800020
J	Qian, XL; ORourke, DM; Zhao, HZ; Greene, MI				Qian, XL; ORourke, DM; Zhao, HZ; Greene, MI			Inhibition of p185(neu) kinase activity and cellular transformation by co-expression of a truncated neu protein	ONCOGENE			English	Article						ErbB receptors; neu ectodomain; trans inhibition	EPIDERMAL GROWTH-FACTOR; FACTOR RECEPTOR FAMILY; MONOCLONAL-ANTIBODIES; DOWN-MODULATION; ERBB-2 ONCOGENE; POINT MUTATION; DEFICIENT NEU; EGF RECEPTOR; HUMAN-BREAST; 3T3 CELLS	The rat nea oncogene product encodes a 185 kDa receptor tyrosine kinase which is constitutively activated as a result of a single amino acid substitution (Va1664-->Glu) within the transmembrane region. In this study, we show that the transforming activity of oncogenic p185(neu) (also termed Tneu) can be inhibited by co-expression of a truncated nea protein with a large cytoplasmic deletion (termed T691stop) which includes the tyrosine kinase domain. In cell lines co-expressing full-length and truncated nea proteins, we observed codimerization between full-length p185(neu) and truncated T691 stop, resulting in the formation of a kinase-inactive heteromeric complex. Phenotypic analysis of several different clones showed that the degree of inhibition of transformation in vitro and tumorigenicity in vivo was related to the ratio of full-length and truncated p185 proteins co-expressed in cells. These results provide evidence that expression of kinase-deficient nea proteins leads to co-dimerization that results in suppression of kinase activation and oncogenicity of associated p185(neu)-activated receptors. The mutant nea protein mediates inhibition in both transfected fibroblasts expressing oncogenic p185(neu) and mammalian cancer cells derived from a rat primary neuroglioblastoma expressing oncogenic p185(neu). This truncated peptide may be important for the design of future therapies directed against erbB family oncoproteins.	UNIV PENN,SCH MED,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,CTR RECEPTOR BIOL,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania			O'Rourke, Donald/AAC-3376-2021	O'Rourke, Donald/0000-0002-8479-7314				AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BROWN VI, 1994, DNA CELL BIOL, V13, P193, DOI 10.1089/dna.1994.13.193; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHOU CK, 1987, J BIOL CHEM, V262, P1842; COLOMER R, 1994, BRIT J CANCER, V70, P819, DOI 10.1038/bjc.1994.405; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; FARNSWORTH C, 1991, MOL CELL BIOL, V11, P4832; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; HACK N, 1993, J BIOL CHEM, V268, P26441; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; LEMOINE NR, 1991, BRIT J CANCER, V64, P79, DOI 10.1038/bjc.1991.243; LEVEA CM, 1993, RECEPTOR, V3, P293; LOFTS FJ, 1993, ONCOGENE, V8, P2813; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MYERS JN, 1992, RECEPTOR, V2, P1; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; QIAN XL, 1995, ONCOGENE, V10, P211; QIAN XL, 1994, ONCOGENE, V9, P1507; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; SAMANTA A, 1995, DNA CELL BIOL, V14, P921, DOI 10.1089/dna.1995.14.921; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	48	25	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 21	1996	13	10					2149	2157						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950982				2022-12-25	WOS:A1996VV14500012
